[{"TITLE":"Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure","CRITERIA":"Inclusion Criteria:\n\n1. Signed written informed consent before any trial-related processes;\n2. Age \u2265 18 years and \u226470 years male or females;\n3. Has a histologically or cytologically confirmed stage IIIB\/IIIC (American Joint Committee on Cancer \\[AJCC\\] 8th edition) NSCLC that is unresectable and not fit for radical concurrent chemoradiotherapy, or metastatic \/ recurrent non-squamous NSCLC;\n4. Patients with EGFR mutation confirmed by tumor histology or cytology or hematology prior to EGFR-TKI treatment\n5. EGFR-TKI resistance, confirmed by RECIST 1.1\n6. The Eastern Cancer Cooperative Group (ECOG) performance score of 0 or 1;\n\nExclusion Criteria:\n\n1. History of severe allergies to any study drug\n2. Has previously received the following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or any other stimulatory or inhibitory agents of T cell receptors\n3. Previous exposure to VEGF inhibitor for anti-cancer treatment\n4. Patients with untreated symptomatic brain metastases. Patients with treated brain metastases will be allowed if brain imaging obtained greater than 4 weeks from trial enrollment reveals stable disease.\n5. Has received a live-virus vaccination within 28 days of planned treatment start\n6. Interstitial lung disease or pneumonitis requiring oral or IV glucocorticoids Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study","SEX":"ALL","AGE_MIN":18,"AGE_MAX":70,"SS_ID":"06334757001","EMAIL":[{}],"GEO":[34.75778,113.64861]},{"TITLE":"SI-B001 Combined With Chemotherapy in the Treatment of EGFR\/ALK WT Recurrent or Metastatic NSCLC.","CRITERIA":"Inclusion Criteria:\n\n1. Voluntarily sign informed consent forms and follow program requirements\uff1b\n2. Male or female;\n3. Age: \u2265 18 years;\n4. Expected survival time \u2265 3 months;\n5. Patients with locally advanced or metastatic EGFR wild-type ALK wild-type lung cancer, disease progression or intolerance after first-line treatment with anti-PD-1\/PD-L1 antibody, disease progression or intolerance after first-line treatment with anti-PD-1\/PD-L1 antibody and platinum-based chemotherapy, or progression or intolerance after first-line treatment with anti-PD-1\/PD-L1 monoclonal antibody;\n6. The subject agrees to provide archival tumor tissue samples or fresh tissue samples of the primary tumor or metastases within 6 months; if the subject is unable to provide tumor tissue samples and the subject is unable to provide the gene sequencing report, the subject shall agree to complete the ctDNA EGFR detection during the screening period, and can be assessed by the investigator if other inclusion criteria are met;\n7. Must have at least one measurable lesion as defined by RECISTv1.1;\n8. Performance status score ECOG0 or 1;\n9. Toxicities from prior anticancer therapy have recovered to grade \u2264 2 as defined by NCI-CTCAEv5.0 (except alopecia);\n10. No severe cardiac dysfunction, left ventricular score \u2265 50%;\n11. The level of organ function must meet the following criteria:\n\n    1. Bone marrow function: Absolute neutrophil count (ANC) \u2265 1.5 \u00d7 109\/L, platelet count \u2265 80 \u00d7 109\/L, hemoglobin \u2265 90 g\/L;\n    2. Liver function: TBIL \u2264 1.5ULN (total bilirubin \u2264 3ULN for subjects with Gilbert's syndrome, liver cancer or liver metastases); AST and ALT \u2264 2.5ULN for subjects without liver metastases; AST and ALT \u2264 5.0ULN for subjects with liver metastases;\n    3. Renal function: creatinine (Cr) \u2264 1.5ULN, or creatinine clearance (Ccr) \u2265 50 mL\/min (according to CockcroftandGault formula).\n12. Coagulation function: international normalized ratio (INR) \u2264 1.5 \u00d7 ULN, and activated partial thromboplastin time (APTT) \u2264 1.5ULN;\n13. Urine protein \u2264 2 + (measured by dipstick) or \\< 1000 mg\/24 h (urine);\n14. Premenopausal women of childbearing potential must have a negative serum or urine pregnancy test 7 before starting treatment and must be non-lactating; all patients (male or female) should take adequate barrier contraception measures throughout the treatment cycle and 6 months after the end of treatment.\n\nExclusion Criteria:\n\n1. Patients with past use of docetaxel\uff1b\n2. Prior to signing the informed consent, the gene sequencing or ctDNA testing report of the previous tissue samples indicated the presence of MET 14 exon jump positive, ROS1 rearrangement positive, BRAF V600E mutation positive, NTRK fusion positive, RET rearrangement positive, HER2 mutation positive, HER2 amplification positive, Patients with KRAS G12C mutation positive\uff1b\n3. Chemotherapy, biotherapy, immunotherapy, radical radiotherapy, and major surgery were used within 4 weeks before the first administration; palliative radiotherapy, targeted therapy (including small-molecule tyrosine kinase inhibitors) and other antitumor therapy were used within 2 weeks;\n4. Screening the history of severe heart disease within the first six months, such as: symptomatic congestive heart failure (CHF) \u22652 (CTCAE v5.0) history, New York Heart Society (NYHA) \u22652 heart failure, acute coronary syndrome, etc.;\n5. Prolonged QT interval (QTc \\> 450 msec in men or 470 msec in women), complete left bundle branch block, and Degree III atrioventricular block;\n6. Active autoimmune diseases and inflammatory diseases, such as systemic lupus erythematosus, psoriasis requiring systemic treatment, rheumatoid arthritis, inflammatory bowel disease and Hashimoto's thyroiditis, except for type I diabetes, hypothyroidism controllable by replacement therapy only, skin diseases not requiring systemic treatment (such as vitiligo, psoriasis);\n7. Other malignancies diagnosed within 5 years prior to first dose,Exceptions include: radical basal cell carcinoma of the skin, scaly cell carcinoma of the skin, and\/or radical resection of carcinoma in situ;\n8. Hypertension poorly controlled by two antihypertensive drugs (systolic blood pressure \\> 150 mmHg or diastolic blood pressure \\> 100 mmHg);\n9. Pulmonary disease defined as \u2265 grade 3 according to CTCAEv5.0, including resting dyspnea, or requiring continuous oxygen therapy, or patients with a history of interstitial lung disease (ILD);\n10. Symptoms of active central nervous system metastases.However, patients with stable parenchymal metastases can be stable, and whether it is stable or not is judged by the investigator;\n11. Patients with a history of hypersensitivity to recombinant humanized antibodies or human-mouse chimeric antibodies or hypersensitivity to SI-B001 or any of the excipient components of Osimertinib;\n12. History of autologous or allogeneic stem cell transplantation;\n13. In previous anthracycline (neo) adjuvant therapy, the cumulative dose of anthracycline was \\> 360 mg\/m2;\n14. Human immunodeficiency virus antibody (HIVAb) positive, active tuberculosis, active hepatitis B virus infection (HBV-DNA copy number \\> 104) or hepatitis C virus (HCV) infection;\n15. Active infection requiring systemic treatment, such as severe pneumonia, bacteremia, sepsis, etc.;\n16. Received other unmarketed clinical study drugs or treatments within 4 weeks prior to study participation;\n17. Other conditions for trial participation were not considered by the investigator to be appropriate.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05020457006","EMAIL":[{}],"GEO":[32.49069,119.90812]},{"TITLE":"A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy","CRITERIA":"Inclusion Criteria:\n\n1. 18 years of age or older\n2. Histologically confirmed stage 4 NSCLC or stage 3B\/3C not able to receive chemoradiation with no sensitizing EGFR or ALK mutations.\n3. PDL-1 of 1%-49%\n4. No previous history of immunotherapy treatment\n5. ECOG PS 0-1\n6. At least one measurable lesion according to RECIST version 1.1\n7. Life expectancy of at least 3 months.\n8. Able to self-administer daily GM-CSF injections\n9. Eligible for treatment with 4 cycles of chemoimmunotherapy followed by maintenance therapy with pembrolizumab +\/- pemetrexed.\n\nExclusion Criteria:\n\n1. Receiving systemic glucocorticoids or other immunosuppressive treatment\n2. Untreated brain metastases\n3. Active autoimmune disease\n4. Active interstitial lung disease, pneumonitis\n5. Solid organ transplant recipients\n6. Subject may not participate in another drug research study while participating in this research study\n7. Pregnant patients\n8. Known hypersensitivity to GM-CSF (sargramostim)","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04856176001","EMAIL":[{"email":"lpai@tuftsmedicalcenter.org"},{"email":"llashley@tuftsmedicalcenter.org"}],"GEO":[42.35843,-71.05977]},{"TITLE":"A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1","CRITERIA":"Inclusion Criteria:\n\n1. Pathologically documented, locally-advanced or metastatic NSCLC with KRAS p.G12C mutation identified through molecular testing.\n2. STK11 co-mutation and KEAP1 Wild-Type (local confirmation)\n3. Treatment na\u00efve or have received at least 1 prior standard therapy for advanced NSCLC\n4. ECOG 0-1\n\nExclusion Criteria:\n\n1. Has CNS metastases or carcinomatous meningitis, except treated CNS metastases with no evidence of radiographic progression or hemorrhage for at least 28 days\n2. Any severe and\/or uncontrolled medical conditions\n3. Active infection requiring systemic treatment within 7 days\n4. Therapeutic radiation therapy within 3 weeks of study day 1","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05276726005","EMAIL":"clinicaltrials@jacobiopharma.com","GEO":[39.9075,116.39723]},{"TITLE":"Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Stage II-IIIB NSCLC\n* EGFR\/ALK negative\n* The subjects voluntarily joined the study, signed informed consent, had good compliance, and cooperated with follow-up\n\nExclusion Criteria:\n\n* A history of other malignancies within the past 5 years\n* Patients with autoimmune disease are not suitable for PD1 monoclonal antibody therapy","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"05965557001","EMAIL":[{"email":"shunlu@sjtu.edu.cn"}],"GEO":[31.22222,121.45806]},{"TITLE":"A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients","CRITERIA":"Inclusion Criteria:\n\n1. Patients with ECOG performance status score of 0 or 1\n2. Histologically or cytologically confirmed diagnosis of relapsed or refractory, locally unresectable advanced or metastatic NSCLC harboring an activating EGFR mutation\n3. Failed standard of care treatments progressed after anti tumor treatments including at least 1 approved EGFR TKI \\[Phase2: TKIs should include the approved EGFR TKIs with activity against T790M (e.g., osimertinib)\\]\n4. Slots may be reserved for patients with certain resistant mutations (i.e., EGFR C797X mutation with or without T790M mutation as required by the sponsor) \\[Phase 1\\]\n5. EGFR C797X mutation with or without T790M mutation \\[Phase 2\\]\n6. Not received more than 1 prior line of platinum based chemotherapy in the metastatic setting \\[Phase 2\\]\n7. Having at least 1 measurable tumor lesion per RECIST v1.1 criteria \\[Phase 2\\]\n8. Having adequate bone marrow, hepatic, and renal function as specified in the protocol\n\nExclusion Criteria:\n\n1. NSCLC with mixed cell histology or a tumor with histologic transformation of small cell elements\n2. Patients having tumor with any additional known driver of alterations\n3. Patients with presence of another active primary malignant tumor that has been diagnosed or required therapy within 2 years prior to the initiation of the study treatment\n4. Patients who have unstable and symptomatic primary CNS tumors\/metastasis, leptomeningeal metastases or spinal cord compression which are not suitable for enrollment, as judged by the Investigator\n5. Patients having clinically active ongoing ILD of any etiology\n6. Clinically significant cardiac conditions, infections, refractory GI diseases as specified in the protocol\n7. Patients having any unresolved toxicities from prior anti tumor therapy and surgery greater than CTCAE Grade 1 at the time of starting the study treatment\n8. Recent anticancer therapy: EGFR-TKI, Immunotherapy or any other systemic anticancer therapy or radiotherapy (specific duration prior to starting study medication per protocol)","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06186076006","EMAIL":[{}],"GEO":[37.566,126.9784]},{"TITLE":"SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations","CRITERIA":"Inclusion Criteria:\n\n* Male or female, aged at least 18 years, younger than 75 years.\n* Histologically confirmed diagnosis of primary non-small lung cancer (NSCLC) on predominantly non-squamous histology.\n* Before surgery or randomization, MRI or CT scan of the brain and bone scan must be done to exclude metastases.\n* Complete resection (R0) and systematic lymphadenectomy are mandatory: all surgical margins must be negative for tumor, and there should be no extranodal invasion of the mediastinal lymph nodes or marginal lymph nodes.\n* Patients with postoperative pathological confirmation of stage II, IIIA and IIIB (only T3N2M0) are eligible.\n* Patients must harbor one of the two common sensitizing EGFR mutations (Ex19del, L858R), either alone or in combination with other EGFR mutations including T790M, the mutations should be confirmed by the central laboratory.\n* Complete recovery from surgery and standard post-operative therapy (if applicable) at the time of randomization.\n* A ECOG performance status equal to 0-1 with a minimum life expectancy of 12 weeks and no deterioration over the past 2 weeks.\n* Adequate bone marrow reserve or organ function, as demonstrated by the following laboratory values (no corrective treatment allowed within one week before blood sampling):\n\n  1. Absolute neutrophil count (ANC\uff09\u22651.5\u00d710\\^9 \/L\n  2. Platelet count \u2265100\u00d710\\^9 \/L\n  3. Hemoglobin \u226590 g\/L\n  4. Alanine aminotransferase (ALT) \u2264 2.5 \u00d7 upper limit of normal (ULN) if no demonstrable liver metastases or \u2264 5 \u00d7 ULN in the presence of liver metastases\n  5. Aspartate aminotransferase (AST) \u2264 2.5 \u00d7 ULN if no demonstrable liver metastases or \u2264 5 \u00d7 ULN in the presence of liver metastases\n  6. Total bilirubin (TBL) \u2264 1.5 \u00d7 ULN if no liver metastases or \u2264 3 \u00d7 ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases\n  7. Creatinine \u2264 1.5 \u00d7 ULN concurrent with creatinine clearance \u2265 50 mL\/min (measured or calculated by the Cockcroft-Gault equation); confirmation of creatinine clearance is only required when creatinine is \u2264 1.5\u00d7ULN\n  8. Serum albumin (ALB) \u226528 g\/L\n  9. Coagulation function: International standardized ratio (INR) \u22641.5, activated partial thromboplastin time (APTT) \u22641.5\u00d7ULN\n* Females of child-bearing potential should be using adequate contraceptive measures throughout the study, should not be breast feeding during the study and until 6 months after treatment, and must have a negative pregnancy test prior to start of dosing.\n* Male patients should be willing to use barrier contraception during the study and until 6 months after treatment.\n* Patients must sign and date written informed consent prior to admission to the study.\n\nExclusion Criteria:\n\n* Patients with unresectable or metastatic lesions, residual lesions after surgery, or those who have had only segmentectomies or wedge resection.\n* Giant mediastinal lymph node metastasis at a single station or mediastinal lymph node fusion into a cluster at multiple stations; lesions invade the heart, aorta, esophagus, or pulmonary veins; Carcinoma of superior lung sulci.\n* Treatment with any of the following (except for standard platinum -based adjuvant chemotherapy), including any EGFR-TKI, systemic chemotherapy\uff0cimmunotherapy, targeted therapy and anti-tumor traditional Chinese medicine therapy.\n* Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study drug.\n* The patient is currently using (or cannot discontinue at least 1 week before the first dose of study drug) a drug or herbal supplement known as a potent inhibitor or inducer of CYP3A4.\n* Severe infections occurred within 4 weeks or active infections that received therapeutic intravenous or oral antibiotics within 2 weeks before the first dose.\n* Any evidence of active infection (including hepatitis B, hepatitis C, and human immunodeficiency virus).\n* Patients received continuous steroid therapy for more than 30 days within 30 days before the first dose; require long-term (\u226530 days) steroid therapy; with acquired or congenital immunodeficiency diseases or have a history of organ transplantation.\n* Severe or uncontrolled systemic diseases, including hypertension or diabetes.\n* Any of the following cardiac criteria:\n\n  1. Mean resting corrected QT interval (QTcF) \\> 470 msec obtained from 3 electrocardiograms (ECGs), using the Screening clinic's ECG machine and Fridericia's formula for QT interval correction.\n  2. Any clinically important abnormalities in rhythm, conduction, or morphology of the resting ECG (e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, PR interval \\>250 msec).\n  3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval.\n  4. Left ventricular ejection fraction (LVEF) \\<50%.\n* Receiving or requiring drugs known to prolong the QT interval or possibly cause tip torsion ventricular tachycardia during the study.\n* History of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.\n* History of any other malignant tumor within five years (except clinically cured cervical carcinoma in situ, basal cells or squamous epithelial skin cancer).\n* Any seriously abnormal gastrointestinal function would affect uptake, transport and absorption of the drug, such as inability to swallow the study medication, refractory nausea and vomiting, previous significant bowel resection, Recurrent diarrhea, atrophic gastritis (age \\< 60 years), unhealed serious gastric diseases, Crohn's disease or ulcerative colitis.\n* History of hypersensitivity to any active or inactive ingredient of SH-1028 or drug with a similar chemical structure or class to SH-1028.\n* Any severe and uncontrolled ocular disease that may, in the Investigator's opinion, present a specific risk to the patient's safety.\n* Participating in another clinical trial within 4 weeks before the first dose (excluding retrospective observational studies without intervention); within 5 half-lives of other study drugs.\n* Hepatic encephalopathy, hepatorenal syndrome, or \u2265Child-Pugh grade B cirrhosis.\n* Lactating Women.\n* Any disease or condition that, in the opinion of the Investigator, would compromise the safety of the patient or interfere with study assessments.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06080776001","EMAIL":"caokun@sanhome.com","GEO":[31.22222,121.45806]},{"TITLE":"A Clinical Imaging Study of the Changes in [18F]F-AraG Uptake Following Anti-PD-1 Therapy in Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Histologically confirmed NSCLC, a histological biopsy is mandatory, negative for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations\n* Be willing to provide either archival biopsy or fresh biopsy at screening.\n* Stage IIIB-IV patients that are planned to be treated with anti-PD-1 monotherapy\n* High PD-L-1 expression (\u226550% TPS)\n* No prior systemic therapy for the treatment of cancer\n* Be willing and able to provide written informed consent for the trial.\n* Have a performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale\n* Be above 18 years of age on day of signing informed consent.\n\nExclusion Criteria:\n\n* Subjects with a condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of day 0. Inhaled or topical steroids, and adrenal replacement steroid \\>10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.\n* Untreated or symptomatic brain metastases\n* Additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.\n* Evidence of interstitial lung disease or active, non-infectious pneumonitis.\n* Active infection requiring systemic therapy.\n* A history of Human Immunodeficiency Virus (HIV) (HIV 1\/2 antibodies).\n* Active Hepatitis B or C.\n* Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Patient is pregnant or breastfeeding or expecting to conceive within the projected duration of the trial, starting with the screening visit through 12 weeks after the last administration of \\[18F\\]F-AraG.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05701176001","EMAIL":[{"email":"i.bahce@amsterdamumc.nl"}],"GEO":[52.37403,4.88969]},{"TITLE":"A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)","CRITERIA":"Inclusion Criteria:\n\n* Has a histologically or cytologically confirmed diagnosis of locally advanced, unresectable NSCLC (not eligible for curative surgery and\/or definitive radiotherapy with or without chemotherapy), or Metastatic NSCLC\n* Has not received prior systemic therapy for their locally advanced or metastatic NSCLC.\n* Provides a fresh tumor tissue sample obtained at the time of or after the initial diagnosis of locally advanced or metastatic NSCLC.\n* Has a PD-L1-high (Tumor cells \\[TC\\] \u226550%) tumor\n* Has measurable disease (at least 1 target lesion) based on RECIST 1.1\n* Has an Eastern Cooperative Oncology Group (ECOG) Performance status (PS) score of 0 or 1.\n* Has adequate organ function\n\nExclusion Criteria:\n\n* Has NSCLC with a tumor that harbors any of the following molecular alterations:\n\n  1. Epidermal growth factor receptor (EGFR) mutations that are sensitive to available targeted inhibitor therapy\n  2. Anaplastic lymphoma kinase (ALK) translocations that are sensitive to available targeted inhibitor therapy\n  3. Any other known genomic aberrations or oncogenic driver mutations for which a locally approved targeted therapy is available for first line treatment of locally advanced or metastatic NSCLC.\n* Has had surgery within 4 weeks of the first dose of study intervention and has not recovered from AEs (i.e., has any ongoing surgery-related events \u2265 Grade 1)\/complications related to surgery or has received lung radiation therapy of \\>30 gray (Gy) within 6 months\n* Has received prior therapy with any immune checkpoint inhibitors, including antibodies or drugs targeting PD-(L)1, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), T cell immunoglobulin and ITIM domain (TIGIT), or other checkpoint pathways.\n* Has never smoked, defined as smoking \\<100 tobacco cigarettes in a lifetime.\n* Has an invasive malignancy or history of invasive malignancy other than the disease under study within the last 5 years, with the exception of those with a negligible risk of metastasis or death and\/or treated with expected curative outcome.\n* Has symptomatic, untreated, or actively progressin g brain metastases or leptomeningeal disease\n* Has autoimmune disease or syndrome (current or history thereof) that required systemic treatment within the past 2 years.\n* Has received any live vaccine within 30 days prior to first dose of study intervention.\n* Has any history of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis.\n* Has symptomatic ascites, pleural effusion, or pericardial effusion.\n* Has active inflammatory bowel disease\n* Has a history of significant acute or chronic cardiac diagnosis requiring intervention\/treatment in the last 6 months.\n* Has severe infection or complication thereof 4 weeks prior to randomisation including active tuberculosis.\n* Has a history of allogeneic tissue\/stem cell transplant or solid organ transplant.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06472076121","EMAIL":[{"email":"GSKClinicalSupportHD@gsk.com"},{"email":"GSKClinicalSupportHD@gsk.com"},{}],"GEO":[52.37403,4.88969]},{"TITLE":"Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB","CRITERIA":"Inclusion Criteria:\n\n1. Primary non-small cell lung cancer confirmed by cytology or histology\n2. According to the TNM stage (8th Edition) of IASLC lung cancer, it is determined to be IIB-IIIB stage non-small cell lung cancer, which is considered to be resectable;\n3. There must be at least one evaluable focus judged according to recist1.1 standard (the longest diameter on spiral CT is at least 10 mm, and the longest diameter on general CT is at least 20 mm)\n4. ECOG PS 0 or 1\n5. There are tumor samples available for gene detection (EGFR \/ ALK \/ ros1) and PD-L1 immunohistochemistry (IHC) in the subjects, and the tumor samples should be obtained within 3 months before enrollment.\n6. If all suspected mediastinal lymph nodes (including those with pathological enlargement or FDG concentration on PET \/ CT) can be examined by EBUS, thoracoscopy or mediastinoscopy, further sampling is required for pathological confirmation.\n7. Male or female, \u2265 18 years old\n8. Adequate blood function: absolute neutrophil count (ANC) \u2265 2 \u00d7 109 \/ L, platelet count \u2265 100 \u00d7 109 \/ L and hemoglobin 110 \u2265 9 g \/ dl\n9. Adequate liver function: total bilirubin \u2264 upper limit of normal value (ULN); AST and alt \u2264 upper limit of normal value (ULN); alkaline phosphatase \u2264 upper limit of normal value (ULN)\n10. Adequate renal function: serum creatinine \u2264 upper limit of normal value (ULN) or calculated creatinine clearance \u2265 60ml \/ min\n11. No anti-tumor drug treatment in the past\n12. For patients who have had previous surgery, it is required that more than 4 weeks have passed since the start of study treatment, and the patients have recovered\n13. Women with a full uterus must have negative pregnancy test results within 28 days before entering the study (unless it is 24 months after amenorrhea). If the pregnancy test is more than 7 days from the first administration, a urine pregnancy test is required for verification (within 7 days before the first administration)\n14. Sign the informed consent form (the informed consent form needs to be approved by the independent ethics committee, and the informed consent of the patient should be obtained before starting any substantive trial procedure)\n\nExclusion Criteria:\n\n1. Have other malignant tumors in the last 5 years\n2. AST and \/ or ALT \\> 2.5 times of the upper limit of normal value (ULN), with alkaline phosphatase \\> 5 times of the upper limit of normal value (ULN)\n3. Previously received radiotherapy\n4. Previously used chemotherapy drugs, targeted and immunotherapy drugs (except bisphosphonates)\n5. There are any uncontrolled systemic diseases, including active infection, uncontrolled hypertension, diabetes, unstable angina, congestive heart failure, myocardial infarction (within 1 year before treatment), serious arrhythmia requiring drug treatment, liver, kidney and metabolic diseases\n6. Women in pregnancy or lactation\n7. The patient (male or female) has the possibility of childbearing but is unwilling or does not take effective contraceptive measures\n8. Receive the experimental treatment of other clinical studies at the same time (in the treatment period of clinical studies)\n9. Known to be allergic to possible chemotherapy drugs\n10. There is evidence of other diseases, neurological or metabolic dysfunction, abnormal physical examination or laboratory examination, and it is suspected that there may be a high risk of contraindications to the study drug or complications related to treatment","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"04197076001","EMAIL":[{}],"GEO":[31.22222,121.45806]},{"TITLE":"A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations","CRITERIA":"Inclusion Criteria:\n\n1. Resectable stage IIIA NSCLC, EGFR mutation-negative and ALK rearrangement negative (8th UICC TNM staging);\n2. No prior anti-tumor therapy for NSCLC;\n3. Age from 18 to 75 years old;\n4. Adequate organ function:\n\n   Hemoglobin \u22659.0g\/L; White blood cell count 4.0\\~10\u00d7109\/L; The absolute value of neutrophils (ANC) \u2265 1.5\u00d7109\/L; Platelet count \u2265100\u00d7109\/L; Total bilirubin \u2264 1.5 times the upper limit of normal; ALT and AST\u22642.5 times the upper limit of normal; The international normalized ratio of prothrombin time is \u22641.5 times the upper limit of normal value, and the partial thromboplastin time is within the range of normal value; Creatinine \u2264 1.5 times the upper limit of normal;\n5. No chemotherapy, radiotherapy or hormone therapy for malignant tumors, no history of other malignant tumors, excluding patients who have received hormone therapy for prostate cancer and have had DFS for more than 5 years;\n6. ECOG 0\uff5e1;\n\nExclusion Criteria:\n\n1. Double primary or multiple primary NSCLC;\n2. EGFR mutation or ALK mutation was positive\n3. patients with psychosis;\n4. Pre-existing or coexisting bleeding disorders;\n5. Other uncontrollable and inoperable patients;\n6. Patients whose previous operations have prevented this operation from being performed;\n7. Female patients who are pregnant or breastfeeding;\n8. For patients who are allergic to the drugs in the program.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05157776001","EMAIL":[{"email":"fan_jiang@tongji.edu.cn"},{}],"GEO":[31.22222,121.45806]},{"TITLE":"Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients","CRITERIA":"Inclusion Criteria:\n\n1. Age: 18-75 years old.\n2. Gender: both men and women are acceptable, as balanced as possible.\n3. Patients with lung adenocarcinoma who underwent R0 resection and were clinically confirmed as IA2-IB by histopathology and whose tumor size was (1-4cm), the surgical tissue samples tested positive for EGFR-sensitive mutations and positive for MRD after surgery.\n4. Accompanied by arbitrary \u2265 2 high-risk factors; High risk factors such as pleural invasion, airway diffusion, vascular infiltration, low differentiation, pathological micropapillary composition \u2265 15%, complex glandular composition \u2265 20%, etc.\n\n4. Achieve R0 resection: For CTR \\< 50% ground glass nodules, wedge resection is acceptable and the margin is negative, and 3 groups of lymph node biopsies are negative; for CTR \u2265 50% or pure solid nodules, at least segmental resection is undergone, and lymph node dissection is systematically performed; if there is no clear evidence of metastasis, if it cannot be judged, it can be determined by an independent review committee for pathological consultation.\n\n5. The ECOG behavioral status score is 0 to 1, and the expected survival time is \\> 1 year.\n\n6. Voluntary MRD screening and voluntary befortinib adjuvant therapy; 7. Have a certain organ system function, defined as follows, based on the researcher's experience A. Absolute neutrophil count (ANC) \u2265 1.5 x 109\/L B. Platelets \u2265 100 x 109\/L; C. Hemoglobin \u2265 9 g\/dL (\u2265 90 g\/L) Note that in order to achieve the required hemoglobin level, blood transfusion is allowed; D. Total bilirubin \u2264 1.5 times the upper limit of normal (ULN); E. If there is no liver metastasis, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u2264 2.5 \u00d7 ULN; if liver metastasis, \u2264 5 \u00d7 ULN; F. Creatinine \u2264 1.5 x ULN. Patients are still eligible for inclusion if the creatinine clearance value calculated by the Cockcroft-Gault method is \u2265 50 mL\/min (0.83 mL\/s).\n\n8. Female subjects of childbearing age must have a serum pregnancy test within 3 days before the start of the study drug, and the result is negative, and they are willing to use a medically approved high-efficacy contraceptive method (such as intrauterine devices, contraceptives or condoms) during the study period and within 3 months after the last administration of the study drug; for significant other male subjects who are women of childbearing age, they should be surgically sterilized, or agree to use effective methods of contraception during the study period and within 3 months after the last study dose.\n\n9. Voluntary and capable of following the test and follow-up procedures. 10. Sign the informed consent form.\n\nExclusion Criteria:\n\n1. There is any other treatment before the operation, and no informed consent is signed;\n2. The patient has been diagnosed with cancer within 2 years;\n3. Have a history of interstitial lung disease, drug-induced interstitial disease or any active interstitial lung disease with clinical evidence; CT scan at baseline revealed idiopathic pulmonary fibrosis.\n4. Patients who are known to be allergic to any component of befortinib or similar drugs;\n5. Pregnant or lactating women;\n6. Situations considered unsuitable for inclusion by other researchers.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06561620001","EMAIL":[{"email":"hqchen1@yahoo.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Signed informed consent\n* Subjects must be \u2265 18 years of age ( \u2265 20 years of age for Taiwan site)\n* Subject with advanced or metastatic solid tumors that is not amenable to surgical resection and is not eligible or has refused other approved therapeutic options that have demonstrated clinical benefit.\n* Histologically confirmed HER2 expression.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status \u2264 1\n* Measurable or non-measurable evaluable disease according to RECIST 1.1\n* Adequate hematologic and end-organ function at baseline\n* Oxygen saturation via pulse oxygenation \u2265 90% at rest on room air\n\nExclusion Criteria:\n\n* Untreated central nervous system (CNS) metastases\n* Multiple primary malignancies\n* Clinically significant cardiovascular disease such as New York Heart Association (NYHA) cardiac disease (class III or greater)\n* Pregnant or lactating female\n* Serious, uncontrolled medical disorder that, in the opinion of the Investigator, would impair the ability of the subject to receive study treatment\n* History of autoimmune or immune mediated symptomatic disease\n* Any anti-cancer chemotherapy or targeted small molecule therapy, or experimental therapy\/device within 4 weeks or 5 half-lives of the drug prior to planned start of the study","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04319757003","EMAIL":"clinical@acepodiabio.com","GEO":[25.04776,121.53185]},{"TITLE":"PhI\/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Written informed consent and HIPAA authorization for release of personal health inf ormation prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.\n2. Age \u2265 18 years at the time of consent.\n3. Histologically or cytologically confirmed non-small cell lung cancer.\n4. Locally advanced or metastatic disease, not amenable to curative surgery or radiotherapy.\n5. Patients must have one of the following:\n\n   * NSCLC which harbors MET Exon 14 skipping alterations detected in the tissue or ctDNA (safety cohort and cohort A \\[MET ex14 TKI-na\u00efve\\] and B \\[MET ex14 TKI-refractory\\])\n   * MET gene amplification determined in tissue by next-generation sequencing (NGS) as copy-number gain (CNG\\>=10) or FISH assay (MET:CEP7\\>=2.0) (safety cohort and cohort C \\[MET amplification or overexpression cohort\\]\n   * MET gene amplification determined in ctDNA (definition of gain per ctDNA testing platform) (safety cohort and cohort C \\[MET amplification or overexpression cohort\\]\n   * MET overexpression by IHC 3+ (safety cohort and cohort C \\[MET amplification or overexpression cohort\\]\n6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n7. Measurable disease per RECIST 1.1.\n8. Patients with brain metastases are eligible if they are asymptomatic, are treated, or are neurologically stable for at least two weeks without the use of steroids or on stable or decreasing dose of \u2264 15 mg daily prednisone (or equivalent).\n9. Ability to take pills by mouth.\n10. Previous treatment with cytotoxic chemotherapy or immunotherapy is allowed.\n11. Patients must have adequate bone marrow and organ functions.\n\n    * Hemoglobin \u226510 g\/dL\n    * ANC \u22651.5 x 109 \/L\n    * Platelets \u226575 x 10 9 \/L\n    * AST and ALT \u22643 x ULN\n    * Total bilirubin \u22641.5 x ULN; subjects with Gilbert's syndrome can enroll if conjugated bilirubin is within normal limits\n    * Serum creatinine \\<1.5 x ULN or if available, calculated or measured creatinine clearance \\>50 mL\/min\/1.73 m2 ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST = aspartate aminotransferase; ULN = upper limit of normal\n12. A woman of childbearing potential must have a negative serum pregnancy test at screening and within 7 days of the first dose of study treatment and must agree to further serum or urine pregnancy tests during the study.\n13. A woman must be compliant with the Contraceptive Guidance and Collection of Pregnancy Information:\n\n    1. Not of childbearing potential\n    2. Of child-bearing potential and practicing true abstinence during the entire period of the study, including up to 6 months after the last dose of study treatment is given\n    3. Of childbearing potential and practicing 2 methods of contraception, including 1 highly effective user independent method and a second method.\n\n    Participant must agree to continue contraception throughout the study and through 6 months after the last dose of study treatment.\n\n    \u2022 Note: If the childbearing potential changes after start of the study (eg, woman who is not heterosexually active becomes active, premenarchal woman experiences menarche) the woman must begin birth control, as described above.\n14. A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 6 months after receiving the last dose of study treatment.\n15. A man must wear a condom when engaging in any activity that allows for passage of ejaculate to another person during the study and for 6 months after receiving the last dose of study treatment. A man who is sexually active with a woman of childbearing potential must agree to use a condom with spermicidal foam\/gel\/film\/cream\/suppository and his partner must also be practicing a highly effective method of contraception (ie, established use of oral, injected, or implanted hormonal methods of contraception; placement of an intrauterine device \\[IUD\\] or intrauterine hormone-releasing system \\[IUS\\]).\n\n    If the participant is vasectomized, he must still use a condom (with or without spermicide) for prevention of passage of exposure through ejaculation, but his female partner is not required to use contraception.\n16. A male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum of 6 months after receiving the last dose of study treatment.\n17. Participant must be willing and able to adhere to the lifestyle restrictions specified in this protocol.\n\nExclusion Criteria:\n\n1. For cohort A (METex14 TKI-na\u00efve only), prior targeted therapy to c-MET is not allowed, which includes small molecule TKIs, such as tepotinib, capmatinib, savolitinib, or crizotinib. Prior amivantamab is also not allowed.\n2. Patients whose tumor harbors other oncogene-driver mutations, such as EGFR mutation, KRASG12C mutation, ALK-fusion, with prior targeted therapies, such as osimertinib, sotorasib, and other TKI, are not allowed.\n3. Positive hepatitis B (hepatitis B virus \\[HBV\\]) surface antigen (HBsAg) Note: Subjects with a prior history of HBV demonstrated by positive hepatitis B core antibody are eligible if they have at Screening 1) a negative HBsAg and 2) a HBV DNA (viral load) below the lower limit of quantification, per local testing. Subjects with a positive HBsAg due to recent vaccination are eligible if HBV DNA (viral load) is below the lower limit of quantification, per local testing.\n4. Positive hepatitis C antibody (anti-HCV). Note: Subjects with a prior history of HCV, who have completed antiviral treatment and have subsequently documented HCV RNA below the lower limit of quantification per local testing are eligible.\n5. Other clinically active or chronic liver disease.\n6. Participant is positive for human immunodeficiency virus (HIV), with 1 or more of the following:\n\n   * Receiving ART that may interfere with study treatment (consult with Principal Investigator for review of medication prior to enrollment)\n   * CD4 count \\<350 at screening\n   * AIDS-defining opportunistic infection within 6 months of start of screening\n   * Not agreeing to start ART and be on ART\\>4 weeks plus having HIV viral load \\<400 copies\/mL at end of 4-week period (to ensure ART is tolerated and HIV controlled).\n7. Participant has active cardiovascular disease including, but not limited to:\n\n   * A medical history of deep vein thrombosis or pulmonary embolism within 1 month prior to first dose of study drug or any of the following within 6 months prior to the first dose of study drug: myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary\/peripheral artery bypass graft, uncontrolled hypertension, clinically significant cardiac arrythmia, or any acute coronary syndrome. Clinically non-significant thrombosis, such as non-obstructive catheter-associated clots, incidental or asymptomatic pulmonary embolism, are not exclusionary.\n   * Congestive heart failure (CHF), defined as New York Heart Association (NYHA) class III-IV or hospitalization for CHF (any NYHA class; refer to Appendix: New York Heart Association Criteria) within 6 months of study Day 1.\n8. Subject has uncontrolled inter-current illness, including but not limited to poorly controlled diabetes, ongoing or active infection (i.e., has discontinued all antibiotics for at least one week prior to first dose of study drug), or psychiatric illness\/social situation that would limit compliance with study requirements. Subjects with medical conditions requiring chronic continuous oxygen therapy are excluded.\n9. Any ophthalmologic condition that is clinically unstable (consult with Principal Investigator for review of the condition prior to enrollment).\n10. Participant has an active or past medical history of ILD\/pneumonitis, including drug-induced or radiation ILD\/pneumonitis.\n11. Immune-mediated rash from prior treatment that has not resolved prior to enrollment.\n12. Any unresolved toxicities from prior therapy greater than CTCAE grade 1 (with the exception of alopecia grade 2) at the time of starting study treatment.\n13. Participant has concurrent or prior malignancy other than the disease under study. The following exceptions require consultation with the Medical Monitor:\n\n    1. Non-muscle invasive bladder cancer (NMIBC) treated within the last 24 months that is considered completely cured. b. Skin cancer (non-melanoma or melanoma) treated within the last 24 months that is considered completely cured. c. Non-invasive cervical cancer treated within the last 24 months that is considered completely cured.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06083857001","EMAIL":[{"email":"xle1@mdanderson.org"},{}],"GEO":[29.76328,-95.36327]},{"TITLE":"A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment","CRITERIA":"Inclusion Criteria:\n\nThe main patient entry criteria included: age\u2265 18 years ; histologically and cytologically proved NSCLC; Eastern cooperative oncology group performance status (ECOG PS)\u22642; adequate hematological , renal, and hepatic functions. Exclusion Criteria:\n\nuncontrolled systemic disease ,any evidence of clinically active interstitial lung diseases, and other chemotherapy at the time of inclusion. The protocol was approved by the Ethical Committee of Cancer Center of Sun Yat-Sen University (CCSU), and written informed consent was obtained form each patient.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":85,"SS_ID":"01994057001","EMAIL":[{"email":"xshuang@mail2.sysu.edu.cn"},{"email":"guanshx6@mail.sysu.edu.cn"},{}],"GEO":[23.11667,113.25]},{"TITLE":"Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors","CRITERIA":"Inclusion Criteria:\n\n1. Histologically confirmed NSCLC, positive for non-exon20insertion uncommon EGFR mutations that are eligible for afatinib therapy in first line\n2. WHO PS 0-2\n3. Be willing and able to provide written informed consent for the trial.\n4. Be above 18 years of age on day of signing informed consent.\n5. Patients must have radiological measurable disease\n6. Demonstrate adequate organ function, as deemed acceptable by the treating physician in the context of metastatic NSCLC.\n\nExclusion Criteria:\n\n1. Inability to provide informed consent\n2. Inability to take study medications\n3. Patients with symptomatic or unstable CNS metastases\n4. Prior EGFR TKI or platinum-doublet therapy for advanced stage NSCLC. Prior (neo)adjuvant treatments are allowed when the last administration is one year or more.\n5. Evidence of interstitial lung disease or active, non-infectious pneumonitis.\n6. Active infection requiring systemic therapy.\n7. Active Hepatitis B or C.\n8. Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n9. Patient is pregnant or breastfeeding, or expecting to conceive within the projected duration of the trial, starting with the screening visit.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05298176001","EMAIL":[{"email":"long@vumc.nl"},{}],"GEO":[52.37403,4.88969]},{"TITLE":"TATE and Pembrolizumab (MK3475) in mCRC and NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Liver metastatic MSS-mCRC or NSCLC without EGFR or AKT mutations\n* mCRC progressed on at least two lines of standard chemotherapy; or\n* NSCLC progressed on chemotherapy and an immune checkpoint inhibitor\n* Measurable disease\n* ECOG 0-1\n* At least 4 weeks from prior chemotherapy and free from chemo-related toxicity\n* Adequate organ function\n\nExclusion Criteria:\n\n* Prior organ transplantation\n* Liver metastasis more than 50%\n* Oxygen saturation less than 92% in room air\n* Prior autoimmune disorder\n* CNS metastasis\n* Major GI bleeding in the last 2 months","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04701476003","EMAIL":[{"email":"sandy6618@teclison.com"}],"GEO":[24.1469,120.6839]},{"TITLE":"Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. The subject voluntarily joins the study, can complete the signing of the informed consent form, and has good compliance;\n2. Age from 18 to 80 years old (when signing the informed consent form), both male and female;\n3. According to the 8th edition of the TNM staging classification of lung cancer by the International Association for the Research of Lung Cancer and the American Joint Committee on Cancer Classification, the driver gene (EGFR\/ALK\/ROS1) is negative and untreated patients with stage IIIB to IV NSCLC;\n4. Archived tumor tissue samples or newly obtained (without anti-tumor treatment since the biopsy) core or tumor lesions (not receiving radiotherapy) excised biopsy tissue have been provided. Formalin-fixed and paraffin-embedded (FFPE) tissue blocks are better than sections. The newly obtained biopsy tissue is better than the archived tissue, and the tissue samples are tested by immunohistochemistry for PD-L1 \u2265 1%;\n5. According to the evaluation criteria for the efficacy of solid tumors (RECIST Version 1.1), there is at least one imaging measurable lesion; that is, in CT or MRI detection, the longest diameter of a single lesion is \u226510mm, or the lymph node is pathologically enlarged, and a single lymph node is scanned by CT Short diameter \u226515mm;\n6. The Eastern Cooperative Oncology Group (ECOG) performance status score is 0-1;\n7. The expected survival period is \u22653 months;\n8. Newly treated patients who have not received systematic anti-tumor therapy, including radiotherapy and chemotherapy, targeted and immunotherapy, or patients who relapse after follow-up after adjuvant chemotherapy for more than 6 months;\n9. With sufficient organ and bone marrow function, the laboratory test values within 7 days before entry into the group meet the following requirements (no blood components, cell growth factors, albumin and other corrective treatment drugs are allowed within the first 14 days of obtaining laboratory tests ),details as follows:\n\n1) Blood routine: absolute neutrophil count (ANC) \u22651.5\u00d7109\/L, platelet (PLT) \u226575\u00d7109\/L, hemoglobin (HGB) \u226590 g\/L (no blood transfusion or no red blood cells within 14 days) Genin-dependent); 2) Liver function: serum total bilirubin (TBIL) \u22642 times the upper limit of normal (ULN); alanine aminotransferase (ALT) and\/or aspartate aminotransferase (AST) \u22645 times ULN, serum Albumin \u226528 g\/L; Alkaline phosphatase (ALP) \u22645\u00d7ULN; 3) Renal function: Serum creatinine (Cr) \u22641.5\u00d7ULN, or creatinine clearance \u226550 mL\/min (using the standard Cockcroft-Gault formula): urine routine results show urine protein \\<2+; urine routine testing at baseline Patients who show urine protein \u22652+ should be collected for 24 hours and the quantification of 24-hour urine protein should be less than 1g; 4) Coagulation function: International normalized ratio (INR) or prothrombin time (PT) \u2264 1.5 times ULN; if the subject is receiving anticoagulation therapy, as long as the INR is within the intended use range of anticoagulant drugs; 10. For female subjects of childbearing age, a urine or serum pregnancy test should be performed 3 days before receiving the first study drug administration and the result is negative; 11. It is necessary to provide tissue samples for biomarker (such as PD-L1) analysis, preferably newly obtained tissues. Patients who cannot provide newly obtained tissues can provide 3-5\u03bcm-thick paraffin sections of tissues that are archived and saved within 2 years before enrollment. 5-8 sheets.\n\nExclusion Criteria:\n\n1. Imaging (CT or MRI) shows that the tumor has invaded large blood vessels or those who are judged to be very likely to invade important blood vessels and cause fatal hemorrhage during the follow-up study;\n2. Currently participating in interventional clinical research treatment, or receiving treatment with other research drugs or research devices within 4 weeks before the first administration;\n3. Received Chinese patent medicines with anti-tumor indications or immunomodulatory drugs (thymosin, interferon, interleukin, etc.) within 2 weeks before the first administration, or received major surgery within 3 weeks before the first administration;\n4. There are active hemoptysis, active diverticulitis, abdominal abscess, gastrointestinal obstruction and peritoneal metastasis that require clinical intervention;\n5. Regardless of the severity, patients with any signs of bleeding or medical history; patients with any bleeding or bleeding event \u2265 CTCAE level 3 within 4 weeks before enrollment, unhealed wounds, ulcers or fractures;\n6. Grade III-IV congestive heart failure (New York Heart Association classification), poorly controlled and clinically significant arrhythmia;\n7. Any arterial thrombosis, embolism or ischemia, such as myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack, occurred within 6 months before being selected for treatment;\n8. Known to have allergic reactions to the drug in this study;\n9. Patients who require long-term systemic use of corticosteroids. Patients who require intermittent use of bronchodilators, inhaled corticosteroids, or local injections of corticosteroids due to COPD and asthma can be included in the group;\n10. Symptomatic central nervous system metastasis. Patients with asymptomatic brain metastases or brain metastases with stable symptoms after treatment can participate in this study as long as they meet all the following criteria: there are measurable lesions outside the central nervous system; no midbrain, pons, cerebellum, meninges, Medulla oblongata or spinal cord metastasis; maintain a clinically stable state for at least 2 weeks; stop hormone therapy 3 days before the first dose of study drug;\n11. There is an active infection that needs to be treated or systemic anti-infective drugs have been used within one week before the first administration;\n12. Before starting treatment, have not fully recovered from toxicity and\/or complications caused by any intervention (ie, \u2264 Grade 1 or reached baseline, excluding fatigue or hair loss);\n13. Known human immunodeficiency virus (HIV) infection history (ie HIV 1\/2 antibody positive);\n14. Untreated active hepatitis B (defined as HBsAg positive and the number of copies of HBV-DNA detected at the same time is greater than the upper limit of the normal value of the laboratory department of the research center);\n\nNote: Hepatitis B subjects who meet the following criteria can also be included in the group:\n\n1. The HBV viral load before the first administration is less than 1000 copies\/ml (200 IU\/ml), and the subject should receive anti-HBV treatment during the entire study chemotherapy drug treatment period to avoid viral reactivation;\n2. For subjects with anti-HBc (+), HBsAg (-), anti-HBs (-) and HBV viral load (-), there is no need to receive preventive anti-HBV treatment, but close monitoring of virus reactivation is required.\n\n15. Active HCV infected subjects (HCV antibody-positive and HCV-RNA level is higher than the lower limit of detection); 16. Live vaccine has been vaccinated within 30 days before the first administration (cycle 1, day 1); Note: It is allowed to receive inactivated virus vaccine for seasonal influenza within 30 days before the first administration; however, it is not allowed to receive live attenuated influenza vaccine for intranasal administration.\n\n17. Pregnant or lactating women; 18. The medical history or disease evidence, abnormal treatment or laboratory test values that may interfere with the test results, prevent the subjects from participating in the study, or the investigator believes that it is not suitable for inclusion in the group. The investigator believes that there are other potential risks and is not suitable for participation this research.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"05203276001","EMAIL":[{}],"GEO":[34.59845,119.21556]},{"TITLE":"GEMINI-NSCLC: NSCLC Biomarker Study","CRITERIA":"For Cohort 1 Inclusion, the participant has\/is:\n\n* A known or suspected NSCLC treated with curative intent -(surgery with or without perioperative (neoadjuvant or adjuvant) therapy).\n\n  * Suspected NSCLC - Patients with a high index of suspicion for the diagnosis of NSCLC that is resectable may sign informed consent prior to undergoing diagnostic procedure at the discretion of the physician. NCCN Guidelines allow for clinical stage IA cancers to proceed directly to definitive surgery. Per NCCN Guidelines, if a preoperative tissue diagnosis has not been obtained, then an intraoperative diagnosis will be obtained. If a diagnosis of NSCLC is not confirmed and\/or the tumor is not resectable, then the patient will be a screen failure.\n* Undergone or planning to undergo a surgical resection - (Patients with stages I-IIIB who are resectable - per NCCN guidelines of resectability)\n* Both patients who lack molecular abnormalities and those with identified molecular abnormalities may enroll. Choice of perioperative therapy is to follow SOC therapeutic guidelines for the participant's molecular and PD-L1 profile.\n* 18 years old or older\n* Willing and able to provide informed consent\n* Willing to have additional blood samples collected during routine surveillance visits\n* Must submit tumor sample representative of current disease\n\nFor Cohort 1 Exclusion, the participant has\/is:\n\n* Patients with superior sulcus tumors who are candidates for preoperative concurrent chemoradiation.\n* Stage III locally advanced and unresectable patients who are candidates for chemoradiation followed by immunotherapy.\n* It is expected that all patients on the cohort will be treated with a definitive surgical resection. Thus, clinical stage IIIB and IIIC patients who subsequently demonstrate pathologically confirmed N3 nodal disease or T4 N2 or 3 per any confirmatory procedure listed in NCCN guidelines for which definitive chemoradiotherapy rather than surgery is recommended per NCCN Guidelines are not eligible.\n* Patients who receive primary radiation (in lieu of surgery if they are not surgical candidates).\n\nFor Cohort 2 Inclusion, the participant has\/is:\n\n* Histologically documented Stage IV NSCLC (de novo metastatic or relapse setting) not amenable to curative surgery or radiation therapy. Palliative radiation (for instance for impending bony fracture or to control pain) is allowed at any time during the protocol at the physician's discretion.\n* Intended to receive first line immunotherapy (as monotherapy or in combination with chemotherapy). Patients who have had previous exposure to immunotherapy in the neoadjuvant or adjuvant setting are allowed to enroll as long as 12 months have elapsed since the prior exposure.\n\n  * Patients in surveillance on Cohort 1 are eligible to roll over to Cohort 2 at the time of recurrence as long as they have had histologic confirmation of recurrence and have been off immunotherapy for 12 months or greater and meet all other inclusion\/exclusion criteria.\n* Tumors that lack activating EGFR mutations (e.g., exon 19 deletion or exon 21 L858R, exon 21 L861Q, exon 18 G719X, or exon 20 S768I mutation) and ALK fusions. Also, per NCCN Guideline recommended testing, tumors must also lack ROS1, BRAF, NTRK 1\/2\/3, METex14 skipping mutations, and RET for which there is available front-line targeted therapy. Only those patients with KRAS G12C mutations and ERBB2 (HER2) mutations with no contraindications to immunotherapy (PD-L1 1) for which there are no approved front-line targeted therapies and for whom immunotherapy would be the preferred front-line therapy are eligible.\n* Patients may be enrolled with local molecular testing and those results will be provided.\n\n  * Patients may be enrolled with local molecular testing and those results will be provided.\n* 18 years and older\n* Willing and able to provide informed consent\n* Willing to have additional blood samples collected during routine surveillance visits\n* Must submit tumor sample representative of current disease\n\nExclusion Criteria (both Cohorts):\n\n* Patients without a known or suspected NSCLC diagnosis, or other disease processes such as sarcoidosis, lymphoma, or metastatic cancer from other sites.\n* Not willing to have additional blood samples collected\n* Patients with a secondary malignancy must have been both diagnosed \\> 2 years from the lung cancer of interest and have completed all therapy for that malignancy (including extended adjuvant therapy) \\> 2 years prior to diagnosis of the lung cancer of interest with the exception of the following:\n* Patients with superficial basal cell carcinoma of low-risk histology per NCCN Guidelines (Low-risk histologic subtypes include nodular, superficial, and other non-aggressive growth patterns such as keratotic, infundibulocystic, and fibroepithelioma of Pinkus) and low-risk for recurrence per NCCN Guidelines (location on trunk or extremities, size \\< 2 cm, primary (not recurrent), with well-defined borders) can be included even if they are diagnosed \\< 2 years from the lung cancer of interest.\n* Patients with superficial squamous cell carcinoma of low-risk pathology per NCCN Guidelines (verrucous, keratoacanthomatous) and low-risk for recurrence per NCCN Guidelines (located on trunk or extremities; 2 cm in size; primary lesion (vs. recurrent); well to moderately differentiated; \\< 2 mm thick and no invasion beyond subcutaneous fat; negative for perineural invasion; and negative for lymphatic or vascular involvement) can be included even if they are diagnosed \\< 2 years from the lung cancer of interest.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05236114042","EMAIL":[{"email":"jmcole@gundersenhealth.org"},{}],"GEO":[43.80136,-91.23958]},{"TITLE":"A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n1. Voluntary participation in this clinical trial, understanding and following the research protocol, and voluntarily signing the Informed Consent Form (ICF).\n2. Age \u226518 and \u226475, male or female.\n3. Participants with histologically or cytologically confirmed diagnosis of advanced solid tumors who have failed standard therapy or for whom no standard therapy is available.\n4. Participants must have at least one measurable lesion according to RECIST Version1.1\n5. Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1\n6. Hepatocellular carcinoma patients with Child-Pugh score \u2264 7\n7. Expected survival time is at least 3 months\n8. Adequate organ function: neutrophil count\u22651.5\u00d7109\/L,platelet count \u2265100\u00d7109\/L,hemoglobin\u226590g\/L,alanine aminotransferase and aspartate aminotransferase \u22642.5\u00d7upper limit of normal (ULN); patients with hepatocellular carcinoma or concomitant hepatic metastases \u22645.0\u00d7ULN, total bilirubin \u22641.5\u00d7ULN, renal function and cardiopulmonary function are basically normal.\n9. Subjects should provide, whenever possible, freshly obtained or archived tumor tissue sample prior to study treatment that can be used for biomarker analysis\n10. Participants of childbearing potential (males and females) must agree to effective contraception for at least 90 days from the time of signing the informed consent form to the time of the last dose; females of childbearing potential must have a negative blood pregnancy test within 7 days prior to the first dose of the HC010\n\nExclusion Criteria:\n\n1. Receipt of any interventional clinical trial treatment or other systemic chemotherapy, radiotherapy, etc. within 28 days or 5 half-lives (whichever is shorter) prior to the first dose of the HC010; Receipt of herbal or proprietary Chinese medicine with an anti-tumor indication within 2 weeks prior to the first dose of HC010;\n2. Underwent surgery, experienced severe trauma, etc,within 4 weeks prior to the first administration of HC010 ;\n3. Receipt of systemic glucocorticoids (prednisone \\>10 mg\/day or equivalent doses of similar drugs) or other immunosuppressive agents within 2 weeks prior to the first dose of HC010;\n4. Receipt of immunomodulatory drugs within 2 weeks prior to the first dose of HC010;\n5. Receipt of live attenuated vaccination within 4 weeks prior to the first dose of HC010;\n6. Patients who have received biomolecule therapy for anti-programmed death receptor 1 (PD-1)\/programmed death ligand (PD-L1), anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4), and anti-vascular endothelial growth factor (VEGF) targets in prior antitumor therapy;\n7. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v5.0 Grade\u22641;\n8. History of immune-related adverse event (irAE) leading to permanent discontinuation from prior immunotherapy ,or grade \u22653 toxicity related to anti-angiogenic therapy from prior anti-angiogenic therapy\uff1b\n9. Previous allogeneic hematopoietic stem cell transplantation or organ transplantation\uff1b\n10. Patients with known active brain metastases, or the presence of meningeal metastases, spinal cord compression, or molluscum contagiosum disease\uff1b\n11. Combination of other malignancies within 5 years prior to the first dose; excludes radically treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, papillary thyroid carcinoma and\/or radically resected carcinoma in situ;\n12. Patients with active autoimmune disease, or a history of autoimmune disease\uff1b\n13. Infections: 1) active hepatitis B and C; Note: HBsAg and\/or hepatitis B core antibody (HBcAb) positive individuals with HBV DNA \u2265500 IU\/ml (\u22652000 IU\/ml in patients with hepatocellular carcinoma) tested within 28 days prior to the initiation of treatment are eligible for inclusion.2) known history of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS); 3) known active syphilis; 4) active tuberculosis; 5) active infection within two weeks prior to first dose of HC010;\n14. Unstable systemic disease, including but not limited to, severe cardiovascular disease; pleural effusion, pericardial effusion or peritoneal effusion requiring repeated drainage;\n15. Severe bleeding tendencies or coagulation disorders;\n16. History of non-infectious pneumonia\/interstitial lung disease requiring systemic glucocorticoid therapy;\n17. Females who are pregnant or breastfeeding;\n18. Inappropriate for this study in the opinion of the investigator;\n19. History of systemic hypersensitivity or anaphylaxis to any component of HC010.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06307925001","EMAIL":[{"email":"zhangli@sysucc.org.cn"}],"GEO":[23.11667,113.25]},{"TITLE":"Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC","CRITERIA":"Inclusion Criteria:\n\n* \u226518\uff0cAdvanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology\n* HER 2 Insertion or Amplification\n* First Diagnosis and Treatment\n* Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody\n\nExclusion Criteria:\n\n* Patients received antitumor treatment before\n* Patients with contraindication of chemotherapy\n* Pregnant or breast feeding women","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04324125001","EMAIL":[{"email":"zhangyongchang@csu.edu.cn"}],"GEO":[28.19874,112.97087]},{"TITLE":"NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing","CRITERIA":"Inclusion Criteria:\n\n1. Has provided written informed consent\n2. Patient\\* 18 years or older at time of signing informed consent form\n3. Histologically confirmed NSCLC of squamous or non-squamous histology\n4. Resectable clinical stage II, IIIA and IIIB (T3N2 only) NSCLC (according to UICC 8)\n5. Adequate disease staging by PET and\/or CT as per SOC (performed \u2264 42 days prior initiation of the study treatment)\n6. At least 1 measurable lesion according to RECIST v1.1\n7. ECOG performance status \u2264 1\n8. Adequate lung and cardiac function for curative intend lung resection (R0) according to German S3 guideline\n9. Eligibility to receive a platinum-based neoadjuvant chemotherapy\n10. The patient is willing and able to comply with the protocol for the duration of the study, including hospital visits for treatment and scheduled follow-up visits and examinations.\n11. The patient is willing and able to provide liquid and tissue samples for the accompanying translation project.\n12. Adequate bone marrow and renal function including the following:\n\n    * Hemoglobin \u2265 9.0 g\/dL\n    * Absolute neutrophil count \u2265 1.0 x 109\/L\n    * Platelets \u2265 75 x 109\/L\n    * Calculated creatinine clearance \u2265 30 mL\/min as determined by the Cockcroft-Gault equation\n13. Adequate hepatic function (with stenting for any obstruction, if required) including the following:\n\n    * Serum bilirubin \u2264 3 x institutional upper limit of normal (ULN)\n    * AST (SGOT) \/ ALT (SGPT) and alkaline phosphatase \u2264 2.5x ULN\n14. Female patients who are considered as women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test within 7 days prior to start of trial.\n15. Female patients who are considered as WOCBP must use any contraceptive method with a failure rate of less than 1% per year during the treatment as well as up to 5 months after the last dose of IMP. Male patients who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year during the treatment as well as at least 5 months after the last dose of IMP. Female patients who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile, see section 5.1.5) as well as azoospermic male patients do not require contraception.\n\nExclusion Criteria:\n\n1. Treatment in any other clinical trial with an investigational product within 30 days before screening\n2. Clinical stage I, IIIB (T4N2), IIIC, nodal NSCLC stage cN3 and stage IV NSCLC\n3. Positive testing of activating (TKI-responsive) EGFR-mutation, ROS1-mutation or known ALK fusion oncogene\n4. Expected pneumonectomy at baseline to achieve curative intend resection\n5. Any concurrent chemotherapy, investigational product (IMP), biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer related conditions (e.g. hormone replacement therapy) is acceptable.\n6. Malignancies other than NSCLC within 3 years prior to study inclusion with the exception of malignancies with a negligible risk of metastases or death (5-year OS \\> 90%) like localized prostate cancer, ductal carcinoma in situ, adequately treated carcinoma in situ of the cervix, Stage I uterine cancer, in-situ bladder cancer treated by BCG-Instillation, or non-melanoma skin carcinoma\n7. History of allogeneic tissue \/ solid organ transplant or allogeneic stem cell transplantation\n8. History of active primary immunodeficiency.\n9. Clinical diagnosis of active tuberculosis.\n10. Positive testing for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus (HCV) RNA indicating acute or chronic infection. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible. Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n11. Positive testing for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).\n12. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 5 months after the last dose of atezolizumab\/tiragolumab.\n13. Active or prior documented autoimmune or inflammatory disorders (including but not limited to diverticulitis \\[with the exception of diverticulosis\\], celiac disease, systemic lupus erythematosus, Sarcoidosis, or Wegener's syndrome \\[granulomatosis with polyangiitis\\], Graves' disease, rheumatoid arthritis, hypophysitis, uveitis). The following are exceptions to this criterion:\n\n    * Patients with vitiligo or alopecia\n    * Patients with hypothyroidism (e.g., following Hashimoto's disease) stable on hormone replacement\n    * Patients with controlled Type I diabetes mellitus on an insulin regimen\n    * Any chronic skin condition that does not require systemic therapy\n    * Patients without active disease in the last 5 years may be included but only after consultation with the study physician.\n14. Active, uncontrolled inflammatory bowel disease \\[e.g. ulcerative colitis or Crohn's disease\\]. Patients in stable remission for more than 1 year may be included.\n15. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, interstitial lung disease, gastrointestinal conditions associated with diarrhea, or psychiatric illness\/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.\n16. Current or prior use of immunosuppressive medication within 14 days before the first dose of atezolizumab\/tiragolumab. The following are exceptions to this criterion:\n\n    * Intranasal, inhaled, topical steroids, or local steroid injections (e.g. intra articular injection)\n    * Systemic corticosteroids at physiologic doses not to exceed 10 mg\/day of prednisone or its equivalent\n    * Steroids as premedication for hypersensitivity reactions (e.g. CT scan premedication)\n17. Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and IL-2) within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment\n18. History of idiopathic pulmonary fibrosis, interstitial lung disease, organizing pneumonia, drug-induced pneumonitis, or evidence of active pneumonitis on screening chest Computed Tomography (CT) scan.\n19. Prior treatment with CD137 agonist or immune checkpoint blockade therapies, such as anti-TIGIT, anti-PD-1 and anti-PD-L1 therapeutic antibody\n20. Live vaccine within 30 days prior to first dose of trial treatment\n21. Known allergy or hypersensitivity to any component of the chemotherapy regimen or to the IMP or any constituents of the products\n22. Any co-existing medical condition that in the investigator's judgement will substantially increase the risk associated with the patient's participation in the study.\n23. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities.\n24. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05825625002","EMAIL":[{}],"GEO":[49.40768,8.69079]},{"TITLE":"Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomatic Brain Metastases","CRITERIA":"Inclusion Criteria:\n\n1. Age \u2265 18 years old; patients with metastatic NSCLC with at least one measurable brain metastases, the longest diameter of the brain metastases is 0.5 to 3 cm, and the brain metastases have not received radiotherapy; stable neurological symptoms and\/or are receiving Corticosteroid therapy. In addition, the following conditions are raised:\n\n1. Patients with negative driver-gene mutations who have not received systemic treatment before, and patients who have progressed after receiving neoadjuvant or adjuvant therapy, and the interval between disease progression or recurrence and the end of the last chemotherapy drug treatment is at least 6 months, and is allowed to enter this study;\n2. Patients with known EGFR sensitive mutation, ALK rearrangement or ROS1 fusion must have received at least one EGFR or ALK, ROS1 fusion inhibitor treatment and had disease progression or drug intolerance.\n3. Subjects with neurological symptoms can receive dexamethasone within 10 days before the first treatment, but the total daily dose is stable at no more than 4 mg or other Corticosteroids at the same dose. Subjects with neurologic symptoms but not receiving steroids should experience no seizures within 10 days prior to first treatment.\n\n2. For patients with non-brain oligometastases, according to Response Evaluation Criteria in Solid Tumors Version 1.1 (mRECIST v1.1), there is at least 1 measurable or evaluable lesion in addition to brain metastases.\n\n3. The Eastern Cooperative Oncology Group Physical Status Score (ECOG PS score) is 0-2 points.\n\n4. The patient has a clear mind, can answer correctly, and has basically normal vision, etc., and can cooperate with cognitive function assessment 5. Expected survival time \u2265 12 weeks. 6. The patient has adequate organ and bone marrow functions, as defined below:\n\n1. Blood routine: absolute neutrophil count \u22651.5\u00d7109\/L; platelet count \u2265100\u00d7109\/L; hemoglobin content \u22659.0 g\/dL.\n2. Liver function: serum total bilirubin (TBIL) \u2264 1.5 \u00d7 upper limit of normal (ULN); for patients with HCC, liver metastases, or a history\/suspect of Gilbert syndrome (persistent or recurrent hyperbilirubinemia , mainly high unconjugated bilirubin, no evidence of hemolysis or liver disease), TBIL \u2264 3 \u00d7 ULN; for patients without HCC and liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u2264 2.5 \u00d7 ULN; for patients with HCC or with liver metastases, ALT or AST \u2264 5 \u00d7 ULN.\n3. Renal function: serum creatinine (Cr) \u2264 1.5\u00d7ULN or creatinine clearance (CCr) \u2265 50mL\/min; urine test paper test results show urine protein \\<2+.\n4. Coagulation function: activated partial thromboplastin time (APTT) and international normalized ratio (INR) \u2264 1.5\u00d7ULN.\n\nExclusion Criteria:\n\n1. Receive live attenuated vaccine within 4 weeks before enrollment or plan to receive live attenuated vaccine during the study.\n2. Active, known or suspected autoimmune disease.\n3. Known history of primary immunodeficiency.\n4. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n5. Female patients who are pregnant or breastfeeding.\n6. Untreated acute or chronic active hepatitis B or hepatitis C infection. Patients who are receiving antiviral treatment will be judged by doctors according to the individual conditions of the patients under the condition of monitoring the virus copy number.\n7. History of dementia, Alzheimer's disease, Parkinson's disease and other diseases that can cause cognitive dysfunction\n8. History of schizophrenia, severe anxiety, depression, or other mental illnesses\n9. Uncontrolled concurrent diseases, including but not limited to:\n\n   1. HIV-infected persons (HIV antibody positive).\n   2. Serious infection that is active or poorly controlled clinically.\n   3. Serious or uncontrolled systemic disease (such as severe mental, neurological disease, epilepsy or dementia, unstable or uncompensated respiratory, cardiovascular, hepatic or renal disease, uncontrolled hypertension \\[i.e. Evidence of greater than or equal to CTCAE grade 2 hypertension after drug treatment\\]).\n   4. Active bleeding or new thrombotic disease is taking therapeutic dose of anticoagulant drugs or bleeding tendency","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05638425001","EMAIL":[{"email":"zhourr@csu.edu.cn"}],"GEO":[28.19874,112.97087]},{"TITLE":"Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment","CRITERIA":"Inclusion criteria:\n\n1. Signed and dated written informed consent form (ICF) in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.\n2. Patients \u226518 years of age or over the legal age of consent in countries where that is greater than 18 years at the time of signature of the ICF.\n3. Histologically or cytologically confirmed diagnosis of an advanced and\/or metastatic non-squamous Non-small cell lung cancer (NSCLC).\n4. Documented Human epidermal growth factor receptor 2 (HER2) mutation in the Tyrosine kinase domain (TKD) as per local lab results.\n5. An archival tumor tissue sample must be submitted to the central laboratory after inclusion of the patient to retrospectively confirm the HER2 status. If no archival tissue is available, this may be acceptable in exceptional cases after written agreement with the sponsor.\n6. Patients who have not received any systemic treatment for unresectable, locally advanced or metastatic disease and are not eligible for curative therapy.\n7. Presence of at least one measurable lesion according to Response evaluation criteria in solid tumors (RECIST) 1.1, as determined by the local site investigator\/radiology assessment.\n8. Eligible to receive treatment with the selected platinum-based doublet-chemotherapy (i.e. cisplatin\/pemetrexed or carboplatin\/pemetrexed) and pembrolizumab in accordance with the Summaries of Product Characteristics (SmPC)\/Product Information.\n\nFurther inclusion criteria apply.\n\nExclusion criteria:\n\n1. Previous or concomitant malignancies other than the one treated in this trial within the last 5 years, except;\n\n   * effectively treated non-melanoma skin cancers\n   * effectively treated carcinoma in situ of the cervix\n   * effectively treated ductal carcinoma in situ\n   * other effectively treated malignancy that is considered cured by local treatment\n2. Tumors with targetable alterations with approved available therapy.\n3. Lung-specific intercurrent clinically significant severe illness based on investigators assessment.\n4. Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.\n5. Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to randomization or planned within 6 months after screening, e.g. hip replacement.\n6. Any history of or concomitant condition that, in the opinion of the investigator, would compromise the patient's ability to comply with the trial or interfere with the evaluation of the safety and efficacy of the test drug.\n7. History or presence of cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of \u2265 III or IV, unstable angina or poorly controlled arrhythmia which are considered as clinically relevant by the investigator. Myocardial infarction, stroke, or pulmonary embolism within 6 months prior to randomization.\n8. Any clinically important abnormalities (as assessed by the investigator) in rhythm, conduction, or morphology of resting electrocardiograms, e.g. complete left bundle branch block, third degree heart block.\n\nFurther exclusion criteria apply.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06151574104","EMAIL":[{"email":"unitedkingdom@bitrialsupport.com"}],"GEO":[51.35,-0.2]},{"TITLE":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","CRITERIA":"Inclusion Criteria:\n\n* Pts with solid and hematological malignancies;\n* Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2, HER2\/Neu, Tumor mutational burden\/load (TMB), ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, APC, AR, ATM, ATRX, AURKA, AURKB, BAP1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BTK, CCND1, CCND2, CCND3, CDK4, CDK6, CDKN1A\/B, CEBPA, CHEK1, CHEK2, CSF1R, CTNNB1, DAXX, DDR1\/2, DNMT3A, EGFR, ERBB2, ERBB3, ERBB4, ERCC4, ER, ESR1, FANCA, FAS, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GATA3, GATA6, GNAS, HDAC1, HGF, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR (VEGFR2), KIT, KRAS, MAP2K2 (MEK2), MAP3K1, MCL1, MDM2, MDM4, MEN1, MET, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL (MYCL1), NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PARP1, PARP2, PARP3, PBRM1, PDCD1 (PD1), PDCD1LG2 (PD-L2), PDGFRA, PDGFRB, PIK3C, PMS2, POLD1, POLE, PRDM1, PTCH1, PTEN, RAF1, RB1, RET, RICTOR, ROS1, RPTOR, SDHA\/B\/C, SMAD, SMARC, SMO, STK11, TGFBR2, TP53, TSC1, TSC2, VEGFA, VHL, WT1, ZNF217, ZNF703, CEACAM, NRG1, among others.\n\nThese biomarkers should be determined by local laboratory, external vendor, or next generation sequencing platform\n\n* Decision to consider clinical trial pre-screening enrollment (CTE) by primary provider and\/or patient\n\nExclusion Criteria:\n\n* ECOG PS \\> 2;\n* Abnormal organ function;\n* Hospice enrollment","SEX":"ALL","AGE_MIN":0,"AGE_MAX":200,"SS_ID":"03452774001","EMAIL":[{"email":"support@massivebio.com"}],"GEO":[40.71427,-74.00597]},{"TITLE":"Complication and Lung Function Impairment Prediction Using Perfusion and CT Air Trapping","CRITERIA":"Inclusion Criteria:\n\n* Patient diagnosed with non-small cell lung cancer\n* Indication for pulmonary excision surgery\n* Patient requiring a more recent pre-surgical computed tomography scan (CT scan)\n* The patient has been correctly informed about the study and has signed the consent form\n* The patient is affiliated with or a beneficiary of the French single-payer social security programme (national health insurance)\n\nExclusion Criteria:\n\n* Patient in an exclusion period determined by another protocol\n* Participation in another study that may affect the results of the present study (anti-cancer treatment studies are allowed)\n* Patient under legal or judicial protection\n* Contraindication to surgery or iodine injection\n* Pregnant or lactating women","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03885765001","EMAIL":[{},{},{},{},{},{},{},{}],"GEO":[43.61092,3.87723]},{"TITLE":"Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.","CRITERIA":"Inclusion Criteria:\n\n1. Provision to sign and date the consent form\n2. Stated willingness to comply with all study procedures and be available for the duration of the study\n3. Be a male or female aged 18-100 years\n4. Pathologically confirmed non-small cell lung cancer\n5. Molecular testing through a CLIA-validated NGS assay. This can be done using either tissue based samples or blood-based samples (ctDNA)\n6. ECOG PS 0-2\n7. Decision to be on a particular standard of care TKI or chemotherapy +\/- immunotherapy (clinical decision that would occur prior to study enrollment)\n8. Patients who will be treated with an osteoclast inhibitor must receive dental clearance prior to starting treatment\n9. Bone metastases must be detected through radiographic imaging prior to enrollment on this study.\n\nExclusion Criteria:\n\n1. Actionable driver mutation NSCLC patient who has been on anti-bone resorptive therapy\n\n   a. Excluded anti-bone resorptive therapy includes: zolendronic acid, pamidronate, alendronate, denosumab or any medication that acts as an osteoclast inhibitor\n2. Have any condition or illness that, in the opinion of the investigator, would compromise participant safety or interfere with evaluation while on standard of care treatments for the NSCLC.\n3. Patients with actionable driver mutation who received TKI in past or currently on TKI prior to screening\n4. Bone metastases that have received prior radiotherapy unless unequivocal progression has occurred since radiation therapy","SEX":"ALL","AGE_MIN":18,"AGE_MAX":100,"SS_ID":"03958565001","EMAIL":[{"email":"vincent.p.johnson@cuanschutz.edu"},{}],"GEO":[39.72943,-104.83192]},{"TITLE":"Detection of Circulating Tumor DNA After Stereotactic Ablative Radiotherapy in Patients With Unbiopsied Lung Tumors","CRITERIA":"Inclusion Criteria:\n\n* Age 18 years or older\n* Willing to provide informed consent\n* Undergoing SABR for a solitary pulmonary nodule (SPN) with tissue confirmation or those without tissue confirmation of malignancy, must have a pretreatment likelihood of malignancy of \u2265 60% using either the Herder or Brock models (60% probability was chosen to have a reasonable chance that there will indeed be cancer in the nodule; however, most patients are expected to have a pretreatment probability of \\> 85%).\n* Tumor stage T1-T2b (\u2264 5 cm)\n* No evidence of nodal or distant metastases\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-3\n\nExclusion Criteria:\n\n* Contraindications to radiotherapy\n* Prior history of any invasive malignancy within 5 years, which might interfere with the interpretation of the ctDNA results. Non-melanoma skin cancer is allowed if under appropriate control.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05921474001","EMAIL":"Daniel.Breadner@lhsc.on.ca","GEO":[42.98339,-81.23304]},{"TITLE":"A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Histologically-confirmed diagnosis of stage IV non-squamous or squamous NSCLC.\n* Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 within one month of first vaccine. Target lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.\n* Have completed 3-4 cycles of chemoimmunotherapy, without evidence of progressive disease. Pembrolizumab has to be included in at least 3 of these cycles.\n* Have not received more than 2 cycles of maintenance pembrolizumab and\/or pemetrexed and be a candidate for continuation of this therapy.\n* At least 1 site of disease that could be biopsied during treatment. This site should not be a site that is used to determine measurable disease for efficacy purposes. Lesions that will be biopsied should not be on a previously irradiated area unless progression has been demonstrated in such lesions.\n* Patients must be at least 28 days post systemic steroids prior to enrollment, unless this is a steroid administered concurrently with chemotherapy or used as part of prophylaxis to prevent intravenous (IV) contrast reactions.\n* Patients must have Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0 or 1.\n* Patients must have recovered from major infections and\/or surgical procedures, and in the opinion of a principle investigator (PI)\/co-PI\/study physician\/physician extender, not have any significant active concurrent medical illnesses precluding protocol treatment.\n* Willing to undergo up to two serial biopsies while on study.\n* Estimated life expectancy of more than 6 months.\n* White blood cells (WBC) \\>= 3000\/mm\\^3 (within 60 days of first vaccination).\n* Lymphocyte count \\>= 800\/mm\\^3 (within 60 days of first vaccination).\n* Platelet count \\>= 75,000\/mm\\^3 (within 60 days of first vaccination).\n* Hemoglobin (Hgb) \\>= 9 g\/dl (within 60 days of first vaccination).\n* Serum creatinine =\\< 1.2 mg\/dl or creatinine clearance \\> 50 ml\/min (within 60 days of first vaccination).\n* Total bilirubin =\\< 1.5 mg\/dl (within 60 days of first vaccination).\n* Aspartate aminotransferase\/serum glutamic oxaloacetic transaminase (AST\/SGOT) =\\< 2 times upper limit of normal (ULN) or SGOT =\\< 5 times upper limit of normal (ULN) in the presence of liver metastasis (within 60 days of first vaccination).\n* If female of childbearing potential has a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication.\n* All patients who are having sex that can lead to pregnancy must agree to contraception for the duration of study.\n* Patients must be at least 18 years of age.\n\nExclusion Criteria:\n\n* Patients with any of the following cardiac conditions:\n\n  * Symptomatic restrictive cardiomyopathy\n  * Unstable angina within 4 months prior to enrollment\n  * New York Heart Association functional class III-IV heart failure on active treatment\n  * Symptomatic pericardial effusion\n* Patients with central nervous system (CNS) metastasis that have not been treated. Patients with previously treated brain metastases may participate provided they are clinically stable for at least 4 weeks and, have no evidence of new or enlarging brain metastases and also are off steroids for 2 weeks prior to dosing with study medication.\n* Patients with any contraindication to receiving recombinant human granulocyte-macrophage colony stimulating factor (rhuGM-CSF) based products.\n* Patients with any clinically significant autoimmune disease that requires active treatment with immunosuppressants. Replacement therapy (e.g., thyroxine, insulin) is not considered a form of systemic treatment. Administration of systemic steroids (i.e., for allergic reactions, computed tomography (CT) scans, or the management of immune related adverse events \\[irAEs\\]) is allowed.\n* Has a known history of another prior invasive malignancy within 2 years, except subjects with early stage cancer that has undergone potentially curative therapy with no evidence of that disease recurrence for 2 years since initiation of that therapy.\n* Patients who are simultaneously enrolled in any other treatment study.\n* Patients who are pregnant or breastfeeding.\n* Patients with genetic driver alterations (e.g EGFR, ALK, ROS1, BRAF, MET ex 14, RET) for which targeted treatment exist and are Food and Drug Association (FDA) approved, except if the subject is not eligible or has progressed through those therapies.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05242965002","EMAIL":[{"email":"CVICoordinators@medicine.washington.edu"},{}],"GEO":[47.60621,-122.33207]},{"TITLE":"Phase III Study of AK112 for NSCLC Patients","CRITERIA":"Inclusion Criteria:\n\n1. Ability to understand and voluntarily sign a written informed consent form (ICF), which must be signed before the specified study procedures required for the study are performed.\n2. Males or females aged \u2265 18 to \u2264 75 years at the time of signing informed consent. (For patients from North America and Europe, there will be no upper age cutoff)\n3. ECOG performance status score of 0 or 1.\n4. Expected survival \u22653 months.\n5. Histologically or cytology-confirmed, locally advanced (Stage IIIB\/IIIC) or metastatic (Stage IV) non-squamous NSCLC (according to TNM staging of lung cancer, 8th edition) that cannot be completely resected by surgery and cannot receive radical concurrent\/sequential chemoradiation.\n6. EGFR activation mutations that are confirmed by tumor histology or cytology or blood test before enrollment (eg, exon 18 point mutations, exon 19 deletions, exon 20 point mutations, and exon 21 point mutations). Patients must provide a previous EGFR mutation test report, otherwise tumor tissue samples, peripheral blood samples, or pleural fluid samples will need to be collected for EGFR status testing prior to enrollment.\n7. Prior treatment with EGFR TKI and treatment failure, meeting any of the following requirements: Progression after treatment with first- or second-generation EGFR TKI, and confirmation of absence of T790M mutation after progression (only for patients enrolled in China). Progression after treatment with a third-generation EGFR TKI (eg, osimertinib, ametinib, vometinib). Note, for North America and Europe patients only.\n8. According to RECIST v1.1, there is at least 1 measurable noncerebral lesion.\n9. Adequate organ function determined by the following requirements\n10. Female patients of childbearing age have a negative serum pregnancy test result within 3 days before the first dose\n11. If a female patient of childbearing potential has sex with an unsterilized male partner, the patient must use a highly effective method of contraception from the beginning of screening and must agree to continue using these precautions until 120 days after the last dose of the study drug or until 6 months after the last carboplatin and pemetrexed dose (whichever is longer).\n12. If an unsterilized male patient has sex with a female partner of childbearing potential, the patient must use an effective method of contraception from the beginning of screening to day 120 after the last dose or until 6 months after the last carboplatin and pemetrexed dose (whichever is longer). The decision to stop contraception after this time point should be discussed with investigator.\n\nExclusion Criteria:\n\n1. Histologic or cytopathologic evidence of the presence of a small cell carcinoma component, or a predominantly squamous cell carcinoma.\n2. Patients who have received immune checkpoint inhibitors (eg, anti-PD-1\/L1 antibodies, anti-CTLA-4 antibodies, anti-LAG-3 antibodies, etc.)\n3. Received prior systemic chemotherapy, anti-angiogenic therapy, or more than one prior line of antitumor therapy (other than EGFR inhibitors) for advanced stage (IIIB to IV) NSCLC.\n4. Concurrent enrollment in another clinical study, unless it is a noninterventional clinical study or the follow-up period of the interventional study is more than 4 weeks from the last dose of the prior clinical study or more than 5 half-lives of the prior study drug, whichever is shorter.\n5. Received EGFR inhibitor therapy within 2 weeks (with the exception of osimertinib to be within 7 days) prior to the first dose; received nonspecific immunomodulatory therapy (eg, interleukin, interferon, thymus peptide, tumor necrosis factor) within 2 weeks prior to the first dose, excluding IL-11 for the treatment of thrombocytopenia; have received Chinese herbal medicines or proprietary Chinese medicines with antitumor indications within 1 week before the first dose.\n6. Imaging during the screening period shows that the tumor surrounds important blood vessels or has obvious necrosis and\/or cavitation of tumor lesions within the lung parenchyma.\n7. Imaging during the screening period shows that the tumor invades the surrounding vital organs and blood vessels, such as the heart and pericardium, trachea, esophagus, aorta, superior vena cava, or patient is at risk of esophageal tracheal fistula or esophageal pleural fistula.\n8. Symptomatic metastases of the central nervous system.\n9. Malignant tumors other than NSCLC within 3 years before the first dose.\n10. Active autoimmune disease requiring systemic therapy (eg, with disease-modifying drugs, corticosteroids, immunosuppressant therapy) within 2 years prior to the first dose (excluding ir AEs due to PD-1\/L1 inhibitors). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy (prednisone \u2264 10 mg daily or equivalent) for adrenal or pituitary insufficiency) is permitted.\n11. There is a history of major diseases before the first dose\n12. History of perforation of the gastrointestinal tract and\/or fistula, history of gastrointestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive bowel resection (partial colectomy or extensive small bowel resection, complicated by chronic diarrhea) within 6 months before the first study drug administration.\n13. Patients with \\>30 Gy of chest radiation therapy within 6 months prior to the first dose, nonthoracic radiation therapy \\>30 Gy within 4 weeks prior to the first dose, and palliative radiation therapy of \u226430 Gy within 2 weeks prior to the first dose and failed to recover from the toxicity and\/or complications of these interventions to NCI CTCAE Grade \u22641 (except hair loss and fatigue). Palliative radiotherapy for symptom control is permitted if it has been completed at least 2 weeks before the first dose, and no additional radiotherapy for the same lesion is planned.\n14. Inactivated vaccines are allowed. Patients are excluded if they have received a live vaccine or live attenuated vaccine within 4 weeks prior to the first dose, or if they are scheduled to receive a live vaccine or live attenuated vaccine during the study period.\n15. Severe infection within 4 weeks prior to the first dose, including but not limited to comorbidities requiring hospitalization, sepsis, or severe pneumonia; active infection that has received systemic anti-infective therapy within 2 weeks prior to the first dose (excluding antiviral therapy for hepatitis B or C)","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06396065075","EMAIL":"medicalinformation@smmttx.com","GEO":[53.48095,-2.23743]},{"TITLE":"PRO1184 for Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\nPart A and B:\n\n* Histologically or cytologically confirmed metastatic or unresectable solid malignancy including ovarian cancer (must have epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer), endometrial cancer, non-small cell lung cancer (Part A), EGFR-mutated NSCLC (Part B), breast cancer (hormone receptor positive, HER2-negative and triple-negative) (Part A), mesothelioma.\n* Previously received therapies known to confer clinical benefit.\n* Willing to provide a tumor sample (archive tissue or fresh biopsy).\n* Eastern cooperative oncology group (ECOG) performance status 0 or 1.\n* Measurable disease per RECIST v1.1 for all tumor types other than pleural mesothelioma which will use mRECIST v1.1 at baseline.\n* Adequate hematologic, hepatic, renal and cardiac function.\n\nPart C:\n\nHigh grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (excluding endometrioid, clear cell carcinomas, mucinous, low grade, and those with a sarcomatous or neuroendocrine element)\n\n* Participants must have received 1 to 3 lines of therapy.\n* Participants must have platinum-resistant\/refractory ovarian cancer.\n* Participants must have received prior bevacizumab.\n* Participants with known or suspected deleterious germline or somatic BRCA mutations (as determined by FDA-approved test in a CLIA-certified laboratory) must have been treated with a poly ADP-ribose polymerase (PARP) inhibitor.\n* Participants must have known FR\u03b1 status based on an FDA approved test (the Ventana FOLR1 RxDx Assay). Those who are FR\u03b1 positive must have previously received mirvetuximab soravtansine, (MIRV), unless the patient has a documented medical exception.\n* Prior induction plus maintenance is considered 1 line of therapy, even if parts of the treatment regimen (induction or maintenance) are interrupted and\/or resumed at a later date, in the absence of disease progression while on active treatment.\n* A switch\/change in regimen due solely to toxicity or participant preference (and not disease progression) is not considered a separate line of therapy.\n\nPart D:\n\nCohort D1 (PRO1184+carboplatin):\n\n* Participants must have platinum-sensitive ovarian cancer.\n* Participants must have received 1 to 3 prior lines of therapy.\n\nCohort D2 (PRO1184+bevacizumab):\n\n* Participants must have platinum-resistant\/refractory ovarian cancer.\n* Patients must have received 1 to 2 prior lines of therapy.\n\nCohort D3 (PRO1184+pembrolizumab):\n\n* Endometrial cancer (any subtype excluding sarcoma).\n* Participants must have received prior platinum-based chemotherapy for recurrent or advanced disease.\n\nExclusion Criteria:\n\n* Other malignancy within 3 years.\n* Active central nervous system (CNS) metastases (treated, stable CNS metastases are allowed).\n* Uncontrolled Grade 3 or greater infection within 2 weeks.\n* Positive for HBV, HCV or human immunodeficiency virus (HIV).\n* History of (non-infectious) interstitial lung disease (ILD)\/pneumonitis that required steroids within the past 2 years, has current ILD\/pneumonitis, or where suspected ILD\/pneumonitis cannot be ruled out by imaging at screening.\n* Use of a strong CYP3A inhibitor within 14 days (dose escalation only).\n* Prior therapy with a topoisomerase 1 inhibitor-based antibody drug conjugate.\n\nNote: Other protocol-defined inclusion\/exclusion may apply.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05579366031","EMAIL":"clinicaltrials@genmab.com","GEO":[31.22222,121.45806]},{"TITLE":"SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation","CRITERIA":"Key Inclusion Criteria:\n\n* Patients must have histologically documented, locally advanced and unresectable, or metastatic solid tumor with documentation of a KRAS-G12C mutation within 2 years prior to screening.\n* Patients must have measurable disease by RECIST v1.1.\n* Patients must have a minimum life expectancy of \\>12 weeks after start of study treatment.\n* Patients must have progression or disease recurrence on or after all available standard of care therapies.\n* Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.\n* Patients must have adequate organ function.\n\nKey Exclusion Criteria:\n\n* Patients that have participated in an interventional clinical study within the last 4 weeks.\n* Patients that have received radiotherapy or proton therapy with a limited field of radiation for palliation within 1 week of the start of study treatment, OR radiation to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the start of study treatment.\n* Patients with untreated and\/or active CNS metastases.\n* Patients that have a history of allogenic bone marrow transplant.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":99,"SS_ID":"05480865025","EMAIL":[{"email":"rocio.oncomacarena@gmail.com"},{}],"GEO":[37.38283,-5.97317]},{"TITLE":"A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer","CRITERIA":"Key Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of \u2264 1\n* Ability to provide informed consent and documentation of informed consent before initiation of any study-related tests or procedures that are not part of standard of care for the participant's disease. Participants must also be willing and able to comply with study procedures, including the acquisition of specified research specimens.\n* Life expectancy \u2265 12 weeks\n* Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria and documented by Computed tomography (CT) and\/or magnetic resonance imaging (MRI). The definitions for measurable lesions are the same whether conventional and modified RECIST criteria are applied. Cutaneous or subcutaneous lesions must be measurable by calipers. Lesions to be used as measurable disease for the purpose of response assessment must either a) not reside in a field that has been subjected to prior radiotherapy, or b) have demonstrated clear evidence of radiographic progression since the completion of prior radiotherapy and before study enrollment or c) have been radiated at least 6 months before study enrollment.\n\n  * Tumor Histology Types:\n* Participants with pathologically proven, unresectable, locally advanced or metastatic solid tumors that based on literature reports are considered to express EGFR. During cohort expansion, participants with locally advanced or metastatic solid tumors expressing EGFR including advanced or metastatic NSCLC, CRC, and HNSCC are eligible for enrollment.\n\n  \\* Tumors During Cohort Expansion:\n* Participants with pathologically proven, unresectable, locally advanced or metastatic solid tumors that based on literature reports are considered to express EGFR are eligible for enrollment:\n\n  * NSCLC: locally advanced or metastatic NSCLC that has progressed during or following treatment with platinum-based chemotherapy, a checkpoint inhibitor (unless known to be PD-L1 negative), or targeted therapy (for participants with a known actionable mutation).\n  * CRC: locally advanced or metastatic CRC that has progressed after systemic therapies, including irinotecan, oxaliplatin, an anti-EGFR inhibitor (if K-RAS or N-RAS is WT), a checkpoint inhibitor (if MSI-H), and a VEGF inhibitor (if locally approved and accessible as a standard-of-care).\n  * HNSCC: HNSCC that has progressed during or following treatment with a checkpoint inhibitor (unless ineligible, e.g, PD-L1 negative) and platinum-based chemotherapy (unless ineligible for or intolerant to platinum-based chemotherapy) with or without cetuximab for metastatic or recurrent disease.\n\n    1. Participants with salivary gland tumors will not be considered as having HNSCC.\n    2. Participants who refuse surgery for potentially curable disease where the surgery or radiotherapy could result in severe morbidity are eligible. The reason for the refusal will be captured in the electronic case report form (eCRFs).\n\n       * Archival Tissue:\n* Participants must allow acquisition of existing formalin-fixed paraffin-embedded (FFPE) archival tumor sample, either a block or unstained slides. Participants who provide fresh pretreatment biopsy samples will not be required to submit archival tumor samples.\n\n  * Tumor Biopsy:\n\n    \u2022 Participants must be willing to consent to mandatory pretreatment (during screening) and on-treatment fresh tumor biopsies for cohort expansion phase and backfill in dose escalation. Once the target number of biopsies have been collected, additional paired pretreatment and on-treatment biopsies will not be required; sample collection will be optional after this time point. For fresh tumor biopsies, the lesion must be accessible (those occurring outside the brain or those that are accessible by an interventional or endoscopic procedure) for a low-risk biopsy procedure that does not place the participant at an unjustifiable risk in the opinion of the investigator. Participants who have an archived biopsy specimen available that was obtained up to 90 days prior to treatment initiation and have received no other treatment from the time of biopsy until the start of treatment with TAK-186, may submit that archived specimen in lieu of a pretreatment biopsy upon agreement from the sponsor.\n  * Laboratory Features:\n* Acceptable laboratory parameters as follows:\n\n  1. Albumin \u2265 3.0 g\/dL\n  2. Platelet count \u2265 75 \u00d7 103\/\u03bcL\n  3. Hemoglobin \u2265 9.0 g\/dL\n  4. Absolute neutrophil count \u2265 1.0 \u00d7 103\/\u03bcL\n  5. Alanine aminotransferase (ALT)\/aspartate aminotransferase (AST) \u2264 3.0 \u00d7 upper limit of normal (ULN); for participants with hepatic metastases, ALT\/AST \u2264 5 \u00d7 ULN\n  6. Total bilirubin \u2264 1.5 \u00d7 ULN, except participants with Gilbert's syndrome, who may enroll if the conjugated bilirubin is within normal limits.\n  7. Creatinine clearance of \u2265 30 mL\/minute using Cockcroft-Gault equation.\n\n     * Reproductive Features:\n* WOCBP must have a negative serum pregnancy test performed within 72 hours before the initiation of study drug administration. WOCBP must use 1 form of highly effective method and 1 additional effective (barrier) method of contraception at the same time throughout the study, starting at screening through 90 days after the last dose of TAK-186. Contraception methods may be considered highly effective if they can achieve a failure rate of less than 1% per year when used consistently and correctly.\n* Male participants with partners of childbearing potential must use barrier contraception during the entire study treatment period through 120 days after the last dose of study drug and must not donate sperm during this period. In addition, male participants should also have their partners use contraception (as documented for female participants) for the same period of time.\n\n  \\* Previous Checkpoint Inhibitor Therapy:\n* Participants who have previously received an immune checkpoint before enrollment must have checkpoint inhibitor immune-related toxicity resolved to either Grade \u2264 1 or baseline\n* Symptomatic central nervous system (CNS) metastases must have been treated, be asymptomatic for \u2265 14 days, and meet the following criteria at the time of enrollment:\n\n  1. No concurrent treatment for CNS disease (e.g., surgery, radiation, corticosteroids \u2265 10 mg prednisone per day or equivalent).\n  2. No concurrent leptomeningeal disease or spinal cord compression.\n\nKey Exclusion Criteria:\n\n* Participants with a history of known autoimmune disease with the exceptions of:\n\n  1. Vitiligo.\n  2. Psoriasis not requiring systemic treatment for \\> 1 year before receiving TAK-186.\n  3. History of Graves' disease in participants now euthyroid for \\> 4 weeks.\n  4. Hypothyroidism managed by thyroid replacement.\n  5. Alopecia.\n  6. Well-controlled diabetes type 1.\n* Major surgery or traumatic injury within 8 weeks before first dose of TAK-186.\n* Unhealed wounds from surgery or injury.\n* Radiation therapy \\< 2 weeks before initiation of TAK-186.\n* Treatment with \\> 10 mg per day of prednisone (or equivalent) or other immune-suppressive drugs within the 7 days before the initiation of study drug. Steroids for topical, ophthalmic, inhaled, or nasal administration are allowed.\n* Prior therapy within the following timeframe before the planned start of TAK-186 as follows:\n\n  1. Cytotoxic chemotherapy, small molecule inhibitors, radiation, interventional radiology procedure, or similar investigational therapies: \u2264 2 weeks or 5 half-lives, whichever is shorter.\n  2. Monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or similar investigational therapies: \u2264 4 weeks.\n  3. Concurrent use of hormones either to maintain castrate levels of testosterone in participants with castration-sensitive prostate cancer or for non-cancer-related conditions (e.g., insulin for diabetes, hormone replacement therapy) is acceptable. Bisphosphonates are permitted for supportive care of bone metastases (e.g., breast or prostate cancer) or osteoporosis.\n* Clinically significant cardiovascular or vascular disease including:\n\n  1. Myocardial infarction or unstable angina \\< 6 months before the initiation of study drug.\n  2. Clinically significant cardiac arrhythmia (e.g., with potential for hemodynamic instability).\n  3. Uncontrolled hypertension: systolic blood pressure \\> 180 mmHg; diastolic blood pressure \\> 100 mmHg.\n  4. Pulmonary embolism, stroke, or transient ischemic attack \\< 6 months before initiation of TAK-186.\n  5. QTcF (QT interval by Fridericia correction) prolongation \\> 480 msec.\n  6. Congestive heart failure (New York Heart Association Class III or IV).\n  7. Pericarditis or clinically significant pericardial effusion.\n  8. Myocarditis.\n  9. Vasculitis not resolved \\< 6 months before TAK-186 initiation.\n* Clinically significant gastrointestinal disorders including:\n\n  1. Gastrointestinal perforation \\< 6 months before study drug administration. Participants must have documented evidence (e.g., upper endoscopy, colonoscopy) of completely healed area of prior perforation.\n  2. Gastrointestinal bleeding \\< 2 months before study drug administration. Participants must have documented evidence (e.g., upper endoscopy, colonoscopy) of completely healed area of prior bleeding.\n  3. Pancreatitis \\< 6 months before the initiation of study drug. Participants must have a CT scan negative for evidence of remaining disease or normal pancreatic enzyme levels for \\> 4 weeks before the initiation of TAK-186.\n  4. Diverticulitis flare \\< 2 months before study drug administration. Participants must have a CT scan negative for evidence of remaining disease before the initiation of TAK-186.\n  5. History of Crohn's disease or ulcerative colitis.\n* Inflammatory process that has not resolved for \u2265 4 weeks from the date of first study dose. Participants with chronic low-grade inflammatory processes such as radiation-induced pneumonitis are excluded regardless of duration.\n* Clinically significant pulmonary compromise (e.g., requirement for supplemental oxygen on a continuous basis).\n* Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days before the initiation of study drug. Systemic antiviral, antifungal, or antibacterial therapy must be completed \\> 1 week before the initiation of study drug. Antimicrobial prophylaxis (e.g., for Pneumocystis carinii infection) may continue the antimicrobial for that purpose.\n* Vaccination with any live virus vaccine within 4 weeks before the initiation of study drug administration or vaccination with other vaccines 2 weeks before the initiation of study drug administration. Inactivated annual influenza vaccination is allowed.\n* Participants who are known to be human immunodeficiency virus positive or who are known to be hepatitis B or C positive. Participants treated for hepatitis C must have viral titers of 0 for \u2265 2 years to be eligible. Participants with hepatitis B having undetectable or \u2264 500 IU hepatitis B viral titers are eligible. Participants with hepatocellular carcinoma (HCC) known history of hepatitis B are excluded, regardless of hepatitis B viral titers.\n* Second primary invasive malignancy not in remission for \u2265 3 years. Exceptions include non-melanoma skin cancer, cervical carcinoma in situ, localized prostate cancer (Gleason score \u2264 7), resected melanoma in situ, or any malignancy considered to be indolent and never having required therapy, excluding indolent lymphoid malignancies.\n* Any serious underlying medical or psychiatric condition that would preclude understanding and rendering of informed consent or impair the ability of the participant to receive or tolerate the planned treatment.\n* Known hypersensitivity to TAK-186 (or any excipient \\[trehalose, histidine, arginine, or polysorbate-80\\] contained in the drug or diluent formulation) known hypersensitivity to tocilizumab.\n* Investigative site personnel or sponsor personnel directly affiliated with this study or known hypersensitivity to tocilizumab.\n* Prisoners or other individuals who are involuntarily detained.\n* Any medical or non-medical issue that would contraindicate the participant's participation in the study or confound the results of the study.\n* Female participants who are breastfeeding.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04844073019","EMAIL":[{"email":"silk.ahn@samsung.com"},{}],"GEO":[37.566,126.9784]},{"TITLE":"Using ctDNA to Detect Minimal Residual Disease After Lung Cancer Resection","CRITERIA":"Inclusion Criteria:\n\n1. Age \u2265 18 years;\n2. Ability to provide written informed consent;\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;\n4. T1-T4 (T3,T4 multifocal) N0M0 NSCLC who are planned for complete surgical resection;\n5. Tumour size must be at least 1 cm (unidimensional) and have at least some solid component on imaging;\n6. Surgical tumour formalin-fixed, paraffin-embedded (FFPE) specimens for ctDNA studies are required.\n\nExclusion Criteria:\n\n1. Prior radiation, surgery or chemotherapy for the current diagnosis of NSCLC is not permitted.\n2. Incomplete surgical resection. Participants who had pre-operative ctDNA samples taken but subsequently do not have a complete surgical resection would not qualify for post-operative ctDNA testing.\n3. Concurrent enrolment in a therapeutic study using drug or radiation therapy. Enrolment in observational, diagnostic or studies of novel surgical techniques will be allowed.\n4. Concurrent active malignancy or other invasive malignancy within previous 2 years. Non-invasive malignancies (i.e., cervical carcinoma in situ, in situ prostate cancer, non-melanomatous carcinoma of the skin, ductal carcinoma in situ of the breast that has been surgically cured) are excluded from this definition.\n5. Pregnancy.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05254782003","EMAIL":[{}],"GEO":[43.70011,-79.4163]},{"TITLE":"A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* All participants must have a histologically or cytologically confirmed, advanced, unresectable\/metastatic, solid malignancy (measurable by Response Evaluation Criteria in Solid Tumors \\[RECIST\\] v1.1), and have received, be refractory to, ineligible for, or intolerant of existing therapy(ies) known to provide clinical benefit for the condition of the participant.\n\n  * Part 1A may have a solid malignancy of any histology.\n  * Part 1B is restricted to participants with Non-small cell lung cancer (NSCLC).\n  * Part 1C is restricted to participants with Triple-negative breast cancer (TNBC).\n* Tumor biopsy must be obtained for all participants (unless medically precluded).\n\nExclusion Criteria:\n\n* History of Grade \u2265 3 toxicity related to prior T-cell agonist or checkpoint inhibitor therapy (eg, anti-cytotoxic T-lymphocyte-associated antigen 4 \\[CTLA-4\\], or anti-PD- 1\/programmed death-ligand 1 \\[PD-L1\\] treatment, or any other antibody or drug specifically targeting T-cell co-stimulation or other immune checkpoint pathways) except those that are unlikely to re-occur with standard countermeasures.\n* Current or recent (within 3 months of study intervention administration) gastrointestinal disease or gastrointestinal surgery (eg, intestinal\/gastric\/colon resection) that could impact the absorption of study intervention.\n* Any significant acute or chronic medical illness which would interfere with study intervention or follow-up in the opinion of the investigator.\n\nOther protocol-defined criteria may apply.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05888831022","EMAIL":[{}],"GEO":[40.4165,-3.70256]},{"TITLE":"LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG","CRITERIA":"Inclusion Criteria:\n\n1. Histologically-proven NSCLC.\n2. Age \u2265 18 years.\n3. Advanced or metastatic stage IV.\n4. Treatment-na\u00efve patient.\n5. Eligibility to first-line treatment with immune checkpoint inhibitor.\n6. Measurable disease according to RECIST 1.1 criteria on CT-Scan.\n7. Availability of expression of PD-L1 at immunohistochemistry analysis of the tumor biopsy.\n8. No ALK or EGFR gene alteration.\n9. Availability of tumor tissue for NGS analysis (7 slides).\n10. PS 0 or 1.\n11. Signed informed consent of the patient.\n\nExclusion Criteria:\n\n1. No social security affiliation.\n2. Person under legal protection.\n3. Pregnant and breastfeeding women.\n\nPatients can participate to another clinical trial that is not modifying immunotherapy or immunotherapy\/chemotherapy treatment nor study follow-up ; after investigator's information","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04790682003","EMAIL":[{},{}],"GEO":[48.84598,2.20289]},{"TITLE":"A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation","CRITERIA":"Inclusion Criteria:\n\n* Confirmation of Biomarker eligibility\n* Pre-treatment tumor tissue along with an associated pathology report is required for all participants enrolled on study. Representative tumor specimens must be in formalin-fixed, paraffin embedded (FFPE) blocks (preferred) or 15 unstained, freshly cut, serial slides. Although 15 slides are required, if only 10 slides are available, the participant may be eligible for the study following consultation with the Sponsor.\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1\n* Histologically or cytologically documented locally advanced unresectable or metastatic NSCLC that is not eligible for curative surgery and\/or definitive chemoradiotherapy\n* No prior systemic treatment for advanced unresectable or metastatic NSCLC\n* Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\n\nExclusion Criteria:\n\n* Known concomitant second oncogenic driver with available targeted treatment\n* Squamous cell histology NSCLC\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* Prior treatment with a KRAS G12C inhibitor\n* Known hypersensitivity to any of the components of divarasib or pembrolizumab; or known hypersensitivity to pemetrexed, carboplatin, or cisplatin (Cohort B only)\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis, active tuberculosis, significant cardiovascular disease within 3 months prior to initiation of study treatment\n* History of malignancy other than NSCLC within 5 years prior to initiation of study treatment, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate more \\>90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal breast carcinoma in situ, or Stage I uterine cancer\n* Uncontrolled tumor related pain, pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures, uncontrolled or symptomatic hypercalcemia","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05789082058","EMAIL":"global-roche-genentech-trials@gene.com","GEO":[51.50853,-0.12574]},{"TITLE":"Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* I01. Subjects who are able to understand the Informed Consent Form (ICF) and sign the ICF;\n* I02. Male or female subjects, aged 18 years or older; willing and able to complete all required study procedures;\n* I03. Subjects with histologically or cytologically confirmed locally advanced (stage IIIB\/IIIC) and stage IV (defined by the Union for International Cancer Control and the American Joint Committee on Cancer Staging System, edition 8) non-small cell lung cancer that is unresectable and unable to receive radical chemoradiotherapy;\n* I04. Subjects who are PD-L1+ (TPS \u2265 1%) confirmed by central laboratory;\n* I05. Subjects who must have negative EGFR mutation and ALK translocation (testing is not mandatory for subjects with squamous cell carcinoma whose EGFR\/ALK gene mutation status is unknown). Subjects with known driver genes for other approved targeted drug therapies are also not eligible.\n* I06. Subjects who have not received systemic therapy for locally advanced\/metastatic NSCLC. Subjects who have received prior neoadjuvant, adjuvant chemotherapy, or radical chemoradiotherapy are allowed if they develop progressive disease at least 6 months after completing the aforementioned treatment;\n* I07. Subjects with at least one measurable lesion per RECIST v1.1 at baseline;\n* I08. Subjects with a ECOG score of 0 or 1;\n* I09. Subjects with adequate organ function assessed within 7 days prior to first trial treatment as follows:\n\n  \u2022 Hematology (without transfusion or use of hematopoietic stimulators within 14 days prior to enrollment)\n* ANC\u22651.5 \u00d7 109\/L;\n* Hemoglobin \u2265 9 g\/dL;\n* Platelets \u2265 100 \u00d7 109\/L;\n* White blood cell count (WBC) \u2265 4.0 \u00d7 109\/L and \u2264 15 \u00d7 109\/L;\n\n  \u2022 Renal function\n* Serum creatinine \u2264 1.5 \u00d7 upper limit of normal (ULN) or creatinine clearance \u2265 60 mL\/min (calculated according to the Cockcroft-Gault method, see Appendix 7 for details);\n* Urine protein \\< 2+ by urinalysis. If urine protein is \u2265 2+, the subject is eligible only if 24-hour urine protein is \\< 1.0 g\/24 hours;\n\n  \u2022 Hepatic function\n* Total bilirubin \u2264 1.5 \u00d7 ULN (\u2264 3 \u00d7 ULN for subjects with Giltert's syndrome);\n* ALT\/AST \u2264 2.5 \u00d7 ULN (\u2264 5.0 \u00d7 ULN for subjects with liver metastases);\n\n  \u2022 Coagulation\n* INR or PT \u2264 1.5 \u00d7 ULN\n* aPTT\u22641.5 \u00d7 ULN;\n* I10. Subjects with a left ventricular ejection fraction (LVEF) of \u2265 50% (by ECHO or MUGA assessment)\n* I11. Subjects who have a life expectancy of \u2265 3 months;\n* I12. Female subjects of childbearing potential who have a negative serum pregnancy test within 7 days prior to the first dose;\n\nExclusion Criteria\n\n* E01. Subjects with untreated metastases to central nervous system. Subjects with a previous diagnosis of metastases to central nervous system are eligible to enroll if they have completed treatment, have been clinically stable (assessed by imaging, preferably MRI with contrast-enhanced MRI or CT) for at least 2 weeks, and their neurological and other clinical symptoms have recovered to \u2264 Grade 1 per NCI-CTC AE at least 2 weeks before the first dose, and steroids for brain metastases are discontinued 7 days prior to the first dose of trial treatment.\n* E02. Subjects who have received prior immune checkpoint inhibitors, including but not limited to anti-PD-1, PD-L1, CTLA-4, LAG3 agent or other immune checkpoint inhibitors; Subjects who have received prior treatment with single\/multi-target inhibitors or monoclonal antibodies to VEGF or VEGFR signaling pathways;\n* E03. Subjects who have undergone major surgery for any reason within 4 weeks prior to the first dose of trial treatment;\n* E04. Subjects who have a history of radiotherapy that meets the following criteria and fail to recover from toxicity\/complications of radiotherapy to \u2264 Grade 1 per NCI-CTCAE (except alopecia and fatigue)\n\n  1. Thoracic radiotherapy: subjects who have received a chest radiation dose of \\> 30 Gy within 24 weeks before the first dose;\n  2. Non-thoracic radiotherapy: subjects who have received a non-thoracic radiotherapy with a dose of \\> 30 Gy within 4 weeks before the first dose.\n  3. Subjects who have received palliative radiotherapy with a dose of \u2264 30 Gy within 2 weeks before the first dose; Palliative radiotherapy for symptom control is permitted and must be completed at least 2 weeks before the start of study drug.\n* E05. Subjects who have participated in a study or received the treatment with other investigational drugs within 4 weeks or less than 5 times of half-life (not less than 2 weeks), whichever is shorter prior to the first dose of trial treatment;\n* E06. Subjects who have received treatment with anti-tumor vaccines, anti-tumor traditional Chinese medicine or other anti-tumor drugs with immunostimulatory effects within 2 weeks prior to the first dose;\n* E07. Subjects who require systemic corticosteroids (\u2265 10 mg\/day prednisone or equivalent dose of other corticosteroids) or immunosuppressive therapy for 7 consecutive days within 14 days prior to the first dose; except inhaled or topical corticosteroids, or physiologic replacement doses of corticosteroids for adrenal insufficiency; short-term (\u2264 7 days) corticosteroids are allowed for prophylaxis (e.g., contrast media allergy) or for the treatment of non-autoimmune disorders (e.g., delayed-type hypersensitivity reactions due to contact allergens);\n* E08. Subjects who have received vaccination within 28 days prior to the first dose of trial treatment, except for inactivated vaccines.\n* E09. Subjects who have interstitial lung disease, or a history of pneumonia requiring oral or intravenous corticosteroids to assist in management;\n* E10. Subjects with uncontrolled hypertension (blood pressure \u2265 150\/95 mmHg at rest) after standard antihypertensive therapy.\n* E11. Subjects who have a history of or current autoimmune diseases, including, but not limited to, Crohn's disease, ulcerative colitis, systemic lupus erythematosus, sarcoidosis, Wegener's syndrome (granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis), autoimmune hepatitis, systemic sclerosis (scleroderma, etc.), Hashimoto's thyroiditis (refer to the following exceptions), autoimmune vasculitis, autoimmune neuropathy (Guillain-Barre syndrome).\n* E12. Subjects who have other malignancies within 5 years before the first dose, except cured skin squamous cell carcinoma, basal cell carcinoma, non-muscle invasive bladder cancer, localized low-risk prostate cancer (defined as stage \u2264 T2a, Gleason score \u2264 6, and PSA \u2264 10 ng\/mL (as measured) at diagnosis of prostate cancer, the subjects had received curative treatment and no prostate-specific antigen (PSA) biochemical recurrence), and in-situ cervical\/breast cancer;\n* E13. Subjects with uncontrolled comorbidities, including but not limited to:\n\n  * Active HBV or HCV infection;\n  * Known HIV infection or known history of acquired immune deficiency syndrome (AIDS);\n  * Active tuberculosis infection;\n  * Active infection within 4 weeks prior to the first dose of trial treatment that requires the use of systemic antibiotics \u2265 7 days;\n  * Subjects with uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated (monthly or more frequent) drainage\n  * Clinically significant (that is, active) cardiovascular disease:\n  * Uncontrolled \u2265 Grade 3 active hemorrhage by medical intervention within 4 weeks prior to the first dose of trial treatment;\n  * Subjects who require long-term anticoagulant therapy with warfarin (prophylactic anticoagulation for maintenance of the venous access device is permitted); Subjects who require long-term antiplatelet therapy (e.g., aspirin or clopidogrel at loading dose; or aspirin at maintenance dose of \u2265 100 mg\/day; or clopidogrel at maintenance dose of \u2265 75 mg\/day).\n  * Serious, non-healing wound, ulcer, or bone fracture;\n* E14. Subjects whose tumor has invaded important blood vessels or, as judged by the investigator, the tumor is highly likely to invade important blood vessels and cause major hemorrhage during treatment.\n* E15. Subjects with impaired gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of Axitinib, including but not limited to:\n\n  * Inability to take oral medication\n  * Prior surgical procedures affecting absorption including total\/partial gastric resection;\n  * Malabsorption syndromes, uncontrolled nausea, vomiting, diarrhea.\n* E16. Subjects with current use or anticipated need for treatment with drugs or foods that are known strong CYP3A4\/5 inhibitors or CYP3A4\/5 inducers within 14 days prior to the first dose of trial treatment (e.g., grapefruit juice or grapefruit\/grapefruit-related citrus fruits \\[e.g., oranges, pomelos\\], ketoconazole, miconazole etc. ). The topical use of these medications (if applicable) such as 2% ketoconazole cream is allowed;\n* E17. Subjects with current use or anticipated need for treatment with drugs that are known strong CYP3A4\/5 inducers within 14 days prior to enrollment or thereafter (e.g., phenobarbital, rifampin);\n* E18. Subjects with toxicity related to prior therapy (including any prior investigational therapy) that has not recovered to \u2264 Grade 1 per CTCAE (NCI-CTCAE v5.0) or baseline, except for alopecia of any grade;\n* E19. Subjects who have received prior allogeneic hematopoietic stem cell transplantation or solid organ transplantation;\n* E20. Subjects who have known serious hypersensitivity to antibody drugs (\u2265 Grade 3 per NCI-CTCAE v5.0), any history of serious drug hypersensitivity (e.g., immune-mediated hepatotoxicity, immune-mediated thrombocytopenia or anemia); or known allergy to the study drug or any of its excipients\n* E21. Pregnant or lactating women;\n* E22. Subjects with other medical conditions that at the discretion of investigator affect the safety or efficacy assessment or treatment compliance of the trial. These include, but are not limited to, mental illness, alcoholism, drug addiction or drug abuse.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05420220004","EMAIL":[{"email":"yhdgcp@163.com"},{}],"GEO":[37.47649,121.44081]},{"TITLE":"VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Voluntarily participate in clinical research, sign written informed consent, and be able to abide by clinical visits and research Relevant procedures;\n2. Male or female patients aged 18-75 (including boundary value) when signing the informed consent form;\n3. NSCLC with advanced EGFR mutation positive \\[exon 19 deletion (19del) and exon 21 L858R (21l858r) point mutation\\] confirmed by cytology or histology A. only applicable to the dose increasing stage: after receiving the first \/ second generation EGFR-TKI treatment failure T790M mutation negative or third-generation EGFR-TKI treatment failed, and then received platinum containing dual drug chemotherapy Terminal NSCLC patients after failure; B. only applicable to the expansion phase: (1) queue 1: after the treatment failure of the first \/ second generation EGFR-TKI NSCLC patients with T790M mutation positive; (2) Cohort 2: NSCLC patients who failed to receive three generations of EGFR-tki treatment;\n4. According to RECIST 1.1 standard, patients must have a passing shadow Measurable lesions assessed by imaging examination;\n5. The EC0G score is 0 or 1;\n6. Estimated survival time \u2265 3 months;\n7. Bone marrow reserve and organ function level within 7 days before administration must meet the following requirements:\n\n   1. Bone marrow reserve: hemoglobin (HB) \u2265 9.0 g\/dl, absolute neutrophil count \uff08ANC\uff09\u2265 1.5 \u00d7 109\/l, platelet (PLT) \u2265 100 \u00d7 109\/l, opened during the study treatment period Blood transfusion (whole blood, platelets or red blood cells) is prohibited 1 month before the start;\n   2. Coagulation function: international normalized ratio (INR) \u2264 1.5 \u00d7 Upper normal value (ULN), active Partial prothrombin time (APTT) \u2264 1.5 \u00d7 ULN\uff1b\n   3. Liver function: aspartate aminotransferase (AST) and alanine in the absence of liver metastasis Transaminase (ALT) \u2264 2.5 \u00d7 ULN\uff1b In case of liver metastasis, AST and alt \u2264 5.0 \u00d7 ULN\uff1bTotal bilirubin in serum (TBIL) \u2264 1.5 \u00d7 ULN (patients known to have Gilbert syndrome Only when total bilirubin \u2264 3 \u00d7 ULN, direct bilirubin \u2264 1.5 \u00d7 In the case of ULN, it will be Consider);\n   4. Renal function: creatinine \u2264 1.5 \u00d7 ULN or creatinine clearance \u2265 40 ml\/min (according to Cockcroft-Gault formula);\n   5. Cardiac function: left ventricular ejection fraction (LVEF) \u2265 50%; ECG is basically normal,QT interval (QTCF) corrected by fridericia formula: male \u2264 450 ms, female \u2264 470 ms\uff1b\n8. Qualified patients (male and female) with fertility must agree to give drugs during the trial or at the end of the trial Use reliable contraceptive methods (hormone or barrier method or abstinence) with their partners for at least 6 months Etc.); Women of childbearing age (refer to the appendix of the text for the definition) within 7 days before the first use of the investigational drug The pregnancy test must be negative.\n\nExclusion criteria\uff1a\n\n1. Known allergy to, or hypersensitivity to, VIC-1911, osimertinib, or any of the excipient ingredients\n2. Subject has previously discontinued osimertinib due to toxicity or other safety events Interstitial lung disease\/non-infectious pneumonia; Symptoms or signs of severe arrhythmia with prolonged QTc interval; Symptomatic congestive heart failure\n3. Other side effects caused by previous treatment did not alleviate to CTCAE\u2264 grade 1, alopecia or otherwise\n4. A history of ocular disease was present, and the patient had occlusion of central or branch retinal arteries or veins with visual acuity Significant decline, or a history of visual impairment due to other retinal diseases as determined by an ophthalmologist or Performance\n5. The following infectious diseases are known to be active, such as:\n\n   Human immunodeficiency virus antibody (HIV-AB) positive; Hepatitis B surface antigen (HBsAg) positive and HBV-DNA exceeding the upper limit of normal value; Hepatitis C virus antibody (HCV-AB) positive and HCV RNA positive\n6. Other active infections requiring intravenous antibiotics within 7 days before administration;\n7. Use of potent CYP inducer 28 days before administration or within 5 half-lives of the drug, whichever is longer A guide or inhibitor;\n8. Had undergone a major surgical procedure within 28 days prior to drug administration or was expected to require a major procedure during the trial Surgery;\n9. Received the latest antitumor therapy (chemotherapy, targeted therapy, radiotherapy, immunotherapy, biological therapy) Therapy or endocrine therapy), less than 5 half-lives after or after the first administration of the drug Less than 28 days (whichever is longer). Had received the drug within 14 days before the first dose with definite resistance The effect of traditional Chinese medicine on tumor;\n10. A history of serious cardiovascular and cerebrovascular diseases, including but not limited to:\n\n    uncontrolled hypertension (systolic blood pressure \\>160 mmHg or shu) after standard clinical treatment Tension \\>100 mmHg for more than 4 weeks); I have severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias that require clinical intervention, Degree II-III atrioventricular block, etc Patients with grade III-IV cardiac insufficiency according to New York Heart Association (NYHA) criteria Any arterial thromboembolic event, including but not limited to myocardial infarction, occurred within 6 months prior to dosing Plug, transient ischemic attack, unstable angina pectoris or other grade 3 or above cardiovascular and cerebrovascular disease Events; Any factor that increases the risk of prolonged QTc intervals or arrhythmias: e.g., heart failure, hypokalemia Haemaemia, congenital long QT syndrome, or the use of anything known to prolong the QT interval Concomitant drugs (see Appendix of the main text for details), except antibiotics used to prevent or treat infection;\n11. Parenchymal or meningeal metastases with clinical symptoms were not eligible for inclusion as judged by the investigator. Such as Previous systemic and radical brain metastases therapy (radiotherapy or surgery) proved stable on imaging It has been maintained for at least 28 days and has stopped systemic hormone therapy for more than 14 days without clinical symptoms Is allowed to enter the group;\n12. Suffers from hematological malignancies;\n13. Other malignant tumors have been diagnosed within 5 years before the first use of the study drug; Effectively treated skin Basal cell carcinoma, squamous cell carcinoma of the skin, and\/or effectively resected cervical cancer in situ and\/or breast Except the cancer;\n14. Inability to swallow medication;\n15. Gastrointestinal diseases that may affect the absorption or tolerability of the trial drug, such as refractory or screening CTCAE\\> grade 2 gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea, etc.);\n16. Patients with difficulty in venous blood collection;\n17. Women who have a positive pregnancy test or are breastfeeding during the screening period;\n18. Administration of an investigational drug that has undergone clinical trials of other drugs within 28 days prior to administration;\n19. Previous treatment with other Aurora kinase inhibitors;\n20. Patients with a history of blood donation or blood loss of more than 400 mL 3 months before screening;\n21. Anything else that, in the opinion of the investigator, may affect the subject to provide informed consent or follow the protocol Circumstances, or the subject's participation in the trial may affect the results of the trial or their own safety.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05489731001","EMAIL":[{}],"GEO":[37.47649,121.44081]},{"TITLE":"Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1\/PD-L1 Blockade","CRITERIA":"Inclusion Criteria:\n\n* Histologically confirmed diagnosis of non-small cell lung cancer\n* Patients must have progressed on a platinum-based chemotherapy and any of the Food and Drug Administration (FDA)-approved PD-1 or PD-L1 immune checkpoint inhibitors, either given sequentially or in combination\n* A male participant must agree to use a contraception during the treatment period plus an additional 120 days after the last dose of study treatment and refrain from donating sperm during this period\n* A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n  * Not a woman of childbearing potential (WOCBP) OR\n  * A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 120 days plus 30 days (a menstruation cycle) after the last dose of study treatment\n* The participant (or legally acceptable representative if applicable) provides written informed consent for the trial\n* Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1\n* Life expectancy \\> 12 weeks as determined by the investigator\n* Absolute neutrophil count (ANC) \u2265 1500\/uL (collected within 10 days prior to the start of study treatment)\n* Platelets \u2265 100 000\/uL (collected within 10 days prior to the start of study treatment)\n* Hemoglobin \u2265 9.0 g\/dL or \u2265 5.6 mmol\/L (collected within 10 days prior to the start of study treatment)\n\n  * Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks\n* Creatinine \u2264 1.5 x upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate \\[GFR\\] can also be used in place of creatinine or creatinine clearance \\[CrCl\\]) \u2265 30 mL\/min for participant with creatinine levels \\> 1.5 x institutional ULN (collected within 10 days prior to the start of study treatment)\n\n  * Creatinine clearance (CrCl) should be calculated per institutional standard\n* Total bilirubin \u2264 1.5 x ULN OR direct bilirubin \u2264 ULN for participants with total bilirubin levels \\> 1.5 x ULN (collected within 10 days prior to the start of study treatment)\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) \u2264 2.5 x ULN (\u2264 5 x ULN for participants with liver metastases) (collected within 10 days prior to the start of study treatment\n* Palliative radiotherapy (to bone or soft tissue lesions) must be completed \\> 1 week prior to start of study drug (exception: palliative radiotherapy for pain may be used any time prior to first dose)\n* Clinically significant toxic effect(s) of the most recent prior anti-cancer therapy must be grade 1 or resolved (except alopecia and sensory neuropathy); patients with grade 2 adrenal insufficiency related to prior anti-cancer therapy (defined as requiring medical intervention, such as concomitant steroids) or grade 2 hypothyroidism (defined as requiring hormone replacement therapy) may be enrolled provided that clinical symptoms are adequately controlled and the daily dose is 10 mg or less of prednisone or equivalent. If the patient received major surgery or radiation therapy of \\> 30 Gy, they must have recovered from the toxicity and\/or complications from the intervention\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better\n\nExclusion Criteria:\n\n* A WOCBP with a positive urine pregnancy test within 72 hours prior of the planned treatment on day 1 of each cycle. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Patients have prior exposure to docetaxel or ramucirumab\n* Patients with proteinuria of \u2265 2+ on dipsticks or urine protein\/creatinine ratio of \\> 1 g\/24-hour\n* Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks or 5 times the half-life time, whichever is shorter \\[could consider shorter interval for kinase inhibitors or other short half-life drugs\\] prior to allocation\n\n  * Note: Participants must have recovered from all adverse events (AEs) due to previous therapies to grade \u2264 1 or baseline. Participants with grade \u2264 2 neuropathy may be eligible\n  * Note: If participant received major surgery, they must have recovered adequately from the toxicity and\/or complications from the intervention prior to starting study treatment\n* Has received prior radiotherapy within 1 week of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (\u2264 2 weeks of radiotherapy) to non-central nervous system (CNS) disease\n* Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\/zoster (chicken pox), yellow fever, rabies, bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist) are live attenuated vaccines and are not allowed\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment\n\n  * Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug\n* Patients with symptomatic brain metastasis (patients with treated brain metastasis without symptoms and not requiring steroid are allowed to participate)\n* Has severe hypersensitivity (grade \u2265 3) to pembrolizumab and\/or any of its excipients\n* Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, significant cardiac arrhythmia, or psychiatric illness\/social situations that would limit compliance with study requirements\n* Patients with significant cardiovascular disease (e.g., myocardial infarction, arterial thromboembolism, cerebrovascular thromboembolism) within 6 months prior to start of study therapy; angina requiring therapy; symptomatic peripheral vascular disease; New York Heart Association class 3 or 4 congestive heart failure; or uncontrolled grade \u2265 3 hypertension (diastolic blood pressure \u2265 100 mmHg or systolic blood pressure \u2265 160 mmHg) despite antihypertensive therapy\n* Patients with any major hemorrhage or thromboembolic events within 3 months prior to start on this study\n* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment\n* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis or established interstitial lung disease\n* Patients who had prior history of immune-related adverse event (irAE) that required treatment with steroids and permanent immune checkpoint inhibitor (ICI) discontinuation per National Comprehensive Cancer Network (NCCN) guidelines\n* Has an active infection requiring systemic therapy\n* Has a known history of Human Immunodeficiency Virus (HIV). Note: no HIV testing is required unless mandated by local health authority\n* Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV RNA is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\n* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04340882002","EMAIL":[{"email":"alexis.lawrence@emory.edu"},{"email":"mashunte.holmes@emory.edu"},{}],"GEO":[33.749,-84.38798]},{"TITLE":"A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse","CRITERIA":"Inclusion Criteria:\n\n* Patient with an early stage of non small cell lung cancer\n* Indication of surgical resection\n* Patient able to understand and give his consent\n* Patient affiliated to the health insurance\n\nExclusion Criteria:\n\n* Patient with another cancer in the last 5 years\n* Patient with an allergy to the contrast medium\n* Patient under legal protection","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05732974001","EMAIL":[{"email":"mazieres.j@chu-toulouse.fr"},{"email":"milia.j@chu-toulouse.fr"}],"GEO":[43.60426,1.44367]},{"TITLE":"GEN1047 for Solid Tumors - First in Human (FIH) Trial","CRITERIA":"Key Inclusion Criteria:\n\nCriteria - Escalation Part:\n\n* Participant must have histologically or cytologically confirmed solid tumor(s) in any of the following selected indications for which there is no further available standard therapy likely to confer clinical benefit (or participant is not a candidate or has previously refused such earlier available therapy), and for whom, in the opinion of the investigator, experimental therapy with GEN1047 may be beneficial (breast cancer, endometrial cancer, ovarian cancer, NSCLC-SCC.\n* Participants with ovarian cancer must have documented progressive disease (PD) on or after last prior treatment and within 60 days of screening.\n* Must be at least 18 years of age (or the legal age of consent in the jurisdiction in which the trial is taking place) on the day of signing informed consent.\n* Must have either recurrence after, or progression on or lack of response to available relevant standard of care (SoC) anticancer therapies; or are deemed intolerant to or ineligible for, standard curative therapy in the recurrent setting.\n* Must have at least 1 measurable lesion per RECIST v1.1. The measurable lesion(s) must be outside the field of radiation therapy (RT) if there was prior treatment with RT.\n* Must have an Eastern Cooperative Oncology Group performance status (ECOGPS) score of 0 to 1 at Screening and on C1D1 pretreatment.\n* Should provide a tumor tissue sample during the Screening period and prior to C1D1.\n* Provide all tumor-assessing pre-trial CT scans since failure of last prior therapy.\n\nCriteria - Expansion Part Stage 1, 1b and Stage 2:\n\n* Participants must have documented PD according to RECIST v1.1 on or after last prior treatment with latest scan performed a maximum of 28 days prior to the first dose.\n* Participant must have advanced (unresectable) or metastatic, histologically confirmed diagnosis (breast cancer, endometrial cancer, ovarian cancer.\n* Must be a female and at least 18 years of age (or the legal age of consent in the jurisdiction in which the trial is taking place) at the time of consent.\n* Must have at least 1 measurable lesion per RECIST v1.1 as assessed by local investigator.\n* Must have an ECOG- PS score of 0 to 1 at Screening and on Cycle 1 Day 1 (C1D1) pretreatment.\n* Must submit a tumor tissue sample during the Screening period and prior to C1D1.\n* Provide all tumor-assessing pre-trial CT scans since failure of last prior therapy.\n\nKey Exclusion Criteria:\n\n* Significant cardiovascular impairment within 6 months of the first dose of trial drug.\n* Participant with new or progressive brain metastases or spinal cord compression.\n* Participant has been exposed to any prior therapy with a compound targeting CD3 and\/or B7H4 or cell based therapies.\n* Current pneumonitis (any grade) including any radiological change of ongoing pneumonitis at baseline or history of non-infectious drug-, immune-, or radiation-related pneumonitis that required steroid.\n\nNote: Other protocol defined inclusion and exclusion criteria may apply.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05180474036","EMAIL":"clinicaltrials@genmab.com","GEO":[53.48095,-2.23743]},{"TITLE":"The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Age 18-75 years; ECOG score 0-2.\n2. Pathologically confirmed locally advanced NSCLC according to the 8th AJCC staging system.\n3. Received definitive radiotherapy, concurrently or sequentially combined with platinum-based doublet chemotherapy.\n4. No serious medical diseases and dysfunction of major organs, such as blood routine, liver, kidney, heart and lung function.\n\nExclusion Criteria:\n\n1. Pathologic type was adenocarcinoma with EGFR gene mutation or ALK gene rearrangement.\n2. Patients with other active malignancies within 5 years or at the same time.\n3. Active or previously documented autoimmune or inflammatory diseases (including inflammatory bowel disease, diverticulitis \\[except diverticular disease\\], systemic lupus erythematosus, Sarcoidosis syndrome, Wegener' s syndrome).\n4. History of allogeneic organ transplantation.\n5. History of active primary immunodeficiency.\n6. Patients with uncontrolled concurrent diseases, including but not limited to persistent or active infection (including tuberculosis, hepatitis B, hepatitis C, human immunodeficiency virus, etc.), symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled arrhythmia, active interstitial lung disease, severe chronic gastrointestinal disease with diarrhea or mental illness.\n7. Women of child-bearing potential who are pregnant or breastfeeding.\n8. The investigator judged other situations not suitable for inclusion in this study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06287320001","EMAIL":[{"email":"binan_email@163.com"}],"GEO":[39.9075,116.39723]},{"TITLE":"Phase 1\/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Men or women greater than or equal to 18 years\n2. Locally advanced or metastatic NSCLC patients confirmed by histology or cytology, for which standard treatment is invalid, unavailable or intolerable\n3. Pathological, tumor tissue samples can be used to test EGFR\/HER2 Exon 20 insertion mutation by central laboratory for subjects\n4. At least one measurable lesion in accordance with RECIST 1.1\n5. Eastern Cooperative Oncology Group (ECOG) performance status: 0\\~1\n6. Estimated life expectancy \\>12 weeks\n7. Reproductive-age women agree to use adequate contraception and cannot breastfeed while participating in this study and for a period of 6 months after the last dose. Likewise, men also consent to use adequate contraceptive method within the same time limit.\n8. Females must have the evidence of non-childbearing potential\n9. Signed and dated Informed Consent Form\n\nExclusion Criteria:\n\n1. Treatment with any of the following:\n\n   * Previous or current treatment with EGFR Exon 20 insertion inhibitors, HER2 Exon 20 insertion inhibitors or EGFR\/HER2 Exon 20 insertion inhibitors\n   * Any cytotoxic chemotherapy, anticancer Chinese medicine and targeted small molecule inhibitors within 14 days of the first dose of HS-10376\n   * Any investigational agents and large molecule antibodies within 28 days of the first dose of HS-10376\n   * Local radiotherapy for palliation within 2 weeks of the first dose of HS-10376, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks of the first dose of HS-10376\n   * Major surgery (including craniotomy, thoracotomy, or laparotomy, etc.) within 4 weeks of the first dose of HS-10376\n2. Inadequate bone marrow reserve or serious organ dysfunction\n3. Uncontrolled pleural, ascites or pericardial effusion\n4. Untreated, symptomatic or active central nervous system metastases\n5. Severe or poorly controlled hypertension\n6. Immunodeficiency disease and active infectious disease\n7. Refractory nausea, vomiting, or chronic gastrointestinal diseases, or inability to swallow oral medications\n8. History of hypersensitivity to any active or inactive ingredient of HS-10376 or to drugs with a similar chemical structure or drugs belonging to the same category of HS-10376\n9. The subject who is unlikely to comply with study procedures, restrictions, or requirements judged by the investigator\n10. The subject whose safety cannot be ensured or study assessments would be interfered judged by the investigator\n11. Pregnant women, breastfeeding women or woman who has a child-bearing plan during the study\n12. History of neuropathy or mental disorders, including epilepsy and dementia","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05435274001","EMAIL":[{"email":"dingzhi72@163.com"}],"GEO":[39.14222,117.17667]},{"TITLE":"A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor","CRITERIA":"Inclusion Criteria:\n\n1. \u226518 years of age.\n2. Subjects with histologically or cytologically confirmed metastatic or unresectable advanced NSCLC or other solid tumors who have progressed on prior standard therapy, have been intolerant to prior standard therapy, or have refused all other currently available therapeutic options.\n3. Subjects must have evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n4. ECOG PS 0-1.\n5. An expected survival time is \u22653 months.\n6. Adequate organ function.\n7. Subjects in Phase II must agree to provide pre-treatment tumor tissue samples.\n\nExclusion Criteria:\n\n1. Subjects who have had prior chemotherapy, targeted cancer therapy, immunotherapy, or any investigational anti-cancer treatment within 2 weeks or five half-lives of the treatment (whichever is longer), prior to the first administration of the study drug.\n2. Toxicity (excluding alopecia, peripheral neuropathy, and hypothyroidism) that did not return to class 0 or class 1 of NCI CTCAE V5.0 from prior antitumor therapy prior to the first administration of the study drug.\n3. Prior radical radiation therapy completed within 4 weeks prior to the first administration of the study drug.\n4. Subjects with untreated symptomatic brain metastases.\n5. History of interstitial lung disease (ILD).\n6. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.\n7. Received live virus vaccination within 30 days of first dose of study treatment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05332574004","EMAIL":"shawn.yu@genorbio.com","GEO":[-37.814,144.96332]},{"TITLE":"Metabolic Response to Food in Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Age greater than or equal to 18 years\n* Diagnosis of non-small-cell lung cancer\n* Reported weight stability or loss after cancer diagnosis\n* Body mass index less than or equal to 35 kilograms per meter squared\n* Ability to provide written informed consent\n* Willing and able to comply with all scheduled visits, treatment plans, lab tests, and other study procedure\n* Allow the collection and storage of biospecimens and data for future use\n\nExclusion Criteria:\n\n* Prior diagnosis of diabetes mellitus (type 1 or type 2)\n* Currently pregnant or breastfeeding\n* Contraindication to consuming the liquid mixed meal\n* Any medications affecting gastric motility\n* Any other condition that, in the investigator's opinion, would preclude participation or successful compliance with the protocol","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05937074001","EMAIL":[{"email":"Stephanie.Compton@pbrc.edu"}],"GEO":[30.45075,-91.15455]},{"TITLE":"Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer","CRITERIA":"Inclusion Criteria\n\n1. Adults with a confirmed diagnosis of unresectable, locally advanced and\/or metastatic Stage IIIB\/IV NSCLC, Stage III\/IV PDAC and\/or Stage III\/IV CRC with no curative-intent treatment options and documented activating KRAS mutation (without known additional actionable driver mutations such as EGFR, ALK or ROS1)\n2. Documented progression and measurable disease after \u2265 1 prior line of systemic therapy (\u2265 2 and\n\n   \u2264 4 prior lines for NSCLC) with adequate washout period and resolution of treatment-related toxicities to \u2264 Grade 2\n3. ECOG PS of 0-2 (0-1 for PDAC) and a life expectancy \\> 3 months in the opinion of the Investigator\n4. Adequate hematological, liver, and renal function\n5. Men and women of childbearing potential must use adequate birth control measures for the duration of the trial and at least 90 days after discontinuing study treatment\n\nExclusion Criteria\n\n1. Symptomatic and\/or untreated CNS or brain metastasis, pre-existing ILD or pericardial\/pleural effusion of \u2265 grade 2 or requiring chronic oxygen therapy for COPD or pleural effusions\n2. Serious concomitant disorder including infection\n3. Known positive test for HIV, HCV, HBV surface antigen\n4. Concurrent malignancy in the previous 2 years\n5. Prior menin inhibitor therapy\n6. Requiring treatment with a strong or moderate CYP3A inhibitor\/inducer\n7. Significant cardiovascular disease or QTcF or QTcB prolongation.\n8. Major surgery within 4 weeks prior to first dose\n9. Women who are pregnant or lactating.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05631574019","EMAIL":"clinicaltrials@biomeafusion.com","GEO":[47.60621,-122.33207]},{"TITLE":"A Phase 1\/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Must be \u226518 years of age\n* Must have histologically or cytologically confirmed diagnosis as follows:\n\n  1. Monotherapy Phase 1: A locally advanced unresectable or metastatic solid tumor malignancy that harbors a RAS (KRAS, NRAS, or HRAS) activating mutation.\n  2. Monotherapy Phase 2a: A locally advanced unresectable or metastatic solid tumor malignancies: pancreatic ductal adenocarcinoma (PDAC), RAS-mutant melanoma, or RAS-mutant non-small cell lung cancer (NSCLC)\n  3. Combination therapy (both phases): A locally advanced unresectable or metastatic PDAC\n* Participants must be treatment naive or received prior systemic standard-of-care treatment as follows:\n\n  1. Monotherapy Phase 1: received at least 1 line of systemic standard-of-care treatment for their advanced or metastatic disease\n  2. Monotherapy Phase 2a:\n\n     1. First-line PDAC participants will have received no previous systemic anti-cancer therapy. Second-line PDAC participants will have received no more than one prior systemic anti-cancer therapy.\n     2. First-line melanoma participants will have received no previous systemic anti-cancer therapy. Second- and third-line participants will have received and failed one or two prior systemic anti-cancer therapies, respectively.\n     3. NSCLC participants will have received at least one and no more than two previous lines of systemic therapy.\n  3. Combination therapy (both phases): PDAC participants will have received no previous systemic anti-cancer therapy for their advanced or metastatic disease.\n* Must have evidence of measurable disease (at least one target lesion) per RECIST v1.1 criteria\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Adequate organ function\n\nExclusion Criteria:\n\n* Inability to swallow oral medications\n* Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases\n* History or concurrent evidence of retinal vein occlusion (RVO) or current risk factors for RVO. History of serous retinopathy, retinal edema, or retinal pigment epithelial detachment (RPED)\n* Impaired cardiovascular function or clinically significant cardiac disease\n* History of rhabdomyolysis within 3 months prior to start of study treatment\n* Active skin disorder requiring systemic treatment within 3 months prior to the start of study treatment\n* Females who are pregnant, breastfeeding, or planning to become pregnant and males who plan to father a child while enrolled in this study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05585320018","EMAIL":[{}],"GEO":[43.07305,-89.40123]},{"TITLE":"A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY","CRITERIA":"Inclusion Criteria\n\n1. Adult (aged \u226518) ALK positive NSCLC participants receiving brigatinib as a first-line treatment in the scope of NDP.\n2. Participants willing to participate in the study and signed ICF.\n\nExclusion Criteria\n\n1. Current or planned participation in an interventional clinical trial for ALK positive non-small cell lung cancer (NSCLC).\n2. Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05735327012","EMAIL":[{"email":"sekretariat@wcpit.org"},{}],"GEO":[52.40692,16.92993]},{"TITLE":"18F-FDG PET\/CT to Evaluate pD-1 Monoclonal Antibody With First-line Chemotherapy in Advanced NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Adult patients (age 18 or above), gender unlimited;\n* Pathological diagnosis of non-small cell lung cancer stage IIIB or above;\n* Agree to carry out the standard first-line chemotherapy combined with immunosuppression established in this study;\n* Consent to 18F-FDG PET\/CT imaging and related laboratory examination before and during treatment;\n* The patients themselves or their legal representatives are aware of this study and can sign the informed consent.\n\nExclusion Criteria:\n\n* Acute systemic diseases and electrolyte disturbances;\n* Pregnant or lactating women;\n* The patient or his legal representative is unable or unwilling to sign the informed consent.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"04996927001","EMAIL":[{"email":"lxl730724@hotmail.com"}],"GEO":[30.58333,114.26667]},{"TITLE":"A Phase 1\/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors","CRITERIA":"Inclusion Criteria\n\n1. Evidence of homozygous loss of MTAP (null) and\/or MTAP deletion.\n2. Presence of advanced\/metastatic solid tumor not amenable to curative treatment\n\n   1. Part 1: MTAP-null or lost MTAP expression solid tumor for which no standard therapy exists\n   2. Part 2: MTAP-null or lost MTAP expression NSCLC with progression after 1 to 2 prior lines of systemic therapy.\n3. Able to swallow and retain PO administered study treatment and willing to record adherence to investigational product\n4. Disease measurable as defined by RECIST v1.1\n5. Adequate organ function as defined in the protocol.\n6. Archived tumor tissue. Participants without archived tumor tissue available may be allowed to enroll by undergoing tumor biopsy before cycle 1 day 1 dosing.\n\nExclusion Criteria\n\n1. Prior treatment with an MAT2A inhibitor or a PRMT5 inhibitor.\n2. Radiologic or clinical evidence of spinal cord compression, untreated or symptomatic brain metastases or leptomeningeal disease.\n3. Cardiovascular and pulmonary exclusion criteria as defined in the protocol.\n4. Gastrointestinal tract disease causing the inability to take PO medication, malabsorption syndrome, requirement for IV alimentation, gastric\/jejunal tube feeds, uncontrolled inflammatory gastrointestinal disease (eg, Crohn's disease, ulcerative colitis)\n5. History of bowel obstruction, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months of study entry.\n6. Prior irradiation to \\> 25% of the bone marrow\n7. Use of prescription medications that are known strong CYP3A4\/5 inducers or strong CYP3A4\/5 inhibitors within 7 days for CYP3A4\/5 inhibitors, 14 days for CYP3A4\/5 inducers or 5 half-lives, whichever is longer, prior to any dose of investigational medical product.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05975073019","EMAIL":"medinfo@amgen.com","GEO":[22.99083,120.21333]},{"TITLE":"A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Written informed consent is provided by patient or legally acceptable representative;\n2. Age \u2265 18 years;\n3. Patient populations:\n\n   1. In the Safety Run-in, patients with histologically or cytologically confirmed advanced or metastatic solid tumors who have disease progression after treatment with standard therapies for metastatic disease that are known to confer clinical benefit, or are intolerant to treatment or refuse standard treatment will be enrolled in therapy\n   2. In Expansion Phase, patient must have urothelial or NSCLC, and have failed prior anti-PD-1 or anti-PD-L1\n4. Have measurable disease per RECIST 1.1 as assessed by the local site investigator\/radiology\n5. Eastern Cooperative Oncology Group performance status of 0 to 1\n6. Life expectancy of \u2265 3 months\n\nExclusion Criteria:\n\n1. Positive urine pregnancy test within 72 hours prior to treatment\n2. Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks (or 5 half-lives, whichever is shorter) prior to treatment;\n3. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137), AND was discontinued from that treatment due to a Grade 3 or higher immune-related adverse event;\n4. Has received prior radiotherapy within 2 weeks of start of study treatment.\n5. For patients with NSCLC:\n\n   1. Patients who have received radiation therapy to the lung that is \\>30 Gy within 6 months of the first dose of trial treatment are excluded;\n   2. Patients with mutations (e.g., EGFR mutations or ALK gene rearrangements) will be excluded unless they have been previously treated with all specific targeted therapies.\n6. Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention.\n7. Has had an allogeneic tissue \/solid organ transplant.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05318573021","EMAIL":"fphu@td2inc.com","GEO":[43.07305,-89.40123]},{"TITLE":"Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients","CRITERIA":"Key Inclusion Criteria:\n\n* Patient must have a known diagnosis of NSCLC, HCC, or HNSCC as defined in the protocol\n* Patient must be willing and able to provide blood samples at the indicated time points\n* Patient must be willing and able to have excisional or core needle biopsies of tumor prior to initiation of cemiplimab as defined in the protocol\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Patient is determined to be a surgical candidate for resection of their tumor\n* Adequate organ and bone marrow function as defined in the protocol\n\nKey Exclusion Criteria:\n\n* Patients who have had any systemic anti-cancer therapy or radiotherapy within 6 months prior to entering the study for their current tumor or a different primary tumor\n* Patients whose tumor burden, or pace of tumor growth, in the opinion of the Investigator will not permit delaying surgery\n* Patients who have participated in a study of an investigational agent or an investigational device within 4 weeks of study therapy or 5 half-lives (whichever is longer)\n* Patients who have had major surgery within 14 days prior to initiation of neoadjuvant Therapy\n* Patients with metastatic disease for whom the intent of surgery would not be curative\n* Uncontrolled, intercurrent illness as defined in the protocol and as determined by the Investigator\n* Is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment\n* Has active autoimmune disease that has required systemic treatment in the past 1 year\n* Has a known, additional malignancy that is progressing and\/or requires active treatment. Exceptions include patients with: basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy; in situ cervical or anal cancer; prostate cancer on stable dose of hormonal therapy without rising prostate-specific antigen (PSA); breast cancer who have been treated with curative intent, who may be on hormonal therapy.\n* Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent\n* History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved \u22656 months prior to study treatment.\n* Uncontrolled infection with human immunodeficiency virus (HIV), HBV or hepatitis C infection (HCV); or diagnosis of immunodeficiency as defined in the protocol\n* NSCLC cohorts only: Patients do not have a history of smoking. History of smoking is defined as smoking \u2265100 cigarettes in a lifetime.\n* NSCLC cohorts only: Patients with tumors tested positive for epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations, or c-ros oncogene 1 (ROS1) fusions.\n\nNote: Other protocol defined Inclusion\/Exclusion criteria apply","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03916627001","EMAIL":[{}],"GEO":[40.71427,-74.00597]},{"TITLE":"A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Advanced or metastatic NSCLC (nonsquamous or squamous) that is histologically or cytologically confirmed\n* Participants who have received no more than 2 lines of prior systemic therapies which must include anti-programmed cell death protein ligand-1 (anti-PD-(L)1) treatment and a platinum-based chemotherapy administered in combination with, or sequentially before or after the anti-PD-(L)1 treatment\n* At least 1 measurable lesion as defined per RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Adequate organ function as indicated by laboratory values during screening\n\nExclusion Criteria:\n\n* With mixed small cell lung cancer\n* Has received prior therapy targeting OX40 or any other T-cell agonists\n* Has received prior therapy containing docetaxel and\/or ramucirumab for advanced or metastatic NSCLC\n* Has received any Chinese herbal medicine or Chinese patent medicines used to control cancer \u2264 14 days before the first dose of study drug(s)\n* Active leptomeningeal disease or uncontrolled and untreated brain metastasis\n\nNOTE: Other criteria may apply","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06029127025","EMAIL":"clinicaltrials@beigene.com","GEO":[37.566,126.9784]},{"TITLE":"A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker","CRITERIA":"Inclusion Criteria:\n\n1. Histologically confirmed patients with locally progressive or metastatic non-small cell lung cancer (IIIB or IV) who have not been diagnosed as squamous cell carcinoma.\n2. Patients with one or more measurable lesions in accordance with the RECIST criteria (Version 1.1), tumor lesions located at the previous irradiation site, are considered measurable if progress has been made in those lesions.\n3. Patients with institutionalized EGFR mutation (exon 19 deletion or L858R)\n4. Patients with a history of smoking, including those who are currently smoking (defined as those who have smoked more than 100 cigarettes in their lifetime)\n5. ECOG PS 0-1 Patient\n6. Patients with appropriate hematological functions ANC\u22651,500\/uL, hemoglobin\u22659.0g\/dL, platelet\u2265100,000\/uL\n7. Patients with adequate liver function Total bilirubin \\< 1 x UNL, AST (SGOT) and ALT (SGPT) \\< 2.5 x UNL (If there is an interruption: total bilirubin \\<3 x UNL, AST (SGOT) and ALT (SGPT) \\<5 x UNL)\n8. a patient with appropriate renal function Cr UN UNL, however, can be registered if the creatinine clearance calculated according to the formula Cocroft and Gault is 50 50 ml\/min outside the normal range.\n\n   Proteinuria test \\<2+ (if 22+ then protein 11g must be in 24-hour urine test)\n9. Patients with a history of receiving radiation therapy must meet the following criteria.\n\n   - In the case of direct radiation irradiation to the lung lesion area, it must have elapsed at least 12 weeks from the time of registration.\n   * In the case of chronic radiation therapy for intracoracic bone metastasis, it must be at least 12 weeks from the time of registration.\n   * 2 weeks or more from the time of registration if radiotherapy has been performed on any non-chest area Must be elapsed.\n10. At the time of registration, the date of completion of the previous treatment or procedure must pass the period specified below.\n\n    - Surgery (including exploratory\/experimental thoracotomy): 4 weeks\n\n    - Pericardial drainage: 1 week\n\n    - pleural adhesion not attributed to anti-species positive substances (including biological response regulators such as Picibanil): 2 weeks\n\n    - Tissue biopsy to confirm selection criteria (including biopsy using thoracoscope): 1 week\n    * Procedures for the treatment of trauma (unregistered patients with untreated wounds): 2 weeks\n    * Blood transfusion, hematopoietic growth factor administration: 2 weeks\n    * The puncture and aspiration cell test: 1 week\n    * Administration of other clinical trial medications: 4 weeks\n11. Women in childbearing age should be negative in serum or urine pregnancy tests within 7 days prior to test treatment.\n12. Male and childbearing female test subjects with female partners' pregnancy must agree to use the following two high-efficiency test methods for at least 180 days after the last dose of the assigned treatment is administered. Bevacizumab can also damage a woman's reproductive ability. Therefore, women who have entered the bevacizumab combination group should be preceded by discussions on preserving the reproductive ability of women who are likely to become pregnant before treatment - asceticism\n\n    - tubal ligation\n\n    - Hormone contraceptives that do not cause drug interactions (such as Mirena)\n    * Medroxyprogesterone injection (Depo-Provera)\n    * Copper bands and intrauterine devices\n    * a partner's vasectomy\n    * Partner's use of condoms\n13. Patients who have agreed to the clinical trial-\n\nExclusion Criteria:\n\n- 1) Patients with other malignant tumors except lung cancer within the past three years (except for properly treated cervical epithelial cancer, basal or squamous cell skin cancer, thyroid cancer, and topical prostate cancer surgically treated for healing purposes).\n\n2) Patients with a history of bleeding above Grade 2 (with blood above Grade 2) 2.5mL within 3 months of registration defined as the above bright red blood.) 3) chemotherapy for advanced lung cancer in the past or other systemic anticancer drugs (single-clone antibodies or Patients with tyrosine kinase inhibitors) (However, pre- and post-operative assisted chemotherapy, which ended 6 months before the time of registration, is allowed.) 4) A patient with evidence of invasion of large blood vessels, such as the pulmonary artery or relative vein of a tumor, in contrast examination.\n\n5) Patients scheduled to undergo hydrophobic surgery (including infantile catheter insertion) within 24 hours of the first injection of bevacizumab 6) Current or recent (within 10 days prior to the initial injection of bevacizumab) aspirin (\\>325 mg\/day) and patients with oral or injectable anticoagulants or thrombolytic agents for therapeutic purposes (provided that preventive use of anticoagulants is permitted).) 7) Patients currently in use (or unable to discontinue prior to the initial dose of lazertinib) with a drug or natural aid known as a potent CYP3A4 inducer that cannot be discontinued throughout clinical trials before enrollment 8) Any evidence of ILD, drug-induced ILD, past history of radiation interstitial pneumonia requiring steroid treatment, or clinically active ILD 9) Patients undergoing or likely to administer bisphosphonate medication 10) Uncontrolled patients with brain-spinal metastasis (Patients with epilepsy can be registered if they are stabilized asymptomaticly, and treated patients with epilepsy can be registered if they do not currently require steroid treatment.) 11) Patients with clinically significant ophthalmic abnormalities on the surface of the eye (not recommended to use contact lenses) (with corneal perforations or ulcers, symptoms and signs of acute or exacerbated corneal inflammation such as ocular inflammation, tear secretion, blurred vision, eye pain and bleeding) 12) Patients with a history of coagulopathy with hereditary bleeding constitution or risk of bleeding 13) Patients with uncontrolled hypertension (systolic blood pressure \\>150 mmHg and\/or diastolic \\>100 mmHg) 14) Patients with clinically significant active cardiovascular disease (within 6 months of registration, patients with cerebrovascular accidents and diseases, myocardial infarction, unstable angina, NYHA ClassIIII congestive heart failure, thrombosis, thromboembolism, and severe cardiac arrhythmia that may interfere with drug administration during clinical trials)\n\nThe following heart criteria are not limited to one. :\n\n* Average of corrected QT intervals at rest (QTc intervals corrected by Fredericia formula) \\>470 msec based on QTc values calculated by ECG equipment by the test institution during screening.\n* clinically significant abnormal findings found in the rhythm, conduction, or morphology of the ECG at rest (e.g., complete left block, 3rd degree heart block, 2nd degree heart block)\n* All factors that increase the risk of QTc prolongation or arrhythmia, including heart failure, hypokalemia, family history of congenital QT prolongation syndrome, sudden death of causes under the age of 40 in the immediate family, combined drugs known to prolong QT spacing and induce Torsades de Points (TdP).\n\n  15) Patients with non-healing wounds, active digestive ulcers, or fractures 16) Patients with active infections and uncontrolled systemic diseases 17) Patients who have a chemical structure similar to lasertinib and bevacizumab or these substances or who have a history of hypersensitivity to active ingredients or inactive excipients of drugs belonging to the family.\n\n  18) Patients who are hypersensitive to CHO (animal cell line from the uterus of Chinese hamsters) cell products or other recombinant human body or humanized antibodies.\n\n  19) Pregnant or lactating women","SEX":"ALL","AGE_MIN":19,"AGE_MAX":200,"SS_ID":"06156527002","EMAIL":[{"email":"abcduke@ncc.re.kr"}],"GEO":[37.65639,126.835]},{"TITLE":"Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone","CRITERIA":"Inclusion criteria:\n\n1. Participant is currently receiving capmatinib treatment (within Novartis-sponsored study which is eligible and approved to transition participants to rollover study) as single agent or in combination or is receiving a combination treatment alone. This includes all participants treated with capmatinib in combination with other treatment that permanently discontinued capmatinib for any reason but are still receiving the combination treatment as single agent. In order to receive the combination treatment as single agent in the rollover study, the treatment needs to be not accessible to the participant outside a clinical trial (e.g. commercially not available or reimbursed).\n2. Participant is currently deriving clinical benefit from study treatment as determined by the Investigator\n3. Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures\n4. Written informed consent obtained prior to enrolling in the rollover study and receiving study medication. If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness.\n\nExclusion criteria:\n\n1. Participant is currently not receiving any study treatment due to unresolved toxicities for which study treatment dosing has been interrupted or permanently discontinued in the parent protocol (participants meeting all other eligibility criteria may be enrolled once toxicities have resolved to allow study treatment dosing to resume)\n2. Pregnant or nursing (lactating) women\n3. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while taking study treatment and for at least 7 days or following combination treatment parent trial recommendation (whichever is longer) of study treatment after stopping medication. Highly effective contraception methods include:\n4. Concurrent participation in another clinical study other than a parent clinical study\n5. Participants who received live vaccines (e.g., intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, TY21a typhoid vaccines and COVID-19 vaccines) within 30 days prior to the first dose of study treatment","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03040973014","EMAIL":"Novartis.email@novartis.com","GEO":[1.28967,103.85007]},{"TITLE":"Psychosocial eHealth in Advanced Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Being adult (\u226518 years)\n* LC diagnosis in advanced stages -III-IV\n* Access to internet and user-level experience\n* Reading and writing skills in Spanish\n\nExclusion Criteria:\n\n* Current major depressive episode\n* Risk of self-harm\n* Active psychotic symptoms\n* Substance abuse","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"05497973001","EMAIL":"mariaserrab@iconcologia.net","GEO":[41.35967,2.10028]},{"TITLE":"A Phase 1\/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria\n\n1. Histologically or cytologically confirmed locally advanced or metastatic NSCLC (all patients).\n2. Documented EGFR ex20ins mutation demonstrated by a validated test listed in Section 9.7 and performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified or equivalent laboratory (all patients other than Module A Food Effect PK Assessment Module). Institutions that don't have access to these tests should contact the sponsor for assistance.\n3. Prior treatment in the recurrent\/metastatic disease setting including:\n\n   1. A platinum-based chemotherapy regiment (or other chemotherapy regimen if platinum-based chemotherapy is contra-indicated)\n   2. Any other approved standard therapy that is available to the patient, unless this therapy is contraindicated, intolerable to the patient, or is declined by the patient. In the case of a patient declining such therapy, documentation that the patient has been informed and declined should be documented in the medical record.\n   3. No prior therapy is required for patients enrolled on Module A.\n   4. Prior therapy with an agent approved by the local regulatory authorities for the treatment of EGFR ex20ins mutant NSCLC (Module C only).\n4. Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (except for patients enrolled on Module A).\n5. Age \u2265 18 years.\n6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n7. Ability to take pills by mouth.\n8. Have the following laboratory values:\n\n   1. Serum creatinine \\< 1.5 \u00d7 upper limit of normal (ULN) or calculated creatinine clearance (CrCl) must be \u2265 50 mL\/min\/1.73 m2 (if calculated by Cockroft-Gault formula, the actual body weight must be used for CrCl unless body mass index \\[BMI\\] \\>30 kg\/m2 then lean body weight must be used).\n   2. Total bilirubin \u2264 1.5 \u00d7 ULN unless prior history of Gilbert's syndrome.\n   3. AST and ALT \u2264 2.5 \u00d7 ULN, or \u2264 5 \u00d7 ULN if due to liver involvement by tumor.\n   4. Hemoglobin \u2265 9.0 g\/dL in the absence of transfusion \u2264 14 days prior to the first dose of study drug on C1D1.\n   5. Platelets \u2265 100 \u00d7 109 cells\/L in the absence of transfusion \\<14 days prior to the first dose of study drug on Cycle 1 Day 1 (C1D1).\n   6. Absolute neutrophil count \u2265 1.5 \u00d7109 cells\/L.\n9. For Module A patients only: patients must have a negative coronavirus disease 2019 (COVID-19) polymerase chain reaction test prior to enrolment.\n10. For Module B and Module C patients only: verification of suitable archived tumor tissue available at the participating center for biomarker analysis. A fresh biopsy is required if an archived sample is not available.\n11. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria\n\nR6, Phase 1 Expansion, Phase 2a, Module A and Module B Patients Only\n\n1. Prior treatment with an EGFR ex20ins -targeting drug (eg, including, but not limited to poziotinib, mobocertinib, amivantamab, DZD9008, BDTX-189).\n\n   Note: enrolment of patients treated previously with EGFR ex20ins-targeting drugs allowed selectively during accelerated titration dose escalation and Module C only.\n\n   Module A Food Effect PK Assessment Module patients only\n2. Conditions that compromise esophageal or gastrointestinal (GI) function, including esophageal, gastric, pancreatic, hepatobiliary, or small bowel carcinomas, or history of gastric resection.\n3. Recurrent diarrhea, nausea, or vomiting.\n4. Unable to refrain from or anticipates the use of:\n\n   1. Any drug, including prescription and non-prescription medications, including drugs that change gastrointestinal motility (eg, loperamide) or gastric pH (eg, antacids, H2 antagonists, proton pump inhibitors), herbal remedies, or vitamin supplements within 14 days prior to the first dosing on Day 1 to follow-up.\n   2. Any drugs known to be inhibitors or inducers of CYP3A enzymes and\/or P-glycoprotein (P-gp), including St. John's Wort and grape fruit juice, within 28 days prior to the first dosing and throughout the PK assessment.\n5. Any allergies to the composition of the high fat meal.\n6. Patients who use tobacco products.\n\n   All Patients\n7. History of COVID-19-related pneumonitis requiring hospitalization.\n8. History of COVID-19 infection within 4 weeks prior to enrolment, or clinically significant pulmonary symptoms related to prior COVID-19 pneumonitis.\n9. Treatment with any of the following:\n\n   1. An EGFR TKI \u2264 8 days or 5 \u00d7 the terminal phase t1\/2, whichever is longer, prior to the first dose of study drug on C1D1.\n   2. Systemic anticancer treatment (excluding EGFR-TKIs as described above) within 14 days prior to the first dose of study drug on C1D1.\n   3. Immunotherapy \u2264 28 days prior to the first dose of study drug on C1D1.\n   4. Radiotherapy \\< 28 days and palliative radiation \u2264 14 days prior to the first dose of study drug on C1D1. If irradiated, lesions must have demonstrated clear-cut progression prior to being eligible for evaluation as target lesions.\n   5. Major surgery (excluding placement of vascular access) \u2264 28 days of the first dose of study drug on C1D1.\n10. Have any unresolved toxicity of Grade \u2265 2 from previous anti-cancer treatment, except for alopecia and skin pigmentation. Patients with chronic but stable Grade 2 toxicities may be allowed to enroll after agreement between the Investigator and Sponsor.\n11. Have known or suspected leptomeningeal metastasis. Have known or suspected brain metastases or spinal cord compression, unless the condition has been asymptomatic, treated with surgery and\/or radiation (if clinically indicated), and has been stable without requiring escalating corticosteroids or anti-convulsant medications for at least four weeks prior to the first dose of study drug on C1D1.\n12. Prior therapy with CLN-081.\n13. Known hypersensitivity to CLN-081 or any drugs similar in structure or class.\n14. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, treatment-related pneumonitis, or any evidence of clinically active interstitial lung disease.\n15. Cardiac conditions as follows: Patient has a history of congestive heart failure (CHF) Class III\/IV according to the New York Heart Association (NYHA) Functional Classification or serious cardiac arrhythmias requiring treatment.\n16. Resting QTcF \\> 470 msec.\n17. Patient is unable to take drugs po due to disorders or diseases that may affect GI function, including but not limited to inflammatory bowel diseases (eg, Crohn's disease, ulcerative colitis) or malabsorption syndrome, or procedures that may affect gastrointestinal function, such as gastrectomy, enterectomy, or colectomy.\n18. Have any condition or illness that, in the opinion of the Investigator, might compromise patient safety or interfere with the evaluation of the safety of the drug.\n19. Pregnant or lactating females; females of child-bearing potential (FOCBP) must have a negative serum pregnancy test at within seven days prior to receiving study drug on C1D1. FOCBP and males with partners of child-bearing potential must agree to use adequate birth control (Section 16.3) throughout their participation and for six months following the last dose of study treatment.\n20. History of another primary malignancy within 2 years prior to starting study drug on C1D1, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ.\n21. Uncontrolled intercurrent illness including, but not limited to, uncompensated respiratory, cardiac, hepatic, or renal disease, active infection (including human immunodeficiency virus (HIV) and active clinical tuberculosis), or renal transplant; ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, or psychiatric illness\/social situations that would limit compliance with study requirements.\n22. For patients with a history of hepatitis B (HBV), negative PCR test is required. Patients with active hepatitis B (HBV) infection \\[as defined by a positive hepatitis B serum antigen (HBsAg) test and detectable HBV deoxyribonucleic acid (DNA)\\]. Patients ineligible due to detectable levels of HBV DNA at baseline may be rescreened for enrolment if their HBV DNA levels become undetectable after treatment with antiviral agents, and upon agreement between the Investigator and Sponsor.\n23. For patients with a history of hepatitis C, active infection as defined by a reactive hepatitis C virus (HCV) antibody test and detectable HCV ribonucleic acid (RNA).\n24. Active bleeding disorders.\n25. The patient is, in the Investigator's opinion, unable or unwilling to comply with the trial procedures.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04036682063","EMAIL":[{"email":"226100@h.tmu.edu.tw"},{}],"GEO":[25.04776,121.53185]},{"TITLE":"Study of IK-595 in RAS- or RAF-altered Advanced Tumors","CRITERIA":"Inclusion Criteria:\n\n1. Patients \u2265 18 years of age.\n2. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n3. Adequate organ function as follows (specimens must be collected during the Screening Period within 7 days prior to entering the Treatment Period):\n\n   1. ANC \u2265 1000\/\u03bcL\n   2. Hemoglobin \\> 9 g\/dL\n   3. Platelet count \\> 75,000\/\u03bcL\n   4. Calculated creatinine clearance \u2265 60 mL\/min (using the Cockcroft-Gault formula or using other formulae per institutional guidelines)\n   5. Serum total bilirubin \u2264 1.5 \u00d7 ULN or direct bilirubin \u2264 ULN for patients with total bilirubin levels \\> 1.5 \u00d7 ULN. Known Gilbert syndrome is allowed if total bilirubin is \\<3 \u00d7 ULN\n   6. AST and ALT \u2264 2.5 \u00d7 ULN (or \u2264 5 \u00d7 ULN if liver function abnormalities are due to underlying liver metastases)\n   7. Coagulation: \u2264 1.5 \u00d7 ULN unless patient is receiving anticoagulant therapy, as long as prothrombin time, international normalized ratio, or activated partial thromboplastin time is within therapeutic range of intended use of anticoagulants when applicable\n4. Left ventricular ejection fraction \u2265 50% by echocardiogram or radionuclide test.\n5. Patients must have recovered from the side effects of prior cancer-specific therapy to a minimum of \u2265 Grade 1 by NCI-CTCAE version 5.0 criteria or return to baseline. Exceptionally, patients with \u2264 Grade 2 neuropathy or other TRAEs may be eligible after discussion with the Sponsor.\n6. Washout period since receipt of the last dose of prior anticancer therapy (including other investigational therapy):\n\n   1. Checkpoint inhibitors such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed death ligand 1 (PD-L1) inhibitors: \u2265 4 weeks\n   2. For all other biologic agents (e.g., antiangiogenics): \u2265 3 weeks or a minimum of their dosing interval if shorter than 3 weeks (e.g., agents administered every 2 weeks would require a 2-week washout period)\n   3. All other investigational agents: \u2265 4 weeks or \u2265 5 \u00d7 t1\/2, whichever is shorter.\n7. If feasible, patients must be willing to consent to the submission of formalin-fixed paraffin-embedded (FFPE) tissue blocks of tumor tissue, preferably from a pretreatment, fresh tumor biopsy. Alternatively, archival tumor FFPE blocks or, \u2265 20 unstained slides of tumor tissue from available archival sources that are \\< 2 years old are acceptable.\n8. Highly effective contraception for both male and female patients from Screening through 5 months after the last dose of study drug if the possibility of conception exists.\n9. Patient or their legally acceptable representative must be able and willing to:\n\n   1. Provide Institutional Review Board-or Institutional Ethics Committee-approved written informed consent in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol-related procedures that are not part of normal patient care.\n   2. Comply with the study protocol and with the planned biopsy procedures.\n\n   Inclusion Criteria for Dose Escalation Patients\n10. Patients must have histologically or cytologically confirmed solid tumor malignancies that are advanced and unresectable, or metastatic with no available therapy known to confer clinical benefit, as evaluated by the treating physician. There is no upper limit on the number of prior lines of anticancer therapy received. Tumors must have confirmed RAS\/RAF gene alterations as determined by next-generation sequencing or fluorescence in situ hybridization, as documented by local testing:\n\n    1. NRASmut solid tumors, including but not limited to melanoma, CRC, and others\n    2. KRASmut solid tumors, including but not limited to NSCLC, pancreatic carcinoma, and CRC\n    3. BRAFmut Class I\/II\/ III or BRAF fusions solid tumors, including but not limited to melanoma, NSCLC, thyroid carcinoma\n    4. CRAF-altered solid tumors (mutations and gene fusions)\n    5. NF1mut solid tumors, including but not limited to nerve sheath tumors, gliomas, malignant melanoma, breast cancer, and others\n11. Patients who have measurable or evaluable disease by RECIST 1.1 criteria, as assessed by the Investigator\/local radiologist.\n\n    Inclusion Criteria for Dose Expansion Patients\n12. All patients must have a histological diagnosis of an advanced, unresectable, locally recurrent, or metastatic disease with no available therapy known to confer clinical benefit, as evaluated by the treating physician. There is no upper limit on the number of prior lines of anticancer therapy received.\n13. Patients must be enrolled in 1 of the following 4 dose expansion cohorts:\n\n    1. Cohort 1: Molecularly confirmed NRASmut CRC as determined by local test results\n    2. Cohort 2: Molecularly confirmed NRASmut malignant melanoma as determined by local test results\n    3. Cohort 3 Molecularly confirmed KRASmut NSCLC as determined by local test results\n    4. Cohort 4: Any solid tumors with molecularly confirmed pathogenic BRAF non-V600X mutations or fusions, or pathogenic CRAF mutations or fusions as determined by local test results\n14. Patients must have \u2265 1 measurable lesion per RECIST 1.1 criteria as assessed by the Investigator\/local radiologist. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions. Exceptionally, patients with tumors that are evaluable but non-measurable per RECIST 1.1 criteria can be enrolled following approval by the Sponsor.\n\nExclusion Criteria:\n\n1. Patients with any active central nervous system (CNS) lesion either symptomatic or radiologically unstable and\/or leptomeningeal metastasis. However, patients previously treated for these conditions that have had stable CNS disease (verified with consecutive imaging studies) for \\> 3 months, are asymptomatic and are not currently taking corticosteroids, or are on stable dose or decreasing of corticosteroids for \u2265 7 days prior to enrollment are eligible.\n2. Patients who have not recovered to \u2264 Grade 1 or baseline from all AEs due to prior anticancer therapies. Exceptionally, patients with \u2264 Grade 2 neuropathy or other TRAEs may be eligible after discussion with the Sponsor.\n3. Any other concurrent antineoplastic treatment or investigational agent except for localized radiation therapy for symptom palliation (to be considered nontarget lesions after treatment) and\/or hormonal therapy for ductal DCIS\/LCIS\/Stage 1 breast cancer that has been stable on therapy for \u2265 3 years.\n4. Uncontrolled or life-threatening symptomatic concomitant disease (including known symptomatic HIV-positive with an active AIDS-defining opportunistic infection or a current CD4 count \\< 350 cells\/\u03bcL; symptomatic active hepatitis B or C checked at screening; or active tuberculosis). Patients with HIV are eligible if:\n\n   1. They have received antiretroviral therapy (ART) as clinically indicated for \u2265 4 weeks prior to entering the Treatment Period of the study;\n   2. They continue on ART as clinically indicated while on study;\n   3. CD4 counts and viral loads are monitored per standard of care by a local health care provider.\n5. Has received prior radiotherapy for palliation \u2264 2 weeks prior to the first dose of study treatment. Patients must have recovered from all radiation-related toxicities.\n6. History of a second malignancy requiring systemic treatment \u2264 3 years prior to enrollment. Patients who have remained cancer-free \u2264 3 years of enrollment are eligible. Patients with history of prior early stage basal\/squamous cell skin cancer or noninvasive or in situ cancers that have undergone definitive treatment at any prior time are eligible.\n7. Clinically significant cardiovascular disease:\n\n   1. Cerebral vascular accident\/stroke (\\< 6 months prior to enrollment)\n   2. Myocardial infarction (\\< 6 months prior to enrollment)\n   3. Unstable angina (\\< 6 months prior to enrollment)\n   4. Congestive heart failure (New York Heart Association Classification Class III or IV)\n   5. The presence of any condition that can increase proarrhythmic risk (e.g., hypokalemia, bradycardia, heart block), including any new, unstable, or serious cardiac arrhythmia requiring medication, or other baseline arrhythmias that might interfere with interpretation of ECGs on study (e.g., bundle branch block).\n   6. Patients with QT interval corrected by Fridericia's formula (QTcF) \\> 470 msec for both men and women on screening ECG are excluded. Patients with a bundle branch block must have QT interval corrected for bundle branch block.\n   7. Patients who are on stable doses of concomitant medication with known prolongation of QTcF if QTcF is \\> 470 msec.\n8. Known previous or current serious ophthalmic disorders, including history of glaucoma, history of retinal vein occlusion (RVO) or current risk factors for RVO, history of retinal pathology or evidence of retinal pathology.\n9. Active skin disorder requiring systemic treatment \u22643 months prior to start of study treatment.\n10. History of rhabdomyolysis \u22643 months prior to start of study treatment.\n11. Patients taking any medication on the prohibited medication list are excluded from the study unless they can be transferred to other medications.\n12. Has an active infection requiring systemic therapy.\n13. A woman of childbearing potential who has a positive pregnancy test prior to initiating study treatment.\n14. Breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the Screening visit through 5 months after the last dose of study treatment.\n15. Patients who are unable to swallow or retain oral medication.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06270082005","EMAIL":[{"email":"mpoole@nextoncology.com"},{}],"GEO":[38.84622,-77.30637]},{"TITLE":"Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed.","CRITERIA":"Inclusion Criteria:\n\n* Histologically confirmed metastatic NSCLC, characterized by a sensitizing EGFR mutation.\n\n  2. Progressive disease, as assessed by the treating physician during osimertinib monotherapy.\n\n  3. Eligible for subsequent treatment. 4. Willing to undergo a histological biopsy and withdrawal of a blood sample for ctDNA analysis.\n\n  5. Technically possible to take a histological biopsy.\n\nExclusion Criteria:\n\n- 1. Osimertinib discontinuation before blood draw and \/ or histological tumor biopsy.\n\n2. Initiation of a new line of anticancer therapy before blood draw and \/ or histological tumor biopsy.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04737382001","EMAIL":[{"email":"j.d.langen@nki.nl"},{"email":"j.jebbink@nki.nl"}],"GEO":[52.37403,4.88969]},{"TITLE":"Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.","CRITERIA":"Inclusion Criteria:\n\n* Patients diagnosed with advanced non-small cell lung cancer (which includes de novo stage IIIB-IV, according to the 8th edition AJCC, or recurrent disease), documented by histology and\/or cytology.\n* Presence of brain metastases, candidates for treatment with holocranial radiation therapy.\n* Documented EGFR sensitivity mutation.\n* Disease measurable by criteria: The Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM).\n* 18 years and up.\n* Functional status, by ECOG scale 0-2\n* Life expectancy at least 12 weeks.\n* Not receive vasodilator treatment as calcium channel blockers.\n* Electrocardiogram\n* Neutrophil count 1.5 x 103\/mm3, platelet count \\>100 x (103\/mm3).\n* Serum bilirubin should be 1.5 of the upper normal limit (ULN, upper normal limit).\n* AST and\/or ALT 2 ULN (or 5 x ULN in patients with liver metastases).\n* Serum creatinine 1.5 (ULN), or creatinine clearance 60ml\/min.\n* Ability to comply with study and follow-up procedures.\n* Informed written (signed) consent to participate in the study.\n* Have tumor tissue (paraffin blocks from diagnostic biopsy) obtained before systemic treatment\n\nExclusion Criteria:\n\n* Any unstable systemic disease (including active infection, grade 4 hypertension, unstable angina, congestive heart failure, ischemic heart disease, liver, kidney disease).\n* Patients with a history of allergy to glyceryl tinistate\n* Any other malignant pathology within the previous 5 years (except for cervical carcinoma in situ or basal-cell skin cancer, treated appropriately).\n* Pregnant and\/or breastfeeding women.\n* Meningeal carcinomatosis corroborated by cytopathological study.\n\nDisposal Criteria:\n\n* Failure to follow protocol rules.\n* Loss of patient follow-up.\n* Patients who express their desire not to continue the study.\n* Patients with unacceptable toxicity","SEX":"ALL","AGE_MIN":18,"AGE_MAX":85,"SS_ID":"06238882001","EMAIL":[{"email":"ogarrieta@gmail.com"}],"GEO":[19.42847,-99.12766]},{"TITLE":"A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Signed informed consent must be obtained prior to participation in the study.\n* Adult men and women \u2265 18 years of age.\n* Histologically confirmed and documented advanced malignancies (locally advanced malignancies, non-curable by surgery or radiotherapy and metastatic disease). Disease must be measurable, including presence of at least one measurable lesion, as determined by RECIST v1.1.\n* In the opinion of the treating investigator, patients must have received, but are not benefitting from standard therapies, be intolerant or ineligible to receive such therapy, or have no standard therapy option for the respective disease types (diseases listed below), as well as any other therapies deemed to be standard by local\/institutional standard.\n* Non-small cell lung cancer\n* Esophageal squamous cell carcinoma\n* Renal cell carcinoma\n* HPV-associated head and neck squamous cell carcinoma\n* Must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines. The patient must be willing to undergo a new tumor biopsy at screening and during treatment.\n\nExclusion Criteria:\n\n* Active previously documented or suspected autoimmune disease. Patients with vitiligo, type I diabetes, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur should not be excluded. Patients previously exposed to anti-PD-1\/PD-L1 treatment who are adequately treated for skin rash or with replacement therapy for endocrinopathies should not be excluded.\n* Patients with a history of or current interstitial lung disease or pneumonitis \u2265 Grade 2.\n* Patients who discontinued prior anti-PD-1 therapy due to an anti-PD-1-related toxicity\n* Clinically significant cardiac disease or risk factors at screening\n* Insufficient bone marrow function at screening:\n* Infections:\n* Known history of testing positive for Human Immunodeficiency Virus infection.\n* Active Hepatitis B and \/ or Hepatitis C.\n* Active, documented COVID-19 infection\n* Known history of tuberculosis\n* Any serious uncontrolled infection (acute or chronic).\n* Systemic chronic steroid therapy (\\>10 mg\/day prednisone or equivalent) or any immunosuppressive therapy, other than replacement-dose steroids in the setting of adrenal insufficiency, within 7 days of the first dose of study treatment. Topical, inhaled, and ophthalmic steroids are allowed.\n\nOther protocol-defined inclusion\/exclusion criteria may apply.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05462873011","EMAIL":"novartis.email@novartis.com","GEO":[25.04776,121.53185]},{"TITLE":"AMAZE-lung: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI","CRITERIA":"Inclusion Criteria:\n\n1. Histologically confirmed non-squamous NSCLC, stage IIIB\/C (not amenable to radical therapy) or stage IV according to 8th TNM classification.\n2. Presence of a sensitising EGFR-mutation (only patients with exon 19 deletion and\/or L858R are eligible) and documentation of T790M status, tested locally by an accredited laboratory.\n3. Radiologically confirmed disease progression on previous treatment with osimertinib or lazertinib.Treatment with osimertinib must have been stopped at least 8 days before enrolment.\n4. Achieved objective clinical benefit from osimertinib or lazertinib treatment (e.g., documented PR\/ CR or SD for \u22656 months while on osimertinib or lazertinib treatment).\n5. Measurable disease as defined according to RECIST v1.1.\n6. Age \u226518 years.\n7. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n8. Life expectancy \u226512 weeks.\n9. Adequate haematological function:\n\n   * Haemoglobin \u2265100 g\/L,\n   * Absolute neutrophil count (ANC) \u22651.5\u00d7 109\/L,\n   * Platelet count \u226575\u00d7 109\/L.\n10. Adequate renal function:\n\n    - Serum creatinine \\<1.5\u00d7 ULN and calculated (Cockcroft-Gault formula) or measured creatinine clearance \\>45 mL\/min.\n11. Adequate liver function:\n\n    * ALT and AST \u22643\u00d7 ULN. If the patient has liver metastases, ALT and AST must be \u22645\u00d7 ULN.\n    * Total bilirubin \u22641.5\u00d7 ULN. Patients with Gilbert's syndrome are eligible if conjugated bilirubin is within normal limits.\n12. Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative pregnancy test (b-human chorionic gonadotropin \\[b-hCG\\]) within 5 weeks before enrolment and within 3 days before the first dose of protocol treatment. Women of childbearing potential must use highly effective contraceptive methods.\n13. Written IC for trial participation must be signed and dated by the patient and the investigator prior to any trial-related intervention.\n\nExclusion Criteria:\n\n1. Patients with known small cell lung carcinoma (SCLC) transformation.\n2. Patients with symptomatic brain metastases. Patients with asymptomatic or previously treated and stable brain metastases may participate in this study. Patients who have received definitive radiotherapy or surgery for symptomatic or unstable brain metastases and have been clinically stable and asymptomatic for at \u22652 weeks before enrolment are eligible, provided they have been either off corticosteroid treatment or are receiving low-dose corticosteroid treatment (\u226410 mg\/day prednisone or equivalent) for at least 2 weeks prior to enrolment.\n3. Patients with an active or past medical history of leptomeningeal disease.\n4. Patients with untreated spinal cord compression. Patients who have been definitively treated with surgery or radiotherapy and have a stable neurological status for \u22652 weeks prior to enrolment are eligible provided they are off corticosteroid treatment or are receiving low-dose corticosteroid treatment \u226410 mg\/day prednisone or equivalent.\n5. Patients with unresolved adverse events (other than alopecia) from prior anticancer therapy that have not resolved to grade \u22641 or baseline.\n6. Patients with positive hepatitis B (hepatitis B virus \\[HBV\\]) surface antigen (HBsAg) test.\n7. Patients with positive hepatitis C antibody (anti-HCV) test.\n8. Patients with other clinically active infectious liver disease.\n9. Patients who are known positive for HIV, with one or more of the following:\n\n   * Receiving antiretroviral therapy (ART) that may interfere with study treatment\n   * CD4 count \\<350 at screening.\n   * AIDS-defining opportunistic infection within 6 months before enrolment.\n   * Not agreeing to start ART and be on ART \\>4 weeks plus having HIV viral load \\<400 copies\/mL at end of 4-week period (to ensure ART is tolerated and HIV is under control).\n10. Patients with active cardiovascular disease including, but not limited to:\n\n    * Medical history of deep vein thrombosis or pulmonary embolism within 1 month prior to enrolment or any of the following within 6 months prior to enrolment: Myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary\/peripheral artery bypass graft, or any acute coronary syndrome.\n    * Prolonged corrected QTcF \\>470 msec, clinically-significant cardiac arrhythmia (e.g., atrial fibrillation with uncontrolled rate) or abnormalities in conduction or morphologiy of electrocardiogram (ECG) (e.g., complete left bundle branch block, third- or second-degree heart block, PR interval \\>250 msec), or electrophysiologic disease (eg, placement of implantable cardioverter defibrillator).\n    * Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years in first degree relatives or any concomitant medications known to prolong QT interval or induce TdP.\n    * Uncontrolled (persistent) hypertension: systolic blood pressure \\>160 mm Hg; diastolic blood pressure \\>100 mm Hg.\n    * Congestive heart failure (CHF), defined as New York Heart Association (NYHA) class III-IV or hospitalisation for CHF (any NYHA class) within 6 months before enrolment.\n    * An active or past medical history of pericarditis, pericardial effusion that is clinically unstable, or myocarditis.\n    * Pericardial effusion considered due to the disease under study is permitted if clinically stable at screening.\n    * Baseline LVEF either \\<50% or below the lower limit of normal (LLN) per institutional guidelines, as assessed by screening echocardiogram (ECHO) or multigated acquisition (MUGA) scan.\n11. Patients with interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis.\n12. Patients with a history of haemoptysis (\u22652.5 mL of bright red blood per episode) within 1 month prior to enrolment.\n13. Patients with evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation).\n14. Patients with current or recent (within 10 days before enrolment) use of aspirin (\\>325 mg\/day) or treatment with dipyridamole, ticlopidine, clopidogrel, and clostazol.\n15. Patients with current use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes that has not been stable for \\>2 weeks prior to enrolment.\n\n    * The use of full-dose oral or parenteral anticoagulants is permitted as long as the INR or aPTT is within therapeutic limits (according to the medical standard of the enrolling institution) and the patient has been on a stable dose of anticoagulants for at least 2 weeks prior to enrolment.\n    * Prophylactic anticoagulation for the patency of venous access devices is allowed, provided the activity of the agent results in an INR \\<1.5\u00d7 ULN and aPTT is within normal limits within 14 days prior to enrolment.\n    * Prophylactic use of low-molecular-weight heparin (i.e., enoxaparin 40 mg\/day) is permitted.\n16. Patients with serious, non-healing wound, active ulcer, or untreated bone fracture.\n17. Patients who had a core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to enrolment.\n18. Patients who had major surgery or significant traumatic injury within 28 days prior to enrolment.\n19. Patients who had placement of a vascular access device within 2 days prior to prior to enrolment.\n20. Patients with a history of abdominal or tracheoesophageal fistula or gastrointestinal perforation within 6 months prior to enrolment.\n21. Patients with clinical signs of gastrointestinal obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding.\n22. Patients with evidence of abdominal free air not explained by paracentesis or recent surgical procedure.\n23. Patients with concurrent or prior malignancy other than the disease under study.\n\n    Some exceptions require consultation with the ETOP IBCSG Partners\n24. Patients with uncontrolled illness, including but not limited to:\n\n    * Uncontrolled diabetes.\n    * Ongoing or active infection, or diagnosed or suspected viral infection.\n    * Active bleeding diathesis.\n    * Impaired oxygenation requiring continuous oxygen supplementation.\n    * Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated drug, or previous significant bowel resection\n    * Psychiatric illness, social situation, or any other circumstances that would limit compliance with study requirements.\n    * Any ophthalmologic condition that is clinically unstable.\n25. History of hypersensitivity to either the drug substance or any excipients in amivantamab, lazertinib and\/ or bevacizumab.\n26. Prior chemotherapy for NSCLC.\n27. Prior treatment with bevacizumab or another anti-angiogenic inhibitor.\n28. Prior treatment with a MET\/EGFR-targeting antibody.\n29. Judgement by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.\n30. Women who are pregnant or in the period of lactation.\n31. Women of childbearing potential or men who are sexually active with a woman of childbearing potential, who are not willing to use at least one method of highly effective contraception while receiving protocol treatment and for at least 6 months after the last dose of protocol treatment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05601973021","EMAIL":[{"email":"sanjay.popat@rmh.nhs.uk"}],"GEO":[51.50853,-0.12574]},{"TITLE":"Anatomical Location and Metastasis Pattern of Intrapulmonary Lymph Nodes in NSCLC (ECTOP-1010)","CRITERIA":"Inclusion Criteria:\n\n1. Preoperative examination showed patients with clinical T1 peripheral non-small cell lung cancer (NSCLC);\n2. The lesion is located in a single lung segment or between two adjacent lung segments;\n3. Perform radical lobectomy;\n4. The preoperative examination did not reveal unresectable lymph nodes;\n5. Have not received any other tumor-related treatments (including chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc.) before surgery;\n6. No malignant tumor history;\n7. No contraindications to surgery (ECOG score 0-1 points);\n\nExclusion Criteria:\n\n1. Pathology revealed patients with non-T1 stage non-small cell lung cancer (NSCLC);\n2. Radical lobectomy is not performed;\n3. Acception of any anti-tumor treatment before surgery (excluding Chinese medicine treatment);\n4. Refused to enter the group or asked to leave the group.","SEX":"ALL","AGE_MIN":0,"AGE_MAX":200,"SS_ID":"05094882001","EMAIL":[{"email":"hqchen1@yahoo.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance","CRITERIA":"Inclusion Criteria:\n\nMetastatic Non-squamous NSCLC is histologically or cytologically proven to be inoperable and cannot receive radical concurrent chemoradiotherapy. The conventional TNM stage was identified as stage IIIa-\u2163b according to the International Association for the Study of Lung Cancer and the American Joint Committee on the Classification of Cancer 8th edition TNM Staging of Lung Cancer.\n\nPatients with EGFR mutation and TP53 mutation advanced Non-squamous NSCLC. Patients who had not previously received systemic radiotherapy and chemotherapy or who had relapsed for more than 6 months of follow-up after onset of adjuvant chemotherapy.\n\nAt least one measurable lesion as determined by RECIST criteria. Male or female patients, age: 18-75 years of age. Performance score 0-1 based on Eastern Cooperative Oncology Group (ECOG) test. Expected survival period \u226512 weeks. Serum absolute number of neutrophils\u2265 1.5 x 10\\^9\/L, platelet \u2265 100 x10\\^9\/L, and hemoglobin\u2265 90g\/L.\n\nSerum bilirubin\u22641.5 times ULNL, aspartate aminotransferase (AST) and adenosine triphosphate(ALT) \u2264 2.5 times ULN, alkaline phosphatase \u2264 5 times ULN.\n\nSerum creatinine\u2264 the ULN or creatinine clearance \u2265 60 mL\/min. Patients who had previously undergone surgery have recovered for more than 4 weeks from the beginning of the project.\n\nWomen with an intact uterus must have a negative pregnancy test within 28 days prior to enrolement in the study (unless it was 24 months after amenorrhea). If the pregnancy test is more than 7 days prior to initial dosing, a urine pregnancy test is required for verification (within 7 days prior to initial dosing).\n\nIf there is a risk of conception, all patients (whether male or female) are required to use contraceptive measures with an annual failure rate of less than 1% throughout the treatment period until 120 days after the last dose of the study drug.\n\nSign the inform consent form with good compliance.\n\nExclusion Criteria:\n\nThose who are known to be allergic to the study drug almonertinib and anlotinib and its any components.\n\nIntolerance to study drug treatment or allergy to the active ingredients or excipients of combined chemotherapy drugs.\n\nPregnancy or breastfeeding women or women who may be pregnant but are unwilling to take appropriate contraception.\n\nExisting severe acute infections that are not under control; Or suppurative and chronic infections with delayed healing.\n\nPre-existing serious heart disease, including: congestive heart failure, uncontrolled high-risk arrhythmias, unstable angina pectoris, myocardial infarction, severe valvular heart disease, and refractory hypertension.\n\nPeople suffering from uncontrollable neuropsychiatric diseases or mental disorders had poor compliance and were unable to cooperate and describe treatment responses; The conditions of patients with primary brain tumor or central nerve metastatic tumor were uncontrollable and the symptoms of cranial hypertension or neuropsychiatric were obvious.\n\nPatients with hereditary bleeding tendency or coagulation dysfunction, or history of thrombosis or bleeding, and abnormal detection results of coagulation function related indicators.\n\nPatients who are receiving thrombolytic or anticoagulant therapy due to high risk of thrombosis.\n\nPatients with unhealed wounds, unhealed ulcers or unhealed fractures. Other conditions that the investigator considers to be inappropriate for the patient to participate in this trial.\n\nCurrently participating in interventional clinical research treatment, or have received other investigational drugs or used investigational device treatment within 4 weeks before the first dose.\n\nPatients who have undergone major surgery within 4 weeks before the start of study treatment or are scheduled to undergo major surgery during the study period (except for surgery such as puncture or lymph node biopsy).\n\nPulmonary interstitial fibrosis with respiratory failure. Chronic obstructive pulmonary disease with respiratory failure. Active pulmonary tuberculosis; Active autoimmune disease requiring systemic therapy (such as the use of disease-modifying drugs, glucocorticoids, or immunosuppressants) within 2 years prior to the first dose. Replacement therapy (such as thyroxine) is not considered systemic therapy; Those who are receiving systemic glucocorticoid therapy (excluding nasal spray, inhalation or other local glucocorticoids) or any other form of immunosuppressive therapy within 14 days before the first dose of the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06043973001","EMAIL":[{"email":"deganlu@126.com"}],"GEO":[36.66833,116.99722]},{"TITLE":"A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression","CRITERIA":"Key Inclusion Criteria:\n\n1. Appropriately enrolled in the BASECAMP-1 A2 Biotherapeutics, Inc. study, with tissue demonstrating LOH of HLA-A\\*02:01 by NGS (whenever possible from the primary site), successful apheresis and PBMC processing, and with sufficient stored cells available for Tmod CAR T-cell therapy\n2. Histologically confirmed recurrent unresectable, locally advanced, or metastatic CRC, NSCLC, PANC, or other solid tumors associated with CEA expression. Measurable disease is required with lesions of \\>1.0 cm by computed tomography (CT). (Soluble CEA is not acceptable as the sole measure of disease).\n3. Received previous required therapy for the appropriate solid tumor disease as described in the protocol\n4. Has adequate organ function as described in the protocol\n5. ECOG performance status of 0 to 1\n6. Life expectancy of \u22653 months\n7. Willing to comply with study schedule of assessments including long term safety follow up\n\nKey Exclusion Criteria:\n\n1. Has disease that is suitable for local therapy or able to receive standard of care therapy that is therapeutic and not palliative\n2. Prior allogeneic stem cell transplant\n3. Prior solid organ transplant\n4. Cancer therapy within 3 weeks or 3 half lives of A2B530 infusion\n5. Radiotherapy within 28 days of A2B530 infusion\n6. Unstable angina, arrhythmia, myocardial infarction, or any other significant cardiac disease within the last 6 months\n7. Any new symptomatic pulmonary embolism (PE) or a deep vein thrombosis (DVT) within 3 months of enrollment. Therapeutic dosing of anticoagulants is allowed for history of PE or DVT if greater than 3 months from time of enrollment, and adequately treated.\n8. Requires supplemental home oxygen\n9. Females of childbearing potential who are pregnant or breastfeeding\n10. Subjects, both male and female, of childbearing potential who are not willing to practice birth control from the time of consent through 6 months post infusion of A2B530","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05736731010","EMAIL":[{"email":"GIClinicalTrials@mdanderson.org"},{}],"GEO":[29.76328,-95.36327]},{"TITLE":"Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Patients must have Stage III nonsmall cell lung cancer confirmed by histologic or cytologic documentation and by clinical assessment. Stage III nonsmall cell lung cancer is defined according to the American Joint Committee on Cancer Staging Manual, 8th Edition (2017).\n* Unresectable or medically inoperable as determined by the investigator.\n* The participant has definitive radiation therapy (e.g., 54 Gy to 66 Gy in 30 to 35 fractions) for lung cancer that is either (a) planned to start within the next 28 days, or (b) currently being administered, or (c) has been completed within the last 14 days.\n* Platinum-based chemotherapy for lung cancer that is either (a) planned to start within the next 28 days, (b) currently being administered, or (c) has been completed within the last 14 days. Chemotherapy must be for at least two cycles and be administered either before radiation therapy (\"induction\" or \"sequential\") or during radiation therapy (\"concurrent\").\n* Consolidation Durvalumab is planned for nonsmall cell lung cancer after radiation and chemotherapy.\n* Eighteen years old or greater.\n* ECOG performance status of 0-2.\n* Life expectancy of greater than three months.\n* Patients with sexual relationships in which either they or their partner may become pregnant must use contraception during the study treatment period.\n* Ability to understand and be willing to sign an IRB-approved informed consent document directly or via a legally authorized representative.\n\nExclusion Criteria:\n\n* Uncontrolled respiratory symptoms (i.e., cough, dyspnea, fevers, chest pain, or an increase from baseline oxygen requirements) that are interfering with activities of daily living.\n* Nonsmall cell lung cancer is known to have progressed during radiation therapy.\n* Nonsmall cell lung cancer is known to have a tumor with a mutation in EGFR associated with sensitivity to first-line therapy with a tyrosine kinase inhibitor (i.e., Ex19del, L858R, EGFR S768I, L861Q, or G719X). If not already known, testing for EGFR mutations is not required for study enrollment.\n* Prior exposure to an immune checkpoint inhibitor targeting CTLA-4, PD-1, or PD-L1.\n* Active autoimmune disease requiring systemic immunosuppression at the time of enrollment.\n* History of autoimmune pneumonitis requiring high-dose systemic steroids (equivalent prednisone \\>20 mg\/day for more than one week).\n* Uncontrolled intercurrent illness includes ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\/social situations that would limit compliance with study requirements.\n* Patients who are pregnant or breastfeeding.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05696782001","EMAIL":[{"email":"saverill@wakehealth.edu"},{}],"GEO":[36.09986,-80.24422]},{"TITLE":"ENCOrafenib With Binimetinib in bRAF NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Subjects must have signed and dated an IRB\/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care.\n\n   Subjects must be willing and able to comply with scheduled visits, treatment schedule, and laboratory testing.\n2. Male or female aged at least 18 years old.\n3. Histologically confirmed diagnosis of NSCLC that is currently Stage IV (M1a, M1b or M1c AJCC 8th edition).\n4. ECOG performance status of 0-1.\n5. Able to swallow and retain oral medication.\n6. Presence of a BRAFV600E mutation in lung cancer tissue as determined by a local laboratory assay.\n7. The Investigator must confirm prior to enrolment that the patient has adequate tumor tissue available to determine BRAFV600E mutation status by central laboratory for confirmation.\n\n   Note: Tumor tissue collected after the patient was diagnosed with metastatic disease is preferred.\n\n   Tumor tissue sample must not be from locations previously radiated. Tumor sample must be 1 block or 10 to 15 unstained slides of analyzable tissue and one H\\&E slide.\n8. Patients i) (COHORT A) who are either treatment-na\u00efve (e.g., no prior systemic therapy for advanced\/metastatic disease), ii) (COHORT B) who are in progression after having received 1) first-line platinum-based chemotherapy OR 2) first-line treatment with an anti-PD-1\/L-1 inhibitor given alone or in combination with platinum-based chemotherapy or in combination with immunotherapy (e.g, ipilimumab) with or without platinum-based chemotherapy.\n\n   Note: Alternative chemotherapy regimens are acceptable if the patient was platinum intolerant or ineligible.\n\n   Patients with early stage disease (e.g., Stages I-III) who have had surgery followed by chemotherapy (e.g., treatment in the adjuvant setting), and present with new lesions or evidence of disease recurrence (e.g., metastatic disease), within 12 months of completing chemotherapy, would be considered as had received a first-line therapy.\n\n   Maintenance therapy given after first-line therapy in the metastatic setting will not be considered a separate regimen, provided there was no documentation of disease progression between completion of first-line therapy and the start of maintenance therapy.\n9. Presence of measurable disease based on RECIST v1.1.\n10. Adequate bone marrow function characterized by the following at screening:\n\n    i) ANC \u2265 1.5 \u00d7 109\/L; ii) Platelets \u2265 100 \u00d7 109\/L; iii) Hemoglobin \u2265 8.5 g\/dL (with or without blood transfusions).\n11. Adequate hepatic and renal function characterized by the following at screening:\n\n    i) Total bilirubin \u2264 1.5 \u00d7 ULN and \\< 2 mg\/dL; OR total bilirubin \\>1.5 \u00d7 ULN with indirect bilirubin \\< 1.5 \u00d7 ULN; ii) ALT and AST \u2264 2.5 \u00d7 ULN, or \u2264 5 \u00d7 ULN in presence of liver metastases; iii) Serum creatinine \u2264 1.5 \u00d7 ULN; or calculated creatinine clearance \u2265 50 mL\/min by Cockcroft-Gault formula; or estimated glomerular filtration rate\\>50 mL\/min\/1.73m2.\n12. Female patients of childbearing potential as described in Appendix 1, must have a negative serum \u03b2 HCG test result.\n13. Female patients of childbearing potential must agree to use methods of contraception that are highly effective or acceptable, as described in Appendix 1, and to not donate ova from Screening until 30 days after the last dose of study treatment.\n14. Male patients must agree to use methods of contraception that are highly effective or acceptable, as described in Appendix 1, and to not donate sperm from Screening until 90 days after the last dose of encorafenib and binimetinib.\n15. Patient covered by a national health insurance\n\nExclusion Criteria:\n\n1. Patients with nonsquamous carcinoma who have documentation of any of the following: EGFR mutation, ALK fusion oncogene or ROS1 rearrangement.\n2. Previous treatment with any other BRAF inhibitor (e.g., dabrafenib, vemurafenib...), or any other MEK inhibitor (e.g., trametinib, cobimetinib...) prior to screening and enrolment.\n\n4. Patients who have received more than 1 prior line of systemic therapy in the advanced\/metastatic setting for Cohort B.\n\nNote: Generally, treatments that are separated by an event of progression are considered to represent another line of therapy.\n\nAny therapeutic intervention including systemic therapy, surgery concurrent with or followed by systemic therapy, radiation concurrent with systemic therapy, or stereotactic radiation\/radiosurgery, initiated or added to an existing therapy for oligometastatic disease will be considered a new line of therapy.\n\nPalliative radiation to solitary lesions is permitted and will not be considered a new line of therapy.\n\nSurgery\/radiosurgery for CNS metastases is permitted and will not be considered a line of therapy as long as the surgery\/radiosurgery was not given with systemic therapy (neoadjuvant or adjuvant).\n\nSurgery followed by chemotherapy in the metastatic setting will be considered a line of therapy.\n\n5. Receipt of anticancer therapies or investigational drugs within the following intervals before the first administration of study treatment: i) \u226414 days for chemotherapy, targeted small molecule therapy, radiation therapy, immunotherapy, or antineoplastic biologic therapy (e.g., erlotinib, crizotinib, bevacizumab etc.).\n\nii) \u226414 days or 5 half-lives (minimum of 14 days) for investigational agents or devices. For investigational agents with long half-lives (e.g., \\> 5 days), enrolment before the fifth half-life requires sponsor approval.\n\niii) Palliative radiation therapy must be complete 7 days prior to the first dose of study treatment.\n\n6. Patients who have had major surgery (e.g., inpatient procedure with regional or general anesthesia) \u2264 6 weeks prior to start of study treatment.\n\n7. For cohort B : Patient has not recovered to \u2264Grade 1 from toxic effects of prior therapy and\/or complications from prior surgical intervention before starting study treatment.\n\nNote: Stable chronic conditions (\u2264 Grade 2) that are not expected to resolve (e.g., neuropathy, myalgia, alopecia, and prior therapy-related endocrinopathies) are exceptions.\n\n8. Current use of a prohibited medication (including herbal medications, supplements, or foods), or use of a prohibited medication \u22641 week prior to the start of study treatment.\n\n9. Impairment of gastrointestinal function or disease which may significantly alter the absorption of oral study treatment (e.g., uncontrolled nausea, vomiting or diarrhea, malabsorption syndrome, small bowel resection).\n\n10. Impaired cardiovascular function or clinically significant cardiovascular diseases, including any of the following: i) History of acute myocardial infarction, acute coronary syndromes (including unstable angina, coronary artery bypass graft, coronary angioplasty or stenting) \u2264 6 months prior to start of study treatment; ii) Congestive heart failure requiring treatment (New York Heart Association Grade \u22652); iii) LVEF \\< 50% as determined by MUGA or ECHO; iv) Uncontrolled hypertension defined as persistent systolic blood pressure \u2265150 mmHg or diastolic blood pressure \u2265100 mmHg despite optimal therapy; v) History or presence of clinically significant cardiac arrhythmias (including uncontrolled atrial fibrillation or uncontrolled paroxysmal supraventricular tachycardia); vi) Baseline QTcF interval \u2265480 ms or a history of prolonged QT syndrome. 11. History of thromboembolic or cerebrovascular events \u226412 weeks prior to the first dose of study treatment. Examples include transient ischemic attacks, cerebrovascular accidents, hemodynamically significant (i.e. massive or sub-massive) deep vein thrombosis or pulmonary emboli. Note: Patients with either deep vein thrombosis or pulmonary emboli that does not result in hemodynamic instability are allowed to enrol as long as they are on a stable dose of anticoagulants for at least 4 weeks. Note: Patients with thromboembolic events related to indwelling catheters or other procedures may be enrolled.\n\n12. History or current evidence of RVO (Retinal Vein Occlusion) or current risk factors for RVO (e.g., uncontrolled glaucoma or ocular hypertension, history of hyper viscosity or hypercoagulability syndromes); history of retinal degenerative disease.\n\n13. Concurrent neuromuscular disorder that is associated with the potential of elevated CK (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy).\n\n14. Evidence of active, noninfectious pneumonitis, history of interstitial lung disease that required oral or intravenous glucocorticoid steroids for management.\n\n15. Evidence of HBV or HCV infection. Note: Patients with laboratory evidence of cleared HBV or HCV infection may be enrolled. Note: Patients with no prior history of HBV infection who have been vaccinated against HBV and who have a positive antibody against hepatitis B surface antigen as the only evidence of prior exposure may enrol.\n\n16. Patient who aas has a known history of a positive test for HIV or known AIDS.\n\n17. Active infection requiring systemic therapy. 18. Patients with symptomatic brain metastasis, leptomeningeal disease or other active CNS metastases are not eligible.\n\nNote: Patients with previously treated or not treated brain metastases may participate provided they are stable (e.g., without evidence of progression by radiographic imaging for at least 28 days before the first dose of study treatment and neurologic symptoms have returned to baseline) Patients must have no evidence of new or enlarging brain metastases or CNS edema.\n\nPatient must have discontinued use of steroids at least 7 days before the first dose of study treatment.\n\n19. Concurrent or previous other malignancy within 2 years of study entry, except curatively treated basal or squamous cell skin cancer, prostate intraepithelial neoplasm, carcinoma in-situ of the cervix, Bowen's disease and Gleason 6 prostate cancer.\n\n20. Known sensitivity or contraindication to any component of study treatment or their excipients.\n\n21. Pregnancy confirmed by a positive \u03b2-HCG laboratory test result, or breastfeeding (lactating).\n\n22. Other severe, acute or chronic medical or psychiatric condition(s) or laboratory abnormality that may increase the risk associated with study participation or study treatment administration or that may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient an inappropriate candidate for the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04526782037","EMAIL":[{"email":"contact@ifct.fr"}],"GEO":[48.7939,2.35992]},{"TITLE":"A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)","CRITERIA":"Inclusion Criteria:\n\n* Be greater than 18 years of age on day of signing informed consent.\n* Have a histologically confirmed diagnosis of stage IV NSCLC (includes patients who have progressed on durvalumab for Stage III NSCLC) without known mutations in (EGFR) or BRAF or rearrangements in ALK (anaplastic lymphoma kinase) or ROS-1.\n* Newly diagnosed metastatic non-small cell lung cancer (NSCLC), including both de novo and secondary metastatic disease, with one or more liver metastases\n* Plan to initiate standard of care anti-PD-(L)1 based immunotherapy +\/- platinum based chemotherapy for at least 3 cycles\n\n  o Regimens combining anti-CTLA-4 immunotherapy with anti-PD-1 (e.g., ipilimumab plus nivolumab) or anti-PD-L1 (e.g., tremelimumab plus durvalumab) immunotherapy are allowed.\n* Have a performance status of 0-2 on the ECOG Performance Scale.\n* Liver function tests:\n\n  * Total Bilirubin \u2264 1.5 x ULN\n  * AST\/ ALT \u2264 5 x ULN\n* Eligible for L- SABR to all liver metastases.\n* Patients with known HIV are eligible provided they are under treatment with effective anti-retroviral therapy with CD4 \\>200 cells\/microliter \u2264 28 days prior to registration\n\nExclusion Criteria:\n\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen should be included.\n* Patients with prior external beam radiation therapy to the liver.\n* Patients with known active Hepatitis B or Hepatitis C.\n* Patients with immunosuppression including pharmacological immunosuppression with chronic steroids or immune modulators like cyclosporin or methotrexate and patients with active autoimmune disease.\n* Patients who are pregnant or breastfeeding\n* Men or women not using effective contraception.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05657873008","EMAIL":[{}],"GEO":[40.60843,-75.49018]},{"TITLE":"Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +\/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers","CRITERIA":"Inclusion Criteria:\n\n* Ability to understand and be willing to sign an informed consent form\n\n  * Males and females aged over 18 years\n  * Eastern Cooperative Oncology Group (ECOG) status of 0 to 1\n  * Locally advanced or metastatic squamous non-small cell lung cancer for which all available standard of care treatment options have been exhausted or refused and for which at least one lesion is measurable\n  * Have an estimated life expectancy of at least 3 months\n  * Participants must be willing to provide a fresh tumor biopsy sample\n  * Have adequate organ function\n  * Females must be non-pregnant and non-lactating, willing to use a highly effective method of contraception from screening until study completion or be either surgically sterile or post-menopausal\n  * Males must be surgically sterile, abstinent, or if engaged in sexual relations with a woman of child-bearing potential, the participant and his partner must be surgically sterile or using an acceptable, highly effective contraceptive method from screening until study completion\n\nExclusion Criteria:\n\n* Prior treatment with HMBD-001, docetaxel, cetuximab or any other agent that targets Epidermal Growth Factor Receptor (EGFR) or HER3, including pan-HER inhibitors\n\n  * Receipt of prior targeted therapy, including but not limited to those targeting EGFR activating mutations, ALK fusions, ROS rearrangements, RET fusions or mutations, BRAF V600E mutation, MET exon 14 skipping mutation, and\/or KRAS G12C mutation\n  * Persistent clinically significant toxicities (Grade \u22652) from previous anti-cancer therapy except for Grade \\>2 toxicities that are considered unlikely to put the participant at an increased risk of treatment-related toxicity and\/or impact the study results e.g., alopecia\n  * Most recent anti-cancer therapy including radiotherapy at least 4 weeks, or nitrosourea or mitomycin 3 at least 6 weeks, or 5 half-lives whichever is shorter prior to starting the assigned study treatment\n  * Symptomatic primary Central Nervous System (CNS) cancer or metastases unless the symptoms are stable for at least 28 days prior to the first dose of the study drug and any symptoms have returned to baseline\n  * Evidence of abnormal cardiac function\n  * History of uncontrolled allergic reactions and\/or known expected hypersensitivity to the study drugs used in the treatment arm to which the participant is to be enrolled into\n  * Any other known active malignancy except for treated cervical intraepithelial neoplasia, or non-melanoma skin cancer\n  * Any uncontrolled illness or significant uncontrolled condition(s) requiring systemic treatment\n  * Known Human Immunodeficiency Virus (HIV) infection\n  * Active hepatitis B or hepatitis C infection\n  * Pregnant or breast feeding\n  * COVID 19 infection within 3 months prior to the first dose of the study drug\n  * COVID 19 vaccination within 14 days prior to the first dose of the study drug\n  * Treatment with strong inhibitors or inducers of CYP3A4","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05910827008","EMAIL":[{},{}],"GEO":[1.28967,103.85007]},{"TITLE":"Study Comparing Two Different Schedules of Radiation for Early-stage Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Histological confirmation of non-small cell cancer will not be required as primary goal of this phase II trial is to look at toxicity. However, all primary non-small cell lung cancers otherwise of following types are eligible: squamous cell carcinoma, adenocarcinoma, large cell carcinoma, bronchioalveolar cell carcinoma, or non-small cell carcinoma not otherwise specified.\n* Eligible patients must have appropriate staging studies identifying them as specific subsets of AJCC stage I or II based on only one of the following combinations of TNM staging:\n* T1, N0, M0\n* T2 (\u2264 5 cm), N0, M0\n* Patients with hilar or mediastinal lymph nodes \u2264 1cm and no abnormal hilar or mediastinal uptake on PET will be considered N0. Patients with \\> 1 cm hilar or mediastinal lymph nodes on CT or abnormal PET (including suspicious but non-diagnostic uptake) may still be eligible if directed tissue biopsy of all abnormally identified areas are negative for cancer. All patients with suspicious nodes will be evaluated for mediastinal and hilar staging with bronchoscopy and (if amenable) bronchoscopic biopsy (preferably navigational biopsy and\/or endobronchial US guided biopsy).\n* Zubrod performance status 0-2 within 4 weeks of study entry.\n* Women of childbearing potential and male participants must use an effective contraceptive method.\n* Evaluations required at time of study entry:\n* History \\& Physical by a radiation oncologist within 4 weeks of study entry;\n* Vitals within 4 weeks of study entry;\n* Evaluation by a thoracic surgeon (either via clinical examination and\/or input at multidisciplinary tumor board) prior to study entry;\n* PFTs: Routine spirometry, lung volumes, diffusion capacity, and arterial blood gases within 8 weeks prior to study entry;\n* CT Chest within 6 weeks of study entry (preferably with intravenous contrast, unless medically contraindicated) - to include the entirety of both lungs, the mediastinum, liver, and adrenal glands; primary tumor dimension will be measured on this CT;\n* Whole body positron emission tomography (PET) scan using FDG with adequate visualization of the primary tumor and draining lymph node basins in the hilar and mediastinal regions within 6 weeks prior to study entry.\n* Informed consent signed by the subject and a member of the study team.\n\nExclusion Criteria:\n\n* Patients with central tumors. Specifically; central location implies a tumor inside the zone of the proximal bronchial tree defined as a volume 2 cm in all directions around the proximal bronchial tree (carina, right and left main bronchi, right and left upper lobe bronchi, intermedius bronchus, right middle lobe bronchus, lingular bronchus, right and left lower lobe bronchi\n* Evidence of regional or distant metastases after appropriate staging studies.\n* Synchronous primary NSCLC.\n* Those with prior malignancy in the past 2 years other than non-melanomatous skin cancer or in situ cancer or thyroid cancer.\n* Previous lung or mediastinal radiotherapy.\n* Plans for the patient to receive concomitant antineoplastic therapy (including standard fractionated radiotherapy, chemotherapy, biological therapy, vaccine therapy, and surgery) while on this protocol.\n* Patients with active systemic, pulmonary or pericardial infection.\n* Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo or fetus.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03706027001","EMAIL":[{"email":"deepinder_singh@urmc.rochester.edu"}],"GEO":[43.15478,-77.61556]},{"TITLE":"Randomized Study of Carbon Ion Boost in Hypoxic Lesions for Locally Advanced Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Between the ages of 18 and 80.\n* ECOG general status score of 0-2 .\n* Primary non-small cell lung cancer (NSCLC) confirmed by histology or cytological pathology, stage IIIa-IIIc (AJCC\/UICC 8th edition). Largest diameter of primary tumor \u2265 4cm before carbon ion radiotherapy.\n* Medically inoperable, or patient refuses surgery.\n* Adequate organ function: 1). Blood function: absolute neutrophil count (ANC) \u22651.5 x 109\/L, platelet count \u226580 x 109\/L, hemoglobin \u22659 g\/dL 2). Lung function: FEV1\\>25%, DLCO\\>25% 3). Cardiac function: no serious pulmonary hypertension, cardiovascular and cerebrovascular diseases, peripheral vascular diseases, serious chronic heart disease and other complications that may affect radiotherapy.4). Adequate liver function: total bilirubin \\<1.5 times the upper limit of normal value, and AST, ALT\\<2 times the upper limit of normal value. 5). Adequate renal function: serum creatinine \u22641.5 times the upper limit of normal or calculated creatinine clearance \u226550 ml \/min, and urinary protein \\<2+. Patients with a baseline urinary protein level of 2+ or more should have a 24-hour urine collection and evidence of a 24-hour urinary protein level of 1g or less.\n* Sign the informed consent.\n\nExclusion Criteria:\n\n* Patients with squamous cell carcinoma treated with bevacizumab before radiotherapy.\n* Patient fails to comply with the treatment protocol.\n* Complicated with other malignant tumors that have not been controlled.\n* Patient whose particle radiotherapy plan cannot meet the minimum target dose coverage and dose volume limitation requirements, or cannot meet the dose constrains of normal tissue or organs.\n* Chest radiation therapy or radioactive particle implantation history.\n* Cardiac pacemakers or other internal metal prosthesis implants that may be affected by high-energy radiation or may affect the dose distribution to the radiation target area.\n* Pregnancy (confirmed by serum or urine \u03b2-HCG test) or lactation period.\n* HIV positive. Hepatitis virus replication phase, need to receive antiviral therapy, but because of concomitant disease cannot receive antiviral therapy. Active stage of syphilis.\n* A history of mental illness may hinder the completion of treatment.\n* With serious comorbidity that may interfere with radiotherapy, including: (a) Acute infectious diseases or acute active phase of chronic infection. b) Unstable angina pectoris, congestive heart failure, myocardial infarction that has been hospitalized in the past 6 months. c) Exacerbations of chronic obstructive pulmonary disease or other respiratory conditions requiring hospitalization. d) Severely impaired immune function. e) Diseases with excessive sensitivity to radiation such as ataxia telangiectasia. f) Other diseases that may affect particle radiotherapy.\n* Other circumstances that the physician considers inappropriate to participate in clinical study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"06205927001","EMAIL":[{"email":"jing.li@sphic.org.cn"},{"email":"kun.liu@sphic.org.cn"},{},{},{}],"GEO":[31.22222,121.45806]},{"TITLE":"TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO","CRITERIA":"Inclusion Criteria:\n\n* Cohort A, B and C :\n\n  * Written Informed consent\n  * Agreement to be followed up (including on-study assessments and sample collection) every 3 months in the first 2 years and then 6 monthly.\n  * Agreement to be followed up at a TRACERx EVO site\n\nCohort A:\n\n* Participants \u226518 years of age, with early stage I-IIIB NSCLC disease who are eligible for primary surgery\n* Histopathologically confirmed NSCLC, or a strong suspicion of cancer on lung imaging necessitating surgery (e.g., diagnosis determined from frozen section in theatre)\n* Primary surgery in keeping with NICE guidelines in (lobectomy, either open or thoracoscopic), lung parenchymal-sparing operations (segmentectomy or wedge resection) if a complete resection can be achieved, extensive surgery (bronchoangioplastic surgery, bilobectomy, pneumonectomy) if necessary to obtain clear margins, hilar and mediastinal lymph node sampling or en bloc resection)\n* For participants proceeding with upfront primary surgery (i.e. no neoadjuvant therapy), a minimum tumour diameter at least 15mm to allow for sampling of at least two tumour regions\n* Participants undergoing neoadjuvant treatment must have at least 1 region of fresh frozen or FFPE surgical or diagnostic biopsy tissue.\n* Considered sufficiently fit for upfront standard of care primary surgery or neoadjuvant therapy if indicated\n* Performance status 0 to 2\n\nCohort B:\n\n* Participants \u226518 years of age, with late-stage unresectable stage IIIB and above NSCLC disease (TNM 8th edition) or presenting with stage IV de novo metastatic disease.\n* Sufficient tissue (at least 1 region\/biopsy), either FFPE or fresh frozen\n* Deemed to be fit for anti-cancer treatment\n* Performance status 0 to 2 Participants who were initially consented into Cohort A with a post-surgical staging of stage IIIB\/C or IV could be included in Cohort B.\n\nCohort C:\n\n* Participants \u226518 years of age, with any stage SCLC or pleural mesothelioma.\n* Sufficient tissue (at least 1 region\/biopsy), either FFPE or fresh frozen\n* Deemed to be fit for anti-cancer treatment\n* Performance status 0 to 2\n\nExclusion Criteria:\n\n* Cohort A, B and C:\n\n  * Other active malignancy\n  * Any other\\* malignancy diagnosed or relapsed at any time, which is currently being treated (including by hormonal therapy).\n  * Any other\\* current malignancy or malignancy diagnosed or relapsed within the past 3 years\\*\\*.\n\n    * \\*Exceptions are: non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer\n    * \\*\\*An exception will be made for malignancies diagnosed or relapsed more than 2, but less than 3, years ago only if a pre-operative biopsy of the lung lesion has confirmed a diagnosis of NSCLC.\n  * Psychological condition that would preclude informed consent\n  * Diagnosis other than NSCLC, SCLC or pleural mesothelioma confirmed following surgery or biopsy\n  * Confirmed diagnosis of known high-risk infections (e.g., Human Immunodeficiency Virus) (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or syphilis infection, tuberculosis and Creutzfeldt-Jacob disease) unless participant case is of a particular scientific interest and agreed in advance with research staff, local mortuary staff and pathologist.\n  * Contra-indicated co-morbid conditions\n\nCohort A:\n\n* Positive margins, incomplete resection or insufficient nodal sampling\n* Participation in a neo-adjuvant or adjuvant therapeutic trial with non-standard of care therapy\n* Insufficient tissue, i.e., for participants having upfront surgery and not having neoadjuvant therapy, a minimum of two tumour regions unlikely to be obtained for the study based on pre-operative imaging. For participants having neoadjuvant therapy i.e., at least one tissue biopsy to be obtained (Fresh Frozen or FFPE).\n* Participant found to have pre-invasive lesions rather than invasive cancer following surgery, such as adenocarcinoma in situ or minimally invasive lesions will be withdrawn. However, the surgical tissue and baseline blood already collected will be sent to the central laboratory. These participants will not be followed-up in the study or required to provide any further blood samples. If these participants subsequently develop invasive cancer, the date of diagnosis and the tumour histology will be reported on the electronic data capture system.\n\nCohort B\/C:\n\n\u2022 Insufficient tissue, i.e., at least one tissue biopsy to be obtained (Fresh Frozen or FFPE)","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05628376001","EMAIL":"ctc.tracerxevo@ucl.ac.uk","GEO":[51.50853,-0.12574]},{"TITLE":"Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations","CRITERIA":"Inclusion Criteria:\n\n1. Willingness to sign informed consent prior to any study specific procedures, and ability to with scheduled visits, treatment plans, laboratory tests, and other study procedures.\n2. Male or female, aged at least 18 years.\n3. Histologically confirmed primary NSCLC, and mainly non-squamous cell carcinoma (including mixed type carcinoma mainly composed of adenocarcinoma components).\n4. Absence of brain metastasis.\n5. Complete resection of histologically confirmed Stage IB, II, IIIA or IIIB(T3N2M0) according to the TNM staging system for lung cancer (AJCC\/UICC 8th edition), with negative margins.\n6. Confirmation by the central laboratory that the tumor harbors one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R).\n7. Patients who fully recover from surgery during randomization (any surgery must achieve complete postoperative wound healing) and should receive adjuvant treatment within 4-10 weeks after surgery.\n8. ECOG-PS score of 0 or 1 and did not deteriorate 2 weeks before the first administration of the investigational drug, with a minimum expected survival greater than 12 weeks.\n9. Female subjects with fertility need to have a negative serum pregnancy test during screening.\n10. Female subjects who have possibility of becoming pregnant, as well as male subjects whose partners are women of childbearing age, must use a highly effective contraceptive method (such as oral contraceptives, intrauterine devices, abstinence or barrier contraception combined with spermicides) throughout the study and continue to use contraception for 3 months after the end of treatment.\n\nExclusion Criteria:\n\n1. There are unresectable or metastatic diseases, pathological reports showing positive surgical margins under the microscope or extranodal invasion, or lesions left after surgery, or suspicious lesions determined by imaging after surgery. Subjects receiving only wedge resection.\n2. Upper lung groove cancer.\n3. Patient with complete resection of the right lung with NSCLC.\n4. Malignancies other than NSCLC within 5 years prior to first dosage, except for malignant tumors that can be cured after treatment (including but not limited to fully treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or breast ductal carcinoma in situ treated with radical surgery).\n5. Received systematic anti-tumor therapy, including chemotherapy, radiotherapy or targeted therapy (including but not limited to monoclonal antibodies, small molecule tyrosine kinase inhibitors), immunotherapy, investigational therapy, etc., before being enrolled in this study.\n6. Within 3 weeks prior to the first administration of the investigational drug, the patient underwent major surgery (including primary tumor surgery, craniotomy, thoracotomy, or laparotomy, excluding vascular pathway establishment procedures).\n7. Within 14 days prior to first dose of the investigational drug, Traditional Chinese medicine with anti-tumor indications have been received.\n8. After the start of the study, any form of systemic or local anti-tumor treatment (including maintenance therapy with another drug, radiotherapy, and\/or surgical resection) is still required.\n9. Clinically significant cardiovascular diseases, including:\n\n   1. QTcF interval \\>450 ms (men) or \\>470 ms (women), symptomatic bradycardia (\\<45 beats \/min), or other significant ECG abnormalities as determined by the investigator (e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, PR interval \\>250 msec).\n   2. Echocardiography showed LVEF \\<50%.\n   3. Hypertension was clinically uncontrollable (e.g., blood pressure \\>160\/100 mmHg; Except that isolated elevated readings that were determined by the investigators to be clinically insignificant or controllable hypertension.)\n\n   Within 6 months before the first medication, there were the following situations:\n   1. Congestive heart failure (New York Heart Association rating III or IV).\n   2. Arrhythmias or conduction abnormalities that require medication treatment. Note: Patients with drug-controlled atrial fibrillation\/flutter, as well as those with pacemaker- controlled arrhythmia, can be selected.\n   3. Severe\/unstable angina, coronary artery\/peripheral bypass grafting, or myocardial infarction (Note: Severe angina is classified as Grade III or IV by the Canadian Society of Cardiology).\n   4. Cerebrovascular accidents or transient ischemic attacks, transient myocardial ischemia.\n10. Previous history of concomitant interstitial lung disease (ILD), drug-induced ILD, radiation pneumonia requiring hormone therapy, or clinical evidence of concomitant active interstitial lung disease.\n11. Patients who have a history of thrombosis or are currently present with thrombosis or have a potential risk of thrombosis assessed by the investigator.\n12. Any clinical evidence of a serious active infection, or any serious concomitant disease that may affect the subject's acceptance of investigational drugs, such as active bleeding predisposition, active hepatitis B, hepatitis C, or tuberculosis, syphilis, or HIV antibody positive.\n13. There are serious gastrointestinal functional abnormalities in clinical practice that may affect drug intake, transportation, or absorption, such as inability to take medication orally, uncontrollable nausea or vomiting, history of extensive gastrointestinal resection, untreated recurrent diarrhea, atrophic gastritis, untreated stomach diseases requiring long-term use of proton pump inhibitors, gastrointestinal obstruction, active diverticulitis, Crohn's disease, ulcerative colitis, etc.\n14. Abnormal laboratory parameters.\n15. Known hypersensitivity to the befotertinib, icotinib or their inactive excipients.\n16. Within one week before the first administration of the investigational drug, it is currently in use or needs to be combined with CYP3A strong inhibitors or inducers during the study period.\n17. Patients who are still using warfarin within 7 days prior to initial dosing (low molecular weight heparin sodium is allowed).\n18. Participating in clinical research and receiving treatment with the study drug or research device, or participating in clinical research and receiving treatment with the study drug or research device within 4 weeks before the first administration, or planning to participate in any other clinical trial during this study period.\n19. Inoculate with a live vaccine within 180 days before the first medication.\n20. Researchers believe that it may affect protocol compliance or affect the signing of informed consent forms by participants (such as a history of mental illness or drug abuse, alcoholism or other addiction), or any other clinically significant disease or condition that is not suitable for participation in this clinical trial (such as laboratory abnormal results, clinically active diverticulitis, abdominal abscess).","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06041776003","EMAIL":"shunlu@sjtu.edu.cn","GEO":[31.22222,121.45806]},{"TITLE":"A Phase 1\/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC","CRITERIA":"\\[Inclusion Criteria\\]\n\n1. Subjects age 18 or above (19 or above for South Korea)\n2. Subjects with pathologically confirmed and finally diagnosed advanced and\/or metastatic NSCLC with active EGFR mutant\n3. Subjects who show disease progression after receiving standard anticancer therapy, including approved EGFR-TKI therapeutic and\/or up to 1 time of platinum-based anticancer chemotherapy. For the Part C dose expansion phase, approved EGFR-TKI with activity against T790M mutant such as Osimertinib must be included.\n4. Subjects with a test result of locally confirmed EGFR mutant obtained through a test method approved by the sponsor using either a tumor tissue and\/or plasma ctDNA. It is preferred that samples used for analysis are collected during or after disease progression from the last EGFR-TKI administration. If there is a sample retained after disease progression from prior therapy, it may be submitted.\n\n   1. Part A dose escalation and Part B exploration studies: Advanced NSCLC subjects who are positive to EGFR mutant C797S or T790M\n   2. Part C dose expansion study: Advanced NSCLC subjects who are positive for EGFR mutations C797S and T790M in Cohort 1, those who are positive for C797S and negative for T790M in Cohort 2, those who are negative for C797S and positive for T790M in Cohort 3, subjects who are positive for any EGFR mutations and stable brain metastasis in Cohort 4, and those who have any EGFR dependent mutations other than C797S or T790M in Cohort 5.\n5. For Part C, subjects with at least 1 measurable lesion that has not been previously radiated as defined by RECIST version 1.1\n6. Subjects with ECOG performance status 0 or 1\n7. Acute effect from a previous therapy that recovers to the baseline severity or \u2264 Common Terminology Criteria for Adverse Events (CTCAE) grade 1, except for an AE not corresponding to a safety risk, as determined by the investigator based on discussion with the sponsor. Note: A chronic condition not expected to recover (\u2264 grade 2, e.g. neuropathy, myalgia, alopecia) is an exception, and a subject with such a condition can be enrolled.\n8. Appropriate bone marrow and organ functions, including the following:\n\n   1. Hemoglobin \u2265 9.0 g\/dL\n   2. Platelet \u2265 75 \u00d7 109\/L\n   3. Absolute neutrophil count \u2265 1.0 \u00d7 109\/L\n   4. Serum Total Bilirubin (TBL) \u2264 1.5 \u00d7 Upper Limit of Normal Range (ULN) (\u2264 3.0 x ULN for a subject with documented Gilbert syndrome)\n   5. Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) \u2264 3.0 \u00d7ULN, or if there is a hepatic metastasis caused by tumor, \u2264 5.0 \u00d7 ULN\n   6. \\*Estimated creatinine clearance calculated using the Cockcroft-Gault formula to \u2265 60 mL\/min\/1.73m2\n\n      * CrCl (male) = (\\[140 - age\\] \u00d7 weight (kg)) \/ (serum creatinine (mg\/dL) \u00d7 72), CrCl (female) = CrCl (male) \u00d70.85\n9. For women with childbearing potential\n\n   1. The serum pregnancy test result must be negative before screening and the first dose of the investigational product\n   2. Women of childbearing potential who are sexually active with a non-sterilized male partner must use at least 1 or more effective contraceptive methods from the first dose of the investigational product to 90 days after the last dose\n\n      \\*Progesterone hormone contraceptive inhibiting ovulation, including an oral, injectable and implant type, intrauterine device, bilateral tubal ligation, use of spermicide or condom by the male partner, etc.\n   3. Must not breastfeed during the study and up to 90 days after the last dose of the investigational product\n10. Male subjects who are sexually active with a non-sterilized female partner of childbearing potential must agree to using an effective contraceptive method (spermicide, condom, etc.) from the first dose of the investigational product to 90 days after the last dose and not donating their sperms\n\n\\[Exclusion Criteria\\]\n\n1. NSCLC with mixed squamous cell histology and tumor with histological transformation (presence of transition from NSCLC to SCLC and epithelial mesenchymal transition)\n2. For Part A, B, and Cohort 4 of Part C\n\n   - Subjects requiring steroid escalation within 28 days before start of the study due to spinal cord compression with uncontrolled symptoms or Central Nervous System (CNS) metastasis or for CNS disease treatment; patients requiring local CNS disease treatment; and subjects with leptomeningeal disease. However, these subjects may be included in the study if they are systemically asymptomatic and stable 2 weeks after gamma knife therapy or 4 weeks after whole-brain irradiation\n3. For Part Part C: all Cohorts except for Cohort 4\n\n   - Subjects without CNS metastasis\n4. Subjects who received the following treatments:\n\n   1. EGFR-TKI treatment within 7 days from the first dose of the investigational product\n   2. Systemic anticancer treatment within 14 days or 5 half-lives (whichever is the shorter period) from the first dose of the investigational product\n   3. Limited field radiation treatment within 7 days or extended field chest radiation treatment within 14 days from the first dose of the investigational product\n   4. Immunotherapy or other antibody therapy within 28 days from the first dose of the investigational product\n   5. Subjects who did not recover from a major surgery or side effects of such treatment, except for vascular access placement, within 28 days from the first dose of the investigational product as determined by the investigator \\*A major surgery refers to a surgery on the abdomen, pelvis, cranium or intrapleural site or local site tissue and is defined as a procedure that may cause a risk to function or recovery of an organ and tissue based on the applicable site, subject's condition, and difficulty or duration of the surgery. A major surgery generally requires hospitalization of a varying period (often 1 week) and can be conducted by a surgical professional.\n5. Subjects with the following cardiac dysfunctions or clinically significant cardiac diseases:\n\n   1. Corrected QT interval using Frederica formula (QTcF) \\> 470 ms\n   2. Cardiac arrhythmia that is clinically significant and uncontrolled (e.g. Type II second degree heart block or third degree heart block)\n   3. Any factors increasing the risk of QTc prolongation or arrhythmia occurrence, such as hypokalemia, congenital long QT syndrome, family history of long QT syndrome, unexplained sudden death of a family member or direct family member at the age less than 40 years, or concomitant drugs known to prolong the QT interval or cause Torsades de Pointes\n   4. Uncontrolled (persistent) hypertension: Systolic blood pressure \\> 180 mmHg, diastolic blood pressure \\> 100 mmHg\n   5. Congestive heart failure defined as New York Heart Association Class III-IV, or hospitalization due to congestive heart failure within 6 months before the first dose of the study intervention\n   6. Medical history of acute myocardial infarction or unstable angina within 6 months before screening\n6. Subjects with active malignancy other than appropriately treated basal cell cancer or squamous cell skin cancer or carcinoma in situ within 2 years before enrollment. However, those who completed all anticancer treatments at least 2 years ago and are considered previously cured at the time of enrollment can be enrolled.\n7. Subjects with evidence\/past history of interstitial lung disease (ILD) or radiological pneumonia requiring steroid treatment. Subjects with prior ILD related to clinically resolved COVID-19 infection may be enrolled after discussion with and approval by the medical monitor.\n8. Subjects who are not able to swallow and keep in the body an orally administered drug and subjects who have a clinically significant gastrointestinal disorder such as major limitations to the stomach or intestine or malabsorption syndrome\n9. Subjects with other uncontrolled active infections, e.g. human immunodeficiency virus (HIV), HBV or HCV, including subjects with suspected active or latent tuberculosis (confirmed with interferon-gamma emission analysis positivity)\n\n   \\*The referential protocol about COVID-19\/SARS-CoV2 excludes subjects with active infections mentioned above. Though SARS-CoV2 test is not required for enrollment to this protocol, it should follow the standard of the local clinical practice. Subjects testing positive for SARS-CoV2 infection or known to have asymptomatic infection or suspected to have SARS-CoV2 are excluded, but they may be rescreened according to the protocol requirements if they test negative in a subsequent test.\n10. Subjects with known sensitivity to the study drug or its related substance\n11. Subjects who have a history of drug abuse or unstable medical, mental or social conditions that may interfere with participation in the study or result interpretation\n12. Subjects considered not able to follow the protocol as determined by the investigator","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05394831008","EMAIL":[{}],"GEO":[37.566,126.9784]},{"TITLE":"IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC","CRITERIA":"Inclusion Criteria\n\n1. Be able to understand and be willing to sign informed consent.\n2. Male or female aged \u2265 18 years old at the time of signing informed consent.\n3. Histologically or cytologically confirmed locally advanced or metastatic NSCLC, who is not suitable for radical surgery or radiotherapy.\n4. Documented EGFR mutations known to be associated with EGFR-TKI sensitivity, including Ex19del or L858R. Except for EGFR-TKI sensitive mutation, coexisting with other EGFR mutation types such as T790M can be allowed.\n5. Prior systemic antitumor therapy allowed are listed as follows:\n\n   * Cohort 1: Subjects who are on the treatment of Furmonertinib as the first-line treatment setting.\n   * Cohort 2: Subjects failed in third-generation EGFR-TKI treatment and also failed in or were intolerant to 1-2 lines of chemotherapy.\n   * Cohort 3: subjects who haven't accepted any systemic therapy before. Prior adjuvant or neoadjuvant chemotherapy is permitted if an interval from the lost dose of adjuvant or neoadjuvant chemotherapy to the first documented PD is \\>6 months.\n6. Measurable lesions at baseline according to RECIST 1.1 criteria.\n7. Has an ECOG performance status of 0 or 1.\n8. Estimated life expectancy is more than 3 months.\n9. Adequate bone marrow, liver, renal, and coagulation function within 7 days prior to the first dose of study treatment\/randomization.\n\nExclusion Criteria\n\n1. Have experienced major surgical procedures or major trauma within 28 days prior to the first dose of study treatment\/randomization.\n2. Have received the following prior systemic antitumor therapy:\n\n   * Cohort 1: Have received chemotherapy, target therapy besides Furmonertinib, immunotherapy, biological therapy, and other antitumor drugs.\n   * Cohort 2: Have received chemotherapy, targeted therapy, immunotherapy, biological therapy, and other antitumor drugs within 28 days prior to the first dose of study treatment.\n   * Cohort 3: Have received systemic antitumor therapy for locally-advanced or metastatic NSCLC including chemotherapy, target therapy, immunotherapy, biotherapy, etc.\n3. Cohort 2 only\uff1a Presence of other gene mutations, including ALK mutation, MET amplification, HER2 amplification, RAS mutation, etc. after progression on prior third-generation EGFR-TKI treatment.\n4. Cohort 3 only\uff1aHas received the treatment of EGFR-TKI\u3002\n5. Prior FAK inhibitors treatment.\n6. Have received systemic administration of potent inhibitors\/inducers of CYP3A4, or P-gp inhibitors within 14 days prior to the first dose of treatment\/randomization or are expected to receive systemic administration of these drugs during study treatment.\n7. Has received radiotherapy for study disease or radiotherapeutic area covered for more than 30% of the bone marrow within 28 days prior to the first dose of study treatment\/randomization.\n8. Has had interstitial lung disease (ILD), drug-induced ILD, radiation pneumonia requiring steroid therapy; or diagnosis of clinically active ILD during the screening period.\n9. Has a prior history of other malignancy within 3 years prior to signing informed consent.\n10. Has known symptoms of spinal cord compression, active central nervous system (CNS) metastases, and\/or carcinomatous meningitis.\n11. Has a history of severe cardiovascular or cerebrovascular diseases within 6 months prior to the first dose of study treatment\/randomization.\n12. Has known uncontrollable pleural effusion, pericardial effusion, and ascites.\n13. Has hemoptysis within 1 month prior to the first dose of study treatment\/randomization with a blood volume of \u22652.5 mL every time or expected to require continuous hemostasis therapy during the study treatment.\n14. Has active infections that are poorly controlled by systemic treatment.\n15. Has active tuberculosis.\n16. Known allergy, hypersensitivity or intolerance to IN10018 and\/or third-generation EGFR-TKI, or their ingredients.\n17. Pregnant or lactating women.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05994131001","EMAIL":[{"email":"caicunzhoudr@163.com"},{}],"GEO":[31.22222,121.45806]},{"TITLE":"Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity","CRITERIA":"Inclusion Criteria:\n\n* Able to comprehend the requirements and procedures for the study and to provide informed consent before entering the study\n* Solid malignant tumour (stage III-IV)\n* Treated with ICI-based therapeutic regimens\n\nExclusion Criteria:\n\n* Inability to give written informed consent\n* Patients with a cognitive impairment, an intellectual disability or a mental condition that will interfere with the patient's ability to understand the requirements of the study","SEX":"ALL","AGE_MIN":0,"AGE_MAX":200,"SS_ID":"04631731002","EMAIL":[{"email":"Bo.Gao@health.nsw.gov.au"},{"email":"Matteo.Carlino@health.nsw.gov.au"}],"GEO":[-33.86785,151.20732]},{"TITLE":"CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Patients must have measurable disease.\n* Age \u2265 18 years\n* Adequate renal function\n* Adequate liver function\n* Adequate hematological function\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Life expectancy of at least three months.\n\nExclusion Criteria:\n\n* Patients must not have clinically significant cardiac disease.\n* Patients must not have known non-controlled CNS metastasis.\n* Patients must not have had prior therapy with a conjugated or unconjugated auristatin derivative\/vinca-binding site targeting payload.\n* Patients must not have a history of \u2265 Grade 3 allergic reactions to mAb therapy as well as known or suspected allergy or intolerance to any agent given during this study.\n* Patients must not have had major surgery within 4 weeks before first BA3011\n* Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and\/or hepatitis C.\n* Patients must not be women who are pregnant or breast feeding.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04681131065","EMAIL":[{"email":"z19901108@gmail.com"},{}],"GEO":[25.04776,121.53185]},{"TITLE":"Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Patients with advanced ALK fusion oncogene positive lung adenocarcinoma that have progressed after 1-2 ALK inhibitors, with at least one prior line of 2nd generation ALKi (i.e. Ceritinib, Alectinib, Brigatinib or Ensartinib)\n* The availability of sufficient plasma\n* Age \u2265 21 years\n* WHO performance status \u2264 2\n* Life expectancy of \u2265 21 weeks\n* Patients should have adequate organ function for potential consideration into clinical trials (routine blood tests are valid within 14 days before enrollment):\n\n  1. Adequate bone marrow function as shown by: ANC \u2265 1.0x10\\^9\/L, Platelets \u2265 75x10\\^9\/L, Hb \u2265 7.5 g\/dL\n  2. Alanine aminotransferase (ALT) and aspirate aminotransferase (AST) normal range (or \u2264 3.0xULN if liver metastases are present)\n* Willing to provide signed informed consent\n* Patients whom do not fulfill the above criteria may be discussed on a case-by-case basis within the study team, for potential enrolment\n\nExclusion Criteria:\n\n* Received more than 2 prior ALK inhibitors (ALKi)\n* Symptomatic or uncontrolled brain metastases requiring concurrent treatment inclusive but not limited to surgery and radiation. Stable\/ tailing doses of corticosteroids is permitted","SEX":"ALL","AGE_MIN":21,"AGE_MAX":200,"SS_ID":"04087473005","EMAIL":"justine.chu.j.h@nccs.com.sg","GEO":[1.28967,103.85007]},{"TITLE":"Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Age \u2265 18 years. Gender is not limited.\n* Histologically and\/or cytologically confirmed stage IV metastatic NSCLC.\n* Eastern Cooperative Oncology Group (ECOG) score of 0-2.\n* Patients who had prior first-line chemotherapy with clinical benefit lasting for \u22653 months.\n* Driver gene-negative NSCLC patients with oligo-progression during first-line chemotherapy combined with Immune Checkpoint Inhibitors (ICI). Driver gene-positive NSCLC patients, such as epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) fusion positivity, are allowed to enroll if oligo-progression occurred during treatment with first-line chemotherapy combined with bevacizumab \u00b1 ICI after failure of Tyrosine Kinase Inhibitor (TKI) therapy.\n* Progressive sites were assessed as \u22645 according to RECIST v1.1 criteria combined with positron emission tomography \/ computertomography (PET\/CT), and all were located extracranially. Progressive lymph node lesions are counted by region, with each lymph node region amenable to concurrent SBRT (which may contain multiple progressive lymph nodes) counted as 1 progressive site.\n* All progressive sites should be visible on radiologic imaging and assessed as suitable for SBRT treatment by a radiotherapist.\n* Intracranial progressive lesions and symptomatic lesions can be treated with palliative radiotherapy and local therapy prior to enrollment and are not counted within the oligo-progressive sites.\n* Expected survival time greater than 3 months.\n* Comprehensive examination completed within 28 days prior to enrollment in the study and a complete blood count\/differential, collected within 15 days, showing that the patient has normal internal organ function and normal bone marrow function.\n* Negative serum or urine pregnancy test in females of childbearing age within 14 days prior to study enrollment.\n* Patients are willing to provide written informed consent and must be willing to adhere to the prescribed follow-up schedule.\n\nExclusion Criteria:\n\n* Currently participating in an interventional clinical study treatment that may affect this study, or have been treated with another investigational drug or investigational device that may affect this study within 4 weeks prior to first treatment.\n* Pregnant or lactating women.\n* Progression sites deemed unsuitable for SBRT treatment as assessed by radiotherapy specialists.\n* Presence of untreated intracranial metastases or symptomatic progressive sites.\n* History of malignancy other than NSCLC or untreated primary malignancy within the past 3 years.\n* Serious active comorbidities that would interfere with treatment in this study.\n* History or evidence of disease that could interfere with the results of the trial, prevent the subject from participating in the study throughout, abnormal values of treatment or laboratory tests, or other conditions that, in the opinion of the investigator, make enrollment inappropriate.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06523673001","EMAIL":[{"email":"qiufuming@zju.edu.cn"}],"GEO":[30.29365,120.16142]},{"TITLE":"Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Patients aged \u226518 years, male and female are not limited;\n2. Patients with ECOG score of 0-1;\n3. Life expectancy \u226512 weeks;\n4. Patients must have histologically- or cytologically-documented NSCLC (according to 2015 WHO Classification);\n5. Patients with stage I - IIA (T1-T2bN0M0, tumor size \u2264 50mm) confirmed by radiographic\uff1band medical inoperable, unable to undergo thoracic surgery, or refusing to surgery (according to the eighth edition of TNM staging);\n6. Patients with measurable target lesions according to the RECIST 1.1 standard;\n7. Patients have not received prior treatment for their NSCLC, including radiotherapy, chemotherapy, surgery and target drugs;\n8. Can provide tumor tissue;\n9. Adequate organ and marrow function;\n10. Fertile female were required to have a serum or urine pregnancy test within 72 hours before the start dose of study medication and the result has been negative;If female of childbearing potential, is willing to use adequate contraception for the course of the study through 90 days after the last dose of study medication; if male with a female partner(s) of child-bearing potential, must agree to use adequate contraception starting with the first dose of study medication through 90 days after the last dose of study medication;\n11. Provision of signed ICF.\n\nExclusion Criteria:\n\n1. Known any distance metastases;\n2. Patients with known EGFR gene mutation or ALK fusion mutation;\n3. Patients with any active autoimmune disease or history of autoimmune disease;\n4. Patients with innate or acquired immune deficiency, such as human immunodeficiency virus (HIV) infection, active hepatitis B, hepatitis C or co-infection with hepatitis B and hepatitis C;\n5. Subjects requiring systemic treatment with corticosteroids (\\> 10 mg \/ day of prednisone or its equivalent) or other immunosuppressants within 14 days prior to the first administration;\n6. Patient must not have received a live, attenuated vaccine within 4 weeks prior to the first administration;\n7. Any therapy for NSCLC treatment;\n8. Patients with other malignant tumors in the past 5 years;\n9. Patients with previous or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiologic pneumonia, drug-induced pneumonia and active pneumonia confirmed by imaging;\n10. Patients with cardiac insufficiency;\n11. Routine urine test indicated that urine protein was \\>= (+ +), or 24-hour urine protein was \\>= 1g, or severe liver and kidney dysfunction;\n12. Patients with severe infection or fever of unknown origin \\>38.5 \u2103 within 4 weeks prior to the first administration;\n13. Patients with known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;\n14. Pregnant or lactating women; those with fertility who are unwilling or unable to take effective contraceptive measures;\n15. Known allergies, hypersensitivity, or intolerance to camrelizumab or its excipients or to pemetrexed or to nab-paclitaxel;\n16. Any condition that, in the opinion of the investigator, would interfere with evaluation of the study drug or interpretation of patient safety or study results\uff0cor the patient is unlikely to comply with study procedures, restrictions, and requirements.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04530227001","EMAIL":[{}],"GEO":[39.14222,117.17667]},{"TITLE":"Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer","CRITERIA":"* INCLUSION CRITERIA:\n* Participants with an appropriate HLA match for available Surgery Branch KRAS TCRs with evaluable metastatic solid cancer (e.g., gastrointestinal, genitourinary, breast, ovarian, non-small cell lung cancer (NSCLC) and other solid cancers) with known KRAS G12V or G12D mutation.\n* Confirmation of diagnosis of cancer by the NCI Laboratory of Pathology.\n* Refractory to standard systemic therapy. Specifically:\n\n  * Participants with metastatic colorectal cancer must have received oxaliplatin and\/or irinotecan.\n  * Participants with breast and ovarian cancer must have received at least two systemic treatments.\n  * Participants with NSCLC must have received at least one platinum-based chemotherapy regimen and at least one FDA-approved targeted treatment (when appropriate).\n  * Participants with other solid tumors must have received at least one prior line of systemic treatment or have declined standard treatment.\n  * Participants with three (3) or fewer brain metastases that are \\< 1 cm in diameter each and asymptomatic are eligible. Lesions that have been treated with stereotactic radiosurgery must be clinically stable for one month after treatment for the participant to be eligible. Participants with surgically resected brain metastases are eligible.\n* Age \\>= 18 years and \\<= 72 years.\n* Clinical performance status of ECOG 0 or 1 (see Appendix A).\n* Women of child-bearing potential (WOCBP) must agree to use highly effective contraception (hormonal, intrauterine device \\[IUD, abstinence, surgical sterilization starting at the time of study entry, for the duration of study therapy, and 12 months after the last dose of combined chemotherapy\n\nMen must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) for the duration of the study treatment and for 4 months after the last dose of combined chemotherapy. We also will recommend men with female partners of childbearing potential to ask female partners to be on highly effective birth control (hormonal, intrauterine device (IUD), surgical sterilization).\n\nNOTE: WOCBP is defined as any female who has experienced menarche and who has not undergone successful surgical sterilization or who is not postmenopausal.\n\nNOTE: Certain malignancies may secrete hormones that produce false positive pregnancy tests. Serial blood testing (e.g. HCG measurements) and\/ or ultrasound may be performed for clarification.\n\n* Participants must have serology results as follows:\n\n  * Seronegative for HIV antibody.\n  * Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then participant must be tested for the presence of antigen by RT-PCR and be HCV RNA negative.\n* Adequate organ and marrow function as defined below:\n\n  --Hematology:\n  * ANC \\> 1000\/mm\\^3 without growth factor support\n  * WBC \\>= 2500\/mm\\^3\n  * Platelet count (Bullet) 80,000\/mm3\n  * Hemoglobin \\> 8.0 g\/dL. Subjects may be transfused to reach this cut-off.\n* Chemistry:\n* Serum ALT\/AST \\<= 5.0 x ULN\n* Serum creatinine \\<= 1.6 mg\/dL\n* Total bilirubin \\<= 2.0 mg\/dL, except in participants with Gilbert s Syndrome, who must have a total bilirubin \\< 3.0 mg\/dL.\n* Participants must have completed any prior systemic therapy at the time of enrollment.\n\nNOTE: Participants may have undergone minor surgical procedures or limited field radiotherapy within the four weeks prior to enrollment, as long as related major organ toxicities have recovered to grade 1 or less.\n\n* For participants with NSCLC or lung metastases, more than two weeks must have elapsed since any prior palliation for major bronchial occlusion or bleeding at the time the patient receives the preparative regimen, and patient s toxicities must have recovered to a grade 1 or less.\n* Ability of subject to understand and the willingness to sign a written informed consent document.\n* Willing to sign a durable power of attorney.\n* Participants must be co-enrolled on protocol 03-C-0277.\n\nEXCLUSION CRITERIA:\n\n* Women who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant.\n* Any form of secondary immunosuppression.\n* Active systemic infections requiring anti-infective treatment, coagulation disorders, or any other active or uncompensated major medical illnesses.\n* For participants with NSCLC or lung metastases, any major bronchial occlusion or bleeding not amenable to palliation.\n* Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease and AIDS).\n* History of major organ autoimmune disease.\n* Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Participants who have decreased immune-competence may be less responsive to the experimental treatment and more susceptible to its toxicities.)\n* History of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, aldesleukin or vaccines.\n* Clinically significant participant history which in the judgment of the Principal Investigator (PI) would compromise the participants ability to tolerate high-dose aldesleukin.\n* History of coronary revascularization or ischemic symptoms.\n* For select participants with a clinical history prompting cardiac evaluation: last known LVEF \\<= 45%.\n* For select participants with a clinical history prompting pulmonary evaluation: known FEV1 \\<= 50% predicted.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":72,"SS_ID":"06253520001","EMAIL":[{"email":"irc@nih.gov"}],"GEO":[38.98067,-77.10026]},{"TITLE":"Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy.\n* Adequate bone marrow, kidney and liver function\n* Performance status of 0 or 1.\n* Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement.\n\nExclusion Criteria:\n\n* Prior treatment targeting ILT3.\n* Prior treatment targeting LAIR1.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05215574009","EMAIL":[{}],"GEO":[29.76328,-95.36327]},{"TITLE":"Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)","CRITERIA":"Inclusion Criteria: -Participants are eligible to be included in the study only if all of the following criteria apply:\n\n* Participant has provided informed consent prior to initiation of any study specific activities\/procedures.\n* Age \u2265 18 years (or \u2265 legal age within the country if it is older than 18 years).\n* Histologically or cytologically confirmed small-cell lung cancer (SCLC).\n* Diagnosed and treated for LS-SCLC with concurrent chemotherapy and radiotherapy.\n* Has completed chemoradiotherapy without progression per Response Evaluation Criteria in Solid Tumors v1.1 (RECIST 1.1.) (ie, achieved complete response \\[CR\\], partial response \\[PR\\], or stable disease \\[SD\\]).\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.\n* Minimum life expectancy of 12 weeks.\n* Adequate organ function.\n* Toxicities attributed to concurrent chemoradiotherapy resolved to grade \u2264 1, unless otherwise specified. Excluding alopecia or fatigue.\n\nExclusion Criteria: -Participants are excluded from the study if any of the following criteria apply:\n\nDisease Related\n\n* Extensive-stage SCLC (ES-SCLC).\n* Any previous diagnosis of transformed non-small-cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) activating mutation positive NSCLC that has transformed to SCLC, or mixed SCLC NSCLC histology.\n* Evidence of interstitial lung disease or active, non-infectious pneumonitis. Other Medical Conditions\n* History of other malignancy within the past 2 years, with certain exceptions.\n* History of solid organ transplantation.\n* Myocardial infarction and\/or symptomatic congestive heart failure (New York Heart Association \\> class II) within 6 months prior to first dose of study treatment.\n* History of arterial thrombosis (eg, stroke or transient ischemic attack) within 6 months prior to first dose of study treatment.\n* Exclusion of human immunodeficiency virus (HIV) and\/or hepatitis infection based on criteria per protocol.\n* Participant with symptoms and\/or clinical signs and\/or radiographic signs that indicate an acute and\/or uncontrolled active systemic infection within 7 days prior to the first dose of study treatment.\n\nPrior\/Concomitant Therapy\n\n* Received sequential chemotherapy and thoracic radiotherapy (no overlap of thoracic radiotherapy with chemotherapy) during chemoradiation.\n* Prior therapy with any selective inhibitor of the delta-like ligand 3 (DLL3) pathway.\n* Prior history of severe or life-threatening events from any immune-mediated therapy.\n* Receiving another anti-cancer therapy. Adjuvant hormonal therapy for resected breast cancer is permitted.\n* Receiving systemic corticosteroid therapy or any other form of immunosuppressive therapy within 7 days prior to enrollment.\n* Major surgical procedures within 28 days prior to first dose of study treatment.\n* Treatment with live virus, including live-attenuated vaccination, within 14 days prior to the first dose of study treatment. Inactive vaccines and live viral non-replicating vaccines within 3 days prior to first dose of study treatment.\n\nPrior\/Concurrent Clinical Study Experience\n\n\u2022 Treatment in an alternative investigational trial within 28 days prior to enrollment.\n\nOther Exclusions\n\n* Female participants of childbearing potential unwilling to use protocol specified method of contraception during treatment and for an additional 60 days after the last dose of study treatment.\n* Female participants who are breastfeeding or who plan to breastfeed while on study through 60 days after the last dose of study treatment.\n* Female participants planning to become pregnant or donate eggs while on study through 60 days after the last dose of study treatment.\n* Female participants of childbearing potential with a positive pregnancy test assessed at screening by a highly sensitive serum pregnancy test.\n* Male participants with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment and for an additional 60 days after the last dose of study treatment.\n* Male participants with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment and for an additional 60 days after the last dose of study treatment.\n* Male participants unwilling to abstain from donating sperm during treatment and for an additional 60 days after the last dose of study treatment.\n* Participant has known sensitivity to any of the products or components to be administered during dosing.\n* Participant likely to not be available to complete all protocol-required study visits or procedures, and\/or to comply with all required study procedures to the best of the participant and investigator's knowledge.\n* History or evidence of any other clinically significant disorder, condition, or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to participant safety or interfere with the study evaluation, procedures or completion.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06117774062","EMAIL":"medinfo@amgen.com","GEO":[36.79526,34.61792]},{"TITLE":"Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Female or male patients, 18 years of age or older, able to understand and give written informed consent\n2. Pathologically proven NSCLC\n3. Tumour tested negative for EGFR and ALK\n4. Measurable disease by CT as per RECIST Version 1.1 criteria by investigator\n5. Tumour tissue is available for translational research (preferably histology, cytology allowed)\n6. AJCC 8th edition Stage II-III based on the following diagnostic workup and tumour is considered potentially resectable\n\n   * Distant metastasis staging by PET\/CT whole body or CT thorax and upper abdomen with contrast\n   * Patients with stage IIIB (N2) that is considered potentially resectable by cardiothoracic surgeon may be enrolled\n7. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1\n8. Adequate haematological values without transfusional or growth factor support within 2 weeks of study drug initiation: haemoglobin \u2265 9.0g\/dL, absolute neutrophil count \u2265 1.5 x 10\\^9\/L, platelet count \u2265 100 x 10\\^9\/L\n9. Adequate hepatic function: bilirubin \u2264 1.5 x ULN, AST\/ALT \u2264 2.5 x ULN\n10. Adequate renal function: calculated creatinine clearance \u2265 30 ml\/min, according to the formula of Cockcroft-Gault equation\n11. Male patients and female patients of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception as described in Appendix V.\n12. Patients with HBV (HBsAg +ve) must be on antiviral therapy and have a well-controlled HBV infection as determined by investigator. Patients who test positive for hepatitis B core antibody (anti-HBc) will require HBV DNA by quantitative polymerase chain reaction (PCR) for confirmation of active disease. Participants should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post completion of study intervention.\n13. Patients with known HCV infection (positive hepatitis C antibody) (testing is not mandatory for trial enrolment) must have been treated with antiviral therapy and have undetectable HCV viral load.\n14. Willing and able to comply with the requirements and restrictions in this protocol.\n\nExclusion Criteria:\n\n1. Presence of any distant metastasis\n2. Previous or concomitant malignancy within 5 years prior registration with the exception of adequately treated localized non-melanoma skin cancer or cervical carcinoma in situ. Prior anti-cancer treatment can be accepted except for drugs listed in exclusion criteria (3) to (8)\n3. Received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to study treatment Day 1\n4. Mixed SCLC and NSCLC histology\n5. Any previous treatment with a PD-1 or PD-L1 or CTLA4 inhibitor, or another agent directed to stimulatory or coinhibitory T-cell receptor (OX40, CD137, etc)\n6. Any previous treatment with sacituzumab govitecan, topoisomerase inhibitor, or TROP-2 targeted therapy.\n7. Previous radiotherapy to the chest including radiation to mediastinal tumours (e.g. germ cell tumours and thymic tumours)\n8. Positive pregnancy test by urine or serum (Appendix V) or women who are breastfeeding\n9. Known hypersensitivity to pembrolizumab or Sacituzumab govitecan, or their metabolites or formulation excipient\n10. Requirement for ongoing therapy with or prior use of any prohibited medications listed in Appendix IV\n11. Absolute contraindications for the use of corticosteroids as premedication\n12. Concurrent treatment with other experimental drugs or other anticancer therapy, treatment in a clinical trial within 30 days prior to registration\n13. Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of enrollment\n14. Current or prior use of immunosuppressive medication within 28 days before the first dose of pembrolizumab or sacituzumab govitecan, with the exceptions of intranasal and inhaled corticosteroid or systemic corticosteroids at physiological doses (i.e. which must not exceed 10mg\/day of prednisone or an equivalent corticosteroid) and the premedication for chemotherapy.\n15. Severe or uncontrolled cardiac disease, congestive heart failure NYHA class III or IV, unstable angina pectoris, history of myocardial infarction during the last 3 months, serious arrhythmias requiring medication (with the exception of atrial fibrillation or paroxysmal supraventricular tachycardia under medical control); history of QTc interval prolongation\n16. Clinically severe pulmonary compromise resulting from intercurrent pulmonary illness including, but not limited to, any underlying pulmonary disorder (ie pulmonary embolism within 3 months of enrolment, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion, etc.); history of (non-infectious) pneumonitis that required steroids or recurrent pneumonitis; any autoimmune\/connective tissue\/inflammatory disorders with pulmonary involvement, or prior pneumonectomy.\n17. Active autoimmune disease requiring systemic treatment within the past 2 years or a documented history of clinically severe autoimmune disease or a syndrome that requires systemic steroids or immunosuppressive agents with the exception of resolved childhood asthma\/atopy, hypothyroidism or adrenal insufficiency on hormone replacement, diabetes mellitus stable on insulin replacement\n18. Active HBV or HCV infection\n19. Known history of Human Immunodeficiency Virus (HIV).\n20. History of primary immunodeficiency\n21. History of allogeneic organ transplant\n22. Receipt of live attenuated vaccination any time during trial therapy and within 30 days of receiving the last dose of trial therapy. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed. COVID-vaccination is allowed.\n23. Any concomitant drugs contraindicated for use with pembrolizumab or sacituzumab govitecan including systemic corticosteroid, methotrexate, azathioprine, TNF-alpha blockers.\n24. Any other serious underlying medical, psychiatric, psychological, familial condition that in the judgement of the investigator, that may interfere with planned staging, treatment and follow up, affect patient compliance, or place the patient at high risk from treatment-related complications.\n25. Patients who refuse surgical treatment of the lung cancer","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06055465001","EMAIL":[{"email":"molly@clo.cuhk.edu.hk"},{"email":"sherlaineyau@clo.cuhk.edu.hk"}],"GEO":[22.27832,114.17469]},{"TITLE":"A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)","CRITERIA":"Participant Inclusion Criteria (both Part I and Part II)\n\nMonitoring Phase\n\n* Stage IV NSCLC. Note that patients are eligible for the study if they have received definitive treatment for early stage disease, presuming that they remain candidates for local ablative therapy (LAT).\n* AJCC 8th Edition Stage IV disease\n* Has had up to four cycles of standard first-line systemic therapy +\/- 3 weeks, defined as: a) platinum-doublet chemotherapy, b) ICI, or c) platinum-doublet chemotherapy + ICI at the baseline ctDNA draw being used for the study.\n* Patient initiated their ctDNA blood draws during their first 4 cycles of first line systemic therapy +\/- 3 weeks (during their first 4 cycles, or up to 3 weeks before\/after they have begun\/ended their first 4 cycles of systemic therapy\n* Ten or less metastatic lesions (Note that this criterion includes lesions, not sites: 3 brain metastases = 3 lesions).\n\n  \u00b0 Imaging defining extent of disease should be performed within 4 weeks of ctDNA blood draw\n  1. PET\/CT scan or CT scan of the chest\/abdomen\/pelvis within 4 weeks of blood draw for ctDNA analysis\n  2. MRI or CT scan of the brain at baseline, AND within 4 weeks of blood draw for ctDNA analysis (optional, per discretion of treating physician)\n* All lesions amenable to LAT.\n\n  o Note that patients who receive local therapy (radiation, surgery, or RFA) prior to enrollment for palliative purposes or to CNS lesions are eligible for enrollment if:\n\n  a) all other eligibility criteria are met and b) at least one other lesion is amenable to LAT and is RECIST evaluable. All lesions treated for palliative purposes will also be counted towards the total number of lesions.\n* At least one site of measurable disease\n* ECOG Performance status 0 - 2.\n* Age \u2265 18 years.\n* The participant, or their legally authorized representative (LAR) are able to provide informed consent.\n* Adequate baseline organ function to allow SBRT to all relevant targets, as determined by the treating radiation oncologist based on lesion location, lesion size, and proximity to relevant organs at risk.\n\nTherapeutic Phase - Being Enrolled from Monitoring Phase\n\n* Has received at least 2 cycles of treatment, remains on first-line therapy\n* No evidence of radiographic RECIST 1.1\\* progression (as defined above), as measured through the following imaging modalities:\n\n  * 1) PET\/CT scan or CT scan of the chest\/abdomen\/pelvis within 4 weeks of blood draw for ctDNA analysis\n  * 2) MRI or CT scan of the brain at baseline, AND within 4 weeks of blood draw for ctDNA analysis (optional, per discretion of treating physician)\n* NR-VAF results within 4 weeks of enrollment\n* All active lesions amenable to LAT\n\n  \u00b0 Note that patients who receive local therapy (radiation, surgery, or RFA) prior to enrollment for palliative purposes or to CNS lesions are eligible for enrollment if:\n\n  a) all other eligibility criteria are met and b) at least one other lesion is amenable to LAT and is RECIST evaluable. All lesions treated for palliative purposes will also be counted towards the total number of lesions. Female subjects must either be of non-reproductive potential (i.e. post-menopausal by history: \\>\/= 60 years old and no menses for 1\\> year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative pregnancy test (serum) within 2 weeks or a urine pregnancy test the day of treatment\n* Note that patients can either be: a) enrolled on the Monitoring Phase, followed by the Therapeutic Phase, or b) enrolled directly on to the Therapeutic Phase if they present for enrollment at the time that the therapeutic phase would be delivered and retrospectively would have met all of the criteria of the monitoring phase.\n\n  * Example: If a patient has received 2 cycles of systemic therapy and has NR-VAF, then presents to the clinic for enrollment, they can be enrolled on to the Therapeutic Phase if they meet all of the criteria in the Therapeutic Phase and upon evaluating their prior ctDNA\/imaging results would have also met the criteria for the Monitoring Phase.\n  * This allowance will substantially increase accrual, as many patients will present after undergoing baseline ctDNA analysis, and does not affect the scientific question that the study addresses.\n\nTherapeutic Phase - Being Enrolled Directly into Therapeutic Phase\n\nAs the criteria below indicate, patients can either be: a) enrolled on the Monitoring Phase, followed by the Therapeutic Phase, or b) enrolled directly on to the Therapeutic Phase if they present for enrollment at the time that the therapeutic phase would be delivered and retrospectively would have met all of the criteria of the monitoring phase. For example, if a patient has received 2 cycles of systemic therapy and has NR-VAF, then presents to the clinic for enrollment, they can be enrolled on to the Therapeutic Phase if they meet all of the criteria in the Therapeutic Phase and upon evaluating their prior ctDNA\/imaging results would have also met the criteria for the Monitoring Phase. This allowance will substantially increase accrual, as many patients will present after undergoing baseline ctDNA analysis, and does not affect the scientific question that the study addresses.\n\nInclusion Criteria for Patients Being Enrolled Directly into the Therapeutic Phase\n\n* Stage IV NSCLC. Note that patients are eligible for the study if, prior to the development of stage IV disease, they have received definitive treatment for early stage disease, presuming that they remain candidates for local ablative therapy (LAT).\n* AJCC 8th Edition Stage IV disease\n* Ten or less metastatic lesions (Note that this criterion includes lesions, not sites: 3 brain metastases = 3 lesions).\n\n  o Imaging defining extent of disease should be performed within 4 weeks of ctDNA blood draw\n* All lesions amenable to LAT.\n* At least one site of measurable disease\n* Detectable ctDNA\n* ECOG Performance status 0 - 2.\n* Age \u2265 18 years.\n* The participant, or their legally authorized representative (LAR) are able to provide informed consent.\n* Female subjects must either be of non-reproductive potential (i.e. post-menopausal by history: \\>\/= 60 years old and no menses for 1\\> year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative pregnancy test (serum) within 2 weeks or a urine pregnancy test the day of treatment.\n* Adequate baseline organ function to allow SBRT to all relevant targets, as determined by the treating radiation oncologist based on lesion location, lesion size, and proximity to relevant organs at risk.\n* Patient initiated their ctDNA blood draws during their first 4 cycles of first line systemic therapy +\/- 3 weeks (during their first 4 cycles, or up to 3 weeks before\/after they have begun\/ended their first 4 cycles of systemic therapy.\n* Has received at least 2 cycles of treatment, remains on first-line therapy\n* No evidence of radiographic RECIST 1.1\\* progression (as defined above), as measured through the following imaging modalities:\n\n  * 1) PET\/CT scan or CT scan of the chest\/abdomen\/pelvis within 4 weeks of blood draw for ctDNA analysis\n  * 2) MRI or CT scan of the brain at baseline, AND within 4 weeks of blood draw for ctDNA analysis (optional, per discretion of treating physician)\n* NR-VAF results within 4 weeks of enrollment\n\n  o For patients that do not have detectable ctDNA at enrollment in the monitoring phase, NR-VAF is defined as the emergence of detectable VAF on follow up blood draws\n* All active lesions amenable to LAT o Note that patients who receive local therapy (radiation, surgery, or RFA) prior to enrollment for palliative purposes or to CNS lesions are eligible for enrollment if: a) all other eligibility criteria are met and b) at least one other lesion is amenable to LAT and is RECIST evaluable. All lesions treated for palliative purposes will also be counted towards the total number of lesions.\n\nExclusion Criteria:\n\n* At the time of therapeutic phase enrollment, complete response radiographically (no lesions to target)\n* Patients with CNS-only disease (due to limited capacity of peripheral blood ctDNA to detect CNS lesions)\n* Planned treatment by targeted agents (e.g. tyrosine kinase inhibitors) or patient not a candidate for systemic therapy\n* Serious medical co-morbidities precluding radiotherapy or ablation, determined at the discretion of the treating investigator.\n* At the time of therapeutic phase enrollment, pregnant or lactating women.\n* Physical limitation to undergo stereotactic radiotherapy.\n* Other active malignancy within the last year except for basal cell carcinoma of the skin and in situ malignancy even if without evidence of disease.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05429320009","EMAIL":[{}],"GEO":[40.70038,-73.59291]},{"TITLE":"An Observational Study on Predicting the Efficacy of Immunotherapy for NSCLC Based on LIRAscore","CRITERIA":"Inclusion Criteria:\n\n1. Patients voluntarily participated in the study, signed the informed consent, and had good compliance;\n2. Histologically and\/or cytologically confirmed previously untreated, locally advanced or metastatic non-small-cell lung cancer (stage IIIB\/IIIC or stage IV) without driver gene mutation;\n3. Patients are willing to receive immunotherapy monotherapy or immunotherapy combined with chemotherapy;\n4. The patient agrees to provide the remaining tissue samples after clinical routine diagnosis during the baseline period for LIRA score and PD-L1 immunohistochemical testing;\n5. The Eastern Organization for Oncology (ECOG) physical fitness score is 0 or 1;\n6. The patient has at least one measurable or unmeasurable but evaluable lesion.\n\nExclusion Criteria:\n\n1. According to clinical routine, patients do not meet the criteria for receiving standard anti-tumor treatment;\n2. Patients with known EGFR mutations, ALK rearrangements or ROS1 rearrangements are not eligible to participate in this study;\n3. According to the researcher's judgment, the patient is not suitable to participate in this study.","SEX":"ALL","AGE_MIN":0,"AGE_MAX":200,"SS_ID":"06232265001","EMAIL":[{"email":"nfyyliaowj@163.com"},{}],"GEO":[23.11667,113.25]},{"TITLE":"Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)","CRITERIA":"Inclusion Criteria:\n\n1. Male and female patients willing and able to give written informed consent;\n2. Histological or cytological confirmed diagnosis of HLA-A2+ NSCLC with no evidence of EGFR mutations or ALK or ROS1 rearrangement;\n3. Evidence of disease progression at the end of at least 4 cycles of chemo-immunotherapy or 2 cycles of chemo-immunotherapy followed by 2 cycles of immunotherapy (CheckMate9LA regimen) and eligible for treatment with docetaxel. This criterion implies that patients with immunotherapy primary resistance are excluded;\n4. Patients must have experienced progressive disease (PD), either during or within 3 months of discontinuing treatment with anti-PD-(L)1-based therapy, occurring after previous clear benefit (any complete -CR- or partial response -PR), or after previous stable disease (SD);\n5. Performance status 0-1 (ECOG);\n6. Patient compliance to trial procedures;\n7. Age \u2265 18 years;\n8. Adequate BM function (ANC \u2265 1.5x109\/L, Platelets \u2265 100x109\/L, HgB \\> 9g\/dl);\n9. Adequate liver function (bilirubin \\< G2, transaminases no more than 3xULN\/\\<5xULN in present of liver metastases);\n10. Normal level of creatinine;\n11. Female patient: childbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of approved contraceptive method \\[complete abstinence, intrauterine contraceptive device (IUD), birth control pills, or barrier device\\] until 5 months after end of treatment.\n\n    or Male patient: should practice complete abstinence or if sexually active with WOCBP must use any contraceptive method with failure rate less than 1%\/year and they should not donate semen as follows: in arm A and C until 6 months since the last dose of docetaxel; in arm B until 3 months since last dose of tedopi.\n12. Prior palliative radiotherapy to non-CNS lesions must have been completed at least 2 weeks prior to treatment. Subjects with symptomatic tumor lesions that may require palliative radiotherapy within 4 weeks of first treatment are strongly encouraged to receive palliative radiotherapy prior to treatment. Patients are eligible if CNS metastases are adequately treated and patients are neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to randomization;\n13. Patients must be either off corticosteroids, or on a stable or decreasing dose of \u226410 mg daily prednisone (or equivalent) for at least 2 weeks prior to randomization.\n\nExclusion Criteria:\n\n1. Patient positive for actionable EGFR mutations or ALK or ROS1 rearrangement;\n2. No previous chemoimmunotherapy for metastatic disease or evidence of disease progression during the first 4 cycles of chemoimmunotherapy (primary resistance). Patients with adjuvant resistance (documented loco-regionally and\/or systemic relapse of their disease occurring \\<6 months after the last dose of anti-PD-(L)1-based systemic adjuvant therapy) are excluded;\n3. Patients with intervening systemic therapy following prior anti-PD-(L)1-based therapy;\n4. Symptomatic brain metastases. Asymptomatic brain metastases are allowed if not requiring corticosteroids use at a dose \\>10mg daily prednisone (or equivalent);\n5. Diagnosis of any other malignancy during the last 3 years, except for in situ carcinoma of cervix uteri and cutaneous squamous cell carcinoma or other local tumors considered cured;\n6. Pregnancy or lactating;\n7. Patients with an active, known or suspected autoimmune disease. Patients with type I diabetes mellitus; hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll;\n8. Patients with a condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization. Inhaled or topical steroids, and adrenal replacement steroid \\> 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease;\n9. Patients should be excluded if they are positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV RNA) indicating acute or chronic infection;\n10. Patients should be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04884282023","EMAIL":[{}],"GEO":[36.72016,-4.42034]},{"TITLE":"A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Age \u226518 years of age at the time consent is signed.\n* Has adequate end organ function per laboratory testing.\n* Pregnancy prevention requirements\n* Has measurable disease per RECIST 1.1 as assessed by the local site Investigator\/radiology.\n* Has a performance status of 0 or 1 on Eastern Cooperative Oncology Group scale.\n* Histologic documentation of incurable, locally advanced or metastatic tumor of the type being evaluated in individual cohorts\n\nExclusion Criteria:\n\n* Has a diagnosis of immunodeficiency.\n* Has a history of a previous, additional malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 5 years.\n* Has known active CNS metastases and\/or carcinomatous meningitis.\n* Has an active autoimmune disease that has required systemic treatment in the past 2 years.\n* Has an active infection requiring systemic therapy.\n* Inability to comply with study and follow-up procedures.\n* Has had a severe hypersensitivity reaction (Grade \u22653) to treatment with pembrolizumab, another monoclonal antibody, or has history of any hypersensitivity to any components of the study treatments or any of their excipients.\n* Has received prior systemic anticancer therapy including investigational agents within 4 weeks (or, if shorter, within 5 half-lives for kinase inhibitors) prior to first dose of study treatment.\n* Has received prior radiotherapy within 2 weeks of start of study treatment or has had a history of radiation pneumonitis.\n* Receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment.\n* Has received previous treatment with another agent targeting the IL-2, IL-7, or IL-15 receptors.\n* Is expected to require any other form of antineoplastic therapy while on study","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05653882010","EMAIL":"clinops@asherbio.com","GEO":[36.16589,-86.78444]},{"TITLE":"Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* men or women of 18 years or older that live in Greece\n* histologically or cytologically confirmed, advanced EGFR positive non-small cell lung cancer\n* untreated patients for advanced NSCLC\n* patients who are expected to receive osimertinib regardless of their enrollment in the study\n* signed written informed consent\n\nExclusion Criteria:\n\n* patients with cancer other than NSCLC that require treatment\n* pretreated patients for NSCLC\n* patients that receive or are expected to receive or have received an investigational drug\/product\/intervention","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05127382001","EMAIL":[{"email":"m_moschoni@hecog.ondsl.gr"}],"GEO":[37.97945,23.71622]},{"TITLE":"Prediction of Mediastinal Station IV Lymph Node Metastasis in Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Surgical resection and systematic lymph node dissection were performed in the department of thoracic surgery, and the postoperative pathological findings were confirmed as NSCLC and complete pathological diagnostic data were retained.\n2. Chest CT enhancement scan was completed within 2 weeks prior to surgery\n3. Image quality meets analysis standards and clinical data is complete.\n4. Lymph nodes that were pathologically confirmed to be metastatic or non-metastatic at station 4 were selected\n\nExclusion Criteria:\n\n1. Preoperative chemoradiotherapy or other treatment\n2. Distant metastasis or other malignant tumors are present\n3. Incomplete clinical data or image artifacts\n4. No metastatic or non-metastatic lymph nodes were found at station 4","SEX":"ALL","AGE_MIN":0,"AGE_MAX":200,"SS_ID":"06496360001","EMAIL":[{"email":"2083884573@qq.com"}],"GEO":[36.66833,116.99722]},{"TITLE":"A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation","CRITERIA":"Inclusion Criteria:\n\n* \u226518 years old\n* Locally-advanced or metastatic solid tumor with KRAS G12D mutation\n* Disease progression on prior standard treatment, intolerance to or ineligibility for standard treatment, or no available standard treatment to improve the disease outcome\n* Cohort specific requirements as follows:\n\n  * Part 1A: Histologically or cytologically confirmed malignant solid tumor of any tissue origin\n  * Part 1B\n\n    * Disease group 1: diagnosis of PDAC\n    * Disease group 2: diagnosis of CRC\n    * Disease group 3: diagnosis of NSCLC\n    * Disease group 4: diagnosis of other advanced solid tumor and not part of Disease groups 1, 2 and 3\n  * Parts 2A and 2B\n\n    * Combination 1: Diagnosis of CRC or CRC\n    * Combination 2: Diagnoses of PDAC, CRC or NSCLC\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\nExclusion Criteria:\n\n* Prior treatment with any KRAS G12D inhibitor\n* Known additional invasive malignancy within 1 year of the first dose of study drug\n* History of organ transplant, including allogeneic stem cell transplantation\n* Significant, uncontrolled medical condition\n* History or presence of an ECG abnormality\n* Inadequate organ function\n\nOther protocol-defined Inclusion\/Exclusion Criteria may apply","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06179160013","EMAIL":"medinfo@incyte.com","GEO":[-31.98184,115.8073]},{"TITLE":"Residual Disease Evaluation of Resected NSCLC by cirDNA Analysis","CRITERIA":"Inclusion Criteria:\n\n* Age: 18 years or older\n* Patients with a resectable NSCLC\n* Definite stage I to IIIA\n* Performance status of 0, 1 or 2\n* Normal end organ functions\n* Written and signed informed consent form\n* Subjects must be covered by public health insurance.\n\nExclusion Criteria:\n\n* Any previous systemic neoadjuvant treatment: targeted therapy, chemotherapy, immune checkpoint blockade\n* Previous radiotherapeutic neoadjuvant treatment\n* Resection margins R1 and R2\n* Non-invasive lung carcinoma\n* Multiple primary lung cancer.\n* Previous malignancy during the past 3 years (except non-melanomatous skin cancer)\n* Preexisting interstitial lung disease\n* known HIV, active viral B hepatitis or C hepatitis\n* Patient with any other situation responsible for cirDNA rate increasing (active auto-immune disease, 10 days following blood transfusion)\n* Patient unable to attend all scheduled visits\n* Woman of childbearing age without efficient contraception, breastfeeding\n* Patient with a legal protection measure (guardianship, curatorship)\n* Vulnerable patient protected by law","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05165160001","EMAIL":[{"email":"b-roch@chu-montpellier.fr"},{}],"GEO":[43.61092,3.87723]},{"TITLE":"Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)","CRITERIA":"Inclusion Criteria:\n\n* Deemed resectable or borderline resectable at baseline, confirmed by MDT evaluation at diagnosis.\n* Previously untreated and pathologically confirmed Stage IIB to select \\[i.e.N2\\] Stage IIIB by AJCC v8.\n* Nodal status confirmed with whole body FDG-PET and biopsy via endobronchial ultrasound, mediastinoscopy, or thoracoscopy.\n* Mandatory brain MRI.\n* EGFR and ALK wild-type.\n* Medically operable: adequate cardiac and lung function to undergo resection.\n* Participant must be \u2265 18 years, at the time of screening.\n* Histologically or cytologically documented NSCLC.\n* Minimum life expectancy of 12 weeks.\n* Minimum body weight of 30 kg.\n* Male and female participants must be willing to use acceptable methods of contraception.\n* Female participants of childbearing potential must have negative pregnancy test.\n\nExclusion Criteria:\n\n* Unresectable NSCLC confirmed by MDT evaluation at baseline\n* Stage IIIC patients\n* Participants whose planned surgery at enrollment is a wedge resection\n* Known EGFR mutation or ALK translocation\n* Participants contraindicated for surgical intervention due to comorbid conditions\n* Participants who are allergic to study intervention.\n* Participants with more than one primary tumour.\n* Known active hepatitis infection, positive HCV antibody, HBsAg or HBV core antibody (anti-HBc), at screening.\n* Female participants who are pregnant or breastfeeding.\n* Judgement by the investigator that the participant should not participate in the study.\n* Previously infected or tested positive for human immunodeficiency virus.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":130,"SS_ID":"05925530066","EMAIL":"information.center@astrazeneca.com","GEO":[59.36004,18.00086]},{"TITLE":"A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)","CRITERIA":"Inclusion Criteria:\n\n1. Age\u226518 years old.\n2. Voluntarily signed written informed consent form, willing and able to comply with scheduled visits and treatment and laboratory tests of the protocol.\n3. Patient has a diagnosis of locally advanced or metastatic NSCLC as determined by histological or cytological results.\n4. Patients with known EGFR-sensitive mutation \/ALK fusion \/ROS1 fusion must have been documented disease progression during or after targeted drugs treatments and platinum-containing chemotherapies; Patients without above positive genes must have been documented disease progression during or after PD-1\/PD-L1 inhibitors treatments and platinum-containing chemotherapies (combined or sequential). Note: For prior adjuvant\/neoadjuvant treatment with platinum-containing regimens of chemotherapy, progression during or within 6 months of completion of adjuvant\/neoadjuvant treatment may be considered a failure of platinum-containing chemotherapy.\n5. At least one measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.\n6. Adequate organ function.\n7. Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n8. Patients of reproductive potential must be willing to use adequate contraception during the study and through 6 months after the last dose of study treatment.\n\nExclusion Criteria:\n\n1. Prior use of docetaxel monotherapy or combination therapy for metastatic disease.\n2. Known \u2265 grade 3 hypersensitivity and\/or contraindications to human albumin or docetaxel; known allergy and\/or contraindications to glucocorticoids (including but not limited to active digestive tract ulcers, severe hypertension, severe hypokalemia, glaucoma, etc.).\n3. Leptomeningeal metastases and\/or untreated active brain metastases; if the patient's brain metastases have been treated, a stable state is required prior to randomization (no radiographically confirmed progression and normal return of all neurologically relevant symptoms within 4 weeks prior to randomization), no new brain metastases or enlargement of the original brain metastases are shown on radiographs, and steroid hormone therapy is not required for at least 7 days prior to randomization.\n4. History of other malignancies within 3 years prior to randomization, excluding basal cell or squamous cell carcinoma of skin and cervical carcinoma in situ that have been radically treated.\n5. Serosal effusion requiring drainage or diuretic treatment (such as pleural effusion, peritoneal effusion, or pericardial effusion) within 2 weeks before randomization.\n6. History of severe cardiovascular disease within 6 months prior to randomization, including but not limited to:\n\n\uff081) Uncontrolled hypertension (defined as persistent systolic blood pressure \u2265 160 mmHg and\/or diastolic blood pressure \u2265 100 mmHg despite the use of antihypertensive medications); \uff082) Severe arrhythmias and conduction abnormalities requiring treatment with antiarrhythmic agents other than beta-blockers or digoxin (except atrial fibrillation and paroxysmal supraventricular tachycardia); \uff083) History of myocardial infarction, unstable angina pectoris, angioplasty, and coronary artery bridging surgery; \uff084) Heart failure, New York Heart Association (NYHA)\u2265grade 3; \uff085) QTcF \\> 480 ms; \uff086) Other heart diseases that investigators identify as clinically significant. 7. Active infection treated with intravenous antibiotics within 2 weeks prior to randomization.\n\n8. Patients who have undergone major organ surgery (excluding needle biopsy) within 4 weeks prior to randomization or who will require elective surgery during the trial period.\n\n9. The toxicity of previous anti-tumor therapy does not return to grade\u22641 (CTCAE v5.0), except for grade 2 neuropathy, alopecia, hypothyroidism caused by prior anti-tumor therapy (including hormone replacement therapy), and toxicity judged by the investigator to be of no safety risk.\n\n10. Receiving antitumor therapy such as chemotherapy, targeted therapy, immunotherapy, and other investigational agents within 4 weeks or 5 half-lives (whichever is shorter but at least 2 weeks) prior to randomization, other conditions as follows: Received radiotherapy within 2 weeks prior to randomization, or received radiotherapy prior to 2 weeks of randomization but patient has not recovered from all acute toxicity and requires hormone therapy; Chinese medicines with anti-tumor indications administered within 2 weeks prior to randomization.\n\n11. Use of potent inhibitors or potent inducers of CYP3A4 within 2 weeks prior to randomization.\n\n12. Life expectancy \\< 3 months. 13. HBsAg\/HBcAb positive with HBV-DNA \u2265 10\\^2 cps\/mL or \u2265 2000 IU\/mL); hepatitis C antibody-positive with a positive PCR result for HCV RNA; Patients infected with human immunodeficiency virus (HIV); Patients with active tuberculosis.\n\n14. Patients are not suitable for the study in the investigator's opinion, include but are not limited to, conditions in which the patient has a serious or uncontrolled medical condition, interferes with the interpretation of the study results, and interferes with compliance with the trial.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05863325001","EMAIL":[{}],"GEO":[43.88,125.32278]},{"TITLE":"Prophylactic Peptide Vaccine in Advanced ALK+ NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Histologically or cytologically confirmed diagnosis of stage IV NSCLC (or recurrent NSCLC not a candidate for definitive multimodality therapy)\n2. Documented ALK rearrangement as detected by: (1) fluorescence in situ hybridization (FISH), (2) immuno-histochemistry (IHC), (3) tissue next-generation sequencing (NGS), or (4) circulating tumor DNA (ctDNA) NGS\n3. Ongoing treatment with crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib with at least stable disease \u2265 4 months\n4. No known presence of the specific ALK acquired resistance alterations targeted by the study vaccine\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1\n6. Males or females at least 18 years old\n\nExclusion Criteria:\n\n1. Known additional malignancy that is progressing or has required active treatment within the past 3 years. Adequately resected non-melanoma skin cancer, curatively treated in-situ disease, and other solid tumors treated with potentially curative therapy are allowed.\n2. Cytotoxic chemotherapy within 14 days of first dose of study vaccine or concurrent with study vaccine\n3. Anti-neoplastic immunotherapy within 28 days of first dose of study vaccine or concurrent with study vaccine\n4. Systemic immune suppression:\n\n   1. Use of chronic oral or systemic steroid medication (topical or inhalational steroids are permitted)\n   2. Other clinically relevant systemic immune suppression\n5. Symptomatic central nervous system (CNS) metastasis. Asymptomatic CNS disease requiring increasing dose of corticosteroids within 7 days prior to study enrollment is also not permitted\n6. Current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging). Patients with leptomeningeal disease and without cord compression are allowed","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05950139001","EMAIL":[{},{},{}],"GEO":[39.29038,-76.61219]},{"TITLE":"I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy","CRITERIA":"Inclusion Criteria:\n\n* Age \\>\/= 18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status \\<\/= 2.\n* Histologically confirmed diagnosis of stage IIIB\/C-IV Non-Small-Cell Lung Cancer\n* Received any line immunotherapy (maintenance therapy with Durvalumab is allowed) for retrospective cohort; clinical indication for frontline treatment with immunotherapy as first line treatment for prospective cohort.\n* Patients with CNS metastasis are allowed\n* Patients with driver genomic alterations are allowed (only for retrospective cohort)\n* Evidence of a personally signed and dated ICF indicating that the patient has been informed of and understands all pertinent aspects of the study before enrolment (only for prospective cohort)\n* Availability of at least one FFPE block for -omics data generation (only for prospective cohort)\n\nExclusion Criteria:\n\n* Patients without minimal treatment information data to be included in the retrospective cohort\n* Prior treatment for advanced disease (only for prospective cohort)\n* Unavailability or inability to comply with the requested study procedures, including compilation of QoL questionnaires","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05537922004","EMAIL":[{}],"GEO":[41.38879,2.15899]},{"TITLE":"Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC","CRITERIA":"Main Inclusion Criteria:\n\n* Histologically proven NSCLC\n* Unresectable or metastatic NSCLC, including squamous cell carcinoma, harboring sensitizing EGFR, ALK, or ROS1 genetic aberrations who have received standard of care targeted therapy and have progressed on treatment. Patients with known T790M mutation should have received osimertinib and failed.\n* Measurable disease per RECIST 1.1\n* ECOG performance status \u2264 1\n* Adequate organ function\n* Adequately controlled blood pressure\n\nMain Exclusion Criteria:\n\n* Prior exposure to immunotherapy or chemotherapy\n* Active untreated brain metastasis and\/or carcinomatous meningitis\n* Active, known or suspected autoimmune disease\n* History of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis\/interstitial lung disease\n* Condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive medications\n* Baseline proteinuria \u2265 1 g\/24 hrs\n* Electrolyte abnormalities that have not been corrected\n* Significant cardiovascular impairment\n* Gastrointestinal pathology that might affect the absorption of lenvatinib\n* Preexisting grade \u2265 3 gastrointestinal or non gastrointestinal fistula\n* Bleeding or thrombotic disorders or subjects at risk for severe hemorrhage\n* Radiographic evidence of intratumoral caviations, encasement, or invasion of a major blood vessel\n* Known history of tuberculosis\n* Active, acute, or chronic clinically significant infections requiring therapy, including hepatitis B, hepatitis C, and HIV\n* ECG with long QTc interval \u2265 470 ms","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04989322001","EMAIL":"jwychiu@hku.hk","GEO":[22.27832,114.17469]},{"TITLE":"Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study","CRITERIA":"Inclusion Criteria:\n\n* Patient has a lung lesion(s) that is either biopsy-proven cancer or shows sequential growth on CT imaging with clinical suspicion for non-small cell lung cancer (NSCLC)-stage I; NSCLC-stage \\> 1; metastatic sarcoma; or metastatic colorectal (CRC) cancer\n* 3 cm or less tumor size\n* Other sites for cancer are either controlled or there are plans for control\n* Expected margin at least 1 cm from critical structures, allowing for protective strategies such as induction of therapeutic pneumothorax. Critical structures include the trachea, main bronchi, esophagus, aorta, aortic arch branches, superior vena cava (SVC), main, right or left pulmonary artery, or heart.\n\nExclusion Criteria:\n\n* Patient is considered high risk for ablation due to major comorbid medical conditions\n* Patient is pregnant or breast feeding","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04430725001","EMAIL":[{},{}],"GEO":[29.76328,-95.36327]},{"TITLE":"First in Human Study of AZD9592 in Solid Tumors","CRITERIA":"Key Inclusion Criteria:\n\n* Age \u2265 18 years\n* Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1\n* Life expectancy \u2265 12 weeks\n* Measurable disease per RECIST v1.1\n* Adequate organ and marrow function as defined in the protocol\n\nAdditional Inclusion Criteria for Module 1:\n\n\u2022 Histologically or cytologically confirmed metastatic or locally advanced EGFRmut., NSCLC; metastatic EGFRwt. NSCLC; recurrent or metastatic HNSCC of the oral cavity; metastatic CRC.\n\nAdditional Inclusion Criteria for Module 2:\n\n\u2022 Histologically or cytologically confirmed metastatic NSCLC EGFRmut.\n\nAdditional Inclusion Criteria for Module 3:\n\n\u2022 Histologically or cytologically confirmed metastatic CRC.\n\nKey Exclusion Criteria:\n\n* History of (non-infectious) ILD\/pneumonitis that required steroids, has current ILD\/pneumonitis, or where suspected ILD\/pneumonitis cannot be ruled out by imaging at screening.\n* Spinal cord compression or a history of leptomeningeal carcinomatosis.\n* Active infection including tuberculosis and HBV, HCV or HIV\n* Brain metastases unless treated (prior treatment required only for Module 1), asymptomatic, stable, and not requiring continuous corticosteroids at a dose of \\> 10 mg prednisone\/day or equivalent for at least 4 weeks prior to start of study treatment.\n* Participants with cardiac comorbidities as defined in the study protocol","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05647122044","EMAIL":"information.center@astrazeneca.com","GEO":[24.95233,121.20193]},{"TITLE":"Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR\/ALK\/ROS1 Mutant Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form.\n2. Age \u2265 18 years.\n3. Histologically or cytologically confirmed, Stage IV NSCLC.\n4. EGFR\/ALK\/ROS1-sensitive mutations confirmed by an accredited local laboratory, progressed from first line systematic therapy.\n5. ECOG 0-1.\n6. Predicted survival \u2265 12 weeks.\n7. Adequate bone marrow hematopoiesis and organ function\n8. Presence of measurable lesions according to RECIST 1.1.\n\nExclusion Criteria:\n\nCancer-Specific Exclusions:\n\n* Active or untreated central nervous system metastases.\n* Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome.\n\nGeneral Medical Exclusions:\n\n* Pregnant or lactating women.\n* History of autoimmune disease.\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.\n* Positive test for human immunodeficiency virus.\n* Active hepatitis B or hepatitis C.\n* Severe infection within 4 weeks prior to randomization.\n* Significant cardiovascular disease.\n* Illness or condition that interferes with the participant's capacity to understand, follow and\/or comply with study procedures.\n\nExclusion Criteria Related to Medications:\n\n\u2022 Prior treatment with cluster of differentiation 137 agonists or immune checkpoint blockade therapies, anti-programmed death-1, and anti-PD-L1 therapeutic antibodies.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05284539001","EMAIL":[{"email":"zhangyongchang@csu.edu.cn"},{"email":"yangnong0217@163.com"}],"GEO":[28.19874,112.97087]},{"TITLE":"A Study of Oncobax\u00ae-AK in Patients With Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n1. Age \\> 18 years\n2. Histologically confirmed Stage IV non-squamous NSCLC or clear cell RCC\n3. NSCLC-specific criterion: Best tumor response (by iRECIST) as Stable Disease\n4. NSCLC-specific criterion: PD-L1 expression \\> 50%\n5. ECOG Performance Status = 0-1\n6. Negative stool PCR test for Akkermansia\n7. At least one measurable lesion per iRECIST\n8. Hemoglobin \u2265 100 g\/L\n9. Albumin \\> 35 g\/L\n10. Signed informed consent\n\nExclusion Criteria:\n\n1. Symptomatic brain metastases\n2. AST or ALT \\> 5 x ULN\n3. Calculated creatinine clearance \\< 45 ml\/min\n4. Auto-immune diseases requiring systemic therapy\n5. Immunosuppressive therapy (\\> 10 mg prednisone\/day equivalent)\n6. Radiotherapy (\\> 30 Gy) to the lung(s) within 6 months of signed informed consent\n7. Active infection\n8. Co-morbidities that may increase the risk of treatment-related adverse events\n9. Pregnancy\n10. Inability to comply with protocol-specific assessments","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05865730004","EMAIL":[{}],"GEO":[48.58392,7.74553]},{"TITLE":"WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Male or female aged 18 years or older;\n* Pathologically confirmed NSCLC who present with investigator-assessed previously untreated, unresectable, locally advanced (Stage II\u3001III) disease (according to TMN staging of AJCC version 8);\n* Has active mutation of ALK or ROS1;\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1;\n* Has at least one evaluable lesion (according to RECIST 1.1);\n* Have adequate pulmonary function test as a forced expiratory volume in 1 second (FEV1) \\>50% of predicted normal volume and carbon monoxide lung diffusing capacity (DLCO) \\>40% of predicted normal value;\n* Have adequate organ and marrow function;\n* If participant is a woman of childbearing potential (WOCBP), must agree to follow the contraceptive guidance from written informed consent until at least 180 days after the last dose of study treatment. The female participant should have negative serum pregnancy test within 7 days prior to the first dose of study drug, and not breastfeeding;\n* A male participant must agree to use contraception from written informed consent until at least 180 days after the last dose of study treatment.\n\nExclusion Criteria:\n\n* Diagnosed other malignant tumor besides NSCLC within 5 years prior to study entry;\n* Mixed small cell and non-small cell lung cancer histology;\n* Has received prior therapy with any ALK TKI;\n* Has a history of extensive diffuse\/bilateral interstitial fibrosis, or grade 3 or 4 pulmonary fibrosis or interstitial lung disease prior to the first dose of study drug.\n\nHas a known history of active tuberculosis; severe infection within 4 weeks prior to study entry;\n\n* History of primary immunodeficiency;\n* Active or prior documented autoimmune disease within the past 2 years. NOTE: Patients with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05351320001","EMAIL":[{}],"GEO":[36.66833,116.99722]},{"TITLE":"Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)","CRITERIA":"Inclusion Criteria:\n\n* Patients must be willing and able to provide written informed consent\/assent for the trial.\n* Patients must be \u2265 18 years of age on day of signing informed consent.\n* Patients must have measurable disease based on RECIST 1.1\n* Patients must have archival tissue where available. Patients enrolled on the phase 1 escalation trial where archival tissue is not available will undergo a fresh biopsy where clinically feasible after discussion with the sponsor.\n* Patients enrolled on the Phase II trial must be willing and able to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion.\n* Tumor proportional score of PD-L1 \u22651%\n* Patients must have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.\n* Patients must demonstrate adequate organ function on all screening labs. Screening labs should be performed within 10 days of treatment initiation.\n* Patients must have a histologic or cytologic diagnosis of Stage IV NSCLC.\n* Patients must harbor an STK11 mutation via CLIA-certified assay.\n* Phase I: Patients may have progression from at least one prior line of therapy.\n* Phase II: Patients must be treatment na\u00efve in the stage IV setting, with the exception of patients whose tumors harbor an activating mutation (including but not limited to EGFR, ALK, ROS1) and were previously treated with targeted therapy.\n* Female patients of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication.\n* Female patients of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication.\n* Male patients should agree to use an adequate method of barrier contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.\n* Patients cannot have clinically significant hearing loss that requires a hearing aid.\n\nExclusion Criteria:\n\n* Patients who are currently participating in and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.\n* Patients that have a diagnosis of immunodeficiency or is receiving systemic steroid therapy at doses \u2265 10 mg prednisone or any other form of systemic immunosuppressive therapy within 7 days prior to the first dose of trial treatment.\n* Patients that have a known history of TB Disease (Mycobacterium tuberculosis).\n* Patients that have a hypersensitivity to pembrolizumab, DFMO or any of its excipients.\n* Patients enrolled on the phase II trial, who have had prior treatment with a PD1 or PDL1 inhibitor, anti-CTLA 4 antibody or any other antibody or drug that specifically targets immune checkpoint pathway in the stage IV setting (i.e. not \"immune therapy na\u00efve\").\n* Patients who have received thoracic radiation \\>30Gy within six months of the first dose of pembrolizumab.\n* Patients that had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., \u2264 Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.\n* Patients that have received major surgery must have recovered adequately from the toxicity and\/or complications from the intervention prior to starting therapy.\n* Patients that have a known additional malignancy that is progressing or requires active treatment.\n\nExceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer.\n\n* Patients that have a known active central nervous system (CNS) metastasis and\/or carcinomatous meningitis.\n* Patients that have active autoimmune disease that has required systemic treatment in the past 2 years.\n* Patients that have an active infection requiring systemic therapy.\n* Patients that have a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, that would substantially increase risk of incurring adverse events (AEs) from the study medications, that would interfere with the subject's participation for the full duration of the trial or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Patients that have a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial.\n* Patients that have a known history of Human Immunodeficiency Virus (HIV) (HIV 1\/2 antibodies).\n* Patients that have known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \\[qualitative\\] is detected).\n* Patients that have received a live vaccine within 30 days of planned start of study therapy.\n* Patients that have a history of, or any evidence of active non-infectious pneumonitis that required or requires steriods.\n* Patients that have evidence of interstitial lung disease (ILD).\n* Patients that have a history of symptomatic (NYHA class II-IV) heart failure.\n* Patients harboring STK11 variants listed in ClinVAR as benign or likely-benign will be excluded from this study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06219174001","EMAIL":[{"email":"Anahid.Aminpour@moffitt.org"},{}],"GEO":[27.94752,-82.45843]},{"TITLE":"Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)","CRITERIA":"Inclusion Criteria:\n\n1. Patient is \u226518 years of age\n2. Written Informed Consent provided by patient\n3. Diagnosis of any kind of carcinoma\n4. Malignant fluid (e.g. pleural effusion or ascites) drainage OR tumor tissue resection OR tumor tissue needle biopsy is clinically indicated as part of SOC\n5. Proceeding onto therapy for treatment\n6. Informed consent obtained for the XCELSIOR longitudinal outcomes registry (NCT03793088)\n\nExclusion Criteria:\n\n1. Lack of informed consent\n2. Unable to obtain sufficient sample","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05461430001","EMAIL":[{"email":"traverastudy@xcures.com"}],"GEO":[37.80437,-122.2708]},{"TITLE":"Primary Tumor Resection With EGFR TKI for Stage IV NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed non-small cell lung cancer\n* Stage IV non-small cell lung cancer which is amenable to thoracic surgery\n* Patients must have one of the following:NSCLC which harbors EGFR exon 19 deletion or L858R mutation.\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\< 1\n* Candidate for therapeutic intent surgery to at least one site of disease\n* Signed and dated written informed consent prior to admission to the study in accordance with International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH)-Good Clinical Practice (GCP) guidelines and to the local legislation\n\nExclusion Criteria:\n\n* Life expectancy \\<= 12 weeks\n* With underlying diseases such as moderate to severe Chronic Obstructive Pulmonary Disease or tuberculosis\n* With uncontrol diseases including acute infection, unstable angina or angina in recent 3 months, Heart failure(NYHA\u22652), myocardial infarction in recent 6 months, severe arrhythmia, moderate to severe cirrhosis, moderate to severe chronic renal insufficiency, immune insufficiency, any systemic disease with poor prognosis after treatment.\n* With Cerebrovascular Accident complicated dependent activities of daily living.\n* Any other cancer with active treatment in recent 5 years.\n* receive thoracic surgery in the ipsilateral site with the lung cancer previously. \uff08the biopsy surgery required for the diagnosis of lung cancer was not excluded)\n* pregnant or breast-feeding woman\n* Previous treatment with other EGFR TKI. NOTE: Patients who are receiving initial afatinib (6-12 weeks) outside this study are not excluded\n* Disagree to receive Next Generation Sequencing for the lesion specimen after surgery.","SEX":"ALL","AGE_MIN":20,"AGE_MAX":200,"SS_ID":"05215548002","EMAIL":[{"email":"chenjs@ntu.edu.tw"}],"GEO":[25.04776,121.53185]},{"TITLE":"Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Age \u226518 years old (calculated on the date of signing the informed consent);\n* ECOG PS: 0-1;\n* Expected survival \u22653 months;\n* histopathologically confirmed non-small cell lung cancer with at least one measurable lesion (according to RECIST 1.1);\n* Patients who provided detectable specimens (tissue or cancerous pleural fluid) for genotype testing before enrollment, and whose EGFR and ALK gene test results were negative; Or patients with negative test results; Or patients with positive test results and who are resistant or intolerant after receiving relevant targeted drug therapy.\n* Have not been treated with a systematic regimen;\n* Patients voluntarily join the project and sign informed consent;\n* The function of vital organs is normal\n* Physicians can benefit from anrotinib hydrochloride combined immunotherapy based on current clinical practice assessment;\n* Patients voluntarily join the project and sign informed consent;\n* Require initiation of antirotinib hydrochloride combined immunotherapy within 28 days of informed consent;\n\nExclusion Criteria:\n\n* Known allergy or metabolic disorder to any drug in the treatment regimen;\n* Those who refuse to take reliable contraceptive methods during pregnancy and lactation or in the appropriate age period;\n* Have any history of uncontrolled medical diseases (including uncontrolled diabetes, severe heart, lung, liver and kidney dysfunction, blood, endocrine system diseases, and other malignant tumors);\n* Have a history of psychotropic substance abuse, alcoholism or drug use;\n* Currently or about to participate in other anti-tumor drug clinical trials;\n* Have active, known, or suspected autoimmune diseases (including but not limited to: uveitis, enteritis, hepatitis, pituitaritis, nephritis, vasculitis, hyperthyroidism, hypothyroidism, and asthma requiring bronchodilator treatment, etc.). Patients with hypothyroidism who only need hormone replacement therapy, skin conditions that do not require systemic treatment (such as vitiligo, psoriasis, or alopecia) may be included;\n* During the 6 months prior to entering the study, the following conditions occurred: Myocardial infarction, severe\/unstable angina pectoris, NYHA grade 2 or higher cardiac dysfunction, poorly controlled arrhythmias (including QTcF interphase \\>450 ms in men, \\> 470 ms in women, \\>450 ms in women, \\>450 ms in men, \\> 470 ms in women, QTcF interval calculated by Fridericia formula), symptomatic congestive heart failure, cerebrovascular accident (including transient ischemic attack or symptomatic pulmonary embolism);\n* Patients receiving hematopoietic stem cells or organ transplants;\n* Other factors that may affect patient safety or compliance as determined by the investigator. Such as a serious illness (including mental illness) requiring co-treatment, serious laboratory abnormalities, or other family or social factors. Severe hepatic and renal insufficiency as judged by researchers.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06341530001","EMAIL":[{"email":"cz711010@163.com"}],"GEO":[34.75778,113.64861]},{"TITLE":"Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent\n* Patients with advanced\/metastatic NSCLC\n* Must be immunotherapy naive\n* Males and females age \u2265 18 years\n* ECOG Performance Status 0 - 2\n* Measurable disease by RECIST 1.1\n* Must have a lesion (either primary or metastatic lesion) that can be safely biopsied to have sufficient tissue (at minimum, 3-4 cores using 20g or larger core biopsy) to generate tumoroids\n* Must have at least one target lesion to evaluate treatment response\n* Will be receiving anti-PD-1\/L1 with or without anti-CTLA-4 per standard of care Adequate organ function defined per standard of care in this setting.\n* Women of child-bearing potential and men with partners of child-bearing potential must agree to practice sexual abstinence or to use the forms of contraception as required\/recommended by each immune checkpoint inhibitor used in the setting of standard of care.\n\nExclusion Criteria:\n\n* Incarcerated\n* Not competent to make medical decision, noncommunicative or noncompliant per investigator's judgement.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":110,"SS_ID":"05332925002","EMAIL":[{"email":"ctnursenav@kumc.edu"}],"GEO":[39.11417,-94.62746]},{"TITLE":"A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria for Neoadjuvant Therapy:\n\n* Pathologically documented NSCLC:\n* Newly diagnosed early-stage NSCLC stages IB, IIA, IIB, IIIA, or selected IIIB (T3N2 only) NSCLC of squamous or non-squamous histology. Staging should be based on the 8th edition of the American Joint Committee on Cancer (AJCC)\/Union Internationale Contre le Cancer (UICC) NSCLC staging system.\n* T4 primary NSCLC will be allowed only on the basis of size. Invasion of the diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodules in a different ipsilateral lobe is not permitted.\n* All patients will undergo clinical staging using CT and PET scanning, as well as brain imaging using MRI. Invasive mediastinal staging by either mediastinoscopyor endo- bronchial ultrasonography is highly encouraged for patients with radiographically suspected mediastinal nodal disease (ie, N2) but not mandated if the CT or PET scans showed no evidence of N2 disease.\n* Molecular testing results from CLIA-certified laboratories and showing at least one of the following abnormalities: ALK fusion, ROS1 fusion, NTRK1\/2\/3 fusion; BRAF V600 mutation (enrollment closed); RET fusion (enrollment closed), PD-L1, KRAS G12C expression in \u2265 1% tumor cells as determined by FDA-approved test.\n* Measurable disease, as defined by RECIST v1.1\n* NSCLC must have a solid or subsolid appearance on CT scan and cannot have a purely ground glass opacity appearance. For subsolid lesions, the tumor size (i.e., clinical T stage) should be measured based on the solid component only, exclusive of the ground glass opacity component.\n* Evaluated by the attending surgeon prior to study enrollment to verify that the primary tumor and any involved lymph nodes are technically completely resectable and verify that the participant is medically operable\n* Adequate pulmonary function to be eligible for surgical resection with curative intent\n* Adequate cardiac function to be eligible for surgical resection with curative intent\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Adequate hematologic and end-organ function\n* Negative hepatitis B surface antigen (HBsAg) test at screening for cohort\n* Negative total hepatitits B core antibody (HBcAb) test at screening for cohort, or positive total HBcAb test followed by a negative hepatitis B virus (HBV) DNA test at screening\n* Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening\n* Male participants must be willing to use acceptable methods of contraception\n* Female participants of childbearing potential must agree to use acceptable methods of contraception\n\nInclusion Criteria for Adjuvant Therapy (TKI Cohorts and KRAS G12C cohort \\[if continuing on Divarasib\\]):\n\n* Participants whose tumors lack radiographic progression\n* ECOG Performance Status of 0 or 1\n* Adequate hematologic and end-organ function\n\nExclusion Criteria\n\n* NSCLC that is clinically T4 by virtue of mediastinal organ invasion or Stage IIIB by virtue of N3 disease\n* Any prior therapy for lung cancer, including chemotherapy, targeted therapy, immunotherapy, or radiotherapy, within 2 years\n* Participants with prior lung cancer\n* Major surgical procedure within 28 days prior to Cycle 1, Day 1\n* Malignancies other than the disease under study within 3 years prior to Cycle 1, Day 1, with the exception of patients with a negligible risk of metastasis or death and with expected curative outcome\n* Treatment with an investigational agent for any condition within 4 weeks prior to Cycle 1, Day 1\n* Participants known to be positive for HIV are excluded if they meet any of the following criteria: CD4+ T-cell count of \\<350 cells\/microliters; detectable HIV viral load; history of an opportunistic infection within the past 12 months; on stable antiretroviral therapy for \\<4 weeks\n* Severe infection within 4 weeks prior to initiation of study treatment, including but not limited to hospitalization for complications of infections, or any active infection that, in the opinion of the investigator, could impact participant safety\n* Pregnant or lactating, or intending to become pregnant during the study","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04302025034","EMAIL":"global-roche-genentech-trials@gene.com","GEO":[38.84622,-77.30637]},{"TITLE":"A Phase 1a\/1b Study of ACTM-838 in Patients With Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n1. Advanced solid tumor for which there is no remaining standard curative therapy and no therapy with a demonstrated survival benefit, or they must be ineligible to receive or refuse to receive such therapy\n2. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST ) v1.1; amenable for biopsy, and radiographically apparent on computed tomography (CT) or magnetic resonance imaging (MRI )\n3. Eastern Cooperative Oncology Group (ECOG) 0-1\n4. Adequate hematologic, hepatic, pulmonary, and cardiac function\n5. CD4 count \\>500\/mL at screening\n6. Additional protocol defined inclusion criteria may apply\n\nExclusion Criteria:\n\n1. Active autoimmune disease requiring systemic treatment (i.e., with use of disease modifying agents, systemic corticosteroids or immunosuppressive drug) within the past 6 months prior to dosing of investigational product.\n2. History of permanent artificial implants (e.g., prosthetic joints, artificial heart valves, pacemakers, orthopaedic screw\\[s\\], metal plate\\[s\\], bone graft\\[s\\], or other exogenous implant\\[s\\]\n3. Known history of cholelithiasis or urolithiasis\n4. History of valvular disease, arterial aneurisms or arterial or venous malformation\n5. Known active brain metastases\n6. Documented active Salmonella infection or vaccination with Salmonella typhi within 6 months prior to investigational product dosing\n7. Additional protocol defined inclusion\/exclusion criteria may apply","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06336148002","EMAIL":[{"email":"clinicaltrials@socru.org.au"}],"GEO":[-35.03333,138.56667]},{"TITLE":"Neoadjuvant Durvalumab\/Anlotinib \/Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study","CRITERIA":"Inclusion Criteria:\n\n* Written informed consent provided.\n* Males or females aged \u226518 years.\n* Pathologically diagnosed of non-small cell lung cancer.\n* Diagnosed as stage III.\n* Tumor should be considered resectable before study entry by a multidisciplinary team.\n* ECOG (Performance status) 0-1.\n* Screening laboratory values must meet the following criteria and should be obtained within 7 days prior to treatment.\n\n  i. Neutrophils \u2265 1500\u00d7109\/L ii. Platelets \u2265 100 x\u00d7109\/L iii. Hemoglobin \\> 9.0 g\/dL iv. Serum creatinine \u2264 1.5 x ULN or creatinine clearance (CrCl) \u2265 40 mL\/min v. AST\/ALT \u2264 3 x ULN vi. Total Bilirubin \u2264 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin \\< 3.0 mg\/dL) vii. The patients need to have a forced expiratory volume (FEV1) \u2265 1.2 liters or \\>40% predicted value viii. INR\/APTT within normal limits.\n* Women of childbearing potential, including women who had their last menstrual period in the last 2 years, must have a negative serum or urine pregnancy test within 7 days before randomization.\n* All sexually active men and women of childbearing potential must use an effective contraceptive method (two barrier methods or a barrier method plus a hormonal method) during the study treatment and for a period of at least 12 months following the last administration of trial drugs.\n* Patient capable of proper therapeutic compliance and accessible for correct follow-up.\n* Measurable or evaluable disease (according to RECIST 1.1 criteria).\n\nExclusion Criteria:\n\n* All patients carrying activating mutations in the TK domain of EGFR or any variety of alterations in the ALK gene.\n* central type, with empty lung squamous cell carcinoma or non-small cell lung cancer with hemoptysis (\\>50 mL\/day).\n* Patients with a condition requiring systemic treatment with either corticosteroids (\\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization. Inhaled or topical steroids, and adrenal replacement steroid doses \\> 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.\n* Patients with a history of interstitial lung disease cannot be included if they have symptomatic ILD (Grade 3-4) and\/or poor lung function. In case of doubt please contact trial team.\n* Patients with other active malignancy requiring concurrent intervention and\/or concurrent treatment with other investigational drugs or anti-cancer therapy.\n* Patients with previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, endometrial, cervical\/dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period.\n* Any medical, mental or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information.\n* Patients who have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways.\n* Patients with positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection.\n* Patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).\n* Patients with history of allergy to study drug components excipients. Women who are pregnant or in the period of breastfeeding.\n* Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04762030001","EMAIL":[{"email":"changchenc@tongji.edu.cn"}],"GEO":[31.22222,121.45806]},{"TITLE":"Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy","CRITERIA":"Inclusion Criteria:\n\n* Provision of signed, written and dated informed consent prior to any study specific procedures;\n* Male or female aged 18-75 years;\n* Histologically- or cytologically-documented SCLC;\n* Stage I-III (AJCC\/UICC 8th TNM Staging), with all lesions can be included in a tolerable radiotherapy field (limited-stage);\n* Previous thoracic radiotherapy (45 Gy twice daily or 60-66 Gy once daily) and concurrent etoposide and platinum for four cycles; Dose coverage \u2265 85% of PTV-GTV. Radiotherapy started before the completion of the third cycle of chemotherapy;\n* CR, PR or SD after concurrent chemoradiotherapy (RECIST v1.1);\n* PCI is allowed and should be completed within 90 days after the completion of chemoradiotherapy;\n* Randommization shoud be completed within 90 days after the completion of chemoradiotherapy;\n* Life expectancy \u226512 weeks;\n* World Health Organization (WHO) Performance Status of 0 or 1;\n* Evidence of post-menopausal status, or negative urinary or serum pregnancy test for female pre-menopausal patients within 7 days before the use of study drug (HCG has a minimum sensitivity of 25 IU\/L or equivalent);\n* Women must be non-breastfeeding;\n* Women of reproductive age (WOCBP) must agree to comply with the contraceptive method during the study toripalimab treatment and for a period of 3 months following the last administration of the study treatment (i.e., 30 days \\[ovulation cycle\\] plus approximately 5 half-lives of the study drug);\n* Men who have sex with WOCBP must agree to comply with the contraceptive method during the study nivolumab treatment and for 5 months after the last administration of the study treatment (i.e. 90 days \\[sperm renewal cycle\\] plus approximately 5 half-lives of the study drug);\n* Spermless men do not have to comply with contraceptive requirements. WOCBP who continues to be asexual with the opposite sex does not have to comply with contraceptive requirements, but must still undergo the pregnancy tests described in this section;\n* Adequate organ and marrow function as defined below:\n\n  1. Forced expiratory volume in 1 second (FEV1) \u2265 800ml;\n  2. Absolute neutrophil count \u22651.5 x 10\\^9\/L (1500 per mm3);\n  3. Platelets \u2265100 x 10\\^9\/L (100,000 per mm3);\n  4. Haemoglobin \u2265 9.0 g\/dL (5.59 mmol\/L);\n  5. Serum creatinine clearance (CL) \u2265 50 mL\/min by the Cockcroft-Gault formula (Cockcroft and -Gault 1976);\n  6. Serum bilirubin \u22641.5 x upper limit of normal (ULN);\n  7. Aspartate Transaminase (AST) and Alanine Transaminase (ALT) \u2264 2.5 x ULN.\n\nExclusion Criteria:\n\n* Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study;\n* Mixed small cell and non-small cell lung cancer histology;\n* Extensive-stage SCLC;\n* Histologically-confirmed malignant pleural or pericardial effusion;\n* Sequential chemoradiotherapy, or radiotherapy did not start before the completion of the third cycle of chemotherapy;\n* Progressive disease after concurrent chemoradiotherapy (RECIST v1.1) and before randomization;\n* Prior use of surgery, radiotherapy or chemotherapy for SCLC, with the exceptions of thoracic concurrent chemoradiotherapy and PCI;\n* Any unresolved toxicity CTCAE \\>Grade 2 from the prior chemoradiation therapy will be excluded from randomization;\n* Patients with Grade \u22652 pneumonitis from prior chemoradiation therapy will be excluded from randomization;\n* Current or prior use of immunosuppressive medication within 28 days before the first dose of toripalimab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg\/day of prednisone, or an equivalent corticosteroid. Systemic steroid administration required to manage toxicities arising from radiation therapy delivered as part of the previous chemoradiotherapy for SCLC is allowed;\n* Prior exposure to any anti-programmed cell death protein(PD)-1 or anti-PD-L1 antibody;\n* Recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access);\n* Active or prior documented autoimmune disease within the past 2 years including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener's granuloma, Sjogren's syndrome, Guillain Barre syndrome or multiple sclerosis;\n* History of primary immunodeficiency;\n* History of organ transplant that requires therapeutic immunosuppression;\n* Mean QT interval corrected for heart rate (QTc) \u2265470 ms calculated from 3 electrocardiograms (ECGs) using Bazett's Correction;\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses, hepatitis C , human immunodeficiency virus (HIV), or patients with positive HBsAg and HBV-DNA \\> 500 IU\/ml, or psychiatric illness\/social situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent;\n* Known history of tuberculosis;\n* Receipt of live attenuated vaccination within 30 days prior to study entry;\n* History of another primary malignancy within 5 years prior to study entry, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ, breast intraductal carcinoma in situ or localized prostate cancer;\n* Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control;\n* Any condition that, in the opinion of the investigator, would interfere with evaluation of the toripalimab or interpretation of patient safety or study results;\n* Any condition that, in the opinion of the investigator, not suitable for study entry.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"04418648001","EMAIL":[{"email":"qiubo@sysucc.org.cn"}],"GEO":[31.22222,121.45806]},{"TITLE":"A Study of GV20-0251 in Patients With Solid Tumor Malignancies","CRITERIA":"Inclusion Criteria:\n\n* \\>= 18 years of age\n* Previously treated, histologically-confirmed advanced solid malignancy with progressive disease requiring therapy\n* Refractory or intolerant to standard therapy(ies)\n* Must have received, be not eligible or decline standard of care therapy\n* One or more metastatic solid tumors that are evaluable or measurable per RECIST v1.1\n* For participants who have received prior treatment with a checkpoint inhibitor there must be documented disease progression\n* ECOG performance status of 0 or 1\n* Life expectancy of \\>=12 weeks\n* Disease-free of active second\/secondary or prior malignancies for \u2265 2 years\n* Laboratory test results within the required parameters\n* Women of child bearing potential (WOCBP) and men must agree to use adequate contraception\n* Part B ONLY must include the following tumor types:\n\n  * Cohort B1: bladder urothelial carcinoma\n  * Cohort B2: cholangiocarcinoma\n  * Cohort B3: proficient MMR (pMMR)\/MSS adenocarcinoma of the colon or rectum\n  * Cohort B4: proficient MMR (pMMR)\/MSS endometrial carcinoma\n  * Cohort B5: deficient MMR (dMMR)\/MSI-H endometrial carcinoma\n  * Cohort B6: squamous head and neck carcinoma\n  * Cohort B7: cutaneous melanoma\n  * Cohort B8: non-small cell lung cancer\n\nExclusion Criteria:\n\n* Participant with acute luekemia or CLL\n* Participant with heart disease or unstable arrhythmia\n* Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy\n* Participant has active autoimmune disease or other medical conditions requiring chronic systemic steroid or immunosuppressive therapy\n* Known human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C infection\n* History of major organ transplant\n* History of a bone marrow transplant\n* Symptomatic central nervous system (CNS) malignancy or metastasis\n* Serious nonmalignant disease\n* Pregnant or nursing women\n* Treatment with PD-1 and equivalent immune modulators or major surgery prior to the first dose of study medication\n* Participants who are currently receiving any other investigational agent or have received an investigational agent within 4 weeks prior to the first dose of study medication\n* Treatment with any anticancer treatments with 2-weeks prior to the first dose of study medication\n* Radiation for symptomatic lesions must have been completed prior to the first dose of study medication\n* Active substance abuse","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05669430013","EMAIL":[{"email":"clinicaltrials@gv20tx.com"},{}],"GEO":[38.84622,-77.30637]},{"TITLE":"Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD","CRITERIA":"Inclusion Criteria:\n\n1. Signed written informed consent before enrollment;\n2. Men and women aged 18-75;\n3. The patient must be able to provide fresh or archived tumor tissue and its pathology report;\n4. No previous antitumor therapy, life expectancy is not less than 12 weeks;\n5. Newly diagnosed NSCLC subjects confirmed by pathology and imaging; Stage: cT1-4N1-3M1 (stage \u2163), AJCC eighth edition clinical staging of lung cancer;\n6. Asymptomatic patients with NSCLC brain metastases\n7. PD-L1 tumor fraction (TPS) \u22651%;\n8. Epidermal growth factor receptor (EGFR) gene mutation negative and anaplastic lymphoma kinase (ALK) negative;\n9. Measurable lesions that meet RECIST v1.1 criteria;\n10. Patients with COPD who met the relevant diagnostic criteria for COPD in the Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (Revised 2021) formulated by Chinese Society of Respiratory Medicine, and whose condition was stable for \u22652 weeks;\n11. ECOG PS: 0 \\~ 2;\n12. The functions of vital organs meet the following requirements (excluding the use of any blood components and cell growth factors within 14 days) :\n\n    Normal bone marrow reserve, neutrophil (ANC) \u22651,500\/mm\u00b3, platelet count (PLT) \u2265100,000\/mm\u00b3, hemoglobin (Hb) \u22655.6 mmol\/L (9g\/dL);Creatinine (Cr) \u22641.5 mg\/d and\/or Clearance of creatinine (CCr) \u226560 ml\/min;Normal liver function or Total Bilirubin (TBIL) \u22641.5 ULN,Aspartate Transaminase (AST) and Alanine Transaminase (ALT) \u22641.5 ULN;\n13. Non-surgical sterilization or use of a medically approved contraceptive method (e.g. intrauterine device, birth control pill, or condom) during the study treatment period and for 3 months after the end of the study treatment period;Patients with non-surgical sterilization or women of childbearing age had to have a negative serum or urine HCG test within 7 days before study enrollment; must be non-lactation period;Male patients who are not surgically sterilized or of childbearing age are required to consent to use a medically approved contraceptive method with their spouse during the study treatment period and for 3 months after the study treatment period;\n14. Subjects volunteered to join this study, with good compliance, safety and survival follow-up.\n\nExclusion Criteria:\n\n1. Previous radiotherapy, chemotherapy, long-term or high-dose hormone therapy, surgery, or molecular targeted therapy;\n2. The subject has previous or concurrent other malignant tumors;\n3. History of asthma or other respiratory diseases (bronchiectasis, tuberculosis, interstitial pneumonia, occupational lung disease, sarcoidosis, etc.);Patients with objective evidence of radiation pneumonitis, drug-associated pneumonitis, or severe impairment of pulmonary function;\n4. History of lobectomy;\n5. A history of clinically significant circulatory failure;\n6. Significant contraindications for spirometry (history of myocardial infarction, cerebral artery or aortic aneurysm, history of eye surgery, hemoptysis);\n7. Patients with rheumatic diseases;Patients with heart, cerebrovascular, liver, kidney, hematopoietic system and other serious primary diseases.\n8. Patients with a history of acute gastrointestinal bleeding within 3 months;\n9. Previous immune checkpoint inhibitor therapy;The subject is known to have a previous allergy to macromolecular protein preparations, or to any PD-1 mab component;\n10. The subject has any active autoimmune disease or a history of autoimmune disease (e.g., but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism;Subjects with vitiligo or complete remission of asthma in childhood without any intervention as adults were included;Subjects with asthma requiring medical intervention with bronchodilators were excluded);\n11. The subject has active infection or unexplained fever \\>38.5 \u2103 during the screening period or before the first administration;\n12. Subjects with innate or acquired immune deficiency, such as HIV infection, or active hepatitis (transaminases did not meet the inclusion criteria, hepatitis B reference: HBV DNA\u226510\u2074\/ml;HCV RNA\u226510\u00b3\/ml);Chronic hepatitis B virus carriers, HBV DNA\u22652000 IU\/ml (\u226510\u2074 copies\/ml), must receive antiviral therapy during the trial to be enrolled;\n13. The subject is participating in another clinical study or it has been less than one month since the end of the previous clinical study;Subjects may receive other systemic antitumor therapy during the study;\n14. Receive live vaccine less than 4 weeks before or possibly during the study period;\n15. The subject cannot or does not agree to pay for the examination and treatment expenses at his own expense;\n16. Pregnant or lactating women;\n17. Other conditions that should be excluded from the study in the opinion of the investigator.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05578222001","EMAIL":[{"email":"qinjianwen2005@aliyun.com"}],"GEO":[39.14222,117.17667]},{"TITLE":"Opioid Free Anaesthesia-Analgesia Strategy on Surgical Stress and Immunomodulation in Elective VATS-Lobectomy for NSCLC","CRITERIA":"Inclusion Criteria:\n\n* patients undergoing elective VATS lobectomy\n* early stage NSCLC (up to T3N1M0)\n\nExclusion Criteria:\n\n* Immunocompromised patients\n* previous lung surgery\n* preoperative corticosteroid or immunosuppressive drug use\n* uncontrolled Diabetes Mellitus\n* cardiac failure (NYHA 3 and 4)\n* preoperative infection (CRP \\>5mg\/ml, WBC \\>10x10\\^9\/L)\n* preoperative anemia (Hb\\<12g\/dl)\n* chronic inflammatory diseases\n* inflammatory bowel disease\n\nGroup-specific exclusion criteria:\n\n* OFA-\u0391: perioperative opioid administration, within the study period\n* OBA-\u0391: perioperative dexmedetomidine or lidocaine infusion, ketamine, gabapentinoid or corticosteroid administration within the study period","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"05172739001","EMAIL":[{"email":"p.vassilos@gmail.com"}],"GEO":[35.32787,25.14341]},{"TITLE":"Macrophage Imaging Using Ga-MMR-VHH2 in Lung Cancer Patients","CRITERIA":"Inclusion Criteria:\n\n* Patients who have given informed consent\n* Patients at least 18 years old\n* Patient with local, locally advanced or metastatic disease of non-small cell lung cancer, who is planned for resection or surgical biopsy of at least one lesion. In order to minimise partial volume effect, the diameter of the tumour to be resected or biopsied should be \u2265 10 mm in short axis for invaded adenopathies and \u2265 10 mm in long axis for all other types of lesions\n* Patients who participated already in this study can be included if the subject meets all of the inclusion and none of the exclusion criteria at time of second inclusion.\n\nExclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status 3 or higher\n* Pregnant patients\n* Breast feeding patients\n* Patients with any serious active infection\n* Patients who have any other life-threatening illness or organ system dysfunction, which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the test radiopharmaceutical\n* Patients who are unlikely to cooperate with the requirements of the study\n* Patients who are unwilling and\/or unable to give informed consent\n* Patients at increased risk of death from a pre-existing concurrent illness","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05933239001","EMAIL":[{"email":"nucg.clinicaltrials@uzbrussel.be"}],"GEO":[50.87309,4.33419]},{"TITLE":"Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.","CRITERIA":"Inclusion Criteria:\n\n* Participants are required to meet all the criteria below in order to be included in the trial:\n\n  1. Confirmed diagnosis of advanced solid tumors by histological or cytological examination, participants have no effective standard anticancer therapy available or is failed to standard anticancer therapy.\n  2. Male or female patient, aged 18 \\~ 70 years.\n  3. Life expectancy \u2265 3 months.\n  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n  5. Participants with at least 1 measurable tumor lesion and\/or assessable non-measurable lesion based on RECIST 1.1.\n  6. No radiotherapy, chemotherapy, immunotherapy or other anti-tumor therapy (such as experimental drugs, biological agents, Chinese herbal medicine, etc.), surgical treatment (except diagnostic biopsy), or complete recovery from previous surgery within 4 weeks prior to enrollment, and no surgical operation was planned during the study period.\n  7. No severe hematopoietic abnormalities(no blood transfusion, no blood products, no granulocyte colony-stimulating factor, platelet stimulating factor, or other hematopoietic growth factors were corrected within 14 days prior to the screening phase laboratory examination):Hb\u226590g\/L , ANC\u22651.5\u00d7109\/L , PLT\u2265100\u00d7109\/L.\n  8. No serious organic disease of heart, liver or kidney:LVEF\u226550% ; ALT(Alanine aminotransferase) or AST(Aspartate transaminase)\u22642.5\u00d7upper limit of normal(ULN)(for patients with hepatic metastases, ALT or AST\u22645 \u00d7 ULN); TBIL(Total bilirubin)\u22641.5\u00d7ULN; creatinine\u22641.5\u00d7ULN and CL\u2265 60 mL\/min\\[The calculation formula was as follows: CCR (140- age)\u00d7 body weight (kg) \/0.818\u00d7 SCR (\u03bcmol\/L), and female was calculated as \u00d70.85\\].\n  9. The coagulation function is normal:PT\u3001APTT and INR\u22641.5\u00d7ULN\u3002\n  10. Participants (including partners) who are willing to follow reliable contraceptive measures during the study and until 3 months after the last dosing\uff08such as intrauterine devices \\[IUDs\\], birth control pills or condoms\uff09.Women of child-bearing age must be negative for serum HCG within 14 days prior to study enrolment and must be non-lactating\u3002\n  11. Participants with voluntarily signature Informed Consent Form (ICF) before the test, and have a full understanding of the test content, process and possible adverse reactions.\n  12. Participants with good compliance, were available for follow-up, and volunteered to comply with study regulations.\n\nExclusion Criteria:\n\n* Eligible participants must not meet any of the following exclusion criteria:\n\n  1. Patients with the toxicity of previous antitumor therapy did not return to grade 1 or below (CTCAE 5.0 grade \\>1, excluding toxicity such as alopecia and other toxicity judged by investigators to be of no safety risk).\n  2. Patients with (including suspected) an allergic history to Paclitaxel, or any of its components, or allergic constitution (excluding mild asymptomatic seasonal allergy).\n  3. Patients with bleeding tendency or who are receiving thrombolytic or anticoagulant therapy.\n  4. Patients who had been treated with paclitaxel and were determined by the researchers to be resistant.\n  5. Patients with active central nervous system metastases,But patients with BMs who have received prior treatment and the metastases were stable can participate in the study.\n  6. Patients with cerebrovascular accident or transient ischemic attack in the previous 6 months were screened.\n  7. People with active infection and need anti-infection or antiviral treatment.\n  8. Patients have suffered from other malignant cancers within 5 years (except for cured basal cell carcinoma and cervical carcinoma in situ).\n  9. Concomitant diseases, as determined by the investigator, that seriously endangers the safety of subjects or affects their completion of the test(such as gastrointestinal bleeding, intestinal obstruction, intestinal paralysis, interstitial pneumonia, pulmonary fibrosis, etc).\n  10. Patients with a clear history of neurological or psychiatric disorders (including epilepsy and dementia).\n  11. Patients who have used any drugs that is CYP2C8 and\/or CYP3A4 inducer or inhibitor Within 30 days before use of the test drug(including ketoconazole and other imidazole antifungal agents, verapamil, diazepam, quinidine, cyclosporine, teniposide, etoposide, vincrine, testosterone, 17-\u03b1 diethylstilbestrol, retinoic acid, quercetin, etc).\n  12. Patients who received blood transfusion and transfusion of blood products, such as albumin, within 2 weeks prior to trial.\n  13. Patients with peripheral neuropathy above grade II.\n  14. Patients with history of myocardial infarction(within 6 months prior to enrollment) ,severe or unstable angina, coronary or peripheral artery bypass grafting or congestive heart-failure (CHF) at NYHA 3-4 level ;and patients with history of uncontrollable hypertension, arrhythmias considered clinically significant by the investigator, or electrocardiogram (ECG) abnormalities.\n  15. HIV infection, or active HBV infection (HBsAg and\/or HBcAb positive, with peripheral blood HBV DNA \u22651 x 103 IU\/ mL), or active HCV infection (HCV antibody positive, HCV RNA\u2265500 IU\/ mL).\n  16. Alcoholics (drinking more than 14 standard units per week. 1 standard unit contains 14g alcohol,such as 360mL beer or 45mL spirits with 40% alcohol or 150mL wine)within 2 weeks before screening, or patients with drug abuse.\n  17. Patients who participated in other study within the last 1 month.\n  18. Pregnant or nursing women.\n  19. Patients who are thought to be unsuitable for participating in the trial by the researchers because of other factors.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":70,"SS_ID":"04778839001","EMAIL":[{"email":"lindaliu87@zju.edu.com"}],"GEO":[26.4965,99.437]},{"TITLE":"Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Pathologically or cytologically proven diagnosis of non-small cell lung carcinoma.\n* Solitary \\[T1bN0M0, T2aN0M0, T2bN0M0\\] lesion measuring 2-7cm in size. Staging is per AJCC 7th edition of TNM classification.\n* Patient must meet criteria for receipt of hypofractionated radiation therapy\n* Medically inoperable pulmonary status, cardiac status, or other serious co-morbidity, or patient refusal of primary surgery for lung cancer.\n* ECOG Performance status of 0-2.\n* Patients may have prior treatment for lung cancer based on the following criteria:\n\n  1. Surgical resection is allowed if surgery was \\> 12 months ago.\n  2. Patients treated with prior radiation are eligible if radiation was \\> 12 months ago and there is no evidence of progression and if the lesion is in a different lobe.\n  3. Prior chemotherapy if \\> 18 months ago\n\nExclusion Criteria:\n\n* Node positive or metastatic disease.\n* Other active malignancy (specifically, risk of recurrence in 3 years estimated to be greater than 50%) except for non-melanoma skin cancer, in-situ cervical carcinoma (CIN), or low-risk prostate carcinoma on active surveillance are to be excluded.\n* Inability to receive systemic therapy or radiation therapy per protocol.\n* Inability to fulfill requirements of the protocol.\n* Any co-morbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this protocol.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"02619448001","EMAIL":[{"email":"binghamE@upstate.edu"},{"email":"simpsons@upstate.edu"},{},{}],"GEO":[43.04812,-76.14742]},{"TITLE":"SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Subjects aged 18 years and older\n* Pathologically or cytologically confirmed non-small cell lung cancer with no known oncogenic EGFR mutation, ALK rearrangement, ROS1 rearrangement or RET rearrangement\n* Tumoral PD-L1 expression \\>=1% by any Clinical Laboratory Improvement Act (CLIA)-certified assay\n* Metastatic or recurrent non-small cell lung cancer (NSCLC). Stage IIIC per 8th edition TNM stage classification is allowed if not amenable to curative surgery or radiation per investigator judgment\n* At least one site of measurable disease as determined by the Investigator, using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1. Subjects must have ECOG PS 0 or 1 at the time of informed consent and at the time of treatment initiation\n* Must be willing to provide pre-treatment archived specimen or undergo a biopsy procedure if archived specimen is not available\n* Must be willing to provide an on-treatment biopsy, if deemed safe by the treating physician\n* Platelet count \\>= 100,000\/uL\n* Absolute neutrophil count \\>= 1,500\/uL\n* Hemoglobin \\>= 8g\/dL\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\\< 2.5 times upper limit of normal\n* Creatinine =\\< 2.0 mg\/dL\n* Women of child-bearing potential and sexually active men must agree to use adequate contraception (hormonal or barrier method) prior to treatment initiation, during treatment and for three months after completing treatment\n* Negative beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of childbearing potential. Pregnant or breast feeding women are not eligible\n* Signed and dated informed consent document indicating that the patient has been informed of all the pertinent aspects of the trial prior to enrollment\n\nExclusion Criteria:\n\n* Prior chemotherapy or immune checkpoint inhibitor or immune-modulatory therapy (e.g. anti-PD\\[L\\]1, anti-CTLA4, anti-TIM3, anti-GITR, anti-TIGIT, anti-LAG3), for metastatic or recurrent disease\n\n  * Prior chemotherapy and immune checkpoint inhibitor and immune modulatory therapy in the curative setting is allowed as long as treatment was completed \\> 6 months prior to consenting\n  * For patients with NSCLC harboring an oncogenic alteration other than listed may have received prior small molecule inhibitor therapy (e.g. MET inhibitor for MET exon 14 mutated NSCLC). A wash-out period of at least 5 half-lives is required prior to start of study treatment\n* Presence of other active cancers within the last 2 years. Patients with any prior early stage cancer who have received definitive local treatment at least 2 years previously and no evidence of recurrence are eligible. All patients with previously treated in situ carcinoma are eligible, as patients with history of non-melanoma skin cancer\n* Symptomatic central nervous system (CNS) metastases; participants with known brain metastasis must be asymptomatic with no steroids or escalating doses of antiepileptics within 7 days prior to start of study treatment\n\n  * Patients with untreated CNS metastases may be enrolled as long as they meet the above criteria. Patients with bulky CNS metastases should consider receiving radiation prior to study entry per investigator judgment\n* Participants with spinal cord compression must have received local treatment and must have been symptomatically stable with no use of steroids for at least 7 days prior to start of study treatment\n* Participants must not have an active autoimmune disease that has required immune modulating treatment within 1 year prior to consenting (i.e., disease modifying agents, corticosteroids). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is allowed\n* Inability to discontinue systemic corticosteroid therapy; systemic steroids must be tapered off 7 days prior to first dose of SX-682\n* Known history of primary immunodeficiency\n* History of organ transplant that requires use of immunosuppressives\n* Current symptomatic pneumonitis and any past history of immune checkpoint inhibitor related pneumonitis regardless of steroid treatment history\n* History of non-infectious pneumonitis (e.g. radiation pneumonitis) that required steroids within 3 months of start of study treatment\n* Radiotherapy within 7 days of start of study treatment\n* Major surgery within 21 days of start of study treatment. Minor surgery within 2 weeks of start of study treatment. Placement of vascular access device and biopsies are not considered major or minor surgery and are allowed\n* Electrocardiogram (EKG) demonstrating a corrected QT (QTc) interval \\> 480 msec on three consecutive EKGs or patients with congenital long QT syndrome\n* Severe lung disease (e.g. chronic obstructive pulmonary disease \\[COPD\\]) who cannot stop steroids 7 days prior to start of study treatment\n* Serious cerebrovascular and cardiac disease defined as:\n\n  * Active unstable angina pectoris\n  * Congestive heart failure NYHA (New York Heart Association) \\> grade 3\n  * Acute myocardial infarction within 3 months of consenting\n  * Stroke or transient ischemic attack within 3 months of consenting\n* Known active chronic infections: Active hepatitis B, hepatitis C and tuberculosis. Testing is not required for assessment of eligibility. Active infection requiring IV antibiotics within 7 days of study treatment initiation\n\n  * Hepatitis C virus (HCV) infection: Patients with known history of HCV infection are eligible if HCV viral load is below the limit of quantification per local assay\n  * Hepatitis B virus (HBV) infection: Patients with known history of HBV infection are eligible if HBV viral load is below the limit of quantification and negative hepatitis B virus surface antigen (HBsAg) per local assay\n* Known uncontrolled HIV (human immunodeficiency virus) infection\n\n  * Participants with known HIV infection are allowed if they are receiving anti-retroviral therapy, have CD4+ T-cell count \\>= 350 cells\/uL within 6 months prior to study treatment initiation and no history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection\n* Any serious or uncontrolled concomitant disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study\n* Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05570825001","EMAIL":[{"email":"rwood1@fredhutch.org"},{}],"GEO":[47.60621,-122.33207]},{"TITLE":"Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Patients must have been histologically or cytologically diagnosed with non-small cell lung cancer, specifically lung adenocarcinoma\n* Patients must have advanced stage disease that is not amenable to combined modality therapy or surgical resection\n* Patients must have known LKB1 mutation\n* COHORT A ONLY: Patients must have known KRAS mutation\n* Patients must have progressed on prior therapy with immune checkpoint inhibitor alone and first line chemotherapy, either combined or sequentially, for advanced stage disease. No other lines of chemotherapy in the advanced stage therapy is allowed. The exception is patients with KRAS G12C are also allowed the use of one line of targeted Food and Drug Administration (FDA) approved therapy\n* Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as \u2265 20 mm with conventional techniques or as \u2265 10 mm with spiral CT scan\n* Age \u2265 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Adequate recovery from toxicities related to prior treatments to at least grade 1 by Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0. Exceptions include alopecia and peripheral neuropathy grade \u2264 2\n* Absolute neutrophil count \u2265 1,500\/mcL\n* Hemoglobin \u2265 8.0\n* Platelets \u2265 100,000\/mcL\n* Total bilirubin \u2264 1.5 x upper limit of normal (ULN) for the institution; patients with Gilbert syndrome may enroll if total bilirubin \\< 3.0 mg\/dL (51 umole\/L)\n* Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \\[SGOT\\])\/alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase \\[SGPT\\]) alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u2264 2.5 x ULN (or \\< 5 x ULN in patients with liver metastases)\n* Creatinine clearance \u2265 60 mL\/min\/1.73 m\\^2 for patients with creatinine levels above institutional normal\n* Patients must have the ability to ingest oral medications\n* The effects of defactinib and avutometinib on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry,for the duration of study participation, for 3 months following the last dose of study therapy for male patients, and 1 month following the last dose of study therapy for female patients. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n* Patients must be able to understand and be willing to sign a written informed consent document\n* Baseline corrected QT (QTc) interval \\< 460 ms for women and \u2264 450 ms for men (average of triplicate readings) (CTCAE grade 1) using Fredericia's QT correction formula. NOTE: This criterion does not apply to patients with a right or left bundle branch block\n\nExclusion Criteria:\n\n* Patients who have had systemic therapy within 3 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier\n* Patients who are receiving any other investigational agents\n* Patients with unstable or symptomatic brain metastasis or known leptomeningeal disease. Asymptomatic brain metastases are allowed if they meet the following criteria:\n\n  * Have been treated and have been stable for greater than or equal to 4 weeks as documented by radiologic imaging\n  * Have not required increasing doses of corticosteroids within 2 weeks prior to study treatment\n* Patients with history of pre-existing auto-immune conditions that would pose a higher risk for toxicity with nivolumab will be excluded\n* Patients who experienced serious auto-immune toxicity with prior immune checkpoint inhibitor therapy\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to avutometinib or defactinib\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\/social situations that would limit compliance with study requirements\n* Known hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection that is active and\/or requires therapy\n* Active skin disorder that has required systemic therapy within the past 1 year. Surgically removed early stage skin cancers are allowed. Topical creams are allowed as well\n* History of rhabdomyolysis\n* Concurrent ocular disorders:\n\n  * Patients with history of glaucoma, history of retinal vein occlusion (RVO), predisposing factors for RVO, including uncontrolled hypertension, uncontrolled diabetes\n  * Patients with history of retinal pathology or evidence of visible retinal pathology that is considered a risk factor for RVO, intraocular pressure \\> 21 mm Hg as measured by tonometry, or other significant ocular pathology, such as anatomical abnormalities that increase the risk for RVO\n  * Patients with active or chronic, visually significant corneal disorders, other active ocular conditions requiring ongoing therapy or clinically significant corneal disease that prevents adequate monitoring of drug-induced keratopathy. Examples of visually significant corneal disorders include corneal degeneration, active or recurrent keratitis, and other forms of serious ocular surface inflammatory conditions. Visually significant corneal disorders do NOT include dry eyes, blepharitis, and uncomplicated corneal erosions\n* Patients with the inability to swallow oral medications or impaired gastrointestinal absorption due to gastrectomy or active inflammatory bowel disease\n* Treatment with warfarin. Patients on warfarin for deep vein thrombosis\/pulmonary embolism should be converted to low-molecular-weight heparin (LMWH) or direct oral anticoagulants (DOACs). Exposure to medications (with or without prescriptions), supplements, herbal remedies, or foods with potential for drug-drug interactions with defactinib within 14 days prior to the first dose of avutometinib or defactinib and during the course of therapy, including:\n\n  * Strong CYP3A4 inhibitors or inducers, strong CYP2C9 inhibitors or inducers, strong P-glycoprotein (P-gp) inhibitors or inducers\n* Patients with a known \"treatable driver mutation\" with FDA approved targeted therapy (such as EGFR, ALK, ROS1, NTRK, BRAF, RET, MET exon 14, HER2). The exception is KRAS as listed in the inclusion section\n* History of prior malignancy within past 2 years prior to study entry, with the exception of curatively treated malignancies or malignancies with very low potential for recurrence or progression\n* Female patients who are pregnant or breastfeeding","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06495125003","EMAIL":[{"email":"csteuer@emory.edu"}],"GEO":[33.749,-84.38798]},{"TITLE":"First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation","CRITERIA":"Inclusion Criteria:\n\n* Provide informed consent prior to any study specific procedures;\n* 18 -70 years of age;\n* ECOG PS of 0 to 1 at screening with no clinically significant deterioration in the previous 2 weeks, life expectancy \u226512 weeks;\n* Pathologically confirmed Non-Small Cell Lung Cancer (NSCLC);\n* Locally advanced or metastatic NSCLC not amenable to curative surgery or radiotherapy (stage IIIB-IV, according to the 8th edition of the AJCC staging system);\n* Patient with EGFR G719X or S768I or L861Q mutation diagnosed histologically or cytologically, the reports must be issued or recognized by Tier 3A hospitals. The mutations above may exist alone or together;\n* No previous systemic anti-tumor therapy for locally advanced or metastatic NSCLC;\n* According to RECIST 1.1, patients have at least one tumor lesion at baseline that meets the following requirements: accurately and repeatably measurable at baseline have no radiotherapy or biopsy;\n* For premenopausal women with childbearing potential, a pregnancy test must be performed within 14 days before the first dose, and the pregnancy test (blood or urine test) must be negative; female subjects must not be lactating;\n* Willing to use contraception (male patients); Voluntary and agree to follow the study treatment protocol as well as follow-up plan, and can accept the oral medicine treatment.\n\nExclusion Criteria:\n\n* small cell lung carcinoma;\n* History of hypersensitivity to active or inactive excipients of investigational product (IP) or drugs with a similar chemical structure or class to investigational product (IP);\n* Confirmed EGFR Ex20ins or Ex19del or L858R or T790M mutant;\n* Patient who receive prior treatment including: any Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI); the patients who have received intrapleural perfusion therapy can only be enrolled 28 days or more after the pleural effusion is stable; major surgery within 4 weeks of the first dose of investigational product (IP); radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of IP; CYP3A4 strong inhibitor or strong inducer is used within 7 days prior to the first dose, or need to receive these drugs during the study period; traditional Chinese medicine and traditional Chinese medicine preparations with anti-tumor as indications and with adjuvant treatment of tumor is used within 7 days prior to the first dose, or need to receive these drugs during the study period; patients who are receiving drugs known to prolong QTc interval or may cause torsade de pointe and need to continue to receive these drugs during the study period; the time from the treatment with any other investigational product or its analogue to the first dose does not exceed 5 half-lives of the drug or 14 days, whichever is longer.\n* Prior treatment with any systemic anti-cancer therapy for advanced Non-Small Cell Lung Cancer (NSCLC) including chemotherapy, biologic therapy, target therapy, immunotherapy, or any investigational drug, except neoadjuvant or adjuvant therapy before 6 months prior to the first dose IP;\n* At the beginning of study treatment, any unresolved toxic reaction to prior treatment is present, which exceeds Grade 1 in accordance with Common Terminology Criteria for Adverse Events (CTCAE) (except for alopecia), and exceeds Grade 2 for prior platinum treatment-related neuropathy;\n* Spinal cord compression; symptomatic and unstable brain metastases, except for those patients who have completed definitive therapy, are not on steroids, and have a stable neurological status for at least 2 weeks after completion of the definitive therapy and steroids.\n* Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of IP;\n* Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, and active infection, which in the Investigator's opinion makes it undesirable for the patient to participate in the trial;\n* Past medical history of Interstitial Lung Disease (ILD), drug-induced Interstitial Lung Disease, radiation pneumonitis that required steroid treatment, or any evidence of clinically active Interstitial Lung Disease;\n* Any evidence of corneal injury;\n* Inadequate bone marrow reserve or organ function;\n* QT prolongation or any clinically important abnormalities in rhythm and heart function;\n* Pregnancy or lactation;\n* Patients who may have poor compliance with the research procedures and requirements, etc., as judged by investigators.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":70,"SS_ID":"05548348003","EMAIL":[{},{}],"GEO":[29.56278,106.55278]},{"TITLE":"Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Subjects have voluntarily participated, signed and dated informed consent;\n2. Male or female subjects aged \u226518 and \u226475 years old;\n3. Locally advanced or metastatic adenocarcinoma NSCLC confirmed by histology or cytology (according to the 8th Edition of the AJCC Staging system), not suitable for surgery or radiotherapy;\n4. ECOG score 0-1, and life expectancy no less than 12 weeks according to the investigator's assessment;\n5. The tumour harbours one of the most common EGFR mutations (19del or L858R) ;\n6. According to RECIST 1.1, subjects have at least one measurable tumor lesion at baseline, and had not received radiotherapy previously;\n7. No previous systemic anti-tumor therapy for locally advanced or metastatic NSCLC. For recurrent disease, adjuvant therapy or neoadjuvant therapy may be accepted, but recurrence occurs \u22656 months from stopping treatment;\n8. Subjects with stable clinical symptoms of pleural effusion or ascites after symptomatic treatment;\n9. For premenopausal women with fertility, the result of serum or urine pregnancy test should be negative within 7 days before the first dose.\n\nExclusion Criteria:\n\n1. Not lung adenocarcinoma, including lung squamous carcinoma, or mixed histology, etc;\n2. Subjects are expected to participate in other clinical studies during this trial period;\n3. Imaging evidence showed that the tumor had invaded critical blood vessels;\n4. Subjects who receive systemic anti-tumor therapy used for locally advanced or metastatic NSCLC previously;\n5. With other malignant tumors at present or history of other malignant tumors within 5 years;\n6. Leptomeningeal metastases or central nervous system metastasis requiring emergency treatment;\n7. At the beginning of study treatment, any unresolved toxic reaction to prior treatment (e.g., adjuvant chemotherapy) exceeds CTCAE Grade 1;\n8. History of ILD, drug-induced ILD, radiation pneumonitis which require steroid treatment, or with suspected clinical manifestations of ILD or high risk factors;\n9. Severe gastrointestinal dysfunction may affect the intake, transport or absorption of the study drugs;\n10. Recent active digestive diseases or other conditions that may cause gastrointestinal bleeding or perforation;\n11. Presence of bleeding constitution or active bleeding; any bleeding event \u2265CTCAE grade 3, unhealed wounds, ulcers, or fractures occurred within 28 days prior to the first dose;\n12. Any of the following organ function criteria is met (no blood or blood product transfusions, no hematopoietic stimulating factors, no albumin or blood product transfusions within 7 days prior to examination): Absolute value of neutrophil (NE)\\<1.5 \u00d7 109\/L, platelet (PLT) count\\<90 \u00d7 109\/L, hemoglobin (HGB)\\<90 g\/L; Serum total bilirubin (TBIL)\\>1.5 \u00d7 ULN, aspartate aminotransferase (AST) and\/or alanine aminotransferase (ALT)\\>2.5 \u00d7 ULN (for liver metastases or Gilbert Syndrome, TBIL\\>3 \u00d7 ULN, and AST and\/or ALT\\>5 \u00d7 ULN); Serum creatinine (SCr)\\>1.5 \u00d7 ULN, or creatinine clearance\\<60ml\/min. (According to the Cockcroft and Gault formula); Urinary protein \u2265 ++, or 24-hour urine protein\\>1.0g; International normalized ratio\uff08INR\uff09\\>1.5 and activated partial thromboplastin time (APTT)\\>1.5 ULN; Fasting blood glucose \\>10mmol\/L\uff1b\n13. Any of the following cardiac criteria is met\uff1a\n\n    * At rest, the mean corrected QT interval (QTc) by ECG \\> 470 msec\uff1b\n    * Seriously abnormal of heart rhythm, conduction, or morphology of resting ECG;\n    * Any factors that may increase the risk of prolonged QTc or risk of arrhythmic events;\n    * Left ventricular ejection fraction (LVEF) \\< 50%;\n    * Uncontrollable hypertension (systolic blood pressure\u2265150 mmHg and\/or diastolic blood pressure\u2265100 mmHg);\n14. With active infection diseases, such as HBV, HCV and HIV;\n15. Known or suspected to be allergic to Furmonertinib and Anlotinib and \/ or other components of their preparations;\n16. Pregnancy or lactation;\n17. Subjects who are considered ineligible for the study for other reasons according to the investigator's assessment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"04895930001","EMAIL":[{}],"GEO":[31.22222,121.45806]},{"TITLE":"Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.","CRITERIA":"Inclusion Criteria:\n\n1. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.\n2. Provision of signed and dated, written ICF prior to any mandatory study specific procedures, sampling, and analyses.\n\n   Age\n3. 18 years or older at the time of signing the ICF. Type of patient and disease characteristics\n4. Histologically- or cytologically-documented NSCLC with locally-advanced, unresectable Stage III disease (according to the IASLC Staging Manual Version 8 \\[IASLC 2016\\]). Positron emission tomography (PET)\/CT, MRI of the brain, and endobronchial ultrasound with biopsy are highly encouraged at diagnosis.\n5. Patients with measurable disease assessed at baseline by CT\/MRI will be entered in this study.\n6. Must have a life expectancy of at least 12 weeks at enrolment.\n7. WHO\/ECOG PS 0-1.\n8. Patient not eligible for concurrent chemo radiation according to investigator assessment\n9. Adequate organ and marrow function at enrollment as defined below. These parameters should be achieved without augmentation by growth factors, transfusions, or infusions within 28 days of screening unless required for SoC:\n\n   1. Haemoglobin \u22659.0 g\/dL;\n   2. Absolute neutrophil count \\>1.0 \u00d7 109\/L;\n   3. Platelet count \\>75 \u00d7 109\/L;\n   4. Serum bilirubin \u22641.5 \u00d7 upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert's syndrome, who will be allowed in consultation with their physician.\n   5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u22642.5 \u00d7 ULN.\n   6. Measured creatinine clearance \\>40 mL\/min or calculated creatinine clearance \\>40 mL\/min as determined by Cockcroft-Gault (using actual body weight) (Cockcroft and Gault 1976).\n\n   Males:\n\n   Creatinine clearance (mL\/min) = \\[Weight (kg) \u00d7 (140 - Age)\\] \/ 72 \u00d7 serum creatinine (mg\/dL)\n\n   Females:\n\n   Creatinine clearance (mL\/min) = \\[Weight (kg) \u00d7 (140 - Age) \u00d7 0.85\\] \/ 72 \u00d7 serum creatinine (mg\/dL)\n10. Body weight \\>30 kg at enrollment\n11. Male or female. Reproduction\n12. Evidence of post-menopausal status, or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n    1. Women \\<50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n    2. Women \u226550 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \\>1 year ago, had chemotherapy-induced menopause with last menses \\>1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).\n\nExclusion Criteria:Patients should not enter the study if any of the following exclusion criteria are fulfilled:\n\n1. Patients who have disease considered for surgical treatment as part of their care plan, such as Pancoast or superior sulcus tumors.\n2. Mixed small-cell lung cancer and NSCLC histology.\n3. History of allogeneic organ transplantation.\n4. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \\[eg, colitis or Crohn's disease\\], diverticulitis \\[with the exception of diverticulosis\\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \\[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc\\]). The following are exceptions to this criterion:\n\n   1. Patients with vitiligo or alopecia.\n   2. Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement.\n   3. Any chronic skin condition that does not require systemic therapy.\n   4. Patients without active disease in the last 5 years at enrolment may be included but only after consultation with the Study Physician.\n   5. Patients with celiac disease controlled by diet alone.\n5. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, ILD, serious chronic GI conditions associated with diarrhoea, or psychiatric illness\/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs, or compromise the ability of the patient to give written informed consent.\n6. History of another primary malignancy except for:\n\n   1. Malignancy treated with curative intent and with no known active disease \u22655 years before the first dose of IP and of low potential risk for recurrence.\n   2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n   3. Adequately treated carcinoma in situ without evidence of disease.\n7. History of leptomeningeal carcinomatosis.\n8. History of active primary immunodeficiency.\n9. Active infection including hepatitis B (known positive hepatitis B surface antigen \\[HbsAg\\] result), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) (positive HIV 1\/2 antibodies). Patients with a past or resolved hepatitis B virus (HBV) infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HbsAg) are eligible. Patients positive for hepatitis C antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA).\n10. Any unresolved toxicity of NCI CTCAE Grade \u22652 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria.\n\n    1. Patients with Grade \u22652 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician.\n    2. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the Study Physician.\n11. Known allergy or hypersensitivity to durvalumab or any of the IP excipients. Prior\/concomitant therapy\n12. Prior chemo-radiotherapy for lung cancer. Prior surgical resection (ie, Stage I or II) is permitted.\n13. Receipt of live attenuated vaccine within 30 days prior to the first dose of IP.\n\n    Note: Patients, if enrolled, should not receive live vaccine while receiving IP and up to 30 days after the last dose of IP.\n14. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP.\n\nNote: Local surgery of isolated lesions for palliative intent is acceptable.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05128630001","EMAIL":[{"email":"alessandra.ferrari@smatteo.pv.it"},{}],"GEO":[45.19205,9.15917]},{"TITLE":"Using Urine Samples to Identify Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Phase I (with NSCLC): Aged 18 to 90 years with histologically proven, previously untreated stage I, II, or IIIA NSCLC\n\n  \u00b0Note: Single, monolateral nodule of at least 50% solid composition visible on a Chest CT scan that is suspicious for a primary neoplasm as confirmed by an official MSK radiologist read\n* Phase I (without NSCLC): Aged 18 to 90 years with patient confirmed absence of NSCLC\n* Phase II: Aged 18 to 90 years with suspected but undiagnosed stage I, II, or IIIA NSCLC by CT and\/or PET scan criteria\n\nExclusion Criteria:\n\n* Aged \\<18 years\n* Lack of available results from low-dose CT\n* Receipt of radiation, chemotherapy, biological therapy, resection, or any other treatment for any cancer in the previous year\n* Pregnant (for women)\n* Taking drugs that affect the immune system\n* Chronic disease related to the immune system\n* Missing clinical data (i.e., current clinical staging)","SEX":"ALL","AGE_MIN":18,"AGE_MAX":90,"SS_ID":"06033248007","EMAIL":[{}],"GEO":[40.70038,-73.59291]},{"TITLE":"Datopotamab (DS-1062a) in Advanced and\/or Unresectable Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Participants with histologically confirmed diagnosis of advanced and\/or unresectable NSCLC\n* Participants who received at least one line and not more than three lines of therapy and considered by the investigator as refractory to standard treatment or for which no standard treatment is available:\n\n  1. Participants who have no known mutation or mutation without an approved targeted therapy: anti programmed cell death (PD-1)\/programmed death-ligand 1 (PD-L1) containing therapy and a platinum-doublet regimen\n  2. Participants who have known EGFR, BRAF, and MET mutation or ALK, ROS1, RET, NTRK fusion: one line of an approved targeted agent and one platinum-doublet regimen\n* Metastatic site easily accessible to biopsy (with exception of bone metastasis)\n* Presence of at least one measurable lesion (different from the biopsy site) according to RECIST v1.1\n* ECOG status should be equal or less to one\n* Life expectancy should be equal or more than 3 months\n* Participants must have adequate bone marrow reserve and organ function, based on local laboratory data within 14 days prior to Cycle 1, Day 1\n* Participants with asymptomatic and clinically stable treated brain metastasis, who require no treatment with corticosteroids and\/or anticonvulsants. Participants must have a stable neurologic status for at least two weeks prior to Cycle 1 Day 1\n* Females of reproductive\/childbearing potential must have a negative serum pregnancy test at screening and must agree to use a highly effective form of contraception or avoid intercourse during the study and for at least 7 months after the last dose of study drug\n\nContraceptive methods considered highly effective:\n\n1. Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal)\n2. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)\n3. Intrauterine device (IUD)\n4. Intrauterine hormone-releasing system (IUS)\n5. Bilateral tubal occlusion\n6. Vasectomized partner\n7. Complete sexual abstinence during and for at least 7 months after the last dose of study drug. Female participants must not donate, or retrieve for their own use, ova from the time of screening and for at least 7 months after the final study drug administration\n\nMale participants must be surgically sterile or must withhold heterosexual intercourse or must be willing to use a highly effective birth control upon enrollment, during the treatment period, and for at least 4 months following the last dose of study drug.\n\nMale participants must not freeze or donate sperm from screening and for at least 4 months after the final study drug administration.\n\n* Participants must understand, sign and date the written informed consent from prior to any protocol-specific procedures performed. Participants should be able and willing to comply with study visits and procedures as per protocol\n* Participants must be affiliated to a Social Security System or beneficiary of the same\n\nExclusion Criteria:\n\n* Participants unwilling to participate to the biological investigations and to perform biopsies and blood sample collection as required in the protocol\n* Participants with only bone metastasis will be excluded, except if they have an accessible primary tumor which could be biopsied at baseline, on-treatment and end-of-treatment.\n* Participant with any history of interstitial lung disease (ILD) (including pulmonary fibrosis or radiation pneumonitis), has current ILD, or is suspected to have such disease by imaging during screening.\n* Participant with clinically severe pulmonary compromise (based on investigator's assessment) resulting from intercurrent pulmonary illnesses including, but not limited to:\n\n  1. Any underlying pulmonary disorder\n  2. Any autoimmune, connective tissue or inflammatory disorder with pulmonary involvement\n  3. OR prior pneumonectomy\n* Participants receiving chronic systemic corticosteroids at a dose higher than 10 mg prednisone or equivalent or any form of immunosuppressive therapy prior to Cycle 1 Day 1. Participants who require use of bronchodilators, inhaled steroids, or local steroid injections may be included in the study\n* Participants with evidence of any leptomeningeal disease\n* Participants with evidence of clinically active spinal cord compression or brain metastases\n* Participants with a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients (including but not limited to polysorbate 80) of DS-1062a\n* Participants with a history of severe hypersensitivity reactions to other monoclonal antibodies\n* Inadequate washout period prior to Cycle 1 Day 1, defined as:\n\n  1. Whole brain radiation therapy within 14 days before treatment or stereotactic brain radiation therapy, within 7 days before treatment\n  2. Any cytotoxic chemotherapy, investigational agents or other anticancer drug(s) from a previous cancer treatment regimen or clinical study (other than Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)), within 14 days before treatment or 5 half-lives, whichever is longer\n  3. Immune checkpoint inhibitor therapy, within 21 days before treatment\n  4. Major surgery (excluding placement of vascular access), within 28 days before treatment\n  5. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation, within 28 days before treatment or palliative radiation therapy within 14 days before treatment\n  6. Chloroquine or hydroxychloroquine within 14 days before treatment\n  7. Live virus vaccination, within 28 days before treatment\n* Prior treatment with an anti-TROP-2 antibody including study drug\n* Participant previously treated with an antibody drug conjugate (ADC) containing a chemotherapeutic agent targeting topoisomerase I inhibitor\n* Participant with unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved according to the NCI-CTCAE v5.0, grade 2 or less\n* Any evidence of primary malignancy other than locally advanced or metastatic lung cancer within three years prior to Cycle 1 Day 1, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated\n* Participant with clinically significant corneal disease\n* Any evidence of severe or uncontrolled systemic diseases including active bleeding diatheses, active infection, psychiatric illness\/social situations, geographical factors, substance abuse, or other factors which in the investigator's opinion makes it undesirable for the participant to participate in the study or which would jeopardize compliance with the protocol\n* Uncontrolled or significant cardiovascular disease prior to Cycle 1 Day 1, including:\n\n  1. Corrected QT interval higher than 470 ms for females and 450 ms for males according to Fridericia's formula (QTcF) and assessed based on triplicate ECGs, approximately 1 minute apart\n  2. Left ventricular ejection fraction (LVEF) less than 50% by either ECHO or Multigated Acquisition Scan (MUGA)\n  3. Uncontrolled hypertension (resting systolic blood pressure higher than 180 mmHg or diastolic blood pressure higher than 110 mmHg)\n  4. Myocardial infarction within six months\n  5. NYHA Classes 2 to 4 within 28 days before treatment\n  6. Uncontrolled angina pectoris within six months.\n  7. Cardiac arrhythmia requiring antiarrhythmic treatment\n* Active hepatitis B and\/or hepatitis C infection, such as those with serologic evidence of viral infection within 28 days of Cycle 1, Day 1.\n\nParticipants with past or resolved hepatitis B virus (HBV) infection are eligible if:\n\n1. Hepatitis surface antigen (HBsAg) negative and hepatitis B core antibody (anti-HBc) positive; OR\n2. HBsAg positive and HBV DNA viral load is documented to be equal or less than 2,000 IU\/mL in the absence of anti-viral therapy and during the previous 12 weeks prior to the viral load evaluation with normal transaminases (in the absence of liver metastasis); OR\n3. HBsAg positive and HBV DNA viral load is documented to be equal or less than 2,000 IU\/mL in the absence of anti-viral therapy and during the previous 12 weeks prior to the viral load evaluation with liver metastasis and abnormal transaminases AST\/ALT less than 3 ULN\n4. Participants with a history of Hepatitis C infection will be eligible for enrollment only if the viral load according to local standards of detection, is documented to be below the level of detection in the absence of anti-viral therapy during the previous 12 weeks (ie, sustained viral response according to the local product label but no less than 12 weeks, whichever is longer)\n\n   * Participants with known human immunodeficiency virus (HIV) or active COVID-19 infection\n   * Female participants who are pregnant or breastfeeding or intend to become pregnant during the study Participants with any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial Participants under guardianship or deprived of his\/her liberty by a judicial or administrative decision or incapable of giving his\/her consent\n   * Participation in another clinical trial evaluating an experimental drug (except non-interventional research)","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04940325001","EMAIL":[{"email":"barbara.pistilli@gustaveroussy.fr"},{"email":"ghada.nachabeh@gustaveroussy.fr"}],"GEO":[48.7939,2.35992]},{"TITLE":"Evaluation ctDNA in Patients of Non-Small-Cell Lung Cancer Following Resection","CRITERIA":"Inclusion Criteria:\n\n* Postoperative histopathological diagnosis of TNM stage I to III NSCLC with R0 resection;\n* No adjuvant chemotherapy, radiotherapy, targeted drug therapy or biotherapy after surgery;\n* Men or women of age \u226518 years and \\<75 years old;\n* Eastern Cooperative Oncology Group (ECOG) behavior status score 0 to 1.\n\nExclusion Criteria:\n\n* Patients with other cancers other than NSCLC within five years prior to this study;\n* Who can not get enough tumor histological specimens (non-cytological) for analysis;\n* Human immunodeficiency virus (HIV) infection;\n* NSCLC mixed with patients with small cell lung cancer;\n* Pregnant or lactating women;\n* There is a clear history of neurological or mental disorders, including epilepsy or dementia;\n* Conditions that investigators think is not suitable for inclusion.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"04238130001","EMAIL":[{"email":"wsysums@163.net"},{}],"GEO":[23.11667,113.25]},{"TITLE":"Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent\/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations","CRITERIA":"Inclusion Criteria:\n\n1. Participant must be \u226518 years of age;\n2. Participant must have histologically or cytologically confirmed locally advanced or metastatic NSCLC not amenable to curative therapy. Participants must be treatment-na\u00efve for metastatic NSCLC. Prior adjuvant and neo-adjuvant therapy for early-stage disease is permitted, prior systemic therapy for potentially curable locally advanced disease is also permitted;\n3. Participant must have a tumor that was previously determined to have Exon 19del or Exon 21 L858R substitution, as detected by a validated test in accordance with site standard of care. Note: A copy of the test report documenting the EGFR mutation must be included in the participant records and must also be submitted to the sponsor prior to enrollment;\n4. Unstained tumor tissue and blood (for ctDNA, biomarker), both collected prior to treatment initiation, must be provided. Unstained FFPE tumor tissue blocks must be provided whenever possible. Alternatively, re-cut unstained sections from FFPE tumor tissue block, presented on slides must be provided (recommended 10-15 slides);\n5. Subject must have specific organ and bone marrow function;\n6. Participant must have ECOG status of 0 to 2;\n7. Any toxicities from prior anticancer therapy must have resolved to CTCAE Grade 1 or baseline level;\n8. Participant must have at least 1 measurable lesion, according to RECIST v1.1 that has not been previously irradiated. Target lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.\n\nExclusion Criteria:\n\n1. Participant has received any prior systemic treatment for metastatic disease (prior systemic therapy for potentially curable locally advanced disease, adjuvant or neoadjuvant therapy are allowed, if administered more than 12 months prior to the development of the recurrent disease);\n2. Participant has symptomatic brain metastases. A participant with asymptomatic or previously treated and stable brain metastases may participate in this study. Participants who have received definitive radiation or surgical treatment for symptomatic or unstable brain metastases and have been clinically stable and asymptomatic for at least 2 weeks before Screening are eligible, provided they have been either off corticosteroid treatment or are receiving low-dose corticosteroid treatment (\u226410 mg\/day prednisone or equivalent) for at least 2 weeks prior to enrollment;\n3. Participant has severe co-morbidities that in the opinion of the investigator pose the patient at undue risk from participating in the study;\n4. Participant has an active or past medical history of leptomeningeal disease;\n5. Participant has spinal cord compression that has not been definitively treated with surgery or radiation or requires steroid treatment within 2 weeks prior to enrollment. Low-dose corticosteroid treatment \u226410mg\/day prednisone or equivalent is allowed;\n6. Participant has an active or past medical history of Interstitial lung disease (ILD)\/pneumonitis, including drug-induced or radiation ILD\/pneumonitis;\n7. Immune-mediated rash from checkpoint inhibitors that has not resolved prior to enrollment;\n8. Subject has uncontrolled inter-current illness;\n9. Participant has active cardiovascular disease;\n10. Participant is currently receiving medications or herbal supplements known to be potent CYP3A4\/5 inhibitors or inducers and is unable to stop use for an appropriate washout period prior to enrollment (see Appendix 8: Prohibited and Restricted Medications and Therapies That Induce, Inhibit, or Are Substrates of CYP3A4\/5);\n11. Participant has received any prior treatment with an EGFR TKI;\n12. Known positive hepatitis B (hepatitis B virus \\[HBV\\]) surface antigen (HBsAg);\n13. Known positive hepatitis C antibody (anti-HCV). Note: Subjects with a prior history of HCV, who have completed antiviral treatment and have subsequently documented HCV RNA below the lower limit of quantification per local testing are eligible;\n14. Other clinically active or chronic liver disease;\n15. Known active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), Patients positive for human immunodeficiency virus (HIV) can be eligible if receiving highly active antiretroviral therapy (ART) and CD4 count \\&gt;350 within 6 months of the start of treatment (consultation of Medical Monitor is required in this case). Screening for tuberculosis, hepatitis B, hepatitis C, and\/or HIV infections is not required, unless there is clinical suspicion of these infections;\n16. Participant had major surgery (e.g., requiring general anesthesia), excluding placement of vascular access or tumor biopsy, or had significant traumatic injury within 2 weeks before signing the ICF, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05299125014","EMAIL":[{"email":"daniele.bracale@hospitalsaocamilosp.org.br"},{}],"GEO":[-23.5475,-46.63611]},{"TITLE":"A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n1. Participants must have histologically confirmed solid tumors that are unresectable, locally advanced, or metastatic and for which standard curative therapies do not exist or are no longer effective.\n2. For Phase 1, participants must have one of the following solid tumors:\n\n   1. High mutational burden (TMB-H)\n   2. Microsatellite Instability (MSI-H)\/DNA mismatch repair (dMMR)\n   3. Virally associated tumors\n3. For Phase 2, participants must have one of the following solid tumors:\n\n   1. TMB-H\n   2. MSI-H\/dMMR\n   3. Virally associated tumors\n   4. Metastatic triple negative breast cancer\n   5. Relapsed and refractory epithelial ovarian cancer\n   6. Metastatic castration-resistance prostate cancer\n   7. K-Ras wild type colorectal cancer (CRC)\n   8. K-Ras mutant CRC\n   9. Primary stage IV or recurrent non-small cell lung cancer\n\n   (Other tumor histologies may also be included in Phase 2 as additional data emerge to support their inclusion.)\n4. Symptomatic central nervous system (CNS) metastases must have been treated, be asymptomatic for \u2265 14 days, and meet the following at the time of enrollment:\n\n   * No concurrent treatment for CNS disease (e.g., surgery, radiation, corticosteroids \\> 10 mg prednisone\/day or equivalent);\n   * No concurrent leptomeningeal disease or cord compression.\n\nExclusion Criteria:\n\n1. Participants with a history of known autoimmune disease with exceptions of:\n\n   * Vitiligo;\n   * Psoriasis, atopic dermatitis or other autoimmune skin condition not requiring systemic treatment;\n   * History of Graves' disease, now euthyroid for \\> 4 weeks;\n   * Hypothyroidism managed by thyroid replacement;\n   * Alopecia;\n   * Arthritis managed without systemic therapy beyond oral nonsteroidal anti-inflammatory drugs.\n   * Adrenal insufficiency well controlled on replacement therapy.\n2. Major surgery or traumatic injury within 8 weeks before first dose of study drug.\n3. Unhealed wounds from surgery or injury.\n4. Treatment with \\>10 mg per day of prednisone (or equivalent) or other immune-suppressive drugs within 7 days prior to the initiation of study drug. Exceptions may be made for patients who have had allergic reaction to iodinated contrast media. Steroids for topical, ophthalmic, inhaled, or nasal administration are allowed.\n5. Clinically significant cardiovascular\/vascular disease, gastrointestinal disorders, inflammatory processes, pulmonary compromises\n6. Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug.\n7. Vaccination with any live virus vaccine within 4 weeks prior to the initiation of study drug administration. Inactivated annual influenza vaccination is allowed.\n8. Participants who are known to be human immunodeficiency virus positive or hepatitis B or C positive and have uncontrolled disease.\n9. Second primary invasive malignancy not in remission for \u2265 1 year. Exceptions include non-melanoma locally advanced skin cancer, cervical carcinoma in situ, localized prostate cancer (Gleason score \u2264 7), resected melanoma in situ, or any malignancy considered to be indolent and never required systemic therapy, with the exception of indolent lymphomas.\n10. Pregnant, likely to become pregnant, or lactating women (where pregnancy is defined as the state of a female after conception and until the termination of gestation).","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05592626007","EMAIL":[{},{}],"GEO":[43.70011,-79.4163]},{"TITLE":"Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Patients must have Stage IV non-small cell lung cancer (NSCLC), based on the 8th edition of the American Joint Committee on Cancer (AJCC) NSCLC Staging System. This includes adenocarcinoma and squamous cell carcinoma.\n2. Patients must have measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.\n3. No prior therapy for advanced NSCLC.\n4. Patients with brain metastasis are eligible if they are asymptomatic or treated and stable.\n5. Age greater than or equal to 18 years.\n6. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n7. Life expectancy of greater than 12 weeks.\n8. Patients must have adequate organ and marrow function, including:\n\n   1. Absolute neutrophil count (ANC) \u2265 1,500\/mcL\n   2. Platelet count \u2265 100,000\/mcL\n   3. Hemoglobin \u2265 9.0 g\/dL (patients may be transfused to meet this)\n   4. Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) \u2264 2.5 x institutional upper limit of normal (ULN)\n   5. Serum bilirubin l\u2264 1.5 x ULN\n   6. Creatinine Clearance \\> 60 mL\/min\n9. Patients must have tumor PD-L1 expression of \u22651% (by 22c3 PD-L1 companion testing); patients whose PD-L1 status could not be determined are also eligible. Patients with known PD-L1 of 0% will be excluded.\n10. For women of childbearing potential or men with sexual partners of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of \\< 1% per year during the treatment period and for at least 5 months after the last dose of study treatment.\n\n    1. A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (\u226512 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and\/or uterus).\n    2. Examples of contraceptive methods with a failure rate of \\< 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.\n11. Ability to understand and the willingness to sign a written informed consent document.\n\n    Exclusion Criteria:\n\n    An individual who meets any of the following criteria will be excluded from participation in this study:\n12. Any prior chemotherapy or immunotherapy for advanced lung cancer.\n13. Prior treatment with anti-PD-1 or anti-PD-L1 therapies or pathway-targeting agents.\n14. Any targetable driver mutation (e.g. ALK, EGFR exon 19 del, etc).\n15. Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation.\n16. Major surgical procedure within 28 days prior to cycle 1, day 1.\n17. Evidence of visceral crisis (severe organ dysfunction as assessed by signs, symptoms, and laboratory values, resulting from rapid progression of neoplastic disease).\n18. Active concomitant malignancy that requires therapy.\n19. Treatment with systemic immunosuppressive medications (e.g., prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \\[anti-TNF\\] agents) within 2 weeks prior to Cycle 1, Day 1.\n\n    1. Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea or premedication for contrast dye allergy) are eligible.\n    2. The use of inhaled corticosteroids for chronic obstructive pulmonary disease (COPD) and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.\n20. History or risk of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sj\u00f6gren's syndrome, Bell's palsy, Guillain-Barr\u00e9 syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis\n\n    1. Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone are eligible.\n    2. Patients with controlled type 1 diabetes mellitus on a stable insulin regimen are eligible.\n    3. Patients with eczema, psoriasis, or lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible provided they meet the following conditions:\n\n       * Rash must cover \\< 10% of body surface area (BSA)\n       * Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%)\n       * No acute exacerbations of underlying condition within the last 12 months (requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, high potency or oral steroids)\n21. History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest CT scan.\n22. QTc of \\>470 msec by EKG.\n23. Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis, cirrhosis, fatty liver, and inherited liver disease.\n24. Known HIV infection.\n25. Active tuberculosis.\n26. Administration of a live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks before Cycle 1, Day 1 or at any time during the study.\n27. Severe infections within 4 weeks prior to Cycle 1, Day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.\n28. Treatment with an investigational agent for any condition within 4 weeks prior to Cycle 1, Day 1 (or within five half-lives of the investigational product, whichever is longer).\n29. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins\n30. Patients who are pregnant or lactating, or who are intending to become pregnant during the study.\n\n    1. Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05493566001","EMAIL":[{"email":"mashunte.holmes@emory.edu"},{}],"GEO":[33.749,-84.38798]},{"TITLE":"Efficacy and Safety of Almonertinib Combined With Stereotactic Body Radiotherapy (SBRT) in the Treatment of Non-small Cell Lung Cancer With EGFR Sensitive Mutation: a Single-arm, Open-label Clinical Trial","CRITERIA":"Inclusion Criteria:\n\n1. Aged 18 years or older (including 18 years) and less than 75 years (including 75 years).\n2. Subjects with histologically or cytologically confirmed unresectable NSCLC and stage IIIB-IV tumours (as determined by the International Association for the Study of Lung Cancer (IASLC) Manual of Thoracic Tumour Staging, 8th edition). Oligometastatic lesions (\u22645) in the brain on head-enhanced MRI were eligible for enrolment, and at least 1 lesion in the brain could be accurately measured at baseline, with the longest diameter at baseline \u22655 mm. Measurements were made by MRI (layer thickness 1.5 mm).\n3. Have not received any systemic therapy after diagnosis of NSCLC or have not progressed with 1-2 cycles of chemotherapy.\n4. Tumour tissue samples or blood samples diagnosed with NSCLC are tested and confirmed to have an EGFR-sensitive mutation (including exon 19 deletion or L858R, either alone or coexisting with mutations in other EGFR loci). Tumour tissue is recommended if the tumour tissue is accessible; if the tumour tissue is inaccessible or the patient is not amenable to tissue biopsy, blood samples will be sent to test EGFR mutation.\n5. Patients with an Eastern Cooperative Oncology Group (ECOG) physical status score of 0 or 1 and no deterioration in the previous 2 weeks, with a minimum expected survival of 12 weeks.\n6. At least 1 tumour lesion in the patient's lungs can be accurately measured at baseline with a longest diameter of \u226510 mm at baseline (in the case of lymph nodes, a short diameter of \u226515 mm is required). The measurement method of choice is suitable for accurate repeat measurements, either computed tomography (CT) or magnetic resonance imaging (MRI). Only 1 measurable lesion is accepted as a target lesion if it is present, subject to baseline evaluation of the tumour lesion at least 14 days after diagnostic biopsy. And the primary residual lung lesion is suitable for SBRT after targeted therapy.\n7. Women of childbearing potential are required to use adequate contraception and should not be breastfeeding from screening until 3 months after discontinuation of study treatment. Negative pregnancy test prior to initiation of dosing or no risk of pregnancy as evidenced by meeting one of the following criteria:\n\n   1. Postmenopausal defined as amenorrhoea for at least 12 months after age greater than 50 years and cessation of all exogenous hormone replacement therapy;\n   2. Women younger than 50 years of age may also be considered postmenopausal if they have had amenorrhoea for 12 months or more after cessation of all exogenous hormone therapy and have luteinising hormone (LH) and follicle-stimulating hormone (FSH) levels in the range of laboratory postmenopausal reference values.\n   3. Previous irreversible sterilisation including hysterectomy, bilateral oophorectomy or bilateral salpingo-oophorectomy, with the exception of bilateral tubal ligation.\n8. Barrier contraception (i.e., condoms) should be used by male patients from screening until 3 months after discontinuation of study treatment.\n9. Subjects participate voluntarily and sign a written informed consent form.\n\nExclusion Criteria:\n\nSubjects will not be enrolled in the study if they fulfil any of the following criteria:\n\n1. Patients with postoperative recurrence.\n2. Non-primary patients who have received any of the following prior treatments:\n\n   1. prior use of any EGFR tyrosine kinase inhibitor (EGFR-TKI);\n   2. prior radiotherapy for any lung cancer;\n   3. patient has undergone major surgery within 4 weeks prior to the first dose of study drug;\n   4. use of a strong inhibitor of CYP3A4, an inducer, or a drug with a narrow therapeutic window that is a CYP3A4-sensitive substrate within 7 days prior to the first dose of study drug.\n3. Patients with other malignancies that require standardised treatment or major surgery within 2 years of the first dose of study treatment.\n4. Patients who are amenable to surgical resection.\n5. Patients with progression within 3 months of targeted therapy.\n6. Patients with unrelieved residual toxicity from prior therapy greater than CTCAE grade 1 at the time of initiation of study treatment, with the exception of alopecia and grade 2 neurotoxicity from prior chemotherapy.\n7. Patients with uncontrolled pleural effusion and\/or pericardial effusion.\n8. Have any serious or poorly controlled systemic disease such as poorly controlled hypertension, active bleeding prone constitution or active infection as judged by the investigator. Exclusion of chronic diseases is not required.\n9. Refractory nausea, vomiting or chronic gastrointestinal disorders, inability to swallow study medication or a history of extensive bowel resection that may interfere with adequate absorption of almonertinib.\n10. Cardiac findings consistent with any of the following:\n\n    1. resting electrocardiogram (ECG) examination yielding a corrected QT interval (QTc) \\> 470 msec, applying the Fridericia formula for QT interval correction (QTcF);\n    2. resting ECG suggests the presence of a variety of clinically significant rhythmic, conduction, or ECG morphological abnormalities (e.g., complete left bundle-branch block, third-degree atrioventricular conduction).\n    3. presence of any factor that increases the risk of QTc prolongation or arrhythmic events, such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome, or sudden unexplained death in an immediate family member under the age of 40 years or any combination of medications that prolong the QT interval;\n    4. left ventricular ejection fraction (LVEF) \u226440%.\n11. History of interstitial lung disease or any evidence of clinically active interstitial lung disease.\n12. Inadequate bone marrow reserve or organ function at the following laboratory limits:\n\n    1. Absolute neutrophil count \\< 1.5 x 10\\^9 \/ L;\n    2. Platelet count \\< 100 x 10\\^9 \/ L;\n    3. Haemoglobin \\< 90 g\/L (\\< 9 g\/dL);\n    4. Alanine aminotransferase \\> 2.5 times the upper limit of normal (ULN);\n    5. Aspartate aminotransferase \\> 2.5 x ULN;\n    6. Total bilirubin \\> 1.5 x ULN; or presence of Gilbert's syndrome (unconjugated hyperbilirubinemia);\n    7. Creatinine \\> 1.5 x ULN and creatinine clearance \\< 50 mL\/min (calculated by the Cockcroft - Gault formula); confirmation of creatinine clearance is required only if creatinine \\> 1.5 x ULN.\n13. Women who are breastfeeding or who have had a positive blood or urine pregnancy test result within 3 days prior to the first dose of study treatment.\n14. History of hypersensitivity to any active or inactive ingredient of almonertinib or to a drug with a similar chemical structure to almonertinib or an analogue of almonertinib.\n15. Any serious or uncontrolled ocular pathology that, in the judgement of the physician, may increase the risk to the patient's safety.\n16. Patients who, in the judgement of the investigator, may have poor compliance with the procedures and requirements of the study.\n17. Patients who, in the judgement of the investigator, have any condition that jeopardises patient safety or interferes with the assessment of the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06481566001","EMAIL":[{"email":"taodan@cqu.edu.cn"}],"GEO":[29.56278,106.55278]},{"TITLE":"Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors","CRITERIA":"Inclusion Criteria\n\n* Participants must have\n\n  * Metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC) (without known targetable EGFR, ALK, ROS1, or BRAF mutations) who either\n\n    * a) have not yet received frontline therapy for metastatic disease and without prior exposure to anti PD-1\/PD-L1 or\n    * b) are relapsed\/refractory with progression on anti PD-1\/PD therapy.\n  * Relapsed\/refractory metastatic cutaneous melanoma (regardless of mutation status) with progression on a PD-1 inhibitor\n  * Metastatic head and neck squamous cell carcinoma (HNSCC) who have not yet received frontline therapy for metastatic disease and without prior exposure to a PD-1\/PD-L1 inhibitor.\n* Cohorts 1-4 only: Melanoma participants must be currently on PD-1 checkpoint inhibitor (CPI) therapy (e.g. nivolumab or pembrolizumab) or had their last dose of PD-1 CPI containing therapy as the last previous line of therapy within 90 days prior to enrollment; PD-1 CPI therapy must be the immediate prior line of treatment.\n* Cohorts 1-4 only: Participants must have progressed on treatment with an anti-PD-1 monoclonal antibody (mAb) administered either as monotherapy, or in combination with other CPIs or other therapies. PD-1 treatment progression is defined by meeting all of the following criteria.\n\n  * Have received at least 2 doses of an approved PD-1 inhibitor.\n  * Have demonstrated disease progression (PD) after a PD-1 inhibitor as defined by RECIST v1.1.\n\n    * Progressive disease has been documented within 90 days from the last dose of PD-1 inhibitor.\n    * Participants with melanoma will need iRECIST confirmation of progression with a second assessment at least four weeks after the initial date of progressive disease\n    * NSCLC participants on PD-1 inhibitor containing therapy for less than 90 days will need iRECIST confirmation of progression at least 4 weeks after the initial date of progressive disease\n* Tumor tissue sample obtained within 3 months prior to enrollment is required, and no systemic anticancer therapy given after the sample was obtained.\n* An Eastern Cooperative Oncology Group (ECOG) Performance Status score of equal or less than 1\n\nExclusion Criteria\n\n* Has known active central nervous system (CNS) metastases and\/or carcinomatous meningitis.\n* Prior immunosuppressive chemotherapy, any immunotherapy other than a PD-1 inhibitor within 4 weeks of first study drug dose.\n* History of another malignancy within 3 years before the first dose of study drug or any evidence of residual disease from a previously diagnosed malignancy.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04609566035","EMAIL":[{}],"GEO":[45.50884,-73.58781]},{"TITLE":"A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Age \u2264 75 years with histologically proven NSCLC\n* No severe major organ dysfunction\n* WHO performance status of 0 or 1\n* No prior cancer chemotherapy\n* A Clinical Stage \u2265 IA (T1a, N0, M0) of lung disease but without diagnosed distant metastasis (according to the 1997 revision of the International Union Against Cancer TNM staging system) as determined by a preoperative evaluation that included a pleural computed tomography (CT) scan.\n\nExclusion Criteria:\n\n* Age \u2265 76\n* Severe major organ dysfunction\n* WHO performance status of \\>1\n* Prior cancer chemotherapy\n* Stage IV","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"02889666003","EMAIL":[{"email":"51917533@qq.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)","CRITERIA":"Select Inclusion Criteria:\n\n* Males or females aged \u226518 years.\n* Parts 1 and 3 (escalation cohorts): Subjects with locally advanced or metastatic non resectable solid tumors, whose disease has progressed despite all standard therapies or for whom no further standard or clinically acceptable therapy exists.\n* Part 2 (single-agent expansion cohort): Subjects with NSCLC, melanoma, HNSCC, G\/GEA, RCC, or TCC, with histologically confirmed, locally advanced or metastatic, non-resectable disease, which has progressed despite all standard therapies including CPI or for whom no standard or clinically acceptable therapy exists.\n* Part 4 (expansion cohorts in combination with pembrolizumab, with or without chemotherapy): Subjects with melanoma (all types), HNSCC, G\/GEA, RCC, TCC, NSCLC, or MSI-high, TMB-high, MMR-deficient tumors, with histologically confirmed, locally advanced or metastatic, non resectable disease, which is either CPI-naive (melanoma, HNSCC, NPC) or progressed despite all standard therapies including CPI (NSCLC, RCC, TCC, uveal melanoma, MSI-high, TMB-high, or MMR-deficient solid tumors) or for whom no standard or clinically acceptable therapy exists.\n* For Cohort F3 (NSCLC), subjects may have progressed on no more than 2 lines of standard therapy that must include at least one PD-1\/L1 regimen.\n* For Cohort F4 (HNSCC and NPC), subjects may be previously treated with no more than 1 prior chemotherapy regimen in metastatic setting. Prior PD-1\/L1 in curative (neo-adjuvant\/adjuvant) setting is allowed only if completed \\>\/= 6 months prior to progression to local recurrence or metastatic disease.\n* All subjects with non-squamous NSCLC must have documentation of absence of tumor activating EGFR mutations and absence of ALK gene rearrangements.\n* PD-L1 by IHC (22C3): Parts 1 and 3: IHC optional. Part 2: IHC result mandatory but any score allowed. Combined Positive Score (CPS) \u2265 1% (or Tumor Proportion Score \u226550% for NSCLC; for TMB-high tumors, any TPS% is allowed). Part 4: Combined Positive Score (CPS) \u2265 1% (or Tumor Proportion Score \u226550% for NSCLC; for TMB-high tumors, any TPS% is allowed).\n* Adequate hematologic, coagulation, hepatic and renal function and ECOG score as defined per protocol.\n\nSelect Exclusion Criteria:\n\n* Prior exposure to OX40 agonists.\n* Receipt of any investigational product or any approved anticancer drug(s) or biological product(s) within 4 weeks prior to the first dose of study drug with certain exceptions.\n* Hematologic malignancies (e.g., ALL, AML, MDS, CLL, CML, NHL, Hodgkin's lymphoma and multiple myeloma)\n* Prior or concurrent malignancies. Exception: Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessments of INBRX-106.\n* Known active central nervous system (CNS) metastases and\/or carcinomatous meningitis. Exception: Subjects who are previously treated and are radiologically and clinically stable without the requirement for steroid treatment for at least 14 days prior to first dose of study treatment may be allowed study entry if certain criteria apply.\n* Grade \u2265 3 immune-related adverse events (irAEs) or irAE that lead to discontinuation of prior immunotherapy. Some exceptions as defined per protocol apply.\n* Active autoimmune disease or documented history of autoimmune disease that required systemic steroids or other immunosuppressive medications. Certain exceptions as defined in protocol apply.\n* Diagnosis of immunodeficiency or treatment with systemic immunosuppressive medications within 7 days prior to the first dose of study drug. Certain exceptions as defined in protocol apply.\n* History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection. Exceptions as defined in protocol apply.\n* Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or pneumonitis requiring treatment with steroids or other immunosuppressive medications.\n* Clinically significant cardiac condition, including myocardial infarction, uncontrolled angina, cerebrovascular accident, or other acute uncontrolled heart disease \\< 3 months; left ventricular ejection fraction (LVEF) \\< 50%; New York Heart Association (NYHA) Class III or IV congestive heart failure; or uncontrolled hypertension; or oxygen saturation \\<92% on room air.\n* Active, hemodynamically significant pulmonary embolism within 3 months prior to enrollment on this trial.\n* Major surgery within 4 weeks prior to enrollment on this trial.\n* Anti-infectious drug treatments (i.e., antibiotics) within 4 weeks prior to the first dose of study drug.\n* Prior organ allograft transplantations or allogeneic peripheral blood stem cell (PBSC) or bone marrow (BM) transplantation.\n* Additional in- and exclusion criteria per protocol.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04198766016","EMAIL":[{"email":"cmcotter@mcw.edu"},{}],"GEO":[43.0389,-87.90647]},{"TITLE":"Physical Activity Coaching After Surgery for Patients With Resectable Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Resectable (I-IIIA) NSCLC patients who had lung resection surgery, one to twelve months before inclusion, with or without (neo-)adjuvant chemotherapy\/radiotherapy\/immunotherapy.\n* If patients received adjuvant chemotherapy\/radiotherapy, the inclusion window is one months to twelve months after the end of adjuvant chemotherapy\/radiotherapy.\n* If patients receive adjuvant immunotherapy after the end of adjuvant chemotherapy, patients can be included during the immunotherapy.\n* Adults (18+ year)\n* Patients who do not systematically perform structured exercise or are planned to do so.\n* Ability to give informed consent\n\nExclusion Criteria:\n\n* Patients having progressive or recurrent lung cancer\n* Patients who had other malignancies in the last 2 years\n* Psychiatric disorders that preclude them from participation in a physical activity intervention and\/or performing the test battery\n* Unable to learn to work with a new electronic device (e.g. smartphone)\n* Not understanding and speaking Dutch\n* Patients with comorbidities or other treatments that preclude them from participation in a physical activity intervention and\/or performing the test battery","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06057766006","EMAIL":[{"email":"ingel.demedts@azdelta.be"},{}],"GEO":[50.94653,3.12269]},{"TITLE":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. . Patients must have a histological or cytological diagnosis of NSCLC or any other type of carcinoma or sarcomas, progressive metastatic disease, or progressive locally advanced disease not amenable to local therapy.\n\n   1. In the Part A Phase I dose escalation study of ONC-392 monotherapy, patients with advanced\/metastatic solid tumors of any histology are eligible for participation.\n\n      Please note: tumor types of primary interest in this study are malignant melanoma, renal cell carcinoma, hepatocellular carcinoma, non-small cell lung cancer, head and neck carcinoma, gastric carcinoma, ovarian carcinoma, colorectal cancer, any type of sarcoma.\n   2. In Part B dose finding of the ONC-392 plus pembrolizumab combination, patients with advanced\/metastatic solid tumors of any histology that Pembrolizumab has been approval as standard of care are eligible for participation.\n   3. In Part C, patients with pancreatic cancer, triple negative breast cancer, non small cell lung cancer, melanoma, Head and Neck cancer, ovarian cancer, and other solid tumors are eligible.\n   4. In Part D, patients with recurrent and\/or metastatic adenoid cystic carcinoma with disease progression within 12 months are eligible.\n   5. Patients must have RECIST V1.1 Measurable disease:\n2. Patient is male or female and \\>18 years of age on day of signing informed consent.\n3. Patient must have a performance status of 0 or 1 on the ECOG Performance Scale\n4. Patient must have adequate organ function as indicated by the following laboratory values:\n\n   Hematological: Absolute neutrophil count (ANC) \u22651,500 \/mcL; Plateletsa \u2265100,000 \/ mcL; Hemoglobin \u22659 g\/dL or \u22655.6 mmol\/L- without qualifications; Renal: Serum creatinine \u22641.5 X upper limit of normal (ULN); Hepatic: Serum total bilirubin \u22641.5 X ULN; OR Direct bilirubin \u2264 ULN for patients with total bilirubin levels \\>1.5 ULN; AST (SGOT) and ALT (SGPT) \u22642.5 X ULN, OR \u22645 X ULN for patients with active liver metastases Coagulation: International Normalized Ratio (INR) or Prothrombin Time (PT) \u22641.5 X ULN Activated Partial Thromboplastin Time (aPTT) \u22641.5 X ULN\n5. Patient has voluntarily agreed to participate by giving written informed consent.\n6. Female patient of childbearing potential has a negative urine or serum pregnancy test.\n7. Female and Male patients must agree to use adequate methods of contraception starting with the first dose of study drug through 90 days after the last dose of study therapy.\n\nExclusion Criteria:\n\nA patient meeting any of the following criteria is not eligible to participate in this study:\n\n1. Patients who have not recovered to CTCAE \u2264 1 from the AE due to cancer therapeutics. The washout period for cancer therapeutic drugs (such as chemotherapy, radioactive, or targeted therapy) is 21 days, and for antibody drug 28 days.\n2. Patients who are currently enrolled in a clinical trial of an investigational agent or device.\n3. Patients who are on chronic systemic steroid therapy at doses \\>10 mg\/day\n4. Patients who have active symptomatic brain metastasis or leptomeningeal metastasis.\n5. Patients who have an active infection requiring systemic IV therapy within 14 days of prior to administration of ONC-392 or combined ONC-392 and Pembrolizumab.\n6. Patients who have a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator.\n7. Patients with known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n8. Patients who are pregnant or breastfeeding.\n9. For the Part B and Part C Arm D to G, the patients that are deemed to be not suitable for Pembrolizumab.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04140526037","EMAIL":[{}],"GEO":[-35.03333,138.56667]},{"TITLE":"To Evaluate the Efficacy\/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations","CRITERIA":"Inclusion Criteria:\n\n1. Patients must be 18 or the legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the informed consent form.\n2. Patients with histologically documented NSCLC of predominantly non-squamous, squamous, and adenosquamous pathology who present with locally advanced, unresectable (Stage III) disease (according to Version 8 of the IASLC Staging Manual in Thoracic Oncology). It is recommended but not required that except for overt cT4 disease, nodal status N2, or N3 should have been proven by biopsy, via endobronchial ultrasound, mediastinoscopy, thoracoscopy, or in absence of biopsy, should have been confirmed with whole body 18FDG PET plus contrast-enhanced CT in addition to or in combination with PET.\n3. Patient who are eligible for and - planning to undergo CCRT or SCRT treatment.\n4. Patients who had recurred from Stage I\/II\/III after complete surgery or had gross incomplete resections can be included if they didn't receive treatment with any chemotherapy, radiation therapy, immunotherapy, targeted therapy, or investigational agents.\n5. Availability of the EGFRm test results confirming that the tumour harbours one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including de novo T790M\n6. WHO performance status of 0 or 1 with no deterioration over the previous 2 weeks prior to baseline at screening and prior to first dose.\n7. Minimum life expectancy of \\> 12 weeks at Day 1.\n8. At least one lesion that can be accurately measured at baseline as \u2265 10 mm in the longest diameter (except lymph nodes, which must have short axis \u2265 15 mm) with CT or MRI and is suitable for accurate repeated measurements.\n9. Adequate organ and bone marrow function\n10. Male and\/or female. Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies\n11. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this CSP.\n12. Provision of signed and dated written Optional Genomics Initiative Research Information and Consent Form prior to collection of samples for optional genomics initiative research that supports the Genomic Initiative\n\nExclusion Criteria:\n\n1. Any presence of small cell and mixed small-cell and non-small cell histology.\n2. Past medical history of ILD\/pneumonitis, drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD\/pneumonitis.\n3. Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment with the exception of alopecia. Patients with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention in the opinion of the investigator may be included after consultation with the AstraZeneca medical monitor (eg, hearing loss).\n4. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol, or active infection (eg, patients receiving treatment for infection, including HCV, HIV, and tuberculosis) or active uncontrolled HBV infection.\n5. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib.\n6. History of another primary malignancy except for malignancy treated with curative intent with no known active disease \u2265 2 years before the first dose of study intervention and of low potential risk for recurrence. Exceptions include adequately resected non-melanoma skin cancer and curatively treated in situ disease. Patients who have received RT with overlapping fields (eg, cured breast cancer) should be excluded.\n7. Patient meets any of the following cardiac criteria:\n\n   1. Mean resting QTc \\> 470 msec, obtained from 3 ECGs, using the screening clinic ECG machine-derived QTc value.\n   2. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG eg, complete left bundle branch block, third degree heart block and second-degree heart block. Patients with atrial fibrillation controlled by medication or arrhythmias controlled by pacemakers may be permitted based on the investigator judgement with cardiologist consultation recommended.\n   3. History of QT prolongation associated with other medications that required discontinuation of that medication.\n8. Congenital long QT syndrome, family history of long QT syndrome, unexplained sudden death under 40 years of age in first-degree relatives or patients with any factors that increase the risk of QTc prolongation\/arrhythmic events such as electrolyte abnormalities, heart failure or any concomitant medication known to prolong the QT interval and cause TdP.\n9. Patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of CYP3A4 (at least 3-week prior to dosing). All patients must try to avoid concomitant use of any medications, herbal supplements and\/or ingestion of foods with known inducer effects on CYP3A4.\n10. Prior treatment with any chemotherapy, radiation therapy, immunotherapy or investigational agents for locally advanced, unresectable Stage III NSCLC. Prior surgical resection (ie, Stage I, II, or III) with no systemic treatment with residual disease or a recurrence is permitted.\n11. Prior exposure to EGFR-TKI therapy\n12. Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study.\n13. Participation in another clinical study with a study intervention or investigational medicinal device administered in the last 4 weeks (unless the safety profile is known prior to first dose of study intervention), or concurrent enrolment in another clinical study (unless the study is observational \\[noninterventional\\], or the patient is in the followup period of an interventional study).\n14. History of hypersensitivity to active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib.\n15. History of hypersensitivity to active or inactive excipients of the chemotherapy regimen of choice (pemetrexed or paclitaxel; cisplatin or carboplatin) or RT or drugs with a similar chemical structure or class to the chemotherapy.\n16. Involvement in the planning and\/or conduct of the study (applies to both AstraZeneca staff and\/or staff at the study site).\n17. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.\n18. Previous enrolment in the present study. Rescreening of individuals who were screen failures is allowed.\n19. For females only: Currently pregnant (confirmed with positive pregnancy test) or breastfeeding.\n20. Patients should refrain from breastfeeding from enrolment throughout the study and until 6 weeks after last dose of study intervention.\n21. In addition, the following are considered criteria for exclusion from the exploratory genetic research:\n\n    * Prior allogeneic bone marrow transplant.\n    * Non-leukocyte depleted whole blood transfusion within 120 days of genetic sample collection.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":130,"SS_ID":"06194448042","EMAIL":"information.center@astrazeneca.com","GEO":[39.46975,-0.37739]},{"TITLE":"Daratumumab in STK11 Mutated NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Participant must be \u2265 18 years of age and satisfy the legal age of consent in the jurisdiction in which the study is being conducted.\n* Participant must have histologically or cytologically confirmed NSCLC that is metastatic or unresectable.\n* Participants must have either progressed after prior immunotherapy with a PD-(L)1 inhibitor, platinum doublet chemotherapy and standard of care targeted therapy (if presence of an activating mutation is identified) for metastatic disease, be ineligible for, or have refused all therapeutic options. In cases where participants refuse currently available therapeutic options, this must be documented in the study records.\n* Participants must have previously identified STK11\/LKB1 mutation (identified locally in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory \\[or equivalent\\])\n* Participant must have organ and bone marrow function as follows:\n\n  * Hemoglobin \u22659 g\/dL\n  * Absolute blood neutrophil count (ANC) \u22651.5 x 109 \/L\n  * Platelets \u226575 x 109 \/L\n  * Aspartate transaminase (AST) and alanine transaminase (ALT) \u22643 x upper limit of normal (ULN)\n  * Total bilirubin =1.5 x ULN; participants with Gilbert's syndrome can enroll if conjugated bilirubin is within normal limits.\n  * Serum creatinine \\<1.5 x ULN or if available, calculated or measured creatinine clearance; \\>50 mL\/min\/1.73 m2\n* Before enrollment, a woman must be either:\n\n  * Not of childbearing potential: postmenopausal (\\>45 years of age with amenorrhea for at least 12 months); permanently sterilized (eg, bilateral tubal occlusion \\[which includes tubal ligation procedures as consistent with local regulations\\], hysterectomy, bilateral salpingectomy, bilateral oophorectomy); or otherwise be incapable of pregnancy,\n  * Of childbearing potential and practicing a highly effective method(s) of birth control consistent with local regulations regarding the use of birth control methods for participants participating in clinical studies, described as follows: practicing true abstinence (when this is in line with the preferred and usual lifestyle of the participant), which is defined as refraining from heterosexual intercourse during the entire period of the study, including up to 6 months after the last dose of study drug is given; OR have a sole partner who is vasectomized; OR practicing 2 methods of contraception, including one highly effective method (ie, established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device \\[IUD\\] or intrauterine system \\[IUS\\]), AND, a second method, (eg, condom with spermicidal foam\/gel\/film\/cream\/suppository or occlusive cap \\[diaphragm or cervical\/vault caps\\] with spermicidal foam\/gel\/film\/cream\/suppository).\n  * Note: If the childbearing potential changes after start of the study (eg, woman who is not heterosexually active becomes active, postmenopausal woman experiences menarche) the woman must begin a highly effective method of birth control, as described above.\n* A woman of childbearing potential must have a negative serum (\u03b2-human chorionic gonadotropin \\[\u03b2-hCG\\]) at Screening and a negative urine or serum pregnancy test within 24 hours before the first dose of study drug.\n* A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 6 months after receiving the last dose of study drug.\n* A man who is sexually active with a woman of childbearing potential must agree to use a condom and his partner must also be practicing a highly effective method of contraception (ie.. established use of oral, injected or implanted hormonal methods of contraception; placement of an IUD or IUS). If the participant is vasectomized, he must still use a condom, but his female partner is not required to use contraception. The participant must also not donate sperm during the study and for 6 months after receiving the last dose of study drug.\n* Participant must be willing and able to adhere to the prohibitions and restrictions specified in this protocol, including the agreement by both male and female participants to continue contraception throughout the study and through 6 months after the last dose of study drug.\n* Each participant must sign an informed consent form (ICF) indicating that he or she understands the study's purpose and the procedures required for the study and is willing to participate in the study, including the requirement to provide information during the Follow-up period.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Participant has uncontrolled inter-current illness, including but not limited to poorly controlled hypertension or diabetes, ongoing or active systemic infection (ie, has discontinued all antibiotics for at least one week prior to first dose of study drug), diagnosed or suspected viral infection (except for HIV), or psychiatric illness\/social situation that would limit compliance with study requirements, including ability to self-care for anticipated toxicities (eg. rash or paronychia).\n* Participants with medical conditions requiring chronic continuous oxygen therapy are excluded.\n* Participants with a history of chronic obstructive pulmonary disease (COPD) with grade \u22653 breathlessness on the modified medical research council (mMRC) dyspnea scale are excluded.\n* Have known moderate or severe persistent asthma within the past 2 years, or current uncontrolled asthma of any classification.\n* Participant has a history of clinically significant cardiovascular disease including, but not limited to:\n\n  * Diagnosis of deep vein thrombosis or pulmonary embolism within 4 weeks prior to the first dose of study drug, or any of the following within 6 months prior to the first dose of study drug: myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary\/peripheral artery bypass graft, or any acute coronary syndrome. Clinically non-significant thrombosis, such as non-obstructive catheter-associated clots, are not exclusionary.\n  * Prolonged QTcF interval \\>480 msec or clinically significant cardiac arrhythmia or electrophysiologic disease (eg, placement of implantable cardioverter defibrillator or atrial fibrillation with uncontrolled rate). Note: Participants with cardiac pacemakers who are clinically stable are eligible.\n  * Uncontrolled (persistent) hypertension: systolic blood pressure \\>180 mm Hg; diastolic blood pressure \\>100 mm Hg\n  * Congestive heart failure defined as New York Heart Association (NYHA) class III-IV or Hospitalization for congestive heart failure (any NYHA class) within 6 months of study Day 1\n  * Pericarditis\/clinically significant pericardial effusion\n  * Myocarditis\n* Participant has had prior chemotherapy, targeted cancer therapy, or treatment with an investigational anti-cancer agent within 2 weeks or 4 half-lives, whichever is longer, before the first administration of study drug; or participant has received prior immunotherapy within 6 weeks before the first administration of study drug. For agents with long half-lives, the maximum required time since last dose is 4 weeks. Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less, (except for alopecia \\[any grade\\], Grade \u22642 peripheral neuropathy, and Grade \\<2 hypothyroidism stable on hormone replacement). Autoimmune toxicities from previous immunotherapy must be fully resolved to baseline levels.\n* Localized, radiotherapy for palliative purposes must be completed at least 7 days prior to treatment with daratumumab and hyaluronidase.\n* Participants with untreated brain metastases. Participants with locally treated metastases that are clinically stable and asymptomatic for at least 2 weeks and who are off or receiving low-dose corticosteroid treatment (\u226410 mg prednisone or equivalent) for at least 2 weeks prior to study treatment are eligible.\n* Participant has leptomeningeal disease.\n* Participant has an active malignancy other than the disease under study requiring treatment or a history of malignancy unless all treatment of that malignancy was completed at least 2 years before consent and the patient has no evidence of disease before the date of randomization. Exceptions are squamous and basal cell carcinomas of the skin, carcinoma in situ of the cervix or breast, or other non-invasive lesion that in the opinion of the investigator is considered cured with minimal risk of recurrence within 3 years.\n* Participant has known allergies, hypersensitivity, or intolerance to daratumumab or hyaluronidase or its excipients.\n* Participants with known allergies, hypersensitivity to any component of montelukast.\n* Participant has received an investigational drug (including investigational vaccines but not including anti-cancer therapy \\[refer to Exclusion Criterion #3\\]) or used an invasive investigational medical device within 6 weeks before the planned first dose of study drug.\n* Participant is a woman who is pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study drug.\n* Participant has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.\n* Participant has at Screening:\n\n  * Positive hepatitis B (hepatitis B virus \\[HBV\\]) surface antigen (HBsAg) Subjects with resolved infection (ie, subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen \\[anti-HBc\\] and\/or antibodies to hepatitis B surface antigen \\[anti-HBs\\]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR.\n  * Positive hepatitis C antibody (anti-HCV). Note: Participants with a prior history of HCV, who have completed antiviral treatment and have a sustained virologic response, defined as aviremia at least 12 weeks after completion of antiviral therapy are eligible. Patients who completed treatment for hepatitis C at least 6 months prior to screening and have no detectable circulating HCV during screening may participate in the study. Such patients will be required to undergo regular assessments for HCV reactivation during the study and are to be withdrawn from the study if he\/she test positive at any time during the study.\n  * Other clinically active infectious liver disease.\n* Seropositive for human immunodeficiency virus.\n* Participant has had prior therapy with daratumumab.\n* Have had major surgery within 2 weeks before randomization or will not have fully recovered from surgery, or has surgery planned during the time the patient is expected to participate in the study or within 2 weeks after the last dose of study treatment. Note, patients with planned surgical procedures to be conducted under local anesthesia may participate.\n* Have received vaccination with live attenuated vaccines within 4 weeks of first study agent administration.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":100,"SS_ID":"05807048001","EMAIL":"Sally.Lau@nyulangone.org","GEO":[40.71427,-74.00597]},{"TITLE":"Hase 1\/2 Study of HS-10375 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)","CRITERIA":"Inclusion Criteria:\n\n1. Men or women greater than or equal to 18 years.\n2. Locally advanced or metastatic NSCLC patients confirmed by histology or cytology, for which standard treatment is invalid, unavailable or intolerable .\n3. Pathological, NSCLC tissue samples can be used to test EGFR C797S mutation by central laboratory for Phase 1b and Phase II subjects.\n4. At least one measurable lesion in accordance with RECIST 1.1.\n5. Eastern Cooperative Oncology Group (ECOG) performance status: 0\\~1.\n6. Estimated life expectancy \\>12 weeks.\n7. Reproductive-age women agree to use adequate contraception and cannot breastfeed while participating in this study and for a period of 6 months after the last dose. Likewise, men also consent to use adequate contraceptive method within the same time limit.\n8. Females must have the evidence of non-childbearing potential.\n9. Signed and dated Informed Consent Form.\n\nExclusion Criteria:\n\n1. Treatment with any of the following:\n\n   * Previous or current treatment with EGFR C797S inhibitors.\n   * Any cytotoxic chemotherapy, anticancer Chinese medicine and targeted small molecule inhibitors within 14 days of the first dose of HS-10375.\n   * Any investigational agents and large molecule antibodies within 28 days of the first dose of HS-10375.\n   * Local radiotherapy for palliation within 2 weeks of the first dose of HS-10375, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks of the first dose of HS-10375.\n   * Major surgery (including craniotomy, thoracotomy, or laparotomy, etc.) within 4 weeks of the first dose of HS-10375.\n2. Inadequate bone marrow reserve or serious organ dysfunction.\n3. Uncontrolled pleural, ascites or pericardial effusion.\n4. Known and untreated, or active central nervous system metastases.\n5. Active autoimmune diseases or active infectious disease.\n6. Refractory nausea, vomiting, or chronic gastrointestinal diseases, or inability to swallow oral medications.\n7. History of hypersensitivity to any active or inactive ingredient of HS-10375 or to drugs with a similar chemical structure or drugs belonging to the same category of HS-10375.\n8. The subject who is unlikely to comply with study procedures, restrictions, or requirements judged by the investigator.\n9. The subject whose safety cannot be ensured or study assessments would be interfered judged by the investigator.\n10. Pregnant women, breastfeeding women or woman who has a child-bearing plan during the study.\n11. History of neuropathy or mental disorders, including epilepsy and dementia.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05435248001","EMAIL":[{"email":"zhangli@sysucc.org.cn"}],"GEO":[23.11667,113.25]},{"TITLE":"Bronchial Mapping (GCC 1635)","CRITERIA":"Inclusion Criteria:\n\n* Patients with primary or metastatic lung lesions to be treated using stereotactic ablative radiotherapy (There is no limitation on the location or number of lesions for this study) OR Conventionally fractionated RT patients with primary or metastatic lung lesions\n* Age \u2265 18 years. No gender or ethnic restrictions.\n* Performance status ECOG \u2265 3\n* Ability to hold breath for \\~20 seconds\n* Ability to understand and the willingness to sign a written informed consent.\n* Any types and amounts of prior therapy will be allowed for this study.\n* Maximum PTV dimension \u2264 70 mm\n\nExclusion Criteria:\n\n* Children (age \\<18 years).\n* Women who are pregnant, nursing, or trying to get pregnant.\n* ECOG performance status \\< 3","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"02745548001","EMAIL":[{"email":"jasmine.newman@umm.edu"},{}],"GEO":[39.29038,-76.61219]},{"TITLE":"Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Age 18 years old and above, male or female.\n2. Histopathological and\/or cytopathological confirmation of locally advanced or metastatic NSCLC patients with \u2264 1 prior line of chemotherapy.\n3. Confirmation that the tumor harbors a non-resistant uncommon EGFR mutation (tumor tissue biopsy), including one or more of L861Q, G719X and S768I mutations, excluding any other EGFR sensitive mutations and\/or oncogenes..\n4. At least one measurable lesion.\n5. ECOG score of 0, 1, or 2.\n6. A minimum life expectancy of \\> 3 months.\n7. Adequate bone marrow reserve, hepatic, renal and coagulation function.\n8. Willingness of all subjects of childbearing potential to use acceptable methods of birth control.\n\nExclusion Criteria:\n\n1. Ever used the epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) for anti-tumor therapy prior to enrollment.\n2. Any systemic anti-tumor therapy such as chemotherapy, immunotherapy and radiation therapy used within 4 weeks prior to enrollment; any palliative radiotherapy for non-target lesions used to relieve symptoms and traditional Chinese medicines indicated for tumor within 2 weeks prior to enrollment.\n3. Use or intake of drugs or foods containing potent inhibitor or inducer of cytochrome P450 isozyme 3A4 (CYP3A4) within 14 days or 5 half-lives, whichever was the longer, prior to enrollment.\n4. Surgical operation (excluding aspiration biopsy) of main organs or a significant injury within 4 weeks prior to enrollment.\n5. Any unresolved toxicities from prior therapy greater than Grade 1 at the time of screening except alopecia.\n6. Inability to swallow the study medication, any seriously chronic gastrointestinal disorder, malabsorption syndrome or any other conditions with influence on gastrointestinal absorption.\n7. Active central nervous system metastases\n8. Previous or current interstitial lung disease, radiation pneumonitis which requires hormone therapy, or drug-related pneumonia, idiopathic interstitial pulmonary fibrosis identified in a baseline CT scan; uncontrolled massive pleural or pericardial effusion.\n9. Any active infection which has not been controlled at screening.\n10. Any serious cardiovascular disease.\n11. History of other serious systemic disease not suitable for clinical trial.\n12. Participation in other interventional clinical trial 4 weeks prior to enrollment or within 5 half-lives from the last dose of investigational product (whichever is longer).\n13. Known alcohol or drug dependence.\n14. Mental disorders or poor compliance.\n15. Previously received solid organ transplantation or hematopoietic stem cell transplantation.\n16. Females who are pregnant or breastfeeding.\n17. Known hypersensitivity to the active ingredients or excipients of the investigational product.\n18. Have any other primary malignant tumors within 3 years (except some low- risk cancers).","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05168566025","EMAIL":[{}],"GEO":[30.29365,120.16142]},{"TITLE":"Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR","CRITERIA":"Inclusion Criteria:\n\nGeneral Inclusion Criteria all cohorts: dose escalation, dose expansion, and dose extension:\n\n1. Have histologically or cytologically confirmed locally advanced or metastatic NSCLC disease (Stage IIIB or IV) .\n2. Male or femal adult\uff0cbe able to provide a signed and dated, written informed consent.\n3. Must have measurable disease by response evaluation criteria in solid tumors (RECIST) v1.1.\n4. Minimum life expectancy of 3 months or more.\n5. Adequate organ function at baseline.\n6. Normal QT interval on screening electrocardiogram (ECG), defined as QT interval corrected (Fridericia) (QTcF) of less than or equal to (\u2264 ) 450 millisecond (ms) in males or \u2264 470 ms in females.\n\nPart 1: Dose Escalation Cohort Specific Inclusion Criteria:\n\n1. Refractory to standard available therapies.\n2. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.\n3. aged 18-65 years old.\n4. previously treated NSCLC patients with EGFR T790M.\n\nPart 2: Expansion Cohort 1\u30012\u30013 Specific Inclusion Criteria:\n\n1. previously treated NSCLC patients with EGFR T790M.\n2. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.\n3. aged 18-75 years old.\n\nPart 2: Expansion Cohort 4\u30015 Specific Inclusion Criteria:\n\n1. previously treated NSCLC patients with EGFR exton 20ins.\n2. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.\n3. aged 18-75 years old.\n\nPart 3: Expansion Cohort 6 Specific Inclusion Criteria:\n\n1. previously untreated NSCLC patients with EGFR exton 20ins.\n2. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.\n3. aged 18-75 years old.\n\nPart 3: Expansion Cohort 7\u30018 Specific Inclusion Criteria:\n\n1. previously treated NSCLC patients with EGFR rare mutation(\uff08G719X\u3001L861Q\u3001S768I).\n2. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.\n3. aged 18-75 years old.\n\nPart 3: Expansion Cohort9 Specific Inclusion Criteria:\n\n1. previously treated NSCLC patients with EGFR exton 20ins.\n2. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.\n3. aged 18-75 years old.\n\nExclusion Criteria:\n\n1. Any cytotoxic chemotherapy, investigational agents or other anticancer drugs from a previous treatment regimen or clinical study within 14 days before screening.\n2. Radiotherapy with a limited field of radiation for palliation within 1 week of the first dose or with a wide field of radiation which must be completed within 4 weeks before screening.\n3. NSCLC patients with EGFR T790M mutation previously treated with third-generation EGFR-TKIs (such as AZD9291, CO-1686, HM61713, EGF816, PF-06747775, vometinib, BPI-15086, Ivirtinib maleate, etc.) and their apis or the same drugs in other clinical trials Drug treatment.\n4. Patients with NSCLC with EGFR ex20ins mutation had previously received EGFR ex20ins inhibitors and\/or EGFR-cMET double antibodies (including but not limited to TAK-788, bociotinib, JNJ-61186372, DZD9008, vometinib, PLB1004, and AZD9291 in excess of the clinically approved dose (cohort 9 prohibited AZD9291 at any dose) and Drug substance or other similar drug treatment in the clinical trial stage.\n5. NSCLC patients with rare EGFR mutations have previously been treated with third-generation EGFR-Tkis (such as AZD9291, etc.) and their apis or other similar drugs in clinical trials.\n6. Received a moderate or strong CYP4503A inhibitor or moderate or strong CYP3A inducer within 10 days prior to first dose of YK-029A.\n7. Have significant, uncontrolled, or active cardiovascular disease.\n8. Have a known history of uncontrolled hypertension. Participants with hypertension should be under treatment on study entry to control blood pressure.\n9. Have prolonged QTcF interval, or being treated with medications known to be associated with the development of torsades de pointes.\n10. Have an ongoing or active infection, including but not limited to, the requirement for intravenous (IV) antibiotics, or a known history of human immunodeficiency virus, hepatitis B virus (HBV), or hepatitis C virus (HCV). Testing is not required in the absence of history.\n11. Currently have or have a history of interstitial lung disease, radiation pneumonitis that required steroid treatment, or drug-related pneumonitis.\n12. Female participants who are lactating and breastfeeding or have a positive urine or serum pregnancy test during the screening period.\n\n    Note: Female participants who are lactating will be eligible if they discontinue breastfeeding.\n13. Have gastrointestinal illness or disorder that could affect oral absorption of YK-029A.\n14. Have any condition or illness that, in the opinion of the investigator, might compromise participant safety or interfere with the evaluation of the safety of the drug.\n15. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05767866034","EMAIL":[{}],"GEO":[39.9075,116.39723]},{"TITLE":"SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI","CRITERIA":"Inclusion Criteria:\n\n* Pathologically confirmed non-small cell lung cancer;\n* Clinical stage IV (AJCC, 8th edition, 2017);\n* EGFR mutations: EGFR L858R, EGFR exon 19 deletion;\n* Age \u226518 years;\n* KPS score \u226570;\n* Brain metastasis at the time of diagnosis;\n* Complete baseline imaging assessment of metastatic lesions, including enhanced MRI for brain;\n* Receiving first-line treatment with third-generation EGFR inhibitors;\n* After 3-6 months of third-generation EGFR inhibitor treatment, imaging review indicates no progression of extracranial lesions, and brain lesions are evaluated by thin-layer (1mm layer) enhanced MRI, meeting the following criteria:\n\n  * No more than 10 remaining brain lesions;\n\n    * The maximum diameter of the remaining brain lesions does not exceed 3cm;\n\n      * At least one remaining brain lesion has a diameter greater than 5mm;\n\n        * After evaluation by the researcher, all remaining brain lesions are suitable for stereotactic radiotherapy.\n* Patient informed consent.\n\nExclusion Criteria:\n\n* Poor compliance with the study protocol in the investigator's opinion;\n* Patients withdrew their informed consent and requested to withdraw from the study;\n* Patients were unable to receive regular doses of third-generation EGFR inhibitors due to other underlying conditions, viral side effects, economic factors, etc. (e.g., continuous discontinuation for more than 1 week, cumulative discontinuation for more than 2 weeks).\n* Patients did not follow the protocol for follow-up visits as required by this study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06020066001","EMAIL":[{"email":"fuscczzf@163.com"},{"email":"nijianjiao8@sina.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET\/CT in Breast Carcinoma Patients","CRITERIA":"COHORT SPECIFIC INCLUSION CRITERIA:\n\nCOHORT 1:\n\nPatients will only be included in the study if they meet all of the following criteria:\n\n* Patient who has given informed consent\n* Patient with age 18 years or older\n* Patient with locally or distantly advanced breast carcinoma, with at least 1 lesion of at least 12 mm maximal diameter. For lymph node metastases, the largest diameter should be at least 15 mm and the short axis at least 12 mm.\n\nCOHORT 2:\n\nPatients will only be included in the study if they meet all of the following criteria:\n\n* Patient who has given informed consent\n* Patient with age 18 years or older\n* Patients with locally advanced, unresectable, or metastatic cancer disease , with at least 1 lesion of at least 10 mm maximal diameter (For lymph node metastases, short axis at least 10 mm) of any of the following types:\n\n  * breast carcinoma with low, intermediate or high HER2-expression, based on IHC 1+ or IHC 2+ or IHC 3+, as determined by local assessment on any of the available cancer tissues\n  * salivary gland cancer\n  * adenocarcinoma of the gastric body or gastro-esophageal junction\n  * endometrial cancer\n  * cancer of cervix uteri\n  * Non-small cell lung cancer\n  * biliary tract cancer including intra- or extrahepatic cholangiocarcinoma and tumors arising in the ampulla of Vater or gallbladder.\n  * pancreatic cancer\n  * colorectal cancer\n  * urothelial carcinoma, including transitional cell or predominantly transitional cell carcinoma of the renal pelvis, ureter, urinary bladder or urethra.\n  * prostate cancer\n  * Other solid malignant tumors with intermediate or high HER2-expression, based on IHC 2+ or IHC 3+, as determined by local assessment on any of the available cancer tissues\n* Patients who have progressed following at least one prior systemic treatment for metastatic or advanced disease, or who have no satisfactory alternative treatment option, according to the treating physician (based on all available data such as medical imaging, lab results, clinical examination, ...), and who are considered for a next line of systemic treatment. Patients who already participated in the trial and who are diagnosed with progressive or recurrent disease can be re-included if all inclusion criteria and none of the exclusion criteria apply.\n\nCOHORT 3:\n\nPatients will only be included in the study if they meet all of the following criteria:\n\n* Patient who has given informed consent\n* Patient with age 18 years or older\n* Patient with local or locally advanced HER2-positive (either IHC 3+ and\/or ISH positive) breast carcinoma, who is planned for neo-adjuvant treatment prior to surgery, and who is suspected for axillary lymph node invasion, based on clinical assessment, ultrasound, CT or MRI, or who has a confirmed lymph node invasion\n* Patients who either had 18F-FDG- PET\/CT in the last 4 weeks before inclusion, or for whom 18F-FDG- PET\/CT is planned before start of neoadjuvant treatment.\n\nGENERAL EXCLUSION CRITERIA:\n\nPatients will not be included in the study if one or more of the following criteria applies:\n\n* Patient is pregnant\n* Patient is breast feeding\n* Patient with recent (\\< 1 week) gastrointestinal disorders with diarrhea as major symptom\n* Patient with any serious active infection\n* Patient who has any other life-threatening illness or organ system dysfunction, which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the test radiopharmaceutical\n* Patient who cannot communicate reliably with the investigator\n* Patient who is unlikely to cooperate with the requirements of the study\n* Patient who is unwilling and\/or unable to give informed consent\n* Patient at increased risk of death from a pre-existing concurrent illness\n\nCOHORT SPECIFIC EXCLUSION CRITERIA\n\nCOHORT 1 \\& 3:\n\n* Patient who participated already in this study","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03924466001","EMAIL":[{"email":"nugmail@uzbrussel.be"},{}],"GEO":[50.85045,4.34878]},{"TITLE":"Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm","CRITERIA":"Inclusion Criteria:\n\n1. Provision of informed consent prior to any study specific procedures, sampling, and analyses.\n2. Male or female, aged at least 18 years.\n3. Histologically confirmed diagnosis of primary non-small cell lung cancer (NSCLC) on predominantly non-squamous histology.\n4. MRI or CT scan of the brain must be done prior to surgery as it is considered standard of care. Patients in whom this was not done prior to surgery may still be enrolled if appropriate imaging is performed prior to enrollment.\n5. Patients must be classified post-operatively as Stage IB, II, IIIA, or IIIB on the basis of pathologic criteria. Staging will be according to the 8th edition of AJCC Cancer Staging Manual.\n6. At least one documented uncommon EGFR mutation of G719X\/L861Q\/S768I\/de novo T790M without EGFR Ex19del\/L858R\/exon 20 insertion as detected in tumour tissue, through real-time PCR or NGS analysis from accredited laboratories approved by the Chinese regulatory authority.\n7. Complete surgical resection of the primary NSCLC is mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumour. Resection may be accomplished by open or Video Associated Thoracic Surgery (VATS) techniques.\n8. Complete recovery from surgery and standard post-operative therapy (if applicable) at the time of enrollment. Treatment cannot commence within 4 weeks following surgery. No more than 10 weeks may have elapsed between surgery and the enrollment for patients who have not received adjuvant chemotherapy; no more than 26 weeks may have elapsed between surgery and enrollment for patients who received adjuvant chemotherapy.\n\n   * Complete post-operative wound healing must have occurred following any surgery.\n   * For patients who received post-operative adjuvant platinum-based chemotherapy, a minimum of 2 weeks must have elapsed (but no more than 10 weeks) from the last administered dose of chemotherapy to the date of enrollment.\n   * Patients must have recovered from all toxicities of prior therapy greater than CTCAE Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2 prior platinum therapy related neuropathy.\n9. World Health Organization Performance Status of 0 to 1.\n10. Females must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of child-bearing potential, or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:\n\n    * Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments.\n    * Women less than 50 years old would be consider postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the institution.\n    * Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation.\n\n    Further information in Appendix D (Definition of Women of Childbearing Potential and Acceptable Contraceptive Methods) Male patients must be willing to use barrier contraception, (see Restrictions, Section 5.3).\n11. For inclusion in the optional part in molecular research study, patients must provide informed consent for the optional analysis.\n\nIf a patient declines to participate in any voluntary exploratory research of the study, there will be no penalty or loss of benefit to the patient and he\/she will not be excluded from other aspects of the study.\n\nExclusion Criteria:\n\n1. Previous enrollment and treatment in the present study.\n2. Participation in another clinical study with a study intervention or investigational medicinal device administered in the last 8 weeks prior to enrollment, or concurrent enrollment and exposure in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.\n3. Treatment with any of the following:\n\n   * Pre-operative or post-operative or planned radiation therapy for the current lung cancer.\n   * Pre-operative (neo-adjuvant) platinum based or other chemotherapy.\n   * Any prior anticancer therapy, including investigational therapy, for treatment of NSCLC other than standard platinum based doublet post-operative adjuvant chemotherapy.\n   * Prior treatment with neoadjuvant or adjuvant EGFR-TKI.\n   * Major surgery (including primary tumour surgery, excluding placement of vascular access) within 4 weeks of the first dose of study drug.\n   * Patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inducers of CYP3A4 (at least 3 week prior) (Appendix F). All patients must try to avoid concomitant use of any medications, herbal supplements and\/or ingestion of foods with known inducer effects on CYP3A4.\n   * Treatment with an investigational drug within five half-lives of the compound or any of its related material, if known.\n4. Patients who have had only segmentectomies or wedge resections.\n5. History of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer, or other solid tumours curatively treated with no evidence of disease for \\> 5 years following the end of treatment and which, in the opinion of the treating physician, do not have a substantial risk of recurrence of the prior malignancy.\n6. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the Investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol; or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).\n\n   * Screening for chronic conditions is not required.\n   * Active infection will include any patients receiving treatment for infection.\n   * Subjects with a resolved or chronic infection HBV are eligible if they are:\n\n     1. Negative for HBsAg and positive for hepatitis B core antibody \\[anti-HBc IgG\\] or\n     2. Positive for HBsAg, negative for HBeAg but for \\> 6 months have had transaminases levels below ULN and HBV DNA levels \u2264 100 IU\/mL (i.e., are in an inactive carrier state). Refer to Restrictions, Section 5.3.\n7. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib.\n8. Any of the following cardiac criteria:\n\n   * Mean resting corrected QT interval (QTc) \\>470 msec, obtained from 3 ECGs, using the screening clinic ECG machine-derived QTcF value.\n   * Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG, e.g., complete left bundle branch block, third-degree heart block, second-degree heart block.\n   * Patient with any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as electrolyte abnormalities\\* including:\n   * Serum\/plasma potassium \\< LLN\n   * Serum\/plasma magnesium \\< LLN\n   * Serum\/plasma calcium \\< LLN heart failure, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes (TdP) .\n\n     * Note: Correction of electrolyte abnormalities to within normal ranges can be performed during the screening period.\n9. Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.\n10. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:\n\n    * Absolute neutrophil count \\<1.5 \u00d7 109\/L.\n    * Platelet count \\<100 \u00d7 109\/L.\n    * Haemoglobin \\<90 g\/L.\n    * Alanine aminotransferase (ALT) \\>2.5\u00d7 the upper limit of normal (ULN).\n    * Aspartate aminotransferase (AST) \\>2.5 \u00d7 ULN.\n    * Total bilirubin \\>1.5 \u00d7 ULN or \\>3 \u00d7 ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia).\n    * Creatinine \\>1.5 \u00d7 ULN concurrent with creatinine clearance \\<50 mL\/min (measured or calculated by Cockcroft and Gault equation); confirmation of creatinine clearance is only required when creatinine is \\>1.5 \u00d7 ULN.\n11. History of hypersensitivity to active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib.\n12. Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.\n13. Involvement in the planning and\/or conduct of the study (applies to both AstraZeneca representative and\/or staff at the study site).\n14. Currently pregnant (confirmed with positive pregnancy test) or breast feeding.\n\nIn addition, the following are considered criteria for exclusion from the exploratory molecular research only:\n\n1. Prior allogeneic bone marrow transplant.\n2. Non-leukocyte depleted whole blood transfusion within 120 days of sample collection.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":130,"SS_ID":"05546866013","EMAIL":"information.center@astrazeneca.com","GEO":[34.25833,108.92861]},{"TITLE":"Immunological Variables Associated to ICI Toxicity in Cancer Patients","CRITERIA":"Inclusion Criteria:\n\n* 1) Age \u2265 18 years old\n* 2) ECOG performance status \u2264 1\n* 3) Must have histologically or cytologically confirmed solid tumour, eligible for treatment with ICI as standard-of-care alone or in combination with another ICI (cohort 1), ICI with chemotherapy (cohort 2), or ICI with targeted therapy (cohort 3) with no restrictions on number of prior systemic therapies\n* 4) All prior anti-cancer treatment-related toxicities (except alopecia) must be \u2264 Grade 1 according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 at the time of enrolment\n* 5) Serum pregnancy test (for subjects of childbearing potential) negative within 15 days prior to study medications administration.\n* 6) Women of childbearing potential must agree to use one highly effective method of contraception prior study entry, during the course of the study and at least 7 months after the last administration of study treatments.\n* 7) Men with childbearing potential partner must agree to use condom during the course of this study and for at least 6 months after the last administration of the study treatments.\n* 8) Completion of all necessary screening procedures within 14 days prior to enrolment.\n* 9) Signed Informed Consent form (ICF) obtained prior to any study related procedure.\n\nExclusion Criteria:\n\n* Subjects meeting one of the following criteria are not eligible for this study:\n\n  1. Subject with a significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the principal investigator's opinion, may interfere with completion of the study.\n  2. Participation in another clinical trial.\n  3. Pregnant and\/or lactating women.\n  4. Subjects already receiving ICI.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05429866001","EMAIL":[{"email":"mireille.langouo@bordet.be"}],"GEO":[50.85045,4.34878]},{"TITLE":"Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion","CRITERIA":"Inclusion Criteria:\n\n* All patients with advanced NSCLC with EGFR ins20 receiving amivantamab as monotherapy in France under ATU or EAP;\n* Age \u2265 18 years;\n* Histologically confirmed advanced NSCLC (metastatic or locally advanced unresectable and not suitable for definitive radiotherapy) with EGFR ins20;\n* Patients included will be required to sign an informed consent form to collect blood samples (liquid biopsy) and tissue biopsy when available at progression on amivantamab;\n* Confirmed progression on amivantamab according to RECIST 1.1;\n* Patient enrolled in the french National Health Insurance program or with a third- party payer.\n\nExclusion Criteria:\n\n* Patients receiving amivantamab in combination with another therapy;\n* Patients who do not consent to liquid biopsy at progression.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06247826017","EMAIL":[{"email":"gonzague.dechabot@ch-bretagne-atlantique.fr"}],"GEO":[47.66667,-2.75]},{"TITLE":"Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. According to the International Association for the Study of Lung Cancer and the Joint Committee on the American Classification of Cancer, 8th edition TNM staging of lung cancer, patients with locally advanced (stage IIIB\/IIIC), metastatic or recurrent (stage IV) NSCLC who are histologically proven to be inoperable and unable to undergo radical synchronous radiotherapy and chemotherapy.\n2. 18 years old \u2264 age \u2264 75 years old; No gender limit; ECOG score 0-1 points; The expected survival period is \u2265 3 months.\n3. According to RECIST 1.1 standard, there should be at least one measurable lesion.\n4. Tumor resistance has progressed after receiving first-line treatment with immune checkpoint inhibitors (including PD-1 or PD-L1 monoclonal or dual antibodies) combined with platinum based drugs in the past. For neoadjuvant\/adjuvant chemotherapy or radiotherapy or concurrent radiotherapy and chemotherapy, if the disease progresses during treatment or within 6 months after discontinuation of treatment, it should be considered as a first-line treatment plan.\n5. It is necessary to provide tumor tissue sections that have been diagnosed with advanced or metastatic NSCLC and have not undergone radiotherapy (at least 5 samples are required for PD-L1 testing of tumor tissue, but if testing has been conducted before the first line treatment, recognized test results from each participating center can be accepted.) Tumor tissue samples must be archived samples or freshly obtained samples within the first 12 months of randomization.\n6. Except for patients with squamous NSCLC, enrolled patients need to demonstrate the absence of EGFR gene sensitive mutations, ALK fusion oncogenes, or ROS1 fusion oncogenes. If it is adenosquamous cell carcinoma, stratification needs to be determined based on the dominant tissue composition.\n7. Good function of main organs\n8. Women of childbearing age should agree to use effective contraceptive measures during the study period and within 6 months after the end of the study. Serum pregnancy or urine pregnancy tests should be negative within 7 days before enrollment in the study; Men should agree to use effective contraceptive measures during the study period and within 6 months after the end of the study period.\n9. The subjects voluntarily joined this study, signed an informed consent form, and had good compliance.\n\n   Exclusion Criteria:\n   1. Tumor diseases and medical history:\n\n      a) If there is a central nervous system metastasis before enrollment, enrollment can be made if all the following criteria are met: i. Previously received brain metastasis treatment and met all of the following criteria:\n\n      \u2460 Only supratentorial and cerebellar metastases are allowed (i.e. transfer to the midbrain, pons, medulla, or spinal cord is not allowed);\n\n      \u2461 No imaging evidence of new or enlarged brain metastases was found;\n\n      \u2462 There are no symptoms of brain metastasis, and the subject must have stopped using corticosteroids\/dehydrating agents for at least 2 weeks before starting to use the investigational drug.\n\n      Ii. Has not received brain metastasis treatment in the past and meets all of the following criteria:\n      * No more than 3 metastatic lesions; \u2461 The total length and diameter of all lesions \u2264 1.5cm;\n\n        * There are no neurological symptoms caused by brain tissue compression;\n\n          \u2463 Before starting to use the investigational drug, the subject must have stopped using corticosteroids\/dehydrating agents for at least 2 weeks.\n\n          b) There were no active malignant tumors for \u2264 2 years before randomization. c) Central type squamous cell carcinoma with a cavity (primary in the main bronchus and around the hilum of the lungs).\n\n          d) Imaging shows that the tumor invades large blood vessels, or the boundary between the tumor and the blood vessels is unclear, or the researcher determines that the tumor is highly likely to invade important blood vessels and cause fatal massive bleeding during subsequent studies.\n\n          e) (1) Severe bone damage caused by tumor bone metastasis, including pathological fractures of load-bearing bones (such as spinal vertebrae, pelvis, femur, tibia, phalanges, calcaneus, etc.) and spinal cord compression that occur within 6 months; (2) Imaging examination suggests the presence of three or more multiple bone metastases in the load-bearing bone.\n\n          f) Patients with serous cavity (pleural, abdominal, or pericardial) effusion that requires repeated drainage to alleviate clinical symptoms (as determined by the researcher), or those who have received serous cavity effusion drainage for treatment purposes within 2 weeks prior to treatment.\n   2. Previous anti-tumor treatment:\n\n      1. Within 2 weeks before the start of the study treatment, he received traditional Chinese patent medicines and simple preparations with anti-tumor indications specified in the NMPA approved drug instructions.\n      2. I have previously used anti angiogenic drug systems such as arotinib, apatinib, lenvatinib, sorafenib, sunitinib, regofinib, and furoquitinib to treat locally advanced or metastatic NSCLC.\n      3. Previously received docetaxel for systematic treatment of locally advanced or metastatic NSCLC.\n      4. Unacceptable toxicity after previous anti PD - (L) 1 treatment.\n      5. Patients who have received medication with immunomodulatory effects within 30 days before starting treatment.\n      6. Before randomization, there are any symptoms that require systemic treatment with corticosteroids (prednisone or equivalent doses of similar drugs above 10 mg\/d) or other immunosuppressive agents for \u2264 14 days.\n      7. Failure to recover from toxicity and\/or complications of previous intervention measures to CTCAE \u2264 1 level, except for peripheral neuropathy with hair loss and \u2264 2 level.\n   3. Concomitant diseases and medical history:\n\n      a) Decompensated cirrhosis (Child Pugh liver function rating B or C), active hepatitis, and active COVID-19 infection.\n\n      b) Renal abnormalities: i. Renal failure requires hemodialysis or peritoneal dialysis; Ii. Previous or existing nephrotic syndrome (excluding cured), chronic nephritis.\n\n      c) Cardiovascular and cerebrovascular abnormalities: d) Gastrointestinal abnormalities: i. Inability to take medication orally; Ii. History of malabsorption syndrome or other diseases that can interfere with gastrointestinal absorption, including a history of partial surgical removal of the stomach or intestines (excluding appendectomy); Iii. Received treatment for active gastrointestinal ulcers within the past 6 months.\n\n      e) History of Immunodeficiency: i. Having a history of immunodeficiency, including HIV positive or suffering from other acquired or congenital immunodeficiency diseases; Ii. A history of active autoimmune diseases or autoimmune diseases, including but not limited to Crohn's disease, ulcerative colitis, autoimmune hepatitis\/enteritis\/vasculitis\/nephritis, etc; Iii. Prepare to undergo or have previously received organ transplantation; f) Bleeding risk: i. Suffering from bleeding, coagulation disorders, or using warfarin, aspirin, and other antiplatelet agglutination drugs within 28 days prior to the start of treatment (excluding preventive medication with aspirin \u2264 100 mg\/d); Ii. Have a history of hemoptysis within 28 days before the start of treatment; Iii. Regardless of the severity, patients with congenital bleeding or coagulation disorders, or those who are currently using anticoagulants for treatment; Iv. Major surgical treatment or obvious traumatic injury received within 28 days prior to the start of the study treatment; v. Long term uncured wounds or fractures, excluding pathological fractures. g) Type I diabetes or II diabetes is poorly controlled. h) Having experienced severe infection of level 4 or higher within one year prior to the start of the study treatment; Subjects with 2-3 levels of active infection within 2 weeks prior to the start of study treatment; Treponema pallidum antibody (TP Ab) positive; Or those who experience unexplained fever of\\>38.0 \u2103 during the screening period or before the first administration, or who require medical intervention.\n\n      i) Previous or existing pneumoconiosis, interstitial pneumonia, non infectious pneumonia requiring corticosteroid treatment, currently suffering from grade 2 or other types of pneumonia, or objective evidence of severe impairment of lung function confirmed by pulmonary function examination (FEV1 or DLCO or DLCO\/VA accounting for% of expected value\\<40%).\n\n      j) Patients with active tuberculosis within one year prior to enrollment. k) Allergic constitution, or a history of severe allergies, or severe hypersensitivity reactions after receiving other monoclonal antibody treatments, or known allergies to the study drug excipients, or allergies to Tween 80.\n\n      l) Previous history of severe mental disorders. m) Individuals with a history of drug abuse, alcohol or drug abuse.\n   4. The end of previous clinical studies (last administration) is less than 4 weeks or the 5 half-lives of the study drug, whichever is shorter.\n   5. Vaccination history within the first 28 days of randomization or vaccination during the planned study period.\n   6. Pregnant or lactating female patients.\n   7. According to the researcher's viewpoint, it may increase the risk associated with participating in the study, or other reasons may make it unsuitable to participate in this clinical study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06141226005","EMAIL":[{"email":"likai@tjmuch.com"},{"email":"wangjing_0220@163.com"}],"GEO":[39.14222,117.17667]},{"TITLE":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","CRITERIA":"Inclusion:\n\n* Participants \u2265 18 years at screening\n* Histologically or cytologically documented NSCLC that at the time of randomisation is Stage IIIB or IIIC disease not amenable to surgical resection or definitive chemoradiation or Stage IV metastatic disease\n* Lacks sensitising EGFR tumour tissue mutation and ALK and ROS1 rearrangements and has no documented tumour genomic alterations in NTRK, BRAF, RET, MET or other actionable driver oncogenes with approved and available therapies (actionable genomic alterations).\n\nTesting is not required for tumors with squamous histology, with exceptions.\n\n* ECOG PS of 0 or 1\n* Archival tumour tissue\n* Has adequate bone marrow reserve and organ function within 7 days before randomization\n\nExclusion:\n\n* Mixed small-cell lung cancer and NSCLC histology; sarcomatoid variant of NSCLC\n* History of another primary malignancy with exceptions\n* Persistent toxicities caused by previous anti-cancer therapy not yet improved to Grade \u2264 1 or baseline, with exceptions.\n* Spinal cord compression or clinically or radiologically active brain metastases\n* History of leptomeningeal carcinomatosis.\n* Known active or uncontrolled hepatitis B or C virus infection.\n* Uncontrolled or suspected infection requiring IV antibiotics, antivirals, or antifungals.\n* Clinically significant corneal disease\n* History of non-infectious ILD\/pneumonitis that required steroids, has current ILD\/pneumonitis, or has suspected ILD\/pneumonitis that cannot be ruled out by imaging at screening.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":130,"SS_ID":"05687266298","EMAIL":"information.center@astrazeneca.com","GEO":[51.01494,-3.10293]},{"TITLE":"A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n1. Age \u226518 years old, male or female;\n2. Patients with advanced malignant solid tumors confirmed by histology or pathology, including colorectal cancer, esophageal cancer, gastric cancer, pancreatic cancer, non-small cell lung cancer, breast cancer, and cholangiocarcinoma;\n3. Progression or intolerance occurs after receiving systematic standard therapy according to guidelines,(systemic therapy including but not limited to systemic chemotherapy, molecular targeting, etc.) and is not suitable for surgery or local therapy (including ablative therapy, interventional therapy, and radiation therapy), among which colorectal cancer needs to receive at least third-line therapy failure or intolerance or inapplicability. Esophageal, gastric, non-small cell lung, breast, and cholangiocarcinoma require at least second-line treatment failure or intolerance or inadequacy, and pancreatic cancer require at least first-line treatment failure or intolerance or inadequacy:\n\n   1. Advanced colorectal cancer: progression or intolerance or inadequacy after third-line standard therapy including cetuximab \u00b1 Irinotecan\/regorafenib \/fruquintinib\/trifluridine\uff1b\n   2. Advanced or metastatic esophageal cancer\/esophagogastric junction cancer: patients with esophageal cancer who progress or are intolerant or inapplicable after second-line therapy including PD-1 MAB \/PD-L1 mab; Patients with esophagogastric junction cancer progressed or were intolerant or inapplicable after second-line therapy including taxane or irinotecan or PD-1 \/PD-L1 monoclonal antibody; For HER-2 positive patients, trastuzumab containing system therapy should fail or be intolerable or not applicable;\n   3. Advanced\/metastatic gastric cancer: the combination of PD-1 MAB \/PD-L1 MAB and chemotherapy has been developed or is not tolerated or suitable; For HER-2 positive patients, systemic treatment containing trastuzumab should fail or be intolerable or inapplicable.\n   4. Patients with advanced, metastatic, or recurrent non-small cell lung cancer who have received systemic treatment progression or intolerance, including: Patients with positive driver genes (EGFR, ALK, ROS1, BRAF, NTRK, MET, RET) should receive targeted therapy failure or drug resistance (squamous cell carcinoma does not require driver gene testing). In addition, patients with EGFR-positive driver gene who are resistant to first-line EGFR-Tkis and who are positive for EGFR T790M mutations need to be treated with third-generation EGFR-TKI (such as Osimertinib, almonertinib, or furmonertinib) after failure or resistance. For patients with positive ALK fusion and drug resistance after first-line crizotinib treatment, second-line treatment with ceritinib or alectinib should fail or be resistant; Patients with PD-L1 expression (PD-L1 TPS\u22651%) should undergo immune checkpoint inhibitor treatment failure or intolerance; In patients with negative driver genes, the disease progresses or becomes intolerable after chemotherapy with platinum-containing regiments-such as Camrelizumab, Pembrolizumab, Tislelizumab, Sintilimab or Atezolizumab combined with pemetrexed\n   5. Advanced, metastatic breast cancer: HER-2 positive patients need to have received anti-HER-2 therapy, hormone receptor positive patients need to receive endocrine therapy and other standard treatments have failed or are intolerable or not applicable, and rescue chemotherapy for those who have failed\/are intolerable or triple-negative breast cancer (including: Gemcitabine + cisplatin\/carboplatin, albumin paclitaxel\/other taxoid drugs + cisplatin\/carboplatin) fail or are not tolerated or suitable;\n   6. Locally advanced or metastatic pancreatic cancer: advanced or intolerant or inappropriate after at least first-line treatment, including: Gemcitabine + albumin-bound paclitaxel\/cisplatin\/erlotinib\/capecitabine\/tegafur\/Nimotuzumab, or FOLFIRINOX (oxaliplatin + irinotecan +LV+5-FU), or mFOLFIRINOX (oxaliplatin + irinotecan + calcium folinate +5-FU);\n   7. Advanced cholangiocarcinoma: progression or intolerance or inapplicability after at least second-line therapy (mFOLFOX); Remarks: Chemotherapy failure is defined as disease progression or intolerable toxicity during treatment or within 3 months after the last dose; If patients cannot receive the above treatment for economic reasons, those whose benefits outweigh the risks of inclusion in the study can be enrolled.\n4. Subjects with positive CEA (IHC score 3+) in tumor tissue samples (paraffin sections or fresh tissue specimens or puncture biopsy samples) within 3 months before screening; If the immunohistochemical results of the tumor samples are more than 3 months from the time of screening, the patient needs to re-biopsy; If the tumor specimens are not available or the amount is too small for immunohistochemical detection of CEA, the CEA positive can be confirmed by re-staining of previous tissue specimens, and the peripheral blood serum CEA\u22652.0\u00d7ULN can be included in the group.\n5. Have at least one evaluable target lesion according to RECIST 1.1 criteria;\n6. Colorectal cancer, esophageal cancer, non-small cell lung cancer, breast cancer, stomach cancer, cholangiocarcinoma ECOG 0 \\~ 1 score, pancreatic cancer ECOG 0 \\~ 2 score;\n7. Expected survival time is more than 12 weeks;\n8. No serious mental disorders;\n9. Unless otherwise stated, the subject's vital organ functions shall meet the following conditions:\n\n   1. Blood routine: white blood cells \\> 3.5\u00d7109\/L, neutrophils \\> 1.8\u00d7109\/L, lymphocytes \\&gt; 0.5 \u00d7109\/L, platelet \\> 80\u00d7109\/L, hemoglobin \\> 90g\/L;\n   2. Cardiac function: Echocardiography indicated cardiac ejection fraction \u226550%, and no obvious abnormality was found in electrocardiogram;\n   3. Renal function: serum creatinine \u22642.0\u00d7ULN;\n   4. Liver function: ALT and AST\u22643.0\u00d7ULN (patients with liver tumor infiltration can be relaxed to \u22645.0 \u00d7ULN);\n   5. Total bilirubin \u22642.0\u00d7ULN (Gilbert syndrome \u22643.0\u00d7ULN; The patients with liver tumor infiltration can be enlarged to \u22645.0\u00d7ULN);\n   6. Blood oxygen saturation in non-oxygen state \\&gt; 92%.\n10. Have the criteria for simple or intravenous blood collection, and no other contraindications for cell collection;\n11. The subject agrees to use a reliable and effective method of contraception (excluding safe period contraception) for 1 year from signing the informed consent to receiving the C-13-60 cell infusion. Including but not limited to: abstinence, can inhibit ovulation implantable progesterone contraceptive; Intrauterine device (IUD); Intrauterine hormone release system; Spousal vasectomy; Combined hormonal contraceptives (oral, vaginal, and transdermal) that inhibit ovulation; Progesterone contraceptives (oral or injectable) that inhibit ovulation; Male subjects who have sex with fertile women must consent to the use of a barrier method of contraception (e.g., condom plus spermicidal foam\/gel\/film\/emulsion\/suppository). At the same time, the subject should promise not to donate eggs (egg cells, oocytes) or sperm for assisted reproduction within 1 year after the cell infusion.\n12. The patient or his\/her guardian agrees to participate in the clinical trial and signs the ICF, indicating that he\/she understands the purpose and procedure of the clinical trial and is willing to participate in the study.\n\nExclusion Criteria:\n\n1. People who have received CAR-T therapy or other gene-modified cell therapy;\n2. Patients with BMS with clinical symptoms or lesions located in key parts of the brain at the time of screening, patients with BMS without clinical symptoms or lesions located in non-critical parts of the brain should be evaluated by researchers or specialists to gain more than the risk.\n3. Received any of the following medications or treatments before screening:\n\n   1. Received other investigational drugs or treatments that are not on the market within 4 weeks prior to screening;\n   2. Received live attenuated vaccine within 4 weeks prior to screening;\n   3. Received radioactive iodine-125 particle implantation within 8 weeks prior to screening;\n4. Received the following drugs or treatments before apheresis:\n\n   1. received the equivalent of \\&gt within 2 weeks prior to apheresis; 10mg\/ day of prednisone for systemic steroids, except inhaled steroids;\n   2. Received anti-PD-1 \/ PD-L1 monoclonal antibody treatment within 4 weeks before apheresis; Received chemotherapy, targeted therapy, or other investigational agents within 2 weeks of preapheresis or at least 5 drug half-lives (whichever is shorter);\n5. There is an active or uncontrolled infection that requires systemic treatment within 1 week prior to screening;\n6. Subjects with intestinal obstruction, active gastrointestinal bleeding, history of massive gastrointestinal bleeding within 3 months, severe gastroduodenal ulcer, severe ulcerative colitis and other severe intestinal inflammation;\n7. History of severe respiratory disease;\n8. There are a large number of serous effusions that cannot be controlled by treatment (such as pleural effusions, abdominal effusions and pericardial effusions);\n9. Have any of the following heart conditions:\n\n   1. New York Heart Association (NYHA) Stage III or IV congestive heart failure;\n   2. Had myocardial infarction or coronary artery bypass grafting (CABG) within \u22646 months before enrollment;\n   3. A history of clinically significant ventricular arrhythmia, or unexplained syncope (other than those caused by vasovagal or dehydration);\n   4. History of severe non-ischemic cardiomyopathy.\n10. Known to have active or uncontrolled autoimmune diseases that require treatment with immunosuppressants, including biologics, such as Crohns disease, rheumatoid arthritis, systemic lupus erythematosus, systemic vasculitis, etc.;\n11. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA test greater than the normal range; Hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C virus (HCV) RNA detection greater than the normal range; Human immunodeficiency virus (HIV) antibody positive; Syphilis positive; Cytomegalovirus (CMV) DNA test positive;\n12. At the time of screening, subjects had venous embolism events (e.g., pulmonary embolism) and required anticoagulant therapy;\n13. Other uncured malignant tumors within the past 3 years or at the same time, except cervical carcinoma in situ and skin basal cell carcinoma;\n14. Women who are pregnant or nursing, and male or female subjects who plan to have a child within 1 year after receiving C-13-60 cell transfusion;\n15. Circumstances deemed unsuitable for participation in the study by other researchers.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06043466002","EMAIL":[{"email":"yuanying1999@tom.com"}],"GEO":[30.29365,120.16142]},{"TITLE":"A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)","CRITERIA":"Inclusion Criteria:\n\n1. Signed written informed consent in accordance with International Conference on Harmonization-Good Clinical Practice and national\/local regulations\n2. Male or female patient aged 18 to 75 years\n3. Histologically confirmed metastatic (stage IV) NSCLC\n4. No known oncogenic driver alteration with available targeted therapy, including EGFR, HER2, KRASG12C, MET or BRAFV600E gene mutations and ALK, ROS1, or RET gene fusion\/rearrangements. Patients with KRASG12C mutation having received a targeted therapy will be eligible\n5. Have received all standard therapeutic options available, including at least 4 months of treatment with an anti-PD1 or PD-L1 monoclonal antibody and doublet platinum-containing chemotherapy\n6. Have documented progression not earlier than 4 months after initiation of the anti-PD(L)1 therapy\n7. Have at least one measurable lesion according to RECIST 1.1 and at least one lesion amenable to biopsy\n8. Expected life expectancy of at least 3 months\n9. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n10. Time from prior immunotherapy or antibody-based therapy to first TG6050 administration of at least 4 weeks, from prior chemotherapy of at least 3 weeks, and from palliative radiotherapy of at least 2 weeks\n11. Adequate hematological, hepatic, and renal functions\n12. Clearance for trial participation after cardiology consultation and cardiologic investigations\n13. Negative pregnancy test in women of childbearing potential (WOCBP)\n14. Commitment to use a highly effective contraception method (i.e., with a failure rate of \u22641 % per year) combined with a barrier method (e.g., condom) during TG6050 administration period and at least 3 months after TG6050 administration, in men and WOCBP\n\nExclusion Criteria:\n\n1. Major surgery within 4 weeks of first TG6050 administration\n2. Prior treatment with ipilimumab\n3. Prior treatment with an oncolytic virus\n4. Prior treatment with another investigational agent within 4 weeks of first TG6050 administration\n5. Immunodeficiency due to underlying illness and\/or immune-suppressive medication\n6. Uncontrolled intercurrent illness\n7. Active auto-immune disease except hypothyroidism or type I diabetes only requiring hormone replacement therapy\n8. Brain metastases, unless treated and stable for at least 4 weeks after medical imaging assessment\n9. Other malignancies than NSCLC except cutaneous basal cell carcinoma and in situ carcinoma of the uterine cervix, unless complete remission for at least 5 years prior to trial entry and no therapy required during the trial\n10. Ongoing antiviral therapy active on vaccinia virus (VV), e.g., ribavirin, interferon\/pegylated interferon\n11. History of monkeypox infection or anti-monkeypox vaccination\n12. History of severe exfoliative skin conditions\n13. History of grade \u2265 3 auto-immune manifestations related to ICI therapy\n14. History of severe systemic reaction or side-effect after a smallpox vaccination\n15. History of solid organ or allogeneic stem cell transplantation\n16. Known hypersensitivity to eggs or any TG6050 excipients\n17. Positive test for hepatitis C virus (HCV) or hepatitis B virus (HBV) indicating acute or chronic infection\n18. Live virus vaccination within 28 days of TG6050 administration\n19. COVID-19 vaccination or infection within 14 days of TG6050 administration\n20. Breastfeeding woman\n21. Any medical, familial, sociological, or psychiatric condition that in the opinion of the investigator would prohibit inclusion in the trial","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05788926005","EMAIL":[{}],"GEO":[47.21765,-1.64841]},{"TITLE":"Lifei Xiaoji Wan in Treatment of Advanced NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Clinical diagnosis of NSCLC.\n2. The tumor stage (TNM) stage is from III to IV.\n3. 18-80 years old.\n4. The expected survival period is\\> 3 months.\n\nExclusion Criteria:\n\n1. Early-stage patients with prior surgery and no recurrence.\n2. Patients with serious dysfunction of the heart, liver, heart, kidney, and other important organs.\n3. Mental illness and other patients were unable to complete the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"06406166001","EMAIL":[{"email":"40685685@qq.com"}],"GEO":[34.75778,113.64861]},{"TITLE":"A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* 1. The subjects volunteered to participate in the study, signed the informed consent form, and had good compliance;\n* 2. ECOG\u22642 ;\n* 3.Life expectancy of \u226512 weeks\uff1b\n* 4.Age \u226518 years;\n* 5. Diagnosed by histological examination and\/or cytology examination, and imaging evaluation (refer to RECIST 1.1) for advanced central NSCLC;\n* 6. He had not received systemic chemotherapy previously.\n* 7.Had at least one measurable tumor lesion according to RECIST v1.1\uff1bThat is, in CT or MRI detection, the longest diameter of a single lesion is \u226510mm, or the lymph node is pathologically enlarged, and the short diameter of a single lymph node on CT scan is \u226515mm\uff1b\n* 8.Have adequate organ function\u3002\n\nExclusion Criteria:\n\n* 1.This study was conducted five years prior to the initiation of treatment or concurrently with other malignant tumors.\n* 2. Have family history of cancer.\n* 3.had previously undergone any form treatment, such as surgery, chemotherapy, radiation therapy, etc.\n* 4.Only individuals experiencing grade 1 or higher unmitigated toxic effects (excluding alopecia and fatigue) resulting from previous therapies were eligible for enrollment; neurologic toxicity needed to return to grade 1 or lower or baseline before participation.\n* 5.Subjects with severe and\/or uncontrollable disease progression\uff1b\n* 6.Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome;\n* 7.Pregnant or lactating women;\n* 8.Other conditions considered unsuitable for this study by the investigator.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06108726001","EMAIL":[{"email":"liuxy0229@163.com"}],"GEO":[31.30408,120.59538]},{"TITLE":"PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Written informed consent\n* Patients irrespective of sex and gender, aged 18 years or older at the time of signing the ICF\n* Patients must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study as determined by the investigator\n* Patients with histologically or cytologically documented NSCLC who present with locally advanced, unresectable (Stage III) disease (according to version 8 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology (IASLC Staging Manual in Thoracic Oncology 2016))\n* Patients fit for simultaneous chemoradiotherapy and consolidation immunotherapy according to interdisciplinary consensus\n* Histologically proven PD-L1-expression of \u2265 1% (tumor proportion score; TPS) in tumor sample as assessed in routine staging using a validated test such as Ventana SP236 assay\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at enrolment\n* Tumor assessment by FDG-PET CT within 21 days prior to start of chemoradiotherapy.\n* Adequate pulmonary function test results\n\n  * Pre- or post-bronchodilator forced expiratory volume 1 of 1.0 L or \\>40% of predicted AND\n  * Diffusing capacity of the lung for carbon monoxide (DLCO) \\>30% of predicted\n* Adequate bone marrow and organ function at enrolment\n\n  * Hemoglobin \u22659.0 g\/dL\n  * Absolute neutrophil count \\>1.5 \u00d7 109\/L\n  * Platelet count \\>100 \u00d7 109\/L\n  * Serum bilirubin \u22641.5 \u00d7 upper limit of normal (ULN)\n  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u22642.5 \u00d7 ULN\n  * Measured creatinine clearance (CrCl) \\>40 mL\/min or calculated CL \\>40 mL\/min as determined by Cockcroft-Gault (using actual body weight)\n* Body weight of \\>30 kg at enrolment\n* Evidence of post-menopausal status, or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they are amenorrhoic for 12 months or more without an alternative medical cause. The following age-specific requirements apply:\n\n  * Women \\<50 years old would be considered post-menopausal if they have been amenorrhoic for 12 months or more following cessation of exogenous hormonal treatments with luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution\n  * Women \u226550 years old would be considered post-menopausal if they have been amenorrhoic for 12 months or more following cessation of all exogenous hormonal treatments, radiation-induced oophorectomy with last menses \\>1 year ago, chemotherapyinduced menopause with \\>1 year interval since last menses, or surgical sterilization (bilateral oophorectomy or hysterectomy)\n* Women of childbearing potential (WOCBP) and male patients with partners of childbearing potential must agree to always use a highly effective form of contraception according to the Clinical Trials Facilitation and Coordination Group during the treatment phase of this study and for at least 90 days after the last dose durvalumab or 6 months after the last dose of chemotherapy, whichever occurs last\n\nExclusion Criteria:\n\n* Mixed small cell and NSCLC histology\n* Neuroendocrine tumor\n* Distant metastases\n* Malignant pleural effusion or pericardial effusion\n* Acute superior vena cava obstruction\n* Receipt of prior or current cancer treatment for NSCLC, including but not limited to, surgical resection, radiation therapy, investigational agents, chemotherapy, and monoclonal antibodies (mAbs). Exception: Prior surgical resection of limited metachronous NSCLC (i.e., stage I or II) is permitted.\n* Receipt of live attenuated vaccine within 30 days prior to the start of therapy. Note: Patients, if enrolled, should not receive live vaccine during treatment phase and up to 30 days end of treatment\n* Major surgical procedure (as defined by the Investigator) within 28 days prior start of treatment.\n* Prior exposure to immune-mediated therapy, including but not limited to, other anti-CTLA-4, anti-PD-1, anti-PD-L1 (including durvalumab), and anti-PD-L2 antibodies, including therapeutic anticancer vaccines\n* Current use of ongoing long-term immunosuppressive medication. The following are exceptions to this criterion\n\n  * Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)\n  * Systemic corticosteroids at physiologic doses not to exceed 10 mg\/day of prednisone or its equivalent\n  * Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)\n* History of allogeneic organ transplantation\n* Active or prior documented autoimmune or inflammatory disorders including inflammatory bowel disease \\[e.g., colitis or Crohn's disease\\], diverticulitis \\[with the exception of diverticulosis\\], systemic lupus erythematosus, Sarcoidosis syndrome, Wegener syndrome \\[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.\\]). The following are exceptions to this criterion:\n\n  * Patients with vitiligo or alopecia\n  * Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement\n  * Any chronic skin condition that does not require systemic therapy\n  * Patients without active disease in the last 5 years at randomization may be included but only after consultation with the local study physician\n  * Patients with celiac disease controlled by diet alone\n* Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, ILD, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness\/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs, or compromise the ability of the patient to give written informed consent\n* Patients with oxygen dependence\n* Acute inflammation of mediastinal lymph nodes\/mediastinal lymphadenopathy in the context of active pneumoconiosis, sarcoidosis or tuberculosis\n* History of another primary malignancy except for o Diagnosis of second malignancy (except basal cell carcinoma) \\< 2 years prior to NSCLC diagnosis, or persistence or progression of previously diagnosed malignancy.\n\nPatients with a previous history of radiation therapy are eligible provided field overlap is minimal and the risk of toxicity to tissues in the overlapping region(s) is deemed to be acceptable by treating radiation oncologist.\n\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\n* Adequately treated carcinoma in situ without evidence of disease\n\n  * History of leptomeningeal carcinomatosis\n  * Positive diagnostic test for hepatitis B (hepatitis B surface antigen) or hepatitis C (hepatitis C antibody or hepatitis C RNA)\n  * Known active infection of tuberculosis or human immunodeficiency virus\n  * Known allergy or hypersensitivity to concomitant chemotherapy and durvalumab or any of the excipients\n  * Any medical contraindication to treatment with platinum-based doublet chemotherapy as listed in the applying SmPCs\n  * Patients who have disease considered for surgical treatment as part of their care plan, such as Pancoast or superior sulcus tumors.\n  * Concurrent enrolment in another clinical study, unless it is an observational (noninterventional) clinical study or the follow-up period of an interventional study\n  * Participation in another clinical study with an investigational product during the 4 weeks prior to enrolment\n  * Pregnancy or breast-feeding","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06102057008","EMAIL":[{}],"GEO":[47.36667,8.54999]},{"TITLE":"Efficacy of Osimertinib in Patients With Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Patients must be \u226518 years.\n* Provision of fully informed consent prior to any study specific procedures.\n* Advanced or metastatic lung squamous cell carcinoma confirmed by histology or cytology.\n* According to the RECIST 1.1 standard, the patient must have at least one measurable lesion.\n\nExclusion Criteria:\n\n* None","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06174857001","EMAIL":[{"email":"zhangyongchang@csu.edu.cn"}],"GEO":[28.19874,112.97087]},{"TITLE":"MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Patient with age \u2265 18 years old, gender is not limited.\n2. Histologically confirmed primary NSCLC, postoperative stage is IIA, IIB, IIIA or T3N2IIIB.\n3. Receiving complete resection\n4. Paraffin-embedded sections (10-15 pieces) or fresh frozen tissue are required.\n5. ECOG score of 0 or 1.\n6. Females of childbearing age should take appropriate contraceptive measures from screening to 3 months after discontinuation of study treatment and should not breastfeed. The pregnancy test was negative before starting dosing.\n7. Male patients should use barrier contraception from screening to 3 months after discontinuation of study treatment.\n8. The subjects themselves participated voluntarily and signed the informed consent in writing.\n\nExclusion Criteria:\n\n1. The patient has received immune checkpoint inhibitors such as anti-PD-1, PD-L1 or CTLA-4, other immunotherapy or systemic immune modulators (including but not limited to interferon, IL-2 and TNF etc).\n2. Histopathology with small cell or large cell endocrine tumor component.\n3. Harboring EGFR sensitizing mutation or ALK gene translocation\n4. History of other malignant tumors, except for non-melanoma skin cancer, carcinoma in situ or other solid tumors that have been effectively treated, and no evidence of any disease for \\>5 years after the last treatment.\n5. At the start of the study treatment, there are residual toxicities of the previous treatment that are greater than CTCAE 1 and have not been alleviated, except for alopecia and grade 2 neurotoxicity caused by previous chemotherapy.\n6. Any serious or uncontrolled systemic disease, including uncontrolled high blood pressure, active bleeding, active infection including hepatitis B, C, HIV, etc., which the investigator considers unsuitable to participate in the study or affect the trial program compliance.\n7. History of ILD, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy, or any evidence of clinically active interstitial lung disease\n8. Insufficient bone marrow reserve or organ function.\n9. History of hypersensitivity reactions to any active or inactive ingredient of tislelizumab or to drugs that are chemically similar to tislelizumab or in the same class of tislelizumab.\n10. Patients who, in the judgment of the investigator, may not comply with the procedures and requirements of the study.\n11. Patients who, in the investigator's judgment, have any condition that compromises patient safety or interferes with the evaluation of the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"05286957001","EMAIL":[{"email":"LF_0604@163.com"}],"GEO":[34.75778,113.64861]},{"TITLE":"Study of XNW5004 Tablet in Combination With KEYTRUDA\u00ae (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)","CRITERIA":"Inclusion Criteria:\n\n* Sign informed consent form prior to the commencement of any research activity\/procedure.\n* Age \u2265 18.\n* Cohort 3 (mCRPC cohort) is male-only, and no gender restrictions for other cohorts.\n* Subjects with advanced solid tumors who meet one of the following requirements can be enrolled in the study. No cohorts planned for the Phase Ib study, whereas the Phase II study is divided into 6 cohorts:\n\n  * Cohort: 1 Histologically or cytologically confirmed recurrent or metastatic head and neck squamous cell carcinoma (including nasopharyngeal carcinoma),has progressed after treatment with a standard regimen containing PD-1\/PD-L1 inhibitors.\n  * Cohort 2: Histologically confirmed advanced urothelial carcinoma (including urothelial carcinoma of bladder, renal pelvis, ureter, and urethral origin) that is not suitable for surgical treatment and has progressed after treatment with a standard regimen containing PD-1\/PD-L1 inhibitors.\n  * Cohort 3:\n\n    1. Metastatic castration-resistant prostate adenocarcinoma with histological or cytological evidence of disease progression except neuroendocrine or small cell carcinoma; Imaging examination (CT\/MRI\/ bone scan) confirmed metastatic lesions.\n    2. Failed previous standard treatments, and at least received one second-generation anti-androgen drug treatment (including but not limited to abiraterone acetate, enzalutamide or apalutamide).\n    3. Disease progression at screening.\n    4. Continuous luteinizing hormone-releasing agonist (LHRHa) or antagonist therapy (drug castration) or prior bilateral orchiectomy (surgical castration).\n    5. Testosterone at screening was at castration level.\n  * Cohort 4: Subjects with histologically or cytologically confirmed extensive-stage small cell lung cancer with disease progression after first-line standard therapy.\n  * Cohort 5: Subjects with histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer.\n\n    1. Cohort 5a: Previous use of and resistant to EGFR inhibitors and failed standard treatment.\n    2. Cohort 5b: No driver gene mutations identified and failed standard therapy containing PD-1\/PD-L1 inhibitors.\n  * Cohort 6: Subjects with advanced solid tumors other than those described in the above cohorts, and failed standard therapy. For recurrent or metastatic cervical cancer, it should be histologically or cytologically confirmed as squamous cell carcinoma, progressed after systematic standard treatment, and is not suitable for radical therapy .\n* For patients who have progressed on treatment with PD-1\/PD-L1 inhibitors administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies, PD-1\/PD-L1 inhibitor treatment progression is defined by meeting all of the following criteria:\n\n  1. Has received at least 2 doses of approved PD-1\/PD-L1 inhibitors.\n  2. Documented objective radiographic progression following initiation of treatment with a PD-1\/PD-L1 inhibitor. Subjects should not be enrolled if they are suspected of permanent withdrawal due to pseudo-progression after previous PD-1\/PD-L1 inhibitor treatment.\n* To the extent possible, provide formalin-fixed, paraffin-embedded (FFPE) tumor tissue section (previously archived or fresh) samples and blood samples that meet the detection requirements for exploratory studies.\n* Life expectancy \u2265 3 months.\n* At least one measurable lesion according to RECIST 1.1 criteria.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.\n* Have adequate organ function.\n* Females of child-bearing potential and males who use adequate birth control through 6 months post last dose.\n\nExclusion Criteria:\n\n* Cohort-specific exclusion criteria:\n\n  1. Cohort 1 (head and neck squamous cell carcinoma cohort)\n\n     * Neuroendocrine carcinoma and small cell carcinoma.\n     * Salivary adenocarcinoma or other non squamous cell carcinoma (such as adenocarcinoma, sarcoma or mixed carcinoma) confirmed by histology or cytology, and metastatic squamous cell carcinoma with unknown primary origin. This exclusion criterion is not applicable to nasopharyngeal cancer.\n  2. Cohort 3 (mCRPC)\n\n     * Severe bone injury caused by tumor bone metastasis, including severe, uncontrolled bone pain as judged by the investigator, bone fractures or spinal cord compression at critical parts of the body that occurred in the last 6 months or are expected to occur in a near future.\n     * Any previous treatment targeting T-cell co-stimulation or checkpoint pathways.\n  3. Cohort 5 (non-small cell lung cancer)\n\n     * Any previous treatment targeting T-cell co-stimulation or checkpoint pathways other than PD-1 \/ PD-L1 inhibitors.\n     * Combined with other targetable driver mutations either alone or in addition to EGFR, including but not limited to: ALK gene rearrangement, ROS1 mutations, BRAFV600E mutation, etc. (For cohort 5a only.)\n* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137), and was discontinued from that treatment due to a Grade 3 or higher irAE.\n* Prior exposure to EZH2 inhibitor(s) or EZH1\/2 inhibitor(s) (including but not limited to tazemetostat).\n* Subjects known to be allergic to the study drug or its active ingredients or excipients, or subjects with prior severe hypersensitivity to other monoclonal antibody therapy in the past.\n* Subjects who received anti-tumor therapies including chemotherapy, immunotherapy, radical radiotherapy, major surgery, targeting therapy and other anti-tumor therapies within 4 weeks or 5 half-lives of the drug (whichever is shorter) before the first dose; or received palliative radiotherapy within 2 weeks before the first dose.\n* Subjects who participated in any other clinical trial of anti-tumor therapy within 28 days before the first dosing, and the last dose of other anti-tumor trial drug is within 28 days prior to the first administration of study drug in this trial.\n* Subjects who underwent major surgery within 4 weeks prior to the start of the study treatment, or who are scheduled to undergo a major surgery during the study period (procedures such as puncture or lymph node biopsy is allowed).\n* Subjects who have an allogenic bone marrow transplantation or solid organ transplantation.\n* Subjects who have diseases requiring systemic therapy with corticosteroids (\\> 10 mg of prednisone or equivalent dose of other glucocorticoids) or other immunosuppressive medications within 14 days prior to the study drug administration. In the absence of active autoimmune disease, inhaled or topical steroids and adrenal replacement therapy is allowed with a dose of \u2264 10 mg of prednisone or equivalent doses of other glucocorticoids.\n* Subjects who took moderate to strong CYP3A4 inhibitor\/inducer medications within 14 days prior to the first dose of study drug.\n* Subjects who have received live vaccines (including attenuated live vaccines) within 28 days prior to the administration of study drug. Inactivated vaccines are permitted.\n* Subjects who experienced toxicity events during previous anti-tumor treatment and the toxicity has not resolved (toxicity has not resolved means the severity of the toxicity events has not been graded as \u2264 level 1 according to National Cancer Institute- Common Terminology Criteria for Adverse Events \\[NCI-CTCAE\\] 5.0). Other toxicities that the investigator does not think it will affect the safety assessment of the subject (such as hair loss, etc.) will be allowed.\n* Subjects who have a history of other malignancies within 3 years prior to enrollment and do not meet the criteria for clinical cure. This exclusion criterion does not apply to skin basal cell carcinoma or squamous cell carcinoma with local treatment methods available and has been cured, superficial bladder cancer, primary cervical carcinoma in situ, intraductal breast carcinoma in situ, and papillary thyroid carcinoma.\n* Subjects who have symptoms of active central nervous system metastases. However, subjects with stable brain parenchymal metastases can be enrolled.\n* Subjects who have active autoimmune disease that has received systemic treatment in the past 2 years (i.e., taking disease control medications, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered to be systemic treatments.\n* Has a history of (non-infectious) pneumonitis \/ interstitial lung disease that required steroids or has current pneumonitis \/ interstitial lung disease. Has had a history of radiation pneumonitis.\n* Subjects who have serious psychiatric illness and are unable to cooperate in completing the clinical study.\n* Has an active infection requiring systemic therapy.\n* Has tuberculosis that is being treated.\n* Subjects who have known history of human immunodeficiency virus (HIV) or Anti- Treponema Pallidum test (anti-TP) positive.\n* Known acute or chronic active hepatitis B (HBsAg positive or HBcAb positive, and HBV DNA \u2265 200 IU\/mL or \u2265 10\\^3 copies\/mL) or acute or chronic active hepatitis C (HCV antibody positive and positive for HCV RNA test).\n* Subjects who have history of T-cell lymphoblastic lymphoma (T-LBL) or T-cell lymphoblastic leukemia (T-ALL).\n* Subjects who have history of any myeloid malignancies including myelodysplastic syndrome (MDS), or subjects who have abnormal test results related to MDS or myeloproliferative neoplasm (MPN).\n* Women during pregnancy or lactation.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06022757001","EMAIL":[{"email":"zhanli@sysucc.org.cn"},{"email":"mayuxiang@sysucc.org.cn"}],"GEO":[23.11667,113.25]},{"TITLE":"Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* All prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) (version 5.0) =\\< grade 1 (except alopecia) at the time of enrollment\n* \\>= 18 years old\n* Non-small cell lung cancer (NSCLC), histologically and\/or cytologically proven\n* Clinical American Joint Committee on Cancer (AJCC) stage II-III NSCLC (T1-4N0-3M0) and patients with oligometastatic disease.\n\n  * For patients with oligometastatic disease (up to 5 total sites of disease) for whom definitive chemoradiation to the primary and regional lymph nodes is recommended by the multidisciplinary team, each individual metastatic tumor would be considered an additional site of disease with the exception of brain metastases. Up to 10 brain metastases would be considered as 1 site.\n  * Patients with oligometastatic disease will be allowed to receive adjuvant systemic therapy at the discretion of the medical oncologist and additional local therapy to metastatic sites at the discretion of the multidisciplinary team\n* Patients must be considered unresectable or medically-inoperable\n\n  * Patients with a local or regional recurrence following surgical resection for whom definitive chemoradiation to disease in the chest is recommended by the multidisciplinary team will be considered eligible\n* Within 60 days of registration: patients must have fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)-computed tomography (CT) scan (or CT chest\/abdomen\/pelvis with IV contrast), and magnetic resonance imaging (MRI) brain with IV contrast (preferred) or CT scan of the brain with contrast. Non-contrast MRI scans of the chest\/abdomen\/pelvis or brain are permitted for workup if patient has allergy to CT contrast or renal insufficiency\n* Within 30 days of registration: patients must have vital signs, history\/physical examination, laboratory studies (CBCP with differential, chemistries including liver function tests, creatinine clearance (CrCl) assessment; pregnancy test if needed within 14 days of registration)\n* Absolute neutrophil count \\>=1.5 x 10\\^9\/L (within 30 days of study registration)\n* Hemoglobin \\>= 9 g\/dL (within 30 days of study registration)\n* Platelets \\>= 100 x10\\^9\/L (within 30 days of study registration)\n* Total bilirubin =\\< 1.5 x upper limit of normal (ULN) (within 30 days of study registration)\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\\< 2.5 x ULN (within 30 days of study registration)\n* Creatinine \\< 1.5 mg\/dL or calculated creatinine clearance\\* \\>= 50 mL\/min or 24-hour urine creatinine clearance \\>= 50 mL\/min (within 30 days of study registration)\n\n  * Calculated by the Cockcroft-Gault formula\n* If a pleural effusion is present and visible on both CT scan AND chest Xray, the investigator should exclude malignant disease by pleurocentesis to confirm cytologically-negative pleural fluid. If fluid is exudative or cytologically positive for tumor cells, patient is excluded\n\n  * Patients with effusions that are minimal (i.e. not visible on chest x-ray) and that are too small to safely tap are eligible\n* Life expectancy of \\> 6 months in the opinion of investigator\n* Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 30 days of registration\n* Patients must be a minimum of 3 weeks from thoracotomy (if performed) and well-healed before starting treatment\n* Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed\n* Women of child-bearing potential (WOCBP) must have a negative pregnancy test within 14 days of registration. Urine human chorionic gonadotropin (HCG) is an acceptable pregnancy assessment\n* Nursing women may participate only if nursing is discontinued, due to the possibility of harm to nursing infants from the treatment regimen\n* Women\/men of reproductive potential must be counselled on contraception\/ abstinence while receiving the study treatment\n* Patient is suitable to receive standard chemotherapy with radiation during study treatment (i.e. carboplatin + paclitaxel or carboplatin + pemetrexed)\n\nExclusion Criteria:\n\n* Patients with history of pneumonectomy\n* History of active connective tissue disease (scleroderma) or idiopathic pulmonary fibrosis\n* History of previous radiation therapy which would result in overlapping radiation fields\n* Uncontrolled neuropathy grade 2 or greater, regardless of cause\n* Subjects who are breast-feeding and plan to continue breast-feeding during therapy, or have a positive pregnancy test will be excluded from the study. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately\n* If patient elects to have two research MRIs during dose-finding phase of trial, medical contraindication to MR imaging (e.g. pacemakers, metallic implants, aneurysm clips, known contrast allergy to gadolinium contrast, pregnancy, nursing mothers, weight greater than 350 pounds) or severe anxiety\/claustrophobia related to MR imaging despite medications to relieve anxiety\/claustrophobia\n* Hepatic insufficiency resulting in jaundice and\/or coagulation defects, or not meeting laboratory values above (albumin, total bilirubin, AST\/ALT)\n* Any serious and\/or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures, in the opinion of the treating physicians. This could include severe, active co-morbidities such as:\n\n  * Unstable angina and\/or congestive heart failure requiring hospitalization within the last 6 months\n  * Transmural myocardial infarction within the last 6 months\n  * Acquired immune deficiency syndrome (AIDS) based upon the current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive\n  * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days of registration\n  * Hepatic insufficiency resulting in jaundice and\/or coagulation defects","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05136846002","EMAIL":[{"email":"Jeremy.Brownstein@osumc.edu"},{}],"GEO":[39.96118,-82.99879]},{"TITLE":"Digital Lifestyle Intervention for Lung Cancer Survivors After Inpatient Rehabilitation","CRITERIA":"Inclusion Criteria:\n\n* Age \u2265 18 years\n* Diagnosis of non-small cell lung cancer (NSCLC)\n* Estimated life expectancy of \u2265 six months (judged by local investigators\/responsible health professionals)\n* Undergoing inpatient rehabilitation\n* Knowledge of German to understand study material and assessments\n* Access to a cell phone or tablet\n* Written informed consent\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Inability to participate in the intervention because of physical, cognitive, or safety reasons (judged by local investigators\/responsible health professionals)","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05819346004","EMAIL":"anja.frei@uzh.ch","GEO":[47.27595,8.91405]},{"TITLE":"Phase 1\/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients","CRITERIA":"Inclusion Criteria:\n\n* Male or female patients \u2265 18 years of age\n* Histologic or cytologic evidence of NSCLC\n* Known KRAS G12C mutation\n* Have not received a KRAS inhibitor to be included in Part A (avutometinib + sotorasib) and Part B (avutometinib + sotorasib + defactinib), Cohort 1\n* Received at least 1 dose of a G12C inhibitor to be included in Part A (avutometinib + sotorasib + defactinib) and Part B, Cohort 2\n* Must have received appropriate treatment with at least one prior systemic regimen, but no more than 2 prior regimens, for Stage 3B-C or 4 NSCLC\n* Measurable disease according to RECIST 1.1\n* An Eastern Cooperative Group (ECOG) performance status \u2264 1\n* Adequate organ function\n* Adequate recovery from toxicities related to prior treatments\n* Agreement to use highly effective method of contraceptive\n\nExclusion Criteria:\n\n* Systemic anti-cancer therapy within 4 weeks of the first dose of study therapy\n* History of prior malignancy, with the exception of curatively treated malignancies\n* Major surgery within 4 weeks, minor surgery within 2 weeks (excluding placement of vascular access)\n* History of treatment with a direct and specific inhibitor of MEK\n* Exposure to strong CYP3A4 inhibitors or inducers within 14 days prior to the first dose and during the course of therapy\n* Symptomatic brain metastases requiring steroids or other local interventions.\n* Known SARS-Cov2 infection \u226428 days prior to first dose of study therapy\n* Known hepatitis B, hepatitis C, or human immunodeficiency virus infection that is active\n* Active skin disorder that has required systemic therapy within the past year\n* History of rhabdomyolysis\n* Concurrent ocular disorders\n* Concurrent heart disease or severe obstructive pulmonary disease\n* Inability to swallow oral medications\n* Female patients that are pregnant or breastfeeding\n* Previously treated with sotorasib and were dose reduced due to toxicity","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05074810032","EMAIL":[{}],"GEO":[51.35,-0.2]},{"TITLE":"Post Marketing Surveillance(PMS) Study of Lorviqua in Korea","CRITERIA":"Inclusion Criteria:\n\nPatients must meet all of the following inclusion criteria to be eligible for inclusion in the study:\n\n1. Use in the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)\n2. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria will not be included in the study:\n\n1. Patients to whom Lorviqua\u00ae is contraindicated as per the local labeling. A. Hypersensitivity to Lorviqua\u00ae or to any of the excipients of this product B. Lorviqua\u00ae is contraindicated in patients taking concomitant use of strong CYP3A4\/5 inducers C. This medicinal product contains lactose as an excipient. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose galactose malabsorption should not take this medicinal product.\n2. Any patients (or a legally acceptable representative) who does not agree that Pfizer and companies working with Pfizer use his\/her information","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05599412001","EMAIL":"ClinicalTrials.gov_Inquiries@pfizer.com","GEO":[37.566,126.9784]},{"TITLE":"Vagus Nerve Preservation and Chronic Cough in Non-small Cell Lung Cancer Surgery","CRITERIA":"Inclusion Criteria:\n\n1. Subjects clearly understand the purpose of the study, are willing and able to comply with the requirements to complete the study, and can sign the informed consent.\n2. Clinically suspicious of non-small cell lung cancer or tissue confirmed preoperatively\n3. Clinical stage T1-3\/N0-1\/M0\n4. Preoperative ECOG performance status 0-1\n5. Preoperative ASA class I-III\n6. Preoperative pulmonary function test FEV1 \u2265 60%, DLCO \u2265 60%\n7. Patients expected to achieve R0 (complete resection) via simple lobectomy and mediastinal lymph node dissection\n\nExclusion Criteria:\n\n1. Patients who smoked within 2 weeks prior to operation\n2. Patients who received antitussives and expectorants 2 weeks prior to operation\n3. Patients who are pregnant or breast feeding\n4. Patients with severe or uncontrolled psychological disorders\n5. Patients with severe pulmonary adhesion\n6. Patients who are ineligible for minimally invasive surgery; thoracotomy conversion\n7. Patients diagnosed with other malignancies within 2 years prior to operation\n8. Patients who received chemotherapy or radiotherapy within 6 months prior to operation\n9. Patients suspicious of clinical N2 or received neoadjuvant therapy prior to operation\n10. Patients with cough-related diseases; COPD, asthma, ILD, GERD\n11. Patients suspicious of lymph node metastasis\/invasion around vagus nerve during the preoperative clinical staging evaluation","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"04923412001","EMAIL":[{"email":"82430@snubh.org"},{}],"GEO":[37.43861,127.13778]},{"TITLE":"Phase I\/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Male or female, age \u2265 18 years at the time of screening.\n2. Must have an Eastern Cooperative Oncology Group (ECOG) performance status \u2264 1.\n3. Estimated Life expectancy \u2265 12 weeks.\n4. Must have either at least one measurable lesion with no prior local treatment or measurable lesions with definite progression (Bone metastases alone were not accepted) after local treatment per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n5. Dose-escalation phase: patients must have histological or cytological confirmed ALK-positive advanced NSCLC. Dose-expansion phase: patients must have histological or cytological confirmed ALK-positive advanced NSCLC and progressed after at least one prior line of ALK TKI therapy. Phase II: patients must have histological or cytological confirmed ALK-positive advanced NSCLC and progressed after only alectinib or \u22652 prior ALK TKIs treatment. The pathological report requires either positivity for ALK gene expression determined by fluorescence in-situ hybridization (FISH) assay, immunohistochemistry (IHC), reverse transcription-polymerase chain reaction (RT-PCR), next-generation sequencing (NGS) or other identified methods from previous reports and provide tissue for ALK retest if possible or providing tissue for ALK test if no previous report is available.\n6. Patients without brain metastasis or with asymptomatic brain metastases (no need for intervention or stable more than 4 weeks after treated).\n7. Adequate organ function within 10 days prior to the study of treatment as defined in the below:\n\n   Hepatic function\n\n   Total serum bilirubin (TBIL) \u2264 1.5 times upper limit of normal (ULN); Aspartate transaminase (AST), alanine transaminase (ALT) and \u03b3- glutamyltransferase (GGT) \u2264 2.5 times ULN if no demonstrable liver metastases, or otherwise \u2264 5 times ULN.\n\n   Bone marrow function\n\n   Absolute neutrophil count (ANC) \u2265 1.5 x 10\u2079\/L; Platelets (PLT) count \u2265 100 x 10\u2079\/L; Hemoglobin (Hb) \u2265 90 g\/L.\n\n   Renal function\n\n   Creatinine clearance \u2265 60 mL\/min.\n\n   Pancreatic function\n\n   Serum total amylase \u22641.5 times ULN; Serum lipase \u2264 1.5 times ULN.\n\n   Blood glucose\n\n   Fasting Blood Glucose (FBG) \u2264 200 mg\/dL (11.1 mmol\/L).\n\n   Serum lipid\n\n   Serum cholesterol \u2264 500 mg\/dL (12.92 mmol\/L).\n\n   Cardiac function\n\n   Left ventricular ejection fraction (LVEF) \u2265 50%.\n8. Any toxicity of previous antineoplastic treatments was restored to \u2264 1 (except hair loss).\n9. Female patients with reproductive potential must have a negative serum pregnancy test, male and female patients of childbearing potential must be willing to completely abstain or agree to use an appropriate method of contraception during the entire study duration and for at least 3 months after the last dose of study medication.\n10. Willingness and ability to give informed consent and follow protocol procedures, and comply with follow-up visit requirements.\n\nExclusion Criteria:\n\n1. Any of the following within 6 months prior to starting trial treatment: Cerebrovascular accident\/ stroke, myocardial infarction, severe\/ unstable angina, congestive heart failure (New York Heart Association Classification Class \u2265II), second- or third- degree atrioventricular (AV) block (unless paced) or any AV block with PR interval \\>220 msec, or any grade of uncontrolled atrial fibrillation.\n2. ECG evaluated QT interval corrected (Fridericia) (QTcF) of \\> 450 msec in males or \\> 470 msec in females or congenital long QT syndrome.\n3. Grade \u2265 3 peripheral neuropathy (CTCAE version 5.0).\n4. Any active autoimmune diseases or history of autoimmune diseases that require long-term steroid or other immunosuppressants treatment.\n5. Previous medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.\n6. Patients being treated with any anticoagulants, prone to bleeding, or have a coagulation disorder.\n7. Active hepatitis (Hepatitis B: HBsAg-positive and HBV-DNA \u2265 2000 IU\/ mL; Hepatitis B: HCV antibody-positive and HCV-RNA \u2265 1000 IU\/ml), HIV antibody-positive; Active syphilis.\n8. Patient underwent major surgery within 4 weeks prior to starting trial treatment.\n9. Patients received radical radiotherapy within 4 weeks, palliative radiotherapy within 2 weeks, or radioactive agents (strontium, samarium, etc.) within 8 weeks prior to starting trial treatment.\n10. Patients received systemic antitumor therapy, including chemotherapy, immunotherapy, biotherapy (cancer vaccine, cytokine or cancer growth control factor), or clearly indicated antitumor traditional Chinese medicine within 4 weeks (targeted therapy within 2 weeks) prior to starting trial treatment.\n11. Patients treated with the following drugs and could not be discontinued at least 7 days prior to starting trial treatment and during the entire study duration: drugs known to be strong inducers or suppressors of CYP3A (for details, see prohibited combination drugs in this trial).\n12. Patients with any active infection requiring systemic therapy within 4 weeks prior to starting trial treatment.\n13. Comorbidities that may seriously endanger the patient's safety or affect the completion of the trial, such as severe diabetes, according to the judgment of investigator.\n14. A clear previous history of neurological or psychiatric disorders, including dementia or diagnosed epilepsy for any reason.\n15. With a history (within 5 years) or presence of other malignancies, excluding cured skin basal cell carcinoma and carcinoma in situ of the cervix.\n16. Other situations that may increase the risks related to the study medication, interfere with the interpretation of the study results, affect compliance of the trial, etc. are determined by the investigator to be not suitable for the trial.\n17. In phase II: previously received third-generation ALK TKIs.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05257512001","EMAIL":[{"email":"syuankai@cicams.ac.cn"}],"GEO":[39.9075,116.39723]},{"TITLE":"A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:Key Inclusion Criteria:\n\n1. Histologically or cytologically confirmed NSCLC that is locally advanced (Stage \u2162B\/\u2162C) or metastatic (Stage IV) NSCLC that is not amenable to radical surgery and\/or radical radiotherapy regardless of concurrent chemotherapy.\n2. No prior systemic anti-cancer therapy for locally advanced or metastatic disease.\n3. Participants whose tumours are PD-L1 TPS \u2265 1%.\n4. At least one measurable lesion per RECIST v1.1.\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 with no worsening within 7 days prior to randomization.\n6. A life expectancy of at least 12 weeks.\n7. Adequate organ and bone marrow function.\n\nExclusion Criteria:Key Exclusion Criteria:\n\n1. Active second malignancy.\n2. Uncontrolled or clinical significant cardiovascular disease.\n3. History of noninfectious pneumonitis\/interstitial lung disease (ILD) that required steroids or has current pneumonitis\/ILD.\n4. Active infection requiring systemic therapy within 2 weeks of randomization.\n5. Active hepatitis B or hepatitis C virus infection.\n6. Human immunodeficiency virus (HIV) positive or history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection.\n7. Known allergy to SKB264 or pembrolizumab or any of its components.\n8. Prior treatment with any of the following (including in the context of adjuvant, neoadjuvant therapy):\n\n   1. Immune checkpoint inhibitors (e.g., anti-PD-1\/L1 antibody, anti-CTLA-4 antibody, etc.), checkpoint agonists (e.g., ICOS, CD40, CD137, GITR, OX40 antibody, etc.), any treatment targeting the immune mechanism of tumors such as immune cell therapy;\n   2. Therapy targeting TROP2.\n   3. Any drug therapy that targets topoisomerase I, including antibody-drug conjugates (ADCs).\n9. Major surgery within 4 weeks prior to randomization or expected major surgery during the study.\n10. Pregnant or lactating women.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06448312001","EMAIL":[{"email":"caicunzhoudr@163.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)","CRITERIA":"Inclusion Criteria:\n\n1. Greater than or equal to 18 years of age and less than or equal to 75 years of age; all genders.\n2. Advanced solid tumors including but not limited to some high frequency somatic mutations,such as melanoma,driver mutation-negative non-small cell lung cancer.\n3. Advanced solid tumors patients who are HLA - A0201 \/A1101\/A2402 subtypes.\n4. Measurable solid tumors with at least one lesion that is resectable or tumor biopsies for DNA extraction.\n5. Patients who failed or were intolerant to standard treatment.\n6. Possess venous access for mononuclear cell collection or intravenous blood collection.\n7. Patients (or their legal representatives) who are able to understand and sign the Informed Consent Form and willing to sign a durable power of attorney.\n8. Clinical performance status of ECOG is 0 or 1.\n9. Patients who are able to cooperate to observe adverse reactions and the effect of the treatment,expected lifetime is greater than six month.\n10. Patients of both genders must be willing to practice birth control from the time of enrollment to three months after treatment on this study,a fertile woman must have a negative pregnancy test.\n11. The laboratory test values and the functions of important organs meet the following requirements:1\uff09Serology: HIV antibody(-), hepatitis B DNA(-), hepatitis C antibody(-) and no active syphilis infection; 2\uff09Hematology: Absolute neutrophil count is greater than or equal to 1.5\u00d710\\^9\/L; WBC is greater than or equal to 3\u00d710\\^9\/L; lymphocyte count is greater than or equal to 0.8\u00d710\\^9\/L; Platelet count is greater than or equal to 80\u00d710\\^9\/L; Hemoglobin is greater than or equal to 90g\/L ; 3\uff09Chemistry: Serum ALT\/AST is less than or equal to 3 times ULN,except in patients with liver metastasis who must have ALT\/AST less than or equal to 5 times ULN; Serum Creatinine is less than or equal to 1.5 times ULN ; Total bilirubin is less than or equal to 1.5 times ULN, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 3 times ULN;4\uff09Blood Clotting Parameters:Prothrombin Time(PT) and International Normalised Ratio (INR) are less than or equal to 1.5 times ULN;Activated Partial Thromboplastin Time (APTT) is less than or equal to 1.5 times ULN;For subjects who frequently take anticoagulant drugs,their blood clotting parameters can meet the value range adptive to this special population;5\uff09Left ventricular ejection fraction\uff08LVEF\uff09is more than or equal to 50%.\n12. More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the lymphodepletion regimen, and toxicities must have recovered to grade 1 or less (except for toxicities such as alopecia or vitiligo).\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. History of severe immediate hypersensitivity reaction to Neo-T and any of the agents used in this study.\n3. Subjects with a history of organ transplantation.\n4. Subjects with unstable brain metastases.\n5. Any active autoimmune disease or subjects with a history of autoimmune diseases that have been assessed by the investigator to be unsuitable for this study.Including but not limited to the following diseases: such as systemic lupus erythematosus, immune related neuropathy, multiple sclerosis, Guillain Barre syndrome, myasthenia gravis, connective tissue diseases, inflammatory bowel diseases(Crohn's disease and ulcerative colitis), excluding vitiligo, eczema, type I diabetes, rheumatoid arthritis and other joint diseases, Sjogren's syndrome and controlled psoriasis by local medication.\n6. Active systemic infections,for example, acute infections requiring systemic antibiotic, antiviral, or antifungal treatment occur within 2 weeks before enrollment.\n7. Severe liver and kidney function damage(gived treatment is still uncontrollable,and biochemical indicators cannot meet the Exclusion Criteria of 11th), uncontrollable diabetes, pulmonary fibrosis, interstitial lung disease, acute lung disease, or poorly controlled hypertension (systolic pressure\\>160mmHg and\/or diastolic pressure\\>90mmHg); active cardiovascular and cerebrovascular diseases, such as acute stroke,myocardial infarction,unstable angina,congestive heart failure rated as Grade II or above by the New York Heart Association, severe cardiac arrhythmias that cannot be controlled with medication,electrocardiograms show significant abnormalities (three consecutive times with an interval of at least 5 minutes) which have been assessed by the investigator that affect subsequent cellular treatment; mental illness and drug abuse, or any situation that the investigator assessments may increase the risk of this study.\n8. Subjects plan to receive glucocorticoid(the dose of prednisone or alternative drug is more than 10mg per day) or other immunosuppressant within 4 weeks before the administration of lymphocyte clearance.Tips: when there is no active autoimmune disease, it is allowed to use prednisone or alternative drug with a dose less than 10 mg per day; Allowing subjects to use topical, ocular, intra articular, intranasal, and inhaled glucocorticoids for treatment.\n9. Subjects plan to receive immunomodulatory drugs (such as interferon, GM-CSF, thymosin, gamma globulin, excluding IL-2) within 4 weeks before the administration of lymphocyte clearance.\n10. The investigator assessed that the subject was unable or unwilling to comply with the requirements of the study protocol.\n11. The genes correlated to functional defects in antigen presentation, antigen recognition, and cell killing have been detected.\n12. With a history of other malignant tumors within the past 5 years; Excluding basal cell carcinoma, thyroid papillary carcinoma, cervical carcinoma in situ, or breast ductal carcinoma in situ.\n13. The subject has any disease or medical condition that may affect the safety or effectiveness evaluation of the study treatment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05798546001","EMAIL":[{"email":"bswhunion@163.com"}],"GEO":[30.58333,114.26667]},{"TITLE":"Study of PULSAR-ICI +\/- IMSA101 in Patients With Oligometastatic NSCLC and RCC","CRITERIA":"Inclusion Criteria:\n\n1. Male or female patients \u2265 18 years of age\n2. Signed informed consent and mental capability to understand the informed consent\n3. Histologically or cytologically documented NSCLC or RCC with radiographically documented presence of \u2264 6 metastatic lesions consistent with the diagnosis of \"oligometastatic\" disease\n4. Patient's disease must be evaluable per RECIST Version 1.1\n5. All metastatic lesions amenable to administration of radiotherapy, at the discretion of the investigator\n6. Must have at least one single pre-defined lesion\/lesion site (longest diameter \u2265 10 mm and \u2264 50 mm) suitable for intra-tumoral injection\n7. Eastern Cooperative Oncology Group (ECOG) performance status of \u2264 1\n8. Electrocardiogram (ECG) without evidence of clinically significant conduction abnormalities or active ischemia as determined by the investigator\n9. Acceptable organ and marrow function as defined below:\n\n   * Absolute neutrophil count (ANC) \\> 1,500 cells\/\u03bcL\n   * Platelets \\> 50,000 cells\/\u03bcL\n   * Total bilirubin \u2264 1.5 times (\u00d7) the upper limit of normal (ULN)\n   * Aspartate aminotransferase (AST)\/alanine aminotransferase (ALT) \u2264 2.5 \u00d7 ULN. If liver metastases are present, AST\/ALT \\< 5 \u00d7 ULN\n   * Serum creatinine \\< 1.5 mg\/dL and a measured creatinine clearance \u2265 50 mL\/min using the Cockcroft-Gault formula\n   * Prothrombin time (PT)\/partial thromboplastin time (PTT) \u2264 1.5 \u00d7 ULN\n10. Women of child-bearing potential (defined as a female who has experienced menarche and who has not undergone successful surgical sterilization \\[hysterectomy, bilateral salpingectomy, or bilateral oophorectomy\\]) or is not postmenopausal (defined as amenorrhea for at least 12 consecutive months with an appropriate clinical profile at the appropriate age, eg, greater than 45 years) must have a negative serum pregnancy test prior to first dose of study treatment\n11. Male and female patients with reproductive potential must agree to use two forms of highly effective contraception throughout the study\n\nExclusion Criteria:\n\n1. Prior disease progression through programmed cell death ligand 1 (PD-L1 or PD-1)-targeted immunotherapy\n2. Prior receipt of stimulator of interferon genes (STING) agonist\n3. Prior receipt of therapeutic radiotherapy to the lesions intended for PULSAR treatment\n4. Anti-cancer therapy, except pembrolizumab and nivolumab, within 4 weeks or \\< 5 half-lives of the first dose of study treatment\n5. Existence of primary tumor that requires therapeutic treatment beyond the provided immune checkpoint inhibitor drug\n6. Failure to recover, to Grade 1 or less, from clinically significant AEs due to prior anti-cancer therapy, as judged by the investigator\n7. Previous life-threatening (Grade 4) immune-related adverse event (irAE)\n8. Existence of actionable mutations that may be eligible for mutation-targeted drug that represents standard-of-care therapy\n9. Presence of brain metastases\n10. Baseline prolongation of QT\/corrected QT (QTc) interval (QTc interval \\> 470)\n11. Uncontrolled intercurrent illness (including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\/social situations) that in the opinion of the investigator would limit compliance with study requirements\n12. Women who are pregnant or breastfeeding\n13. Sponsor reserves the right to exclude any patient from the study on the basis of pre-study medical histories, physical examination findings, clinical laboratory results, prior medications, or other entrance criteria","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05846646009","EMAIL":[{"email":"clinicaltrials@cancer.wisc.edu"},{}],"GEO":[43.07305,-89.40123]},{"TITLE":"Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* 18-75 years old;\n* Eastern Cooperative Oncology Group (ECOG) 0-1;\n* Non-small cell lung cancer, including squamous-cell carcinoma, adenocarcinoma, large-cell carcinoma, adenosquamous carcinoma;\n* Stage IVA and IVB confirmed by radiological examination (AJCC 8th Edition);\n* Driven-genes negative including EGFR (Epidermal Growth Factor Receptor), ALK (Anaplastic Lymphoma Kinase), ROS1 (ROS Proto-Oncogene 1), KRAS G12C (Kirsten Rat Sarcoma Viral Oncogene), BRAF V600E (v-raf murine sarcoma viral oncogene homolog B1), MET exon14 (Mesenchymal Epithelial Transition Factor), RET (Rearranged during Transfection Proto-oncogene), NTRK1\/2\/3 (NeuroTrophin Receptor Kinase);\n* First-line treatment of ICI\u00b1chemotherapy;\n* Partial response (PR) or stable (SD) after first-line treatment;\n* Signature of inform consent.\n\nExclusion Criteria:\n\n* younger than 18 years old or older than 75 years old;\n* ECOG\\>1;\n* Small-cell lung cancer and other neuroendocrine carcinoma;\n* Non stage IV confirmed by radiological examination;\n* Driven-genes positive including EGFR, ALK, ROS1, KRAS G12C, BRAF V600E, MET exon14, RET, NTRK1\/2\/3;\n* First-line treatment of other therapy rather than ICI\u00b1chemotherapy;\n* Complete response (CR) or progression (PD) after first-line treatment;\n* Contraindications for radiotherapy, chemotherapy and ICI;\n* No signature of inform consent.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05348668001","EMAIL":[{"email":"qiandong@ustc.edu.cn"},{"email":"drxyl@ustc.edu.cn"}],"GEO":[31.86389,117.28083]},{"TITLE":"Patient's Whole Process Follow-up Management(HOPE-1)","CRITERIA":"Inclusion Criteria:\n\n1. Fully understand the research and voluntarily sign the informed consent form (ICF)\n2. Male or female subjects who are over 18 years old (inclusive) at the time of signing the informed consent form.\n3. The subject is diagnosed pathologically or cytologically with non-small cell lung cancer(NSCLC).\n4. According to the 8th edition of the American Joint Committee on Cancer \\[AJCC\\], it is classified as stage IIB, stage III, stage IV NSCLC.\n5. Not suitable for radical treatment or refuse surgery.\n6. The life expectancy is not less than 3 months.\n7. Be able to use a smartphone.\n\nExclusion Criteria:\n\n1. Patients with mental illness.\n2. Presence of any other malignant tumor.\n3. Patients who are expected to undergo radical surgery.\n4. Currently participating in clinical trials.\n5. Subjects who judged by the investigator to be unsuitable to participate in the trial.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05339568001","EMAIL":[{"email":"zhangjd165@sina.com"}],"GEO":[36.66833,116.99722]},{"TITLE":"A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents","CRITERIA":"Inclusion Criteria:\n\n1. Informed consent signed by the subject prior to conducting study-specific procedures.\n2. Male or female subjects \u2265 18 and \u2264 100 years of age.\n3. Histological diagnosis as follows:\n\n   1. Part A (dose-escalation Cohorts A1-A3): histological diagnosis of any type of carcinoma, sarcoma, or melanoma with progressive metastatic disease, or progressive locally advanced disease not amenable to local therapy.\n   2. Part B (expansion Cohorts B1-B3): histological diagnosis of the relevant tumor type (NSCLC or melanoma) with advanced\/metastatic disease not amenable to local therapy.\n\n   a. Part C (biology cohort): histological or cytological diagnosis of any type of carcinoma, sarcoma, or melanoma with progressive metastatic disease, or progressive locally advanced disease not amenable to local therapy. At least 10 subjects each must have a diagnosis of SCCHN, dedifferentiated liposarcoma, or leiomyosarcoma with prior treatment described below.\n4. Prior therapies:\n\n   a. Part A (dose-escalation) i. Subjects must have experienced PD on an established standard systemic anti-cancer therapy for a given tumor type or have been intolerant to such therapy, or in the opinion of the Investigator have been considered ineligible for a particular form of standard therapy on medical grounds. Subjects must have no available proven curative or life-prolonging therapies.\n\n   b. Part B (dose-expansion) i. Part B1 subjects (NSCLC) must have received platinum-based therapy, unless contraindicated, and a PD-1 or PD-L1 inhibitor. Subjects eligible for targeted therapies to EGFR, ALK, ROS, RET or NTRK (e.g., crizotinib) must have previously received and exhausted such therapies. Prior therapies may have been administered alone or in combination. Subjects must have received prior PD-(L)1-based therapy as the most recent prior therapy and demonstrated progression while on that therapy.\n\n   ii. Part B2 subjects (NSCLC) must have received platinum-based therapy and a PD-1 or PD-L1 inhibitor unless contraindicated. Subjects eligible targeted therapies to EGFR, ALK, ROS, RET or NTRK (e.g., crizotinib) must have exhausted such therapies. Prior therapies may have been administered alone or in combination. Part B2 subjects may have received a total of 3 lines of prior therapy and are not required to have received a PD-(L)1-based therapy as the most recent therapy.\n\n   iii. For melanoma: subjects must have received a PD-1 inhibitor, alone or in combination with another immunotherapy. Eligible subjects may have received BRAF- and MEK-targeted therapies. Subjects must have received prior PD-1-based therapy as the most recent therapy and demonstrated radiographic progression while on that therapy.\n\n   c. Part C (biology cohort): subjects other than those with liposarcoma, leiomyosarcoma, or SCCHN must have experienced PD on an established standard medical anti-cancer therapy for a given tumor type or have been intolerant to such therapy, or in the opinion of the Investigator have been considered ineligible for a particular form of standard therapy on medical grounds and must have no available demonstrated curative or life-prolonging therapies. Subjects with liposarcoma must have dedifferentiated liposarcoma, have received at least 1 prior systemic therapy, and require additional treatment. For leiomyosarcoma, subjects must have received at least 1 prior therapy for advanced or metastatic disease. For SCCHN, subjects must have received 1 prior line of chemotherapy and a PD-1- or PD-L1-targeted agent alone or in combination with chemotherapy unless contraindicated. No more than 2 chemotherapy regimens in the advanced setting for SCCHN are allowed. All subjects must have demonstrated progression on the most recent line of therapy.\n5. Subjects must have measurable disease per RECIST v1.1. Subjects in Part C must have at least one 1 lesion amenable to biopsy and that is not to be used for response assessment per RECIST v1.1.\n6. If not postmenopausal or surgically sterile, subjects must be willing to practice at least one of the following highly effective methods of birth control for at least a menstrual cycle (or partner's menstrual cycle, for male subjects) before and for 3 months after study medication administration: (1) true abstinence, when this is in line with the preferred and usual lifestyle of the subject, from sexual intercourse with a member of the opposite sex; (2) sexual intercourse with vasectomized male\/sterilized female partner; (3) hormonal female contraceptive (oral, parenteral, intravaginal, implantable, or transdermal) for at least 3 consecutive months prior to investigational product administration (when not clinically contraindicated as in breast, ovarian, and endometrial cancers); (4) use of an intrauterine contraceptive device or intrauterine hormone-releasing system.\n7. Resolution of prior-therapy-related AEs (excluding alopecia and grade \u2264 2 peripheral neuropathy) to \u2264 grade 1 per CTCAE v5.0, and no treatment for these AEs for at least 2 weeks prior to the time of enrollment. Electrolyte and hormonal supplementation may be used to treat these AEs provided the subject is stable on these supplements.\n8. Minimum of 2 weeks since the last dose of other hormone therapy and 3 weeks since the last dose of other systemic cancer therapy or radiotherapy (\\> 4 weeks in case of nitrosoureas or radio-immuno conjugate therapy). Adjuvant hormonal therapy (for example tamoxifen) is allowed provided the original tumor diagnosis was more than 3 years before the first dose of study medication.\n9. Subjects must have adequate organ function.\n10. All subjects must be able to supply an archival tumor biopsy specimen. For Part C (biology cohort), subjects must consent to a newly obtained tumor biopsy (that can be biopsied based on Investigator's assessment) and to providing the acquired tissue for biomarker analysis. An additional on-treatment biopsy is required for subjects in Part C.\n11. Subject is able and willing to comply with the protocol and the restrictions and assessments therein.\n\nExclusion Criteria:\n\n1. Subject previously had a severe hypersensitivity reaction to treatment with another mAb.\n2. Subject has ECOG PS \\> 2.\n3. Life expectancy \\<12 weeks.\n4. Prior organ or stem cell transplant.\n5. Subjects with symptomatic ascites or pleural effusion.\n6. Subject has a known active CNS primary tumor or metastases and\/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are clinically stable for at least 4 weeks prior to study entry, have no radiological evidence of new or enlarging brain metastases, and are off steroids or on a stable dose up to an equivalent of prednisone 10 mg\/day for at least 15 days prior to first dose of study medication. Subjects who have symptoms consistent with CNS metastasis, must have a negative MRI during in the screening period.\n7. Subject has a known history of a hematologic malignancy, malignant primary brain tumor, or another malignant primary solid tumor (other than that under study), unless the subject has undergone potentially curative therapy with no evidence of that disease for at least 3 years.\n8. Recent or ongoing serious infection including the following:\n\n   1. Any uncontrolled grade 3 or higher (per CTCAE v5.0) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of OR2805. Routine antimicrobial prophylaxis is allowed.\n   2. Uncontrolled infection with HIV. Subjects on stable HARRT therapy with undetectable viral load and normal CD4 counts for at least 6 months prior to study entry are eligible. Serological testing for HIV at screening is not required.\n   3. Known to be positive for hepatitis B surface antigen, or any other positive test for hepatitis B indicating acute or chronic infection. Subjects who are or have received anti-HBV therapy and have undetectable HBV DNA for at least 6 months prior to study entry are eligible.\n   4. Known active hepatitis C as determined by positive serology and confirmed by PCR. Subjects on or having received antiretroviral therapy are eligible provided they are virus-free by PCR for at least 6 months prior to study entry.\n   5. Known active or latent tuberculosis (testing at screening is not required).\n9. Autoimmune disease or inflammatory condition requiring systemic therapy with exceptions as noted in exclusion criterion 10.\n10. Use of systemic corticosteroids within 15 days or other immunosuppressive drugs within 30 days prior to start of the study, with the exception of corticosteroids as replacement therapy up to an equivalent of prednisone 10 mg\/day which are allowed. Pretreatment with dexamethasone is allowed for subjects receiving OR2805 in combination with docetaxel. Inhaled, topical, or intraarticular steroids are allowed.\n11. Subject has received an investigational product or been treated with an investigational device within 30 days prior to first administration of study medication.\n12. For Part B:\n\n    1. Known contraindication to receiving cemiplimab.\n    2. Interstitial lung disease.\n    3. Prior pneumonitis requiring systemic corticosteroid therapy.\n    4. Receiving immunosuppressive therapy, with exceptions as noted in exclusion criterion 10.\n    5. A history of severe immune-related adverse reactions from treatment with ipilimumab, defined as any grade 4 toxicity or grade 3 toxicity requiring corticosteroid treatment (\\> 10 mg\/day prednisone or equivalent) for more than 12 weeks.\n13. Concurrent therapy with anti-cancer or anti-neoplastic drugs, with the exception of adjuvant hormonal therapy, which is allowed provided the subject has undergone potentially curative therapy with no evidence of disease for at least 3 years.\n14. History or clinical evidence of any surgical or medical condition that the Investigator judges as likely to interfere with the results of the study or pose an additional risk in participating, e.g., rapidly progressive or uncontrolled disease involving a major organ system-vascular, cardiac, pulmonary, gastrointestinal, gynecologic, hematologic, neurologic, neoplastic, renal, endocrine, autoimmune or an immunodeficiency, or clinically significant active psychiatric or abuse disorders.\n15. Subjects who, at the time of signing informed consent, had a recent history (within the last year) of chronic substance abuse.\n16. Subject is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05094804003","EMAIL":[{"email":"atolcher@nextoncology.com"}],"GEO":[29.42412,-98.49363]},{"TITLE":"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)","CRITERIA":"Inclusion Criteria (All Cohorts):\n\n* Body weight \\>\/= 30 kg at screening\n* Willingness and ability to use the electronic device(s) or application(s) for the electronic patient-reported outcome (PRO)\n* Whole-body positron emission tomography\/computed tomography scan (PET\/CT) (from the base of skull to mid-thighs) for the purposes of staging, performed prior and within 42 days of the first dose of cCRT or sCRT\n* Histologically or cytologically documented locally advanced, unresectable Stage III NSCLC of either squamous or non-squamous histology\n* Prior receipt of at least two prior cycles of platinum-based chemotherapy given concurrently with radiotherapy (cCRT); or at least two prior cycles of platinum-based chemotherapy given prior to radiotherapy (sCRT)\n* The RT component in the cCRT or sCRT must have been at a total dose of radiation of 60 (+\/-10%) Gy (54 Gy to 66 Gy) administered by intensity-modulated radiotherapy (preferred) or three dimension (3D)-conforming technique\n* No disease progression during or following platinum-based cCRT or sCRT\n* Life expectancy \\>\/= 12 weeks\n* Confirmed availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen\n* Documented tumor PD-L1 status (TC score \\< 1% vs. \\>\/= 1% vs. unknown) as determined: centrally with the SP263 IHC assay on the confirmed available FFPE tumor specimen; locally, with the SP263 (preferred) or 22C3 IHC assays\n* Eastern Cooperative Oncology Group Performance Status of 0, 1, or 2\n* Adequate hematologic and end-organ function\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating eggs, as defined by the protocol\n* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating sperm, as defined by the protocol\n\nInclusion criteria specific to Cohort A1:\n\n* Documented ALK fusion positivity by an eligible result from: centralized multiplex molecular testing of tumor tissue at the Sponsor's designated central laboratory under Study BX43361 or available results from a Sponsor pre-approved local, appropriately validated ALK fusion test on tumor tissue performed in a Clinical Laboratory Improvement Amendments certified or equivalent laboratory\n\nInclusion criteria specific to Cohort A2:\n\n* Documented ROS1 fusion positivity by an eligible result from: centralized multiplex molecular testing of tumor tissue at the Sponsor's designated central laboratory under Study BX43361 or available results from a Sponsor pre-approved local, appropriately validated ROS1 fusion test on tumor tissue performed in a Clinical Laboratory Improvement Amendments certified or equivalent laboratory\n* Ability to swallow entrectinib intact, without chewing, crushing, or opening the capsules\n\nExclusion Criteria (All Cohorts):\n\n* Any history of previous NSCLC and\/or any history of prior treatment for NSCLC (patients must be newly diagnosed with unresectable Stage III disease)\n* Any evidence of Stage IV disease, including, but not limited to, the following: pleural effusion, pericardial effusion, brain metastases, history of intracranial hemorrhage or spinal cord hemorrhage, bone metastases, distant metastases\n* If a pleural effusion is present, the following criteria must be met to exclude malignant involvement (T4 disease): when pleural fluid is visible on both the CT scan and chest X-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative; participants with exudative pleural effusions are excluded regardless of cytology; participants with effusions that are minimal (i.e., not visible on chest X-ray) that are too small to safely tap are eligible\n* NSCLC known to have a known or likely oncogenic-driver mutation in the EGFR gene, as identified by site local testing or Sponsor central testing\n* Liver disease, characterized by any of the following: impaired excretory function (e.g., hyperbilirubinemia), synthetic function, or other conditions of decompensated liver disease, such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices or active viral or active autoimmune, alcoholic, or other types of acute hepatitis\n* Positive hepatitis B surface antigen (HBsAg) test at screening\n* Participants known to be positive for hepatitis C virus (HCV) antibody (Ab) are excluded with the following exception: participants who are HCV Ab positive but HCV RNA negative due to prior treatment or natural resolution are eligible\n* HIV infection: participants are excluded if not well-controlled as defined by the protocol\n* Known active tuberculosis\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on the screening chest CT scan\n* Grade \\>\/= 2 pneumonitis from prior cCRT or sCRT\n* Any Grade \\> 2 unresolved toxicity from prior cCRT or sCRT\n* Any gastrointestinal (GI) disorder that may affect absorption of oral medications, such as malabsorption syndrome or status post-major bowel resection\n* Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications\n* Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sj\u00f6gren syndrome, Guillain-Barr\u00e9 syndrome, or multiple sclerosis, with the following exceptions: participants with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study; participants with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study\n* History of malignancy other than NSCLC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate \\> 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal breast carcinoma in situ, or Stage I uterine cancer\n* Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer\n* Major surgical procedure, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study\n* Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin-2) within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment\n* Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during study treatment or within 5 months after the final dose of study treatment\n* Treatment with investigational therapy within 28 days prior to initiation of study treatment\n* Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor-alpha agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with exceptions defined by the protocol\n* Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-cytotoxic T lymphocyte-associated protein 4, anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies\n* Prior allogeneic stem cell or solid organ transplantation\n* Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study\n* Any condition that, in the opinion of the investigator, would interfere with the evaluation of the study drug or interpretation of patient safety or study results\n* Any prior Grade \\>\/= 3 immune-mediated adverse event or any unresolved Grade \\> 1 immune-mediated adverse event while receiving any previous immunotherapy agent other than immune checkpoint blockade agents\n\nExclusion criteria specific to Cohort A1:\n\n* Presence of clinically symptomatic interstitial lung disease or interstitial pneumonitis, including radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention)\n* NSCLC known to have one or more of the following ALK point mutations, as identified by site local testing or Sponsor central testing: I1171X (where X is any other amino acid), V1180L, G1202R\n* Symptomatic bradycardia\n* Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina; participants with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction \\< 50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate\n* Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia\n* Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment\n* Prior treatment with ALK inhibitors\n* History of hypersensitivity to alectinib, durvalumab, or any of their excipients\n* Inability to swallow oral study drug\n* Known hereditary problems of galactose intolerance, a congenital lactase deficiency, or glucose-galactose malabsorption\n* Pregnancy or breastfeeding, or intending to become pregnant during the study treatment or within 90 days after the final dose of alectinib or durvalumab\n\nExclusion criteria specific to Cohort A2:\n\n* Symptomatic bradycardia\n* Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina; participants with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction \\< 50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate\n* Left ventricular ejection fraction less than or equal to 50% observed during the screening for the study\n* History of prolonged QTc interval (e.g., repeated demonstration of a QTc interval \\> 450 ms from ECGs performed at least 24 hours apart)\n* History of additional risk factors for torsade de pointes (e.g., family history of long QT syndrome)\n* Familial or personal history of congenital bone disorders or bone metabolism alterations\n* Incomplete recovery from any surgery prior to the start of study treatment that would interfere with the determination of safety or efficacy of the treatment\n* Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia\n* Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment\n* Prior treatment with ROS1 inhibitors\n* History of hypersensitivity to entrectinib, durvalumab, and their excipients\n* Grade \\>\/= 3 toxicities due to any prior therapy (e.g., RT) (excluding alopecia) that have not shown improvement or are not stable and are considered to interfere with current study drug\n* Known hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption\n* Grade \\>\/= 2 peripheral neuropathy\n* Pregnancy or intention of becoming pregnant during study treatment, within 35 days after the final dose of entrectinib, or within 90 days after the final dose of durvalumab","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05170204156","EMAIL":"global-roche-genentech-trials@gene.com","GEO":[53.48095,-2.23743]},{"TITLE":"First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and\/or Human Epidermal Growth Factor Receptor 2 (HER2)","CRITERIA":"Inclusion Criteria:\n\n* Documented histologically or cytologically confirmed locally advanced NSCLC, not suitable for definitive therapy or recurrent or metastatic NSCLC at screening (small cell or mixed histologies are excluded).\n* Documented disease progression after treatment with at least one prior systemic therapy for advanced disease. Participants who do not have standard of care access due to any reason, are intolerant to, or are not eligible for standard treatments, may also be eligible.\n\nNote: Except for participants eligible for one of the groups (Expansion or Extension) who should have received no prior systemic treatment for locally advanced or metastatic disease.\n\n* Adequate archival tumor tissue (ideally taken after last targeted treatment and not older than 6 months) has to be available, either from primary or metastatic sites. If archival material is not available, a fresh tumor biopsy should be performed if feasible and if the procedure poses no significant risk for the participant.\n* Measurable disease by RECIST v1.1 with at least one lesion not chosen for biopsy during the screening period (if a biopsy is taken during screening) that can be accurately measured at baseline with computed tomography (CT) or magnetic resonance imaging (MRI) and that is suitable for accurate repeated measurements. A biopsied lesion should not be used as a target lesion for RECIST 1.1 tumor assessments (or, for participants in Expansion Group G, for RANO-BM tumor assessments). Previously irradiated lesions must have shown progression to be considered measurable.\n* Documented activating EGFR and\/or HER2 mutation assessed by a Clinical Laboratory Improvement Amendments (CLIA)-certified (United States \\[US\\] sites) or an equally accredited (outside of the US) local laboratory\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n* Minimum life expectancy of 12 weeks.\n* Adequate bone marrow function as assessed by the following laboratory tests to be conducted within 7 days before the first dose of study treatment:\n\n  1. Hemoglobin \u2265 9.0 g\/dL. Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within 2 weeks prior to testing.\n  2. Platelets \u2265 100 \u00d7 10\\^9 cells\/L.\n  3. Absolute neutrophil count \u2265 1.5 \u00d710\\^9 cells\/L. Criteria must be met without the use of hematopoietic growth factors (e.g., G-CSF) within 2 weeks prior to testing.\n* Adequate kidney function as assessed by following laboratory test to be conducted within 7 days before the first dose of study treatment:\n\n  a. Estimated glomerular filtration rate (eGFR) \\> 50 mL\/min per 1.73 m\\^2 according to the Modification of Diet in renal Disease Study Group (MDRD) formula.\n* Adequate liver function as assessed by following laboratory tests to be conducted within 7 days before the first dose of study treatment:\n\n  1. Total bilirubin \u2264 1.5 \u00d7 ULN (or \u2264 3 X ULN for participants with documented Gilbert-Meulengracht Syndrome, or for participants with hyperbilirubinemia considered due to liver metastasis).\n  2. Aspartate transaminase and alanine transaminase \u2264 2.5 \u00d7 ULN (or \u2264 5 \u00d7 ULN if due to liver involvement by tumor).\n\nExclusion Criteria:\n\n* Treatment with an EGFR tyrosine kinase inhibitor (TKI) \u2264 8 days or 5x the terminal phase, elimination half-lives, whichever is shorter, prior to the first dose of study drug.\n* Treatment with a systemic anti-cancer treatment (excluding EGFR TKIs as described above) \u2264 14 days prior to the first dose of study drug.\n* Radiation therapy, stereotactic radiosurgery (SRS) and palliative radiation \u2264 14 days prior to the first dose of study drug.\n* Treatment with immunotherapy \u2264 28 days prior to the first dose of study drug.\n* Have any unresolved toxicity of Grade \u2265 2 from previous anti-cancer treatment, except for alopecia and skin pigmentation. Participants with chronic, but stable Grade 2 toxicities may be allowed to enroll after agreement between the Investigator and Sponsor.\n* Any history of primary brain or leptomeningeal disease (symptomatic or asymptomatic), presence of symptomatic central nervous system (CNS) metastases, or CNS metastases that require local treatment (such as radiotherapy or surgery).\n* History of spinal cord compression or brain metastases with the following exceptions:\n\n  1. Participants with treated brain metastases that are asymptomatic at screening and who are off or receiving low-dose corticosteroids (\u226410 mg prednisone or equivalent) for at least 7 days prior to first dose of BAY 2927088 are eligible to enroll in Dose Escalation and Backfill.\n  2. Participants with treated brain metastases that are asymptomatic at screening are eligible in Dose Expansion\/Extension (with the exception of Group G) if all of the following criteria are met:\n\n     * there is no evidence of progression (new or enlarging brain metastases) for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period.\n     * Participants must be off or receiving low-dose corticosteroids (\u226410 mg prednisone or equivalent) for 7 days prior to first dose of BAY2927088.\n  3. Participants with history of spinal cord compression \\>3 months from definitive therapy and stable by imaging (MRI or CT) during the screening period and clinically asymptomatic.\n  4. Expansion Group G only: Participants with active (new or progressing) clinically stable brain metastases who do not require immediate CNS-directed treatment as per Investigator's judgement and who are off or receiving low-dose corticosteroids (\u226410 mg prednisone or equivalent such as \u2264 1.5 mg\/day dexamethasone) in the 7 days prior to first dose of BAY2927088 are eligible.\n* History of congestive heart failure (CHF) Class \\>II according to the New York Heart Association (NYHA) Functional Classification or serious cardiac arrhythmias requiring treatment (e.g. ventricular arrhythmias, atrial fibrillation) or any clinically important abnormalities in rhythm, conduction or morphology or resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval \\>250 msec)\n* Participants with:\n\n  1. Known human immunodeficiency virus (HIV), except as noted below: Participants with history of HIV infection are eligible at the Investigator's discretion provided that: \u2022 CD4+ T-cell (CD4+) counts are \u2265 350 cells\/uL \u2022 The participant has been on established antiretroviral therapy (ART) for at least 4 weeks prior to the start of study drug and has an HIV viral load less than 400 copies\/mL prior to start of the study treatment \u2022 The ART being used does not contain strong inducers or inhibitors of CYP3A4, and is not anticipated to cause overlapping toxicities with study drug \u2022 The participant has not had an opportunistic infection within the past 12 months\n  2. Active Hepatitis B infection (positive for Hepatitis B surface antigen \\[HbsAg\\]) and Hepatitis B virus \\[HBV\\] DNA).\n  3. Active Hepatitis C infection (positive anti-HCV Antibody and quantitative HCV RNA results greater than the lower limits of detection of the assay).\n\n     NOTE: Participants with history of chronic HBV or HCV infection are eligible at the Investigator's discretion provided that the disease is stable and sufficiently controlled under treatment.\n* Use of strong CYP3A4 inhibitors and inducers from 14 days prior to first administration of study drug. Strong CYP3A4 inhibitors and inducers are prohibited during the study and until Safety FU (follow up) visit.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05099172095","EMAIL":"clinical-trials-contact@bayer.com","GEO":[24.95233,121.20193]},{"TITLE":"Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Patients aged between 18 and 70 years\n* Histological diagnosis of primary NSCLC\n* Patients received curative surgery for primary NSCLC\n* Tumor stage IB-IIA after curative-intent surgical resection\n* ECOG score: 0-1\n* Participant is willing to use an acceptable form of contraception during the study.\n* Participant is willing and able to give informed consent for participation in the study.\n\nExclusion Criteria:\n\n* The patient has received neoadjuvant therapy, including radiotherapy and chemotherapy, targeted therapy and immunotherapy\n* Patients are unwilling or unable to receive the curative-intent resection\n* Patients have or have had history of malignant tumor\n* Patients who suffer from severe uncontrolled disease that require systemic treatment or considered unsuitable for participating this trial due to other reasons by the investigator\n* Patients with severe gastrointestinal dysfunction, cardiac dysfunction, interstitial lung disease, etc.\n* Laboratory test results showed inadequate bone marrow or organ function\n* Blood transfusion during or within 2 weeks before the surgery\n* History of alcohol abuse or drug overdose\n* Pregnant or breastfeeding women\n* Patients who are currently or have participated in any other anti-tumor clinical trials\n* Inadequate baseline data, such as preoperative and postoperative blood samples (Lack of 2 consecutive blood test or a total of 3 blood samples), surgical tumor tissues, and ctDNA test.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":70,"SS_ID":"05167604001","EMAIL":[{},{},{}],"GEO":[34.25833,108.92861]},{"TITLE":"Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy","CRITERIA":"Inclusion Criteria:\n\n* Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent\n* Life expectancy \u226512 weeks\n* Males and females age \u2265 18 years\n* Allowable type and amount of prior therapy:\n\nFirst line anti-Programmed death receptor and ligand (PD1\/PD-L1), either single agent or in combination with chemotherapy\n\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1\n* Measurable disease per RECIST version 1.1\n* Diagnoses of advanced\/metastatic NSCLC and have failed or are intolerant to 1st line anti-PD1\/PD-L1, either single agent or in combination with chemotherapy, and have either exhausted or decline or not be candidates for all available standard of care therapies.\n* Adequate organ function\n* Women of child-bearing potential and men with partners of child-bearing potential must agree to practice sexual abstinence, or to use an acceptable form of contraception for the duration of study participation, and for 90 days following completion of therapy\n* Men of child-bearing potential must agree not to donate sperm while on this study and for 90 days after their last study treatment\n\nExclusion Criteria:\n\n* Is not concurrent enrolled in another clinical study, unless it is an observational (non-interventional) clinical study or if the participant is in the follow-up period of an interventional study\n* Is not currently on or is not anticipated to use other investigational agents within 14 days prior to and while participating in this study\n* Does not have mixed small cell and non-small cell lung cancer histology\n* Does not have any unresolved toxicity CTCAE \\>Grade 2 from the prior 1st immunotherapy. Patients with irreversible toxicity that is not reasonably expected to be exacerbated by study drug may be included\n* Patients who have targetable mutations that qualify for targeted therapy (e.g. mutations of epidermal growth factor receptor (EGFR), serine\/ threonine- protein kinase (BRAF), anaplastic lymphoma kinase (ALK), tyrosine- protein kinase (ROS1), neurotrophic receptor tyrosine kinase (NTRAK)) will be excluded from this study\n* Is not on concomitant therapy intended for the treatment of cancer (including, but not limited to, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, and herbal therapy) for 14 days prior to starting study treatment, depending on the agent and during study treatment, until disease progression is documented and the patient has discontinued study treatment, with the exception of palliative radiotherapy and local therapy per PI discretion\n* Does not chronically use a strong cytochrome P4503A4 (CYP3A4\/5) inhibitor or inducer, or sensitive CYP3A substrates with a narrow therapeutic window\n* Has not had recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access) that would prevent administration of study drug\n* Does not have uncontrolled systemic disease\n* Does not have uncontrolled brain metastasis\n* Does not have history of allergy to taxanes\n* Does not have history of leptomeningeal carcinomatosis\n* Does not have recent history of myocardial infarction (MI) or symptomatic coronary artery disease within 6 months of screening\n* Is not receiving active therapy for HIV, hepatitis B or hepatitis C\n* Does not have history of malabsorption syndrome or other condition that would interfere with enteral absorption or results in the inability or unwillingness to swallow pills\n* Does not have history of Type I or Type II diabetes mellitus requiring insulin (Patients who are on a stable dose of oral diabetes medication greater than or equal to 2 weeks prior to initiation of study treatment\n* Does not have Grade greater than or equal to 2 uncontrolled or untreated hypercholesterolemia or hypertriglyceridemia\n* Does not have history of or active inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis) or active bowel inflammation (e.g., diverticulitis)\n* Does not have active pneumonitis\n* Does not have history of lung disease: interstitial lung disease, idiopathic pulmonary fibrosis, cystic fibrosis, Aspergillosis, active tuberculosis, or history of opportunistic infections\n* Does not have uncontrolled pleural effusion\/pericardial effusion\/or ascites as determined by the investigator\n* Does not have active ventricular arrhythmia requiring medication\n* Does not have psychiatric illness\/social situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent\n* Is not pregnant, breast feeding or planning to become pregnant while receiving study treatment or for less than 90 days after the last dose of study treatment\n* For males with partners of childbearing potential, is not planning to father a child or donate sperm while receiving study treatment or for less than 90 days after the last dose of study treatment\n* Does not have any condition that, in the opinion of the investigator, would interfere with evaluation or interpretation of patient safety or study results","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04467801002","EMAIL":[{"email":"ctnursenav@kumc.edu"}],"GEO":[39.11417,-94.62746]},{"TITLE":"Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis","CRITERIA":"Inclusion Criteria:\n\n* Aged 18-75 years\n* Histologically or cytologically confirmed non-small cell lung cancer\n* 1-10 metastases on contrast-enhanced MRI\n* Radiotherapy for extracranial lesions is permitted\n* Tyrosine kinase inhibitors (TKI) are permitted in patients with progression of\n* intracranial metastases during previous TKI therapy\n* Patients have measurable or evaluable lesions based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Normal function of organs and bone marrow within 14 days: Total bilirubin 1.5 times or less the upper limits of normal (ULN); AST and ALT 1.5 times or less the ULN; absolute neutrophil count\u2265 500 cells\/mm3; creatinine clearance rate(CCR) \u226545 mL\/min; Platelet count\u226550,000 cells\/mm3; international normalized ratio(INR) \u22641.5#Prothrombin Time (PT)\u2264 1.5 \u00d7 ULN\n* Informed-consent\n\nExclusion Criteria:\n\n* Small cell carcinoma of lung\n* Intracranial metastases needed surgical decompression\n* Patients with contraindications for MRI\n* Previous radiotherapy or excision for intracranial metastases\n* Hypertensive crisis, hypertensive encephalopathy, symptomatic heart failure (New York class II or above), active cerebrovascular disease or cardiovascular disease occurred within 6 months\n* Uncontrolled hypertension (systolic \\> 150mmHg and\/or diastolic \\> 100mmHg)\n* Major surgery within 28 days or minor surgery or needle biopsy within 48 hours\n* Urine protein 3-4+, or 24h urine protein quantitative \\>1g\n* Severe uncontrolled disease\n* Uncontrollable seizure or psychotic patients without self-control ability\n* Women in pregnancy, lactation period\n* Other not suitable conditions determined by the investigators","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06582940001","EMAIL":[{"email":"liuhuisysucc@126.com"}],"GEO":[23.11667,113.25]},{"TITLE":"Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Age over 18;\n2. Histologically or cytologically documented metastatic NSCLC, HER2 activation amplification or mutation stage IIIB-IV NSCLC patient;\n3. At least 1 measurable lesion according to RECIST 1.1;\n4. ECOG score 0 or 1;\n5. Life expectancy of at least 3 months;\n6. Within one week before admission, blood routine examination was basically normal:\n\n   1. hemoglobin \u226590g\/L or \u22655.6mmol\/L;\n   2. neutrophil count (ANC) \u2265 1.5 \u00d7 10 \\^ 9 \/ L;\n   3. platelet count (PLT) \u2265 100 \u00d7 10 \\^ 9 \/ L;\n   4. Liver and kidney function tests were basically normal within one week before enrollment;\n   5. total bilirubin (TBIL) \u2264 1.5 \u00d7 upper limit of normal value (ULN);\n   6. alanine aminotransferase (ALT \/ AST) \u2264 2.5 \u00d7 ULN (liver metastasis patients \u2264 5xuln);\n   7. serum creatinine \u2264 1.5 \u00d7 ULN;\n   8. Partially activated thrombin time(APTT)\u2264 1.5 \u00d7 ULN;\n7. For fertile women had negative blood pregnancy tests 7 days before screening;\n8. willing to participate and sign the informed consent in person.\n\nExclusion Criteria:\n\n1. Patients who have received anti-HER2 monoclonal antibody therapy;\n2. Have received chemotherapy, biotherapy, targeted therapy, immunotherapy and other anti-tumor therapies within 4 weeks prior to the first use of the study drug including: oral small molecule targeted drugs within 2 weeks prior to the first use of the study drug or within 5 half-lives of known drugs (depending on the time);Radiotherapy was performed within 2 weeks prior to the first administration of the study drug;\n3. Have received other clinical study drugs within 4 weeks prior to the first study drug administration;\n4. Patients who underwent major surgery within 4 weeks prior to the first dosing of the study drug(except needle biopsy or significant trauma);\n5. Those who have been known to have allergic history to the drug components of this regimen;\n6. Study drugs that had used a CYP3A4 inhibitor, inducer, or a narrow therapeutic window with a CYP3A4-sensitive substrate ,P-ep strong inducer and inhibitor within 14 days before first administration;\n7. The adverse reactions of previous antitumor therapy have not recovered to CTCAE 5.0 grade 1(Hair loss and other toxicities were excluded for which the researchers judged no safety risk);\n8. Patients with central nervous system metastasis and clinical symptoms;\n9. History of immunodeficiency, including positive HIV test, or suffering from other acquired, congenital immunodeficiency diseases, or history of organ transplantation;\n10. Active hepatitis B (HBV virus titer 1000 copies \/ml or 200IU\/ml);Hepatitis C virus, syphilis infection;\n11. Severe heart disease or discomfort, including, but not limited to, the following: complete left bundle branch block or degree atrioventricular block, history of myocardial infarction, angioplasty, coronary artery bridging, patients with prolonged QT\/QTc interval at baseline (QTcF men \\>450 ms, women \\>480ms), significant ventricular arrhythmias (such as ventricular tachycardia), history of heart failure or systolic dysfunction (LVEF \\< 50%), cardiac failure, New York College of Cardiology (NYHA) grade II or higher, uncontrolled hypertension (systolic blood pressure \\> 180 mmHg ), history or current history of cardiomyopathy that the investigator judged to have an impact on the study;\n12. Inability to swallow medications orally, or that the investigator determines severely affect gastrointestinal absorption;\n13. Other malignant tumors in the past 5 years, excluding cured cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma or in situ cervical cancer and\/or breast cancer;\n14. Any history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonia requiring steroid treatment, or evidence of clinically active interstitial lung disease;\n15. Patients with a history of other serious systemic diseases who were judged by the investigator to be unsuitable for clinical trials;\n16. Alcohol or drug dependence;\n17. Have a clear history of neurological or mental disorders, including epilepsy or dementia;\n18. Pregnant and\/or breastfeeding;\n19. Any other reason the investigator considers the patient is not suitable to participate in the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05016544001","EMAIL":[{"email":"zhangli6@mail.sysu.edu.cn"}],"GEO":[23.11667,113.25]},{"TITLE":"K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation","CRITERIA":"Main inclusion criteria:\n\n1. Histological or cytological confirmed advanced NSCLC\n2. KRASG12C mutation\n3. Previous at least one line of treatment with immune- or\/and chemotherapy or contraindications for immune- and\/or chemotherapy.\n4. Adequate organ function to tolerate sotorasib (see section 6.1 and 6.2 for details)\n5. 2-5 lesions technically amenable to SBRT with 15 Gy x 3, 10 Gy x 5, or 7-8 Gy x 5.\n6. Adequate organ function to tolerate SBRT:\n\n   o Fulfilment of dose constraints to adequate organs at risk\n7. ECOG performance status (PS) 0-1\n8. FEV1 \u22651 litre (only applicable for lung targets)\n9. Age \u2265 18 years\n10. Measurable lesions according to RECIST\n\nMain exclusion criteria:\n\n1. Leptomeningeal carcinosis (on MRI or in cerebrospinal fluid) or metastases in the central nervous system\n2. Previous RT for any cancer within the last 3 years possibly interfering with the planned RT within this study\n3. Life expectancy of less than 6 months\n4. Inability to understand given information or undergo study procedures according to protocol\n5. Has evidence or a past medical history of interstitial lung disease or active, non-infectious pneumonitis or known pulmonary fibrosis\n6. Woman who is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 7 days after the last dose of sotorasib\n7. Women of childbearing potential (WOCBP) unwilling to use a highly effective method of contraception during treatment and for an additional 7 days after the last dose of sotorasib. WOCBP using hormonal contraceptives should also use a barrier method\n8. WOCBP with a positive pregnancy test assessed at screening or day 1 by a serum pregnancy test and\/or urine pregnancy test\n9. Centrally located pulmonary target (i.e., within 1 cm of the main bronchi or intermedius bronchus) and targets located within 1 cm of the gut, for SBRT\n10. Use of known cytochrome P450 (CYP) 3A4 or P-gp sensitive substrates (with a narrow therapeutic window), within 14 days or 5 half-lives of the drug or its major active metabolite, whichever is longer, prior to study day 1 that was not reviewed and approved by the principal investigator\n11. Use of strong inducers of CYP3A4 (including herbal supplements such as St. John\u00b4s wort) within 14 days or 5 half-lives, whichever is longer, prior to study day 1 that was not reviewed and approved by the principal investigator\n12. Use of proton pump inhibitors (PPIs) within 3 days or H2-receptor antagonists within 1 day prior to study intervention\n13. Use of warfarin. Use of Direct-Acting Oral Anticoagulants (DOAC) within 14 days or 5 half-lives, whichever is longer, prior to study day 1. Other anticoagulation may be allowed with principal investigator approval.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06127940001","EMAIL":[{},{}],"GEO":[59.33258,18.0649]},{"TITLE":"ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation","CRITERIA":"Inclusion Criteria:\n\n* Age \\> 18 years old AND\n* Were treated with curative intent AND\n* Are planning to undergo regular follow-up and monitoring for cancer recurrence per standard of care at the enrolling site AND\n* Provided written informed consent to participate in the study AND\n* Are willing to have de-identified clinical data shared with investigators at regular intervals as outlined in the study protocol and informed consent AND\n* Are willing to provide blood samples at enrollment and at subsequent clinical visits coinciding with standard of care follow-up, for up to 5 years as outlined in the study protocol and informed consent AND\n* Have at least one blood sample collected 4-12 weeks after completion of primary treatment of the Index Cancer\n* Have a histologically confirmed Index Cancer that qualifies for inclusion, defined as:\n\nPrimary Study Cohorts\n\n* Cohort 1: Muscle invasive carcinoma of the bladder, ureter, or renal pelvis (stage II-III),\n* Cohort 2: Non-small cell lung cancer (stage II-III),\n* Cohort 3: Invasive breast carcinoma with all of the following:\n\nClinical stage T1-4\/N0-3\/M0 at presentation AND Completed preoperative systemic chemotherapy-containing regimen AND Underwent definitive surgical resection of the primary tumor AND Has pathological evidence of residual invasive carcinoma in the breast and\/or axillary lymph nodes AND Hormone receptor and HER2 status are known\n\nExploratory Cohorts\n\n* Cohort 4: Stage IIb-III cutaneous melanoma or limited (resectable) stage IV melanoma treated with curative intent,\n* Cohort 5: Esophageal or gastroesophageal junction carcinoma (stage II-III),\n* Cohort 6: Gastric adenocarcinoma (stage II-III),\n* Cohort 7: Surgically resected pancreatic adenocarcinoma,\n* Cohort 8: Invasive squamous cell carcinoma of the head and neck (includes stage I-III oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, nasal cavity, paranasal sinus, and salivary gland cancers),\n* Cohort 9: High-risk epithelial ovarian or Fallopian tube carcinoma (defined as stage IC-III or stage I that has high grade (grade 3-4) or clear cell histology),\n* Cohort 10: High-risk endometrial carcinoma (defined as having any of the following: serous or clear cell adenocarcinoma histology (any stage), grade 3 or 4 deeply invasive (T1b or greater) endometrioid carcinoma, stage III disease (any histology)),\n* Cohort 11: High-risk renal cell carcinoma (defined as high grade (grade 3-4) stage II, stage III or limited (resectable) stage IV treated with curative intent)\n\nExclusion Criteria:\n\n* History of allogeneic organ or tissue transplant\n* Index cancer has neuroendocrine histology\n* History of another primary cancer, with the exception of the following (if adequately treated and the patient is without evidence of disease at the time of enrollment): in situ cancers, non-melanoma skin carcinoma, localized low-risk prostate cancer (Gleason score \\< 6) with PSA in the normal range, and stage I papillary thyroid carcinoma.\n* Known distant metastasis at time of enrollment (with the exception of participants with limited\/resectable stage IV cutaneous melanoma or RCC)\n* Is participating in a clinical trial or another observational study that is evaluating the performance of another genomic test in the post-treatment surveillance setting at predicting\/detecting recurrence","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05059444001","EMAIL":[{}],"GEO":[37.48522,-122.23635]},{"TITLE":"Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy","CRITERIA":"Inclusion Criteria:\n\n* Age \u2265 18 years of age on day of signing informed consent\n* Histopathology confirmed non-small cell lung cancer\n* Asymptomatic brain metastases\n* EGFR\/ALK ROS1 driver gene mutation negative\n* RECIST 1.1 based available assessment of lesions\n* ECOG 0-1\n* Brain metastases 1-4\n* Single lesion \u22644cm\n\nExclusion Criteria:\n\n* Patients with contraindication of chemotherapy Pregnant or breast feeding women","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05584267001","EMAIL":[{"email":"zhangyongchang@csu.edu.cn"},{"email":"yangnong0217@163.com"}],"GEO":[28.19874,112.97087]},{"TITLE":"Combination Study of Guadecitabine\/ASTX727 and Pembrolizumab","CRITERIA":"Inclusion Criteria:\n\n1. Part A and B1\/2:\n\n   Histologically or cytologically confirmed advanced solid tumours, refractory to conventional treatment, or for which no conventional therapy exists or is declined by the patient.\n\n   Part B1:\n\n   Histologically or cytologically confirmed advanced solid tumours, refractory to conventional treatment, or for which no conventional therapy exists or is declined by the patient AND:\n   * Patients with any tumour type that previously responded to a PD-1 or PD-L1 inhibitor and subsequently progressed (defined as secondary resistance to PD-1\/PD-L1 inhibitors ie CR or PR by RECIST, or SD by RECIST for 6 months' duration) or\/\n   * Patients with microsatellite-instability-high (MSI-High) tumours, provided they have been defined by validated assays or patients with deficient mismatch repair (dMMR) defined by immunohistochemistry, who have previously received and have progressed on a PD-1 or PD-L1 inhibitor (primary resistance to PD-1\/PD-L1 inhibitors) or\/\n   * Patients with other solid tumour types who could benefit, based on emerging anti-tumour activity data, from combination therapy with a demethylating agent and PD-1 or PD-L1 inhibitors, in consultation with any other relevant preclinical or clinical data, at the Chief Investigator's discretion.\n\n   Part B2:\n\n   Patients with histologically or cytologically confirmed NSCLC previously treated with PD-1 or PD-L1 inhibitor for advanced or metastatic disease.\n2. Life expectancy of at least 12 weeks.\n3. Eastern Co-operative Oncology Group (ECOG) performance status of 0-1 with no significant deterioration over the previous 2 weeks (Appendix 1).\n4. Evaluable or measurable disease as assessed by RECIST 1.1.\n5. Haematological and biochemical indices within the ranges shown below. These measurements must be performed within one week (Day -7 to Day 1) prior to administration of any investigational medicinal product.\n\n   * Haemoglobin (Hb) \u2265 9.0 g\/dL\n   * Absolute neutrophil count \u2265 1.5 x 109\/L\n   * Platelet count \u2265 100 x 109\/L\n   * International normalised ratio (INR) \u2264 1.5x upper limit of normal (ULN)\n\nOr:\n\nProthrombin time \u2264 1.5x upper limit of normal (ULN)\n\n* Serum bilirubin \u22641.5x ULN\n\nOr:\n\nDirect bilirubin (for patients with total bilirubin \\>1.5x ULN) \u2264 1.5x ULN\n\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u2264 2.5x ULN (for patients with liver metastases \u2264 5x ULN is permissible)\n* Calculated creatinine clearance (per institutional standard) \u2265 50 mL\/min 6.18 years or over. 7. Written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up.\n\n  8. Agree to the use of archival paraffin embedded tissue (if available) for PD-L1 (programmed death-ligand 1) analysis 9. Agree to provide a fresh tumour biopsy at baseline and on Cycle 2 Day 8 of a tumour lesion not previously irradiated (tumours progressing in a prior site of radiation are allowed for PD-L1 characterization, other exceptions may be considered after consultation with the Chief Investigator).\n\n  10. Female subjects of childbearing potential should have a negative urine or serum pregnancy test within 14 days prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n\n  11. Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 6 months after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \\>1 year. Decitabine, a metabolite of Guadecitabine\/ASTX727, can affect fertility and so oocyte cryopreservation should be discussed with female patients.\n\n  12. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study therapy. Decitabine, a metabolite of Guadecitabine\/ASTX727, can affect fertility and so cryopreservation of sperm should be discussed with male patients.\n\nExclusion Criteria:\n\n1. Radiotherapy (except brief course for palliative reasons), endocrine therapy, immunotherapy or chemotherapy during the previous four weeks (six weeks for nitrosoureas, Mitomycin-C and 4 weeks for investigational medicinal products) before treatment, except for hormonal therapy with luteinizing hormone-releasing hormone (LHRH) analogues for medical castration in patients with CRPC, which are permitted.\n2. Patient has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ bladder or cervical cancer that has undergone potentially curative therapy.\n3. Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring steroids for at least 4 weeks prior to start of study treatment.\n4. Ongoing toxic manifestations of previous treatments. Exceptions to this are:\n\n   * Grade 1 toxicities, which in the opinion of the investigator should not exclude the patient\n   * Alopecia of any grade\n5. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 14 days prior to the first dose of trial treatment. The use of physiologic doses of corticosteroids may be approved after consultation with the chief Investigator.\n6. Has an active autoimmune disease that has required systemic treatment in past 3 months (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Patients with Sjogren's syndrome will not be excluded from the study. In addition patients that experienced a Grade 2 or higher immune-related AE's on treatment with immunotherapy will be excluded from the study.\n7. Has evidence of interstitial lung disease.\n8. Has a history of (non-infectious) pneumonitis that required steroid treatment or has active pneumonitis. Pneumonitis includes acute interstitial pneumonitis, pneumonitis and idiopathic pneumonia syndrome.\n9. Active infection, requiring systemic therapy.\n10. Has received a live vaccine within 30 days of planned start of study therapy. Note: The killed virus vaccines used for seasonal influenza vaccines for injection are allowed; however intranasal influenza vaccines (e.g. FluMist\u00ae) are live attenuated vaccines and are not allowed.\n11. Major surgery (excluding minor procedures, e.g. placement of vascular access) from which the patient has not yet recovered.\n12. At high medical risk because of severe or uncontrolled non-malignant systemic disease including active uncontrolled infection, active bleeding diathesis.\n13. Known to be serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV). Screening for chronic conditions is not required.\n14. Any of the following cardiac criteria:\n\n    * Mean resting corrected QT interval (QTc) \\> 470 msec obtained from 3 consecutive electrocardiograms (ECGs) within 5 minutes of each other.\n    * Any clinically significant abnormalities in rhythm, conduction or morphology of resting ECG, e.g. complete left bundle branch block, third degree heart block.\n    * Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval\n    * Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure New York Heart Association \\[NYHA Grade 2 (refer to Appendix 4)\\]\n    * Uncontrolled hypertension - Systolic BP \\>160mmHg and\/or diastolic BP \\>100mmHg\n    * Left ventricular ejection fraction (LVEF) below institutional lower limit of normal.\n15. History of hypersensitivity to active or inactive excipients of guadecitabine or pembrolizumab or drugs with a similar chemical structure or class to either agent.\n16. Is a participant or plans to participate in another interventional clinical trial, whilst taking part in this Phase I study of guadecitabine and pembrolizumab. Participation in an observational trial would be acceptable.\n17. Any other condition which in the Investigator's opinion would not make the patient a good candidate for the clinical trial.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"02998567002","EMAIL":[{"email":"James.Wilton@uclh.nhs.uk"},{}],"GEO":[51.50853,-0.12574]},{"TITLE":"Proton Therapy to Reduce Acute Normal Tissue Toxicity in Locally Advanced Non-small-cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* NSCLC (confirmed by cytology or histology) staged UICC IIIA or IIIB or UICC II if the patient declines surgery\n* no distant metastases (M1)\n* patient' age between 18 and 70 years\n* Patient medically suited for primary radiochemotherapy with curative intent\n* signed declaration of informed consent\n* adequate compliance for treatment and clinical follow up\n* adequate contraception during and after therapy if indicated\n\nExclusion Criteria:\n\n* Participation in other interventional trial\n* T1 or T2 N0 tumours that are candidates for stereotactic radiotherapy\n* relevant neurological or psychiatric disorders that hinder treatment, follow-up or understanding of the procedures\n* pregnant or breastfeeding women\n* prior thoracic radiotherapy\n* history of other malignancies during the last 5 years (exceptions can be made for tumours with excellent outcome)\n* weight loss greater than 15% before therapy\n* serological alterations (liver, kidney) prohibiting application of simultaneous chemotherapy\n* respiratory motion of the tumour \\> 10 mm (evaluated by 4D CT), also when methods for motion reduction (abdominal compression) are used","SEX":"ALL","AGE_MIN":18,"AGE_MAX":70,"SS_ID":"02731001001","EMAIL":[{"email":"str.studien@uniklinikum-dresden.de"}],"GEO":[51.05089,13.73832]},{"TITLE":"NSCLC Isotoxic Hypofractionated Radiotherapy","CRITERIA":"Inclusion Criteria:\n\n1. Pathological or cytological diagnosis of non-small cell lung cancer patients, the clinical stage using the eighth edition of American Joint Committee on Cancer\uff08AJCC\uff09, including stage III without resectable or who when SBRT\/SABR are not suitable;\n2. Age \u2265 18 years;\n3. The expected survival period is \u2265 3 months;\n4. KPS score \u2265 60;\n5. Normal blood count,liver and kidney function \u2264 2.5 times the upper limit of normal;\n\nExclusion Criteria:\n\n1. Serious medical problems require hospitalization, included (but not limited to ): history of pulmonary fibrosis, previous myocardial infarction within 6 months, heart failure grade II and above, uncontrolled heart failure, uncontrolled COPD, uncontrolled diabetes Wait;\n2. Esophageal invasion (cT4);\n3. Others are not suitable for receiving radiotherapy.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03606291001","EMAIL":[{"email":"xxy0636@163.com"}],"GEO":[38.04139,114.47861]},{"TITLE":"Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies","CRITERIA":"Inclusion Criteria:\n\n* Patient or legal guardian, if permitted by local regulatory authorities, provides informed consent to participate in the study must be performed before any procedure's protocol related\n* age of \u226525 years old\n* Performance Score \u226570 in accordance with the Karnofsky Performance Score (KPS),\n* life expectancy period of at least 3 months on the screening day,\n* Have measurable disease according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\n* subject (or his\/her partner) of childbearing potential willingness to use acceptable forms of contraception\n* adequate blood, liver, renal and urine parameters\n* phosphate levels within normal range\n* HIV, HCV (hepatitis C virus) and HBV negative (hepatitis B virus),\n* adequate cardiac function\n\nInclusion Criteria Specific for parts:\n\nPart 1\n\n* Patients with histologically confirmed advanced gastric cancer, bladder cancer, squamous lung cancer or non-small cell lung cancer with squamous immunophenotype, cholangiocarcinoma, sarcoma or endometrial cancer, be refractory to prior therapies and without effective further treatment options.\n\nPart 2 and 3\n\n* Patients with histologically confirmed advanced gastric cancer, bladder cancer, squamous lung cancer or non-small cell lung cancer with squamous immunophenotype, be refractory to prior therapies and without effective further treatment options.\n* Subject's archival formalin-fixed paraffin-embedded (FFPE) tumour sample available for molecular alteration diagnostics, and\/or a possibility to collect a new biopsy.\n* Present molecular alteration within FGFR 1, 2 or 3\n\nExclusion Criteria:\n\n* Any other current malignancy or malignancy diagnosed within the past five (5) years.\n* Active brain metastases or leptomeningeal metastases.\n* concurrent anticancer treatment within 28 days before the start of trial treatment; major surgery within 28 days before the start of trial treatment); use of blood transfusion within 7 days before the start of trial treatment,\n* prior therapy with an agent directed to another FGFR inhibitor,\n* pregnancy and\/or breastfeeding,\n* phosphate levels above the upper limit of normal,\n* ectopic calcification\/mineralization,\n* endocrine alteration related to calcium\/phosphate homeostasis e.g. parathyroid disorders, history of parathyroidectomy,\n* concomitant therapies increasing calcium\/phosphate serum levels,\n* inability to take oral medicines,\n* corneal disorder and\/or keratopathy,\n* persisting toxicity related to prior therapy Grade \\> 1 CTCAE v5.0, except polyneuropathy and alopecia,\n* clinically significant (i.e., active) cardiovascular disease. History of abdominal fistula, bowel obstruction (Grade IV), gastrointestinal perforation, intra-abdominal abscess within 6 months of enrollment. Other significant diseases, which, in the opinion of the investigator, might impair the subject's tolerance of trial treatment.\n* Receipt of any organ transplantation including allogeneic stem-cell transplantation.\n\nExclusion Criteria Specific for parts:\n\nPart 2 and 3\n\n* No FFPE tumour sample available to conduct FGFR alteration eligibility tests and no biopsy option.","SEX":"ALL","AGE_MIN":25,"AGE_MAX":200,"SS_ID":"04149691006","EMAIL":"clinicaltrials@cros-cro.com","GEO":[52.22977,21.01178]},{"TITLE":"Synapse 3D With Intravascular Indocyanine Green","CRITERIA":"Inclusion Criteria:\n\n* Tumour size \\<3 cm\n* Clinical Stage 1 Non-Small Cell Lung Cancer (NSCLC)\n* CT-imaging confirming that the tumour is confined to one broncho-pulmonary segment, rendering the patient a candidate for segmental resection.\n\nExclusion Criteria:\n\n* Hypersensitivity or allergy to ICG, sodium iodide, or iodine\n* Women who are currently pregnant or breastfeeding; or women of childbearing potential who are not currently taking adequate birth control.\n* Patients with clinical evidence of N1 or N2 disease on preoperative imaging\n* Pulmonary Function tests demonstrating Forced Expiratory Volume in 1s (FEV1) or diffusion capacity of the lung for carbon monoxide (DLCO) less than or equal to 30% of predicted.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03953144001","EMAIL":[{"email":"patelys@mcmaster.ca"},{}],"GEO":[43.25011,-79.84963]},{"TITLE":"A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib","CRITERIA":"Key Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of stage IV ALK positive NSCLC.\n* Patients must be in progression extracranially on Lorlatinib; Lorlatinib may be in first- or further-line, without limitations regarding previously received therapies.\n* Age at the time of signing the informed consent at least 18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n* Patients must have measurable disease according to RECIST 1.1 by computed tomography (CT) and magnetic resonance imaging (MRI).\n* Radiologically confirmed multiple extracranial progression on Lorlatinib without progression in the central nervous system (CNS) defined as absence of CNS metastasis or CNS metastasis stable on Lorlatinib and\/or stereotactic brain irradiation (SBRT).\n* Adequate organ function (kidney, bone marrow and liver).\n* Estimated life expectancy of at least 3 months irrespective of the diagnosis of ALK+ NSCLC.\n* For women of childbearing potential and males with partners of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of \\< 1% per year during the treatment period and for at least 6 months after the last dose of study drugs.\n\nKey Exclusion Criteria:\n\n* Known hypersensitivity reaction to one of the compounds or substances used in this protocol.\n* Diagnosis of any secondary malignancy within the last 3 years except for: adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, definitively treated nonmetastatic prostate cancer or patients with another primary malignancy who are definitively relapse-free with at least 3 years elapsed since the diagnosis of the other primary malignancy.\n* Patients deemed unsuitable by the investigator for treatment of chemo-Lorlatinib combination.\n* Presence of toxicities contraindicating the continuation of therapy with Lorlatinib.\n* Concomitant use of potent CYP3A4\/5 inducers.\n\nOther inclusion\/exclusion criteria may apply.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06378892001","EMAIL":[{"email":"abearz@cro.it"}],"GEO":[46.07056,12.59472]},{"TITLE":"Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Is \u226518 years of age at the time of signature of the main study ICF.\n* Has ECOG performance status of 0 or 1.\n* Has measurable disease based on RECIST v1.1.\n* All participants must have documented STK11 mutation in a solid tumor, which is identified through a validated analytical method\n* Has confirmed histologic or cytologic diagnosis of a locally advanced or metastatic solid tumor.\n* Adequate organ function\/reserve per local labs\n* Adequate liver function per local labs\n* Adequate renal function per local labs\n* Negative serum pregnancy test result at screening\n* Written informed consent must be obtained according to local guidelines\n\nExclusion Criteria:\n\n* Known allergies, hypersensitivity, or intolerance to TNG260, PD-1 antibody or its excipients\n* Uncontrolled intercurrent illness that will limit compliance with the study requirements\n* Active infection requiring systemic therapy\n* Currently participating in or has planned participation in a study of another investigational agent or device\n* Impairment of GI function or disease that may significantly alter the absorption of oral TNG260\n* Active prior or concurrent malignancy.\n* Central nervous system metastases associated with progressive neurological symptoms\n* Current active liver disease from any cause\n* Clinically relevant cardiovascular disease\n* A female patient who is pregnant or lactating","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05887492009","EMAIL":[{}],"GEO":[38.84622,-77.30637]},{"TITLE":"Repositioning Immunotherapy in VetArans With Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Participants must be more than 18 years of age.\n* Patient must have a performance status of 0-1 (ECOG Performance Scale).\n* Patient must be a candidate for concurrent chemoradiation.\n* Unresectable Stage III NSCLC as assessed by investigator or multidisciplinary tumor board assessment\n* PD-L1 tumor expression greater than or equal to 1%\n* Presence of measurable disease according to RECIST v1.1\n* Adequate organ function\n* Available tissue (archival FFPE preferred) with adequate tumor content ( 20% tumor cellularity).\n\nExclusion Criteria:\n\n* Active autoimmune disease that has requires immunosuppressive therapy in the previous year.\n* Uncontrolled primary or acquired immunodeficiency (including HIV)\n* Baseline corticosteroid usage (\\>10 mg prednisone or equivalent daily) aside from supportive medication use.\n* Tumor with known EGFR, ALK, ROS1, MET or RET mutations\/fusions.\n* Presence of significant comorbidities precluding participation in a clinical study as determined by investigator.\n* Prior thoracic radiotherapy or prior systemic treatment for stage IIIB\/IV NSCLC\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with informed consent through 180 days after the last dose of trial treatment.\n* Has a known history of active TB (Bacillus Tuberculosis)\n* Has known active Hepatitis B or Hepatitis C.\n* Has received a live vaccine within 30 days of enrollment.\n* Known diagnosis of Interstitial Lung Disease\n* Inability to provide informed consent.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06275360003","EMAIL":[{"email":"brittany.pannecouk@va.gov"},{"email":"Laura.Randolph@va.gov"},{},{}],"GEO":[42.27756,-83.74088]},{"TITLE":"The Effects of an Nutritional Intervention on PD-1 ICI in NSCLC","CRITERIA":"Inclusion criteria:\n\n* Capable of oral intake and digestion of the nutritional test product\n* Subjects with cytologically confirmed Stage IV or recurrent NSCLC, who have not received prior systemic therapy treatment for their advanced NSCLC. Completion of treatment with cytotoxic chemotherapy, biological therapy, and\/or radiation as part of neoadjuvant\/adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic disease.\n* Subjects must have programmed death-ligand 1 (PD -L1) immunohistochemical (IHC) testing.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2\n* Measurable disease by CT per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) criteria\n* Adequate haematological, renal and liver function\n\nExclusion criteria:\n\n* Subject with an active auto-immune disease requiring systemic treatment\n* Lung disease requiring systemic steroids in doses of \\>10 mg prednisolone (or equivalent dose of other steroid)\n* Previous allogeneic or organ transplant Serious concomitant systemic disorders (for example active infection, unstable cardiovascular disease) which in the opinion of the investigator would compromise the patient's ability to complete the study, or would interfere with the evaluation of the efficacy and safety of the study treatment\n* Known positive test for hepatitis B virus or hepatitis C virus or human immunodeficiency virus (HIV) indicating acute or chronic infection\n* Allergy to cow's milk protein, soy or fish, requiring a fibre-free diet or suffering galactosemia or lactose intolerance\n* Moderate to severe hypercalcemia, i.e. total calcium level corrected for albumin \u226514.0 mg\/dL (3.5 mmol\/L)\n* Patient has had other malignancies within the past 3 years, except for stable non-melanoma skin cancer, fully treated and stable early stage prostate cancer or carcinoma in situ of the cervix or breast without need of treatment\n* Simultaneous participation in other clinical trial\n* Pregnant or lactating women","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05902260001","EMAIL":[{"email":"d.dumoulin@erasmusmc.nl"}],"GEO":[51.9225,4.47917]},{"TITLE":"Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy","CRITERIA":"Inclusion Criteria:\n\n* 1. Male or female, aged \u2264 80 years old\n* 2. ECOG performance status of 0-1\n* 3. Histologically or cytologically confirmed, unresectable Stage III (IIIA-N2, IIIB and IIIC) NSCLC according to 8th version of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology.\n* 4. Patients who have documentation of KRAS p.G12C prior to enrollment. This determination can be done either by solid or liquid biopsy.\n* 5. No prior treatment for unresectable Stage III (IIIA-N2, IIIB and IIIC) NSCLC.\n* 6. Having a life expectancy \u2265 12 weeks\n* 7. Patients must be ineligible for concurrent chemo-radiotherapy because of:\n\n  1. Tumor size \u2265 5 cm and lymph node N2 involvement\n  2. The target lesion has to be bulky disease and\/or more than 35% of the total volume of the two lungs should receive more than 20 Gy (V20) or inadequate pulmonary function\n  3. Interstitial Lung diseases\n  4. Prior treatment with thoracic radiotherapy for any reason\n  5. Or under decision of a tumor committee as inappropriate due to local characteristics to perform treatment upfront\n* 8. PET-CT at baseline is mandatory to confirm the absence of distant disease and to confirm unresectable disease\n* 9. PET-CT positive mediastinic adenopathies must be histologically confirmed. Mediastinic involvement could be considered without histological test when no margin can be distinguished in the lymph node mass.\n* 10. Brain CT or MRI is mandatory\n* 11. Patients with at least 1 measurable lesion, as defined by RECIST v1.1.\n* 12. Adequate hematologic and organ function.\n* 13. All patients are notified of the investigational nature of this study and signed a written informed consent in accordance with institutional and national guidelines, including the Declaration of Helsinki prior to any trial-related intervention.\n* 14. Willingness and ability to comply with scheduled visits and study procedures\n* 15. For female patients of childbearing potential, a negative pregnancy test must have been documented prior to enrollment (within 14 days prior to enrollment).\n* 16. For female patients of childbearing potential, agreement (by patient and\/or partner) to usea highly effective form(s) of contraception that results in a low failure rate (\\< 1% per year)when used consistently and correctly, and to continue its use for 7 days after the last dose of AMG510 (Sotorasib). No hormonal methods and preferably barrier method always containing a spermicide, intrauterine device (IUD): intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner (on the understanding that this is the only one partner during the whole study duration), and sexual abstinence.\n* 17. For male patients with female partners of childbearing potential, agreement (by patient and\/or partner) to use a highly effective form(s) of contraception that results in a low failure rate \\[\\< 1% per year\\] when used consistently and correctly, and to continue its use for 7 days after the last dose of AMG510 (Sotorasib).\n* 18. Women who are not postmenopausal (\u2265 12 months of non-therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 14 days prior to enrollment.\n* 19. QTc interval must be \u2264 470 msec in females and \u2264 450 msec in males, based on the average obtained from three ECG.\n\nExclusion Criteria:\n\n* 1. Patients with a known sensitizing mutation in the epidermal growth factor receptor (EGFR) gene, ALK translocations or ROS1 mutations\n* 2. Weight loss \\>10% within the previous 3 months\n* 3. Patients with uncontrolled neuropathy (sensory) grade 2 or greater regardless of cause according to CTCAE v5.0\n* 4. Major surgery within 28 days of study day 1\n* 5. Significant gastrointestinal disorder that results in significant malabsorption, requirement for intravenous alimentation, or inability to take oral medication\n* 6. Significant cardiovascular disease, such as New York Heart Association cardiac disease (ClassII or greater), myocardial infarction within 6 months prior to study day 1, unstable arrhythmias or unstable angina\n* 7. Ongoing cardiac dysrhythmias of CTCAE grade \u22652, uncontrolled atrial fibrillation of any grade or QTcF interval \\> 470ms\n* 8. Severe infections within 4 weeks prior to randomization including, but not limited to hospitalization for complications of infection, bacteremia or severe pneumonia\n* 9. Therapeutic oral or intravenous antibiotics within 2 weeks prior to randomization\n* 10. Patients with any concomitant and uncontrolled medical disorder\n* 11. Patients with vena cava syndrome\n* 12. Malignant pleural or pericardial effusion: both will be considered as suggestive of metastaticdisease. Also, are excluded those with negative cytology but being exudates. Patients with non-visible by thoracic X-ray pleural effusion or too small to be safely punctured could be included.\n* 13. Prior treatment with anti-neoplasic drugs\n* 14. Malignancies other than NSCLC within 3 years prior to enrollment\n* 15. Women who are pregnant, lactating, or intending to become pregnant during the study.\n* 16. Positive test for HIV. All patients will be tested for HIV prior to inclusion into the study; patients who test positive for HIV will be excluded from the clinical study.\n* 17. Patients with active hepatitis B or hepatitis C.\n* 18. Active tuberculosis.\n* 19. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patient at high risk from treatment complications.\n* 20. Patients with illnesses or conditions that interfere with their capacity to understand follow and\/or comply with study procedures.\n* 21. Known or suspected hypersensitivity to drugs with similar chemical structures to the study drug\n* 22. Evidence of any other disorder or significant laboratory finding that makes the patient undesirable to participate in the study\n* 23. Use of strong inducers of CYP3A4 within 14 days of half-lives (whichever is longer) prior to study day 1\n* 24. Use of proton pump inhibitors within 14 days to study day","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05398094020","EMAIL":[{},{}],"GEO":[39.46975,-0.37739]},{"TITLE":"Observational Retro-prospective Study on PD1\/PDL1 Inhibitors Treatment Duration in Patients With NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Age \u2265 18 years\n2. Histologically \/ cytologically confirmed diagnosis of NSCLC, with or without brain metastases\n3. Illness measurable according to Response Evaluation Criteria in Solid Tumours (iRECIST) criteria\n4. At least 24 months of treatment with Pembrolizumab, Nivolumab or Atezolizumab\n5. Complete response (CR)\/ partial response (RP)\/ stable disease at the end of 24-month treatment. The maintenance of the response may also have been obtained after loco-regional treatment, e.g. surgery or radiotherapy, in the case of oligoprogression for a maximum of 3 locoregional treatments (e.g. radiotherapy, surgery) throughout the period of treatment and suspension. Even progression at the brain level, treated with radiation therapy or surgery, can be considered, provided that it is followed by a disease control for at least 3 months.\n6. At least 3 months of follow-up or death within three months after stopping the 24-month treatment.\n7. Informed consent freely granted and acquired before the start of the study, for alive and contactable patients.\n\nExclusion Criteria:\n\n1. Initial chemo-immunotherapy treatment or association with other immunotherapy or other drugs in the context of clinical trials.\n2. Permanent discontinuation of treatment with anti PD-1 \/ PD-L1 for adverse events.\n3. More than 3 loco-regional treatments for maintaining the radiological response\n4. Suspension of immunotherapy for a period longer than 40 days during the 24-month treatment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05418660010","EMAIL":[{}],"GEO":[46.0693,13.23715]},{"TITLE":"Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* \u226518\uff0cAdvanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology\n* ROS1 Arranged Positive\n* ROS1 Arranged Detection Method is NGS\n* First Diagnosis and Treatment\n* Treatment Plan is Kazolinib 250mg po bid\n\nExclusion Criteria:\n\n* Patients received antitumor treatment before\n* Patients with contraindication of chemotherapy\n* Pregnant or breast feeding women","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03646994001","EMAIL":[{"email":"zhangyongchang@csu.edu.cn"},{"email":"yangnong0217@163.com"}],"GEO":[28.19874,112.97087]},{"TITLE":"Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Patients must be \u2265 18 years of age\n* Histologically or cytologically confirmed diagnosis of metastatic solid tumors\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* All patients should have at least 1 measurable disease per RECIST v1.1. An irradiated lesion can be considered measurable only if progression has been demonstrated on the irradiated lesion.\n* All contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n* Adequate hematologic, hepatic and renal function\n* Capable of giving signed informed consent\n\nExclusion Criteria:\n\n* Any clinically significant cardiac disease\n* Unresolved toxicities from previous anticancer therapy\n* Prior solid organ or hematologic transplant\n* Known untreated, active, or uncontrolled brain metastases\n* Known positivity with human immunodeficiency virus (HIV), known active hepatitis B or C, or uncontrolled chronic or ongoing infectious requiring intravenous treatment.\n* Receipt of a live-virus vaccination within 28 days of planned treatment start\n* Patient not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions.\n* Participation in a concurrent clinical study in the treatment period.\n* Known hypersensitivity to MDX2001 or any of its ingredients\n\nThe above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06239194004","EMAIL":[{}],"GEO":[29.42412,-98.49363]},{"TITLE":"Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders","CRITERIA":"Inclusion Criteria:\n\n1. Participant must be 18 years of age, at the time of signing the informed consent\n2. Histologically confirmed malignant melanoma, NSCLC, CSCC, HNSCC, renal clear cell carcinoma or MSI+ solid cancer\n3. Metastatic disease or local recurrence not curable by standard therapy\n4. PD-L1 positivity is required for subjects with HNSCC (\\>20% combined positive score) and NSCLC (\\>20% PD-L1 expression)\n5. Measurable disease according to iRECIST\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n7. Progressive disease, as considered by the treating physician, on therapy with PD1\/PD-L1 blockers and\/or CTLA4-blockers and\/or LAG-3 blockers, or combinations regimes comprising any of these agents. Further treatment with ICI is considered to be within standard practice.\n8. Patients without any response to ICI at any time point during their disease history are eligible, without a need for re-introduction of ICI before enrollment, even if subsequent lines of anti-cancer therapy have been given. For patients with prior response to ICI, the criteria depend on the cancer form:\n\n   1. Malignant melanoma, NSCLC and MSI-H\/dMMR solid cancers: Prior response to ICI is allowed only if PD under ICI has been documented \\<9 months before enrolment and without subsequent lines of anti-cancer therapy. For patients with prior response to ICI followed by subsequent lines of anti-cancer therapy, and patients that have not received ICI the last 9 months, ICI has to be re-introduced, and these patients have to again show progressive disease while on ICI therapy.\n   2. CSCC, HNSCC and renal clear cell carcinoma: Prior response to ICI is allowed, without a need for re-introduction, even if subsequent lines of anti-cancer therapy have been given, provided that disease progression has been documented under ICI therapy the last 12 months.\n9. Mandatory pre-FMT biopsy and lesion accessible for further biopsies\n10. Life expectancy \\>3 months\n11. Adequate organ function as defined below:\n\n    1. Hemoglobin \\> 9 g\/dL\n    2. Absolute neutrophil count (ANC) \u2265 1.0 x 109\/L\n    3. Platelet count \u226580 x 109\/L\n    4. INR\u22641.2\n    5. Serum bilirubin \u22641.5 x institutional upper limit of normal (ULN).\n    6. AST and ALT \u22642.5 x ULN unless liver metastases are present, in which case it must be \u22645x ULN\n    7. Albumin \\>25 g\/L\n    8. Serum creatinine \u22641.5 X ULN OR measured creatinine clearance (CL) \\>40 mL\/min or Calculated creatinine CL\\>40 mL\/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance.\n12. Capable of giving signed informed consent\n\nExclusion Criteria:\n\n1. Other cancer within 3 years prior to study entry, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer)\n2. Spinal cord compression not definitively treated with surgery and\/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for \\> 2 weeks prior to first FMT\n3. Uncontrolled pleural effusion, pericardial effusion, or ascites. Patients with indwelling catheters are allowed\n4. Uncontrolled tumor-related pain. Patients requiring narcotic pain medication must be on a stable regimen at study entry. Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to enrolment. Asymptomatic metastatic lesions whose further growth would likely cause functional deficits or intractable pain (e.g., epidural metastasis that is not presently associated with spinal cord compression) should be considered for loco-regional therapy if appropriate prior to enrolment.\n5. Significant cardiovascular disease, such as New York Heart Association (NYHA) cardiac disease (Class II or greater), myocardial infarction within 3 months prior to study entry, unstable arrhythmias, or unstable angina. Patients with a known left ventricular ejection fraction (LVEF) \\< 40% will be excluded. Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or LVEF \\< 50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate\n6. Undergone allogeneic stem cell or solid organ transplantation\n7. A positive test for HIV\n8. Active hepatitis B (defined as having a positive hepatitis B surface antigen \\[HBsAg\\] test at screening) or hepatitis C. Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as having a negative HbsAg test and a positive antibody to hepatitis B core antigen \\[anti-HBc\\] antibody test) are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.\n9. Active tuberculosis\n10. Ongoing immune-related adverse effects from immunotherapy treatments that are of Grade \u22652, excluding endocrine adverse effects. An ongoing grade 2 cutaneous reaction is allowed.\n11. Severe infection within 14 days prior to first FMT, requiring hospitalization.\n12. Any condition that significantly increases the risk of perforation during endoscopy for FMT.\n13. A history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator.\n14. Known psychiatric or substance abuse disorders that would interfere with cooperation and the requirements of the trial\n15. A requirement of systemic antibiotics at the time of study entry.\n16. Received oral or IV antibiotics within 5 days prior to first FMT.\n17. Currently receiving other study therapy that may interfere with the interpretation of data in this study.\n18. Received treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \\[TNF\\] agents) within 10 days prior to first FMT, or anticipated requirement for systemic immunosuppressive medications during the trial. A daily dose equivalent to \u226410mg prednisolone is allowed.\n\n    1. Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled in the study.\n    2. Patients with a history of allergic reaction to IV contrast requiring steroid pre-treatment should have baseline and subsequent tumor assessments performed using MRI.\n    3. The use of inhaled corticosteroids for chronic obstructive pulmonary disease, mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension, and low-dose supplemental corticosteroids for adrenocortical insufficiency are allowed.\n19. Pregnant or breastfeeding\n20. Any reason why, in the opinion of the investigator, the patient should not participate","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05286294001","EMAIL":[{},{"email":"andull@ous-hf.no"},{},{}],"GEO":[59.91273,10.74609]},{"TITLE":"Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration","CRITERIA":"Inclusion Criteria:\n\n* At least 18 years of age\n* Body weight at least 30 kg\n* Eastern cooperative oncology group performance status score of 0-2 at enrolment\n* Patient with pleural carcinosis that qualify for a surgical intervention for pleurodesis or placement of an indwelling permanent catheter.\n* Life expectancy of at least 3 months\n* Pathology-confirmed pleural carcinosis with malignant pleural effusion (either histological confirmation is already available based on a previous tru-cut pleural biopsy or previous pleural fluid cytology is positive for malignant cells or high suspicion of pleural carcinosis based on computed tomography imaging which must be confirmed by fresh frozen section analyses of tissue harvested during pithac operative procedure)\n* Non-small cell lung cancer, breast cancer, lymphoma, ovarian cancer, oesophageal cancer, gastric cancer, and malignant tumour of the serous membranes (mesothelioma) confirmed by pathology either as part of a diagnostic workup of suspected pleural carcinosis OR available from other previous examinations patients undergoing a planned videothoracoscopy to perform pleurodesis or a placement of a tunnelled catheter\n* Adequate liver, kidney, and bone marrow functions as assessed by laboratory tests (serum total bilirubin \\<1.5 mg\/dl, aspartate transaminase and alanine transaminase less than 2.5 times the upper limit of the normal range, creatinine clearance \u226560 ml\/min, absolute neutrophil count \u22651,500\/\u03bcl, haemoglobin \u226590 g\/L, platelets \u2265100,000\/\u03bcl)\n* I) Patients with past\/resolved HBV infection (defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen \\[anti-HBc\\] antibody test) are eligible, if HBV DNA test is negative. Ii) HBV DNA must be obtained in patients with positive hepatitis B core antibody prior start of study treatment.\n* Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA\n* Adequate cardiac functions as assessed by echocardiography\n* Adequate birth control measures\n* Signed informed consent\n\nExclusion Criteria:\n\n* Patients with active or chronic hepatitis B (defined as having a positive hepatitis B surface antigen \\[HBsAg\\] test at pre-screening)\n* Patients with active hepatitis C\n* Any known formal contra-indication for video-assisted thoracoscopy (VATS) according to pulmonary and cardiac preliminary investigations.\n* Systemic cytotoxic anticancer treatment within 10 days before and after enrolment except for inhibitors of vascular endothelial growth factor for which this period should be decided according to the used drug (for bevacizumab the period involves 4 weeks before and after enrolment, for lenvatinib 1 week before and 2 weeks after, and for sorafenib 1 week before and after), no limitations applied for immune checkpoint inhibitors\n* Major surgery within 28 days prior to enrolment\n* Any unresolved toxicity from previous anticancer therapy of grade \u22652 according to the CTCAE except for alopecia, vitiligo, and laboratory values considered as adequate in the inclusion criteria and any irreversible toxicity that is expected to have impact on the study results or be a contraindication for the planned surgical intervention or be worsened by the investigational procedure\n* Long lasting exposure to corticosteroids\n* Known allergy to platinum compounds\n* Non-small cell lung cancer with egfr or alk mutations unless refractory to tyrosine kinase inhibitor (thus off treatment)\n* Uncontrolled intercurrent illness\n* Clinically relevant hearing loss or tinnitus\n* Clinically relevant neuropathy\n* Life-threatening conditions (uncontrolled systemic infection etc.)\n* Previous administration (by any route) of a total cumulative dose of more than 500 mg\/m2 of cisplatin\n* Secondary resistance to platinum compounds defined as tumour progression during platinum treatment or within 6 months after its cessation\n* pregnancy\n* judgement of the investigator that the patient is unlikely to comply with the study requirements\n* current enrolment in another prospective clinical trial\n* Incapacity of judgement\n* Patients in emergency situation\n* Myelossupression\n* Yellow fever vaccine\n* Concurrent prophylactic use of phenytoin","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06281860001","EMAIL":[{},{}],"GEO":[46.516,6.63282]},{"TITLE":"MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Ability to understand and provide informed consent.\n2. Willingness and ability to comply with scheduled study visits and procedures.\n3. Adult men or women age \u2265 18 years.\n4. ECOG performance status of 0 or 1.\n5. Part 1 monotherapy: Advanced\/metastatic NSCLC, cSCC, Merkel cell, melanoma, TNBC, pancreatic cancer, or head and neck cancer.\n6. Part 2 MEM-288 plus nivolumab combination: Advanced\/metastatic NSCLC which has progressed following front-line anti-PD-1\/PD-L1 with or without concurrent chemotherapy. No more than one prior line of therapy for advanced\/metastatic disease.\n7. Per each tumor type shown below, the specific initial standard of care therapies after which the subjects with specific histologies must have progressed have been included. Subjects will have been treated with at least one or more than one line of therapy prior to enrollment in the study.\n\n   1. Non-small cell lung cancer (NSCLC)\n\n      Part 1 monotherapy\n      * Must have progressed on standard therapy, including platinum-based chemotherapy and checkpoint inhibitor therapy (combined or sequential).\n      * Patients with tumors that have known actionable molecular alteration such in EGFR, ALK, ROS-1, BRAF, RET, MET, and KRAS must have progressed on standard directed molecular therapy, and platinum-based chemotherapy.\n\n      Part 2 MEM-288 plus nivolumab combination\n      * Must have first progression more than (\\>) 84 days following initiation (cycle 1 day 1) of their most recent anti-PD-1 or PD-L1 checkpoint inhibitor therapy with or without concurrent chemotherapy\n   2. Cutaneous squamous-cell carcinoma (cSCC)\n\n      * Must have progressed on standard therapy, including platinum-based chemotherapy and\/or checkpoint inhibitor therapy.\n   3. Merkel cell Carcinoma\n\n      * Must have progressed on standard checkpoint inhibitor therapy.\n   4. Melanoma\n\n      * Subjects must have received a BRAF inhibitor as monotherapy or in combination with other targeted agents for BRAF V600E mutant melanoma.\n      * Subjects must have received an anti-PD-1\/ PD-L1inhibitor as monotherapy or combination with anti-CTLA-4 inhibitor or other therapies.\n   5. Pancreatic cancer\n\n      * Progression after systemic chemotherapy which included either gemcitabine or Fluorouracil (5-FU)-based regimen (including capecitabine).\n   6. Triple negative breast cancer (TNBC)\n\n      * Prior treatment (for advanced, metastatic or (neo)adjuvant) must have included a taxane and\/or anthracycline-based therapy.\n   7. Head and Neck Cancer\n\n      * Prior treatment requirement in the metastatic or unresectable locally advanced setting include:\n      * Subjects must have received a platinum containing chemotherapy regimen for treatment of primary tumor in locally advanced, or metastatic settings\n      * Subjects must have received an anti-PD-1\/ PD-L1 as monotherapy or in combination with chemotherapy.\n8. Progressed following therapy with at least one PD-1 or PD-L1 checkpoint inhibitor (regardless of PD-L1 expression status), except for patients with pancreatic cancer.\n\n   a) Prior progression on a PD-1 or PD-L1 checkpoint inhibitor should be unequivocal; progression that occurs within the first 8 weeks of treatment on these agents should be confirmed with a second CT at least 4 weeks apart (to exclude pseudo-progression).\n9. Patients with activating EGFR mutation or ALK rearrangement which is expected to be responsive to available tyrosine kinase inhibitor therapy, must have been previously treated with an applicable tyrosine kinase inhibitor.\n10. Tumor lesion which is deemed feasible for biopsy and injection under CT or ultrasound guidance (based on size, location, and visibility) by an interventional radiologist, and patient willing and able to provide tissue from biopsy of this lesion. Injected tumor should be \\> 1 cm3 in volume and should not encase or be inseparable from vital structures such as major nerves or blood vessels.\n\n    a) For Part 1 monotherapy patients treated at the first dose level, the tumor for injection must be an accessible cutaneous, subcutaneous, or superficial lymph node lesion that is palpable.\n11. Measurable disease, as defined per RECIST version 1.1.\n12. Prior history of brain metastases are eligible, provided:\n\n    1. Brain metastases have been treated\n    2. Asymptomatic from the brain metastases\n    3. Corticosteroids prescribed for the management of brain metastases have been discontinued at least 7 days before registration to study\n    4. Brain metastases are stable on pre-registration imaging\n    5. No evidence of leptomeningeal disease\n13. Life expectancy \\> 3 months.\n14. Adequate organ and marrow function as defined below:\n\n    1. Absolute neutrophil count (ANC) \u22651.5 x 10\\^9\/L\n    2. Hemoglobin \u226590 g\/L (or \u22659 g\/dL)\n    3. Platelets \u2265100 x 10\\^9\/L\n    4. Calculated creatinine clearance of \\>50 mL\/min using Cockcroft Gault equation\n    5. Total bilirubin \u2264 1.5 x institutional upper limit of normal\n    6. AST (SGOT) and ALT (SGPT) \u22642.5 x institutional upper limit of normal\n    7. If Alkaline Phosphatase \u2265 2.5 x institutional upper limit of normal, then AST and ALT must be \u2264 1.5 x institutional upper limit of normal\n15. Patients of childbearing age must not be pregnant and must use established contraceptive strategies:\n\n    1. Female subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n    2. Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \\> 1 year.\n    3. Male subjects should agree to use an adequate method of barrier contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.\n\nExclusion Criteria:\n\n1. Pregnant or breast feeding.\n2. Serious uncontrolled medical disorder, psychiatric condition or laboratory abnormalities that, in the opinion of the investigator, may increase the risk associated with study participation or may interfere with the interpretation of study results.\n3. Major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic), or significant traumatic injury, within 4 weeks prior to starting study treatment or has not recovered from side effects of such procedure. Video-assisted thoracic surgery (VATS) and mediastinoscopy are exceptions and patients can receive study treatment \u22651 week after these procedures.\n4. History of clinically significant noninfectious interstitial pneumonitis (i.e., limiting activities of daily living or requiring therapeutic intervention), including clinically significant radiation pneumonitis.\n5. Residual toxicity from prior anticancer therapy of grade 3 or greater (CTCAE v5.0), with the exception of alopecia.\n6. Concurrent use of other anticancer approved or investigational agents.\n7. Clinically significant, uncontrolled heart disease and\/or recent cardiac event (within 6 months), such as:\n\n   1. unstable angina within 6 months prior to screening\n   2. myocardial infarction within 6 months prior to screening\n   3. history of documented congestive heart failure (New York Heart Association functional classification III-IV)\n   4. cardiac arrhythmias not controlled with medication\n8. Active autoimmune disease requiring disease modifying therapy (except vitiligo, Grave's, or psoriasis not requiring systemic treatment).\n9. Any form of active primary or secondary immunodeficiency.\n10. Receiving \u226510 mg daily prednisone (or equivalent).\n11. Prior malignancy (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, cervical\/dysplasia endometrial, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required or anticipated to be required during the study period.\n12. Active systemic infections requiring intravenous antibiotics.\n13. Prior therapy with anti-tumor vaccines or other immune-stimulatory antitumor agents (other than FDA approved and National Comprehensive Cancer Network \\[NCCN\\] recommended systemic therapies).\n14. Prisoners or subjects who are involuntarily incarcerated, or who are compulsorily detained for treatment of either a psychiatric or physical illness.\n15. Any unresolved grade 2 irAE (except adequately treated endocrine irAE).\n16. Any toxicity that led to permanent discontinuation of prior anti-PD-1\/PD-L1 immunotherapy.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05076760002","EMAIL":[{"email":"CCI-TrialReferrals@duke.edu"},{}],"GEO":[35.99403,-78.89862]},{"TITLE":"Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC","CRITERIA":"Inclusion Criteria:\n\n* A confirmed diagnosis of locally advanced or metastatic NSCLC.\n* The tumor harbored common EGFR mutations (Del19, L858R) at start of first-line treatment\n* Age \u2265 18 years\n* Had never received any EGFR TKI therapy.\n* Patients that treated with dacomitinib (Vizimpro\u00ae) as first-line treatment\n* Confirmation of the T790M variant after first line dacomitinib treatment and receive any 3rd generation EGFR-TKI as second-line treatment.\n* Asymptomatic CNS metastases allowed\n* At least one lesion that can be accurately measured at baseline according to the RECIST 1.1, and which is suitable for accurate repeated measurements.\n* Start second-line treatment with third generation EGFR TKI no later than 01 JAN2023\uff08\\>10 month before data cutoff date\uff09\n* All eligible patients are required to sign an informed consent before initiating the study\n\nExclusion Criteria:\n\n* Patients who received drug(s) other than 3rd generation EGFR-TKI as the second-line treatment and\/or patients who received drug(s) other than Dacomitinib (Vizimpro\u00ae) as the first-line treatment\n* Received or currently receiving dacomitinib from any interventional clinical trial","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04768491001","EMAIL":[{}],"GEO":[39.9075,116.39723]},{"TITLE":"The Study of Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic Monitoring","CRITERIA":"Inclusion Criteria:\n\n* All eligible patients must have histologically or cytologically confirmed stage IIIB-IV unresectable NSCLC positive or negative for EML4-ALK4 fusion as defined by FISH. Patients must have an ECOG PS of 0- 1 and have at least 1 measurable lesions (RECIST 1.1 standard). For eligible patients, prior ALK inhibitor therapy or previous systemic anticancer therapy is not allowed or has been completed over 12 months. Patients with brain metastasis are eligible only in a stable central nervous system condition and treatment outcome, cannot receive glucocorticoids and drugs prohibited in the exclusion criteria \u226414 days before the first dose of study drug.\n\nExclusion Criteria:\n\n* Eligible patients must not have received any major surgery \u226428 days before the first dose of study drug and must not have received any minor surgery or radiotherapy \u226414 days before the first dose of study drug. Any acute toxic reaction must have recovered to \u2264 Grade 1 (except for hair loss). Patients with carcinomatous meningitis, leptomeningeal disease or spinal cord compression must be excluded.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04499794001","EMAIL":[{"email":"13911901165@139.com"}],"GEO":[39.9075,116.39723]},{"TITLE":"A Phase 1\/2a Study of DB-1303\/BNT323 in Advanced\/Metastatic Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Has a pathologically documented HER2-positive or HER2-expressing (except for cohort 2h where the requirement is HER2-null), advanced\/unresectable, recurrent, or metastatic malignant solid tumor that is refractory to or intolerable with standard treatment, or for which no standard treatment is available.\n* At least 1 measurable lesion (per RECIST 1.1)\n* Provide signed informed consent\n* ECOG performance status (PS) of 0-1.\n* LVEF \u2265 50% by ECHO or MUGA\n* Adequate organ functions\n* Provide pre-existing diagnosis of HER2 status or resected tumor samples or undergo fresh tumor biopsy for HER2 testing.\n* Life expectancy of \u2265 3 months.\n\nAdditional Inclusion Criteria for Part 2 Expansion Group 9:\n\n1. Has pathologically documented advanced\/unresectable, recurrent, or metastatic EC (including UCS and USPC) and has progressed on or after at least 1 line of systemic treatment including platinum-based therapy and exposure to ICI but no more than prior 3 lines of therapy for advanced\/unresectable, or metastatic disease. Note: endocrine therapy will not qualify as a systemic therapy line.\n\nExclusion Criteria:\n\n* History of symptomatic CHF (New York Heart Association \\[NYHA\\] classes II-IV) or serious cardiac arrhythmia requiring treatment.\n* History of myocardial infarction or unstable angina within 6 months before Day 1.\n* Average QTcF \\> 450 ms in males and \\> 470 ms in females\n* History of clinically significant lung diseases\n* Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals.\n* HIV infection with AIDS defining illness or active viral hepatitis.\n* Clinically active brain metastases\n* Unresolved toxicities from previous anticancer therapy, defined as toxicities not yet resolved to NCI-CTCAE version 5.0, Grade \u2264 1 or baseline.\n* A known hypersensitivity to either the drug substances or inactive ingredients in the drug product.\n* Part 2 (expansion) Only:Multiple primary malignancies within 3 years, except adequately resected non- melanoma skin cancer, curatively treated in-situ disease, other solid tumors curatively treated, or contralateral breast cancer.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05150691077","EMAIL":"britney.winterberger@tigermedgrp.com","GEO":[18.20107,-67.13962]},{"TITLE":"To Evaluate OBI-833\/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Aged \u2265 20 years.\n2. Pathologically or cytologically confirmed diagnosis of non-small cell lung cancer whose stage is IIIB, IIIC, IVA, or IVB according to the AJCC Cancer Staging System, 8th Edition.\n3. The tumor harbors an exon 19 deletion or exon 21 L858R mutation in EGFR, confirmed locally.\n4. Patient must have a documented Globo H H-score of at least 100 using a validated central IHC assay.\n5. Patient must have received 3\u00b11 months of first-line erlotinib therapy under a stable dosage of 150 mg\/day, have achieved SD or PR before randomization (as confirmed by the Investigator), and plan to continue the erlotinib treatment at 150 mg\/day.\n6. At least one measurable tumor lesion according to RECIST version 1.1 as assessed by the Investigator (local radiological image assessment).\n7. Life expectancy \u2265 6 months.\n8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n9. Organ Function Requirements - Subjects must have adequate organ functions as defined below:\n\n   * AST\/ALT \u2264 3X ULN (upper limit of normal); AST\/ALT \u2264 5X ULN in the presence of liver metastases\n   * Total bilirubin \u2264 2.0 X ULN\n   * Serum creatinine \u2264 1.5X ULN\n   * ANC \u2265 1,500 \/\u00b5L\n   * Platelets \u2265 100,000\/\u00b5L\n10. All eligible patients of childbearing potential must use effective contraception during study treatment, and for at least 2 months after the last dose of OBI-833\/OBI-821 and for at least 2 weeks after the last dose of erlotinib. Subjects not of childbearing potential (i.e., permanently sterilized, postmenopausal) can be included in the study. Postmenopausal is defined as 12 months with no menses without an alternative medical cause.\n11. Understand and provide a written informed consent document according to institutional guidelines.\n\nExclusion Criteria:\n\n1. Patient who has CNS metastasis.\n2. Patient who is pregnant or breast-feeding at entry.\n3. Patient with splenectomy.\n4. Patient with HIV infection, active hepatitis B infection, or active hepatitis C infection.\n5. Patient with a positive test result for SARS-CoV-2 detected by standard reverse transcription-polymerase chain reaction (RT-PCR) at screening.\n6. Patient with any autoimmune or other disorders requiring IV\/oral steroids or immunosuppressive or immunomodulatory therapies.\n\n   (e.g., type 1 juvenile onset diabetes mellitus, antibody positive for rheumatoid arthritis, Graves disease, Hashimoto thyroiditis, lupus, scleroderma, systemic vasculitis, hemolytic anemia, immune mediated thrombocytopenia, Crohn disease, ulcerative colitis, and psoriasis).\n7. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to Grade 0 or 1 (using National Cancer Institute Common Terminology Criteria for Adverse Events \\[NCI CTCAE\\] version 5.0), except for alopecia and laboratory values listed in the inclusion criteria.\n8. A history of other malignancies (except non-melanoma skin carcinoma, carcinoma in situ of the uterine cervix, follicular or papillary thyroid cancer) within 5 years prior to randomization.\n9. Patient with any known uncontrolled comorbid illness including ongoing or active infections, symptomatic congestive heart failure (NYHA\\>2), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\/social situations that would limit compliance with study requirements.\n10. Treatment with any of the following therapies within 4 weeks prior to randomization:\n\n    * Anti-cancer therapies, including chemotherapy and targeted therapy (except erlotinib).\n    * Radiotherapy.\n    * Immunotherapy, including monoclonal antibodies, cytokines, interferons, and checkpoint inhibitors.\n    * Immunosuppressants, including cyclosporin, rapamycin, tacrolimus, rituximab, alemtuzumab, natalizumab, and cyclophosphamide.\n    * Other biologics, including G-CSF and other hematopoietic growth factors.\n    * Live attenuated vaccines.\n    * IV\/oral steroids except single prophylactic use in CT\/MRI scan or other one-time use in approved indications. Use of inhaled and topical (except on the injection site) steroids is allowed.\n    * Alternative and complementary medicine that may affect the immune system.\n    * Other investigational drugs.\n11. Subject with pleural effusions and\/or ascites, due to malignancy, requiring paracentesis every 2 weeks or more frequently.\n12. Subject with any known severe allergies (e.g., anaphylaxis) to any active or inactive ingredients in the study drugs.\n13. Any other reason that the investigator deems the patient to be unsuitable for the study.","SEX":"ALL","AGE_MIN":20,"AGE_MAX":200,"SS_ID":"05442060007","EMAIL":"annahu@obipharma.com","GEO":[24.1469,120.6839]},{"TITLE":"First in Human Phase 1 Study of AG01 Anti-Progranulin\/GP88 Antibody in Advanced Solid Tumor Malignancies","CRITERIA":"Inclusion Criteria:\n\n1. Signed informed consent\/authorization is obtained prior to conducting any study-specific screening procedures.\n2. 18 years of age or older.\n3. Histologic or cytologic diagnosis of advanced cancer.\n4. Radiographic evidence of at least 1 measurable metastatic lesion per RECIST 1.1 criteria.\n5. Patients with relapsed\/refractory solid tumor malignancies who failed one or more standard chemotherapy or targeted therapy regimens per SOC guidelines such as NCCN guidelines and for whom no standard therapy exists (Phase 1A). No GP88 expression pre-required for phase 1A.\n6. For phase 1B, patients must have GP88 tissue tumor tissue expression of 1+, 2+ or 3+ by IHC, archival tumor tissue will be used whenever possible. If no archival tissue is available, subject will be asked to consent to a study specific tumor biopsy for GP88 testing (phase1B). Patients who do not have archival tissue available for the dose expansion cohort (1B) will not be exposed to significant risk procedure to obtain tissue and may still be eligible for the study, after discussion with the Sponsor and Medical Monitor.\n7. At least 4 weeks after the last dose of chemotherapy or radiation therapy; 6 weeks for mitoxantrone or mitomycin therapy.\n8. ECOG performance status must be \u22642 (Appendix A).\n9. Adequate hepatic, renal, and bone marrow function:\n\n   Absolute neutrophil count \u2265 1,000\/uL Platelets \u2265 100,000\/\u00b5L Total bilirubin WNL per Institution ULN AST (SGOT)\/ALT (SGPT) \u2264 2.5 X institutional ULN Creatinine \u22641.2 mg\/dL Clearance \u226550ml\/min (Cockcroft-Gault)\n10. All study participants (male and female) with reproductive potential must practice highly effective methods of contraception (failure rate \\<1% annually) while on this study and for 90 days after completion of study therapy.\n11. Men and women of all ethnic groups are eligible for this trial.\n12. Females at reproductive age must have a negative urine pregnancy test prior to entry to this study.\n13. Males with partners at reproductive age must use highly effective birth control methods to prevent partners' pregnancy while on study and for 90 days after completion of study treatments.\n14. Life expectancy is greater than 12 weeks.\n15. Subjects with triple negative breast cancer (TNBC) cohort must have received 1 or more standard of care (SOC) or targeted therapies for metastatic TNBC. If PD(L)1-positive, must have received a combination of chemotherapy and a PD (L)-1 agent (Atezolizumab or Pembrolizumab), unless not a candidate for these therapies. If gBRCA 1 or 2 mutation is present, must have received SOC therapies including a PARPi, unless not a candidate for these therapies. is FDA approved for treatment of advanced TNBC. Prior exposure to Sacituzumab Govitecan ADC therapy does not preclude eligibility in the current study.\n16. Subjects with Cohort 2-Breast Cancer ER and\/or PR positive, hormone-resistant breast cancer who received 1 or more hormonal (HT) therapies or HT\/CD4\/6 kinase inhibitor or HT\/MTOR inhibitor for treatment of metastatic breast cancer are eligible. If the tumor has known PIK3CA mutation, HT\/Alpelisib combination should be considered unless not a candidate for this therapy.\n17. Subjects with metastatic\/recurrent NSCLCA who failed 2 or more SOC therapies, including platinum-based chemotherapy and an anti-PD (L) -1 agent (sequentially or consecutively). Patients with sensitizing mutations\/alterations\/rearrangements are eligible if received 1 or more SOC agent\/s targeting these mutations unless not a candidate for these therapies.\n18. Mesothelioma patients who have received at least 1 SOC therapy for metastatic\/recurrent mesothelioma per NCCN recommendations or not a candidate for SOC therapy.\n\nExclusion Criteria:\n\n1. Uncontrolled inter-current illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmias not well controlled with medication, myocardial infarction within the previous 6 months, or psychiatric illness\/social situations that would limit compliance with study requirements.\n2. Uncontrolled or untreated CNS metastases and treated CNS metastases are allowed, as long as the patient is clinically stable.\n3. Presence carcinomatous meningeal involvement.\n4. Patients may not be receiving any other investigational agents, or have participated in any investigational drug study \\< 28 days prior to starting on the current study.\n5. Since the teratogenic potential of AG01 is currently unknown, females who are pregnant or lactating are excluded.\n6. Males and females unable to adhere to abstinence or use highly effective methods of contraception (annual failure rate \\< 1%) to prevent study subjects' pregnancy or study subjects' partner pregnancy.\n7. History of any other malignancies in the last 2 years except for in-situ cancer, basal or squamous cell skin cancer treated with curative intent.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05627960001","EMAIL":[{"email":"ktkaczuk@umm.edu"},{"email":"Amelia.Barkman@umm.edu"},{},{},{}],"GEO":[39.29038,-76.61219]},{"TITLE":"To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)","CRITERIA":"Inclusion Criteria:\n\n1. voluntary participation in clinical research; Fully understand and Informed the study and sign the Informed Consent Form (ICF); Be willing to follow and be able to complete all trial procedures.\n2. Age \u226518 years old and \u226475 years old when signing ICF.\n3. histologically or cytologically confirmed advanced or postoperative recurrent non-small cell lung cancer (AJCC 8th edition).\n4. STK11 mutations were detected by NGS, and no other sensitive mutations could be targeted therapy (including EGFR, ALK, ROS1, RET, c-Met, HER2, BRAF gene rearrangement, fusion, amplification, and skipping).\n5. The patient had not received systemic antitumor therapy.\n6. Patients who had received one prior chemotherapy regimen were allowed, regardless of whether chemotherapy was administered before, after, or concurrently with targeted therapy.\n7. Patients receiving adjuvant or neoadjuvant therapy were allowed if adjuvant\/neoadjuvant therapy had been completed at least 12 months before diagnosis of advanced or postoperative recurrent NSCLC.\n8. The interval between the end of previous nonsystemic antitumor therapy and the start of study medication had to be 4 weeks or more. Treatment-related AE recovered to CTCAE 4.03\u2264 grade 1 (except grade 2 alopecia).\n9. have at least one measurable target lesion as assessed by the investigator according to iRECIST requirements within 4 weeks before enrollment.\n10. If available, patients can provide eligible tumor tissue for PD-L1 expression level measurement.\n11. an ECOG PS score of 0 or 1 within 7 days before the first dose of study medication.\n12. predicted survival time \u226512 weeks (3 months).\n13. had good major organ function, defined as meeting the following criteria, and had not received blood transfusions, albumin, recombinant human thrombopoietin, or colony-stimulating factor (CSF) within 14 days before the first dose of study medication.\n14. Female patients must meet one of the following conditions:\n\n(1)menopause, defined as absence of menses for at least 1 year and no confirmed cause other than menopause, or (2) having undergone sterilization (removal of ovaries and\/or uterus) 3) be fertile, provided that: Patients had to have a negative serum pregnancy test within 7 days before randomization and agree to use contraception with an annual failure rate of \\<1% or to abstain from heterosexual intercourse for at least 120 days from the date of written informed consent until the last dose of trial drug was administered. At least 150 days after the last dose of chemotherapy) (contraceptive methods with an annual failure rate of \\<1% include bilateral tubal ligation, male sterilization, proper use of ovulation-suppressing hormonal contraceptives, hormone-releasing intrauterine devices, and copper intrauterine devices or condoms), and Do not breastfeed.\n\n15.Male patients had to agree to either abstain from sex (avoid heterosexual intercourse) or to use contraception, as specified by either abstinence or use of condoms to prevent exposure of the drug to the embryo during chemotherapy (paclitaxel\/pemetrexed\/carboplatin) for the duration of treatment with a woman of reproductive age or a pregnant partner and for at least 150 days after the last dose of chemotherapy. Regular abstinence (e.g., calendar day, ovulation, basal body temperature, or postovulatory methods of contraception) and in vitro ejaculation are ineligible methods of contraception.\n\nExclusion Criteria:\n\n1. received systemic therapy for advanced NSCLC within 4 weeks after enrollment;\n2. the subjects had a history or concurrent history of other malignant tumors (except 3.cured basal cell carcinoma of the skin and carcinoma in situ of the cervix).\n\ncandidates for or prior recipients of organ or bone marrow transplantation. 4.uncontrollable pleural, pericardial, or ascites with appropriate interventions.\n\n5.subjects with clinically symptomatic CNS metastases (e.g., brain edema, need for hormonal intervention, or progression of brain metastases). Patients who had received previous treatment for brain or meningeal metastases were eligible if they had been clinically stable (on MRI) for at least 2 months and had stopped systemic hormone therapy (at a dose of \\>10mg per day of prednisone or other iso-efficacy hormones) for more than 2 weeks.\n\n6.spinal cord compression that cannot be cured by surgery and\/or radiotherapy. 7. have a history of hemoptysis (\\> 50ml\/day) within 3 months before screening; Or clinically significant bleeding symptoms or a definite tendency to bleed.\n\n8. received definitive thoracic radiotherapy within 28 days before enrollment; Subjects who received palliative radiotherapy to a bone lesion outside the chest within 2 weeks before receiving the first dose of study drug.\n\n9. severe unhealed wound ulcers or fractures, or major surgery within 28 days before randomization or expected to undergo major surgery during the study period.\n\n10.Any unstable systemic disease: These included, but were not limited to, active pulmonary tuberculosis, active infection, unstable angina, cerebrovascular accident or transient ischemic attack (within 6 months before screening), myocardial infarction (within 6 months before screening), and congestive heart failure (New York Heart Association \\[NYHA\\] class \u2265 2 Grade II), severe cardiac arrhythmias requiring medical therapy, and hepatic, renal, or metabolic disorders 11. poorly controlled hypertension (defined as systolic blood pressure (BP) \u2265160 mmHg and\/or diastolic blood pressure \u2265100 mmHg) with a history of hypertensive crisis or hypertensive encephalopathy.\n\n12. clinically significant hemoptysis (\\> 50ml\/day) within 3 months before enrollment; Or clinically significant bleeding symptoms or a clear bleeding tendency, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occult blood ++ or above, or large vessel vasculitis; Arterial\/venous thrombotic events occurred within 12 months before enrollment, such as cerebrovascular accident, deep vein thrombosis, and pulmonary embolism.\n\n13. patients with CTCAE 4.03 peripheral neuropathy grade \u22652.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06341660001","EMAIL":[{"email":"doctorzcz@163.com"}],"GEO":[39.29038,-76.61219]},{"TITLE":"Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC.","CRITERIA":"Inclusion Criteria:\n\n* Patients are diagnosed with advanced non-small cell lung cancer and indicated for TKI (first or second line). TKI combined with chemotherapy is allowed.\n* FFPE\/FNA sample is available.\n* Compliant with treatment protocol.\n* Patients consented to participate in the study.\n\nExclusion Criteria:\n\n* Patients already started TKI before enrollment.\n* Patients already started chemotherapy before enrollment.\n* Medical or psychiatric conditions or occupational responsibilities that may preclude compliance with the protocol.\n* Patients did not agree to participate in the studies.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"06167460001","EMAIL":[{"email":"lantu@genesolutions.vn"},{"email":"vanphan@genesolutions.vn"},{}],"GEO":[10.82302,106.62965]},{"TITLE":"Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types","CRITERIA":"Inclusion Criteria:\n\n* Histologically confirmed, unresectable, locally advanced, or metastatic melanoma, HCC, NSCLC, RCC, MSI-H\/dMMR malignancies, urothelial carcinoma, esophageal squamous cell carcinoma, mesothelioma, SCCHN, or cervical carcinoma not amenable to standard treatment, or standard treatment is not available, or in the Investigator's opinion, the standard treatment would not be in the patient's best interest.\n\nPart A only: Evaluable only or measurable disease according to RECIST v1.1 Part B only: At least 1 measurable tumor lesion according to RECIST v1.1\n\n* Prior treatment must include a PD-1 or programmed cell death - ligand 1 (PD-L1) inhibitor. Prior treatment with a CTLA-4 inhibitor is not required.\n* Eastern Cooperate Oncology Group (ECOG) performance score of 0 or 1\n* Adequate bone marrow function, as determined by:\n\n  * Absolute neutrophil count (ANC) \u2265 1500\/ \u03bcL (should not have received growth factors within 2 weeks prior to screening)\n  * Platelet count \u2265 75,000\/ \u03bcL\n  * Hemoglobin \u2265 8.0 g\/dL (no red blood cell transfusion within 2 weeks of study treatment start is allowed)\n* Adequate renal function, based on estimated creatinine clearance (eCrCl) \u2265 50 mL\/min, calculated by the Cockcroft-Gault equation.\n* Adequate hepatic function, as determined by:\n\n  * Total bilirubin \u2264 1.5x upper limit of normal (ULN) or \u2264 2x ULN direct bilirubin for patients with Gilbert's Syndrome\n  * Aspartate transaminase (AST) \u2264 3x ULN (or \u2264 5x ULN if liver metastasis or HCC).\n  * Alanine transaminase (ALT) \u2264 3x ULN (or \u2264 5x ULN if liver metastasis or HCC).\n  * Adequate serum albumin (albumin \u2265 2.5 g\/dL)\n* Availability of a lesion that can be biopsied with acceptable risk.\n* Patients capable of bearing children must have a negative highly sensitive pregnancy test within 72 hours before the start of treatment. Patients who are postmenopausal (\\> 1 year since last menstrual cycle) or permanently sterilized (e.g., bilateral tubal occlusion, hysterectomy, bilateral salpingectomy) may be considered as not of reproductive potential.\n* Patients of reproductive potential must agree either to abstain continuously from heterosexual intercourse or to use a highly effective birth control method from signing the informed consent form (ICF) until 30 days after the last dose of MT-8421 and\/or 5 months after the last dose of nivolumab for patients capable of bearing children and until 90 days after the last dose of MT-8421 for patients capable of fathering a child. Patients must not donate sperm during the study and for 90 days after the last dose of nivolumab or MT-8421.\n\nExclusion Criteria:\n\n* Unwilling or unable to undergo 2 sets of 3 to 6 core tumor biopsies: one set at study baseline (prior to first dose of study drug) and one set between Weeks 6 through 8. A final optional set will be collected time of disease progression.\n* Received approved or investigational treatment for the disease under study (except ipilimumab) where Exclusion Criterion 4 applies, requiring a washout that will be dependent upon prior ipilimumab dose and planned MT-8421 dose) within 4 weeks before the start of treatment. For small molecules \\[Molecular Weight (MW) \\< 0.9 kDa\\], the washout is 5 half-lives, but at least 2 weeks.\n* Received tremelimumab within 30 days or ipilimumab 3 mg\/kg within 60 days or ipilimumab 1 mg\/kg within 30 days before the start of treatment. Once dose cohort of 32 \u00b5g\/kg MT-8421 has been completed in dose escalation, a 30-day washout of ipilimumab is acceptable irrespective of prior dose.\n* Any concurrent cancer treatment, apart from local treatment of non-target lesions for palliative intent (e.g., local surgery or radiotherapy). Patient must have recovered from the effects of the local treatment and be discussed with the medical monitor.\n* History or current evidence of another neoplastic disease, except cervical carcinoma in situ; superficial non-invasive bladder tumors, curatively treated; Stage I to II non-melanoma skin cancer; prostate cancer managed by active surveillance; or any previous cancer curatively treated \\< 2 years before the start of treatment.\n* Active autoimmune disease that required systemic treatment in the past. Patients who have not required systemic treatment for at least 2 years may be enrolled if permission is provided after discussion with the Medical Monitor (replacement therapy, e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency is allowed)\n* Evidence of active, non-infectious \u2265 Grade 2 pneumonitis or current evidence of \u2265 Grade 3 other underlying pulmonary disease.\n* Ongoing \\> Grade 1 immune-related toxicity caused by prior CPI therapy (i.e., PD-1 inhibitors, PDL1 inhibitors, or CTLA-4 inhibitors). Patients with stable endocrinological AEs (e.g., hypothyroidism, adrenal insufficiency, hypopituitarism, or diabetes mellitus) must have been on a stable dose of supplemental therapy for at least 2 weeks before screening to be eligible for this study. History of repeat Grade 2 pneumonitis or myocarditis on previous CPI and\/or Grade 3 irAE on previous CPI treatment.\n* Current evidence of new or growing central nervous system (CNS) metastases during screening. Patients with known CNS metastases will be eligible if they meet all the following criteria:\n\n  * Received radiotherapy or another appropriate therapy for the CNS metastases, if clinically Indicated\n  * Have stable CNS disease on the computed tomography (CT) or magnetic resonance imaging (MRI) scan within 4 weeks before signing the ICF compared with prior neuroimaging.\n* History or current evidence of significant cardiovascular disease before the start of treatment.\n* Current evidence of active, uncontrolled hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV) (evidenced by detectable viral load by polymerase chain reaction) or acquired immunodeficiency syndrome (AIDS)-related illness.\n\n  * Serology and virology measurements are not required to be performed at screening, but any previously reported results should be used for eligibility purposes. Investigators will test per their discretion\n  * Patients with a history of treated hepatitis C and non-quantifiable hepatitis C virus- ribonucleic acid (RNA) may be enrolled.\n  * Patients on treatment for hepatitis B, hepatitis C, and\/or HIV will be eligible if they have undetectable viral load (patients with HIV with CD4+ T-cell \\[CD4+\\] counts \u2265 350 cells\/\u00b5L may be enrolled).\n* Patients with unintentional weight loss greater than 10% of their body weight over the preceding 2 months or less prior to first dose in the first cycle.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06034860005","EMAIL":[{"email":"mpoole@nextoncology.com"},{}],"GEO":[38.84622,-77.30637]},{"TITLE":"A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)","CRITERIA":"Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has undergone margin negative, completely resected non-small cell lung cancer (NSCLC), and has pathological Stage II, IIIA, IIIB (N2) squamous or nonsquamous tumor, node, metastasis (TNM) staging per American Joint Committee on Cancer (AJCC) Eighth Edition guidelines.\n* Has no evidence of disease before randomization.\n* Has received at least one dose of adjuvant treatment with standard of care platinum doublet chemotherapy.\n* No more than 24 weeks have elapsed between surgical resection of curative intent and the first dose of pembrolizumab.\n* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization.\n* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening.\n* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART).\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Diagnosis of small cell lung cancer (SCLC) or, for mixed tumors, presence of small cell elements, or has a neuroendocrine tumor with large cell components or a sarcomatoid carcinoma.\n* HIV-infected participants with a history of Kaposi's sarcoma and\/or Multicentric Castleman's Disease.\n* Received prior neoadjuvant therapy for their current NSCLC diagnosis.\n* Received or is a candidate to receive radiotherapy for their current NSCLC diagnosis.\n* Received prior therapy with an anti-programmed cell death 1 protein (PD-1), anti-PD-ligand 1 (L1), or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor.\n* Received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization.\n* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.\n* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration.\n* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication.\n* Known additional malignancy that is progressing or has required active treatment within the past 5 years.\n* Active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed.\n* History of (noninfectious) pneumonitis\/interstitial lung disease that required steroids or has current pneumonitis\/interstitial lung disease.\n* Active infection requiring systemic therapy.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06077760105","EMAIL":[{}],"GEO":[25.04776,121.53185]},{"TITLE":"Clinical Effects of Absorbable and Non-absorbable Suture in Bronchial Sleeve Resection","CRITERIA":"Inclusion Criteria:\n\n1. Age 18 to 75 years old.\n2. The tumor is located in the opening of bronchus, or the edge of the tumor is less than 2 cm away from the opening of the bronchi, while the distance between the edge of the tumor and the carina is more than 1.5 cm.\n3. Patients with pathological diagnosis of non-small cell lung cancer.\n4. No distant metastasis in preoperative clinical evaluation.\n5. Adequate cardiac function, pulmonary function, liver function and renal function for anesthesia and bronchial sleeve resection.\n6. American Society of Anesthesiologists (ASA) score: Grade I-III.\n7. Patients who can coordinate the treatment and research and sign the informed consent.\n\nExclusion Criteria:\n\n1. Patients with a significant medical condition which is thought unlikely to tolerate the surgery or unsuitable for this study after the evaluation of the investigator.\n2. Patients with psychiatric disease who are expected lack of compliance with the protocol.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06344962001","EMAIL":[{"email":"17863934867@163.com"}],"GEO":[36.06488,120.38042]},{"TITLE":"A Study of PF-08046054\/SGN-PDL1V in Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Parts A and B:\n\n  * Participants must have one of the following histologically- or cytologically-confirmed metastatic or unresectable solid tumor types\n\n    * Non-small cell lung cancer (NSCLC)\n    * Head and neck squamous cell carcinoma (HNSCC) (except nasopharyngeal cancer)\n    * Esophageal squamous cell carcinoma (SCC)\n    * Triple negative breast cancer (TNBC)\n  * Participants must have disease that is relapsed or refractory, that has progressed on approved therapies, be intolerant to or refused such therapies, or such and therapies are contraindicated and in the judgement of the investigator, should have no appropriate SoC therapeutic option\n  * Participants must have PD-L1 expression based on historical testing\n* Part C:\n\n  * Participants must have disease that is relapsed or refractory or be intolerant to SoC therapies and must have one of the following tumor types\n\n    * HNSCC\n\n      * Participants with HNSCC must have histologically or cytologically-confirmed HNSCC\n    * NSCLC\n\n      * Participants must have histologically or cytologically-confirmed NSCLC. Participants with SCC and non--SCC histology are eligible. Note: Participants with a neuroendocrine component or histology are not eligible.\n    * Esophageal SCC\n    * Ovarian cancer\n    * Melanoma\n    * TNBC\n    * Gastric cancer\n  * Participants must have been previously tested for PD-L1 expression and should have PD-L1 expression \u22651 or \\<1 by CPS or TPS based on historical testing\n* Part D and Part E:\n\n  * Participants must have histologically or cytologically-confirmed disease of the HNSCC or NSCLC\n  * Participants must have PD-L1 expression based on historical testing\n  * Participants with NSCLC; PD-L1 expression \u2265 1% by TPS\n  * Participants with HNSCC; PD--L1 expression \u22651 by CPS\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n* Measurable disease per RECIST v1.1 at baseline\n\nExclusion Criteria:\n\n* History of another malignancy within 3 years of first dose of study treatment or any evidence of residual disease from a previously diagnosed malignancy.\n* Known active central nervous system metastases. Participants with previously-treated brain metastases may participate provided they:\n\n  * Are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment\n  * Have no new or enlarging brain metastases\n  * And are off of corticosteroids prescribed for symptoms associate with brain metastases for at least 7 days prior to first dose of study treatment\n* Lepto-meningeal disease\n* Prior treatment with an anti-PD-L1 agent within less than 5 half-lives. This duration of time will vary according to the half-life of the specific agent.\n* Previous receipt of an monomethylauristatin E (MMAE)-containing agent.\n* Pre-existing neuropathy \u2265Grade 2 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0.\n\nThere are additional inclusion criteria. The study center will determine if criteria for participations are met.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05208762024","EMAIL":[{}],"GEO":[51.50853,-0.12574]},{"TITLE":"Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS","CRITERIA":"Inclusion Criteria:\n\n1. Stage 3 or Stage 4 CRC, NSCLC, or STS who have failed, are ineligible, refused, or become intolerant to at least first line (but no more than 4 lines) of systemic therapy\n2. Life expectancy of \\> 6 months. Only have lesions with the longest diameter of \u2264 5 cm.\n3. Presence of at least one non-bone tumor lesion that is ablation-accessible, with a minimum size of 1.0 cm.\n4. Measurable disease according to RECIST 1.1.\n5. Age \u2265 18 years.\n6. ECOG performance status 0-1.\n7. Bone marrow function: neutrophil count \u2265 1.5 \u00d7 109\/L, platelet count \u2265 100 \u00d7 109\/L, hemoglobin \u2265 90 g\/L.\n8. Adequate hematological function defined by white blood cell count \u2265 2.5 \u00d7 109\/L with absolute neutrophil count \u2265 1.5 \u00d7 109\/L, and hemoglobin \u2265 9 g\/dL (transfusions allowed on study).\n9. Adequate hepatic function defined by a total bilirubin level \u2264 1.5 \u00d7 the upper limit of normal (ULN) range and aspartate transaminase (AST) and alanine aminotransferase (ALT) levels \u2264 2.5 \u00d7 ULN for all patients, or for patients with documented metastatic disease to the liver and AST and ALT levels \u2264 5 \u00d7 ULN. Patients with documented Gilbert disease are allowed if total bilirubin is less than 3 \u00d7 ULN.\n10. Adequate renal function defined by an estimated creatinine clearance \u2265 50 mL\/min according to the Cockcroft-Gault formula (or local institutional standard method).\n11. Men and women with childbearing potential agree to use effective contraception. Women of childbearing potential must have a negative pregnancy test (serum) before inclusion.\n\nExclusion Criteria:\n\n1. Known allergic reaction to shellfish, crabs, crustaceans, or any trial components, used in trial treatment.\n2. Malignant primary brain tumors or evidence of brain metastases or leptomeningeal disease.\n3. Patients who have received chemotherapy, radiotherapy, immunotherapy, or concurrent or recent treatment with any other investigational agents within 21 days prior to treatment.\n4. Patients who have not recovered to common terminology criteria for adverse events (CTCAE) Grade \u2264 1 from all side effects of prior therapies except for residual toxicities.\n5. Patients with a history of malignancy, with the exception of non-melanoma skin cancers and in situ cancers.\n6. Concomitant treatment with systemic corticosteroids (10 mg prednisolone or equivalent) or other immunosuppressive therapy.\n7. Anti-coagulation therapies which cannot be stopped 24 hours prior to trial treatment.\n8. Severe or uncontrolled cardiovascular disease (congestive heart failure New York Heart Association classification III or IV).\n9. Documented HIV positive.\n10. Active Hepatitis C or Hepatitis B Viral infection.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05688280016","EMAIL":[{}],"GEO":[51.75222,-1.25596]},{"TITLE":"Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation","CRITERIA":"Inclusion Criteria:\n\n1. Age \u2265 18 years, Male and female patients, at time of signing informed consent form (ICF).\n2. ECOG=0-1, with no deterioration in 2 weeks before first dose of HSK40118.\n3. Histological or cytological confirmed diagnosis of unresectable locally advanced or metastatic NSCLC.\n4. Patients will provide blood or tumor sample according to their own willingness.\n5. Patients in Phase Ia and Ib will fulfill the different criteria of the following:\n\n   Phase Ia(Part A): Previous treatment with at least one EGFR-TKI, including 1st, 2nd and 3rd-generation EGFR-TKI; Phase Ia(Part B)\/Phase Ib: Previous treatment with 3rd-generation EGFR-TKI.\n6. tumour lesions\/lymph nodes: Phase Ia(Part A): Patients should have at least one assessable tumour lesions\/malignant lymph nodes; Phase Ia(Part B) \/Phase Ib: Patients should have at least one measurable tumour lesions\/malignant lymph nodes.\n7. Life expectancy \u2265 3 months.\n8. Adequate hematologic and organ function per protocol.\n9. Women of childbearing potential (WOCBP) and fertile males with WOCBP partners must use highly effective contraception per protocol throughout and after 90 days of the last dose of the study.\n\nExclusion Criteria:\n\n1. malignant tumor within 5 years, with the exception of cutaneous squamous cell carcinoma, cervical carcinoma in situ, papillary thyroid carcinoma, or other tumors with low malignancy.\n2. Unstable spinal cord compression or brain metastases per protocol.\n3. Uncontrollable pleural effusion, ascites, or pericardial effusion per protocol.\n4. Prior treatment with 4th-generation EGFR-TKIs(TKI for 3th-generation resistance).\n5. Treatment with any of the following:\n\n   Prior treatment with an EGFR-TKI or other small-molecule anti-tumor drug within 7 days or approximately 5 \u00d7 t1\/2 prior to the first dose of HSK40118, whichever is shorter; Prior treatment with chemotherapy, palliative radiotherapy, or Herbal therapy within 2 weeks or approximately 5 \u00d7 t1\/2 prior to the first dose of HSK40118, whichever is shorter; Prior treatment with radiotherapy, immunotherapy\/biotherapy therapy, or other pharmaceutical clinical trial within 4 weeks or approximately 5 \u00d7 t1\/2 prior to the first dose of HSK40118, whichever is shorter.\n6. Treatment with inhibitors for P-glycoprotein (P-gp) within 7 days prior to the first dose of HSK40118.\n7. Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatment, with the exception of alopecia, dermal toxicity, and other toxicity considering no safety risks by investigator.\n8. Any disease which would cause chronic diarrhea, eg. Crohn's disease, or irritable bowel syndrome.\n9. Any disease which would preclude drug absorption, metabolism or pharmacokinetics, eg. active peptic ulcer or chronic gastroesophageal reflux disease.\n10. Any severe disease of respiratory system, eg. interstitial lung disease, radiation pneumonitis, drug-induced pneumonitis, or uncontrolled asthma.\n11. Patient who have clinically significant or uncontrolled cardiac disease, include: QTc interval \u2265 450(male)\/470(female) msec; any clinically significant arrhythmia; left ventricular ejection fraction \\< 50%; myocardial infarction, unstable angina, or class III\/IV cardiac failure by the NYHA that occurred within 6 months prior to the first dose of HSK40118.\n12. Any thromboembolic events within 6 months prior to the first dose of HSK40118; any familial or aquired thrombophilia.\n13. Active bleeding at screening, history of visceral hemorrhage within 3 months prior to the first dose of HSK40118, or visceral bleeding tendency within 6 months prior to the first dose of HSK40118.\n14. Patient who is undergoing, or receiving long-term(\\> 6 months) anticoagulant\/antiplatelet therapy; receiving drugs affecting coagulation function 1 week prior to the first dose of HSK40118.\n15. INR, APTT \\> 1.5xULN, or any bleeding tendency or coagulopathy at screening.\n16. Uncontroled hypertension(systolic pressure \u2265160mmHg, or diastolic pressure \u2265100mmHg).\n17. Any unstable systemic disease, eg. severe metabolic disease: liver cirrhosis, renal failure, or uremia.\n18. Any disease of the eyes \\> CTCAE v5.0 Grade 1.\n19. Autologous transplantation surgery within 3 months prior to the first dose of HSK40118; Allogeneic transplantation, or stem-cell Transplant surgery within 6 months prior to the first dose of HSK40118; Major surgery or significant traumatic injury occurring within 4 weeks prior to the first dose of HSK40118.\n20. Patients with HIV, HBV or HCV infection.\n21. Patients with active syphilis infection.\n22. Patients who have an uncontroled systematic infection, eg. fungal, bacterial, or virus infection.\n23. Patients who would interfere with cooperation or outcome-assessment of the trial.\n24. Allergic to any HSK40118 active constituent or ingredients.\n25. (Child-bearing period women only)Patients testing positive for pregnancy, or during lactation.\n26. Any other circumstances that would, in the investigator's judgment, prevent the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06050980012","EMAIL":[{"email":"lvdq@enzemed.com"}],"GEO":[32.49069,119.90812]},{"TITLE":"Low Volume High Intensity Interval Training in Operated Lung Cancer Patients","CRITERIA":"Inclusion Criteria:\n\n* Diagnosed with Non-Small Cell Lung Cancer\n* Stage 3A and earlier\n* Operated and at least 6 months have expired since the surgery\n* Having completed adjuvant treatments such as chemotherapy and radiotherapy and at least 6 months have expired\n* Being clinically stable and in remission\n* Not having new recurrence and active cancer\n\nExclusion Criteria:\n\n* Pneumonectomy surgery\n* Presence of symptoms, signs and diagnoses indicating the presence of lung and cardiac disease such as advanced COPD\n* Having any orthopedic or neurological problem that may prevent exercise\n* Presence of recurrence or active cancer","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"05837429001","EMAIL":[{"email":"hamideshn128@gmail.com"},{}],"GEO":[39.91987,32.85427]},{"TITLE":"Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Pathologically diagnosed IIIB or IV non-small cell lung cancer.\n2. Previously accepted first-line standard treatment failure or recurrence\n3. At least one measurable lesion.\n4. The patient has not received any other anti-cancer treatment within four weeks.\n5. Any gender, age \u226518 years\n6. ECOG PS : 0-2 points\n7. Expected survival \u2265 6 months\n8. The level of organ function meets the following criteria.\n\n(1) subject to the standard blood test: ANC \u2265 1.5\u00d7109 \/ L, PLT \u2265 50\u00d7109 \/ L, Hb \u2265 90g\/L.\n\n(2) biochemical tests must meet the following criteria: TBIL\\<1.5\u00d7ULN, ALT, AST \\<2.5\u00d7ULN ( if liver metastasis ALT, AST can be \\<5\u00d7ULN), BUN, and Cr \u2264 1\u00d7ULN).\n\n9. Female patients in child bearing period must have evidence of negative pregnancy test, and agree to take effective contraceptive measures until 6months after therapy.\n\n10. Subjects volunteered to join the study, signed informed consent, good compliance, with follow-up.\n\nExclusion Criteria:\n\n1. Patients with two or more kinds of tumors.\n2. Patients with active viral or bacterial infection, and have failed to be controlled by anti-infective treatment.\n3. Patients with seropositive response of Human immunodeficiency virus (HIV) and syphilis, or fail to control the hepatitis B virus or hepatitis C virus infection.\n4. Patients with active rheumatic diseases, organ transplantation and other diseases affecting the immune system seriously.\n5. Patients with severe heart and lung dysfunction.\n6. Patients with severe chronic diseases of kidney, liver and other important organs.\n7. Patients with any other serious illness that the investigators consider it will may affect the patient's treatments, follow-up or assessment, including any uncontrolled clinically significant neurological or psychiatric disorders, immunoregulatory diseases, metabolic diseases, infectious diseases and so on.\n8. Patients who take part in clinical trials of other drugs or biological therapy at present or within 30 days before enrollment.\n9. Patients who need long-term use of immunosuppressive drugs or patients who are undergoing treatment of autoimmune diseases.\n10. Patients who need long-term use of glucocorticoid.\n11. Women patients in gestation period or suckling period.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03769129001","EMAIL":[{"email":"zhangzhf@gzhmu.edu.cn"}],"GEO":[23.11667,113.25]},{"TITLE":"A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* patients with stage II-IIIB (T3N2M0 only) Non-Small Cell Lung Carcinoma (NSCLC) and determined to be eligible for curable R0 excision, after pathologic diagnosis of puncture specimens;\n* \u226518 years old (calculated on the date of signing the informed consent); Both men and women; Eastern Cooperative Oncology Group (ECOG) score 0\\~1; Predicted survival \u22653 months;\n* Have at least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 criteria within 28 days prior to initiation of treatment;\n* Has not received systemic antitumor therapy, including radiotherapy, chemotherapy and immunotherapy;\n* Agree to provide fresh or 6 month tumor tissue for programmed death ligand -1 (PD-L1) testing.\n* Major organs are functioning well.\n* Women of reproductive age should agree that they must use effective birth control during the study period and for 6 months after the study, and that a negative serum or urine pregnancy test occurred within 7 days prior to study enrollment; Men should agree that effective contraception must be used during the study period and for 6 months after the study period ends.\n* The subjects voluntarily joined the study and signed the informed consent with good compliance.\n\nExclusion Criteria:\n\n* Present or complication with other malignancies within 5 years.\n* Subjects are known to have genetic abnormalities with approved targeted drug therapy.\n* Cirrhosis, active hepatitis;\n* Cardio-cerebrovascular abnormalities;\n* Subjects with severe active infection within 4 weeks prior to initiation of study treatment; Or unexplained fever \\>38.0 \u2103 occurred during screening and before first administration;\n* Patients with active tuberculosis within 1 year prior to enrollment;\n* Immunodeficiency disease;\n* History of active autoimmune disease or autoimmune disease;\n* Preparing for or having previously received an organ transplant, or having received a hematopoietic stem cell transplant within 60 days prior to initial medication, or having a significant host transplant response;\n* Patients who required immunosuppressive, systemic, or absorbable topical hormone therapy for immunosuppressive purposes and continued use within two weeks prior to randomization\n* Severe infection of grade 4 or higher occurred within 1 year prior to initiation of study therapy;\n* Severe lung disease;\n* History of pituitary or adrenal dysfunction;\n* History of severe mental disorder;\n* History of drug abuse, alcoholism or drug use;\n* Participated in clinical trials of other drugs within 30 days;\n* History of live attenuated vaccine vaccination within 28 days prior to randomization or planned live attenuated vaccine vaccination during the study period;\n* Received Chinese patent drugs with anti-tumor indications specified in the National Medical Product Administration approved drug package inserts within 2 weeks prior to initiation of administration\n* Had major surgery within 4 weeks prior to initiation of medication;\n* Other severe, acute, or chronic medical conditions or laboratory abnormalities that, in the investigator's opinion, may increase the risks associated with study participation or may interfere with the interpretation of the study results, or are otherwise unsuitable for participation in the clinical study;\n* The compliance of patients to participate in this clinical study is estimated to be insufficient.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"05913089010","EMAIL":[{"email":"sdqmd@163.com"}],"GEO":[39.14222,117.17667]},{"TITLE":"Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients With EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)","CRITERIA":"Inclusion Criteria:\n\n* Aged at least 18 years old, be able to provide a signed and dated, written informed consent.\n* Patients must have documented histologically or cytologically confirmed locally advanced or metastatic NSCLC with EGFR or HER2 mutations and have progressed from, been refractory to or are intolerant to prior standard therapy without preferred alternative therapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1 at ICF signature with no deterioration over the previous 2 weeks.\n* Predicted life expectancy \u2265 12 weeks\n\nExclusion Criteria:\n\n* Patients with a known hypersensitivity to DZD9008, rosuvastatin, digoxin, midazolam, or any of the excipients of the products.\n* Concomitant medication or any clinical condition contraindicated for use with rosuvastatin, digoxin, midazolam.\n* Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study treatment.\n* Patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inhibitors or inducers of CYP3A4, BCRP, OATP1B1 and P-gp.\n* Patients who have BCRP (ABCG2) polymorphism c.421C\\>A (p.Q141K, rs2231142).\n* Patients with previous allogenic bone marrow transplant or non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection.\n* Patients with liver metastases, spinal cord compression or leptomeningeal metastasis.\n* Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses.\n* Participants with active infection including but not limited to hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) (refer to CSP) and active infection of COVID-19.\n* Inadequate bone marrow reserve or organ function.\n* Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.\n* Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of study treatment.\n* Women who are pregnant or breast feeding.\n* Known history of bleeding diathesis, i.e., hemophilia, Von Willebrand disease.\n* History of stroke or intracranial haemorrhage within 6 months\n\nOther protocol-defined inclusion\/exclusion criteria may apply.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05926180001","EMAIL":[{"email":"xinglg@medmail.com.cn"}],"GEO":[36.66833,116.99722]},{"TITLE":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","CRITERIA":"Inclusion Criteria:\n\n* Histological or cytological diagnosis of advanced, unresectable, and\/or metastatic or relapsed\/refractory solid tumor.\n\nECOG PS 0 or 1\n\n* Presence of at least 1 measurable lesion based on RECIST version 1.1 that has not been previously irradiated.\n* Documentation of mutated KRAS gene\n\n  1. PDAC, CRC, Other tumor types: Confirmed KRAS mutation, any variant\n  2. NSCLC: Confirmed KRAS mutation, any variant except previously treated G12C. If driver mutation, must have failed precision medicine therapy \\[eg, inhibitors of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), and others\\].\n* Part 1 and Part 2a: Participant must have progressed on standard treatment(s) for which no additional, effective therapy is available.\n\n  1. PDAC (2-3L): Participants must have received and radiologically progressed on prior lines of systemic therapy for metastatic pancreatic adenocarcinoma. If participants received prior neoadjuvant or adjuvant chemotherapy and progressed within 6 months of the last dose, then this should be considered as a prior line of systemic therapy.\n  2. NSCLC (2-3L): Participants must have received prior lines of anti-cancer treatment and progressed on at least a platinum-containing chemotherapy regimen and checkpoint inhibitor therapy; for participants with EGFR, ALK, or other genomic tumor alterations, participants must have progressed on approved therapy for these alterations.\n  3. CRC (2-3L): Participants must have had one or two prior systemic treatment regimens for mCRC. For either one or two prior treatments, these regimens must have included a fluoropyrimidine, oxaliplatin, or irinotecan; for one prior treatment, exposure to VEGF\/VEGF receptor (VEGFR) inhibitor is optional;\n  4. Other tumors: Participants, in the judgment of the investigator, must have progressed or become intolerant to all available standard therapies, or have refused such therapy.\n* Part 2b:\n\n  1. PDAC (1L) Cohort A2: Participants must not have received prior chemotherapy for metastatic disease. Participant could have received neoadjuvant therapy, adjuvant therapy, or adjuvant chemo-radiotherapy, as long as relapse did not occur within 6 months of completing these forms of adjuvant treatment. If so, the relapse within 6 months would be considered a line of therapy; the participant would be considered 2L, and not 1L.\n  2. CRC (2-3L) Cohort B2: Participants must have had one or two prior systemic treatment regimens for mCRC. For either one or two prior treatments, these regimens must have included a fluoropyrimidine, irinotecan, oxaliplatin; for one prior treatment, exposure to a VEGF\/VEGF receptor (VEGFR) inhibitor is optional.\n  3. CRC (1L) Cohort B3: Participants must not have had prior chemotherapy for advanced or metastatic disease. Participant could have received adjuvant chemotherapy or adjuvant chemo-radiotherapy, as long as relapse did not occur within 6 months of complete of adjuvant therapy. If so, the relapse within 6 months would be considered a line of therapy; the participant would be considered 2L, and not 1L.\n  4. NSCLC (1L) Cohort C2: Participants must have a TPS \u226550% and must not have received prior systemic treatment setting.\n  5. NSCLC (1L) Cohort C3: Participants with any TPS and must not have received prior systemic treatment setting.\n\nExclusion Criteria:\n\n* Active or history of pneumonitis\/ILD, pulmonary fibrosis requiring treatment with systemic steroid therapy, including evidence to suggest pneumonitis\/ILD on baseline assessments including imaging.\n* Diagnosis of immunodeficiency or an active autoimmune disease that require systemic treatment with chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy in the past 2 years.\n* Sensory peripheral neuropathy \u2265Grade 2\n* Active or history of clinically significant gastrointestinal (GI) disease (including but not limited to inflammatory GI disease \\[eg, ulcerative colitis, Crohn's disease, inflammatory bowel disease\\], immune-mediated colitis, peptic ulcer disease, GI bleeding, chronic diarrhea) and other conditions that are unresolved and\/or may increase the risk associated with study participation or study treatment administration.\n* Active bleeding disorder, including GI bleeding, as evidenced by hematemesis, significant hemoptysis or melena in the past 6 months.\n* Major surgery or completion of radiation therapy \u22644 weeks prior to enrollment\/randomization or radiation therapy that included \\>30% of the bone marrow.\n* Known sensitivity or contraindication to any component of study intervention (PF 07934040, gemcitabine, nab-paclitaxel, cetuximab, bevacizumab, FOLFOX, 5-FU, pembrolizumab, cisplatin, carboplatin, pemetrexed, SHP2 inhibitor(s), cyclin-dependent kinase (CDK) inhibitor(s), antibody drug conjugates (ADCs) or EGFR inhibitor(s)).\n* Hematologic abnormalities.\n* Renal impairment.\n\n  * Hepatic abnormalities.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06447662005","EMAIL":"ClinicalTrials.gov_Inquiries@pfizer.com","GEO":[18.39745,-66.04989]},{"TITLE":"RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil","CRITERIA":"Inclusion Criteria\n\n* Confirmed diagnosis of patients with non-squamous NSCLC stage IIIB\/IIIC not eligible for curative-intent therapies or stage IV\/M1 (a\/m NSCLC) with or without actionable genomic mutations (i.e., EGFR, ALK, ROS1, NTRK, BRAF, MET exon 14 skipping, RET, HER-2)\n* Aged at least 18 years at first diagnosis of a\/m NSCLC\n* For the AGA subgroup, having received platinum-based chemotherapy, having received at least one target approved therapy.\n* For the non_AGA subgroup,should have received either sequential or concurrent use of ICI and PTC)\n* Patient must have received at least line of therapy of an active agent after failing PTC.\n\nExclusion Criteria\n\n* Patients with evidence of other primary malignancies (apart from basal cell carcinoma and melanoma) within 1 year prior to the index date will be excluded from both the study cohorts.\n* Patients who participated in an investigational clinical trial for the treatment of any cancer, including NSCLC, or any early access program from 2018 onward.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06491862005","EMAIL":"information.center@astrazeneca.com","GEO":[-23.5475,-46.63611]},{"TITLE":"A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC","CRITERIA":"Inclusion Criteria:\n\nNote: patients who have a small pleural effusion that is too small to safety tap and is not visible on a chest x-ray are still eligible\n\n* Pathologic diagnosis (i.e., cell sample, biopsy, tissue swap, bronchoscopy) of non-small cell lung cancer.\n* Recommended to receive carboplatin \\& paclitaxel with radiation therapy as a treatment\n* Tumor or metastatic disease must measure at least 1 cm using a CT scan (CAT scan)\n* Physician determined the patient is healthy enough for chemotherapy and radiation therapy\n* At least part of the lung cancer must be viewable and measurable by CT or MRI\n* A platelet count of at least 100,000 cells per mililiter\n* A creatinine level of less than 1 1\/2 times the upper limit of normal for the local lab test, or, a creatinine clearance of at least 60 mL\/(min\\*1.73m2)\n* Not pregnant, and commit to using birth control during the study\n\nExclusion Criteria:\n\n* Exudative pleural effusion\n* Recurrent non-small cell lung cancer\n* Glucose-6-phosphate dehydrogenase (G6PD) deficiency\n* Patients actively receiving insulin or patients whose doctors have recommended current insulin use\n* Patients requiring daily finger-stick blood glucose measurements\n* Patients who are on the following drugs and cannot have a substitution or who decline the substitution:\n\n  * warfarin\n  * flecainide\n  * methadone\n  * amphetamines\n  * quinidine\n  * chlorpropamide\n* Prior radiation therapy that would result in a field overlap\n* Enrolled in another therapeutic clinical trial\n* Uncontrolled, intercurrent illness\n* Lactating women\n* HIV positive individuals undergoing therapy due to known drug:drug interaction between antiretroviral drugs and high-dose ascorbate therapy\n\nIf all the above are met, the potential participant will receive a 15 gram challenge dose of ascorbate via intravenous infusion. This is the final screening procedure.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"02905591001","EMAIL":[{"email":"sandy-vollstedt@uiowa.edu"},{"email":"heather-brown@uiowa.edu"},{},{}],"GEO":[41.66113,-91.53017]},{"TITLE":"Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Histologically confirmed diagnosis of primary NSCLC within 90 days of enrollment to a substudy, according to WHO Classification of Tumours\n* Unless otherwise specified in a substudy, patients must be classified as Stage IA2 to IIIA according to the AJCC 8th edition TNM classification with disease that is amenable to anatomical surgical resection.\n* Pre-surgical staging of patients with newly diagnosed lung cancer should include: CT thorax, abdomen and pelvis; PET scan imaging; Brain MRI or CT brain with IV contrast. Patients with mediastinal lymph nodes suspicious for metastases on PET imaging are required to undergo invasive staging by EBUS or mediastinoscopy to confirm or disprove pathological involvement of suspected nodes.\n* All patients must have evaluable disease as defined by RECIST 1.1 although measurable disease is recommended.\n* Patients that are eligible for one or more substudies must consent for release of tissue biopsies, surgical specimens and blood samples for conduct of tissue analyses. If there is insufficient tissue to conduct the proposed research studies without exhausting the diagnostic biopsies, please consult CCTG\n* Patients must be \u2265 18 years of age\n* No prior anticancer therapy for treatment of NSCLC. Patients with a history of NSCLC treated in the curative setting may be eligible but must be discussed with CCTG prior to enrollment\n* Patient must have an ECOG performance status of 0 or 1\n* Patients with synchronous primary tumours may be eligible if all of the following conditions are met:\n\n  * The synchronous tumour is located within the planned resection area\n  * The radiological appearance of the tumour is compatible with ground-glass opacity (GGO)\n  * The synchronous tumour is not FDG-avid on PET imaging\n  * The local multidisciplinary thoracic oncology tumour board has approved the surgical treatment plan\n* Surgery for participants enrolled on this protocol will be according to generally accepted standards of care. Operative approach (VATS, RATS vs open) will be determined by the surgeon. Accepted types of resection must aim to achieve an R0 resection, as defined by the IASLC, including the highest resected mediastinal being negative for carcinoma.\n* Unless otherwise specified in specific substudies, surgery must be performed between 2 to 4 weeks following the last dose of neoadjuvant therapy\n* Patients must have adequate organ and marrow function within 7 days prior to enrollment. Some substudies may require different cutoff values.\n* Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements.\n* Patient is able and willing to complete the Patient Related Outcomes questionnaire\n* Patients must be accessible for treatment and follow-up.\n* Protocol treatment is to begin within 2 working days of patient enrollment\n* Women\/men of childbearing potential must have agreed to use a highly effective contraceptive method\n\nExclusion Criteria:\n\n* Presence of locally advanced, unresectable cancer (regardless of stage), or metastatic cancer (Stage IV).\n* Patients with a history of other malignancy may be eligible if curatively treated and\/or the malignancy does not affect the determination of safety or efficacy of the investigational regimen (must be confirmed with CCTG).\n* Clinically significant, uncontrolled cardiac disease and\/or recent cardiac events (within 6 months), such as:\n\n  * Unstable angina or myocardial infarction within 6 months prior to enrollment;\n  * Symptomatic congestive heart failure (defined as New York Heart Association Grade II or greater);,\n  * Documented cardiomyopathy;,\n  * Clinically significant cardiac arrhythmias; (Note: patients with clinically controlled, asymptomatic atrial arrhythmias without any ventricular function compromise may be eligible; please consult CCTG).\n  * Uncontrolled hypertension defined by a Systolic Blood Pressure (SBP) \u2265 160 mm Hg and\/or Diastolic Blood Pressure (DBP) \u2265 100 mm Hg, unless controlled prior to first dose of study treatment.\n  * Patients with a significant cardiac history, even if controlled, should have LVEF \u2265 50%\n* History or current diagnosis of ECG abnormalities indicating significant risk of safety for participants participating in the study such as:\n\n  * Concomitant clinically significant cardiac arrhythmias e.g. sustained ventricular tachycardia, and clinically significant second or third-degree AV block without a pacemaker;\n  * History of familial long QT syndrome or known family history of Torsades de Pointes;\n  * Resting QT interval corrected with Fridericia's formula (QTcF) \\> 480 msec on screening ECG or congenital long QT syndrome.\n* Patients with prior allogenic bone marrow transplant, double umbilical cord blood transplantation (dUCBT) or solid organ transplant.\n* Patients with active or uncontrolled infections or with serious illnesses or medical conditions which would not permit the patient to be managed according to the protocol. This includes but is not limited to:\n\n  * Known clinical diagnosis of tuberculosis;\n  * Pneumonitis or any history of pneumonitis requiring steroids (any dose);\n  * Known primary immunodeficiency;\n  * For Hepatitis B (HBV), Hepatitis C (HCV) and human immunodeficiency virus (HIV) infections, requirements will be substudy dependent.\n* History of hypersensitivity to any drugs in any substudy, or to drugs of similar chemical class.\n* Concurrent treatment with other investigational drugs or anti-cancer therapy.\n* Pregnant or breastfeeding women.\n* Patients who are unable to swallow oral medication and\/or have impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the specific substudy drug(s)\n* Patients with a history of non-compliance to medical regimens.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05714891010","EMAIL":[{}],"GEO":[46.81228,-71.21454]},{"TITLE":"A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)","CRITERIA":"Key Inclusion Criteria\n\n1. Participants with non-squamous or squamous histology NSCLC with stage IIIB or stage IIIC disease who are not candidates for surgical resection or definitive chemoradiation per investigator assessment or stage IV (metastatic) disease who received no prior systemic treatment for recurrent or metastatic NSCLC\n2. Availability of an archival or on-study obtained formalin-fixed, paraffin-embedded tumor tissue sample as defined in the protocol.\n3. Expression of Programmed cell death ligand-1 (PD-L1) \u226550%, as described in the protocol.\n4. Participants must have at least 1 radiographically measurable lesion by computerized tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) criteria\n5. Eastern Cooperative Oncology Group (ECOG) performance status \u22641\n\nKey Exclusion Criteria\n\n1. Participants who have never smoked, defined as smoking \u2264100 cigarettes in a lifetime\n2. Active or untreated brain metastases or spinal cord compression. Participants are eligible if central nervous system (CNS) metastases are adequately treated and patients have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to enrollment\n3. Participants with tumors tested positive for epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations, or C-ros oncogene receptor tyrosine kinase 1 (ROS1) fusions\n4. Encephalitis, meningitis, or uncontrolled seizures in the year prior to enrollment\n5. Participants with history of interstitial lung disease (eg, idiopathic pulmonary fibrosis or organizing pneumonia), of active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management, or of pneumonitis within the last 5 years\n6. Prior splenectomy\n7. Uncontrolled infection with human immunodeficiency virus (HIV), HBV or hepatitis C infection (HCV); or diagnosis of immunodeficiency as defined in the protocol\n8. Ongoing or recent (within 2 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk of immune-related treatment-emergent adverse events (imTEAEs)\n9. Participants requiring corticosteroid therapy (\\>5 mg prednisone\/day or equivalent) within 14 days of randomization\n10. Another malignancy that is progressing or requires treatment, except for non melanomatous skin cancer that has undergone potentially curative therapy, in situ cervical carcinoma, or any other localized tumor that has been treated, and the participant is deemed to be in complete remission for at least 2 years prior to enrollment, and no additional therapy is required during the study period\n11. Documented or suspected ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection as defined in the protocol\n12. Patients who have received prior systemic therapies for NSCLC are excluded except for of the following:\n\n    1. Adjuvant or neoadjuvant platinum-based doublet chemotherapy (after surgery and\/or radiation therapy) if recurrent or metastatic disease develops more than 6 months after completing therapy if toxicities have resolved to CTCAE grade \u22641 or baseline except for alopecia and peripheral neuropathy.\n    2. Anti-PD-(L)1 with or without LAG-3 as an adjuvant or neoadjuvant therapy as long as the last dose is \\>12 months prior to enrollment.\n    3. Prior exposure to other immunomodulatory or vaccine therapies as an adjuvant or neoadjuvant therapy such as anti-cytotoxic T lymphocyte-associated antigen (anti-CTLA-4) antibodies if the last dose is \\>6 months prior to enrollment\n13. History or current evidence of significant cardiovascular disease including, myocarditis, congestive heart failure (as defined by New York Heart Association Functional Classification III and IV), unstable angina, serious uncontrolled arrhythmia, and myocardial infarction 6 months prior to study enrollment.\n14. Hypersensitivity to cemiplimab or BNT116 or any of their excipients, or contraindicated to cemiplimab per approved local labeling.\n15. Patients treated with immunostimulatory agents that may influence the efficacy of the investigational medicinal products (IMPs) are not allowed if they received such agents within 6 weeks or five halve lives of the drug.\n\nNote: Other protocol-defined Inclusion\/Exclusion criteria apply","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05557591039","EMAIL":"clinicaltrials@regeneron.com","GEO":[39.46975,-0.37739]},{"TITLE":"A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy","CRITERIA":"Inclusion Criteria:\n\n1. Patients aged \u226518 years, male and female are not limited;\n2. Patients with ECOG score of 0-1;\n3. Life expectancy \u226512 weeks;\n4. Patients must have histologically or cytologicallyproved NSCLC, and present with locally advanced, unresectable Stage III disease(according to 8th AJCC\/UICC Classification);\n5. Receipt of concurrent or sequential chemoradiation therapy which must have been completed within 42 days prior to first dose administration of the study; Consolidation chemotherapy is not permitted.\n6. No progression following definitive, platinum-based, concurrent or sequential chemoradiation therapy;\n7. Subject with prior anti-cancer treatment can only be enrolled when all toxicities of prior anti-cancer treatment has recovered to baseline or \u2264 Grade 1, except for hearing loss, alopecia and fatigue. (according to National Cancer Institute \\[NCI\\] Common Terminology Criteria for Adverse Events \\[CTCAE\\] V5.0);\n8. No prior exposure to any anti-CTLA-4, anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-VEGF treatments, as well as therapeutic anticancer vaccines;\n9. Agreement to provide tumor histological specimens required for this study;\n10. Adequate organ and marrow function required;\n11. Fertile female were required to have a negative serum or urine pregnancy test within 72 days before the start dose of study medication; If female of childbearing potential, is willing to use adequate contraception for the course of the study through 90 days after the last dose of study medication; if male with a female partner(s) of child-bearing potential, he must agree to use adequate contraception starting with the first dose of study medication through 90 days after the last dose of study medication or have been surgically sterilized;\n12. Provision of signed ICF.\n\nExclusion Criteria:\n\n1. Mixed small cell lung cancer histology;\n2. Disease progression after concurrent\/sequential chemoradiotherapy;\n3. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of treatment;\n4. Receipt of live attenuated vaccine within 28 days prior to the first dose of treatment;\n5. Previous enrolment of another study and receiving any study drug within 28 days prior to the first dose of treatment;\n6. Patients with \u2265Grade 2 pneumonitis from the prior anti-cancerchemoradiation therapy;\n7. Imaging (CT or MRI) shows the tumor invading large vessels or blurring the boundary with vessels;\n8. History of organ transplant or allogeneic hematopoietic stem cell transplantation;\n9. Patients with any active autoimmune disease or history of autoimmune disease;\n10. Patients with innate or acquired immune deficiency, such as human immunodeficiency virus (HIV) infection;\n11. Uuntreated active hepatitis B or, hepatitis C or active tuberculosis or currently receiving anti-tuberculosis treatment co-infection with hepatitis B and hepatitis C;\n12. Subjects receiving systemic treatment with corticosteroids (\\>10mg\/day of prednisone or its equivalent) or other immunosuppressants within 14 days prior to the first administration;\n13. History of another primary malignancy within 5 years prior to enrollment, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ and the disease under study;\n14. Pulmonary function test: FEV1\\< 1.2L or DLCO \\< 50% of predicted value;\n15. Patients with cardiac insufficiencyheart diseases including: 1) NYHA III-IV; 2\uff09Acute coronary syndrome; 3) Supraventricular or ventricular arrhythmias requiring clinical intervention; 4) Pericardial and myocardial diseases; 5) Echocardiography indicates that the left ventricular ejection fraction (LVEF) is \\< 50%;\n16. Patients with uncontrollable hypertension (systolic blood pressure \u2265 140 mmHg or diastolic blood pressure \u2265 90 mmHg, despite the best drug treatment);\n17. Patients who have had arteriovenous thrombosis events within 6 months, such as cerebrovascular accident (including cerebral embolism, deep vein thrombosis, pulmonary embolismcerebral hemorrhage, cerebral infarction, transient ischemic attack, etc.);\n18. Patients with hemoptysis, active bleeding, ulcer, intestinal perforation and intestinal obstruction within 3 months before administration;\n19. Significant hemoptysis symptoms or daily amount of hemoptysis up to 2.5mL or more within 30 days before the first administration;\n20. Known hereditary or acquired bleeding and thrombosis tendency (such as hemophilia, coagulation dysfunction, thrombocytopenia, hypersplenism, etc.);\n21. Routine urine test indicated that urine protein was \u2265 (++), or 24-hour urine protein was \u2265 1g, or severe liver and kidney dysfunction;\n22. Patients with severe infection or fever of unknown origin \\> 38.5 degrees C within 24 weeks before medication;\n23. Pregnant or lactating women; those with fertility who are unwilling or unable to take effective contraceptive measures;\n24. Known allergies, hypersensitivity, or intolerance to camrelizumab or its excipients, apatinib and chemotherapy drugs;\n25. Any conditions, judged by investigators, that may impair the subject or cause the subject to be unable to meet or perform the study requirements.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04749394001","EMAIL":[{"email":"drhuizg@163.com"},{}],"GEO":[39.9075,116.39723]},{"TITLE":"A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases","CRITERIA":"Inclusion Criteria:\n\n1. Newly diagnosed metastatic NSCLC, not amenable to curative surgery or curative radiotherapy.\n2. Documented EGFR mutation (at any time since the initial diagnosis of NSCLC) known to be sensitive to Osimertinib - These include exon 19 del; L858R (exon 21); G719X (exon 18); L861G (exon 21); S768I (exon 20) and T790M (exon 20) NOTE: Mutation analysis is to be done as per local practice.\n3. An MRI showing brain metastases. At randomization, number of brain lesions is under 20. Patients with over 20 brain lesions at randomization MRI will be suitable for whole brain radiation, and will not be randomized.\n4. Brain metastases are asymptomatic or with minor symptoms (ECOG\u22642) at study randomization.\n5. ECOG performance status \u22642 and a minimum life expectancy of at least 6 months\n6. Must be eligible and receive Osimertinib as their anti EGFR TKI at time of randomization.\n7. Must be eligible for SRS treatment at time of randomization.\n8. Provided written informed consent.\n9. Be male or female and at least 18 years of age on the day of signing informed consent.\n10. Female patients:\n\n    1. Willing to use adequate contraceptive measures until 6 weeks after the final dose of study treatment\n    2. Not breast feeding\n    3. Have a negative pregnancy test prior to the start of dosing if of childbearing potential or have evidence of non-childbearing potential by fulfilling one of the following criteria at screening:\n    4. Post-menopausal, defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments ii. Women under 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) levels in the post-menopausal range for the institution iii. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation\n11. Male patients who are willing to use barrier contraception (i.e. condoms) until 4 months after the final dose of study treatment.\n\nExclusion Criteria:\n\n* a. Prior treatment with:\n\n  1. Anti EGFR TKI treatment.\n  2. Checkpoint inhibitors immunotherapy for metastatic NSCLC.\n  3. Whole brain radiation (WBRT) and\/or Stereotactic Radiosurgery (SRS).\n  4. Medications or herbal supplements known to be potent inducers of CYP3A4 and are unable to stop use within the recommended wash out period prior to receiving the first dose of Osimertinib.\n  5. An investigational drug within five half-lives of the compound.\n  6. Any other cytotoxic chemotherapy, investigational agents or other anticancer drugs from a previous treatment regimen or clinical study within 14 days of entry to the study.\n\n     b. Systemic progression under Osimertinib treatment between screen and randomization systemic scan, per RECIST1.1.\n\n     c. Spinal cord compression unless asymptomatic and stable. d. Leptomeningeal disease. e. Moderate or severe symptomatic brain metastases defined as per Radiation Therapy Oncology Group acute morbidity grade 3 to 4.\n\n     NOTE: Grade 3 refers to neurological findings requiring hospitalization for initial management. Grade 4 refers to serious neurological impairment including paralysis, coma or seizures more than three times per week despite medication and requires hospitalization.\n\n     f. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.\n\n     g. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of Osimertinib.\n\n     h. Involvement in the planning and conduct of the study i. Judgement by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":120,"SS_ID":"05033691001","EMAIL":[{"email":"amichaym@hadassah.org.il"},{"email":"philipb@hadassah.org.il"}],"GEO":[31.76904,35.21633]},{"TITLE":"HER3-DXd in Metastatic or Unresectable Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria for both Dose Escalation and Dose Expansion:\n\n1. Has locally advanced or metastatic NSCLC, not amenable to curative surgery or radiation\n2. Has at least one measurable lesion per RECIST version 1.1\n3. Has Eastern Cooperative Oncology Group performance status of 0 or 1 at Screening\n\nInclusion Criteria for Dose Escalation only:\n\n1. Has histologically or cytologically documented adenocarcinoma NSCLC\n2. Has acquired resistance to EGFR TKI according to the Jackman criteria (PMID: 19949011)\n\n   1. Historical confirmation that the tumor harbors an epidermal growth factor receptor (EGFR) mutation known to be associated with EGFR tyrosine kinase inhibitor (TKI) sensitivity (including G719X, exon 19 deletion, L858R, L861Q)\n   2. Has experienced clinical benefit from an EGFR TKI, followed by systemic progression of disease \\[Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1\\] or World Health Organization (WHO)\\] while on continuous treatment with an EGFR TKI\n3. Is currently receiving and able to discontinue erlotinib, gefinitib, afatinib, or osimertinib\n4. Has been receiving erlotinib, gefitinib, afatinib, or osimertinib for at least 6 weeks with well-controlled related toxicities less than Grade 3 in severity at the time of Screening\n5. Has radiological documentation of disease progression while receiving continuous treatment with erlotinib, gefitinib, afatinib, or osimertinib\n6. Is willing to provide archival tumor tissue from a biopsy performed within 6 months of progression during treatment with erlotinib, gefitinib, afatinib, or osimertinib OR has at least one lesion, not previously irradiated, amenable to core biopsy and is willing to undergo screening tumor biopsy\n7. Demonstrates absence of EGFR T790M mutation if treated with erlotinib, gefitinib, or afatinib. No EGFR mutation testing is required if treated with osimertinib.\n\nInclusion Criteria for all cohorts of Dose Expansion only:\n\n1. Has received systemic therapy for locally advanced or metastatic disease including at least 1 platinum-based chemotherapy regimen\n2. Has documented radiological disease progression during\/after most recent treatment regimen for locally-advanced or metastatic disease\n3. For Cohorts 1, 2, 3a, and 3b: Is willing to provide archival tumor tissue from a biopsy performed within 6 months of consent and performed after progression during\/after treatment with most recent cancer therapy regimen OR has at least 1 lesion, not previously irradiated, amenable to core biopsy and is willing to undergo tumor biopsy. Tumor tissue must be of sufficient quantity as defined in the laboratory manual and contain adequate tumor tissue content as confirmed by haematoxylin and eosin (H\\&S) staining at central laboratory.\n\n   * For Cohort 4: Neither archival tumor tissue nor core tumor biopsy will be collected\n\nInclusion Criteria specific to Cohorts 1, 3a, 3b, and 4 of Dose Expansion:\n\n1. Has histologically or cytologically documented:\n\n   1. Cohort 1: Adenocarcinoma NSCLC\n   2. Cohorts 3a, 3b, and 4: NSCLC (including any histology other than small-cell or combined small cell and non-small cell)\n2. Has documentation of radiological disease progression following one or more lines of EGFR TKI treatment. Participants with EGFR T790M mutation following treatment with erlotinib, gefitinib afatinib, or dacomitinib must have received and have documentation of radiological disease progression following treatment with osimertinib unless unable or unwilling.\n3. Has documentation of EGFR-activating mutation(s) detected from tumor tissue: G719X, exon deletion 19, L858R, or L861Q. Participants with other EGFR-activating mutations may be eligible following discussion with the Sponsor.\n\nInclusion Criteria specific to Cohort 2 of Dose Expansion:\n\n1. Has histologically or cytologically documented squamous or non-squamous NSCLC (ie, without EGFR-activating mutations).\n2. Has received prior treatment with anti-PD-1 or anti-PD-L1 antibody-based regimen in the locally advanced or metastatic setting unless unable or unwilling. Participants with NSCLC known to harbor a genomic alteration(s) other than EGFR mutation(s) (eg, ALK or ROS1 fusion) for which treatment is available must have also received prior treatment with at least 1 genotype-directed therapy.\n\nInclusion Criteria for Cohort 5:\n\n1. Sign and date the main study ICF, prior to the start of any study-specific qualification procedures. A separate tissue screening consent will be obtained from all participants.\n2. Male or female subjects aged \u226518 years (follow local regulatory requirements if the legal age of consent for study participation is \\>18 years old)\n3. Has locally advanced or metastatic NSCLC not amenable to curative surgery or radiation.\n4. Has histologically or cytologically documented squamous or nonsquamous NSCLC\n5. Has documentation of KRAS-G12C mutation(s) detected from tumor tissue or liquid biopsy.\n6. Has received at least two prior systemic therapies for locally advanced or metastatic disease, including one approved KRAS-G12C-targeted therapy (e.g., sotorasib or adagrasib, including as part of a clinical trial).\n7. Has documentation of radiological disease progression according to RECIST v1.1 while either on or following the most recent treatment regimen for locally advanced or metastatic disease.\n8. Has \u22651 measurable lesion on computed tomography (CT) or magnetic resonance imaging (MRI) as per RECIST v1.1 by Investigator assessment that has not been previously irradiated.\n9. Provides a pre-treatment tumor tissue sample of sufficient quantity, as defined in the laboratory manual.\n10. ECOG PS 0 or 1 at the time of Screening.\n11. Has adequate bone marrow reserve and organ function based on local laboratory data within 14 days prior to Cycle 1 Day 1 as specified in the protocol.\n12. If the participant is a female of childbearing potential, she must have a negative serum pregnancy test at screening and must be willing to use a highly effective birth control upon enrollment, during the Treatment Period, and for 7 months following the last dose of study drug.\n13. Female subjects must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and for at least 7 months after the time of final study drug administration.\n14. If male, the subject must be surgically sterile or willing to use highly effective birth control upon enrollment, during the treatment period, and for at least 4 months following the last dose of study drug.\n15. Male subjects must not freeze or donate sperm starting at screening and throughout the study period, and for at least 4 months after the final study drug administration.\n16. Is willing and able to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions.\n\nExclusion Criteria for Dose Escalation and Dose Expansion:\n\n1. Has any evidence of small cell histology, or combined small cell and non-small cell histology, in original tumor biopsy or in Screening biopsy performed after progression\n2. Treatment with any of the following:\n\n   1. Any cytotoxic chemotherapy, investigational agent or other anticancer drug(s) from a previous cancer treatment regimen or clinical study (other than EGFR TKI in Cohorts 1, 3a, 3b, and 4 only), within 14 days of the first dose of study treatment\n   2. Immune checkpoint inhibitor therapy within 21 days of the first dose of study treatment\n   3. Prior treatment with an anti-HER3 antibody (dose escalation only)\n   4. Prior treatment with a topoisomerase I inhibitor (dose escalation only)\n   5. Prior treatment with an antibody-drug conjugate (ADC) that consists of an exatecan derivative that is a topoisomerase I inhibitor (eg, DS-8201a) (dose escalation only)\n   6. Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study drug treatment\n   7. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug treatment, or palliative radiation therapy within 2 weeks of the first dose of study drug treatment, or stereotactic radiotherapy within 1 week prior to the first dose of U3-1402\n3. Has history of other active malignancy within 3 years prior to enrollment, except:\n\n   1. Adequately treated non-melanoma skin cancer OR\n   2. Superficial bladder tumors (Ta, Tis, T1) OR\n   3. Curatively treated in situ disease\n4. Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Participants with clinically inactive brain metastases may be included in the study. Participants with treated brain metastases that are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 2 weeks must have elapsed between the end of whole brain radiotherapy and study enrollment (1 week for stereotactic radiotherapy)\n5. Has history of myocardial infarction within the past 6 months\n6. Has symptomatic congestive heart failure\\[New York Heart Association (NYHA) Classes II-IV\\], unstable angina within the past 6 months, or cardiac arrhythmia requiring antiarrhythmic treatment\n7. Has left ventricular ejection fraction (LVEF) \\< 50% by either echocardiogram (ECHO) or multigated acquisition scan (MUGA)\n8. Has any clinically important abnormalities in rhythm, conduction or morphology of resting electrocardiogram (ECG), eg, complete left bundle branch block, third-degree heart block, second-degree heart block, or PR interval \\> 250 milliseconds (ms)\n9. Has a mean corrected QT interval using Fridericia's Correction Formula (QTcF) prolongation to \\> 470 ms for females and \\> 450 ms for males in three successive Screening measurements\n10. Unable or unwilling to discontinue concomitant drugs that are known to prolong the QT interval\n11. Has any factors that increase the risk of corrected QT (QTc) interval prolongation or risk of arrhythmic events, such as congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives.\n12. Has any history of interstitial lung disease (ILD) (including pulmonary fibrosis or severe radiation pneumonitis), has current ILD\/pneumonitis, or is suspected to have such disease by imaging during screening\n13. Has clinically significant corneal disease\n\nAdditional Exclusion Criteria for Dose Expansion Cohort 2:\n\n1. Has documentation of one or more of the following EGFR-activating mutations: G719X, exon 19 deletion, L858R, or L861Q\n\nAdditional Exclusion Criteria for Dose Expansion Cohort 4:\n\n1. Evidence of any leptomeningeal disease\n2. Clinically severe respiratory compromise (based on Investigator's assessment) resulting from intercurrent pulmonary illnesses including, but not limited to:\n\n   1. Any underlying pulmonary disorder\n   2. Any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement OR prior complete pneumonectomy\n3. Is receiving chronic systemic corticosteroids dosed at \\>10 mg\/day prednisone or equivalent anti-inflammatory activity or any form of immunosuppressive therapy prior to enrollment\n4. Resting systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg\n5. Prior or ongoing clinically relevant illness, medical condition, surgical history, physical finding, or laboratory abnormality that could affect the safety of the subject; alter the absorption, distribution, metabolism or excretion of the study drug; or confound the assessment of study results.\n\nExclusion Criteria for Cohort 5:\n\n1. Has any evidence of small-cell histology or combined small cell and non-small-cell histology in the original tumor tissue or in Screening biopsy performed after progression.\n2. Has received a targeted therapy for an actionable genomic alteration other than KRAS-G12C.\n3. Any history of interstitial lung disease (ILD) (including pulmonary fibrosis or radiation pneumonitis) has current ILD, or is suspected to have such disease by imaging during screening.\n4. Has clinically severe respiratory compromise (based on the Investigator's assessment) resulting from intercurrent pulmonary illnesses.\n5. Is receiving chronic systemic corticosteroids dosed at \\>10 mg\/day prednisone or equivalent anti-inflammatory activity or any form of immunosuppressive therapy prior to Cycle 1 Day 1.\n6. Has any history of or evidence of current leptomeningeal disease.\n7. Has clinically significant corneal disease.\n8. Evidence of spinal cord compression or brain metastases, defined as being symptomatic and untreated, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms.\n9. Inadequate washout period prior to Cycle 1 Day 1 as specified in the protocol.\n10. Prior treatment with an anti-HER3 antibody and\/or antibody drug conjugate (ADC) that consists of an exatecan derivative that is a topoisomerase I inhibitor (eg, trastuzumab deruxtecan).\n11. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to National Cancer Institute- Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0), Grade \u22641 or baseline.\n12. Has known hypersensitivity to either the drug substance or inactive ingredients in the drug product.\n13. Has history of other active malignancy within 3 years prior to Cycle 1 Day 1, with exceptions as specified in the protocol.\n14. Uncontrolled or significant cardiovascular disorder prior to Cycle 1 Day 1,\n15. Active Hepatitis B and\/or Hepatitis C infection, such as that with serologic evidence of active viral infection within 28 days of randomization.\n16. Participants with past or resolved Hepatitis B virus (HBV) infection are eligible if meeting certain criteria as specified in the protocol.\n17. Participants with a history of Hepatitis C infection will be eligible for enrollment only if the viral load according to local standards of detection is documented to be below the level of detection in the absence of anti-viral therapy during the previous 12 weeks.\n18. Has any evidence of severe or uncontrolled diseases, psychiatric illness\/social situations, geographical factors, substance abuse, or other factors that, in the Investigator's opinion, make it high risk for the subject to participate in the study or that would jeopardize compliance with the protocol.\n19. Is a female participant who is pregnant or breastfeeding or intends to become pregnant during the study.\n20. Has a known HIV infection that is not well controlled.\n21. Prior or ongoing clinically relevant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the Investigator's opinion, could affect the safety of the participant; alter the absorption, distribution, metabolism or excretion of the study drug; or confound the assessment of study results.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03260491019","EMAIL":[{}],"GEO":[40.4165,-3.70256]},{"TITLE":"A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced\/Metastatic Solid Tumors","CRITERIA":"Inclusion Criteria:\n\nMolecular Pre-screening Inclusion criteria (Phase II only)\n\n1. The patient must sign the molecular pre-screening Inform Consent to allow for the molecular pre-screening process. All patients must have documented evidence of EGFR and\/or cMet aberrations.\n\nScreening Inclusion Criteria\n\n1. Able to understand and willing to sign the Informed Consent Form (ICF).\n2. Histologically\/cytologically confirmed advanced\/metastatic solid tumors with measurable disease \\[Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\\]:\n\n   Phase I: advanced\/metastatic solid tumors including but not limited to NSCLC, colorectal cancer, gastric cancer and liver cancer refractory to standard therapy or for which no standard therapy is available or accessible.\n\n   Phase II: Advanced\/metastatic NSCLC Patients have confirmed EGFR mutant and\/or cMET aberration, and have progressed after standard treatment (including platinum-based therapy) or are intolerant to standard treatment. Additionally, patients with T790M mutation have received FDA\/Health Authority approved therapies (if accessible) for this indication (i.e., osimertinib) and have progressed or became intolerant.\n\n   A patient who has refused all currently available therapy is allowed to enroll, but must be documented in the source record.\n3. Must have adequate organ function.\n4. Regarding prior anti-tumor therapy:\n\n   1. Must have stopped treatment at least 4 weeks or within 5 half-lives.\n   2. Generalized radiation therapy must have stopped 3 weeks before first dose of EMB 01, or local radiotherapy or radiation therapy for bone metastases must have stopped 2 weeks before first dose of EMB-01. No therapeutic radiopharmaceuticals are taken within 8 weeks before first dose of EMB-01.\n   3. Patients must have recovered to \u2264Grade 1 from the adverse effects of such above treatment before beginning study treatment.\n5. Female patient with fertility or male patient whose partner has fertility should use one or more contraceptive methods for contraception starting from screening period and continue throughout the study treatment and for 3 months.\n6. ECOG score 0 or 1 for phase I, and \u22642 for phase II.\n\nExclusion Criteria:\n\nMolecular Pre-screening Exclusion Criteria (Phase II only)\n\nSubject who meets any of the follow criteria can't be proceeded to clinical screening:\n\n1. Patients who are unwilling to sign the molecular pre-screening ICF.\n2. Patients for whom local EGFR and\/or cMET data or the results of central laboratory testing do not meet the molecular pre-screening inclusion criteria.\n\nScreening Exclusion Criteria\n\n1. Life expectancy \\< 3 months.\n2. Subject with primacy central nervous system (CNS) malignancy or symptomatic CNS (leptomeningeal or brain) metastases.\n3. Pregnant or nursing females.\n4. Subjects who have had major surgery within 28 days prior to screening.\n5. Serious underlying medical conditions, including but not limited to un-controlled hypertension, other cardiovascular disease or diabetes, ongoing or active infection, psychiatric, psychological, familial or geographical condition that, in the judgment of the investigator, may interfere the compliance with study treatment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03797391005","EMAIL":"xdsun@epimab.com","GEO":[31.22222,121.45806]},{"TITLE":"Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients","CRITERIA":"Inclusion Criteria:\n\n* Male or female subjects \u2265 18 years of age\n* Histologic or cytologic evidence of NSCLC\n* Known KRAS G12C mutation\n* The subject must have received prior therapy with a KRAS G12C inhibitor and experienced progression\n* Must have received appropriate treatment with at least one prior systemic regimen, but no more than 3 prior regimens, for Stage 3B-C or 4 NSCLC\n* Measurable disease according to RECIST 1.1\n* An Eastern Cooperative Group (ECOG) performance status \u2264 1\n* Adequate organ function\n* Adequate recovery from toxicities related to prior treatments\n* Agreement to use highly effective method of contraceptive\n\nExclusion Criteria:\n\n* Prior chemotherapy, targeted therapies, radiotherapy, immunotherapy or treatment with an investigational agent within 14 days of receipt of study drug (within 6 weeks for nitrosoureas, mitomycin C and chest radiation; within 6 months prior to Cycle 1 Day 1 for chest radiation \\> 30Gy)\n* History of prior malignancy, with the exception of curatively treated malignancies\n* Major surgery within 4 weeks (excluding placement of vascular access)\n* Exposure to strong CYP3A4 inhibitors or inducers within 14 days prior to the first dose and during the course of therapy\n* Exposure to strong inhibitors of breast cancer resistance protein (BCRP) within 14 days prior to the first dose and during the course of therapy\n* Symptomatic brain metastases requiring steroids or other local interventions within the 2 weeks prior to initiation of therapy\n* Known SARS-Cov2 infection \u226428 days prior to first dose of study therapy\n* Known hepatitis B, hepatitis C, or human immunodeficiency virus infection that is active\n* Active skin disorder that has required systemic therapy within the past 1 year\n* History of rhabdomyolysis or interstitial lung disease\n* Concurrent ocular disorders\n* Concurrent heart disease or severe obstructive pulmonary disease\n* Subjects with the inability to swallow oral medications","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05375994008","EMAIL":[{"email":"npucek@mcw.edu"},{}],"GEO":[43.0389,-87.90647]},{"TITLE":"APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Target population is advanced NSCLC (IIIB-IV) without EGFR mutation, ALK gene rearrangement, and ROS1 gene rearrangement.\n* Written informed consent provided.\n* Male and female patients aged \u226518 years, \\< 75 years.\n* Able to comply with the required protocol and follow-up procedures, and able to receive oral medications.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Life expectancy \u226512 weeks.\n* Adequate hematological function: Absolute neutrophil count (ANC) \u22652.0 x 109\/L, and Platelet count \u2265100 x 109\/L, and Hemoglobin \u22659 g\/dL (may be transfused to maintain or exceed this level).\n* Adequate liver function: Total bilirubin \u2264 1.5 x upper limit of normal (ULN), Aspartate aminotransferase (AST), alanine aminotransferase (ALT) \u2264 2.5 x ULN in subjects without liver metastases; \u2264 5 x ULN in subjects with liver metastases.\n* Adequate renal function: Serum creatinine \u2264 1.25 x ULN, or \u2265 60 ml\/min.\n* Female subjects should not be pregnant or breast-feeding.\n\nExclusion Criteria:\n\n* Known severe hypersensitivity to apatinib or any of the excipients of this product.\n* Inability to comply with protocol or study procedures.\n* A serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study.\n* A serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease.\n* Patients with prior chemotherapy or therapy with systemic anti-tumour therapy (e.g. monoclonal antibody therapy).\n* Patients with prior radiotherapy\n* History of another malignancy in the last 5 years with the exception of the following: other malignancies cured by surgery alone and having a continuous disease-free interval of 5 years are permitted. Cured basal cell carcinoma of the skin and cured in situ carcinoma of the uterine cervix are permitted.\n* Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease).\n* Eye inflammation or eye infection not fully treated or conditions predisposing the subject to this.\n* Evidence of any other disease, neurological or metabolic dysfunction, physical examination or laboratory finding giving reasonable suspicion of a disease or condition that contraindicated the use of an investigational drug or puts the subject at high risk for treatment-related complications.\n* Patient who has active serious infection (e.g. pyrexia of or 38.0\u2103 over)","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"03164694001","EMAIL":[{"email":"wsysums@163.net"}],"GEO":[23.11667,113.25]},{"TITLE":"Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma","CRITERIA":"Inclusion Criteria:\n\n* Pathology-proven or suspected stage 1 or 2 NSCLC and Stage 3 tumor stage 3, node stage 0 (T3N0) RCC, that require surgical resection as the treatment of choice\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2\n* Ability to understand and the willingness to sign an informed written consent\n\nExclusion Criteria:\n\n* Individuals with pure lung ground-glass opacity (GGO) lesions or mixed GGO with \\<50% solid component\n* Patients undergoing pneumonectomy\n* History of cancer in the 3 years prior to surgery (except for basal-cell carcinoma of the skin or cervical neoplasia).\n* Contraindication for NSAIDs, including peptic ulcer disease, preoperative chronic kidney disease with estimated glomerular filtration rate (eGFR) \\<45, allergies or intolerance to NSAIDs, coagulation disorder, or age \\> 80 years\n* Having taken an NSAID within 5 days prior to surgery\n* Immunocompromised status\n* Refusal or inability to understand the protocol and consent form or to receive follow-up in line with the recommendations\n* Preoperative hemoglobin \\< 9.0","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"04495894004","EMAIL":"vmaster@emory.edu","GEO":[33.749,-84.38798]},{"TITLE":"A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Patients aged 18-75 years;\n2. Patients enrolled must be eligible for patients with recurrent or metastatic advanced non-small cell lung cancer, with a clear pathological diagnosis report or history of disease, with guidelines that do not clearly recommend standard treatment regimens or who are unable to tolerate standard treatment regimens, and with clear measurable metastatic lesions (\\>1cm);\n3. No congestive heart failure, unstable angina, or unstable arrhythmia within the last 6 months.\n4. Patient activity status score of 0-3 on the Eastern Cooperative Oncology Group (ECOG) scale with life expectancy assessed at \u22653 months.\n5. No previous severe haematopoietic, cardiac, pulmonary, hepatic or renal abnormalities and immunodeficiency.\n6. Absolute T-lymphocyte values \u2265 0.5 times the lower limit of normal and neutrophils \u2265 1.0 x 109\/L; AST and ALT \u2264 3.0 times the upper limit of normal (\u2264 5.0 times the upper limit of normal for hepatocellular carcinoma\/metastatic liver cancer); creatinine \u2264 3.0 times the upper limit of normal, 1 week prior to enrollment.\n7. Patients must have the ability to understand and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women;\n2. Persons with a history of other malignant disease in the last 5 years, except cured skin cancer and carcinoma in situ of the cervix;\n3. Persons with a history of uncontrolled epilepsy, central nervous system disorders or psychiatric disorders whose clinical severity, as judged by the investigator, may prevent the signing of an informed consent or affect the patient's compliance with drug therapy;\n4. Clinically significant (i.e., active) cardiac disease such as symptomatic coronary artery disease, New York Heart Association (NYHA) class II or worse congestive heart failure or severe arrhythmias requiring pharmacological intervention, or a history of myocardial infarction within the last 12 months;\n5. Persons requiring immunosuppressive therapy for organ transplantation;\n6. Known major active infection or, in the judgement of the investigator, major haematological, renal, metabolic, gastrointestinal, endocrine dysfunction or metabolic disorders, or other serious uncontrolled concomitant disease;\n7. Hypersensitivity to any investigational drug component;\n8. Persons with a history of immunodeficiency, including those who have tested positive for HIV or have other acquired or congenital immunodeficiency diseases, or a history of organ transplantation, or other immune-related diseases requiring long-term oral hormone therapy\n9. Persons with active tuberculosis infection;\n10. Those with interstitial lung disease or non-infectious pneumonia that may prevent the assessment of pulmonary toxicity associated with the study or the manager;\n11. Other conditions that, in the opinion of the investigator, are not suitable for enrolment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06047860001","EMAIL":[{"email":"drxingpengfei@126.com"}],"GEO":[31.30408,120.59538]},{"TITLE":"Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)","CRITERIA":"Inclusion Criteria:\n\n1. Age from 18 to 80 years old;\n2. Patients with blood pressure\\<160\/100mmHg, 5.6\\<blood glucose\\<11.2mmol\/L, major organs function normally: (1) Goldman index between grade 1 and 2; (2) Predicted forced expiratory volume in 1s (FEV1) \\>= 40 % and diffusing capacity of the lung for carbon monoxide (DLCO) \\>= 40 %; (3) total bilirubin \\<= 1.5 upper limit of normal; (4) Alanine aminotransferase (ALT)\/Aspartate aminotransferase (AST) \\<= 2.5 upper limit of normal; (5) creatinine \\<= 1.25 upper limit of normal and creatinine clearance rate (CCr) \\>= 60ml\/min;\n3. The first clinical diagnosis before surgery was non-small cell lung cancer, including adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and other unknown types;\n4. Clinical stage T1-2N0-1 (cI-II): Maximum diameter of tumor \\<= 5cm and short diameter of mediastinal lymph node \\<= 1cm in thin layer CT;\n5. Performance status of Eastern Cooperative Oncology Group (ECOG) 0-1;\n6. All relevant examinations were completed within 28 days before the operation;\n7. Patients who understand this study and have signed an approved Informed Consent.\n\nExclusion Criteria:\n\n1. Patients with radiotherapy, chemotherapy, targeted therapy, or immunotherapy before surgery.\n2. Patients with the previous history of other malignancies;\n3. Patients with secondary primary cancer when enrolled;\n4. Patients diagnosed as pure ground glass opacity (GGO) before surgery;\n5. Patients diagnosed as mixed GGO whose solid part \\<= 50% and Maximum diameter of tumor \\<= 2cm;\n6. Patients with small cell lung cancer;\n7. Patients with prior unilateral open thoracic surgical procedures;\n8. Woman who is pregnant or breastfeeding;\n9. Patients with interstitial pneumonia, pulmonary fibrosis, or severe emphysema;\n10. Patients with an active bacterial or fungal infection that is difficult to control;\n11. Patients with serious psychosis;\n12. Patients with a history of severe heart attack, heart failure, myocardial infarction, or angina within the last 6 months.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"06524427021","EMAIL":[{"email":"2237454336@qq.com"}],"GEO":[30.66667,104.06667]},{"TITLE":"A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients","CRITERIA":"Inclusion Criteria:\n\n1. Males and\/or females over age 18\n2. Histologically and\/or cytologically documented local advanced or metastatic NSCLC .\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n4. Expected survival \\>=3 months.\n5. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Known uncontrolled or symptomatic central nervous system metastatic disease.\n2. Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \\>1 (National Cancer Institute Common terminology Criteria \\[NCI CTCAE\\] v.5.0).\n3. Inadequate organ or bone marrow function.\n4. Pregnant or breast-feeding woman.\n5. Known allergies, hypersensitivity, or intolerance to SSGJ-707. The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06361927001","EMAIL":[{"email":"wulin-calf@vip.163.com"}],"GEO":[28.19874,112.97087]},{"TITLE":"A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Willing and able to provide written informed consent.\n* Male or female aged \u226518 years at the time of signing the informed consent.\n* Have one of the following histologically or cytologically confirmed locally advanced (unresectable) or metastatic solid tumor:\n* Head and neck cancer\n* Cervical cancer\n* Non-small cell lung cancer\n* Melanoma\n* Ovarian cancer\n* HPV positive anogenital cancers\n* Other cancers with a reasonable likelihood of expressing 1 or more antigens included in a TScan clinical trial, following approval by the TScan Medical Monitor or their delegate.\n* Willing to provide a buccal swab for HLA testing\n* Willing to provide a saliva sample to use as a normal control for the LOH assay\n* Have access to an FFPE tumor block that is \\<8 months old or is willing to provide a fresh core-needle biopsy.\n\nExclusion Criteria:\n\n\u2022 Participants undergoing anticancer therapy with curative intent such as tumor surgical resection with or without neoadjuvant\/adjuvant therapy, or definitive chemoradiation, unless they have locoregionally advanced disease and are expected to have a high risk of relapse after their curative intent therapy as determined by the treating investigator.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05812027015","EMAIL":[{"email":"stadtermanbm@upmc.edu"},{}],"GEO":[40.44062,-79.99589]},{"TITLE":"Ladarixin With Sotorasib in Advanced NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Written informed consent, according to local guidelines, signed and dated by the participant prior to the performance of any study-specific procedures, sampling, or analyses.\n* Participant must be \u226518 years of age at the time of signature of the informed consent form (ICF).\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n* Histologically confirmed diagnosis of NSCLC (squamous or nonsquamous).\n* Patients with metastatic or locally advanced NSCLC who are not candidates for curative surgery or curative radiation.\n* Do not have an epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) translocation, rearranged during transfection (RET), ROS1 or other actionable molecular alterations that can be treated with FDA approved targeted agents.\n* Patients must have documentation of presence of KRASG12C mutation in tumor tissue.\n* Patients must have demonstrated progression of disease following treatment with anti-PD (L)-1 with or without platinum-based chemotherapy.\n* Participants must have at least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Tumor lesions that have been irradiated \u22654 weeks before the start of treatment, and have subsequently had documented progression, may be chosen as target lesions in the absence of measurable lesions that have not been irradiated.\n* Participants whose laboratory data at Screening meet the following criteria:\n\n  * Absolute neutrophil count \u22651.5 \u00d7 109\/L\n  * Platelets \u2265100 \u00d7 109\/L\n  * Hemoglobin \u22658 g\/dL without transfusion within 7 days\n  * Albumin \u22653 g\/dL\n  * Lymphocyte count \u22650.5 \u00d7 109\/L\n  * Serum bilirubin \u22641.5 \u00d7 upper limit of normal (ULN), or \u2264 3.0 \u00d7 ULN for subjects with Gilbert's Syndrome\n  * AST and ALT \u2264 2x upper limit of normal (ULN)\n  * International normalization ratio (INR) \\<1.5 if the patient is not on anticoagulants, or INR \\<3 after dose titration has been completed if the patient is on anticoagulants.\n  * Renal clearance as estimated glomerular filtration rate (eGFR) by Modification of Diet in Renal Disease (MDRD) Study equation \u226550 mL\/min\/1.73m2.\n* Persons of childbearing potential (POCBP, defined as a sexually mature person assigned female at birth) must have a negative serum pregnancy test prior to study entry. Women of non-childbearing potential will have had at least 12 continuous months of natural (spontaneous) amenorrhea, and an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms), or have had surgical bilateral oophorectomy, hysterectomy, or bilateral tubal ligation \\>6 weeks prior to Screening.\n* Persons assigned male at birth or persons assigned female at birth participants: Persons assigned male at birth participants with partners of childbearing potential and participants of childbearing potential are required to use 2 forms of acceptable contraception, including 1 barrier method, during their participation in the study and for 3 months following last dose. Persons assigned male at birth participants must also refrain from donating sperm during their participation in the study and for 12 months after the last dose of study medication.\n* Participants must be able to swallow and retain orally administered medication.\n\nExclusion Criteria:\n\n* History (\u22641 years) or presence of hematological malignancies except stable CLL.\n* History (\u22641 years) of other cancer that is histologically distinct from the cancers under study, except for cervical carcinoma in situ, ductal carcinoma in situ, prostatic intraepithelial neoplasia, superficial non-invasive bladder tumors, or curatively treated stage I non-melanoma skin cancer.\n* Known serious allergy to ladarixin, sotorasib, or excipients (e.g., microcrystalline cellulose).\n* History (\u22646 months before the start of treatment with the study drugs) of severe autoimmune disease (including \u2265 Grade 3 or recurrent Grade 2 immune-related AEs of prior immuno-oncology therapy) or autoimmune disorder that requires chronic systemic corticosteroid treatment at immunosuppressive doses (prednisone \\>10 mg\/day or equivalent).\n* Brain or spinal metastases, except if treated by surgery or surgery plus radiotherapy or radiotherapy alone, with no clinical evidence of progression or hemorrhage for \u22647 days before the start of treatment with the study drugs, and has not received any systemic corticosteroids for \u22657 days before the start of treatment with the study drugs.\n* History (\u22646 months before the start of treatment with the study drugs) of pericarditis (any grade) or pericardial effusion (Grade \u22652).\n* History of interstitial lung disease, radiation pneumonitis which required steroid treatment, idiopathic pulmonary fibrosis, drug-induced pneumonitis, idiopathic pneumonitis, or organizing pneumonia.\n* Active infection requiring systemic treatment at the start of treatment in this trial. A washout period of 7 days after the last dose of antibiotics prior to first dose of study drug is required.\n* History of seropositive status for human immunodeficiency virus (HIV) at any time before the start of treatment as determined by presence of anti-HIV-1 or anti-HIV-2 antibodies.\n\n  -- Note: Testing for seropositive status during Screening will be at the discretion of the investigator in participants without previously reported results.\n* Has active hepatitis B, or hepatitis C infection.\n\n  * Note: Participants with hepatitis B (HepBsAg+) who have controlled infection (serum hepatitis B virus DNA polymerase chain reaction (PCR) that is below the limit of detection) are permitted. Participants with controlled infections must undergo periodic monitoring of hepatitis B virus DNA.\n  * Note: Participants who are hepatitis C virus antibody positive (HCV Ab+), who have controlled infection (undetectable HCV RNA by PCR either spontaneously or in response to a successful prior course of anti-HCV therapy) may be enrolled into the study. Participants with controlled infections must undergo periodic monitoring of HCV RNA per treating physician.\n* History (\u22646 months before the start of treatment) of any severe and\/or uncontrolled medical conditions or other conditions that, in the opinion of the investigator and sponsor, could affect the patient's participation in the study such as:\n\n  * Nonmalignant illnesses that are uncontrolled or whose control may be jeopardized by this study treatment.\n  * Nonmalignant decompensated liver disease.\n  * Significant gastrointestinal abnormalities or a chronic condition, including inability to swallow the formulated product, delayed gastric emptying, chronic active Crohn's disease that requires steroid therapy at any dose, refractory nausea and vomiting, and\/or prior surgical procedures affecting absorption or requirement for intravenous alimentation.\n* History (\u22646 months before the start of treatment with the study drugs) of any of the following: acute myocardial infarction, unstable angina pectoris, coronary artery bypass graft, or cerebrovascular accident.\n* Participants who have impaired cardiac function or clinically significant cardiac diseases, including any of the following:\n\n  * Significant ventricular or supraventricular arrhythmias (patients with sinus arrhythmia or chronic rate-controlled atrial fibrillation in the absence of other cardiac abnormalities are eligible).\n  * Left ventricular ejection fraction (LVEF) \\<50% assessed by echocardiogram (ECHO) or multigated acquisition scan (MUGA) within 6 months before the start of treatment with the study drugs and at screening.\n  * Resting bradycardia (\\<50 beats per minute) determined as the mean of 3 heart rate values from the screening triplicate 12-lead electrocardiograms (ECGs) obtained.\n  * Other clinically significant heart disease such as congestive heart failure New York Heart Association Class II-IV.\n* Participants with QT interval \\>470 msec at screening using Fridericia's formula (QTcF), determined as the mean of 3 QTcF values from the screening triplicate ECG.\n* Known history (\u22646 months before the start of treatment with the study drugs) of significant inflammatory eye disease, central serous retinopathy, uveitis, or evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndrome).\n* Participants experiencing unresolved Grade \\>1 toxicity before the start of treatment with the study drug except for hair loss (alopecia), Grade 2 neuropathy is permitted if the investigator permits and written approval is granted by the medical monitor.\n* Participants who have neuromuscular disorders that are associated with elevated creatine kinase (CK) (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis spinal muscular atrophy).\n* History (\u22646 months before the start of treatment with the study drugs) of malignant biliary obstruction, except for patients with a functioning biliary stent.\n* Persons who are pregnant or breast-feeding.\n* Has received or will receive a live vaccine within 30 days prior to the first administration of study medication. Seasonal flu vaccines that do not contain live vaccine are permitted.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Is at the time of signing informed consent, a regular user (including \"recreational use\") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol).\n* Known or suspected hypersensitivity to the active pharmaceutical ingredient, non-steroidal anti-inflammatory drugs or any excipient of the investigational medicinal products (e.g. lactose and croscarmellose) as well as patients with congenital lactase deficiency, galactosaemia or glucose-galactose intolerance.\n* History of treatment with KRAS inhibitors.\n* History of an allogeneic bone marrow or solid organ transplant.\n* Use of systemic anticancer agent (except for antiandrogen therapy for prostate cancer, therapy for bone metastases or cancer-related hypercalcemia) or investigational drug is prohibited \u226428 days for biologics and intravenous chemotherapy, or \u226414 days or 2 half-lives for small molecules, whichever is longer, prior to the first dose of ladarixin.\n* History of radiation therapy \u22647 days prior to the first dose of ladarixin.\n* Use of drugs known to be moderate or strong CYP3A4 inhibitors or inducers or sensitive CYP3A4 substrates with a narrow therapeutic index is prohibited \u226414 days before the start of treatment with the study drug until the end-of-treatment visit. Some of these medications may be allowed at the investigator's discretion after written approval by the medical monitor.\n* Treatment with drugs metabolized by CYP2C9 with a narrow therapeutic index \\[i.e., phenytoin, warfarin, and high dose of amitriptyline (\\>50 mg\/day)\\].\n* Use of herbal drugs and supplements known to be moderate or strong CYP3A4 inhibitors or inducers or sensitive CYP3A4 substrates with a narrow therapeutic index is prohibited \u226414 days before the start of treatment with the study drug until the end- of-treatment visit. These herbal medications include but are not limited to: St. John's wort, cannabis (including \"medical marijuana\"), kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng.\n* History (\u226428 days before the start of treatment with the study drugs) of major surgery or trauma or likelihood to require surgery at any time until the permanent discontinuation of treatment (the significance will be determined by the investigator after consultation with the medical monitor).\n* Participants who start erythropoietin or G-CSF, pegfilgrastim, or filgrastim \u22642 weeks before start of treatment with the study drug.\n* History (\u22641 weeks before the first dose of ladarixin) of transfusion of whole blood, red blood cells or platelet packets.\n* History (\u22642 weeks before the start of treatment with the study drugs) of medications with known risk of Torsades de Pointes (cardiac arrhythmia due to drug-induced QTc prolongation).\n* Use of H2-receptor antagonists, proton pump inhibitors, and\/or intraluminal antacids within 3 days or 5 half-lives (whichever is longer) prior to starting ladarixin.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":100,"SS_ID":"05815173006","EMAIL":"Salman.punekar@nyulangone.org","GEO":[40.71427,-74.00597]},{"TITLE":"Immunonutrition for Improving the Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Confirmed histological diagnosis of metastatic non-small cell lung cancer (both squamous and non-squamous histology);\n* First-line treatment with immunotherapy (alone or in combination with chemotherapy) for metastatic disease by investigators' choice within the framework of good clinical practice and in agreement with current guidelines;\n* Will to participate by providing written informed consent;\n* Availability to administer oral supplements and immunotherapy with or without chemotherapy;\n* Eastern Cooperative Oncology Group Performance Status \u2264 2;\n* Life expectancy \u2265 6 months.\n\nExclusion Criteria:\n\n* Age \\< 18 years;\n* Inability to sign an informed consent;\n* Indication to or ongoing artificial nutrition support (totally compromised spontaneous food-intake) and incapacity or unavailability to consume oral nutritional supplements","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05384873001","EMAIL":[{"email":"r.caccialanza@smatteo.pv.it"}],"GEO":[45.19205,9.15917]},{"TITLE":"A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors","CRITERIA":"Key Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed because of disease progression or unacceptable toxicities. Also includes patients who cannot be treated with standard therapy because of underlying\/existing medical condition.\n* Cohort 1 (colorectal cancer): a) CRC (including microsatellite instability-high \\[MSI-H\\] and microsatellite-stable \\[MSS\\]) regardless of RAS mutation. b) Disease progression within 3 months after last administration of approved standard therapies. c) Prior cytotoxic chemotherapy for metastatic disease include all the following agents: fluoropyrimidine, oxaliplatin, and irinotecan\n* Adjuvant chemotherapy-based treatments count as prior therapy, as long as relapse had occurred within 6 months of completion of such therapies, prior anti-epidermal growth factor receptor (EGFR) therapy (cetuximab, panitumumab), anti-angiogenic therapy (bevacizumab, aflibercept, ramucirumab), regorafenib, and TAS-102 are allowed. d) No more than 5 prior therapies for metastatic disease. For participants who had disease recurrence within 6 months of completing adjuvant chemotherapy, the adjuvant regimen can be considered as 1 chemotherapy regimen for metastatic disease\n* Cohort 2 (NSCLC): a) NSCLC without known EGFR, anaplastic lymphoma kinase (ALK), and ROS1 genomic tumor aberrations. b) No standard therapy exists or standard therapy has failed. c) No more than 3 prior therapies for metastatic disease\n* Phase 2: At least 1 measurable lesion per RECIST version 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2\n* Adequate organ and bone marrow function (Hemoglobin \\>9.0 g\/dL, Absolute neutrophil count \u22651,500\/\u03bcL, Absolute lymphocyte count \u2265600 and \u22642,500\/\u03bcL, Platelet count \u2265100,000\/\u03bcL, Total bilirubin \u22641.5 \u00d7 upper limit of normal, Alanine aminotransferase and aspartate aminotransferase \u22642.5 \u00d7 ULN, Serum creatinine \u22641.5 \u00d7 ULN or creatinine clearance \\>30 mL\/min, Prothrombin time and activated partial thromboplastin time \u22641.5 \u00d7 ULN)\n* Life expectancy of at least 12 weeks\n* Voluntarily provided a written consent to participate in the study\n* Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within the 7 days before study drug administration\n* WOCBP and sexually active fertile male patients with partners who are WOCBP must agree to use 2 highly effective methods of contraception throughout the course of the study and for 12 weeks after the last dose of study drug.\n\nKey Exclusion Criteria:\n\n* Primary central nervous system (CNS) tumor (Phase 1), CNS metastasis, and\/or carcinomatous meningitis. Participants with prior brain metastases treated at least 4 weeks before the first dose of EU101 that are clinically stable and do not require chronic corticosteroid treatment are allowed. Untreated but asymptomatic and clinically stable brain metastases per investigator's discretion are allowed\n* Received prior therapy with any anti-CD137 monoclonal antibody (mAb) or agent\n* Major surgery requiring general anesthesia within 3 weeks before first dose of EU101 or still recovering from prior surgery\n* Active infection that is not controlled or requires intravenous antibiotics in the last 2 weeks\n* History of allogeneic tissue or organ transplant\n* Active hepatitis B virus or hepatitis C virus infection\n* History of any noninfectious hepatitis\n* Human immunodeficiency virus (HIV) infection\n* Received or receiving systemic corticosteroid therapy or any other form of systemic immunosuppressive medicaion 1 week before first dose of EU101\n* Known severe (\u2265Grade 3) hypersensitivity reactions to antibody, or severe reaction to immuno-oncology agents requiring treatment with steroids\n* Konwn or suspected hypersensitivity to EU101 or any component of its formulation\n* Current or history of interstitial lung disease, anaphylaxis, uncontrolled asthma, or pneumonitis that has required systemic corticosteroids\n* Patients with second primary cancer\n* Clinically significant concurrent cardiovascular disease\n* Pregnant women, breasfeeding women, WOCBP, or men with partners who are WOCBP who do not agree to use adequate contraceptive measures\n* Determined as unable to participate in the study per investigator's judgment\n\nOther protocol defined Inclusion\/Exclusion criteria may apply","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04903873006","EMAIL":[{},{},{},{},{},{},{},{},{}],"GEO":[37.566,126.9784]},{"TITLE":"REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)","CRITERIA":"Inclusion-\n\n1. Provide written informed consent.\n2. \u226518 years of age (or meets the country's regulatory definition for legal adult age, whichever is greater).\n3. Pathologically confirmed, locally advanced or metastatic nonsquamous NSCLC\n4. Has not received any prior systemic treatment for their locally advanced or metastatic nonsquamous NSCLC. Prior adjuvant\/neoadjuvant treatment received \\>6 months prior to first dose of study treatment is allowed for early-stage\n\n   NSCLC. Prior monotherapy with an approved EGFR TKI (ie, gefitinib, erlotinib, afatinib, dacomitinib, or osimertinib) as nonstandard first-line therapy for the treatment of locally advanced or metastatic disease is allowed if all of the following criteria are met:\n   1. Treatment duration did not exceed 8 weeks;\n   2. Lack of disease response was documented (radiographically) by an increase in tumor burden (a copy of the computerized tomography \\[CT\\] report showing increase in tumor burden from baseline should be submitted);\n   3. Associated toxicities have resolved to baseline; and\n   4. The EGFR TKI was discontinued at least 2 weeks or 4 half-lives prior to randomization, whichever is longer.\n\n   Prior therapy with EGFR TKI agents targeting exon20ins mutations including amivantamab, mobocertinib, sunvozertinib, furmonertinib, and poziotinib is not allowed.\n5. Documented EGFR mutation status, as determined by local testing performed at a CLIA certified (US) or accredited (outside of the US) local laboratory, defined as follows:\n\n   1. Part A: EGFR ex20ins or other uncommon single or compound EGFR mutation\n   2. Part B: EGFR ex20ins mutation\n6. Archival tumor tissue available for submission, with minimum quantity sufficient to evaluate EGFR mutation status and, where possible, other biomarkers. Patients with insufficient tissue (details provided in laboratory manual) may be eligible following discussion with the sponsor; a fresh biopsy will not be required.\n7. Patients with brain metastasis(es) who have previously received definitive local treatment and have stable central nervous system (CNS) disease (defined as being neurologically stable and off corticosteroid for at least 2 weeks prior to enrollment) are eligible. If brain metastases are diagnosed on screening imaging, the patient may be rescreened for eligibility after definitive treatment.\n\n   b. Asymptomatic brain metastases \u22642 cm in size can be eligible for inclusion if, in the opinion of the Investigator, immediate definitive treatment is not indicated.\n8. At least one measurable lesion as determined per RECIST 1.1 for patients enrolling to Part B. Patients enrolling to Part A may be enrolled without measurable disease.\n9. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n10. Adequate organ function, as defined by the laboratory value\n11. Have a life expectancy of at least 3 months as assessed by the investigator.\n12. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test prior to administration of the first dose of study treatment. Female patients are not considered to be of childbearing potential if they are postmenopausal (no menses for 12 months without an alternative medical cause) or permanently sterile (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).\n13. Both males and females of reproductive potential must agree to use effective birth control during the study prior to the first dose and for 6 months after the last dose of study treatment or longer, based on local requirements.\n\nExclusion -\n\n1. Is currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged not to be scientifically or medically compatible with this study.\n2. Prior treatment with any of the following within the specific time frame specified:\n\n   1. Zipalertinib (TAS6417\/CLN-081) at any time.\n   2. Thoracic radiotherapy \u226428 days, palliative radiation of nonthoracic disease \u226414 days, or palliative radiation of a single lesion \u22647 days prior to first dose of study treatment.\n   3. Major surgery (excluding placement of vascular access) \u226428 days prior to first dose of study treatment.\n   4. All prescribed medication, over-the-counter medication, vitamin preparations and other food supplements, or herbal medications that are strong or moderate CYP3A4 inducers or inhibitors within 7 days prior to first dose.\n3. Have any unresolved toxicity of Grade \u22652 from previous anticancer treatment in the neoadjuvant or adjuvant setting, except for Grade 2 alopecia or skin pigmentation. Patients with other chronic but stable Grade 2 toxicities may be allowed to enroll after agreement between the investigator and Sponsor.\n4. Past medical history of interstitial lung disease, treatment-related pneumonitis (any grade), or any evidence of clinically active interstitial lung disease.\n5. Impaired cardiac function or clinically significant cardiac disease, including any of the following:\n\n   1. History of congestive heart failure (CHF) Class III\/IV according to the New York Heart Association (NYHA) Functional Classification .\n   2. Serious cardiac arrhythmias requiring treatment.\n   3. Resting corrected QT interval (QTc) \\>470 msec calculated using Fridericia's formula (QTcF).\n6. Unable to swallow tablets or has any disease or condition that may significantly affect gastrointestinal (GI) absorption of zipalertinib (such as inflammatory bowel disease, malabsorption syndrome, or prior GI resection).\n7. History of another primary malignancy \u22642 years prior to the date of first dose of study treatment unless at least one of the following criteria are met:\n\n   1. Adequately treated basal or squamous cell carcinoma of the skin\n   2. Cancer of the breast or cervix in situ\n   3. Previously treated malignancy, if all treatment for that malignancy was completed at least 2 years prior to first dose of study treatment, and no current evidence of disease\n   4. Concurrent malignancy determined to be clinically stable and not requiring tumor directed treatment\n8. Known history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) that is unstable or not controlled with treatment.\n9. History of COVID-19 infection within 4 weeks prior to enrolment and\/or have persistent, clinically significant pulmonary symptoms related to prior COVID-19 infection.\n10. Active bleeding disorders.\n11. Known hypersensitivity to the ingredients in zipalertinib or any drugs similar in structure or class. To platinum-containing drugs (ie, cisplatin, carboplatin), pemetrexed, or any known excipients of these drugs. b. Contraindications toning drugs (ie, cisplatin, carboplatin) or pemetrexed according to the respective local labels.\n12. History of leptomeningeal disease and spinal cord compression.\n13. Is unable or unwilling to take dexamethasone, folic acid, and\/or vitamin B12 supplementation during treatment with pemetrexed.\n14. Is pregnant or lactating or planning to become pregnant\n15. The patient is, in the investigator's opinion, unable or unwilling to comply with the trial procedures.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05973773069","EMAIL":[{}],"GEO":[40.4165,-3.70256]},{"TITLE":"Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Age greater than or equal to 18 years\n* Diagnosis of stage IV or recurrent non-small cell lung cancer (NSCLC) with an activating genomic alteration within either: EGFR, ALK, ROS1, or ERBB2 receptor tyrosine kinase domains\n* ECOG performance status of 0 or 1\n* Expected survival \u2265 4 months\n* Participants must have had disease progression after at least one prior line of systemic therapy for NSCLC, including appropriate prior targeted therapy for cases in which a targeted therapy is conventionally used for this genomic alteration, prior to initiating nivolumab trial therapy\n* Measurable disease, not including any lesion that is used for TIL harvest, prior to initiation of nivolumab trial therapy\n* In accordance with the criteria above, safely accessible tumor for TIL harvest by excisional biopsy expected to yield 1.5 cm3 of tissue, in aggregate\n* Participants with known brain metastases are eligible for study enrollment if the brain metastases have received appropriate central nervous system-directed therapy or are found to be clinically stable \u2264 10 mm when comparing scans obtained during the screening period with a scan obtained \u226528 days prior, or if the treating physician determines that immediate CNS-specific treatment is not required prior to the first cycle of therapy. Please also refer to eligibility section on corticosteroids below.\n* Adequate normal organ and marrow function as defined below:\n* a. Hemoglobin \u2265 9.0 g\/dL, with transfusions permissible;\n* b. Absolute neutrophil count (ANC) \u2265 1000 per mm3);\n* c. Platelet count \u2265 75,000 per mm3, without platelet transfusions for 7 days;\n* d. Prothrombin Time \u2264 1.7x the institutional upper limit of normal (ULN), unless participant is receiving intended anticoagulant therapy.\n* e. Serum bilirubin \u2264 2.0x the institutional ULN, or \u2264 4.0x ULN if confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology) with PI approval.\n* f. AST\/ALT \u2264 2.5x institutional ULN unless liver metastases are present, in which case it must be \u2264 5x ULN\n* g. Serum creatinine of \u2264 1.5x institutional ULN, or \u226530 mL\/min for participant with creatinine levels \\>1.5 \u00d7 institutional ULN\n* h. Albumin \u2265 2.0 g\/dl\n* Pulmonary function tests within past 4 months showing DLCO \u226545% of predicted. Adjusted DLCO based on hemoglobin concentration should be used, if available.\n* Human immunodeficiency virus (HIV)-infected participants must be receiving on effective antiretroviral therapy for past 6 months with undetectable viral load and normal CD4 count\n* Participants with history of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load on suppressive therapy, if indicated, and no overt cirrhosis\n* Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they must have an undetectable HCV viral load and no overt cirrhosis\n* Participants with a prior or concurrent malignancy must have a natural history which does not have the potential to interfere with safety or efficacy assessment of the investigational regimen\n\nExclusion Criteria:\n\n* No more than six prior lines of systemic therapy for NSCLC\n* No prior PD-1 or PD-L1 inhibitor treatment for metastatic NSCLC. Examples of inhibitors include: nivolumab, atezolizumab, pembrolizumab, avelumab, cemplimumab, spartalizumab, or durvalumab.\n* Participants with rapidly progressing tumors, as judged by the investigator\n* Active or prior documented autoimmune disease within the past 2 years. NOTE: Subjects with vitiligo, Grave's disease, limited site eczema, or limited site plaque psoriasis not requiring systemic treatment (within the past 2 years), or other autoimmune conditions which are not expected to recur, are allowed after approval from the medical monitor or PI\n* Active leptomeningeal or pachymeningeal metastases, or carcinomatous meningitis. This is due to prognostic implications and timeline for cell therapy\n* Has a diagnosis of primary immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to enrollment.\n* a. Oral hydrocortisone, only for the purposes of a documented adrenal insufficiency diagnosis, is permitted if \u2264 25 mg daily total dose\n* b. Inhaled, intranasal, or topical corticosteroids are permitted\n* Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (other than atrial fibrillation or supraventricular tachycardia), and significant \u226585% carotid artery stenosis\n* Unresolved toxicity (grade 2) from previous anti-cancer therapy. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripheral neuropathy)\n* Mean QT interval corrected for heart rate (QTc) \u2265480 ms calculated from electrocardiograms (EKGs) using Bazett's Correction\n* Participants with active systemic infections requiring intravenous antibiotics within 1 week prior to nivolumab. Prophylactic, empiric, or suppressive antibiotics are permitted with sponsor approval\n* History of allogeneic organ transplant\n* Participants with psychiatric illness\/social situations that would limit compliance with study requirements\n* Participants with a history of anaphylaxis to beta-lactam antibiotics. Patients may be evaluated for reported history by conducting a history and physical, and a skin test\/challenge where appropriate under medical guidance","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05681780001","EMAIL":[{"email":"Tanner.Pearson@moffitt.org"},{},{}],"GEO":[27.94752,-82.45843]},{"TITLE":"A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Age 18-75 years old, male or female\n2. Histopathological and\/or cytopathological confirmation of locally advanced or metastatic NSCLC\n3. Confirmation that the tumor harbors an uncommon epidermal growth factor receptor (EGFR) mutation (tumor tissue biopsy)\n4. At least one measurable lesion\n5. Eastern Cooperative Oncology Group (ECOG) score of 0, 1, or 2\n6. A minimum life expectancy of \\> 3 months\n7. Adequate bone marrow reserve, hepatic, renal, and coagulation function\n\nOther inclusion criteria apply for participating in the study\n\nExclusion Criteria:\n\n1. Participant ever used the epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) for anti-tumor therapy prior to enrollment (Cohort 1), or second generation EGFR TKI (Cohort 2)\n2. Any systemic anti-tumor therapy such as chemotherapy and radiation therapy (including curative radiotherapy or spinal radiotherapy portion \\>30%) used within 3 weeks prior to enrollment; immunotherapy within 4 weeks; any palliative radiotherapy for non-target lesions used to relieve symptoms and traditional Chinese medicines indicated for the tumor within 2 weeks prior to enrollment\n3. Use or intake of drugs or foods containing potent inhibitors or inducers of cytochrome P450 isozyme 3A4 (CYP3A4) within 14 days or 5 half-lives, whichever is the longer, prior to enrollment\n4. Surgical operation (excluding aspiration biopsy) of main organs or a significant injury within 4 weeks prior to enrollment\n5. Any unresolved toxicities from prior therapy greater than Grade 1, at the time of screening except for alopecia\n6. Inability to swallow the study medication, any seriously chronic gastrointestinal disorder, malabsorption syndrome or any other conditions with influence on gastrointestinal absorption\n7. Active central nervous system metastases\n8. Any active infection which has not been controlled at screening.\n\nOther exclusion criteria apply for participating in the Study","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06010329006","EMAIL":"Xiaoyang.xia@teligene.com","GEO":[29.76328,-95.36327]},{"TITLE":"Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)","CRITERIA":"Inclusion Criteria:\n\n* Prevention cohort 1:\n\n  1. Histopathology or cytology confirmed advanced non-small cell lung cancer or esophageal squamous cell carcinoma; no previous systemic therapy (patients who had progressed \u22656 months after \\[neo\\] adjuvant therapy were eligible).\n  2. A treatment regimen of Camrelizumab combined with platinum-containing chemotherapy is planned.\n  3. ECOG: 0-1;\n  4. Age \u226518 years old;\n  5. Have a life expectancy of at least 12 weeks;\n  6. No prior therapy with anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody (including any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).\n  7. Can swallow pills normally;\n  8. Adequate organ and bone marrow function\uff1aStandard of blood routine examination (without transfusion within 14 days) : Hemoglobin (HB) \u226580 g\/L; Neutrophil absolute value (ANC) \u22651.5\u00d710\\^9\/L; Platelet (PLT) \u226590\u00d710\\^9\/L;Biochemical examination should meet the following criteria: Total bilirubin (TBIL) \u22641.5 times the upper limit of normal value (ULN); Alanine aminotransferase (ALT), aspartate aminotransferase (AST) \u22643\u00d7ULN; Serum creatinine (Cr) \u22641.5 ULN;\n  9. Female Subjects of childbearing potential must have a negative serum pregnancy test within 72 hours before the first dose and must be willing to use very efficient barrier methods of contraception for the course of the study through 2 months after the last dose of study treatment. Male Subjects with a female partner(s) of child-bearing potential must be willing to use very efficient barrier methods of contraception for the course of the study through 2 months after the last dose of study treatment;\n  10. Subjects has voluntarily agreed to participate by giving written informed consent\/assent for the trial.\n* Treatment cohort 2:\n\n  1. Histopathology or cytology confirmed advanced lung cancer or esophageal carcinoma;\n  2. Subjects had\u2265G2 grade RCCEP for the first time after treatment with a Camrelizumab based regimen;\n  3. ECOG: 0-2;\n  4. Age \u226518 years old;\n  5. Have a life expectancy of at least 12 weeks;\n  6. Can swallow pills normally;\n  7. No ongoing grade 3 or higher adverse events except for RCCEP (according to CTCAE version 5.0).\n  8. Female Subjects of childbearing potential must have a negative serum pregnancy test within 72 hours before the first dose and must be willing to use very efficient barrier methods of contraception for the course of the study through 2 months after the last dose of study treatment. Male Subjects with a female partner(s) of child-bearing potential must be willing to use very efficient barrier methods of contraception for the course of the study through 2 months after the last dose of study treatment;\n  9. Subjects have voluntarily agreed to participate by giving written informed consent\/assent for the trial.\n\nExclusion Criteria:\n\n* Prevention cohort 1:\n\n  1. Known allergy to the investigational drug or excipient, history of severe hypersensitivity reactions to other monoclonal antibodies.\n  2. Subjects with a condition requiring systemic treatment with other immunosuppressive medications within 14 days of first administration of study treatment.\n  3. Subjects had administration of a live, attenuated vaccine within 4 weeks of the first dose of study treatment or anticipation that such a live attenuated vaccine will be required during the study.\n  4. Advanced patients who have symptoms, have spread to the internal organs, and are at risk of developing life-threatening complications in the short term;\n  5. Subjects with a history of interstitial lung disease, or other disease may interfere with the detection or treatment of suspected drug-related lung toxicity.\n  6. Subjects with active, known or suspected autoimmune disease. Subjects in conditions not expected to recur in the absence of an external trigger, or not requiring systemic treatment are permitted to enroll.\n  7. HIV infection; Combined hepatitis B and hepatitis C co-infection\n  8. Subjects with active CNS metastases are excluded.\n  9. Subjects with clinically significant cardiovascular and cerebrovascular diseases.\n  10. Coagulation abnormalities, with bleeding tendency or are receiving thrombolytic or anticoagulant therapy;\n  11. Disposition evidence of hemoptysis in 2 months (bright red blood, 1\/2 teaspoon).\n  12. History of hemorrhage within 3 months prior to the start of study treatment or clear tendency of hemorrhage\n  13. Thrombosis or thromboembolic event within 6 months prior to the start of study treatment;\n  14. Active infection (CTCAE\\> Grade 2)\n  15. Subjects had or plan to have allogeneic bone marrow transplantation or solid organ transplant.\n  16. Subjects are currently participating and receiving study therapy or had participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks or 5 half-value period life of the agent, before the first dose of trial treatment.\n  17. Subjects have known psychiatric or substance abuse disorder\n  18. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator.\n* Treatment cohort 2:\n\n  1. Known allergy to the investigational drug or excipient\n  2. Advanced patients who have symptoms, have spread to the internal organs, and are at risk of developing life-threatening complications in the short term;\n  3. Subjects with a history of interstitial lung disease, or other disease may interfere with the detection or treatment of suspected drug-related lung toxicity.\n  4. HIV infection; Combined hepatitis B and hepatitis C co-infection\n  5. Active infection (CTCAE\\> Grade 2)\n  6. Subjects have known psychiatric or substance abuse disorder\n  7. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06231680001","EMAIL":[{"email":"yaya7207@126.com"},{}],"GEO":[34.75778,113.64861]},{"TITLE":"Low-dose Radiotherapy Combined With Conventional Fractionated Radiotherapy in Lung Cancer After Immunotherapy Resistance","CRITERIA":"Inclusion Criteria:\n\n* 1. Patients are able to understand the informed consent form, voluntarily participate and sign the informed consent form.\n\n  2. Age range from 18 to 65 years old, regardless of gender.\n\n  3. ECOG level 0-1; Expected life\\>6 months.\n\n  4. At least get into a liquid diet.\n\n  5. No history of severe allergies.\n\n  6. Hemoglobin \u2265 100 g\/L, WBC \u2265 3.5 x10\\~9\/L, neutrophils \u2265 1.8 x10\\~9\/L, platelets \u2265 10 x10\\~9\/L; AST and ALT \u2264 2.5 \u00d7 normal upper limit, AKP \u2264 2.5 \u00d7 normal upper limit.\n\n  7. Non small cell lung cancer (adenocarcinoma, large cell carcinoma, squamous carcinoma, adenosquamous carcinoma, sarcomatoid carcinoma) confirmed by cytology or histology.\n\n  8. Complete clinical data.\n\n  9. \u2264 10 primary and regional metastatic lymph nodes and distant metastatic lesions, and \u2264 5 organ metastases.\n\n  10. Malignant tumor patients with immune therapy resistance (evaluated after 6-8 weeks of treatment and no improvement in clinical symptoms) without standard treatment options.\n\n  11. There are measurable primary lesions, regional lymph node metastasis, and distant metastatic lesions.\n\nExclusion Criteria:\n\n* 1. Missing key patient information (pathological diagnosis, radiation dose, imaging examination, previous treatment plans, etc.).\n\n  2. Refusal or lack of cooperation in research.\n\n  3. Patients who have participated in other clinical studies\/trials within three months.\n\n  4. Patients with brain metastases.\n\n  5. The researcher determines that there are any patients who are not suitable to participate in the study.\n\n  6. Accompanied by severe infections.\n\n  7. Serious liver disease (such as cirrhosis), kidney disease, respiratory disease or chronic system diseases such as uncontrollable diabetes and hypertension; Patients who cannot tolerate radiation therapy.\n\n  8. Previous occurrence of immune related toxic side effects (immune myocarditis, pneumonia, etc.).\n\n  9. Previous history of radiation therapy.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":65,"SS_ID":"05906329001","EMAIL":[{"email":"zhangjd165@sina.com"}],"GEO":[36.66833,116.99722]},{"TITLE":"A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers","CRITERIA":"Inclusion Criteria:\n\n* Non-small cell lung cancer with historic PD-L1 \u2265 1%, as determined locally using a clinically accepted assay. Patients must have experienced benefit from previous anti-PD(L)1-containing therapy for at least 4 months based on investigator-assessed disease stability or response prior to developing documented disease progression. Patients must have also received prior platinum-based chemotherapy, either in combination or in sequence with anti-PD-(L)1, unless patient was ineligible to receive such treatment.\n* Renal cell carcinoma, clear cell histology, previously treated with anti-PD(L)1-containing therapy and a VEGF targeted therapy as monotherapy or in combination. Patients should have documented disease progression following anti-PD(L)1-containing therapy.\n* Cutaneous melanoma, previously treated with anti-PD(L)1-containing therapy. Patients should have documented disease progression following anti-PD(L)1-containing therapy. Patients with BRAF V600-mutant melanoma must have also received prior therapy with a BRAF V600 inhibitor, with or without a MEK inhibitor.\n* Ovarian cancer, high-grade serous histology, na\u00efve to anti-PD(L)1 therapy, must have received one prior systemic therapy in platinum-resistant setting.\n* Nasopharyngeal carcinoma, non-keratinizing locally advanced recurrent or metastatic. Depending on the study arm, patients may be na\u00efve to anti-PD(L)1 therapy, or previously treated with platinum-based chemotherapy with or without anti-PD-(L)1.\n* Locally advanced unresectable or metastatic triple negative breast cancer, ovarian cancer (high-grade serous histology), anal cancer (squamous), MSI-H CRC, esophagogastric cancer, mesothelioma, and HNSCC.\n* Locally advanced unresectable or metastatic anal cancer (squamous), thymic carcinoma, MSI-H CRC, esophagogastric cancer, mesothelioma, and HNSCC, all na\u00efve to anti-PD(L)1 therapy and for whom anti PD(L)1 therapy is not available.\n* Triple negative breast cancer with historic PD-L1 CPS \u2265 1%, must have received at least one line of chemotherapy. In addition, these patients must have previously received sacituzumab govitecan, and in the case of a BRCA mutation a PARP inhibitor, if these treatments are locally approved and accessible to the patient.\n\nExclusion Criteria:\n\n* Impaired cardiac function or clinically significant cardiac disease.\n* Use of agents known to prolong the QT interval unless they can be permanently discontinued for the duration of study.\n* History of severe hypersensitivity reactions to any ingredient of study drug(s) and other mAbs and\/or their excipients.\n* Active, known or suspected autoimmune disease. Patients with vitiligo, type I diabetes, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur may be considered. Patients previously exposed to anti-PD-1\/PD-L1 treatment who are adequately treated for skin rash or with replacement therapy for endocrinopathies should not be excluded.\n* Any evidence of interstitial lung disease (ILD) or pneumonitis, or a prior history of ILD or non-infectious pneumonitis requiring high-dose glucocorticoids.\n* Patients who discontinued prior anti-PD-(L)1 therapy due to an anti-PD-(L)1-related toxicity (applicable to the KFA115 in combination with pembrolizumab treatment arms).\n* Patients with symptomatic peripheral neuropathy limiting instrumental activities of daily living.\n\nOther protocol-defined inclusion\/exclusion criteria may apply","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05544929012","EMAIL":"novartis.email@novartis.com","GEO":[25.04776,121.53185]},{"TITLE":"A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations","CRITERIA":"Inclusion Criteria:\n\nParticipants must meet all of the following inclusion criteria to be eligible for this study:\n\n1. Signed written informed consent and ability to comply with the scheduled visits and study procedures outlined in the protocol.\n2. Age \u2265 18 years, any gender.\n3. Histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer (mainly adenocarcinoma) not suitable for curative surgery or radiation therapy.\n4. ECOG Performance Status (ECOG PS) score of 0-1. Expected survival of at least 12 weeks.\n5. Prior treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI) targeted therapy, with radiological evidence of disease progression. The last treatment before enrollment must show radiological evidence of disease progression, intolerance to chemotherapy toxicity, or the patient being ineligible for standard treatment or unable to tolerate the current treatment regimen.\n6. At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria that has not been previously irradiated.\n7. Tissue, plasma, or cytological samples collected after disease progression confirmed by imaging following treatment with a third-generation EGFR TKI, demonstrating an EGFR-positive gene mutation sensitive to EGFR TKI treatment (including exon 19 deletion, 21 L858R mutation, etc.), with or without T790M mutation.\n8. Adequate organ and bone marrow function, with clinical laboratory test results meeting the following criteria:\n\n   * Hematology: Neutrophils \u2265 1.5 \u00d7 10\\^9\/L; Platelets \u2265 100 \u00d7 10\\^9\/L; Hemoglobin (Hgb) \u2265 100 g\/L;\n   * Liver function: Total bilirubin (TBIL) \u2264 1.5 \u00d7 upper limit of normal (ULN) (\u22643 \u00d7 ULN for patients with Gilbert's syndrome); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u2264 3 \u00d7 ULN;\n   * Renal function: Serum creatinine (Cr) \u2264 1.5 \u00d7 ULN or creatinine clearance rate (CCr, Cockcroft-Gault formula) \u2265 50 mL\/min; Semi-quantitative urine testing (e.g., urine dipstick) result showing urine protein \\< 2+; patients with urine protein \u2265 2+ at baseline should undergo a 24-hour urine collection, and the protein content in the urine within 24 hours should be \\< 1g;\n   * Coagulation function: Activated partial thromboplastin time (APTT) and international normalized ratio (INR) both \u2264 1.5 \u00d7 ULN;\n   * Cardiac function: Left ventricular ejection fraction (LVEF) \u2265 50%;\n   * At rest, male QTcF \\< 450 msec or female QTcF \\< 470 msec.\n9. Ability to swallow oral medications.\n10. Reproductive-age female patients must agree to use effective contraception throughout the study period until 60 days after discontinuing BPI-1178 and osimertinib. Female patients must have a negative pregnancy test result before the start of treatment or prove the absence of pregnancy possibility. Male patients must agree to use effective contraception throughout the study period until 120 days after discontinuing BPI-1178 and osimertinib.\n11. Apart from stable Grade 2 peripheral neuropathy (CTCAE v5.0) and alopecia, any treatment-related clinical toxicity before enrollment must have recovered to baseline or Grade 1.\n12. All patients must have sufficient mental capacity to understand the nature, significance of the study, and risks associated with the study.\n\nExclusion Criteria:\n\nSubjects with any of the following cannot be included in this study:\n\n1. History of prior or current use of anti-tumor drugs targeting CDK4\/6.\n2. Individuals with allergies or a history of severe allergic reactions.\n3. Tissue, plasma, or cytological samples collected after radiological confirmation of disease progression, with testing confirming the presence of specific therapeutic targets such as anaplastic lymphoma kinase (ALK), BRAF V600E, or retinoblastoma (Rb) protein loss.\n4. Received the last dose of anti-tumor treatment (chemotherapy, targeted therapy, investigational drugs, immunotherapy, tumor embolization, herbal medicine for anti-tumor purposes, etc.) within the 2 weeks preceding the start of study drug administration.\n5. Presence of third-space effusion (such as significant pleural or abdominal fluid) that cannot be controlled by drainage or other methods.\n6. Long-term use of steroids is required.\n7. Unresolved hypokalemia and hypomagnesemia at the time of enrollment.\n8. Meets any of the following criteria: Various clinically significant arrhythmias and conduction abnormalities, such as atrial fibrillation, complete left bundle branch block, third-degree heart block, second-degree heart block, PR interval \\> 250 msec; various factors that may increase the risk of QT interval prolongation or arrhythmia events, such as symptomatic heart failure - New York Heart Association (NYHA) class II-IV, congenital long QT syndrome, Brugada syndrome, history of QT interval prolongation (male \\> 470 ms, female \\> 480 ms) or torsades de pointes (TdP), family history of long QT syndrome or unexplained sudden death before the age of 40, various concomitant medications that may prolong QT interval; within the 6 months before starting the study drug, had the following diseases, including unstable angina, myocardial infarction, cerebrovascular accident, pulmonary embolism, etc., or underwent cardiac revascularization surgery.\n9. History of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid treatment, or any clinically evident active interstitial lung disease.\n10. Known active infections, such as hepatitis B (HBsAg positive and hepatitis B virus (HBV) DNA copy number \u2265 200 IU\/ml), hepatitis C, and human immunodeficiency virus (HIV) infection.\n11. Cannot be included if there has been a relapse or concurrent malignancy in the past 5 years. Cervical cancer treated with curative intent, non-melanoma skin cancer, superficial bladder tumors (non-invasive tumors), or cancer with no recurrence for 3 years after curative treatment can be considered for inclusion.\n12. History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.\n13. Various factors judged by the investigator to potentially affect the intake and absorption of BPI-1178 or osimertinib, including gastrointestinal factors (such as uncontrolled inflammatory gastrointestinal diseases, history of abdominal fistula or gastrointestinal perforation within 6 months, extensive small intestine resection requiring enteral or parenteral supplementation, inability to swallow, chronic diarrhea, intestinal obstruction, etc.).\n14. Spinal cord compression, leptomeningeal metastases, or symptomatic brain metastases cannot be included. Asymptomatic patients with brain metastases may be allowed to participate under the following conditions: Asymptomatic brain metastases discovered during screening, determined by the investigator not to require steroids and\/or local treatment; asymptomatic brain metastases treated with local therapy (such as radiation) with the patient discontinuing steroids and\/or antiepileptic treatment for at least 7 days before the first administration of BPI-1178 in combination with osimertinib.\n15. Major surgery (craniotomy, thoracotomy, or laparotomy) or severe unhealed wounds, ulcers, or fractures within the 4 weeks preceding the start of study drug administration.\n16. Local radiation therapy for symptom relief within 1 week before the first administration of the study drug; bone marrow radiation therapy or extensive radiation therapy exceeding 30% within 4 weeks before the first administration of the study drug.\n17. Presence of factors, according to the investigator's judgment, that may interfere with patient participation in the trial or the assessment of study results, such as substance abuse, alcohol addiction, medical, psychiatric illness, and social disorders, or any factors that the investigator deems the patient unsuitable for receiving the study drug (such as severe hypertension, diabetes, thyroid disease, severe infection, portal hypertension, cirrhosis, etc.). Patients who were unwilling or unable to comply with the requirements of this study protocol will be excluded.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06362980001","EMAIL":[{}],"GEO":[39.9075,116.39723]},{"TITLE":"Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* 1. Participants with histologically confirmed Stage IB (\u2265 4 cm), II, IIIA (N2) NSCLC (as per the 8th American Joint Committee on Cancer (AJCC)) who are considered to have resectable disease.\n\n  2. Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).\n\n  3. Participants must have tumor tissue available for PD-L1 immunohistochemical (IHC) testing.\n\n  4. Eastern Cooperative Group (ECOG) Performance Status 0-2. 5. Able to give informed consent.\n\nExclusion Criteria:\n\n* 1. Presence of locally advanced, unresectable, or metastatic disease. 2. Participants with known EGFR mutations, ALK or ROS1 translocation. 3. Subjects with active, known, or suspected autoimmune disease (except subjects with type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment).\n\n  4. Subjects with a condition requiring systemic treatment with either corticosteroids (10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids are permitted in the absence of active autoimmune disease.\n\n  5. Subjects with previous malignancies are excluded unless a complete remission was achieved at least 5 years prior to study entry and no additional therapy is required or anticipated to be required during the study (non-melanoma skin cancer and other indolent malignancies not requiring any treatment and that are unlikely to affect blood-based biomarkers are allowed).","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06250829001","EMAIL":[{"email":"Morgan.Black@lhsc.on.ca"}],"GEO":[42.98339,-81.23304]},{"TITLE":"Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Be willing and able to provide written informed consent\/assent for the trial.\n2. Histologically documented, metastatic NSCLC with no previous systemic therapy\n3. At least 2 distinct measurable metastatic sites, which are 1 cm or larger; patients can have radiation to multiple measurable disease sites as clinically indicated, however, there must be at least 1 measurable non-radiated target lesion for response assessment.\n4. Agreeable to provide archival tissue for correlative studies; if no archival tissue available may obtain an exemption by the study team.\n5. Be at least 18 years of age on day of signing informed consent.\n6. Have measurable disease based on RECIST 1.1.\n7. Have a performance status of \u22641 ECOG Performance Scale.\n8. Demonstrate adequate organ function as defined in Table 2, all screening labs should be performed within 10 days of treatment initiation\n9. Have one measurable lesion of at least 1 cm outside the planned radiation field (defined as not receiving direct beam from any of the treatment portals).\n10. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n11. Female subjects of childbearing potential must be willing to use an adequate method of contraception as outlined in Section - Contraception, for the course of the study through 120 days after the last dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n12. Male subjects of childbearing potential must agree to use an adequate method of contraception as outlined in Section- Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n\nExclusion Criteria:\n\n1. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.\n2. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.\n3. Has a known history of active TB (Bacillus Tuberculosis)\n4. Hypersensitivity to pembrolizumab or any of its excipients.\n5. Has had prior chemotherapy, immunotherapy or targeted small molecule therapy within 6 months prior to study Day 1.\n6. Patient who have previously received radiation overlapping, as determined by the treating radiation oncologist, with the current planned radiation treatment fields are ineligible.\n7. Patient's treated with whole brain radiation therapy are ineligible.\n8. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.\n9. Has known active central nervous system (CNS) metastases and\/or carcinomatous meningitis. Subjects with previously treated brain metastases (with SRS and\/or neurosurgery) may participate provided they are clinically stable and, have no evidence of new or enlarging brain metastases and also are off steroids 3 days prior to dosing with study medication.\n10. Patients who have not recovered (i.e., \u2264 Grade 2 or at baseline) from adverse events due to a previously administered agent. \\*Note: If subject received major surgery, they must have recovered adequately from the toxicity and\/or complications from the intervention prior to starting therapy. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n11. Has history of autoimmune disorders, (non-infectious) pneumonitis that required steroids, evidence of interstitial lung disease or active, non-infectious pneumonitis.\n12. Has an active infection requiring systemic therapy.\n13. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n14. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n15. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.\n16. Patients with prior history of chemoradiation for lung cancer\n17. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1\/2 antibodies).\n18. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \\[qualitative\\] is detected).\n19. Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist\u00ae) are live attenuated vaccines, and are not allowed.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":100,"SS_ID":"05691829001","EMAIL":[{"email":"Vamsidhar.Velcheti@nyulangone.org"}],"GEO":[40.71427,-74.00597]},{"TITLE":"Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* All patients \u2265 18 years of age undergoing consideration of surgical resection, including lobar resections, sublobar resections, and pneumonectomies, for primary lung cancer will be eligible.\n* Patients with previously resected disease and\/or previous radiation therapy will be considered on a case by case basis.\n\nExclusion Criteria:\n\n* Patients with active infection or pneumonia which may impact exosome makeup\n* Additionally, if at the discretion of the operating surgeon, obtaining bronchial washings would lead to undue morbidity, the patient would be excluded and replaced","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05424029007","EMAIL":[{}],"GEO":[40.70038,-73.59291]},{"TITLE":"Biology of Young Lung Cancer Study: The YOUNG LUNG Study","CRITERIA":"Inclusion Criteria:\n\n* Age 45 and under at lung cancer diagnosis\n* Pathologically confirmed bronchogenic lung carcinoma (NSCLC or SCLC of any stage) at any treatment time point\n* Provision of written informed consent\n* Willingness to undergo no more than two (2) peripheral blood draws in a four (4) week period, with no more than 50 ml peripheral blood collected over eight (8) weeks\n* Individuals under age 18 are eligible for study if they meet defined criteria; in addition, consent for participation must be given by a legal guardian or parent\n\nExclusion Criteria:\n\n* Individuals who decline to sign consent\n* Individuals who are unable to give consent or assent and are without a designated healthcare proxy\n* Compromise of patient diagnosis or staging if tissue is used for research","SEX":"ALL","AGE_MIN":15,"AGE_MAX":45,"SS_ID":"05265429004","EMAIL":[{"email":"Pasi_Janne@dfci.harvard.edu"},{}],"GEO":[42.35843,-71.05977]},{"TITLE":"Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Cindilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Sign written informed consent before implementing any test related process.\n* Age \u2265 18 years old and \u2264 75 years old.\n* Subjects with histologically or cytologically confirmed locally advanced (iiib-iiic), metastatic or recurrent (stage IV) squamous NSCLC (TNM lung cancer staging, 8th Edition, International Association for the study of lung cancer and Joint Committee on American Classification of cancer), inoperable and radical concurrent radiotherapy and chemotherapy, and who have not received systematic treatment before.\n* The gene status is unknown, or the gene status of known histological specimens confirms that there is no EGFR gene sensitive mutation or ALK gene fusion mutation.\n* According to the evaluation criteria of solid tumor efficacy (RECIST v1.1), at least one lesion can be measured by imaging. Lesions located in the radiation field of previous radiotherapy can be regarded as measurable lesions if they are confirmed to have progression.\n* Have not received any systematic antitumor treatment for advanced \/ metastatic diseases in the past. Subjects who have previously received platinum containing adjuvant \/ neoadjuvant chemotherapy or radical chemoradiotherapy for advanced diseases, if the interval between disease progression or recurrence and the end of the last chemotherapeutic drug treatment is at least 6 months, are allowed to be included in this study.\n* Subjects with brain metastases who are asymptomatic or have stable symptoms after local treatment are allowed to be included as long as they meet the following conditions: 1) measurable lesions outside the central nervous system, 2) no symptoms of the central nervous system or no aggravation of symptoms for at least 2 weeks, 3) no glucocorticoid treatment is required, or glucocorticoid treatment is stopped within 7 days before the first administration, Or the dosage of glucocorticoid is stable and reduced to less than 10mg \/ day prednisone (or equivalent dose) within 7 days before the first administration.\n* Patients were allowed to receive palliative radiotherapy, but the end time of radiotherapy was 7 days before the administration of the first study drug, and the toxicity related to radiotherapy recovered to less than or equal to grade 1 (CTCAE V5.0).\n* ECoG score: 0-1.\n* Expected survival time \\> 3 months.\n* For adequate organ function, the subjects shall meet the following laboratory indexes: 1) the absolute value of neutrophils (ANC) \u2265 1.5x109\/l without granulocyte colony stimulating factor in recent 14 days; 2) Platelets \u2265 100 without blood transfusion in recent 14 days \u00d7 109\/L 3) Hemoglobin \\> 9g \/ dl without blood transfusion or erythropoietin in recent 14 days; 4) Total bilirubin \u2264 1.5 times the upper limit of normal value (ULN) 5) aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are \u2264 2.5 times ULN (ALT or AST \u2264 5 is allowed for subjects with liver metastasis \u00d7 ULN\uff09 6) Serum creatinine \u2264 1.5 times ULN and creatinine clearance rate (calculated by Cockcroft Gault formula) \u2265 60 ml \/ min; 7) Good coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT) \u2264 1.5 times ULN; 8) Normal thyroid function is defined as thyroid stimulating hormone (TSH) within the normal range. If the baseline TSH is beyond the normal range, subjects with total T3 (or FT3) and FT4 within the normal range can also be enrolled; 9) The myocardial enzyme spectrum is within the normal range (for example, simple laboratory abnormalities that are not clinically significant according to the comprehensive judgment of the researcher are also allowed to be included in the group).\n* For female subjects of childbearing age, urine or serum pregnancy test shall be conducted within 3 days before receiving the first study drug administration (day 1 of cycle 1) and the result is negative. If the urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is required. Women of non childbearing age are defined as having been postmenopausal for at least 1 year or having undergone surgical sterilization or hysterectomy.\n* If there is a risk of pregnancy, all subjects (male or female) are required to use contraceptives with an annual failure rate of less than 1% throughout the treatment period until 120 days after the last study drug administration (or 180 days after the last study drug administration).\n\nExclusion Criteria:\n\n* Pathology is adenocarcinoma or small cell lung cancer (SCLC), including lung cancer mixed with SCLC and NSCLC.\n* Received radiotherapy before administration of the first study drug, Meet one of the following conditions: 1) more than 30% of bone marrow had received radiotherapy within 14 days before treatment; 2) received radiotherapy for lung lesions within 6 weeks before treatment and the dose was \\> 30Gy (the enrolled subjects must recover from the toxicity of previous radiotherapy to grade 1 or below, do not need glucocorticoid treatment and have no history of radiation pneumonia) 3) The end time of palliative radiotherapy was within 7 days before the administration of the first study drug.\n* Other malignant diseases other than NSCLC diagnosed within 5 years before the first administration (excluding radical skin basal cell carcinoma, skin squamous epithelial carcinoma, and \/ or radical resection of carcinoma in situ).\n* Currently participating in intervention clinical research treatment, or receiving other research drugs or using research instruments within 4 weeks before the first administration.\n* Previously received the following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or drugs that stimulate or co inhibit T cell receptors (e.g., CTLA-4, OX-40, CD137).\n* Received systemic treatment with Chinese patent medicine with anti NSCLC indications or drugs with immunomodulatory effect (including thymosin, interferon and interleukin, except for local use to control pleural effusion) within 2 weeks before the first administration.\n* Active autoimmune diseases requiring systemic treatment (such as the use of disease relief drugs, glucocorticoids or immunosuppressants) occurred within 2 years before the first administration. Alternative therapies (such as thyroxine, insulin or physiological glucocorticoids for adrenal or pituitary insufficiency) are not considered systemic treatment.\n* Being treated with systemic glucocorticoids (excluding nasal spray, inhaled or other local glucocorticoids) or any other form of immunosuppressive therapy within 7 days before the first administration of the study; Note: it is allowed to use glucocorticoids in physiological doses (\u2264 10 mg \/ day prednisone or equivalent).\n* There is clinically uncontrollable pleural effusion \/ peritoneal effusion (subjects who do not need to drain effusion or stop drainage for 3 days and have no significant increase in effusion can be enrolled).\n* Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation.\n* Those who are known to be allergic to active ingredients or excipients such as cindilimab, pemetrexed, gemcitabine, carboplatin and cisplatin.\n* Not fully recovered from toxicity and \/ or complications caused by any intervention before starting treatment (i.e. \u2264 grade 1 or reaching baseline, excluding fatigue or hair loss).\n* Known history of human immunodeficiency virus (HIV) infection (i.e. HIV 1 \/ 2 antibody positive).\n* untreated active hepatitis B (defined as HBsAg positive and HBV-DNA copy number at the same time was higher than the upper limit of normal value in the laboratory of the research center). Note: hepatitis B patients who met the following criteria can also be admitted into the group: 1) HBV viral load \\<1000 copy \/ml (200 IU\/ml) before the first dose, the subjects should receive anti HBV therapy to avoid reactivation of the virus during the whole course of chemotherapy (2). Subjects with anti HBc (+), HBsAg (-), anti HBs (-) and HBV viral load (-), Prophylactic anti HBV treatment is not required, but virus reactivation needs to be closely monitored.\n* Active HCV infected subjects (HCV antibody positive and HCV-RNA level above the lower limit of detection).\n* Have received live vaccine within 30 days before the first administration (cycle 1, day 1); Note: it is allowed to receive inactivated virus vaccine for injection against seasonal influenza within 30 days before the first administration; However, live attenuated influenza vaccines administered intranasal are not allowed.\n* Pregnant or lactating women.\n* There are any serious or uncontrollable systemic diseases, such as: 1) there are significant abnormalities in rhythm, conduction or morphology of resting ECG and the symptoms are serious and difficult to control, such as complete left bundle branch block, heart block above grade II, ventricular arrhythmia or atrial fibrillation; 2) Unstable angina pectoris, congestive heart failure, chronic heart failure with New York Heart Association (NYHA) grade \u2265 2; 3) Myocardial infarction occurred within 6 months before enrollment; 4) Poor blood pressure control (systolic blood pressure \\> 140 mmHg, diastolic blood pressure \\> 90 mmHg); 5) A history of noninfectious pneumonia requiring glucocorticoid treatment within 1 year before the first administration, or the current presence of clinically active interstitial lung disease; 6) Active pulmonary tuberculosis; 7) There are active or uncontrolled infections requiring systemic treatment; 8) There were clinically active diverticulitis, abdominal abscess and gastrointestinal obstruction; 9) Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis; 10) poor control of diabetes (fasting blood glucose (FBG) \\> 10mmol\/L). 11) Urine routine examination showed that urinary protein was \u2265 + +, and the 24-hour urinary protein was confirmed to be more than 1.0 g; 12) Subjects with mental disorders and unable to cooperate with treatment.\n* There is no evidence that the participants in the study group have abnormal medical history or other potential conditions that may hinder the study group from participating in the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05312840001","EMAIL":[{"email":"hjh2018hjh@163.com"}],"GEO":[28.95944,118.86861]},{"TITLE":"Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Age: 18 Years and older\n2. ECOG physical score 0-1 points; expected survival time \u2265 3 months;\n3. Pathologically confirmed diagnosis with Stage IIB-IIIB NSCLC which harbored rare driver alteration including RET fusions, BRAF (V600E or non-V600E but confirmed driver mutations), ERBB2 exon20 insertion, MET amplification (FISH confirmed) or exon 14 skipping. Suspected N2 disease should be confirmed by either mediastinoscopy or EBUS. N1 disease could be determined through PET\/CT but biopsy of primary lung cancer is needed;\n4. Lung function capacity capable of tolerating the proposed lung surgery\n5. Available tissue of tumor for PD-L1 test\n6. Subjects voluntarily joined the study and signed informed consent, with good compliance to follow-up.\n\nExclusion Criteria:\n\n1. Stage I and stage IV NSCLC;\n2. Patients who have previously used any other anti-tumor drugs or radiotherapy;\n3. Large panel NGS indicated sensitive EGFR alteration, ALK fusion, ROS1 fusion or any other driver mutations combined with MDM2\/MDM4 amplification;\n4. Histologically confirmed small cell lung cancer (including lung cancer mixed with small cell lung cancer and non-small cell lung cancer);\n5. A history of active bleeding within the 6 months before enrollment, or receiving thrombolysis or anticoagulant therapy, or the investigator believes that there is a clear tendency to gastrointestinal bleeding (such as esophageal varices with bleeding risk, local activity) Ulcer lesions, etc.) or active hemoptysis;\n6. Patients with any underlying disease that investigators consider it may affect patient's prognosis including sever cardiovascular, pulmonary disease or serious infections; Clinically obvious gastrointestinal abnormalities, which may affect the intake, transport or absorption of drugs (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.), or patients with total gastrectomy;\n7. Known or suspected autoimmune disease with activity. Participants may be enrolled if they have type 1 diabetes, hypothyroidism that requires only hormone replacement therapy, skin diseases that require no systemic treatment (such as purpura, psoriasis, or hair loss), or other conditions that are not expected to return without external trigger.\n8. Patients with active hepatitis B (positive for HBsAg) or hepatitis C (positive for HCV RNA).\n9. Patients with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)\n10. Patients with other active malignancies within five years\n11. Pregnant or lactating women; those who have fertility are unwilling or unable to take effective contraceptive measures;\n12. Patients with low compliance or willingness to take the drugs and surveillance.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05800340001","EMAIL":[{"email":"syzhongwenzhao@scut.edu.cn"},{"email":"ruifu66@foxmail.com"},{},{},{}],"GEO":[28.95944,118.86861]},{"TITLE":"NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations","CRITERIA":"Inclusion Criteria:\n\n* Aged \u2265 18 years\n* Decision to start first-line (1L) treatment with TDC according to the current SmPCs\n* Histologically or cytologically confirmed diagnosis of NSQ mNSCLC (incl. LCNEC if considered NSCLC-like by the treating physician)\n* Treatment-na\u00efve for metastatic disease\n* No sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) alterations\n* Molecular Next Generation Sequencing (NGS) panel as per institutional standard has been initiated (including the following genes: KRAS, STK11, KEAP1, and TP53)\n* TTF-1 expression analysis has been initiated\n* PD-L1 expression analysis has been initiated\n* Women of childbearing potential must use effective contraception during treatment with durvalumab and for at least 3 months after the last dose of durvalumab\n* Ability to understand the study concept\n* Provision of signed informed consent form in accordance with applicable local provisions\n\nExclusion Criteria:\n\n* Current participation in interventional clinical trials\n* Contraindications according to current SmPCs","SEX":"ALL","AGE_MIN":18,"AGE_MAX":120,"SS_ID":"06494540005","EMAIL":"information.center@astrazeneca.com","GEO":[50.24636,10.20187]},{"TITLE":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","CRITERIA":"Inclusion Criteria:\n\n* Have histologically or cytologically confirmed, locally advanced or metastatic non-small cell lung cancer (NSCLC) that is treatment-naive and not amenable to curative therapy including surgical resection or (chemo) radiation. Adjuvant or neoadjuvant therapy for Stage I or Stage II disease is allowed if administered more than 12 months prior to the development of locally advanced or metastatic disease\n* Have a tumor that harbors an epidermal growth factor receptor (EGFR) exon 19del or exon 21 L858R substitution, as detected by an Food and Drug Administration (FDA)-approved or other validated test in a clinical laboratory improvement amendments (CLIA)-certified laboratory (sites in the United States) or an accredited local laboratory (sites outside of the United States) in accordance with site standard of care\n* Participants with a history of brain metastases must have had all lesions treated as clinically indicated (that is, no current indication for further definitive local therapy). Any definitive local therapy to brain metastases must have been completed at least 14 days prior to randomization, and the participant can be receiving no greater than 10 milligram (mg) prednisone or equivalent daily for the treatment of intracranial disease\n* Can have prior or concurrent second malignancy (other than the disease under study)which natural history or treatment is unlikely to interfere with any study endpoints, safety, or the efficacy of the study treatment(s)\n* Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1\n\nExclusion Criteria:\n\n* History of uncontrolled illness, including but not limited to uncontrolled diabetes; ongoing or active infection (includes infection requiring treatment with antimicrobial therapy \\[participants will be required to complete antibiotics 1 week prior to starting background anticancer treatment\\] or diagnosed or suspected viral infection); active bleeding diathesis; impaired oxygenation requiring continuous oxygen supplementation; refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of background anticancer treatment or doxycycline\/minocycline; psychiatric illness, social situation, or any other circumstances that would limit compliance with study requirements; any ophthalmologic condition that is clinically unstable; pre-existing skin condition that would prevent adequate evaluations of dermatologic toxicity, as determined by the investigator\n* Medical history of interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis\n* Known allergy, hypersensitivity, or intolerance to the excipients of amivantamab, lazertinib, or to tetracyclines, doxycycline, minocycline, or their excipients or to any component of the enhanced dermatologic management\n* Participant has received any prior systemic treatment at any time for locally advanced stage III or metastatic stage IV disease (adjuvant or neoadjuvant therapy for stage I or II disease is allowed if administered more than 12 months prior to the development of locally advanced or metastatic disease)\n* Participant has an active or past medical history of leptomeningeal disease","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06120140075","EMAIL":"Participate-In-This-Study@its.jnj.com","GEO":[41.27976,36.3361]},{"TITLE":"A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations","CRITERIA":"Inclusion Criteria:\n\n* Histologically or cytologically documented non-squamous NSCLC. NSCLC of mixed histology is allowed.\n* Newly diagnosed locally advanced or metastatic NSCLC or recurrent non-squamous NSCLC, not amenable to curative surgery or radiotherapy.\n* WHO PS of 0 to 1 with no deterioration over the 2 weeks prior to enrolment.\n* Minimum life expectancy \\> 12 weeks at Day 1.\n* Confirmation by the local laboratory that the tumour harbours one of the 2 common EGFRm known to be associated with (Epidermal Growth Factor Receptor- Tyrosine Kinase Inhibitor) EGFR-TKI sensitivity.\n* At least 1 lesion that can be accurately measured at baseline as \u226510 mm in the longest diameter with computed tomography (CT) or magnetic resonance imaging (MRI) and that is suitable for accurate repeated measurements.\n* Contraceptive use by males or females should be consistent with local regulations\n\nExclusion Criteria:\n\n* Any evidence of diseases, history of allogenic organ transplant, which in the investigator's opinion makes it undesirable for the participant to participate in the study or would jeopardise compliance with protocol.\n* Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the osimertinib, or previous significant bowel resection that would preclude adequate absorption distribution, metabolism, or excretion of osimertinib.\n* History of another primary malignancy except for malignancy treated with curative intent with no known active disease \u22652 years.\n* Any unresolved toxicities from prior therapy with Common Terminology Criteria for Adverse Events CTCAE) Grade \u22651, at the time of first dose of study intervention, with the exception of alopecia and Grade 2 prior platinum therapy related neuropathy.\n* Spinal cord compression or brain metastases unless asymptomatic, stable, and not requiring corticosteroids for at least 2 weeks prior to start of study intervention.\n* Active infection, including tuberculosis and infections with HBV (verified by known positive HBsAg result) or HCV.\n* Should participants with HIV infection be included, patients are only eligible if they meet the criteria per protocol.\n* Patient with protocol defined cardiac issue.\n* History of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD.\n* Any concomitant medications known to be associated with Torsade de Pointes.\n* Prior exposure to any systemic anti-cancer therapy for advanced NSCLC not amenable to curative surgery or radiation including chemotherapy, biologic therapy, immunotherapy, or any investigational drug.\n* Any concurrent anti-cancer treatment without an adequate washout period prior to the first dose of study intervention.\n* Palliative radiotherapy with a limited field of radiation within 2 weeks, or with wide field of radiation or to more than 30% of the bone marrow within 4 weeks, prior to the first dose of study intervention.\n* Major surgical procedure or significant traumatic injury.\n* Current use of medications or herbal supplements known to be strong inducers of CYP 3A4.\n* Prior treatment with an EGFR-TKI.\n* Participants with a history of hypersensitivity, or intolerance to the active or inactive excipients of osimertinib, amivantamab, or recommended pre-treatments of amivantamab or drugs with a similar chemical structure or class to these drugs.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":130,"SS_ID":"05801029043","EMAIL":"information.center@astrazeneca.com","GEO":[7.19882,100.5951]},{"TITLE":"A Study to Explore the Role and Impact of Wearable Smart Devices in Perioperative NSCLC Patients","CRITERIA":"Inclusion Criteria:\n\n1. Participants must provide voluntary consent to participate in this research and possess the capacity to sign an informed consent form.\n2. Participants must be aged over 18 years.\n3. Participants must have undergone pulmonary resection surgery with a postoperative pathological confirmation of primary lung cancer.\n\nExclusion Criteria:\n\n1. Patient refusal to participate in this research.\n2. Inability to wear wearable smart monitoring devices due to various reasons.\n3. The pathological report suggests a non-small cell lung cancer (NSCLC) exclusion.\n4. History of secondary lung cancer surgery.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06118229001","EMAIL":[{"email":"liangwh1987@163.com"},{}],"GEO":[23.11667,113.25]},{"TITLE":"Lung Tumor Protein Synthesis Rates in Lung Cancer Patients","CRITERIA":"Inclusion Criteria:\n\n1. Aged 18-65 years\n2. Compos mentis\n3. Diagnosed with lung cancer, with treatment requiring a thoracotomy or VATS lobectomy\n\nExclusion Criteria:\n\n1. Neoadjuvant chemo- or radiotherapy in the past four weeks\n2. Use of systemic steroids in the past four week\n3. Insulin-dependent diabetes mellitus\n4. Pregnancy","SEX":"ALL","AGE_MIN":18,"AGE_MAX":65,"SS_ID":"05794529001","EMAIL":[{"email":"e.deloos@zuyderland.nl"}],"GEO":[50.88365,5.98154]},{"TITLE":"Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer","CRITERIA":"Randomized Pilot Inclusion\n\n* Patients planned to receive Stereotactic Body Radiotherapy (SBRT) to a biopsy-proven or clinically-suspected NSCLC\n* Age \\>18 years' old\n* Patient capable of giving informed consent\n\nRandomized Pilot Exclusion\n\n* Use of antibiotics, antifungal, antivirals or antiparasitics during the 4 weeks prior to registration\n* Active infection with oral temperature \\>100\u00b0F\n* Use of corticosteroids, methotrexate or immunosuppressive drugs during the 4 weeks prior to registration\n* Use of chemotherapy during the 4 weeks prior to radiotherapy or during radiotherapy. Chemotherapy cannot begin before the collection of the 30-day post treatment sample (S4).\n* Documented history of HIV, HBV or HCV\n* Active uncontrolled gastrointestinal disorders such as inflammatory bowel disease, moderate\/severe irritable bowel syndrome, persistent, infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhea of unknown etiology, Clostridium Difficile infection (within 2 years of lung cancer diagnosis) or Helicobacter Pylori infection (untreated)\n* Major surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in the past five years. Any major bowel resection at any time\n* Patients on anti-diarrheal medications\n* Patients on probiotics\n\nSafety Trial Inclusion\n\n* Patients planned to receive precision hypofractionated radiation (SBRT or an ablative dose of radiation is used if SBRT is not appropriate or if insurance does not approve - i.e. \\> 30 Gy in 10 fraction equivalent) to all sites of oligoprogressive NSCLC who progressed after 1st line systemic therapy which included immunotherapy\n* The number of sites of progression are \\< 5 sites.\n* Age \\>18 years' old\n* Patient capable of giving informed consent\n\nSafety Trial Exclusion\n\n* Evidence of CNS or leptomeningeal disease\n* Use of antibiotics, antifungal, antivirals or antiparasitics during the 4 weeks prior to registration\n* Active infection with oral temperature \\>100\u00b0F\n* Use of corticosteroids, methotrexate or immunosuppressive drugs during the 4 weeks prior to registration\n* Use of chemotherapy during the 4 weeks prior to radiotherapy or during radiotherapy. Chemotherapy cannot begin before the collection of the 30-day post treatment sample (S3).\n* Documented history of HIV, HBV or HCV\n* Active uncontrolled gastrointestinal disorders such as inflammatory bowel disease, moderate\/severe irritable bowel syndrome, persistent, infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhea of unknown etiology, Clostridium Difficile infection (within 2 years of lung cancer diagnosis) or Helicobacter Pylori infection (untreated)\n* Major surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in the past five years. Any major bowel resection at any time\n* Patients on anti-diarrheal medications\n* Use of probiotics during the 4 weeks prior to radiotherapy or during radiotherapy","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03546829001","EMAIL":[{"email":"ching.lai@pennmedicine.upenn.edu"},{"email":"radonccru@pennmedicine.upenn.edu"},{}],"GEO":[39.95233,-75.16379]},{"TITLE":"Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics","CRITERIA":"Inclusion Criteria:\n\n* Provision of informed consent prior to any study-specific procedures.\n* Male or female aged at least 18 years.\n* ECOG PS - 0\/1-2.\n\nExclusion Criteria:\n\n* Any concurrent and\/or other active malignancy that has required systemic treatment within 2 years of first dose of treatment.\n* Generalized impairment or mental incompetence that would render the patient unable to understand his\/her participation in the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05736029001","EMAIL":[{"email":"Himabindu.Pappu@BSWHealth.org"},{}],"GEO":[32.78306,-96.80667]},{"TITLE":"A Study of DF6002 Alone and in Combination With Nivolumab","CRITERIA":"Inclusion Criteria:\n\n* Advanced\/metastatic solid tumors, for which no standard therapy exists or standard therapy has failed among the following tumor types: melanoma, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell, urothelial, gastric, esophageal, cervical, hepatocellular, merkel cell, cutaneous squamous cell carcinoma, renal cell, endometrial, triple-negative breast, ovarian, and prostate\n* ECOG performance status of 0 or 1\n* Clinical or radiological evidence of disease\n* Adequate hematological, hepatic and renal function\n* Anticoagulants are required for the following: Khorana Risk Score \u2265 2 or as assessed by Investigator as being at high risk for venous thromboembolism (VTE) or history of VTE \u2265 6 months from enrollment\n\nExclusion Criteria:\n\n* Concurrent anticancer treatment (with the exception of palliative bone directed radiotherapy), immune therapy, or cytokine therapy (except for erythropoietin), major surgery (excluding prior diagnostic biopsy), concurrent systemic therapy with steroids or other immunosuppressive agents, or use of any investigational drug within 28 days before the start of study treatment\n* Previous malignant disease other than the current target malignancy within the last 3 years, with the exception of basal or squamous cell carcinoma of the skin, localized prostate cancer or cervical carcinoma in situ\n* Rapidly progressive disease\n* Serious cardiac illness or medical conditions\n* Known diagnosis of antiphospholipid syndrome or clinically significant hereditary thrombophilia\n\nOther protocol-defined inclusion\/exclusion criteria apply","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04423029054","EMAIL":[{}],"GEO":[42.81687,-1.64323]},{"TITLE":"Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent\n* Males and females age \u2265 18 years\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 - 2\n* Measurable disease by RECIST 1.1\n* Women of childbearing potential must have a negative serum pregnancy test within one month prior to initiating treatment\n* Pathologically proven diagnosis of Stage IIIA or IIIB non-small cell lung cancer (NSCLC)\n* No Positron Emission Tomography (PET)\/CT evidence of metastatic disease\n* An MRI of the brain with contrast excluding intracranial metastatic disease (or CT with contrast if MRI is medically contraindicated). An MRI without contrast is only permitted if the subject cannot have contrast for medical reasons\n* If a pleural effusion is present, it must be tapped and confirmed to be cytologically negative. If an effusion is deemed too small to safely tap, the subject will be eligible\n* Women of child-bearing potential and men with partners of child-bearing potential must agree to practice sexual abstinence or to use the forms of contraception listed in Child-Bearing Potential\/Pregnancy section for the duration of study participation and for 90 days following completion of therapy\n* Adequate organ function per laboratory results\n\nExclusion Criteria:\n\n* Current or anticipating use of other anti-neoplastic or investigational agents while participating in this study\n* Diagnosed with a psychiatric illness or is in a social situation that would limit compliance with study requirements\n* Evidence of severe or systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease) that would interfere with study protocol as judged by the investigator\n* Is pregnant or breastfeeding\n* Active connective tissue disorders, such as active lupus or scleroderma\n* Known Acquired Immune Deficiency (HIV (+)\/AIDS)\n* Has a known allergic reaction to any excipient contained in the study drug formulations\n* Active Grade 3 (per the NCI CTCAE, Version 5.0) or higher viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study treatment\n* Prior thoracic radiotherapy","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04992780006","EMAIL":[{"email":"ctnursenav@kumc.edu"}],"GEO":[39.13,-94.56218]},{"TITLE":"Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies","CRITERIA":"Key Inclusion Criteria\n\n* Life expectancy \u226512 weeks.\n* Patients must have measurable disease per RECIST 1.1.\n* Part A-1 cohorts:\n* Must have exhausted all standard treatment options, including appropriate targeted therapies; or patients for which no standard therapy is considered appropriate\n* Patients with advanced, histologically confirmed urothelial (transitional cell) carcinoma that recurred after or has been refractory to prior therapy (fresh tumor biopsy or an archived sample must be submitted); or\n* Patients with advanced, histologically confirmed pancreatic, breast, non-small-cell lung cancer (NSCLC), gastric, esophageal, head and neck, or ovarian tumors that recurred after or has been refractory to prior therapy (fresh tumor biopsy or an archived sample testing for Nectin-4 expression).\n* Part A-2:\n* Must have exhausted all standard treatment options, including appropriate targeted therapies; or patients for which no standard therapy is considered appropriate\n* Patients with advanced, histologically confirmed urothelial (transitional cell) carcinoma that have progressed following prior therapy\n* Cohort B-1: Histologically documented urothelial carcinoma, previously treated with enfortumab vedotin (EV). Patients with resectable, locally advanced urothelial carcinoma are ineligible. Must have had progression or recurrence of urothelial cancer during or following receipt of most recent therapy.\n* Cohort B-2 and B-3: Histologically documented urothelial carcinoma, not previously treated with enfortumab vedotin (EV). Patients with resectable, locally advanced urothelial carcinoma are ineligible. Must have had progression or recurrence of urothelial cancer during or following receipt of most recent therapy.\n* Cohort B-4: Patients with histologically confirmed non-mucinous epithelial ovarian, fallopian tube, or primary peritoneal cancer that is Stage III or IV according to the International Federation of Gynecology and Obstetrics (FIGO) or tumor, node and metastasis staging criteria that have progressed following prior therapy.\n* Cohort B-5: Patients with triple-negative breast cancer confirmed negative for estrogen receptor (ER) and progesterone receptor (PR) and negative for human epidermal growth factor receptor 2 (HER2) (i.e., triple-negative) that have progressed following prior therapy.\n* Cohort B-6: Patients with histologically confirmed non-small cell lung cancer (NSCLC) with no actionable mutations, such as Epidermal Growth Factor Receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) fusion oncogene, or ROS1 that have progressed following prior therapy.\n* Cohort B-7: Locally advanced or metastatic, histologically confirmed urothelial (transitional cell) carcinoma, ineligible for cisplatin, no prior systemic anticancer treatment for advanced urothelial carcinoma.\n* Cohort C renal insufficiency cohort: Patients with histologically documented urothelial carcinoma, ovarian, triple negative breast, or non-small cell lung cancer that have been previously treated with a locally approved therapy.\n\nKey Exclusion Criteria (all patients):\n\n* Clinically relevant troponin elevation\n* Uncontrolled diabetes\n* Known active or untreated CNS and\/or carcinomatous meningitis\n* Grade \u22652 peripheral neuropathy\n* Active keratitis or corneal ulcerations\n* Patients with uncontrolled hypertension\n* History of another malignancy within 3 years before first dose of BT8009 or residual disease from a previously diagnosed malignancy (with some exceptions).\n* Active systemic infection requiring therapy, or fever within the last 14 days prior to first dose of BT8009.\n* Prior Stevens-Johnson syndrome\/toxic epidermal necrolysis on any MMAE-conjugated drug\n* Parts A-2 and B-7 Pembrolizumab Combination Cohorts:\n* Prior organ transplant (including allogeneic)\n* Diagnosis of clinically relevant immunodeficiency\n* History of interstitial lung disease\n* Parts B-2 and B-3: Prior treatment with enfortumab vedotin Other protocol-defined Inclusion\/Exclusion criteria may apply","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04561362029","EMAIL":"clinicalstudies@bicycletx.com","GEO":[53.48095,-2.23743]},{"TITLE":"177Lu-anti-PD-L1 sdAb in Metastatic Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Willing and able to provide informed consent prior to start of any study procedures and assessments and must be willing to comply with all study procedures.\n2. Adult participants \u2265 18 years of age.\n3. Participants with a documented history of histopathological confirmed metastatic NSCLC that is unresectable, progressive and for which standard treatment measures are no longer effective.\n4. Participants with a documented history of PD-L1 positive NSCLC. Any number of prior treatment lines are allowed in this study, however at least one of the treatment line(s) must include an anti-PD(L)-1 antibody. Participants with any documented PD-L1 positivity by immunohistochemistry (IHC) without prior treatment with anti-PD(L)-1 antibody may be allowed on a case-by-case basis in discussion with study Sponsor, if it is determined not to put the participant at an increased risk of adverse drug effects and\/or interfere with the integrity of study outcome.\n5. Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2.\n6. Participants must have a life expectancy of \\>4 months in the opinion of the Investigator.\n7. Women of childbearing potential (WOCBP) must have a negative beta-human chorionic gonadotropin (\u03b2-hCG) test and must not be breastfeeding. WOCBP are defined as those who are not surgically sterile or post-menopausal. Female subjects will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. Female subjects \\< 50 years old who meet the criteria for post-menopausal status without previous surgical sterilization should be considered for further investigation with luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels to confirm serological post-menopausal status.\n8. WOCBP must agree to use a highly effective method of contraception during the study and for 14 days after the last injection of 177Lu-RAD204im and\/or 6 months after the last dose of 177Lu-RAD204tr, whichever occurs later. Acceptable methods of contraception are described the Protocol.\n9. Male subjects who are able to father a child must agree to avoid impregnating a partner and to adhere to a highly effective method of contraception during the study and for 14 days after the last injection of 177Lu-RAD204im and\/or 6 months after the last dose of 177Lu-RAD204tr, whichever occurs later. All male subjects must agree to not donate sperm during the study and for 14 days after the last injection of 177Lu-RAD204im and\/or 4 months after the last dose of Lu-RAD204tr, whichever occurs later. Acceptable methods of contraception are described in the Protocol.\n10. Subjects with previously treated brain metastases are eligible to participate if: they are clinically and radiologically stable (no evidence of progression by imaging; same imaging modality \\[magnetic resonance imaging (MRI) or computed tomography (CT) scan\\] must be used for each assessment) for at least 28 days prior to the first dose of 177Lu-RAD204; and any neurologic symptoms returned to baseline. Note: Subjects with a history of leptomeningeal disease may not participate even if stable clinically.\n11. For Phase I: Participants must have positive lesion(s) by 177Lu-RAD204im SPECT\/CT as described in Image Review Manual. Estimated total radiation dose to healthy organs derived from phase 0 dosimetry must not exceed dose constraints according to the American Association of Physicists in Medicine Quantitative Analysis of Normal Tissue Effect in the Clinic (QUANTEC) and International Commission on Radiological Protection (ICRP), in discussion with study Sponsor.\n\nExclusion Criteria:\n\n1. History of prior organ transplant.\n2. Any other known, active malignancy, except for treated cervical intraepithelial neoplasia, or non-melanoma skin cancer. Patients with a history of malignancies of low recurrence potential who have received curative-intent therapy may be approved on a case-by-case basis in discussion with study Sponsor, if it is determined not to put the patient at an increased risk of adverse drug effects and\/or interfere with the integrity of study outcome.\n3. Have any medical condition that would, in the Investigator's judgment, prevent the participant's full participation in the clinical study due to safety concerns or compliance with clinical study procedures such as participants with severe claustrophobia who are unresponsive to oral anxiolytics, participants with low back pain who cannot lie comfortably on an imaging table, participants who are hyperactive or hyperkinetic such that they cannot tolerate lying still for multiple time point imaging procedures, etc.\n4. Residual toxicity \\> Grade 1 from prior anti-cancer therapy (except alopecia). Participants with \\> Grade 1 toxicity from prior anti-cancer therapy may be approved on a case-by-case basis in discussion with study Sponsor, if it is determined not to put the patient at an increased risk of adverse drug effects and\/or interfere with the integrity of study outcome.\n5. History of uncontrolled allergic reactions and\/or known or expected hypersensitivity to protein therapeutics, 177Lu-RAD204 or any of its excipients.\n6. Inadequate organ functions as reflected in laboratory parameters:\n\n   * Creatinine clearance (calculated using Cockcroft-Gault formula, or measured) \\< 60 mL\/min or serum creatinine \\>1.5 x upper limit of normal (ULN)\n   * Platelet count of \\< 75 x 109\/L\n   * Absolute neutrophil count (ANC) \\< 1.0 x 109\/L\n   * Haemoglobin \\< 9 g\/dL\n   * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 3 x ULN, or \\> 5 x ULN for patients with known liver metastases\n   * Total bilirubin \\> 1.5 x ULN, except for patients with documented Gilbert's syndrome who are eligible if total bilirubin \u2264 3 x ULN\n   * For participants not taking warfarin or other anticoagulants: international normalized ratio (INR) \u22641.5 or prothrombin time (PT) \u22641.5 x ULN; and either partial thromboplastin time or activated partial thromboplastin time (PTT or aPTT) \u22641.5 x ULN. Participants taking warfarin must be on a stable dose that results in a stable INR \\<3.5. Among participants receiving other anticoagulant therapy, PT or aPTT must be within the intended therapeutic range of the anticoagulant.\n7. Patients requiring blood product transfusion within 4 weeks of first dose of 177Lu-RAD204tr are not eligible to participate.\n8. Clinically significant cardiovascular disease including but not limited to:\n\n   * Unstable angina or acute myocardial infarction within 6 months prior to screening\n   * Clinically significant and\/or uncontrolled heart disease such as congestive heart failure requiring treatment (New York Heart Association (NYHA) grade \u2265 2)\n   * Uncontrolled arterial hypertension or unstable clinically significant arrhythmia\n   * Known LVEF \\< 50%\n   * QTcF \\> 470 msec for females and QTcF \\> 450 msec for males on screening electrocardiogram (ECG) or congenital long QT syndrome.\n9. Participation in any other investigational trial at the time of informed consent signature.\n10. Pregnant or lactating women.\n\n    The following exclusion criteria apply to participants in Phase I:\n11. Major surgery within 4 weeks prior to first dose of 177Lu-RAD204tr. Exceptions may be approved on a case-by-case basis in discussion with study Sponsor, if it is determined not to put the participant at an increased risk of adverse drug effects and\/or interfere with the integrity of study outcome.\n12. Received anti-cancer therapy, including chemotherapy, immunotherapy, radiation therapy, biologic, herbal therapy, or any investigational therapy or investigational device, within 28 days (or 5 half-lives for biologic\/noncytotoxic agents, whichever is shorter), prior to the first dose of 177Lu-RAD204tr. Focal palliative radiotherapy given within 28 days prior to the first dose of 177Lu-RAD204tr may be approved on a case-by-case basis in discussion with the Sponsor, if it is determined not to put the participant at an increased risk of adverse drug effects and\/or interfere with the integrity of study outcome. For participants who received radiotherapy more than 28 days prior to the first dose of 177Lu-RAD204tr, efforts should be made to calculate the prior radiation absorbed dose to each critical organ such as the kidneys, liver, lungs, and bone marrow. The absorbed dose limits for critical organs should not exceed the cumulative absorbed dose from the prior radiopharmaceutical and\/or external beam radiation therapy (EBRT) treatment(s) and the planned course of treatment in this study. Participants who would have cumulative absorbed dose to critical organs exceeded will not be enrolled in the study.\n13. Has had or is scheduled to have major surgery \\< 28 days prior to the first dose of 177Lu-RAD204tr. Elective surgical procedures not considered to put participants at higher risk of AEs may be allowed on a case-by-case basis in discussion with the Sponsor.\n14. Positive status for human immunodeficiency virus (HIV).\n15. Active or chronic hepatitis B or C. Chronic hepatitis B or hepatitis C with undetectable viral loads on stable suppression therapy may be allowed on a case-by-case basis in discussion with study Sponsor.\n16. Any medical condition which, in the opinion of the Investigator, places the participant at an unacceptably high risk for toxicities.\n17. Any uncontrolled intercurrent illness or clinically significant uncontrolled condition(s), including but not limited to active bacterial, fungal, or viral infections requiring systemic therapy.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06305962003","EMAIL":[{"email":"jcardaci@dni.com.au"}],"GEO":[-31.98184,115.8073]},{"TITLE":"Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC","CRITERIA":"Inclusion Criteria:\n\n1. Voluntary participation in clinical studies; fully understand, be informed about the study and have signed the informed consent form (ICF).\n2. Male or female aged \u2265 18 and \u2264 75 years, at the time of signing the ICF.\n3. Willingness to follow and ability to complete all trial procedures.\n4. Histologically or cytologically diagnosed with ES-SCLC (according to the Veterans Administration Lung Study Group staging system).\n5. No prior systemic therapy for ES-SCLC\uff1bat the end of the combination chemotherapy with serplulimab, the efficacy evaluation is CR, PR, or SD.\n6. At least one measurable lesion as assessed according to RECIST 1.1 , lesions that have received radiation therapy in the past are only considered measurable if they show clear progression.\n7. An ECOG PS score of 0 or 1.\n8. An expected survival \u2265 3 months.\n9. Normal major organ functions\n10. For participants receiving therapeutic anticoagulation: stable anticoagulant regimen\n11. Negative human immunodeficiency virus (HIV) test at screening\n12. Negative hepatitis B surface antigen (HBsAg) test at screening\n13. Positive hepatitis B surface antibody (HBsAb) test at screening, and positive hepatitis B virus core antibody (HBcAb), no HBV-DNA test is required; or negative HBsAb at screening accompanied by either of the following: Negative total hepatitis B core antibody (HBcAb), or positive total HBcAb test followed by a negative hepatitis B virus (HBV) DNA test. The HBV DNA test will be performed only for participants who have a negative HBsAg test, a negative HBsAb test, and a positive total HBcAb test.\n14. Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening. The HCV RNA test will be performed only for participants who have a positive HCV antibody test.\n15. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception.\n16. For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm.\n\nExclusion Criteria:\n\n1. Complete response or tumor progression occurred during the combination of serplulimab and chemotherapy treatment.\n2. Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.Patients with CNS lesions treated and Asymptomatic are eligible to participate in this study if they meet all of the following criteria: Measurable lesions exist outside of CNS that meet the definition of RECISTv1.1; The patient has no history of Intracranial hemorrhage or intracerebral hemorrhage; The patient did not receive stereotactic radiotherapy within 7 days before the start of the study treatment, whole brain radiotherapy within 14 days before the start of the study treatment, or Neurosurgery resection within 28 days before the start of the study treatment; Patients do not need to continue to receive Corticosteroid treatment for CNS diseases. Allowing stable doses of anticonvulsant drugs for treatment; Transfer is limited to the cerebellum or supratentorial area (i.e. not transferred to the midbrain, pons, medulla oblongata, or spinal cord); There is no evidence to suggest progress between the completion of CNS local treatment and the initiation of study treatment; New Asymptomatic patients with central nervous system metastasis found during screening are eligible to participate in this study after receiving radiotherapy and\/or surgery\n3. History of leptomeningeal disease.\n4. The total number of liver metastases was \u22653 or a single liver metastases was greater than 3cm\n5. Uncontrolled tumor-related pain\n6. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.\n7. Uncontrolled or symptomatic hypercalcemia (\\> 1.5 mmol\/L ionized calcium or calcium \\> 12 mg\/dL or corrected serum calcium \\> ULN).\n8. Known active or suspected autoimmune diseases. Subjects in a stable state with no need for systemic immunosuppressant therapy are allowed to enroll.\n9. Have a history of Idiopathic pulmonary fibrosis, organized pneumonia (such as Bronchiolitis obliterans), drug-induced pneumonia or idiopathic pneumonia, or chest computed tomography (CT) at screening shows evidence of active pneumonia.\n10. Active or latent pulmonary tuberculosis.\n11. Serious cardiovascular disease (such as heart disease, myocardial infarction or cerebrovascular accident of New York Heart Association Grade II or above), unstable arrhythmia or unstable angina pectoris occurred within 3 months before the start of the study treatment.\n12. Major surgical procedures other than diagnosis have been performed within 4 weeks prior to the start of the study treatment, or significant surgical procedures are expected to be required during the study period.\n13. Malignant tumors other than small cell lung cancer (SCLC) occurred within 5 years before the start of the study treatment, but the cancer under study and malignant tumors with negligible risk of metastasis or death (such as the 5-year overall survival rate\\>90%) were excluded, such as fully treated cervical Carcinoma in situ, non Melanoma skin cancer, localized prostate cancer, ductal carcinoma in situ or stage I Uterine cancer.\n14. Severe infection occurred within 4 weeks before the start of study treatment, including but not limited to hospitalization due to infection, Bloodstream infections, severe pneumonia or any active infection that may affect the safety of patients.\n15. Previously received allogeneic stem cell or solid organ transplantation.\n16. Any other diseases, metabolic disorders, physical examination abnormalities, or clinical laboratory abnormalities that may affect the interpretation of results or treatment complications that may pose a high risk to patients, may result in contraindications to the use of research drugs.\n17. Received attenuated live vaccines within 4 weeks prior to the start of research treatment, or expected to receive such vaccines during the treatment period of sulumab or within 5 months after the last administration of serplulimab.\n18. Currently undergoing anti HBV treatment.\n19. Received any other investigational drug treatment within 28 days prior to the start of the study treatment.\n20. Previous treatment with CD137 agonists or immune checkpoint blockade therapy, including anti CTLA-4, anti PD-1, and anti PD-L1 therapeutic antibodies.\n21. Received systemic immunostimulatory therapy (including but not limited to interferon and interleukin-2 \\[IL-2\\]) within 4 weeks prior to the start of study treatment or within 5 drug elimination half-lives (whichever is longer).\n22. Systemic immunosuppressive drugs (including but not limited to Corticosteroid, Cyclophosphamide, Azathioprine, methotrexate, Thalidomide and anti TNF - \u03b1 preparations) were used within 2 weeks before the start of the study treatment, or systemic immunosuppressive drugs were expected to be used during the study treatment, with the following exceptions: 1)Patients receiving short-term, low-dose systemic immunosuppressive drugs or patients receiving one-time pulse therapy of systemic immunosuppressive drugs (for example, receiving Corticosteroid for 48 hours to treat contrast allergy) may be qualified to participate in this study after being confirmed by the medical supervisor; 2) Patients who receive Mineralocorticoid (such as fluhydrocortisone), inhaled or low-dose Corticosteroid to treat Chronic obstructive pulmonary disease (COPD) or asthma, or low-dose Corticosteroid to treat orthostatic Hypotension or adrenal insufficiency are eligible to participate in this study.\n23. Has a history of severe allergies to chimeric or humanized antibodies or fusion proteins.\n24. Known hypersensitivity to serplulimab.\n25. Known hypersensitivity to carboplatin or etoposide.\n26. Pregnant or lactating women, or women who plan to become pregnant during the study treatment or at least 5 months after the last administration of Slulimab or 6 months after the last administration of cisplatin\/carboplatin or Etoposide.\n27. Researchers determine that patients cannot benefit from TRT.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06350162001","EMAIL":[{}],"GEO":[30.29365,120.16142]},{"TITLE":"Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI","CRITERIA":"Inclusion Criteria:\n\nPatients must meet all of the following criteria to be eligible to participate in this study:\n\n1. Age \u2265 18 years at the time of signing the informed consent form (ICF).\n2. Histologically or cytologically confirmed locally advanced (tumor lesion could not be radically cued by surgery or radiation as asessed by the investigators) or metastatic NSCLC.\n3. Prior treated with at least one second-generation ALK TKI (including unmarketed investigational drugs) and imaging evidence of disease progression (PD) or intolerance to prior treatment toxicity.\n4. Agree to provide fresh tumor tissue samples to test positive for ALK fusion (ALK-positive) by the central laboratory:\n\n   1. If the patient is indeed unable to provide fresh tumor tissue samples (e.g., repuncture has been assessed by the investigator as having a higher clinical risk) and cannot provide archived tissue samples within 2 years prior to initial administration, but can provide ALK-positive testing reports within 2 years prior to the first administration (detection methods include FISH, RT-PCR, IHC \\[Ventana method\\] or NGS, etc.), inclusion or not of the patient will be discussed and decided by the investigator and the sponsor;\n   2. If the patient is indeed unable to provide either fresh tumor tissue samples (e.g., repuncture has been assessed by the investigator as having a higher clinical risk) or ALK-positive testing reports within 2 years prior to the first administration, but can provide archived tissue samples within 2 years prior to the first administration and confirmed as ALK-positive by the central laboratory, inclusion or not of the patient will be discussed and decided by the investigator and the sponsor.\n5. Must have at least one extracranial target lesion that meets the RECIST 1.1 criteria; For a lesion that has previously received radiotherapy, it can be assessed as a target lesion only when it shows definite progression after radiotherapy.\n6. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n7. Estimated Life expectancy \u2265 3 months.\n8. Prior antitumor treatment-related AE had recovered to \u2264 Grade 1 as defined by NCI-CTCAE v 5.0 prior to initial administration (except for toxicities without safety risk as determined by the investigator, such as alopecia, Grade 2 peripheral neurotoxicity associated with prior platinum therapy, etc.).\n9. Organ function shall meet the following requirements:\n\n   1. No blood products, hematopoietic cell growth factors (e.g., granulocyte colony stimulating factor, erythropoietin), or other medication received to correct abnormal blood routine at least 2 weeks before initial administration, and blood routine: Absolute neutrophil count (ANC) \u22651.5\u00d7109\/L, Platelets (PLT) \u2265100\u00d7109\/L, Platelets (Hb) \u226590g\/L;\n   2. Pancreatic function: Serum total amylase \u22641.5\u00d7 upper limit of normal (ULN); Serum lipase \u22641.5\u00d7ULN (it is allowed to be included if serum total amylase\\>1.5\u00d7 ULN, but the pancreatic amylase is in the ULN range);\n   3. Hepatic function: Total serum bilirubin (TBIL) \u2264 1.5\u00d7ULN, Aspartate transaminase (AST) and alanine transaminase (ALT) \u2264 2.5\u00d7ULN if no liver metastases, or otherwise TBIL \u2264 3\u00d7ULN, AST and ALT \u2264 5\u00d7ULN.\n   4. Renal function: Creatinine clearance \u2265 50 mL\/min (according to Cockcroft-Gault Equation).\n   5. Coagulation function: International normalized ratio (INR) and prothrombin time (PT)\u2264 1.5\u00d7ULN (except for patients receiving anticoagulant therapy).\n10. Be able to swallow medication, follow protocol procedures, and comply with follow-up visit requirements.\n11. Female patients with reproductive potential agreed to use effective method of contraception throughout the entire study duration and for at least 3 months after the last dose of study medication.\n\nExclusion Criteria:\n\nPatients who meet any of the following criteria are not eligible to participate in this study:\n\n1. Patients with known driver alterations other than ALK, such as EGFR, MET, RET, ROS1, NTRK, etc. (If ALK co-mutation exists, the patient can discuss with the investigator for enrollment);\n2. Previous treated with any third-generation ALK TKI (including marketed drugs such as loratinib, and unmarketed investigational drugs);\n3. History of allergy to any component or excipient of SY-3505 capsules;\n4. With other primary malignancies, except those that have been cured and have not recurred within 2 years prior to screening, and those that have been cured of basal or squamous cell carcinoma of the skin, carcinoma in situ of cervix, or carcinoma in situ of breast;\n5. The presence of symptomatic primary CNS tumors, symptomatic CNS metastases, leptomeningeal carcinomatosis, or untreated spinal cord compression. Except: Patient had stable CNS disease (no evidence of progression identified by imaging for at least 4 weeks prior to initial administration, and all neurological symptoms had recovered to baseline), no evidence of new or progressive brain metastases, no CNS surgery or radiotherapy within 4 weeks prior to initial administration, and no stereotactic radiosurgery (SRS) within 2 weeks prior to initial administration. Steroid administration was stopped or the dose stabilized within 2 weeks prior to initial administration. (This exception does not include cancerous meningitis, which should be excluded regardless of clinically stable conditions).\n6. The following symptoms or diseases occurred prior to initial administration and remain poorly controlled after optimal treatment:\n\n   1. Systemic bacterial, viral or fungal infection with uncontrolled activity;\n   2. Poorly controlled (poorly control refers to the effusion increases significantly within 2 weeks after extraction, with obvious symptoms, requiring further puncture or other intervention) pleural effusion, abdominal effusion or pericardial effusion after intervention (such as drainage) ;\n   3. Poorly controlled diabetes (fasting blood glucose \u226511.1 mmol\/L and\/or HbA1c \u2265 8%);\n   4. Uncontrolled symptomatic hyperthyroidism or hypothyroidism as assessed by the investigator;\n   5. Uncontrolled electrolyte disturbances (e.g., hypocalcemia, hypomagnesium, hypokalemia) as assessed by the investigator;\n   6. Clinically significant gastrointestinal disorders included active ulcerative colitis, Crohn's disease, gastrointestinal ulcers, or prior surgical procedures that could significantly affect drug absorption as assessed by the investigator.\n7. Presence with severe cardiovascular diseases\/abnormalities, meeting any of the following criteria:\n\n   1. Patients with corrected QT interval for heart rate according to Fridericia's formula \\> 470 msec (females) and \\> 450 msec (males) during the screening period (If prolonged QTcF suspected to be caused by medication and was assessed as safe and controllable by the investigator, the patient can be enrolled after drug correction);\n   2. Left ventricular ejection fraction (LVEF) \\< 50%;\n   3. Myocardial infarction or unstable angina or clinically significant uncontrolled arrhythmias, including bradyarrhythmia (such as type II second degree heart block or third degree heart block) that may lead to prolonged QTcF within 6 months prior to initial administration;\n   4. Class III or IV congestive heart failure according to New York Heart Association (NYHA) classification;\n   5. History of poorly controlled hypertension, unstable hypertension, or poor compliance with antihypertensive therapy as assessed by the investigator.\n8. Presence or with histiory of the following active viral infection:\n\n   1. Active hepatitis B (HBsAg positive and HBV-DNA \u22652\u00d7103 IU\/mL, patients could be included if the HBV-DNA value decreased to below 2\u00d7103 IU\/mL after regular antiviral therapy) or active hepatitis C virus infection (HCV-RNA \\>ULN on central test) at screening;\n   2. HIV positive at the time of screening or have a known history of other immunodeficiency diseases;\n   3. History of organ transplantation, hematopoietic stem cell or bone marrow transplantation.\n9. Presence of other lung diseases that require systematic therapy or are severe, such as active tuberculosis, interstitial lung disease, etc., that may affect the interpretation of the study results or put patients at high risk according to the judgment of the investigator;\n10. Have used CYP3A4 potent inhibitors (atazanavir, clarithromycin, Indinavir, Itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telomycin, troleandomycin, voriconazole, grapefruit \\[juice\\]) or inducers (carbamazepine, phenobarbital, phenytoin, rifabutin, St. John's Wort, Rifampicin) within 2 weeks prior to initial administration or cannot be stopped during the study;\n11. The following antitumor treatments were administered prior to initial administration: More than 30% of bone marrow radiation or extensive radiotherapy (within 4 weeks prior to initial administration); Palliative radiotherapy (within 7 days prior to initial administration); Other antitumor agents treatment (within 2 weeks prior to initial administration or within 5 half-life times of the agent, whichever is longer), such as chemotherapy, targeted therapy (immunotherapy or other antibody-based therapies).\n12. Major surgery (defined as Grade \u22653 surgery, excluding central venous catheter placement, tumor punch biopsy, and gastric tube placement) or significant trauma within 4 weeks prior to initial administration, and did not fully recover.\n13. Have participated in other clinical studies within 4 weeks prior to initial administration (Note: Patients who did not use the investigational drug or investigational medical device or who had discontinued treatment from other clinical studies and only followed up for survival were excluded) or plan to participate in other clinical studies during the study.\n14. History of severe arteriovenous thrombosis (such as cerebrovascular accident \\[including transient ischemic attack\\], deep vein thrombosis, and pulmonary embolism) within 1 year prior to initial administration and has the potential to increase the risk in the study as assessed by the investigators, or a tendency to bleed within 30 days prior to initial administration, or a risk of major gastrointestinal bleeding as determined by the investigators.\n15. Pregnant or lactating woman.\n16. Other conditions assessed unsuitable for participation in this study, such as other serious acute or chronic diseases, or laboratory abnormalities that may increase the risk for the patient, or may interfere with interpretation of the study results.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05869162001","EMAIL":[{"email":"syuankai@cicams.ac.cn"}],"GEO":[39.9075,116.39723]},{"TITLE":"Safety and Efficacy of NK510 to Treat NSCLC","CRITERIA":"Inclusion Criteria:\n\n* age\u226518 years;\n* Epidermal growth factor receptor (EGFR) gene mutation negative, ROS oncogene 1 (ROS1) negative, and anaplastic lymphoma kinase (ALK) negative, stage III or IV non-small cell lung cancer that cannot be operated on or treated with radiotherapy, locally advanced or relapsed or metastatic non-small cell lung cancer;\n* Biopsy tissue or pathological sections can be obtained, and tumor PD-L1 expression is positive (defined as \u2265 1% of TPS);\n* After receiving \u2265 4 courses of PD-1 monoclonal antibody \u00b1 chemotherapy in the past, the disease is currently in a stable or progressive state;\n* According to RECIST v1.1 (Solid Tumor Efficacy Evaluation Criteria), there is at least one CT scan measurable lesion present;\n* ECOG physical status score of 0-2;\n* Expected survival \\>=3 months;\n* Except for hair loss and fatigue, all AE after anti-tumor treatments have alleviated toxicity to level 1 (CTCAE v5.0) or original baseline;\n* Female of childbearing age must be non lactating and have a negative serum pregnancy test within 1 week prior to enrollment;\n* Voluntarily sign an informed consent form to participate in this study.\n\nExclusion Criteria:\n\n* Pregnant or lactating female patients;\n* Patients with central nervous system metastasis (CNS) and\/or cancerous meningitis and obvious symptoms;\n* Other malignancies have been diagnosed within 3 years prior to the first use of the study drug;\n* Subjects with active, known or suspected autoimmune diseases \\[excluding type I diabetes, hypothyroidism requiring hormone replacement therapy only, skin diseases not requiring systemic treatment (such as vitiligo, psoriasis or alopecia) or diseases that are not expected to recur without external triggers;\n* subjects have a history of immune deficiency, including HIV testing positive, or other acquired or congenital immune deficiency diseases or organ transplantation history;\n* Have a history of serious cardiovascular and cerebrovascular diseases, including but not limited to: severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, third degree atrioventricular block, etc; At rest, the QTc interval obtained from a 12 lead electrocardiogram examination is\\>480 ms; Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other Grade 3 or above cardiovascular and cerebrovascular events occurred within 6 months prior to enrollment; The New York Heart Association (NYHA) has a heart function rating of \u2265 II or a left ventricular ejection fraction (LVEF) of\\<50%; Clinically uncontrollable hypertension;\n* Radical radiotherapy was performed within 4 weeks prior to enrollment; Local palliative radiotherapy or Chinese herbal medicine\/traditional Chinese patent medicines and simple preparations with anti-tumor indications within 2 weeks before enrollment;\n* Not fully recovered from major surgery or trauma within 2 weeks prior to enrollment;\n* Participated in research drug trials and received research treatment or used research instruments within 4 weeks before enrollment;\n* Other anti-tumor treatments outside of this research protocol are currently underway or planned;\n* Received blood transfusion, erythropoietin, granulocyte colony stimulating factor (G-CSF), or granulocyte macrophage colony stimulating factor treatment within 2 weeks prior to enrollment;\n* Subjects who received systemic treatment with corticosteroids (prednisone\\>10 mg\/day or equivalent) or other immunosuppressive\/enhancing drugs (such as thymosin, interleukin-2, and interferon) within 2 weeks prior to enrollment. Allowing selected subjects to inhale or topically use corticosteroids in the absence of active autoimmune diseases;\n* The virological examination of hepatitis B or hepatitis C during screening meets any of the following criteria:\n\n  1. HBsAg positive and peripheral blood HBV-DNA titer detection\u22651\u00d710\\^3 copies\/mL or upper limit of normal value;\n  2. HCV antibody positive;\n* Subjects who are known to be allergic or intolerant to PD-1 monoclonal antibody.\n* Meet any of the following standards:\n\n  1. Hematological:Neutrophil count \\<1.5\u00d710\\^9\/L; Platelet count \\< 75\u00d710\\^9\/L; Hemoglobin \\< 9 g\/dL;\n  2. Hepatic:ALT \\> 3 \u00d7 ULN (tumor liver metastasis \u2265 5\u00d7ULN); AST \\> 3\u00d7ULN (tumor liver metastasis \u2265 5\u00d7ULN); TBIL \\> 1.5 \u00d7ULN or TBIL\\>2.5 \u00d7 ULN (3.0 mg\/dL) in Gilbert syndrome subjects;\n  3. Renal:Serum creatinine \\> 1.5 \u00d7 ULN or creatinine clearance \\< 50mL\/min;\n* Any uncertain factors that affect the safety or compliance of patients.\n* Investigators believe that any other serious or uncontrollable medical disease, active infection, abnormal physical examination, laboratory examination, mental state change, or mental illness increases the risk of the subject or affects the research results.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06097962001","EMAIL":[{"email":"bairoushui@163.com"}],"GEO":[32.06167,118.77778]},{"TITLE":"Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Subjects must sign the written informed consent form (ICF), and be able to follow the visits and relevant procedures specified in the protocol.\n2. Age \u2265 18 years.\n3. Cytologically or histologically confirmed primary NSCLC (including adenocarcinoma, squamous cell carcinoma).\n4. Subjects with Stage II, IIIA or IIIB (resectable N2 only) disease based on the 8th edition of the TNM staging classification for lung cancer issued by the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer Classification (AJCC8).\n5. Deemed radically resectable with curative intent.\n6. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.\n7. Have not received any prior systemic anti-tumor therapy or local radiotherapy for NSCLC.\n\nExclusion Criteria:\n\n1. Subjects with confirmed or suspected brain metastases.\n2. Currently participating in an interventional clinical study or treatment with another study drug or study device within 4 weeks prior to randomization.\n3. Received Chinese herbal medicine, Chinese traditional medicine with anti-tumor indications, or drugs with immunomodulatory effects (including thymosin, interferon, interleukin) within two weeks prior to randomization\n4. Received a live attenuated vaccine 4 weeks prior to randomization (or planned to receive a live attenuated vaccine during the study).\n5. Requiring long term systemic corticosteroids\n6. Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1\/2 antibody positive), known active syphilis.\n7. Active hepatitis B.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05116462001","EMAIL":[{"email":"caicunzhoudr@163.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial","CRITERIA":"Inclusion Criteria:\n\n* \u226518\uff0cAdvanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology\n* RET Fusion Positive\n* First Diagnosis and Treatment\n* Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody\n\nExclusion Criteria:\n\n* - Patients received antitumor treatment before\n* Patients with contraindication of chemotherapy\n* Pregnant or breast feeding women","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04322591001","EMAIL":[{"email":"zhangyongchang@csu.edu.cn"}],"GEO":[28.19874,112.97087]},{"TITLE":"A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors","CRITERIA":"Inclusion Criteria:\n\n* Must weigh at least 35 kilograms (kg).\n* An Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2.\n* Life expectancy of \u2265 12 weeks.\n* Laboratory values meeting protocol criteria.\n* QT interval corrected for heart rate \\< 470 msec (using Fridericia's correction), and no clinically significant electrocardiographic findings.\n* Measurable disease defined by RECIST 1.1 criteria.\n\nFor Monotherapy and Combination Dose Escalation:\n\n\u2022 Subjects with histologically or cytologically proven metastatic or locally advanced tumors, for which no effective standard therapy exists, or where standard therapy has failed. Subjects must have received at least 1 prior systemic anticancer therapy for the indication being considered.\n\nFor Monotherapy Dose Expansion only:\n\n* Subjects must have received at least 1 prior line containing PD-1\/PD-L1 targeted therapy with a best response by RECIST v1.1 of CR\/PR\/stable (any duration) or stable disease (for greater than 6 months); AND\n* Must have been previously treated with 1 or more prior lines of therapy in the locally advanced or metastatic setting with the following tumor types:\n\n  * Relapsed\/refractory HNSCC\n  * Relapsed\/refractory NSCLC\n  * Advanced ccRCC\n\nFor PD-1 Targeting Agent Combination Dose Expansion only:\n\n* For the following tumor types, subject must have received at least 1 prior line containing PD-1\/PD-L1 targeted therapy with response by RECIST v1.1 of CR\/PR (any duration) or stable disease (for greater than 6 months):\n* Relapsed HNSCC\n* Relapsed NSCLC\n* Relapsed Advanced ccRCC\n* For the following tumor types, subject must have received at least 1 prior line containing PD-1\/PD-L1 targeted therapy and have had disease progression with PD-1\/PD-L1 targeted therapy:\n* Locally Advanced or metastatic MSI-H tumors\n\nFor VEGFR TKI Combination Dose Expansion only:\n\n* Relapsed advance ccRCC with no more than 1 prior VEGFR TKI\n* Subjects no recent history of hemorrhage, including hemoptysis, hematemesis, or melena\n* Subjects with poorly controlled hypertension are excluded\n\nExclusion Criteria:\n\n* Untreated brain or meningeal metastases (i.e., subjects with history of metastases are eligible provided they do not require ongoing steroid treatment and have shown clinical and radiographic stability for at least 28 days after definitive therapy)\n* Unresolved Grade 2 or higher toxicities related to previous anticancer therapy except alopecia.\n* Unresolved Grade 2 or higher peripheral neuropathy.\n* History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection.\n* Recent history (within 6 months) of congestive heart failure (defined as New York Heart Association, Class 2 or higher), ischemic cardiovascular event, pericarditis, or clinically significant pericardial effusion or arrythmia.\n* Recent history (within 6 months) of Childs-Pugh B or C classification of liver disease.\n* History of clinically significant medical and\/or psychiatric conditions or any other reason that, in the opinion of the investigator, would interfere with the subject's participation in this study or would make the subject an unsuitable candidate to receive study drug.\n* History of uncontrolled, clinically significant endocrinopathy.\n* Known gastrointestinal disorders making absorption of oral medications problematic; subject must be able to swallow capsules.\n* If treated with a PD-1\/aPD-L1 targeting or other immune-oncology agents in the past, excluded if had prior pneumonitis, prior Grade 3 or higher immune mediated toxicity, hypersensitivity to administered drug or drug related toxicity requiring discontinuation.\n* Active autoimmune disease requiring systemic treatment in past 2-years (exceptions for endocrinopathies, vitiligo or atopic conditions).\n* History of solid organ transplant or allogeneic stem cell transplant.\n* History of other malignancy, with the following exceptions:\n\n  * No known active disease present within \u2265 3 years before first dose of study treatment and felt to be at low recurrence by investigator.\n  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n  * Adequately treated carcinoma in situ without evidence of disease.\n* History of interstitial lung disease or pneumonitis.\n* Major surgery \u2264 28 days prior to first dose of study drug\n* Known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection per local testing practices.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04777994021","EMAIL":[{},{}],"GEO":[40.4165,-3.70256]},{"TITLE":"Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed stage IV metastatic NSCLC, not amenable to curative treatment.\n* Fit for systemic treatment (PS 0-2) according to standard of care.\n* No symptoms of brain disease disease assessed according to standard clinical care by the thoracic oncologist.\n\nExclusion Criteria:\n\n* Prior\/concomitant therapy for stage IV disease.\n* Oncogenic diver mutation (e.g. EGFR, ALK, ROS1, RET, MET, and BRAF) with approved targeted treatment.\n* Contraindications for MRI scan with contrast as per standard of care protocol of the institution.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05864794001","EMAIL":[{}],"GEO":[53.21917,6.56667]},{"TITLE":"Investigating the Feasibility of a Physical Activity (Tele)Coaching Intervention in Patients With Non-small Cell Lung Cancer: an Explorative Study","CRITERIA":"Inclusion Criteria:\n\n* Three to nine months after a lung resection surgery for non-small cell lung cancer\n* If patients received adjuvant chemotherapy, the inclusion window will be three months to nine months after the end of adjuvant chemotherapy\n* Adults (+18 year)\n\nExclusion Criteria:\n\n* Progressive or recurrent lung cancer\n* Who had other malignancies in the last 2 years\n* Psychiatric disorders\n* Other ongoing treatments\n* Involved in or planned to start a multidisciplinary rehabilitation program\n* Unable to learn to work with a new electronic device (e.g. smartphone)\n* Not understanding and speaking Dutch\n* Patients with comorbidities precluding them from participation in a physical activity intervention","SEX":"ALL","AGE_MIN":45,"AGE_MAX":200,"SS_ID":"05569291002","EMAIL":[{"email":"h.demeyer@ugent.be"}],"GEO":[51.05,3.71667]},{"TITLE":"Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies","CRITERIA":"Inclusion Criteria:\n\nSubjects must meet all the following criteria to be enrolled in this study:\n\n1. Age \u226518 years at the time of consent.\n2. Written informed consent in accordance with national, local, and institutional guidelines obtained prior to any study procedures. (Screening assessments performed prior to informed consent but within the 28-day screening window are acceptable for inclusion purposes).\n3. Subjects must have histologically confirmed diagnosis of one of the following tumors: triple negative adenocarcinoma of the breast (human epidermal growth factor receptor 2 negative, estrogen receptor negative and progesterone receptor negative \\[HER2-\/ER-\/PR-\\]), adenocarcinoma of the colon or rectum, hepatocellular carcinoma (HCC), osteosarcoma, epithelial ovarian cancer, malignant melanoma, non-small cell lung cancer (NSCLC), or gastric cancer. Documentation of the diagnosis with the original pathology report, or a recent biopsy, is required.\n4. Subjects must have relapsed disease or refractory disease. Subjects must have received, completed, or become intolerant of prior standard of care therapies or are not expected to derive any clinical benefit from standard of care therapies.\n5. Subjects with Ovarian cancer must have received at least one prior standard of care for their relapsed or refractory disease, which must include a platinum-based regimen.\n6. Subjects agree to provide fresh tumor tissue that has not been previously irradiated. If biopsy procedure is not safe to perform, then archival tumor tissue (20 slides or a tissue block) can be submitted.\n7. Subjects must have iRECIST evaluable disease using computed tomography (CT) or magnetic resonance imaging (MRI) with IV contrast, with at least one measurable target lesion.\n8. Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n9. Subjects are expected to have a life expectancy of at least 12 weeks from the time of enrollment.\n10. Adequate hematologic function at the time of screening, defined as: absolute lymphocyte count (ALC) \\>500 cells\/mm3, absolute neutrophil count (ANC) \\>750 cells\/mm3, hemoglobin \\>8 g\/dL, and platelet count \\>50,000 cells\/mm3. For subjects enrolling into the LDC cohorts, the criteria are defined as: ALC\\>500 cells\/mm3, ANC\\>1000 cells\/mm3, hemoglobin\\>8g\/dL, and platelet count\\>100,000 cells\/mm3.\n\n    a. Hemoglobin and platelet count thresholds must be achievable without transfusion of red blood cells or platelets, or use of growth factors administered within two weeks.\n11. Adequate organ function, defined as:\n\n    1. Renal function: serum creatinine \\<1.5x institutional upper limit of normal (ULN) or calculated creatinine clearance \\>50 mL\/min.\n    2. Adequate hepatic function: total bilirubin \u22641.5x institutional ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u22642.5x institutional ULN, unless liver metastases are present, in which case it must be \u22645x ULN; International Normalized Ratio (INR) \u22641.5. For subjects with HCC, adequate hepatic function is defined as: total bilirubin \u22643x institutional upper limit of normal, AST\/ALT \u22645x institutional ULN, INR \u22641.7, Child-Turcotte-Pugh score \\<8.\n12. Women of childbearing potential (defined as all subjects physiologically capable of becoming pregnant) must have negative serum \u00df-human chorionic gonadotropin (hCG) or urine pregnancy test.\n13. Women of childbearing potential must agree to use highly effective methods of contraception throughout the study and for six months after the last dose of CRX100.\n14. Males who have partners of childbearing potential must agree to use an effective barrier contraceptive method throughout the study and for six months after the last dose of CRX100.\n15. Subjects must be willing and able to comply with all study procedures, requirements, and follow-up examinations.\n\nExclusion Criteria:\n\nSubjects who meet any of the following criteria will be excluded from participation in this study:\n\n1. Subjects with new or progressive brain metastasis. Subjects with treated brain metastases are eligible if there is no evidence of progression for at least four weeks after central nervous system-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period.\n2. Subjects who received any chemotherapy or immunotherapies (non-cell-based therapies) or oncolytic virus therapy, radiotherapy, radiosurgery or investigational agents within three weeks of enrollment.\n3. Subjects who still are experiencing Grade 2 or higher AEs from prior therapies such as surgery, radiation therapy and systemic anti-cancer therapies unless approved by sponsor.\n4. Subjects who received any type of cell-based therapies within the last 12 weeks from the planned apheresis date.\n5. Subjects experiencing any active infections (bacterial, viral, or fungal) for which systemic antimicrobials are required. Subjects who need prophylactic anti-viral agents that can inhibit the replication of VACV will be excluded from participating.\n6. Subjects must not have history of active or symptomatic autoimmune disease or evidence of symptomatic autoimmune pneumonitis, glomerulonephritis, vasculitis, other symptomatic autoimmune disease, documented history of autoimmune disease or syndrome requiring systemic treatment in the past two years (i.e., with use of disease modifying agents, steroids or immunosuppressive agents) Exceptions are permitted for vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition requiring only hormone replacement, psoriasis not requiring systemic treatment, conditions not expected to recur in the absence of an external trigger or other conditions approved by the medical monitor.\n7. Have a condition requiring systemic treatment with either corticosteroids (\\>10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days prior to apheresis, and within 14 days prior to infusion. Inhaled, intramuscular injection, or topical steroids and adrenal replacement doses (\u226410 mg daily prednisone equivalents) are permitted. Stable doses of steroids are permitted for subjects with pre-treated brain metastases. Short-term (\\<48 hr) steroid pretreatment for contrast allergy for imaging is permitted.\n8. Known human immunodeficiency virus (HIV) infection, active chronic hepatitis B or C, life-threatening illnesses unrelated to cancer, or any serious medical or psychiatric illness that could, in the Investigator's opinion, interfere with participation in this study.\n9. Pregnant or nursing an infant (subject or household contacts).\n10. Clinically significant immunodeficiency (e.g., due to underlying illness and\/or medication) in a subject or household contacts.\n11. Have any underlying medical condition (including, but not limited to, ongoing or active infection requiring treatment, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia), psychiatric condition that, in the opinion of the Investigator, would compromise study administration as per protocol or compromise the assessment of AEs.\n12. Have a history of another invasive malignancy, except for the following circumstance: individuals with a history of invasive malignancy are eligible if they have been disease free and off treatment for at least two years or are deemed by the Investigator to be at low risk for recurrence of that malignancy; individuals with the following cancers are eligible if diagnosed and treated: carcinoma in situ of the breast, oral cavity, or cervix, localized prostate cancer, or basal cell or squamous cell carcinoma of the skin. When enrolling a subject with another malignancy, the Investigator must discuss the subject with the Medical Monitor.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04282044003","EMAIL":[{"email":"ccto-office@stanford.edu"},{}],"GEO":[37.42411,-122.16608]},{"TITLE":"THIO Sequenced With Cemiplimab in Advanced NSCLC","CRITERIA":"Inclusion Criteria:\n\nTo be eligible for participation in this study, subjects must meet all the following:\n\n1. At least 18 years of age at the time of signing the Informed Consent Form (ICF) prior to initiation of any study specific activities\/procedures.\n2. Stage 3 or Stage 4 NSCLC who either progressed or relapsed after ICI, as defined by the Society for Immunotherapy of Cancer (SITC) immunotherapy resistance task force.\n\n   Subjects with drug exposure \\>6 weeks but not meeting the criteria for either primary or secondary resistance, can also be included (e.g., have achieved initially a PR, then progressed before 6 months).\n\n   Subjects who received neoadjuvant or adjuvant therapies with ICIs for the initial cancer diagnosis may also be eligible, following consultation with Sponsor's Medical Monitor (or designee). Prior treatment with PD-1\/PD-L1 ICIs therapy alone or in combination with a platinum-based chemotherapy (i.e., platinum-based chemotherapy followed by ICI therapy) will be allowed. ICI treatment may have been part of 1st or 2nd line, but not both.\n3. Must have histologically or cytologically confirmed NSCLC.\n4. At least one measurable target lesion that meets the definition of RECIST v1.1.\n5. Willing to provide archived tumor tissue samples either formalin fixed paraffin embedded (FFPE) block OR at least 10 unstained slides.\n6. Life expectancy of greater than 12 weeks.\n7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n8. Demonstrate adequate organ function as defined below. All screening laboratories should be performed within 14 days of initiating IP:\n\n   * Bone marrow function: neutrophil count \u2265 1500\/mm3, hemoglobin \u2265 9.0 g\/dL, platelet count \u2265 100,000\/mm3;\n   * Liver function: total bilirubin \u2264 1.5 x the upper limit of normal (ULN) based on the standard value of each institution, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u2264 2.5 x ULN;\n   * Renal function: serum creatinine \u2264 1.5 x ULN based on the reference laboratory.\n9. Women of childbearing potential (WOCBP) must have negative serum pregnancy test (minimum sensitivity 25 IU\/L or equivalent units of human chorionic gonadotropin \\[HCG\\]) within 72 hours prior to receiving the first administration of IP.\n\n   Contraception use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n10. WOCBP must agree to use a highly effective birth control and refrain from oocyte donation during the study (prior to the first dose with THIO, for the duration of the treatment with THIO plus 6 months after last dose of IP), if conception is possible during this interval.\n11. Male subjects and WOCBP partners of male subjects should use a combination of a male condom from first dose of THIO (Cycle 1, Day 1), for the duration of the treatment with THIO plus 6 months after last dose of IP, unless permanently sterile by bilateral orchidectomy. Male subjects should also refrain from sperm donation during this time.\n12. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.\n\nExclusion Criteria:\n\n1. Have not recovered from adverse events (must be Grade \u22641) due to agents administered more than 4 weeks earlier.\n2. Untreated or symptomatic central nervous system (CNS) metastases. Note: subjects with treated asymptomatic brain metastasis are eligible.\n3. Active gastrointestinal bleeding as evidenced by either hematemesis or melena.\n4. History of another concurrent malignancy other than the present condition (except nonmelanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission and off all therapy for that disease for a minimum of 3 years.\n5. A condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids, adrenal replacement doses 10 mg daily prednisone equivalents, and systemic corticosteroids to manage adverse events (AEs) are permitted in the absence of active autoimmune disease.\n6. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy within 2 weeks of screening.\n7. Positive for Human Immunodeficiency Virus (HIV) (HIV 1\/2 antibodies), active hepatitis B or hepatitis C.\n8. Positive for COVID-19 using polymerase chain reaction (PCR) test; subjects with positive PCR test will be eligible after 2 consecutive negative results are obtained, minimum 1 week apart.\n9. Significant cardiovascular impairment (history of New York Heart Association Functional Classification System Class III or IV) or a history of myocardial infarction or unstable angina within the past 6 months prior to IP initiation.\n10. Ongoing immune-related\/stimulated adverse events (irAEs) from other agents or required permanent discontinuation of prior ICIs due to immune-related AEs (irAEs). Subjects with resolved irAE may be allowed to enroll following consultation with Sponsor's Medical Monitor (or designee).\n11. Active autoimmune diseases or history of autoimmune diseases that may relapse, with the following exceptions:\n\n    * Controlled type 1 diabetes;\n    * Hypothyroidism (provided it is managed with hormone replacement therapy only);\n    * Controlled celiac disease;\n    * Skin diseases not requiring systemic treatment (eg, vitiligo, psoriasis, or alopecia);\n    * Any other disease that is not expected to recur in the absence of external triggering factors.\n12. Pregnancy or lactating.\n13. A serious nonmalignant disease (eg, psychiatric, substance abuse, uncontrolled intercurrent illness, etc.) that could compromise protocol objectives in the opinion of the investigator and\/or the Sponsor.\n14. Any other condition that, in the opinion of the investigator, would prohibit the subject from participating in the study.\n15. Prior chemotherapy, targeted therapy, and immunotherapy within the 28 days prior to Screening.\n16. Undergone major surgery within 4 weeks prior to Cycle 1, Day 1.\n17. Received blood, red blood cell or platelet transfusion within 2 weeks before the first dose of IP.\n18. Any vaccines (live, attenuated, inactivated or research vaccines) within 30 days prior to the first dose of IP. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed.\n19. Prior allogeneic hematopoietic stem cell transplant or solid organ transplant.\n20. Actively participating in another clinical study.\n\n20. Currently enrolled in a clinical study involving another IP or nonapproved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.\n\n21. Participated, within the last 30 days, in a clinical study involving an IP (other than the IP used in this study), unless a minimum of 30 days or 5 half-lives (whichever is longer) have passed before enrollment in the present clinical study.\n\n22. History of allergy to excipients of THIO or cemiplimab.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05208944021","EMAIL":[{}],"GEO":[50.04132,21.99901]},{"TITLE":"All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Age \\>= 18 years\n* Confirmed recurrent or metastatic non-small cell carcinoma of the lung of any histology for which there is no curative treatment option\n* Measurable disease based on RECIST 1.1\n* Patients must have received standard of care chemotherapy and\/or immunotherapy. No limits to prior lines of therapy. Prior PD-1 and\/or PD-L1 directed therapies are permitted\n* Patients with adenocarcinoma and known actionable mutations with FDA-approved treatment options must have received all approved and standard of care treatment options (ie osimertinib for EGFR, alectinib for ALK, etc). Mutational testing is not required for patients with squamous cell non-small cell lung carcinoma\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Absolute neutrophil count (ANC) \\>= 1,500\/mcL\n* Lymphocytes \u2265500\/mcL\n* Platelets \\>=100,000\/mcL\n* Serum creatinine =\\< 1.5 X upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate \\[GFR\\] can also be used in place of creatinine or creatinine clearance \\[CrCl\\]) \\>= 60 mL\/min for subject with creatinine levels \\> 1.5 X institutional ULN\n* Serum total bilirubin =\\< 1.5 X ULN OR direct bilirubin =\\< ULN for subjects with total bilirubin levels \\> 1.5 ULN\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\< 2.5 X ULN OR =\\< 5 X ULN for subjects with liver metastases\n* Albumin \\>= 2.5 mg\/dL\n* International normalized ratio (INR) or prothrombin time (PT) =\\< 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants\n* Activated partial thromboplastin time (aPTT) =\\< 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants\n* Anticipated life expectancy of \\>= 3 months\n* Willing to comply with study procedures\n* Female subjects of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study medication\n* Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 5 months days after the last dose of study medication. Subjects should agree to ongoing pregnancy testing during the course of the study and after the end of study therapy. Female subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \\> 1 year\n* Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 7 months after the last dose of study therapy. Males must refrain from donating sperm during study participation and for 7 months after the last dose of study medication\n* Be willing and able to understand and sign the written informed consent document\n* Ability to swallow and retain oral medication\n* HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible.\n* History of hepatitis C virus (HCV) infection treated and cured.\n\nExclusion Criteria:\n\n* Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment\n* Has active autoimmune disease, including myasthenic syndrome, which has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment\n* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment\n* Cirrhosis (Child-Pugh B or worse) or cirrhosis with history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis\n* Untreated central nervous system (CNS) metastases. Patients with treated brain metastases are eligible if they were clinically stable with regard to neurologic function, off steroids after cranial irradiation (whole brain radiation therapy, focal radiation therapy, and stereotactic radiosurgery) ending at least 2 weeks prior to randomization, or after surgical resection performed at least 28 days prior to randomization. The patient must have no evidence of grade \\>= 1 CNS hemorrhage based on pretreatment magnetic resonance imaging (MRI) or IV contrast computed tomography (CT) scan (performed within screening window)\n* Pregnancy or breastfeeding\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator\n* Any patient who has experienced an unacceptable toxicity on prior checkpoint inhibitor therapy as detailed below:\n\n  * \\>= grade 3 adverse events (AE) related to checkpoint inhibitor\n  * Ongoing \\>= grade 2 immune-related AE associated with checkpoint inhibitor with the exception of endocrine toxicities as detailed below\n  * CNS, ocular or cardiac AE of any grade related to checkpoint inhibitor\n\n    * NOTE: Patients with a prior or ongoing endocrine AE are permitted to enroll if they are stably maintained on appropriate replacement therapy and are asymptomatic","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04919369001","EMAIL":[{"email":"Dwight.Owen@osumc.edu"},{}],"GEO":[39.96118,-82.99879]},{"TITLE":"Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed non-small cell lung cancer; if a diagnostic biopsy is available, a pre-treatment biopsy is not required. Patients with a suspected lung cancer may be consented, but pathology must be confirmed prior to initiating treatment on study. Neuroendocrine carcinomas (e.g. small cell lung cancer \\[SCLC\\], carcinoid tumors) are not eligible. Carcinomas with neuroendocrine differentiation are eligible.\n* Stage IV (according to the American Joint Committee on Cancer \\[AJCC\\] 8th edition) measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.\n* Signed and dated written informed consent prior to admission to the study in accordance with International Conference on Harmonization-Good Clinical Practice (ICH-GCP) guidelines and to the local legislation.\n* For lung adenocarcinoma patients, patients must not harbor any EGFR sensitizing or ALK fusion where there are standard care therapy options available. For patients with histologies other than adenocarcinoma, EGFR and ALK status is not required. Adenocarcinoma patients may be consented prior to the EGFR and ALK status being known, but EGFR and ALK status must be determined prior to initiating therapy. EGFR and ALK status may be determined using either tumor- or plasma-based, Clinical Laboratory Improvement Amendments (CLIA)-certified assays. For patients with non-small cell lung cancer (NSCLC), not otherwise specified (NOS), EGFR\/ALK testing is not required, as the frequency of alterations is exceedingly rare in this histology. Also, note that patients with ROS1\/RET alterations can be enrolled, as tyrosine kinase inhibitor such as crizotinib aren't established as first line therapy for patients with these alterations.\n* One prior line of chemotherapy and\/or targeted agents for metastatic disease are permitted. This chemotherapy can include maintenance therapy, as long as it was given in the front line setting. In addition, prior antiangiogenic therapy (e.g. bevacizumab) is permitted if used as frontline treatment.\n\nPatients must have organ and marrow function as defined below:\n\n* Performance status of 0 or 1 if using Eastern Cooperative Oncology Group (ECOG)\/Zubrod.\n* Screening laboratory values must meet the following criteria and should be obtained within 14 days prior to treatment initiation\n* White blood cell (WBC ) \\>= 2000\/uL\n* Neutrophils \\>= 1500\/uL (obtained within 14 days prior to randomization\/registration)\n* Platelets \\>= 100 x 10\\^3\/uL (obtained within 14 days prior to randomization\/registration)\n* Hemoglobin \\> 9.0 g\/dL (obtained within 14 days prior to randomization\/registration)\n* Serum creatinine \u2264 1.5 x upper limit of normal (ULN) or creatinine clearance (CrCl) \u2265 50 mL (if using the Cockcroft-Gault formula)\n* Aspartate aminotransferase (AST)\/alanine aminotransferase (ALT) \u2264 3 x ULN (obtained within 14 days prior to randomization\/registration)\n* Total Bilirubin \u2264 1.5 x ULN (except subjects with Gilbert syndrome, who can have total bilirubin \\< 3.0 mg\/dL) (obtained within 14 days prior to randomization\/registration)\n* Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. Appropriate methods of contraception are as follows. Women will be instructed to adhere to contraception for a period of 26 weeks after the last dose of investigational product. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 35 weeks after the last week of nivolumab\/ipilimumab (nivo\/ipi). Note: WOCBP is defined as any female who has experienced menarche and who has not yet undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented negative serum or urine test.\n* Women of childbearing potential must have a negative serum or urine pregnancy test within 48 hours prior to the start of nivolumab.\n* Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 35 weeks after the last dose of investigational product. Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraception.\n* Subjects with brain metastases are eligible if metastases are adequately treated and subjects are neurologically stable (except for residual signs or symptoms related to the central nervous system \\[CNS\\] treatment) for at least 2 weeks prior to the first dose of nivolumab. In addition, subjects must be either off corticosteroids, or on a stable or decreasing dose of \u2264 10 mg daily prednisone (or equivalent) for at least 2 weeks prior to the first dose of nivolumab. Patients with asymptomatic, small (e.g. =\\< 1 cm) brain metastases are 1) eligible provided that the patient is off corticosteroids, or on a stable or decreasing dose of \u2264 10 mg daily prednisone (or equivalent) for at least 2 weeks prior to the first dose of nivolumab\n* For cohort 1 subjects may receive radiotherapy for symptomatic metastases prior to enrollment provided that there is at least one other non-irradiated lesion amenable to LCT at the time of enrollment. When feasible, stereotactic body radiation therapy (SBRT) or other hypofractionated techniques are strongly encouraged.\n\nInclusion Criteria In Cohort 2:\n\n* Patients must have disease progression per imaging radiologic studies prior to randomization in LONESTAR study (during induction phase)\n* Patient in this cohort must start therapy with platinum doublet and immune checkpoint inhibitor therapy no longer than 6 weeks after their last day of immune checkpoint inhibitor therapy\n* Patients must have organ and marrow function as defined below:\n\nPerformance Status of 0 or 1 if using ECOG\/Zubrod. Screening laboratory values must meet the following criteria and should be obtained within 14 days prior to treatment initiation\n\nWBC \u2265 2000\/\u03bcL Neutrophils \u2265 1500\/\u03bcL Platelets \u2265 100 x103\/\u03bcL Hemoglobin \\> 9.0 g\/dL\n\nSerum creatinine \u2264 1.5 x ULN or creatinine clearance (CrCl) \u2265 50 mL (if using the Cockcroft-Gault formula below):\n\nAST\/ALT \u2264 3 x ULN Total Bilirubin \u2264 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin \\< 3.0 mg\/dL)\n\n* Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. Appropriate methods of contraception are as follows. Women will be instructed to adhere to contraception for a period of 26 weeks after the last dose of investigational product. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 35 weeks after the last week of nivo\/ipi. Note: WOCBP is defined as any female who has experienced menarche and who has not yet undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented negative serum or urine test.\n* Women of childbearing potential must have a negative serum or urine pregnancy test within 48 hours prior to the start of therapy.\n* Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 35 weeks after the last dose of investigational product Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile as well as azoospermic men do not require contraception.Subjects with brain metastases are eligible if metastases are adequately treated (exception of \u22641 cm asymptomatic brain metastases, as specified below) and subjects are neurologically stable (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to the first dose of nivolumab. In addition, subjects must be either off corticosteroids, or on a stable or decreasing dose of \u2264 10 mg daily prednisone (or equivalent) for at least 2 weeks prior to the first dose of nivolumab. In addition, subjects must be either off corticosteroids or on stable or decreasing dose of \u2264 10 mg daily prednisone (or equivalent) for at least 2 weeks prior to the first dose of nivolumab. Patients with asymptomatic, small (e.g. \u22641 cm) brain metastases are eligible and do not require prior local therapy for eligibility, provided that the patient is off corticosteroids, or on a stable or decreasing dose of \u2264 10 mg daily prednisone (or equivalent) for at least 2 weeks prior to the first dose of nivolumab.\n* Participants enrolled in the cohort 2 must be willing to undergo tumor biopsy prior to the initiation of therapy with immune checkpoint inhibitor and platinum doublet therapy and on treatment biopsies. In cases when such a biopsy is clinically unsafe to perform, archival (meaning obtained at earlier times) tumor biopsies may be accepted the discretion of the study PI.\n* For cohort 2 subjects may receive radiotherapy for symptomatic metastases at the time of their progression prior to enrollment to cohort 2\n\nExclusion Criteria:\n\n* Systemic immunotherapy for metastatic NSCLC. Immunotherapy agents include, but are not limited to, agents targeting the PD1\/PD-L1 axis (e.g. nivolumab, pembrolizumab, atezolizumab, durvalumab) or CTLA-4 (ipilimumab, tremelimumab) pathways.\n* Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to the initiation of study treatment. The following exceptions are allowed: hormone-replacement therapy or oral contraceptives\n* Women must not be breastfeeding.\n* Patients excluded with any prior treatment of pneumonitis requiring corticosteroids within 60 days prior to the first dose of nivolumab\n* Unwillingness or inability to follow the procedures required in the protocol.\n* Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results.\n* Prior malignancy active within the previous 2 years. Patients with locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast with local control measures (surgery, radiation) are eligible.\n* Patients should be excluded if they have an active, known or suspected autoimmune disease. Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger.\n* Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration (i.e. disease-modifying antirheumatic drugs). Inhaled or topical steroids and adrenal replacement doses \\> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Note that subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted, even if \\>10 mg\/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (e.g. contrast dye allergy) or for treatment of non-autoimmune conditions (e.g. delayed-type hypersensitivity reaction caused by contact allergen) is permitted.\n* As there is potential for hepatic toxicity with nivolumab or nivolumab\/ipilimumab combinations, drugs with a predisposition to hepatoxicity should be used with caution.\n* Patients should be excluded if they are known to be positive for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection.\n* Patients should be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).\n* History of allergy to study drug components.\n* History of severe hypersensitivity reaction to any monoclonal antibody.\n* Prisoners or subjects who are involuntarily incarcerated.\n* Subjects who are compulsorily detained for treatment of either a psychiatric or physical (infection disease) illness.\n* Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule.\n* Any condition that, in the opinion of the investigator, would interfere with the study treatment or interpretation of the study results.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03391869005","EMAIL":[{"email":"oOyewuwo@mdanderson.org"},{}],"GEO":[29.61968,-95.63495]},{"TITLE":"Patient-centered, Optimal Integration of Survivorship and Palliative Care","CRITERIA":"Inclusion Criteria:\n\n* Age 18 or older\n* MGH Cancer Center patient\n* Within 6 months of diagnosis of metastatic NSCLC with oncogenic driver mutation (EGFR, ALK, ROS1, RET)\n* Receiving targeted therapy\n* Ability to respond in English or Spanish\n\nExclusion Criteria:\n\n* Cognitive impairment or serious mental illness that limits ability to provide informed consent\n* Need for urgent palliative care or hospice referral\n* Pregnant women\n* Prisoners","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04900935001","EMAIL":[{"email":"lpetrillo2@mgh.harvard.edu"},{}],"GEO":[42.35843,-71.05977]},{"TITLE":"Microbiota and the Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* non small cell lung carcinoma patient suitable for surgery, or chemotherapy followed by surgery\n* BMI \\<29.9 kg\/m\u00b2\n* not taking antibiotics, corticosteroids and\/or immunosuppressants at least during two months before inclusion\n* not taking prebiotics, probiotics or symbiotics at least during two months before inclusion\n* signing the written consent before enrollment in the study\n* affiliation to the national health insurance (or system alike) according to the law from 9th August 2004\n\nExclusion Criteria:\n\n* cognitive difficulties\n* refusal of participation or inability to give a clear consent\n* digestive or pulmonary infection of a long duration during the two months preceding the study (with antibiotic treatment)\n* inflammatory digestive pathology\n* concurrent treatment with experimental medication, participation in another clinical therapeutic study within 30 days\n* presence of colostomy, total or partial gastrectomy\n* previous esophageal surgery\n* previous ORL (otho-rhino-laryngo) cancer treated by radiotherapy or surgery\n* patient enable to follow the requirements of the study\n* patient deprived of his rights by administrative or judicial decision","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"03068663001","EMAIL":[{"email":"marc.filaire@clermont.unicancer.fr"}],"GEO":[45.77966,3.08628]},{"TITLE":"Robotic Lobectomy vs. Thoracoscopic Lobectomy for Early Stage Lung Cancer: RCT","CRITERIA":"Inclusion Criteria:\n\n1. Age \\>\/= 18 years\n2. Clinical stage I, II or IIIa non-small cell lung cancer (NSCLC)\n3. Candidates for minimally invasive pulmonary lobectomy, as determined by the operating surgeon.\n\nExclusion Criteria:\n\n1. Clinical stage IIIb or IV NSCLC\n2. Not a candidate for minimally invasive surgery.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"02617186001","EMAIL":[{"email":"patelys@mcmaster.ca"}],"GEO":[43.25011,-79.84963]},{"TITLE":"Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Have proven diagnosis of recurrent advanced NSCLC, irrespective of histological subtype.\n2. Be willing and able to provide written informed consent\/assent for the trial.\n3. Must still have measurable disease based on RECIST 1.1 after application of study SBRT. Lesions that were irradiated prior to the study, but have progressed since irradiation but prior to study inclusion will be allowed as measurable disease.\n4. Must provide newly obtained tissue from a core or excisional biopsy of a tumor lesion and are willing to have a second biopsy performed from any non-irradiated lesion after the radiation and immune-modulating treatment. This lesion may be used for RECIST measurements.\n5. Have a performance status of 0 or 1 on the ECOG Performance Scale.\n6. Stage IV NSCLC treated with at least PD-(L)1 blockade. There is no maximum number of previous lines of systemic treatment. Patients with both primary or acquired resistance to PD-(L)1 inhibition may be considered eligible. However, in the 1st stage \u22654 of 12 patients, in the 2nd stage a total of \u22658 of 25 patients and in the 3rd stage a total of \u226527 of 54 patients need to fulfill the definition of acquired resistance. Also, a maximum of 27 patients with a PD-L1 negative tumor will be included.\n7. Have at least 2 separate (metastatic) lesions of which one is eligible for irradiation and another for biopsy and RECIST tumor evaluation.\n8. Demonstrate adequate organ function. All screening labs should be performed within 14 days of treatment initiation.\n9. Female subject of childbearing potential should have a negative serum pregnancy test within 72 hours prior to receiving the 1st dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n10. Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 6 months after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \\> 1 year.\n11. Male subjects should agree to use an adequate method of contraception starting with the 1st dose of study therapy through 6 months after the last dose of study therapy\n\nExclusion Criteria:\n\nThe subject must be excluded from participating in the trial if the subject:\n\n1. Has a non-smoking-related targetable driver mutation, e.g. EGFR, ALK, RET or ROS1. Patients with advanced NSCLC with a smoking-related targetable driver mutation, e.g. KRAS or BRAF, may be found eligible if they have a history of \u226510 PY, but only when all options for targeted therapy have been exhausted and when progression on previous PD-(L)1 blockade has occurred.\n2. Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the 1st dose of treatment.\n3. Has not recovered (i.e. \u2264 Grade 1 or at baseline) from adverse events due to a previously administered agent.\n\n   * Note: Subjects with \u2264 Grade 2 neuropathy are an exception to this criterion and may qualify for the study.\n   * Note: Patients who experienced significant autoimmune side effects related to previous PD-(L)1 checkpoint inhibition, i.e. requiring use of steroids or other anti-inflammatory drugs and\/or the need to (temporarily) withhold PD-(L)1 checkpoint inhibition, may be considered eligible after discussion with the coordinating investigator if adverse events have recovered, i.e. \u2264 Grade 1 or at baseline.\n   * Note: If subjects received major surgery (defined as surgical intervention requiring general or spinal anesthesia and hospital admission), they must have recovered adequately from the toxicity and\/or complications from the intervention prior to starting therapy. Major surgery within 14 days prior to start of study treatment is not allowed.\n4. Has had previous radical radiation to any tumor site within 3 months prior to study Day 1. Previous palliative radiation to any tumor site is not considered an exclusion criterion; however, this site will not be eligible for SBRT, biopsy location or RECIST tumor evaluation within this study.\n5. Has received prior therapy with any antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways other than PD-(L)1 blockade, e.g. anti-CD137 or a CTLA-4 antibody.\n6. Patients who have uncontrolled central nervous system (CNS) metastases. Patients who have untreated asymptomatic CNS metastases no greater than 2cm before start of treatment may be eligible. Patients who have any CNS lesion that is symptomatic, greater than 2cm, show significant surrounding edema on MRI scan or have leptomeningeal disease will not be eligible. Patients who have previously been treated for CNS metastases are eligible when they comply with the hereby mentioned criteria.\n\n   NB. A brain lesion is not amendable for study SBRT.\n7. Has a known additional malignancy that is progressing or requires active treatment.\n8. Has an active autoimmune disease or a documented history of clinically severe autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents. Subjects who require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Patients with an active or history of autoimmune disease or syndrome who underwent previous PD-(L)1 checkpoint inhibition without significant side effects, i.e. not requiring use of steroids or other anti-inflammatory drugs and\/or the need to (temporarily) withhold PD-(L)1 checkpoint inhibition, may be considered eligible for this trial after discussion with the coordinating investigator. Requirement for immunosuppressive doses of systemic corticosteroids \u226410 mg\/day prednisone or equivalent may be considered eligible after discussion as well.\n9. Has evidence of symptomatic interstitial lung disease or an active, non-infectious pneumonitis.\n10. Has an active infection requiring systemic therapy.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05401786001","EMAIL":[{"email":"w.theelen@nki.nl"}],"GEO":[52.37403,4.88969]},{"TITLE":"A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy","CRITERIA":"Inclusion Criteria:\n\n1. Aged \u2265 18 years old;\n2. Histologically or cytologically confirmed unresectable stage IIIB-IIIC or stage IV NSCLC (staged according to the 8th Edition of the TNM Classification for Lung Cancer published by the International Association for the Study of Lung Cancer and American Joint Committee on Cancer);\n3. Have at least one measurable lesion according to RECIST v1.1;\n4. Histologically confirmed FGFR 1-3 alterations, including but not limited to amplification, mutation, fusion\/rearrangement, etc.;\n5. Have failed or intolerated second-line and above standard therapies. Patients who have EGFR-sensitive mutations or are positive for ALK\/ROS1 rearrangements shall receive at least one line of EGFR\/ALK\/ROS1 inhibitor treatment; Note: Patients who have a relapse within 6 months after a radical surgery or radical concurrent chemoradiotherapy can be enrolled if they have failed at least one line of systematic therapy after the relapse.\n6. No previous use of small molecule multi-target inhibitors targeting the FGFR pathway (including anlotinib, lenvatinib, sorafenib, etc.);\n7. ECOG physical performance status score of 0-1;\n8. Expected survival time \\> 3 months;\n9. Patients with brain metastases who are asymptomatic or have stable symptoms after locoregional treatment can be enrolled as long as they:\n\n1) Have measurable lesions outside the central nervous system; 2) Have no central nervous system symptoms or no aggravation of symptoms for at least 2 weeks; 3) Do not need glucocorticoid treatment or stop glucocorticoid treatment within 7 days before the first dose of the investigational drug.\n\n10. Patients who have completed palliative radiotherapy one week prior to study enrollment with their radiotherapy-related toxicity reduced to grade 1 or lower (CTCAE5.0) can be enrolled.\n\n11. For evidence of sufficient organ functions, the subjects shall meet the following laboratory parameters:\n\n1. Absolute neutrophil count (ANC) \u2265 1.5 \u00d7 109\/L without use of granulocyte colony stimulating factor in recent 14 days;\n2. Platelet count \u2265 100 \u00d7 109\/L without blood transfusion in recent 14 days;\n3. Hemoglobin \\> 9 g\/dL without blood transfusion or erythropoietin use in recent 14 days;\n4. Total bilirubin \u2264 1.5 \u00d7 upper limit of normal (ULN); or total bilirubin \\> ULN, direct bilirubin \u2264 ULN;\n5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u2264 2.5 \u00d7 ULN (ALT or AST \u2264 5 \u00d7 ULN for patients with liver metastasis);\n6. Blood creatinine \u2264 1.5 \u00d7 ULN and creatinine clearance (calculated by Cockcroft-Gault formula) \u2265 50 mL\/min;\n7. Good coagulation function: international normalized ratio (INR) or prothrombin time (PT) \u2264 1.5 \u00d7 ULN. (For subjects receiving an anticoagulant therapy, PT within the range proposed for the anticoagulant drug is acceptable).\n\n12. Women of childbearing potential shall obtain a negative result in the urine or serum pregnancy test performed within 3 days before the first dose of the investigational drug (cycle 1, day 1). If the urine pregnancy test result cannot be identified as negative, a blood pregnancy test is needed. Women of non-childbearing potential are defined as those who have not had menses for at least 1 year or who have undergone surgical sterilization or hysterectomy; 13. All subjects at risk of conception (including their partners) shall use contraceptives with an annual failure rate of less than 1% throughout the entire treatment period up to 120 days after the last dose of the investigational drug (or 180 days after the last dose of the chemotherapy drug).\n\nExclusion Criteria:\n\n1. Diagnosed with malignant tumors other than non-small cell lung cancer within 5 years before the first dose, excluding radically cured cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, and\/or radically resected carcinoma in situ;\n2. Previously treated with selective FGFR inhibitors;\n3. Have received any other investigational drug treatment or participated in another interventional clinical trial within 28 days before the first dose of the investigational drug, or have received anti-tumor drug treatment within 28 days before the first dose of the investigational drug (including Chinese herbal medicine with anti-tumor indications);\n4. Have not recovered (i.e., reaching \u2264 grade 1 or the baseline status, excluding asthenia and alopecia) from toxicity and\/or complications caused by any intervention before the start of treatment;\n5. With known symptomatic central nervous system metastasis and\/or carcinomatous meningitis. Subjects with previously treated brain metastases are eligible if the disease is stable (no imaging evidence of progression in at least 4 weeks prior to the first dose of study treatment), there is no evidence of new or enlarging brain metastases on repeated imaging, and corticosteroids are not required in at least 14 days prior to the first dose of study treatment. Patients with carcinomatous meningitis should be excluded regardless of their clinically stability;\n6. During pregnancy or lactation;\n7. Known history of allotransplantation or allogeneic hematopoietic stem cell transplantation;\n8. Subjects with abnormal laboratory parameters listed below:\n\n   1. Serum phosphate \\> ULN;\n   2. Serum calcium exceeds the normal range, or the calcium concentration corrected for serum albumin exceeds the normal range when serum albumin exceeds the normal range;\n   3. Potassium level \\< lower limit of normal (LLN); potassium levels can be corrected by supplements at screening.\n9. With known history of human immunodeficiency virus (HIV) infection or confirmed with positive immune test results;\n10. Presence of severe infection in the active phase or with poor clinical control;\n11. Pleural effusion, ascites, or pericardial effusion with obvious clinical symptoms that require drainage;\n12. Acute or chronic active hepatitis B or C infection; hepatitis B virus (HBV) DNA \\> 2000 IU\/mL or 104 copies\/mL; hepatitis C virus (HCV) RNA \\> 103 copies\/mL; hepatitis B surface antigen (HbsAg) and anti-HCV antibody positive concurrently. Those who with relevant parameters lower than the above criteria after nucleotide antiviral treatment can be enrolled;\n13. With clinically significant or uncontrolled heart diseases, including unstable angina, acute myocardial infarction within 6 months before the first dose, grade III\/IV congestive heart failure (New York Heart Association), and uncontrolled arrhythmia (subjects with pacemakers or with atrial fibrillation but well controlled heart rate are allowed);\n14. With ECG changes or medical history considered clinically significant by the investigator; QTcF interval \\> 480 ms at screening; for subjects with intraventricular conduction block (QRS interval \\> 120 ms), JTc interval can be used instead of QTc interval upon approval of the sponsor (in such cases, JTc must be \u2264 340 ms);\n15. With uncontrolled hypertension (systolic pressure \\> 160 mmHg or diastolic pressure \\> 100 mmHg after the optimal medical treatment), or a history of hypertensive crisis or hypertensive encephalopathy;\n16. With hepatic encephalopathy, hepatorenal syndrome, or liver cirrhosis with Child-Pugh grade B or C.\n17. Have received a major surgery (craniotomy, thoracotomy, or laparotomy) within 4 weeks prior to the first dose of study treatment, or will receive a major surgery during the study treatment period;\n18. Pregnant or lactating women, or subjects expected to conceive or give birth during the study period from the screening visit to the completion of the safety follow-up visit (90 days after the last dose for male subjects);\n19. Have received radiotherapy within 4 weeks before the first dose of the investigational drug. The subjects must be completely recovered from radiotherapy-related toxicity, with no need for corticosteroid treatment, and radiation pneumonitis must be excluded. For palliative radiotherapy for non-CNS diseases, a 2-week washout period is allowed;\n20. Have a history of disorders of calcium and phosphorus metabolism or systemic electrolyte metabolism imbalance with ectopic calcification of soft tissues (excluding calcification of soft tissues such as skin, kidneys, tendon, or blood vessels without systemic electrolyte metabolism imbalance caused by injury, disease, and old age);\n21. Clinically significant corneal or retinal diseases confirmed by ophthalmological examination;\n22. Have used any potent CYP3A4 inhibitor (see Appendix A for details) or inducer within 14 days or 5 half lives (whichever is shorter) before the first dose of the investigational drug. Ketoconazole is allowed for external use;\n23. With known allergic reactions to pemigatinib or excipients of pemigatinib;\n24. Unable or unwilling to swallow pemigatinib or are suffering from significant digestive system diseases that may interfere with absorption, metabolism, or excretion;\n25. Subjects with a history of vitamin D deficiency who require supraphysiological dose of vitamin D (except dietary vitamin D supplements);\n26. Other acute or chronic diseases, psychiatric disorders, or laboratory abnormalities that may result in an increased risk associated with study participation or investigational drug administration or interfere with the interpretation of study results, and disqualify patients from the study in the investigator's judgment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05287386001","EMAIL":[{"email":"yefengdoctor@sina.com"}],"GEO":[24.47979,118.08187]},{"TITLE":"Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial","CRITERIA":"Inclusion Criteria:\n\n1. Patients who presented with resectable disease ( Clinical stage 1a to 3a)\n2. Patients who received tumor resection\n\nExclusion Criteria:\n\n1. Pathologic stage greater than stage 3b or 4\n2. Pathologic stage less than stage 1a1\n3. Could not complete treatment course\n4. Could not receive blood sampling for CTC (circulating tumor cell) or regular surveillance","SEX":"ALL","AGE_MIN":20,"AGE_MAX":90,"SS_ID":"06262386001","EMAIL":[{"email":"wu.chingyang@gmail.com"},{"email":"wisdom5000@gmail.com"},{},{}],"GEO":[24.95233,121.20193]},{"TITLE":"Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer","CRITERIA":"Inclusion Criteria:\n\nPatients should have clinical, radiographical, cytological, or histological confirmation of NSCLC or lung or nodal metastases from another primary cancer defined as within or touching the zone of the proximal bronchial tree, defined as a volume 2 cm in all directions around the trachea and proximal bronchial tree (carina, right and left main bronchi, right and left upper lobe bronchi, intermedius bronchus, right middle lobe bronchus, lingular bronchus right and left lower lobe bronchi). Tumors that are immediately adjacent (\\<1 cm) to mediastinal or pericardial pleura or other radiation-sensitive organs such as the esophagus and brachial plexus also are considered central tumors and are eligible for this protocol.\n\nOR Histologically or cytologically confirmed pancreatic ductal adenocarcinoma of the pancreatic head, body or tail.\n\n* Participants must have measurable disease, defined as a lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as \u226520 mm with conventional techniques or as \u226510 mm with spiral CT scan, MRI, or calipers by clinical exam. See Section 11 for the evaluation of measurable disease.\n\nEligible NSCLC patients must have no evidence of nodal involvement (N0), and disease has to be determined unresectable by a thoracic oncologist or the patient is medically inoperable.\n\n* Locally advanced, unresectable pancreatic cancer as determined by a pancreaticobiliary surgeon as part of a multidisciplinary discussion at the investigative site, including multi-phasic CT demonstrating tumor abutment of the SMA or celiac axis, SMV or PV involvement which is not resectable without vascular reconstruction.\n* Completion of at least 3 months of standard induction chemotherapy for LAPC, which should consist of either FOLFIRINOX, gemcitabine and nab-paclitaxel, or another standard combination of induction chemotherapy agent, with a washout period no longer than 10 weeks prior to first dose of study drug.\n* No evidence of distant metastasis.\n* Pancreatic or central NSCLC size \u2264 5cm.\n* Age 18 years or older.\n* ECOG performance status \u22642 (Karnofsky \u226560%, see Appendix A).\n* Ability to understand and follow the breathing instructions involved in the respiratory gating procedure.\n* Participants must have normal organ and marrow function as defined below:\n\n  * absolute neutrophil count \u22651,500\/mcL\n  * platelets \u2265100,000\/mcL\n  * total bilirubin within normal institutional limits\n  * AST(SGOT)\/ALT(SGPT) \u22642.5 \u00d7 institutional upper limit of normal\n  * creatinine within normal institutional limits OR\n* Creatinine clearance \u226560 mL\/min\/1.73 m2 for participants with creatinine levels above institutional normal.\n* The effects of AGuIX on the developing human fetus are unknown. For this reason, as well as the known teratogenic effects of radiation, women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Participants who have had prior radiation therapy to the chest or abdomen that would overlap with the current treatment field.\n* Participants who are receiving any other investigational agents.\n* Participants with known metastatic disease.\n* History of allergic reactions attributed to gadolinium-based IV contrast.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\/social situations that would limit compliance with study requirements.\n* Pregnant women are excluded from this study because AGuIX is contrast agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with AGuIX, breastfeeding should be discontinued if the mother is treated with AGuIX.\n* Severe claustrophobia or anxiety.\n* Known HIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with AGuIX. In addition, these participants are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated.\n* Active duodenal or gastric ulcer disease or evidence of tumor invasion of the bowel or stomach based on endoscopy.\n* Presence of a duodenal stent.\n* Unable to undergo magnetic resonance imaging (MRI) due to any of the following:\n\n  1. Presence of MRI-incompatible metal material or devices in the human body\n  2. MRI-incompatible Pacemaker or defibrillator\n  3. Insulin pump\n  4. Aneurysm clip\n  5. Artificial heart valve\n  6. Cochlear implant\n  7. Shrapnel or gunshot injury\n  8. Cataract surgery with implant unsafe for MRI","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04789486002","EMAIL":[{"email":"jonathe_leeman@dfci.harvard.edu"},{}],"GEO":[42.35843,-71.05977]},{"TITLE":"Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor","CRITERIA":"Inclusion Criteria:\n\n* Age: 18 to 75 years, Male or Female\n* Histological or cytologically diagnosis of advanced non-small cell lung cancer, or advanced gastric cancer, or advanced hepatocellular carcinoma, or advanced colorectal cancer\n* Patients' tumor tissue (formalin-fixed, paraffin-embedded) must be sufficient for diagnosis of cancer by a certified Laboratory of Pathology\n* Laboratory values within the following ranges prior to receiving treatment of study agent: Hemoglobin\u226711.0 g\/dL, Neutrophils count\u22671.5\u00d7l09\/L, Lymphocytes count\u2267lower limit of institutional normal, Platelet count\u226780\u00d7l09\/L, Serum creatinine\u22662.0 mg\/dL, Serum bilirubin\u22662 x upper limit of institutional normal, AST\/ALT\u22662 x upper limit of institutional normal\n* No dyspnea at rest. Oxygen saturation \u226590% on room air\n* Able to tolerate apheresis procedure including placement of temporary apheresis catheter\n* No genetic disease\n* No chemotherapy and radiation therapy to be planned recently\n* Fertile females\/males must consent to use contraceptives during participation of the trial. Women of child bearing potential must have a negative pregnancy test prior to receiving treatment of study agent within 7 days\n* Patients must have a Karnofsky performance status greater than or equal to 80%\n* Life expectancy greater than twelve months\n* Able and willing to give witnessed, written informed consent form prior to receiving any study related procedure\n* Agree that progress of the disease must be radiographically measurable by computerized tomography (CT) scanning technique or magnetic resonance imaging (MRI) (per RECIST1.1 criteria)\n* Agrees to participate in long-term follow-up for up to 3 years, if received NKT infusion\n\nExclusion Criteria:\n\n* Organ dysfunction defined as follows: Significant cardiovascular disease (i.e. New York Heart Association \\[NYHA\\] class 3 congestive heart failure, myocardial infarction within the past six months, unstable angina, coronary angioplasty within the past six months, uncontrolled atrial or ventricular cardiac arrhythmias; Child-Pugh C; Renal function failure or uremia; Respiratory failure; Disturbance of consciousness\n* Suffering from lymphoma or leukemia\n* Serious infections requiring antibiotics, bleeding disorders\n* Patients with myelodysplastic syndrome (MDS)\n* History of immunodeficiency disease or autoimmune disease\n* Known or suspected allergy to the investigational agent or any agent given in association with this trial\n* Known central nervous system tumors including metastatic brain disease, unless treated and stable\n* Other malignancy within 3 years prior to entry into the study\n* Negative HIV antigen and antibody, Hepatitis B surface antigen and Hepatitis C PCR within 21 days prior to enrollment\n* Patients with chronic disease which is undergoing immune reagents or hormone therapy\n* Previous bone marrow or stem cell transplant, or organ allograft\n* Within concurrent chemotherapy\n* Concomitant treatment with corticosteroids (Topical or inhalational corticosteroids are permitted)\n* Concurrent other medical condition that would prevent the patient from undergoing protocol-based therapy\n* Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dose of study agent\n* Pregnant or breast-feeding patients\n* Mental impairment or addictive disorders that may compromise the ability to give informed consent\n* Lack of availability of a patient for immunological and clinical follow-up assessment","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"02562963002","EMAIL":[{"email":"zhangxiaoyan@shaphc.org"},{}],"GEO":[31.22222,121.45806]},{"TITLE":"Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients","CRITERIA":"Inclusion Criteria:\n\n* Patient with non operable and \/ or metastatic non-small cell lung cancer documented histologically.\n* Pathological diagnosis of NSCLC carrying an EGFR activating mutation associated with sensitivity to the tyrosine kinase inhibitors (TKI) (exons 18, 19 and 21).\n* Sufficient tissue sample quantity and quality for translational research\n* Na\u00efve TKI-treated EGFR patient who can receive first-line treatment with Osimertinib or second-line after chemotherapy\n\nExclusion Criteria:\n\n* Any patient with an exon 20 EGFR mutation.\n* Any disease or pathology that recommend not to perform blood samples collection\n* Any psychological, family, geographical or social condition that could potentially, according to the investigator's judgment, prevent the collection of informed consent or interfere with compliance with the study protocol\n* Patient with a resistance mutation of EGFR\n* Patient under State Medical Assistance\n* Patient deprived of liberty on administrative or judicial decision, or patient under guardianship, curatorship or safeguard of justice","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04222335001","EMAIL":[{"email":"bernard.s@chu-toulouse.fr"},{},{},{},{},{},{},{}],"GEO":[43.60426,1.44367]},{"TITLE":"A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)","CRITERIA":"Inclusion Criteria:\n\n1. 18-75 years old ; Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; Life expectancy \u2265 3 months.\n2. Histologically or cytologically confirmed unresectable (Stage III) Non-Small Cell Lung Cancer.\n3. At least has one measurable lesion before radiotherapy.\n4. At least has one type of platinum-containing chemotherapy, Absence of progression after concurrent\/sequential chemoradiotherapy.\n5. Adequate laboratory indicators.\n6. No pregnant or breastfeeding women, and a negative pregnancy test.\n7. Understood and signed an informed consent form.\n\nExclusion Criteria:\n\n1. Squamous cell carcinoma meets following conditions should be excluded:\n\n   1. Cavernous lung cancer.\n   2. Has hemoptysis and maximum daily hemoptysis volume \u2265 2.5ml within 1 month before the first administration.\n2. Has received anti-angiogenic drugs or other PD-1 \/ PD-L1 \/ CTLA-4 antibody therapy or other immunotherapy against PD-1 \/ PD-L1 \/ CTLA-4.\n3. Severe hypersensitivity occurs after administration of other monoclonal antibodies.\n4. Diagnosed and\/or treated additional malignancy within 5 years with the exception of cured basal cell carcinoma of skin ,carcinoma in situ of prostate,and carcinoma in situ of cervix.\n5. Pathologically confirmed mixed small cell and non-small cell lung cancer.\n6. EGFR gene mutations.\n7. Has any active autoimmune disease or history of autoimmune disease.\n8. After the early stage of chemoradiotherapy, the treatment toxicity \u2265 grade 2 is not fully alleviated.\n9. Has \u2265grade 2 pneumonia.\n10. Immunosuppressant or systemic or absorbable local hormone therapy is required to achieve the aim of immunosuppression (dose \\&gt; 10mg\/ day prednisone or other therapeutic hormones) and is still used within 2 weeks after the first administration.\n11. Has multiple factors affecting oral medication.\n12. Has active bleeding or a persistent decrease in hemoglobin.\n13. Has any bleeding or bleeding events \u2265grade 3 in the first 4 weeks before the first administration.\n\n2.Has received anti-angiogenic drugs or other PD-1 \/ PD-L1 \/ CTLA-4 antibody therapy or other immunotherapy against PD-1 \/ PD-L1 \/ CTLA-4.\n\n14. Has unhealed wounds, fractures, active gastric and duodenal ulcers, positive continuous fecal occult blood, ulcerative colitis in the first 4 weeks before the first administration.\n\n15. Has received NMPA approved anti-tumor drugs or immunomodulatory drugs for systemic treatment within 2 weeks before the first administration.\n\n16.Has a history of a hematological system transplantation or organ transplantation.\n\n17. Has active diverticulitis\u3001peritoneal abscess, intestinal obstruction. 18. Has any serious and\/or uncontrollable disease. 19. According to the judgement of the investigators, there are other factors that may lead to the termination of the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"04325763030","EMAIL":[{"email":"jiyl@zjcc.org.cn"}],"GEO":[30.29365,120.16142]},{"TITLE":"Comparison of Segmentectomy Versus Lobectomy for Non-small Cell Lung Cancer \u2264 2 cm in the Middle Third of the Lung Field","CRITERIA":"Inclusion Criteria:\n\n1. Patient aged 18-75 years old;\n2. 6 mm \u2264 tumor size \u2264 20 mm;\n3. 0.25 \\< CTR \\< 1;\n4. Center of tumor located in the middle third of the lung field;\n5. ECOG score of 0,1 or 2;\n6. Lung function (FEV1 \u2265 1 L and \u2265 70%);\n7. Both lung segmentectomy and lobectomy could achieve R0 resection;\n8. No serious cardiopulmonary complications, and could withstand both lung segmentectomy and lobectomy;\n9. No hilus pulmonis and mediastinal lymph node metastasis and no distant metastasis;\n10. Single tumor nodule or the concomitant nodule \\< microinvasive tumor;\n11. Written informed consent.\n\nExclusion Criteria:\n\n1. The tumor nodule is located in right middle lobe;\n2. A history of other malignancies in the last 5 years (exclusion of early-staged thyroid cancer);\n3. Have received preoperative anti-tumor therapy, including prior chemotherapy, radiation therapy, target therapy and so on;\n4. A serious mental illness;\n5. Pregnant and lactating women;\n6. Congestive heart failure, myocardial infarction, severe stenosis of coronary artery within recent 6 months;\n7. With the history of cerebral infarction or cerebral hemorrhage within 6 months;\n8. With the history of sustained systemic corticosteroid therapy within 1 month;\n9. The predicted surgical margin is less than 2 cm or the maximum diameter of the tumor at the 3D-CTBA\n10. Other unsuitable situations;","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"04944563001","EMAIL":[{"email":"lizhihua_njmu@126.com"},{},{}],"GEO":[32.06167,118.77778]},{"TITLE":"Immune and Genomic Markers in ALK+ NSCLC","CRITERIA":"Inclusion Criteria:\n\nCohort 1 - Alive Individuals\n\n* Men or women 18 years of age or the age of majority for their residential state of the United States, or older, at the time of consent.\n* Histologically or cytologically confirmed advanced stage IIIB-IIIC not amenable to curative approach multi-modality (e.g., chemoradiation and\/or surgery) treatment, or stage IV non-small cell lung cancer (NSCLC)\n* Demonstration of having advanced ALK+ NSCLC, as assessed by fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), next-generation sequencing (NGS) or circulating tumor DNA analysis (ctDNA). For ALK FISH, fusions must have been detected in at least 15% of tumor cells.\n* Willingness to provide clinical and medical information to the study team as required.\n* Willingness to provide archival tumor tissue, if available. Patients may enroll even if no tumor tissue is available.\n* Ability to read, write and communicate in English.\n* Ability to sign a web-based informed consent form.\n\nCohort 2 - Deceased Individuals\n\n* Deceased individuals diagnosed with advanced ALK+ lung cancer at age 18 years or older may be studied on a case by case basis. Inclusion will require availability of adequate archived tissue and release of tissue and records by next of kin, if available.\n\nExclusion Criteria:\n\n* Participants who are unwilling to provide informed consent.\n* Participants who are younger than 18 years of age.\n* Participants who are unable to comply with the study procedures.\n* Known existence of an uncontrolled intercurrent illness including, but not limited to, psychiatric illness or social situations that would impair compliance with study requirements.\n* Participants who have previously enrolled to the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04881916001","EMAIL":[{"email":"jjlin1@partners.org"},{}],"GEO":[42.35843,-71.05977]},{"TITLE":"Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients","CRITERIA":"Inclusion Criteria:\n\n1. It is diagnosed as non-small cell lung cancer by pathological examination or cytological examination; it is assessed as locally advanced, unresectable stage III non-small cell lung cancer by imaging;\n2. Plan to receive radical radiotherapy and chemotherapy \u00b1 immunotherapy;\n3. Male or female between 18 and 75 years old;\n4. Life expectancy \u2265 12 weeks;\n5. The World Health Organization (WHO) PS score is 0 or 1;\n6. Organ and bone marrow function meet the following conditions: Forced expiratory volume per second (FEV1) \u22651000 ml; absolute neutrophil count \u22651.5\u00d710\\^9\/L; platelets \u2265100\u00d710\\^9\/L; hemoglobin \u226590 g\/L ; Serum creatinine clearance calculated according to the Cockcroft-Gault formula \u226550 mL\/min (Cockcroft and Gault 1976); serum bilirubin \u22641.5 times the upper limit of normal (ULN); alanine aminotransferase and aspartate aminotransferase \u22642.5 times ULN;\n7. A signed informed consent form is required before proceeding with any step in the research;\n8. There is an abnormality in the initial cardiac output index.\n\nExclusion Criteria:\n\n1. PS score 2-4;\n2. Organ function impairment: FEV1 \\<1000ml; absolute neutrophil count \\<1.5\u00d710\\^9\/L; platelets \\<100\u00d710\\^9\/L; hemoglobin \\<90 g\/ L; Serum creatinine clearance calculated according to Cockcroft-Gault formula \\<50 mL\/min; serum bilirubin\\>1.5 times ULN; alanine aminotransferase and aspartate aminotransferase\\>2.5 times ULN;\n3. Unstable angina or myocardial infarction occurred in the past month;\n4. Arrhythmia that has not been controlled and can cause symptoms or abnormal hemodynamics;\n5. Active endocarditis;\n6. Symptomatic severe aortic stenosis;\n7. Heart failure that has not been controlled;\n8. Acute pulmonary embolism, pulmonary infarction or low thrombosis (artery or vein) formation;\n9. Suspected or confirmed aortic dissection;\n10. Uncontrolled bronchial asthma;\n11. Pulmonary edema;\n12. Fingertip blood oxygen saturation at rest \u226485%;\n13. Acute non-cardiopulmonary diseases (such as infection, renal failure, thyrotoxicosis, etc.) that may affect sports performance or aggravate due to exercise;\n14. Mental disorders make it impossible to cooperate.\n15. Patients for whom drug intervention is clearly recommended according to the 2022 edition of the European Society of Cardiology Guidelines on Cardio-Oncology.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"04980716001","EMAIL":[{}],"GEO":[23.11667,113.25]},{"TITLE":"A Post Approval Commitment Study on Tabrecta\u00ae (Capmatinib) in South Korea","CRITERIA":"Inclusion Criteria:\n\n* Signed informed consent must be obtained prior to participation in the study.\n* Subject who are diagnosed as exon 14 skipping mutated NSCLC from tissue or plasma(ctDNA) sample analysis by treating physician (i.e. Any kind of diagnostic methods the institution currently has. Diagnostic modalities for research purpose would be also allowable.)\n* Subject who plan to receive Tabrecta\u00ae (Capmatinib) as per locally approved label\n\nExclusion Criteria:\n\n* Subject with contraindication according to the locally approved label\n* Subject whose medical record is not accessible\n* Subject who are not willing to provide informed consent","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05703516011","EMAIL":"novartis.email@novartis.com","GEO":[37.566,126.9784]},{"TITLE":"Palliative RadIotherapy of Multiple Metastatic Sites Before First Line of Systemic Therapy With Immune Checkpoint Inhibitors and Chemotherapy in Metastatic Non-Small-Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Signed consent to the study before the start of the procedures related to the protocol\n* Age \u2265 18 years at time of study entry\n* ECOG performance status 0-2\n* Histologically or cytologically confirmed non-small cell lung cancer, with expression of PD-L1 of less than 50%\n* Stage IV metastatic Non-Small Cell Cancer confirmed by CT scan (of brain, chest and abdomen) or PET CT\n* Patients must be eligible for first line of systemic treatment with standard of care checkpoint inhibitor immune therapy and chemotherapy - according to the recommendations\n* inclusion of patients treated for few brain metastases (with surgery or ablative radiosurgery) is permitted (if the disease in the central nervous system is under control)\n* Prior surgery (diagnostic and therapeutic) and irradiation (for example: stereotactic irradiation of brain metastases) is permitted, provided that patients have fully recovered from the procedure at least 2 weeks before inclusion in the study\n* Patients treated with surgery or radiation and chemotherapy for limited non-small cell carcinoma in the past is permitted\n\nExclusion Criteria:\n\n* Metastatic non-small cell carcinoma with known oncogenic alterations suitable for targeted treatment\n* Brain or meningeal metastases that are not under control\n* Other malignancy (other than non-small cell carcinoma) present that has progressed and\/or requires active treatment\n* Previous malignancy, unless cured or complete remission has been achieved for at least 2 years prior to enrolment and does not require maintenance treatment. With the exception of basal cell carcinoma or squamous cell carcinoma of skin, which was treated and precancerous diseases and in situ cancers\n* Patients with interstitial lung disease\n* The possibility of radical treatment of oligometastatic disease (primary tumour and metastases)\n* Patients who are not eligible for checkpoint immune inhibitor treatment due to contraindications such as autoimmune diseases, with the exception of some exceptions (Vitiligo; type I diabetes; hormone replacement hypothyroidism; psoriasis that does not require systemic treatment or other autoimmune diseases that do not limit checkpoint immune inhibitors treatment)\n* Previous treatment with anti PD-1, anti PD-L1, anti CTLA-4 antibodies, or any other treatment that affects T lymphocytes or checkpoint pathways\n* Patients with known sensitivity to monoclonal antibodies\n* Patients with known HIV infection\n* Patients with active or chronic hepatitis B and \/ or C\n* Pregnant and breastfeeding mothers\n* Patients with serious and uncontrollable health problems (physical and mental), which, according to researchers, could affect the poor participation of patients and make it difficult to interpret the results\n* Patients on corticosteroid therapy (more than 10 mg methylprednisolone or equivalent) prior to enrolment\n* Irradiation 2 months before inclusion in the study, except for stereotactic irradiation of brain metastases (or radiation and chemotherapy for limited non-small cell carcinoma in the past)","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05440916003","EMAIL":[{"email":"tanja.znidaric@ukc-mb.si"}],"GEO":[46.55472,15.64667]},{"TITLE":"AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures).\n* \u226518 years old(at the time consent is obtained).\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Has a life expectancy of at least 3 months.\n* Has a histologically or cytologically confirmed diagnosis of squamous NSCLC.\n* Has Stage IIIB\/C or IV NSCLC (American Joint Committee on Cancer \\[AJCC\\]).\n* Has no prior systemic anti-tumor therapy for locally advanced or metastatic NSCLC.\n* Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.\n* Has adequate organ function.\n\nExclusion Criteria:\n\n* Histological diagnosis of non-squamous NSCLC.\n* Has EGFR-sensitive mutations or ALK gene translocations.\n* Known ROS1 rearrangement, MET exon 14 skipping mutation, or RET gene fusion positivite.\n* Is currently participating in a study of an investigational agent or using an investigational device.\n* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy within 2 years prior to the first dose of study treatment.\n* Has undergone major surgery within 30 days of Study Day 1.\n* Has known active central nervous system (CNS) metastases.\n* Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).\n* Has an active infection requiring systemic therapy.\n* Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \\[qualitative\\] is detected).\n* History of myocardial infarction, unstable angina, congestive heart failure within 12 months prior to day 1 of study treatment.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.\n* Has received a live virus vaccine within 30 days of the planned first dose of study therapy.\n* Has any concurrent medical condition that, in the opinion of the Investigator, would complicate or compromise compliance with the study or the well-being of the subject.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05840016001","EMAIL":[{}],"GEO":[31.22222,121.45806]},{"TITLE":"A Phase I\/II Trial of UCB4594 in Participants With Advanced Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Written (signed and dated) informed consent and capable of co-operating with investigational medicinal product (IMP) administration and follow-up\n2. Participant population: Histologically or cytologically proven advanced solid tumours (as specified below), refractory to conventional treatment, or for which no conventional therapy is considered appropriate by the Investigator or is declined by the participant. Module A (dose escalation): Tumour types which have shown high levels of human HLA-G expression (as reported in the literature): head and neck squamous cell carcinoma, non-small cell lung cancer, colorectal cancer, triple-negative breast cancer, renal cell cancer (clear cell only), oesophago-gastric cancer (excluding gastrointestinal stromal tumour), cervical cancer, ovarian cancer, pancreatic cancer. N.B. Participants with small cell type cancers on histology\/cytology are excluded. Pre-treatment biopsies are mandatory for all participants. Paired biopsies will be mandatory for participants from doses of 30 mg and higher. Participants must have disease amenable to biopsy (excluding bone metastases) as deemed safe by the Investigator\n3. Measurable disease, according to RECIST v1.1\n4. Life expectancy of at least 12 weeks\n5. Eastern Cooperative Oncology Group performance status of 0 or 1\n6. Haematological and biochemical indices within defined ranges. These measurements should be performed to confirm the patient's eligibility to participate in the trial\n7. Aged 18 years or over at the time consent is given. Participants aged 16-17 years may be eligible for recruitment to the backfill cohorts in dose escalation once adequate safety and toxicity data have been established in participants aged 18 years or over. All relevant data will be reviewed and a decision on the inclusion of participants aged 16-17 years will be made by the Trial Management Group\n\nExclusion Criteria:\n\n1. Radiotherapy (except palliative), endocrine therapy (unless for non-malignant disease), chemotherapy, targeted therapy or immunotherapy, or any other IMPs during the previous 4 weeks or 5 half-lives (whichever is shorter) before the first dose of IMP\n2. Ongoing toxicity of previous treatments \\>CTCAE Grade 1 (except alopecia of any grade, stable Grade 2 peripheral neuropathy or hormone-replacement therapy (HRT)-managed endocrine disorders)\n3. Patients with rapidly progressing \/ symptomatically deteriorating brain\/leptomeningeal metastases\/untreated brain metastases are excluded. Patients with previously treated brain metastases are eligible if they haven't had a seizure or a clinically significant change in neurological status or required steroids in the last 2 weeks\n4. Pregnant or breastfeeding female patients (or planning to breastfeed)\n5. Women of childbearing potential. However, those not already pregnant or breastfeeding (or who discontinue breastfeeding) and meet the following are eligible:\n\n   5.1. Have a negative serum pregnancy test within 7 days before enrolment and either:\n\n   5.2.1. Agree to a form of highly effective contraception plus a barrier method, or\n\n   5.2.2. Agree to sexual abstinence\n\n   Effective from the negative pregnancy test, throughout the trial and for 10 months after the last dose of UCB4594\n6. Male patients with partners of childbearing potential. However, patients who meet the following are eligible:\n\n   6.1. Agree to a barrier method of contraception or sexual abstinence\n\n   6.2. Males with pregnant or breastfeeding partners must use barrier method contraception to prevent exposure of the foetus or neonate\n\n   6.3. Non-vasectomised males must also ensure any partner of childbearing potential uses highly effective contraception or agrees to sexual abstinence\n\n   Effective from the date of the first dose of UCB4594, throughout the trial and for 5 months after the last dose of UCB4594 N.B. Males must refrain from donating sperm for the same period\n7. Surgery from which the patient has not yet recovered\n8. High medical risk because of non-malignant systemic disease, including serious or uncontrolled infection (requiring intravenous antibiotics) or unexplained fever \\>38\u00b0C within 2 weeks prior to the first dose of UCB4594\n9. Known to be serologically positive for hepatitis B virus, hepatitis C virus or human immunodeficiency virus\n10. Active or suspected autoimmune disease, or any history of autoimmune condition that required systemic corticosteroids or immunosuppressive agents. Patients who have ever had a transplant are excluded. This does not apply to patients with: vitiligo, alopecia, or type I diabetes mellitus, psoriasis not requiring chronic systemic immunosuppressive treatment within the past 2 years, stable autoimmune-mediated hypothyroidism on HRT, and Raynaud's syndrome\n11. Are being treated with escalating or supraphysiologic doses of corticosteroids or immunosuppressive agents. Participants with immunotherapy-related hypophysitis adequately treated with physiologic doses of steroids are not excluded. Use of topical, ophthalmic, inhaled, intermittent steroid injections, and intranasal corticosteroids are permitted\n12. Hypersensitivity to the ingredients\/excipients (including polysorbate 80) in UCB4594\n13. History of significant toxicities from treatment of immune checkpoint inhibitors (CPIs) that necessitated permanent discontinuation (Patients who started on combination CPI \\[e.g., ipilimumab\/nivolumab\\] and had toxicity requiring discontinuation of one CPI \\[e.g., continued with nivolumab single agent\\] are not excluded)\n14. History of Grade \u22653 infusion-related reaction to monoclonal antibodies or similar drugs\n15. Prior treatment with HLA-G, immunoglobulin-like transcript (ILT)2 or ILT4-targeting drug\n16. Live, attenuated vaccine within 28 days prior to the first dose of IMP\n17. Increased risk due to tumour flare (e.g., an initial increase in tumour size that may lead to obstruction of airways, etc)\n18. Significant active pulmonary disease or condition at screening, including:\n\n    18.1. Lymphangitis carcinomatosa\n\n    18.2. History of interstitial lung disease or pulmonary fibrosis\n\n    18.3. History of pulmonary inflammatory disease\n19. Evidence of bleeding diathesis\n20. Significant cardiovascular disease, defined as a history of: congestive heart failure requiring therapy or left ventricular ejection fraction \\<40%, unstable angina pectoris or myocardial infarction within 6 months prior to entry, or current poorly controlled angina (symptoms weekly or more), clinically significant cardiac arrhythmia within 6 months prior to entry (asymptomatic atrial fibrillation or asymptomatic first-degree heart block permitted), or myocarditis. Presence of symptomatic or severe valvular heart disease. Baseline QT interval corrected by Fridericia \\>450 msec for males and \\>470 msec for females on triplicate electrocardiogram is ineligible\n21. Participant in or plans to join another interventional trial\n22. Other current malignancies. Cancer survivors who have undergone potentially curative therapy for prior malignancy with no evidence of disease for 3+ years are eligible\n23. Any other condition that, in the Investigator's opinion, means the trial is not in the patient's best interest","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06380816001","EMAIL":[{"email":"fiona.thistlethwaite@nhs.net"}],"GEO":[53.48095,-2.23743]},{"TITLE":"Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients","CRITERIA":"Inclusion Criteria\n\n1. Informed consent and HIPAA authorization for release of personal health information signed by the subject. Note: Data from tumor samples, blood samples and radiographic scans prior to enrollment date may be used.\n2. Age greater than or equal to18 years at the time of consent.\n3. Patients with metastatic non-small cell lung carcinoma have completed first line who, at immunotherapy discontinuation, have completed at least 20 of an anticipated 24 months of pembrolizumab monotherapy or pembrolizumab combination chemotherapy in the first line setting.\n4. Patients are allowed to continue maintenance chemotherapy.\n5. Ability to understand and comply with study procedures for the entire length of the study.\n6. Known PD-L1 prior to initiation of first-line treatment for NSCLC.\n\nExclusion Criteria\n\n1. Enrollment\/collection of baseline sample earlier than 7 days prior to scheduled last dose of pembrolizumab or more than 30 days after last dose of pembrolizumab.\n2. Patients whose tumors harbor known first line treatment druggable gene abnormalities (e.g. EGFR, BRAF, ALK, ROS1).\n3. Patients who have ever received or are currently receiving other types of immunotherapies (nivolumab, ipilimumab, durvalumab or atezolizumab).\n4. Known pregnancy.\n5. Patients who progress per the enrolling investigator while on treatment with pembrolizumab prior to enrollment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05415358002","EMAIL":[{"email":"Jada.Kluttz@wakehealth.edu"},{}],"GEO":[36.09986,-80.24422]},{"TITLE":"OFA in Thoracic Surgery","CRITERIA":"Inclusion Criteria:\n\n* going through thoracoscopic lung surgery including lobectomy, segmentectomy, single or multiple wedge resection, and two of the above procedures combined;\n* able to complete the pain scoring face-to-face;\n* no cognitive dysfunction or history of anesthetic drug allergy;\n* ASA grade I-II\n\nExclusion Criteria:\n\n-psychological disorders","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"05063396002","EMAIL":[{}],"GEO":[31.22222,121.45806]},{"TITLE":"First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations","CRITERIA":"Inclusion Criteria:\n\n1. \u226518 years of age and \u226475 years;\n2. Provision of a voluntarily given, personally signed and dated, written informed consent document;\n3. Histologically documented, unresectable, inoperable, locally advanced, recurrent or metastatic stage IIIB or IV non-small cell lung cancer (NSCLC);\n4. It is acceptable for subjects with the presence of EGFR activating mutation (exon 19 deletion and the L858R mutation in exon 21) to be included in this Phase I study; Only subjects with the L858R mutation in exon 21 to be included in this Phase IIb;\n5. At least one measurable disease by RECIST criteria version 1.1;\n6. Patients with controlled or stable brain metastases;\n7. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1, and life expectancy of at least 3 months;\n8. No prior treatment with systemic therapy for advanced NSCLC, including TCM treatments;\n9. Able to comply with required protocol procedures and able to receive oral medications;\n10. Adequate organ function, including:\n\n(1) Adequate bone marrow function Hemoglobin\u226590g\/L, absolute neutrophil count (ANC) should be \u2265 1.5x109\/L, platelets should be \u2265 80x109\/L; (2) Adequate liver function Total bilirubin \u2264 1.5 x upper normal limit (ULN), Aspartate Aminotransferase (AST) (SGOT) \u2264 2.5 x ULN (\u2264 5.0 x ULN if hepatic metastases), Alanine Aminotransferase (ALT) (SGPT) \u2264 2.5 x ULN (\u2264 5.0 x ULN if hepatic metastases), Creatinine\u2264 1.5 x upper normal limit (ULN), or \u2265 60 mL\/min; (3) Cardiac function: LVEF\u226550% assessed by Doppler ultrasound\uff1b\n\nExclusion Criteria:\n\n1. Small cell lung cancer (including mixed small cell and non-small cell lung cancer) and squamous cell carcinoma with cavitation;\n2. Patients with concurrent EGFR T790M mutation or unknown mutation status or other mutation types;\n3. Diagnosis of any other malignancy during the last 5 years, or with other malignancies at present;\n4. Patients with pre-existing meningeal metastases;\n5. Patients who have concurrent other malignant tumors;\n6. Any history of hemoptysis, hematochezia, bloody sputum;\n7. Tumor invasion or adjacent major vessels;\n8. Patients with uncontrolled or significant systematic disease, including: active infection, thyroid dysfunction, uncontrolled hypertension, unstable angina pectoris, congestive heart failure, or myocardial infarction within 6 months, or severe arrhythmia requiring medication;\n9. A history of other diseases, or metabolic dysfunction, or physical examination or laboratory results suggestive of a disease or condition that precludes the use of an investigational drug, or may affect the interpretation of the study results, or expose the patient to a high risk of treatment complications;\n10. Any astrointestinal disorders resulting in inability to take medications orally, or requiring intravenous (IV) nutrition, or previous surgery impair drug absorption;\n11. Pregnant or lactating females;\n12. Patients allergic to any pharmaceutical ingredient.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05271916001","EMAIL":[{}],"GEO":[31.22222,121.45806]},{"TITLE":"Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Male or female, at least 18 years old.\n2. Histologically or cytologically confirmed diagnosis of locally advanced (with a tumor lesion that cannot be eradicated by surgery or radiotherapy as assessed by the investigators) or metastatic NSCLC.\n3. No prior systemic antitumor therapy for locally advanced or metastatic NSCLC (Note: enrollment is permitted in the following 2 situations: 1) received only adjuvant therapy and the end of treatment was \u2265 6 months prior to the first dose; 2) received only radical radiotherapy and the end of treatment was \u2265 6 months prior to the first dose).\n4. The patient's tumor tissue or blood sample test result meets 1 of the following two criteria: a. Previous tumor tissue or blood samples are confirmed as RET fusion positive by local laboratory testing. b. If there is no previous RET fusion positive test report, a compliant tumor tissue or blood sample is required to be provided at the central laboratory, using a next-generation sequencing (NGS)-based assay to confirm RET fusion positive.\n5. Patients have at least one measurable lesion per RECIST version 1.1. (except for patients with measurable lesions in the brain only) (Note: a lesion that has been treated with radiotherapy or localized therapy is generally not considered a measurable lesion unless there is definitive progression of that lesion).\n6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1;\n7. Life expectancy of at least 3 months.\n8. Patients must have adequate organ function as defined in the below:\n\n   Bone marrow function:\n\n   patients must not have received any blood products, hematopoietic cell growth factors or other blood medications for at least 7 days prior to the first dose, and have a blood count: absolute neutrophil count (ANC) \u2265 1.5 x 10\\^9 \/L, platelet (PLT) count \u2265 75 x 10\\^9 \/L, and hemoglobin (Hb) \u2265 90 g\/L;\n\n   Liver function:\n\n   total bilirubin (TBIL) \u2264 1.5 times upper limit of normal (ULN) and both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u2264 2.5 times ULN in the absence of liver metastases; in the presence of liver metastases, both AST and ALT \u2264 5.0 times ULN and TBIL \u2264 3 times ULN;\n\n   Renal function:\n\n   creatinine clearance (Ccr) \u2265 50 mL\/min.\n\n   Coagulation function:\n\n   prothrombin time (PT) or International Normalized Ratio (INR) \u2264 1.5 times ULN.\n9. Patients can swallow the drug orally and are able to comply with follow-up visit requirements.\n10. Male and female patients of childbearing potential must be willing to abstain completely or agree to use an appropriate method of contraception for the duration of the study and for at least 3 months after the last dose of study medication.\n\nExclusion Criteria:\n\n1. Patients carried known major driver genetic alterations other than RET. e.g. EGFR, MET, ALK, ROS1, NTRK, BRAF V600, KRAS G12C, etc. (If a patient has a co-mutation, discuss with the investigators whether enrollment is possible).\n2. History of allergy to any components or excipients of SY-5007 tablets.\n3. Patients with malignancies other than NSCLC treated in this study (except: malignancies that are cured and have not recurred within 2 years prior to study entry; completely resected basal cell and squamous cell skin cancer; completely resected carcinoma in situ of the cervix or breast).\n4. Patient has clinically symptomatic primary central nervous system (CNS) tumor, symptomatic CNS metastases, molluscum contagiosum, or untreated spinal cord compression; exclusion: patient has stable CNS disease (no evidence of progression as determined by imaging for at least 4 weeks prior to the first dose and all neurological symptoms have returned to baseline levels), no evidence of new or enlarging brain metastases, and has not had CNS surgery or radiotherapy within 4 weeks prior to the first dose, has not undergone stereotactic radiosurgery within 2 weeks, and has discontinued or stabilized steroid dosing within 2 weeks.\n5. Comorbidities of the following symptoms or conditions prior to the first dose that remain poorly controlled with optimal therapy:\n\n   active uncontrolled systemic bacterial, viral, or fungal infections; pleural, abdominal, or pericardial effusions that are poorly controlled with interventions (e.g., drainage) (poorly controlled is defined as growth that is significant and symptomatic within 2 weeks of fluid collection and requires re-puncturing or other interventions); poorly controlled diabetes mellitus \\[fasting blood glucose \u2265 10 mmol\/L and\/or glycated hemoglobin (HbA1c) \u2265 8%\\]; uncontrolled symptomatic hyperthyroidism or hypothyroidism as assessed by the investigators; uncontrolled electrolyte disorders (e.g., hyper\/hypocalcemia, hyper\/hypomagnesemia, hyper\/hypokalemia) as assessed by the investigators; clinically significant severe gastrointestinal disorders as assessed by the investigators, including active ulcerative colitis Crohn's disease, peptic ulcers, or previous surgical procedures that may have significantly interfered with the absorption of the drug.\n6. Presence of serious cardiovascular disease\/abnormalities as indicated by any of the following:\n\n   a QTcF \\> 470 msec (females) or \\> 450 msec (males) using the Fridericia formula for heart rate correction at screening, (If drug-induced prolongation of the QTcF is suspected, it is assessed by the investigators to be safe and manageable and may be corrected with medication and then enrolled.); left ventricular ejection fraction (LVEF) \\< 45%; myocardial infarction or unstable angina pectoris or clinically significant uncontrolled arrhythmia within 6 months prior to the first dose of the drug, including bradyarrhythmias (e.g., type II second or third-degree heart block) that may result in prolongation of the QTcF; classified as class III or IV according to New York Heart Association (NYHA) criteria Congestive heart failure; poorly controlled hypertension (systolic blood pressure \\>150 mmHg or diastolic blood pressure \\>100 mmHg), history of unstable hypertension, or history of poor compliance with antihypertensive therapy.\n7. Presence of active viral infection or history of:\n\n   Hepatitis B (Hepatitis B surface antigen \\[HBsAg\\] positive with HBV DNA test \\> 2 x 10\\^3 IU\/mL, eligible for enrollment if re-tested to less than 2 x 10\\^3 IU\/mL with regular antiviral therapy); positive test for Human Immunodeficiency Virus (HIV) at screening or a known history of other immune deficient disorders; a history of prior organ transplantation, hematopoietic stem cell or bone marrow transplantation therapy.\n8. Presence of other lung diseases that require systemic treatment or are serious, such as active tuberculosis, interstitial lung disease, etc., which in the opinion of the investigators may influence the interpretation of the study results or put the patient at high risk.\n9. Patients who had used or were unable to discontinue the following potent inhibitors or inducers of CYP3A4 during the study period within 2 weeks prior to the first dose. CYP3A4 potent inhibitors: atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, vinpocetine, voriconazole; and CYP3A4 potent inducers: carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin.\n10. Palliative radiotherapy within 1 week prior to the first dose, or any lung radiotherapy with more than 30 Gy of radiation within 6 months prior to the first dose.\n11. Major surgical procedure (except central venous catheterization, tumor puncture biopsy, and gastric tube placement) or significant trauma within 4 weeks prior to the first dose.\n12. Participation in another clinical trial within 4 weeks prior to the first dose (note: except for those who are not using the investigational drug or investigational medical device; or those who have discontinued treatment from another clinical trial and are only being followed for subsequent survival) or are planning to participate in another clinical trial during the study period.\n13. Serious arterial\/venous thrombotic event within 1 year prior to the first dose, such as cerebrovascular accident, deep vein thrombosis, pulmonary embolism, or bleeding tendency within 30 days prior to the first dose, or risk of gastrointestinal bleeding as judged by the investigators.\n14. Female patients who are pregnant or breastfeeding.\n15. Any other conditions that, in the opinion of the investigators, makes participation in this clinical trial inappropriate.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06031558001","EMAIL":[{"email":"caicunzhoudr@163.com"},{}],"GEO":[31.22222,121.45806]},{"TITLE":"Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. All subjects or legal guardians must sign the informed consent form approved by the ethics committee in writing before starting any screening procedure;\n2. 18 Years to 75 Years, Histologically or cytologically confirmed Routine treatment of patients with advanced non-small cell lung cancer(Including TKI treatment failure patients);\n3. After the signature of the informed consent and prior to the collection of a single nuclear cell, the immuno- histochemical test must determine that the expression of EGFR in the tumor site of the patient reaches the positive standard and the score is 2 + or more;\n4. Pathological results suggest that CXCL13 factor positive rate \u2265 10 %;\n5. According to RECIST 1.1. The patient has at least one tumor lesion that can be measured (Results available within one month prior to screening period);\n6. Expected survival time \u2265 12 weeks;\n7. The Eastern oncology group strength status score (ECOG) was 0-1;\n8. Patients must have evidence of adequate hepatic and renal function as evidenced by the following laboratory parameters: Serum creatinine\u2264 1.6 mg\/ml or the creatinine clearance \u2265 40 ml\/min\/1.73m. Total bilirubin \\< 1.5 times upper limits of normal;\n9. The hemodynamics determined by echocardiography or multichannel radionuclide angiography(MUGA) are stable and the left ventricular ejection fraction (LVEF)\u226550%;\n10. Have sufficient bone marrow reserves (subjects can meet this requirement through blood transfusion), defined as: The number of white blood cells should not be less than 2 \u00d7 10\\^9\/L;Platelet\u2265100 x 10\\^9\/L; Hemoglobin \u2265100 g\/L;\n11. If the patient uses the following drugs, the following conditions must be met:\n\n    Glucocorticoid: The therapeutic dose of glucocorticoid must be stopped 2 weeks before the EGFR CAR-T infusion. However, the following physiological replacement doses of glucocorticoids are allowed: 12 mg\/m2 \/ dihydrogenated cortisone or equivalent; Immunosuppressive drugs: any immunosuppressive drugs must be stopped before they are selected for 4 weeks; Stop using granulocyte colony factor a week before plasmaphoresis.\n12. Women of childbearing age and all male subjects must agree to use effective contraceptive methods for at least 52 weeks after EGFR CAR-T infusion, and until two consecutive PCR tests show that CAR-T cells are no longer present in the body.\n\nExclusion Criteria:\n\n1. Patients who have previously received any gene therapy product treatment, including CAR-T treatment;\n2. Patients with uncontrolled hypertension (\\> 160\/95), unstable coronary artery disease confirmed by uncontrolled arrhythmias, unstable angina, decompensated congestive heart failure(\\>New York Heart Association Class II) or myocardial infarction within 6 months before cell infusion;\n3. Patients with severe liver and kidney dysfunction or consciousness disorders;\n4. Patients who had undergone antitumor chemotherapy other than lymphocyte clearance chemotherapy within 14 days before the EGFR CAR-T infusion;\n5. Screening of patients who had received other research drugs within 30 days before infusion;\n6. Patients undergoing radiotherapy and TKI treatment within 2 weeks before infusion ;\n7. Patients with active hepatitis B: HBVDNA \\>1000 cps\/ml;\n8. Patients with HIV antibody, hepatitis C antibody, syphilis spirocyte positive\uff1b\n9. Patients with The sputum smear and tuberculosis infection T cell test positive;\n10. Patients with Interstitial lung disease or pneumonia;\n11. Patients with acute life-threatening bacteria, viruses or fungal infections that have not yet been controlled(for example, before transfusion \u2264 72 hours of blood culture positive);\n12. Patients with central nervous system metastasis (after cerebral metastasis treatment is stable for more than 4 weeks and patients with asymptomatic brain metastasis do not need treatment), pericardial metastasis accompanied by a large amount of pericardial effusion;\n13. Patients with a previous or concurrent second tumor, with the following exceptions:\n\n    Adequate treatment of basal or squamous cell carcinoma(adequate wound healing prior to entry into the study);In situ cancer of the cervix or breast cancer with no signs of recurrence at least three years prior to the study following curable treatment; The primary malignant tumor has been completely removed and has been completely relieved for 5 years.\n14. Pregnant or lactating women;\n15. Patients with history of T cell tumors or present with the disease.\n16. Having autoimmune or inflammatory disorders of active nerves (such as Guillian-Barre syndrome, amyotrophic lateral sclerosis);\n17. The researchers believe that other circumstances such as compliance should not be involved in this clinical trial.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05060796001","EMAIL":[{"email":"zhangzhf@gzhmu.edu.cn"},{"email":"464677938@qq.com"},{}],"GEO":[23.11667,113.25]},{"TITLE":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7","CRITERIA":"Inclusion Criteria:\n\n* Phase 2: Histologically confirmed diagnosis of unresectable or metastatic NSCLC with KRAS G12C mutation and any PD-L1 TPS\n* Phase 3: Histologically confirmed diagnosis of unresectable or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS \\>=50%\n* Phase 3: Presence of evaluable or measurable disease per RECIST\n* Phase 3: CNS Inclusion - Based on screening brain imaging, patients must have one of the following:\n\n  1. No evidence of brain metastases\n  2. Untreated brain metastases not needing immediate local therapy\n  3. Previously treated brain metastases not needing immediate local therapy\n\nExclusion Criteria:\n\n* Phase 2 and Phase 3: Prior systemic treatment for locally advanced or metastatic NSCLC including chemotherapy, immune checkpoint inhibitor therapy, or a therapy targeting KRAS G12C mutation (e.g., AMG 510).\n* Phase 2: Active brain metastases\n* Phase 3: Patients with known central nervous system (CNS) lesions must not have any of the following:\n\n  1. Any untreated brain lesions \\> 1.0 cm in size\n  2. Any brainstem lesions\n  3. Ongoing use of systemic corticosteroids for control of symptoms of brain lesions at a total daily dose of \\> 10 mg of prednisone (or equivalent) prior to randomization.\n  4. Have poorly controlled (\\> 1\/week) generalized or complex partial seizures, or manifest neurologic progression due to brain lesions notwithstanding CNS-directed therapy\n* Phase 3: Radiation to the lung \\> 30 Gy within 6 months prior to the first dose of study treatment","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04613596329","EMAIL":[{}],"GEO":[53.48095,-2.23743]},{"TITLE":"A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Participant has locally advanced (unresectable) or metastatic solid tumor malignancy with documented KRAS G12D mutation and has received prior standard therapy.\n* Participant has at least 1 measurable lesion per RECIST v1.1.\n* Participant has an ECOG performance status of 0 or 1.\n* Participant has adequate organ function.\n\nExclusion Criteria:\n\n* Participant has symptomatic or untreated central nervous system (CNS) metastases. Participants with asymptomatic and treated and stable CNS metastases are eligible.\n* Participant has leptomeningeal disease as a manifestation of the current malignancy.\n* Participant has another prior malignancy active (i.e., requiring treatment or intervention) within the previous 2 years different from the primary malignancy for this study, except for local malignancies that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast, which are allowed.\n* Participant with active hepatitis B or hepatitis C virus (HCV).\n* Participant has a known history of human immunodeficiency virus (HIV) infection with acquired immunodeficiency syndrome (AIDS)-related complications.\n* Participant has an active infection requiring intravenous antibiotics within 14 days prior to study intervention.\n* Participant is expected to require another form of anticancer therapy while on study intervention.\n* Participant has any condition that makes the participant unsuitable for study participation.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06364696004","EMAIL":"Astellas.registration@astellas.com","GEO":[38.84622,-77.30637]},{"TITLE":"Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)","CRITERIA":"Inclusion Criteria:\n\n* stage IB-IIIA, operable non-small cell lung cancer, confirmed in tissue.\n* Able and willing to give written informed consent and has signed the informed consent form (ICF), prior to performance of any trial activities.\n* Eligible male and female subjects aged 18-75 years.\n* Lung function capacity capable of tolerating the proposed lung surgery.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.\n* Available tissue of primary lung tumor.\n\nExclusion Criteria:\n\n* Presence of locally advanced, inoperable or metastatic disease.\n* Subjects with EGFR mutation or ALK\u3001ROS1 gene rearrangement.\n* Participants with active, known or suspected autoimmune disease.\n* Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors).\n\nOther protocol defined inclusion\/exclusion criteria apply","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05775796001","EMAIL":[{"email":"fufangqiu12@163.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients","CRITERIA":"Inclusion Criteria:\n\n1. Patients with stage III(AJCC 8th) unresectable NSCLC, or resectable but intolerant or refusing surgery;\n2. Intolerable of concurrent chemoradiation;\n3. No progression after radiotherapy or sequential chemoradiation;\n4. Chemotherapy: standard dose of 2-6 cycles of paclitaxel, pemetrexed or gemcitabine in combination with platinum; Radiotherapy: starting within 3 months after chemotherapy using IMRT or VMAT technique. The target volume includes the primary tumor and regional lymph nodes, and the prescription dose 95% PTV ranges from 50Gy to 66Gy;\n5. ECOG PS0-2;\n6. PD-L1\u22651%;\n7. Age\u226518 years, and life expectancy\\>3 months;\n8. Adequate Hematologic, biochemistry and organ function (to be confirmed by test results within 7 days prior to the first dose);\n9. Be able to provide written informed consent (ICF) and able to understand and agree to comply with study requirements and assessment schedule.\n\nExclusion Criteria:\n\n1. Patients with EGFR-sensitive mutations and ALK rearrangements;\n2. Any prior use of anti-PD-1, anti-PD-L1, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibodies (including Ipilimumab or any other antibody targeting the T-cell co-stimulation or checkpoint pathway);\n3. History of allergy to components of Tislelizumab;\n4. Any active malignancy within 2 years prior to enrollment, except for the specific cancers examined in this study and any locally recurrent cancers that have been eradicated (e.g., resected basal or squamous cell skin cancer, superficial bladder cancer, cervical or breast cancer in situ);\n5. History of interstitial lung disease or pneumonia requiring oral or intravenous steroids;\n6. Progression after radiotherapy or sequential chemoradiation;\n7. Unresolved \u2265grade2 toxicities from radiotherapy and sequential chemoradiation, (excluding those that the investigator determines do not affect study treatment, such as alopecia);\n8. Grade 2 or severe Pneumonia from radiotherapy or sequential chemoradiation;\n9. Administration of a live vaccine within 30 days prior to treatment start (seasonal influenza vaccine without live vaccine is allowed);\n10. Severe chronic or active infections (including tuberculosis infections, etc.) requiring systemic antibacterial, antifungal or antiviral therapy \u2264 14 days prior to treatment start;\n11. History of immunodeficiency, including a positive HIV test, or other acquired or congenital immunodeficiency disease, or a history of organ transplantation;\n12. History of active autoimmune disease requiring systemic therapy;\n13. Treatment with long-term systemic immunosuppressive medications (\u226510 mg\/d prednisone or equivalent doses of other steroids) or other immunosuppressive medications;\n14. History of uncontrolled cardiovascular disease; or clinically significant QT interval prolongation, or QTc interval \\>480 ms during screening period;\n15. Abnormal liver function \\[total bilirubin \\> 1.5 times of the upper limit of normal value; ALT\/AST \\> 2.5 times of the upper limit of normal value in patients without liver metastases and ALT\/AST \\> 5 times of the upper limit of normal value in patients with liver metastases\\], abnormal renal function (serum creatinine \\> 1.5 times of the upper limit of normal value);\n16. History of serious concomitant diseases (e.g., severe hypertension, diabetes, thyroid disease, active infection, etc.) ;\n17. History of diagnosed neurological or psychiatric disorders, including epilepsy or dementia;\n18. Unsuitable for participation in this study assessed by investigators;\n19. Patients who were already enrolled in other clinical studies;\n20. Mixed lung cancer with small cell components.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05758116001","EMAIL":[{"email":"yurong311@aliyun.com"},{"email":"sherrydw@126.com"}],"GEO":[39.9075,116.39723]},{"TITLE":"RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC","CRITERIA":"Inclusion Criteria:\n\n* NSCLC patients with stage IIIB-IV\n* Driver gene positive (EGFR,ALK,C-MET, ROS,RET, HER2);\n* First line targeted therapy.\n* Performance status of 0-2 on the ECOG criteria.\n* Any one of the tumor markers is more than three times higher than the normal level, and the tumor markers include: CEA\\>15ng\/ml,CA-199\\>105U\/ml,CA-125\\>105 U\/ml, NSE\\>60 ng\/ml, SCCAg\\>7.5 ng\/ml, CYFRA21-1\\>21 ng\/ml, et al.\n* Measurable lesions present\n* Age\\>=18\n* Adequate hematologic (neutrophil count \\>= 1,500\/uL, platelets \\>= 60,000\/uL,hemoglobin\u226570g\/L), hepatic (transaminase =\\< upper normal limit(UNL)x2.5, bilirubin level =\\< UNLx1.5), and renal (creatinine =\\< UNL) function.\n* Informed consent from patient or patient's relative.\n\nExclusion Criteria:\n\n* Patients with dysphagia;\n* Unable to taking medication on time;\n* Patients with a history of abuse of psychotropic substances who are unable to quit or have mental disorders","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06142058001","EMAIL":[{"email":"yangxueqin@hotmail.com"},{}],"GEO":[29.56278,106.55278]},{"TITLE":"Biomarkers for Risk Stratification in Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Age \u2265 40 years\n* Ability to understand and provide written informed consent\n* Willingness to comply with study protocols and provide blood samples.\n* Willingness to complete 3-year clinical follow up\n\nExclusion Criteria:\n\n* Active non-cutaneous malignancy within the past 5 years as per medical record or patient report.\n* Exclusion criteria for possible follow-up visit blood draw:\n* Anemia - measured by hematocrit level of less than 30%, measured after the first blood draw.\n* Malnourishment - determined by BMI less than 19. If subject has BMI greater or equal to 19, but has a history of malnourishment, study staff will measure albumin level of subject's blood after initial blood draw. Albumin level must be greater than 2.5 mg per deciliter, or subject will be excluded.\n* Severe Chronic Obstructive Pulmonary Disease (COPD) - defined by Gold Stage IV.\n* Unstable heart conditions - defined by stable or unstable angina, recent myocardial infarction (within the last 2 years), active congestive heart failure, ischemic cardiomyopathy, or history of complications because of previous blood donation.\n* Liver cirrhosis.","SEX":"ALL","AGE_MIN":40,"AGE_MAX":200,"SS_ID":"03774758003","EMAIL":[{"email":"cancertrials@ucsf.edu"},{}],"GEO":[37.77493,-122.41942]},{"TITLE":"A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda\u00ae(EU\/US) in Participants With IV nqNSCLC","CRITERIA":"Inclusion Criteria:\n\n* Participants are eligible to be included in the study only if all the following criteria are met:\n\n  1. Male or female, age \u226518 years on the day of signing informed consent.\n  2. Participants are able to give voluntary informed consent and understand the study and are willing to follow and complete all the test procedures.\n  3. Life expectancy \u22653 months.\n  4. Eastern Cooperative Oncology Group (ECOG) performance status \u22641.\n  5. Histologically\/cytologically confirmed diagnosis of Stage IV (AJCC 8th edition) nsNSCLC.\n  6. Tumors without EGFR mutation\/ROS1 rearrangement \/ALK rearrangement.\n\nExclusion Criteria:\n\n* Participant must be excluded from participating in the study if the participant:\n\n  1. Is pregnant or a nursing female.\n  2. Has predominantly squamous cell histology NSCLC. Mixed tumors will be categorized by the predominant cell type; if small cell elements are present, the participant is ineligible.\n  3. Is currently participating and receiving an investigational agent or has participated in a study of an investigational agent and received an investigational agent or used an investigational device within 4 weeks prior to administration of the first dose of study intervention.\n  4. Before the first dose of study intervention:\n\n     * Had received prior systemic antineoplastic chemotherapy and targeted, biological therapy\n     * Had prior treatment with any other anti-PD-1, PD-L1 or PD-L2 agent or an antibody targeting other immuno-regulatory receptors or mechanisms. Examples of such antibodies include (but are not limited to) antibodies against TIGIT, IDO, PD-L1, CTLA-4, and LAG3.\n     * Has participated in any other BAT3306 study and has been treated with BAT3306.\n     * Had major surgery \\<3 weeks prior to first dose\n     * Received radiation therapy to the lung that is \\> 30 Gy within 6 months of the first dose of study intervention.\n     * Completed palliative radiotherapy within 14 days of the first dose of study intervention.\n  5. Is expected to require any other form of antineoplastic therapy while participating in the study. and so on","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06280196001","EMAIL":[{}],"GEO":[23.11147,114.41523]},{"TITLE":"Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers","CRITERIA":"Inclusion Criteria: Inital\n\n* Age \u2265 18 years\n* Biopsy proven metastatic non-small cell lung cancer, confirmed at enrolling institution\n* Somatic activating mutation in EGFR in pre-treatment tumor biopsy\/ cytology from pleural fluid or cfDNA\n* Either have not started a prior EGFR TKI therapy or may have started osimertinib within 3 weeks of confirming eligibility and enrollment criteria of measurable disease per approval of PI, with no prior chemotherapy for treatment of metastatic disease (adjuvant therapy \\> 6 months prior to study start is acceptable)\n* Measurable (RECIST 1.1) indicator lesion not previously irradiated with measurable disease determined per treating investigator. If a patient has already started on osimertinib there must be available pre-osimertinib baseline tumor assessments, to be utilized for RECIST 1.1 assessment.\n* Karnofsky performance status (KPS)\u226570%,\n* Ability to swallow oral medications\n* Adequate organ function (use of G-CSF and\/or transfusion to meet these criteria are not allowed)\n\n  * Hemoglobin \u2265 9 g\/dL\n  * Platelets \u2265 150,000mm\\^3 or 150 x 10\\^9\/L\n  * AST, ALT \u2264 2.5 x ULN with no liver metastases or \\< 5x ULN with the presence of liver metastases\n  * Total bilirubin \u2264 1.5 x ULN if no liver metastases or \\< 3 x ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases\n  * Absolute neutrophil count (ANC) \u2265 1500 cells\/mm\\^3\n  * Creatinine \u2264 ULN OR calculated creatinine clearance \u2265 60ml\/min calculated by Cockcroft and Gault equation\n  * Creatinine clearance \u2265 60 mL\/min calculated by Cockcroft and Gault equation\n* Willing to use highly effective contraceptive measures if of child-bearing potential or if the patient's sexual partner is a woman of child-bearing potential:\n\n  * Female subjects should be using highly effective contraceptive measures, and must have a negative pregnancy test and not be breast-feeding prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:\n  * Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments\n  * Women under 50 years old would be consider postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range for the institution\n  * Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation\n  * Male subjects should be willing to use barrier contraception\n\nExclusion Criteria: Initial\n\n* Pregnant or lactating women\n* Any radiotherapy within 1 week prior to starting treatment on protocol. The washout window only applies for patients who have not started Osimertinib.\n* Any major surgery within 2 weeks of starting treatment on protocol. The washout window only applies for patients who have not started Osimertinib.\n* Any evidence of clinically significant interstitial lung disease\n* Treatment with an investigational drug within five half-lives of the compound or 3 months, whichever is greater\n* Currently receiving (or unable to stop prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of CYP3A4. All patients must try to avoid concomitant use of any medications, herbal supplements and\/or ingestion of foods with known inducer effects on CYP3A4.\n* Any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting study treatment, with the exception of alopecia and grade 2 prior platinum-therapy- related neuropathy\n* Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial\n* active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.\n* Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the tablets or previous significant bowel resection that would preclude adequate absorption of osimertinib.\n* Any of the following cardiac criteria:\n\n  * Mean resting corrected QT interval (QTc) \\> 470 msec where QT interval is corrected for heart rate using Frederica's formula (QTcF).\n  * Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block and second degree heart block.\n  * Patient with any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, electrolyte abnormalities (including: Serum\/Plasma potassium \\<LLN, Serum\/Plasma Magnesium \\<LLN; Serum\/Plasma Calcium \\<LLN), congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes\n* Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.\n* History of hypersensitivity to active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib.\n* Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.\n\nInclusion Criteria: Randomization\n\n* Patients with detectable plasma EGFR mutations at C2D1\n* Karnofsky performance status (KPS) \u2265 70%\n* Adequate organ function\n\n  * Hemoglobin \u2265 9 g\/dL\n  * Platelets \u2265 100,000mm\\^3 or 100 x 10\\^9\/L\n  * Creatinine \u2264 ULN OR calculated creatinine clearance \u2265 60ml\/min\n  * AST, ALT \u2264 3x ULN with no liver metastases or \u2264 5x ULN with the presence of liver metastases\n  * Total bilirubin \u2264 1.5 x ULN if no liver metastases or \u2264 3 x ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases\n  * Absolute neutrophil count (ANC) \u2265 1500 cells\/mm3Must have at least stable disease per RECIST 1.1 assessment prior to initiating chemotherapy at C4D1\n  * Eligibility testing (KPS, bloodwork) should be tested at C3D1. If the subject's evaluation does not meet eligibility criteria, any result obtained between C3 and C4 can be used\n\nPlease note: All 'Initial' Exclusion Criteria must be re-confirmed prior to randomization.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04410796016","EMAIL":[{}],"GEO":[36.16589,-86.78444]},{"TITLE":"Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Diagnosis of any stage melanoma, Non-Small Cell Lung Cancer or genitourinary (GU) malignancies (Project 1).\n2. Diagnosis of any cancer type (Projects 2 and 3)\n3. Treatment with any ICPI agent\n4. Ability to understand and willingness to sign an informed consent form and rate surveys\n5. Life expectancy \\> 4 months (Project 3)\n6. ICPI-related diarrhea and\/or colitis of any grade with or without concurrent non- GI toxicity as the toxicity group (project 1)\n7. Patients with no organ toxicity as the control group (project 1)\n8. ICPI-related colitis and\/or diarrhea of grade \u2265 2 as GI toxicity (initial episode or recurrence) receiving standard treatment of immunosuppressive agents (steroid, infliximab, vedolizumab, or ustekinumab) any time during the colitis disease course until sustained resolution of GI toxicity, or one- year time point after enrollment (Project 2)\n9. ICPI-related colitis and\/or diarrhea of grade \u2265 2 as GI toxicity without involvement of non- GI toxicity within 45 days prior to FMT (Project 3)\n10. ICPI-related colitis and\/or diarrhea of grade \u2265 2 within 45 days prior to FMT with ANY of the following characteristics (project 3):\n\n    (i) refractory to treatment of steroid and two doses of non-steroidal immunosuppressants e.g. infliximab, vedolizumab or ustekinumab,\n\n    (ii) contraindication for immunosuppressive treatment,\n\n    (iii) recurrence after successful initial treatment,\n\n    (iv) recurrent symptoms once steroid is tapered down\/off or diarrhea\/colitis symptoms are steroid dependent, or\n\n    (v) patients with a history of refractory ICPI-related colitis and\/or diarrhea to medical treatment, even if they have improved symptoms from supportive care within 45 days prior to FMT\n11. No concern for active concomitant GI infection for the ICPI diarrhea\/colitis work up at the time of protocol therapy initiation as confirmed by stool tests or as per the treating physician based on clinical presentation (project 3)\n12. Patient who has been cleared for enrollment by Infectious Diseases consultant or treating physician if positive infection workup or screening tests (e.g. lifelong positive T-spot due to BCG inoculation, chronic colonization) prior to initiation of diarrhea\/colitis treatment (project 3)\n\nExclusion Criteria:\n\n1. Age younger than 18 years\n2. History of inflammatory bowel disease, and\/or radiation enteritis or colitis with active disease status at the time of study treatment initiation\n3. Pregnant and breastfeeding women\n4. Women of child-bearing potential who have positive urine or serum pregnancy test or refuse to do pregnancy test unless last menstrual cycle was \\> 1 year prior to consent and\/ or clear documentation states that patient is peri- or post-menopausal or there was recent supporting objective evidence of 'no pregnancy' status (e.g. blood or imaging) within 30 days prior to date of study treatment\n5. Patients who develop concurrent non- GI toxicity at the time of FMT treatment (project 3)\n6. Patients with active bacterial or fungal infection (Project 3)\n7. Donors at risk for monkeypox infection and\/ or exposure as determined by a questionnaire (Project 3)\n\nWithdrawal Criteria\n\n1. Patients may withdraw from the trial at any time\n2. Patients who develop GI perforation or toxic colitis that require surgery from ICPI colitis\n3. In project 3, if the first 30% of cases fail the fecal transplant treatment, then project 3 will be terminated","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03819296001","EMAIL":[{"email":"ywang59@mdanderson.org"},{}],"GEO":[29.76328,-95.36327]},{"TITLE":"A Study to Investigate LYL845 in Adults With Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Age \u2265 18 years up to \u2264 75 years at the time of informed consent\n* Confirmed diagnosis of melanoma, non-small cell lung cancer (NSCLC), or colorectal cancer (CRC) that is metastatic or locally advanced or unresectable and is relapsed and\/or refractory (R\/R) after standard therapy for each tumor histology\n* Participants must have received prior systemic treatment for their metastatic disease or locally advanced disease based on tumor type as follows:\n* Melanoma: participants with disease progression following an immune checkpoint inhibitor (CPI)\n* NSCLC: participants with disease progression following at least 1 approved systemic therapy, including an immune CPI-containing regimen for appropriate patients or an approved targeted therapy for known molecular abnormalities if applicable to their disease\n* CRC: participants with disease progression following at least 1 line of therapy, including a fluoropyrimidine with oxaliplatin or irinotecan. Microsatellite instability (MSI) high\/mismatch repair deficient (dMMR) CRC participants must have disease progression following systemic therapy with immune CPIs.\n* Measurable disease including at least 1 lesion that is safely resectable AND a target lesion to measure response and an additional lesion for biopsy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Adequate organ and marrow function\n* Women of childbearing potential must have a negative pregnancy test at screening\n* All participants must agree to practice highly effective methods of contraception\n* Fully recovered from toxicity from prior systemic anticancer therapy\n\nExclusion Criteria:\n\n* Prior treatment with adoptive cellular therapy\n* Prior solid organ transplantation\n* Central nervous system (CNS) involvement of disease that is extensive, symptomatic or untreated, or patients with leptomeningeal disease\n* Uncontrolled or symptomatic pleural effusion or ascites\n* Untreated or active systemic infection\n* Active autoimmune disease requiring treatment or primary immunodeficiency syndrome\n* Systemic corticosteroids at a dose of \\>10 mg of prednisone or equivalent per day\n* Other primary malignancy within 3 years prior to enrollment\n* Impaired cardiac function or clinically significant cardiovascular disease\n* Required chronic anticoagulation, such as warfarin, low molecular weight heparin, or Factor Xa inhibitors\n* Pregnant or nursing (lactating) women","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05573035018","EMAIL":[{}],"GEO":[47.60621,-122.33207]},{"TITLE":"Prognostic Value of Combined Approach Based on KEAP1\/NFE2L2 Mutations and Pre-therapeutic FDG-PET\/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 \u2265 50% Treated With Pembrolizumab (PEMBROMIC)","CRITERIA":"Inclusion Criteria:\n\n* Age \u2265 18 years\n* Histologically or cytologically proven non-small-cell lung cancer (NSCLC)\n* Stage IV NSCLC. Stage III NSCLC unresectable and not amenable to radiotherapy\n* PD-L1 expression \u2265 50%.\n* No previous systemic treatment for NSCLC.\n* Patients treated for 1st-line metastatic disease with immunotherapy alone (pembrolizumab)\n* No opposition expressed\n* Patient affiliated to a social security scheme\n\nExclusion Criteria:\n\n* PD-L1 expression \\<50\n* Neuroendocrine tumors\n* Secondarily metastatic patients\n* Previous treatments\n* Opposition formulated\n* Patient under legal protection (guardianship, curatorship, etc.)","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05996263001","EMAIL":[{"email":"vincent.bourbonne@chu-brest.fr"}],"GEO":[48.3903,-4.48628]},{"TITLE":"Observational Study of the Efficacy and Safety of Anlotinib Combined With Penpulimab in Elderly Lung Cancer Patients","CRITERIA":"Inclusion Criteria:\n\n* At least 65 years old;\n* Non-small cell lung cancer with locally advanced, recurrent or metastasis, which confirmed by histologically or cytologically (except sputum cytology) and evaluated as IIIB-IV stage, who are unresectable or unable to undergo radical radiotherapy or refuse radical radiotherapy. (If multiple tumor components are mixed, it should be classified according to their predominant cell type);\n* Participants are required to have one measurable disease per RECIST 1.1;\n* Unsuitable or unwilling to receive radical treatment methods (such as radical chemoradiotherapy and\/or surgery) and have not received prior systemic therapy;\n* ECOG performance status of 0 to 2; The expected survival is more than 3 months;\n* Adequate organ and marrow function defined as follows:\n\n  * Hemoglobin (HB) \u226590 g\/L (no blood transfusion within 28 days);\n  * Absolute neutrophil count (ANC) \u22651.5\u00d7109\/L;\n  * Platelet count (PLT) \u2265 100\u00d7109\/L;\n  * Aspartate Transaminase (AST) \u2264 1.5 x upper limit of normal (ULN);\n  * Alaninetransaminase (ALT) \u2264 1.5 x ULN (ALT and AST \u2264 5 x ULN if liver metastases are present);\n  * Alkaline phosphatase (ALP) \u2264 1.5 x ULN;\n  * Albumin (ALB) \u2265 30g\/L;\n  * Creatinine \u22641.5 x ULN or Creatinine Clearance (CCr) \u2265 60 ml\/min;\n  * International normalized ratio (INR) \u2264 1.5 x ULN;\n  * Partial thromboplastin time (APTT) \u2264 1.5 x ULN;\n  * Prothrombin time (PT) \u2264 1.5 x ULN ;\n  * Thyrotropic hormone (TSH) \u2264 ULN (When TSH value is abnormal, T3 and T4 levels is normal, which can be enrolled);\n  * Urine protein \\< (++), or 24-hour urine protein amount \\< 1.0 g ;\n  * Patients must have adequate cardiac function, defined as:\n\nLeft ventricular ejection fraction (LVEF) \\> 50% as determined by cardiac echocardiogram.\n\n-Patients enrolled in this study voluntarily and signed an informed consent with a good compliance.\n\nExclusion Criteria:\n\n* Participants who have active infection;\n* Patients with known immunodeficiency diseases (e.g. psoriasis, active arthritis, immune nephropathy, HIV, etc);\n* Participants with no measurable disease;\n* Patients with cancerous meningitis and spinal cord compression;\n* Participants with active central nervous system (CNS) metastases (clinically stable and maintained for at least 2 weeks after adequate treatment of CNS metastases and do not require treatment such as glucocorticoids and dehydrating drugs are eligible for enrollment);\n* Previously treated with chemotherapy drugs (except neoadjuvant therapy) \/ targeted drugs \/ immunotherapy;\n* Participants who were confirmed severe abnormalities of gastrointestinal function (e.g. inability to take oral medications, uncontrollable nausea or vomiting, history of major gastrointestinal resection, untreated recurrent diarrhea, untreated gastric disease requiring long-term acid-suppressing PPI-like medications, Crohn's disease, ulcerative colitis);\n* Patients with central squamous lung cancer on imaging;\n* Patients who had an arterial\/venous thrombotic event within 6 months, such as cerebrovascular accident (temporary ischemic attack is excluded), deep vein thrombosis and pulmonary embolism;\n* Patients whose imaging shows that the tumor has invaded a significant vessel or have a high risk of fatal hemorrhage due to tumor invasion of a significant vessel during the follow-up study judged by the investigator; or who have bleeding tendencies (e.g., active peptic ulcer) or receiving thrombolytic or anticoagulant therapy such as warfarin, heparin, or their analogs;\n* Patients who had antineoplastic therapy against other malignancies, including radiotherapy, chemotherapy, immunotherapy and herbal medicine (except previously eradicated malignancies without recurrent metastases for \u2265 5 years);\n* Patients with uncontrollable pleural effusion, pericardial effusion or ascites requiring repeated drainage (except patients who do not require drainage of effusion or whose effusion does not increase significantly after 3 days of cessation of drainage);\n* Patients who have used immunosuppressive drugs within 4 weeks prior to the study treatment, except for topical glucocorticoids by nasal spray, inhalation or other routes or physiologic doses of systemic glucocorticoids (no more than 10 mg\/day of prednisone or equivalent doses of other glucocorticoids);\n* Patients who have known or suspected active autoimmune disease (congenital or acquired), such as interstitial pneumonia, uveitis, enterocolitis, hepatitis, pituitary inflammation, vasculitis, nephritis, thyroiditis, etc. (Patients with vitiligo or asthma that has completely resolved in childhood and does not require any intervention in adulthood may be enrolled; Patients with type I diabetes with good insulin control may be enrolled);\n* Patients who have known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation;\n* Anticipants who have hypersensitivity to any component of anlotinib and monoclonal antibodies;\n* Anticipants who have active interstitial lung disease requiring treatment;\n* Anticipants who have a history of psychotropic substance abuse and are unable to abstain or have a psychiatric disorder;\n* Anticipants who have participated in another anti-tumor clinical trial within four weeks;\n* Anticipants who administered anti-infective vaccines (e.g., influenza virus vaccine, human papillomavirus vaccine) within 4 weeks prior to study therapy; During the treatment period, in addition to inactive vaccines, other vaccines are prohibited;\n* Anticipants who have undergone major surgery (except for diagnostic purposes) within 4 weeks (28 days) prior to the administration of the study;\n* Patients who are not suitable for enrollment in the judgment of the investigator.","SEX":"ALL","AGE_MIN":65,"AGE_MAX":200,"SS_ID":"05319886001","EMAIL":[{"email":"54234317@qq.com"},{"email":"Drzhangyana@hotmail.com"}],"GEO":[35.19033,113.80151]},{"TITLE":"Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.","CRITERIA":"Inclusion Criteria:\n\n1. Signed informed consent form (ICF) must be obtained prior to participation in the study.\n2. Adult \u226518 years old at the time of informed consent.\n3. Stage IIIB\/IIIC (not amenable to surgery, radiation or multi-modality therapy) or Stage IV NSCLC (according to Version 8 of the AJCC Staging Manual) either treatment naive or progressed on 1 or more lines of therapy at the time of study entry.\n4. Histologically or cytologically confirmed diagnosis of NSCLC with confirmed EGFR wild-type and ALK rearrangement negative and who have tested positive test for MET exon14 skipping mutation (Locally available MET report either by RT-PCR or Next Generation Sequencing \\[NGS\\] would be considered, in case not available MET testing would be done through NGS based platform during molecular pre-screening done as part of the study).\n5. Patients must have recovered from all toxicities related to prior systemic therapies to grade \u22641 (Common Terminology Criteria for Adverse Events \\[CTCAE\\] version 5.0).\n6. At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.\n7. Patients must have adequate organ function including the following laboratory values at the screening visit:\n\n   * Absolute neutrophil count \u22651.5 x 109\/L without growth factor support\n   * Platelets \u2265100 x 109\/L\n   * Hemoglobin \u22659 g\/dL\n   * Calculated creatinine clearance (using Cockcroft-Gault formula) \u226545 mL\/min\n   * Total bilirubin \u22641.5 upper limit of normal (ULN) (except in patients with Gilbert's syndrome, who may be included if total bilirubin is \u22643.0 x ULN and direct bilirubin is \u22641.5 x ULN))\n   * Aspartate transaminase (AST) \u22643 x ULN, except for patients with liver metastasis, who may only be included if AST \u22645 x ULN\n   * Alanine transaminase (ALT) \u22643 x ULN, except for patients with liver metastasis, who may only be included if ALT \u22645 x ULN\n   * Alkaline phosphatase \u22645.0 x ULN\n   * Asymptomatic serum amylase \u2264 grade 2. Patients with grade 1 or grade 2 serum amylase at the beginning of the study must be confirmed to have no signs and\/or symptoms suggesting pancreatitis or pancreatic injury (e.g., elevated P-amylase, abnormal imaging findings of pancreas, etc.)\n   * Serum lipase \u2264 ULN.\n8. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2.\n9. Willing and able to comply with scheduled visits, treatment plan, and laboratory tests.\n\nExclusion Criteria:\n\n1. Prior treatment with any MET inhibitor or hepatocyte growth factor -targeting therapy.\n2. Presence or history of a malignant disease other than NSCLC that has been diagnosed and\/or required therapy within the past 3 years. Exceptions to this exclusion include the following: completely resected basal cell and squamous cell skin cancers and completely resected carcinoma in situ of any type\n3. Patients with symptomatic central nervous system (CNS) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms.\n4. Patients with known druggable molecular alterations (such as ROS1 translocation or BRAF mutation, etc.) which might be a candidate for alternative targeted therapies as applicable per local regulations and treatment guidelines.\n5. Presence or history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention).\n6. Patients with clinically significant heart diseases like unstable angina\/acute myocardial infarction within 6 months prior to screening, NYHA class III-IV congestive cardiac failure, uncontrolled hypertension, arrhythmias or QTcF\u2265470 ms on the screening electrocardiogram (ECG)\n7. Major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) within 4 weeks prior (2 weeks for resection of brain metastases) to starting capmatinib or who have not recovered from side effects of such procedure. Video-assisted thoracic surgery and mediastinoscopy will not be counted as major surgery and patients can be enrolled in the program \u22651 week after the procedure\n8. Thoracic radiotherapy to lung fields \u22644 weeks prior to starting capmatinib or patients who have not recovered from radiotherapy-related toxicities.\n\n   For all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs), radiotherapy \u22642 weeks prior to starting capmatinib or patients who have not recovered from radiotherapy-related toxicities. Palliative radiotherapy for bone lesions \u22642 weeks prior to starting capmatinib is allowed.\n9. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of capmatinib or patients who are unable to swallow oral tablets.\n10. Patients receiving treatment with strong inducers of CYP3A that cannot be discontinued at least 1 week prior to the start of treatment with capmatinib and for the duration of the study\n11. Unable or unwilling to swallow tablets as per dosing schedule\n12. Patients with known hypersensitivity to capmatinib and any of the excipients of capmatinib.\n13. Patients with any other severe, acute or chronic medical or psychotic conditions or significant abnormal physical findings that in the opinion of the investigator may increase the risk associated with study participation or that may interfere with the interpretation of study results.\n14. Previous (within 28 days) or concomitant participation in another clinical study with investigational medicinal product(s).\n15. Pregnant or nursing (lactating) women.\n16. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while taking study treatment and for 7 days after stopping study treatment. Highly effective contraception methods include:\n\n    * Total abstinence (when this is in line with the preferred and usual lifestyle of the patient. Note that periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not considered highly effective and therefore not acceptable methods of contraception.\n    * Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or bilateral tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment.\n    * Male sterilization (at least 6 months prior to screening). For female patients on the study, the vasectomized male partner should be the sole partner for that patient\n    * Use of oral, (estrogen and progesterone), injected, or implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine system, or other forms of hormonal contraception that have comparable efficacy (failure rate \\<1%), for example hormone vaginal ring or transdermal hormone contraception. In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking treatment.\n17. Sexually active males unwilling to use a condom during intercourse while taking study treatment and for 7 days after stopping study treatment. A condom is required for all sexually active male patients to prevent them from fathering a child AND to prevent delivery of study treatment via seminal fluid to their partner. In addition, male patients must not donate sperm for the time period specified above.\n18. Any other condition that would, in the Investigator's judgment, contraindicate patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., active infection (including active hepatitis B and C, SARS-CoV-2), inflammation, intestinal obstruction, unable to swallow medication, social\/ psychological issues, etc.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":99,"SS_ID":"05110196015","EMAIL":"novartis.email@novartis.com","GEO":[11.93381,79.82979]},{"TITLE":"Phase 1b\/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients","CRITERIA":"Inclusion Criteria:\n\n* Male or female aged \u2265 20 years or adult age as per local regulations, at time of informed consent\n* Histologically or cytologically confirmed advanced solid tumor (Part 1) or NSCLC with HER2 mutations as determined by the central result (Part 2)\n* For patients in Part 2 only: Patients has measurable disease per RECIST 1.1 criteria\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Part 1), 0 to 2 (Part 2)\n* Appropriate candidate for experimental therapy\n* Adequate organ function\n\nExclusion Criteria:\n\n* Known active or untreated central nervous system (CNS) metastases and\/or carcinomatous meningitis\n* For patients in Part 2 only: Previously treated with EGFR or HER2 TKIs.\n* Serious acute or chronic infections\n* Received a live-virus vaccination\n* Received prior anticancer or other investigational therapy within 28 days or 5\u00d7 the half-life prior to the first dose.\n* Not recovered from prior- treatment toxicities to Grade \u22641\n* Major surgery within 28 days prior to the study treatment\n* Concurrent malignancy within 2 years prior to first dose\n* History or presence of clinically relevant cardiovascular abnormalities. QTcF \u2265 470 ms\n* Significant gastrointestinal disorder(s) that could interfere with absorption of ABT101\n* Known to have a history of alcoholism or drug abuse","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05532696005","EMAIL":[{}],"GEO":[24.95233,121.20193]},{"TITLE":"T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer","CRITERIA":"* INCLUSION CRITERIA:\n\n  1. Measurable metastatic (stage IV) or unresectable non-small cell lung cancer (including but not limited to squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinomas) with at least one lesion that is resectable for TIL generation. (Note: neuroendocrine tumors are not eligible.)\n  2. Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and asymptomatic are eligible. Lesions that have been treated with stereotactic radiosurgery must be clinically stable for 1 month after treatment for the patient to be eligible. Patients with surgically resected brain metastases are eligible.\n  3. All patients must have had at least one appropriate first line systemic therapy and progressed.\n  4. Clinical performance status of ECOG 0 or 1.\n  5. Age Greater than or equal to 18 years of age and less than or equal to 72 years of age.\n  6. Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after treatment.\n  7. Willing to sign a durable power of attorney\n  8. Able to understand and sign the Informed Consent Document\n\nI. Hematology:\n\n* Absolute neutrophil count greater than 1000\/mm3 without support of filgrastim\n* Normal WBC (\\> 2500\/mm3).\n* Hemoglobin greater than 8.0 g\/dl. Subjects may be transfused to reach this cut-off.\n* Platelet count greater than 80,000\/mm3\n\n  j. Serology:\n* Seronegative for HIV antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities.)\n* Seronegative for active hepatitis B, and seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then patient must be tested for the presence of antigen by RTPCR and be HCV RNA negative.\n\n  k. Chemistry:\n* Serum ALT\/AST less than or equal to2.5 times the upper limit of normal.\n* Serum creatinine less than or equal to 1.6 mg\/dl.\n* Total bilirubin less than or equal to 2 mg\/dl, except in patients with Gilbert s Syndrome, who must have a total bilirubin less than or equal to 3 mg\/dl.\n\n  l.Women of child-bearing potential must have a negative pregnancy test or evidence that they are not pregnant (e.g., ultrasound or serial HCG measurements) prior to the start of treatment because of the potentially dangerous effects of the treatment on the fetus.\n\n  m. Patients must have completed any prior systemic therapy at the time of enrollment.\n\nNote: Patients may have undergone minor surgical procedures or local radiotherapy within the past 4 weeks, as long as related major organ toxicities have recovered to grade 1 or less.\n\nn. More than two weeks must have elapsed since any prior palliation for major bronchial occlusion or bleeding at the time the patient receives the preparative regimen, and patient s toxicities must have recovered to a grade 1 or less.\n\no. Subjects must be co-enrolled in protocol 03-C-0277\n\nEXCLUSION CRITERIA:\n\n1. Women who are breastfeeding because of the potentially dangerous effects of the treatment on the infant.\n2. Ongoing need for pharmacological immunosuppression, including steroids\n3. Active systemic infections (e.g.: requiring anti-infective treatment), coagulation disorders or any other active or uncompensated major medical illnesses.\n4. Major bronchial occlusion or bleeding not amenable to palliation.\n5. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency\n\n   Disease and AIDS).\n6. Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities.)\n7. History of severe immediate hypersensitivity reaction to any of the agents used in this study.\n8. For select patients with a clinical history prompting cardiac evaluation: last known LVEF less than or equal to 45%.\n9. For select patients with a clinical history prompting pulmonary evaluation: known FEV1 less than or equal to 50%\n10. Any of the following will exclude patients from the high-dose aldesleukin arm, but may be eligible for the low-dose aldesleukin arm:\n\n    * Greater than 2 invasive thoracic procedures\n    * Poor exercise tolerance\n    * Greater than 66 years of age\n    * Clinically significant patient history which in the judgment of the Principal Investigator would compromise the patient s ability to tolerate high-dose.\n11. Patients who are receiving any other investigational agents.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":72,"SS_ID":"02133196001","EMAIL":[{"email":"irc@nih.gov"}],"GEO":[38.98067,-77.10026]},{"TITLE":"Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers","CRITERIA":"Inclusion Criteria:\n\n* The subject provides written informed consent.\n* Adults \u2265 18 years of age on day of signing informed consent.\n* Disease must be measurable per RECIST 1.1, as assessed by the Site(s) Investigator\/radiologist. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in these lesions.\n* Subject has histologically or cytologically documented, locally advanced (Stage IIIB or IIIC) disease (not candidate for surgical resection, local therapies with curative intent, or definitive chemoradiation) or the subject has metastatic NSCLC (Stage IV). Staging will be based on the American Joint Committee on Cancer, Eighth Edition. Subjects with adenocarcinoma, large cell carcinoma, undifferentiated carcinoma, squamous carcinoma, or mixed histology are eligible. Subjects with a small cell component are not eligible.\n* Phase 1b Subjects additional eligibility criteria:\n\n  1. Subjects must have received a minimum of one prior systemic treatment for advanced unresectable or metastatic NSCLC and progressed following prior SOC.\n  2. Maximum of up to 4 prior lines of therapy in an advanced or metastatic setting is allowed.\n  3. Subjects who had disease recurrence or progression following neoadjuvant or adjuvant therapy or definitive chemoradiation therapy are eligible.\n  4. Subjects who received treatment with an approved\/available targeted therapy for an actionable genomic alteration (including but not limited to EGFR, ALK, ROS1, KRAS, etc.) can participate if they have documented disease progression or were unable to tolerate the approved targeted therapy.\n\nPhase 1b Notes:\n\n* Targeted therapy for advanced setting is counted as a prior line of therapy.\n* Prior use of a PD(L)-1, anti-CTLA-4 (Cytotoxic T-lymphocyte associated protein 4) antibody, or any other antibody or drug that specifically targets immune checkpoint pathway is allowed and is counted as a prior line of therapy.\n* Neoadjuvant and adjuvant therapies initiated \\< 12 months prior to the first dose of study drug(s) will be counted as one prior line of therapy for advanced setting.\n* Neoadjuvant and adjuvant therapies initiated \u2265 12 months prior to the first dose of study drug(s) are not counted as prior lines of therapy.\n* Maintenance therapy is not counted as a prior line of therapy.\n* Phase 2a Subjects additional eligibility criteria:\n\nCohort 1:\n\n1. Tumors must have PD-L1 expression (TPS \u2265 1% as determined by SOC).\n2. Subjects are eligible to participate if they did not receive any prior therapy (SOC or investigational) or prior immunotherapy of any kind for advanced or metastatic disease. See Exclusion Criteria 1.0.\n3. Subjects with disease recurrence or progression following neoadjuvant or adjuvant therapy or definitive chemoradiation therapy are eligible.\n4. Prior adjuvant or neoadjuvant immunotherapy is allowed if completed more than 12 months before documented relapse.\n\nCohort 2:\n\n1. Subjects should have received at least 2 doses of an approved anti PD(L) 1 monoclonal antibody (mAb) in an advanced or metastatic setting.\n2. Progressive disease should be documented during treatment or within 12 weeks from the last dose of anti-PD(L)-1 mAb.\n3. Up to a maximum of 2 prior lines of approved cancer therapy in an advanced or metastatic setting, including an anti-PD(L)-1 mAb administered either as monotherapy or in combination with other therapies, is allowed.\n4. Subjects who received treatment with an approved\/available targeted therapy for an actionable genomic alteration (including but not limited to EGFR, ALK, ROS1, KRAS, etc.) can participate if they have documented disease progression or were unable to tolerate the approved targeted therapy. Only these subjects are allowed to receive up to a maximum of 3 prior lines of cancer therapy in an advanced or metastatic setting.\n5. Subjects with disease recurrence or progression following neoadjuvant or adjuvant therapy or definitive chemoradiation therapy are eligible.\n\nCohort 2 Notes:\n\n* Targeted therapy for advanced setting is counted as a prior line of therapy.\n* Maintenance therapy is not counted as a prior line of therapy.\n* Neoadjuvant and adjuvant therapies initiated \\< 12 months prior to first dose of study drug(s) will be counted as one prior line of therapy for advanced setting.\n* Neoadjuvant and adjuvant therapies initiated \u2265 12 months prior to first dose of study drug(s) are not counted as prior lines of therapy.\n* Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Life expectancy of at least 3 months.\n* An archival tumor tissue sample or newly obtained biopsy of a tumor lesion not previously irradiated must exist to participate in the study (Mandatory in Phase 2a but subjects in Phase 1b may be enrolled in the absence of a tumor tissue sample). Only core needle and\/or excisional biopsy samples, from archival or fresh tissue, will be accepted in this study.\n* Adequate organ function as defined below must be met for subjects to participate in the study. Clinical laboratory specimens must be collected within 10 days prior to first dose of study drug(s):\n\n  1. Absolute neutrophil count (ANC) \u2265 1500\/\u00b5L or \u2265 1.5 \u00d7 109\/L (in the absence of growth factor support).\n  2. Platelets \u2265 100,000\/\u00b5L or 100 \u00d7 109\/L (in the absence of transfusion or growth factor support).\n  3. Hemoglobin \u2265 9 g\/dL or \u2265 90 g\/L (in the absence of transfusion). Note: Criteria must be met without packed red blood cell transfusion within the prior 2 weeks. Subjects can be on stable dose of erythropoietin (\u2265 approximately 3 months).\n  4. Creatinine Clearance (CCr) \u2265 50 mL\/minute using the Cockcroft and Gault formula.\n\n     Note: The Cockcroft and Gault formula (1973): CCr = (\\[{140 - age} \u00d7 weight\\]\/\\[72 \u00d7 SCr\\]) \u00d7 0.85 (if female); where CCr = mL\/minute; age = years; weight = kg; SCr (serum creatinine) = mg\/dL.\n  5. Total bilirubin \u2264 1.5 \u00d7 upper limit of normal (ULN) (unless a diagnosis of Gilbert's syndrome in which case \u2264 3 \u00d7 ULN) OR direct bilirubin \u2264 1 \u00d7 ULN for participants with total bilirubin \\>1.5 \u00d7 ULN.\n  6. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u2264 2.5 \u00d7 ULN (\u2264 5\u00d7 ULN for subjects with liver metastases).\n  7. International normalized ratio (INR) or prothrombin time (PT) \u2264 1.5 \u00d7 ULN; if the subject is receiving anticoagulant therapy PT or INR should be within the therapeutic range of the intended use of anticoagulants.\n  8. Activated partial thromboplastin time\/partial thromboplastin time (aPTT\/PTT) \u2264 1.5 \u00d7 ULN; if the subject is receiving anticoagulant therapy PTT should be within the therapeutic range of intended use of anticoagulants.\n\nNote: Low molecular weight heparin, warfarin (INR monitoring required), direct oral anticoagulants, and drugs in the anticoagulant class (e.g., Lovenox \\[enoxaparin\\]) administered for deep vein thrombosis are permitted.\n\n* Women who are not of childbearing potential must be documented and will not be tested for pregnancy or required to utilize contraception if they meet one or more of the following definitions of non-childbearing potential:\n\n  1. Amenorrheic for \\> 2 years without a hysterectomy and oophorectomy, and a follicle stimulating hormone (FSH) value in the postmenopausal range upon screening evaluation.\n  2. Post-hysterectomy, bilateral oophorectomy, or tubal ligation. Tubal ligation should be confirmed with medical records of the actual procedure.\n* 12. Women of childbearing potential (WOCBP) must have a negative pregnancy test (serum) within 72 hours prior to first dose of study drug(s) and meet the following criteria throughout the study, starting with the screening visit through 120 days after the last dose of study drug(s) (or 30 days if new cancer therapy is initiated):\n\n  1. Agrees to follow contraceptive guidance throughout the study as per protocol.\n  2. Willing to use 2 highly effective birth control methods throughout the study. The 2 birth control methods can be either 2 barrier methods or a barrier method plus a hormonal method to prevent pregnancy. Refer to Appendix 4 for complete list of acceptable birth control methods.\n  3. Refrain from egg donation. Note: If there is any question that a subject will not reliably comply with the requirements for contraception, that subject should not be enrolled.\n* Male subjects must agree to use an acceptable method of contraception and refrain from sperm donation throughout the study: from screening, during the treatment period, and for at least 120 days after the last dose of study drug(s) (or 30 days if new cancer therapy is initiated).\n* Willing and able to participate in blood sampling and all other required study procedures.\n\nExclusion Criteria:\n\n* Phase 2a - Cohort 1 (only) exclusion criteria:\n\n  1. Subjects have tumors that have actionable genomic alterations with approved targeted therapy in first line setting are not eligible to participate.\n  2. Subjects are not eligible if they received any prior therapy (SOC or investigational) for advanced or metastatic disease including chemotherapy, targeted therapy, or immunotherapy of any kind such as the following: pembrolizumab, an anti-PD(L)-1 or anti-programmed death ligand 2 (PD-L2) agent, or an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA4, OX40 (Tumor necrosis factor receptor superfamily, member 4), CD137(Tumor necrosis factor receptor superfamily member 9)).\n* Undergone prior treatment with a known AXL inhibitor such as bemcentinib (see Section 8.2.2 for full list of AXL inhibitors).\n* Received prior systemic anticancer therapy within 5 half-lives or 3 weeks, whichever is shorter, prior to starting the first dose of study drug(s). Examples of prior systemic anticancer therapy includes cytotoxic agents, targeted therapy such as small molecules, mAbs and hormonal therapy etc..\n* Received immunotherapies \\[including but not limited to PD(L)-1 inhibitors, etc.\\] within 4 weeks prior to starting the first dose of study drug(s).\n* Received prior radiotherapy within 2 weeks of the first dose of study drug(s) or had a history of radiation pneumonitis.\n\nNote: Subjects must have recovered from all radiation-related toxicities and not require corticosteroids. A 1 week washout is permitted following palliative radiation (\u2264 2 weeks of radiotherapy) for non-central nervous system (CNS) disease.\n\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study drug(s).\n\nNote: Subjects who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent, follow-up is primarily non-invasive, and the subject can comply with protocol requirements.\n\n* Has not recovered to \u2264 Grade 1 or to baseline from prior cancer therapy toxicity.\n\nNote: Subject with \u2264 Grade 2 neuropathy may be an exception to this criterion and may qualify for the study after discussion with Sponsor. Subjects with endocrine-related AEs \u2264 Grade 2 requiring treatment or hormone replacement may be eligible after discussion with Sponsor.\n\nNote: Toxic effects also include laboratory results that have not resolved to \u2264 Grade 1. Subjects with \u2264 Grade 2 alopecia are an exception to this criterion.\n\n* Has not adequately recovered from major surgery and\/or complications from the procedure prior to the first dose of study drug(s).\n* Pulmonary hemorrhage or hemoptysis \\> 2.5 mL blood within 6 weeks of screening (or within 2 weeks if the source of bleeding is treated).\n* Received a live or live-attenuated vaccine within 30 days prior to the first dose of study drug(s). Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\/zoster (chicken pox), yellow fever, rabies, Bacille Calmette-Guerin, and typhoid vaccine. Seasonal influenza vaccines are generally killed virus vaccines and are permitted; however, intranasal influenza vaccines (e.g., Flu-Mist\u00ae) are live-attenuated vaccines and are not allowed.\n\nNote: The administration of killed vaccines, mRNA vaccines, and DNA vaccines is allowed.\n\n* Has an active diagnosis of immunodeficiency or is receiving systemic steroid therapy (exceeding 10 mg daily of prednisone equivalent) or has received any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug(s).\n* Has active autoimmune disease which required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs).\n\nNote: Hormone therapy (e.g., thyroxine, insulin, or corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.\n\n* Known additional malignancy that is progressing or has required active treatment within the past 2 years.\n\nNote: Subjects with curatively treated basal or squamous cell carcinoma of the skin (non-melanoma skin cancer), cervical or vaginal intra-epithelial neoplasia, non-invasive breast cancer in situ, or localized prostate cancer with a prostate-specific antigen level of \\< 4 ng\/mL (\u00b5g\/L) at screening are not excluded. Subjects with other curatively treated malignancies who have had a \\> 2-year disease-free interval and whose natural history or treatment does not have the potential to interfere with investigational agents (e.g., hormone maintenance) may be enrolled after approval by the Medical Monitor\/Sponsor.\n\n* Known active CNS metastases and\/or carcinomatous meningitis. Subjects with adequately treated brain metastases may participate provided they meet the following criteria:\n\n  1. Are radiologically stable (no progression) for at least 4 weeks as documented by screening computed tomography (CT) or magnetic resonance imaging (MRI) scan.\n  2. Clinically stable.\n  3. No evidence of new or enlarging brain metastases. Does not require steroids for at least 14 days before starting first dose of study drug(s) (anticonvulsants at a stable dose are allowed). Low dose steroids equivalent of prednisone \u2264 10 mg orally once a day is allowed.\n  4. No history of intracranial or spinal cord hemorrhage.\n  5. No evidence of significant vasogenic edema.\n* Severe hypersensitivity (\u2265 Grade 3) to pembrolizumab or SLC-391 and\/or any excipients.\n* A history of non-infectious pneumonitis\/interstitial lung disease that required steroids or has current pneumonitis\/interstitial lung disease.\n* A known history of human immunodeficiency virus (HIV) infection (HIV 1\/2 antibodies). No HIV testing is required unless mandated by the local health authority.\n* Known history of Hepatitis B (Anti-HBc and HBsAg reactive) or known active Hepatitis C virus (RNA, qualitative) infection.\n\nNote: No testing for Hepatitis B or C is required unless mandated by a local health authority.\n\n* A history or current evidence of any severe acute or chronic medical or psychiatric condition that requires treatment, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject, in the opinion of the Principal Investigator (PI; also referred to as Investigator). Examples include, but are not limited to, active uncontrolled infection (including tuberculosis \\[TB\\]) requiring systemic therapy, transfusion dependent anemia, recent (within 90 days) stroke or myocardial infarction, unstable angina, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, symptomatic congestive heart failure (New York Heart Association class \u2265 III\/IV), and recent severe Coronavirus disease 2019 (COVID-19).\n\nNote: TB testing is required for subjects recently exposed to persons with active TB or who have traveled recently to areas where TB is endemic.\n\n* Systolic blood pressure (BP) \u2265 160 mmHg or diastolic BP \u2265100 mmHg.\n* Has a corrected QT interval by Fridericia (QTcF) \u2265 470 msec. Note: Apply the Fridericia QT correction to calculate QTcF using the following formula: QTcF = QT\/RR1\/3 where QT = the time between the start of the QRS complex and the end of the T wave and RR = the time between the start of one QRS complex and the start of the next QRS complex.\n\nNote: If a subject has a prolonged QT interval and the prolongation is deemed to be due to a pacemaker as deemed by the Investigator (i.e., the subject otherwise has no cardiac abnormalities), the subject may be eligible to participate in the study following discussion with the Sponsor.\n\n* History or presence of sustained or symptomatic bradycardia (\u2264 55 bpm), left bundle branch block, ventricular arrhythmia excluding premature ventricular contractions, or uncontrolled ventricular arrhythmia. Subjects with a supraventricular arrhythmia requiring medical treatment and a normal ventricular rate are eligible.\n* Psychological, familial, sociological, or geographical conditions including known psychiatric or substance abuse disorder that could interfere with the subject's ability to provide informed consent, comply with the protocol, or interfere with the interpretation of the study results.\n* Inability to swallow oral medication and\/or the presence of active gastrointestinal (GI) disease and\/or other GI conditions, including bowel resection, that is expected to interfere significantly with the absorption, distribution, metabolism, or excretion of oral SLC-391 therapy.\n* Received radiation therapy to the lung that is \\> 30 Gy within 6 months of the first dose of study drug(s).\n* Had an allogenic tissue, marrow, or solid organ transplant.\n* Females who are pregnant or nursing. Note: SLC reserves the right to deny any subject enrollment based upon potential safety concern(s) or factors that could confound the study results.\n\nNote: The Investigator or licensed, medically qualified Sub-Investigator must review and confirm eligibility prior to the first dose of study drug(s).","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05860296011","EMAIL":"zzhang@signalchemcorp.com","GEO":[43.70011,-79.4163]},{"TITLE":"Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy","CRITERIA":"Inclusion Criteria:\n\n1. Age \u2265 19 years\n2. Patients with suspected lung cancer on chest CT findings\n3. Patients with the following EGFR gene mutations in the test on bronchoalveolar lavage fluid: E19Del, L858R alone or concurrent rare EGFR gene mutations (T790M, G719X, exon 20 insertion, S768I)\n4. Patients whose tumor can be completely resected by surgery: patients with stage I-IIIB, or stage IVA who has single metastasis\n5. Patients not previously treated with EGFR-TKIs such as gefitinib, erlotinib, afatinib, dacomitinib\n6. Patients with the measurable lesion of 1 cm or more according to RECIST v1.1\n7. Eastern Cooperative Oncology Group (ECOG) 0-1\n8. EGFR-TKIs (gefitinib, erlotinib, afatinib,dacomitinib) naive patients\n9. Patients with adequate pulmonary and heart function for surgery\n10. Adequate organ function defined as Hemoglobin \u2265 9.0g\/dL Absolute neutrophil count \u2265 1500\/mm3 Platelet \u2265 100,000 \/mm3 Serum creatinine\u2264 normal range\\*1.5x Aminotransferase\/Alkaline phosphatase \u2264normal range\\*2.5x Total bilirubin \u22641.5 mg\/dL Liver metastasis: Aminotransferase\/Alkaline phosphatase \u2264 normal range\\* 5x Bone metastasis Alkaline phosphatase \u2264 normal range\\* 5x\n11. Female patients with childbearing potential should be using adequate contraceptive measures. Female patients must have evidence of non-child-bearing potential(Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments)\n12. Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception for at least 14 days prior to administration of the first dose of study treatment, during the study, and for 3 months following the last dose of Lazertinib.\n\nExclusion Criteria:\n\n1. Uncontrolled active interstitial lung disease\n2. Pathologically confirmed N3 disease\n3. Uncontrolled stage III-IV other malignancy\n4. Uncontrolled Hypertension, Congestive Heart failure with New York Heart Association(NYHA) \u2265 3, acute myocardial infarct history within 6 months before screening. 2nd- 3rd Atrio-Ventricular(AV) block or complete AV block\n5. Gastrointestinal diseases (e.g. Chron's disease, ulcerative colitis) or malabsorption syndrome that would impact on drug absorption\n6. Active infection requiring ongoing treatment(e.g. active Hepatitis B virus, Hepatitis C virus or Human immunodeficiency virus)\n7. History of hypersensitivity to active or inactive excipients of Lazertinib or drugs with a similar chemical structure.\n8. No ability to comply with protocol requirements.","SEX":"ALL","AGE_MIN":19,"AGE_MAX":200,"SS_ID":"05469022001","EMAIL":[{}],"GEO":[37.566,126.9784]},{"TITLE":"A Study of PF-08046049\/SGN-BB228 in Advanced Melanoma and Other Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* All Parts: Participants must have disease that is relapsed, refractory, or intolerant to standard of care. Participants must have histologically or cytologically confirmed metastatic malignancy.\n* Participants must have one of the following tumor types:\n\n  * Parts A and B: Participants must have metastatic or unresectable cutaneous melanoma.\n  * Part C: Participants must have one of the following tumor types:\n\n    * Cutaneous Melanoma\n    * Non-small Cell Lung Cancer (NSCLC)\n    * Colorectal Cancer (CRC)\n    * Pancreatic Cancer\n    * Mesothelioma\n* A pre-treatment biopsy or submission of archival tissue is required\n* For participants with cutaneous melanoma\n\n  * Must have been previously treated with an anti-programmed death-1 (anti-PD-1) or anti-programmed death ligand-1 (anti-PD-L1) agent given alone or with other therapies.\n  * Participants with a targetable BRAF mutation must have been treated with, been intolerant of, or been deemed ineligible to receive treatment with BRAF\/MEK targeted therapy prior to study entry.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1\n* Measurable disease per RECIST v1.1 at baseline\n\nExclusion Criteria:\n\n* History of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.\n* Active central nervous system metastases or leptomeningeal disease. Participants with previously treated brain metastases may participate provided they are:\n\n  * clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment,\n  * they have no new or enlarging brain metastases,\n  * and are off of corticosteroids prescribed for symptoms associated with brain metastases for at least 7 days prior to the first dose of study drug.\n* Prior therapies cannot include any drugs targeting CD228 or 4-1BB\n* Immunotherapy, biologics, and\/or other approved or investigational antitumor treatment that is not completed 4 weeks prior to first dose of study drug, or within 2 weeks prior to the first dose of study drug if the underlying disease has progressed on treatment\n* Melanoma subtypes including acral, uveal, and mucosal are excluded","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05571839019","EMAIL":[{}],"GEO":[55.86515,-4.25763]},{"TITLE":"Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation\/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan","CRITERIA":"Inclusion Criteria:\n\n1. Provision of informed consent prior to study initiation.\n2. Age between 18 and 75 years.\n3. Preoperative clinical evaluation indicating non-small cell lung cancer (NSCLC) stage I-IIIB (without initial treatment sought).\n4. Newly treated patients who have consented to undergo surgery.\n5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1.\n\nExclusion Criteria:\n\n1. Non-small cell lung cancer (NSCLC) histopathologically determined to be other than stage I-IIIB following surgical evaluation.\n2. Presence of other active malignant tumor diseases.\n3. Evidence of any serious or uncontrolled systemic illness, including uncontrolled hypertension and active bleeding, as assessed by the investigator, which may contribute to reluctance to participate in the trial or decrease adherence to the study regimen. Additionally, active infectious diseases such as hepatitis B, hepatitis C, and human immunodeficiency virus (HIV) infection are grounds for exclusion.\n4. History of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis requiring steroid therapy, or any indication of clinically active ILD.\n5. Patients considered by the investigator to be unable to comply with the study protocol, restrictions, and requirements, or those facing circumstances at the investigator's discretion that would impede their participation in the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06358222001","EMAIL":[{"email":"yaofeng@shsmu.edu.cn"}],"GEO":[31.22222,121.45806]},{"TITLE":"PD-L1 PET Imaging in Patients With the Immunotherapy for Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* (1) Subjects must be diagnosed with histologically confirmed stage IV non-small cell lung cancer and \\>18 years of age with driver mutations (-).\n\n  (2) Planned for anti-PD-1\/PD-L1 therapy. (3) At least one easy accessible lesion of which a biopsy can be taken within one month prior to PET scan.\n\n  (4) Subjects must sign informed consent prior to inclusion in this trial.\n\nExclusion Criteria:\n\n- (1) Female patients during pregnancy and lactation. (2) Patients with psychiatric disease, severe hepatic and renal insufficiency. (3) Patients who refuse anti-PD-1\/PD-L1 therapy. (4) Patients who are claustrophobic or unable to undergo PET\/CT examination. (5) Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways, except anti-CTLA4 antibody.\n\n(6) Those who, in the opinion of the investigator, are otherwise unsuitable for clinical trials.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05533086001","EMAIL":[{"email":"evazhu@vip.sina.com"}],"GEO":[30.58333,114.26667]},{"TITLE":"A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs","CRITERIA":"Key Inclusion Criteria:\n\n* Histologically confirmed diagnosis of advanced solid tumor malignancy affecting the lungs and the individual has progressed on standard of care therapy, cannot tolerate standard of care therapy, refused standard of care therapy, or there is no standard of care therapy.\n* Age 18 years or older at the time of informed consent\n* Life expectancy \\>12 weeks\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Have at least one measurable lesion per RECIST v1.1 at Screening\n\nKey Exclusion Criteria:\n\n* Prior oncology therapy (chemotherapy, immunotherapy, biological therapy) or use of an investigational agent or an investigational device within 21 days or 5 half-lives before administration of first dose of KB707, whichever is shorter\n* The subject is pregnant, nursing, or plans to become pregnant during study treatment and through three months after the last dose of KB707\n* Have known history of positive human immunodeficiency virus (HIV 1\/2)","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06228326006","EMAIL":[{"email":"maya.fleyhan@renovatioclinical.com"}],"GEO":[30.15799,-95.48938]},{"TITLE":"The Impact of Probiotic on Survival and Treatment Response in Metastatic Non-small Cell Lung Cancer Patients","CRITERIA":"Inclusion Criteria:\n\n* Volunteering to participate in the study.\n* Histologically confirmed diagnosis of Non-Small Cell Lung Cancer (NSCLC).\n* Patients must be in an advanced stage (incurable with surgery or radiotherapy) or have metastatic disease (Stage IV).\n* Male or female patients aged \\>18 years.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status less than 2.\n* Laboratory findings must confirm adequate bone marrow function, indicated by:\n\nWhite Blood Cell (WBC) count \\> 2,000\/mm\u00b3, Neutrophil count \\> 1,500\/mm\u00b3,Platelet count \\> 100,000\/mm\u00b3\n\nExclusion Criteria:\n\n* Previously received treatment with any of the following antibody blockers: anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4.\n* Currently taking probiotic supplements or consuming probiotic bacteria-supported yogurt and similar food supplements.\n* Antibiotic utilization within the past month\n* Active interstitial lung disease or a history of interstitial lung disease requiring systemic steroid treatment.\n* A condition requiring systemic corticosteroids (greater than 10 mg of prednisone daily or equivalent) or who have received immunosuppressive treatment within 14 days prior to the first dose of the study.\n* Presence of uncontrolled adrenal insufficiency.\n* Pregnancy or breastfeeding.\n* Severe congestive heart failure (Class III or higher according to the New York Heart Association Functional Classification) or a history of myocarditis.\n* Uncontrolled cardiac arrhythmia that developed within six months prior to the start of the study.","SEX":"ALL","AGE_MIN":19,"AGE_MAX":90,"SS_ID":"06428422001","EMAIL":[{"email":"martac@erbakan.edu.tr"},{},{},{},{},{},{},{},{},{},{}],"GEO":[37.87135,32.48464]},{"TITLE":"Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial","CRITERIA":"Inclusion Criteria:\n\n* Age \\>= 60 years\n* Diagnosed with an advanced lung cancer: unresectable stage IIIA, IIIB, or stage IV non-small cell lung cancer (NSCLC) or extensive stage small cell lung cancer (SCLC)\n* Intent to receive treatment from the Ohio State University Comprehensive Cancer Center (OSUCCC) Thoracic Oncology Clinic\n* A score of 2 or higher on the three functional items of the European Quality of Life Five Dimension Five Level Scale (EQ5D5L) patient reported outcome (PRO) assessment\n* Patients are eligible at any time point during their treatment here at Ohio State University (OSU). Rationale for this timeframe is due to the overwhelming nature of the first few visits and uncertainty around an eventual treatment plan. Patients at any stage of their treatment can participate and benefit from a physical therapy and psychosocial intervention. Patients will be approached at their initial visit but the investigators can also offer enrollment at any one of the patients regularly scheduled clinic visits or via phone or email\n* Ability to understand and willingness to sign an informed consent document (or indicate approval or disapproval by another means)\n\nExclusion Criteria:\n\n* Prisoners are excluded from participation\n* There is NO exclusion criteria pertaining to Eastern Cooperative Oncology Group (ECOG) performance status, laboratory values, prior cancer diagnoses, presence of comorbidities or brain metastases","SEX":"ALL","AGE_MIN":60,"AGE_MAX":200,"SS_ID":"05339022001","EMAIL":[{"email":"carolyn.presley@osumc.edu"},{"email":"madison.grogan@osumc.edu"},{}],"GEO":[39.96118,-82.99879]},{"TITLE":"The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n1. Men or women \u226518 years of age\n2. Screened negative for COVID-19 symptoms at time of consent, as per institutional policy and as applicable for the duration of the COVID-19 pandemic\n3. Diagnosed with stages I-IV primary NSCLC, MM, TNBC or RCC\n4. Plan to be treated at a partner cancer site with a checkpoint inhibitor (anti-PD-1, anti-PD-L1, or anti-CTLA-4) as a single agent or in combination with another checkpoint inhibitor or other treatment agent or modality (e.g., targeted therapy, chemotherapy, surgery, radiation, etc.) in accordance with FDA-labeled use of the agent\n5. Able to provide informed consent and answer study questionnaires in either English or Spanish\n6. Able to provide stool specimens for research purposes\n\nExclusion Criteria:\n\n1. Mental incapacity\n2. Incarcerated individuals\n3. Pregnancy (by self-report of pregnancy status)\n4. Experiencing active brain metastasis\/metastases\n5. Treatment with checkpoint inhibitor in off-label capacity or through a clinical\/interventional trial\n6. Active participation in an immuno-oncology clinical\/interventional trial or pharma-sponsored observational study","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05037825001","EMAIL":[{"email":"Delores.Drobny@bhsi.com"}],"GEO":[37.69395,-85.85913]},{"TITLE":"A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Diagnosis of advanced\/metastatic solid tumor including primary brain tumor for monotherapy phase 1a dose escalation\n* Disease progressed during\/following last prior treatment and no satisfactory alternative treatment options for monotherapy phase 1a dose escalation\n* For Substudy B, histological or cytological diagnosis of advanced\/metastatic melanoma\n* For Substudy C, unresectable or adv\/metastatic solid tumor progressed on, or with demonstrated intolerance to SOC, excluding melanoma,\n* For Substudy B and C, measurable disease by RECIST version 1.1\n* For Substudy B, evidence of a BRAF V600 mutation or BRAF Class II\/III alteration in tumor tissue and\/or blood\n* For Substudy C, evidence of a BRAF founder alteration (non-V600 Class II\/III BRAF alteration)\n\nExclusion Criteria:\n\n* Brain metastasis larger than 4 cm\n* History or current evidence of retinal vein occlusion (RVO) or concurrent neuromuscular disorder associated with elevated creatine kinase (CK)","SEX":"ALL","AGE_MIN":16,"AGE_MAX":200,"SS_ID":"05538130029","EMAIL":"ClinicalTrials.gov_Inquiries@pfizer.com","GEO":[46.81228,-71.21454]},{"TITLE":"A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+\/-Bevacizumab) for Patients With Stage IIIB\/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies","CRITERIA":"Inclusion Criteria:\n\n* Patient older than 18 years\n* Subject affiliated to an appropriate social security system\n* Signed informed consent before any trial related activities and according to local guidelines\n* ECOG performance status of 0 or 1\n* Histologically or cytologically confirmed, stage IIIB\/IV non-squamous NSCLC (per the Union Internationale contre le Cancer\/American Joint Committee on Cancer staging system, 7th edition).\n* Patient with a sensitizing mutation in the EGFR gene must have experienced disease progression (during or after treatment) or intolerance to treatment with one or more EGFR TKIs, such as erlotinib, gefitinib, osimertinib or another EGFR TKI appropriate for the treatment of EGFR-mutant NSCLC. Patients with stage IIIB had to be not operable (that means not eligible for radiochemotherapy followed by a maintenance treatment by Durvalumab)\n* Patient with an ALK fusion oncogene (confirmed in local laboratory) must have experienced disease progression (during or after treatment) or intolerance to treatment with one or more ALK inhibitors (i.e., crizotinib, alectinib, ceritinib) appropriate for the treatment of NSCLC in patients having an ALK fusion oncogene\n* Patient with a ROS1 fusion oncogene (confirmed in local laboratory) must have experienced disease progression (during or after treatment) or intolerance to treatment with one or more ROS inhibitors (i.e., crizotinib,) appropriate for the treatment of NSCLC in patients having an ROS1 fusion oncogene\n* No prior chemotherapy treatment for Stage IV non-squamous NSCLC except if less than 3 cycles, with treatment free-interval of at least 1 year from C1 since last chemotherapy\n* Patient who has received prior neo-adjuvant, adjuvant chemotherapy, radiotherapy, or chemoradiotherapy with curative intent for non-metastatic disease must have experienced a treatment-free interval of at least 6 months from C1since the last chemotherapy, radiotherapy, or chemoradiotherapy\n* Patient with an history of asymptomatic CNS metastases is eligible, provided he meets all of the following criteria:\n\n  * Only supratentorial and cerebellar metastases allowed (i.e., no metastases to midbrain, pons, medulla, or spinal cord)\n  * No ongoing requirement for corticosteroids as therapy for CNS disease\n  * No stereotactic radiation within 7 days or whole-brain radiation within 14 days prior to inclusion\n* Measurable disease, as defined by RECIST v1.1\n* Adequate hematologic and end-organ function, defined by the following laboratory\n* Adequate method of contraception during the treatment period and at least 5 months after the last dose of atezolizumab or 6 months after the last dose of chemotherapy\n\nExclusion Criteria:\n\nCancer-specific exclusions\n\n* Active CNS metastases as determined by CT or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments\n* Spinal cord compression not definitively treated with surgery and\/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for \\> or = 2 weeks prior to C1\n* Leptomeningeal disease (Presence of cancer cells in cerebral CSF or MRI with leptomeningeal lesion strongly suspected of leptomeningeal disease )\n* Uncontrolled tumour-related pain\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently); Patients with indwelling catheters (e.g., PleurX) are allowed.\n* Uncontrolled or symptomatic hypercalcemia (\\>1.5 mmol\/L ionized calcium or calcium \\>12 mg\/dL or corrected serum calcium \\> ULN)\n* Malignancies other than NSCLC within 5 years prior to C1, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous-cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent)\n\nGeneral medical exclusions\n\n* Women who are pregnant, lactating, or intending to become pregnant during the study\n* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins\n* Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation\n* History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Guillain-Barre\u0301 syndrome, multiple sclerosis, vasculitis, or glomerulonephritis\n\n  * Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone are eligible for this study.\n  * Patients with controlled Type 1 diabetes mellitus on a stable dose of insulin regimen are eligible for this study\n  * Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only are permitted provided that they meet the following conditions:\n  * Rash must cover less than 10 percent of body surface area (BSA).\n  * No acute exacerbations of underlying condition within the previous 12 months (not requiring PUVA \\[psoralen plus ultraviolet A radiation\\], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, high-potency or oral steroids)\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan; History of radiation pneumonitis in the radiation field (fibrosis) is permitted.\n* Positive test for HIV. All patients will be tested for HIV prior to C1 into the study; patients who test positive for HIV will be excluded from the study.\n* Patients with active hepatitis B (chronic or acute; defined as having a positive hepatitis B surface antigen \\[HBsAg\\] test at screening) or hepatitis C. Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[HBcAb\\] and absence of HBsAg) are eligible only if they are negative for HBV DNA. Patients positive for hepatitis C virus (HCV) antibody are eligible only if PCR is negative for HCV RNA.\n* Active tuberculosis\n* Severe infections within 4 weeks prior to C1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia\n* Received therapeutic oral or IV antibiotics within 1 week prior to C1; Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or to prevent chronic obstructive pulmonary disease exacerbation) are eligible.\n* Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within 3 months prior to inclusion, unstable arrhythmias, or unstable angina\n* Major surgical procedure other than for diagnosis within 28 days prior to C1 or anticipation of need for a major surgical procedure during the course of the study\n* Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patient at high risk from treatment complications\n* Symptomatic brain metastases;\n* Patients with illnesses or conditions that interfere with their capacity to understand, follow and\/or comply with study procedures\n* Concurrent participation in any therapeutic clinical trial\n* Patient deprived of liberty or placed under the authority of a tutor\n* Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol\n\nExclusion criteria related to medications\n\n* Any approved anti-cancer therapy, including hormonal therapy within 7 days prior to C1 of study treatment.\n* Treatment with any other investigational agent with therapeutic intent within 28 days prior to C1\n* Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-PD-1, and anti-PD-L1 therapeutic antibodies\n\n  * Patients who have had prior anti-cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) treatment may be enrolled, provided the following requirements are met:\n  * Last dose of anti-CTLA-4 at least 6 weeks prior to C1\n  * No history of severe immune-related adverse effects from anti-CTLA-4 (NCI CTCAE Grade 3\/4)\n* Treatment with systemic immunostimulatory agents (including, but not limited to, interferons, interleukin 2) within 4 weeks or 5 half-lives of the drug, whichever is longer, prior to C1 ; Prior treatment with cancer vaccines is allowed.\n* Treatment with systemic immunosuppressive medications (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \\[anti-TNF\\] agents) within 2 weeks prior to C1\n\nExclusion criteria related to chemotherapy\n\n* History of allergic reactions to cisplatin, carboplatin, or other platinum-containing compounds\n* Patients with hearing impairment (cisplatin)\n* Grade \\> or = 2 peripheral neuropathy as defined by NCI CTCAE v5.0 (cisplatin)\n* CRCL \\< 60 mL\/min for cisplatin or \\< 45 mL\/min for carboplatin using the Cockcroft-Gault Method\n\nExclusion criteria related to Bevacizumab\n\n* Medically uncontrolled hypertension (defined as PAS\\>150 and\/or PAD \\>100 mmHg)\n* Prior history of hypertensive crisis or hypertensive encephalopathy\n* Clinically significant cardiovascular disease (within 6 months prior to C1) that is uncontrolled by medication or may interfere with administration of trial treatment:\n\n  * Aortic aneurysm requiring surgical repair\n  * Recent arterial thrombosis\n  * Haemoptysis (\\>one-half teaspoon of bright red blood per episode (within one months prior to C1) (grade 2 haemoptysis)\n* History of documented haemorrhagic diathesis or coagulopathy\n* History of abdominal or tracheosphageal fistula or perforation within 6 months prior to C1\n* Core biopsy or other minor surgical procedure within 7 days before bevacizumab\n* Clinical signs or gastrointestinal obstruction or requirement for routine parenteral hydration, nutrition or tube feeding\n* Evidence of abdominal free air not explained by paracentesis or recent surgical procedure\n* Major surgery within 28 days before C1\n* Serious, non-healing wound, active ulcer or untreated bone fracture\n* Proteinuria \\>1g\/24h urine collection\n* All patient with \\>2+ protein on dipstick urinalysis at baseline must undergo a 24-hour urine collection and must demonstrate \\< or = 1g of protein in 24 hours.\n* Known sensitivity to any component of bevacizumab\n* Radiation therapy within 21 days before C1 (except Symptomatic lesions amenable to palliative radiotherapy)\n* Adequate hematologic, liver, and renal function required (including creatinine clearance 45 mL\/min at baseline and 45 mL\/min before the start of any subsequent cycle using the Cockcroft-Gault Method.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"04042558031","EMAIL":[{},{}],"GEO":[44.77327,-0.5442]},{"TITLE":"Blood-brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets","CRITERIA":"Inclusion Criteria:\n\n* Participant is \u2265 18 years of age\n* The participant provides written informed consent for the trial\n* Participant is willing to comply with all study procedures for the duration of the study\n* Subject has tumor biomarkers that are EGFR (epidermal growth factor receptor) and ALK (anaplastic lymphoma kinase) negative\n* Participant is a NSCLC subject prescribed pembrolizumab monotherapy per standard of care\n* Participant is diagnosed with at least 1 measurable brain metastasis \u2265 0.5 cm in longest diameter that is untreated, device-accessible and MR visible\n* Participant has a Karnofsky Performance Status \u2265 70% and\/or ECOG 0-2\n* Female subject is confirmed NOT PREGNANT each procedure day. Male and Female subjects are utilizing highly effective contraception during the study and through 120 days (4 months) after the study\n* Screening\/Baseline laboratory values\n\nExclusion Criteria\n\n* Subject is pregnant or breastfeeding,\n* Participant has evidence of acute intracranial hemorrhage or significant calcifications in the focused ultrasound sonication beam path\n* Participant at risk for spontaneous intracranial hemorrhage (e.g., history of metastatic melanoma or other tissue histology)\n* Participant has signs and symptoms of increased intracranial pressure or symptomatic mass effect, midline shift or evidence of subfalcine, uncal or tonsillar herniation\n* Participant receiving Bevacizumab (Avastin) therapy, or other drugs with a proclivity for causing bleeding\n* History of bleeding disorder, coagulopathy or with a history of spontaneous brain tumor hemorrhage, anticoagulation or antiplatelet therapy or medication known to increase the risk of hemorrhage within washout period prior to treatment (i.e., antiplatelet or vitamin K inhibitor anticoagulants within 7 days, non-vitamin K inhibitor anticoagulants within 72 hours, or heparin-derived compounds within 48 hours of treatment)\n* Participant has a known chronic viral infection such as Hepatitis B, Hepatitis C or HIV or has a known history of\/active TB (Bacillus tuberculosis)\n* Subjects with evidence of cranial or systemic infection\n* Participant has received a solid organ or hematopoietic stem cell transplant\n* Participant has received a live vaccine within 28 days prior to the first dose of study agent Examples of live vaccines include, but are not limited to measles, mumps, rubella, varicella\/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Gu\u00e9rin (BCG), typhoid vaccine, and intranasal influenza vaccines (e.g., FluMist\u00ae)\n* Participant has a severe or uncontrolled medical disorder that would, in the investigator's opinion, impair ability to receive study intervention\n* Known sensitivity to DEFINITY\u00ae ultrasound contrast agent or hypersensitivity to perflutren microsphere or its components, e.g., polyethylene glycol, as found in MiraLAX and bowel prep products\n* Contraindications to MRI and gadolinium-DTPA including non-MRI-compatible implanted devices, severe claustrophobia, unable to lie supine in MRI\n* Severely impaired renal function with estimated glomerular filtration rate \\<30 mL\/min\/1.73m2, creatinine \\>1.5 ULN and\/or on dialysis\n* Subjects with significant liver dysfunction, e.g., history of cirrhosis (hemochromatosis or severe alcohol abuse), or active hepatitis (autoimmune or infectious) with elevated AST, ALT INR or bilirubin (ALT: Male 21-72 units\/L; Female 9-52 units\/L; AST: Male 17-59 units\/L, Female 14-36 units\/L; INR \\>1.3; bilirubin \\>5 times lab normal)\n* Subject is currently enrolled in another intervention based clinical trial\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug\n* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Presence of leptomeningeal disease\n* Contraindications to pembrolizumab or has severe hypersensitivity (\u2265Grade 3) to pembrolizumab and\/or any of its excipients\n* Has a diagnosis of active autoimmune disease (e.g., autoimmune Hepatitis, Guillain-Barre Syndrome, etc.) requiring systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. History of (non-infectious) pneumonitis that requires steroids or has current pneumonitis\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial","SEX":"ALL","AGE_MIN":18,"AGE_MAX":100,"SS_ID":"05317858005","EMAIL":[{"email":"maheleth.llinas@sunnybrook.ca"},{}],"GEO":[43.70011,-79.4163]},{"TITLE":"The Effect of Combined Cryotherapy and Immunotherapy on Systemic T Cell Changes and Clinical Outcomes in Metastatic Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Patients with Eastern Cooperative Oncology Group (ECOG) performance score 0 - 1;\n* Patients with histologically confirmed metastatic non-small cell lung cancer and PD-L1 expression on tumor cells was evaluated;\n* CT examination shows measurable tumor formations according to the RECIST 1.1 criteria;\n* Primary lung tumor or metastasis accessible to flexible bronchoscopy;\n* Patients may have received surgery, adjuvant or neoadjuvant chemotherapy prior to the study if it was completed at least 12 months before relapse;\n* Patients informed about the purpose and course of the study and provided a written consent to participate.\n\nExclusion Criteria:\n\n* Patients who refused to participate in the clinical trial and did not sign the informed consent form;\n* Men and women under the age of 18, pregnant women;\n* Patients belonging to a vulnerable social group;\n* High risk of general anesthesia, defined as American Society of Anesthesiologists (ASA) class 4 - 6;\n* Documented allergy to medications used during general and local anesthesia, systemic cancer treatment;\n* Patients previously treated with immune checkpoint inhibitors;\n* EGFR mutations or ALK translocations have been identified in patients;\n* Patients with previously diagnosed autoimmune diseases, active viral hepatitis, uncontrolled human immunodeficiency virus (HIV) infection or untreated tuberculosis;\n* Patients treated with immunosuppressive drugs, systemic corticosteroids, with equivalent doses of prednisolone exceeding 10 mg\/day;\n* Patients with an increased risk of bleeding during an interventional procedure;\n* Acute untreated conditions that would make it impossible to perform an interventional lung procedure.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":99,"SS_ID":"06000358001","EMAIL":[{"email":"rektoratas@lsmuni.lt"}],"GEO":[54.90272,23.90961]},{"TITLE":"TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)","CRITERIA":"Inclusion Criteria:\n\n* Willing to follow the treatment protocol and visit schedule, and participate in the study with the ICF signed;\n* \u2265 18 years of age on the day of ICF signing, regardless of gender.\n* Diagnosed as incurable stage IIIB - IV ALK-positive NSCLC;\n* Providing prior ALK positive test results at screening;\n* Na\u00efve to ALK-inhibitor; patients could be intolerant or have progressive disease from previous first-line chemotherapy;\n* Patients could have metastases to central nervous system at screening if the condition is asymptomatic, stable or completely recovered;\n* At least one measurable lesion;\n* An ECOG PS score within 0-2;\n* Adequate bone marrow, liver, kidney, coagulation and pancreatic functions;\n* Expected survival \u2265 3 months;\n* Willing to take effective contraceptive measures (for men of reproductive potential and women of reproductive age only) from ICF signing to 6 months after last administration of the investigational drug. Women of reproductive age include women before menopause and within 1 year after menopause; those women must have a negative pregnancy test \u2264 7 days prior to the first dose of the investigational drug.\n\nExclusion Criteria:\n\n* Known hypersensitivity to any of the active ingredients or excipients of TGRX-326 or crizotinib pills; or a history of severe allergic reactions;\n* Having another type of cancer except for lung cancer;\n* Radiotherapy within 14 days prior to the first dose;\n* Received other systemic anti-tumor treatment within 4 weeks prior to the first dose, or is within 5 half-lives of the said treatment; received traditional Chinese medicine indicated for anti-tumor purposes within 14 days prior to the first dose;\n* Major surgery within 4 weeks prior to the first dose;\n* Spinal cord compression caused by tumor, unless the subject achieves significant pain control and full recovery of neurological function within 4 weeks prior to the first dose.\n* Abnormal gastrointestinal function that affect absorption within the past 6 months;\n* History of active pneumonia or clinically significant interstitial pneumonia, or radiation or drug-induced lung disorder with treatment needs;\n* Cardiac insufficiency;\n* Abnormal and clinically significant QTc on ECG or need of concomitant use of any drug known to prolong QT interval and cause torsades de pointes;\n* Uncontrolled hypertension after drug treatment;\n* Uncontrolled hyperglycaemia, acute attack of cholelithiasis, and susceptibility to acute pancreatitis;\n* Severe or uncontrolled systemic diseases causing expected intolerance to the investigational drug as judged by the investigator;\n* Toxic reactions associated with prior surgery and prior antineoplastic therapies that have not recovered and may affect the subject safety as assessed by the investigator.\n* Clinically significant active bacterial, fungal or viral infections, including a positive result for hepatitis B surface antigen and HBV DNA \u2265 ULN, one or more positive results for hepatitis C antibody or HIV antibody, or the presence of any uncontrolled infection.\n* Use of strong CYP3A4 inducers or inhibitors or CYP3A4 substrates with a narrow therapeutic window within two weeks prior to the first dose of the investigational drug;\n* Pregnant and breastfeeding female;\n* Women of childbearing age who are unwilling or unable to use acceptable methods for contraception during the entire treatment period in the trial and within 6 months after the last dose of the investigational drug (women of childbearing age include: any one with menarche, and those who have not received successful artificial sterilization \\[hysterectomy, bilateral fallopian tube ligation, or bilateral oophorectomy\\] or premenopausal women); a fertile male patient who is unwilling or unable to take effective contraceptive measures, and whose partner is a woman of childbearing age;\n* Being involved in other clinical studies (except for the non-interventional phase of interventional clinical study, such as survival follow-up period); less than 4 weeks from the end of the dose of other investigational drug to the first dose of the investigational drug or 5 half-lives of the previous drug, whichever is shorter;\n* Any mental or cognitive disorders which may limit subjects' understanding and implementation of the informed consent form;\n* Other situations, such as poor compliance, which are considered by the investigator to be not suitable for participation in the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06082635001","EMAIL":[{}],"GEO":[23.11667,113.25]},{"TITLE":"A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Voluntarily sign the informed consent and follow the requirements of the protocol;\n2. No gender limit;\n3. Age \u226518 years old;\n4. Expected survival time \u22653 months;\n5. Patients with histologically and\/or cytologically confirmed locally advanced or metastatic non-small cell lung cancer;\n6. Documentation of EGFR sensitive mutations detected from tumor tissue or blood samples;\n7. Consent to provide archived tumor tissue or fresh tissue samples from primary or metastatic sites within 2 years for biomarker testing;\n8. At least one measurable lesion meeting the RECIST v1.1 definition was required;\n9. ECOG \u22641;\n10. Toxicity of previous antineoplastic therapy has returned to \u2264 grade 1 defined by NCI-CTCAE v5.0;\n11. No severe cardiac dysfunction, left ventricular ejection fraction \u226550%;\n12. The level of organ function must meet the requirements on the premise that blood transfusion is not allowed within 14 days before the screening period and no cell growth factor drugs are allowed;\n13. Blood coagulation function: international standardization ratio of 1.5 or less, and the part activated clotting time live enzymes acuities were 1.5 x ULN;\n14. Urine protein \u22642+ or \u22641000mg\/24h;\n15. Fertile female subjects or male subjects with fertile partners must use highly effective contraception from 7 days before the first dose until 6 months after the dose. Female subjects of childbearing potential had to have a negative serum pregnancy test within 7 days before the first dose.\n\nExclusion Criteria:\n\n1. Patients with prior systemic therapy;\n2. Previous treatment with EGFR-TKI;\n3. Participants who participated in any other clinical trial within 4 weeks before the trial dose;\n4. Traditional Chinese medicine (TCM) which had received radiotherapy within 4 weeks before the first use of the study drug and had anti-tumor indications within 2 weeks before the first use of the study drug;\n5. Had undergone major surgery within 4 weeks before the first dose;\n6. History of severe heart disease or cerebrovascular disease;\n7. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening; Infusion-related thrombosis was excluded;\n8. QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;\n9. Previous history of interstitial lung disease requiring steroid therapy, or current ILD or grade \u22652 radiation pneumonitis;\n10. Complicated pulmonary diseases leading to clinically severe respiratory function impairment;\n11. Severe systemic infection within 4 weeks before screening;\n12. Patients at risk for active autoimmune disease or with a history of autoimmune disease;\n13. Other malignant tumors within 5 years before the first dose;\n14. HIV antibody positive, active tuberculosis, active hepatitis B virus infection, or hepatitis C virus infection;\n15. Hypertension poorly controlled by two antihypertensive drugs;\n16. Patients with poor glycemic control;\n17. Patients with massive effusions, or effusions with obvious symptoms, or poorly controlled effusions;\n18. Patients with active central nervous system metastases;\n19. Imaging examination showed that the tumor had invaded or enveloped the large blood vessels in the abdomen, chest, neck, and pharynx;\n20. Severe unhealed wound, ulcer, or fracture within 4 weeks before consent signing;\n21. Sign a four weeks before there were clinically significant bleeding or bleeding tendency obviously subjects;\n22. Previous history of allogeneic stem cell, bone marrow or organ transplantation;\n23. Patients with a history of allergy to recombinant humanized antibodies or to any of the excipients of BL-B01D1;\n24. A history of severe neurological or psychiatric illness;\n25. Pregnant or lactating women;\n26. Subjects who were scheduled to receive live vaccine or received live vaccine within 28 days before study randomization;\n27. Other conditions for participation in the trial were not considered appropriate by the investigator.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06498986001","EMAIL":[{}],"GEO":[31.22222,121.45806]},{"TITLE":"Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC","CRITERIA":"Inclusion Criteria:\n\nInclusion Criteria of CROWN Criteria (CC) Cohort\n\nSubjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:\n\n1. Diagnosis:\n\n   1. Study Population: Patients with histologically or cytologically confirmed diagnosis of locally advanced \\[(Stage IIIB\/C not amenable for multimodality treatment) or metastatic (Stage IV) by American Joint Committee on Cancer (AJCC) v 7.0\\] ALK-positive NSCLC where ALK status is determined by the Ventana ALK (D5F3) Companion Diagnostic (CDx) IHC test performed on the Ventana ULTRA or XT Platforms, FISH, PCR, or next generation sequencing (NGS), or circulating tumor DNA (ctDNA).\n   2. Tumor Requirements: At least 1 extracranial measurable target lesion per RECIST v. 1.1 that has not been previously irradiated. CNS metastases are allowed if asymptomatic and:\n\n      1. Either untreated and not currently requiring corticosteroid treatment, or on a stable or decreasing dose of \u226410 mg QD prednisone or equivalent; or\n      2. Local treatment has been completed with full recovery from the acute effects of radiation therapy or surgery prior to randomization, and if corticosteroid treatment for these metastases has been withdrawn for at least 4 weeks with neurological stability; or\n      3. In case of leptomeningeal disease (LMD) or carcinomatous meningitis (CM) if visualized on magnetic resonance imaging (MRI), or if baseline CSF positive cytology is available.\n   3. Tissue Requirements: All patients must have an archival formalin fixed, paraffin embedded (FFPE) tissue specimen available and collected prior to randomization. If archived tissue is unavailable, then a mandatory de novo biopsy must be performed.\n2. No prior systemic NSCLC treatment for advanced (Stage IIIB\/C not amenable for multimodality treatment) or metastatic (Stage IV) disease, including molecularly targeted agents (e.g., ALK TKIs), angiogenesis inhibitors, immunotherapy, or chemotherapy. Prior treatment for earlier Stages of the NSCLC only allowed if completed more than 12 months prior to randomization.\n3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0, 1, or 2.\n4. Age \u226518 years.\n5. Adequate Bone Marrow Function, including:\n\n   1. Absolute Neutrophil Count (ANC) \u2265 1,500\/mm3 or \u22651.5 x 109\/L;\n   2. Platelets \u2265100,000\/mm3 or \u2265100 x 109\/L;\n   3. Hemoglobin \u22659 g\/dL.\n6. Adequate Pancreatic Function, including:\n\n   1. Serum total amylase \u22641.5 x upper limit of normal (ULN)\\*;\n   2. Serum lipase \u22641.5 x ULN. \\*if total amylase \\>1.5 x ULN, but pancreatic amylase is within the ULN, then patient may be enrolled.\n7. Adequate Renal Function, including:\n\n   a. Serum creatinine \u22641.5 x ULN or estimated creatinine clearance \u226560 mL\/min as calculated using the method standard for the institution.\n8. Adequate Liver Function, including:\n\n   1. Total serum bilirubin \u22641.5 x ULN;\n   2. Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) \u22642.5 x ULN (\u22645.0 x ULN in case of liver metastases).\n9. Acute effects of prior radiotherapy resolved to baseline severity or to CTCAE Grade \u22641 except for AEs that in the investigator's judgment do not constitute a safety risk for the patient.\n10. Serum pregnancy test (for females of childbearing potential) negative at screening. Female patients of non-childbearing potential must meet at least 1 of the following criteria:\n\n    1. Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause (which may be confirmed with a serum follicle-stimulating hormone \\[FSH\\] level confirming the postmenopausal state if appropriate);\n    2. Have undergone a documented hysterectomy and\/or bilateral oophorectomy;\n    3. Have medically confirmed ovarian failure. All other female patients (including female patients with tubal ligations) are considered to be of childbearing potential.\n11. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.\n12. Willing and able to comply with scheduled visits, treatment plans, laboratory tests and other procedures.\n\nInclusion Criteria of Compassionate use (CU) Cohort\n\n1. Diagnosed as ALK-positive NSCLC as in CC cohort, but not fulfilled CC cohort inclusion criteria 2\\~9 as above mentioned.\n2. No prior ALK TKI treatment for advanced (Stage IIIB\/C not amenable for multimodality treatment) or metastatic (Stage IV) disease (e.g., alectinib, brigatinib).\n3. Serum pregnancy test (for females of childbearing potential) negative at screening.\n4. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.\n5. Willing and able to comply with scheduled visits, treatment plans, laboratory tests and other procedures.\n\nExclusion Criteria:\n\nSubjects presenting with any of the following characteristics\/conditions will not be included in this clinical study:\n\n1. Spinal cord compression unless the patient has good pain control attained through therapy, and there is stabilization or recovery of neurological function for the 4 weeks prior to randomization.\n2. Major surgery within 4 weeks prior to randomization. Minor surgical procedures (e.g., port insertion) are not excluded, but sufficient time should have passed for adequate wound healing.\n3. Radiation therapy within 2 weeks prior to randomization, including stereotactic or partial brain irradiation. Patients who complete whole brain irradiation within 4 weeks prior to randomization or palliative radiation therapy outside of the CNS within 48 hours prior to randomization will also not be included in the study.\n4. Gastrointestinal abnormalities, including inability to take oral medication; requirement for intravenous alimentation; prior surgical procedures affecting absorption including total gastric resection or lap band; active inflammatory gastrointestinal disease, chronic diarrhea, symptomatic diverticular disease; treatment for active peptic ulcer disease in the past 6 months; malabsorption syndromes.\n5. Known prior or suspected severe hypersensitivity to study drugs or any component in their formulations.\n6. Active and clinically significant bacterial, fungal, or viral infection including hepatitis B virus (HBV) or hepatitis C virus (HCV) (e.g., in case of known HBsAg or HCV antibody positivity), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS)-related illness.\n7. Clinically significant vascular (both arterial and venous) and non-vascular cardiac conditions, (active or within 3 months prior to enrollment), which may include, but are not limited to:\n\n   1. Arterial disease such as cerebral vascular accident\/stroke (including Transient Ischemic Attack -TIA), myocardial infarction, unstable angina;\n   2. Venous diseases such as cerebral venous thrombosis, symptomatic pulmonary embolism;\n   3. Non-vascular cardiac disease such as congestive heart failure (New York Heart Association Classification Class \u2265 II), second-degree or third-degree AV block (unless paced) or any AV block with PR \\>220 msec; or ongoing cardiac dysrhythmias of NCI CTCAE Grade \u22652, uncontrolled atrial fibrillation of any grade, bradycardia defined as \\<50 bpm (unless patient is otherwise healthy such as long-distance runners, etc.), machine-read Electrocardiogram (ECG) with QTc \\>470 msec, or congenital long QT syndrome.\n8. Patients with predisposing characteristics for acute pancreatitis according to investigator judgment (e.g., uncontrolled hyperglycemia, current gallstone disease) in the last month prior to randomization.\n9. History of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis.\n10. Evidence of active malignancy (other than NSCLC, non-melanoma skin cancer, or localized prostate cancer or any in situ cancer which does not currently require treatment) within the last 3 years prior to randomization.\n11. Concurrent use of any of the following food or drugs (consult the sponsor if in doubt whether a food or a drug falls into any of the above categories) within 12 days prior to the first dose of lorlatinib.\n\n    1. Known strong CYP3A inhibitors (e.g., strong CYP3A inhibitors: grapefruit juice or grapefruit\/grapefruit related citrus fruits \\[eg, Seville oranges, pomelos\\], boceprevir, cobicistat, conivaptan, itraconazole, ketoconazole, posaconazole, ritonavir alone and with danoprevir or elvitegravir or indinavir or lopinavir or paritaprevir or ombitasvir or dasabuvir or saquinavir or tipranavir, telaprevir, troleandomycin, and voriconazole. The topical use of these medications (if applicable), such as 2% ketoconazole cream, is allowed.\n    2. Known CYP3A substrates with narrow therapeutic index, such as astemizole\\*, terfenadine\\*, cisapride\\*, pimozide, quinidine, tacrolimus, cyclosporine, sirolimus, alfentanil, fentanyl (including transdermal patch) or ergot alkaloids (ergotamine, dihydroergotamine) (\\*withdrawn from US market).\n    3. Known strong CYP3A inducers (e.g., carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's Wort). d. Known P-gp substrates with a narrow therapeutic index (e.g., digoxin).\n12. Other severe acute or chronic medical or psychiatric condition, including recent (within the past year) or active suicidal ideation or behavior, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.\n13. Patients who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the Investigator, or patients who are Pfizer employees, including their family members, directly involved in the conduct of the study.\n14. Participation in other studies involving investigational drug(s) within 2 weeks prior to study entry and\/or during study participation.\n15. Pregnant female patients; breastfeeding female patients; fertile male patients and female patients of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 97 days, if male or 35 days if female, after the last dose of investigational product under lorlatinib.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06092086001","EMAIL":[{"email":"linjiaxin@gdph.org.cn"},{}],"GEO":[23.11667,113.25]},{"TITLE":"Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy","CRITERIA":"Inclusion Criteria:\n\n1. \u2265 18 years old at the time of informed consent\n2. Diagnosed with non-small cell lung cancer (NSCLC) OR melanoma AND initiating therapy with single agent or combination therapy that includes an immune checkpoint inhibitor, (e.g., atezolizumab, cemiplimab, durvalumab, ipilimumab, nivolumab, pembrolizumab)\n3. Ability to provide written informed consent and HIPAA authorization\n\nExclusion Criteria:\n\n1. Diagnosis or past medical history of autoimmune disorder, including systemic lupus erythematosus, Crohn's disease, Sjogren's syndrome, multiple sclerosis, type 1 diabetes mellitus, Behcet's disease, and ankylosing spondylitis\n2. Current infection requiring medical treatment (note: if a prospective subject's infection resolves, they can be re-screened for trial inclusion)\n3. Concomitant treatment with systemic immunosuppressant drugs (see Table A1 in appendix for complete list)","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05707286001","EMAIL":[{"email":"rossrobi@indiana.edu"},{}],"GEO":[39.76838,-86.15804]},{"TITLE":"The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Eligible subjects selected for this study must meet all of the following criteria:\n\n  1. Sign written informed consent before implementing any trial-related procedures;\n  2. Age \u226518 years old;\n  3. No limit on the gender;\n  4. Histological or cytological confirmed advanced or metastatic non-small cell lung cancer, ineligible for radical surgery, relapse after failure of previous treatment with first-line (including first, second, and third generation)EGFR inhibitors.\n\n     Cohort A\uff1aMET amplification,(by FISH, NGS or IHC) Cohort B\uff1aRET fusion.\n  5. Laboratory tests for organ function levels must meet the following requirements:\n\n     1. Absolute neutrophil count \u2265 1.5 \u00d7 109\/L;\n     2. Platelet count \u2265 100 \u00d7 109\/L;\n     3. Hemoglobin \u2265 9 g\/dL;\n     4. Bilirubin \u22641.5 times ULN; e) AST and ALT \u22642.5 times ULN (total bilirubin \u22643 times the upper limit of normal and AST and ALT \u22645 times the upper limit of normal are permitted if hepatic metastases are present);\n\n     f) Serum creatinine \u2264 1.5 times ULN or creatinine clearance \u2265 60 mL\/min (according to the Cockcroft-Gault formula);\n  6. For premenopausal women of childbearing potential a pregnancy test must be performed within 7 days prior to initiation of treatment, a serum pregnancy test must be negative, and they must be non-lactating; all enrolled patients (whether male or female) should use adequate barrier contraception throughout the treatment period and for 3 months after completion of treatment.\n\nExclusion Criteria:\n\n1. Subjects treated with CYP isozyme inducers or inhibitors (see Appendix 4 for details) within 3 weeks prior to enrollment;\n2. Pregnant or lactating women;\n3. History of immunodeficiency or other acquired, congenital immunodeficiency diseases;\n4. Patients with prior bone marrow transplantation or prior solid organ transplantation;\n5. Patients with a combination of gastrointestinal perforation, gastrointestinal fistula, or non-gastrointestinal fistula;\n6. Prior history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy, or any evidence of clinically active interstitial lung disease.\n7. Hepatitis B, hepatitis C, or human immunodeficiency virus (HIV-positive). Hepatitis B is eligible for this study at \\<500 IU\/mL (or 2500 cps\/mL) by quantitative HBV-DNA testing, and hepatitis C (HCV) antibody-positive patients are eligible for this study only if the polymerase chain reaction shows HCV RNA negativity;\n8. Fulfillment of any of the following cardiac criteria: (i) Bazetts' mean corrected QT interval (QTc) derived from electrocardiogram (ECG) examination at rest \\>470 msec (women) or \\>450 msec (men) (in the case of the 1st abnormality, retested once within 48 h and calculated by averaging the results of the 2 times); and (ii) a wide variety of clinically significant rhythmic, conduction, and resting ECG morphologic Abnormalities, such as complete left bundle branch block, grade III conduction block, grade II conduction block, PR interval \\>250 msec; (iii) Myocardial ischemia or myocardial infarction of grade I or higher, or congestive heart failure of grade \u22652 (New York Heart Association (NYHA) classification); (iv) Factors that may increase the risk of prolongation of QTc or the risk of arrhythmic events, such as coronary artery disease, heart failure hypokalemia, congenital long QT syndrome, family history of a first-degree relative with long QT syndrome or sudden unexplained death before the age of 40, and ongoing use of any medication known to prolong the QT interval;","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06109558001","EMAIL":[{"email":"yangnong0217@163.com"},{"email":"zhangyongchang@csu.edu.cn"}],"GEO":[28.19874,112.97087]},{"TITLE":"Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study","CRITERIA":"Inclusion Criteria:\n\n* Patients with radiographic findings consistent with lung cancer or solitary or oligometastatic disease in the lung. Most patients will have primary non-small cell lung cancer. For primary lung cancers, we include lesions with ground glass opacities with a solid component of 50% or greater. Patients with solitary or oligo-metastatic disease in the lung may have any other histology or cancer type\n* Patients must have radiographically measurable or evaluable disease per RECIST v. 1.1\n* Patients must be age \\>= 18 years\n* Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Patients of child-bearing potential (POCBP) must have a negative urine or serum pregnancy test prior to registration on study\n\n  * NOTE: A POCBP is any person with an egg-producing reproductive tract (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n\n    * Has not undergone a hysterectomy or bilateral oophorectomy\n    * Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for \\> 12 months)\n* Radiation therapy is known to be teratogenic. Patients of child-bearing potential (POCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from time of informed consent, for the duration of study participation, and for 7 days following completion of therapy. Should a patient become pregnant or suspect they are pregnant while they or their partner are participating in this study, they should inform their treating physician immediately. People who can impregnate their partners treated or enrolled on this protocol must also agree to use adequate contraception from time of informed consent, for the duration of study participation, and 90 days after completion of administration\n* Patients must have the ability to understand and the willingness to sign a written informed consent document. Informed consent must be signed prior to registration on study\n\nExclusion Criteria:\n\n* Patients who have had prior radiotherapy with radiation field overlap\n* For primary lung cancers, patients with ground glass opacities without a solid component will be excluded\n* Patients who have not recovered from adverse events confined to the thorax (i.e. pneumonitis, bronchial insufficiency, bronchial hemorrhage, esophagitis) due to prior anticancer therapy (i.e., have residual toxicities \\>= grade 2) with the exception of alopecia. low blood counts (neutropenia, anemia, etc), or anatomically distinct toxicities (i.e. cystitis)\n* Patients who are receiving any other concurrent investigational agents or genotoxic chemotherapy for cancer treatment\n\n  * Note: Patients receiving targeted therapies are permitted to enroll on the study. However, patients must pause treatment with targeted therapy 3 days prior to SBRT and restart medication at least 3 days after SBRT. Concurrent immunotherapy (if not investigational) is permitted. Coronavirus disease 2019 (COVID-19) vaccinations are allowed\n* Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen. Patients who have an uncontrolled intercurrent illness including, but not limited to any of the following, are not eligible:\n\n  * Ongoing or active infection requiring systemic treatment\n  * Unstable angina pectoris\n  * Stage 3 or greater idiopathic pulmonary fibrosis\n  * Cardiac arrhythmia\n  * Psychiatric illness\/social situations that would limit compliance with study requirements\n  * Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety or study endpoints\n* Female patients who are pregnant or nursing. Pregnant women are excluded from this study because radiation therapy has teratogenic or abortifacient effects","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05802186001","EMAIL":[{},{}],"GEO":[41.85003,-87.65005]},{"TITLE":"Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC\uff08neoSCORE \u2161\uff09","CRITERIA":"Inclusion Criteria:\n\n1. Sign the informed consent form before starting any trial related procedure.Be willingness and able to undergo planned visits, protocol therapy, laboratory tests and other testing procedures.\n2. 18-75 years old, male or female.\n3. Squamous Cell Non-small cell lung cancer confirmed by cytology or histology.\n4. There must be at least one evaluable focus judged according to recist1.1 standard.\n5. Evaluation by the researchers and classified by the 8th version of AJCC TNM staging to confirm resectable stage c\u2161A-\u2162B squamous NSCLC patients without any treatment before.\n6. ECOG PS 0-1.\n7. Life expectancy \\> 6 months.\n8. Adequate organ function and it should meet the following criteria:\n\n   Absolute value of neutrophils (ANC) \u22651.5\u00d7109\/L in the absence of granulocyte colony stimulating factor for the past 14 days; Platelet \u2265100\u00d7109\/L in the last 14 days without blood transfusion; Hemoglobin \\>9g\/dL in the absence of blood transfusion or erythropoietin in the last 14 days ;\n\n   Total bilirubin(TBIL)\u22641.5ULN, ALT\u3001AST\u2264 2.5 ULN, serum creatinine(sCr)\u22641.5ULN;\n\n   Good blood coagulation: INR\u22641.5 or PT\u22641.5 ULN;\n\n   Normal thyroid function: TSH within normal institutional limits;\n9. For women of reproductive age, a urine or serum pregnancy test with negative results should be performed within 3 days prior to receiving the first study drug administration (day 1 of cycle 1). If a urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is requested. Women of nonreproductive age were defined as at least 1 year after menopause or having undergone surgical sterilization or hysterectomy. If there is a risk of conception, all subjects (both men and women) will use a medically approved highly effective contraceptive (e.g., an intrauterine device, birth control pill, or condom) for the entire treatment period up to 120 days after the last study drug (or 180 days after the last chemotherapy drug).\n\nExclusion Criteria:\n\n1. Malignancies within 5 years prior to the first dose(excluding radical skin basal cell carcinoma, skin squamous cell carcinoma and \/ or radical resection of carcinoma in situ).\n2. Currently participating in the intervention clinical treatment, or receiving other drugs or research instruments within 4 weeks before the first dose.\n3. Patients who have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or drugs for another stimulation or synergistic inhibition of T cell receptor (e.g. CTLA-4, OX-40, CD137).\n4. Active autoimmune diseases requiring systemic treatment (e.g. using disease improving drugs, corticosteroids or immunosuppressants) occurred within 2 years before the first dose. Alternative therapies (e.g. thyroxine, insulin or corticosteroids in physiological doses for adrenal or pituitary insufficiency) are not considered systemic treatment.\n5. Systemic glucocorticoid therapy (excluding local glucocorticoids by nasal spray, inhalation or other routes) or any other form of immunosuppressive therapy is in progress within 7 days before the first dose.\n\n   Note: it is allowed to use physiological dose of glucocorticoid (Prednisone\u226410 mg\/d or equivalent drug).\n6. Received allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation.\n7. Allergic to study drug(sintilimab, carboplatin, albumin-bound paclitaxel) components excipients.\n8. Not fully recovered from toxicity and\/ or complications caused by any intervention before treatment (\u2264level 1 or reach baseline, excluding fatigue or hair loss).\n9. Has a known history of human immunodeficiency virus (HIV) infection (HIV 1\/2 antibody positive).\n10. Untreated active Hepatitis B (defined as HBsAg positive and HBV-DNA copies\\>ULN).\n11. Active Hepatitis C (HCV antibody positive and HCV-RNA level higher than the detection limit).\n12. Inoculate the live vaccine within 30 days before the first dose (cycle 1 day 1).\n\n    Note: it is allowed to receive the injection inactivated virus vaccine for seasonal influenza within 30 days before the first dose; however, it is not allowed to accept the live attenuated influenza vaccine for intranasal medication.\n13. Pregnant or lactating women.\n14. There are any serious or uncontrollable systemic diseases, such as:\n\n    Resting ECG has significant abnormalities in rhythm, conduction or morphology, and the symptoms are serious and difficult to control,such as complete left bundle branch block, heart block above degree \u2161, ventricular arrhythmia or atrial fibrillation;\n\n    Unstable angina, congestive heart failure, chronic heart failure with NYHA grade \u2265 2;\n\n    Within 6 months before inclusion, there were any arterial thrombosis, embolism or ischemia, such as myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic attack etc;\n\n    History of noninfectious pneumonia requiring glucocorticoid treatment within 1 year before the first dose,or having currently clinical active interstitial lung diseases;\n\n    Active pulmonary tuberculosis;\n\n    Active or uncontrolled infections requiring systemic treatment;\n\n    Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis;\n\n    Poorly controlled diabetes (Fasting blood glucose (FBG)\\>10mmol\/L);\n\n    Urine routine test indicates that urine protein\u2265++, and confirmed that 24 hours proteinuria\\>1.0 g;\n\n    Patients with mental disorders who are unable to cooperate with the treatment;\n15. There are medical history, disease, treatment or laboratory abnormal results that may interfere with the test results, prevent the subjects from participating in the whole process of the study, or the researchers think that participating in the study is not in the best interests of the subjects or there are other potential risks that the subjects are not suitable for the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05429463001","EMAIL":[{"email":"qiufuming@zju.edu.cn"},{},{}],"GEO":[30.29365,120.16142]},{"TITLE":"Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients","CRITERIA":"Inclusion Criteria:\n\n1. Patients of age \u226518.\n2. Histological or cytological confirmation of locally advanced or metastatic, non-squamous cell lung carcinoma (NSCLC) in patients who are not candidates for local curative treatment through radical surgery and\/or radiotherapy.\n3. Stage IV, according to Tumor-nodes-metastasis (TNM) Version 8, including M1a (malignant effusion) or M1b (distant metastasis), or locally advanced disease for which there is no curative treatment (including patients who progress after chemoradiotherapy in Stage III disease).\n4. Patients must have been locally diagnosed with EGFR activating mutation (including exon 18, exon 19, exon 21 and mutation T790M) based on FDA approved test (or a local equivalent laboratory developed) test (LDT)). Confirmatory central review will be performed for all patients, in case of discrepancy on EGFR status, central review will prevail.\n5. Eastern cooperative oncology group (ECOG) performance status 0-1.\n6. Existence of measurable or evaluable disease (according to RECIST 1.1 criteria).\n7. Patients with asymptomatic central nervous system (CNS) metastases (treated or untreated) and\/or asymptomatic leptomeningeal carcinomatosis are eligible to enroll if they satisfy the following criteria:\n\n   * Patients requiring steroids at a stable or decreasing dose (\u2264 12 mg\/day dexamethasone or equivalent) for at least 14 days are eligible. Patients on stable doses of levetiracetam (same dose for 14 days) are eligible to be enrolled.\n   * A minimum of 14 days must have elapsed from the completion of whole brain radiation treatment (WBRT) before the start of treatment with repotrectinib, and all side effects (with the exception of alopecia) from WBRT are resolved to CTCAE grade \u2264 1.\n8. Having available tumor tissue samples, via a biopsy or surgical resection of the primary tumor or metastatic tumor tissue, within 60 days prior to the start of treatment.\n9. Life expectancy \u226512 weeks, as determined by a physician.\n10. Adequate hematological function, defined as: absolute neutrophil count (ANC) \\>1.5 x 109\/L, platelet count \\>100.0 x 109\/L, and hemoglobin \\>9.0 g\/dL (transfusion allowed at baseline).\n11. Adequate liver function, defined as: total bilirubin \\<1.5 x upper limit of normal (ULN), alanine aminotransferase (ALT) and\/or aspartate aminotransferase (AST) \\<2.5 x ULN.\n12. Adequate renal function, defined as: calculated (Cockcroft-Gault formula) or measured creatinine clearance \\>50 mL\/min and proteinuria \\<2+ (dipstick).\n13. Ability to take part in all study procedures, per investigators.\n14. Prior cytotoxic chemotherapy and prior immunotherapy (e.g., anti-PD-1, anti-programmed death ligand 1 (PDL1), anti-T cell immunoglobulin and mucin domain- containing protein 3 (TIM3), anti-OX40) for advanced or metastatic disease is allowed if:\n\n    * At the time of starting treatment with repotrectinib, at least 14 days or 5 half-lives (whichever is shorter) must have elapsed after discontinuation of prior therapy (or at least 42 days for prior nitrosoureas, mitomycin C, and liposomal doxorubicin).\n    * All side effects from prior treatments must have resolved to grade \u2264 1 (NCI CTCAE Version 5.0) with the exception of alopecia or other side effects that the investigator does not consider to be a risk to patient safety.\n    * Patients with advanced solid tumors harboring ALK, ROS1, neurotrophic tyrosine kinase (NTRK) 1, 2, or 3 rearrangements are eligible if at the time of starting treatment at least 14 days or 5 half-lives (whichever is shorter) have elapsed after discontinuation of prior therapy.\n    * There is no limit to the number of prior chemotherapies, immunotherapy, or TKI regimens.\n15. All women of childbearing potential (WOCBP), must agree to use highly effective contraception methods during the study treatment period and for at least 2 months after the last dose of EGFR TKI. Male partners of female (WOCBP) patients agree to use condoms during the study and for 2 months after the last dose. Male patients with female partners of WOCBP should use condom protection for 6 months in addition to their female partner (WOCBP) using highly effective contraceptive methods for 4 months after the last dose. Sexually active men, and women of childbearing potential, who are unwilling to use a contraception method are not eligible for the study.\n16. Provision of written informed consent, signed and dated by the patient and the investigator, before any study interventions are performed.\n17. Part B expansion cohorts only (after the RP2D has been identified):\n\n    * Disease progression following osimertinib with no evidence of tertiary EGFR mutation (i.e., C797S) or MET amplification.\n    * Disease progression following first or second generation EGFR TKI (for example, erlotinib,gefitinib, afatinib, dacomitinib) regardless of T790M status.\n\nExclusion Criteria:\n\n1. Prior exposure to repotrectinib.\n2. Diagnosis with any other lung cancer subtype apart from adenocarcinoma including patients with mixed NSCLC with predominantly squamous cell cancer, or with any small-cell lung cancer component, or a tertiary mutation.\n3. Presence or history of any other primary malignancy other than NSCLC within 5 years prior to enrollment into the study.\n4. Patients with a history of adequately treated basal or squamous cell carcinoma of the skin or any adequately treated in situ carcinoma may be included in the study.\n5. Presence of only one measurable or evaluable tumor lesion that has already been resected or irradiated prior to enrollment in the study.\n6. Known presence of EGFR exon 20 insertion mutation based on most recent applicable molecular testing.\n7. Clinically significant cardiovascular disease (either active or within 6 months prior to enrollment): myocardial infarction, unstable angina, coronary\/peripheral artery bypass graft, symptomatic congestive heart failure (New York Heart Association Classification Class \u2265 II), cerebrovascular accident or transient ischemic attack, symptomatic bradycardia, requirement for anti-arrhythmic medication. Ongoing cardiac dysrhythmias of NCI CTCAE grade \u22652.\n8. Any of the following cardiac criteria:\n\n   * Mean resting corrected QT interval (ECG interval measured from the onset of the QRS complex to the end of the T wave) for heart rate (QTc) \\> 470 msec obtained from 3 ECGs, using the screening clinic ECG machine-derived QTc value\n   * Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval \\> 250 msec)\n   * Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or any concomitant medication known to prolong the QT interval\n9. Known active infections requiring ongoing treatment (bacterial, fungal, viral including HIV positivity).\n10. Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact on drug absorption.\n11. Peripheral neuropathy \u2265 grade 2.\n12. History of extensive, disseminated, bilateral, or presence of CTCAE grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis. Patients with a history of prior radiation pneumonitis are not excluded.\n13. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or that may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study or could compromise the protocol objectives in the opinion of the Investigator.\n14. For Part B expansion cohorts only (after the RP2D has been identified), presence of a tertiary EGFR mutation (i.e., GFR C797S) mutations and hepatocyte growth factor receptor (MET) amplification.\n15. Current use or anticipated need for drugs that are known to be strong Cytochrome P450, family 3, subfamily A (CYP3A) inhibitors or inducers.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04772235004","EMAIL":[{"email":"investigacion@mfar.net"},{}],"GEO":[40.4165,-3.70256]},{"TITLE":"First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI","CRITERIA":"Inclusion Criteria:\n\n1. Histologically or cytologically confirmed Stage III (locally advanced) NSCLC not amenable to curative therapy or stage IV NSCLC.\n2. Patients must have received treatment with at least 1 third-generation EGFR TKI (eg, Osimertinib, Lazertinib).\n3. Confirmation that the tumor harbors an EGFR mutation as follows:\n\n   1. Phase 1a (Dose Escalation): Confirmation that the tumor harbors an EGFR mutation known to be associated with EGFR TKI sensitivity (exon 19 deletion or L858R).\n   2. Phase 1b (RP2D Selection): Have complex EGFR mutations containing C797S confirmed.\n   3. Phase 2 (Dose Expansion): Have complex EGFR mutations containing C797S confirmed by a central laboratory.\n4. Documented partial or complete response (CR) or durable (at least 16 weeks) stable disease, based on the RECIST criteria, after treatment of an EGFR TKI.\n5. Radiological documentation of disease progression or intolerance to a previous continuous (at least 30 days) treatment with an approved EGFR TKI therapy (including, but not limited to osimertinib, afatinib, dacomitinib, gefitinib, or erlotinib).\n6. All patients must have documented radiological progression or intolerance to the last treatment administered prior to enrolling in the study.\n7. Has Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n8. Adequate organ function test result.\n9. All standard therapeutic options have been exhausted, refused by the patient, or are contraindicated; or the patient is deemed by the investigator not to be an appropriate candidate for standard-of-care treatment (as defined in the country of participation).\n\nExclusion Criteria:\n\n1. Has symptomatic brain or spinal cord metastases with exceptions.\n2. Any of the following cardiac conditions within the last 6 months from the first dose of study treatment:\n\n   1. Unexplained or cardiovascular cause of presyncope or syncope, tachycardia, ventricular fibrillation, or sudden cardiac arrest.\n   2. Prolonged corrected QT interval (mean resting corrected QT interval using Fridericia's formula \\[QTcF\\] \\>470 msec from 3 ECGs).\n   3. Clinically significant, uncontrolled, cardiovascular disease including congestive heart failure grade 3 or 4 according to the New York Heart Association classification; myocardial infarction or unstable angina, uncontrolled hypertension, or clinically significant, uncontrolled arrhythmias, including bradyarrhythmia that may cause QT prolongation (eg, Type II second degree heart block or third-degree heart block).\n\n   \\<Prior or Concomitant Anticancer Therapy\\>\n3. An EGFR TKI, including but not limited to osimertinib, afatinib, dacomitinib, gefitinib, or erlotinib within 8 days of the first dose of study treatment.\n4. Small molecule targeted inhibitor other than EGFR inhibitor class or cytotoxic chemotherapy within 14 days, or biologic anticancer medicine (cytokines or antibodies, etc.) within 28 days (before the initiation of BBT-207 treatment) for the systemic treatment of advanced NSCLC.\n5. Has toxicities from previous anticancer therapies that have not resolved to baseline levels or to CTCAE grade \u22641, with the exception of alopecia and peripheral neuropathy.\n6. Has had radiotherapy within 14 days before the initiation of study treatment. Note: Palliative radiotherapy for pain can be administered at any time before the first dose of study treatment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05920135004","EMAIL":[{}],"GEO":[37.566,126.9784]},{"TITLE":"Using ctDNA to Determine Therapies for Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Age \u2265 18 years at the time of screening\n2. Written informed consent obtained from the subject prior to performing any protocol-related procedures\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n4. Weight \u2265 35 kg\n5. Must have a life expectancy of at least 24 months\n6. Complete surgical resection of T1-2N0M0 NSCLC or T3\/T4 multifocal NSCLC\n7. Any pathologic subtype of NSCLC is eligible, including adenocarcinoma and squamous carcinoma. Patients with targetable genomic alterations without approved or available targeted adjuvant therapy options are eligible\n8. Patients with detectable plasma ctDNA before or after complete surgical resection are eligible (RaDaR TM assay, Inivata Morrisville, North Carolina, USA).\n9. No prior chemotherapy or radiotherapy is allowed for the current diagnosis of resected NSCLC.\n10. Adequate organ and marrow function as defined in Table 4 (3.1.1)\n11. Females of childbearing potential who are sexually active with a non-sterilized male partner must use at least one highly effective method of contraception from screening to 180 days after the final dose of study treatment. A serum pregnancy test within 72 hours prior to the initiation of therapy will be required for women of childbearing potential. It is strongly recommended for the male partner of a female subject to also use male condom plus spermicide throughout this period\n12. Non-sterilized male subjects who are sexually active with a female partner of childbearing potential must use a male condom with spermicide from screening to 180 days after receipt of the final dose of study treatment. It is strongly recommended for the female partner of a male subject to also use a highly effective method of contraception throughout this period. In addition, male subjects must refrain from sperm donation while on study and for 180 days after the final dose of study treatment.\n\n4.1.2 Exclusion Criteria\n\n1. Participants that should receive adjuvant chemotherapy per standard of care (resected N1 or N2 disease, primary tumour \\>=4 cm).\n2. Receipt of any conventional or investigational anticancer therapy within 21 days or radiotherapy within 14 days prior to the scheduled first dose of study treatment;\n3. Prior receipt of any immune-mediated anti-cancer therapy including, but not limited to, anti-CTLA-4, anti-PD-1, anti-PD-L1 antibodies including nivolumab and agents targeting CD73, CD39, or adenosine receptors;\n4. Incomplete surgical resection;\n5. Concurrent enrolment in another therapeutic clinical study of systemic anti-cancer treatment. Enrolment in observational or supportive studies will be allowed;\n6. Subjects with a recent history of myocardial infarction, congestive heart failure \u2265 Class 3 based on New York Heart Association Functional Classification or stroke within the past 3 months prior to the scheduled first dose of study treatment;\n7. Active autoimmune disorders within the past 3 years prior to the scheduled first dose of study treatment. The following are exceptions to this criterion:\n\n   1. Subjects with vitiligo or alopecia.\n   2. Subjects with hypothyroidism (e.g., following Hashimoto syndrome) not requiring systemic treatment or stable on hormone replacement.\n   3. Subjects with psoriasis not requiring systemic treatment.\n   4. Any chronic skin condition that does not require systemic therapy.\n   5. Subjects with celiac disease controlled by diet alone;\n8. Have known uncontrolled human immunodeficiency virus (HIV)-1\/2 infection.\n\n   \u2022 Participants with HIV (known HIV 1\/2 antibodies positive) are allowed if all of the following conditions are met: CD4+ T-cell counts \u2265350 cells\/uL; no opportunistic infection within the past 12 months; on established anti-retroviral therapy for at least 4 weeks; and an HIV viral load less than 400 copies\/mL.\n9. History of primary immunodeficiency, solid organ transplantation, or active tuberculosis (by clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice). In settings where there is clinical or radiographic evidence of tuberculosis, active disease must be excluded prior to enrolment. Subjects who have had adequately treated tuberculosis may be enrolled upon discussion with the coordinating Principal Investigator.\n10. Other invasive malignancy within 2 years. Non-invasive malignancies (i.e., cervical carcinoma in situ, in situ prostate cancer, non-melanomatous carcinoma of the skin, ductal carcinoma in situ of the breast that has been surgically cured) are permitted.\n11. Known allergy or hypersensitivity to investigational product formulations.\n12. History of more than one event of infusion related reactions (IRR) requiring permanent discontinuation of IV drug treatment.\n13. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection requiring antibiotic therapy, uncontrolled hypertension, bleeding diatheses, or psychiatric illness\/social situations that would limit compliance with study requirements, substantially increase risk of incurring AEs, or compromise the ability of the subject to give written informed consent.\n14. Current or prior use of immunosuppressive medication within 14 days prior to the scheduled first dose of study treatment. The following are exceptions to this criterion:\n\n    1. Intranasal, topical, inhaled corticosteroids or local steroid injections (e.g., intra articular injection).\n    2. Systemic corticosteroids at physiologic doses not to exceed 10 mg\/day of prednisone or equivalent.\n    3. Steroids as premedication for hypersensitivity reactions (e.g., computed tomography \\[CT\\] scan premedication).\n15. Receipt of live, attenuated vaccine within 30 days prior to the scheduled first dose of study treatment (Note: Subjects, if enrolled, should not receive live vaccine during the study and 180 days after the last dose of study treatment). Vaccination with an inactivated vaccine is permitted at any time.\n16. Major surgery (as defined by the investigator) within 28 days prior to the scheduled first dose of study treatment or still recovering from prior surgery. Local procedures (e.g., placement of a systemic port, core needle biopsy, etc) are allowed without needing to wait for the 28-day recovery period.\n17. Females who are pregnant, lactating, or intend to become pregnant during their participation in the study.\n18. Subjects who are involuntarily incarcerated or are unable to willingly provide consent or are unable to comply with the protocol procedures.\n\n    Any condition that, in the opinion of the investigator, would interfere with safe administration or evaluation of the investigational products or interpretation of subject safety or study results\n19. Any condition that, in the opinion of the investigator, would interfere with safe administration or evaluation of the investigational products or interpretation of subject safety or study results.\n20. History of allergic reactions attributed to compounds of similar chemical or biologic composition to Nivolumab or other agents used in the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04966663001","EMAIL":[{}],"GEO":[43.70011,-79.4163]},{"TITLE":"AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer","CRITERIA":"Key Inclusion Criteria:\n\n1. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n2. Have previously untreated and pathologically confirmed resectable Stage II-IIIA NSCLC.\n3. Have at least one measurable lesion per RECIST 1.1 assessed by investigator.\n4. Have adequate organ function.\n\nKey Exclusion Criteria:\n\n1. Mixed NSCLC and small cell lung cancer histology.\n2. Patients with other active malignancies within 3 years prior to enrollment.\n3. Known active autoimmune diseases.\n4. Use of immunosuppressive agents within 14 days prior to the first dose of study treatment.\n5. Presence of other uncontrolled serious medical conditions.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05377658001","EMAIL":[{"email":"18638561588@163.com"}],"GEO":[34.75778,113.64861]},{"TITLE":"Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway","CRITERIA":"Inclusion Criteria:\n\nGeneral Inclusion Criteria ModA Part 1 and 2:\n\n* Able to provide a fresh tumor biopsy from a primary or metastatic cancer lesion and an archival tumor tissue sample, if available\n* Able to take oral medication\n* If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements\n* Adequate organ function and electrolytes\n* Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of 0 to 1 at Screening\n* Has a life expectancy of more than 6 months\n* In addition to these general inclusion criteria, participants must meet all the module cohort-specific inclusion criteria\n\nInclusion Criteria ModA Part 1 Cohort Specific:\n\n* Pathologically confirmed diagnosis of solid cancer and documentation of Kirsten rat sarcoma (KRAS), Harvey rat sarcoma virus (HRAS), neuroblastoma ras viral oncogene homolog (NRAS), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), v-raf murine sarcoma viral oncogene homolog C1(CRAF), and\/or neurofibromatosis 1 (NF1) mutation\n* Have exhausted all available standard of care therapies that are known to provide benefit for the participant's condition, as judged by the Investigator\n\nInclusion Criteria ModA Part 2 Cohort Specific:\n\n* Documented BRAF gene mutation\n* Pathologically confirmed diagnosis with PD after at least one prior line of therapy in the advanced or metastatic setting\n\nExclusion Criteria:\n\nGeneral Exclusion Criteria ModA Part 1 and 2:\n\n* Prior treatment with certain BRAF dimer inhibitors\n* Female participant is pregnant or lactating\n* Received any prior or concurrent medications or therapies known to be prohibited with DCC-3084 within 14 days\n* Received any prior antitumor therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-3084\n* Known allergy or hypersensitivity to any component of the study drug\n* Invasive malignancy within 2 years prior to the first dose of study drug other than the study indication or specific types of cancer treated with curative intent\n* Have not recovered from all clinically relevant toxicities from prior therapy\n* Impaired cardiac function\n* History of recent thrombotic or embolic events\n* Malabsorption syndrome or other illness that could affect oral absorption\n* Major surgery within 28 days of the first dose of study drug\n* In addition to the general exclusion criteria, participants will also be excluded based on the cohort-specific exclusion criteria\n\nExclusion Criteria: Module A Part 2 Cohort Specific:\n\n\u2022 Has known co-occurring mutation of KRAS, HRAS, NRAS, NF1, epidermal growth factor receptor, Phosphoinositide-3-kinase, catalytic, alpha polypeptide (PI3KCA), or Phosphatase and TENsin homolog deleted on chromosome 10 (PTEN)","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06287463006","EMAIL":[{}],"GEO":[38.84622,-77.30637]},{"TITLE":"Study of DF9001 in Patients With Advanced Solid Tumors","CRITERIA":"Inclusion Criteria: General (applies to all cohorts)\n\n1. Signed written informed consent.\n2. Male or female patients aged \u2265 18 years.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at study entry and an estimated life expectancy of at least 3 months.\n4. Adequate hematological function per protocol.\n5. Adequate hepatic function per protocol.\n6. Adequate renal function per protocol.\n7. Participation in the use of contraception during the study, and for 150 days after the last dose of study drug for women of child-bearing potential (WOCBP) and 30 days after the last dose of study drug for male patients, as defined by the Clinical Trial Facilitation Group (CTFG) guidelines.\n\nInclusion Criteria: Dose Escalation (Monotherapy)\n\n1. Histologically proven locally advanced or metastatic solid tumors of epithelial origin that (1) have squamous NSCLC or HNSCC, (2) has documented EGFR protein expression or EGFR amplification or polysomy in their medical history from previous testing, or (3) test positive for EGFR expression via archival or fresh biopsy tissue prior to study enrollment using a validated immunohistochemistry (IHC) assay.\n2. Evidence of objective disease, but participation does not require a measurable lesion.\n\nInclusion Criteria: Head and Neck Squamous Cell Carcinoma (HNSCC) Expansion Cohorts\n\n1. Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST 1.1.\n2. Histologically documented relapsed or metastatic HNSCC. Primary tumor locations include oropharynx, oral cavity, hypopharynx, or larynx. Patients may not have a primary tumor site of nasopharynx (any histology).\n3. Patients must have radiographic disease progression while on or after having received both platinum-based or fluoropyrimidine-based chemotherapy and an anti-PD-(L)1 therapy, administered either concurrent or sequentially.\n4. Willing and able to provide the most recently available tissue blocks representing tumor biopsy obtained prior to treatment initiation. If recent tissue is not available, then a newly obtained baseline biopsy of an accessible tumor is required. Note that \"recent\" is defined as no intervening systemic anticancer therapies from the time of the last treatment of the prior therapy until screening for this trial.\n5. Willing to undergo on-treatment biopsies, if safe and medically feasible.\n\nInclusion Criteria: Renal Cell Carcinoma (RCC) Expansion Cohorts\n\n1. Patients must have radiographic progression during treatment or after completing treatment for advanced (recurrent\/unresectable\/metastatic) disease or be intolerant to prior therapy.\n2. Histologically documented relapsed or metastatic RCC that has documented EGFR expression or EGFR gene amplification or polysomy in their medical history from previous testing or test positive for EGFR expression (Section 6.2 EGFR Positivity) via archival (only if a block is available) or fresh biopsy tissue prior to study enrollment using a validated IHC assay. Cytology specimens cannot be used for the purpose of defining EGFR expression to meet eligibility.\n3. Patients with clear cell RCC (ccRCC) must have radiographic progression after receipt of one of the following combination regimens as the preceding line of therapy:\n\n   1. PD-1\/PD-L1-targeting mAb with or without a VEGFR-TKI.\n   2. PD-1-targeting mAb with a CTLA-4 monoclonal.\n   3. Patients with non-clear cell RCC (nccRCC) are not required to have received prior therapy in the metastatic setting.\n   4. Patients with RCC in general are not required to have received TKI therapy (eg, axitinib, cabozantinib, lenvatinib + everolimus, tivozanib).\n4. Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST 1.1.\n5. Willing and able to provide the most recently available tissue blocks representing tumor biopsy obtained prior to treatment initiation. If recent tissue is not available, then a newly obtained baseline biopsy of an accessible tumor is required. Note that \"recent\" is defined as no intervening systemic anticancer therapies from the time of the last treatment of the prior therapy until screening for this trial.\n6. Willing to undergo on-treatment biopsies, if safe and medically feasible.\n\nInclusion Criteria: Non-Small Cell Lung Cancer (NSCLC) Expansion Cohorts\n\n1. Histologically confirmed NSCLC meeting stage criteria for stage IIIB, stage IIIC, or stage IV NSCLC disease with or without actionable genomic alterations (AGA) (per the 7th IASLC classification of NSCLC), or recurrent disease.\n\n   1. Patients with squamous NSCLC do not require EGFR testing as part of this study to be eligible.\n   2. Non-squamous NSCLC patients who have documented EGFR expression or EGFR gene amplification or polysomy in their medical history from previous testing or test positive for EGFR expression (Section 6.2 EGFR Positivity) via archival (only if a block is available) or fresh biopsy tissue prior to study enrollment using a validated IHC assay.\n   3. Patients with stage IIIB or IIIC must be ineligible for local therapies with curative intent (eg, radiotherapy or surgery).\n2. Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST 1.1.\n3. Patients must have recurrent or progressive disease during or after first line combination therapy with checkpoint inhibitors and platinum-based chemotherapy OR must have recurrent or progressive disease within 6 months after completing platinum- based chemotherapy for local disease, including those with actionable genetic alterations. They must not have received any subsequent lines of therapy.\n4. Status for actionable mutations (EGFR, ALK, ROS1, RET, etc.) must be known (when testing is available as per country\/region standard of care practices); patients with actionable mutations must have received and progressed on, have been intolerant to, or not be a candidate for standard TKIs (as available per country\/region standard of care practices).\n5. Willing and able to provide the most recently available tissue blocks representing tumor biopsy obtained prior to treatment initiation. If recent tissue is not available, then a newly obtained baseline biopsy of an accessible tumor is required. Note that \"recent\" is defined as no intervening systemic anticancer therapies from the time of the last treatment of the prior therapy until screening for this trial.\n6. Willing to undergo on-treatment biopsies, if safe and medically feasible.\n\nExclusion Criteria:\n\n1. Patients must not have had chemotherapy, radiotherapy (other than palliative bone- directed radiotherapy, as described in in exclusion criterion #2), or major surgery, or received another investigational agent within 28 days or 5 half-lives of the drug (if known), whichever is shorter, before the start of study treatment.\n2. Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids.\n\n   a. Note: Two weeks or fewer of palliative radiotherapy for non-central nervous system (CNS) disease is permitted. The last radiotherapy treatment must have been performed at least 7 days before the first dose of study intervention.\n3. Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.\n4. Concurrent anticancer treatment (eg, cytoreductive therapy, radiotherapy \\[except for palliative bone-directed radiotherapy, which is not a target lesion\\], immune therapy, or cytokine therapy \\[except for erythropoietin\\]), major surgery (excluding prior diagnostic biopsy), concurrent systemic therapy with steroids or other immunosuppressive agents, or use of any investigational drug within 28 days or 5 half-lives of the drug (if known), whichever is shorter, before the start of study treatment. Short-term administration of systemic steroids (eg, for allergic reactions or the management of irAEs) is allowed. Note: Patients receiving bisphosphonate or denosumab are eligible, provided treatment was initiated at least 14 days before the first dose of DF9001.\n5. Previous malignant disease other than the target malignancy to be investigated in this study within the last 3 years. Exceptions (eg, basal or squamous cell carcinoma of the skin, or cervical carcinoma in situ) can be considered on a case-by-case basis, in consultation with the Medical Monitor.\n6. Life expectancy of less than 6 months.\n7. Receipt of any organ transplantation, including autologous or allogeneic stem-cell transplantation.\n8. Significant acute or chronic infections (including historic positive test for human immunodeficiency virus \\[HIV\\], or active or latent hepatitis B or active hepatitis C tested during the screening window). If HBsAg is negative and the anti-hepatitis B core antibody is positive, then hepatitis B viral DNA load must be undetectable.\n9. Preexisting autoimmune disease (except for patients with vitiligo) needing treatment with systemic immunosuppressive agents for more than 28 days within the last 3 years, or clinically relevant immunodeficiencies (eg, dysgammaglobulinemia or congenital immunodeficiencies). Patients with a history of immune-related endocrinopathies (eg, hypothyroidism, type 1 diabetes mellitus \\[TIDM\\], and adrenal insufficiency) that are stable on hormone replacement therapy may be eligible for this study.\n10. Patients with a known medical history that may place them at risk of known toxicities of EGFR blockade.\n\n    1. History of or ongoing keratitis, ulcerative keratitis, or corneal perforation.\n    2. History of cardiopulmonary arrest unless this was caused by an acute, reversible etiology that is no longer present.\n    3. History of or ongoing pulmonary fibrosis or interstitial lung disease.\n11. Known severe hypersensitivity reactions to mAbs (\u2265 Grade 3 of the NCI-CTCAE v5.0), any history of anaphylaxis, or uncontrolled asthma (ie, 3 or more features of partly controlled asthma).\n12. Persisting toxicity related to prior therapy \\>Grade 1 NCI-CTCAE v5.0; however, alopecia \u2264Grade 2, endocrinopathies \u2264Grade 2, and sensory neuropathy \u2264 Grade 2 is acceptable.\n13. Patients who have received an anti-PD-(L)1 as a previous line of therapy that have experienced either of the following:\n\n    1. a Grade 3 or Grade 4 drug-related toxicity.\n    2. a Grade 2 drug-related toxicity that impacted either the lungs, cardiac, or the nervous system, caused by the administration of the anti-PD-(L)1.\n14. Received any prior immunotherapy and was discontinued from that treatment due to a Grade 3 or higher irAE (except endocrine disorders that can be treated with replacement therapy) or was discontinued from that treatment due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis.\n15. A WOCBP who has a positive urine pregnancy test (within 72 hours) prior to treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n16. Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention. Administration of killed vaccines are allowed.\n17. Pregnancy or lactation in females during the study.\n18. Known alcohol or drug abuse.\n19. Serious cardiac illness or medical conditions, including but not limited to:\n\n    1. History of New York Heart Association class III or IV heart failure or systolic dysfunction (left ventricular ejection fraction \\[LVEF\\] \\<55%).\n    2. High-risk uncontrolled arrhythmias (eg, tachycardia with a heart rate \\>100\/min at rest).\n    3. Significant ventricular arrhythmia (ventricular tachycardia) or higher-grade atrioventricular (AV) block (eg, AV-block, second degree AV block Type 2 \\[Mobitz 2\\], or third-degree AV-block).\n    4. Angina pectoris requiring anti-anginal medication.\n    5. Clinically significant valvular heart disease.\n    6. Evidence of transmural infarction on electrocardiograms (ECGs).\n    7. Poorly controlled hypertension (defined as systolic \\>160 mm Hg or diastolic \\>100 mm Hg).\n    8. Clinically relevant uncontrolled cardiac risk factors, clinically relevant pulmonary disease, or any clinically relevant medical condition in the opinion of the Investigator that may limit participation in this study.\n    9. Severe dyspnea at rest due to complications of advanced malignancy or requiring supplementary oxygen therapy.\n20. All other significant diseases (eg, inflammatory bowel disease), which, in the opinion of the Investigator, might impair the patient's ability to participate.\n21. Any psychiatric condition that would prohibit the understanding or rendering of informed consent.\n22. Legal incapacity or limited legal capacity.\n23. Incapable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.\n24. Has received radiation therapy to the lung that is \\>30 Gy within 6 months of the first dose of study treatment (for NSCLC cohorts only).\n25. Patients with brain metastases, unless all of the following criteria are met:\n\n    1. CNS lesions are asymptomatic, previously treated and no active therapy is required (ie, no corticosteroids for edema),\n    2. Radiologically stable (ie, without evidence of progression) for at least 4 weeks as confirmed by repeat imaging performed during the study screening, are clinically stable and have not required steroid treatment for at least 14 days before the first dose of study intervention.\n    3. Imaging demonstrates stability of disease 28 days from last treatment for CNS metastases.\n26. Active autoimmune disease that has required systemic treatment in past 2 years except replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid).\n27. Patients with leptomeningeal disease are excluded.\n28. History of (noninfectious) pneumonitis\/interstitial lung disease that required steroids or has current pneumonitis\/interstitial lung disease.\n29. Active infection requiring systemic therapy.\n30. Severe hypersensitivity (\u2265Grade 3) to pembrolizumab, and\/or any of its excipients.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05597839017","EMAIL":[{}],"GEO":[43.07305,-89.40123]},{"TITLE":"A Trial of AK112 (PD-1\/VEGF Bispecific Antibody) in Patients With NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Has a histologically or cytologically confirmed diagnosis of NSCLC.\n* Has StageIIIB\/C or IV NSCLC (American Joint Committee on Cancer \\[AJCC\\]).\n* 18 to 75 years old (at the time consent is obtained).\n* Be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures).\n* Be able to provide formalin fixed, paraffin-embedded (FFPE) tumor tissue obtained from either a core or excisional tumor biopsy.\n* Has a life expectancy of at least 3 months.\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the site study team.\n* Has adequate organ function.\n* Has recovered from the effects of any prior radiotherapy or surgery.\n* All female and male subjects of reproductive potential must agree to use an effective method of contraception, as determined by the Investigator, during and for 120 days after the last dose of study treatment.\n\nExclusion Criteria:\n\n* Is currently participating in a study of an investigational agent or using an investigational device.\n* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy within 2 years prior to the first dose of study treatment.\n* Has undergone major surgery within 30 days of Study Day 1.\n* Has a known additional malignancy that is progressing or requires systemic treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.\n* Has known active central nervous system (CNS) metastases.\n* Has carcinomatous meningitis.\n* Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n* Has an active infection requiring systemic therapy.\n* Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \\[qualitative\\] is detected).\n* History of myocardial infarction, unstable angina, congestive heart failure within 12 months prior to day 1 of study treatment.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of this subject to participate, in the opinion of the treating investigator.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.\n* Has received a live virus vaccine within 30 days of the planned first dose of study therapy.\n* Is pregnant, breastfeeding, or expecting to conceive or father a child within the projected duration of the study including 120 days following the last dose of study treatment.\n* Has any concurrent medical condition that, in the opinion of the Investigator, would complicate or compromise compliance with the study or the well-being of the subject.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"04900363001","EMAIL":[{"email":"caicunzhoudr@163.com"},{}],"GEO":[31.22222,121.45806]},{"TITLE":"A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery","CRITERIA":"Inclusion Criteria:\n\nCohort 1:\n\n* Participants who have diagnosed with unresectable stage IIIB\/IIIC\/IV NSCLC\n* Participants who have been diagnosed six months before the start of the study were required to have two complete tumor assessments within at least 6 months intervals after the diagnosis\n* Participants who were newly diagnosed within six months before the start of the study were required to have complete baseline information (see section 6.4.1)\n* Participants who have received standard first-line treatment defined by guideline CSCO (https:\/\/www.csco.org.cn\/cn\/index.aspx) and NCCN (https:\/\/www.nccn.org\/)\n\nCohort 2:\n\n* Participants who are newly diagnosed with unresectable Stage IIIB\/IIIC\/IV NSCLC after the start of the study\n* Participants who are able to be followed up by the participating site\n* Participants planned to receive first line anti-cancer treatment targeting unresectable stage IIIB\/IIIC\/IV NSCLC in the study site after study initiation\n\nExclusion Criteria:\n\n* Participants who have received prior systematic treatment for unresectable Stage IIIB\/IIIC\/IV NSCLC\n* Participants who have participated in any anti-cancer, regimen-specified clinical study of first-line treatment for unresectable Stage IIIB\/IIIC\/IV NSCLC","SEX":"ALL","AGE_MIN":0,"AGE_MAX":200,"SS_ID":"05872763006","EMAIL":"global-roche-genentech-trials@gene.com","GEO":[34.75778,113.64861]},{"TITLE":"A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of locally advanced, unresectable (Stage IIIB, IIIC), or metastatic Stage IV (M1a, M1b, or M1c) NSCLC\n* Participants must have NSCLC with nonsquamous histology\n\n  * Tumors with squamous, or predominantly squamous histology are excluded.\n  * Tumors with small cell elements are excluded.\n* Participants who have NSCLC with known actionable genomic alteration (AGAs) are permitted\n* Participants must have received the following prior therapies and progressed during or relapsed after receiving their most recent prior therapy:\n\n  * Participants with no known AGAs must fulfill 1 of the following conditions:\n\n    * Received a platinum-based combination therapy for the treatment of metastatic or recurrent disease and a PD-(L)1 monoclonal antibody (concurrently or sequentially with platinum-based chemotherapy), unless contraindicated.\n    * Experienced disease progression within 6 months of the last dose of platinum-based chemotherapy in the adjuvant or neoadjuvant setting and received a PD-(L)1 monoclonal antibody at any time during the course of treatment.\n  * Participants with known AGAs must fulfill the following conditions:\n\n    * Must have received at least 1 relevant AGA targeted therapy and in the opinion of the investigator, additional AGA targeted therapy is not in the best interest of the participant.\n    * Received a platinum-based combination therapy for the treatment of metastatic or recurrent disease, or experienced disease progression within 6 months of the last dose of platinum-based chemotherapy in the adjuvant or neoadjuvant setting\n    * May have received up to 1 PD-(L)1 monoclonal antibody (concurrently or sequentially with platinum-based chemotherapy).\n* Measurable disease based on RECIST v1.1\n* Eastern cooperative Oncology Group (ECOG) performance status score of 0 or 1\n\nExclusion Criteria:\n\n* Life expectancy of less than (\\<) 3 months\n* Known allergies\/hypersensitivity\/intolerance to or contraindication of taxanes, docetaxel, or any excipient contained in the drug formulation of sigvotatug vedotin\n* History of another malignancy within 3 years before Cycle 1 Day 1, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death\n* Participants with any of the following respiratory conditions:\n\n  * Evidence of noninfectious interstitial lung disease (ILD) or pneumonitis that:\n\n    * Was previous diagnosed and required systemic steroids, or\n    * Is currently diagnosed and managed, or\n    * Is suspected on radiologic imaging at screening\n  * Known diffusing capacity of the lung for carbon monoxide (DLCO) \\< 50%\n  * Any Grade greater than or equal to (\u2265) 3 pulmonary disease unrelated to underlying malignancy\n* Pre-existing peripheral neuropathy Grade greater than or equal to (\u2265) 2\n* Uncontrolled diabetes mellitus\n* Prior therapy:\n\n  * Prior treatment with antimicrotubule agents (taxanes, vinca alkaloids, or MMAEs) in the locally advanced, unresectable, or metastatic setting\n  * Received more than 1 prior line of cytotoxic chemotherapy in the locally advanced, unresectable, or metastatic setting\n  * At least 14 days must have elapsed from the last dose of radiotherapy until Cycle 1 Day 1.\n  * Prior radiation therapy to the lung parenchyma that is \\>30 Gray (Gy) within 6 months of Cycle 1 Day 1.\n  * Any systemic anticancer therapy (standard or experimental) within 21 days prior to Cycle 1 Day 1.\n* Active central nervous system (CNS) lesions, including leptomeningeal metastasis, are excluded. Participants with definitively treated brain metastases are eligible in they meet the following criteria:\n\n  * Have been clinically stable for at least 4 weeks prior to treatment initiation and baseline scans show no evidence of new or enlarged metastasis\n  * On a stable dose of less than or equal to (\u2264) 10mg\/day of prednisone or equivalent for a least 2 weeks (if requiring steroid treatment)\n  * Treatment with corticosteroids greater than (\\>) 1 month prior to Screening visit\n  * No evidence of clinical and radiographic disease progression in the CNS for \u2265 21 days after definitive radiotherapy and\/or surgery","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06012435112","EMAIL":[{}],"GEO":[22.61626,120.31333]},{"TITLE":"A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors","CRITERIA":"Major Inclusion Criteria:\n\n* Age \u226518 years\n* Patients with histologically confirmed locally advanced or metastatic solid tumors who have disease progression, intolerance to prior therapy, are ineligible for available therapies, or refuse standard of care therapy in the metastatic setting.\n* In Part A, patients with solid tumors including but not limited to NSCLC (adenocarcinoma and squamous cell carcinoma), breast cancer, KRAS-wild type colorectal cancer, and head \\& neck cancer based on previous biopsy result.\n* In Part B, Cohort 1 will exclusively include NSCLC patients with documented EGFR mutations based on previous biopsy result and Cohort 2 will be patients with other cancer(s) suggested to have sensitivity to CPO301 in Part A.\n* At least 1 measurable target lesion present and documented by CT or MRI according to RECIST v1.1\n* ECOG performance status 0 or 1 at screening\n* Life expectancy \\>12 weeks\n\nMajor Exclusion Criteria:\n\n* Known, active, or uncontrolled central nervous system (CNS) metastasis or carcinomatous meningitis.\n* Has AEs due to previous anti-tumor treatments not recovered to \u2264Grade 1 (except for alopecia; some tolerable chronic toxicities of Grade 2 may be excluded after consultation with the sponsor, as judged by the investigator) according to NCI-CTCAE v5.0.\n* Any serious and\/or uncontrolled concurrent illness that may interfere with study participation\n\nPrior therapy\n\n* Received other investigational drugs or treatments within 4 weeks before the first dose of the investigational drug in the study\n* The time interval between the latest anti-tumor treatment and the first dose of the investigational drug meets the following requirements: Have received anti-tumor treatments such as chemotherapy, radiotherapy, targeted therapy, immunotherapy and other clinical investigational drugs within 4 weeks before the first dose of the investigational drug; have received oral fluoropyrimidines, small molecule targeted drugs within 2 weeks before the first dose of the investigational drug; have received palliative radiotherapy or local therapy within 2 weeks before the first dose of investigational drug.\n* Had major surgery within 4 weeks before the first dose of the investigational drug in the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05948865013","EMAIL":[{}],"GEO":[43.70011,-79.4163]},{"TITLE":"Comparison Between Wedge Resection and Segmentectomy for Ground Glass Opacity- Dominant Stage IA NSCLC","CRITERIA":"Inclusion criteria:\n\n1. Preoperative thin-section computed tomography (TSCT) will fulfill all of the following conditions:\n\n   * Lung cancer is suspected.\n   * Lesion size is more than 5 mm but equal to or less than 20 mm.\n   * Consolidation\/tumor (C\/T) ratio is equal to or less than 0.25.\n   * The center of the tumor is located in the outer third of the lung field.\n   * Preoperative TSCT estimates a surgical margin of more than1.5 cm or the tumor's diameter.\n2. Preoperative clinical staging: T1a-T1bN0M0 (according to UICC2017-8thTNM staging).\n3. R0 resectable in segmentectomy and wedge resections plus mediastinal lymph node resection.\n4. Aged 18 to 75 years old.\n5. No prior chemotherapy or thoracic radiation therapy for any malignant diseases.\n6. Preoperative FEV1.0\\>=1.0 L.\n7. Performance status of ECOG 0 or 1.\n8. Preoperative ASA scoring (American society of anesthesiology) class I -III.\n9. Sufficient organ functions.\n10. The patient agrees to participate in the trial and signs the informed consent form.\n\nExclusion criteria:\n\n1. Quit smoking \\<2 weeks.\n2. Preoperative FEV1 \\< 50% of the expected value.\n3. Mediastinal lymph node metastasis confirmed by biopsy.\n4. Pregnant or lactating women.\n5. Serious mental illness.\n6. With other malignant disease history within 5 years.\n7. With the history of unstable angina or myocardial infarction within 6 months.\n8. With the history of cerebral infarction or cerebral hemorrhage within 6 months.\n9. With the history of sustained systemic corticosteroid therapy within 1 month.\n10. The patient requires simultaneous surgical treatment of other diseases.\n11. TSCT shows that the lesion is located in the right middle lobe.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"02718365001","EMAIL":[{},{},{}],"GEO":[30.66667,104.06667]},{"TITLE":"[68Ga]Ga-NOTA-RW102 PET Imaging in the Diagnosis of PD-L1-expressing Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Patients with PD-L1-positive non-small cell lung cancer\n\n  1. Age between 18 and 65 years old, gender is not limited.\n  2. Patients with CT findings that can be occupied on the lung with a diameter greater than 1cm or more who have not undergone surgery.\n  3. Lung cancer patients with a clinical diagnosis of positive PD-L1 expression;\n  4. Written informed consent must be signed by the subject or his\/her legal guardian or caregiver.\n  5. Willingness and ability to cooperate with all programs of this study.\n\nExclusion Criteria:\n\n* Subjects meeting any of the following criteria will be excluded from the study:\n\n  1. Severe hepatic and renal insufficiency;\n  2. Targeted therapy prior to radiotherapy or PET\/CT scan. PD-L1 expression in existing lesions was assessed by immunohistochemistry using antibody clone 22C3. Renal function: serum creatinine less than or equal to the upper limit of the normal range;\n  3. Liver function: bilirubin, AST(SGOT)\/ALT(SGPT) less than or equal to the upper limit of the normal range.\n  4. History of serious surgery in the last month.\n  5. Those who have participated in other clinical trials during the same period.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":65,"SS_ID":"06165874001","EMAIL":[{"email":"guanyihui@hotmail.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"A Study of NX-1607 in Adults With Advanced Malignancies","CRITERIA":"Key Inclusion Criteria:\n\n* Age \u2265 18 years.\n* Measurable disease per disease-specific response criteria.\n* Patients must have disease that is metastatic or unresectable and have received standard treatment options, are not candidates for standard treatment options, or will otherwise be prevented from receiving any standard treatment options.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Minimum of 3 weeks or 5 half-lives (whichever is shorter) since last dose of systemic cancer therapy (unless otherwise specified) or minimum of 2 weeks since last radiotherapy, or minimum of 6 weeks since last systemic therapy with nitrosoureas, antibody-drug conjugate, or radio immuno-conjugate therapy.\n* Adequate organ and bone marrow function, in the absence of growth factors (with limited exception for DLBCL), as defined by laboratory parameters.\n* Patients of child-bearing potential must use adequate contraceptive measures to avoid pregnancy for the duration of the study as defined in the protocol.\n* Patient must be willing and able to adhere to the prohibitions and restrictions specified in the protocol.\n* Each patient must sign an informed consent form (ICF).\n* Histological or cytological diagnosis of platinum-resistant EOC, including primary peritoneal and fallopian tube carcinoma; gastric\/GEJ cancer; HNSCC; recurrent and either metastatic or unresectable melanoma; NSCLC; mCRPC; MPM; TNBC; locally advanced or metastatic urothelial cancer; cervical cancer; MSS CRC; or DLBCL (including DLBCL-RT)\n* Accessible tumor (for all cohorts) or lymph node (DLBCL only) for biopsy (Phase 1b only).\n\nKey Exclusion Criteria:\n\n* Active untreated brain metastases.\n* Patient has any of the following:\n* Uncontrolled intercurrent illness including, but not limited to, poorly controlled hypertension or diabetes, or ongoing active infection requiring systemic therapy.\n* Patients with primary refractory EOC defined as patients who do not respond to their first platinum-containing regimen or who relapse less than 6 months after completion of that first platinum-containing regimen\n* Psychiatric illness that would limit compliance with study requirements.\n* Treatment with any of the following prior to the first dose of NX-1607: CPI (anti-PD-1, PD-L1, cytotoxic T-lymphocyte-associated protein 4, etc) within 3 weeks; autologous or allogeneic stem cell transplant within 100 days; prior systemic cancer therapy within 3 weeks or 5 half-lives (whichever is shorter) (unless otherwise specified) (including hormonal therapy except for hormonal prophylaxis for a prior malignancy); prior radiotherapy within 2 weeks; prior systemic therapy with nitrosoureas, antibody-drug conjugate, or radio-immuno-conjugate therapy within 6 weeks; use of strong or moderate CYP3A4 inducers or inhibitors within 14 days or 7 days, respectively, or 5 half-lives (whichever is longer)\n* History of CAR-T therapy within 30 days prior to the first dose of NX-1607.\n* Toxicities from previous anti-cancer therapies that have not resolved to baseline levels or to Grade 1 or less except for Grade 2 alopecia and Grade 2 peripheral neuropathy or patients receiving endocrine replacement therapy\n* Patients who experienced Grade 3 or higher irAEs with prior immunotherapy.\n* History of uveitis, or an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.\n* Unable to swallow capsules or has malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction likely to interfere with the delivery, absorption, or metabolism of NX-1607.\n* Known allergies, hypersensitivity, or intolerance to components of NX-1607.\n* Pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of NX-1607.\n* Patient is a man who plans to father a child while enrolled in this study or within 3 months after the last dose of NX-1607 and, as applicable, within 6 months after the last dose of paclitaxel.\n* Patient has had major surgery (e.g., requiring general anesthesia) within 4 weeks before the planned first dose of NX-1607, or will not have fully recovered from surgery, or has surgery planned during the time the patient is expected to participate in the study or within 4 weeks after the last dose of NX-1607. Note: Patients with minor planned surgical procedures to be conducted under local anesthesia may participate.\n* Vaccinated with a live vaccine within 28 days (with the exception of the annual inactivated influenza vaccine) or COVID-19 vaccination within 14 days prior to the first dose of NX-1607.\n* Active known second malignancy with the exception of any of the following:\n\n  * Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer.\n  * Adequately treated Stage I cancer from which the patient is currently in remission and has been in remission for \u2265 2 years.\n  * Low-risk prostate cancer with Gleason score \\< 7 and PSA \\< 10 ng\/mL.\n  * Any other cancer from which the patient has been disease-free for \u2265 2 years.\n* Infection with human immunodeficiency virus (HIV)-1 or HIV-2. Exception: Patients with well controlled HIV (e.g., CD4 \\> 350\/mm3 and undetectable viral load) are eligible.\n* Current active hepatitis, including hepatitis A (hepatitis A virus immunoglobulin M \\[IgM\\] positive), hepatitis B (hepatitis B virus \\[HBV\\] surface antigen positive), or hepatitis C (hepatitis C virus \\[HCV\\] antibody positive, confirmed by HCV RNA). Patients with HCV with undetectable virus after treatment are eligible. Patients with prior exposure to HBV may be entered if quantitative PCR is negative.\n* Use of systemic corticosteroids (\\> 20 mg prednisone or equivalent) within 15 days (except for prophylaxis for radio diagnostic contrast reactions and\/or prophylaxis for patients receiving paclitaxel), or other immunosuppressive drugs within 30 days, prior to the first dose of NX-1607.\n* Use of biotin (i.e., Vitamin B7) or supplements containing biotin higher than the daily adequate intake of 30 \u00b5g \\[NIH 2020\\] (Note: Patients who switch from a high dose to a dose of 30 \u00b5g\/day or less at least 1 day prior to Screening assessments are eligible for study entry).\n* Receipt of an IP or has been treated with an investigational device within 3 weeks or 5 half-lives (whichever is shorter) prior to the first dose of NX-1607.\n* Any of the following within 6 months prior to the first dose of NX-1607 or ongoing:\n\n  * Myocardial infarction\n  * Unstable angina\n  * Unstable symptomatic ischemic heart disease\n  * New York Heart Association Class III or IV heart failure\n  * Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events)\n  * Any other significant cardiac condition (e.g., pericardial effusion, restrictive cardiomyopathy, severe untreated valvular stenosis, or severe congenital heart disease)\n  * Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating Investigator in consultation with the Medical Monitor.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05107674020","EMAIL":"nx1607101@nurixtx.com","GEO":[51.75222,-1.25596]},{"TITLE":"A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Participants must have a confirmed diagnosis of Stage IIIC, IIID, or IV unresectable or metastatic melanoma (Cohort 1) or Stage III or IV NSCLC (Cohort 2).\n2. Participants who have received the following previous therapy:\n\n   1. Cohort 1 (melanoma): Participants who have progressed within 12 weeks of last dose of anti-PD-1\/PD-L1 blocking antibody and received BRAF\/MEK inhibitor in those with BRAF mutations.\n   2. Cohort 2 (NSCLC): Participants who should have received no more than 3 prior lines of therapy and:\n\n      * those without oncogene-driven tumors: Have progressed within 12 weeks after last dose of anti-PD-1\/PD-L1 blocking antibody\n      * those with oncogene-driven tumors: Have progressed during\/after \u22651 targeted therapy AND either:\n\n        * platinum doublet chemotherapy\n        * Or within 12 weeks after last dose of anti-PD-1\/PD-L1 blocking antibody\n3. Participants who have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n4. Participants who is assessed as having at least one resectable lesion.\n5. Participants who have at least one measurable lesion, following resection of the lesion for IOV-4001 generation.\n6. Participants who have adequate organ function.\n7. Cardiac function test required.\n8. Pulmonary function test may be required.\n9. Participants of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control during treatment and up to 12 months.\n\nExclusion Criteria:\n\n1. Participants who have melanoma of uveal\/ocular origin.\n2. Participants who have symptomatic untreated brain metastases.\n3. Participants who have had a history of allogeneic organ transplant or any form of cell therapy involving prior conditioning chemotherapy within the past 20 years.\n4. Participants who require systemic steroid therapy \\> 10 mg\/day prednisone or another steroid equivalent dose.\n5. Participants who have any form of primary immunodeficiency.\n6. Participants who have another primary malignancy within the previous 3 years.\n7. Participants who have received or will receive a live or attenuated vaccination within 28 days prior to the start of the NMA-LD.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05361174009","EMAIL":"Clinical.Inquiries@iovance.com","GEO":[43.0389,-87.90647]},{"TITLE":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation","CRITERIA":"Inclusion Criteria:\n\n* Histologically documented advanced or metastatic solid tumor with KRAS G12C mutation.\n* Women of childbearing potential must agree to remain abstinent or use contraception, and agree to refrain from donating eggs during the treatment period and after the final dose of study treatment as specified in the protocol.\n* Men who are not surgically sterile must agree to remain abstinent or use a condom, and agreement to refrain from donating sperm during the treatment period and after the final dose of study treatment as specified in the protocol.\n\nExclusion Criteria:\n\n* Active brain metastases.\n* Malabsorption or other condition that interferes with enteral absorption.\n* Clinically significant cardiovascular dysfunction or liver disease.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04449874075","EMAIL":"global-roche-genentech-trials@gene.com","GEO":[53.48095,-2.23743]},{"TITLE":"Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI","CRITERIA":"Inclusion Criteria:\n\n1. Patients signed informed consent, willing to accept this regimen, able to adhere to the medication, and had good compliance.\n2. Patients with advanced or metastatic non-small cell lung cancer (stage IIIB, IIIC, or IV according to the AJCC staging system, 8th edition) diagnosed by histopathology or cytopathology\n3. Histologically or cytologically confirmed, locally advanced or metastatic nonsquamous non-small-cell lung cancer (stage IIIB, IIIC, or IV according to the AJCC staging manual, 8th edition) patients with EGFR sensitive mutations (confirmed by tumour histology, cytology, or cell-free or circulating tumour DNA) progressed after receiving EGFR tyrosine-kinase inhibitor therapy; confirmed EGFR Thr790Met negative mutation status after receiving first-generation, second-generation or third-generation EGFR tyrosine-kinase inhibitor as first-line or second-line treatment\n4. Eastern Cooperative Oncology Group performance status of 0 to 2\n5. Presence of at least one measurable lesion\n6. An estimated life expectancy of at least 3 months\n7. Good organ function was defined as hemoglobin\u226590g\/L (no blood transfusion within 7 days), absolute neutrophil count \u22651.5\u00d7109\/L, and platelet count\u2265100\u00d7109\/L. Total bilirubin level\u22641.5 times of the upper limit of normal value (ULN), albumin \u226530g\/L, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u22642.5 times of upper limit of normal (ULN), in cases with liver metastasis, AST and ALT\u22645 times of ULN; Creatinine \u22641.5 times of ULN; International normalized ratio (INR) or prothrombin time (PT) \u22641.5 times of ULN, if the participant is receiving anticoagulant therapy normally, as long as the PT is within the prescribed range of anticoagulant drugs\n\nExclusion Criteria:\n\n1. Concomitant driver mutations for which there were known therapies were identified, including but not limited to ALK rearrangement, ROS1 fusion, or BRAF V600E mutation\n2. Previously received systemic anti-tumour therapy (including cytotoxic chemotherapy and antiangiogenic therapy) except EGFR tyrosine-kinase inhibitors for advanced NSCLC\n3. Previously received immunotherapy (including anti-PD-1, anti-PD-L1, or anti-CTLA-4) antibodies or agents\n4. The presence of an active malignancy within 2 years prior to the first dose was not allowed. Participants with locally cured tumors, such as basal-cell carcinoma or squamous-cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ of the breast, were not excluded\n5. The enrollment of another clinical study was excluded except for observational or noninterventional studies or interventional studies with a follow-up period exceeding four weeks after the last dose of the study drug or more than five half-lives of the study drug\n6. Patients received systemic treatment with Chinese patent medicine or Chinese herbal medicine exhibiting anti-tumor properties or immunomodulatory drugs (such as thymosin, interferon, interleukin) indicated for anti-tumor purposes within a 2-week period prior to the initial dosage\n7. Participants with an active, known, or suspected autoimmune disease or a history of autoimmune disease are excluded from the study, except for those with Vitiligo, alopecia, Graves' disease, psoriasis, or eczema that do not require systemic treatment for nearly 2 years. Additionally, Participants with asymptomatic hypothyroidism (due to autoimmune thyroiditis) or stable doses of hormone replacement therapy and type I diabetes requiring only stable doses of insulin replacement therapy are also exempted. Furthermore, participants who had childhood asthma that has completely resolved and no longer require any intervention in adulthood or whose disease does not recur without an external trigger are eligible for inclusion\n8. Participants who have received systemic treatment with corticosteroids (prednisone equivalent dose \\> 10 mg\/day) or other immunosuppressive drugs within 14 days prior to the first dose are excluded\n9. Documented history of immunodeficiency\n10. Documented history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation\n11. Major surgical procedures (such as laparotomy, thoracotomy, viscerectomy, etc.) or severe trauma within 28 days prior to the initial administration (intravenous drip replacement is acceptable); Surgery aimed at improving or reducing the risk of oncologic complications within 14 days before the first dose; Or incomplete recovery from any of the aforementioned previous surgeries. Major surgical procedures were planned (at the investigator's discretion) within 30 days after the initial dose. Local surgery (e.g., placement of systemic ports, core needle biopsy) was permitted if performed at least 24 hours prior to initiation of study treatment\n12. Patients with a medical history of gastrointestinal perforation, gastrointestinal fistula, or female genital fistula (such as vesicovaginal fistula, urethrovaginal fistula, etc.) within the past 6 months prior to the initial drug administration were eligible for enrollment if the perforation or fistula had been surgically treated (e.g., excision or repair) and if complete recovery or resolution of the condition was confirmed by the investigator\n13. The presence of interstitial lung disease, whether symptomatic or not, may hinder the detection or management of suspected drug-related pulmonary toxicity\n14. The presence of active pulmonary tuberculosis (TB). Patients suspected to have active TB underwent examination through chest X-ray and sputum analysis, while being assessed for clinical signs and symptoms","SEX":"ALL","AGE_MIN":65,"AGE_MAX":200,"SS_ID":"06277674001","EMAIL":[{"email":"haibozh@gzucm.edu.cn"}],"GEO":[23.11667,113.25]},{"TITLE":"A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS\/MAPK Mutation-Positive Cancers","CRITERIA":"Key Inclusion Criteria:\n\n1. Disease criteria:\n\n   1. Histologically or cytologically confirmed recurrent\/advanced (unresectable) or metastatic solid tumors or histiocytic neoplasms with documented RAS or BRAF mutations.\n\n      Note: Patients may have stable central nervous system (CNS) metastases. Patients with active CNS metastases or primary CNS tumors associated with progressive neurological symptoms or needing increased doses of corticosteroids to control the CNS disease are excluded from the study.\n   2. Dose Escalation cohorts:\n\n      * NSCLC with KRAS non-G12C mutations, including other mutations at KRAS-G12 (eg, G12V\/G12D) and other oncogenic variants of KRAS mutations on G13 and Q61 amino acid residues, BRAF, or CRAF mutations.\n      * Melanoma with BRAF, CRAF, or NRAS mutations.\n      * Histiocytic neoplasms with BRAF or NRAS mutations.\n      * Thyroid carcinoma with BRAF mutations.\n      * Colorectal carcinoma with BRAF (Class II or III) mutations with Sponsor approval.\n      * Other solid tumors with BRAF Class I mutations after prior treatment with a BRAF\/MEK inhibitor or local standard-of-care with Sponsor approval.\n   3. Dose Expansion cohort:\n\n   Recurrent advanced\/metastatic NSCLC with KRAS non-G12C mutations without small cell lung cancer transformation with progressive disease confirmed by radiographic assessment.\n2. Prior standard-of-care\n\n   For dose levels \\<200 mg once daily and\/or not at preliminary RP2D(s):\n   1. Exhausted all available standard-of-care therapies or, in the opinion of the Investigator, would be unlikely to tolerate or derive clinically meaningful benefit from available standard-of-care therapy.\n   2. Patients with eligible tumors harboring BRAF V600E mutations must have received FDA approved BRAF targeted therapy, BRAF\/MEK inhibitors combination, or BRAF inhibitors combination.\n\n   For dose levels \u2265200 mg once daily or at preliminary RP2D(s):\n\n   a. Patients must have received at least 1 but no more than 2 prior lines of systemic therapy for metastatic\/advanced disease (adjuvant and maintenance therapy do not count towards the limit).\n3. Evaluable or measurable disease in dose escalation and measurable disease only for dose expansion cohorts.\n4. Adequate bone marrow and organ function.\n5. Recovered from toxicity to prior anti-cancer therapy.\n6. Appropriate candidate for BDTX-4933 monotherapy.\n7. Life expectancy of \\>=12 weeks in the opinion of the Investigator.\n\nKey Exclusion Criteria:\n\n1. Cancer that has a known MEK1\/2 mutation.\n2. Major surgery within 4 weeks of study entry or planned during study.\n3. Ongoing anticancer therapy.\n4. Ongoing radiation therapy.\n5. Uncontrolled or active clinically relevant bacterial, fungal, or specific viral infection requiring systemic therapy.\n6. Symptomatic spinal cord compression.\n7. Evidence of active malignancy (other than study-specific malignancies) requiring systemic therapy within the next 2 years.\n8. History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO.\n9. Females who are pregnant or breastfeeding.\n10. Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study.\n11. Prior use of experimental agents that target the KRAS\/BRAF\/MEK\/ERK pathway.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05786924014","EMAIL":[{"email":"rwood1@seattlecca.org"}],"GEO":[47.60621,-122.33207]},{"TITLE":"PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung","CRITERIA":"Inclusion Criteria:\n\n* Histologically documented recurrent and\/or metastatic non-small cell lung cancer\n* Progression after prior PD-1 directed therapy (as monotherapy or in combination with chemotherapy and\/or anti-CTLA4, or anti-VEGF agents) - defined as investigator assessed progression from prior treatment\n* If molecularly altered NSCLC including EGFR, ALK, ROS1, MET exon 14, RET, BRAF, NTRK, progression on prior targeted therapy is required\n* Measurable disease by RECIST 1.1\n* ECOG Performance Status 0 or 1\n* Signed written informed consent\n* Minimum of 4 weeks from any other experimental anti-cancer therapies or prior PD-1 treatment\n* Meet all the laboratory criteria per protocol\n\nExclusion Criteria:\n\n* Prior treatment with PCSK9 inhibitors\n* Cardiac issues including MI, uncontrolled arrhythmia, symptomatic angina pectoris, active ischemia, or cardiac failure not controlled by medications.\n* Uncontrolled diabetes mellitus, defined as HbA1c \\> 10\n* Major surgery less than 4 weeks prior to study enrollment\n* Another malignant condition diagnosed within 3 years of study enrollment\n* Intolerance to prior PD-1\/L1 treatment including discontinuation for severe or recurrent severe toxicity (including myocarditis or other myocardiotoxity, encephalitis, colitis, diarrhea, pancreatitis, hypo\/hyperthyroidism, hypopituitarism, adrenal insufficiency, rash, autonomic neuropathy, myasthenia gravis, Guillain-Barre, myositis\/polymyositis, hepatitis, Type 1 Diabetes, thrombocytopenia) or developed an immune checkpoint blockade related immune adverse event that was refractory to steroids and required additional systemic immunosuppressive medication.\n* Known history of HIV seropositivity or known acquired immunodeficiency syndrome (AIDS)\n* Additional exclusion criterion as per listed in the protocol","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05553834002","EMAIL":[{},{}],"GEO":[35.99403,-78.89862]},{"TITLE":"Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm","CRITERIA":"Inclusion Criteria:\n\n* The participant (or legally acceptable representative if applicable) must provide written informed consent for the study. The participant may also provide consent for future unspecified research samples. However, the participant may participate in the study without participating in the future unspecified research sample collection. NOTE: Initial informed consent will remain valid throughout the 12-week period between surgical resection and study registration unless, in the opinion of the treating investigator, the participant experiences a significant change in medical or mental status.\n* Males and females age \u2265 18 years at the time of consent.\n* ECOG Performance Status of 0-1 within 28 days prior to registration.\n* Patients must have undergone complete surgical resection of their stage I NSCLC between 4-12 weeks prior to registration and have negative surgical margins (R0).\n\n  * NOTE: Both squamous and non-squamous histologies are allowed into the study. Cancers with a histology of \"adenosquamous\" are considered a type of adenocarcinoma and thus \"non-squamous histology\".\n  * NOTE: Staging will be according to the AJCC 8th edition.\n* Pathological tumor size must be 1.0 - 4.0 cm in greatest dimension. NOTE: According to AJCC 8th edition, subjects with lepidic predominant adenocarcinoma should be staged based on their invasive tumor size and not their total tumor size (i.e., subjects with lepidic predominant tumors whose invasive tumor size is less than 1 cm are not eligible, even if their total tumor size is 1.0 cm or greater).\n* Surgery for this lung cancer must be completed at least 28 days prior to registration.\n* Must have either previous NGS and PD-L1 results available using the Dako 22C3 antibody or have archival tissue of surgical specimen from current diagnosis available to perform analyses. If prior PD-L1 results with Dako 22C3 antibody are not available from a CLIA-accredited laboratory, subjects must be able to provide 5 x 5\u00b5m unstained slides for prospective analysis to be used for stratification. If NGS results are not available, subjects must be able to provide at least 10 x 10\u00b5m unstained and 1 x 4\u00b5m H\\&E slides from current diagnosis for future NGS and\/or other genetic analyses.\n* Demonstrate adequate organ function as defined in the protocol; all screening labs to be obtained within 28 days prior to registration.\n* Females of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to registration. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. For subjects randomized to the pembrolizumab arm: If there is \\> 72 hours between the screening test and C1D1, another pregnancy test (urine or serum) must be performed and must be negative before the subject may start C1D1.\n\n  * NOTE: Females are considered of childbearing potential unless: they are postmenopausal; are surgically sterile; or they have a congenital or acquired condition that prevents childbearing. See Section 5.1.4 for definitions.\n  * NOTE: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n* A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n  * Not a woman of childbearing potential (WOCBP) OR\n  * A WOCBP who is using a highly effective contraceptive method (failure rate of \\<1% per year), or is abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) during the intervention period and for at least 120 days after the last dose of study drug. The investigator should evaluate the potential for contraceptive method failure (i.e., noncompliance, recently initiated) in relationship to the first dose of study drug. See contraceptive guidance in Section 5.1.4 of the protocol.\n* As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study\n\nExclusion Criteria:\n\n* Current lung cancer is \\<1 cm or \\> 4 cm in size or is stage II, III, or IV.\n* Patients with tumors that are known to harbor actionable EGFR mutations.\n* Prior chemotherapy, radiation therapy, or immunotherapy for the treatment of this lung cancer.\n* Has a known active additional malignancy that is progressing or has required active treatment within the past 3 years. NOTE: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma in situ, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.\n* Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).\n* Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study drug. Administration of killed vaccines is allowed.\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.\n\n  * Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to randomization.\n* Has had an allogenic tissue\/solid organ transplant.\n* Has severe hypersensitivity (\u2265Grade 3) to pembrolizumab and\/or any of its excipients.\n* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n* Has a history of (non-infectious) pneumonitis\/interstitial lung disease that required steroids or has current pneumonitis\/interstitial lung disease.\n* Has an active infection requiring systemic therapy.\n* Has a known history of Human Immunodeficiency Virus (HIV). Note: HIV testing is not required unless mandated by local health authority.\n* Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV RNA \\[qualitative\\] is detected) infection. Note: Hepatitis B and Hepatitis C testing is not required unless mandated by local health authority.\n* Has active TB (Bacillus Tuberculosis) infection.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04317534013","EMAIL":[{"email":"mndykstra@wisc.edu"},{}],"GEO":[43.07305,-89.40123]},{"TITLE":"Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas","CRITERIA":"Key Inclusion Criteria:\n\nPhase 1:\n\n1. Males and females \u226518 years of age at the time of consent\n2. Patients who have histologically or cytologically-documented, unresectable locally advanced, or metastatic solid malignancy or designated lymphoma that is progressing or has failed the therapies listed below or who are intolerant of or are ineligible for or refuse standard of care therapy as detailed below.\n\n   * Patients previously pre-treated with a checkpoint inhibitor must be anti-PD-L1 relapsed\/refractory defined as having clear evidence of radiologic or clinical progression while on or within 4 months of their last anti-PD-L1 dose.\n   * There is no limit to the number of prior treatment regimens a patient may have had prior to enrollment.\n\n   Has one of the following solid tumor or lymphoma indications:\n   * Non-small cell lung cancer (NSCLC) - squamous or non-squamous:\n\n     * Must have received prior chemotherapy and a checkpoint inhibitor (either sequentially or in combination) per PD-L1 status\n     * Must not have a documented EGFR, ALK, ROS, RET, BRAFV600E, Met exon 14 skipping, KRAS mutation\n   * Head and neck squamous cell carcinoma (HNSCC) HPV+ or -:\n\n     * Must have received prior treatment with a platinum-based chemotherapy and a checkpoint inhibitor (either sequentially or in combination) per PD-L1 status\n   * Triple negative breast cancer (TNBC):\n\n     * Must have received prior treatment with chemotherapy (anthracycline, and\/or taxanes, and\/or platinum, and\/or gemcitabine); sacituzumab govitecan; a checkpoint inhibitor if PD-L1+; a PARPi for patients with gBRCA mutations\n   * Cutaneous squamous cell carcinoma:\n\n     * Must have received prior treatment with a checkpoint inhibitor\n   * Hormone receptor positive (HR+) breast cancer:\n\n     - Must have received endocrine therapy, a CDK 4\/6 inhibitor (preferably in combination with endocrine therapy in the 1st line or 2nd line setting or as monotherapy), a PI3K inhibitor and endocrine therapy for tumors with PIK3CA activating mutation; and a PARPi for patients with gBRCA mutations\n   * Small bowel carcinoma:\n\n     * Must have received prior treatment with at least one 5FU or capecitabine based regimen (such as but not limited to FOLFOX, FOLFIRI or CAPOX) with or without bevacizumab, and a PD1\/PD-L1 inhibitor alone or in combination with CTLA4 inhibitor (for MSI-H or dMMR tumors)\n   * Esophageal cancer:\n\n     * Must have received prior treatment with a platinum-based chemotherapy and a checkpoint inhibitor (either sequentially or in combination per PD-L1 status), and an anti-HER2 agent for patients with known HER2 overexpressing tumors\n   * Colorectal cancer (MSS \\& MSI-H\/dMMR):\n\n     * Must have received at least one 5FU chemotherapy-based regimen, with bevacizumab or cetuximab\/panitumumab, and \/ or a PD1\/PD-L1 (single agent or combination with CTLA4) for dMMR\/MSI-H tumors\n     * For patients with known BRAF V600E mutation: must have received prior treatment with a combination of encorafenib and cetuximab or panitumumab\n   * Histologically confirmed diffuse large B cell lymphoma (DLBCL)\n\n     * Must have received at least 2 prior lines of therapy including prior treatment with chemotherapy and an anti-CD20 antibody (ie, CHOP)\n     * Must be ineligible or refuse therapies with demonstrated clinical benefit such as for example CAR-T or autologous stem cell transplant\n   * Hodgkin lymphoma:\n\n     - Must have received at least 3 prior systemic therapies, including combination chemotherapy (ie, ABVD).\n   * Burkitt lymphoma:\n\n     * Must have received at least 2 prior lines of therapy\n     * Must be ineligible or refuse therapies with demonstrated clinical benefit\n   * Follicular lymphoma:\n\n     * Must have received 3 prior lines of therapy, and must have received rituximab and chemotherapy\n3. Patients with solid tumors have measurable disease based on RECIST 1.1. In hematological malignancies LYRIC\/Lugano will be used.\n4. In defined cohorts must have confirmed positive expression of CD161. Patients must have an available archival biopsy sample or agree to have a fresh biopsy obtained to confirm positivity and must agree to a mandatory newly obtained on-treatment biopsy.\n\nPhase 1B:\n\nMust meet all of eligibility criteria in Phase 1, AND the following:\n\n1. Must have histologically or cytologically-documented, unresectable, locally-advanced or metastatic MSS CRC with documented IHC for MMR and\/or DNA for MSI consistent with MSS CRC.\n2. Eligible for treatment with fruquintinib according to the FDA-approved USPI\n3. Must have received no more than 3 prior lines of therapy, consisting of prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy\n4. Body weight \u226540kg\n\nPhase 2A:\n\nInclusion criteria for these patients will remain similar to those used during Phase 1.\n\nKey Exclusion Criteria:\n\nPhase 1:\n\n1. Any prior Grade 4 immune-mediated adverse event (imAE) or Grade 3 imAE requiring steroid treatment (\\>10 mg\/day prednisone or equivalent dose for more than 12 weeks) while receiving immunotherapy that has been documented within the 12 months prior to enrollment.\n2. Unresolved toxicity higher than Grade 1 CTCAE v 5 (or higher) attributed to any prior therapy\/procedure at screening, except for alopecia.\n3. Prior history of serious hypersensitivity reaction to treatment with a monoclonal antibody\n4. Patients who are currently pregnant or breastfeeding\n5. Use of other investigational drugs (drugs not marketed for any indication) within 14 days or at least 5 half-lives (whichever is shorter) before investigational enrollment (Day 1, Cycle 1 dosing)\n6. Patient with history of malignancy (other than the one for which he\/she participates in the study or than basal cell carcinoma definitively resected, or other in situ cancers) - unless the patient has undergone curative therapy with no evidence of that disease for 3 years\n7. Patients currently receiving cancer therapy (ie, chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery, and\/or tumor embolization) or expected to require any other form of antineoplastic therapy while on study.\n8. Patients with active, known or suspected autoimmune disease requiring systemic treatment (corticosteroids or other active immunosuppressive medications) within the past 6 months - with the exclusion of vitiligo, resolved asthma\/atopia or alopecia areata; hypothyroidism stable on hormone replacement.\n9. Known CNS metastases (unless clinically stable for at least 4weeks prior to enrollment and off steroids for at least 7 days- exceptions above for physiologic replacement doses of hydrocortisone)\n10. Myocardial infarction, symptomatic congestive heart failure (NYHA\\> Class II), unstable angina, or serious uncontrolled cardiac arrhythmia within the last 6 months of screening\n11. Patient has history of or current HIV, Hepatitis B or C infection, even if not active and\/or controlled\n\nPhase 1B:\n\nMust not have met any exclusion criteria for Phase 1, and must not have any of the following:\n\n1. Serum electrolytes, potassium, calcium, or magnesium levels outside of the normal laboratory reference range and clinically significant in the investigator's judgment\n2. Serum creatinine \\>1.5 \u00d7 ULN or creatinine clearance \\<60 L\/min.\n3. Urine dipstick protein \u22652+ or 24-hour urine protein \u22651.0 g\/24-h\n4. Uncontrolled hypertension, defined as: systolic blood pressure \u2265140 mm Hg and\/or diastolic blood pressure \u226590 mm Hg despite optimal medical management\n5. History of thromboembolic events\n6. Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction or coronary artery bypass surgery, symptomatic congestive heart failure (New York Heart Association \\[NYHA\\] Classification \\> Class II), severe or unstable angina, or serious uncontrolled cardiac arrhythmia within the last 6 months of screening\n7. Patient has history of or current human immunodeficiency virus (HIV), or hepatitis B infection, even if not active and\/or controlled. Prior hepatitis C virus (HCV) infection treated with a full course of curative intent antivirals with an undetectable viral load (below the lower limit of detection) are eligible\n8. Use of strong inducers or inhibitors of CYP3A4 within 2 weeks prior to the first dose of study drug and while on study\n9. Planned major surgery within 2 weeks prior to study start or during the study\n\nPhase 2A:\n\nExclusion criteria are expected to remain the same as Phase 1 unless there is a need to further refine expansion cohort populations for Phase 2a. Patients must have a CD161 positive tumor demonstrated by the IHC CLIA assay for each analyte.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05565417010","EMAIL":"CTInformation@immuntastx.com","GEO":[38.84622,-77.30637]},{"TITLE":"Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain Metastases","CRITERIA":"Inclusion Criteria:\n\n1. Male\/female participants who are at least 19 years of age on the day of signing informed consent with histologically confirmed diagnosis of stage IV non-small cell lung cancer with brain metastases will be enrolled in this study.\n2. Must have at least one intracranial target lesion. Intracranial lesion must be equal or greater than the 10mm in longest diameter.\n3. Have confirmation that EGFR or ALK-directed therapy is not indicated\n4. Have measurable disease based on RECIST 1.1 as determined by the local site investigator\/radiology assessment. Target lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions. Otherwise, previously treated with radiation is not considered as measurable lesion.\n5. Have not received prior systemic treatment for their advanced\/metastatic NSCLC. Subjects who received adjuvant or neoadjuvant therapy are eligible if the adjuvant\/neoadjuvant therapy was completed at least 6 months prior to the development of metastatic disease.\n6. Have a life expectancy of at least 3 months\n7. Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status.\n8. Have adequate organ function\n9. Male participants: A male participant must agree to use a contraception during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period.\n10. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n    * a. Not a woman of childbearing potential (WOCBP) as defined in Appendix 3 OR\n    * b. A WOCBP who agrees to follow the contraceptive guidance in Appendix 3 during the treatment period and for at least 120 days after the last dose of study treatment.\n11. The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.\n\nExclusion Criteria:\n\n1. A WOCBP who has a positive urine pregnancy test within 72 hours prior to IP administration. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n2. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).\n3. Has received prior systemic anti-cancer therapy including investigational agents prior to IP administration as a metastatic disease treatment, including tyrosine kinase inhibitor.\n4. Had major surgery \\< 3 weeks prior to first dose\n5. No measurable CNS lesion other than CNS lesion treated with stereotactic radiotherapy or surgery\n6. Had received whole brain radiotherapy or stereotactic radiotherapy to CNS disease.\n7. Has received prior radiotherapy within 1 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation to non-CNS disease.\n8. Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Gu\u00e9rin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist\u00ae) are live attenuated vaccines and are not allowed.\n9. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.\n10. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.\n11. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, thyroid cancer or early gastric cancer or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.\n12. Has known active carcinomatous meningitis.\n13. Has severe hypersensitivity (\u2265Grade 3) to pembrolizumab and\/or any of its excipients.\n14. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.\n15. Has a history of (non-infectious) pneumonitis that currently required steroids or has current pneumonitis.\n16. Has an active infection requiring systemic therapy.\n17. Has a known history of Human Immunodeficiency Virus (HIV) infection.\n18. Has a active Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive with HBV DNA positive) or known active Hepatitis C virus (defined as HCV RNA is detected) infection. These patients can be participated with appropriate treatment and prophylactic treatment based on the investigator's decision.\n19. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n20. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n21. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.\n22. Has had an allogenic tissue\/solid organ transplant.","SEX":"ALL","AGE_MIN":19,"AGE_MAX":200,"SS_ID":"04967417001","EMAIL":[{}],"GEO":[37.566,126.9784]},{"TITLE":"Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors.","CRITERIA":"Inclusion Criteria:\n\n1. - Advanced lung cancer (stage IV)\n2. - Treatment - immune-checkpoint inhibitors or chemotherapy\n3. - Data is fully available for the whole period of observation\n\nExclusion Criteria:\n\n1. - Radiologically reported liver metastases\n2. - Concurrent treatment with both therapeutic regimes","SEX":"ALL","AGE_MIN":0,"AGE_MAX":200,"SS_ID":"04595734003","EMAIL":[{"email":"Deme.Karikios@health.nsw.gov.au"}],"GEO":[-33.86785,151.20732]},{"TITLE":"Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Age \u2265 18 years old.\n2. Signed informed consent and willing and able to comply with study procedures and scheduled visits.\n3. For Dose Escalation, patients with one of the following histologically diagnosed unresectable, locally advanced, or metastatic tumor types:\n\n   * Non-small cell lung cancer (NSCLC).\n   * Small cell lung cancer (SCLC).\n   * Melanoma.\n   * Clear cell or papillary renal cell carcinoma (RCC).\n   * Urothelial cancer (UC).\n   * Head and neck squamous cell cancer (HNSCC).\n   * Luminal B (ER+, PR-, any HER2 status) or triple-negative breast cancer.\n   * Gastric or gastro esophageal adenocarcinoma (GC\/GEJ).\n   * Esophageal squamous cell cancer.\n   * Skin squamous cell carcinoma (SCC).\n   * Pancreatic adenocarcinoma.\n   * Hepatocellular carcinoma (Childs-Pugh A or B7 only).\n   * Colorectal adenocarcinoma (CRC).\n   * Epithelial ovarian cancer.\n   * Cervical cancer.\n   * Endometrial adenocarcinoma.\n   * Thyroid cancer (follicular or papillary).\n4. Expansion Pembrolizumab Combination Cohorts\n\n   1. Non-Small Cell Lung Cancer \\[limited to squamous and non-squamous carcinoma histology only\\]: patients must have received no more than 2 prior lines of therapy, including PD-(L)1 therapy and platinum-based chemotherapy. Patients must have been tested for relevant tumor mutations, translocation or other genomic aberrations for which an approved targeted therapy is available; if present, patients must have progressed on or be intolerant to mutation specific treatment.\n   2. Colorectal Cancer: Patients must have disease burden outside of liver; i.e., absence of liver metastasis. Patients must also have had recurrence, progression or intolerance to standard therapy consisting of at least 2 prior standard regimens (containing a fluoropyrimidine plus a platinum analogue and\/or irinotecan) for metastatic disease.\n5. Eastern Cooperative Oncology Group (ECOG) performance status \u2264 1.\n6. Life expectancy \u2265 12 weeks.\n7. Measurable disease as per RECIST 1.1 criteria and documented by computed tomography (CT) and\/or magnetic resonance imaging (MRI).\n\n   Note: lesions treated previously with radiation must demonstrate clear evidence of radiographic progression since the completion of prior radiotherapy and prior to study enrollment.\n8. Acceptable laboratory parameters:\n\n   * Albumin \u2265 2.8 g\/dL.\n   * Platelet count \u2265 75,000.\n   * Hemoglobin \u2265 8.0 g\/dL.\n   * Absolute neutrophil count \u2265 1,500\/\u00b5L.\n   * ALT\/AST \u2264 3.0 times ULN.\n\n     * ALT\/AST \u2264 5 \u00d7 ULN for patients with liver metastases.\n   * Total bilirubin \u2264 1.5 ULN or \u2264 3 x ULN for patients with Gilbert's disease.\n\n     * Direct bilirubin \u2264 ULN for patients with total bilirubin \\> 1.5 ULN.\n   * Creatinine \u2264 1.8 mg\/dL.\n\n     * Or calculated\/measured creatinine clearance \\> 30 mL\/minute.\n9. Identification of an archival tumor sample (i.e., tissue block (formalin-fixed paraffin-embedded \\[FFPE\\]) or a series of approximately 10-15 slides).\n10. Consent to pre- and on- treatment fresh tumor biopsy for all patients enrolled as back fill in Dose Escalation or for at least 6 additional patients per expansion cohort in Cohort Expansion in Simon Stage 2. Note: Biopsies are not required for the Basket Cohort.\n11. Women of childbearing potential (WOCBP) not surgically sterilized and between menarche and 1 year post menopause must:\n\n    * Have a negative serum or urine pregnancy test performed within 72 hours prior to the initiation of study drug administration.\n    * Be willing to use 2 forms of effective contraception throughout the study, starting with the screening and through 90 days after the last dose of JK08.\n    * Abstinence is considered a highly effective method if this is the established and preferred contraception method for the patient and is defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. Periodic abstinence \\[e.g., calendar, ovulation, symptothermal, postovulation methods\\], withdrawal, spermicides only, and lactational amenorrhea method are not acceptable methods of contraception. Female and male condoms should not be used together.\n12. Male patients with partners of childbearing potential, even if surgically sterilized (i.e., status post-vasectomy) must agree to:\n\n    * Use effective barrier contraception from the time of consent through 90 days after discontinuation; or\n    * Agree to practice true abstinence, if this is the established and preferred contraception method by the patient and is defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. Periodic abstinence \\[e.g., calendar, symptothermal, post-ovulation methods\\], withdrawal, spermicides only, and lactational amenorrhea method are not acceptable methods of contraception. Female and male condoms should not be used together.\n    * In addition, male patients should also have their partners use contraception for the same period of time.\n13. Central nervous system (CNS) metastases must have been treated, be asymptomatic for \u226514 days, and meet the following at the time of enrollment:\n\n    * No concurrent treatment for CNS disease (e.g., surgery, radiation, corticosteroids \u2265 10 mg prednisone\/day or equivalent).\n    * No concurrent or past history of leptomeningeal disease or cord compression.\n14. Must be willing and able to comply with clinic visits and procedures outlined in the study protocol.\n15. Concurrent use of hormones for breast cancer or for non cancer related conditions (e.g., insulin for diabetes, hormone replacement therapy) is acceptable. Bisphosphonates or RANK-L inhibitor or analogues are permitted for supportive care of patients with bone metastases.\n\nExclusion Criteria:\n\n1. Patients with symptomatic or unstable CNS primary tumor or metastases and\/or carcinomatous meningitis. Patients with documented treated CNS metastases stable for at least 4 weeks may be enrolled at the discretion of the investigator.\n2. Patients with active, or history of, severe autoimmune disease who in the opinion of the investigator and\/or the Sponsor or Sponsor's designee would be exposed to unacceptable risk by participating in the study.\n3. Major surgery within 6 weeks from treatment initiation.\n4. Clinically significant cardiovascular\/vascular disease \u2264 6 months before first dose:\n\n   * Myocardial infarction or unstable angina.\n   * Clinically significant cardiac arrhythmias.\n   * Uncontrolled hypertension: systolic blood pressure (SBP) \\> 180 mmHg, diastolic blood pressure (DBP) \\> 100 mmHg.\n   * Pulmonary embolism, symptomatic cerebrovascular events or any other serious cardiac condition (e.g., pericardial effusion or restrictive cardiomyopathy).\n   * QTcF prolongation \\> 480 msec.\n   * Congestive heart failure (New York Heart Association class III-IV).\n   * Myocarditis\/clinically significant pericarditis.\n5. Clinically significant gastrointestinal disorders including:\n\n   * Gastrointestinal perforation or unhealed ulcerations \\< 6 months prior to study drug administration. Patients must have documented evidence (e.g., upper endoscopy, colonoscopy) of completely healed area of prior perforation.\n   * Clinically significant gastrointestinal bleeding \\< 3 months prior to study drug administration.\n   * Pancreatitis \\< 6 months prior to study drug administration.\n   * History of Crohn's disease or ulcerative colitis.\n6. Clinically significant pulmonary compromise requiring supplemental oxygen use.\n7. History of Grade 3 or greater drug-related immune-mediated AE during treatment with CPIs such as anti-PD-(L)1 or anti-CTLA-4 antibodies.\n8. Vaccination with any live virus vaccine within 4 weeks prior to the initiation of study drug administration. Inactivated annual influenza vaccination is allowed. At least 2 doses of COVID-19 vaccination must have been completed prior to enrollment (see Section 8.2 for further details).\n9. Known hypersensitivity to JK08 or any excipient (histidine\/histidine-HCl, sucrose, glycine, PS-80).\n10. Second primary invasive malignancy not in remission for \u2265 1 year. Exceptions include non melanoma skin cancer, cervical carcinoma in situ, resected melanoma in situ, or any malignancy considered to be indolent and never required therapy.\n11. Any serious underlying medical or psychiatric condition that would preclude understanding and rendering of informed consent or impair the ability of the patient to receive or tolerate the planned treatment.\n12. Recent or ongoing serious infection including the following:\n\n    * Any uncontrolled Grade 3 or higher (per CTCAE v5.0) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of JK08. Routine antimicrobial prophylaxis is allowed.\n    * Uncontrolled infection with human immunodeficiency virus (HIV). Patients on stable highly active antiretroviral therapy (HAART) therapy with undetectable viral load and normal CD4 counts for at least 6 months prior to study entry are eligible. Serological testing for HIV at screening is not required.\n    * Known to be positive for hepatitis B (HBV) surface antigen, or any other positive test for hepatitis B indicating acute or chronic infection. Patients who are or have received anti-HBV therapy and have undetectable HBV DNA for at least 6 months prior to study entry are eligible. Serological testing for hepatitis B at screening is not required.\n    * Known active hepatitis C (HCV) as determined by positive serology and confirmed by polymerase chain reaction (PCR). Patients on or having received antiviral therapy are eligible provided they are virus-free by PCR for at least 6 months prior to study entry. Serological testing for hepatitis C at screening is not required.\n    * Known active or latent tuberculosis (testing at screening not required).\n13. Use of systemic corticosteroids within 15 days or other immunosuppressive drugs within 30 days prior to start of the study, with the exception of corticosteroids as replacement therapy up to an equivalent of prednisone 10 mg\/day which is allowed. Inhaled, topical, or intraarticular steroids are allowed.\n14. Prior systemic anti-cancer treatment as follows:\n\n    * For cytotoxic chemotherapy, small molecule inhibitors, radiation, or similar investigational treatments, \u2264 2 weeks or 5 half lives, whichever is shorter.\n    * For monoclonal antibodies or similar experimental therapies: \u2264 3 weeks or 5 half-lives, whichever is shorter.\n    * Antibody drug conjugates and radioimmunoconjugates or other similar experimental therapies \u2264 6 weeks or 5 half-lives, whichever is shorter.\n15. Ascites or pleural effusions requiring large volume para- or pleurocentesis within 4 weeks of treatment initiation.\n16. Pregnant or nursing.\n17. Therapeutic anticoagulation for a thromboembolic event that occurred within 3 months of dosing; prophylactic anticoagulation is permitted.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05620134011","EMAIL":[{}],"GEO":[39.46975,-0.37739]},{"TITLE":"A Study of TAS3351 in NSCLC Patients With EGFRmt","CRITERIA":"Inclusion Criteria:\n\n* Locally advanced, non-resectable or metastatic NSCLC\n* Have adequate organ function\n* Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale\n* Has tumor tissue available to allow for analysis of EGFRmt status\n\nDose Escalation:\n\n\u2022 Has any EGFRmt status\n\nDose Escalation back-fill part, Dose Expansion and Phase II:\n\n* Has any sensitizing EGFRmt and a confirmed C797S EGFRmt\n* Has measurable disease per RECIST v1.1\n\nExclusion Criteria:\n\n* Participating in medical research not compatible with this study\n* Symptomatic and unstable CNS metastases\n* Have not recovered from prior cancer treatment\n* Have a significant cardiac condition\n* Are a pregnant or breastfeeding female\n* A serious illness or medical condition\n* Unable to swallow or digest pills","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05765734009","EMAIL":[{"email":"ha.murakami@scchr.jp"},{}],"GEO":[35.86224,139.97732]},{"TITLE":"Efficacy and Safety of Neoantigen Peptide Vaccine in the Treatment of Advanced NSCLC Progressed After EGFR-TKI Treatment","CRITERIA":"Inclusion Criteria:\n\n1. The patient voluntarily joined this study and signed an informed consent form;\n2. \u2265 18 years old, both male and female;\n3. Pathologically confirmed IIIB-IV stage NSCLC, with at least one measurable lesion that has not undergone local treatment (according to RECIST v1.1, the length of the measurable lesion on spiral CT or MRI scans is \u2265 10 mm or the short diameter of the enlarged lymph node is \u2265 15 mm);\n4. Metastatic advanced EGFR mutated lung cancer confirmed by histology or cytology, with EGFR-TKI monotherapy or EGFR-TKI combined anti angiogenic therapy failing;\n5. Patients who have received first-line chemotherapy in the past can be included in the inclusion criteria;\n6. ECOG score: 0-2;\n7. Expected survival time \u2265 12 weeks;\n8. The functions of important organs meet the following requirements:Absolute neutrophil count \u2265 1.5 \u00d7 109\/L;Absolute lymphocyte count \u2265 0.8 \u00d7 109\/L;Platelets \u2265 80 \u00d7 109\/L;Hemoglobin \u2265 90g\/L;Bilirubin \u2264 1.5 \u00d7 ULN (within 7 days before the first medication);ALT and AST \u2264 1.5 \u00d7 ULN (within 7 days before the first medication); Serum creatinine \u2264 1.5 \u00d7 ULN;\n9. Thyroid stimulating hormone (TSH) \u2264 1 \u00d7 ULN (if abnormal, FT3 and FT4 levels should be examined simultaneously, and if FT3 and FT4 levels are normal, they can be included in the group level);\n10. For female patients of childbearing age, effective methods of contraception should be used during the trial period and within 3 months after the last administration of treatment medication;\n11. Agree to provide blood samples and histological specimens.\n\nExclusion Criteria:\n\n1. The patient has any active autoimmune disease or a history of autoimmune disease;\n2. The patient is currently using immunosuppressive agents or systemic hormone therapy to achieve immunosuppressive effects (dosage\\>10mg\/day of prednisone or other therapeutic hormones) ;\n3. The patient experienced severe allergic reactions to other monoclonal antibodies;\n4. Suffering from hypertension and unable to achieve good control through antihypertensive medication treatment (systolic blood pressure \u2265 140mmHg or diastolic blood pressure \u2265 90mmHg);\n5. There are clinical symptoms or diseases of the heart that cannot be well controlled, such as:NYHA grade 2 or above heart failure;Unstable angina pectoris; Have experienced myocardial infarction within 1 year;Clinically significant supraventricular or ventricular arrhythmias require treatment or intervention; QTc\\>450ms (male); QTc\\>470ms (female);\n6. Abnormal coagulation function (INR\\>2.0, PT\\>16s), with bleeding tendency or undergoing thrombolysis or anticoagulation treatment, allowing prophylactic use of low-dose aspirin and low molecular weight heparin;\n7. Received previous anti-tumor immunotherapy and anti-tumor vaccine treatment;\n8. The patient has active infection, unexplained fever \u2265 38.5 \u00b0 C within 7 days before medication, or baseline white blood cell count\\>15 \u00d7 109\/L; Those who may have purulent or chronic infections, and the wound persists without healing;\n9. Patients who have experienced bone metastasis have received palliative radiotherapy in areas greater than 5% of the bone marrow area within the 4 weeks prior to participating in this study;\n10. The patient has previously received anti PD-1, anti PD-L1, and anti PD-L2 treatment;\n11. Those who are known to be allergic to the components of recombinant humanized anti-PD-1 monoclonal antibody drugs and vaccines;\n12. Pregnant or lactating women, or female patients with fertility who have not taken contraceptive measures;\n13. Other malignant tumors (excluding basal cell or squamous cell carcinoma, superficial bladder cancer cancer, cervical carcinoma in situ or breast cancer) in the past 5 years;\n14. Patients who participate in other clinical trials at the same time;\n15. HIV positive; HCV positive; Uncontrolled active hepatitis B;\n16. Those who have received live vaccination within 4 weeks before the start of treatment;\n17. Patients with a history of asymptomatic brain metastasis who meet all the following conditions can be selected:During screening, brain imaging showed no evidence of immediate progression.There is currently no need to use glucocorticoids to treat brain metastases, and stable doses of anticonvulsants are allowed.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06095934001","EMAIL":[{"email":"ssnine@126.com"}],"GEO":[32.06167,118.77778]},{"TITLE":"First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations","CRITERIA":"Key Inclusion Criteria:\n\n1. Has histologically- or cytologically confirmed diagnosis of NSCLC Stage IIIB\/C or IV not eligible for curative intent surgery or chemoradiation.\n2. Tumor tissue EGFR exon 20 insertion mutations confirmed by qualified local laboratories.\n3. Has new or recent tumor biopsy (collected at screening, if feasible) or archival tumor specimen collected in the past 10 years available for genomic profiling (see lab manual for minimum tissue requirements).\n4. Is \u226518 years of age at the time of signing the ICF.\n5. Has Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n\nKey Exclusion Criteria:\n\n1. Has a tumor that is known to harbor concurrent T790M and C797S resistance mutations.\n2. Has history (within \u22642 years before screening) of solid tumor or hematological malignancy that is histologically distinct from NSCLC.\n3. Has symptomatic brain or spinal metastases.\n4. Has toxicities from previous anticancer therapies that have not resolved to baseline levels or to CTCAE Grade \u22641, except for alopecia and peripheral neuropathy.\n5. Has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g., could compromise the participant's well-being) or would prevent, limit, or confound the protocol-specified assessments.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06043817015","EMAIL":"clinicaltrials@scorpiontx.com","GEO":[25.04776,121.53185]},{"TITLE":"Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb\u00ae808 in Combination With Pembrolizumab in Advanced Solid Tumors","CRITERIA":"Key Inclusion Criteria:\n\n* Part A: Histologically confirmed advanced\/metastatic castration-resistant prostate adenocarcinoma, epithelial ovarian cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, urothelial carcinoma, melanoma, renal cell carcinoma, triple-negative breast cancer, or colorectal cancer that has progressed on standard therapies\n* Part B: Histologically confirmed advanced\/metastatic castration-resistant prostate cancer that is PD1-na\u00efve; head and neck squamous cell carcinoma that is PD1-na\u00efve or has progressed on prior PD1 therapy; or melanoma that is PD1-na\u00efve or has progressed on prior PD1 therapy\n* Measurable disease by RECIST 1.1; subjects with prostate cancer who have evaluable disease according to PCWG3 criteria may enroll\n* Life expectancy \\> 3 months\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\nKey Exclusion Criteria:\n\n* Subjects currently receiving other anticancer therapies\n* Any prior treatment with an investigational agent targeting CD28\n* History of a life-threatening adverse event related to prior immunotherapy\n* Known active central nervous system involvement by malignant disease. Subjects with previously treated brain metastases may participate provided they are radiologically and clinically stable","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05585034012","EMAIL":"mchiarella@xencor.com","GEO":[43.0389,-87.90647]},{"TITLE":"Cell Free DNA for the Diagnosis and Treatment in Early NSCLC","CRITERIA":"Inclusion Criteria:\n\n* All subjects need to sign the informed consent form\n* All subjects have Non-small cell lung cancer which suspected on chest CT or confirmed pathologically preoperatively.\n* Non-small cell lung cancer have to confirmed pathologically after operation\n* Clinical stage I - IIIA by AJCC 7th staging system\n\nExclusion Criteria:\n\n* Have been undergone chemotherapy or radiotherapy due to non-small call lung cancer\n* Have been diagnosed any type of cancer other than cancer of skin, thyroid, uterine cervix with 3 years before enrollment\n* Recurrent lung cancer\n* Stage IIIB, IV by AJCC 7th staging system","SEX":"ALL","AGE_MIN":18,"AGE_MAX":90,"SS_ID":"03791034001","EMAIL":[{"email":"jkimsmc@skku.edu"}],"GEO":[37.566,126.9784]},{"TITLE":"WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases","CRITERIA":"Inclusion Criteria:\n\n* Pre-Registration - Inclusion Criteria Specific to Dose Escalation Cohort\n* Histolopathological and\/or molecular confirmation of either glioblastoma, IDH wildtype (GBM), (as defined by either the 2016 or 2021 World Health Organization \\[WHO\\] classifications) anaplastic astrocytoma, IDH wildtype (AA) (as defined by the 2016 WHO classification) or non-small cell lung cancer (NSCLC)\n* EGFR Status:\n\n  * GBM\/AA must either EGFR amplification and\/or any activating EGFR mutation (e.g. A289T, EGFRvIII , etc.)\n  * NSCLC must have a confirmed activating EGFR mutation (e.g. Del19, L858R, EGFRvIII, G719A, L861Q, T790M, C797S, etc.)\n* Pre-Registration - Inclusion Criteria Specific to Dose Expansion Cohorts\n* Glioblastoma, IDH wildtype\/Anaplastic astrocytoma, IDH wildtype (GBM\/AA) Cohort:\n\n  * Diagnosis: Histological or molecular confirmation of either glioblastoma, IDH wildtype (GBM) (as defined by either the 2016 or 2021 WHO classifications) or anaplastic astrocytoma, IDH wildtype (AA) (as defined by the 2016 WHO classification)\n  * EGFR status: GBM\/AA must have EGFRvIII mutation\n* Brain Tumor Penetration (BTP) Cohort:\n\n  * Diagnosis: Histopathological or molecular confirmation of either glioblastoma, IDH wildtype (GBM) (as defined by either the 2016 or 2021 WHO classifications) or anaplastic astrocytoma, IDH wildtype (AA) (as defined by the 2016 WHO classification)\n  * EGFR status: GBM\/AA must have been previously demonstrated to have either EGFR amplification and\/or any activating EGFR mutation based on any prior resection\n* Non-Small Cell Lung Cancer (NSCLC) cohort:\n\n  * Diagnosis: Histological confirmation of non-small cell lung cancer (NSCLC)\n  * EGFR status: NSCLC must have confirmed activating EGFR mutation. Following protocol amendment 7, NSCLC must have EGFR C797S mutation.\n* Registration -Inclusion Criteria Specific to Dose Escalation Cohort\n* Previous treatments:\n\n  * Patients with GBM\/AA must have been previously treated with radiation and temozolomide\n  * Patients with NSCLC must have been previously treated with at least one line of single-agent therapy with an EGFR TKI e.g. gefitinib, erlotinib, afatinib, or osimertinib)\n* Radiographic progression:\n\n  * Patients with GBM\/AA must have radiographic progression based on RANO criteria\n  * Patients with NSCLC must have new or radiographic progression in the central nervous system (brain metastases and\/or leptomeningeal metastases). Positive confirmation of CSF cytology is both necessary and sufficient to define the presence of leptomeningeal metastases for patients in this study. Patients with positive CSF cytology and brain metastases will be categorized as \"leptomeningeal metastases.\"\n* Measurable disease\n* Eastern Cooperative Oncology Group (ECOG) 0 or 1. For patients with NSCLC with leptomeningeal metastases, ECOG 2 is also acceptable\n* Registration - Inclusion Criteria Specific to Dose Expansion Cohorts\n* Glioblastoma, IDH wildtype\/Anaplastic astrocytoma, IDH wildtype (GBM\/AA) Cohort:\n\n  * Previous treatments: Patients must have been previously treated with radiation and temozolomide. First recurrence only (no additional systemic therapies have been administered for recurrent disease)\n  * Radiographic progression: Patients with GBM\/AA must have radiographic progression based on RANO criteria\n  * Patients remain eligible for enrollment if the recurrent disease has been surgically removed\n  * Performance status: ECOG 0 or 1\n* Brain Tumor Penetration (BTP) Cohort:\n\n  * Previous treatments: Patients must have been previously treated with radiation and temozolomide\n  * Radiographic progression: Patients with GBM\/AA must have radiographic progression based on RANO criteria\n  * Therapeutic surgical resection of GBM\/AA required as part of routine clinical care\n  * Performance status: ECOG 0 or 1\n* Non-Small Cell Lung Cancer (NSCLC) cohort:\n\n  * Previous treatments: No limitations\n  * Radiographic progression: Patients must have radiographic progression based on RECIST 1.1 criteria.\n  * Measurable Disease\n  * Performance Status: ECOG 0 or 1\n* Registration - Inclusion Criteria Common to Dose Escalation and Dose Expansion Cohorts:\n* Age \\>= 18 years old\n* Ability to understand and the willingness to sign a written informed consent document\n* Hemoglobin \\>= 9.0 g\/dL (obtained =\\< 14 days prior to registration)\n* Leukocytes \\>= 3.0 x 10\\^9\/L (obtained =\\< 14 days prior to registration)\n* Absolute neutrophil count \\>= 1.5 x 10\\^9\/L (obtained =\\< 14 days prior to registration)\n* Platelets \\>= 100 x 10\\^9\/L (obtained =\\< 14 days prior to registration)\n* International normalized ratio (INR) =\\< 1.5 x upper limit of normal (ULN) (obtained =\\< 14 days prior to registration)\n\n  * Patients on a stable dose of anti-coagulation therapy will be allowed to participate if they have no signs of bleeding or clotting and the INR\/prothrombin time (PT) and partial thromboplastin time (PTT)\/activated (a)PTT results are compatible with an acceptable risk-benefit ratio as per the investigator's discretion\n* aPTT =\\< 1.5 x ULN (obtained =\\< 14 days prior to registration)\n\n  * Patients on a stable dose of anti-coagulation therapy will be allowed to participate if they have no signs of bleeding or clotting and the INR\/PT and PTT\/aPTT results are compatible with an acceptable risk-benefit ratio as per the investigator's discretion\n* Total bilirubin =\\< 1.5 x ULN and =\\< 3 mg\/dL for patients with Gilbert's disease (obtained =\\< 14 days prior to registration)\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\< 3 x ULN or =\\< 5 x ULN if due to liver involvement by tumor (obtained =\\< 14 days prior to registration)\n* Creatinine =\\< 1.5 x ULN or estimated glomerular filtration rate (estimated glomerular filtration rate \\[eGFR\\]) \\>= 60 mL\/minute (obtained =\\< 14 days prior to registration)\n* Negative pregnancy test done =\\< 7 days prior to registration, for persons of childbearing potential only\n* Provision of signed and dated written informed consent prior to any study specific procedures, sampling, and analyses\n* Willingness to provide mandatory blood specimens for correlative research\n* Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study i.e., active treatment and clinical follow-up)\n* Male and female patients of child bearing potential must be willing to use contraception, (i.e., condoms, birth control) while on study and until 3 months after the last dose of study drug is taken\n* Must be willing to take light-protective measures during the study and for 2 weeks after their last dose of WSD0922-FU\n* Must have a minimum life expectancy of \\>= 3 months\n* Must be stable on no more than 2 mg of dexamethasone (or equivalent steroids) per day. Steroid dose adjustments should be minimized during cycle 1 of therapy. Patients enrolling to the BTP expansion cohort do not have any restrictions on current steroid\/dexamethasone dosing.\n* Must not take enzyme-inducing anticonvulsants treatment for at least 2 weeks prior to enrollment. Patients on enzyme-inducing anticonvulsants will be changed to non-enzyme inducing anticonvulsants\n* Strong inducers and strong inhibitors of CYP3A should be discontinued at least 14 days prior to registration\n* Willingness to provide mandatory tissue specimens for correlative research (BTP cohort only)\n\nExclusion Criteria:\n\n* Registration - Exclusion Criteria for Dose Escalation and Dose Expansion\n* Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:\n\n  * Pregnant persons\n  * Nursing persons\n  * Persons of childbearing potential who are unwilling to employ adequate contraception\n* Any of the following prior therapies:\n\n  * Any cytotoxic chemotherapy or other anticancer drugs for the treatment of advanced NSCLC from a previous treatment regimen =\\< 14 days prior to registration\n  * In patients with NSCLC, treatment with an EGFR TKI (e.g., erlotinib, gefitinib, afatinib or osimertinib) must be discontinued prior to registration. Additionally, prior EGFR TKI therapy must be discontinued within 8 days or 5 half-lives, whichever is longer, prior to study therapy initiation. If sufficient wash-out time has not occurred due to schedule or PK properties, an alternative appropriate wash-out time based on known duration and time to reversibility of drug related adverse events could be agreed upon by the Investigator and Wayshine)\n  * Radiation therapy to the brain =\\< 12 weeks prior to registration\n  * Patients with GBM\/AA must not have received (i) nitrosoureas within 42 days of registration, (ii) any chemotherapy or experimental therapy within 28 days or 5 half-lives, whichever is longer, prior to registration\n  * Patients with GBM\/AA must not have received prior anti-EGFR or EGFRvIII therapies (erlotinib, gefitinib, afatinib, osimertinib, ABT-414, ABBV-221, AMG-595, AMG-596 etc.)\n  * Patients with GBM\/AA who have been treated with bevacizumab within the last four months are not eligible\n  * Received prior systemic biologic therapy (CAR-T, anti-PD-1 \/ anti-PD-L1, anti-CTLA-4, etc.) within 28 days prior to registration.\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol. Screening for chronic conditions is not required\n* Subjects who are human immunodeficiency virus (HIV), hepatitis virus B (HBV), and\/or hepatitis virus C (HCV) positive\n* Uncontrolled inter-current illness including, but not limited to:\n\n  * Symptomatic CNS complications that require urgent neurosurgical or medical (e.g. mannitol) intervention\n  * Seizures requiring a change in anti-epileptic medications (addition of new anti-epileptic or increase in dose) =\\< 2 weeks of registration\n  * Known intracranial hemorrhage which is unrelated to tumor\n  * Significant medical or psychiatric illness that would interfere with compliance and ability to tolerate treatment as outlined in the protocol\n  * Illness\/social situations that would limit compliance with study requirements\n* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm\n* Patients with a \"currently active\" second malignancy other than non-melanoma skin cancers and carcinoma-in-situ of the cervix. Patients are not considered to have a \"currently active\" malignancy if they have completed therapy and are free of disease for more than three years prior to registration\n* Any of the following cardiac criteria:\n\n  * A marked baseline prolongation of QT\/corrected QT (QTc) interval\n  * (e.g., repeated demonstration of a QTc interval \\> 480 milliseconds (ms) (Common Terminology Criteria for Adverse Events \\[CTCAE\\] grade 1) using Fridericia's QT correction formula\n  * A history of additional risk factors for torsade de pointes (TdP) (e.g., heart failure, hypokalemia, family history of long QT syndrome)\n  * The use of concomitant medications that prolong the QT\/QTc interval\n* Patients confirmed to have a cis double mutation (Del19\/T790M or L858R\/T790M) or cis triple mutation (Del19\/T790m\/C797S or L858R\/T790M\/C797S)\n* Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease. History of hypersensitivity to active or inactive excipients of WSD0922-FU or drugs with a similar chemical structure or class to WSD0922-FU\n* Refractory nausea and vomiting if not controlled by supportive therapy, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of WSD0922-FU\n* Inadequate bone marrow reserve or organ function\n* Patients with NSCLC LM who are unable to undergo collection of CSF\n* Patients who are unable to tolerate dairy (GBM\/AA cohort only). This is to ensure that patients on this cohort can participate in the food effect study","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04197934003","EMAIL":[{"email":"mayocliniccancerstudies@mayo.edu"},{}],"GEO":[44.02163,-92.4699]},{"TITLE":"Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment","CRITERIA":"Inclusion Criteria:\n\n1. voluntarily enrolled in this study and signed the Informed Consent Form (ICF).\n2. age \u2265 18 years and both sexes\n3. patients with metastatic or recurrent stage IV non-squamous NSCLC (AJCC 8th edition TNM stage) proven by histopathological or cytopathological diagnosis, mainly including adenocarcinoma, large cell lung cancer, adenocarcinoma with squamous differentiation or adenosquamous carcinoma with predominantly adenocarcinoma component may also be enrolled if eligible by study assessment.\n4. objective imaging progression (RECIST v1.1 assessment) after subjects have received a first-line regimen containing immune checkpoint inhibitor therapy.\n5. the best outcome of first-line immune checkpoint inhibitor-containing therapy is SD, PR, CR, and PFS of \u2265 3 months on first-line therapy.\n6. imaging evaluation (CT or MRI) with at least one measurable target lesion (according to RECIST v1.1 criteria) within 4 weeks prior to enrollment.\n7. an ECOG PS score of 0-1 within 4 weeks prior to enrollment.\n8. an expected survival of \u2265 12 weeks.\n9. function of vital organs in accordance with the following requirements. (1) blood routine: white blood cell count (WBC) \u2265 3.0\u00d7109\/L; absolute neutrophil count (ANC) \u2265 1.5\u00d7109\/L; platelets (PLT) \u2265 100\u00d7109\/L; hemoglobin level (HGB) \u2265 9.0 g\/dL (no corresponding supportive treatment such as blood transfusion and leukocyte boosting within 7 days).\n\n(2) Liver function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u2264 2.5 times ULN in patients without liver metastases, ALT and AST \u2264 5 times ULN in patients with liver metastases; serum total bilirubin (TBIL) \u2264 1.5 times ULN (except total bilirubin \\< 3.0 mg\/dL in Gilbert syndrome); albumin (ALB) \u2265 30 g\/L, alkaline phosphatase (ALP) \u2264 2.5\u00d7ULN, and in patients with bone metastases, ALP \u2264 5\u00d7ULN.\n\n(3) renal function: serum creatinine \u2264 1.5 times ULN or creatinine clearance (CrCl) \u2265 50 mL\/min (using Cockcroft\/Gault formula); urine protein (UPRO) \\< (++), or 24-hour urine protein amount \\< 1.0 g.\n\n(4) Coagulation function: international normalized ratio (INR) \u2264 1.5 and activated partial thromboplastin time (APTT) \u2264 1.5 times ULN; if the patient is receiving anticoagulation therapy, as long as PT or APTT is within the therapeutic range of the intended use of anticoagulants, referring to the relevant drug instructions.\n\n(5) Thyrotropin (TSH) \u2264 upper limit of normal (ULN); if abnormal, T3 and T4 levels should be examined; normal T3 and T4 levels are eligible for enrollment.\n\n10. Non-surgical sterilization or female patients of childbearing age must have a negative serum pregnancy test within 7 days prior to the first dose and must be non-lactating. Female patients of childbearing age or male patients whose partners are women of childbearing age must agree to use highly effective methods of contraception during the study period and for 6 months after the last administration of the study drug.\n\nExclusion Criteria:\n\n1. patients with other pathological tissue types of non-small cell lung cancer (including squamous cell carcinoma, mixed non-small cell and small cell lung cancer, and predominantly squamous adenosquamous carcinoma of the lung)\n2. patients with known EGFR-sensitive mutations (19Exon del\/21Exon L858R), positive ALK\/ROS1 fusion, BRAFV600E mutation, MET gene exon 14 jump mutation, positive RET gene fusion, and other patients with approved targets for targeted agents.\n3. patients with imaging showing signs of tumor invasion into the great vessels, where the tumor has completely approached, encircled, or invaded the lumen of a great vessel (e.g., pulmonary artery or superior vena cava)\n4. patients with hypertension whose blood pressure is not satisfactorily controlled by antihypertensive medication (sitting systolic blood pressure \\> 150 mmHg, or diastolic blood pressure \\> 100 mmHg), previous hypertensive crisis or hypertensive encephalopathy\n5. those with a known hereditary bleeding tendency or coagulation disorders; those who have received full-dose anticoagulant or thrombolytic therapy within 10 days prior to enrollment, or those who have taken non-steroidal anti-inflammatory drugs with platelet inhibitory effects within 10 days prior to enrollment (except for prophylactic use of low-dose aspirin (\u2264325 mg\/day)).\n6. had a hemoptysis of 2nd degree or greater with a single hemoptysis of \u22651\/2 teaspoon (2.5 ml) within 3 months prior to enrollment\n7. thrombosis in the 6 months prior to enrollment and an arterial\/venous thrombotic event within 1 year prior to screening, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis, and pulmonary embolism.\n8. those with severe vascular lesions (including aneurysms or arterial thrombosis requiring surgical treatment) within 6 months prior to enrollment\n9. late first-line treatment with anti-angiogenic agents, including but not limited to bevacizumab, apatinib, anlotinib, ramucirumab, lenvatinib, etc.; treatment with paclitaxel, including paclitaxel, albumin paclitaxel, paclitaxel liposome, docetaxel (polyene paclitaxel), etc;","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05738317001","EMAIL":[{}],"GEO":[30.58333,114.26667]},{"TITLE":"A Study of XMT-2056 in Advanced\/Recurrent Solid Tumors That Express HER2","CRITERIA":"Inclusion Criteria:\n\n* Participant has recurrent or metastatic solid tumors with HER2 expression and has disease progression after treatment, is intolerant to treatment, or is contraindicated with available anti-cancer therapies known to confer benefit, based on investigator's judgement. Note: Participants must have HER2 positivity per the results of their most recent tumor tissue testing, defined as IHC 3+ or IHC 2+ in combination with in situ hybridization (ISH)+. Participants with ERBB2-activating mutations or ERBB2 gene amplification in the absence of HER2 positivity are considered ineligible.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n* Participant must have measurable disease as defined by RECIST version 1.1.\n* Participant has fresh tumor biopsy tissue available for submission to central laboratory. If obtaining fresh tumor tissue is medically contraindicated, archival tumor tissue can be submitted following written approval of the request by the study Medical Monitor. Samples must be obtained after the participant's most recent HER2-targeting therapy unless determined to be medically contraindicated after discussion with the medical monitor.\n\nExclusion Criteria:\n\n* \u2022 Participant is receiving immunosuppressive doses of systemic medications, (doses \\>10 mg\/day prednisone or equivalent) that cannot be discontinued for at least 2 weeks before the first dose and during study drug treatment administration. Note: physiologic hormone replacement therapy is an exception.\n* Participant has received prior treatment targeting STING pathway.\n* Diagnosis of additional malignancy that required active treatment (including surgery, systemic therapy, and radiation) within the last 2 years, expect for adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the breast or the cervix. Participants with an additional malignancy that has a low risk for recurrence may be eligible after discussion with the study Medical Monitor.\n* Participants have untreated CNS metastases (including new and progressive brain metastases), history of leptomeningeal metastasis, or carcinomatous meningitis.\n\n  1. Participants are eligible if CNS metastases are adequately treated and participants are neurologically stable for at least 2 weeks prior to enrollment.\n  2. In addition, participants must be either off corticosteroids, or on a stable\/decreasing dose of \u2264 10 mg prednisone daily (or equivalent).","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05514717007","EMAIL":[{}],"GEO":[29.76328,-95.36327]},{"TITLE":"A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer","CRITERIA":"Key Inclusion Criteria: Study-Wide Eligibility (Across All Study Parts):\n\nA subject will be eligible for inclusion in this study only if all of the following criteria apply.\n\n1. Have histologically or cytologically confirmed locally advanced or metastatic NSCLC (Stage IIIB\/IIIC or IV) \\[JACC edition 8\\], and inclusion of Stage IIIB only if not a candidate for curative therapy\n2. Must have sufficient tumor tissue (either archived sample or recent biopsy) available for analysis:\n\n   1. Phase 1 Dose-escalation part: EGFR and HER2 mutations (including but not limited toL858R, exon 19 deletion, T790M, ex20ins, 21exon, G719X, S768I, L861Q, etc. for EGFR and A775YVMG, C776insVC, P780ins GSP etc. for HER2) should be confirmed by previously documented evidence or central lab\n   2. Patients with both EGFR and HER2 mutations may be included in the dose escalation phase\n   3. Phase 1 Dose-expansion part and Phase 2: Have an EGFR in-frame exon 20 insertion test by any central lab\n3. Must have at least one measurable lesion as defined by response evaluation criteria in solid tumors (RECIST v1.1)\n4. Prior anti-cancer therapies:\n\n   1. Previously treated with one or more regimens of systemic therapy for locally advanced or metastatic disease\n   2. Disease progressed or intolerant to at least one line of systematic therapies including but not limited to any EGFR-target therapies or immunotherapies, for metastatic \/ local relapsed settings\n5. Male or female adult participants (aged 18 years or older, or as defined per local regulations)\n6. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1\n7. Minimum life expectancy of 3 months or more\n8. Adequate organ function at baseline\n\n   1. Bone marrow function\n\n      * Absolute neutrophil count (ANC)\u22651.5 x 10\\^9\/L\n      * Platelets \u2265100 x 10\\^9\/L\n      * Hemoglobin \u22659 g\/dL, criteria must be met without a transfusion within 2 weeks of the blood draw\n   2. Hepatic function\n\n      * AST and ALT \u22643 x upper limit of normal (ULN); if liver metastases, then \u2264 5 x ULN\n      * Bilirubin \u22641.5 x ULN or \u22643 x ULN in the presence of documented Gilbert's Syndrome\n   3. Renal function\n\n      * Creatinine clearance \u226550 ml\/min (calculated by Cockcroft and Gault equation (Cockcroft DW, 1976) (Appendix 3)\n9. Willingness and ability to comply with scheduled visits and study procedures\n\nExclusion Criteria:\n\nA subject will be not eligible for inclusion in this study if any of the following criteria apply:\n\n1. Received anticancer therapy including cytotoxic chemotherapy, biological products and investigational agents, \u2264 21 days prior to first dose of FWD1509 MsOH; or received prior EGFR TKIs (e.g., gefitinib, erlotinib or osimertinib) \u22647 days prior to the first dose FWD1509 MsOH\n2. Have been diagnosed with another primary malignancy other than NSCLC except for patients with adequately treated non-melanoma skin cancer, cervical cancer in situ or definitively treated non-metastatic prostate cancer, or participants with another primary malignancy who are definitively relapse-free with at least 3 years elapsed since the diagnosis of the other primary malignancy\n3. Received radiotherapy \u226414 days prior to the first dose of FWD1509 MsOH or have not recovered from radiotherapy-related toxicities; palliative radiation administered outside the chest and brain, stereotactic radiosurgery (SRS), and stereotactic body radiotherapy are allowed up to 7 days prior to the first dose of FWD1509 MsOH\n4. Received strong CYP3A inhibitors and inducers within 2 weeks prior to the first dose of FWD1509 MsOH; they should be discontinued at least 2 weeks prior to the first dose of FWD1509 MsOH and avoided throughout the study duration (see Appendix 6)\n5. Received concomitant medications (e.g., statins) which are substrates of BCRP, p-glycoprotein or OATP1B1\/1B3 (dose escalation part of phase 1 study)\n6. Have undergone major surgery within 28 days prior to first dose of FWD1509 MsOH. Minor surgical procedures, such as catheter placement or minimally invasive biopsy, are allowed\n7. Brain Metastasis: Have known active brain metastases (have either previously untreated intracranial CNS metastases or previously treated intracranial CNS metastases with radiologically documented new or progressing CNS lesions), except for the following conditions\n\n   1. Brain metastases are allowed if they have been treated with surgery and\/or radiation and have been stable without requiring corticosteroids to control symptoms within 7 days before the first dose of FWD1509 MsOH and have no evidence of new or enlarging brain metastases\n   2. Requiring corticosteroids to control symptoms within 7 days prior to the first dose of FWD1509 MsOH or during study period; patients previously treated for CNS metastases who are clinically stable, have no new lesions, and who do not need treatment with a corticosteroid within the 7 days before the first dose of FWD1509 MsOH and during study period are allowed to be enrolled\n8. Have current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging) or leptomeningeal disease (symptomatic or asymptomatic)\n9. Have significant, uncontrolled, or active cardiovascular disease\n10. QCc-related criteria:\n\n    1. A marked baseline prolongation of QT\/QTc interval (e.g., repeated demonstration of a QTc interval \\>480 milliseconds (ms) (CTCAE grade 1) using Fredericia's QT correction formula\n    2. A history of additional risk factors for Torsades de Pointes (TdP) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome\n11. Have significant, uncontrolled, or active renal disease\n12. Have a known history of uncontrolled hypertension (per institution practice); participants with hypertension should be under treatment on study entry to control blood pressure\n13. Have any abnormal changes in the cornea or retina that may increase the risk of ocular toxicity during screening\n14. Have an ongoing or active infection, including but not limited to, the requirement for intravenous (IV) antibiotics, or a known history of human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Testing is not required in the absence of history\n15. Currently have or have a history of interstitial lung disease, radiation pneumonitis that required steroid treatment, or drug-related pneumonitis\n16. Female participants who are lactating and breastfeeding or have a positive urine or serum pregnancy test during the screening period\n17. Have gastrointestinal illness or disorder that could affect oral absorption of FWD1509 MsOH\n18. Have any condition or illness that, in the opinion of the investigator, might compromise participant safety or interfere with the evaluation of the safety of the drug","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05068024002","EMAIL":[{"email":"TLAlexander@mdanderson.org"}],"GEO":[29.76328,-95.36327]},{"TITLE":"A Phase 1\/2 Study of DCC-3116 in Patients With RAS\/MAPK Pathway Mutant Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n1. Male or female participants \u226518 years of age\n2. Dose Escalation Phase (Part 1):\n\n   Escalation Cohort B combination with trametinib and Cohort C combination with binimetinib closed on January 8, 2024.\n   1. Participants must have a pathologically confirmed diagnosis of an advanced or metastatic solid tumor with a documented RAS, NF1, or RAF mutations. A molecular pathology report documenting mutational status of RAS, NF1, or RAF must be available.\n   2. Progressed despite standard therapies, and received at least 1 prior line of anticancer therapy.\n\n      * Participants with a documented mutation in BRAF V600E or V600K must have received approved treatments known to provide clinical benefit prior to study entry.\n   3. Participants enrolled in the DCC-3116 and sotorasib cohort (Cohort D) must have a KRAS G12C mutation.\n3. Dose Expansion Phase (Part 2):\n\n   Expansion Cohorts 1, 2, 3 and 4 combinations will not open for enrollment.\n\n   Cohort 5: Patients with KRAS G12C mutant NSCLC\n   * Pathologically confirmed NSCLC with a documented mutation in KRAS G12C.\n   * Received at least 1 prior line but no more than 3 prior lines of systemic therapy in the advanced or metastatic setting.\n   * Have not received prior sotorasib or other KRAS G12C inhibitor therapy.\n4. Must provide a fresh tumor biopsy from a primary or metastatic cancer lesion that can be biopsied with acceptable risk as determined by the Investigator, and archival tumor tissue sample, if available. If a fresh tumor biopsy is not possible, then an archival tumor tissue sample must be provided.\n5. Eastern Cooperative Oncology Group (ECOG) score of 0 to 2 (Dose Escalation) or 0 to 1 (Dose Expansion) at Screening\n6. Adequate organ function and bone marrow function.\n7. If a female of childbearing potential must have a negative pregnancy test prior to enrollment and agree to follow the contraception requirements.\n8. Male participants must agree to follow contraception requirements.\n9. Must provide signed consent to participate in the study and is willing to comply with study-specific procedures.\n\nExclusion Criteria:\n\n1. Must not have received the following within the specified time periods prior to the first dose of study drug:\n\n   1. Prior therapies (anticancer or therapies given for other reasons) that are known strong or moderate inhibitors or inducers of CYP3A4 or P-gp including certain herbal medications (e.g., St. John's Wort): 14 days or 5\u00d7 the half-life of the medication (whichever is longer)\n   2. All other prior anticancer therapies or any therapy that is investigational for the participant's condition with a known safety and PK profile: 14 days or 5\u00d7 the half-life of the medication (whichever is shorter)\n   3. Investigational therapies with unknown safety and PK profile: 28 days. If there is enough data on the investigational therapy to assess the risk for drug-drug interactions and late toxicities of prior therapy as low, the Sponsor's Medical Monitor may approve a shorter washout of 14 days\n   4. Grapefruit or grapefruit juice: 14 days\n2. Have not recovered from all toxicities from prior therapy according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE).\n3. Presence or history of central nervous system (CNS) metastases or leptomeningeal disease, with some exceptions\n4. New York Heart Association Class III or IV heart disease, active ischemia, or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia requiring therapy, uncontrolled hypertension, congestive heart failure, or myocardial infarction within 6 months prior to the first dose of study drug.\n5. Prolongation of the QT interval corrected by Fridericia's formula (QTcF) based on repeated demonstration of QTcF \\>450 ms in males or \\>470 ms in females at screening, or history of long QT syndrome.\n6. Left ventricular ejection fraction (LVEF) \\<50% at Screening\n7. Systemic arterial thrombotic or embolic events within 6 months prior to the first dose of study drug\n8. Systemic venous thrombotic events within 1 month prior to the first dose of study drug\n9. Malabsorption syndrome\n10. Bone disease that requires ongoing treatment or has required treatment.\n11. Major surgery within 4 weeks of the first dose of study drug. All surgical wounds must be healed and free of infection or dehiscence before the first dose of the study drug.\n12. Any other clinically significant comorbidities.\n13. For participants receiving DCC-3116 and trametinib combination or DCC-3116 and binimetinib combination: previous treatment with trametinib or binimetinib that resulted in treatment discontinuation due to intolerability as a result of an adverse event (AE) that was considered related to trametinib or binimetinib.\n14. For participants receiving DCC-3116 and sotorasib combination in Dose Escalation Part 1: previous treatment with sotorasib that resulted in treatment discontinuation due to intolerability as a result of an adverse event (AE) that was considered related to sotorasib.\n15. For participants receiving DCC-3116 and sotorasib combination: Use of proton pump inhibitors (PPIs) and H2 receptor antagonists that cannot be discontinued 3 days prior to the start of study drug administration.\n16. Known allergy or hypersensitivity to any component of the investigational drug products.\n17. Known human immunodeficiency virus unless the following requirements are met:\n\n    1. CD4 count \\>350\/\u00b5L\n    2. No AIDS-defining opportunistic infection in the last 12 months\n    3. Stable anti-retroviral regimen with medications that are not prohibited by the protocol for at least 4 weeks with HIV viral load less than 400 copies\/mL prior to enrollment.\n18. Known active hepatitis B, active hepatitis C infection or if the participant is taking medications that are prohibited per protocol.\n19. If female, the participant is pregnant or lactating.\n20. Ongoing participation in an interventional study.\n21. For participants receiving DCC-3116 and binimetinib combination: Known Gilbert's syndrome","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04892017009","EMAIL":[{"email":"cancerconnect@uwcarbone.wisc.edu"}],"GEO":[43.07305,-89.40123]},{"TITLE":"Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients","CRITERIA":"Inclusion Criteria:\n\n1. Patients with non-small cell lung cancer diagnosed by histopathology or cytopathology.\n2. Presence of bone metastases.\n3. EGFR\/ALK gene wild type.\n4. No prior treatment with PD-1 inhibitors (combination or monotherapy)\n5. Those who have not received prior antitumor therapy or have not received further antitumor therapy after failure of first-line antitumor therapy.\n6. PS score (ECOG) \u2264 2 points\n7. Normal hepatic and renal function.\n\n   Normal hepatic function: total serum bilirubin level \u2264 1.5 times of the upper limit of normal value(ULN), serum serum aspartate aminotransferase(AST) \\& alanine aminotransferase(ALT) \u2264 2.5 times ULN\n\n   Normal renal function: serum creatinine \u2264 1.5 mg\/dl (133 \u03bcmol\/L) and\/or creatinine clearance \u2265 60 ml\/min.\n8. Presence of at least one assessable lesion.\n9. Signed informed consent, patient willing to accept this regimen, able to adhere to the medication, and good compliance.\n\nExclusion Criteria:\n\n1. Unable to complete the baseline assessment form\n2. Combination of other serious illnesses, including uncontrolled active infection, severe electrolyte disturbances, and significant bleeding tendencies.\n3. Pregnant or lactating women.\n4. Combined autoimmune diseases, hematologic disorders, or long-term use of hormones or immunosuppressive drugs.\n5. Combination of other uncontrolled tumors.\n6. Combination of severe brain or mental illness that affects the patient's ability to self-report.\n7. Combined organ transplant history (including bone marrow autotransplantation and peripheral stem cell transplantation).\n8. Those who are legally incompetent and whose medical or ethical reasons affect the continuation of the research.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05378334001","EMAIL":[{}],"GEO":[23.11667,113.25]},{"TITLE":"Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer","CRITERIA":"Inclusion criteria\n\n* Diagnosis of non-small cell lung cancer\n\n  * Clinical stage I and II disease\n  * Resectable disease and complete surgical resection planned\n* Treated on companion studies at Vanderbilt University, the Veterans Administration hospital, St. Thomas, and Vanderbilt-Ingram Cancer Center Affiliate Network\n* Tumor specimen samples must be available at resection\n\nExclusion criteria\n\n* Chemotherapy before surgery\n* Radiotherapy before surgery","SEX":"ALL","AGE_MIN":18,"AGE_MAX":120,"SS_ID":"00897117003","EMAIL":[{}],"GEO":[36.16589,-86.78444]},{"TITLE":"Study of Crizotinib for ROS1 and MET Activated Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of stage IV or incurable non-squamous non-small cell lung cancer with a documented ROS1 rearrangement (cohort 1) or MET-activating mutation (exon 14) (cohort 2) or MET-amplification (cohort 3) tested in either plasma or tissue, as applicable\n* 18 years of age or older.\n* Measurable disease as per RECIST v1.1.\n* Adequate hematologic and organ function within 7 days of the proposed start date of treatment and adequate cardiac function within 28 days of the proposed start date of treatment\n* Life expectancy \\>12 weeks.\n* Have the ability to understand and the willingness to sign a written informed consent document\n* Eastern Cooperative Oncology Group (ECOG) performance status \u22642\n* No contraindication to Crizotinib therapy\n* Able to swallow and retain oral medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.\n* No pregnant\n* Agree to use methods (as agreed upon by the study doctor and participant) before the study and for at least 120 days after the last dose of study drug to prevent pregnancy\n\nExclusion Criteria:\n\n* Symptomatic untreated brain metastases.\n* Had chemotherapy (including investigational cytotoxic chemotherapy), biologic agents (e.g. targeted therapy or antibodies) within 4 weeks or radiotherapy within 2 weeks prior to the proposed first dose of study treatment.\n* Adverse events attributed to prior anti-cancer therapy \\> Grade 1 if clinically relevant.\n* Receiving medications or substances known to be strong inhibitors or inducers of CYP3A4.\n* Any known intolerance to agents structurally similar to crizotinib.\n* Congenital long QT syndrome or persistent corrected QT interval by Fredericia formula (QTcF) \u2265 500 msec.\n* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., infection\/inflammation, intestinal obstruction, unable to swallow medication, social\/ psychological issues","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04084717001","EMAIL":[{"email":"natasha.leighl@uhn.ca"},{}],"GEO":[43.70011,-79.4163]},{"TITLE":"A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Participant must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC) (any histology), and must have metastatic NSCLC at the time of enrollment: Phase 1 (Combination Dose Selection) Cohort; Metastatic NSCLC progressed on or after standard of care systemic anti-cancer therapy and participant is declining other systemic treatment options, if any;1. Participants without known mutations must have had disease progression on, or have intolerance to, prior platinum-based chemotherapy and PD-(L)1-targeted immunotherapy given concurrently or sequentially, OR 2. Participants with NSCLC characterized by known driver mutations must have had disease progression on, or have intolerance to, appropriate targeted therapies as per local standard of care. Participants may have received prior therapy with amivantamab as long as discontinuation was not due to toxicity. Participants with EGFR mutation must not have had an anti-PD-1\/PD-L1 therapy, Phase 2 Expansion Cohorts; Cohort A: Participant's tumor must have an EGFR exon19del or L858R mutation, as determined by local molecular testing, Cohort B: Participants must have tumors lacking known primary driver mutations and must have PD-L1 expression of greater than or equal to (\\>=)50 percentage (%), per local testing, and are treatment-na\u00efve in the metastatic setting\n* Participant must have at least 1 measurable lesion, according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, that has not been previously irradiated\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\nExclusion Criteria:\n\n* Participant has an uncontrolled illness, including but not limited to: a. Uncontrolled diabetes, b. Ongoing or active infection (includes infection requiring treatment with antimicrobial therapy \\[participants will be required to complete antibiotics 1 week prior to starting study treatment\\] or diagnosed or suspected viral infection), c. Active bleeding diathesis, d. Impaired oxygenation requiring continuous oxygen supplementation, e. Psychiatric illness or any other circumstances (including social circumstances) that would limit compliance with study requirements\n* Medical history of (non-infectious) interstitial lung disease (ILD)\/pneumonitis, or has current ILD\/pneumonitis, or where suspected ILD\/pneumonitis cannot be ruled out by imaging at screening\n* Has an active autoimmune disease or a documented history of autoimmune disease that requires systemic steroids or immunosuppressive agents\n* Participant has received radiotherapy for palliative purposes less than 14 days prior to the first dose of study treatment\n* Participant has a. (or has a history of) leptomeningeal disease (carcinomatous meningitis), b. spinal cord compression not definitively treated with surgery or radiation","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05908734022","EMAIL":"Participate-In-This-Study@its.jnj.com","GEO":[41.01384,28.94966]},{"TITLE":"Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Newly diagnosed patients with a solid tumor cancer diagnosis or hematologic malignancy\n2. Patients must have the ability to understand and willingness to provide consent\n3. Participants must speak English or Spanish\n\nExclusion Criteria:\n\n1. Inability to consent to the study\n2. Plans to change oncologist within 12 months\n3. Employed by the practice site\n4. Patients who anticipate moving from the area within 12 months","SEX":"ALL","AGE_MIN":21,"AGE_MAX":200,"SS_ID":"05297734017","EMAIL":"manalip@stanford.edu","GEO":[40.76078,-111.89105]},{"TITLE":"JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Age \\> 18 years.\n* ECOG performance status (PS) 0, 1, or 2.\n* Radiographic findings consistent with non-small cell lung cancer, including lesions with ground glass opacities with a solid component of 50% or greater. Those with ground glass opacities and \\<50% solid component will be excluded.\n* The primary tumor in the lung must be biopsy confirmed non-small cell lung cancer within 180 days prior to randomization.\n* Tumor \u2264 4 cm maximum diameter, including clinical stage IA and selected IB by PET\/CT scan of the chest and upper abdomen performed within 180 days prior to randomization. Repeat imaging within 90 days prior to randomization is recommended for re-staging but is not required based on institutional norms.\n* All clinically suspicious mediastinal N1, N2, or N3 lymph nodes (\\> 1 cm short-axis dimension on CT scan and\/or positive on PET scan) confirmed negative for involvement with NSCLC by one of the following methods: mediastinoscopy, anterior mediastinotomy, EUS\/EBUS guided needle aspiration, CT-guided, video-assisted thoracoscopic or open lymph node biopsy within 180 days of randomization.\n* Tumor verified by a thoracic surgeon to be in a location that will permit sublobar resection.\n* Tumor located peripherally within the lung. NOTE: Peripheral is defined as not touching any surface within 2 cm of the proximal bronchial tree in all directions. See below. Patients with non-peripheral (central) tumors are NOT eligible.\n* No evidence of distant metastases.\n* Availability of pulmonary function tests (PFTs - spirometry, DLCO, +\/- arterial blood gases) within 180 days prior to registration. Patients with tracheotomy, etc, who are physically unable to perform PFTs (and therefore cannot be tested for the Major criteria in 3.1.11 below) are potentially still eligible if a study credentialed thoracic surgeon documents that the patient's health characteristics would otherwise have been acceptable for eligibility as a high risk but nonetheless operable patient (in particular be eligible for sublobar resection).\n* Patient at high-risk for surgery by meeting a minimum of one major criteria or two minor criteria\n* Major Criteria\n\n  * FEV1 \u2264 50% predicted (pre-bronchodilator value)\n  * DLCO \u2264 50% predicted (pre-bronchodilator value)\n* Minor Criteria\n\n  * Age \u226575\n  * FEV1 51-60% predicted (pre-bronchodilator value)\n  * DLCO 51-60% predicted (pre-bronchodilator value)\n  * Pulmonary hypertension (defined as a pulmonary artery systolic pressure greater than 40mm Hg) as estimated by echocardiography or right heart catheterization\n  * Study credentialed thoracic surgeon believes the patient is potentially operable but that a lobectomy or pneumonectomy would be poorly tolerated by the patient for tangible or intangible reasons. The belief must be declared and documented in the medical record prior to randomization.\n  * Poor left ventricular function (defined as an ejection fraction of 40% or less)\n  * Resting or Exercise Arterial pO2 \u2264 55 mm Hg or SpO2 \u2264 88%\n  * pCO2 \\> 45 mm Hg\n  * Modified Medical Research Council (MMRC) Dyspnea Scale \u2265 3.\n* No prior intra-thoracic radiation therapy for previously identified intra-thoracic primary tumor (e.g. previous lung cancer) on the ipsilateral side. NOTE: Previous radiotherapy as part of treatment for head and neck, breast, or other non-thoracic cancer is permitted so long as possible radiation fields would not overlap. Previous chemotherapy or surgical resection specifically for the lung cancer being treated on this protocol is NOT permitted.\n* No prior lung resection on the ipsilateral side.\n* Non-pregnant and non-lactating. Women of child-bearing potential must have a negative urine or serum pregnancy test prior to registration. Peri-menopausal women must be amenorrheic \\> 12 months prior to registration to be considered not of childbearing potential.\n* No prior invasive malignancy, unless disease-free for \u2265 3 years prior to registration (exceptions: non-melanoma skin cancer, in-situ cancers).\n* Ability to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n* evidence of distant metastases\n* prior intra-thoracic radiation therapy. NOTE: Previous radiotherapy as part of treatment for head and neck, breast, or other non-thoracic cancer is permitted so long as possible radiation fields would not overlap. Previous chemotherapy or surgical resection specifically for the lung cancer being treated on this protocol is NOT permitted. No prior lung resection on the ipsilateral side.\n* pregnant and lactating women\n* prior invasive malignancy, unless disease-free for \u2265 3 years prior to registration (exceptions: non-melanoma skin cancer, in-situ cancers).","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"02468024048","EMAIL":[{"email":"joeldunning@nhs.net"},{"email":"charlotte.jacobs@nhs.net"}],"GEO":[54.57623,-1.23483]},{"TITLE":"Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Male or female\uff0cAge: 18 Years and older,\n2. Subjects voluntarily joined the study and signed informed consent,\n3. pathological proven resectable stage II-IIIB non small cell lung cancer (AJCC 8th edition),\n4. ECOG PS=0 or 1,\n5. resectable or potentially resectable, or resectability discussed by MDT,\n6. harboring EGFR mutation: Ex19del, L858R, T790M, G719X, Exon20 insertions, S768I or L861Q\n7. measurable lesion as per RECIST1.1.\n\nExclusion Criteria:\n\n1. pathologica or cytological proven small cell lung cancer, mixed small cell lung cancer or other than non small cell lung cancer,\n2. non small cell lung cancer harboring other driver gene alteration with approved targeted drugs,\n3. with malignant plural effusion,\n4. previous treatment to non small cell lung cancer other than this regimen,\n5. received thoracic radiotherapy,\n6. currently enrolled in other clinical trial,\n7. active or known or suspected autoimmune disease.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06300424001","EMAIL":[{"email":"syzhongwenzhao@scut.edu.cn"},{"email":"237801160@qq.com"},{},{}],"GEO":[23.11667,113.25]},{"TITLE":"Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Age \u226518 years\n2. Patients with advanced NSCLC, progressing on frontline anti-PD-1\/PD-L1 containing therapy (patient with rapid tumor progression will be excluded) and PDAC patients who failed one prior treatment.\n3. Measurable disease as defined by irRECIST criteria (See Section 7) NOTE: Tumor lesions in a previously irradiated area are not considered measurable disease; Disease that is measurable by physical examination only is not eligible.\n4. All patients with mutant KRAS status in either codon 12 (12A, C, D, R, S, V) or 13 (13D) will be included. The status of KRAS and LKB1 will be determined. For patients with KRAS G12C-mutated NSCLC, prior treatment with G12C-targeted therapy will be allowed; a wash-out period of 1 week from the last administration of targeted therapy would be allowed.\n5. Patients with known actionable driver alterations such as EGFR, ALK, ROS1, BRAF, NTRK1\/2\/3, METex14, RET, ERBB2 (HER2) and concurrent KRAS mutations will be reviewed on a case-by-case basis and patients must have experienced progression on appropriate first-line targeted therapy and anti-PD-1\/PD-L1 as indicated.\n6. Prior treatment:\n\n   * For NSCLC: Anti-PD1\/PD-L1 containing therapy; a wash-out period of 4 weeks from the last administration of therapy would be allowed.\n   * For PDAC: Patients who failed one prior treatment.\n7. Provide written informed consent.\n8. Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study).\n9. Ability to complete questionnaire(s) by themselves or with assistance.\n10. Willingness to provide mandatory blood specimens for correlative research.\n11. Willingness to provide mandatory tissue specimens for correlative research.\n12. ECOG Performance Status (PS) 0, 1 or 2.\n13. The following laboratory values obtained \u226414 days prior to registration:\n\n    \u2022 Hemoglobin \u22659.0 g\/dL\n    * Absolute neutrophil count (ANC) \u22651500\/mm3\n    * Platelet count \u2265100,000\/mm3\n    * Total bilirubin \u22641.5 x ULN (upper limit of normal)\n    * ALT and AST \u22643 x ULN (\u22645 x ULN for patients with liver involvement)\n    * PT (prothrombin time)\/INR\/aPTT (activated partial thromboplastin time) \u22641.5 x ULN OR if patient is receiving anticoagulant therapy and INR or aPTT is within target range of therapy\n    * Calculated creatinine clearance (CrCl) \u226520 mL\/min using the Cockcroft-Gault formula\n14. Negative pregnancy test done \u22647 days prior to registration, for persons of childbearing potential only.\n\nExclusion Criteria:\n\n1. Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:\n\n   \u2022 Pregnant persons\n   * Nursing persons\n   * Persons of childbearing potential who are unwilling to employ adequate contraception\n2. Any of the following prior therapies:\n\n   \u2022 Daratumumab or other anti-CD38 therapies\n   * Surgery \u22643 weeks prior to registration\n   * Chemotherapy \u22644 weeks prior to registration\n   * For NSCLC: anti-PD-1\/PD-L1 therapy \u22644 weeks prior to registration; for PDAC: Prior treatment with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathways.\n   * Focal radiation therapy within 14 days prior to first study treatment with the exception of palliative radiotherapy for symptomatic management but not on measurable extramedullary plasmacytoma. Participants must have recovered (ie, Grade \u22641 or at baseline) from radiation-related toxicities prior to first study treatment.\n   * Treatment with complementary medications (e.g., herbal supplements or traditional Chinese medicines) to treat the disease under study within \\<2 weeks prior to first study treatment. Such medications are permitted if they are used as supportive care.\n   * Treatment with any live \/ attenuated vaccine within 30 days of first study treatment.\n3. Co-morbid systemic illnesses or other severe concurrent disease, which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.\n4. Uncontrolled intercurrent illness including, but not limited to:\n\n   \u2022 Ongoing or active infection\n\n   \u2022 Symptomatic CHF (class II and above that are not properly controlled on maintenance therapy or that have been hospitalized in the last 4 weeks for heart failure)\n\n   \u2022 Unstable angina pectoris\n\n   \u2022 Cardiac arrhythmia\n   * Or psychiatric illness\/social situations that would limit compliance with study requirements.\n5. Receiving any other investigational agent, which would be considered as a treatment for the primary neoplasm.\n6. Other active malignancy \u22645 years prior to registration. EXCEPTIONS: Squamous and basal cell carcinomas of the skin, carcinoma in situ of the cervix or breast, or other non-invasive lesions that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 3 years.\n7. History of myocardial infarction \u22646 months, or CHF (class II and above that are not properly controlled on maintenance therapy or that have been hospitalized in the last 4 weeks for heart failure) requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias.\n8. Patients with known primary CNS malignancy or symptomatic CNS metastases are excluded, with the following exceptions:\n\n   * Patients with asymptomatic untreated CNS disease may be enrolled, provided all of the following criteria are met:\n\n     o Evaluable or measurable disease outside the CNS\n\n     o No metastases to brain stem, midbrain, pons, medulla, cerebellum, or within 10 mm of the optic apparatus (optic nerves and chiasm)\n     * No history of intracranial hemorrhage or spinal cord hemorrhage\n     * No ongoing requirement for dexamethasone for CNS disease; patients on a stable dose of anticonvulsants are permitted.\n     * No neurosurgical resection or brain biopsy \u226428 days prior to registration\n   * Patients with asymptomatic treated CNS metastases may be enrolled, provided all the criteria listed above are met as well as the following:\n\n     * Radiographic demonstration of improvement upon the completion of CNS-directed therapy and no evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study\n     * No stereotactic radiation or whole-brain radiation \u226428 days prior to registration\n     * Screening CNS radiographic study \u22654 weeks from completion of radiotherapy and \u2265 2 weeks from discontinuation of corticosteroids\n9. a. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins or vaccines.\n\n9. b. Patients with a plan to receive yellow fever or other live (attenuated) vaccines during the course of study.\n\n9. c. Patients who have a history or current evidence of bleeding disorder, i.e., any hemorrhage\/bleeding event of CTCAE Grade \u22652, \u226428 days prior to registration.\n\n9. d. Patients on supraphysiologic doses of steroids or use of such \u2264 6weeks prior to registration.\n\n9. e. Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease.\n\n9. f. History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sj\u00f6gren's syndrome, Bell's palsy, Guillain-Barr\u00e9 syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis. Note: Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone are eligible. Patients with controlled Type 1 diabetes mellitus (T1DM) on a stable insulin regimen are eligible. Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\n\no Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations\n\n* Rash must cover less than 10% of body surface area (BSA)\n* Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, flucinolone 0.01%, desonide 0.05%, aclometasone dipropionate 0.05%)\n* No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation \\[PUVA\\], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids).\n\n  9. g. History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest CT scan. Note: History of radiation pneumonitis in the radiation field (fibrosis) is permitted.\n\n  9. h. Any infection \\> Grade 2 \u22644 weeks prior to registration, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia.\n\n  9. i. History of peripheral neuropathy \u2265Grade 2.\n\n  10. Subject is Seropositive for HIV. Seropositive for hepatitis B (defined by a positive test for HBsAg). Subjects with resolved infection (i.e., subjects who are HBsAg negative but positive for anti-HBc and\/or anti-HBs) must be screened using RT-PCR measurement of HBV DNA levels. Those who are PCR positive will be excluded. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR. Seropositive for hepatitis C (except in the setting of a SVR, defined as aviremia at least 12 weeks after completion of antiviral therapy).\n\n  11. COPD with a FEV1 \\< 50% of predicted normal. Note that FEV1 testing is required for participants suspected of having COPD and participants must be excluded if FEV1 is \\< 50% of predicted normal.\n\n  12. Moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification. Note that participants who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed to participate.\n\n  13. Prisoners or subjects who are compulsory detained.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06015724001","EMAIL":[{"email":"jem257@georgetown.edu"},{"email":"cnb54@georgetown.edu"},{},{},{}],"GEO":[38.89511,-77.03637]},{"TITLE":"Ph I\/II Trial of Systemic VSV-IFN\u03b2-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Histologically confirmed diagnosis of:\n\n  * Arm 1: dose level 1 and below: Advanced and\/or metastatic solid tumors for which no existing options are felt to provide clinical benefit\n  * Arm 2: dose level 2: Advanced and\/or metastatic NSCLC OR NEC in which radiological progression has been demonstrated during therapy with a PD-1\/PD-L1 immune checkpoint inhibitor, and for which no existing options are felt to provide clinical benefit.\n  * Arm 3: Advanced and\/or metastatic NEC in which radiological progression has been demonstrated during therapy with a PD-1\/PD-L1 immune checkpoint inhibitor, and for which no existing options are felt to provide clinical benefit.\n  * Arm4: Advanced and\/or metastatic NSCLC in which radiological progression has been demonstrated during therapy with a PD-1\/PD-L1 immune checkpoint inhibitor, and for which no existing options are felt to provide clinical benefit.\n* Measurable disease based on RECIST 1.1. The first 3 patients in the safety run-in phase do not need measurable disease. Part C: advanced NEC (neuroendocrine carcinoma based on histopathology according to WHO criteria. Patients with small cell carcinoma, large cell neuroendocrine carcinoma, and neuroendocrine carcinoma not otherwise specified, of any primary organ are eligible in which radiological progression has been demonstrated during therapy with a PD-(L)1 immune checkpoint inhibitor, and for which no existing options are felt to provide clinical benefit.\n* Performance status of 0 or 1 on the ECOG Performance Scale.\n* Life expectancy of \\>3 months if not on active anti-cancer therapy\n* Willingness to provide biological samples required for the duration of the study including a fresh tumor biopsy sample (See Section 14.0).\n* Adequate organ function using predefined laboratory values obtained \u226414 days prior to registration.\n* Negative pregnancy test for female patients of childbearing potential\n* Absence of active CNS involvement. NOTE: Pre-enrollment imaging of asymptomatic patients not mandatory\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Availability of and patient acceptance of curative therapy.\n* Recent or ongoing serious infection, including:\n\n  1. Any active Grade 3 or higher (per the NCI CTCAE, version 4.03) viral, bacterial, or fungal infection within 2 weeks of registration.\n  2. Known seropositivity for or active infection by the human immunodeficiency virus (HIV).\n  3. Acute hepatitis B or acute hepatitis C. Patients with chronic hepatitis B or hepatitis C may be enrolled provided their liver function is adequate as per section 3.17\n  4. Known history of active TB (Bacillus tuberculosis).\n* Any serious health condition, which, in the opinion of the investigator, would place the patient at undue risk from the study, including uncontrolled hypertension and\/or diabetes, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease requiring hospitalization within 3 months) or neurological disorder (e.g., seizure disorder active within 3 months)\n* Prior therapy within the following timeframe before the planned start of study treatment as follows:\n\n  * Chemotherapy, small molecule inhibitors, radiation, interventional radiology procedure, and\/or other investigational agent: \u22643 weeks or 5 half-lives, whichever is shorter\n  * Other monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or experimental therapies: \u22644 weeks (\u22643 weeks with documented disease progression)\n* New York Heart Association classification III or IV, known symptomatic coronary artery disease, or symptoms of coronary artery disease on systems review, or known cardiac arrhythmias (atrial fibrillation or SVT) (Appendix II).\n* Any known or suspected active organ-threatening autoimmune disease, such as inflammatory bowel disease, autoimmune hepatitis, lupus, or pneumonitis, with the exception of hypothyroidism and type 1 diabetes that are controlled with treatment.\n* Immunodeficiency or immunosuppression, including systemic corticosteroids at \\>10mg\/day prednisone or equivalent within 1 week prior to planned start of study treatment\n* History of severe immune-mediated adverse reaction to immune checkpoint inhibitors.\n* Toxicities from previous therapies that have not resolved to a grade 1 or less.\n* History of non-infectious pneumonitis that required steroids, or current pneumonitis.\n* High volume disease, as assessed clinically via parameters such as radiologic impression and tumor markers or LDH.\n* Portal vein thrombosis involving more than intrahepatic portal vein branches: thrombosis of the right or left portal vein branch or the bifurcation, partial or complete obstruction of the portal vein trunk.\n* Known concurrent malignancy that is progressing or requires active treatment. EXCEPTIONS: basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in-situ cervical cancer that has been treated with curative intent, prostate cancer confined to the prostate gland with Gleason score \\<6 or PSA \\<1, as well as any stage I cancer treated with curative intent or any prior cancer with a disease-free interval of \u22653 years.\n* Other concurrent anti-cancer therapy (chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (used for a non-FDA approved indication and in the context of a research investigation)).\n* Has received a live vaccine within 30 days of planned start of study treatment. Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines and are NOT allowed.\n* Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:\n\n  * Pregnant women or women of reproductive ability who are unwilling to use highly effective contraception\n  * Nursing women\n  * Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 4 weeks after stopping treatment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03647163002","EMAIL":[{},{"email":"loftuse@CCF.org"}],"GEO":[41.4995,-81.69541]},{"TITLE":"A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","CRITERIA":"Subjects must meet all the following inclusion criteria to be eligible for participation in this study:\n\n* The subject fully understands the requirements of the study and voluntarily signs the ICF.\n* At least 18 years of age at the time of informed consent.\n* Life expectancy of 3 months or more.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n* Subjects with histologically or cytologically confirmed locally advanced or metastatic solid tumor harboring KRAS G12D mutation; subjects must be refractory or intolerable to standard treatment, or have no standard treatment available, etc.\n* Patients with adequate cardiac, liver, renal function, etc.\n\nExclusion Criteria\n\nSubjects will be excluded if they meet any of the following criteria:\n\n* Leptomeningeal disease or Active central nervous system (CNS) metastases.\n* Prior systemic anti-cancer treatment within 21 days or 5 half-lives (whichever is shorter will be used as the criteria) prior to the first dose of study drug.\n* Radical radiation within 4 weeks prior to the first dose of study drug; palliative radiotherapy within 1 week prior to the first dose of study drug.\n* Any unresolved Grade 2 or higher toxicity from previous anticancer therapy except alopecia.\n* Has participated in a study of investigational agent and received the investigational agent within 21 days or 5 half-lives, if known (whichever is shorter) prior to the first dose of study drug.\n* History of interstitial lung disease (ILD), drug induced IDL, or current active pneumonitis, radiation pneumonitis requiring therapeutic intervention, or uncontrolled other lung disease.\n* Any of the following in the past 6 months: myocardial infarction, unstable angina, symptomatic congestive heart failure, stroke or transient ischemic attack, pulmonary embolism.\n* Prior treatment with KRAS G12D targeted therapy.\n* Has a history or current evidence of any severe condition, concurrent therapy, or laboratory abnormality that might confound the interpretation of the study results, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the investigator.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06385925003","EMAIL":[{}],"GEO":[38.84622,-77.30637]},{"TITLE":"Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed non-squamous\/adenocarcinoma or adenosquamous NSCLC that is either unresectable Stage IIIb\/c disease not amenable for definitive chemoradiation, or Stage IV.\n* Age \u2265 18 years\n* ECOG performance status 0 to 1.\n* Received at least 2 but no more than 4 prior lines of systemic therapy for advanced NSCLC\n* Disease progression during or following the most recent systemic anti-cancer therapy.\n* Positive FOLR1 expression per central testing\n* At least 1 measurable target lesion per RECIST 1.1\n* Adequate organ function\n\nExclusion Criteria:\n\n* Prior treatment with a FOLR1- targeting ADCs or with ADCs that contain a tubulin inhibitor\n* Untreated central nervous system metastases\n* Ongoing immunosuppressive therapy, except for treated brain metastases, per criterion above.\n* History of severe allergic or anaphylactic reactions to monoclonal antibody therapy or to antibody-related fusion protein treatment\n* Pre-existing clinically significant ocular disorders, severe chronic obstructive pulmonary disease or asthma, clinically significant cardiac or cerebrovascular disease, or other significant concurrent, uncontrolled medical condition\n* Previous solid organ transplantation\n* Concurrent participation in another therapeutic treatment trial","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06555263002","EMAIL":"lung@sutrobio.com","GEO":[32.78306,-96.80667]},{"TITLE":"A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Phase 1 and Phase 1b lazertinib+Amivantamab combination cohorts: Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) with previously epidermal growth factor receptor (EGFR) mutation (identified locally in a Clinical Laboratory Improvement Amendments \\[CLIA\\]-certified laboratory \\[or equivalent\\]) that is metastatic or unresectable, and have progressed after standard of care front-line therapy, and exhausted available options with targeted therapy. A participant who has refused all other currently available therapeutic options is allowed to enroll\n* For the Phase 1b Lazertinib, Amivantamab and Platinum-doublet Chemotherapy (LACP) combination cohort: histologically or cytologically confirmed advanced or metastatic EGFR-mutated NSCLC who have progressed on or after an EGFR-TKI as the most recent line of treatment with a maximum of 3 prior lines of therapy in the metastatic setting allowed\n* For all expansion cohorts, the EGFR mutation must have been previously histologically or cytologically characterized, as performed by a CLIA-certified (US sites) or an accredited (outside of US) local laboratory, with a copy of the mutation analysis being submitted during screening (Phase 1b expansion Cohort B, C, D, E, and F)\n\n  1. Expansion Cohort A: Participant must have advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) that has progressed on prior treatment with osimertinib in the first or second line, followed by progression on a platinum-based chemotherapy regimen as the last line of therapy prior to study enrollment. Prior use of first or second generation EGFR tyrosine kinase inhibitor (TKI) is allowed if administered prior to osimertinib\n  2. Expansion Cohort B: Participant must have previously treated, advanced or metastatic NSCLC with documented primary EGFR Exon 20ins activating mutation. Participants should have been treated with standard of care, platinum-based chemotherapy regimens, but may have treated with approved EGFR TKI, investigational EGFR, or immunotherapy agents if refusing front line platinum-based chemotherapy standard of care. Up to 3 lines of prior systemic anti-cancer treatment are allowed\n  3. Expansion Cohort C: Participant must have advanced or metastatic NSCLC characterized by an uncommon activating mutation Additional uncommon EGFR mutations\/alterations, beyond those listed above, may be considered for enrollment after agreement with the medical monitor. Participants may be treatment na\u00efve or have been treated with one prior line of therapy which must be a first or second generation TKI (that is gefitinib, erlotinib, afatinib) in the most recent line of therapy. Prior chemotherapy is allowed if administered prior to EGFR TKI therapy, or as the only systemic anti-cancer therapy prior to study enrollment. Up to 2 lines of prior systemic anti-cancer treatment are allowed\n  4. Expansion Cohort D, E, and F: Participant must have advanced or metastatic EGFR-mutated NSCLC (EGFR Exon19 deletion or L858R) that has progressed on prior treatment with osimertinib in the first or second line (after first- or second-generation EGFR TKI), as the immediate prior line of therapy. Only previous treatment in the metastatic setting with a first, second, or third generation EGFR TKI is allowed. In addition, participants considered for Cohorts E and F must be eligible for, and agree to comply with, the use of prophylactic anticoagulation with a direct oral anticoagulant or a low molecular weight heparin during the first 4 months (from Day 1 through Day 120) according to national comprehensive cancer network (NCCN) or local guidelines, if assigned to the combination Cohort E\n* Evaluable disease\n* Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1\n* Participants must meet the study protocol defined laboratory criteria without having a history of red blood cell transfusion, platelet transfusion, or granulocyte-colony stimulating factor support within 7 days prior to the date of the test\n* A woman of childbearing potential: Must have a negative serum beta human chorionic gonadotropin at screening; Must agree not to breast-feed during the study and for 6 months after the last dose of study intervention. (Enrollment is not allowed even if a woman who is breast-feeding stops breast-feeding); Must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 6 months after receiving the last dose of study intervention\n\nExclusion Criteria:\n\n* Participant has an uncontrolled illness, including but not limited to uncontrolled diabetes, ongoing or active infection (includes infection requiring treatment with antimicrobial therapy \\[participants will be required to complete antibiotics 1 week prior to study treatment\\] or diagnosed or suspected viral infection); active bleeding diathesis; Impaired oxygenation requiring continuous oxygen supplementation; Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of study treatment; or psychiatric illness or any other circumstances (including social circumstances) that would limit compliance with study requirements. Any ophthalmologic condition that is either clinically unstable or requires treatment\n* Prior treatment with anti programmed cell death-1 (PD-1) or anti programmed cell death-ligand 1 (PD-L1) antibody within 6 weeks of planned first dose of study intervention\n* Untreated brain or other central nervous system (CNS) metastases whether symptomatic or asymptomatic. Participants who have completed definitive therapy, are not on steroids, and have a stable clinical status for at least 2 weeks prior to study treatment may be eligible for Phase 1b expansion cohorts. If brain metastases are diagnosed on Screening imaging, the participant may be enrolled, or rescreened for eligibility, after definitive treatment if above criteria are met\n* Any Toxicities from prior anticancer therapy must have resolved to common terminology criteria for adverse events (CTCAE) version 5.0 Grade 1 or baseline level (except for alopecia \\[any grade\\], Grade \\<=2 peripheral neuropathy, and Grade \\<=2 hypothyroidism stable on hormone replacement therapy)\n* Allergies, hypersensitivity, or intolerance to Lazertinib or JNJ-61186372 or their excipients. For the LACP combination cohort: participant has a contraindication for the use of carboplatin or pemetrexed (refer to local prescribing information for each agent). Participant has a history of hypersensitivity to, or cannot take, vitamin B12 or folic acid","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04077463077","EMAIL":"Participate-In-This-Study@its.jnj.com","GEO":[25.04776,121.53185]},{"TITLE":"Non-small Cell Lung Cancer With Central Nervous System Metastasis","CRITERIA":"Inclusion Criteria:\n\n- A. Non-small cell lung cancer patients diagnosed with brain metastases or meningeal metastases on brain computed tomography (CT) or magnetic resonance (MRI) images.\n\nB. Patients with non-small cell lung cancer who are about to undergo surgical brain surgery, such as brain tumor resection, lumbar abdominal drainage, Euclidean storage, or ventriculoperitoneal drainage.\n\nExclusion Criteria:\n\n- A. Non-small cell lung cancer patients without brain metastases or meningeal metastases.\n\nB. Physical condition does not allow surgical removal of the tumor.","SEX":"ALL","AGE_MIN":20,"AGE_MAX":90,"SS_ID":"06026735001","EMAIL":[{"email":"how.how0622@gmail.com"}],"GEO":[25.04776,121.53185]},{"TITLE":"A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Subject must have measurable disease per RECIST version 1.1\n* Part 1:\n\n  o Histologically confirmed advanced solid tumor that is not amenable to surgical resection or other approved therapeutic options that have demonstrated clinical benefit or subject is intolerant or has refused available therapies\n* Part 2, Expansion Cohort A:\n\n  * Histologically confirmed, inoperable non-small cell lung cancer (Stage 3b or Stage 4). Squamous and non-squamous histologies are both acceptable\n  * Wildtype for actionable oncogenic driver mutations (e.g., ALK, EGFR, ROS1, RET, NTRK). Driver mutations for KRAS, BRAF and c-METex14skip will be allowed.\n  * Received no more than 2 lines of prior systemic treatment, including anti PD-1 or anti PD-L1 therapeutic agent \u00b1 chemotherapy. Targeted therapies for KRAS, BRAF and c-METex14skip will not be counted towards the previous lines of therapy.\n* Part 2, Expansion Cohort B:\n\n  * Histologically confirmed, inoperable microsatellite stable colorectal carcinoma (Stage 3b or Stage 4)\n  * Received two previous lines of therapy including standard chemotherapy and\/or targeted antibodies\n\nExclusion Criteria:\n\n* Life expectancy of \u2264 3 months\n* Central nervous system (CNS) metastases\n* Life-threatening (grade 4) immune-mediated adverse event related to prior immunotherapy\n* Immune-mediated adverse reaction that required discontinuation of prior immunotherapy\n* Past or current history of autoimmune disease or immune deficiency\n* History of autoimmune hemolytic anemia or autoimmune thrombocytopenia\n* History of hematological malignancy\n* History of organ or stem cell transplantation\n* Clinically significant liver disease, including alcoholic hepatitis, cirrhosis, fatty liver disease and inherited liver disease\n* Previously treatment with CAR-T cells\n* Treatment with systemic immunosuppressive medication within 2 weeks prior to first dose of study treatment\n* Received live, attenuated vaccine within 4 weeks prior to first dose of study treatment\n* Treatment with systemic immunostimulatory agents within 4 weeks prior to first dose of study treatment\n* Treatment with atezolizumab, any CD47\/SIRP\u03b1 targeting agent or immune agonists (e.g., anti-CD137, anti-CD40, anti-OX40)\n* Known allergy or hypersensitivity to any of the test compounds, materials or contraindication to test product\n* Clinically significant abnormal laboratory safety tests\n* Detection of anti DSP107 antibodies at screening\n* History of HIV infection or active Hepatitis B or C infection\n* Pregnant or breast feeding or planning to become pregnant while enrolled in the study\n* History or evidence of any other clinically unstable\/uncontrolled disorder, condition, or disease","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04440735007","EMAIL":[{"email":"fudurichj@upmc.edu"},{}],"GEO":[40.44062,-79.99589]},{"TITLE":"Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Newly pathologically proven diagnosis of stage IIIA\/B\/C (per AJCC 8) NSCLC\n2. Age at least 18 years.\n3. Availability of a representative tumor specimen that is suitable for BOTH determination of PD-L1 status via local testing and, independently, other required correlative study biomarkers. Tissue submission should include:\n\n   a. A representative FFPE tumor specimen in a paraffin block, along with an associated pathology report, which will be sent to the biorepository. Patients may be eligible despite not meeting this additional tissue requirement at the discretion of the AFT Study Team. If institutional policy prevents the submission of a block, refer to the Correlative Science Manual (CSM) for alternative submission instructions.\n4. If archival tumor tissue is unavailable or is determined to be unsuitable for required testing, tumor tissue must be obtained from a biopsy performed at screening. Questions about biopsy adequacy should be directed to the study team. No active autoimmune disease or uncontrolled infection\n5. FEV1 \u2265 1.2L or \\> 40% predictive\n6. No underlying heart or lung disease precluding treatment per protocol.\n7. Measurable (RECIST v1.1) stage IIIA, IIIB or IIIC disease per AJCC 8.\n8. Patients must be considered unresectable or inoperable. Patients who decline surgery for stage III NSCLC are also eligible. Patients with nodal recurrence after surgery for early-stage NSCLC are eligible if the following criteria are met:\n\n   * No prior systemic therapy or radiation for this lung cancer\n   * Prior curative-intent surgery at least 3 months prior to the nodal recurrence Note: Patients may be medically unfit for surgery, (e.g., due to general anesthesia risk), but remain fit for chemoradiotherapy. Thus, the criterion does not necessarily have to exclude all patients who are medically unfit for surgery.\n9. Stage III A\/B\/C disease (per AJCC 8) with minimum diagnostic evaluation to include:\n\n   * History\/physical examination within 4 weeks\n   * Contrast enhanced CT of the chest including upper abdomen (or CT without contrast if contrast is medically contraindicated) within 4 weeks\n   * MRI of the brain with contrast (or CT with contrast if MRI is medically contraindicated) within 6 weeks\n   * PET\/CT skull to thigh within 6 weeks If pleural fluid is visible on CT scan, thoracentesis to exclude malignancy should be obtained unless the effusion is too small to tap in which case the patient is eligible.\n10. Patients must be at least 4 weeks from major surgery and must be fully recovered.\n11. Adequate hematologic and end organ function, defined by the following laboratory results obtained within 14 days prior to the first study treatment (Cycle 1, Day 1); if repeat labs are obtained on or prior to C1D1 they must re-meet eligibility criteria to treat):\n\n    * ANC \u2265 1500 cells\/\u00b5L\n    * WBC counts \\> 2500\/ \u00b5 L\n    * Lymphocyte count \u2265 500\/ \u00b5 L\n    * Platelet count \u2265 100,000\/ \u00b5 L\n    * Hemoglobin \u2265 9.0 g\/dL (patients may be transfused to meet this criterion).\n    * Total bilirubin \u2264 1.5 \u22c5 upper limit of normal (ULN) with the following exception:\n    * Patients with known Gilbert disease who have serum bilirubin level \u2264 3 \u22c5 ULN may be enrolled.\n    * AST, ALT and Alkaline phosphatase \u2264 2.5 \u22c5 ULN\n    * Serum albumin \u2265 25 g\/L (2.5 g\/dL)\n    * For patients not receiving therapeutic anticoagulation: INR and aPTT \u2264 1.5 \u22c5 ULN\n    * For patients receiving therapeutic anticoagulation: stable anticoagulant regimen\n    * Serum creatinine \u2264 1.5 \u22c5 ULN or creatinine clearance \u2265 45 mL\/min on the basis of the Cockcroft-Gault glomerular filtration rate estimation:\n    * (140 - age) \u22c5 (weight in kg) \u22c5 (0.85 if female) 72 \u22c5 (serum creatinine in mg\/dL)\n12. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n13. Negative HIV test at screening with the following exception: patients with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy, have a CD4+ T-cell count \\> 200\/vL, and have an undetectable viral load.\n14. Negative hepatitis B surface antigen (HBsAg) test at screening\n15. Positive hepatitis B surface antibody (HBsAb) test at screening, or negative HBsAb at screening accompanied by either of the following:\n\n    * Negative total hepatitis B core antibody (HBcAb)\n    * Positive total HBcAb test followed by quantitative hepatitis B virus (HBV) DNA \\< 500 IU\/mL\n    * The HBV DNA test will be performed only for patients who have a negative HBsAg test, a negative HBsAb test, and a positive total HBcAb test.\n16. Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening. The HCV RNA test will be performed only for patients who have a positive HCV antibody test.\n17. Non-pregnant and non-nursing. The effect of atezolizumab and tiragolumab on the fetus is unknown.\n18. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating eggs, as defined below:\n\n    * Women must remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of \\< 1% per year during the treatment period and for 90 days after the final dose of tiragolumab, 5 months after the final dose of atezolizumab, and 6 months after the final dose of paclitaxel, pemetrexed, gemcitabine, carboplatin or cisplatin. Women must refrain from donating eggs during this same period.\n    * A woman is considered to be of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (\u2265 12 continuous months of amenorrhea with no identified cause other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and\/or uterus) or another cause as determined by the investigator (e.g., M\u00fcllerian agenesis). The definition of childbearing potential may be adapted for alignment with local guidelines or regulations.\n    * Examples of contraceptive methods with a failure rate of \\< 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.\n    * The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception. If required per local guidelines or regulations, locally recognized adequate methods of contraception and information about the reliability of abstinence will be described in the local Informed Consent Form.\n    * Women of childbearing potential (WOCBP) must be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 6 months after the last dose of study medication. Patients of childbearing potential are those who have not been surgically sterilized or have not been free of menses \\> 1 year.\n\n    Women who would like to become pregnant after study treatment discontinuation should seek advice on oocyte cryopreservation prior to initiation of study treatment because of the possibility of irreversible infertility due to treatment with carboplatin.\n19. For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below:\n\n    * With a female partner of childbearing potential, men who are not surgically sterile must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \\< 1% per year during the treatment period, for 90 days after the final dose of tiragolumab, and for 6 months after the final dose of paclitaxel and\/or carboplatin. Men must refrain from donating sperm during this same period.\n    * With a pregnant female partner, men must remain abstinent or use a condom during the treatment period for 90 days after the final dose of tiragolumab, and for 6 months after the final dose of paclitaxel or carboplatin to avoid exposing the embryo.\n    * The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception. If required per local guidelines or regulations, locally recognized adequate methods of contraception and information about the reliability of abstinence will be described in the local Informed Consent Form.\n    * Male patients must agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study therapy Men who would like to father a child after study treatment initiation should be advised regarding the conservation of sperm prior to treatment because of the possibility of irreversible infertility resulting from chemotherapies used in this study.\n20. Patients are capable of giving informed consent and\/or have an acceptable surrogate capable of giving consent on the subject's behalf.\n\nExclusion Criteria:\n\n1. Active autoimmune disease.\n2. Greater than minimal, exudative, or cytologically positive pleural effusions.\n3. Involved contralateral hilar nodes.\n4. More than 10% unintentional weight loss within the past month.\n5. Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years; non-invasive conditions such as carcinoma in situ of the breast, localized prostate cancer or thyroid nodules, carcinoma in situ of the oral cavity or cervix are all permissible.\n6. Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable.\n7. Prior radiotherapy to the region of the study cancer that would result in clinically significant overlap of radiation therapy fields.\n8. Prior severe infusion reaction to a monoclonal antibody.\n9. Significant history of uncontrolled cardiac disease; i.e., uncontrolled hypertension, unstable angina, myocardial infarction within the last 6 months, uncontrolled congestive heart failure, and cardiomyopathy with decreased ejection fraction.\n10. Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration or within 2 weeks of cycle 1 day 1.\n\n    * Severe active infection, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia, or any active infection that, in the opinion of the investigator, could impact patient safety\n    * Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment\n    * Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study\n11. Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days before registration.\n12. Hepatic insufficiency resulting in clinical jaundice and\/or coagulation defects.\n13. Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, HIV testing is required for entry into this protocol due to the immunologic basis for induction treatment.\n14. Uncontrolled or symptomatic hypercalcemia (ionized calcium \\> 1.5 mmol\/L, calcium \\> 12 mg\/dL or corrected serum calcium \\> ULN).\n15. Prior allogeneic stem cell or solid organ transplantation.\n16. Pregnancy, lactation, or inability or unwillingness to use medically acceptable forms of contraception if pregnancy is a risk.\n17. Any history of allergic reaction to paclitaxel or other taxanes, or to carboplatin.\n18. Uncontrolled neuropathy grade 2 or greater regardless of cause.\n19. Any approved or unapproved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment; however, the following are allowed:\n\n    * Hormone-replacement therapy or oral contraceptives\n    * Herbal therapy \\> 1 week prior to Cycle 1, Day 1 (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to Cycle 1, Day 1)\n20. Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease.\n\n    * Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen \\[HBsAg\\] test and a positive anti-HBc \\[antibody to hepatitis B core antigen\\] antibody test) are eligible.\n    * Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.\n21. Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies.\n22. Inability to comply with study and follow-up procedures.\n23. History of active autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sj\u00f6gren's syndrome, Bell's palsy, Guillain-Barr\u00e9 syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis.\n\n    1. Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible.\n    2. Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible.\n    3. Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\n\n       * Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations.\n       * Rash must cover less than 10% of body surface area (BSA).\n       * Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%).\n       * No acute exacerbations of underlying condition within the last 6 months (not requiring psoralen plus ultraviolet A radiation \\[PUVA\\], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids).\n24. History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan.\n25. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.\n26. Active tuberculosis.\n27. Major surgical procedure within 28 days prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during the course of the study.\n28. Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live, attenuated vaccine will be required during the study.\n\n    o Patients must not receive live, attenuated influenza vaccine (e.g., FluMist\u2192) within 4 weeks prior to Cycle 1, Day 1 or at any time during the study.\n29. Illness or condition that may interfere with a patient's capacity to understand, follow, and\/or comply with study procedures.\n30. Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and IL-2) within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment.\n31. Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor- TNF-\u03b1 agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions:\n\n    * Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study after Medical Monitor confirmation has been obtained.\n    * Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.\n32. Tumors with known EGFR mutations or ALK fusion positive\/mutations. However, tumors do not need to be tested specifically for these alterations for trial eligibility.\n33. Positive Epstein-Barr virus (EBV) viral capsid antigen immunoglobulin M (IgM) test at screening; should be confirmed with PCR testing.\n\n    o An EBV polymerase chain reaction (PCR) test should be performed as clinically indicated to screen for acute infection or suspected chronic active infection. Patients with a positive EBV PCR test are excluded.\n34. Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, anti-TIGIT, and anti-PD-L1 therapeutic antibodies procedures.\n35. Treatment with systemic immunostimulatory agents (including but not limited to interferon \\[IFN\\]-\u03b1 or interleukin \\[IL\\]-2) within 4 weeks or 5 drug-elimination half-lives of the drug (whichever is shorter) prior to Cycle 1, Day 1.\n36. Treatment with investigational agent within 42 days prior to Cycle 1, Day 1 (or within 5 half-lives of the investigational product, whichever is longer).\n37. Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, or anti-tumor necrosis factor \\[anti-TNF\\] agents) within 2 weeks prior to Cycle 1, Day 1.\n\n    1. Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled.\n    2. The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.\n    3. The use of prednisone premedication required prior to iodinated contrast for CT scans is allowed.\n38. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05798663005","EMAIL":[{},{"email":"karl.haglund@osumc.edu"},{}],"GEO":[39.96118,-82.99879]},{"TITLE":"A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours","CRITERIA":"Key Inclusion Criteria:\n\n1. Willing and able to give written informed consent\n2. Male or female patients, \u226518 years of age\n3. Histological or cytological confirmation of a locally advanced (unresectable) and\/or metastatic pancreatic (PDAC), CRC, NSCLC, HNSCC, CUP, ovarian, breast, soft tissue sarcoma, bladder, oesophageal, prostate, and biliary tract cancer, who have either relapsed or progressed on SoC treatment or are intolerant or nonamenable to SoC treatment\n4. In Phase 1b part of the study only: At least 1 lesion, not previously irradiated, that can be accurately measured at baseline as \u226510mm in the largest diameter (except lymph nodes, which must have a short axis \u226515 mm) with CT or MRI scan and that is suitable for accurate repeated measurements.\n5. Life expectancy of greater than 12 weeks, in the opinion of the investigator\n6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1\n7. Recovered from all acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure (must have resolved to CTCAE grade \u22641 or returned to baseline, except alopecia and peripheral neuropathy, which can be up to CTCAE grade 2)\n8. Adequate haematological function (applies only to patients not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose):\n\n   1. Neutrophil count of \u22651.5\u00d7 10\\^9 cells\/L\n   2. Haemoglobin \u22659g\/dL (with or without transfusion support)\n   3. Platelet count of \u226575,000\/\u03bcL (without transfusion within 2 weeks prior to Cycle 1, Day 1)\n   4. International normalised ratio (INR) and activated partial thromboplastin time (aPTT) \u22641.5 times the upper limit of normal (ULN)\n9. Adequate liver function:\n\n   1. Total bilirubin \u22641.5 \u00d7 ULN (in patients with Gilbert's Syndrome, \\<3 \u00d7 ULN is allowed)\n   2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u22642.5 \u00d7 ULN (in patients with liver metastases, \\<5 \u00d7 ULN is allowed)\n   3. Alkaline phosphatase (ALP) \\<5 \u00d7 ULN (patients with documented liver or bone metastases only)\n10. Adequate renal function:\n\n    a. Serum creatinine \u22641.5 \u00d7 ULN (in patients for whom, in the Investigator's judgment, serum creatinine levels do not adequately reflect renal function, creatinine clearance by Cockcroft-Gale formula \u2265 50 mL\/min may be used)\n11. Women of childbearing potential (WOCBP) and women who have \u2264 2 years amenorrhea after start of menopause: has a negative serum pregnancy test within 7 days prior to Cycle 1, Day 1\n12. Contraception requirements:\n\n    1. Female patients of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use a highly effective contraceptive method (Pearl Index failure rate \\<1% per year) during the treatment period and for at least 6 months after the last dose of study drug\n    2. Male patients with female partners of childbearing potential must agree to use 2 acceptable methods of contraception (Pearl Index failure rate \\<1% per year), including a barrier method (with or without spermicide) during the treatment period and for at least 6 months after the last dose of study drug\n\nKey Exclusion Criteria:\n\n1. Received trastuzumab within 7 months of the planned Cycle 1, Day 1 AVA6000 infusion\n2. Received a prior total cumulative anthracycline dose of \\>350mg\/m\\^2 doxorubicin hydrochloride (or equivalent anthracycline dose)\n3. Clinically significant or untreated central nervous system (CNS) metastases requiring treatment, as determined by the Investigator.\n4. Has leptomeningeal disease\n5. Any history of an active (requiring treatment) other malignancy (except any in-situ carcinoma, non-melanoma skin carcinoma and early prostate cancer with a normal PSA) within 2 years of study entry\n6. Has a significant, uncontrolled, concomitant disease that could affect compliance with the protocol\n7. Has uncontrolled hypertension (systolic blood pressure \\[SBP\\] \\>150 mmHg and\/or diastolic \\[DBP\\] \\>100 mm Hg), unstable angina, congestive heart failure (New York Heart Association (NYHA) Class \\>II), left ventricular ejection fraction (LVEF) \\<55% or the low limit of institutional normal limit (whichever is lower) by echocardiogram (ECHO), serious cardiac arrhythmia requiring treatment (exceptions include atrial fibrillation, paroxysmal supraventricular tachycardia), history of myocardial infarction within 6 months prior to Cycle 1, Day 1; history of uncontrolled cardiovascular disease or high-sensitivity troponin above normal at baseline\n8. Screening baseline mean QTcF interval (Fridericia's) of \\>470 msec, obtained from 3 electrocardiograms (ECGs). Has any clinically significant abnormalities in rhythm, conduction, or morphology of resting ECG (e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, PR interval \\>250msec). Has any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, known family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval, a baseline resting bradycardia \\<45 beats\/min or a baseline resting tachycardia of \\>100 beats\/min\n9. Known uncontrolled HIV infection\n10. Active hepatitis B (HBV) or hepatitis C (HCV) infection:\n\n    1. Positive hepatitis B surface antigen (HBsAG) test at Screening. Patients with a past or resolved HBV infection (defined as having a negative HBsAG test and a positive antibody to hepatitis B core antigen \\[antiHBc\\] antibody test) are eligible.\n    2. Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA\n11. Severe infection(requiring IV treatment)within 21 days prior to Cycle 1, Day 1 including, but not limited to, hospitalisation for complications of infection, bacteraemia, or severe pneumonia\n12. Any other clinically significant active disease, metabolic dysfunction, physical examination finding, clinical laboratory finding, or reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drugin the opinion of the investigator.\n13. Major surgery within 21 days prior to Cycle 1, Day 1 (excluding biopsies) or anticipates the need for major surgery during study treatment\n14. Has dementia or altered mental status that in the opinion of the investigator would preclude providing informed consent\n15. Pregnant or breastfeeding woman\n16. Known hypersensitivity to any of the components of AVA6000 or any excipient related to the product\n17. Received prior investigational therapy (defined as a treatment for which there is no Regulatory Authority-approved indication) within 21 or 42 days of Cycle 1 Day 1, for small molecule and biologic investigational therapies, respectively.\n18. Received any approved anticancer therapy, including chemotherapy or hormonal therapy, within 28 days prior to Cycle 1, Day 1, with the following exceptions:\n\n    1. Hormone-replacement therapy or oral contraceptives\n    2. Tyrosine kinase inhibitors (TKIs) that have been discontinued more than 7 days prior to Cycle1, Day 1\n19. Is planned for on study treatment or has received within 21 days prior to Cycle 1, Day 1: St John's Wort, any strong inhibitor or inducer of CYP3A4, CYP2D6, narrow therapeutic index CYP1A2, CYP2B6, or P-glycoprotein (PGP) \u0327 or any moderate OATP1B3 inhibitor (will include statins)\n20. Received systemic immunosuppressive medication (for any indication) at doses of \\>10mg prednisolone (or equivalent) within 28 days prior to Cycle 1, Day 1.\n21. Received radiotherapy within 28 days prior to Cycle 1, Day 1, except for limited field palliative radiotherapy. Patients who have received prior or concomitant radiotherapy to the mediastinal area are also excluded.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04969835007","EMAIL":[{}],"GEO":[54.97328,-1.61396]},{"TITLE":"Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation","CRITERIA":"Inclusion Criteria:\n\n* Man or woman aged \u226518 years;\n* Histologically or cytopathologically confirmed primary non-small cell lung cancer (NSCLC) with predominant non-squamous cell histology;\n* The treated patients must have radiological disease progression following the last anti-tumor therapy; and the treatment-na\u00efve patients must have documented positive EGFR exon 20 insertion mutation by laboratory tests prior to enrollment;\n* Subjects meeting either of the following conditions (in accordance with the AJCC 8th edition TNM stage classification for lung cancer):\n* Treated patients: patients with locally advanced (judged by investigators as not suitable for surgery or radiotherapy) or metastatic NSCLC who are confirmed to have radiological or pathological disease progression during or after the last systematic anti-tumor therapy before the first dose of investigational product\n* Treatment-na\u00efve patients: patients with locally advanced (judged by investigators as not suitable for surgery or radiotherapy) or metastatic NSCLC who have no prior systematic anti-tumor therapy before the first dose of investigational product. If the time from the completion of adjuvant or neoadjuvant therapy to the first disease progression is \\> 6 months, the patients will be eligible for enrollment to the study; if it is \u22646 months, the patients will be regarded as treated patients and evaluated in accordance with the criteria for treated patients\n* Having at least one measurable lesion (in accordance with RECIST1.1). Note: measurable lesion can neither be subject to local therapy as radiotherapy nor used for biopsy in screening period; if there is only one measurable lesion, this lesion will be permitted to be biopsied. However, the baseline radiological examination can be performed for this lesion at least 14 days after biopsy.\n* Adequate organ function as shown in the laboratory test, including:\n* Life expectancy \\>12 weeks after the first dose of investigational product;\n* Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose of investigational product; female subjects of non-childbearing potential may not undergo pregnancy test or contraception. Non-childbearing potential is defined as: 50 years and above, no use of hormone therapy and amenorrhea for at least 12 months; or having received sterilization operation. Female subjects at childbearing age and male subjects agree to take effective contraceptive measures during the study and within 6 months after drug discontinuation;\n* Being able to understand and voluntarily participate in the study, and sign the informed consent form.\n\nExclusion Criteria:\n\n* NSCLC with predominant squamous cell histology, small cell lung cancer or neuroendocrine carcinoma indicated by Histology or cytology test;\n* Expected to receive other anti-tumor therapy other than the investigational product during the study;\n* Treatment-na\u00efve patients: having previously received systematic anti-tumor therapy targeting EGFR pathway (marketed drugs or drugs under development, EGFR TKI or antibody)\n* Treated patients: having previously received systematic anti-tumor therapy with 3rd-generation EGFR TKI (marketed drugs or drugs under development) ;\n* Having received the following therapies:\n* Having been irradiated for \\>30% bone marrow or a large area within 4 weeks prior to the first dose of investigational product;\n* Having received major surgery within 4 weeks prior to the first dose of investigational product or plan to receive major surgery during the study with exception of the surgical procedures to establish vascular access, biopsy through mediastinoscopy or thoracoscopy;\n* Use of a potent CYP3A4 inhibitor within 7 days prior to the first dose of investigational product or a potent CYP3A4 inducer within 21 days prior to the first dose of investigational product; use of the traditional Chinese medicine or traditional Chinese medicine preparation with tumor indication, or traditional Chinese medicine or traditional Chinese medicine preparation with adjuvant anti-tumor effect within two weeks prior to the first dose of investigational product or expected to be required during the study;\n* Having participated in the clinical trial and received the investigational product or device within 4 weeks or at least 5 half-lives prior to the first dose of investigational product;\n* Having received other anti-tumor drugs within 14 days prior to the first dose of investigational product;\n* Concurrent spinal cord compression or symptomatic brain metastasis. Subjects with stable brain metastasis will be eligible. Stable brain metastasis is defined as the patients who have completed regular treatment for brain metastasis, are clinically stable or asymptomatic for at least two weeks and do not need steroid therapy. If the investigator considers there is no indication of immediate radical treatment, patients with asymptomatic brain metastasis will be eligible.\n* The toxicity caused by previous anti-tumor therapy has not recovered to \u2264CTCAE grade 1 (CTCAE 5.0) ( except alopecia, sequelae of previous platinum-related neurotoxicity) or the level specified in the inclusion\/exclusion criteria;\n* Unstable pleural effusion or peritoneal effusion with obvious symptoms; those with stable clinical symptoms for at least 28 days after drainage of pleural effusion or ascites will be eligible;\n* Having a history of other malignant tumor, or other concurrent malignant tumors (except those that have undergone radical operation and have no recurrence within 5 years post operation, e.g., cervical carcinoma in situ, basal cell carcinoma of skin and papillary thyroid carcinoma);\n* Previous interstitial lung disease (ILD), drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy; or having the clinical manifestations of suspected interstitial lung disease;\n* Having severe or uncontrolled systemic disease requiring treatment that is considered by investigators as ineligible for the study, including hypertension, diabetes, chronic heart failure (NYHA Functional Classification III-IV), unstable angina pectoris, myocardial infarction within one year, active hemorrhagic disease, etc.;\n* Left ventricular ejection fraction (LVEF) \\<50% on echocardiography;\n* Clinically significant prolonged QT interval or other arrhythmia or clinical status considered by investigators that may increase the risk of prolonged QT interval; for example, QTc\\>470 ms on ECG at resting state, complete left bundle branch block, degree III atrioventricular block, congenital long QT syndrome, serious hypokalemia, or current use of drugs that may lead to prolonged QT interval;\n* Serious gastrointestinal dysfunction, or disease that may affect the intake, transportation or absorption of investigational product;\n* Known hepatitis B virus (positive HBsAg), hepatitis C virus (positive HCV Ab) or human immunodeficiency virus (positive HIV antibody) infection;\n* Infectious disease requiring intravenous medication;\n* Known history of mental disease or drug abuse, and currently having an attack or still taking drugs;\n* Known or suspected allergy to Furmonertinib or other components of its preparation;\n* Female subjects or female partners of male subjects who are pregnant or lactating, or plan to be pregnant during the study;\n* Poor compliance, inability to comply with the study procedures, restriction or requirements;\n* Other conditions that are considered by investigators as unsuitable to participate in this study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"04858958001","EMAIL":[{}],"GEO":[31.22222,121.45806]},{"TITLE":"Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance","CRITERIA":"Inclusion Criteria:\n\n* Age \u2265 18 years of age.\n* Patients with non-squamous locally advanced lung cancer defined by American Joint Committee on Cancer (AJCC) version 8 stage IIIA, IIIB, or IIIC disease.\n* Histology described as adeno-squamous or not otherwise specified favoring squamous are eligible.\n* Patients may be enrolled before or after the start of radiation therapy but must be enrolled and have their first surveillance MRI brain at 120 +\/- 10 days of their first treatment of radiation therapy for their locally advanced lung cancer. The first radiation treatment is defined as day 1.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 3.\n* Epidermal growth factor receptor (EGFR) \\> 30 mL\/min\/1.73m2.\n* Patients must be eligible for a brain MRI per the Wake Forest MRI safety screening checklist questionnaire. This will be completed by a MRI imaging technician, enrolling physician, CPDM staff member, a magnetic resonance safety officer, and\/or a radiologist as indicated in the form.\n\nExclusion Criteria:\n\n* Known brain metastases on staging MRI.\n* Questionable findings that may represent a differential of vasculature abnormalities\/stroke\/ and or metastatic disease with recommended short interval follow-up are not an exclusion factor for study participation. The recommended follow-up imaging for such findings should have no bearing on the imaging schedule in this protocol, and this research protocol imaging should NOT serve as an official follow-up scan for such findings.\n* Patients who are pregnant or breastfeeding.\n* Premenopausal persons of childbearing potential must have a negative pregnancy test within 14 days of enrollment. If women are not of childbearing potential as defined by women who are menopausal female or has had a hysterectomy, bilateral oophorectomy, or medically-documented ovarian failure, they will not require a pregnancy test. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05692635001","EMAIL":[{},{}],"GEO":[36.09986,-80.24422]},{"TITLE":"A Study of DB-1311 in Advanced\/Metastatic Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n1. Male or female adults (defined as \u2265 18 years of age or acceptable age according to local regulations at the time of voluntarily signing of informed consent).\n2. Histologically or cytologically confirmed unresectable advanced\/metastatic solid tumor that has relapsed or progressed on or after standard systemic treatments, or is intolerable with standard treatment; or for which no standard treatment is available.\n3. At least one measurable lesion as assessed by the investigator according to response evaluation criteria in solid tumors (RECIST) version 1.1 criteria. Castrate-resistant prostate cancer (CRPC) participants with bone only disease may be eligible on a case-by- case basis after discussion with the Medical Monitor.\n4. Has a life expectancy of \u2265 3 months.\n5. Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1.\n6. Has LVEF \u2265 50% by either echocardiography (ECHO) or multiple-gated acquisition (MUGA) within 28 days before enrollment.\n7. Is willing to provide pre-existing resected tumor samples or undergo fresh tumor biopsy for the measurement of B7-H3 level and other biomarkers if no contraindication.\n\n   Note: there is no minimum B7-H3 expression level mandatory for entry into the study.\n8. Is capable of comprehending study procedures and risks outlined in the informed consent and able to provide written consent and agree to comply with the requirements of the study and the schedule of assessments.\n9. Male and female subjects of reproductive\/childbearing potential must agree to use adequate contraceptive methods (e.g., double barrier or intrauterine contraceptive) during the study and for at least 4 months and 7 months after the last dose of study drug, respectively.\n10. Male subjects must not freeze or donate sperm starting at screening and throughout the study period, and at least 4 months after the final study drug administration.\n11. Female subjects must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and for at least 7 months after the final study drug administration.\n12. SCLC participants (Phase 2a Cohort 1 ONLY):\n\n    * Pathologically documented locally advanced, or metastatic SCLC not amenable to curative surgery or radiation.\n    * Relapsed\/progressed on or after 2 cycles of platinum-based chemotherapy in combination with\/without anti-PD-1\/anti-PD-L1 monoclonal antibody or intolerant to completion of 2 cycles of platinum-based chemotherapy due to the toxicity for locally advanced or metastatic disease.\n13. NSCLC participants (Phase 2a Cohort 2 ONLY):\n\n    * Pathologically documented locally advanced, or metastatic NSCLC and is not amenable to curative surgery or radiation.\n    * Has received prior treatment with platinum-based chemotherapy regimen and\/or anti-PD-1\/PD-L1 antibody-based regimen in the advanced\/unresectable, or metastatic setting unless unable or unwilling. Participants with NSCLC known to harbor a genomic alteration(s) other than EGFR mutation(s) (e.g., ALK rearrangement, ROS1 rearrangement, KRAS G12C mutation, BRAF V600E mutation, NTRK1\/2\/3 Gene fusion, MET Exon 14 skipping, RET rearrangement etc.) for which treatment is available must have also received prior treatment with at least 1 genotype-directed therapy.\n14. ESCC participants (Phase 2a Cohort 3 ONLY):\n\n    * Pathologically documented locally advanced, or metastatic ESCC and is not amenable to curative surgery or radiation.\n    * Having received at least one prior therapy for unresectable disease. Patients with recurrence within 6 months of completion of neoadjuvant or adjuvant therapy will be considered as having received one prior therapy for unresectable disease.\n15. CRPC participants (Phase 2a Cohort 4 ONLY):\n\n    * Pathologically documented metastatic adenocarcinoma of the prostate cancer.\n    * Progressive metastatic CRPC as defined: 1) castrate levels of serum testosterone \\< 50 ng\/dL AND 2) progressive disease as defined by PCWG3 criteria.\n    * Having received prior docetaxel (before or after an AR-targeted therapy). Docetaxel rechallenge was allowed.\n    * Having received prior novel hormone therapy.\n16. Melanoma participants (Phase 2a Cohort 5 ONLY)\n\n    \u2022 Histologically or cytologically confirmed diagnosis of unresectable Stage III or metastatic melanoma not amenable to local therapy, must have had either:\n    * Previously treated with a PD-1 or PD-L1 inhibitor.\n    * If participants with BRAF gene mutant melanoma, must have had a prior treatment regimen that included vemurafenib, dabrafenib, or another BRAF gene and\/or mitogen-activated protein kinase (MEK) protein inhibitor.\n17. Participants with other solid tumors (Phase 2a Cohort 6 ONLY)\n\n    * Histologically or cytologically confirmed solid tumors.\n    * Progressed or relapsed after at least one prior standard therapeutic regimen (Patients who have not received all approved or standard treatments for their cancer must be informed that these alternatives to receiving DB-1311 are available prior to consenting to participate in this trial).\n\nExclusion Criteria:\n\nUnless otherwise specified, the exclusion criteria are common to both Phase 1 and Phase 2a. Subjects who meet any of the following criteria will be excluded from the study:\n\n1. Prior treatment with B7-H3 targeted therapy.\n2. Prior treatment with antibody drug conjugate with topoisomerase inhibitor (e.g., trastuzumab deruxtecan).\n3. Has a medical history of symptomatic congestive heart failure (CHF) (New York Heart Association \\[NYHA\\] classes II-IV) or serious cardiac arrhythmia requiring treatment.\n4. Has a medical history of myocardial infarction or unstable angina within 6 months before enrollment.\n5. Has an average of Fredericia's formula-QT corrected interval (QTcF) prolongation to \\> 470 millisecond (ms) in males and females based on a 12-lead electrocardiogram (ECG) in triplicate.\n6. Unable or unwilling to discontinue concomitant drugs that are known to prolong the QT interval.\n7. Has a medical history of interstitial lung diseases (e.g., non-infectious interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or current interstitial lung diseases or who are suspected to have these diseases by imaging at screening.\n8. Has a history of underlying pulmonary disorder including, but not limited to, pulmonary emboli within 3 months of the start of study treatment, severe asthma, severe COPD, restrictive lung disease, and other clinically significant pulmonary compromise or requirement for supplemental oxygen.\n9. Any autoimmune, connective tissue or inflammatory disorders (e.g., rheumatoid arthritis, Sj\u00f6gren's, sarcoidosis) where there is documented, or a suspicion of pulmonary involvement at the time of screening.\n10. Has an uncontrolled infection requiring intravenous injection of antibiotics, antivirals, or antifungals.\n11. Know human immunodeficiency virus (HIV) infection.\n12. Subjects have active viral (any etiology) hepatitis are excluded. However, subjects with serologic evidence of chronic hepatitis B virus (HBV) infection (defined by a positive hepatitis B surface antigen \\[HBsAg\\] test or a positive hepatitis B core antibody test) who have a viral load below the limit quantification (HBV DNA titer \\< 1000 cps\/mL or 200 IU\/mL) and are not currently on viral suppressive therapy may be eligible and should be discussed with the Sponsor's Medical Monitor. However, subjects with a history of hepatitis C virus (HCV) infection who have completed curative antiviral treatment and have a viral load below the limit of quantification are eligible for study entry.\n13. Is a lactating mother (women who are willing to temporarily interrupt breastfeeding will also be excluded), or pregnant as confirmed by pregnancy tests performed within 7 days prior to enrollment.\n14. Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Subjects with clinically inactive brain metastases may be included in the study. Subjects with treated brain metastases that are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 2 weeks must have elapsed between the end of whole brain radiotherapy and study randomization.\n15. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI-CTCAE version 5.0, grade \u2264 1 or baseline. Subjects with chronic Grade 2 toxicities (e.g., Grade 2 neuropathy) may be eligible based on the discussion and agreement between Investigator and Sponsor.\n16. Has multiple primary malignancies within 3 years before enrollment, except adequately resected non-melanoma skin cancer (e.g., resected basal or squamous cell skin cancer), curatively treated in-situ disease (e.g., carcinoma in situ of the cervix or breast), other solid tumors curatively treated (e.g., superficial bladder cancer), or contralateral breast cancer.\n17. Has substance abuse or any other medical conditions that would increase the safety risk to the subject or interfere with participation or evaluation of the clinical study in the opinion of the investigator.\n18. Has known hypersensitivity to either the drug substances or inactive ingredients in the drug product.\n19. Patients with other reasons that, in the opinion of the Investigator, make them unsuitable to participate in this study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05914116003","EMAIL":[{}],"GEO":[-33.86785,151.20732]},{"TITLE":"MRD Monitoring in Lung Cancer After Resection","CRITERIA":"Inclusion Criteria:\n\n* Diagnosis of histologically confirmed NSCLC (WHO 2015 classification) with resectable (stage I-IIIA) disease.\n* Complete resection\n* Age \u226518 years at the time of screening\n* Capable of giving signed informed consent\n\nExclusion Criteria:\n\n* Mixed small cell and NSCLC histology\n* Rx, R1 or R2 resection\n* History of other malignant tumors within 5 years","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04976296001","EMAIL":[{"email":"yangxuening@gdph.org.cn"},{"email":"Z18820792959@hotmail.com"}],"GEO":[23.11667,113.25]},{"TITLE":"Effect of DM on Outcomes and Response Rate in Patients With Advanced NSCLC on ICI","CRITERIA":"Inclusion Criteria:\n\n* All consecutive patients with advanced Non Small Cell Lung Cancer who received Immune Check Inhibitors alone or in combination with chemotherapy, either as first line or as a subsequent line\n\nExclusion Criteria:\n\n* None","SEX":"ALL","AGE_MIN":0,"AGE_MAX":200,"SS_ID":"06100796001","EMAIL":[{"email":"vp_grad@aun.edu.eg"}],"GEO":[27.18096,31.18368]},{"TITLE":"An Observational Study to Assess the Effectiveness and Safety of Cemiplimab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe (CEMI-LUNG)","CRITERIA":"Inclusion Criteria:\n\n* At least 18 years of age at the time of cemiplimab treatment initiation\n* Has been diagnosed with histologically or cytologically documented squamous or non-squamous NSCLC\n* Treated with a cemiplimab-based regimen as part of routine clinical practice as determined by the treating physician (independent of the study) and in accordance with approved prescribing information, as follows:\n* Initiating treatment within the eligibility period after the study launch and site initiation Or\n* Has received one or two doses of cemiplimab within the eligibility period prior to the study launch and site initiation\n* Can understand and complete the study-related questionnaires\n* Must have given signed informed consent prior to any study activities\n\nExclusion Criteria:\n\n* Has received more than two doses of cemiplimab prior to enrolment\n* Has uncontrolled autoimmune disease\n* Is receiving cemiplimab for an indication other than advanced NSCLC\n* Has a contraindication to cemiplimab as noted in the local summary of product characteristics\n* Presence of estimated glomerular filtration rate (EGFR), anaplastic lymphoma receptor (ALK), or c-ros oncogene 1 (ROS1) driver mutations\n* Is concurrently participating in any other study of an investigational drug or procedure\n\nThe above information is not intended to contain all considerations relevant to a potential participation in a clinical trial","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05363319023","EMAIL":"clinicaltrials@regeneron.com","GEO":[52.52437,13.41053]},{"TITLE":"Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI","CRITERIA":"Inclusion Criteria:\n\n1. Provision of informed consent prior to any study specific procedures\n2. Male or female, aged at least 18 years\n3. Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1\n4. Life expectancy of at least 3 months\n5. Histologically or cytologically documented metastatic NSCLC, which are not amenable to curative surgery or radiotherapy, patients must be classified as stage IIIB-IV. Staging will be according to the TNM staging system for lung cancer (8th edition)\n6. Histologically documented that with sensitizing EGFR mutations(either L858R or Exon19del)\n7. symptomatic brain metastasis, with at least three metastatic lesions in the brain which need WBI based on investigator's decision. Symptom score 1-6 point.(notes: Symptomatic definition: Symptoms without acute intervention or hospitalization, symptoms including but not limited in headache, nausea, dizziness, and sensory disturbance, but without hospitalization or medical emergency.)\n8. HVLT-R score 15 point (Notes: this number is based on the data in a study in Chinese population)\n9. At least 1 measurable lesion in the brain according to RECIST 1.1; At least one lesion, not previously irradiated, that can be accurately measured at baseline as \u2265 10 mm in the longest diameter with computed tomography (CT) or magnetic resonance imaging (MRI).\n10. No previous treatment with EGFR-TKI or other systemic treatment, as well as radiotherapy for brain metastases.\n11. Female subjects should be using highly effective contraceptive measures, and must have a negative pregnancy test and not be breast-feeding prior to start of dosing if of child-bearing potential, or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:\n\n    * Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments\n    * Women under 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range for the institution\n    * Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation Further information in Appendix E(Definition of Women of Childbearing Potential and Acceptable Contraceptive Methods)\n12. Male subjects should be willing to agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm, as defined below: a. With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 4 months after the last dose of Osimertinib. b. Men must refrain from donating sperm during this same period\n\nExclusion Criteria:\n\n1. Involvement in the planning and\/or conduct of the study (applies to both Investigator staff and\/or staff at the study site)\n2. Previous randomisation in the present study or previous treatment with osimertinib\n3. Leptomeningeal met alone or synchronously is not allowed\n4. History of hypersensitivity to active or inactive excipients of Osimertinib or drugs with similar chemical structure or class to Osimertinib\n5. For patients, inability to collect plasma, CSF and tissue at baseline\n6. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.\n7. Currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of CYP3A4 (at least 3 week prior) (Appendix D). All patients must try to avoid concomitant use of any medications, herbal supplements and\/or ingestion of foods with known inducer effects on CYP3A4.\n8. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib.\n9. Any of the following cardiac criteria:\n\n   * Mean resting corrected QT interval (QTc) \\> 470 msec obtained from 3 electrocardiograms (ECGs), using the screening clinic ECG machine derived QTc value (Note: patients with congenital long QT syndrome (CLQTS) are excluded from this study.)\n   * Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block and second degree heart block.\n   * Patient with any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, electrolyte abnormalities (including: Serum\/plasma potassium \\< LLN; Serum\/plasma magnesium \\< LLN; Serum\/plasma calcium \\< LLN) , congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes\n10. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.\n11. Inadequate bone marrow reserve or organ function (as demonstrated by any of the following laboratory values:\n\n    * Absolute neutrophil count \\<1.5 x 109\/L;\n    * Platelet count \\<100 x 109\/L;\n    * Haemoglobin \\<90 g\/L;\n    * Alanine aminotransferase \\>2.5 x ULN if no demonstrable liver metastases or \\>5 times ULN in the presence of liver metastases;\n    * Aspartate aminotransferase \\>2.5 x ULN if no demonstrable liver metastases or \\>5 times ULN in the presence of liver metastases;\n    * Total bilirubin \\>1.5 x ULN if no liver metastases or \\>3 x ULN in the presence of documented Gilbert's Syndrome \\[unconjugated hyperbilirubinaemia\\] or liver metastases;\n    * Serum creatinine \\>1.5 x ULN concurrent with creatinine clearance \\<50 mL\/min \\[measured or calculated by Cockcroft and Gault equation\\]\n12. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.\n13. Women who are pregnant or breast-feeding.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04829019001","EMAIL":[{"email":"yangyp@sysucc.org.cn"}],"GEO":[23.11667,113.25]},{"TITLE":"Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Histologically confirmed diagnosis of non-small cell lung carcinoma with tumour PDL-1 TPS\u226550% by 22C3 pharmDx immunohistochemistry. Patients must have EGFR wild-type, ALK-rearrangement negative metastatic or advanced NSCLC (stage IV or incurable stage III). Patients with neuroendocrine (carcinoid) carcinoma, small cell or mixed small cell and non-small cell carcinoma are not eligible.\n* Must agree to use methods to prevent pregnancy as agreed upon between the investigator and the participant for at least 120 days after the last dose of study treatment.\n* The participant provides written informed consent for the trial.\n* Have measurable disease.\n* Provide archival tumor tissue sample for KRAS\/BRAF\/STK11 mutation analysis or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated.\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n* Have a life expectancy of greater than 3 months.\n* Be able to swallow and retain oral medication and not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.\n* Have adequate organ function.\n\nExclusion Criteria:\n\n* Female with positive urine pregnancy test.\n* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor, or a prior MEK inhibitor.\n* Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to registration, excluding supportive medications such as bisphosphonates.\n* Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (\u22642 weeks of radiotherapy) to non-central nervous system disease.\n* Has received a live vaccine within 30 days prior to the first dose of study drug.\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.\n* Has a known additional malignancy that is progressing or has required active treatment within the past year.\n* Has known active central nervous system metastases and\/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.\n* Has severe hypersensitivity (\u2265Grade 3) to pembrolizumab and\/or any of its excipients, or history of allergic reactions attributed to compounds of similar composition to binimetinib.\n* Has active autoimmune disease that has required systemic treatment in the past 2 years.\n* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.\n* Has an active infection requiring systemic therapy.\n* Has a known history of Human Immunodeficiency Virus.\n* Has a known history of Hepatitis B or known active Hepatitis C virus infection.\n* Has a known history of active (untreated) bacillus tuberculosis (TB).\n* Has a history or current evidence\/risk of retinal vein occlusion (RVO) or predisposing factors to RVO\n* Has a history of retinal degenerative disease.\n* Has a history of Gilbert's syndrome\n* Has any factors that increase the risk of QTc prolongation or risk of arrhythmic events or baseline QTcB interval \\>480 msec\n* Has a history of acute coronary syndromes, coronary artery bypass grafting, angioplasty, or stenting within the past 6 months prior to screening or cardiac metastases.\n* Has history or evidence of current clinically significant uncontrolled arrhythmias.\n* Has a history or evidence of current \u2265Class II congestive heart failure as defined by New York Heart Association (NYHA).\n* Has an intra-cardiac defibrillator or permanent pacemaker.\n* Has treatment-refractory hypertension defined as a systolic blood pressure \\>140 mmHg and\/or diastolic \\>90 mmHg which cannot be controlled by anti-hypertensive therapy.\n* Has a history of neuromuscular disorders associated with elevated creatine phosphokinase (CK).\n* Is planning to embark on a new strenuous exercise regimen after the first dose of study treatment.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03991819002","EMAIL":[{"email":"natasha.leighl@uhn.ca"},{}],"GEO":[43.70011,-79.4163]},{"TITLE":"MR-Linac Guided Adaptive FSRT for Brain Metastases From Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Aged 18-75 years\n* Histologically or cytologically confirmed non-small cell lung cancer\n* 1-10 metastases on contrast-enhanced MRI\n* Radiotherapy for extracranial lesions is permitted\n* Tyrosine kinase inhibitors (TKI) are permitted in patients with progression of intracranial metastases during previous TKI therapy\n* Patients have measurable or evaluable lesions based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Normal function of organs and bone marrow within 14 days: Total bilirubin 1.5 times or less the upper limits of normal (ULN); AST and ALT 1.5 times or less the ULN; absolute neutrophil count\u2265 500 cells\/mm3; creatinine clearance rate(CCR) \u226545 mL\/min; Platelet count\u226550,000 cells\/mm3; international normalized ratio(INR) \u22641.5#Prothrombin Time (PT)\u2264 1.5 \u00d7 ULN\n* Informed-consent\n\nExclusion Criteria:\n\n* Small cell carcinoma of lung\n* Intracranial metastases needed surgical decompression\n* Patients with contraindications for MRI\n* Previous radiotherapy or excision for intracranial metastases\n* The tumor has completely approached, encircled, or invaded the intravascular space of the great vessels (e.g., the pulmonary artery or the superior vena cava)\n* A cavity over 2cm in diameter of primary tumor or metastasis\n* Bleeding tendency or coagulation disorder\n* Hemoptysis (1\/2 teaspoon blood\/day) happened within 1 month\n* The use of full-dose anticoagulation within the past 1 month\n* Severe vascular disease occurred within 6 months\n* Gastrointestinal fistula, perforation or abdominal abscess occurred within 6 months\n* Hypertensive crisis, hypertensive encephalopathy, symptomatic heart failure (New York class II or above), active cerebrovascular disease or cardiovascular disease occurred within 6 months\n* Uncontrolled hypertension (systolic \\> 150mmHg and\/or diastolic \\> 100mmHg)\n* Major surgery within 28 days or minor surgery or needle biopsy within 48 hours\n* Urine protein 3-4+, or 24h urine protein quantitative \\>1g\n* Severe uncontrolled disease\n* Uncontrollable seizure or psychotic patients without self-control ability\n* Women in pregnancy, lactation period\n* Other not suitable conditions determined by the investigators","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"04946019001","EMAIL":[{"email":"liuhui@sysucc.org.cn"}],"GEO":[23.11667,113.25]},{"TITLE":"SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)","CRITERIA":"Inclusion Criteria:\n\n* Histologically confirmed BM from NSCLC or BC by local pathology\n* Single BM (maximum diameter of 3 cm) on MRI before surgery\n* Complete surgical resection (MRI-verified within 14 days prior randomization)\n* pSTAT3 score in reactive astrocytes of peritumoral tissue confirmed by local or central assessment\n* patient must have recovered from the effects of surgery, including post-operative infection, suture\/stample removal from brain surgery and wound healing before randomization\n* \u2265 18 - 70 years of age\n* Karnofsky performance status \u2265 70 at assessment \u2264 14 days prior to randomization\n* patient has adequate bone marrow, renal, and hepatic function \u2264 21 days prior to randomization as follows:\n\n  1. absolute neutrophil count (ANC) \u2265 1500\/mm3\n  2. platelets \u2265 100000\/ mm3\n  3. Hemoglobin \u2265 9.0 g\/dl (Note: the use of transfusion or other intervention to achieve hemoglobin \u2265 9.0 g\/dl is acceptable)\n  4. renal function: calculated creatinine clearance \u2265 30 ml\/min by the Cockcroft-Gault formula\n  5. hepatic function: total bilirubin \u2264 1.5 times upper limit of normal (ULN), aspartate aminotransferase (AST), and alanine transferase (ALT) \u2264 3 times ULN. Subjects with Gilbert's syndrome documented in medical history may be enrolled if total bilirubin is \\< 3 times ULN\n* Electrocardiogram (ECG) without evidence of acute cardiac ischemia \u2264 21 days prior to randomization\n* Female subject of childbearing potential (i.e. those who are not postmenopausal for at least 1 year or surgically sterile by bilateral salpingectomy, bilateral oophorectomy or hysterectomy) should practice at least one accepted method of birth control listed below during study entry, for the entire duration of the study and for at least 6 months after treatment with silibinin has ended. Male subjects should practice at least one accepted method of birth control listed below during study entry, for the entire duration of the study and for at least 6 months after treatment with silibinin has ended. If using a condom, practice at least one other method of birth control listed below during the study for at least 6 months after silibinin treatment:\n\n  * Combined (estrogen and progesterone contained) hormonal contraception (oral, intravaginal, transdermal) associated with the inhibition of ovulation\n  * Progesterone-only hormonal contraception (oral, intravaginal, transdermal) associated with the inhibition of ovulation\n  * Bilateral tubal occlusion\/ligation\n  * True abstinence: refraining from heterosexual intercourse when this is in line with the preferred and usual lifestyle of the subject\n  * A vasectomized male subject or a vasectomized partner of a female subject\n  * Intrauterine device, IUD (females)\n  * Double-barrier method (condoms, contraceptive sponge, diaphragm or vaginal ring with spermicidal jellies or cream) unless not deemed acceptable as highly effective contraception by local regulations\n* Women of child-bearing potential must have a negative pregnancy test (urine o serum) within 7 days prior the randomization\n* Must voluntarily sign and date informed consent form, for both tumor tissue biomarker testing and study participation, approved by an Independent Ethic Committee (IEC)\/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures\n\nExclusion Criteria:\n\n* Absence of expression of STAT3 on the reactive astrocytes of brain metastases\n* Incomplete surgical resection and\/or diameters \\> 3 centimeters of brain metastasis before surgery\n* Brain metastases that previously received any type of radiation therapy\n* Progressive systemic disease requiring a change of the antineoplastic therapy\n* Prior invasive malignancy (except for non-melanomatous skin cancer, oral cavity, or cervix) unless disease free for \u2265 2 years\n* Prior, concomitant, or planned treatment with experimental agents\n* Patients has had major immunologic reaction\n* Patient has had a history of hypersensitivity to silibinin or excipient\n* Patient is unsuitable to receive steroids\n* Patient is a lactating or pregnant female\n* Severe, active co-morbidity, defined as follows:\n\n  * Severe hepatic impairment (Child-Pugh C or higher \\[score of 10 or higher\\]); subject with mild or moderate hepatic impairment (Child-Pugh score of 5-9) may be eligible for treatment\n  * Unstable angina and\/or congestive heart failure within the last 6 months\n  * Transmural myocardial infarction within the last 6 months\n  * Evidence of recent myocardial infarction or ischemia by the findings of S-T elevations \u2265 2 mm using the analysis of an EKG performed within 21 days prior to enrollment\n  * New York Heart Association grade2 or greater congestive heart failure requiring hospitalization within 12 months prior to enrollment\n  * History of stroke, cerebral vascular accident or transient ischemic attack within 6 months\n  * Serious and inadequately controlled cardiac arrhythmia\n  * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of enrollment\n  * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of enrollment\n  * Subject with clinically defined Acquired Immune-Deficiency Syndrome (AIDS)-defining illness. This is necessary to ensure subjects are likely to be able to receive silibinin plus standard of care according to the systemic disease\n  * Active connective tissue disorders, such as lupus or scleroderma, that in the opinion of the Investigator may put the subject at high risk of toxicity\n  * Any other major medical illnesses or psychiatric impairments that in the Investigator's opinion will prevent administrations or completion of protocol therapy\n* Patient treated on any other therapeutic clinical protocols within 30 days prior to study entry or during participation in the study except intra-operative therapy to guide resection or experimental imaging without therapeutic intent\n* Inability to undergo contrast-enhanced MRI scans","SEX":"ALL","AGE_MIN":18,"AGE_MAX":70,"SS_ID":"05689619006","EMAIL":[{"email":"alessia.pellerino85@gmail.com"},{"email":"botta.neuro.oncologia@gmail.com"}],"GEO":[45.07049,7.68682]},{"TITLE":"Lung Cancer Biomarkers and Screening","CRITERIA":"DISEASE CHARACTERISTICS:\n\n* Screening Cohort\n\n  * At high- or low-risk for lung cancer\n  * Smoking history \u2265 20 pack years\\*\n\n    * With or without workplace exposure to asbestos\n* NOTE: \\* Participants with \\< 20 pack years of smoking are eligible if 50 years of age or older\n* Rule-Out Lung cancer group\n\n  * Referred for evaluation of suspicious nodules with 1 of the following diagnoses:\n\n    * Lung cancer\n    * Nonmalignant nodules (control group)\n\nPATIENT CHARACTERISTICS:\n\n* Not pregnant\n* No prior malignancy except nonmelanoma skin cancer\n\nPRIOR CONCURRENT THERAPY:\n\n* Not specified","SEX":"ALL","AGE_MIN":50,"AGE_MAX":200,"SS_ID":"00301119001","EMAIL":[{"email":"Jun-Chieh.Tsay@nyulangone.org"}],"GEO":[40.71427,-74.00597]},{"TITLE":"Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers","CRITERIA":"Inclusion Criteria:\n\n* Diagnosis of extensive and severe dysplasia of the respiratory epithelium\n* Those without dysplasia of the respiratory epithelium\n\n  * Recruited from the SPORE Tissue Procurement Screening Project or by private or academic physicians (for patients with moderate or severe dysplasia)\n* Survived 1 or more aerodigestive system carcinoma for \u2265 1 year\n* Completely resected stage I non-small cell cancer\n* Undergoing any of the following procedures:\n\n  * Routine panendoscopy for patients with head and neck cancer\n  * Resection of a bronchogenic carcinoma\n  * Bronchoscopy for diagnosis or staging of suspected lung cancer\n  * Subsequent bronchoscopy for surveillance or monitoring of response to endobronchial treatment in patients with prior high-grade dysplasia or worse\n  * No asthma\n  * No lung disease\n  * No respiratory illness within the past 2 weeks Patients suspected of or at risk for neoplastic lung disease who are undergoing a bronchoscopy in which differential diagnostic considerations may include multiple other etiologies such as infection and other processes.\n\nPATIENT CHARACTERISTICS:\n\n* No clinically apparent bleeding diathesis\n* No known bleeding disorder\n* No anginal\n* No clinically active coronary artery disease\n* No multifocal premature ventricular contractions\n* No poorly controlled congestive heart failure\n* No myocardial infarction within the past 6 weeks\n* No cardiac dysrhythmia that is potentially life threatening\n* Well-controlled atrial fibrillation or rare (\\< 2\/min) premature ventricular contractions allowed\n* No ventricular tachycardia or supraventricular tachycardia with a rapid ventricular response\n* No other serious medical condition that would preclude a patient from undergoing a bronchoscopy\n* No acute bronchitis or pneumonia within the past 8 weeks except when clinically proven as a possible result of lung cancer\n* No hypoxemia (i.e., \\< 90% saturation with supplemental oxygen) before bronchoscopy\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics","SEX":"ALL","AGE_MIN":21,"AGE_MAX":90,"SS_ID":"00900419001","EMAIL":[{}],"GEO":[39.72943,-104.83192]},{"TITLE":"Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Male or female aged between 18 and 75 years.\n2. Histologically or cytologically confirmed diagnosis of NSCLC with single activating EGFR mutations (L858R or Exon19Del).\n3. Confirmed diagnosis of leptomeningeal metastasis according to ESMO\/EANO guidelines.\n4. Normal liver and kidney function; WBC\u22654000\/mm3, Plt\u2265100000\/mm3.\n5. No history of severe nervous system disease.\n6. No severe dyscrasia.\n\nExclusion Criteria:\n\n1. Any evidence of nervous system failure, including severe encephalopathy, grade 3 or 4 leukoencephalopathy on imaging, and Glasgow Coma Score less than 11.\n2. Any evidence of extensive and lethal progressive systemic diseases without effective treatment.\n3. Patients with poor compliance or other reasons that were unsuitable for this study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06304441001","EMAIL":[{"email":"dr-zypan@163.com"},{"email":"guoziyang_1982@163.com"}],"GEO":[23.11147,114.41523]},{"TITLE":"Dietary Intervention for NSCLC Patients Treated With ICI","CRITERIA":"Inclusion Criteria:\n\n* Signed, informed consent\n* Age 18 years or older\n* Confirmed histological diagnosis of non-small cell lung cancer (NSCLC); Treatment with standard-of-care ICI\n* Ability to eat solid foods\n\nExclusion Criteria:\n\n* Severe dietary allergies (e.g. shellfish, nuts, seafood)\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05805319001","EMAIL":[{"email":"wiam.belkaid.chum@ssss.gouv.qc.ca"},{"email":"arielle.elkrief.med@ssss.gouv.qc.ca"},{}],"GEO":[45.50884,-73.58781]},{"TITLE":"A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy","CRITERIA":"Inclusion Criteria:\n\n1. 18 years and older\n2. Histologically and cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC) non-squamous cell carcinoma who present with locally advanced, unresectable, Stage III disease\n3. ECOG PS 0,1\n4. Expected life expectancy of 6 months and more\n5. Patients who have received at least 2 cycles of definitive platinum-based concurrent chemoradiation therapy (CCRT) and who must be within 1 to 42 days after completion of radiation therapy\n6. Patients must not have had disease progression during or following CCRT\n7. Patients with adequate organ and bone marrow function\n8. Patients who give in written consent voluntarily to participate in this study\n\nExclusion Criteria:\n\n1. History of interstitial lung disease, drug-induced interstitial lung disease, or radiation interstitial pneumonia\n2. History of other primary malignancy\n3. Mixed small cell and NSCLC histology\n4. Prior treatment with EGFR-TKI Therapy\n5. Unresolved toxicity of CTCAE grade 2 or higher following chemoradiation\n6. Current history of CTCAE grade 2 or higher pneumonia prior to chemoradiation therapy\n7. Patients with severe hypersensitivity to active ingredient or excipient of the investigational medicinal product\n8. Pregnant or breastfeeding patients\n9. Patients who do not agree to contraception with medically acceptable method for at least 6 months after the end of study intervention treatment\n10. Patients who participated in clinical trials within 4 weeks before participating in this study\n11. Judgment by the investigator that the patient is unsuitable to participate in this study","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05338619013","EMAIL":[{},{}],"GEO":[37.566,126.9784]},{"TITLE":"Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab","CRITERIA":"Inclusion Criteria:\n\n1. Pathologically diagnosed NSCLC (squamous cell carcinoma, adenocarcinoma, large- cell carcinoma, or non-small-cell lung cancer not otherwise specified), clinical stage III (AJCC 8th Ed.))\n2. At time of consent, potential subjects must be a candidate for dCRT OR Must have received dCRT with at least 2 cycles of platinum-based chemotherapy concurrent with conventional fractionated radiation therapy with a total dose of 5700 - 6300 cGy\n3. Patients must be aware of the nature of his\/her disease and willingly provide written, informed consent. Including compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization (e.g., Health Insurance Portability and Accountability Act in the US) obtained from the patient\/legal representative prior to performing any protocol-related procedures, including screening evaluations.\n4. Age \\> 19 years at time of study entry\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at time of enrollment.\n6. Life expectancy of \\> 12 weeks\n7. Adequate normal organ and marrow function as defined below:\n\n   * Hemoglobin \u22659.0 g\/dL (5.59 mmol\/L) (patients can be transfused to meet this criterion)\n   * Absolute neutrophil count (ANC) \\> 1500 per mm3\n   * Platelet count \u2265100 x 109\/L (\\>100,000 per mm3)\n   * Serum bilirubin \u22641.5 x institutional upper limit of normal (ULN).\n   * AST (SGOT)\/ALT (SGPT) \u22642.5 x institutional upper limit of normal.\n   * Calculated creatinine CL\\>40 mL\/min by the Cockcroft-Gault formula\n8. Evidence of post-menopausal status or negative serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.\n9. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up\n\nExclusion Criteria:\n\n1. Involvement in the planning and\/or conduct of the study (applies to both AstraZeneca staff and\/or staff at the study site)\n2. Patients who have received prior anti-PD-1, anti PD-L1 or anti CTLA-4\n3. Participation in another clinical study with an investigational product during the last 4 weeks\n4. Concurrent enrolment in another clinical study, unless it is an observational (non- interventional) clinical study or during the follow-up period of an interventional study\n5. Mixed small cell and non-small cell lung cancer histology\n6. Patients who receive sequential chemoradiation therapy for locally advanced NSCLC\n7. Patients with locally advanced NSCLC who have progressed during definitive platinum based, concurrent chemoradiation therapy\n8. Any unresolved toxicity NCI CTCAE Grade \\>2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria\n\n   1. Patients with Grade \u22652 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician.\n   2. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the Study Physician. For example, post-operative neurological deficits for previous benign brain tumors, urinary incontinence from radical prostectomy for prostate cancer, peripheral neuropathy from chemotherapy for breast cancer.\n9. Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.\n10. Major surgical procedure (as defined by the investigator) within 28 days to the first dose of immunotherapy (excluding the placement of vascular access) that would prevent administration of study drug or radiation therapy.\n11. History of allogenic organ transplantation.\n12. Active or prior documented autoimmune or inflammatory disorders within the past 2 years (including inflammatory bowel disease \\[e.g., colitis or Crohn's disease\\], diverticulitis \\[with the exception of diverticulosis\\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \\[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis hypophysitis, uveitis, etc\\]). The following are exceptions to this criterion:\n\n    1. Patients with vitiligo or alopecia\n    2. Patients with hypothyroidism (e.g., following Hashimoto syndrome stable on hormone replacement or Graves' disease).\n    3. Any chronic skin condition including psoriasis that does not require systemic therapy (within the past 2 years).\n    4. Patients without active disease in the last 5 years may be included but only after consultation with the study physician.\n    5. Patients with celiac disease controlled by diet alone.\n13. Known allergy or hypersensitivity to Durvalumab or any excipient.\n14. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness\/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent\n15. History of another primary malignancy except for\n\n    1. Malignancy treated with curative intent and with no known active disease \u22655 years before the informed consent and of low potential risk for recurrence\n    2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\n    3. Adequately treated carcinoma in situ without evidence of disease\n16. History of primary immunodeficiency\n17. Known history or active infection of tuberculosis, hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1\/2 antibodies).\n18. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab.\n\n    1. Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)\n    2. Systemic corticosteroids at doses \u226410 mg\/day of prednisone or its equivalent\n    3. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)\n    4. Systemic steroid administration required to manage toxicities arising from radiation therapy delivered as part of the chemoradiation therapy for locally advanced NSCLC is allowed.\n19. Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP.\n20. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab therapy.\n21. Prior randomization or treatment in a previous durvalumab and\/or tremelimumab clinical study regardless of treatment arm assignment.\n22. Any prior Grade \u22653 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE \\>Grade 1.\n23. Previous history of RT (other than RT as part of the dCRT for the current course of NSCLC) involving any part of lungs, chest wall, thoracic spine or breast(s).\n24. Judgment by the investigator that the patient is unsuitable to participate in the study for any condition and the patient is unlikely to comply with study procedures, restrictions and requirements.\n25. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) \u2265470 ms calculated from 3 ECGs (2-5 minutes apart). Triplicate ECGs should only be performed if screening ECG shows QTcF \u2265470 ms.","SEX":"ALL","AGE_MIN":19,"AGE_MAX":200,"SS_ID":"04748419001","EMAIL":[{"email":"kimberly.shields@unmc.edu"}],"GEO":[41.25626,-95.94043]},{"TITLE":"Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing","CRITERIA":"Key Eligibility Criteria (additional criteria may apply) Part 1 Key Inclusion Criteria\n\n1. Pathologically confirmed solid tumors, e.g., Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), or Pancreatic Cancer (PANC), that is metastatic, unresectable locally advanced, or in the Investigator's opinion the subject is high risk for incurable relapse within two years.\n\nPart 1: Key Exclusion Criteria\n\n1. History of any of other malignancy in the past 5 years other than non-melanoma skin carcinoma, low grade localized prostate cancer, superficial bladder cancer, ductal carcinoma in situ (CIS) of the breast, CIS of the Cervix, or Stage I uterine cancer.\n2. Prior allogeneic stem cell transplant.\n3. Prior solid organ transplant.\n\nPart 2 : Key Inclusion Criteria\n\n1. Pathologically confirmed solid tumors, e.g., Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer (PANC), Mesothelioma, or Ovarian Cancer (OVAC) that is metastatic, unresectable locally advanced, or in the Investigator's opinion the subject is high risk for incurable relapse within two years.\n2. Participants are germline HLA-A\\*02 heterozygous confirmed by HLA typing.\n3. Primary tumor tissue showing LOH of HLA-A\\*02 by NGS testing.\n4. Eastern Cooperative Oncology Group (ECOG) 0 or 1 performance status.\n\nPart 2: Key Exclusion Criteria\n\n1. History of any of other malignancy in the past 5 years other than non-melanoma skin carcinoma, low grade localized prostate cancer, superficial bladder cancer, ductal carcinoma in situ (CIS) of the breast, CIS of the Cervix, or Stage I uterine cancer.\n2. Prior allogeneic stem cell transplant.\n3. Prior solid organ transplant.\n4. Participants who have received any cancer therapy on any investigational therapy for any indication, including but not limited to chemotherapy, small molecules, monoclonal antibodies, or radiotherapy (with bone marrow impact) within 2 weeks of planned apheresis or 3 half-lives, whichever is shorter.\n5. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment necessitating specific treatment, or any major episode of infection requiring treatment with Intravenous (IV) antimicrobials (e.g., IV antibiotics) or hospitalization (relating to completion of antibiotic course).\n6. Has known active central nervous system metastases. Subjects with previously treated brain metastases may participate upon medical monitor agreement.\n7. In the Investigator's judgement, any other condition or reason the subject would not complete the required study visits and procedures, and follow up visits, or comply with the study requirements for participation.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04981119013","EMAIL":[{},{"email":"scolden2@fredhutch.org"},{}],"GEO":[47.60621,-122.33207]},{"TITLE":"Deep Learning Signature for Predicting Occult Nodal Metastasis of Clinical N0 Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n(1) Participants scheduled for surgery for radiological finding of pulmonary lesions from the preoperative thin-section CT scans; (2) The maximum short-axis diameter of N1 and N2 lymph nodes less than 1 cm on CT scan; (3) The SUVmax of N1 and N2 lymph nodes less than 2.5; (4) Pathological confirmation of primary NSCLC; (5) Age ranging from 20-75 years; (6) Obtained written informed consent.\n\nExclusion Criteria:\n\n(1) Multiple lung lesions; (2) Poor quality of PET-CT images; (3) Participants with incomplete clinical information; (4) Participants not receiving systematic lymph node dissection; (5) Participants who have received neoadjuvant therapy.","SEX":"ALL","AGE_MIN":20,"AGE_MAX":75,"SS_ID":"05425134003","EMAIL":[{}],"GEO":[29.87819,121.54945]},{"TITLE":"A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.","CRITERIA":"Inclusion Criteria:\n\nSubject must meet all of the following applicable inclusion criteria to participate in this study:\n\n1. Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.\n2. Age \u2265 18 years at the time of consent.\n3. Histologically or cytologically confirmed non-squamous, non-small cell lung cancer\n4. Locally advanced or metastatic disease.\n5. Patients must have one of the following:\n\n   Cohort A:\n   * NSCLC which harbours EGFR Exon 19 deletion.\n   * NSCLC which harbours EGFR L858R mutation.\n   * NSCLC with activating EGFR exon20 insertion or exon 18\/21 atypical mutations EGFR deletion\/mutation must be documented by a Clinical Laboratory Improvement Amendments (CLIA) certified test (either from tissue or ctDNA from blood is allowed)\n\n   The documentation of EGFR mutation status can be obtained any time since the initial diagnosis of non-small cell lung cancer.\n\n   For cohort A, the patient must have received an EGFR TKI treatment, if approval targeted therapy exists.\n\n   For patients whose tumor harboring EGFR Exon19 deletion or L858R mutation, prior osimertinib treatment is required, unless contraindicated for medical reasons.\n\n   Cohort B:\n\n   \u2022 NSCLC which harbours LKB1 mutation. LKB1 mutation must be documented by a Clinical Laboratory Improvement Amendments (CLIA) certified test (either from tissue or ctDNA from blood is allowed) The documentation of LKB1 mutation status can be obtained any time since the initial diagnosis of non-small cell lung cancer.\n6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (Appendix A)\n7. At least one lesion, not previously irradiated and not chosen for biopsy during the study screening period, that can be accurately measured at baseline at equal or greater than 10mm in the longest dimension by RECIST 1.1.\n8. Prior treatment with cytotoxic chemotherapy or immunotherapy is allowed for both cohorts. Up to 3 lines of prior therapy is allowed.\n9. Patients must have adequate hematologic, coagulation, hepatic, and renal function. All laboratory tests must be obtained less than 4 weeks from study entry. This includes:\n\n   * ANC \\>\/= 2,000\/mm3 and white blood cells \\>\/= 3,000\/mm3\n   * platelet count \\>\/=150,000\/mm3\n   * HgB \u2265 8.5 g\/dL\n   * Creatinine \u2264 30 mL\/minute (using Cockroft-Gault formula).\n   * Total Serum Bilirubin \u2264 ULN (unless with documented Gilbert Syndrome diagnosed by genetic testing)\n   * SGOT, SGPT \u2264 1.5 X ULN\n   * Cholestrol \u2264 350 mg\/dL, 9.1 mmol\/L, and triglyceride \u2264 500 mg\/dL, 5.6 mmol\/.\n10. Females of childbearing potential must not be breast feeding and must have a negative serum or urine pregnancy test within 7 days of starting of treatment. The patient must agree to use adequate contraception for a minimum of two weeks prior to receiving study medication until 3 months after discontinuation of the study medication. Acceptable methods of contraception include total and true sexual abstinence, hormonal contraceptives that are not prone to drug-drug interactions (IUS Levonorgestrel Intra Uterine System (Mirena), Medroxyprogesterone injections (Depo-Provera)), copper-banded intra-uterine devices, and vasectomized partner. All hormonal methods of contraception should be used in combination with the use of a condom by their sexual male partner. Females of childbearing potential are defined as those who are not surgically sterile (i.e., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as 12 months with no menses without an alternative medical cause). Women will be considered post-menopausal if they have been amenorrheic for the past 12 months without an alternative medical cause. The following age-specific requirements must also apply: Women \\< 50 years old: they would be considered post-menopausal if they have been amenorrheic for the past 12 months or more following cessation of exogenous hormonal treatments. The levels of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) must also be in the post-menopausal range (as per the institution). Women \u2265 50 years old: they would be considered post-menopausal if they have been amenorrheic for the past 12 months or more following cessation of all exogenous hormonal treatments, or have had radiation-induced oophorectomy with the last menses \\> 1 year ago, or have had chemotherapy-induced menopause with \\>1 year interval since last menses, or have had surgical sterilization by either bilateral oophorectomy or hysterectomy.\n11. Non-sterilized males who are sexually active with a female partner of childbearing potential must use adequate contraception for the duration of the study and 3 months after the last dose of study medication. Adequate contraception methods include: birth control pills (e.g. combined oral contraceptive pill), barrier protection (e.g. condom plus spermicide, cervical\/vault cap or intrauterine device), and abstinence. Patients should not father a child for 6 months after completion of the study medication. Patients should refrain from donating sperm from the start of dosing until 6 months after discontinuing the study medication. If male patients wish to father children they should be advised to arrange for freezing of sperm samples prior to the start of the study medication.\n12. Patients who meet eligibility criteria to either Cohort A or B will be allowed to enroll to the run-in cohort.\n\nExclusion Criteria:\n\nSubjects should not enter the study if any of the following exclusion criteria are fulfilled:\n\n1. Spinal cord compression or brain metastases unless asymptomatic or stable for at least 2 weeks prior to start of study treatment.\n2. Any unresolved toxicities from prior therapy greater than CTCAE grade 1 (with the exception of alopecia grade 2) at the time of starting study treatment.\n3. Any evidence of severe or uncontrolled systemic diseases. Screening for chronic conditions is not required.\n4. Woman of childbearing potential (WOCBP) not protected by highly-effective contraceptive method(s) of birth control, and\/or who are unwilling or unable to be tested for pregnancy.\n5. Pregnant or breastfeeding woman\n6. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirement.\n7. Active or severe autoimmune disorders, including rheumatoid arthritis\n8. Exclusion related to Tuberculosis (TB):\n\n   * Active TB or a history of incompletely treated TB regardless of screening Quantiferon result\n   * Quantiferon positive patients (no active disease) are excluded from the study unless the following conditions are met:\n   * Patients with a history of prior documented completed chemoprophylaxis for latent tuberculosis infection (eg, acceptable treatments include 9 months of isoniazid 300 mg oral daily or equivalent proven regimen per local guidelines) or treatment of active tuberculosis infection (TBI) who has obtained consultation with a specialist to rule out active TBI or the need to receive further treatment.\n   * Patients with no prior history of chemoprophylaxis for latent TBI or treatment for active TBI but have obtained consultation with a specialist to initiate an appropriate regimen of chemoprophylaxis, based on local epidemiology and applicable guidelines and have demonstrated compliance and tolerated treatment for 1 month.\n\n   Consultations with and prior approval from IND sponsor are required in either of the aforementioned scenarios.\n   * Clinically significant abnormality consistent with prior\/active TB infection based upon chest radiograph with at least posterior-anterior view (See Section 10.8.1). Additional lateral view is recommended but not required.\n   * Suspected extra-pulmonary TB infection regardless of screening Quantiferon result.\n   * Patients at high risk of contracting TB, such as close contact with individuals with active or latent TB.\n   * Patient who received Bacille Calmette Guerin -vaccination within 12 months prior to screening.\n9. Patients with a history of invasive opportunistic infections, including but not limited to histoplasmosis, listeriosis, coccidioidomycosis, candidiasis, pneumocystis jirovecii, aspergillosis despite resolution or John Cunningham virus (progressive multifocal leukoencephalopathy).\n10. Patients with fever (\\>38\u00b0C) associated with infection, or chronic, persistent, or recurring infection(s) requiring active treatment with antibiotics, antivirals, or antifungals within 4 weeks prior to the screening visit or other frequent recurrent infections deemed unacceptable as per Investigator judgment.\n11. Patients with uncontrolled diabetes mellitus, defined as glycosylated hemoglobin (HbA1c) greater than 9% at the screening visit.\n12. Patients with non-healed or healing skin ulcers.\n13. Patients who received any live, attenuated vaccine within 3 months prior to the baseline visit, such as varicella-zoster, oral polio or rubella vaccines.\n14. Patients who are positive for hepatitis B surface antigen (HBsAg) or are positive for total hepatitis B core antibody (HBcAb) with negative hepatitis B surface antibody (HBsAb) or are positive for both HBcAb and HBsAb with presence of HBV DNA at screening. E 25. Patients who are positive for hepatitis C antibody (HCV Ab).\n15. Patients who are positive for human immunodeficiency virus (HIV) antibody test at screening or who previously had a positive HIV antibody test, or who are suspected to be positive for HIV.\n16. Patients with a history of recurrent herpes zoster or active herpes zoster.\n17. Patients with a history of prior articular or prosthetic joint infection.\n18. Prior or current history of malignancy, including lymphoproliferative diseases, other than adequately treated carcinoma in-situ of the cervix, non-metastatic squamous cell or basal cell carcinoma of the skin, within 5 years prior to the baseline visit.\n19. Prior or current history of other significant concomitant illness(es) that, according to Investigator's judgment, would adversely affect the patient's participation in the study. These include, but are not limited to, cardiovascular (including Stage III or IV cardiac failure according to the New York Heart Association classification), renal, neurological (including demyelinating disease), active infectious diseases, endocrinological, gastrointestinal, hepato-biliary, metabolic, pulmonary, non-malignant lymphoproliferative disease or other lymphatic disease(s).\n20. Patients who have had surgery within 4 weeks prior to the screening visit or with planned surgery during the course of the study.\n21. Patients with a history of a systemic hypersensitivity reaction, other than localized injection site reaction, to any biologic drug and known hypersensitivity to any constituent of the sarilumab product.\n22. Patients with a history of inflammatory bowel disease or severe diverticulitis or previous gastrointestinal perforation.\n23. Cognitively impaired adults.\n24. Uncontrolled or significant heart disease, such as long QTc interval greater than 480ms on baseline EKG, NYHA III\/IV heart failure or uncontrolled arrhythmia.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05704634001","EMAIL":[{"email":"xle1@mdanderson.org"},{}],"GEO":[29.76328,-95.36327]},{"TITLE":"Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)","CRITERIA":"Inclusion Criteria:\n\n* Participants who are diagnosed with nsqNSCLC histologically or cytologically confirmed\n* Participants with Radiologically confirmed\/documented disease progression during or after the following systemic therapies (all required):\n\n  * At most, 1 line of anti-PD-(L)1 therapy for locally advanced or metastatic disease. Rechallenge with the same anti-PD-(L)1 for disease considered sensitive to anti-PD-(L)1 therapy (e.g. after a treatment break) is considered 1 line\n  * Platinum-based therapy for locally advanced or metastatic disease, given in combination or sequentially with anti-PD-(L)1 therapy. Participants who received adjuvant platinum-based therapy meet this criterion if disease progression occurred within 6 months from the last dose that the participant received that therapy. No additional cytotoxic therapies after progression on platinum-based therapy are allowed\n  * Prior best overall response of stable disease or better with anti-PD-(L)1 therapy\n  * Disease progression must have occurred while the participant has been receiving anti-PD-(L)1 therapy or within 16 weeks of the last dose of anti-PD-(L)1 therapy\n* Participants with Measurable disease per RECIST v1.1\n* Participants with Eastern Cooperative Oncology Group (ECOG) PS 0 or 1\n* Adequate hematological, hepatic, and renal function as defined in the protocol.\n* Phase 2a part only: central liquid biopsy analysis of tumor molecular alterations with an assay with appropriate regulatory status\n* Other protocol defined inclusion criteria could apply\n\nExclusion Criteria:\n\n* Participants with tumors harboring actionable epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic aberrations. Participants with tumors with other actionable aberrations are eligible and allowed to have received up to 1 line of available targeted therapy\n* Participants with history of additional malignancy within 3 years before the date of enrollment. Exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the Investigator, with concurrence of the Sponsor's Medical Monitor, is considered cured with minimal risk of recurrence within 3 years\n* Participants with known brain metastases, unless clinically stable\n* Participant with history of (noninfectious) pneumonitis that required systemic corticosteroids or current pneumonitis\/interstitial lung disease\n* Other protocol defined exclusion criteria could apply","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05882734054","EMAIL":[{"email":"francisco_aparisi@iislafe.es"},{}],"GEO":[39.46975,-0.37739]},{"TITLE":"Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)","CRITERIA":"Inclusion Criteria:\n\n1. The subject will voluntarily sign the informed consent in person, and provide the informed consent before any specific study procedures;\n2. Male and female, \u226518 years old;\n3. Primary non-squamous NSCLC confirmed histologically by the central laboratory;\n4. Brain imaging examinations should be performed before surgery or enrollment;\n5. The patient was clinically confirmed as stage I by imaging, and was staged according to the eighth edition of TNM lung cancer;\n6. As confirmed by the central laboratory, the tumor contains one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), alone or in conjunction with other EGFR mutations, including T790M;\n7. The primary NSCLC must be completely resected by surgery, and all lesions must be removed at the end of the surgery.All surgical margins must be negative. Lobectomy can be done with open surgery or thoracoscopic (VATS);\n8. Central laboratory pathology confirmed solid and\/or micropapillary component \u226510%, or STAS;\n9. The interval from operation to adjuvant Osimertinib treatment is no more than 10 weeks;\n10. WHO physical status score is 0\\~1;\n11. Paraffin-embedded sections (10-15 sheets), or wax blocks or fresh frozen tissue for surgical resection of the lesion should be provided;\n12. At least 2 weeks prior to initiation of the study drug, female subjects should be using highly effective contraceptive methods, pregnancy tests must be negative, and there must be no ongoing breastfeeding prior to initiation of the drug, or else one of the following criteria must be met at the time of screening to demonstrate the possibility of non-fertility:\n\n    * Postmenopausal was defined as over 50 years of age and amenorrhea for at least 12 months after cessation of all exogenous hormone therapy.\n    * Women under 50 should be considered to have stopped menstruating if they have stopped menstruating for 12 months or more after stopping exogenous hormone therapy and their LH and FSH levels are within the agency's postmenopausal range.\n13. Irreversible surgical sterilization recorded by hysterectomy, bilateral oophorectomy or bilateral salpingectomy, but not tubal ligation;Male subjects must be willing to use barrier contraception.\n\nExclusion Criteria:\n\n1. Exposure to other antitumor therapies before enrollment;\n2. Patients who only received segmental resection and wedge resection;\n3. History of other malignancies, other than non-melanoma skin cancer, carcinoma in situ or other solid tumors that have been effectively treated, and the treating physician has determined that there is no evidence of disease recurrence for 5 years after treatment;\n4. Evidence of any severe or uncontrolled systemic disease, including uncontrolled hypertension and active bleeding, any condition that the investigator considers to be detrimental to patient participation in the study or to adherence to the protocol, or active infections including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV). Omission requirement for screening chronic diseases;\n5. Any of the following cardiac criteria:\n\n   * QTc values obtained using screening clinic ECG machines mean resting corrected QT interval (QTc) \\> 470 milliseconds from 3 electrocardiogram (ECG) tests,\n   * Any abnormalities in rhythm, conduction, or morphology of a clinically significant resting ECG, such as left bundle branch block, third degree heart block, and second degree heart block.\n   * Any factors that increase the risk of prolonged QTc or arrhythmia events, such as heart failure, hypokalemia, congenital long QT syndrome, sudden unexplained death under 40 years of age in a first-degree relative or any concomitant medication known to prolong the QT interval.\n6. Any evidence of prior history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonia requiring steroid treatment, or active interstitial lung disease;\n7. Lack of adequate bone marrow reserve or organ function (demonstrated by any of the following laboratory values: absolute neutrophil count \\<1.5\u00d710\u2079\/L;Platelet count \\<100\u00d710\u2079\/L;Hemoglobin \\<90 g\/L;Alanine aminotransferase \\> 2.5 ULN; Aspartate aminotransferase \\>2.5 times ULN;Total bilirubin \\> 1.5 ULN;Serum creatinine \\>1.5 ULN with creatinine clearance \\<50 mL\/min \\[as measured or calculated by Cockcroft and Gault formulas\\] - creatinine clearance only needs to be confirmed when creatinine \\>1.5 ULN);\n8. History of hypersensitivity to active or inactive excipients of Osimertinib or drugs with similar chemical structures or classes to ocitinib;\n9. Uncontrolled nausea and vomiting, chronic gastrointestinal illness, inability to swallow formulated drugs, or prior major bowel resection that prevents adequate absorption of Osimertinib;\n10. Any evidence of corneal injury confirmed by ophthalmic examination through slit lamp evaluation;\n11. The patient is pregnant or nursing;\n12. History of allergy to ocitinib active or inactive excipients or drugs similar in chemical structure or class to Osimertinib;\n13. If the patient is unlikely to comply with study procedures, restrictions, and requirements, the investigator judges that the patient should not participate in the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05686434001","EMAIL":[{"email":"chen_checn@tmu.edu.cn"}],"GEO":[39.14222,117.17667]},{"TITLE":"ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers","CRITERIA":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed extensive stage small cell or metastatic non-small cell lung cancer that has progressed on frontline therapy who are fit for treatment with gemcitabine and docetaxel in the opinion of the treating physician. Phase II enrollment will occur separately to the SCLC and NSCLC cohorts, with up to 36 enrolled in each cohort.\n* Measurable disease per RECIST 1.1.\n* Treated with at least one previous line of systemic therapy. The allowable window between treatments is 21 days for chemotherapy or a TKI or 5 half-lives for a TKI (whichever is shorter), 21 days and progression by CT for immunotherapy, 21 days for RT, 21 days for surgery, or 28 days for an investigational agent.\n\n  * Patients with ES-SCLC must have been treated with first-line therapy of platinum doublet + anti-PD(L)1 therapy, if eligible.\n  * Patients with NSCLC without a driver mutation must have been treated with first-line therapy of platinum doublet + anti-PD(L)1 therapy, if eligible.\n  * Patients with NSCLC with a driver mutation (EGFR, ALK, ROS1) must have been treated with an FDA approved targeted therapy and subsequent platinum doublet therapy, if eligible.\n* At least 18 years of age.\n* ECOG performance status \u2264 1.\n* Normal bone marrow and organ function as defined below:\n\n  * Absolute neutrophil count \u2265 1.5 K\/cumm\n  * Platelets \u2265 100 K\/cumm\n  * Hemoglobin \u2265 9 g\/dL\n  * Total bilirubin \u2264 2 x IULN, patients with Gilberts must be below 3xIULN\n  * AST(SGOT)\/ALT(SGPT) \u2264 3 x IULN (or \u2264 5 x IULN if liver metastases are present)\n  * Creatinine clearance \\> 60 mL\/min by MDRD or by 24 hour urine\n  * Serum uric acid \u2264 8 mg\/dL (with or without medication control)\n* The effects of ADI-PEG 20 on the developing human fetus are unknown. For this reason and because chemotherapeutics are known to be teratogenic, women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry, for the duration of study participation, and for one month after completion of study treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of the study, and for one month after completion of study treatment.\n* Ability to understand and willingness to sign an IRB approved written informed consent document.\n\nExclusion Criteria:\n\n* A history of other malignancy with the exception of:\n\n  * Malignancies for which all treatment was completed at least 2 years before registration and the patient has no evidence of disease\n  * Basal cell or squamous cell carcinoma of the skin which was treated with local resection only\n  * Carcinoma in situ of the cervix\n  * Other tumors discussed with the study PI\n* Currently receiving any other investigational agents.\n* Prior treatment with ADI-PEG 20 or gemcitabine (prior docetaxel is allowed).\n* Presence of untreated or unstable brain metastases. Patients with treated\/stable brain metastases, defined as patients who have received prior therapy for their brain metastases and whose CNS disease is radiographically stable at study entry, are eligible.\n* A history of allergic reactions attributed to compounds of similar chemical or biologic composition to ADI-PEG 20, gemcitabine, pegylated compounds, or other agents used in the study.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.\n* History of seizure disorder not related to underlying cancer.\n* Grade 2 or higher neuropathy\n* Pregnant and\/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.\n* Patients with known active Hepatitis B or C or HIV.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05616624001","EMAIL":[{"email":"bvantine@wustl.edu"},{},{},{},{},{},{},{}],"GEO":[38.62727,-90.19789]},{"TITLE":"A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients","CRITERIA":"Inclusion Criteria:\n\n1. Males or females aged \u226518 to \u226475 years at the time of signing the ICF;\n2. Histologically or cytologically confirmed non-squamous NSCLC and locally advanced (stage IIIB\/IIIC) or metastatic (Stage IV) non-squamous NSCLC not amenable to radical surgery and\/or radical concurrent\/sequential chemoradiotherapy;\n3. EGFR-sensitive mutations;\n4. Failure of prior EGFR-TKI therapy;\n5. At least one measurable target lesion per RECIST 1.1 as assessed by the investigator;\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;\n7. Expected survival \u226512 weeks;\n8. Adequate organ and bone marrow function;\n9. Female subjects of childbearing potential and male subjects with partners of childbearing potential who use effective medical contraception from the time of signing the informed consent form until 6 months after the last dose;\n10. Subjects voluntarily participate in the study, sign the ICF, and will be able to comply with the protocol-specified visits and relevant procedures\n\nExclusion Criteria:\n\n1. Histologically or cytologically confirmed presence of small cell lung cancer, neuroendocrine carcinoma, and carcinosarcoma components or squamous cell carcinoma components of more than 10%;\n2. Other malignancies within 3 years prior to the first dose;\n3. History of (noninfectious) interstitial lung disease (ILD)\/noninfectious pneumonitis requiring steroid therapy and current ILD\/noninfectious pneumonitis;\n4. Subjects with active chronic inflammatory bowel disease, GI tract obstruction, severe ulcers, perforation gastrointestinal, abdominal abscess, or acute GI tract bleed;\n5. Toxicities from prior anti-tumor therapy not recovering to \u2264 Grade 1 (per NCI CTCAE 5.0) or to the level specified in the eligibility criteria;\n6. Subjects with human immunodeficiency virus (HIV) test positive or history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection;\n7. Prior TROP2-targeted therapy;\n8. Prior treatment with any drug therapy targeting topoisomerase I inhibitor, including antibody-drug conjugates (ADCs);\n9. Major surgery within 4 weeks prior to the first dose or expected to require major surgery during the study;\n10. Subjects who have received live vaccines within 30 days prior to the first dose, or are scheduled to receive live vaccines during the study;\n11. Pregnant or lactating women;","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05870319001","EMAIL":[{"email":"zhangli@sysucc.org.cn"}],"GEO":[23.11667,113.25]},{"TITLE":"Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)","CRITERIA":"Inclusion Criteria:\n\n* Age \u2265 18 years,\n* ECOG, Performance status \u2264 1,\n* Minimum 3 measurable lesions, with at least one lesion which cannot be irradiated for testing the abscopal effect and at least 2 irradiable lesions.\n* Life expectancy \\> 6 months,\n* At least one non irradiated tumor site that can be biopsied for research purpose,\n* Participant must have following advanced disease and must not be a candidate for other approved therapeutic regimen known to provide significant clinical benefit based on investigator judgement:\n\nCohort 1 : patient with metastatic non small lung cancer \/ tumor without oncogenic addiction (EGFR\/ALK\/ROS\/BRAF) which progress after platin based chemotherapy and immunotherapy given as sequential or concomitant therapy.\n\nCohort 2 : Bladder cancer \/ Patient with progression following platin based therapy or without maintenance with anti PD1\/PD-L1. Patient have to recieve Enfortumab Vedotin before inclusion if the treatment is available. Unless indication by the investigator Cohort 3 : Renal cell carcinoma \/ Second-line therapy after an anti-angiogenic plus immunotherapy or immunotherapy.\n\nCohort 4 : Head and neck carcinoma \/ First line locoregional or metastatic recurrence\n\n* Participants who received prior anti-PD-1\/L1 therapy must fulfill the following requirements Have achieved a complete response, partial response or stable disease and subsequently had disease progression while still on anti-PD-1\/L1 therapy Have received at least two doses of an approved anti-PD-1\/L1 therapy (by any regulatory authority)\n* Adequate hematological, renal, metabolic and hepatic functions:\n\nHemoglobin \u2265 9 g\/dl (participants may have received prior red blood cell \\[RBC\\] transfusion, if clinically indicated); absolute neutrophil count (ANC) \u2265 1.5 G\/l, platelet count \u2265 100 G\/l, white blood cell count \u2265 2.5 G\/l (or within local laboratory normal limits) and lymphocyte count \u2265 0.75 G\/l Alkaline phosphatase (AP), alanine aminotransferase (ALT) and aspartate aminotransferase (ASP) \u2264 2.5 x upper limit of normality (ULN) (\u2264 5 x ULN in case of extensive skeletal involvement for AP exclusively and \u2264 5 x ULN in case of liver metastasis for AST and ALT).\n\nTotal bilirubin \u2264 1.5 x ULN, (3 x ULN for gilbert disease) Albumin \u2265 25 g\/l. Serum creatinine \u2264 1.5 x ULN or calculated creatinine clearance (CrCl) \u2265 30 ml\/min (according to Cockcroft and Gault formula).\n\nINR \u2264 1.5 x ULN aPTT \u2264 1.5 X ULN Serum calcium within normal laboratory ranges,\n\n* No prior or concurrent malignant disease if more recent than 3 years\n* At least three weeks since last chemotherapy, immunotherapy or any other pharmacological treatment and\/or radiotherapy\n\nCriteria to confirm inclusion:\n\n* At least 2 mesurable lesions should be able to receveid 3 X 8 Gy by SBRT according to the dose constraints to organs at risk (OAR) imposed by the protocol\n* In case of lesion previously treated by radiotherapy, the constraints on the organs at risk must be respected after having summed up the treatment plans.\n* Confirmation of 3 measureable lesions, with at least one lesion which cannot be irradiated for testing the abscopal effect and at least 2 irradiable lesions. Those lesions must be uni-dimensionally \u2265 10 mm considered as measurable according to RECIST v1.1\n\nExclusion Criteria:\n\n* Evidence of symptomatic central nervous system (CNS) or leptomeningeal metastases,\n* Women who are pregnant or breast feeding,\n* Participation in a study involving a medical or therapeutic intervention in the last 30 days from first treatment administration,\n* Previous enrolment in the present study,\n* Participant unable to follow and comply with the study procedures because of any geographical, familial, social or psychological reasons,\n* Known hypersensitivity to any involved study drug or of its formulation components,\n* History of severe allergic anaphylactic reactions to chimeric, human or humanized antibodies, or fusion proteins,\n* Treatment with systemic immunosuppressive medications including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF agents within 2 weeks prior to inclusion. Systemic corticosteroids is not allowed but at physiologic doses meaning less than 10 mg\/day of prednisone or its equivalent. The use of inhaled corticosteroids and mineral corticoids is allowed.\n* Major surgical procedure, open biopsy or significant traumatic injury within 28 days before pre inclusion,\n* Any of the following cardiac criteria:\n\nCongestive heart failure \u2265 New York Heart Association (NYHA) class 2,\n\n* Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months), Myocardial infarction less than 6 months before pre-inclusion Uncontrolled cardiac arrhythmias, Known left ventricular ejection fraction (LVEF) \\<50%\n* Individuals deprived of liberty or placed under legal guardianship, curatorship or judicial protection.\n* Prior organ transplantation, including allogeneic stem cell transplantation,\n* Known clinically significant liver disease, including, alcoholic, or other hepatitis, cirrhosis, fatty liver and inherited liver disease, active viral with positive viralDNA detection.\n* History of intra-abdominal inflammatory process within the last 12 months such as, but not limited to, diverticulitis, peptic ulcer disease or colitis.\n* History of autoimmune disease including, but not limited to systemic lupus erythematosus (SLE), Sj\u00f6gren's syndrome, glomerulonephritis, multiple sclerosis, rheumatoid arthritis, vasculitis, systemic immune activation, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Guillain-Barr\u00e9 syndrome, Bell's palsy.\n\nParticipants with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone are eligible, Participants with controlled Type I diabetes mellitus on a stable insulin regimen are eligible, Participants with eczema, psoriasis, lichen simplex chronicus, or vitiligo with only dermatologic manifestations \\<10% of the skin (e.g., participants with psoriatic arthritis would be excluded) are eligible.\n\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g. bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.\n* Poorly controlled Type II diabetes mellitus defined as a screening fasting plasma glucose \u2265160 mg\/dL (or 8.8 mmol\/L).\n* Severe infections within 2 weeks prior to inclusion, including but not limited to SARS-Cov-2 infection, hospitalization for complications of infection, bacteremia, or severe pneumonia.\n* Received therapeutic oral or IV antibiotics within 2 weeks prior to pre-inclusion. Participants receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible.\n* Any contraindication to tumor biopsy,\n* Participant with spinal cord compression not definitively treated with surgery and\/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for \\>2 weeks prior to pre-inclusion.\n* Administration of a live, attenuated vaccine within 4 weeks before the start of study medication or anticipation that such a live attenuated vaccine will be required during the study. Influenza vaccination is allowed during influenza season only (approximatively October to March).\n* Patient with a known history of Human Immunodeficiency Virus (HIV) (HIV1\/2 antibodies) or known acquired immunodeficiency syndrome (AIDS),\n* Patients with EBV infection (Positive EBV viral capsid antigen IgM test at screening)\n* Active tuberculosis\n* Concomitant use of prohibited concomitant therapy (cf paragraph 6.5.2.2) or anticipation that such concomitant medication\/therapies will be required during the study\n* For NSCLC indication, patients with lymphoepithelioma-like carcinoma are excluded.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05259319001","EMAIL":[{"email":"FGhiringhelli@cgfl.fr"},{"email":"sparnalland@cgfl.fr"}],"GEO":[47.31667,5.01667]},{"TITLE":"SLND or Not in cT1 GGO Invasive Lung Adenocarcinoma (ECTOP-1009)","CRITERIA":"Inclusion Criteria:\n\n* Clinical stage T1N0M0 and planned curative surgery.\n* A single lesion detected on computed tomography (CT) scan featured as ground glass nodule(GGO) and C\/T ratio \u22640.5.\n* Age 18 to 75.\n* Patients who have signed the informed consent form.\n\nExclusion Criteria:\n\n* Other than invasive adenocarcinoma by pathological analysis.\n* Other than lobectomy or sublobar resection in surgical procedure.\n* Not complete resected or curative intent.\n* Patients who have history of other malignant tumors.\n* Patients who have history of thoracic surgery.\n* Patients who have received radiation, chemotherapy or other treatments previously.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"04527419001","EMAIL":[{"email":"haoxuanwu@hotmail.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n1. Voluntarily sign the informed consent and follow the requirements of the protocol;\n2. No gender limit;\n3. Age: \u226518 years old;\n4. expected survival time \u22653 months;\n5. Histologically and\/or cytologically confirmed locally advanced or metastatic non-small cell lung cancer and other solid tumors that have failed standard treatment;\n6. Consent to provide archival tumor tissue specimens (10 unstained sections (anti-slip) surgical specimens (thickness 4-5\u03bcm)) or fresh tissue samples from primary or metastatic lesions within 3 years. If participants cannot provide tumor tissue samples, they can be enrolled if they meet other inclusion and exclusion criteria, after the evaluation of the investigator;\n7. Must have at least one measurable lesion according to RECIST v1.1 definition;\n8. ECOG 0 or 1;\n9. Toxicity from previous antineochemical therapy has returned to grade 1 or less as defined by NCI-CTCAE v5.0 (asymptomatic laboratory abnormalities such as elevated ALP, hyperuricemia, elevated serum amylase\/lipase, and elevated blood glucose were considered by the investigator, and toxicity with no safety risk was judged by the investigator; Excluding alopecia, grade 2 peripheral neurotoxicity, hypothyroidism stabilized by hormone replacement therapy, or decreased hemoglobin (\u226590g\/L).\n10. No severe cardiac dysfunction, left ventricular ejection fraction \u226550%;\n11. The level of organ function must meet the following requirements and meet the following standards:\n\n    1. Bone marrow function: absolute neutrophil count (ANC) \u22651.5\u00d7109\/L, platelet count \u2265100\u00d7109\/L, hemoglobin \u226590 g\/L;\n    2. Liver function: total bilirubin (TBIL\u22641.5 ULN), AST and ALT \u22642.5 ULN in patients without liver metastasis, AST and ALT \u22645.0 ULN in patients with liver metastasis;\n    3. Renal function: creatinine (Cr) \u22641.5 ULN, or creatinine clearance (Ccr) \u226550 mL\/min (according to Cockcroft and Gault formula).\n12. Coagulation function: international normalized ratio (INR) \u22641.5, and activated partial thromboplastin time (APTT) \u22641.5ULN;\n13. Urine protein \u22642+ or \u22641000mg\/24h;\n14. Female subjects of childbearing potential or male subjects with a fertile partner must use highly effective contraception from 7 days before the first dose until 6 months after the dose. Female subjects of childbearing potential had to have a negative serum pregnancy test within 7 days before the first dose.\n\nExclusion Criteria:\n\n1. Antineoplastic therapy, including chemotherapy, biologic therapy, immunotherapy, definitive radiotherapy, major surgery (investigator-defined), or targeted therapy (including small-molecule tyrosine kinase inhibitors), has been administered within 4 weeks or 5 half-lives (whichever is shorter) before the first dose; Mitomycin and nitrosoureas were administered within 6 weeks before the first dose; Oral fluorouracil drugs such as S-1, capecitabine, or palliative radiotherapy within 2 weeks before the first dose; The TCM with anti-tumor indications was within 2 weeks before the first administration.\n2. Prior treatment with Trop2-targeted ADC drugs or with camptothecin derivatives (topoisomerase I inhibitors) as toxins;\n3. A history of severe cardiovascular and cerebrovascular diseases, including but not limited to:\n\n   1. severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmia requiring clinical intervention, third degree atrioventricular block, complete left bundle branch block, frequent and uncontrollable arrhythmias, such as atrial fibrillation, atrial flutter, ventricular fibrillation, and ventricular flutter (except transient);\n   2. prolonged QT interval at rest (QTc \\> 450 msec in men or QTc \\> 470 msec in women);\n   3. acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other grade 3 or higher cardiovascular and cerebrovascular events occurred within 6 months before the first dose;\n   4. patients with New York Heart Association (NYHA) functional class \u2265II heart failure;\n4. Patients at risk for active autoimmune disease, or with a history of autoimmune disease, Including but not limited to Crohn's disease, ulcerative colitis, systemic lupus erythematosus, sarcoidosis, Wegener syndrome, autoimmune hepatitis, systemic sclerosis, Hashimoto's thyroiditis, autoimmune vasculitis, autoimmune neuropathy (Guillain-Barre syndrome), etc. Exceptions were type I diabetes, hypothyroidism that was stable with hormone-replacement therapy (including that due to autoimmune thyroid disease), psoriasis or vitiligo that did not require systemic therapy, and hypothyroidism that was stable with hormone-replacement therapy.\n5. Patients with other malignant tumors within 5 years before the first administration, except those who have been cured skin squamous cell carcinoma, basal cell carcinoma, superficial bladder cancer, prostate\/cervix\/breast cancer in situ and so on are considered to be eligible for enrollment;\n6. Unstable deep vein thrombosis, arterial thrombosis, and pulmonary embolism requiring medical intervention within 6 months before screening; Infusion-related thrombosis was excluded.\n7. Patients with massive or symptomatic effusions, or poorly controlled effusions (poorly controlled was defined as requiring 2 or more paracentesis within a month).\n8. Hypertension poorly controlled by two antihypertensive drugs (systolic blood pressure \\&gt; 150 mmHg or diastolic blood pressure \\&gt; 100 mmHg);\n9. Current interstitial lung disease, drug-induced interstitial pneumonia, radiation pneumonitis requiring steroid therapy, or a history of these diseases;\n10. Patients with central nervous system (CNS) metastases and\/or carcinomatous meningitis (meningeal metastases). Patients who had received treatment for brain metastases (radiotherapy or surgery; Patients with stable brain metastases who had stopped radiotherapy or surgery 28 days before the first dose were eligible. Patients with cancerous meningitis (meningeal metastasis) were excluded even if they were treated and judged to be stable. Stable disease was defined as being asymptomatic, in stable condition, and not requiring steroid therapy for more than 4 weeks before starting study treatment.\n11. Patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or any of the excipients of BL-M02D1;\n12. Previous history of allogeneic stem cell, bone marrow, or organ transplantation;\n13. Human immunodeficiency virus antibody (HIVAb) positive, active tuberculosis, active hepatitis B virus infection (HBsAg positive or HBcAb positive and HBV-DNA copy number \\> central detection lower limit) or hepatitis C virus infection (HCV antibody positive and HCV-RNA \\> central detection lower limit);\n14. Severe systemic infection occurred within 4 weeks before screening, including but not limited to severe pneumonia caused by fungi, bacteria, viruses, bacteremia, or serious infectious complications;\n15. A history of autologous or allogeneic stem cell transplantation;\n16. Pregnant or lactating women;\n17. Other conditions for participation in the trial were not considered appropriate by the investigator.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05949619001","EMAIL":[{"email":"caicunzhoudr@163.com"},{}],"GEO":[31.22222,121.45806]},{"TITLE":"I-125 Seeds Implantation in the Treatment of Recurrent Lung Cancer After Radiotherapy","CRITERIA":"Inclusion Criteria:\n\n* (1) Age 18-75 years old\n* (2) Pathological diagnosis of NSCLC, recurrence after radiotherapy, lesion diameter less than 5 cm\n* (3) No systemic metastasis or metastasis, metastasis has been controlled by pre-treatment\n* (4) No bleeding tendency, anticoagulant therapy and\/or anti-platelet coagulant drugs should be stopped for at least one week before seed implantation\n* (5) No serious or uncontrolled underlying diseases (such as severe or uncontrolled high). Blood pressure, diabetes mellitus, cardiovascular and cerebrovascular diseases and organ dysfunction, etc.\n* (6) There is a suitable puncture path, which is expected to achieve the therapeutic dose\n* (7) KPS \\> 70 points, which is expected to be able to tolerate puncture\/RISI therapy, and the expected survival time is longer than 3 months.\n\nExclusion Criteria:\n\n* (1) Poor basic pulmonary function with severe emphysema, bullae and interstitial pneumonia\n* (2) Liquefaction and necrosis in a large area near the mediastinum or focus, with high risk of puncture bleeding or poor seeds distribution\n* (3) Infection and ulcer in puncture site\n* (4) Pregnant women, lactating women, children and psychiatric patients\n* (5) Patients who are participating in other clinical studies\n* (6) Poor compliance, unable to complete the treatment\n* (7) The researchers think that it is not appropriate to participate in this clinical trial","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"04071418001","EMAIL":[{"email":"aschoff@163.com"}],"GEO":[39.9075,116.39723]},{"TITLE":"Personalized DC Vaccines in Non Small Cell Lung Cancer","CRITERIA":"INCLUSION CRITERIA AT SCREENING:\n\n1. Signed informed consent form\n2. Histologically confirmed diagnosis of the NSCLC\n3. Patients with metastatic, recurrent and\/or unresectable NSCLC from stage IIIA (not amenable to radical treatment) to stage IVB provided they have not experienced disease progression on their current standard-of-care therapy at screening, as compared to the tumor assessment at the initiation of standard-of-care therapy as confirmed by Computed tomography\/Magnetic Resonance Imaging (CT\/MRI).\n4. Patients may have received any number of prior treatments without restriction and any prior immunotherapy before enrollment to the study. However, only patients receiving the maintenance\/continuation of standard of care (SOC) treatment options mentioned below are permitted to enter the study.\n5. Patient may receive only the following maintenance\/continuation of SOC therapy during study treatment, as indicated in each case.\n\n   1. Cohort 1: advanced or metastatic non-small cell lung cancer of any histology without any actionable oncogenic driver treated by SOC. Maintenance pemetrexed and\/or maintenance pemetrexed + pembrolizumab, pembrolizumab alone, nivolumab, or atezolizumab is allowed.\n   2. Cohort 2: advanced or metastatic NSCLC with actionable oncogenic driver such as Epidermal Growth Factor Receptor (EGFR) or anaplastic lymphoma kinase (ALK) or ROS-1-rearrangement, currently receiving osimertinib, alectinib, lorlatinib or crizotinib as per SOC in each disease entity\n6. Top 10 personalized peptides (PEP) for the preparation of PEP-DC vaccine has been determined before screening.\n7. Patients \\>18 years of age\n8. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n9. Adequate hematologic and end organ function, defined by the following laboratory results obtained within 21 days prior registration:\n\n   * Hemoglobin \u2265 90 g\/L\n   * Neutrophil count \u2265 1.0 G\/L (independently of administration of growth factor within 4 weeks prior registration)\n   * Platelet count \u2265 100 G\/L\n   * Serum creatinine \u2264 1.5x Institutional Upper Limit of Normal (ULN), or Creatinine clearance (CrCl) \u2265 40 mL\/min (calculated using the Cockcroft-Gault formula.\n   * Serum bilirubin \u2264 1.5 ULN (except subjects with Gilbert's syndrome who must have a total bilirubin level of \\<3.0 x ULN)\n   * Aspartate Aminotransferase\/Alanine Aminotransferase (AST\/ALT) \u2264 3 x ULN\n   * Alkaline phosphatase \u2264 1.5 x ULN\n   * Coagulation (INR, PT, aPTT): International Normalized Ratio (INR) or Prothrombin Time (PT) \u2264 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants; Activated Partial Thromboplastin Time (aPTT) \u2264 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants.\n10. Willing and able to comply with study procedures\n11. For women of childbearing potential (WOCBP: sexually mature women who have not undergone a hysterectomy, have not been naturally post-menopausal for at least 12 consecutive months or have a serum follicle-stimulating hormone (FSH) \\< 40 mIU\/ml):\n\n    1. Agreement to follow instructions for method(s) of contraception for the couple from screening until 6 months after last vaccine dose, or last cyclophosphamide\n    2. WOCBP must have a negative urine pregnancy test within 7 days, before registration. A positive urine test must be confirmed by a serum pregnancy test.\n\n13. For men and their female partners: agreement to follow instructions for method(s) of contraception for the couple from screening until 6 months after last vaccine dose, or last cyclophosphamide\n\n14. Patient is able to undergo leukapheresis\n\nEXCLUSION CRITERIA AT SCREENING:\n\n1. Pregnant or breast-feeding women\n2. Other malignancy within 2 years prior study enrollment, except for those treated with surgical intervention as curative intent in remission.\n3. Current, recent (within 4 weeks prior registration), or planned participation in an experimental drug study\n4. Patients who show signs of progression according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 at screening\n5. Planned SOC therapy other than the following:\n\n   * Cohort 1: Maintenance pemetrexed and\/or maintenance pemetrexed + pembrolizumab, pembrolizumab alone, nivolumab or atezolizumab is allowed.\n   * Cohort 2: osimertinib, alectinib, lorlatinib or crizotinib\n6. Known hypersensitivity to any component of the study treatment\n7. Any contraindication for using cyclophosphamide\n8. Treatment with systemic immunosuppressive medications within 4 weeks prior vaccination (more than an equivalent of 10mg prednisone per day). Patient who has to receive steroid treatment as premedication before pemetrexed are eligible.\n9. Administration of a live, attenuated vaccine within 8 weeks before registration\n\n   \u2022 Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine within 4 weeks prior registration or at any time during the study.\n10. Positive serology defined by the following laboratory results:\n\n    * Positive test for Human Immunodeficiency Virus (HIV)\n    * Patients with active or chronic hepatitis B (defined as having a positive hepatitis B surface antigen \\[HBsAg\\] test at screening).\n\n      * Patients with past \/ resolved Hepatitis B Virus (HBV) infection (defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen \\[anti-HBc\\] antibody test) are eligible, if HBV deoxyribonucleic acid (DNA) test is negative.\n      * HBV DNA must be obtained in patients with positive hepatitis B core antibody prior start of study treatment.\n    * Patients with active hepatitis C. Patients positive for Hepatitis C Virus (HCV) antibody are eligible only if Polymerase Chain Reaction (PCR) is negative for HCV ribonucleic acid (RNA).\n11. Severe infections within 8 weeks prior registration including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia or signs or symptoms of infection requiring oral or IV antibiotics within 8 weeks prior registration.\n\n    \u2022 Patients receiving routine antibiotic prophylaxis (e.g., to prevent chronic obstructive pulmonary disease exacerbation or for dental extraction) are eligible.\n12. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications\n13. Treatment with systemic immunostimulatory agents (including but not limited to interferon (IFN)-alpha, interleukin (IL)-2 for any reason within 4 weeks or five half-lives of the drug, whichever is shorter, prior to registration.\n14. Treatment with systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \\[anti-TNF\\] agents) within 2 weeks prior registration.\n\n    * Patients who are receiving acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) or physiologic replacement doses (i.e., prednisone 5-7.5 mg\/day, or other) for adrenal insufficiency may be enrolled in the study.\n    * The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) is allowed.\n\nTREATMENT ELIGIBILITY CRITERIA:\n\nTreatment eligibility criteria will be assessed within 14 days before the vaccination period start. Patients are eligible to receive PEP-DC vaccination if they meet all the following criteria:\n\nKey conditions required to initiate vaccination:\n\n1. Confirmation from the CTE GMP laboratory that at least six doses of PEPDC vaccines have been produced and released, and are available for the patient at the CTE GMP facility.\n2. Patient does not have any diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that occurred since enrollment and that give reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results or render the patient at high risk from treatment complications.\n3. Adequate hematologic and end organ function, defined by the following laboratory results obtained within 2 weeks of first vaccine injection:\n\n   * Hemoglobin \u2265 90 g\/L\n   * Neutrophil count \u2265 1.0 G\/L (independently of administration of growth factor within 4 weeks prior registration)\n   * Platelet count \u2265 100 G\/L\n   * Serum creatinine, \u2264 1.5x Institutional Upper Limit of Normal (ULN), or Creatinine clearance (CrCl) \u2265 40 mL\/min (calculated using the Cockcroft-Gault formula.\n   * Serum bilirubin \u2264 1.5 ULN (except subjects with Gilbert's syndrome who must have a total bilirubin level of \\<3.0 x ULN)\n   * AST\/ALT \u2264 3 x ULN\n   * Alkaline phosphatase \u2264 1.5 x ULN\n   * Coagulation (INR, PT, aPTT): International Normalized Ratio (INR) or Prothrombin Time (PT) \u2264 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants; Activated Partial Thromboplastin Time (aPTT) \u2264 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants.\n\nEXCLUSION CRITERIA FOR VACCINATION:\n\n1. Progression since screening (confirmed by CT scan) according to RECIST 1.1\n2. Production of vaccine was not successful (or less than 6 was produced)\n3. Treatment with systemic immunosuppressive medications within 4 weeks prior vaccination (more than an equivalent of 10mg prednisone per day) except for premedication given for pemetrexed.\n4. Any other diseases, cardiac, metabolic or other dysfunction, physical examination finding or clinical laboratory finding since the screening visit giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05195619001","EMAIL":[{"email":"hasna.bouchaab@chuv.ch"}],"GEO":[46.516,6.63282]},{"TITLE":"Real World Study on Erlotinib\/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* EGFR mutation(19del\/L858R)\n* advanced non-saquamous non-small cell lung cancer\n* primary treatment of first diagnosis\n* performance status\uff080-1)\n\nExclusion Criteria:\n\n* other genes mutation\n* saquamous","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"03647592001","EMAIL":[{"email":"yangnong0217@163.com"},{"email":"zhouchunhua@hnszlyy.com"},{}],"GEO":[28.19874,112.97087]},{"TITLE":"Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Clinical diagnosis of NSCLC\n* Must be adult patients (\u2265 18 years old) who have received definitive surgery and have a permanent pathology of nodal metastasis\n* Platinum-based chemotherapy is mandatory\n* Good performance status better than Eastern Cooperative Group (ECOG) of 2 or a general status of Karnofsky (KPS) \\> 70 %\n* Should have sufficient proficiency in Mandarin language\n\nExclusion Criteria:\n\n* Have received prior cranial irradiation\n* Presence of other active primary cancer (exception of basal cell carcinoma of skin and cervical carcinoma in situ)\n* Radiographic evidence of brain metastasis\/metastases\n* Clinical evidence of extracranial metastatic disease\n* Hypersensitivity to magnetic resonance (MR) contrast enhancer\n* Serious medical or psychiatric illness","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"02448992001","EMAIL":[{"email":"rt3126@gmail.com"}],"GEO":[24.95233,121.20193]},{"TITLE":"Surgical Strategy of NSCLC Patients After Neo-adjuvant or Induction Treatment","CRITERIA":"Inclusion Criteria:\n\n* The patients voluntarily participate in the study, have good compliance, can cooperate with the requirements of the experiment to complete the observation and follow-up, and sign the informed consent form.\n* Aged over 18 years old, under 75 years old; male and female are not limited;\n* Pathologically confirmed non-small cell lung cancer with clinical stage T2-4N0-2, resectable non-small cell lung cancer, potentially needing pneumonectomy and receiving neoadjuvant or induction therapy.\n* ASA score: Grade I-III;\n* The cardiopulmonary function evaluation can meet the requirements for radical lung cancer surgery, and the liver and kidney functions are normal.\n\nExclusion Criteria:\n\n* Those with serious cardiac, pulmonary, hepatic, and renal dysfunctions, unable to tolerate the surgery;\n* Those with uncontrollable neurological or psychiatric diseases or mental disorders, poor compliance, and being unable to cooperate and describe the treatment response.\n* Those who are going to undergo emergency surgery or palliative surgery due to lung abscess or hemoptysis.\n* Those who have been treated, or are undergoing neoadjuvant or induction radiotherapy or targeted therapy.\n* Those who have a combined history of other malignant tumors\n* Those who have a history of thoracic surgery\n* Those who are pregnant or breastfeeding women\n* Patients of childbearing age who refuse to use contraception.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06534489001","EMAIL":[{"email":"lihecheng2000@hotmail.com"},{"email":"hunterfh1@163.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy","CRITERIA":"Inclusion Criteria:\n\n1. Eligible patients will have newly diagnosed, previously untreated histologically documented Stage IV NSCLC\n2. Eligible patients will be required to have positive PD-L1 expression \u22651% by IHC using Dako 22C3 assay.\n3. Patients will require a baseline Guardant360 CDx test prior to enrollment\n4. Patients willing to undergo serial ctDNA testing as required by protocol\n5. Patients will be over the age of 18\n6. Life expectancy \u226512 weeks\n7. Measurable (RECIST 1.1) indicator lesion not previously irradiated, with measurable disease determined per the treating investigator.\n8. Prior palliative radiotherapy to non-CNS lesions must have been completed at least 2 weeks prior to randomization\n9. ECOG Performance Score \u22642\n10. Adequate organ function\n11. Hemoglobin \\> 9 g\/dL\n12. Platelets \\> 100,000mm3 or 100 x 109\/L\n13. AST, ALT \\< 2.5 x ULN with no liver metastases or \\< 5x ULN with the presence of liver metastases\n14. Total bilirubin \\< 1.5 x ULN if no liver metastases or \\< 3 x ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases\n15. Absolute neutrophil count (ANC) \\> 1500 cells\/mm3\n16. Creatinine \u2264 1.5 x ULN OR calculated creatinine clearance \u2265 60ml\/min calculated by Cockcroft and Gault's equation\n17. Willing to use highly effective contraceptive measures if child-bearing potential or if the patient's sexual partner is a woman of childbearing potential: a. Female subjects should be using a highly effective contraceptive measures, and must have a negative pregnancy test and not be breast-feeding prior to starting of dosing if of child-bearing potential or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening: i. Post-menopausal is defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments ii. Women under 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the the post-menopausal range for the institution iii. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not a tubal ligation b. Male subjects should be willing to use barrier contraception\n\nExclusion Criteria:\n\n1. Patients under the age of 18\n2. Inability to provide informed consent by either the patient or the authorized representative\n3. Patients with known EGFR, ALK, ROS1, MET, and RET oncogenic driver alterations that have approved first-line targeted therapies are excluded from the study (All patients must have a tissue or blood-based testing to identify these driver alterations)\n4. Patients with no detectable ctDNA or ctDNA VAF \u2264 0.3% on Guardant360 CDx at baseline\n5. Subjects with untreated CNS metastases are excluded.\n6. Subjects are eligible if CNS metastases are adequately treated and subjects are neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to randomization. In addition, subjects must be either off corticosteroids, or on a stable or decreasing dose of 10 mg daily prednisone (or equivalent) for at least 2 weeks prior to randomization.\n7. Subjects with carcinomatous meningitis\n8. Subjects must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before randomization\n9. Subjects with previous malignancies (except non-melanoma skin cancers, and in situ cancers such as the following: bladder, gastric, colon, cervical\/dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to randomization and no additional therapy is required or anticipated to be needed during the study period.\n10. Other active malignancy requiring concurrent intervention.\n11. Subjects with an active, known, or suspected autoimmune disease. Subjects with type I diabetes mellitus, and hypothyroidism only require hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.\n12. Subjects with a condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization. Inhaled or topical steroids, and adrenal replacement steroids \\> 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.\n13. Subjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity.\n14. Significant uncontrolled cardiovascular disease, including but not limited to, any of the following:\n\n    1. Uncontrolled hypertension, which is defined as systolic blood pressure \\> 160 mm Hg or diastolic blood pressure \\> 100 mm Hg despite optimal medical management.\n    2. Active coronary artery disease, including unstable all newly diagnosed angina within 3 months of study enrollment.\n    3. Myocardial infarction in the past 6 months.\n    4. History of congenital long QT syndrome.\n    5. History of clinically significant arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or torsade de pointes.\n    6. Uncontrolled heart failure, defined as class III of 4 by the New York Heart Association functional classification.\n    7. History of a current diagnosis of myocarditis.\n15. the Known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug administration or interfere with the interpretation of safety results.\n16. Any positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection\n17. Subjects with Grade 2 peripheral neuropathy\n18. Life expectancy \\<12 weeks","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05715229002","EMAIL":[{}],"GEO":[40.88593,-74.04347]},{"TITLE":"Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)","CRITERIA":"Inclusion Criteria:\n\n1. Male\/female participants who are at least 18 years of age on the day of signing informed consent histologically confirmed diagnosis of metastatic squamous or non-squamous NSCLC (AJCC Staging Manual, version 8) will be enrolled in this study.\n2. Male participants:\n\n   A male participant must agree to use a contraception as detailed in Appendix 3 of this protocol during the treatment period and for at least 180 days after the last dose of study treatment and refrain from donating sperm during this period.\n3. A female participant is eligible to participate if she is not pregnant (see Appendix 3), not breastfeeding, and at least one of the following conditions applies:\n\n   1. Not a woman of childbearing potential (WOCBP) as defined in Appendix 3 OR\n   2. A WOCBP who agrees to follow the contraceptive guidance in Appendix 3 during the treatment period and for at least 180 days after the last dose of study treatment.\n   3. Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU\/L or equivalent units of HCG) within 72 hours prior to the start of study drug.\n4. Participants must have progressed on treatment with an anti-PD-1\/L1 mAb administered either as monotherapy or in combination with platinum-doublet chemotherapy.\n\n   PD-1 treatment progression is defined by meeting all of the following criteria:\n   1. Has received at least 2 doses of an approved anti-PD-1\/L1 mAb.\n   2. Has demonstrated disease progression after anti-PD-1\/L1 as defined by RECIST v1.1.\n   3. Progressive disease has been documented within 12 weeks from the last dose of anti-PD-1\/L1 mAb.\n\n      Once disease progression is confirmed, the initial date of disease progression documentation will be considered the date of disease progression.\n   4. Progression-free survival of ICIs treatment at least 6 months\uff1a PD after platinum doublet chemotherapy AND immunotherapy either sequentially or concomitantly for advanced NSCLC with negative driver gene mutations.\n\n   If subjects have disease progression within six months of the last dose of chemotherapy for neoadjuvant\/adjuvant ICIs in combination with platinum-doublet chemotherapy for resectable NSCLC, the ICIs combination treatment can be defined as first-line treatment.\n\n   For unresectable stage III NSCLC subjects who received CCRT followed by ICI as maintain treatment has disease progression within 1 year of the last dose of chemotherapy, the ICIs treatments can be defined as first-line treatment.\n5. Have confirmation that EGFR-, ALK-, or ROS1-directed therapy is not indicated as primary therapy\n6. The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.\n7. Have measurable disease based on RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.\n8. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 7 days before the first dose of the study intervention.\n9. Have adequate organ function as defined in the following table. Specimens must be collected within 10 days before the start of the study intervention.\n10. Have a life expectancy of at least 3 months.\n\nExclusion Criteria:\n\n1. Has received docetaxel or Plinabulin as monotherapy or in combination with other therapies.\n2. Has received other antitumor regimens before the initiation of the study regimen for those who had disease progression after prior ICI therapy.\n3. Currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.\n4. Participants must have recovered from all AEs due to previous therapies to Grade 1 or less (except alopecia). Participants with \u2264Grade 2 neuropathy may be eligible. Participants with endocrine-related AEs Grade \u22642 requiring treatment or hormone replacement may be eligible.\n5. Major surgery, open biopsy, or obvious trauma within 4 weeks before enrollment.\n6. Has received prior radiotherapy within 2 weeks before the start of study intervention or has received lung radiation therapy \\>30 Gy within 6 months before the first dose of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (\u22642 weeks of radiotherapy) to non-CNS disease.\n7. Has received a live vaccine or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Gu\u00e9rin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist\u00ae) are live attenuated vaccines and are not allowed.\n8. History of hemorrhagic diarrhea, inflammatory bowel disease or active uncontrolled peptic ulcer disease. (Concomitant therapy with ranitidine or its equivalent and\/or omeprazole or its equivalent is acceptable). History of ileus or other significant gastrointestinal disorder known to predispose to ileus or chronic bowel hypomotility.\n9. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.\n10. Known additional malignancy that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of the bladder, that have undergone potentially curative therapy are not excluded.\n11. Has known active CNS metastases and\/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression, clinically stable and without requirement of steroid treatment for at least 14 days prior to the first dose of study intervention.\n12. Has severe hypersensitivity (\u2265Grade 3) to pembrolizumab\/ Plinabulin\/Docetaxel and\/or any of its excipients.\n13. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease-modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.\n14. Has a history of (non-infectious) pneumonitis\/interstitial lung disease that required steroids or has current pneumonitis\/interstitial lung disease.\n15. Has an active infection requiring systemic therapy.\n16. Has a known history of Human Immunodeficiency Virus (HIV) infection. Note: No HIV testing is required unless mandated by the local health authority.\n17. Concurrent active Hepatitis B (defined as HBsAg positive and\/or detectable HBV DNA) and Hepatitis C virus (defined as anti-HCV Ab positive and detectable HCV RNA) infection.\n\n    Note: Hepatitis B and C screening tests are not required unless:\n\n    Known history of HBV and HCV infection\uff1a As mandated by the local health authority.\n18. Has known history of active TB (Bacillus Tuberculosis).\n19. Any medical conditions that in the Investigator's opinion, would impose excessive risk to the patient. Examples of such conditions include uncontrolled diabetes, infection requiring parenteral anti-infective treatment, liver failure, any altered mental status or any psychiatric condition that would interfere with the understanding of the ICF. Has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n20. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n21. Pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 180 days after the last dose of trial treatment.\n22. Has had an allogeneic tissue\/solid organ transplant.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05599789001","EMAIL":[{"email":"maraxu@163.com"},{}],"GEO":[39.9075,116.39723]},{"TITLE":"Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure\uff1aPhase I\/II","CRITERIA":"Inclusion Criteria:\n\n1. To provide a signed and dated, written informed consent.\n2. 80\u2265Age \u2265 18 years old\n3. Histologically or cytologically confirmed non-squamous NSCLC with documented EGFR mutations from a local laboratory\n4. EGFR-sensitive mutations including exon 19 deletion and exon 21 L858R mutated, and exon 20 T790M mutated.\n5. Predicted life expectancy \u2265 12 weeks\n6. EGFR-TKI resistance or intolerant to standard EGFR TKIs therapy.\n7. No previous systemic chemotherapy for advanced or metastatic disease.\n8. Adequate organ system function:\n9. Patient must have measurable disease according to RECIST 1.1.\n10. Patients with stable or pre-treated brain metastasis (BM) can be enrolled\n\nExclusion Criteria:\n\n1. Spinal cord compression or meningeal metastasis\n2. A history of malignant tumors within 2 years.\n3. With known resistant mutations that have approved target therapy\n4. Recover from AEs caused by previous treatment\n5. A history of stroke or intracranial hemorrhage within 6 months prior to initial dosing.\n6. Any severe or poorly controlled systemic disease per investigator's judgment active infections, including but not limited to hepatitis B (HBV), hepatitis C (HCV), and human immunodeficiency (HIV)","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"06195189001","EMAIL":[{"email":"radyoulu@hotmali.com"},{"email":"nafeifei@foxmail.com"},{},{}],"GEO":[30.66667,104.06667]},{"TITLE":"A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Voluntarily sign the informed consent and follow the requirements of the protocol;\n2. Age \u226518 years old;\n3. Expected survival time \u22653 months;\n4. Patients with histologically or cytologically confirmed locally advanced or metastatic EGFR wild-type non-small cell lung cancer;\n5. Consent to provide archival tumor tissue samples or fresh tissue samples of primary or metastatic lesions within 3 years;\n6. Must have at least one measurable lesion according to RECIST v1.1 definition;\n7. ECOG 0 or 1;\n8. Toxicity of previous antineoplastic therapy has returned to \u2264 grade 1 defined by NCI-CTCAE v5.0;\n9. No severe cardiac dysfunction, left ventricular ejection fraction \u226550%;\n10. The organ function level must meet the requirements on the premise that blood transfusion is not allowed within 14 days before the screening period, and no cell growth factor drugs are allowed;\n11. Urine protein \u22642+ or \\< 1000mg\/24h;\n12. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, serum pregnancy must be negative, and must be non-lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.\n\nExclusion Criteria:\n\n1. Previous histological or cytological evidence of small cell or mixed small\/non-small cell components;\n2. Patients with EGFR L858R mutation, EGFR 19DEL mutation or EGFR T790M positive;\n3. Chemotherapy, targeted therapy, biological therapy, etc., and palliative radiotherapy or antineoplastic therapy within 2 weeks before randomization;\n4. Previous ADCs with TOPI inhibitors as toxins, antibodies\/ADCs targeting EGFR and\/or HER3;\n5. History of severe heart disease or cerebrovascular disease;\n6. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening;\n7. QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;\n8. Active malignancy diagnosed within 3 years before randomization;\n9. Hypertension poorly controlled by two antihypertensive drugs;\n10. Patients with poor glycemic control;\n11. A history of interstitial lung disease (ILD) requiring steroid therapy, or current ILD or grade \u22652 radiation pneumonitis, or suspicion of such disease on imaging during screening;\n12. Complicated pulmonary diseases leading to clinically severe respiratory function impairment;\n13. Patients with active central nervous system metastases;\n14. Severe infection within 4 weeks before randomization; evidence of pulmonary infection or active pulmonary inflammation within 2 weeks before randomization;\n15. Patients with massive or symptomatic effusions or poorly controlled effusions;\n16. Imaging examination showed that the tumor had invaded or wrapped around the large blood vessels in the abdomen, chest, neck, and pharynx;\n17. Severe unhealed wound, ulcer, or fracture within 4 weeks before signing the informed consent;\n18. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;\n19. Patients with inflammatory bowel disease, extensive bowel resection history, immune enteritis history, intestinal obstruction or chronic diarrhea;\n20. Have a history of allergy to recombinant humanized antibodies or any of the ingredients of BL-B01D1;\n21. A history of autologous or allogeneic stem cell transplantation;\n22. Human immunodeficiency virus antibody positive, active hepatitis B virus infection or hepatitis C virus infection;\n23. A history of severe neurological or psychiatric illness;\n24. Received other unmarketed investigational drug or treatment within 4 weeks before randomization;\n25. Subjects who were scheduled to receive live vaccine or received live vaccine within 28 days before study randomization;\n26. Any other circumstances in which the investigator considered it inappropriate to participate in the trial because of complications or other circumstances.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06382129001","EMAIL":[{}],"GEO":[39.9075,116.39723]},{"TITLE":"A Beta-only IL-2 ImmunoTherapY Study","CRITERIA":"Key Inclusion Criteria:\n\n1. Aged at least 18 years (inclusive at the time of informed consent).\n2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.\n3. Must be able and willing to provide written informed consent prior to start of any study procedures and assessments and must be willing to comply with all study procedures.\n4. Histologically or cytologically confirmed locally advanced or metastatic solid tumor (see tumor types listed under conditions)\n5. Demonstrated adequate organ function\n6. Measurable disease as per Response Evaluation Criteria in Solid Tumors, (RECIST v1.1) and documented by CT and\/or MRI.\n7. Life expectancy of \u2265 12 weeks.\n8. Women of childbearing potential (WOCBP) must have a negative pregnancy test at screening and within 72 hours before the first dose of study drug(s). Women must not be breastfeeding.\n9. Agree to use highly effective contraception methods. WOCBP must agree to use highly effective birth control.\n\nKey Exclusion Criteria:\n\n1. Last administration of prior antitumor therapy:\n\n   * Prior systemic anti-cancer therapy including investigational agents within 4 weeks (could consider shorter interval for kinase inhibitors or other short half-life drugs) prior to start of treatment.\n   * Prior radiotherapy within 2 weeks prior to start of treatment or has had a history of radiation pneumonitis. A 1-week washout is required for palliative radiation (\\<2 weeks of radiotherapy) to non-CNS disease.\n   * Radiation therapy to the lung that is \\> 30Gy within 6 months prior to start of treatment.\n   * Currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to start of treatment. Concomitant participation in an observational study must be discussed on a case-by-case basis with the MM for approval.\n2. Has known active CNS metastases and\/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to start of treatment, subject to discussion with MM.\n3. Active malignancy (other than the disease under treatment in the study) within the previous 3 years except for curable cancers.\n4. Condition requiring long-term systemic treatment with either corticosteroids \\> 10 mg daily prednisone equivalent or any other form of immunosuppressive therapy within 7 days prior to start of treatment.\n5. Clinically significant active, known or suspected autoimmune disease, or diseases that can be exacerbated with immunotherapy.\n6. Severe pulmonary, cardiac or other systemic disease.\n7. Known hepatitis B or C virus infection.\n8. Females who are pregnant or lactating or planning to become pregnant during the study.\n9. Has had an allogeneic tissue\/solid organ transplant.\n10. Active infection requiring systemic therapy.\n11. Any medical, emotional or psychiatric condition that interfere with the patient's ability to adhere to the protocol\n12. Any other underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug(s) unsafe or obscure the interpretation of toxicity determination or adverse events.\n13. Known severe hypersensitivity to any component of study drug(s).\n14. Inability to comply with study and follow up procedures as judged by the Investigator.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05086692011","EMAIL":"nmerchant@medicenna.com","GEO":[43.70011,-79.4163]},{"TITLE":"A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Patients must have histologically or cytologically confirmed EGFR mutant NSCLC.\n* Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as \\>20 mm with conventional techniques or as \\>10 mm with spiral CT scan, MRI, or calipers by clinical exam.\n* Prior therapy: Patient with recurrent and\/or metastatic EGFR mutant NSCLC, that has progressed on osimertinib as most recent line of treatment, and the primary doctor intends to continue with osimertinib treatment.\n* Patients with no matched alterations (tumor or plasma) where clinical trials or approved systemic anti-cancer therapy are available, are eligible\n* Patients with matched alterations on rebiopsy (tumor or plasma) who declined matching clinical trials, or approved systemic anti-cancer therapy, are eligible\n* Age \u226521 years.\n* ECOG performance status \u22642 (Karnofsky \u226560%, see Appendix A).\n* Patients must have adequate organ and marrow function as defined below:\n\n  * absolute neutrophil count \u22651,500\/mcL\n  * platelets \u2265100,000\/mcL\n  * total bilirubin \u2264 institutional upper limit of normal (ULN)\n  * AST(SGOT)\/ALT(SGPT) \u22643 \u00d7 institutional ULN\n  * creatinine \u2264 institutional ULN OR glomerular filtration rate (GFR) \u226550 mL\/min\/1.73 m2\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial provided that DDI with osimertinib has been addressed.\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n* Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.\n* Patients with asymptomatic new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy.\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.\n* The effects of S-1 on the developing human fetus are unknown. For this reason and because cytotoxic agents are known to be teratogenic, women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU\/L or equivalent units of HCG) within 24 hours prior to the start of treatment. Women must not be breastfeeding. Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier (i.e., have residual toxicities \\> Grade 1) with the exception of alopecia.\n* Patients who are receiving any other investigational agents.\n* Patients are excluded if they have symptomatic brain metastases or leptomeningeal metastases.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to S-1.\n* Concomitant medications: Patients should only be excluded from trial participation when clinically relevant known or predicted drug-drug interactions or potential overlapping toxicities will impact safety or efficacy. Please include scientific or clinically based rationale for exclusion.\n* Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\/social situations\n* Pregnant women are excluded from this study because both compounds are potentially teratogenic.\n* Subjects with concomitant second malignancies (except adequately treated non-melanomatous skin cancers, in situ cervical cancers, localized prostate cancer or in situ breast cancer) are excluded unless a complete remission was achieved at least 3 years prior to study entry and no additional therapy is required or anticipated to be required\n* Prior organ allograft or allogeneic bone marrow transplantation\n* Prisoners or subjects who are involuntarily incarcerated\n* Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness\n* Inability to comply with restrictions and prohibited activities\/treatments in this study.","SEX":"ALL","AGE_MIN":21,"AGE_MAX":99,"SS_ID":"05773092001","EMAIL":"darren.lim.w.t@singhealth.com.sg","GEO":[1.28967,103.85007]},{"TITLE":"A Phase 1\/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway","CRITERIA":"Inclusion Criteria:\n\n* Histologically confirmed diagnosis of a solid tumor malignancy with any of the following oncogenic mutations detected in tumor tissue or ctDNA by a sponsor-approved test:\n\n  1. MRTX0902 monotherapy: known KRAS mutations, known annotated recurrent activating SOS1, PTPN11, class III BRAF, or EGFR mutation, or known annotated recurrent inactivating NF1 mutation;\n  2. MRTX0902 and adagrasib combination therapy: KRAS G12C mutation.\n* Unresectable or metastatic disease\n* No available treatment with curative intent; standard treatment is not available or patient declines\n* Presence of tumor lesions to be evaluated per RECIST 1.1:\n\n  1. Phase 1 dose escalation, RECIST 1.1 measurable or evaluable disease\n  2. Phase 1b and Phase 2 cohorts, RECIST 1.1 measurable disease\n* Presence of a tumor lesion amenable to mandatory biopsy for pharmacodynamic evaluation at baseline and on-study unless Sponsor-confirmed as medically unsafe or infeasible.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate organ function\n\nExclusion Criteria:\n\n* Active brain metastases or carcinomatous meningitis\n* Prior treatment with a KRAS G12C inhibitor (for Phase 1b expansion for MRTX0902 and adagrasib combination, and Phase 2 cohorts only)\n* History of significant hemoptysis or hemorrhage within 4 weeks of the first dose of study treatment.\n* Major surgery within 4 weeks of first dose of study treatment\n* History of pneumonitis or interstitial lung disease\n* Ongoing need for medication with following characteristics: substrate of CYP3A; strong inducer or inhibitor or CYP3A and\/or P-gp; strong inhibitors of BRCP and proton pump inhibitors\n* Cardiac abnormalities\n* History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05578092012","EMAIL":[{}],"GEO":[18.39745,-66.04989]},{"TITLE":"Second Primary Lung Cancer Cohort Study (SPORT)","CRITERIA":"Inclusion Criteria:\n\n* previous treatment with curative intent (surgery or radical (chemo)radiotherapy) for stage I-IIIA primary NSCLC\n* at least two years post first treatment date of first primary NSCLC\n* able to provide informed consent\n\nExclusion Criteria:\n\n* Primary lung tumour was a carcinoid tumour\n* in the opinion of the managing clinician, thought unlikely to survive 12 months from time of potential recruitment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":99,"SS_ID":"04178889001","EMAIL":[{}],"GEO":[52.2,0.11667]},{"TITLE":"A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.","CRITERIA":"Inclusion Criteria:\n\n1. Written informed consent\n2. \u226518 years of age (or meets the country's regulatory definition of legal adult age, whichever is greater\n3. Pathologically confirmed, locally advanced or metastatic NSCLC meeting all the following criteria:\n\n   Cohort A patients:\n   * Documented EGFR ex20ins mutation status, as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US).\n   * Progressed on or after systemic therapy with an agent targeting ex20ins, either alone or in combination with standard platinum-based chemotherapy for the treatment of advanced disease. Patients who discontinued previous treatment due to unacceptable toxicity are eligible.\n   * Patients with brain metastasis must be neurologically stable. Patients must have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the screening period, and they must be on a stable or decreasing dose of corticosteroids and\/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Patients with history of uncontrolled seizures or leptomeningeal disease are not eligible.\n\n   Cohort B patients:\n   * Documented EGFR ex20ins mutation status, as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US).\n   * Not received prior systemic therapy for locally advanced or metastatic disease. Prior adjuvant\/neoadjuvant treatment for early-stage disease must have been completed \\>6 months prior to the first dose of study treatment.\n   * Patients with brain metastasis must be neurologically stable. Patients must have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the screening period, and they must be on a stable or decreasing dose of corticosteroids and\/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Patients with history of uncontrolled seizures or leptomeningeal disease are not eligible.\n\n   Cohort C patients:\n   * Documented EGFR ex20ins mutation status, as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US).\n   * Presence of brain metastasis(es), which may be measurable or nonmeasurable by RANO-BM criteria, characterized as one of the following:\n\n     * Newly diagnosed and\/or progressive brain metastasis (es) not subjected to CNS-directed therapy, OR\n     * Leptomeningeal disease (LMD) confirmed by a positive cerebrospinal fluid cytology, or unequivocal radiographic and\/or clinical determination.\n\n   Cohort D patients:\n   * Documented other non-ex20ins uncommon single or compound EGFRmt status, as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US). A list of eligible mutations will be provided in a separate manual.\n   * Patients with brain metastasis must be neurologically stable. Patients must have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the screening period, and they must be on a stable or decreasing dose of corticosteroids and\/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Patients with history of uncontrolled seizures or leptomeningeal disease are not eligible.\n4. Measurable disease per RECIST 1.1.\n5. Archival tumor tissue available for submission, with minimum quantity sufficient to evaluate EGFRmt status and, where possible, other biomarkers (details provided in a laboratory manual). Patients with insufficient tissue may be eligible following discussion with the sponsor.\n6. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 17. Adequate organ function, as defined by the hematologic, renal and hepatic laboratory values\n\n4. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test prior to administration of the first dose of study treatment. Female patients are not considered to be of childbearing potential if they are post-menopausal (no menses for 12 months without an alternative medical cause) or permanently sterile (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).\n\n5. Both males and females of reproductive potential must agree to use effective birth control during the study prior to the first dose of study drug and for 6 months after the last dose of study treatment.\n\nExclusion Criteria:\n\n1. Patient is currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged to be scientifically or medically incompatible with this study.\n2. Has received any of the following within the specific time frame specified:\n\n   1. Patient has received Zipalertinib (TAS6417\/CLN081) at any time\n   2. Thoracic radiotherapy \u226428 days or palliative radiation \u226414 days prior to the first dose of study treatment\n   3. Anticancer immunotherapy \u226428 days prior to the first dose of study treatment\n   4. Major surgery (excluding placement of vascular access) \u226428 days prior to the first dose of study treatment.\n3. Have any unresolved toxicity of Grade \u22652 from previous anticancer treatment, except for Grade 2 alopecia or skin pigmentation. Patients with other chronic but stable Grade 2 toxicities may be allowed to enroll after agreement between the investigator and Sponsor.\n4. Past medical history of interstitial lung disease, treatment-related pneumonitis (any grade), or evidence of clinically active interstitial lung disease.\n5. Impaired cardiac function or clinically significant cardiac disease including any of the following:\n\n   1. History of congestive heart failure (CHF) Class III\/IV according to the New York Heart Association (NYHA) Functional Classification (Appendix A)\n   2. Serious cardiac arrhythmias requiring treatment.\n   3. Resting corrected QT interval (QTc) \\>470 msec using Fridericia's formula (QTcF).\n6. Is unable to swallow tablets\/capsules or has any disease or condition that may significantly affect gastrointestinal absorption of zipalertinib (eg, inflammatory bowel disease, malabsorption syndrome, or prior gastric\/bowel resection).\n7. History of another primary malignancy \u22642 years prior to the date of first dose of study treatment unless at least one of the following criteria are met:\n\n   1. Adequately treated basal or squamous cell carcinoma of the skin\n   2. Cancer of the breast or cervix in situ\n   3. Patients with previously treated malignancy if all treatment for that malignancy was completed at least 2 years prior to first dose and no evidence of disease\n   4. Patients with concurrent malignancy clinically stable and not requiring tumor-directed treatment\n8. Known history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) that is not controlled with treatment.\n9. History of COVID-19 infection within 4 weeks prior to enrolment and\/or has persistent clinically significant pulmonary symptoms related to prior COVID-19 infection.\n10. Active bleeding disorders.\n11. Known hypersensitivity to the ingredients in zipalertinib or any drugs similar in structure or class.\n12. Is pregnant or lactating.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05967689114","EMAIL":"medicalinformation@taihooncology.com","GEO":[52.9536,-1.15047]},{"TITLE":"Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules","CRITERIA":"Inclusion Criteria:\n\n1. Subject has provided informed consent to participate in the study and agrees to comply with all protocol requirements\n2. Subject is \\> 40 years of age at the time of the discovery of the lung nodule of concern\n3. Subject's lung nodule of concern meets the following:\n\n   * Was incidentally identified or detected during lung cancer screening\n   * Is a solid nodule\n   * Has maximal dimension of \\> 8mm and \\< 30mm\n4. The first CT scan identifying the lung nodule of concern was performed within 60 days of subject enrollment\n5. The pre-test risk of cancer as determined by the Mayo risk prediction algorithm is 65% or less\n\nExclusion Criteria:\n\n1. Nodule work-up at the time of subject enrollment indicating any prior attempted or completed diagnostic biopsy procedure or blood-based testing for the lung nodule of concern\n2. Nodule of concern is part-solid or Ground Glass Opacity (GGO)\n3. Prior diagnosis of lung cancer\n4. Any active cancer within 5-years of nodule detection, with the exception of non-melanoma skin cancer\n5. Administration of blood products (i.e. packed red blood cells, fresh frozen plasma, or platelets) within 30 days of subject enrollment\n6. Concurrent participation in any unrelated clinical trial that may impact or alter the management of the subject's nodule of concern\n7. Any illness or factor that will inhibit compliance with study participation","SEX":"ALL","AGE_MIN":40,"AGE_MAX":200,"SS_ID":"04171492026","EMAIL":[{},{}],"GEO":[45.50884,-73.58781]},{"TITLE":"A Randomized Pilot Study of Evolocumab Plus Nivolumab\/Ipilimumab in Treatment-Na\u00efve Patients With Metastatic NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. All patients must have histologically documented or suspected recurrent incurable and\/or stage 4 squamous or non-squamous NSCLC.\n2. NO prior chemotherapy, radiation therapy or biologic\/targeted therapy for current diagnosis recurrent\/metastatic NSCLC. Medical therapy (including adjuvant or maintenance immune therapy) for early stage NSCLC allowed if completed \\> 6 months prior to study enrollment.\n3. TPS PD-L1 \\< 50%\n4. Performance Status ECOG 0-1 (Appendix B).\n5. Age \\>18 years old.\n6. No active invasive malignancy in the past 2 years other than non-melanoma skin cancer. Cancers that are in-situ are not considered invasive.\n7. No autoimmune disease that would constitute contraindication to receive nivolumab\n8. Patients must have core needle biopsy tissue that is available and adequate for dedicated research purposes.\n9. No excessive risk for CT or ultrasound guided percutaneous biopsy to obtain research biopsy specimen. Risk assessment is to be determined by the treating oncologist and the interventional radiologist.\n10. Patients who do not have an indication for a diagnostic biopsy must undergo an elective 'research only' core needle biopsy.\n11. Signed written informed consent including HIPAA according to institutional guidelines.\n12. Safety laboratory values within institutional normal ranges.\n\nExclusion Criteria:\n\n* 1) Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.\n\n  2) Has a known history of active TB (Bacillus Tuberculosis) 3) Hypersensitivity to nivolumab or ipilimumab or any of its excipients 4) Hypersensitivity to evolocumab or any of its excipients 5) Patient does not have a site of suspected malignancy that is accessible to pre-treatment biopsy.\n\n  6) Concurrent administration of any other anti-tumor therapy. 7) Has received prior therapy with a PD1, PDL1, or PDL2 inhibitor. 8) Has received therapy with PCSK9 inhibitor within 90 days of study entry. 9) Known active CNS metastases which are symptomatic. Eligible if metastases have been locally treated 14 days prior to cycle 1 day 1, are clinically controlled, and asymptomatic off high dose steroids on cycle 1 day 1(\\< 2 mg decadron or 10 mg prednisone daily or equivalent allowed). Untreated, asymptomatic brain metastases allowed if subject does not require corticosteroids or anticonvulsant therapy.\n\n  10) Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \\[qualitative\\] is detected).\n\n  11) Inability to comply with protocol or study procedures. 12) Active infection requiring antibiotics, antifungal or antiviral agents, that in the opinion of the investigator would compromise the patient's ability to tolerate therapy.\n\n  13) Has known history of, or any evidence of active, non-infectious pneumonitis.\n\n  14) Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1\/2 antibodies) 15) Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency etc) is not considered a form of system treatment. Patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohn's Disease, are excluded from this study, as are patients with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic progressive sclerosis \\[scleroderma\\], systemic lupus erythematosus, autoimmune vasculitis \\[eg, Wegener's Granulomatosis\\]); motor neuropathy considered of autoimmune origin (e.g. Guillain-Barre Syndrome and Myasthenia Gravis).\n\n  16) Subjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity 17) Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.\n\n  18) Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.\n\n  19) Major surgery (other than definitive lung cancer surgery) within two weeks of study or other serious concomitant disorders that in the opinion of the investigator would compromise the safety of the patient of compromise the patient's ability to complete the study.\n\n  20) Any non-oncology vaccine therapy used for prevention of infectious diseases (for up to 30 days before or after any dose of nivolumab). Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist\u00ae) are live attenuated vaccines and are not allowed. COVID19 vaccines will be allowed on protocol.\n\n  21) Myocardial infarction having occurred less than 6 months before inclusion, any known uncontrolled arrhythmia, symptomatic angina pectoris, active ischemia, or cardiac failure not controlled by medications. Patients with CAD recently treated with surgery and\/or stent, if stable without symptomatic angina pectoris, active ischemia are eligible.\n\n  22) Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n\n  23) Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either psychiatric or physical (e.g., infectious) illness.\n\n  24) Patient takes daily prednisone \\> 10 mg or the equivalent dose of a different steroid.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05144529001","EMAIL":[{"email":"christy.arrowood@duke.edu"},{"email":"annemarie.peters@duke.edu"}],"GEO":[35.99403,-78.89862]},{"TITLE":"A Multicenter Cancer Biospecimen Collection Study","CRITERIA":"Inclusion Criteria:\n\n1. Subject must have a disease of interest. Specifically, subject must have one of:\n\n   1. head and neck squamous cell carcinoma (HNSCC)\n   2. non-small-cell lung cancer (NSCLC)\n   3. small cell lung cancer (SCLC)\n   4. urothelial carcinoma (UCC)\n   5. gastric or gastroesophageal junction adenocarcinoma\n   6. cervical cancer\n   7. esophageal squamous cell carcinoma (ESCC)\n   8. triple-negative breast cancer (TNBC)\n   9. hepatocellular carcinoma (HCC)\n   10. renal cell carcinoma (RCC)\n   11. colorectal cancer (CRC)\n2. Subject must have received, or be scheduled to receive, at least one dose of anti-PD-1\/PD-L1 immunotherapy for treatment of their cancer.\n3. Subject must have had, or will have, a tumor biopsy prior to treatment with anti-PD-1\/PD-L1 immunotherapy.\n4. Subject must have undergone, or will undergo, medical imaging (e.g. CT or MRI) of the tumor prior to treatment with anti-PD-1\/PD-L1 immunotherapy.\n5. Willing to provide electronic informed consent per IRB-approved protocol.\n6. Able to speak, read, and comprehend English fluently.\n7. Subject is 18 years of age or older.\n8. Subjects must have sufficient tissue available to fulfill the specimen requirements of the study.\n\nExclusion Criteria:\n\n1. Inability or unwillingness to provide informed consent.\n2. Subject who does\/did not have one of the cancers listed above (other histologies).\n3. Subject has already participated in this trial.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04510129001","EMAIL":[{"email":"arsheen@curebase.com"}],"GEO":[37.77493,-122.41942]},{"TITLE":"A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue","CRITERIA":"Inclusion Criteria:\n\n* Patients with biopsy confirmed advanced\/metastatic solid tumors of the following types: invasive ductal or lobular breast carcinoma (all histological and intrinsic subtypes), non-small cell lung cancer (NSCLC, all subtypes), gastrointestinal squamous cell or adenocarcinomas (including pancreatic cancer), bladder cancer, renal cell carcinoma, melanoma, and soft tissue sarcoma (all subtypes), who require and are being planned for palliative radiation therapy to at least one site of RECIST-measurable extracranial metastastic disease. If a patient, requires palliative radiotherapy to additional sites, these can be treated with standard of care SBRT per departmental guidelines.\n* Patients with at least one additional site of RECIST-measurable extracranial metastasis measuring at least 4 cm in one axis and suitable for elective palliative radiation therapy. Patients should be asymptomatic or minimally symptomatic (e.g controlled by oral pain medications) and not in urgent need for palliation to this site of elective experimental treatment.\n* Age \u2265 18 years\n* ECOG Performance Status of 0 or 1.\n\nExclusion Criteria:\n\n* Patients who are pregnant or breastfeeding\n* Prior radiation therapy to the candidate metastatic sites under consideration for treatment (\"re-irradiation\" is disallowed).\n* Medical condition such as uncontrolled infection (including HIV), uncontrolled diabetes mellitus, or connective tissue diseases (lupus, systemic sclerosis, or other collagen vascular diseases) that, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient.\n* Patients with a \"currently active\" metastatic second malignancy.\n* Patients on oral or parental corticosteroids. Physiological doses of steroids are permitted (eg for patients with adrenal insufficiency). If patients are on supraphysiological doses of steroids, these must be discontinued and held during the period of the study.\n* Concomitant anti-neoplastic treatment is not allowed during the days of radiation treatment delivery and should be completed or held for 3 days prior to commencement of protocol treatment and for 3 days following completion of radiotherapy, or with resolution of associated acute toxicities.\n* Unwilling or unable to participate in all required study evaluations and procedures.\n* Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local patient privacy regulations).","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05837767007","EMAIL":[{}],"GEO":[40.65871,-73.64124]},{"TITLE":"Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90\/KEYNOTE-E90)","CRITERIA":"Inclusion Criteria:\n\n\\[Stage 1: monotherapy\\]\n\n1. Be \u226519 and \\<75 years of age\n2. Participant with histologically and\/or cytologically confirmed diagnosis of unresectable advanced or metastatic solid tumors that have been confirmed as progressed disease after standard of care or for which no further standard therapy is available due to intolerance or incompatibility\n3. IGSF1 positive expression\n4. Have measurable disease defined as at least one lesion based on Response Evaluation Criteria In Solid Tumors (RECIST) v1.1\n5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n6. Have life expectancy \u2265 12 weeks\n7. Have adequate organ functions defined as the following laboratory test criteria at screening (During the screening phase, one re-test will be permitted):\n\n   1. Absolute neutrophil count (ANC) \u2265 1,500\/mm3\n   2. Platelet count \u2265 100,000\/mm3\n   3. Hemoglobin (Hb) \u2265 9 g\/dL\n   4. Total bilirubin \u2264 1.5 X Institutional Upper Limit of Normal (IULN) (Not applicable to patients with Gilbert syndrome)\n   5. Serum creatinine \u2264 1.5 X IULN\n   6. Aspartate aminotransferase (AST) and\/or Alanine aminotransferase (ALT) \u2264 2.5 X IULN (AST and ALT \u2264 5 X IULN in patients with confirmed liver metastasis)\n   7. Prothrombin time (PT) \u2264 1.5 X IULN \\*IULN: Institutional Upper Limit of Normal\n8. Have provided archival tumor tissue sample obtained within 3 months prior to IP administration or newly obtained biopsy\n9. Have agreed to undergo up to 2 tumor tissue biopsies after IP administration\n10. Participant (or legally acceptable representative if applicable) provides written informed consent for the trial\n\n\\[Stage 2: Combination therapy\\]\n\n1. Be \u2265 19 and \\< 75 years of age\n2. Participant with histologically and\/or cytologically confirmed diagnosis of unresectable advanced or metastatic NSCLC\n\n   1. Have been confirmed as progressive disease after standard of care or for which no further standard therapy is available due to intolerance or incompatibility\n   2. Have been confirmed as progressive disease during or after anti-cancer therapy including programmed cell death protein 1 (PD-1) inhibitors and programmed cell death-Ligand 1 (PD-L1) inhibitors\n   3. IGSF1 positive expression\n   4. PD-L1 low or negative expression (tumor proportion score \\[TPS\\] \\< 50%)\n3. Have measurable disease defined as at least one lesion based on Response Evaluation Criteria In Solid Tumors (RECIST) v1.1\n4. Have ECOG performance status score of 0 or 1\n5. Have life expectancy \u2265 12 weeks\n6. Have adequate organ functions defined as the following laboratory test criteria at screening (During the screening period, one re-test will be permitted):\n\n   1. Absolute neutrophil count (ANC) \u2265 1500\/mm3\n   2. Platelet count \u2265 100,000\/mm3\n   3. Hemoglobin (Hb) \u2265 9 g\/dL\n   4. Total bilirubin \u2264 1.5 X IULN (Not applicable to patients with Gilbert's syndrome)\n   5. Serum creatinine \u2264 1.5 X IULN\n   6. Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) \u2264 2.5 X IULN (AST and ALT \u2264 5 X IULN in patients with confirmed liver metastasis)\n   7. Prothrombin time (PT) \u2264 1.5 X IULN \\*IULN: Institutional Upper Limit of Normal\n7. Have provided archival tumor sample obtained within 3 months prior to IP administration or newly obtained biopsy prior to IP administration\n8. Have agreed to undergo up to 2 tumor tissue biopsies after IP administration\n9. Participant (or legally acceptable representative if applicable) provides written infromed consent for the trial\n\nExclusion Criteria:\n\n\\[Common\\]\n\n1. Have experienced hypersensitivity to IP, any of its excipients or other monoclonal antibody\n2. Have any of the following documented medical history or surgical\/procedure history:\n\n   1. Other primary malignant tumor (subject may be enrolled if they have neither received any treatment nor experienced disease progression within 3 years) or hematologic malignancy\n   2. Major surgery within 4 weeks or minor surgery within 2 weeks prior to IP administration\n   3. Clinically significant arrhythmia, acute myocardial infarction, unstable angina pectoris, or New York Heart Association (NYHA) class \u2162 or \u2163 heart failure within 6 months prior to IP administration\n   4. Severe cerebrovascular disease within 6 months prior to IP administration\n   5. Pulmonary thrombosis, deep vein thrombosis, bronchial asthma, obstructive pulmonary disease, or other severe or life-threatening lung diseases (e.g., acute respiratory distress syndrome, lung failure) considered to be inappropriate for study participationt, within 6 months prior to IP administration\n   6. Pneumonia or interstitial lung disease requiring steroids\n\n   f. Infection requiring systemic antibiotics or antiviral agents, etc. or uncontorlled Grade \u2265 3 active infectious diseases within 2 weeks prior to IP administration g. Risk factors of ileus or intestinal perforation (including but not limited to history of acute diverticulitis, intra-abdominal abscess, and abdominal carcinomatosis) h. Auto-immune diseases\n3. Have any of the following diseases:\n\n   1. Central nervous system or brain metastasis that is uncontrolled or with clinically significant symptoms (except for patients who stopped systemic corticosteroids at least 4 weeks before IP administration and have been stable for at least 4 weeks)\n   2. Abnormal ECG regarded as clinically significant by the investigator\n   3. Uncontrolled hypertension (systolic blood pressure \\[SBP\\] \\> 160 mmHg or diastolic blood pressure \\[DBP\\] \\> 100 mmHg)\n   4. Active infection requiring treatment\n   5. Active hepatitis B or C virus infection\n   6. History of human immunodeficiency virus infection (HIV) infection\n   7. Symptomatic ascites or pleural effusion (except for patients who were treated and clinically stable)\n   8. Diseases that may affect the study results based on the judgement of the investigator\n4. Have any of the following medication or treatment history:\n\n   1. Anticancer therapy (chemotherapy, hormonal therapy, targeted therapy, or radiotherapy) within 4 weeks prior to IP administration\n   2. Immunotherapy such as anti-PD-1, anti PD-L1, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), etc. within 4 weeks prior to IP administration\n   3. Treatment with live attenuated vaccine within 4 weeks prior to IP administration\n   4. Treatment with drugs classified as Immunosuppressants, immunomodulators, or immunocytokines within 1 week prior to IP administration (Immunosuppressants, topical corticosteroids, prednisolone 10 mg\/day or \u2264 equivalent dose of systemic corticosteroids may be permitted for the treatment or prevention of AEs.)\n   5. Allogeneic bone marrow or solid organ transplantation\n5. Pregnant women, lactating women or men\/women of child-bearing potential who are unwilling to maintain abstinence or use adequate methods of contraception or do not consent to refrain from donation of sperm\/ova for at least 6 months after the last IP administration\n\n   \\* Adequate methods of contraception\n   1. Oral or injectable hormonal therapy\n   2. Implantation of intrauterine device or intrauterine system\n   3. Surgical sterilization (vasectomy, tubal ligation, etc.)\n6. Have received any other IP or implantation of investigational medical device within 4 weeks prior to IP administration in the present study\n7. Patients who are considered ineligible or unable to participate in the study for other reasons based on the judgement of the investigator","SEX":"ALL","AGE_MIN":19,"AGE_MAX":200,"SS_ID":"05872867002","EMAIL":[{}],"GEO":[37.45646,126.70515]},{"TITLE":"The Lived Experiences of Persons With Early Stage Non-small Cell Lung Cancer and Their Significant Other(s) Following Surgery: a Rapid Ethnographic Approach","CRITERIA":"Inclusion Criteria:\n\n* Persons who got surgery for early stage I-IIIA NSCLC, one to three months before inclusion;\n* If persons received adjuvant chemotherapy\/radiotherapy, the inclusion window is one to three months after the end of adjuvant chemotherapy\/radiotherapy. If persons receive adjuvant immunotherapy after the end of adjuvant chemotherapy, persons can be included during the immunotherapy;\n* Adults (18+ year);\n* Ability to give informed consent.\n\nExclusion Criteria:\n\n* Persons having progressive or recurrent lung cancer;\n* Persons who had other malignancies in the last 2 years;\n* Persons who do systematically perform or plan to perform structured exercise;\n* Persons not living independently at home (e.g. care home, psychiatric institution);\n* Psychiatric or cognitive disorders;\n* Not understanding and speaking Dutch;\n* Not living at home (e.g. nursing home, prison ...).","SEX":"ALL","AGE_MIN":0,"AGE_MAX":200,"SS_ID":"06536140001","EMAIL":[{"email":"chris.burtin@uhasselt.be"},{},{}],"GEO":[50.90769,5.41875]},{"TITLE":"A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)","CRITERIA":"Key Inclusion Criteria:\n\n1. Patients with non-squamous or squamous histology NSCLC with stage IIIB or stage IIIC disease who are not candidates for surgical resection or definitive chemoradiation per investigator assessment or stage IV (metastatic disease), who received no prior systemic treatment for recurrent or metastatic NSCLC.\n2. Availability of an archival or on-study formalin-fixed, paraffin-embedded (FFPE) tumor tissue sample, without intervening therapy between biopsy collection and screening as described in the protocol\n3. For enrollment in phase 2, patients should have PD-L1 levels \u2265 50%, as determined by a College of American Pathologists (CAP)\/Clinical Laboratory Improvement Amendments (CLIA) (or equivalently licensed, according to local regulations) accredited laboratory, as described in the protocol. For enrollment in phase 3, patients should have expression of programmed cell death ligand-1 (PD-L1) in \u226550% of tumor cells stained using an assay performed by a central laboratory, as described in the protocol.\n4. At least 1 radiographically measurable lesion by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) criteria. Target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site.\n5. Eastern Cooperative Oncology Group (ECOG) performance status of \u22641.\n6. Adequate organ and bone marrow function, as described in the protocol.\n\nKey Exclusion Criteria:\n\n1. Patients who have never smoked, defined as smoking \u2264100 cigarettes in a lifetime.\n2. Active or untreated brain metastases or spinal cord compression. Patients are eligible if central nervous system (CNS) metastases are adequately treated, and patients have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to enrollment. Patients must be off (immunosuppressive doses of) corticosteroid therapy.\n3. Patients with tumors tested positive for actionable epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations, or c-ros oncogene 1 (ROS1) fusions, as described in the protocol.\n4. Encephalitis, meningitis, or uncontrolled seizures in the year prior to enrollment.\n5. History of interstitial lung disease (eg, idiopathic pulmonary fibrosis or organizing pneumonia), of active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management, or of pneumonitis within the last 5 years. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved \u22656 months prior to enrollment.\n6. Known primary immunodeficiencies, either cellular (eg, DiGeorge syndrome, T-cell-negative severe combined immunodeficiency \\[SCID\\]) or combined T- and B-cell immunodeficiencies (eg, T- and B-cell negative SCID, Wiskott Aldrich syndrome, ataxia telangiectasia, common variable immunodeficiency).\n7. Ongoing or recent (within 2 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk of immune-mediated treatment-emergent adverse events (imTEAEs). Patients with uncontrolled type 1 diabetes mellitus or with uncontrolled adrenal insufficiency are excluded. The following are not exclusionary: vitiligo, childhood asthma that has resolved, residual hypothyroidism that required only hormone replacement, or psoriasis that does not require systemic treatment.\n8. Patients with a condition requiring corticosteroid therapy (\\>10 mg prednisone\/day or equivalent) within 14 days of randomization. Physiologic replacement doses are allowed even if they are \\>10 mg of prednisone\/day or equivalent, as long as they are not being administered for immunosuppressive intent. Patients with clinically relevant systemic immune suppression within the last 3 months before trial enrollment are excluded. Inhaled or topical steroids are permitted, provided that they are not for treatment of an autoimmune disorder.\n9. Patients who have received prior systemic therapies are excluded with the exception of the following:\n\n   1. Adjuvant or neoadjuvant platinum-based doublet chemotherapy (after surgery and\/or radiation therapy) if recurrent or metastatic disease develops more than 6 months after completing therapy as long as toxicities have resolved to CTCAE grade \u22641 or baseline with the exception of alopecia and peripheral neuropathy.\n   2. Anti-PD-(L) 1 with or without LAG-3 as an adjuvant or neoadjuvant therapy as long as the last dose is \\>12 months prior to enrollment.\n   3. Prior exposure to other immunomodulatory or vaccine therapies as an adjuvant or neoadjuvant therapy, Cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibodies as long as the last dose is \\>6 months prior to enrollment. Immune-mediated AEs must be resolved to CTCAE grade \u22641 or baseline by the time of enrollment. Endocrine immune-mediated AEs controlled with hormonal or other non-immunosuppressive therapies without resolution prior to enrollment are allowed.\n\nNote: Other protocol-defined Inclusion\/ Exclusion Criteria apply.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05785767064","EMAIL":[{"email":"drumutdemirci@gmail.com"}],"GEO":[39.91987,32.85427]},{"TITLE":"Deciphering Mechanisms Underlying Cancer Immunogenicity","CRITERIA":"Inclusion Criteria:\n\n1. Patient with histologically documented local or metastatic solid malignant tumor (head and neck, ovarian, cervical, and other tumor types including, but not limited to glioblastoma, NSCLC and anal cancer) or patients with pre-invasive cervical high grade dysplasia (CIN II or III)\n2. Age \u2265 18 years at the time of study entry\n3. Patient followed within a standard of care procedure or clinical trial\n4. ECOG Performance status 0-2\n5. Patient able to participate and willing to give informed consent prior performance of any study-related procedures and to comply with the study protocol\n6. Patient affiliated to a Social Health Insurance in France\n7. Patient may participate to other clinical trials\n\nExclusion Criteria:\n\n1. Known history of positive test for Hepatitis B virus or Hepatitis C virus or Immunodeficiency Virus (HIV) or Hanta virus\n2. Any condition contraindicated with blood sampling procedures required by the protocol (including Hemoglobin \\< 8g\/dl)\n3. Patient pregnant, or breast-feeding\n4. Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure\n5. Patient who has forfeited his\/her freedom by administrative or legal award or who is under guardianship","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03958240003","EMAIL":[{"email":"martinez.alejandra@iuct-oncopole.fr"}],"GEO":[43.60426,1.44367]},{"TITLE":"PET\/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Histologically-confirmed or cytologically-confirmed metastatic NSCLC in patients who have not received chemotherapy or immunotherapy for their advanced disease (stage IV or recurrent, using the American Joint Committee on Cancer \\[AJCC\\]\/Union for International Cancer Control \\[UICC\\] 8th edition for staging)\n* Evidence of stage IV disease on imaging by CT, PET\/CT, or magnetic resonance imaging (MRI)\n* Plan to treat with a platinum doublet with a PD1 or PDL1 inhibitor\n* Adjuvant chemotherapy or concurrent chemoradiation for early stage disease does not count as prior therapy unless subject progressed within 6 months of completion of regimen.\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1, at treating physician's discretion\n* Patients with known activating mutations in EGFR, BRAF or known translocation in ALK or ROS-1 are eligible provided they have progressed on or were intolerant to Food and Drug Administration (FDA) approved targeted therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2\n* Creatinine =\\< 2 mg\/dL or creatinine clearance \\> 50 mL\/min\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\])\/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\< 5x institutional upper limit of normal\n* Total bilirubin =\\< 1.5 mg\/dL\n* Absolute neutrophil count (ANC) \\>= 1.5 x 10\\^9\/L (\\>= 1500 per mm\\^3)\n* Platelet count \\>= 100 x 10\\^9\/L (\\>=100,000 per mm\\^3)\n* Capability to understand and comply with the protocol requirements and signed informed consent documents\n\nExclusion Criteria:\n\n* Any known additional malignancy (with exception of non-melanoma skin cancer, in-situ breast cancer, low risk prostate cancer, or a malignancy diagnosed \\>= 3 years prior to the current NSCLC diagnosis and with no evidence of requiring active treatment)\n* Had prior treatment with an anti-PD-1, or PD-L1 or PD-L2 agent or an antibody targeting other immuno-regulatory receptors or mechanisms\n* Has any serious or uncontrolled active infection that could create false positives on a PET\/CT scan, in the opinion of the treating investigator\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator\n* Has an active autoimmune disease currently requiring systemic treatment (e.g. disease modifying agents, corticosteroids or immunosuppressive drugs)\n\n  \\*\\*Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment\n* Has known, active, and symptomatic central nervous system (CNS) metastases and\/or carcinomatous meningitis\n\n  * Patients with stable or previously treated brain metastases are eligible as long as they are not receiving more than 10 mg of prednisone, or equivalent, per day","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04151940001","EMAIL":[{"email":"srbowen@uw.edu"},{},{},{}],"GEO":[47.60621,-122.33207]},{"TITLE":"A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer","CRITERIA":"INCLUSION CRITERIA:\n\n* Participant must be \u2265 18 years at the time of screening.\n* Histologically- or cytologically-documented NSCLC and have been treated with concurrent CRT for locally advanced, unresectable (Stage III) disease\n* Provision of a tumour tissue sample obtained prior to CRT\n* Documented tumour PD-L1 status by central lab\n* Documented EGFR and ALK wild-type status (local or central).\n* Patients must not have progressed following definitive, platinum based, concurrent chemoradiotherapy\n* Participants must have received at least 2 cycles of platinum-based chemotherapy concurrent with radiation therapy\n* Participants must have received a total dose of radiation of 60 Gy \u00b110% (54 Gy to 66 Gy) as part of the chemoradiation therapy, to be randomised. Radiation therapy should be administered by intensity modulated RT (preferred) or 3D-conforming technique.\n* WHO performance status of 0 or 1 at randomization\n* Adequate organ and marrow function\n\nEXCLUSION CRITERIA:\n\n* History of another primary malignancy except for malignancy treated with curative intent with no known active disease \u22655 years before the first dose of study intervention and of low potential risk for recurrence, adequately resected non-melanoma skin cancer and curatively treated in situ disease, or adequately treated carcinoma in situ or Ta tumours without evidence of disease.\n* Mixed small cell and non-small cell lung cancer histology.\n* Participants who receive sequential (not inclusive of induction) chemoradiation therapy for locally advanced (Stage III) unresectable NSCLC.\n* Participants with locally advanced (Stage III) unresectable NSCLC who have progressed during platinum-based cCRT.\n* Any unresolved toxicity CTCAE \\>Grade 2 from the prior chemoradiation therapy (excluding alopecia).\n* Participants with \u2265grade 2 pneumonitis from prior chemoradiation therapy.\n* History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, or idiopathic pneumonitis - regardless of time of onset prior to randomisation. Evidence of active non-CRT induced pneumonitis (\u2265 Grade 2), active pneumonia, active ILD, active or recently treated pleural effusion, or current pulmonary fibrosis - diagnosed in the past 6 months prior to randomization.\n* Active or prior documented autoimmune or inflammatory disorders (with exceptions)\n* Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05221840232","EMAIL":"information.center@astrazeneca.com","GEO":[10.82302,106.62965]},{"TITLE":"A Study of PF-08046050 (SGN-CEACAM5C) in Adults With Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Tumor type:\n\n  1. Participants in Part A (dose escalation) and Part B (dose optimization) must have histologically- or cytologically-confirmed metastatic or unresectable solid tumor malignancy. Participants must have relapsed, refractory, or progressive disease, and should have no appropriate standard therapy available at the time of enrollment in the judgement of the investigator. Participants in Part A must have one of the following tumor types:\n\n     * Colorectal cancer (CRC)\n     * Gastric carcinoma (GC) (including signet-ring cell histology) and gastroesophageal junction adenocarcinoma (GEJ)\n     * Non-small cell lung cancer (NSCLC), squamous or non-squamous histology\n     * Pancreatic ductal adenocarcinoma (PDAC)\n     * The tumor types to be enrolled in Part B will be identified by the sponsor from among those specified in Part A (dose escalation).\n  2. Part C (dose expansion):\n\n     * Participants must have histologically- or cytologically-confirmed metastatic or unresectable solid tumor malignancy.\n     * CRC\n\n       * Prior therapy: Participants must have received prior treatment (in 1 or more lines of therapy) containing fluoropyrimidine, oxaliplatin, and irinotecan.\n     * PDAC\n\n       * Prior therapy: Participants must have received 1 prior line of therapy and received no more than 3 prior lines of therapy in the advanced or metastatic setting.\n     * GC\/GEJ\n\n       * Prior therapy: Participants must have received prior platinum and fluoropyrimidine-based chemotherapy.\n     * NSCLC - non-squamous\/squamous\n\n       * Prior therapy: Participants must have received platinum-based therapy. If eligible and consistent with local standard of care must have received a PD-1\/PD-L1 inhibitor.\n       * In addition, Participants with tumor genomic mutations\/alterations for which approved targeted therapies are available per local standard of care, must have received such therapies.\n     * Small cell lung cancer (SCLC)\n\n       * Prior therapy: Participants must have received platinum-based therapy for extensive-stage disease and no more than 3 prior lines of therapy. If eligible and consistent with local standard of care must have received a PD 1\/PD-L1 inhibitor.\n* Participants enrolled in the following study parts should have a tumor site that is accessible for biopsy(ies) and agree to biopsy(ies) and\/or submission of archival tissue\n\n  1. Dose optimization\n  2. Disease-specific expansion cohorts\n* An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1\n* Measurable disease per Response Evaluation in Solid Tumors (RECIST) v1.1 at baseline.\n\nExclusion Criteria:\n\n* Previous exposure to CEACAM5-targeted therapy.\n* Prior treatment with an antibody-drug conjugate (ADC) with a camptothecin payload\n* History of another malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy.\n* Active cerebral\/meningeal disease related to the underlying malignancy. Participants with a history of cerebral\/meningeal disease related to the underlying malignancy are allowed if prior central nervous system disease has been treated and the participant is clinically stable (defined as not having received steroid treatment for symptoms related to cerebral\/meningeal disease for at least 2 weeks prior to enrollment and with no ongoing related AEs).","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06131840017","EMAIL":[{}],"GEO":[51.50853,-0.12574]},{"TITLE":"Study of High Efficient Killing Cell Therapy for Advanced NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Male or female patients' age from 18 years to 70 years.\n* Patients who have a life expectancy of at least 3 months.\n* pathologically confirmed non-small cell lung cancer.\n* failed in previous standard chemotherapy and targeted therapy.\n* Karnofsky performance status 0-1.\n* adequate organ functions.\n\nExclusion Criteria:\n\n* Pregnant and lactating women.\n* Patients with T cell lymphoma, syphilis, AIDS or combination\n* Patients with highly allergic or have a history of severe allergies\n* Patients with severe hepatic or renal dysfunction\n* Patients with severe autoimmune disease or who is being treated with immunosuppressive agents\n* Patients with severe infection not controlled or High fever\n* Patients with organ transplantation or waiting for organ transplantation.\n* Patients with brain metastasis\n* Patients with severe coagulopathy (e.g. hemophilia)\n* Patients without adequate ability to understand, sign informed consents and take part in the clinical research voluntarily.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":70,"SS_ID":"03193567001","EMAIL":[{}],"GEO":[31.22222,121.45806]},{"TITLE":"Study of CTDNA Response Adaptive Immuno-Chemotherapy in NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed metastatic NSCLC. Patients with stage III disease are eligible if they are not candidates for surgical resection or definitive chemoradiation. Patients with Large Cell Neuroendocrine Carcinoma (LCNEC) are not eligible.\n* Confirmed EGFR and ALK mutation-negative disease based on testing consistent with local guidelines.\n* Patients must have a PD-L1 test result from a certified laboratory indicating PD-L1 expression Tumour Proportion Score (TPS) \u2265 50%. Patients with lower PD-L1 TPS scores treated with single agent pembrolizumab consistent with local guidelines and regulatory approvals may be eligible following discussion with CCTG.\n* Patients must have received at least and not more than 2 cycles of the 200mg or 2mg\/kg IV Q3W dose\/schedule of pembrolizumab, or at least and not more than 1 cycle of 400mg or 4mg\/kg IV Q6W dose\/schedule of pembrolizumab as first-line systemic immunotherapy for advanced metastatic NSCLC at the time of screening.\n* Prior chemotherapy or immunotherapy for non-metastatic disease (e.g. adjuvant and or neoadjuvant therapy) is allowed if at least 6 months have elapsed between the completion of prior therapy and start of pembrolizumab as first-line treatment for metastatic disease. Local therapy, e.g. palliative extra-cranial radiation, is allowed as long as a period of 2 weeks has passed since completion and screening as ctDNA levels may be altered by radiotherapy. There is no requirement for delay for patients who have received brain radiation.\n* Patients must have recovered to \u2264 grade 1 from all reversible toxicity related to prior systemic or radiation therapy.\n* Previous major surgery is permitted provided that surgery occurred at least 14 days prior to screening of ctDNA and 28 days prior to patient enrollment and that wound healing has occurred.\n* Eligible and suitable to receive continued treatment with pembrolizumab OR the addition of chemotherapy to pembrolizumab. Patients should be clinically stable without evidence of clinical progression or symptomatic deterioration that requires change in cancer treatment. Reimbursement of pembrolizumab may not be uniform across all sites. In the event that the site\/investigator is unable to provide access to the drug, the patient will not be eligible for this trial.\n* Must be \u2265 18 years of age.\n* ECOG performance status 0-2.\n* Clinically and\/or radiologically documented and evaluable disease. Measurable disease as defined by RECIST is not required.\n* Imaging investigations including CT of the chest, abdomen and pelvis and MRI\/CT of the brain (if known brain metastases) or other scans as necessary to document all sites of disease must be done within 14 days prior to randomization to ensure patients do not have clinical progression requiring change in systemic treatment.\n* Patients must have RECIST non-PD or clinically stable PD documented prior to enrollment that can continue on IO therapy if randomized to that arm.\n* Detectable ctDNA on screening is required for subsequent enrollment and randomization.\n* Adequate hematology and organ function to continue immunotherapy or receive standard platinum combination therapy (must be done prior to registration for ctDNA testing).\n\n  * White Blood Cells \u2265 2.0 x 10\\^9\/L (2000\/\u03bcL)\n  * Absolute neutrophils \u2265 1.5 x 10\\^9\/L (1500\/\u03bcL)\n  * Platelets \u2265 100 x 10\\^9\/L (100 x 10\\^3\/\u03bcL)\n  * Bilirubin \u2264 1.5 x ULN (upper limit of normal)\\*\n  * AST and\/or ALT \u2264 3 x ULN, \\< 5 x ULN for patients with liver metastases\n  * Serum creatinine or Creatinine clearance \u2264 1.5 x ULN OR \u2265 40 mL\/min\n* Patients must consent to the provision of, and investigator must agree to submit, a representative archival formalin-fixed paraffin block of tumour tissue for correlative analyses when tumour tissue is available.\n* Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to registration to the trial to document their willingness to the collection of liquid biopsy (blood) samples for ctDNA analysis by CLIA central laboratory and for correlative analysis by a research central laboratory, and to subsequent enrollment and randomization to continued pembrolizumab or the addition of chemotherapy to pembrolizumab if ctDNA is detected.\n* Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients enrolled on this trial will be available for complete documentation of the treatment, adverse events, collection of blood samples, response assessments and follow-up. Patients must agree to return to their primary care facility for response assessments as well as any adverse events which may occur through the course of the trial.\n* In accordance with CCTG policy, protocol treatment is to begin within 5 working days of patient randomization.\n* Women\/men of childbearing potential must have agreed to use a highly effective contraceptive method. Women of childbearing potential will have a pregnancy test to determine eligibility as part of the Pre-Study Evaluation.\n\nExclusion Criteria:\n\n* Patients with a prior malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the protocol treatment regimens are eligible for this trial.\n* Patients with symptomatic central nervous system (CNS) metastases and\/or CNS metastases requiring immunosuppressive doses of systemic corticosteroids (\\>10 mg\/day prednisone equivalents). Patients with known central nervous system metastases who are asymptomatic and on a stable dose of corticosteroids \u2264 10 mg\/day prednisone equivalents are eligible.\n* Patients who are not suitable candidates for treatment with pembrolizumab as a single agent or in combination with standard platinum combination chemotherapy according to the current guidance\/indications described in the Product Monograph (Canada) or Drug Label (U.S.) and practice guidelines including but not limited to patients with active infection, autoimmune disease, conditions that require systemic immunosuppressive therapy (such as transplant patients) and patients with a history of severe immune-mediated adverse reactions, or known hypersensitivity to pembrolizumab or its components. Patients with pre-existing conditions such as colitis, hepatic impairment, respiratory or endocrine disorders (such as hypo or hyperthyroidism or diabetes mellitus), can be considered for enrollment to this study provided pembrolizumab is administered with caution and patients are closely monitored. Patients should not have contraindications to platinum combination chemotherapy.\n* History of significant neurologic or psychiatric disorder that would impair the ability to obtain consent or limit compliance with study requirements.\n* Concurrent treatment with other anti-cancer therapy or other investigational anti-cancer agents\n* Pregnant or lactating women.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04093167006","EMAIL":[{}],"GEO":[43.70011,-79.4163]},{"TITLE":"CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease","CRITERIA":"Inclusion Criteria:\n\n* Subject age is greater than or equal to 18 years at the time of signature of informed consent.\n* Histologically or cytologically confirmed metastatic EGFR mutant NSCLC.\n* Leptomeningeal disease based on brain MRI or CSF cytology.\n* ECOG 0-3.\n* Life expectancy of at least 8 weeks.\n* Adequate hematologic and end organ function for testing.\n* Ability to give informed consent for the study procedures defined in this protocol.\n\nExclusion Criteria:\n\n* Inability to undergo a lumbar puncture due to thrombocytopenia, bleeding disorders, as well as inability to cooperate or consent to procedure.\n* Subjects who are otherwise felt by the treating clinician to be unfit to proceed with this protocol.\n* MRI spine demonstrating spinal leptomeningeal disease preventing a safe lumbar puncture.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05257967001","EMAIL":[{}],"GEO":[49.24966,-123.11934]},{"TITLE":"A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia","CRITERIA":"Inclusion Criteria:\n\nPatients are eligible to be included in the study only if all of the following inclusion criteria and none of the exclusion criteria apply:\n\n* Written informed consent obtained from the patient prior to performing any protocol-related procedures\n* Age \u226518 years at time of study entry\n* Patients must have histologically or cytologically documented diagnosis of NSCLC with a locally advanced, or locally recurrent, unresectable (stage III) disease (according to American Joint Committee on Cancer \\[AJCC\\] lung cancer edition 8)\n* Patients must have completed a platinum-based chemotherapy with radiation therapy (concurrent or sequential) without evidence of disease progression\n* Patients must have been treated with at least one dose of durvalumab\n\nExclusion Criteria:\n\nAny subject who meets any of the following criteria will not qualify for entry into the study:\n\n* Absence or missing of written informed consent form\n* Patients treated with durvalumab in clinical studies\n* Absence of essential data to obtain all necessary information\n* Confirmation that the subject was already included in this study before","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05456867023","EMAIL":"information.center@astrazeneca.com","GEO":[46.95407,142.73603]},{"TITLE":"Study of PRO in Patients With Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay)","CRITERIA":"Inclusion Criteria:\n\n* Adult (aged 18 and over)\n* Confirmed by cytology or histology advanced lung (NSCLC) or pancreatic cancer\n* Written informed consent before any study procedures\n* Planning to receive 1st line systemic anticancer therapy within \u22642 weeks\n* Performance status: ECOG 0-2\n* Access to the internet\n* Ability to read and respond to questions or able to complete questions with minimal assistance required from an interpreter or family member\n\nExclusion Criteria:\n\n* No mobile device\n* Exhibiting signs of overt psychopathology or cognitive dysfunction\n* Any medical condition that the Investigator considers significant to compromise the safety of the patient or that impairs the interpretation of study assessments\n* Patient participating in another interventional study during the surveillance period. This is only relevant for studies that might interfere with the intervention. Participation in protocols related only to treatment will not preclude participation in the present study. Cases of doubt will be settled by the protocol responsible.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04611867001","EMAIL":[{"email":"Inna.Chen@regionh.dk"},{"email":"Dorte.Nielsen.01@regionh.dk"}],"GEO":[55.72366,12.43998]},{"TITLE":"SHR-1701 Combined With Fluzoparib in Lung Squamous Cell Carcinoma","CRITERIA":"Inclusion Criteria:\n\n* 1.The age at the time of signing the informed consent form is 18-75 years old, both male and female;\n* 2.Advanced or metastatic lung squamous cell carcinoma confirmed by histology or cytology;\n* 3.Has not received systemic treatment for the recurrence or metastasis stage in the past. If you have received neoadjuvant or adjuvant chemotherapy\/radiotherapy in the past, those who have relapsed or metastasized\\> 6 months from the end of treatment can be included in the group.\n* 4.ECOG PS score: 0-1 points;\n* 5.According to the RECIST 1.1 standard, the patient must have at least one measurable lesion;\n* 6.The function of major organs is normal, that is, it meets the following standards: a) Routine blood examination (under 14 days without blood transfusion and no hematopoietic stimulating factor drugs for correction): hemoglobin (Hb) \u226590g\/L; absolute neutrophil count (ANC) ) \u22651.5\u00d7109\/L; platelet (PLT) \u2265100\u00d7109\/L; white blood cell count (WBC) \u22653.0\u00d7109\/L; b) Biochemical examination: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u22642.5 \u00d7Upper limit of normal (ULN); serum total bilirubin (TBIL)\u22641.5\u00d7ULN; serum creatinine (Cr)\u22641.5\u00d7ULN or creatinine clearance \u226550ml\/min; c) coagulation function: activated partial thromboplastin time (APTT), international normalized ratio (INR), prothrombin time (PT)\u22641.5\u00d7ULN; d) Doppler ultrasound assessment: left ventricular ejection fraction (LVEF)\u226550%;\n* 7.Expected survival period \u2265 3 months; Women of childbearing age must undergo a negative pregnancy test (serum or urine) within 14 days before enrollment, and voluntarily use appropriate methods of contraception during the observation period and within 3 months after the last administration of the study drug; for men, surgical sterilization should be performed Or agree to use appropriate methods of contraception during the observation period and within 3 months after the last administration of the study drug;\n* 8.The patient voluntarily participates and signs the informed consent form (or signed by the legal representative). It is expected to have good compliance and be able to cooperate with the research according to the requirements of the plan.\n\nExclusion Criteria:\n\n* 1) Untreated brain metastases (persons who have previously received treatment for brain metastases (radiotherapy or surgery), if the images have been confirmed to be stable for at least 4 weeks before randomization, and systemic hormone therapy has been discontinued (dose\\>10mg\/day prednisone or Other equivalent hormones), those without clinical symptoms can be included in the group);\n* 2) With meningeal metastasis, spinal cord compression, etc.;\n* 3) Patients with pleural effusion, pericardial effusion or ascites who need to be drained with clinical symptoms, or who have received drainage of serous cavity effusion for treatment purposes within 2 weeks before randomization;\n* 4) Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), untreated active hepatitis (hepatitis B, defined as hepatitis B virus surface antigen \\[HBsAg\\] test results are positive, HBV-DNA \u2265 500 IU\/ml and abnormal liver function; hepatitis C is defined as hepatitis C antibody \\[HCV-Ab\\] positive, HCV-RNA higher than the detection limit of the analysis method and abnormal liver function) or combined hepatitis B and C co-infection \uff1b\n* 5) Suffer from any active autoimmune disease or history of autoimmune disease (such as interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (hormone replacement) Can be included after treatment)); patients with childhood asthma have been completely relieved and no intervention is required after adulthood or vitiligo can be included, and patients who require medical intervention with bronchodilators cannot be included;\n* 6) Severe infection (such as intravenous infusion of antibiotics, antifungal or antiviral drugs required) within 2 weeks before the first administration, or unexplained fever \\>38.5\u00b0C during the screening period\/before the first administration;\n* 7) Arterial\/venous thrombosis events that occurred within 6 months before enrollment, such as cerebrovascular accidents (including temporary ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism;\n* 8) Persons with a history of significant clinical significance of cardiovascular disease, including but not limited to; (1) Congestive heart failure (NYHA grade\\> 2); (2) Unstable angina pectoris; (3) 3 months before signing the ICF Myocardial infarction occurred within; (4) Any supraventricular arrhythmia or ventricular arrhythmia that requires treatment or intervention;\n* 9) Suffered from or accompanied with other systemic malignancies in the last 5 years, (except for cured skin basal cell carcinoma, cervical carcinoma in situ and ovarian cancer);\n* 10) Have received a preventive vaccine or attenuated vaccine within 4 weeks before the first administration;\n* 11) Those who are known to be allergic to any test drug or its excipients;\n* 12) Pregnant and lactating patients, and reproductive patients are unwilling to take effective contraceptive measures;\n* 13) Have a clear history of neurological or mental disorders, including epilepsy and dementia;\n* 14) Patients who are unable to swallow the study drug, such as chronic diarrhea (including but not limited to irritable bowel syndrome, Crohn's disease, ulcerative colitis) and intestinal obstruction and other factors that affect drug intake and absorption;\n* 15) Other situations that the researcher thinks are not suitable for inclusion.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"04937972001","EMAIL":[{"email":"yangnong0217@163.com"},{"email":"zhangyongchang@csu.edu.cn"}],"GEO":[28.19874,112.97087]},{"TITLE":"A Study of LY4170156 in Participants With Selected Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Have one of the following solid tumor cancers:\n\n  * Cohort A1: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer, endometrial cancer, cervical cancer, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), pancreatic, and colorectal cancer (CRC)\n  * Cohort A2\/B1\/B2: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer\n  * Cohort C1\/C2: Endometrial cancer, cervical cancer, NSCLC, TNBC, CRC or pancreatic cancer\n\nExclusion Criteria:\n\n* Individual with known or suspected uncontrolled central nervous system (CNS) metastases\n* Individual with history of carcinomatous meningitis\n* Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection\n* Individual with evidence of corneal keratopathy or history of corneal transplant\n* Any serious unresolved toxicities from prior therapy\n* Significant cardiovascular disease\n* Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) \u2265 470 milliseconds (ms)\n* History of pneumonitis\/interstitial lung disease\n* Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06400472006","EMAIL":"ClinicalTrials.gov@lilly.com","GEO":[35.6895,139.69171]},{"TITLE":"Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers","CRITERIA":"Inclusion Criteria:\n\n* Provision of a voluntarily given, personally signed and dated, written informed consent document. If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness;\n* Age \u2265 21 years, male or female;\n* Documentation of the presence of low EGFR-AS1 lncRNA expression as determined using the specifically designed companion diagnostic biomarker suite provided by the Sponsor (cohorts 1 to 3) or the presence of a novel emerging biomarker of EGFR family pathway addiction as determined by the Sponsor (cohort 4);\n* Study cohorts:\n\n  * Cohort 1: advanced or metastatic EGFR wildtype squamous NSCLC, after progression on or after, or intolerance to, one or more lines of standard of care (SOC) therapy, per local SOC guidelines. In subjects without an activating oncogenic driver mutation, after progression on or after, or intolerance to, platinum-containing combination chemotherapy. In subjects harbouring an activating oncogenic driver mutation, after progression on one or more SOC mutation-targeting TKI, per local SOC guidelines, or for whom no SOC mutation-targeting TKI is available. TKI therapy need not be the most recent prior therapy. Subjects harbouring an activating EGFR mutation are not eligible;\n  * Cohort 2: advanced or metastatic head and neck squamous cell carcinoma, after progression on or after, or intolerance to, platinum-containing combination chemotherapy. This need not be the most recent or prior regimen;\n  * Cohort 3: all advanced or metastatic solid tumours (excluding squamous NSCLC and HNSCC), after progression on or intolerance to at least one line of SOC therapy per local guidelines;\n  * Cohort 4: all advanced or metastatic solid tumours, after progression on or intolerance to at least one line of SOC therapy per local guidelines;\n* Have an ECOG PS of \u22642;\n* Life expectancy of at least 3 months;\n* Site of disease amenable to biopsy and be a candidate for tumour biopsy according to the treating institution's own guidelines and requirements for such procedure. Subjects must be willing to undergo a tumour biopsy at screening, and on treatment on this study;\n* Radiologically measurable disease by RECIST v1.1 criteria:\n\n  * At least one target lesion that has not previously been radiated and is measurable according to RECIST v1.1;\n  * Acceptable radiologic procedures for disease assessment include contrast enhanced conventional or spiral computed tomography (CT), or contrast enhanced magnetic resonance imaging (MRI);Non contrast CT scan is acceptable only for subjects who are both allergic to intravenous contrast and unable to cooperate with MRI, or MRI is not available. The following are not allowed as sole documentation of target lesions: CT component of a positron emission tomography (PET)\/CT, ultrasound alone, nuclear scans (including bone or PET scans), chest X-ray or bone radiographs, and tumour markers;\n* Adequate organ function, including:\n\n  * Estimated creatinine clearance \u226530 mL\/min (as determined by Cockcroft-Gault formula or the study site's standard formula);\n  * Absolute neutrophil count (ANC) \u22651500 cells\/mm3;\n  * Platelets \u2265100,000 cells\/mm3;\n  * Hemoglobin \u226510.0 g\/dL;\n  * Bilirubin \u22641.5 x upper limit of normal (ULN);\n  * Aspartate aminotransferase (AST; also known as SGOT) and Alanine aminotransferase (ALT; also known as SGPT) \u22642.5 x ULN (\u22645.0 x ULN if hepatic metastases).\n* Female subjects must be postmenopausal (defined as 12 months of amenorrhea following last menses), or they or their partners must be surgically sterile, or must agree to use effective contraception while receiving study treatment and for at least 3 months thereafter. The definition of effective contraception will be based on the judgment of the investigator using following criteria:\n\n  * Acceptable contraception for women include implants, injectables, combined oral contraceptives, intrauterine devices (IUDs), sexual abstinence, or a partner who has been surgically sterile (e.g. by vasectomy) for at least 6 months. Acceptable contraception for a male includes surgical sterility (e.g. by vasectomy) for at least 6 months, sexual abstinence, or condoms plus spermicide.\n* All female subjects with reproductive potential must have a negative pregnancy test (serum or urine) before starting study treatment;\n* Male subjects or their female partners must be surgically sterile or must agree to use effective contraception while receiving study treatment and for at least 3 months thereafter. The definition of effective contraception will be based on the judgment of the investigator. Or female partners must be postmenopausal (defined as 12 months of amenorrhea following last menses);\n* Willing and able to comply with study scheduled visits, treatment plans, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n* Subjects with symptomatic brain metastases or leptomeningeal metastases who are neurologically unstable or require increasing doses of steroids to manage central nervous system (CNS) symptoms within two weeks prior to starting dacomitinib;\n* Any surgery (not including minor procedures such as lymph node biopsy), palliative radiotherapy or pleurodesis within 2 weeks of baseline assessments;\n* Any clinically significant gastrointestinal abnormalities that may impair intake, transit or absorption of the study drug, such as the inability to take oral medication;\n* Current enrollment in another therapeutic clinical study;\n* Any psychiatric or cognitive disorder that would limit the understanding or rendering of informed consent and\/or compromise compliance with the requirements of this study or known drug abuse\/alcohol abuse;\n* History of, or currently suspected, diffuse non-infectious pneumonitis or interstitial lung disease including:\n\n  * Past medical history of interstitial lung disease, drug-induced interstitial disease, radiation pneumonitis which required steroid treatment or any evidence of clinically active interstitial lung disease;\n  * Pre-existing idiopathic pulmonary fibrosis evidenced by CT scan at baseline;\n  * Insufficient lung function as determined by either clinical examination or an arterial oxygen tension of \\<70 Torr.\n* Any history of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption;\n* Clinically important abnormalities in cardiac rhythm, conduction or morphology of resting ECG (e.g. complete left bundle branch block, second degree heart block, third degree heart block) OR:\n\n  * Diagnosed or suspected congenital long QT syndrome;\n  * Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes);\n  * Prolonged QTc interval on electrocardiogram (ECG); QTc must be less than CTCAEv5.0 Grade 2 (\u2264480 msec) using Fridericia's or Bazett's correction formula with a manual reading by the investigator if required. The ECG may be repeated for evaluation of eligibility after management of correctable causes for observed QTc prolongation;\n  * Any history of second- or third-degree heart block;\n  * Heart rate \\<45 beats per minute on ECG in the presence of clinical symptoms (e.g., hypotension, evidence of hypoperfusion);\n* Severely impaired (defined as Child-Pugh Class C) hepatic dysfunction;\n* Prior malignancy: Subjects will not be eligible if they have history of, or evidence of another concurrent malignancy within 2 years prior to registration. Exception would be effectively treated past history of non-melanoma skin cancer or in-situ cervical cancer with no evidence of active disease. Patients with a history of other malignancies are eligible if they have been continuously disease free for at least 2 years after definitive primary treatment;\n* Other severe acute or chronic medical condition that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study;\n* Use of narrow therapeutic index drugs that are CYP2D6 substrates (procainamide, pimozide, and thioridazine etc.) from screening to randomization.","SEX":"ALL","AGE_MIN":21,"AGE_MAX":99,"SS_ID":"04946968001","EMAIL":[{}],"GEO":[1.28967,103.85007]},{"TITLE":"Phase 1 Study of Oral RH324 in Advanced Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Advanced Non-Small Cell Lung Cancer\n* Measurable Target Lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\n* Failed all standard of care including chemotherapy, targeted therapy, and immunotherapy\n* Adults over 18 years\n* Performance status (Eastern Cooperative Oncology Group) less than or equal to 2\n* Life expectancy greater than 2 months\n* Laboratory Values:\n\nHemoglobin greater than or equal to 9; neutrophils greater than 1,000; platelets greater than 50,000 Liver function tests less than or equal to twice upper limit of normal Serum Creatinine less than or equal to 2 Creatinine clearance greater than or equal to 30 mL per minute Hemoglobin A1C less than 7 Normal Thyroid function\n\n* No history of hyperthyroidism\n* Abstinence from alcohol and supplements\n* Not pregnant, lactating and willing to use birth control throughout study\n* Able to provide consent\n* Positive Emission Tomography\/Computer Tomography part of subjects care plan at baseline\n\nExclusion Criteria:\n\n* Prior use of Withania somnifera\n* Phenylketonuria\n* Inability to swallow capsules\n* Hypersensitivity to study drug ingredients\n* Unstable medical or surgical condition\n* History of additional cardiac risk factors\n* Requiring drugs that are \"strong\" inhibitors of cytochrome P450\n* Requiring irradiation\n* Requiring intravenous fluids or hyperalimentation\n* Requiring transfusions, dialysis, or other procedures\n* Active infection\n* Human Immunodeficiency Virus\n* Must exceed washout period of prior treatments\n* Psychiatric, neurological or other reason that precludes subjects ability to participate","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05580172001","EMAIL":[{"email":"Afshin.Dowlati@UHhospitals.org"}],"GEO":[41.4995,-81.69541]},{"TITLE":"A Study of SI-B003, a PD-1\/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n1. The participants could understand and sign the informed consent form, and must participate voluntarily.\n2. No gender limit.\n3. Age: \u226518 years old and \u226475 years old (phase Ia); \u226518 years old (phase Ib).\n4. Expected survival time \u2265 3 months.\n5. Histologically or cytologically confirmed recurrent or metastatic solid tumor, clinical stage IIIB\/IV, with radiographic or other objective evidence of disease progression after standard therapy; Or subjects were patients with solid tumors that were refractory to treatment, patients with solid tumors that did not have standard treatment, or patients who could not tolerate or had contraindications to standard treatment.\n6. For the phase Ib study:\n\n   Cohort_A: Histologically or cytologically confirmed advanced gastric adenocarcinoma (GC) or gastroesophageal junction (GEJ) adenocarcinoma after exposure to platinum-based chemotherapy after receiving only first-line anti-PD-1 (L1) monoclonal antibody during systemic therapy; Cohort_B: Histologically or cytologically confirmed patients with malignant mesothelioma not suitable for surgery;\n7. Consent to provide archival tumor tissue or fresh tissue samples of the primary or metastatic tumor, if not available, at the discretion of the investigator (only for stage Ib );\n8. At least one measurable lesion that meets the definition of RECIST v1.1 at baseline (only for stage Ib).\n9. Patients treated with anti-PD-1 (L1) -containing monoclonal antibody must have progression of resistance after benefit from anti-PD-1 (L1) -containing monoclonal antibody (phase Ib only);\n10. Physical fitness score ECOG 0 or 1 point.\n11. The adverse reactions of previous antineoplastic therapy returned to CTCAE 5.0 grade \u22641 (except for toxicities without safety risks judged by investigators, such as alopecia, grade 2 peripheral neurotoxicity, and hypothyroidism stable with hormone replacement therapy);\n12. No severe cardiac dysfunction, left ventricular ejection fraction \u226550%;\n13. The organ function within 7 days prior to the first administration meets the following requirements:\n\n    1. Bone marrow: absolute neutrophil count (ANC) \u22651.5\u00d7109\/L, hemoglobin \u226590 g\/L, platelet count \u2265100\u00d7109\/L (participants with liver cancer ANC \u226575\u00d7109\/L);\n    2. Liver: total bilirubin (TBIL) \u22641.5 ULN (TBIL \u22643 ULN in participants with Gilbert's syndrome, liver cancer or liver metastasis), transaminase (AST\/ALT) \u2264 3 ULN (for participants with liver cancer or liver metastasis \u2264 5.0 ULN); for participants with liver cancer or liver metastasis, transaminase \u2265 3 ULN and TBIL \u2265 1.5 ULN must be excluded;\n    3. Kidney: Creatinine (Cr) \u22641.5 ULN and creatinine clearance rate (Ccr) \u2265 50mL\/min (according to Cockcroft-Gault formula).\n14. Female participants with fertility or male participants whose partners are fertile must take effective contraceptive measures from 7 days prior to the first administration to 24 weeks after the administration. Female participants with fertility must have a negative serum\/urine pregnancy test in 7 days prior to the first dose.\n15. The participants are capable and willing to comply with the visits, treatment plans, laboratory examinations and other study-related procedures stipulated in the study protocol.\n\nExclusion Criteria:\n\n1. Parenchymal or leptomeningeal metastases with clinical symptoms who were judged by the investigator to be ineligible for enrollment;\n2. Participants who participated in any other clinical trial within 28 days before the administration of this trial, except for clinical trials of marketed drugs;\n3. Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, major surgery, targeted therapy (including small molecule inhibitor of tyrosine kinase), and other anti-tumor therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to the first administration; mitomycin and nitrosoureas treatment within 6 weeks prior to the first administration; oral fluorouracil-like drugs such as S-1, capecitabine, or palliative radiotherapy within 2weeks prior to the first administration.\n4. Major surgery (investigator-defined) within 4 weeks before the first dose.\n5. In 14 days prior to administration of this study, those who have received systemic corticosteroids (\\>10mg\/day prednisone, or equivalent other corticosteroids) or immunosuppressive therapy should be excluded except for those who have received inhaled or topical corticosteroids, or hormone therapy of physiological replacement dose due to adrenal insufficiency.\n6. Pulmonary disease grade \u22653 according to NCI-CTCAE v5.0; Patients with existing interstitial lung disease (ILD).\n7. Severe systemic infection occurred within 4 weeks before screening, including but not limited to severe pneumonia caused by fungi, bacteria, viruses, bacteremia, or serious infectious complications.\n8. Participants at risk of active autoimmune diseases, or with a history of autoimmune diseases, including but not limited to Crohn's disease, ulcerative colitis, systemic lupus erythematosus, sarcoidosis, Wegener syndrome (polyangiitis granuloma Disease, Graves' disease, rheumatoid arthritis, pituitary inflammation, uveitis), autoimmune hepatitis, systemic sclerosis, Hashimoto's thyroiditis, autoimmune vasculitis, autoimmune neuropathy (Guillain-Barr\u00e9 syndrome), etc. Except for the following conditions: Type I diabetes, hormone replacement therapy for stable hypothyroidism (including hypothyroidism caused by autoimmune thyroid disease), psoriasis or vitiligo that does not require systemic treatment.\n9. Complicated with other malignant tumors within 2 years prior to the first administration, except for cured skin squamous cell carcinoma, basal cell carcinoma, superficial bladder cancer, prostate\/cervix\/breast carcinoma in situ (only phase Ib).\n10. Participants with human immunodeficiency virus antibody (HIVAb) positive, active tuberculosis, active hepatitis B virus infection (HBV-DNA copy number\\> 104) or hepatitis C virus (HCV) infection.\n11. Participants with poorly controlled hypertension by two kinds of antihypertensive drugs (systolic blood pressure\\>150 mmHg or diastolic blood pressure\\>100 mmHg).\n12. A history of severe cardiovascular and cerebrovascular diseases, including but not limited to:\n\n    Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmia requiring clinical intervention, \u2162 degree atrioventricular block, etc.\n\n    At rest, the QT interval was prolonged (QTc \\> 450 msec in men or QTc \\> 470 msec in women); Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other grade 3 or higher cardiovascular and cerebrovascular events occurred within 6 months before the first dose; Patients with New York Heart Association (NYHA) functional class \u2265II heart failure.\n13. Previous history of allogeneic bone marrow or organ transplantation.\n14. Participants who have a history of allergies to recombinant humanized antibodies or human-mouse chimeric antibodies or any of the components of SI-B003.\n15. In the adjuvant (or neoadjuvant) treatment of anthracyclines, the cumulative dose of anthracyclines is\\> 360 mg\/m2.\n16. Pregnant or breastfeeding women.\n17. Other conditions that the investigator believes that it is not suitable for participating in this clinical trial.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04606472008","EMAIL":[{}],"GEO":[30.66667,104.06667]},{"TITLE":"A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC","CRITERIA":"Core Inclusion Criteria (Radiation Phase)\n\n1. Histologically or cytologically confirmed NSCLC (patients where the local MDT agree the diagnosis is NSCLC after review of the available pathology and imaging at MDT can be enrolled after discussion with the CI).\n2. Not suitable for concurrent chemoradiotherapy\/surgery due to tumour or patient factors\n3. Stage IIB and III (TNM 8th Edition).\n4. Planned to receive RT at curative intent doses (i.e., 60Gy) as part of treatment plan (either with or without induction chemotherapy).\n5. Patient considered suitable for radical RT by the local lung cancer multidisciplinary team and a clinical oncologist.\n6. If chemotherapy has been given previously, the maximum interval between the last day of chemotherapy and the start of RT \\<10 weeks.\n7. Age \u226518\n8. Life expectancy estimated to be greater than 6 months.\n9. Karnofsky Performance status \u226570.\n10. MRC dyspnoea score \\<3.\n11. Forced expiratory volume in one second (FEV1) \u226535% predicted and diffusing capacity of the lungs for carbon monoxide (DLCO or TLCO) \u226535% predicted.\n12. Patient must be fully informed about the study and have signed the informed consent form.\n13. Patient must be willing and able to comply with the protocol, have mental capacity and (if relevant) use effective contraception throughout treatment and for 4 months for women of childbearing potential, and 6 months for men after treatment completion. Treatment is defined as including the last dose of durvalumab or DDRi in the consolidation phase.\n14. Adequate organ function as defined in master protocol.\n15. Patient has a body weight of \\>30kg.\n\nCore Exclusion Criteria (Radiation Phase)\n\n1. Mixed non-small cell and small cell tumours.\n2. Confirmed progressive disease during induction chemotherapy.\n3. Participation in a study of an investigational agent or using an investigational device within 4 weeks prior to the anticipated start of treatment.\n4. Current or previous malignant disease which may impact on a patient's estimated life expectancy (other than NSCLC).\n5. History of interstitial pneumonitis.\n6. Prior thoracic radiotherapy.\n7. Prior treatment with pneumotoxic drugs, e.g. busulfan, bleomycin, within the past year. If prior therapy in lifetime, then exclude if history of pulmonary toxicities from administration. Patients who have received treatment with nitrosoureas (e.g., carmustine, lomustine) in the year before study entry without experiencing lung toxicity are allowed on study.\n8. Mean resting corrected QT interval (QTcF) \\>470 msec obtained from 3 electrocardiograms.\n9. Received a prior autologous or allogeneic organ or tissue transplantation.\n10. Patients unable to swallow orally administered medications or chronic gastrointestinal (GI) disease likely to interfere with absorption of IMP in the opinion of the treating investigator (e.g. malabsorption syndrome, resection of the small bowel, poorly controlled inflammatory bowel disease etc.).\n11. Grade 2 or higher peripheral sensory neuropathy.\n12. Known positive test for human immunodeficiency virus, active hepatitis B or C infection.\n13. Positive pregnancy test (at eligibility assessment for women of childbearing potential) or breast-feeding women.\n14. Patients with persistent toxicities (\\>CTCAE grade 2) caused by previous cancer therapy, excluding alopecia.\n15. Patients with myelodysplastic syndrome (MDS)\/acute myeloid leukaemia (AML) or with features suggestive of MDS\/AML.\n16. Major surgery within 2 weeks of confirmation of eligibility.\n17. Patients considered a poor medical risk by the investigator due to a serious, uncontrolled medical disorder, non-malignant system disease or active uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, uncontrolled hypertension, uncontrolled atrial fibrillation, active bleeding, recent (within 3 months) myocardial infarction, major seizure, active COVID-19, any psychiatric disorder that prohibits obtaining informed consent.\n18. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease (e.g., ulcerative colitis or Crohn's disease), systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome (granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.\n19. Exclusions as described in the relevant study arm protocol. Patients ineligible for a particular study arm may be considered for entry into an alternative study arm if an appropriate slot is available and they meet all the inclusion and exclusion criteria for that arm. This will need to be discussed with CTRU and the patient will be required to reconsent using the appropriate study arm PIS\/ICF.\n\nCore Inclusion Criteria (Consolidation Phase)\n\n1. A minimum of 4 and a maximum of 8 weeks\\* have elapsed following completion of RT\n2. Any toxicities from RT have resolved to grade 1. If patient has pneumonitis following RT treatment, this must be asymptomatic (grade 1). If pneumonitis is \u22652 or requiring steroids, then participant is not eligible\n3. Karnofsky Performance status \u226570\n4. The laboratory requirements set out in Table 1 of the master protocol are met\n5. Patient has no known hypersensitivity to the excipients of durvalumab\n6. Patient has body weight of \\>30kg \\*Investigators should ideally aim to start consolidation treatment within 6 weeks, following the receipt of the CT scan results to rule out progression.\n\nCore Exclusion Criteria (Consolidation Phase)\n\n1. Progressive disease during RT or at the end of RT treatment response assessment.\n2. Participant declines treatment in the consolidation phase.\n3. Patients who have received prior anti-PD-1 or anti PD-L1 treatment.\n4. Major surgery within 4 weeks of confirmation of eligibility for consolidation phase.\n5. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab.\n6. Patients considered a poor medical risk by the investigator due to a serious, uncontrolled medical disorder, non-malignant system disease, active GI infection or active uncontrolled infection.\n7. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease e.g., colitis or Crohn's disease), systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc).","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04550104011","EMAIL":[{"email":"CTRU_CONCORDE@leeds.ac.uk"},{}],"GEO":[51.35,-0.2]},{"TITLE":"EF-36\/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of stage III or metastatic NSCLC without EGFR sensitizing mutation or ALK translocation\n* Age \u2265 22 years\n* Have a PD-L1 positive (TPS\u22651%) tumor by local laboratory assessment\n* Have evaluable (measureable or non-measureable) disease in thorax per RECIST 1.1\n* ECOG performance status of 0 to 1\n* Have not received prior treatments for metastatic or current advanced NSCLC. Palliative treatment is allowed and subjects who received adjuvant, neoadjuvant chemotherapy or chemoradiotherapy with curative intent for non-metastatic disease are eligible if therapy completed at least 12 months prior to the development of metastatic or current advanced disease.\n* Life expectancy of at least 3 months\n* Able to operate the NovoTTF-200T device\n\nExclusion Criteria:\n\n* Has known active or untreated CNS metastases and\/or carcinomatous meningitis\n* Has an EGFR sensitizing mutation and\/ or ALK translocation\n* Can be treated with curative intent with either surgical resection and\/or chemoradiation\n* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or an agent directed to another stimulatory or co-inhibitory T cell receptor within the past 12 months\n* Has received prior systemic anti-cancer therapy for metastatic or current advanced NSCLC (palliative radiotherapy is allowed)\n* Being unable to operate the NovoTTF-200T device independently or with the help of a caregiver\n* Pregnancy or breastfeeding\n* Received live vaccine in the past 30 days or had major surgery in the last 3 weeks\n* Is expected to require any other form of systemic or localized antineoplastic therapy while on study","SEX":"ALL","AGE_MIN":22,"AGE_MAX":200,"SS_ID":"04892472024","EMAIL":[{"email":"Plopez3@mdanderson.org"},{}],"GEO":[29.76328,-95.36327]},{"TITLE":"A Study of SGN-B7H4V in Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Participants must have one of the following histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumor types:\n\n  * High-grade serous epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer\n  * HER2-negative, HR positive breast cancer\n  * Triple-negative breast cancer (TNBC)\n  * Endometrial carcinoma\n  * Non-small cell lung cancer (Squamous cell carcinoma \\[SqCC\\], Adenocarcinoma \\[AC\\])\n  * Cholangiocarcinoma or gallbladder carcinoma\n  * Adenoid cystic carcinoma (ACC)\n* Parts A and B: Participants must have disease that is relapsed or refractory or be intolerant to SOC therapies, and, in the judgement of the investigator, should have no appropriate SOC therapeutic option\n* Part C: Participants must have disease that is relapsed or refractory or be intolerant to SOC therapies, unless contraindicated\n* Tumor tissue is required for enrollment.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Measurable disease per RECIST version 1.1 at baseline\n\nExclusion Criteria:\n\n* History of another malignancy within 3 years before the first dose of study drug. Any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.\n* Known active central nervous system metastases. Participants with previously treated brain metastases may participate provided they:\n\n  * are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment\n  * have no new or enlarging brain metastases\n  * and are off corticosteroids prescribed for symptoms associated with brain metastases for at least 7 days prior to the first dose of study treatment.\n* Carcinomatous meningitis\n* Previous receipt of an MMAE-containing agent or an agent targeting B7-H4\n* Pre-existing neuropathy \u2265 Grade 2 per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0\n* Corneal disease or injury requiring treatment or active monitoring","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05194072019","EMAIL":[{}],"GEO":[51.50853,-0.12574]},{"TITLE":"Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies","CRITERIA":"Key Inclusion Criteria:\n\n* Age \u2265 18 at the time of screening\n* Histological or cytological confirmation of advanced malignancy considered to be suitable for study treatment and meeting module specific eligibility criteria..\n* Eastern Cooperative Oncology Group Performance status (ECOG PS: 0-2)\n* Life expectancy \u2265 12 weeks\n* Progressive cancer at the time of study entry\n* Patients must have evaluable disease as defined in module-specific criteria for Part A and Part B\n* Adequate organ and marrow function as defined by the protocol.\n* For Part B expansion cohorts: Provision of formalin-fixed and paraffin embedded (FFPE) tumour specimen is mandatory, where available, except if stated that it is optional in a specific Module.\n\nFor Part A:\n\n- Patients may have received up to one prior line of therapy with a PARPi-based regimen (either as a treatment or as maintenance)\n\nFor Part B:\n\n- Patients must not have received prior therapy with a PARPi-based regimen (either as a treatment or as maintenance).\n\nKey Exclusion Criteria:\n\n* Treatment with any of the following:\n\n  1. Nitrosourea or mitomycin C within 6 weeks of the first dose of study treatment\n  2. Any investigational agents or study drugs from a previous clinical study within 5 half-lives or 3 weeks (whichever is shorter) of the first dose of study treatment\n  3. Any other chemotherapy, immunotherapy or anticancer agents within 3 weeks of the first dose of study treatment\n  4. Any live virus or bacterial vaccine within 28 days of the first dose of study treatment\n* Concomitant use of medications or herbal supplements known to be cytochrome P450 3A4 (CYP3A4) strong and moderate inhibitors or inducers.\n* Concomitant use of drugs that are known to prolong or shorten QT and have a known risk of Torsades de Pointes.\n* Receiving continuous corticosteroids at a dose of \\>10 mg prednisone\/day or equivalent for any reason.\n* Major surgery within 4 weeks of the first dose of study treatment.\n* Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study treatment.\n* Any history of persisting (\\> 2 weeks) severe pancytopenia due to any cause\n* Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring continuous corticosteroids at a dose of \\>10mg prednisone\/day or equivalent for at least 4 weeks prior to start of study treatment. Patients with leptomeningeal carcinomatosis are excluded.\n* patient with known predisposition to bleeding (e.g., active peptic ulceration, recent \\[within 6 months\\] haemorrhagic stroke, proliferative diabetic retinopathy).\n* Cardiac conditions as defined by the clinical study protocol\n* Other cardiovascular diseases as defined by any of the following:\n\n  1. Symptomatic heart failure,\n  2. uncontrolled hypertension,\n  3. hypertensive heart disease with significant left ventricular hypertrophy\n  4. acute coronary syndrome (ACS)\/acute myocardial infarction (AMI), unstable angina pectoris, coronary intervention procedure with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within 6 months.\n  5. cardiomyopathy of any etiology\n  6. presence of clinically significant valvular heart disease\n  7. history of atrial or ventricular arrhythmia requiring treatment; subjects with atrial fibrillation and optimally controlled ventricular rate (\\< 100 beats per minute) are permitted.\n  8. subjects with atrial fibrillation and optimally controlled ventricular rate are permitted\n  9. transient ischaemic attack, or stroke within 6 months prior to screening\n  10. patients with symptomatic hypotension at screening\n* Patients with myelodysplastic syndrome\/acute myeloid leukaemia or with features suggestive of myelodysplastic syndrome (MDS)\/acute myeloid leukaemia (AML).\n* Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD5305\n* Known allergy or hypersensitivity to investigational product(s) or any of the excipients of the investigational product(s).\n\nPrior malignancy whose natural history, in the Investigator's opinion, has the potential to interfere with safety and efficacy assessments of the investigational regimen.\n\nother module-specific criteria may apply","SEX":"ALL","AGE_MIN":18,"AGE_MAX":130,"SS_ID":"04644068074","EMAIL":"information.center@astrazeneca.com","GEO":[51.35,-0.2]},{"TITLE":"Advanced Patient Monitoring and A.I. Supported Outcomes Assessment in Lung Cancer Using Internet of Things Technologies (A.I. - APALITT)","CRITERIA":"Inclusion Criteria:\n\n* Aged \\< 75\n* Clinically able to use portable technologies\n* Able to understand and sign informed consent\n\nExclusion Criteria:\n\n* Major psychiatric disorder\n* ECOG\\>2 performance status\n* Not able to use portable technologies","SEX":"ALL","AGE_MIN":0,"AGE_MAX":75,"SS_ID":"05815472001","EMAIL":"filippo.lococo@policlinicogemelli.it","GEO":[41.89193,12.51133]},{"TITLE":"MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Written informed consent must be signed before implementing any enrollment-related procedures;\n2. Age \u226518 years old;\n3. Patients with histologically or cytologically confirmed stage IIA-IIIC NSCLC (International Association for the Study of Lung Cancer and American Joint Committee on Classification of Cancer, 8th Edition TNM staging)\uff1b\n4. There is no special restriction on the source of genetic test report.\n5. According to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1), there is at least one radiographically measurable lesion.\n6. Have not received any previous systemic antitumor therapy for advanced diseases.\n7. No serious abnormalities of hematopoietic function, heart, lung, liver, kidney function and immune system.\n8. ECOG score: 0-1;\n9. Expected survival time \\> 3 months.\n\nExclusion Criteria:\n\n1. Received surgical treatment for lung tumors.\n2. Received neoadjuvant chemotherapy or radiotherapy.\n3. Received cellular therapy within the last 1 year.\n4. Treated but uncontrolled diabetes, mellitus, asthma, autoimmune diseases and other chronic diseases.\n5. Participated in other clinical trials (including research vaccines, drugs, medical devices, etc.) within one month.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06198868001","EMAIL":[{"email":"fjif@vip.sina.com"},{"email":"wangsiwei@njmu.edu.cn"}],"GEO":[32.06167,118.77778]},{"TITLE":"Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer","CRITERIA":"Inclusion Criteria:\n\nFor inclusion in the trial, all of the following inclusion criteria must be fulfilled, as no waivers will be permitted:\n\n1. Provision of signed and dated written informed consent prior to any study specific procedures. Participation in pharmacogenomics testing is optional.\n2. Histologically or cytologically confirmed diagnosis of metastatic or locally advanced solid tumor for which no standard therapy is available or standard therapy has failed.\n3. Measurable disease on imaging based on RECIST 1.1, except for prostate cancer.\n4. Life expectancy of \u2265 3 months and Eastern Cooperative Oncology Group performance status of 0 or 1.\n5. Adequate organ and bone marrow reserve function, as indicated by the following laboratory values:\n\n   1. Adequate hematological function, defined as absolute neutrophil count \u2265 1.5 \u00d7 10\\^9\/liter (L), platelet count \u2265 100 \u00d7 10\\^9\/L, and hemoglobin \u2265 8 grams\/deciliter without recent transfusion (defined as a transfusion that has occurred within 2 weeks of the hemoglobin measurement).\n   2. Adequate liver function, defined as total bilirubin level \u2264 1.5 \u00d7 institutional upper limit of normal (IULN) (except for participants with Gilbert syndrome who must have a total bilirubin level of \u2264 3.0 \u00d7 IULN), aspartate aminotransferase \u2264 2.5 \u00d7 IULN, and alanine aminotransferase \u2264 2.5 \u00d7 IULN.\n   3. Adequate renal function defined as creatinine \u2264 1.5 \u00d7 IULN or measured or calculated creatinine clearance \u2265 40 milliliters (mL)\/minute per institutional standard. Assessment methods should be recorded.\n   4. Adequate coagulation, defined as international normalized ratio or prothrombin time \u2264 1.5 \u00d7 IULN and activated partial thromboplastin time \u2264 1.5 \u00d7 IULN (unless participant receiving anticoagulant therapy) or stable known coagulopathy with sponsor approval.\n6. A sufficient and adequate formalin-fixed paraffin embedded tumor tissue sample (fresh or archival tumor tissue) collected since last treatment and before the first dose from a site not previously irradiated, if clinically feasible.\n7. Female participants of childbearing potential must have a negative serum pregnancy test at screening (within 72 hours of first dose of study medication). Non-childbearing potential is defined as 1 of the following:\n\n   1. \u2265 45 years of age and has not had menses for \\> 1 year and there is no alternative medical cause.\n   2. Amenorrheic for \\> 2 years without a hysterectomy and\/or oophorectomy and follicle stimulating hormone value in the postmenopausal range upon pretrial (screening) evaluation.\n   3. Status is post-hysterectomy, -oophorectomy, or -tubal ligation.\n8. Female participants of childbearing potential must be willing to use highly effective contraceptive measures starting with the Screening visit through 90 days after last dose of study treatment. For the UK only, highly effective contraceptive measures are defined as follows:\n\n   1. Combined (estrogen and progesterone containing) hormonal contraception associated with inhibition of ovulation.\n\n      * Oral\n      * Intravaginal\n      * Transdermal\n   2. Progesterone-only hormonal contraception associated with inhibition of ovulation.\n\n      * Oral\n      * Injectable\n      * Implantable\n   3. Intrauterine device\n   4. Intrauterine hormone-releasing system\n   5. Bilateral tubal occlusion\n   6. Vasectomized partner\n   7. Sexual abstinence\n9. Male participants with a female partner(s) of childbearing potential must agree to use highly effective contraceptive measures throughout the trial starting with the Screening visit through 90 days after the last dose of study treatment is received. Males with pregnant partners must agree to use a condom (which is not considered \"highly effective\"); no additional method of contraception is required for the pregnant partner. Note: Abstinence is acceptable if this is the established and preferred contraception method for the participant.\n\n   The following inclusion criteria are in addition to the above criteria. If there are criteria below that differs from above, the below indication-specific criteria take precedence.\n\n   Additional Inclusion Criteria for Angiosarcoma Cohort\n10. Histologically or cytologically confirmed diagnosis of metastatic or locally advanced angiosarcoma for which no standard therapy is available or standard therapy has failed.\n\n    Additional Inclusion Criteria for the Hepatocellular Cancer (HCC) Cohort\n11. Histologically or cytologically confirmed diagnosis or radiological diagnosis following the guidelines from the American Association for the Study of Liver Diseases of metastatic or locally advanced HCC.\n12. Must have progressed while receiving, or following, programmed death-ligand 1 (PD(L)-1)-based therapy.\n13. Child-Pugh score of A. Note: Participants on anticoagulant treatment would have an assigned value of 1 point when scoring prothrombin time\/international normalized ratio so the overall Child-Pugh score is not adversely affected.\n14. Adequate organ and bone marrow reserve function as indicated by the following laboratory values:\n\n    1. Platelet count \u2265 60 \u00d7 10\\^6\/cubic millimeter (mm\\^3) and absolute neutrophil count \u2265 1,000 \u00d7 10\\^6\/L are acceptable provided that the investigator assesses these abnormalities as being due to liver disease.\n    2. Adequate liver function, defined as aspartate aminotransferase and alanine aminotransferase \u2264 5 \u00d7 IULN, bilirubin \u2264 2 \u00d7 IULN.\n15. Participants are eligible to enroll if they have non-viral-HCC or if they have hepatitis B (HBV), or hepatitis C virus (HCV) related HCC, defined as follows:\n\n    1. Chronic HBV infection as evidenced by detectable HBV surface antigen or HBV DNA. Participants with chronic HBV infection must be on antiviral therapy and have HBV DNA \\< 500 international units\/mL.\n    2. Active or resolved HCV infection as evidenced by detectable HCV RNA or antibody.\n\n    Additional Inclusion Criteria for the Non-Small Cell Lung Cancer (NSCLC) Cohort\n16. Histologically or cytologically confirmed diagnosis of metastatic or locally advanced NSCLC for which no standard therapy is available or standard therapy has failed:\n\n    1. Adenocarcinoma or squamous cell carcinoma at the time of enrollment. If other histologies are also present, must be approved by the medical monitor prior to study entry.\n    2. For participants without targetable alterations: Prior treatment with anti PD(L)-1-based therapy.\n    3. Participants with targetable alterations (for example, estimated glomerular filtration rate, anaplastic lymphoma kinase, Kirsten rat sarcoma virus-single point mutation with a glycine-to-cysteine substitution at codon 12, reactive oxygen species, mesenchymal epithelial transition factor receptor, etc.): must have received or be intolerant of at least one approved targeted therapy.\n\n    Additional Inclusion Criteria for the Prostate Cancer Cohort\n17. Diagnosis of metastatic castrate resistant prostate cancer.\n18. Must have demonstrated serologic or radiographic progression on or following the most recent therapy in the setting of castrate-level testosterone (\\< 50 nanograms per mL \\[ng\/mL\\] and\/or maintained on medical\/surgical castration throughout) as defined by at least one of the following:\n\n    1. Baseline PSA \u2265 2.0 ng\/mL and 2 sequential rises in prostate-specific antigen (PSA) with each rising value being at least 1 week apart.\n    2. Progression by RECIST 1.1.\n    3. Progression by PCWG3 criteria for bone disease (\"2+2\" rule) with or without PSA progression.\n19. Must maintain castration status defined as serum testosterone \\< 50 ng\/mL. Must be either surgically castrate or on luteinizing hormone-releasing hormone analog for the duration of the study.\n\n    Additional Inclusion Criteria for Breast Cancer\n20. Must have received PD-(L)1 therapy if indicated. Note: Premenopausal participants may continue ongoing ovarian suppression on study. Permitted agents are goserelin, triptorelin or analogs.\n\nExclusion Criteria:\n\nFor inclusion in the trial, participant must meet none of the following exclusion criteria, as no waivers will be permitted:\n\n1. Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigation device within 3 weeks of first dose of current study drug.\n2. Received prior systemic cytotoxic chemotherapy, biological therapy, radiotherapy, or major surgery within 3 weeks prior to first dose of study drug; for tyrosine kinase inhibitor or similar within 4 \u00d7 half-life prior to first dose of study drug. A 1-week washout is permitted for palliative radiation to non-central nervous system disease, with Sponsor approval.\n3. Participants who have received prior CTLA-4 therapy may be enrolled in selected indications upon agreement with the Sponsor.\n4. Persistent toxicity of NCI CTCAE version 5.0 Grade \\> 1 severity that is related to prior therapy. Note: Sensory neuropathy, hypothyroidism or alopecia of Grade \u2264 2 are acceptable. Other Grade 2 toxicities of prior treatments that are controlled with medication (for example, diabetes or hypertension) may be permitted with sponsor approval.\n5. Expected to require any other form of systemic or localized antineoplastic therapy while on trial (including maintenance therapy with another agent, radiation therapy, and\/or surgical resection).\n6. History of:\n\n   1. Severe (Grade \u2265 3) hypersensitivity reaction to a fully human monoclonal antibodies\n   2. Immune-related adverse event requiring treatment with systemic steroids for \\> 7 days excluding Grade 1 or 2 rash.\n   3. Interstitial lung disease or lung disease which may interfere with the assessment of pneumonitis.\n   4. Uncontrolled asthma (that is, \u2265 3 features of partly controlled asthma)\n   5. Pneumonitis that has required oral or IV corticosteroids.\n7. Receiving systemic corticosteroid therapy 1 week prior to the first dose of study drug or receiving any other form of systemic immunosuppressive medication. Note: Corticosteroid use as a premedication for IV contrast allergies\/reactions is allowed. Participants who are receiving daily corticosteroid replacement therapy are also an exception to this rule. Daily prednisone at doses of \u2264 7.5 mg or equivalent hydrocortisone dose are examples of permitted replacement therapy. Use of inhaled or topical corticosteroids is permitted.\n8. Brain metastases or leptomeningeal metastases with the following exceptions: Note: Brain metastases which have been treated with either surgical resection or stereotactic radio surgery. These participants must be off steroids \u2265 10 days prior to enrollment for the purpose of managing their brain metastases. Repeat brain imaging following surgical resection or stereotactic radiosurgery is not required if their last brain magnetic resonance imaging is within screening window. Note: Untreated isolated brain metastases that are too small for treatment by surgical resection or stereotactic radiosurgery (that is, 1-2 mm) and\/or of uncertain etiology are potentially eligible but must be approved by the sponsor.\n9. Active or history of autoimmune disease that requires systemic treatment within 2 years of the start of study drug (that is, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Note: Participants with autoimmune conditions requiring hormone replacement therapy or topical treatments are eligible.\n10. Has had an allogeneic tissue\/solid organ transplant, except for corneal transplants.\n11. Active infection requiring systemic treatment.\n12. Known history of human immunodeficiency virus type 1 or 2 antibodies.\n13. Known active infection with hepatitis B and\/or hepatitis C virus.\n14. Clinically significant (that is, active) cardiovascular disease: cerebral vascular accident\/stroke or myocardial infarction within 6 months of enrollment, unstable angina, congestive heart failure (New York Heart Association class \u2265 II), or serious uncontrolled cardiac arrhythmia requiring medication.\n15. History or current evidence of any condition, therapy, any active infections, or laboratory abnormality that might confound the results of the trial, interfere with the participant's participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating Investigator.\n16. Known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study.\n17. Legally incapacitated or has limited legal capacity.\n18. Pregnant or breastfeeding.\n19. Concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study treatment. Exceptions: participants with completely resected prior early-stage basal\/squamous cell skin cancer or treated cervical carcinoma in situ.\n\n    The following exclusion criteria are in addition to the above criteria. If there are criteria below that differs from above, the below indication-specific criteria take precedence.\n\n    Additional Exclusion Criteria for the HCC Cohort\n20. Received locoregional therapy (for example, transcatheter chemoembolization, radiation, surgery) within 6 weeks or yttrium-90 within 12 weeks.\n21. Hepatic encephalopathy within the last 6 months requiring admission or initiation of or intensification of therapy. Participants taking rifaximin\/lactulose as encephalopathy prophylaxis are allowed as long as they have not had clinically evident encephalopathy in the past 6 months.\n22. Gastro-esophageal varices bleeding in the last 6 months.\n23. Ascites requiring paracentesis within the last 3 months. Participants with previous ascites that is managed with stable doses of diuretics and have a Child Pugh score of A are allowed.\n\n    Exclusion Criterion Specific for the UK\n24. Hypersensitivity to the active ingredient or any other component of the investigational medicinal products.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03860272019","EMAIL":[{"email":"benjamin.durand@rmh.nhs.uk"},{}],"GEO":[51.50853,-0.12574]},{"TITLE":"89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Written and voluntarily given Informed Consent.\n* Male or female \u226518 years of age at time of consent.\n* Have the capacity to understand the study and be willing and able to comply with all protocol requirements.\n* Participants must have histologically or cytologically proven solid tumors of the following types, but not limited to:\n\n  * cervical cancer\n  * colorectal cancer\n  * esophageal cancer (esophageal SCC and esophageal\/esophagogastric junction adenocarcinoma)\n  * gastric cancer (gastric adenocarcinoma)\n  * glioblastoma multiforme\n  * head and neck cancer (head and neck SCC and nasopharyngeal carcinoma)\n  * liver cancer (cholangiocarcinoma and hepatocellular carcinoma)\n  * lung cancer (non-small cell and small cell)\n  * ovarian cancer (epithelial ovarian carcinoma)\n  * pancreatic cancer (pancreatic ductal adenocarcinoma)\n  * soft tissue sarcoma\n* At least one non-CNS, measurable target lesion as per RECIST 1.1 documented at conventional imaging, performed within 30 days prior to Day 0.\n* Participant agrees not to participate in another interventional study while participating in the present study, defined as signing the informed consent form (ICF) until completion of the last study visit.\n* Negative serum pregnancy tests in female patients of childbearing potential at screening and confirmation of negative pregnancy test result from urine within24 hours prior to receiving investigational product. Female patients of non-child-bearing potential must provide evidence by fulfilling one of the following criteria at screening:\n\n  * Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments.\n  * Women under 50 years old would be consider postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the institution.\n  * Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation\n* For all participants, consent to practice double-barrier contraception until a minimum of 42 days after 89Zr-girentuximab administration.\n\nExclusion Criteria:\n\n* Exposure to murine or chimeric antibodies within the last 5 years.\n* Previous administration of any radionuclide within 10 half-lives (of the radionuclide) prior to the intended administration of 89Zr-girentuximab(i.e., within 10 half-lives of Day0).\n* Exposure to any CAIX targeting compound (diagnostic\/therapeutic) in the last 3 months\n* Serious non-malignant disease (e.g. psychiatric, infectious, autoimmune or metabolic) that may interfere with the objectives of the study or with the safety or compliance of the subject, as judged by the Investigator.\n* Any clinically significant abnormalities detected during screening laboratory tests or physical exam that in the opinion of the Investigator would adversely affect the participants ability to participate in the study. Principal Investigator to assess patient suitability for inclusion based on pathology and tumor type.\n* Mental impairment that may compromise the ability to give Informed Consent and comply with the requirements of the study.\n* Exposure to any antineoplastic treatment within 14 days from the date of planned administration of 89Zr-girentuximab(i.e. within 14 days of Day 0).\n* Women who are pregnant or breastfeeding.\n* Known allergy, hypersensitivity, or intolerance to girentuximab, DFO (desferrioxamine),or any of the components of the investigationalagent.10.Renal insufficiency with glomerular filtration rate (GFR) \u2264 45 millilitres\/min\/1.73m2\n* Vulnerable patients (e.g. being in detention).","SEX":"ALL","AGE_MIN":18,"AGE_MAX":95,"SS_ID":"05563272005","EMAIL":[{"email":"kwolfer@inlandimaging.com"}],"GEO":[47.65966,-117.42908]},{"TITLE":"A Nutritional Supplement to Support People With Non-small Cell Lung Cancer","CRITERIA":"Subject inclusion criteria\n\n1. Systemic therapy-na\u00efve patients with a histologically confirmed diagnosis of incurable or metastatic stage IIIB\/IV non-small cell lung cancer with no EGFR and ALK mutation, who have agreed to receive chemotherapy or both immunotherapy and chemotherapy. Patients who have received prior platinum-based chemotherapy +\/- immunotherapy in the curative setting will be allowed to enroll as long as the curative therapy ended at least 12 months prior to enrolment.\n2. Age \\> or = 18 years.\n3. A diagnostic CT image taken with a maximum of 60 days before initiation of systemic therapy.\n4. An Eastern Cooperative Oncology Group Performance Status of \u2264 2.\n5. Patients must have the ability to read, understand, and sign an informed consent and must be willing to comply with study treatment and follow-up.\n\nSubject exclusion criteria.\n\n1. Prior other malignancy, active (i.e., requiring treatment or intervention) within the previous 2 years, except for locally curable malignancies that have been apparently cured, which are allowed, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast.\n2. Life expectancy \\<6 months at the discretion of the treating physician\n3. Patients currently taking a supplement containing the nutritional supplement under study. Patients should have stopped taking supplements containing the nutritional supplement under study at least 30 days prior to enrolment.\n4. A known hypersensitivity \/ allergy to the investigational product, placebo or to any ingredient in their formulations (e.g. gelatin or glycerin).\n5. Enrolment in any other clinical protocol or investigational study with an interventional agent or assessments that may interfere with study procedures.\n6. Weight loss \\>10% over past 6 months (weight 6 months ago minus weight today, divided by weight 6 months ago) x 100 = weight loss%.\n7. Blood transfusions within 2 weeks of blood collection for the trial.\n8. Untreated brain metastases (patients with previously resected and\/or radiated brain metastases without neurologic symptoms are permitted).\n9. Subject requires or has received systemic steroid therapy or any other immunosuppressive therapy within 14 days prior to study drug administration. Subjects using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 30 mg per day of hydrocortisone, 2 mg per day of dexamethasone or up to 10 mg per day of prednisone) are allowed. Patients may take corticosteroids for \u22644 days as part of routine cancer-directed therapy prophylaxis (e.g., chemotherapy-induced nausea and vomiting).\n10. Active autoimmune disease. Subjects with type 1 diabetes mellitus, stable endocrinopathies maintained on appropriate replacement therapy and skin disorders (e.g., vitiligo, psoriasis or alopecia) not requiring systemic treatment are allowed.\n11. Uncontrolled diabetes, i.e. with random blood glucose \\>15.0 mmol\/L.\n12. Current or expected difficulty or inability to swallow capsules.\n13. Use of non-steroidal anti-inflammatory drugs (NSAIDs) for \u22657 consecutive days. Patients are allowed to receive single doses of NSAIDs and may take daily 81 mg ASA.\n14. In the investigators' opinion, patients who have medical conditions that could interfere with drug metabolism or absorption (e.g., short bowel syndrome, history of small bowel obstruction, Crohn's disease, etc.)\n15. Serum albumin \\<35 g\/L","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04175769001","EMAIL":[{}],"GEO":[53.55014,-113.46871]},{"TITLE":"A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Have one of the following solid tumor cancers:\n\n  * Cohort A1: urothelial carcinoma, triple negative breast cancer, non-small cell lung cancer, esophageal cancer, pancreatic cancer, ovarian cancer, cervical cancer (squamous cell carcinoma), head and neck squamous cell carcinoma or prostate cancer\n  * Cohort A2\/B1\/B2: urothelial carcinoma\n  * Cohort C: triple negative breast cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, head and neck squamous cell carcinoma, esophageal cancer, pancreatic cancer, or prostate cancer\n* Prior Systemic Therapy Criteria:\n\n  * Cohort A1\/C: Individual has received all standard therapies for which the participant was deemed to be an appropriate candidate by the treating investigator; OR there is no standard therapy available for the disease. There is no restriction on number of prior therapies\n  * Cohort A2\/B1\/B2: Individual must have received at least one prior regimen in the advanced or metastatic setting. There is no restriction on number of prior therapies.\n* Prior enfortumab vedotin specific requirements:\n\n  * Cohorts A1\/A2\/C: prior treatment with enfortumab vedotin is allowed, but not required\n  * Cohort B1: individual must be enfortumab vedotin naive in the advanced\/metastatic setting\n  * Cohort B2: individual must have received enfortumab vedotin in the metastatic\/advanced setting.\n* Measurability of disease\n\n  * Cohort A1: measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST 1.1)\n  * Cohorts A2, B1, B2, C: measurable disease required as defined by RECIST v1.1\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Have adequate archival tumor tissue sample available or undergo a screening biopsy if allowed per country specific regulations\n\nExclusion Criteria:\n\n* Individual with known or suspected uncontrolled CNS metastases\n* Individual with uncontrolled hypercalcemia\n* Individual with uncontrolled diabetes\n* Individual with evidence of corneal keratopathy or keratitis, and history of corneal transplant\n* Any serious unresolved toxicities from prior therapy\n* Significant cardiovascular disease\n* Recent thromboembolic event or bleeding disorder\n* Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) \u2265 470 ms\n* History of pneumonitis\/interstitial lung disease\n* History of Grade \u22653 skin toxicity when receiving enfortumab vedotin\n* Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06465069003","EMAIL":"ClinicalTrials.gov@lilly.com","GEO":[29.42412,-98.49363]},{"TITLE":"A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Patient must have one of the following cancers and previously received the following lines of systemic therapy for the advanced\/metastatic disease:\n\n  * Renal cell carcinoma: at least 2 lines of therapy\n  * Non-small cell lung cancer: at least 2 lines of therapy\n  * Melanoma:\n\n    * BRAF V600E positive: must have received at least 2 lines of therapy\n    * BRAF V600E negative: must have received at least 1 line of therapy\n  * Gastric cancer: at least 1 line of therapy\n  * Colorectal cancer: at least 3 lines of therapy\n* Suitable site to biopsy at pre-treatment and on-treatment\n* Measurable disease as determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\n* Eastern Cooperative Oncology Group performance status of 0 or 1\n\nExclusion Criteria:\n\n* Systemic anti-cancer therapy within 2 weeks prior to start of study drug or within 4 weeks for immune-oncologic therapy. For cytotoxic agents with major delayed toxicity (e.g., mitomycin C), 6 weeks of washout are mandated.\n* Therapeutic radiation therapy within the past 2 weeks\n* Active autoimmune diseases or history of autoimmune disease that may relapse\n* Any malignancy \u2264 5 years before first dose of study drug except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively\n* Systemic steroid therapy (\\>10 mg\/day of prednisone or equivalent) or any immune suppressive medication \u2264 14 days before first dose\n* Patients with toxicities (as a result of prior anticancer therapy) which have not recovered to baseline or stabilized, except for adverse events not considered a likely safety risk (e.g., alopecia, neuropathy, and specific laboratory abnormalities)\n* Severe or unstable medical condition, including uncontrolled diabetes, coagulopathy, or unstable psychiatric condition\n* Major surgery within 28 days of the first dose of study drug\n* History of interstitial lung disease, non-infectious pneumonitis, or uncontrolled lung diseases including pulmonary fibrosis or acute lung diseases. For combination only: non-small cell lung cancer patients, or patients with significantly impaired pulmonary function or who require supplemental oxygen at baseline must undergo an assessment of pulmonary function at screening\n* History of allergic reactions, immune related reactions, or cytokine release syndrome (CRS) attributed to compounds of similar chemical or biologic composition to monoclonal antibodies or any excipient of HFB200603 or tislelizumab\n* For combination only: Prior randomization in a tislelizumab study regardless of the treatment arm, until the primary and key secondary endpoints of the study have read out","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05789069011","EMAIL":"e.steele@medpace.com","GEO":[39.46975,-0.37739]},{"TITLE":"Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.","CRITERIA":"Inclusion Criteria:\n\nAged 18 years or over Be able to give voluntary, written informed consent to participate in the study\n\nExclusion Criteria:\n\nParticipants with symptoms that would make proctoscopic examination inappropriate, including acute anal fissure, symptomatic thrombosed haemorrhoids or obstructing anorectal lesions as determined by rectal examination Participants with a previous history of cancer Participants who have received previously radiotherapy, chemotherapy or immunotherapy for a malignancy.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":99,"SS_ID":"05102110001","EMAIL":[{"email":"Ian.Daniels@originsciences.com"}],"GEO":[50.7236,-3.52751]},{"TITLE":"Ruxolitinib for Cancer Cachexia","CRITERIA":"Inclusion Criteria:\n\n1. Male or female subjects at least 18 years of age;\n2. Ability to understand and the willingness to sign a written informed consent;\n3. Histological or biopsy proven Non-Small Cell Lung Cancer (squamous or non-squamous);\n4. ECOG performance status of 0-2;\n5. Patients with evidence of:\n\n   * cancer cachexia, defined by the International Cancer Cachexia Consensus Definition (\\>5% weight loss over the preceding 6 months prior to diagnosis); OR\n   * Patients with evidence of cancer pre-cachexia, defined by the International Cancer Cachexia Consensus Definition (0 to \\<=5% weight loss over the preceding 6 months prior to diagnosis);\n6. Any de novo stage IV NSCLC disease diagnosis as defined by AJCC 8th edition staging. Staged with PET\/CT, MRI brain, or other acceptable staging tool; measurable disease as defined by RECIST 1.1;\n7. Adequate end-organ function, based on routine clinical and laboratory workup and institutional guidelines, as determined by oncology team offering patient standard of care therapy, including:\n\n   1. ANC \\>1,000 cells\/\u00b5l, Platelets \\> 100,000 cells\/\u00b5l, Hemoglobin \\> 10.0 g\/dl;\n   2. Serum creatinine \u2264 1.5 x ULN or calculated creatinine clearance \u2265 45 ml\/min;\n   3. Total bilirubin \u2264 1.5 x ULN (or direct bilirubin below the ULN), AST and ALT \u2264 2.5 x ULN;\n   4. International normalized ratio (INR) (or prothrombin time (PT)) and activated partial thromboplastin time (aPTT) \u2264 1.5 x ULN unless participant is receiving anticoagulant therapy, if values are within the intended therapeutic range;\n8. Women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: a. Has not undergone a hysterectomy or bilateral oophorectomy; or b. Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months);\n9. Male subjects who are surgically sterile or are using a medically acceptable form of contraception for 90 days following the completion of therapy;\n10. Life expectancy anticipated to be 6 months or greater;\n11. No prior therapy for advanced lung cancer.\n\nExclusion Criteria:\n\n1. Subjects with confirmed stage I-III NSCLC;\n2. Patients whose tumors have actionable mutations treatable with targeted therapies;\n3. Patients with no evidence of cancer cachexia, defined by the International Cancer Cachexia Consensus Definition (\\>5% weight loss over the preceding 6 months prior to diagnosis); OR Patients with no evidence of cancer pre-cachexia, defined by the International Cancer Cachexia Consensus Definition (0 to \\<=5% weight loss over the preceding 6 months prior to diagnosis);\n4. Active malignancy other than lung cancer that requires concurrent treatment other than hormonal therapy and is deemed by the treating physicians to be likely to affect the subject's survival duration;\n5. Subjects who have not recovered or have disease control from prior treatment-related to toxicities judged by treating physician;\n6. History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib or other agents used in study;\n7. Uncontrolled intercurrent illness including, but not limited to, serious ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\/social situations that, in the opinion of the investigator, would limit compliance with study requirements;\n8. Inadequate liver or renal function, if out of the acceptable ranges of the inclusion criteria;\n9. Significant bacterial, fungal, parasitic, or viral infection requiring treatment;\n10. Previous treatment with a JAK inhibitor;\n11. Uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4), angina, myocardial infarction, cerebrovascular accident, coronary\/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within 3 months prior to initiation of ruxolitinib;\n12. Females who are pregnant, breast-feeding or plan to become pregnant;\n13. Participation in other clinical trials either to treat diagnosed lung or other cancers (patients on registry trials are eligible);\n14. Requirement for treatment with drugs that may, in the judgment of the treating investigator, create a risk for a precipitous change in patient's health;\n15. Any other conditions that, in the Investigator's opinion, might indicate the subject to be unsuitable for the study;\n16. Life expectancy of less than 6 months;\n17. Prior therapy for the newly diagnosed advanced lung cancer.\n18. Patients taking therapies that are strong CYP3A4 inhibitors and fluconazole.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04906746001","EMAIL":[{"email":"tu.dan@utsouthwestern.edu"}],"GEO":[32.78306,-96.80667]},{"TITLE":"Safety of Effivia\u00ae, a Bevacizumab Biosimilar","CRITERIA":"Inclusion Criteria:\n\n* Male and female patients, 18 years and older.\n* Patients with metastatic colorectal cancer,unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, metastatic renal cell carcinoma, persistent, recurrent, or metastatic cervical cancer, or epithelial ovarian, fallopian tube, or primary peritoneal cancer naive to bevacizumab therapy (Effivia\u00ae).\n* Provide written informed consent.\n\nExclusion Criteria:\n\n* History of recent surgery or wound healing complications.\n* History of gastrointestinal perforations or fistula.\n* History of renal injury and proteinuria.\n* Recent surgical intervention.\n* Pregnant or nursing women.\n* History of bevacizumab, monoclonal antibodies, or CHO cells-derived products hypersensitivity.\n* Other safety concerns or bevacizumab contraindications.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06313268005","EMAIL":[{},{}],"GEO":[19.03793,-98.20346]},{"TITLE":"Phase 1b\/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)","CRITERIA":"Inclusion Criteria:\n\n* Adult patient aged \u2265 18 years\n* Written informed consent\n* Histologically (squamous or non-squamous) or cytologically documented locally advanced NSCLC not eligible for surgical resection and\/or definitive chemoradiation, or metastatic NSCLC\n* No prior systemic treatment for locally advanced or metastatic NSCLC\n* High tumor cell PD-L1 expression \\[Tumor Proportion Score (TPS) \u226550%\\] based on documented status as determined by an approved test\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Measurable disease as determined by RECIST v1.1\n\nExclusion Criteria:\n\n* Tumors harboring driver mutations\/genetic aberrations for which targeted therapies are approved as frontline treatment (e.g. EGFR mutation, ALK fusion oncogene, ROS1 aberrations)\n* Prior immune checkpoint inhibitor therapy\n* Active brain metastases\n* Participants with active and uncontrolled hepatitis B virus (HBV) or hepatitis C virus (HCV) infection\n* Uncontrolled HIV infection. Participants with HIV who have controlled infection (undetectable viral load and CD4 count above 350 either spontaneously or on a stable antiviral regimen) are allowed to enroll\n* Active, known or suspected autoimmune disease or immune deficiency\n* History of hypersensitivity reactions to any ingredient of the investigational medicinal product (IMP) and other monoclonal antibody (mAbs) and\/or their excipients\n* History of interstitial lung disease, idiopathic pulmonary fibrosis, drug-induced pneumonitis, idiopathic pneumonitis or active pneumonitis \u2265 grade 2\n* History of inflammatory bowel disease or colitis \u2265 grade 2\n* Systemic chronic steroid therapy (\\>10mg\/d prednisone or equivalent)\n* Active infection, including infection requiring systemic antibiotic therapy\n* Pregnant or breast-feeding (lactating) women\n* Participants with a history of allogeneic organ transplantation (e.g., stem cell or solid organ transplant)\n* Any medical condition that would in the investigator's judgement prevent the participant's participation in the clinical study","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06162572040","EMAIL":"scientificinformation@servier.com","GEO":[47.78257,19.928]},{"TITLE":"Study of Novel Treatment Combinations in Patients With Lung Cancer","CRITERIA":"Key Inclusion Criteria:\n\nAll Substudies:\n\n* Histologically or cytologically documented non-small-cell lung cancer (NSCLC).\n* No known actionable genomic alterations for which targeted therapies are available.\n* Eastern cooperative oncology group (ECOG) performance status score of 0 or 1.\n* Measurable disease per response evaluation criteria in solid tumors.\n* Adequate hematologic and end-organ function.\n* Individuals of childbearing potential who engage in heterosexual intercourse must agree to use specified method(s) of contraception.\n\nSubstudy 01: All Experimental arms\n\n* Stage IV NSCLC.\n* For individuals with nonsquamous histology: Epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alteration negative.\n* PD-L1 status by central confirmation.\n* No prior systemic treatment for metastatic NSCLC.\n\nSubstudy 02: All Experimental arms\n\n* Stage IV NSCLC.\n* In individuals with nonsquamous histology and actionable EGFR, ALK, or other known genomic alterations must have received treatment with at least 1 targeted therapy to the appropriate genomic alteration.\n\nSubstudy 03: All Experimental arms\n\n* Previously untreated individuals with resectable (Stage II, IIIA, IIIB (T\\[3-4\\]N2) NSCLC (per American Joint Committee on Cancer (AJCC) Edition 8).\n* Planned surgery must comprise of lobectomy, sleeve lobectomy, or bi-lobectomy.\n* PD-L1 status by central confirmation.\n* For individuals with nonsquamous histology: Epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alteration negative.\n\nKey Exclusion Criteria:\n\nAll Substudies:\n\n* Mixed small-cell lung cancer and NSCLC histology.\n* Active second malignancy.\n* Active autoimmune disease.\n* History of or current non-infectious pneumonitis\/interstitial lung disease.\n* Active serious infection within 4 weeks prior to study treatment.\n\nSubstudy 01 and 02\n\n* Known active central nervous system (CNS) metastases and\/or carcinomatous meningitis.\n* Received previous anticancer therapy within 4 weeks prior to enrollment.\n\nSubstudy 03: All Experimental arms\n\n* NSCLC previously treated with systemic therapy or radiotherapy.\n* Received prior treatment with any anti-PD-(L)-1 or other immune checkpoint inhibitors (CPIs).\n\nNote: Other protocol defined inclusion\/exclusion criteria may apply","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05633667069","EMAIL":"GileadClinicalTrials@gilead.com","GEO":[51.50853,-0.12574]},{"TITLE":"Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers","CRITERIA":"Inclusion Criteria:\n\n* Signed written informed consent.\n* Male or female subjects aged greater than or equal to 18 years.\n* For NSCLC: Histologically or cytologically confirmed diagnosis of unresectable recurrent or metastatic non-small cell lung cancer.\n* For CRC: Histologically confirmed diagnosis of recurrent or metastatic colorectal cancer assessed as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).\n* For EC: Histologically or cytologically confirmed advanced, recurrent or metastatic endometrial carcinoma.\n* For cSCC: Histologically confirmed diagnosis of unresectable or metastatic cutaneous squamous cell carcinoma not amenable to local therapy.\n* For SCLC: Histologically or cytologically confirmed diagnosis of unresectable small cell lung cancer.\n* For MPM: Histologically or cytologically confirmed diagnosis of unresectable malignant pleural or peritoneal mesothelioma.\n* For HNSCC: Histologically or cytologically confirmed diagnosis of recurrent or metastatic HNSCC (oral cavity, pharynx, larynx), stage III\/IV and not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy).\n* For MEL: Histologically confirmed diagnosis of unresectable Stage III or metastatic melanoma not amenable to local therapy (excluding uveal or ocular melanoma).\n* For MCC: Histologically confirmed diagnosis of metastatic Merkel cell carcinoma not amenable to local therapy.\n* For RCC: Histologically confirmed diagnosis of renal cell carcinoma (with clear cell component) with advanced or metastatic disease that is not amenable to cure by surgery or other means.\n* For UC: Histologically or cytologically documented locally advanced or metastatic transitional cell carcinoma of the urothelium (including renal pelvis, ureters, urinary bladder, urethra) not amenable to cure by surgery or other means.\n* For HL: Histologically confirmed primary diagnosis of classical Hodgkin's lymphoma.\n* For B-cell NHL: Histologically confirmed diagnosis of non-Hodgkin lymphoma.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at trial entry and an estimated life expectancy of at least 3 months\n* Must have at least one measurable lesion based on RECIST 1.1.\n* Have provided a formalin fixed tumor tissue sample from a biopsy of a tumor lesion either at the time of or after the diagnosis of metastatic disease has been made AND from a site not previously irradiated.\n* Adequate hematological, hepatic and renal function as defined in the protocol.\n* Effective contraception for both male and female subjects if the risk of conception exists.\n* Other protocol defined inclusion criteria could apply.\n\nExclusion Criteria:\n\n* Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.\n* Concurrent treatment with a non-permitted drug.\n* History of severe hypersensitivity reactions to other monoclonal antibodies.\n* Prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast, or localized prostate cancer.\n* Chemotherapy, radioactive, biological cancer therapy, or tyrosine kinase inhibitor (TKI) therapy, within four weeks prior to the first dose of study drug, or who has not recovered to NCI CTCAE Grade 1 or better from the AEs due to cancer therapeutics administered more than four weeks earlier.\n* Significant acute or chronic infections as defined in the protocol.\n* Active or history of interstitial lung disease (ILD), or has had a history of pneumonitis that has required oral or IV steroids.\n* Active or suspected autoimmune disease or a documented history of autoimmune disease.\n* Known current drug or alcohol abuse.\n* Underlying medical conditions that will make the administration of study drug hazardous or obscure the interpretation of toxicity determination or adverse events.\n* Use of other investigational therapy within 28 days before study drug administration.\n* Pregnant or breastfeeding.\n* Uncontrolled or significant cardiovascular disease.\n* Psychiatric illness or social situation that would preclude study compliance.\n* Receipt of live, attenuated vaccine within 28 days prior to the first dose of study drug.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03212404014","EMAIL":"info@checkpointtx.com","GEO":[-43.53333,172.63333]},{"TITLE":"'SOURCE - LUNG' Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours (SOURCE Lung)","CRITERIA":"Inclusion Criteria:\n\n1. Written informed consent obtained prior to any study-specific procedures\n2. \u2265 18 years of age\n3. Life expectancy \\>6 months\n4. ECOG (Eastern Cooperative Oncology Group) performance status 0-2\n5. Histological diagnosis (biopsy or cytology) or radiological diagnosis (PET-positive FDG-avid tumour which requires local ablative therapy per Multi-Disciplinary Team (MDT) recommendations) of either:\n\n   (i) Primary NSCLC (Squamous Cell Carcinoma (SCC), Adenocarcinoma, Large Cell) OR (ii) Single pulmonary oligometastatic lesion\n6. Patients with central lung tumours whose radiotherapy plan meets the following criteria:\n\n   (i) OAR eligibility constraints are initially exceeded when full PTV coverage is met; (ii) subsequently meets the CTRIAL-IE 18-33 SOURCE OAR Lung constraints and meets CTRIAL-IE 18-33 SOURCE Lung minimum constraints\n7. Inoperable (as per MDT) or patient refuses surgery,\n8. Females of childbearing potential must not be pregnant or lactating, must be prepared to take adequate contraception methods during treatment. Males whose female partners are of childbearing potential must be prepared to take adequate contraception methods during treatment. Examples of effective contraception methods are a condom or a diaphragm with spermicidal jelly, or oral, injectable or implanted birth control\n9. Absence of psychological, familial, sociological or geographical condition, or psychiatric illness\/social situation potentially hampering compliance with the study protocol and follow-up schedule\n\nExclusion Criteria:\n\n1. Known co-existing or prior malignancy within the last 5 years (except for adequately treated basal cell carcinoma (BCC) or Squamous Cell Carcinoma (SCC) of the skin)) which is likely to interfere with treatment or assessment of outcomes\n2. Tumour\/oligometastatic lesion that is abutting the oesophagus\n3. Evidence of regional (nodal) or distant metastases or metastatic pleural effusion\n4. Spinal canal involvement\n5. Patients with syndromes or conditions associated with increased radiosensitivity\n6. Idiopathic pulmonary fibrosis \/ usual interstitial pneumonia\n7. Chemotherapy and\/or other targeted treatment administered within 3 months prior to study registration or planned for \\<6 weeks following radiotherapy\n8. Any previous radiotherapy to the thorax or mediastinum (excluding previous breast or chest wall radiotherapy) which is likely to interfere with treatment or assessment of outcomes\n9. Any tumour not clinically definable on the treatment planning CT scan (e.g. surrounding consolidation or atelectasis)\n10. Patients unable to undergo 4D-CT scan\n11. Uncontrolled intercurrent illness that is likely to interfere with treatment or assessment of outcomes\n12. Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study, or if it is felt by the research \/ medical team that the patient may not be able to comply with the protocol.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04375904002","EMAIL":[{},{},{}],"GEO":[53.33306,-6.24889]},{"TITLE":"Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS","CRITERIA":"* Inclusion Criteria:\n\n  1. Eligible for, or on active study drug treatment according to the approved prescribing information;\n* The first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations\n* Treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC who have been previously treated with EGFR TKI therapy\n* The adjuvant treatment after complete tumour resection in patients with non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations 2. Provision of signed and dated written informed consent by the patient or legally acceptable representative\n* Exclusion Criteria:\n\n  1. History of hypersensitivity to the active substance or to any of the excipients of this drug\n  2. Pregnancy and\/or breast feeding\n  3. Current participation in any interventional trial","SEX":"ALL","AGE_MIN":0,"AGE_MAX":200,"SS_ID":"03918304008","EMAIL":"information.center@astrazeneca.com","GEO":[37.566,126.9784]},{"TITLE":"Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis\/ILD","CRITERIA":"Inclusion Criteria:\n\n1. Patient must be 18 years of age or older, at the time of signing the ICF (Informed consent).\n2. Have histologically or cytologically documented unresectable Stage III or Stage IV NSCLC.\n3. Are initiating treatment with an FDA (Food and Drug Administration)-approved immune checkpoint inhibitor (alone or in combination with other agents), antibody drug conjugate, or small molecule EGFR inhibitor.\n4. Minimum life expectancy of 12 weeks at the time of signing the ICF.\n5. Able and willing to provide written signed informed consent.\n6. Able and willing to use the digital health tool throughout the duration of the study.\n\nExclusion Criteria:\n\n1. Concurrent participation in a research study or a clinical trial.\n2. Unable to receive SoC for the treatment and management of NSCLC including clinical or imaging assessments for up to 6 months.\n3. Judgment by the Investigator that the patient is unsuitable to participate in the study and\/or the patient is unlikely to comply with study procedures and requirements.\n4. Confirmed or suspected diagnosis of pneumonitis\/ILD at the time of signing ICF. This does not apply to historical pneumonitis\/ILD events that have resolved prior to signing ICF.\n5. More than 2 weeks have passed from the administration of the first dose of qualifying FDA-approved treatment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06192004015","EMAIL":"information.center@astrazeneca.com","GEO":[31.84568,-102.36764]},{"TITLE":"A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.","CRITERIA":"This study is seeking participants who meet the following eligibility criteria:\n\nInclusion Criteria:\n\n* Diagnosis of advanced\/metastatic solid tumor including primary brain tumor.\n* Qualifying BRAF alteration (V600 or non-V600 Class II\/Class III BRAF alteration), in tumor tissue and\/or blood (ie circulating tumor deoxyribonucleic acid \\[DNA\\], or ctDNA).\n* Disease progressed during\/following last prior treatment and no satisfactory alternative treatment options (Part 1 and Part 2).\n* Tumor specific cohorts (melanoma, colorectal cancer) must have received specific prior approved therapies\n\nExclusion Criteria:\n\n* Brain metastasis larger than 4 cm\n* Systemic anti-cancer therapy or small molecule therapeutics ongoing at the start of study treatment.\n* For participants who may get binimetinib on study, history or current evidence of retinal vein occlusion (RVO) or concurrent neuromuscular disorder associated with elevated creatine kinase (CK)","SEX":"ALL","AGE_MIN":16,"AGE_MAX":200,"SS_ID":"05355701045","EMAIL":"ClinicalTrials.gov_Inquiries@pfizer.com","GEO":[31.76904,35.21633]},{"TITLE":"Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+\/- Atezolizumab in Stage IV NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Must have histologically or cytologically confirmed stage IV non-squamous non-small cell lung cancer\n* Must have either tumors that harbor an EGFR mutation in exon 19 or exon 21, or must be never smoker wild-types. Never smoker wild-types are defined as patients with tumors without an ALK or ROS1 rearrangement, and are not harboring any EGFR mutation (this includes exons 19 or 21, exon 20, and any other rare EGFR mutations). Never smoker wild-type patients must have smoked less than 100 cigarettes in a lifetime. Patients with an EGFR mutation in exon 19 or 21 may be included irrespective of their smoking history. If a patient whose tumor originally had an exon 19 or 21 mutation develops a secondary activating or sensitizing mutation in exon 18-21 as a result of resistance to EGFR TKI therapy, then that patient is eligible. If tissue-based testing for EGFR mutation status is not available, blood-based EGFR testing that confirms presence of a mutation in exon 19 or 21 is acceptable, and these patients may be included in the stud\n* Must have measurable disease by CT or MRI, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria v 1.1\n* Tumors that harbor an EGFR exon 19 or exon 21 mutation must have received prior treatments with one or more TKIs. A minimum washout period of 3 days is required to begin treatment in this trial. Patients who are never smoker wild-types must be treatment na\u00efve\n* Must be chemotherapy, anti-VEGF therapy alone, and immunotherapy naive, with the exception of prior oral TKIs which are required for EGFR mutated patients. Patients who have received prior anti-VEGF therapy in combination with a TKI for advanced stage EGFR-mutated disease may be included. The number of prior oral TKIs and duration of use is neither specified nor limited.\n* History of treated asymptomatic CNS metastases are eligible, provided they meet all of the following criteria:\n\n  * No ongoing requirement for corticosteroids as therapy for CNS disease\n  * No stereotactic radiation within 7 days or whole-brain radiation within 14 days prior to randomization\n  * No clinical evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study\n  * New asymptomatic CNS metastases detected at the screening scan must be \u22641 cm in size with no prior radiation therapy. These patients may then be eligible without the need for an additional brain scan prior to randomization, if all other criteria are met\n* May have received curative intent therapy (adjuvant therapy or therapy for locally advanced NSCLC), if this therapy was completed greater than 1 year from entry into the trial\n* Age \\> 18 years\n* ECOG performance status of 0 or 1\n* Must have normal organ and marrow function as defined below. The use of G-CSF should follow standard recommendations and physician discretion. If blood transfusion is performed for achieving hemoglobin levels, the levels should stay at \u2265 9.0 mg\/ml for at least a week after transfusion.\n\nAbsolute neutrophil count \\> 1,500\/mcL Hemoglobin \u2265 9.0 mg\/ml Platelets \\> 100,000\/mcL Total bilirubin \u22641.5 X institutional upper limit of normal (ULN) AST\/ALT (SGOT\/SGPT) \\< 3 times institutional normal limits, or up to 5 times institutional normal limits if the patient has liver metastases Creatinine OR Creatinine clearance \u22641.5 X ULN, OR \\> 40 Ml\/min\/1.73 m2 for patients with creatinine levels above institutional normal as per Cockcroft-Gault formula International Normalized Ratio (INR) or Prothrombin Time (PT) \u22641.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants Activated Partial Thromboplastin Time (aPTT) \\<1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants Thyroid stimulating hormone (TSH) Within normal limits a\n\na: If TSH is not within normal limits at baseline, the subject will still be eligible if total T3 or free T4 are within normal limits.\n\n* Full-dose anticoagulation must be on a stable dose (minimum duration 14 days) of oral anticoagulant or low molecular weight heparin (LMWH). If receiving warfarin, the patient must have an INR \u22643.0. For heparin and LMWH there should be no clinically significant active bleeding (with no bleeding within 14 days prior to first dose of protocol therapy) or pathological condition present that carries a high risk of bleeding (for example, tumor involving major vessels or known varices).\n* Ability to understand and willingness to sign a written informed consent and HIPAA consent document.\n* A biopsy, either core, cell block from FNA or cell block from surgical resection, must be available for the study. If the sample is not adequate, the patient must agree to provide a fresh biopsy specimen before the start of treatment. Any available archival tissue will also be collected. While a biopsy sample must be adequate and available for the study, an inadequate tissue sample would not be explicitly exclusionary and further discussion with the sponsor is allowed to assess the eligibility of the patient for the trial if, for clinical or other reasons, a new biopsy sample cannot be obtained.\n* Urinary protein must be \u22641+ on dipstick or routine urinalysis (UA; if urine dipstick or routine analysis is \u22652+, a 24 hour urine collection for protein must demonstrate \\<1000 mg of protein in 24 hours to allow participation in the protocol).\n* Females of child-bearing potential must be willing to use an effective method of contraception, for the course of the study through at least 6 months after the last dose of study medication.\n* Males who have Women of Child-bearing Potential (WOCBP) partners must agree to use effective method of contraception for the course of the study through 8 months after the last dose of study medication.\n\n  * Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n\nExclusion Criteria:\n\n* Patients currently receiving any other investigational agents, immunomodulatory agents, chemotherapy, or TKIs. EGFR mutation-positive patients must have received prior TKI treatment\n* Any Grade 3-4 GI bleeding within 3 months prior to first dose of protocol therapy.\n* Untreated CNS metastases that are \\>1 cm in size are excluded, even if they are asymptomatic. Patients with treated brain metastases will be allowed if brain imaging obtained within 30 days of trial enrollment reveals stable disease.\n* Cirrhosis at a level of Child-Pugh B or worse, or cirrhosis of any degree and a history of hepatic encephalopathy, or clinically meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis.\n* Any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, within 6 months prior to first dose of protocol therapy.\n* Uncontrolled or poorly-controlled hypertension (\\>150 mmHg systolic or \\> 100 mmHg diastolic for \\>4 weeks) despite standard medical management\n* Prior history of hypertensive crisis or hypertensive encephalopathy\n* Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to randomization\n* Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation)\n* History of abdominal or tracheosphageal fistula or gastrointestinal perforation within 6 months prior to randomization\n* Clinical signs of gastrointestinal obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding\n* Evidence of abdominal free air not explained by paracentesis or recent surgical procedure\n* Serious, non-healing wound, active ulcer, or untreated bone fracture within 28 days prior to first dose of protocol therapy\n* Subjects with a history of smoking greater than a 100 cigarettes in a lifetime, unless their tumor has an EGFR exon 19 or exon 21 mutation.\n* Patients with active, suspected, or known autoimmune disease that has required systemic treatment in the past one year (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Hormone replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n* Patients with a history of hemoptysis (defined as bright red blood or \u22651\/2 teaspoons) within 1 month prior to first dose of protocol therapy or with radiographic evidence of major blood vessel invasion or encasement by cancer.\n* Undergone major surgery within 28 days prior to first dose of study treatment, or minor surgery\/ subcutaneous venous access device placement within 7 days prior to first dose of protocol therapy. The patient has elective or planned major surgery to be performed during the course of the clinical trial.\n* Receiving chronic anti-platelet therapy other than aspirin, including non-steroidal anti-inflammatory drugs (NSAIDs, including ibuprofen, naproxen, and others), dipyridamole or clopidogrel, or similar agents. Once-daily aspirin use (maximum dose 325 mg\/day) is permitted. Occasional use of NSAIDs is allowed (for example daily use for less than a week; treating physician discretion is permitted to differentiate between occasional vs chronic use)\n* Have not recovered from adverse events due to agents administered earlier except neuropathy and alopecia. Physician's discretion is allowed to decide which unresolved adverse events from previous therapy (for NSCLC) prohibit patient participation in this study.\n* Requiring more than 10 mg prednisolone (or its equivalent) per day are excluded.\n* Any evidence of interstitial lung disease (ILD) or pneumonitis or a prior history of ILD or pneumonitis requiring oral or IV glucocorticoids. History of radiation pneumonitis in the radiation field (fibrosis) is permitted\n* Patients with known latent or active tuberculosis infection are excluded.\n* Have received a live vaccine within 30 days prior to cycle 1 Day 1.\n* Uncontrolled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (significant), cirrhosis, or psychiatric illness\/ social situations that would limit compliance with the study requirements.\n* Known history of testing positive for immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).\n* Known history of chronic hepatitis B virus infection or chronic hepatitis C virus indicating chronic infection that is not cured.\n* Subjects with previous malignancies (except non-melanoma skin cancers, and in situ cancers, such as, bladder, gastric, colon, cervical\/ dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study registration and no additional therapy is required or anticipated to be required during the study period.\n* Leptomeningeal disease\n* Uncontrolled tumor-related pain\n\n  * Requiring pain medication must be on a stable regimen at study entry.\n  * Symptomatic lesions amenable to palliative radiotherapy (e.g., bone metastases or metastases causing nerve impingement) should be treated prior to randomization. Patients should be recovered from the effects of radiation. There is no required minimum recovery period.\n  * Asymptomatic metastatic lesions whose further growth would likely cause functional deficits or intractable pain (e.g., epidural metastasis that is not currently associated with spinal cord compression) should be considered for locoregional therapy, if appropriate, prior to randomization.\n* Ca \\> 12 mg\/dl or corrected serum calcium \\> ULN\n\n  * Patients who are receiving denosumab prior to randomization must be willing and eligible to receive a bisphosphonate instead while in the study\n* Pregnant or breast feeding\n* Known hypersensitivity to Chinese hamster ovary cell products or any of the study drugs.\n* Prior allogeneic bone marrow transplantation or solid organ transplant\n* Clear tumor infiltration into the thoracic great vessels is seen on imaging\n* Clear cavitation of pulmonary lesions is seen on imaging\n* Diagnosis of squamous cell carcinoma of the lung.\n* Lung tumor with a known ALK or ROS1 rearrangement or an EGFR mutation other than in exon 19 or exon 21.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03786692001","EMAIL":[{"email":"joseph.treat2@fccc.edu"}],"GEO":[39.95233,-75.16379]},{"TITLE":"Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\nWritten informed consent\n\nAge \u2265 18 years\n\nAble to comply with the protocol, including acceptable candidacy for adjuvant chemotherapy according to local institutional standards and likely compliance with follow-up for anticipated length of study (i.e. 5 years from the initiation of enrollment).\n\nWilling to be randomized to chemotherapy.\n\nHistologically documented completely resected (R0) Stage I or IIA non-squamous NSCLC (per 8th edition, TNM staging system)\n\nAdequate tissue sample for the 14-Gene Prognostic Assay\n\nLife expectancy excluding NSCLC diagnosis \u2265 5 years\n\nECOG performance status 0-1\n\nCompletely healed incisions","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"01817192054","EMAIL":[{}],"GEO":[53.14118,8.21467]},{"TITLE":"Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer","CRITERIA":"Inclusion Criteria:\n\n* Adult patients aged \\>\/=18 years, able to provide informed consent and willing to comply with all study procedures.\n* Histologically confirmed advanced or metastatic solid tumors that are relapsed or refractory to standard of care. Subjects must have exhausted all available standard therapies or be deemed ineligible for potential available therapies.\n* Adequate bone marrow, liver, and renal functions.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\n\nExclusion Criteria:\n\n* Subjects who have new or progressive brain or meningeal or spinal metastases.\n* Clinically significant cardiac disease including congestive heart failure \\> New York Heart Association (NYHA) Class II), evidence for coronary artery disease (eg, unstable angina (anginal symptoms at rest) or new-onset angina (within the last 6 months or myocardial infarction within the past 6 months before first dose.\n* Major surgery or significant trauma within 4 weeks before the first dose of study drug.\n* Medical history of chronic obstructive pulmonary disease (COPD) and other respiratory disorders.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05712889006","EMAIL":[{}],"GEO":[-34.92866,138.59863]},{"TITLE":"PRO1107 in Patients With Advanced Solid Tumors","CRITERIA":"Inclusion Criteria\n\n* Pathologically confirmed diagnosis of one of the following tumor types:\n\n  * Ovarian cancer (epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer)\n  * Endometrial cancer (any subtype excluding sarcoma)\n  * Triple negative breast cancer (TNBC)\n  * Non-small cell lung cancer (NSCLC)\n  * Gastric or gastroesophageal junction (GEJ) adenocarcinoma\n  * Esophageal squamous cell carcinoma (ESCC)\n  * Urothelial cancers (bladder, ureter, or renal pelvis)\n* Metastatic or unresectable locally advanced, recurrent, disease not amenable to further local therapy following prior systemic therapies known to confer clinical benefit. Measurable disease at baseline as defined per RECIST, Version 1.1 (Eisenhauer et al. 2009)\n* Willing to provide a pre-treatment tumor specimen (archival or fresh biopsy samples).\n* ECOG performance status score 0 or 1.\n\nExclusion Criteria\n\n* Prior treatment with anti-PTK7 directed therapy.\n* Had progressive disease as best response while on treatment with an auristatin (vedotin, pelidotin)-based antibody drug conjugate (ADC) as the most recent line of therapy.\n* Other malignancy within 3 years\n* Active CNS metastases (treated, stable CNS metastases are allowed)\n* Uncontrolled infection within 2 weeks.\n* Positive for HBV, HCV or HIV\n* Use of a strong P450A CYP3A inhibitor within 2 weeks\n* Additional protocol defined inclusion\/exclusion criteria may apply","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06171789004","EMAIL":"clinicaltrialinfo@profoundbio.com","GEO":[40.76078,-111.89105]},{"TITLE":"Pembrolizumab and Chemotherapy Neoadjuvant\/Adjuvant of NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Male\/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of \\[Stage II, IIIA or IIIB(N2) NSCLC (AJCC Version 8)\\] will be enrolled in this study.\n\n   Note: mixed cellularity tumors are allowed. tumor should be considered resectable in terms of surgeon's determinations before study entry by investigators. Lymph nodes disease are recommended to have pathological confirmation. A PET-CT may be utilized as a surrogate for pathologic staging by site's feasibility.\n2. Male participants:\n\n   A male participant must agree to use a contraception as detailed in Appendix 3 of this protocol during the treatment period and for at least 1 year after the last dose of study treatment and refrain from donating sperm during this period.\n3. Female participants:\n\n   A female participant is eligible to participate if she is not pregnant (see Appendix 3), not breastfeeding, and at least one of the following conditions applies:\n   1. Not a woman of childbearing potential (WOCBP) as defined in Appendix 3 OR\n   2. A WOCBP who agrees to follow the contraceptive guidance in Appendix 3 during the treatment period and for at least \\[180 days after the last dose of carboplatin and for at least 120 days after the last dose of pembrolizumab, whichever occurs latest\\].\n4. The participant (or legally acceptable representative if applicable) provides written informed consent for the trial and may also provide consent for future biomedical research.\n5. Have measurable disease based on RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions. Participants suspected with secondary lung cancer (eg. ground glass nodules) were also eligible for this study (For solid nodules, biopsy, if available, should be performed in case of any intrapulmonary metastasis).\n6. Archival tumor tissue sample or newly obtained \\[core, incisional or excisional\\] biopsy of a tumor lesion not previously irradiated has been provided. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue.\n7. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 7 days prior to the first dose of study intervention.\n8. Have adequate organ function as defined in the following table. Specimens must be collected within 10 days prior to the start of study intervention.\n\nExclusion Criteria:\n\n1. Have confirmed sensitizing EGFR mutation or ALK alterations. Note: EGFR and ALK testing will be performed in local hospital, and do not need to be sent to the central laboratory.\n2. A WOCBP who has a positive urine pregnancy test within 72 hours prior to treatment (see Appendix 3). If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n\n   Note: in the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for subject to start receiving study medication.\n3. Has one of the following tumor locations\/types:\n\n   * NSCLC involving the superior sulcus\n   * Large cell neuro-endocrine cancer\n   * Sarcomatoid tumor\n4. Has had an allogenic tissue\/solid organ transplant.\n5. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).\n6. Has received prior systemic anti-cancer therapy including investigational agents for the current malignancy prior to \\[allocation\\].\n7. Has received prior radiotherapy within 2 weeks of start of study intervention or radiation-related toxicities requiring corticosteroids.\n8. Has received a live vaccine or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.\n\n   Note: please refer to Section 5.5.2 for information on COVID-19 vaccines\n9. Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration.\n10. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.\n11. Known additional malignancy that is progressing or has required active treatment within the past 5 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ, excluding carcinoma in situ of the bladder, that have undergone potentially curative therapy are not excluded.\n12. Has a known severe hypersensitivity (\u2265Grade 3) to any of the study chemotherapy agents and\/or to any of their excipients.\n13. Has active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid)\n14. Has a history of (non-infectious) pneumonitis\/interstitial lung disease that required steroids or has current pneumonitis\/interstitial lung disease.\n15. Has an active infection requiring systemic therapy.\n16. Has a known history of Human Immunodeficiency Virus (HIV) infection. Note: No HIV testing is required unless mandated by local health authority.\n17. Concurrent active Hepatitis B (defined as HBsAg positive and\/or detectable HBV DNA) and Hepatitis C virus (defined as anti-HCV Ab positive and detectable HCV RNA) infection.\n\n    Note: Hepatitis B and C screening tests are not required unless:\n    * Known history of HBV and HCV infection\n    * As mandated by local health authority\n18. Has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n19. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n20. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.\n21. Participants who have had major surgery within 14 days of first treatment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05894889002","EMAIL":[{"email":"chenthoracic@163.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer","CRITERIA":"Key Inclusion Criteria:\n\n* Patients must have histologically confirmed NSCLC and measurable disease by RECIST v1.1. Note: Patients in Cohort 1 and Cohort 5 do not have to present with measurable disease.\n\n  1. Patients in Cohorts 1 to 4 must present with unresectable Stage III or metastatic Stage IV NSCLC by American Joint Commission on Cancer (AJCC) Cancer Staging Manual, Eighth Edition.\n  2. Patients in Cohort 5 must present with unresectable Stage III NSCLC by AJCC Cancer Staging Manual, Eighth Edition before receiving pre-trial chemoradiotherapy.\n  3. Patients in Cohort 6 with the initial diagnosis of resectable Stage II and Stage III NSCLC by AJCC Cancer Staging Manual, Eighth Edition.\n* Patients in Cohorts 2, 4, 5, and 6 must be able to tolerate (additional) anti-PD-1 therapy (i.e., did not permanently discontinue anti-programmed death protein 1 \\[PD-1\\] \/ programmed death ligand 1 \\[PD-L1\\] therapy due to toxicity).\n* Patients in Cohorts 2, 3, and 6 must have an Eastern Cooperative Oncology Group performance status (ECOG-PS) \u22641. Patients in Cohort 1, 4, and 5 with an ECOG-PS of 0-2 are eligible.\n\nCohort-specific inclusion criteria:\n\nCohort 1:\n\n* Patients' prior therapy must have included at least a PD-1\/PD-L1 inhibitor and a platinum-based chemotherapy regimen as well as one other line of systemic therapy (except if a patient is not candidate for a platinum-based chemotherapy and\/or PD-1\/PD-L1 inhibitor and\/or another line of systemic therapy).\n\n  * Note: Patients newly enrolled in Cohort 1B under clinical trial protocol v4.0 and subsequent versions of the clinical trial protocol must consent to mandatory blood sampling for peripheral blood mononuclear cells (PBMCs).\n* Patients who are to start cemiplimab at Cycle 3 must present with PD-L1 expression of tumor proportion score (TPS) \u22651% in tumor cells (as determined locally).\n\nCohort 2:\n\n* Patients must present with PD-L1 expression of tumor proportion score (TPS) \u226550% in tumor cells (as determined locally prior to inclusion in this trial).\n* Patients must present with progressive disease either\n\n  1. in the advanced or metastasized stage of NSCLC: while on a PD-1\/PD-L1 inhibitor therapy or within 6 months of termination of this treatment as first-line treatment. Or\n  2. be refractory to ongoing adjuvant therapy with a PD-1\/PD-L1 inhibitor that has been given for at least 3 months in monotherapy (i.e., after an initial combination therapy) before being enrolled into this trial.\n\nCohort 3:\n\n* Patients' prior therapy must have included at least a PD-1\/PD-L1 inhibitor and a platinum-based chemotherapy regimen (except if a patient is not candidate for a platinum-based chemotherapy and\/or PD-1\/PD-L1 inhibitor).\n* Patients must present with progressive disease.\n\nCohort 4:\n\n* Patients' who are not candidates for chemotherapy as first-line treatment for the advanced or metastasized stage of NSCLC may be enrolled if presenting with PD-L1 expression: TPS \u22651% in tumor cells (as determined locally).\n\nCohort 5:\n\n* Patients' NSCLC must have been considered unresectable due to patients' condition and\/or tumor-related factors and the patients must have undergone chemoradiotherapy before entering the trial.\n\nCohort 6:\n\n* Patients' NSCLC must be considered technically and medically resectable.\n* Patients must be considered eligible for neo-adjuvant treatment.\n\nKey Exclusion Criteria:\n\n* Ongoing active systemic treatment against NSCLC.\n* Presence of a driver mutation for which approved target therapies are available except if the patient is not a candidate for the respective targeted therapy.\n* Ongoing or recent evidence (within the last 5 years) of significant autoimmune disease that required treatment with systemic immunosuppressive treatments which may suggest risk for immune-related adverse events. Note: Patients with autoimmune-related hyperthyroidism, autoimmune-related hypothyroidism who are in remission, or on a stable dose of thyroid-replacement hormone, vitiligo, or psoriasis may be included.\n* Current evidence of new or growing brain or spinal metastases during screening. Patients with leptomeningeal disease are excluded. Patients with known brain or spinal metastases may be eligible in Cohorts 1 to 4 if they:\n* had radiotherapy or another appropriate therapy for the brain or spinal bone metastases, AND\n* have no neurological symptoms that can be attributed to the current brain lesions, AND\n* have stable brain or spinal disease on the computed tomography (CT) or magnetic resonance imaging (MRI) scan within 4 weeks before signing the informed consent (confirmed by stable lesions on two scans at least 4 weeks apart), AND\n* do not require steroid therapy for the treatment of brain or spinal metastases within 14 d before the first dose of trial treatment. Note: Spinal bone metastases (i.e., of the vertebrae) are allowed, unless imminent fracture or cord compression is anticipated.\n* Systemic immune suppression:\n* Current use of chronic systemic steroid medication (\u22645 mg\/day prednisolone equivalent is allowed); patients using physiological replacement doses of prednisone for adrenal or pituitary insufficiency are eligible.\n\n  * Note: Steroid medication given for supportive or prophylactic reasons during CRT for patients in Cohort 5 needs to be tapered to \u22645 mg\/day prednisolone equivalent at latest on the day before the trial treatment starts.\n* Other clinically relevant systemic immune suppression within the last 3 months before trial enrollment.\n* Known history of seropositivity for human immunodeficiency virus (HIV) with CD4+ T-cell (CD4+) counts \\<350 cells\/\u00b5L and with a history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections.\n* Prior splenectomy.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05142189033","EMAIL":"patients@biontech.de","GEO":[51.50853,-0.12574]},{"TITLE":"A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors","CRITERIA":"Inclusion Criteria:\n\n* Advanced or metastatic solid or primary CNS tumor which has failed standard of care therapies\n* Evidence of an activating RET gene alteration in the tumor and\/or blood\n* Measurable or non-measurable disease\n* Karnofsky (participants 16 years and older) or Lansky (participants younger than 16) performance score of at least 50\n* Participant with primary CNS tumors or cerebral metastases must be neurologically stable for 7 days prior and must not have required increasing doses of steroids within the last 7 days\n* Adequate hematologic, hepatic and renal function.\n* Ability to receive study drug therapy orally or via gastric access\n* Willingness of men and women of reproductive potential to observe conventional and effective birth control\n\nExclusion Criteria:\n\n* Major surgery within two weeks prior to planned start of LOXO-292\n* Clinically significant, uncontrolled cardiac, cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of LOXO-292\n* Active uncontrolled systemic bacterial, viral, fungal or parasitic infection\n* Clinically significant active malabsorption syndrome\n* Pregnancy or lactation\n* Uncontrolled symptomatic hyperthyroidism or hypothyroidism (i.e. the participant required a modification to current thyroid medication in the 7 days before start of LOXO-292)\n* Uncontrolled symptomatic hypercalcemia or hypocalcemia\n* Known hypersensitivity to any of the components of the investigational agent, LOXO-292 or Ora-Sweet\u00ae SF and OraPlus\u00ae, for participants who will receive LOXO-292 suspension\n* Prior treatment with a selective RET inhibitor(s) (including investigational selective RET inhibitor\\[s\\])","SEX":"ALL","AGE_MIN":6,"AGE_MAX":21,"SS_ID":"03899792026","EMAIL":[{}],"GEO":[51.50853,-0.12574]},{"TITLE":"An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Patient has histologically or cytologically proven clinical stages IIA (tumors \\> 4 cm), IIB, IIIA, and IIIB (T3 or T4, N2) NSCLC (AJCC version 8) and is considered eligible for surgical resection with curative intent. Patients with 2 primary non-small cell lung cancers are allowed.\n2. Measurable disease, as defined by RECIST v1.1.\n3. Parenchymal lung tumor deemed to be amenable to treatment with sub-ablative stereotactic body radiation therapy, as determined by a co-investigator from Radiation Oncology\n4. Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) obtained from the subject prior to performing any protocol-related procedures.\n5. Age \\> 18 years at time of study entry\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n7. Adequate normal organ and marrow function as defined below:\n\n   * Hemoglobin \u2265 9.0 g\/dL\n   * Absolute neutrophil count (ANC) \u2265 1.5 x 109\/L (\\> 1500 per mm3)\n   * Platelet count \u2265 100 x 109\/L (\\>100,000 per mm3)\n   * Serum bilirubin \u2264 1.5 x institutional upper limit of normal (ULN). This will not apply to subjects with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician.\n   * Aspartate aminotransferase (SGOT)\/Alanine Aminotransferase (SGPT), and alkaline phosphatase \u2264 2.5 x institutional upper limit of normal (ULN).\n   * Serum creatinine clearance\\>50 mL\/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance (CL):\n\n   Males:\n\n   Creatinine CL (mL\/min)\n\n   = Weight (kg) x (140 - Age) . 72 x serum creatinine (mg\/dL)\n\n   Females:\n\n   Creatinine CL (mL\/min)\n\n   = Weight (kg) x (140 - Age) x 0.85 72 x serum creatinine (mg\/dL)\n8. Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n   Women \\<50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n\n   Women \u226550 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \\>1 year ago, had chemotherapy-induced menopause with last menses \\>1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).\n9. Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.\n10. No prior therapy for their lung cancer.\n\nExclusion Criteria:\n\nSubjects should not enter the study if any of the following exclusion criteria are fulfilled:\n\n1. Participation in another clinical study with an investigational product during the last 3 weeks.\n2. Active other primary malignancy excepting:\n\n   * Malignancy treated with curative intent and with no known active disease and of low potential risk for recurrence.\n   * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n   * Adequately treated carcinoma in situ without evidence of disease eg, cervical cancer in situ, in-situ urinary bladder cancer, treated localized prostate cancer and ductal carcinoma-in situ.\n3. Current or prior use of immunosuppressive medication within 14 days before the first dose of nivolumab, with the exceptions of intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection), corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg\/day of prednisone, or an equivalent corticosteroid, and steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).\n4. Patients with Grade \u22652 neuropathy.\n5. Previous receipt of immunotherapy.\n6. Active or prior documented autoimmune or inflammatory disorders that has required systemic treatment in the past year (including inflammatory bowel disease \\[e.g., colitis or Crohn's disease systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \\[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc\\]). No active diverticulitis within the previous 3 months. The following are exceptions to this criterion:\n\n   * Patients with vitiligo or alopecia\n   * Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement\n   * Any chronic skin condition that does not require systemic therapy\n   * Patients without active disease in the last 5 years may be included but only after consultation with the study physician\n   * Patients with celiac disease controlled by diet alone\n7. History of allogeneic organ transplant.\n8. History of hypersensitivity to nivolumab or any excipient.\n9. Uncontrolled intercurrent illness that would limit compliance with study requirements, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.\n10. Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis (TB) testing in line with local practice), active hepatitis B (known positive HBV surface antigen (HBsAg) result), active hepatitis C.\n11. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of nivolumab monotherapy.\n12. History of interstitial lung disease, idiopathic pulmonary fibrosis, pneumonitis (including drug induced), or evidence of active pneumonitis on screening chest CT scan.\n13. Receipt of the last dose of therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, or other investigational agent) for an accepted other malignancy as defined in Section 3.3.2 within 30 days prior to the first dose of study drug for lung cancer.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05500092001","EMAIL":"brstiles@montefiore.org","GEO":[40.84985,-73.86641]},{"TITLE":"Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)","CRITERIA":"Inclusion Criteria:\n\n1. Age from 18 to 80 years old;\n2. The first clinical diagnosis before surgery was non-small cell lung cancer, including adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and other unknown types;\n3. Clinical stage T1-2N0-1 (cI-II): Maximum diameter of tumor \\<= 5 cm and short diameter of mediastinal lymph node \\<= 1cm in thin layer computed tomography (CT);\n4. The patient's physical condition is able to tolerate lobectomy: (1) Goldman index 0-1; (2) Predicted forced expiratory volume in 1s (FEV1) \\>= 40% and diffusing capacity of the lung for carbon monoxide (DLCO) \\>= 40%; (3) Total bilirubin \\<= 1.5 upper limit of normal; (4) Alanine aminotransferase (ALT)\/Aspartate aminotransferase (AST) \\<= 2.5 upper limit of normal; (5) Creatinine \\<= 1.25 upper limit of normal and creatinine clearance rate (CCr) \\>= 60 ml\/min;\n5. Performance status of Eastern Cooperative Oncology Group (ECOG) = 0-1;\n6. All relevant examinations were completed within 28 days before the operation;\n7. Patients who understand this study and have signed an approved Informed Consent.\n\nExclusion Criteria:\n\n1. Patients who have undergone anti-tumor therapy (radiotherapy, chemotherapy, targeted therapy, immunotherapy) before surgery;\n2. Patients with previous medical history of other malignant tumors or combined with second primary cancer at the time of enrollment;\n3. Patients who meet all of the following criteria are eligible for sublobar resection (segment\/wedge resection): (1) Ground glass opacity (GGO) with a solid component \\<= 50%; (2) The largest diameter of nodule is \\<= 2 cm; (3) The nodule is located in the outer third of the lung field;\n4. Patients with preoperative diagnosis of pure GGO;\n5. Patients with previous medical history of unilateral thoracotomy;\n6. Women who are pregnant or breastfeeding;\n7. Patients with active bacterial or fungal infection that is difficult to control;\n8. Patients with serious psychosis;\n9. Patients with a history of severe heart disease, heart failure, myocardial infarction or angina pectoris in the past 6 months.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"06577792032","EMAIL":[{"email":"chenxiaobo0416@163.com"}],"GEO":[25.03889,102.71833]},{"TITLE":"Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2\n* histologically confirmed NSCLC\n* synchronous oligo-M NSCLC as determined by Positron emission tomography- computed tomography (PET\/CT) and brain MRI (AJCC 8th edition)\n* metachronous oligo-M NSCLC (oligo-persistence, oligo-progressive, oligo-induced) as determined by PET\/CT and brain magnetic resonance imaging (MRI) (AJCC 8th edition)\n* patients with at least one target to be treated by SABR at the body\n* patients with brain metastases synchronous to the body will be enrolled only if amenable to radiosurgery (the number of brain metastases does not enter into the count of the number of oligo-M)\n* patients with a previous history of brain metastases will be enrolled only if the previously treated brain metastases are in control\n\nExclusion Criteria:\n\n* Ability to understand and the willingness to sign an institutional review board (IRB)- approved informed consent document (either directly or via a legally authorized representative)\n* Inability to safely treat target lesions\n* Pregnant women are excluded from this study because radiation therapy has known potential for teratogenic or abortifacient effects.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06207292001","EMAIL":[{"email":"f.arcidiacono@aospterni.it"},{"email":"p.anselmo@aospterni.it"},{},{},{}],"GEO":[42.56335,12.64329]},{"TITLE":"Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols","CRITERIA":"* INCLUSION CRITERIA:\n\n  1. Diagnosis of cancer, a premalignant condition or an immunodeficiency that increases the risk of being diagnosed with a cancer or premalignant condition\n  2. Age \\>=18 years of age\n  3. ECOG performance status of 0-3.\n\n  5. Ability and willingness of subject to provide informed consent\n\nAdditional inclusion criteria pertinent only for patients undergoing apheresis\n\n1. Hemoglobin \\>= 8 mg\/dL and platelet count \\> 75 K\/uL\n2. Weight \\>= 48 kg\n3. Central line in place or adequate venous access\n\nEXCLUSION CRITERIA:\n\n1. Active concomitant medical or psychological illnesses that may increase the risk to the subject.\n2. Inability to provide informed consent\n3. Pregnant or breastfeeding women (not applicable to patients enrolled only for collection of tissue and blood from outside sources)","SEX":"ALL","AGE_MIN":18,"AGE_MAX":120,"SS_ID":"02682667001","EMAIL":"scott.norberg@nih.gov","GEO":[38.98067,-77.10026]},{"TITLE":"Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations","CRITERIA":"Inclusion Criteria:\n\n1. Written informed consent;\n2. Male or female patient aged \u226518 years;\n3. Histologically\/cytologically confirmed diagnosis of stage IIIB\/IV NSCLC with evidence of activating EGFR mutations including exon 19 deletion, exon 21 L858R or other activating\/sensitizing EGFR mutations such as exon 21 L861Q, exon 18 G719S, G719A, G719C, exon 20 S768I and V769L; co-occurrence of de novo T790M is not an exclusion criterion; EGFR status assessed in circulating DNA is allowed;\n4. Patients eligible and candidate to receive osimertinib as first- or second-line treatment according to clinical practice and study design, as decided by Investigator regardless study participation;\n5. Patients with brain metastases are allowed provided they are asymptomatic and stable (i.e. without evidence of progression by imaging for at least two weeks prior to the first dose of trial treatment and without deterioration of any neurologic symptoms);\n6. No evidence of concomitant drivers including KRAS mutations, HER2 mutations, ALK or ROS1 rearrangements, MET mutations, BRAF mutations;\n7. No previous EGFR-TKI therapy; Previous palliative radiotherapy or surgery allowed. Prior brain radiotherapy and Stereotactic Radiosurgery (SRS) are allowed. Previous neo\/adjuvant chemotherapy is allowed as long as therapy was completed at least 6 months before diagnosis of advanced or metastatic NSCLC;\n8. At least one radiological measurable disease according to RECIST criteria version 1.1;\n9. Performance status 0-1 (ECOG PS);\n10. Patient compliance to trial procedures;\n11. Adequate bone marrow function (ANC \u2265 1.5x109\/L, platelets \u2265100x109\/L, haemoglobin \\>9 g\/dl);\n12. Adequate liver function (AST (SGOT)\/ALT (SGPT) \u22642.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be \u22645x ULN, bilirubin \\< grade 2, transaminases no more than 3xULN\/\\<5xULN in presence of liver metastases);\n13. Normal level of alkaline phosphatase, and creatinine;\n14. Female patients should be using adequate contraceptive measures, should not be breastfeeding, until 12 months after the last dose, and must have a negative pregnancy test (serum or urine) prior to first dose of study drug (within 72 hours); or female patients must have an evidence of non-childbearing potential by fulfilling one of the following criteria at screening:\n\n    * Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments.\n    * Women under 50 years old would be consider postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the institution. Documentation of irreversible surgical by hysterectomy, bilateraloophorectomy, or bilateral salpingectomy but not tubal ligation.\n15. Male patients should be willing to use barrier contraception, i.e. condoms;\n16. No significant comorbidity that according to the investigator would hamper the participation on the trial;\n\nExclusion Criteria:\n\n1. Previous therapy with any EGFR-TKI;\n2. Previous systemic anti-cancer therapy for advanced\/metastatic NSCLC including chemotherapy, biologic therapy, immunotherapy, or any investigational drug;\n3. Absence of measurable lesions;\n4. Concomitant radiotherapy or chemotherapy;\n5. Symptomatic or immediately requiring therapy brain metastases or carcinomatous meningitis. Subjects with asymptomatic and stable or treated brain metastases may participate;\n6. Diagnosis of any other malignancy during the last 3 years, except for in situ carcinoma of cervix uteri and squamous cell carcinoma of the skin;\n7. History of extensive disseminated\/bilateral or known presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis and pulmonary fibrosis (but not history of prior radiation pneumonitis);\n8. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV);\n9. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of the study drugs;\n10. Any of the following cardiac criteria:\n\n    * Mean resting corrected QT interval (QTc) \\>470 msec, obtained from 3 ECGs using local clinic ECG machine-derived QTcF value;\n    * Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG, e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, PR interval \\>250 msec or history of episodes of bradycardia (\\<50 BPM);\n    * Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval;\n    * Abnormal cardiac function: LVEF \\< 50% (assessed by MUGA or ECHO)\n11. Pregnancy or lactating female;\n12. Other serious illness or medical condition potentially interfering with the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04811001020","EMAIL":[{}],"GEO":[45.44694,8.62118]},{"TITLE":"Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance","CRITERIA":"Inclusion Criteria:\n\n* Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older\n* Prior exposure to 4-6 cycles of Pem\/Carbo\/Pembro and PD after at least 18 weeks of maintenance Pemetrexed, Pembrolizumab or the combination of the two.\n* PS 0-1\n\nExclusion Criteria:\n\n* Presence of a driver mutation that is susceptible to targeted therapy\n* Other active invasive malignancy requiring ongoing therapy\n* Grade 2 or higher sensory neuropathy\n* Evidence of untreated brain metastases\n* History of bleeding diatheses or recent, antecedent hemoptysis (\\> 1\/2 teaspoon in prior 2 months)","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04332367001","EMAIL":[{"email":"Melissa.volpe@pennmedicine.upenn.edu"}],"GEO":[39.95233,-75.16379]},{"TITLE":"Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT","CRITERIA":"Inclusion Criteria:\n\n1\u300118 years or older. 2\u3001Histologically or cytologically confirmed small cell lung cancer. 3\u3001ECOG PS=0-1 at enrollment; 4\u3001Limited-stage SCLC (Stage I-III, by AJCC 8th Edition Cancer Staging), and can be safely treated with definitive radiation doses).\n\n5\u3001Inoperable SCLC, or the patient has contraindications to surgery, or the patient refuses surgery.\n\n6\u3001Completion of 4 cycles of chemotherapy (etoposide + carboplatin\/cisplatin) concurrent or sequential with radiotherapy during the first two cycles of chemotherapy.\n\n7\u3001After the completion of concurrent or sequential chemoradiotherapy, prophylactic intracranial irradiation (PCI) is allowed based on the common practice of individual sites.\n\n8\u3001The start of concurrent radiotherapy should be no later than the last day of the second course of chemotherapy (the first day of the third cycle of chemotherapy). The interval between the end of chemotherapy cycle and beginning of radiotherapy must not exceed 35 days for sequential chemoradiotherapy.\n\n9\u3001Radiotherapy must be either total 60-66Gy over 6 weeks for the standard qd regimen or total 45Gy over 3 weeks for hyperfractionated bid schedules.\n\n10\u3001Absence of progression after concurrent\/sequential chemoradiotherapy (responses should be complete response \\[CR\\], partial response \\[PR\\] and stable disease \\[SD\\]); 11\u3001For patients not receiving PCI, the first dose of sugemalimab shall be administered within 42 days after the completion of chemoradiation therapy. For patients receiving PCI, the first dose of sugemalimab shall be administered within 56 days after the completion of chemoradiation therapy.\n\n12\u3001Life expectancy \u2265 12 weeks. 13\u3001Can provide tumor tissue samples (fresh or archived) for whole exome sequencing; 14\u3001Women of childbearing potential and fertile men must agree to use an effective contraceptive method from signing the master ICF until 180 days after the last dose of investigational product. Women of childbearing potential include premenopausal women and women who became menopausal less than 2 years ago. Women of childbearing potential must have a negative pregnancy test \u22647 days prior to the first dose of investigational product.\n\n15\u3001The subject should have good compliance, who would participate in the research voluntarily, and sign the informed consent.\n\nExclusion Criteria:\n\n1. Histologically or cytologically diagnosed mixed small cell lung cancer or non-small cell lung cancer.\n2. Extensive-stage small cell lung cancer.\n3. Has malignant pleural or pericardial effusion.\n4. Previously received systemic anti-tumor therapy for SCLC or anti-tumor therapy with immune checkpoint inhibitors.\n5. Subjects with active, unstable systemic diseases, such as active infection, uncontrolled hypertension, heart failure (NYHA class \\>= II), unstable angina pectoris, acute coronary syndrome, severe arrythmia, severe liver, kidney or metabolic diseases, HIV infection.\n6. Has history of interstitial lung disease (ILD), drug-induced ILD, or active ILD which required systemic glucocorticoid or immunosuppressive therapy.\n7. History of other malignancies within 5 years (excluding basal cell carcinoma of the skin or other carcinoma in situ that has been resected).\n8. Pregnant or lactating women.\n9. Those who are allergic to the research drug or its components.\n10. Subjects who are deemed unable to comply with the study requirements or complete the study.\n11. Those with insufficient function of bone marrow or other important organs.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05623267001","EMAIL":[{"email":"zhangli@sysucc.org.cn"}],"GEO":[23.11667,113.25]},{"TITLE":"Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients","CRITERIA":"Inclusion Criteria:\n\n1. Be able to understand and voluntarily sign the written informed consent, which must be signed before the designated research procedure.\n2. Age \u2265 18 and \u2264 75, male or female.\n3. Local advanced or metastatic non-squamous NSCLC confirmed by histology or cytology according to eighth edition of the TNM classification for lung cancer.\n4. EGFR activating mutation confirmed by tumor histology, cytology or hematology.\n5. Failed to previous EGFR-TKI treatment.\n6. ECOG performance status 0 to1.\n7. Life expectancy \u22653 months.\n8. At least one measurable lesion according to RECIST v1.1.\n9. Adequate organ function.\n\nExclusion Criteria:\n\n1. Histological or cytological pathology confirmed the presence of small cell carcinoma or squamous cell carcinoma.\n2. Have suffered from the second primary active malignant tumor in the past 3 years.\n3. There are other driving gene mutations that can obtain effective treatment.\n4. Receipt of the following treatments or procedures: immunotherapy, including immunocheckpoint inhibitors, immunocheckpoint agonists, immunocellular therapy, and any other treatment targeting tumor immune mechanism; systematic chemotherapy in the advanced stage (IIIB-IV); anti-angiogenesis drugs, except for small molecule anti-angiogenesis drugs with drug withdrawal more than 4 weeks; extensive radiotherapy within 4 weeks; EGFR-TKIs within 2 weeks.\n5. Symptomatic central nervous system metastases.\n6. The toxicity of previous anti-tumor therapy has not been alleviated.\n7. Uncontrolled massive ascites, pleural effusion or pericardial effusion.\n8. Active autoimmune diseases in the past 2 years.\n9. History of interstitial lung disease or noninfectious pneumonitis.\n10. Suffering from clinically significant cardiovascular or cerebrovascular diseases.\n11. History of severe bleeding tendency or coagulation dysfunction.\n12. History of deep vein thrombosis, pulmonary embolism or any other serious thromboembolism in the past 3 months.\n13. Serious infection in the past 4 weeks.\n14. Acute exacerbation of chronic obstructive pulmonary disease or asthma in the past 4 weeks.\n15. History of human immunodeficiency virus (HIV) infection.\n16. History of severe hypersensitivity reactions to other mAbs.\n17. History of organ transplantation.\n18. Any other conditions that, in the opinion of the investigator, may increase the risk when receiving the investigational product.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05636267001","EMAIL":[{}],"GEO":[23.11667,113.25]},{"TITLE":"Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Diagnosis of NSCLC Stage IV (stratification according to the American Joint Committee on Cancers - 7th edition)\n* Candidates for treatment with carboplatin plus paclitaxel 1st line\n* Performance status (ECOG 0-2)\n* Laboratory studies that demonstrate adequate renal, hepatic and hematologic function (blood chemistry and blood count)\n* Normal renal ultrasound prior to initiation of treatment\n\nExclusion Criteria:\n\n* Patients with renal impairment (KDOQI 3-5)\n* Patients who do not have computed tomography study at baseline\n* Uncontrolled blood pressure (\\> 140 mmHg)\n* Uncontrolled diabetes (\\> 130 mg \/ dL)\n* Obstruction in kidney (s) or ureter (s)\n* Dehydrated patients\n* Patients with high consumption of NSAIDs (aspirin, ibuprofen, etc.\\> 1 month)","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"02734069001","EMAIL":[{}],"GEO":[19.42847,-99.12766]},{"TITLE":"PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Advanced non-small cell lung cancer confirmed by histology or cytology\n* HER2 insertion mutation-positive\n* Failure with first-line standard chemotherapy\n* with measurable lesions.\n\nExclusion Criteria:\n\n* no measurable tumor lesions\n* Patients received PD-1 or Pyrotinib before","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"04144569001","EMAIL":[{"email":"yangnong0217@163.com"},{"email":"zhangyongchang@csu.edu.cn"},{},{}],"GEO":[28.19874,112.97087]},{"TITLE":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Disease Characteristics - Breast, Prostate, and Lung Cancer\n* Part 1A (Monotherapy Dose Escalation) Histological or cytological diagnosis of locally advanced or metastatic ER+HER2- breast cancer, CRPC, or NSCLC that is intolerant or resistant to standard therapy or for which no standard therapy is available.\n* Part 1B, Part 1C and Part 1D (Combination Dose Escalation) Histological or cytological diagnosis of locally advanced or metastatic ER+HER2- breast cancer. Participants must have progressed after at least 1 prior line of treatment with an endocrine therapy and CDK4\/6 inhibitor in the advanced or metastatic setting.\n* Part 2A (ER+HER2- breast cancer 2L+, monotherapy) Histological or cytological diagnosis of locally advanced or metastatic ER+HER2- breast cancer. Participants must have progressed after at least 1 prior line of CDK4\/6 inhibitor and 1 line of endocrine therapy.\n* Part 2B (ER+HER2- breast cancer 2-4L, combination with fulvestrant) Histological or cytological diagnosis of advanced or metastatic ER+HER2- breast cancer. Participants must have progressive disease after at least 1 prior line of a CDK4\/6 inhibitor and at least 1 prior line of endocrine therapy.. Participants must not have received more than 3 prior lines of systemic therapies including up to 1 line of cytotoxic chemotherapy for visceral disease in advanced or metastatic setting; Participants may have but are not required to have prior treatment with fulvestrant.\n* Part 2D (ER+HER2- breast cancer 2-4L, combination with PF-07220060 (CDK4i) and fulvestrant):\n\nHistological or cytological diagnosis of advanced or metastatic ER+HER2- breast cancer. Participants must have progressive disease after at least 1 prior line of a CDK4\/6 inhibitor and at least 1 prior line of endocrine therapy.\n\n* Participants must have not received more than 3 lines of systemic therapies including up to 1 line of cytotoxic chemotherapy for visceral disease in advanced or metastatic setting; Participants may have but are not required to have prior treatment with fulvestrant.\n* Participants with ER+HER2- advanced or metastatic breast cancer must have documentation of ER-positive tumor (\u22651% positive stained cells) based on most recent tumor biopsy utilizing an assay consistent with local standards.\n* Participants with ER+HER2- advanced or metastatic breast cancer must have documentation of HER2-negative tumor: HER2-negative tumor is determined as immunohistochemistry score 0\/1+ or negative by in situ hybridization (FISH\/CISH\/SISH\/DISH) defined as a HER2\/CEP17 ratio \\<2 or for single probe assessment a HER2 copy number \\<4.\n* Female participants with ER+HER2- advanced or metastatic breast cancer considered to be of childbearing potential (or have tubal ligations only) must be willing to undergo medically induced menopause by treatment with the approved LHRH agonist such as goserelin, leuprolide or equivalent agents to induce chemical menopause.\n* Female participants with ER+HER2- advanced or metastatic breast cancer of nonchildbearing potential must meet at least 1 criteria of achieving postmenopausal status.\n* Participants must have at least 1 measurable lesion as defined by RECIST version 1.1 that has not been previously irradiated.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status PS 0 or 1\n* Female or male patients aged \u2265 18 years (Japan \u2265 20 years) (South Korea \u2265 19 years).\n* Adequate renal, liver, and bone marrow function.\n* Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for adverse events (AEs) not constituting a safety risk by investigator judgment.\n\nExclusion Criteria:\n\n* Unmanageable ascites (limited medical treatment to control ascites is permitted, but all participants with ascites require review by sponsor's medical monitor).\n* Participants with any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.\n* Major surgery, radiation therapy, or systemic anti-cancer therapy within 3 weeks prior to study entry.\n* Prior irradiation to \\>25% of the bone marrow.\n* ECG clinically relevant abnormalities (eg, QTc \\>470 msec, complete LBBB, second\/third degree AV block, ST elevation or EKG changes suggesting myocardial infarction or active myocardia ischemia).\n* Therapeutic anticoagulation. However, low molecular weight heparin is allowed. Vitamin K antagonists or factor Xa inhibitors may be allowed following discussion with the Sponsor.\n* Known or suspected hypersensitivity or severe allergy to active ingredient\/excipients of PF-07248144.\n* Active inflammatory GI disease, refractory and unresolved chronic diarrhea or previous gastric resection, lap band surgery or other GI conditions and surgeries that may significantly alter the absorption of PF-07248144 tablets. Gastroesophageal reflux disease under treatment is allowed.\n* Pregnant or breastfeeding female participants.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04606446056","EMAIL":"ClinicalTrials.gov_Inquiries@pfizer.com","GEO":[37.566,126.9784]},{"TITLE":"A Single-Arm Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients","CRITERIA":"Inclusion Criteria:\n\nSubjects must sign a written ICF prior to the implementation of any procedures related to the study;\n\n1. Aged \u2265 18 years old;\n2. Patients with histologically or cytologically confirmed unresectable stage IIIB-IIIC or stage IV NSCLC (staged according to the 8th Edition of the TNM Classification for Lung Cancer published by the International Association for the Study of Lung Cancer and American Joint Committee on Cancer);\n3. Have at least one measurable lesion according to RECIST v1.1;\n4. With histologically confirmed FGFR 1-3 alterations, including but not limited to amplification, mutation, fusion\/rearrangement, etc.;\n5. Have failed second-line and above standard therapies. Patients who have EGFR-sensitive mutations or are positive for ALK\/ROS1 rearrangements shall receive at least one line of EGFR\/ALK\/ROS1 inhibitor treatment (Patients with EGFR-sensitive mutations who have received a first- or second-generation TKI should fail the treatment with a third-generation TKI (e.g., osimertinib) if they are positive for T790M mutations); Note: Patients who have a relapse within 6 months after a radical surgery or radical concurrent chemoradiotherapy can be enrolled if they have failed at least one line of systematic therapy after the relapse.\n6. No previous use of small molecule multi-target drugs targeting the FGFR pathway (including anlotinib, lenvatinib, sorafenib, apatinib, bevacizumab, Endostar, etc.);\n7. ECOG physical performance status score of 0-1;\n8. Expected survival time \\> 3 months;\n9. Patients with brain metastases who are asymptomatic or have stable symptoms after locoregional treatment can be enrolled as long as they:\n\n1) Have measurable lesions outside the central nervous system; 2) Have no central nervous system symptoms or no aggravation of symptoms for at least 2 weeks; 3) Do not need glucocorticoid treatment or stop glucocorticoid treatment within 7 days before the first dose of the investigational drug.\n\n10. Patients who have completed palliative radiotherapy one week prior to study enrollment with their radiotherapy-related toxicity reduced to grade 1 or lower (CTCAE5.0) can be enrolled.\n\n11. For evidence of sufficient organ functions, the subjects shall meet the following laboratory parameters:\n\n1. Absolute neutrophil count (ANC) \u2265 1.5 \u00d7 109\/L without use of granulocyte colony stimulating factor in recent 14 days;\n2. Platelet count \u2265 100 \u00d7 109\/L without blood transfusion in recent 14 days;\n3. Hemoglobin \\> 9 g\/dL without blood transfusion or erythropoietin use in recent 14 days;\n4. Total bilirubin \u2264 1.5 \u00d7 upper limit of normal (ULN); or total bilirubin\n\n   \\> ULN, direct bilirubin \u2264 ULN;\n5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)\n\n   \u2264 2.5 \u00d7 ULN (ALT or AST \u2264 5 \u00d7 ULN for patients with liver metastasis);\n6. Blood creatinine \u2264 1.5 \u00d7 ULN and creatinine clearance (calculated by Cockcroft-Gault formula) \u2265 50 mL\/min;\n7. Good coagulation function: international normalized ratio (INR) or prothrombin time (PT) \u2264 1.5 \u00d7 ULN. (For subjects receiving an anticoagulant therapy, PT within the range proposed for the anticoagulant drug is acceptable).\n\n12. Women of childbearing potential shall obtain a negative result in the urine or serum pregnancy test performed within 3 days before the first dose of the investigational drug (cycle 1, day 1). If the urine pregnancy test result cannot be identified as negative, a blood pregnancy test is needed. Women of non-childbearing potential are defined as those who have not had menses for at least 1 year or who have undergone surgical sterilization or hysterectomy; 13. All subjects at risk of conception (including their partners) shall use contraceptives with an annual failure rate of less than 1% throughout the entire treatment period up to 120 days after the last dose of the investigational drug (or 180 days after the last dose of the chemotherapy drug).\n\nExclusion Criteria:\n\n* 1. Diagnosed with malignant tumors other than non-small cell lung cancer within 5 years before the first dose, excluding radically cured cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, and\/or radically resected carcinoma in situ; 2. Previously treated with selective FGFR inhibitors; 3. Have received any other investigational drug treatment or participated in another interventional clinical trial within 28 days before the first dose of the investigational drug, or have received anti-tumor drug treatment within 28 days before the first dose of the investigational drug (including Chinese herbal medicine with anti-tumor indications); 4. Have not recovered (i.e., reaching \u2264 grade 1 or the baseline status, excluding asthenia and alopecia) from toxicity and\/or complications caused by any intervention before the start of treatment; 5. With known symptomatic central nervous system metastasis and\/or carcinomatous meningitis. Subjects with previously treated brain metastases are eligible if the disease is stable (no imaging evidence of progression in at least 4 weeks prior to the first dose of study treatment), there is no evidence of new or enlarging brain metastases on repeated imaging, and corticosteroids are not required in at least 14 days prior to the first dose of study treatment. Patients with carcinomatous meningitis should be excluded regardless of their clinically stability; 6. During pregnancy or lactation; 7. Known history of allotransplantation or allogeneic hematopoietic stem cell transplantation; 8. Subjects with abnormal laboratory parameters listed below:\n\n  1. Serum phosphate \\> ULN;\n  2. Serum calcium exceeds the normal range, or the calcium concentration corrected for serum albumin exceeds the normal range when serum albumin exceeds the normal range;\n  3. Potassium level \\< lower limit of normal (LLN); potassium levels can be corrected by supplements at screening.\n\n     9. With known history of human immunodeficiency virus (HIV) infection or confirmed with positive immune test results; 10. Presence of severe infection in the active phase or with poor clinical control; 11. Pleural effusion, ascites, or pericardial effusion with obvious clinical symptoms that require drainage; 12. Acute or chronic active hepatitis B or C infection; hepatitis B virus (HBV) DNA \\> 2000 IU\/mL or 104 copies\/mL; hepatitis C virus (HCV) RNA \\> 103 copies\/mL; hepatitis B surface antigen (HbsAg) and anti-HCV antibody positive concurrently. Those who with relevant parameters lower than the above criteria after nucleotide antiviral treatment can be enrolled; 13. With clinically significant or uncontrolled heart diseases, including unstable angina, acute myocardial infarction within 6 months before the first dose, grade III\/IV congestive heart failure (New York Heart Association), and uncontrolled arrhythmia (subjects with pacemakers or with atrial fibrillation but well controlled heart rate are allowed); 14. With ECG changes or medical history considered clinically significant by the investigator; QTcF interval \\> 480 ms at screening; for subjects with intraventricular conduction block (QRS interval \\> 120 ms), JTc interval can be used instead of QTc interval upon approval of the sponsor (in such cases, JTc must be \u2264 340 ms); 15. With uncontrolled hypertension (systolic pressure \\> 160 mmHg or diastolic pressure \\> 100 mmHg after the optimal medical treatment), or a history of hypertensive crisis or hypertensive encephalopathy; 16. With hepatic encephalopathy, hepatorenal syndrome, or liver cirrhosis with Child-Pugh grade B or C.\n\n     17. Have received a major surgery (craniotomy, thoracotomy, or laparotomy) within 4 weeks prior to the first dose of study treatment, or will receive a major surgery during the study treatment period; 18. Pregnant or lactating women, or subjects expected to conceive or give birth during the study period from the screening visit to the completion of the safety follow-up visit (90 days after the last dose for male subjects); 19. Have received radiotherapy within 4 weeks before the first dose of the investigational drug. The subjects must be completely recovered from radiotherapy-related toxicity, with no need for corticosteroid treatment, and radiation pneumonitis must be excluded. For palliative radiotherapy for non-CNS diseases, a 2-week washout period is allowed; 20. Have a history of disorders of calcium and phosphorus metabolism or systemic electrolyte metabolism imbalance with ectopic calcification of soft tissues (excluding calcification of soft tissues such as skin, kidneys, tendon, or blood vessels without systemic electrolyte metabolism imbalance caused by injury, disease, and old age); 21. Clinically significant corneal or retinal diseases confirmed by ophthalmological examination; 22. Have used any potent CYP3A4 inhibitor (see Appendix A for details) or inducer within 14 days or 5 half lives (whichever is shorter) before the first dose of the investigational drug. Ketoconazole is allowed for external use; 23. With known allergic reactions to pemigatinib or excipients of pemigatinib; 24. Unable or unwilling to swallow pemigatinib or are suffering from significant digestive system diseases that may interfere with absorption, metabolism, or excretion; 25. Subjects with a history of vitamin D deficiency who require supraphysiological dose of vitamin D (except dietary vitamin D supplements); 26. Other acute or chronic diseases, psychiatric disorders, or laboratory abnormalities that may result in an increased risk associated with study participation or investigational drug administration or interfere with the interpretation of study results, and disqualify patients from the study in the investigator's judgment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05210946001","EMAIL":[{"email":"shenxurui@suda.edu.cn"}],"GEO":[31.30408,120.59538]},{"TITLE":"A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy","CRITERIA":"Inclusion and Exclusion Criteria for Phase 1b\n\nInclusion Criteria\n\n1. Adult patients (age 18 or older)\n2. Patient has a histologically confirmed diagnosis of any of the following advanced solid tumors: melanoma, pleural mesothelioma, renal cell carcinoma, MSI-high or mismatch repair-deficient colorectal cancer, hepatocellular carcinoma, and non-small cell lung cancer with no EGFR or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, or tumor types for which the combination of ipilimumab and nivolumab has been approved. Patients should have received and progressed following at least one line of Anti PD-1\/Anti-PD-L1 treatment prior to enrollment.\n3. ANC \\> 1000\/\u00b5L without use of G-CSF, Hgb \\> 9 g\/dL without required blood transfusion for at least 5 days prior to pretreatment baseline, and platelet count \\> 75,000\/\u00b5L without transfusions for at least 5 days prior to pretreatment baseline.\n4. ECOG performance status of 0 or 1.\n5. Has a life expectancy of \\> 12 weeks.\n6. Renal and hepatic function requirements:\n\n   * a. Renal function with either an eCrCL \\> 60 mL\/min (modified Cockcroft-Gault) or eGFR \\> 60 mL\/min\/1.73 m2 (using MDRD or CKD-EPI or similar equations).\n   * b. Hepatic function with ALT\/AST \u2264 3 x ULN, total bilirubin \\< 1.5 x ULN (except for patients with Gilbert Syndrome). If patients have hepatic metastases, then AST\/ALT \\< 5 x ULN will be allowed.\n7. Men receiving the investigational drug and are sexually active with women of child-bearing potential (WCBP) must use contraception during treatment and for 5 half-lives after the last dose of the investigational drug or Women, not otherwise meeting other exclusion criteria, who are WCBP must be on contraception for a minimum duration of 3 months prior to treatment and continue contraception during treatment and for 5 half-lives after the last dose of the investigational drug.\n8. All Grade 3 AEs related to prior therapies have returned to Grade 1 or resolved to baseline (this includes with appropriate therapy in the case of thyroid dysfunction).\n9. All patients must have measurable disease by applicable RECIST criteria.\n10. Willing to allow blood samples to be used for research.\n\nExclusion Criteria:\n\n1. Patients must not have received prior anticancer therapy or radiation therapy within the 3 weeks and must not have undergone major surgery within 4 weeks prior to initiation of treatment on protocol. Palliative radiation therapy is allowed. For small molecules (MW \\< 0.9 kDA), the washout period is 3 weeks or 5 half-lives, whatever comes first.\n2. Active brain metastasis or leptomeningeal disease. Patients with treated brain metastasis must have stable disease, evidenced by MRI brain imaging for at least 4 weeks, and the patient must have been off steroids for at least 2 weeks prior to first dose of study drug.\n3. Previous episodes of \u2265 Grade 3 (G3) immune-related toxicity that includes G3 colitis, G3 pneumonitis, G3 skin rash, G3 increase in liver enzymes (with the exception of symptoms that in the opinion of the investigator will not compromise the patients' safety on the trial. Patients with stable endocrinological AEs (e.g., hypothyroidism, adrenal insufficiency, hypopituitarism, or diabetes mellitus) are allowed.\n4. Persistent toxicity of NCI CTCAE version 5 Grade \\> 1 severity that is related to prior therapy.\n\n   Note: Sensory neuropathy, hypothyroidism or alopecia of Grade \u2264 2 are acceptable. Other Grade 2 toxicities of prior treatments that are controlled with medication (e.g., diabetes or hypertension) are permitted.\n5. Concurrent administration of medications or foods that are strong inhibitors or inducers of cytochrome p450 3A (CYP3A) within 2 weeks before study intervention. Alintegimod may increase exposure to CYP3A4 substrates; consider a dose reduction of such substrates and monitor for signs of toxicities of co-administered sensitive CYP3A substrates (see listing of strong inhibitors and inducer drugs in FDA tables). An alternative is to replace such agents with drugs that are not CYP3A4 metabolized if at all feasible.\n6. The patient has cardiac conditions as follows:\n\n   * a) myocarditis;\n   * b) uncontrolled hypertension (blood pressure \\> 160\/100) despite optimal therapy;\n   * c) uncontrolled angina; ventricular arrhythmias; congestive heart failure (New York Heart Association Class II or above);\n   * d) prior or current cardiomyopathy;\n   * e) uncontrolled atrial fibrillation with heart rate \\> 100 beats per minute (bpm); unstable ischemic heart disease (myocardial infarction within 6 months prior to starting treatment or angina requiring use of nitrates more than once weekly);\n   * f) concomitant medication with drugs known to cause Torsades de Pointes;87\n   * g) QT interval correction for heart rate using Fridericia's formula (QTcF) \u2265 470 ms (average from 3 QTcF values on the triplicate 12-lead electrocardiogram \\[ECG\\]) at screening.\n7. Known history of a positive test for HIV, or positive test for hepatitis B (positive for HBsAg) or hepatitis C (HCV RNA).\n8. Concurrent malignancies are permitted if they were previously treated, and all treatment of that malignancy was completed at least 2 years before enrollment and no evidence of disease exists, or with agreement from the Principal Investigator (PI), patients who have a concurrent malignancy that is clinically stable and does not require tumor-directed treatment are eligible to participate if the risk of the prior malignancy interfering with either safety or efficacy endpoints is very low, or with agreement from the PI, other malignancies may be permitted if the risk of the prior malignancy interfering with either safety or efficacy end points is very low. Adequately treated basal or squamous cell carcinoma or carcinoma in situ is allowed.\n9. Men receiving the investigational drug and are sexually active with women of child-bearing potential (WOCBP) must use contraception during treatment and for 5 half-lives after the last dose of the investigational drug or Women, not otherwise meeting other exclusion criteria, who are WOCBP must be on contraception for a minimum duration of 3 months prior to treatment and continue contraception during treatment and for 5 half-lives after the last dose of the investigational drug.\n10. The patient has concurrent severe and\/or uncontrolled medical disease that could compromise participation in the study (i.e., uncontrolled diabetes, severe infection requiring active treatment, severe malnutrition, chronic severe liver or renal disease).\n11. Use of corticosteroids or other immunosuppressive medication, current or within 14 days of administration of Alintegimod with the following exceptions:\n\n    * a) Topical, intranasal, inhaled, ocular, intra-articular corticosteroids;\n    * b) Physiological doses of replacement corticosteroids (e.g., for adrenal insufficiency) are not to exceed 10 mg\/day of prednisone or equivalent.\n12. Corticosteroid premedication for infusion and\/or hypersensitivity reactions.\n13. Receipt of live attenuated vaccine within 28 days of the first dose of Alintegimod.\n14. Serious autoimmune disease at the discretion of the treating Investigator: patients with a history of active serious inflammatory bowel disease (including Crohn's disease and ulcerative colitis) and autoimmune disorders such as rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus or autoimmune vasculitis (e.g., Wegener's Granulomatosis) are excluded from participation in this study\n15. Active or history of pneumonitis (drug-induced), idiopathic pulmonary fibrosis, Interstitial Lung Disease (ILD), or lung disease that may interfere with assessment of pneumonitis. History of radiation pneumonitis in a previous radiation field is permitted.\n16. Previous participation in a study of any investigational agent within 21 days of enrollment or within 5 half-lives of the study treatment, whichever is the least.\n17. Use of mechanical ventilation or having a resting O2 saturation \\< 90% (on room air) by pulse-oximetry, require renal dialysis, require vasopressors, and\/or severe hepatic sinusoidal obstruction syndrome.\n18. Proven or suspected ongoing systemic infection requiring IV antibiotics.\n19. Women who are pregnant or lactating.\n\n    Note: Women of childbearing potential (WOCBP) must have a \"negative\" serum pregnancy test within 1 week prior to treatment. Non-childbearing potential is defined as 1 of the following:\n    * i. Postmenopausal with \\> 1 year since last menses and:\n    * 1. If \\< 65 years old, follicle-stimulating hormone (FSH) \\> 40 mIU\/mL.\n    * 2. If \u2265 65 years old and not on hormone replacement therapy (HRT), FSH \\> 30 mIU\/mL.\n    * 3. If \u2265 65 years old and on HRT, the FSH requirement is not applicable. Postmenopausal females on HRT will be allowed if HRT has been stable for \u2265 6 months prior to dosing of study drug(s).\n    * ii. Written medical documentation of being sterilized (e.g., hysterectomy, double oophorectomy, bilateral salpingectomy) with the procedure performed \u2265 6 months prior to dosing study drug(s).\n\n    Note: Tubal ligation is not considered a form of permanent sterilization.\n20. Psychiatric illness\/social circumstances that would limit compliance with study requirements and substantially increase the risk of adverse events or have compromised ability to provide written informed consent.\n21. Patients who have had allogeneic tissue or solid organ transplantation. Prior T cell therapy is allowed\n22. Use of biotin (i.e., Vitamin B7) or supplements containing biotin higher than the daily adequate intake of 30 \u00b5g (NIH-ODS 2022; Section 5.9.2.1).88 Note: Patients who switch from a high dose to a dose of \u226430 \u00b5g\/day are eligible for study entry.\n23. Any condition that in the opinion of the investigator may compromise patient's participation in the trial.\n24. Active peptic ulcer disease or gastritis, active diverticulitis, or other serious gastrointestinal disease associated with diarrhea within the past 2 years before the start of therapy or GI disease which affects oral drug absorption.\n25. Patients with known soy allergy.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06362369003","EMAIL":[{},{}],"GEO":[29.76328,-95.36327]},{"TITLE":"A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","CRITERIA":"Inclusion Criteria:\n\n* Projected life expectancy of at least 12 weeks.\n* Participants must have c-Met overexpressing non-small cell lung cancer (NSCLC) as assessed by an AbbVie designated immunohistochemistry (IHC) laboratory using the VENTANA MET (SP44) RxDx assay.\n* Archival or fresh tumor material must be submitted for assessment of c-Met levels during the Pre-Screening period. Tumor material from the primary tumor site and\/or metastatic sites are allowed.\n\n  * If a participant was prescreened for Study M14-239 but did not enroll, tumor material previously submitted for Study M14-239 may be used for Study M18-868 Pre-Screening upon confirmation from AbbVie that sufficient evaluable tumor material is available (Except China).\n* A histologically or cytologically documented non-squamous cell NSCLC that is locally advanced or metastatic.\n* A known epidermal growth factor receptor (EGFR) activating mutation status.\n* Actionable alterations in genes other than EGFR .\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n* An Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.\n* Have received no more than 1 line of prior systemic cytotoxic chemotherapy in the locally advanced or metastatic setting.\n\n  * Neoadjuvant and adjuvant systemic cytotoxic chemotherapy will count as a prior line for eligibility purposes if progression occurred within 6 months of the end of therapy.\n* Have progressed on at least 1 line of prior therapy for locally advanced\/metastatic NSCLC:\n\n  * Participants WITHOUT an actionable gene alteration: must have progressed on (or be considered ineligible for) platinum-based chemotherapy and immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy).\n  * Participants WITH an actionable gene alteration for which immune checkpoint inhibitor therapy is not standard of care (e.g., anaplastic lymphoma kinase \\[ALK\\] translocation): must have progressed on (or be considered ineligible for) anti-cancer therapy targeting driver gene alterations and platinum-based chemotherapy.\n\n    * Participants with actionable gene alterations for which immune checkpoint inhibitor is standard of care must have also progressed on (or be considered ineligible for) immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy).\n* Must be considered appropriate for docetaxel therapy based on the assessment of the treating physician.\n* Participants with metastases to the central nervous system (CNS) are eligible only after adequate treatment (such as surgery, radiotherapy, or drug therapy) is provided and:\n\n  * They are asymptomatic and off or on a stable or reducing dose of systemic steroids (on no more than 10 mg per day \\[QD\\] prednisone or equivalent) and\/or anticonvulsants for at least 2 weeks prior to randomization.\n\nExclusion Criteria:\n\n* Evidence of new, untreated CNS metastases.\n* Evidence of leptomeningeal disease.\n* Participants with adenosquamous or neuroendocrine histology, nor sarcomatoid features.\n* Actionable epidermal growth factor receptor (EGFR) activating mutations.\n* Participants who have received prior c-Met-targeted antibodies, prior telisotuzumab vedotin, or prior antibody-drug conjugates either targeting c-Met or consisting of monomethylauristatin E..\n* Participants who have received prior docetaxel therapy.\n* A history of other malignancies except:\n\n  * Malignancy treated with curative intent and with no known active disease present for \\>=2 years before the first dose of study drug and felt to be at low risk for recurrence by investigator.\n  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n  * Adequately treated carcinoma in situ without current evidence of disease.\n* A history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. A history of prior radiation pneumonitis in the radiation field (fibrosis) is permitted.\n* Unresolved or neuroendocrine histology, nor sarcomatoid features adverse event (AE) \\>= Grade 2 from prior anticancer therapy, except for alopecia or anemia. Participants with hormone deficiencies caused by prior anticancer therapy who are asymptomatic and on a stable dose of replacement hormone are eligible for study.\n* Major surgery within 21 days prior to randomization.\n* Clinically significant condition(s) as listed in the protocol.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04928846269","EMAIL":"abbvieclinicaltrials@abbvie.com","GEO":[53.48095,-2.23743]},{"TITLE":"Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT","CRITERIA":"Inclusion Criteria:\n\n1. Age \u2265 18 years\n2. Patients with ECOG performance status of 0-2\n3. Patients with pathologically proven diagnosis of NSCLC\n4. Patients with positive oncogene mutation status (EGFR\/ALK)\n5. Patients with radiologically confirmed parenchymal brain metastases\n6. Patients with asymptomatic Synchronous or Metachronous brain metastases\n7. Patients willing for written informed consent and must be willing to comply with the specified follow-up schedule\n\nExclusion Criteria:\n\n1. Patients with CSF dissemination only without any parenchymal brain metastases\n2. Patients with brain metastases in the brain stem\n3. Patients with prior history of radiation therapy to the brain\n4. Patient not suitable for TKI therapy as per the medical oncologist\n5. Pregnant or lactating females","SEX":"ALL","AGE_MIN":18,"AGE_MAX":99,"SS_ID":"05236946001","EMAIL":[{"email":"aniltibdewal@gmail.com"},{}],"GEO":[19.07283,72.88261]},{"TITLE":"Identification and Characterisation of Sleep Disorders in a Population of Patients With Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Patient aged 18 and over.\n* Being monitored and treated for non-small cell lung cancer.\n* With or without ongoing cancer-specific treatment. With no neurocognitive impairment (MoCA test score \u226526\/30).\n* With a clinically assessed life expectancy of more than 3 months (Royal Marsden Hospital 0-1) and general health (ECOG \\<2).\n* Able to understand the study documents written in French\n* Able to complete the study questionnaires written in French.\n* Contactable by telephone throughout the study\n* Affiliated to a social security scheme or entitled beneficiary\n* Not opposed to taking part in the study\n\nExclusion Criteria:\n\n* Patient refusing to take part in the study\n* With a mental illness of the psychosis type monitored and treated prior to the study\n* Patient under guardianship or curatorship\n* Patient under court protection","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06495346001","EMAIL":[{"email":"laurent.calvel@chru-strasbourg.fr"}],"GEO":[48.58392,7.74553]},{"TITLE":"SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.","CRITERIA":"Inclusion Criteria:\n\n1. Voluntarily sign the informed consent and follow the requirements of the protocol;\n2. Male or female;\n3. Age: \u2265 18 years;\n4. Expected survival time \u2265 3 months;\n5. Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) confirmed by histopathology and\/or cytology, T790M-negative, Exon20ins mutation resistant to the third generation EGFR TKI after the first or second line treatment, or resistance to the first or second generation TKI after the first line treatment;\n6. Consent to provide an archived tumor tissue specimen or fresh tissue sample (an FFPE block or approximately 6-12 white slides with a size of 5\u03bcm) from the primary or metastatic tumor within 6 months of the date of consent. Participants who were unable to provide tumor tissue samples could be enrolled if they met other inclusion and exclusion criteria after evaluation by investigators.\n7. Must have at least one measurable lesion as defined by RECISTv1.1;\n8. Performance status score ECOG0 or 1;\n9. Toxicity from previous antineochemical therapy has returned to grade 1 or less as defined by NCI-CTCAE v5.0 (asymptomatic laboratory abnormalities such as elevated ALP, hyperuricemia, elevated serum amylase\/lipase, and elevated blood glucose were considered by the investigator, and toxicity with no safety risk was judged by the investigator; Except for alopecia, grade 2 peripheral neurotoxicity, and hypothyroidism stable with hormone replacement therapy).\n10. No severe cardiac dysfunction, left ventricular score \u2265 50%;\n11. The level of organ function must meet the following criteria:\n\n    1. Bone marrow function: Absolute neutrophil count (ANC) \u2265 1.5 \u00d7 10\\^9\/L, platelet count \u2265 80 \u00d7 10\\^9\/L, hemoglobin \u2265 90 g\/L;\n    2. Liver function: TBIL \u2264 1.5ULN (total bilirubin \u2264 3ULN for subjects with Gilbert's syndrome, liver cancer or liver metastases); AST and ALT \u2264 2.5ULN for subjects without liver metastases; AST and ALT \u2264 5.0ULN for subjects with liver metastases;\n    3. Renal function: creatinine (Cr) \u2264 1.5ULN, or creatinine clearance (Ccr) \u2265 50 mL\/min (according to CockcroftandGault formula).\n12. Coagulation function: international normalized ratio (INR) \u2264 1.5 \u00d7 ULN, and activated partial thromboplastin time (APTT) \u2264 1.5ULN;\n13. Urine protein \u2264 2 + (measured by dipstick) or \\< 1000 mg\/24 h (urine);\n14. Premenopausal women of childbearing potential must have a negative serum or urine pregnancy test 7 before starting treatment and must be non-lactating; all patients (male or female) should take adequate barrier contraception measures throughout the treatment cycle and 6 months after the end of treatment.\n\nExclusion Criteria:\n\n1. Gene sequencing showed that there were MET, ALK, RET, HER2 and other driver gene mutations related to the occurrence and development of tumors.\n2. Patients with prior systemic chemotherapy as part of first - or second-line systemic therapy;\n3. Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, and major surgery were used within 4 weeks before the first dose, and palliative radiotherapy, targeted therapy (including small molecule tyrosine kinase inhibitors), and other anti-tumor treatments were used within 2 weeks before the first dose.\n4. The history of severe heart disease within the past six months was screened, such as symptomatic congestive heart failure (CHF) \u2265 grade 2 (CTCAE v5.0), New York Heart Association (NYHA) \u2265 grade 2 heart failure, acute coronary syndrome, etc.\n5. Prolonged QT interval (QTc \\> 450 msec in men or QTc \\> 470 msec in women), complete left bundle branch block, atrioventricular block III degree;\n6. Active autoimmune and inflammatory diseases, such as systemic lupus erythematosus, psoriasis requiring systemic treatment, rheumatoid arthritis, inflammatory intestinal diseases and Hashimoto's thyroiditis, etc., excluding type I diabetes mellitus, hypothyroidism that can be controlled only by replacement therapy, and skin diseases without systemic treatment (such as vitiligo and psoriasis);\n7. Other malignant tumors diagnosed within 5 years before the first dose of treatment, except those with radical basal cell carcinoma, squamous cell carcinoma of the skin, and\/or radical resection in situ carcinoma considered by investigators to be eligible;\n8. Hypertension poorly controlled by two antihypertensive drugs (systolic blood pressure \\>150 mmHg or diastolic blood pressure \\>100 mmHg);\n9. Pulmonary disease grade \u22653 was defined according to CTCAE v5.0, including dyspnea at rest, or requiring continuous oxygen therapy, or a history of interstitial lung disease (ILD).\n10. There were symptoms of active central nervous system metastasis. However, patients with stable parenchymal metastases could be enrolled, and whether they were stable was defined by the investigators.\n11. Patients with a history of allergy to the recombinant humanized or human-mouse chimeric antibody or to SI-B001 or any of the excipients of the chemotherapeutic agents used in this trial;\n12. A history of autologous or allogeneic stem cell transplantation;\n13. The cumulative dose of anthracyclines in previous (new) adjuvant therapy was \\> 360 mg\/m\\^2;\n14. Human immunodeficiency virus antibody (HIVAb) positive, active tuberculosis, active hepatitis B virus infection (HBV-DNA copy number \\> 10\\^4) or hepatitis C virus infection (HCV-RNA \\> the lower limit of detection in the research center);\n15. Active infections requiring systemic therapy, such as severe pneumonia, bacteremia, sepsis, etc.;\n16. Received other unmarketed investigational drugs or treatments within 4 weeks before study enrollment;\n17. Other conditions for trial participation were not considered by the investigator to be appropriate","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05020769003","EMAIL":[{"email":"zhangli6@mail.sysu.edu.cn"}],"GEO":[25.28194,110.28639]},{"TITLE":"A Real World Study of Camrelizumab in the Treatment of Advanced Non-squamous Non-small-cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* 1) Histopathological diagnosis of non-squamous non-small cell lung cancer; 2) EGFR gene mutation negative and ALK negative, and did not receive systematic chemotherapy; 3) Older than 18 years of age; 4) Pathological stage IIIB or IV; 5) ECOG (Eastern Oncology Collaboration group) score 0-1; 4) Ecg and liver and kidney function are normal; 6) No second primary tumor disease or serious complications.\n\nExclusion Criteria:\n\n* 1) Patients with lung squamous cell carcinoma diagnosed by histopathology; (2) Patients with serious cardiovascular disease, active gastrointestinal bleeding, obvious coagulopathy, complicated with other malignant tumors, and drug allergy were excluded; 3) Patients with poor treatment compliance and incomplete case data.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":100,"SS_ID":"05387512001","EMAIL":[{"email":"tina2951@sina.com"}],"GEO":[32.03028,120.87472]},{"TITLE":"Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\nPart 1:\n\n* Histologically or cytologically confirmed locally advanced, recurrent or metastatic NSCLC and have received available standard of care therapy.\n* There is no limit on the number of prior therapies that can have been received.\n\nPart 2:\n\nCohort A:\n\n* Have histologically or cytologically confirmed locally advanced, recurrent (and not a candidate for curative therapy), or metastatic non-squamous NSCLC.\n* Tumor sample with high cMET expression by IHC confirmed by central laboratory testing.\n\nCohort B:\n\n* Have histologically or cytologically confirmed locally advanced, recurrent (and not a candidate for curative therapy), or metastatic non-squamous NSCLC.\n* Tumor sample with intermediate cMET expression by IHC confirmed by central laboratory testing.\n\nCohort C:\n\n* Have histologically or cytologically confirmed locally advanced, recurrent (and not a candidate for curative therapy), or metastatic squamous NSCLC.\n* Tumor sample with cMET overexpression by IHC confirmed by central laboratory testing.\n\nCohort D:\n\n* Have histologically or cytologically confirmed locally advanced, recurrent (and not a candidate for curative therapy), or metastatic NSCLC.\n* Tumor sample that does not meet cMET IHC entry criteria for Cohorts A-C\n* Known MET amplification or exon 14 skipping mutations respectively. Patients with MET exon 14 skipping mutations must have received MET TKI therapy if available and considered standard of care.\n\nCohort E:\n\n* Have histologically or cytologically confirmed locally advanced, recurrent (and not a candidate for curative therapy), or metastatic NSCLC.\n* Evidence of cMET expression by IHC as documented in medical records.\n* No more than 3 prior lines of systemic therapy including prior cMET targeted ADC or antibody.\n\nPart 2 Cohorts A-D\n\n- No more than two prior lines of therapy in the locally advanced\/metastatic setting.\n\nPart 2 Cohorts A-E:\n\n* Known to not have an actionable EGFR mutation. Patients with or without other driver mutations are permitted to enroll.\n* Patients without any actionable gene alteration: must have progressed on (or be considered ineligible for) standard of care therapy\n* Patients with actionable gene alterations (other than EGFR) must have progressed on (or be considered ineligible for) or be intolerant to anti-cancer therapy targeting driver gene alterations and available standard of care therapy\n\nAll patients (Part 1 and Part 2)\n\n* Patient has at least one measurable lesion per RECIST 1.1\n* ECOG performance status 0 or 1\n* For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective method of birth control for the duration of the study treatment and for at least 6 months after the last dose of study drug.\n* Able to provide informed consent, and willing and able to comply with study protocol requirements\n\nExclusion Criteria:\n\n* Radiation to the lung within 2 months prior to screening.\n* Major surgery within 28 days of first dose of study drug administration.\n* Untreated, uncontrolled CNS metastases.\n* History of interstitial lung disease or pneumonitis that required treatment with systemic steroids or evidence of active interstitial lung disease or pneumonitis. A history of prior radiation pneumonitis in the radiation field (fibrosis) is permitted.\n* Clinically significant systemic illness that could pose undue risk to the subject or confound the ability to interpret study results.\n* Active infection requiring IV antibiotics, antivirals, or antifungal medication\n* Neuropathy \\> Grade 1\n* History of cirrhosis, hepatic fibrosis, esophageal or gastric varices, or other clinically significant liver disease.\n* Active or chronic corneal disorder","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05652868034","EMAIL":[{"email":"trialadminhub@oncology.ox.ac.uk"},{}],"GEO":[51.75222,-1.25596]},{"TITLE":"Efficacy and Safety of PVT-1 Treatment in Patients With Advanced Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\nFemale or male with age \\> 18 years' old Personally signed and dated informed consent that indicating that the participant ( or a legal representative) has been informed of all aspects of the study Histologically or cytologically confirmed non-small cell lung cancer(NSCLC) NSCLC patients who are not suitable for surgery or radical radiotherapy or chemotherapy, or who have failed to or are intolerable for standard treatment in local advanced or metastatic NSCLC Diagnosis of a metastatic or locally advanced NSCLC with molecular profile EGFR (-), ALK (-) and ROS-1 (-), refractory to existing treatments Evidence of disease radiological measurable. Defined as at least one target lesion that can be accurately measured by imaging, at least one dimension as \u226520 mm with conventional computed tomography (CT), \u226510 mm with spiral CT scan (\u226515mm for lymph node) Absence of untreated or symptomatic brain metastases or that requires the use of steroids.\n\nLife expectancy of at least three months in the opinion of investigators ECOG performance status of 0-1 Time since last treatment received: 3 weeks from last QT cycle or 6 weeks if nitrosiureas, at least 2 weeks from the last RT session before the first administration of study drug (The administration of palliative radiotherapy for bone pain is allowed by any time)\n\nLaboratory results required at the screening visit:\n\nNeutrophils\\> 1500 \/ mm3 Haemoglobin\\> 9.0g \/ dl Platelets\\> 100,000 \/ mm3 Total bilirubin \\<1.5 times above the normal ranges Transaminases: AST, ALT \\<2 times above the normal ranges, If there are liver metastases \\<5 times above normal values.\n\nSerum creatinine \\<1.5 times above the normal ranges Female participants childbearing potential, must have a negative pregnancy test\n\nExclusion Criteria:\n\nPregnant female patients, Breastfeeding female patients Patients unable to meet the requirements (inclusion criteria) of the study Know hypersensitivity, history of allergic or anaphylactic reaction to the drug.\n\nECOG performance status \u22652 Any acute, chronic or psychiatric medical condition or laboratory abnormality that may increase the risk associated with the participation or PVT-1 administration in the study or may interfere with interpretation of the results, and in judgment of the investigator, would make the participant inappropriate for entry into this study.\n\nCurrent history of alcoholism or drug addiction to DSM-IV criteria within 12 months prior to screening.\n\nPatients with major organ dysfunctions and heart disease Patients with active tuberculosis Participation in any other clinical studies (phases I - IV) within 1 month or 5 half-lives, or participation in any clinical study of drugs that could present interaction within 1 year of screening visit.\n\nSubjects who are directly involved in the conduct of the study, and their family members, site staff members supervised by study investigators.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04840004004","EMAIL":"sahin.lacin@yeditepe.edu.tr","GEO":[41.27976,36.3361]},{"TITLE":"A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy","CRITERIA":"Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group performance status of 0 or 1\n* Histological or cytological diagnosis of Stage IIB, IIIA, and select IIIB NSCLC of either non-squamous or squamous histology\n* Participants must have had complete resection of NSCLC\n* Participants must have received between one to four cycles of adjuvant histology-based platinum doublet chemotherapy\n* Participants must have recovered adequately from surgery and from adjuvant chemotherapy\n* Tumor cell PD-L1 expression at \\>\/= 1%\n* Adequate hematologic and end-organ function.\n\nExclusion Criteria:\n\n* Any history of prior NSCLC within the last 5 years\n* Any evidence of residual disease or disease recurrence following surgical resection of NSCLC, or during or following adjuvant chemotherapy\n* NSCLC known to have mutation in the EGFR gene or an ALK fusion oncogene","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06267001142","EMAIL":"global-roche-genentech-trials@gene.com","GEO":[39.91987,32.85427]},{"TITLE":"A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)","CRITERIA":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of an advanced, unresectable and\/or metastatic non-haematologic malignancy. Patient must show presence of at least one measurable lesion according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.\n* Eastern Cooperative Oncology Group (ECOG) score of 0, 1 or 2 (ECOG=2 only for Cohorts 6 and 7) .\n* Availability and patient willingness to provide a sample of tumour for confirmation of the patient\u00b4s Human epidermal growth factor receptor 2 (HER2) status. This sample can be archival material obtained at any time prior to study enrollment.\n* Patient willing and able to comply with the protocol requirements for tumour biopsies (biopsies from brain metastases are not allowed).\n* Adequate organ function defined as all of the following:\n\n  * Absolute neutrophil count (ANC) \u2265 1.5 x 10\\^9\/L (\u2265 1.5 x 10\\^3\/\u03bcL) (\u2265 1500\/mm\\^3); haemoglobin \u2265 9.0 g\/dL (\u2265 90 g\/L) (\u2265 5.6 mmol\/L); platelets \u2265 100 x 10\\^9\/L (100 x 10\\^3\/\u03bcL) (100 x 10\\^3\/mm3) without the use of hematopoietic growth factors within 4 weeks of start of trial medication.\n  * Total bilirubin \u2264 1.5 times the upper limit of normal (ULN), except for patients with Gilbert's syndrome: total bilirubin \u2264 3 x ULN or direct bilirubin \u2264 1.5 x ULN.\n  * Estimated Glomerular Filtration Rate (eGFR) \u2265 50 mL\/min - calculated using Chronic Kidney Disease Epidemiology (CKD-EPI) formula.\n  * Aspartate transaminase (AST) and alanine transaminase (ALT) \u2264 3 x ULN if no demonstrable liver metastases, or otherwise \u2264 5 x ULN if transaminase elevation is attributable to liver metastases.\n  * Alkaline Phosphatase \\< 5 x ULN.\n* Recovered from any previous therapy-related toxicity to \u2264 Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 at start of treatment (except for alopecia, stable sensory neuropathy and hypothyroidism (patients on thyroid replacement therapy) which must be \u2264 CTCAE Grade 2)\n* Life expectancy of at least 12 weeks at the start of treatment in the opinion of the investigator.\n* At least 18 years of age at the time of consent or over the legal age of consent in countries where that is greater than 18 years.\n* Signed and dated written informed consent in accordance with International Council on Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.\n* Male or female patients. Women of childbearing potential (WOCBP)1 and men who are able to father a child must be ready and able to use highly effective methods of birth control per International Council on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly.\n\nAdditional inclusion criteria for Phase Ia\n\n* Patients with a documented diagnosis of HER2 aberration: overexpression OR gene amplification OR non-synonymous somatic mutation OR gene rearrangement involving HER2 or Neuregulin 1 (NRG1)\n* Patient who has failed conventional treatment or for whom no therapy of proven efficacy exists or who is not eligible for established treatment options. Patient must have exhausted, or not be a suitable candidate for, available treatment options known to prolong survival for their disease\n\nAdditional inclusion criteria for Phase Ib - Cohort 1 only\n\n* Non-squamous non-small cell lung cancer (NSCLC) patients with documented human epidermal growth factor receptor 2 (HER2) mutation in the tyrosine kinase domain (TKD) as per local lab results.\n* Patient who had received, in the advanced\/metastatic setting, at least one line of systemic therapy. Patients with non-squamous NSCLC harboring additionally genomic aberrations for which approved targeted therapy is available as standard of care.\n\nAdditional inclusion criteria for Phase Ib - Cohort 2 only\n\n* Non-squamous NSCLC patient with a documented HER2 mutation in the tyrosine kinase domain (TKD) as per local lab results.\n* Treatment na\u00efve for non-squamous NSCLC.\n\nAdditional inclusion criteria for Phase Ib - Cohort 3 only\n\n* NSCLC Patient with a documented HER2 mutation outside of the tyrosine kinase domain (TKD) as per local lab results or squamous NSCLC patient with mutation in the TKD as per local lab results.\n* Patient who had received, in the advanced\/metastatic setting, at least one line of systemic therapy. Patients with NSCLC harboring additionally genomic aberrations for which approved targeted therapy is available as standard of care.\n\nAdditional inclusion criteria for Phase Ib - Cohort 4 only\n\n* NSCLC patients with documented HER2 mutation in the TKD as per local lab results.\n* NSCLC patients who are either treatment na\u00efve or who had received any prior line of treatment, in the advanced\/metastatic setting. Patients with NSCLC harboring additional genomic aberrations for which approved targeted therapy is available as standard of care.\n* Patient with active brain metastases who are not eligible for immediate local therapy, as per investigator evaluation.\n\nAdditional inclusion criteria for Phase Ib - Cohort 5 only\n\n* Non-squamous NSCLC patients with documented HER2 mutation in the TKD as per local lab results.\n* Patient should have received, in the advanced\/metastatic setting, at least one line of systemic therapy that includes a platinum-based combination chemotherapy and should have been treated with previous HER2 directed antibody-drug conjugates (ADC) in the same advanced\/metastatic setting and developed disease progression recurrence during or after completing this therapy. Patients with NSCLC harboring additional genomic aberrations for which approved targeted therapy is available as standard of care.\n\nAdditional inclusion criteria for Phase Ib - Cohort 6 only\n\n* Non-squamous NSCLC Patient with documented HER2 mutation in the TKD as per local lab results.\n* Patient who had received, in the advanced\/metastatic setting, at least one line of systemic therapy.\n* Patient without active brain metastases or patient with active brain metastases who are not eligible for immediate local therapy, as per investigator evaluation.\n* Patient who is not eligible for any other recruiting cohort.\n\nAdditional inclusion criteria for Phase Ib - Cohort 7 only\n\n* Non-squamous NSCLC patient with documented HER2 mutation in the TKD as per local lab results.\n* Patient who had received, in the advanced\/metastatic setting, at least one line of systemic therapy.\n* Patient without active brain metastases or patient with active brain metastases who are not eligible for immediate local therapy, as per investigator evaluation.\n* Patient who is not eligible for any other recruiting cohort.\n\nExclusion Criteria:\n\n* Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to first trial treatment or planned within 6 months after screening\n* Previous or concomitant malignancies other than the one treated in this trial within the last 2 years, except;\n\n  * effectively treated non-melanoma skin cancers\n  * effectively treated carcinoma in situ of the cervix\n  * effectively treated ductal carcinoma in situ\n  * other effectively treated malignancy that is considered cured by local treatment.\n* Treatment with a systemic anti-cancer therapy or investigational drug within 21 days or 5 half-lives (whichever is shorter) of the first treatment with the study medication\n* Patients who must or wish to continue the intake of restricted medication or any drug considered likely to interfere with the safe conduct of the trial\n* Previous treatment with zongertinib. For Phase Ib only: Previous treatment with any HER2 targeted treatment.\n* Radiotherapy within 2 weeks prior to first study treatment, except palliative radiotherapy to regions other than the chest, which is allowed up to 1 week prior to first study treatment.\n\nFurther exclusion criteria apply","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04886804074","EMAIL":[{"email":"sverige@bitrialsupport.com"}],"GEO":[59.33258,18.0649]},{"TITLE":"ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)","CRITERIA":"Inclusion Criteria:\n\n* Age \u2265 18 years\n* Able to understand the written informed and able to give informed consent\n* Locally advanced or metastatic NSCLC with oncogenic driver mutation\n* Treatment with TKI according to standard of care\n\nExclusion Criteria:\n\n* Unable to draw blood for study purposes","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05221372001","EMAIL":[{"email":"a.dingemans@erasmusmc.nl"}],"GEO":[51.9225,4.47917]},{"TITLE":"Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)","CRITERIA":"Inclusion Criteria:\n\n1. Histological or cytological confirmed NSCLC:\n\n   * Stage IV NSCLC OR\n   * Stage III NSCLC not suitable for surgery or radiochemotherapy OR\n   * Recurrent NSCLC after previous surgery (not amendable for curative multimodal therapy)\n2. ALK-rearrangement\n3. Adequate organ function to tolerate alectinib and clinical tolerance to alectinib\n4. Stable disease (SD) or partial response (PR) after 2-3 months induction treatment with alectinib\n5. Maximum 5 tumour lesions +\/- thoracic lymph nodes active on an 18F-FDG-PET scan post induction treatment with alectinib\n6. All active tumour lesions amendable to RT under the following conditions:\n\n   * All metastases possible to treat with\n\n     * Extracranial metastases: SBRT of at least 7 Gy x 5 (corresponding to 50 Gy EQD2 using alfa\/beta 10Gy)\n     * Intracranial metastases: SRS or f-SRS\n   * The primary tumour and\/or lymph nodes and\/or pulmonary metastases amendable to SBRT (\u2265 7Gy x 5, see above) or moderately hypofractionated RT of 3 Gy x 15 (corresponding to 49 Gy EQD2 using alfa\/beta 10Gy)\n7. Adequate organ function to tolerate SBRT\/RT:\n\n   * Fulfilment of dose constraints to adequate organs at risk\n8. ECOG performance status (PS) 0-2\n9. FEV1 \u22651 litre (only applicable for lung targets)\n10. Age \u2265 20 years\n11. Measurable lesions according to RECIST v 1.1\n12. Signed written informed consent\n\nExclusion Criteria:\n\n1. Leptomeningeal carcinosis (on MRI or in cerebrospinal fluid (CSF))\n2. Persistent malignant pleural effusion, malignant pericardial effusion or malignant ascites after induction treatment\n3. PD after 2-3-month-induction treatment with alectinib\n4. Previous TKI, chemotherapy or immunotherapy (previous adjuvant chemotherapy for early stage NSCLC is allowed) for metastatic NSCLC\n5. Previous RT for NSCLC (any stage)\n6. Previous RT for any other cancer within the last 3 years possibly interfering with the planned RT within this study\n7. Life expectancy of less than 6 months\n8. Inability to understand given information or undergo study procedures according to protocol.\n9. Has evidence or a past medical history of interstitial lung disease or active, non-infectious pneumonitis or known pulmonary fibrosis.\n10. Pregnant or breast-feeding. Patients must agree to use safe contraception during and for 3 months after study treatment.","SEX":"ALL","AGE_MIN":20,"AGE_MAX":200,"SS_ID":"05724004001","EMAIL":[{"email":"katja.tobin@regionstockholm.se"},{},{}],"GEO":[59.33258,18.0649]},{"TITLE":"A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Patients should understand, sign, and date the written informed consent form prior to screening.\n2. Male or female aged 18 years or older.\n3. Patients with histologically or cytologically confirmed locally advanced (and not a candidate for definitive therapy) or metastatic NSCLC.\n4. Cohort-specific inclusion criteria:\n\n   1. For the escalation part (except for the RDE confirmation part), patients have progressed on, rejected, or are intolerant of standard therapy, or for whom no standard therapy exists\n   2. For RDE confirmation in the escalation part: same as Cohort 1 in the expansion part\n   3. For the expansion part, patients have documented EGFR in-frame exon 20 insertion mutations confirmed by certificated local laboratories; and must also meet all criteria for the cohort in which their entry is proposed.\n5. Patients must have at least one measurable target lesion according to RECIST v1.1\n6. ECOG performance status 0 or 1\n7. 7. Life expectancy \u22653 months\n8. Adequate organ function and bone marrow function.\n9. Electrolyte: magnesium within 0.85 to 1.25 \u00d7 institutional normal limits, sodium \u2265130 mmol\/L, potassium within institutional normal limits\n10. Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP \u2264150\/90 mmHg at screening and no change in antihypertensive medications within 1 week prior to the Cycle1 Day1.\n11. For patients participating in food effect exploration part:\n\n    1. Be able to eat a standardized high-fat meal within 30 minutes\n    2. Be able to fast for 10 hours.\n12. Non-surgically sterilized male or female patients of childbearing potential must agree to use highly effective methods of birth control during the study treatment and for approximately 6 months after the last dose of study drug. A condom is also required to be used by vasectomized men to prevent delivery of the drug via seminal fluid.\n\nExclusion Criteria:\n\n1. Known allergy or hypersensitivity to any component of the investigational product.\n2. NSCLC patients with EGFR Cys797Ser (C797S) mutation.\n3. Cohort-specific exclusion criteria.\n4. Have been diagnosed with another primary malignancy other than NSCLC except for adequately treated non-melanoma skin cancer or cervical cancer in situ; definitively treated non-metastatic prostate cancer; or patients with another primary malignancy who are definitively relapse-free with at least 3 years elapsed since the diagnosis of the other primary malignancy.\n5. Unable to swallow capsules or malabsorption syndrome, disease significantly affecting GI function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction, or current evidence of GI disease that present with diarrhea. If any of these conditions exist, the sites' staff should discuss with the sponsor to determine patient eligibility.\n6. Previous anti-cancer therapy, including chemotherapy, radiotherapy, molecular targeted therapy, antibody therapy or other investigational drugs received \u22644 weeks prior to initiation of study treatment.\n7. Major surgery within 4 weeks prior to the first dose of study drug. Or any surgical wound is infected, dehisced, or not completely healed before the screening.\n8. Prior toxicities from chemotherapy, radiotherapy, and other anti-cancer therapies, including immunotherapy that have not regressed to Grade \u22641 severity (CTCAE v5.0) with the exception of which eligibility criteria allows, or alopecia, vitiligo, hypothyroidism stable on hormone replacement, or Grade 2 peripheral neurotoxicity.\n\n   Note: Refer to inclusion criteria regarding hypertension.\n9. Potent moderate and strong inhibitors or inducers of CYP3A family within 2 weeks before the first dose of study treatment (3 weeks for St John's Wort); consumption of grapefruit juice, grapefruit hybrids, pomegranates, starfruits, pomelos, seville oranges or juice products within 3 days prior to the first dose of study treatment.\n10. Have current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging) or leptomeningeal disease (symptomatic or asymptomatic).\n11. Impaired cardiac function or clinically significant cardiac disease.\n12. Known acquired immunodeficiency syndrome (AIDS)-related illness, or positive test for HIV 1\/2 antibody.\n13. Exclusion of hepatitis infection based on the following results and\/or criteria:\n\n    1. Active hepatitis B infection: positive tests for hepatitis B surface antigen (HbsAg), or antibody to hepatitis B core antigen (anti-HBc). A patient with positive tests for HbsAg or anti-HBc but with HBV-DNA measurements lower than detectable can be enrolled.\n    2. Active hepatitis C infection: positive Hepatitis C virus antibody. If positive antibody to hepatitis C Virus (anti-HCV) is detected, Hepatitis C virus RNA by polymerase chain reaction (PCR) is necessary. A patient with positive anti-HCV but with a negative test for HCV RNA can be enrolled.\n14. Patients with ascites or pleural effusion, or pericardial effusion which is refractory\/uncontrolled, or requiring the intervention within 2 weeks prior to the first dose.\n15. Current evidence of radiation pneumonitis that required steroid treatment or unresolved drug-related pneumonitis, or current evidence or history of interstitial lung disease (ILD).\n16. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test within 7 days prior to the start of study drug.\n17. Vaccination with a live, attenuated vaccine within 4 weeks prior to the first dose of study treatment except for administration of inactivate vaccines (e.g., COVID-19 vaccines, inactivated influenza vaccines).\n18. Current evidence or previous history of corneal pathology such as keratopathy, corneal abrasion or ulceration, or any other abnormal changes that may increase the risk of corneal toxicity during the study treatment\n19. Any other clinically significant comorbidities, such as uncontrolled pulmonary disease, active infection, or any other condition, which in the judgment of investigators, could compromise compliance with the protocol, interfere with the interpretation of study results, or predispose the patient to safety risks.\n20. Planned major surgery during study treatment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06225804012","EMAIL":[{},{}],"GEO":[31.22222,121.45806]},{"TITLE":"Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer With Osimertinib Third-line Rechallenge","CRITERIA":"Inclusion Criteria:\n\n* Provision of informed consent prior to any study specific procedures\n* Male or female patients of at least 18 years of age\n* Pathologically proven advanced non-small cell lung cancer (i.e. stage M1 (metastasis), or earlier stages if unfit or unsuitable for radical treatment). Patients must have a tissue diagnosis of lung cancer, either by histology or cytology, however, in the event that there is insufficient tissue for molecular analysis, mutations identified in circulating tumor deoxyribonucleic acid (ctDNA) analysis will be permitted.\n* Patients must have a known activating Epidermal Growth Factor Receptor (EGFR) mutation. Atypical Epidermal Growth Factor Receptor (EGRF) mutations are allowed. Atypical mutations may require sponsor approval. Exon 20 insertions will not be allowed.\n* Patients must have an Eastern Cooperative Oncology Group\/World Health Organisation Performance Status (ECOG\/WHO-PS) of 0-3 and an expectation that they could potentially receive second-line chemotherapy\n* Patients must have an expected life expectancy of at least 12 weeks\n* Female subjects should be using highly effective contraceptive measures, and must have a negative pregnancy test and not be breast-feeding prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:\n\n  * Post-menopausal defined as aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments\n  * Women under 50 years old are consider postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and with Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) levels in the post-menopausal range for the institution\n  * Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation\n* Male subjects should be willing to use barrier contraception\n* Additional Criteria for patients enrolling after first-line progression and prior to second-line chemotherapy::\n* Subjects must have complete baseline demographic data available (age at diagnosis of metastatic non-small cell lung cancer, ethnicity, smoking status, sex, history of brain metastasis) and the following must be available (if applicable):\n\n  o Date of first dose of osimertinib, date that first-line osimertinib was permanently discontinued, date of first-line progression.\n* Additional Criteria for patients enrolling at the time of third-line osimertinib rechallenge:\n* Subjects must have complete baseline demographic data available (age at diagnosis of metastatic non-small cell lung cancer (NSCLC), ethnicity, smoking status, sex, history of brain metastasis) and the following must be available (if applicable):\n\n  o Date of first dose of osimertinib, date that first-line osimertinib was permanently discontinued, date of first-line progression, date second-line chemotherapy was started, which platinum chemotherapy was given, if pemetrexed maintenance was given, date that second-line chemotherapy was permanently stopped, and date of progression on second-line treatment.\n* Patients must have received platinum\/ pemetrexed chemotherapy in the second-line chemotherapy\n* Subjects must have measurable disease defined as at least one measurable lesion that can be accurately assessed by Computerized Tomography (CT) or Magnetic Resonance Imaging (MRI) at baseline and follow up visits.Subjects must have measurable disease defined as at least one measurable lesion that can be accurately assessed by Computerized Tomography (CT) or Magnetic Resonance Imaging (MRI) at baseline and follow up visits.\n\nExclusion Criteria:\n\n* Involvement in the planning and\/or conduct of the study (applies to both Investigator staff and\/or involved staff at the study site).\n* A second invasive malignancy in the previous three years, other than localized non-melanoma skin cancer, which might be confused with the Epidermal Growth Factor Receptor (EGFR) mutated lung cancer.\n* Any other serious and uncontrolled medical or psychiatric condition which would likely interfere in the conduct of the study.\n* Pregnancy or lactation\n* Treatment with an investigational drug within five half-lives of the compound or 3 months, whichever is greater.\n* Currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inducers of Cytochrome P450 3A4 (CYP3A4) (at least 3 weeks prior). All patients must try to avoid concomitant use of any medications, herbal supplements and\/or ingestion of foods with known inducer effects on Cytochrome P450 3A4 (CYP3A4).\n* Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatment, with the exception of alopecia and grade 2, prior platinum-therapy-related neuropathy.\n* Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.\n* Patients with spinal cord compression, symptomatic and unstable brain metastases except for those patients who have completed definitive therapy and have had a stable neurological status for at least 2 weeks after completion of definitive therapy. Patients may be on corticosteroids to control brain metastases if they have been on a stable dose for 2 weeks (14 days) prior to the start of study treatment and are clinically asymptomatic.\n* Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib.\n* Past medical history of Interstitial Lung Disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.\n* Inadequate bone marrow reserve or organ function (as demonstrated by any of the following laboratory values: absolute neutrophil count less than1.5 x 10 to the power of 9\/L, platelet count less than 100 x 10 to the power of 9\/L, haemoglobin less than 90 g\/L), alanine aminotransferase greater than 2.5 times upper limit of normal (ULN) if no demonstrable liver metastases or greater than 5 times ULN in the presence of liver metastases; aspartate aminotransferase greater than 2.5 times ULN if no demonstrable liver metastases or greater than 5 times ULN in the presence of liver metastases; total bilirubin greater than 1.5 times ULN if no liver metastases or greater than 3 times ULN in the presence of documented Gilbert's Syndrome \\[unconjugated hyperbilirubinaemia\\] or liver metastases; serum creatinine greater than 1.5 times ULN concurrent with creatinine clearance less than 50 mL\/min \\[measured or calculated by Cockcroft and Gault equation\\]-confirmation of creatinine clearance is only required when creatinine is greater than 1.5 times ULN.\n* History of hypersensitivity to any of the active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib.\n* Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.\n* Previous adjuvant cytotoxic chemotherapy within the 6 months prior to enrollment.\n* Previous adjuvant anti programmed cell death protein 1(anti-PD-1) or anti programmed death-ligand 1 (anti-PD-L1) therapy within 90 days prior to enrollment.\n* For patients enrolling prior to first-line treatment with osimertinib:\n* Any previous systemic therapy for Epidermal Growth Factor Receptor mutated (EGFR+) advanced Non-Small Cell Lung Cancer (aNSCLC).\n* Any of the following cardiac criteria:\n\n  * Mean resting corrected QT interval (QTc) greater than 470 msec obtained from 3 electrocardiograms (ECGs), using the screening clinic ECG machine derived QTc value\n  * Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block and second degree heart block.\n  * Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, electrolyte abnormalities \\[including serum\/plasma potassium less than the Lower Limit of Normal (LLN), serum\/plasma magnesium greater than the Lower Limit of Normal (LLN), serum\/plasma calcium less than the Lower Limit of Normal (LLN)\\], congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes.\n* For patients enrolling after progression on first-line osimertinib and prior to second-line chemotherapy all patients must have:\n* Received osimertinib in the first-line and no other systemic therapy for their Epidermal Growth Factor Receptor mutated (EGFR+) Advanced Non-Small Cell Lung Cancer (aNSCLC).\n* For patients enrolling at the time of third-line osimertinib rechallenge all patients must have:\n* Received osimertinib in the first-line followed by second-line platinum (carboplatin\/cisplatin) with pemetrexed (pemetrexed maintenance is permitted), and no other systemic therapy for their Epidermal Growth Factor Receptor mutated (EGFR+) advanced Non-Small Cell Lung Cancer.\n* Received a minimum of 1 dose of platinum (carboplatin\/cisplatin) with pemetrexed.\n\n  * AND\n* At least 90 days have lapsed since the last dose of first-line osimertinib.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04335292010","EMAIL":[{}],"GEO":[43.70011,-79.4163]},{"TITLE":"The Beneficial Value of PET\/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients","CRITERIA":"Eligible for this study are patients with stage III NSCLC (8th edition TNM Classification) who (are about to) start(ed) follow-up care (which may include adjuvant treatment) at a participating hospital. Patients may already be included during their curative intent treatment. Patients enter a screening period that runs until their randomization.\n\nInclusion Criteria:\n\nTo be eligible to participate in this study, a subject must meet all of the following criteria at the timing of randomization:\n\n* Cytological or histologically proven stage III non-small cell lung cancer before start of curative intent treatment\n* Treated with curative intent and started follow-up care\n* All adjuvant treatments are permitted as co-intervention during follow-up care\n* Age 18 years or older\n* ECOG Performance Status classification 0-2 at moment of inclusion\n* Written and signed informed consent by the patient or patient's representative (with the understanding that consent may be withdrawn by the patient or patient's representative at any time without consequences to future medical care)\n\nExclusion Criteria:\n\nA potential subject who meets any of the following criteria will be excluded from participation in this study:\n\n* Life expectancy shorter than 6 months at the end of curative intent treatment\n* Evidence of recurrence after end of curative intent treatment and before randomization (4 months follow-up)\n* Any condition that, in the opinion of the investigator, would interfere with evaluation of the intervention or interpretation of HRQOL or other study results.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06082492016","EMAIL":[{},{}],"GEO":[52.09083,5.12222]},{"TITLE":"Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Lung tumors will be \u2264 5 cm and centrally located, meaning any portion of gross tumor volume located within 2 cm of (but not abutting) the proximal bronchial tree (trachea, carina, right and left main bronchi, right and left upper lobe bronchi, bronchus intermedius, right middle lobe bronchus, lingular bronchus, right and left lower lobe bronchi), or within 2 cm of (whether abutting or not) major vessels, esophagus, or heart (based on RTOG and MD Anderson Cancer Center definitions 33,34). Multiple concurrent isocenters are allowed if at least one tumor meets the above criteria, and if all dose constraints for the plan summation can be met. These concurrent tumors other than study target lesion can be treated as per SOC and does not necessarily have to meet the above size limit. The PI will review and prospectively approve any lesions abutting these organs\n* ECOG Performance Status of 0-2\n* Age \\> 18\n* Patients must sign a study-specific consent form.\n\nExclusion Criteria:\n\n* prior history of radiotherapy near target lesion resulting in overlapping treatment fields. Previously irradiated will be defined as organ at risk (OAR) structures in the receiving the following doses ( in \\<3 Gray (Gy) per fraction): Spinal cord previously irradiated to \\> 40 Gy, Brachial plexus previously irradiated to \\> 50 Gy, Small intestine, large intestine, or stomach previously irradiated to \\> 45 Gy, Brainstem previously irradiated to \\> 50 Gy, Lung previously irradiated with prior V20Gy \\> 35%.\n* No active systemic, pulmonary, or pericardial infection\n* No interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung\n* No significant cardiac disease, including the following: unstable angina, New York Heart Association class II-IV congestive heart failure, myocardial infarction within six months prior to study enrollment\n* May not be pregnant or lactating\n* No other medical condition or reason that, in the opinion of the investigator, would preclude study participation","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04210492001","EMAIL":[{"email":"Jennifer.Pope@yale.edu"}],"GEO":[41.30815,-72.92816]},{"TITLE":"Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study","CRITERIA":"Inclusion Criteria:\n\n* 18\uff0cPathologically proven Non squamous non small cell lung cancer\n\n  * No-drive gene mutaion (EGFR\u3001ALK\u3001ROS1\uff09 by NGS\n  * Progress after second line\n  * PS score 0-2\n\nExclusion Criteria:\n\n* Patients received second line treatment\n* Patients received treatment of Anlotinib or Docetaxel\n* Patients with contraindication of chemotherapy\n* Pregnant or breast feeding women","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03646968001","EMAIL":[{"email":"zhangyongchang@csu.edu.cn"},{"email":"zhangyongchang@csu.edu.cn"},{}],"GEO":[28.19874,112.97087]},{"TITLE":"Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Subject aged between 19-80 at the time of signing the informed consent form, male or female.\n2. Histologically or cytologically confirmed non-squamous non-small cell lung cancer (NSCLC), Stage IIIB-IV (as per the International Association for the Study of Lung Cancer (IASLC) Staging Handbook in Thoracic Oncology, 8th Edition).\n3. The site must provide documented information on EGFR mutation and ALK translocation and both must be negative. Subject cannot be randomized before receiving the source document for EGFR mutation and ALK translocation.\n4. A tumor tissue specimen collected upon or after diagnosis of advanced or metastatic disease, either fresh or archival (within 6 months prior to the first dose), must be provided. At least 10 unstained slides can be generated from the formalin fixed, paraffin-embedded (FFPE) tumor tissue block for immunohistochemistry assay or biomarker testing (or may be less than 10 slides as approved by the sponsor's medical monitor). Specimen obtained from fine needle aspiration, pleural fluid smear, or drill biopsy are unacceptable. For bone lesions, specimen without soft tissue components or decalcified bone tumor specimen is also unacceptable.\n5. Subjects who have not previously received systemic chemotherapy for advanced\/metastatic NSCLC. Chemotherapy as neo-adjuvant\/adjuvant therapy or chemoradiotherapy is permitted, as long as the treatment has been completed at least 12 months before the diagnosis of advanced or metastatic disease.\n6. Radiographically measurable lesions via CT or MRI, as per RECIST 1.1. The tumor assessment of baseline should be performed within 28 days prior to the first dose.\n7. ECOG PS score: 0-1.\n8. Expected survival \u2265 3 months.\n9. Subjects must undergo all screening laboratory tests as per the protocol within 14 days prior to the first dose. Laboratory tests at screening must meet the following criteria:\n\n1) Hematology: (without blood transfusion, G-CSF, or medication within 14 days prior to screening)\n\n1. Hemoglobin (HB) \u2265 90 g\/L;\n2. Absolute neutrophil count (ANC) \u2265 1.5 x 109\/L;\n3. Platelet (PLT) \u2265 100 x 109\/L;\n4. White blood cell (WBC) \u2265 4.0 x 109\/L and \u2264 15 x 109\/L; 2) Biochemistry: (no blood or albumin transfusion within 14 days prior to screening)\n5. AST and ALT \u2264 1.5 x ULN (\u2264 5 x ULN for liver metastasis);\n6. ALP \u2264 2.5 x ULN (\u2264 5 x ULN for bone metastasis);\n7. TBIL \u2264 1.5 x ULN;\n8. ALB \u2265 30 g\/L;\n9. Cr \u2264 1.5 x ULN, and creatinine clearance (CrCL) \u2265 60 mL\/min (Cockcroft-Gault equation);\n10. APTT \u2264 1.5 x ULN, and INR or PT \u2264 1.5 x ULN (no anticoagulant therapy).\n\n    10. Female subjects of childbearing potential must have a negative serum pregnancy test within 3 days prior to the first dose. Female subjects of childbearing potential and male subjects with partners of childbearing potential must agree to use adequate method of contraception during the study period and 180 days after the last dose of study medication.\n\n    11. Subject has voluntarily agreed to participate by giving written informed consent\/assent.\n\n    Exclusion Criteria:\n\n    1. Exclusion criteria for the target indication\n    1. Subjects with other histological types besides non-squamous non-small cell lung cancer, including mixed carcinomas or NSCLC with small cell lung cancer components\/neuroendocrine differentiation.\n    2. Subjects with EGFR mutation or ALK translocation.\n    3. Subjects without radiographically measurable lesions.\n    4. Subjects with carcinomatous meningitis and spinal cord compression.\n    5. Subjects with untreated central nervous system (CNS) metastasis. Subjects with previously treated CNS metastases may participate if the CNS metastasis is limited to the supraentorial and cerebellar regions, adequately treated, and clinically stable (by radiological tumor assessments, preferably enhanced MRI or CT) for at least 4 weeks, and if the subject's neurological symptoms can return to NCI-CTCAE Grade \u2264 1 within 2 weeks prior to the first dose. In addition, subjects who are using corticosteroids for clinical symptoms are not eligible, unless the doses of corticosteroids stable or gradually reduced to prednisone \u2264 10 mg\/day (or equivalent) -for at least 2 weeks.\n    6. Subjects who can be treated with surgical resection or radical radiotherapy.\n    7. Subjects who previously received treatment with any other anti-PD-1(L1) or CTLA4 monoclonal antibodies.\n\n    2. Medical history and complications\n    1. Subjects with any active, known, or suspected autoimmune diseases. Subjects who are clinically stable and do not require systemic immunosuppressants, such as those with Type I diabetes, hypothyroidism requiring only hormone replacement therapy, or skin diseases that do not require systemic treatment (for example, vitiligo, psoriasis or alopecia), or subjects in whom recurrence are not expected without external triggers may be eligible.\n    2. Subjects with any complication that require systemic corticosteroids like prednisone (\\> 10 mg\/day or equivalent) or other immunosuppressants within 14 days prior to the first dose. In the absence of active autoimmune disease, inhaled or topical use of corticosteroids, and physiologic hormone replacement therapy for adrenal insufficiencylike prednisone \\> 10 mg\/day or equivalent are permitted;\n    3. Subjects who received cancer vaccines or other immunostimulatory anti-cancer agents (interferon, interleukin, thymosin, or immune cell therapy) within 1 month prior to the first dose.\n    4. Subjects who are currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks (or 5 half-lives of the previous investigational agent) prior to the first dose.\n    5. Subjects who are expected to require any other forms of anti-cancer treatment (including maintenance treatment with other drugs, radiotherapy, and\/or surgical resection) for NSCLC while on study.\n    6. Subjects who received major surgery within 4 weeks prior to the first dose, non-thoracic radiation therapy \\> 30 Gy within 4 weeks prior to the first dose, thoracic radiation therapy \\> 30 Gy within 24 weeks prior to the first dose, or palliative radiation \u2264 30 Gy within 2 weeks prior to the first dose, and failed to recover from the toxicities and\/or complications of these interventions to NCI-CTC AE Grade \u2264 1 (except for alopecia and fatigue). Palliative radiotherapy for symptomatic control is permitted, but must be completed within 2 weeks prior to the first dose and no additional radiotherapy should be scheduled for the same lesion.\n    7. Subjects highly suspected of interstitial lung disease, or with conditions that may interfere with the testing or management of suspected treatment-related pulmonary toxicities, or other moderate to severe lung diseases that seriously affect pulmonary function.\n    8. Subjects who require concomitant treatment for other active malignant tumors.\n    9. Subjects with a history of prior malignant tumors, except for basal cell carcinoma, superficial bladder cancer, squamous cell carcinoma of the skin, or cervical carcinoma in situ with complete remission for at least 5 years prior to screening and no additional treatment is required or expected while on study.\n    10. Subjects with Grade II or higher myocardial ischemia or myocardial infarction, or poorly controlled arrhythmias. Subjects with NYHA Class III-IV cardiac insufficiency or an LVEF (left ventricular ejection fraction) \\< 50% by echocardiography.\n    11. Subjects with significant hemoptysis or coughing a daily volume up to half a teaspoon (2.5 mL) or more of blood within 1 month prior to randomization.\n    12. Subjects with clinically significant hemorrhage or clear bleeding tendency within 1 month prior to randomization, such as GI bleeding, hemorrhagic gastric ulcer, or vasculitis.\n    13. Events of arterial\/venous thrombosis within 3 months prior to randomization, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, brain infarction), deep vein thrombosis, and pulmonary embolism.\n    14. Subjects with active pulmonary tuberculosis (TB). Active TB should be ruled out in subjects suspected of such condition, by chest X-ray, sputum test, and examinations of clinical symptoms and signs. Subjects with a history of active TB infection within 1 year prior to the screening are excluded, despite being treated. Subjects with a history of active TB infection more than 1 year ago can be enrolled if the course and type of TB treatment are appropriate.\n    15. Subjects with serious infection within 4 weeks prior to the first dose, including but not limited to infective complications, bacteremia and severe pneumonia that require hospitalization. Subjects with any active infections are excluded, lymphangitic spread of the NSCLC is not exclusionary.\n    16. Subjects who prepare to receive or have previously received tissue\/organ transplants.\n    17. Subjects who plan to receive or have received live vaccines within 30 days prior to the first dose.\n    18. Subjects with contraindications for platinum-based medications before the first dose: gout, varicella, herpes zoster, and Grade \u2265 2 peripheral neuropathy.\n    19. It is not recommended to enroll subjects with uncontrolled tumor-related pain. Subjects requiring pain medication must have a stable regimen before randomization. Palliative radiotherapy for symptomatic lesions (such as bone metastasis or perineural invasion) should be completed at least 2 weeks before enrollment. Loco-regional treatment should be considered before randomization, if appropriate, for asymptomatic metastatic lesions where further growth may result in functional deficits or intractable pain (e.g., epidural metastasis without spinal cord compression).\n\n    3. Physical examination and laboratory tests\n    1. Subjects have known history of human immunodeficiency virus (HIV) seropositive status or acquired immunodeficiency syndrome (AIDS).\n    2. Subjects with untreated active hepatitis. Hepatitis B: Hepatitis B surface antigen (HBV sAg) positive and HBV DNA greater than the upper limit of normal; Hepatitis C: HCV antibody (HCV Ab) positive and HCV RNA positive, and abnormal hepatic function; Hepatitis B and C coinfection.\n    3. Subjects with uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.\n\n    4. Allergies and adverse drug reactions\n    1. Severe allergic, anaphylactic, or other hypersensitivity reactions to other monoclonal antibodies.\n    2. Allergy or intolerance during an infusion.\n    3. History of severe allergies to pemetrexed, carboplatin, or their premedications.\n\n    5. Subjects with mental illness, alcohol abuse, inability to quit smoking, and drug or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n\n    6. Based on the investigator's opinion, subjects with a history or current evidence of any condition, diseases, treatments, or laboratory abnormalities that may confound the study results, interfere with study procedures, or are not in the best interests of the subjects, should be excluded.","SEX":"ALL","AGE_MIN":19,"AGE_MAX":80,"SS_ID":"05841472007","EMAIL":[{}],"GEO":[35.34199,129.03358]},{"TITLE":"Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) \u226550% (MK-3475-D46)","CRITERIA":"Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has a histologically or cytologically confirmed diagnosis of metastatic non-small cell lung cancer (NSCLC)\n* Has confirmation that epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase 1 (ALK-1), or ROS proto-oncogene 1 (ROS-1)-directed therapy is not indicated as primary therapy\n* Has provided tumor tissue that demonstrates PD-L1 tumor proportion score (TPS) \u226550% of tumor cells as assessed by immunohistochemistry (IHC) at a central laboratory\n* Has a life expectancy of at least 3 months\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years\n* Has received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC\n* Has previously received treatment with Topoisomerase 1 inhibitors or Trop-2 targeted therapy\n* Has received prior therapy with an anti-programmed cell death 1 protein (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), or anti anti- programmed cell death ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor\n* Has received prior radiotherapy within 2 weeks of start of study intervention or has radiation-related toxicities requiring corticosteroids\n* Has received radiation therapy to the lung that is \\>30 Gray (Gy) within 6 months of the first dose of study intervention\n* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention\n* Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration\n* Has cardiac disease\n\n  * Myocardial infarction or unstable angina pectoris within 6 months of enrollment\n  * History of serious ventricular arrhythmia, high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications; history of QT interval prolongation\n  * New York Heart Association (NYHA) Class III or greater congestive heart failure or left ventricular ejection fraction of \\<40%\n* Has active chronic inflammatory bowel disease\n* Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication\n* Has known active central nervous system (CNS) metastases and\/or carcinomatous meningitis\n* Has severe hypersensitivity (\u2265Grade 3) to pembrolizumab or sacituzumab govitecan and\/or any of their excipients\n* Has active autoimmune disease that has required systemic treatment in past 2 years except replacement therapy\n* History of (noninfectious) pneumonitis\/interstitial lung disease that required steroids or has current pneumonitis\/interstitial lung disease\n* Has active infection requiring systemic therapy\n* Has history of human immunodeficiency virus (HIV) infection\n* History of hepatitis B or known active hepatitis C virus infection\n* Has history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator\n* Have not adequately recovered from major surgery or have ongoing surgical complications","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05609968159","EMAIL":[{}],"GEO":[53.37616,-3.10501]},{"TITLE":"Fruquintinib Combined With Sintilimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Voluntary provision of informed consent.\n2. Males or females aged 18-75.\n3. Histological or cytologically confirmed NSCLC, metastatic or non-resectable (stage IIIB-\u2163).\n4. Not suitable for targeted therapy (patients with non-squamous NSCLC have no EGFR, ALK, gene mutation)\n5. At least one lesion can be measured by imaging.\n6. Have not received systemic treatment in the past.\n7. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1.\n8. Life expectancy \u2265 12 weeks.\n9. Female of childbearing age must have a negative pregnancy test (serum or urine) within 7 days before enrolment.\n\nExclusion Criteria:\n\n1. Histological or cytologically confirmed small cell lung cancer (SCLC), including lung cancer mixed with SCLC and NSCLC.\n2. Diagnosed with other malignant diseases other than NSCLC within 5 years.\n3. Have participated in other interventional clinical research treatments now or within 4 weeks.\n4. Have previously received multi-targeted kinase inhibitors therapy.\n5. Have active autoimmune diseases requiring systemic treatment within 2 years.\n6. Received systemic glucocorticoid therapy or immunosuppressive therapy within 2 weeks.\n7. Clinically uncontrollable pleural effusion\/abdominal effusion.\n8. Vaccinated vaccines or attenuated vaccines within 4 weeks before the group;\n9. Pregnant or breastfeeding females.\n10. Other serious hazards to the safety of patients.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"04956146001","EMAIL":[{"email":"mapei@jsph.org.cn"}],"GEO":[32.06167,118.77778]},{"TITLE":"Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer","CRITERIA":"Inclusion criteria Participants with unresectable advanced\/recurrent ALK fusion gene-positive non-small cell lung cancer.\n\nExclusion criteria Participants who has a history of hypersensitivity to any component of birigatinib.","SEX":"ALL","AGE_MIN":0,"AGE_MAX":200,"SS_ID":"05100069001","EMAIL":"medinfoUS@takeda.com","GEO":[35.6895,139.69171]},{"TITLE":"Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy","CRITERIA":"Inclusion Criteria:\n\n* At least one intact brain metastasis or resection cavity \u2265 2 cm in diameter or \u2265 4 cc volume.\n\n  * Patients at initial diagnosis of brain metastases and patients with known brain metastasis treated with systemic therapy alone are eligible.\n  * Patients who have previously undergone SRS for brain metastases are eligible if all MRIs and DICOM-RT files from prior SRS courses are available for upload to TRIAD and there are no lesions requiring re-irradiation. Prior SRS data upload is NOT required prior to enrollment and randomization. Both SSRS and FSRS are acceptable.\n  * Lesion volume will be approximated by measuring the lesion's three perpendicular diameters on contrast-enhanced, T1-weighted MRI and the product of those diameters will be divided by 2 to estimate the lesion volume (e.g., xyz\/2). Alternatively, direct volumetric measurements via slice-by-slice contouring on a treatment planning software package can be used to calculate the total tumor volume.\n  * Any extent of non-CNS disease is allowed. There is no requirement for non-CNS disease to be controlled prior to study entry.\n  * For patients considered to be borderline or potentially eligible by size or volume criteria, sites have the option to send in DICOM films for central review screening.\n* Age \u2265 18 years at the time of enrollment.\n* Total number of brain metastases (including resection cavities) \u2264 15 on diagnostic MRI; all lesions must be amenable to SSRS and FSRS as determined by the treating radiation oncologist. Treatment must take place at a facility credentialed by the Imaging and Radiation Oncology Core (IROC) for SRS and that offers both SSRS and FSRS as treatment options.\n* Total gross tumor volume must be \u2264 30 cc. Lesion volume will be approximated by measuring each lesion's three perpendicular diameters on contrast-enhanced T1 MRI and the product of those diameters will be divided by 2 (V = xyz\/2). Direct volumetric measurements by contouring all lesions on all visible slices on treatment planning software is also acceptable. If there is a cavity, only gross residual disease within or adjacent to the cavity is counted toward the 30 cc total volume.\n* Ability to tolerate MRI brain with gadolinium-based contrast.\n* Pathologically confirmed melanoma, renal cell carcinoma, non-small cell lung cancer, small cell lung cancer, or breast cancer.\n* Has received, is currently receiving, or is planned to receive immune checkpoint inhibitor therapy (defined as agent targeted to PD-1\/PD-L1 axis) within 30 days of the planned first day of SSRS\/FSRS. Dual ICI therapy with PD-1\/PD-L1 and CTLA-4 targeted agents are allowed, but patients treated with a single agent CTLA-4 targeted agent only are ineligible.\n\n  o It is not mandatory to wait for the results of next generation sequencing (NGS) or other molecular tumor testing to determine if the patient is planned to receive ICI if the enrolling physician feels that identification of a mutation that would preclude ICI therapy (such as an EGFR mutation in a patient with NSCLC) is unlikely to be identified.\n* Karnofsky Performance Status (KPS) \u2265 50. Refer to Appendix A.\n* Negative serum or urine pregnancy test within 14 days of randomization for women of child-bearing potential.\n* Ability to understand and the willingness to sign written informed consent.\n* Patients must be able to provide informed consent.\n* Must be able to speak, read and understand English or Spanish\n\nExclusion Criteria:\n\n* Prior fractionated, whole, or partial brain radiation therapy. Prior fractionated SRS is acceptable.\n* Prior courses of SRS for benign tumors such as meningiomas, pituitary adenomas, schwannomas may be acceptable if the treatment is \\> 2cm away from the site of a metastatic lesion that would be treated on this study. The study PI or a designated co-PI must review this type of case to confirm eligibility prior to enrollment.\n* Prior diagnosis ARE, including pseudoprogression or radiation necrosis\/radionecrosis, or previously treated lesions being actively evaluated for possible ARE or local failure such as concerning imaging findings currently being tracked with short interval MRI.\n* Leptomeningeal carcinomatosis established by lumbar puncture cytology, or MRI imaging. In the absence of a clinical indication, a lumbar puncture is not required to confirm eligibility.\n* A brain metastasis that is 5 mm or less from the optic chiasm or optic nerves\n* Inability to tolerate brain MRI or receive gadolinium-based contrast\n* Planned or prior therapy with bevacizumab (or bevacizumab biosimilar) within 30 days of the planned first day of SRS as part of a systemic therapy regimen at study enrollment.\n* Serious intercurrent illness or medical condition judged by the local investigator to compromise the patient's safety, preclude safe administration of the planned protocol treatment, or would not permit the patient to be managed according to the protocol guidelines.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05703269027","EMAIL":[{},{}],"GEO":[44.38358,-89.81735]},{"TITLE":"A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors","CRITERIA":"Key Inclusion Criteria:\n\n* Histologically or cytologically documented locally advanced, unresectable or metastatic solid tumor.\n* Having received and failed or was intolerant to standard of care for advanced disease or not eligible for standard of care therapy with the following tumor types for patients in Phase 1 dose expansion cohorts:\n\n  1. Microsatellite Stable (MSS) CRC (both monotherapy and combination cohorts); no more than 3 lines of prior systemic therapy for metastatic disease.\n  2. H\\&N cancer (combination cohort only); no more than 2 lines of prior systemic therapy for metastatic disease.\n  3. Melanoma (combination cohort only); no more than 3 lines of prior systemic therapy for metastatic disease, including at least 1 prior treatment with a BRAF inhibitor for patients with a BRAF mutation.\n  4. NSCLC (combination cohort only); no more than 2 lines of prior systemic therapy for metastatic disease, including at least 1 prior treatment with a targeted therapy for patients with a mutation such as EGFR, ALK, KRAS, or RET.\n  5. Patients with H\\&N cancer, melanoma, and NSCLC (or additional tumor types that typically respond to PD1\/PD-L1 monotherapy) must have received a prior PD1\/PD-L1 where best response was stable disease and progression occurred during treatment or within 3 months of last dose of PD1\/PD-L1.\n\nAdditional tumor types and doses may be considered.\n\n* Measurable disease\n* ECOG performance status 0 or 1.\n* Life expectancy of \u2265 3 months.\n* Willing to provide pre-treatment (archival or fresh) and on-treatment tumor biopsy samples.\n* Adequate organ function\n* Women of childbearing potential and fertile males with WOCBP partners must use highly effective contraception during the study and for 180 days after the study. Patients must agree not to donate eggs (ova, oocytes) or sperm during the study.\n\nKey Exclusion Criteria:\n\n* Use of anti-PD-1\/PD-L1 targeting monoclonal antibody therapy, monoclonal antibody therapy, chemotherapy, biologic, investigational, or radiotherapy within 2 weeks of Cycle 1 Day 1.\n* Clinically significant unresolved toxicities from prior anticancer therapy.\n* Grade 3 or higher immune-related adverse event on prior PD-1\/PD-L1 blockade or prior agents targeting stimulatory or co-inhibitory T cell receptor.\n* Known other previous\/current malignancy requiring treatment within \u2264 2 years except for limited disease treated with curative intent, such as carcinoma in situ, squamous or basal cell skin carcinoma, or superficial bladder carcinoma.\n* Known asymptomatic or symptomatic brain metastasis or leptomeningeal disease.\n* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.\n* Women who are pregnant or breastfeeding.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05864144006","EMAIL":[{"email":"marie.asay@startthecure.com"}],"GEO":[40.69161,-112.00105]},{"TITLE":"Pre-Operative Immuno-Modulatory SBRT (POIMS Trial): A Pilot Trial in Early Stage NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Stage I-II NSCLC\n* Adequate diagnostic biopsy tissue to allow pre-SBRT tumor analysis\n* Candidate for oncologic surgery (lobectomy or sub lobar resection) for the lung cancer\n* Lesion located peripherally, \u2265 2 cm from bronchial margin, and 1 cm from visceral pleura, with location deemed acceptable by cardio-thoracic surgeon for resection.\n* Adequate pulmonary function test results\n\nExclusion Criteria:\n\n* Prior history of lung\/chest wall surgery\n* Prior chest radiation\n* Prior immunotherapy\n* History of autoimmune disease\n* Currently using immunosuppressive drugs","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05094544001","EMAIL":[{"email":"aschroeder3@kumc.edu"},{}],"GEO":[39.11417,-94.62746]},{"TITLE":"Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer","CRITERIA":"Key Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 2.\n* Have previously untreated and histological examination confirms resectable stage II-IIIA\/IIIB non-small cell lung cancer (according to the 8th edition of the AJCC TNM staging criteria), and the pathological type of squamous cell carcinoma and non-squamous cell carcinoma needs to be distinguished, and EGFR, ALK, and ROS1 should be negative for non-squamous non-small cell lung cancer\n* Adequate organ function and expected survival time \u2265 12 weeks;\n* Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients.\n\nKey Exclusion Criteria:\n\n* Presence of mixed carcinoma component on histology.\n* Patients with other active malignancies within 5 years prior to enrollment.\n* Known active autoimmune diseases.\n* Currently participate in an interventional clinical study treatment or have been treated with another drug or investigational device within 4 weeks prior to the first dose.\n* Use of immunosuppressive agents within 14 days prior to the first dose of study treatment.\n* Presence of other uncontrolled serious medical conditions.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06267144001","EMAIL":[{}],"GEO":[43.88,125.32278]},{"TITLE":"Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1","CRITERIA":"Inclusion Criteria:\n\npatients treated with nivolumab\n\nExclusion Criteria:\n\n* Age \\<18 years\n* Preliminary cardiac disease with FeVG \\<50%\n* Cardiomyopathy dilated, hypertrophic or restrictive\n* History of cardiac arrhythmia\n* History of cardiac toxicity under another anti-cancer treatment\n* Known coronary disease\n* History of stroke less than 3 months old\n* Patient not wishing to participate in the study\n* Vulnerable persons (pregnant women, adults under guardianship or guardianship, persons deprived of their liberty)","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03313544001","EMAIL":[{"email":"jennifer.cautela@ap-hm.fr"},{}],"GEO":[43.29551,5.38958]},{"TITLE":"The Use of Molecular Radiogenomics in Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Age at least 20-years\n* Pathological proven non-small cell lung cancer and received complete staging work-up\n* Pre-treatment pathological specimen of the primary tumor\n\nExclusion Criteria:\n\n* Coexistence of non-aerodigestive tract cancer.\n* Unable to comply to FDG PET\/CT exam or poor image quality\n* Unable to determine the primary tumor","SEX":"ALL","AGE_MIN":20,"AGE_MAX":200,"SS_ID":"05541744001","EMAIL":[{"email":"jedimasterchen@hotmail.com"}],"GEO":[23.97694,121.60444]},{"TITLE":"A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Capable of giving signed informed consent.\n* Has received, been intolerant to, or been ineligible for all treatment options proven to confer clinical benefit.\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.\n* Eastern Cooperative Oncology Group (ECOG) Performance status (PS) of 0 or 1.\n* Adequate renal and liver function.\n* Male individuals and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use methods of contraception.\n* Female participants are eligible if they are not pregnant, not breastfeeding or not a Woman of childbearing potential (WOCBP).\n* Inclusion criterion for the dose-escalation: Individuals with histologically or cytologically confirmed, advanced or metastatic solid tumors.\n* Inclusion criteria for disease-specific combination expansion: Individuals with histologically or cytologically confirmed Triple-negative breast cancer (TNBC), Non-small cell lung cancer (NSCLC), Head and neck squamous cell carcinoma (HNSCC), or melanoma.\n* Inclusion criterion for the monotherapy-MoA expansion: Individuals with histologically or cytologically confirmed NSCLC.\n* Willingness and medical feasibility (as per Investigator assessment) to undergo paired tumor biopsies with a non-significant risk.\n\nExclusion Criteria:\n\n* A known additional malignancy that is progressing or has required active treatment within the past 3 years.\n* Primary central nervous system malignancy.\n* Major surgery \u2264 28 days before start of study treatment.\n* Any unresolved toxicity of Grade \u2265 2, not otherwise specified in other eligibility criteria, from previous anticancer treatment, except for alopecia and skin pigmentation.\n* Uncontrolled intercurrent illness requiring systemic treatment or solid organ transplant.\n* Known hypersensitivity to study treatment or any drugs similar in structure or class, including severe hypersensitivity (\u2265 Grade 3) to pembrolizumab and\/or any of its excipients.\n* Any toxicity (Grade 3 or 4) related to prior immunotherapy leading to prior treatment discontinuation.\n* History of congestive heart failure New York Heart Association (NYHA) \\>II.\n* Medical history of (non-infectious) pneumonitis\/interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically-active pneumonitis\/ILD.\n* HIV-infection with a history of Kaposi sarcoma and\/or Multicentric Castleman Disease.\n* Known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.\n* History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating Investigator.\n* Any other history, condition, therapy, or uncontrolled intercurrent illness which could in the opinion of the Investigator affect compliance with study requirements.\n* New brain metastases on screening brain MRI\/CT; previously treated brain metastases that are progressive at screening or leptomeningeal disease.\n* Prior therapy with a C-C motif chemokine receptor 8 (CCR8) depleting antibody.\n* Prior allogeneic tissue\/solid organ transplant.\n* Radiation therapy to the lung that is \\> 30 Gy within 6 months before the start of study treatment.\n* Diagnosis of immunodeficiency or current chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent).\n* Active autoimmune disease that has required systemic treatment in the past 2 years.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05537740026","EMAIL":"clinical-trials-contact@bayer.com","GEO":[51.35,-0.2]},{"TITLE":"Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Patients with pathologically proven diagnosis of NSCLC\n2. Patients with positive oncogene driver mutation (EGFR or ALK\/ROS)\n3. Patients who have received at least 2-4 months of TKI therapy without progression\n4. Patients with 1-5 sites of metastatic disease not including the primary tumor and regional nodes (less than 3 metastatic lesions in one organ will be eligible and 4 or more metastatic lesions in one organ will be ineligible)\n5. Patients suitable for local consolidative therapy\n6. Adequate end-organ function CBC\/differential obtained within 15 days prior to registration on study, with adequate bone marrow function defined as follows:\n\n   * Absolute neutrophil count (ANC) \u2265 500 cells\/mm3;\n   * Platelets \u2265 50,000 cells\/mm3;\n   * Hemoglobin \u2265 8.0 g\/dl (Use of transfusion or other intervention to achieve Hgb \u2265 8.0 g\/dl is acceptable);\n7. Patients with ECOG performance status of 0-2\n8. Age \\> 18 years\n9. For females of child-bearing potential, negative serum or urine pregnancy test within 14 days prior to study registration\n\nExclusion Criteria:\n\n1. Patients with progressive disease after 2-3 months of initial TKI therapy\n2. Patients with negative oncogene driver mutations (EGFR\/ALK\/ROS)\n3. Patients not suitable for local consolidative radiation therapy\n4. Patients who are not suitable for further continuation of TKI therapy due to toxicity\n5. Severe, active co-morbidity defined as follows:\n\n   * Unstable angina and\/or congestive heart failure requiring hospitalization within the last 6 months;\n   * Transmural myocardial infarction within the last 6 months;\n   * Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration;\n6. Patients with prior history of radiation therapy to thorax\n7. Patients with second malignancy (Synchronous or Metachronous)\n8. Pregnancy","SEX":"ALL","AGE_MIN":18,"AGE_MAX":99,"SS_ID":"05277844001","EMAIL":[{"email":"aniltibdewal@gmail.com"},{}],"GEO":[19.07283,72.88261]},{"TITLE":"Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations","CRITERIA":"Inclusion Criteria:\n\nParticipants eligible for inclusion in the study must meet all inclusion criteria within 28 days of randomization into the study.\n\n* Sign and date the Tissue Screening and Main Informed Consent Forms, prior to the start of any study-specific qualification procedures.\n* Adults \u226518 years or the minimum legal adult age (whichever is greater) at the time of informed consent.\n* Histologically documented NSCLC that meets all of the following criteria:\n\n  1. Stage IIIB or IIIC disease and not candidates for surgical resection or definitive chemoradiation, or Stage IV NSCLC disease at the time of randomization (based on the American Joint Committee on Cancer, Eighth Edition). Participants with early-stage NSCLC who have relapsed should be restaged during screening to ensure their eligibility for the study.\n  2. Documented negative test results for epidermal growth factor receptor (EGFR), lymphoma kinase (ALK), and proto-oncogene1 (ROS1) actionable genomic alterations based on analysis of tumor tissue.\n  3. No known actionable genomic alterations in neurotrophic tyrosine receptor kinase (NTRK), proto-oncogene B-raf (BRAF), rearranged during transfection (RET), mesenchymal-epithelial transition factor (MET), or other actionable driver kinases with locally approved therapies.\n* Has provided a formalin-fixed tumor tissue sample for the measurement of trophoblast cell surface protein 2 (TROP2) protein expression and for the assessment of other exploratory biomarkers.\n* Tumor has high programmed death receptor-1 (PD-L1) expression (TPS \u226550%) as determined by PD-L1 immunohistochemistry (IHC) 22C3 pharmDx assay by central testing (minimum of 6 slides).\n* Has an adequate treatment washout period before Cycle 1 Day 1.\n* Measurable disease based on local imaging assessment using RECIST Version 1.1.\n* Has left ventricular ejection fraction (LVEF) \u226550% by either an echocardiogram (ECHO) or multigated acquisition scan (MUGA) within 28 days before randomization.\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at screening.\n* Has a life expectancy of at least 3 months.\n* Adequate bone marrow function within 7 days before randomization.\n\nExclusion Criteria:\n\n* Has received prior systemic treatment for advanced or metastatic NSCLC.\n* Has received prior treatment for NSCLC with any of the following, including in the adjuvant\/neoadjuvant setting:\n\n  1. Any agent, including an antibody-drug conjugate, containing a chemotherapeutic agent targeting topoisomerase I.\n  2. TROP2-targeted therapy.\n  3. Any anti-programmed death receptor-1 (PD-1), anti-PD-L1, or anti-PD-ligand 2 (L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX40, CD137).\n  4. Any other immune checkpoint inhibitors. Participants who received adjuvant or neoadjuvant therapy OTHER than those listed above, are eligible if the adjuvant\/neoadjuvant therapy was completed at least 6 months prior to the diagnosis of advanced\/metastatic disease.\n* Has spinal cord compression or active and untreated central nervous system (CNS) metastases and\/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable.\n* Has received prior radiotherapy \u22644 weeks of start of study intervention or more than 30 Gy (unit of ionizing radiation dose in the International System of Units) to the lung within 6 months of Cycle 1 Day 1.\n* History of another primary malignancy (beyond NSCLC) except for:\n\n  1. Malignancy treated with curative intent and with no known active disease \u22653 years before the first dose of study treatment and of low potential risk for recurrence.\n  2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n  3. Adequately treated carcinoma in situ without evidence of disease.\n  4. Participants with a history of prostate cancer (tumor\/node\/metastasis stage) of Stage \u2264T2cN0M0 without biochemical recurrence or progression and who in the opinion of the Investigator are not deemed to require active intervention.\n* Has a history of (non-infectious) interstitial lung disease (ILD)\/pneumonitis including radiation pneumonitis that required steroids, has current ILD\/pneumonitis, or where suspected ILD\/pneumonitis cannot be ruled out by imaging at screening.\n* Clinically severe pulmonary compromise, as judged by the investigator, resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, or any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement or prior complete pneumonectomy.\n* Uncontrolled or significant cardiovascular disease, including:\n\n  1. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) interval \\>470 msec regardless of sex (based on the average of the 12-lead electrocardiogram determination at screening).\n  2. Myocardial infarction within 6 months prior to randomization.\n  3. Uncontrolled angina pectoris within 6 months prior to randomization.\n  4. LVEF \\<50% by ECHO or MUGA scan within 28 days before randomization.\n  5. New York Heart Association Class 2 to 4 congestive heart failure (CHF) at screening.\n  6. Uncontrolled hypertension (resting systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg) within 28 days before randomization.\n\nParticipants with a history of Class 2 to 4 CHF prior to screening, must have returned to Class 1 CHF and have LVEF \u226550% (by either an ECHO or MUGA scan within 28 days before randomization) in order to be eligible.\n\n* Clinically significant corneal disease.\n* Has received a live vaccine or live-attenuated vaccine (messenger ribonucleic acid and replication-incompetent adenoviral vaccines are not considered attenuated live vaccines) within 30 days prior to the first dose of study drug. For any participant receiving an approved severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine, please follow the vaccine label and\/or local guidance.\n* Active, known, or suspected autoimmune disease (has an active autoimmune disease that has required systemic treatment in the past 2 years).\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosage \\>10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy \u22647 days prior to the first dose of study drug.\n* Has known human immunodeficiency virus (HIV) infection that is not well controlled.\n* Has an active hepatitis or uncontrolled hepatitis B or active hepatitis C infection.\n* Has an uncontrolled infection requiring IV antibiotics, antivirals, or antifungals.\n* Had an allogeneic tissue\/solid organ transplant.\n* Has a history of severe hypersensitivity reactions to either the drug or inactive ingredients (including but not limited to polysorbate 80) of Dato-DXd or pembrolizumab.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05215340219","EMAIL":[{}],"GEO":[52.9536,-1.15047]},{"TITLE":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)","CRITERIA":"Inclusion Criteria:\n\n* Patients have measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).\n* Patients must have disease with evidence of KRAS G12C mutation in tumor tissue or circulating tumor deoxyribonucleic acid (DNA).\n* Participants must have a histological or a cytologically proven diagnosis of locally advanced, unresectable, and\/or metastatic cancer and meet cohort-specific criteria.\n* Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n* Have adequate organ function.\n* Have discontinued all previous treatments for cancer with resolution of any significant ongoing adverse events (AEs), (except in certain scenarios).\n* Must be able to swallow capsule\/tablet.\n* Agree and adhere to contraceptive use, if applicable.\n* For some parts of the study, (i.e., one of the two arms with LY3537982 in combination with pembrolizumab and the arm of LY3537982 in combination with pembrolizumab, pemetrexed, and platinum therapy) histologically or cytologically confirmed Stage IIIB-IIIC or Stage IV NSCLC that is previously untreated in the advanced\/metastatic setting and not suitable for curative intent radical surgery or radiation therapy. Previously untreated patients who received adjuvant and neoadjuvant therapy are eligible if the last dose of the systemic treatment was completed at least 6 months prior to enrollment. For untreated patients in the arm with LY3537982 in combination with pembrolizumab noted above, a single cycle of pembrolizumab may be initiated within 21 days prior to enrollment. For untreated patients in the arm of LY3537982 in combination with pembrolizumab, pemetrexed, and platinum therapy, a single cycle of any or all of the drugs other than LY3537982 may be initiated within 21 days prior to enrollment. Start of study treatment may be delayed to allow sufficient time for recovery from treatment-related toxicity.\n* For one part of the study, participants must have received at least one prior oxaliplatin- or irinotecan-containing regimen for advanced or metastatic CRC.\n\nExclusion Criteria:\n\n* Disease suitable for local therapy administered with curative intent.\n* Have an active, ongoing, or untreated infection.\n* Have a serious pre-existing medical condition(s) that, in the judgment of the investigator, would preclude participation in this study.\n* Have a serious cardiac condition.\n* Have a second active primary malignancy or have been diagnosed and\/or treated for an additional malignancy within 3 years prior to enrollment.\n* For some parts of the study only: have untreated active central nervous system (CNS) metastases and\/or leptomeningeal disease. Patients with treated CNS metastases are eligible for this study if their disease is asymptomatic, radiographically stable for at least 30 days, and they do not require treatment with steroids in the two-week period prior to study treatment. Patients with active CNS metastases are eligible for one part of the study.\n* Have received prior treatment with any KRAS G12C small molecule inhibitor, except in certain scenarios where such prior therapy is allowed as per protocol.\n* The following patients will be excluded from some parts of the study:\n\n  * Experienced certain serious side effects with prior immunotherapy.\n  * Have an active autoimmune disease that has required systemic anti-autoimmune treatment in the past 2 years.\n  * Have received a live vaccine within 30 days prior to the first dose of study drug.\n* Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial through 180 days after the last dose of study medication.\n* Known allergic reaction against any of the components of the study treatments.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04956640048","EMAIL":[{}],"GEO":[37.566,126.9784]},{"TITLE":"Icotinib for Completed Resected IB NSCLC With EGFR Mutation","CRITERIA":"Inclusion Criteria:\n\n* Written informed consent provided.\n* Males or females, Aged 18-75 years.\n* Able to comply with the required protocol and follow-up procedures, and able to receive oral medications.\n* Had completely resected pathological confirmed stage IIA-IIIA NSCLC.\n* EGFR activating mutation in exon 19 or 21.\n* Patient who can start the investigational therapy within 3-6 weeks after the complete resection.\n* ECOG performance status of 0-1.\n* Had a life expectancy of 12 weeks or more.\n* Adequate hematological function, adequate liver function and renal function.\n* Female patients, except those who are postmenopausal or surgically sterilized, must have a negative pre-study serum or urine pregnancy test.\n\nExclusion Criteria:\n\n* Had had previous chemotherapy, radiotherapy, or agents directed at the HER axis (e.g. erlotinib, gefitinib, cetuximab, trastuzumab).\n* Inability to comply with protocol or study procedures.\n* Had a history another malignancy in the last 5 years with the exception of cured basal cell carcinoma of the skin, cured in situ carcinoma of the uterine cervix and cured epithelial carcinoma of the bladder.\n* Any evidence confirmed tumor recurrence before investigational therapy.\n* Known severe hypersensitivity to icotinib or any of the excipients of this product.\n* Evidence of clinically active interstitial lung disease.\n* Eye inflammation not fully controlled or conditions predisposing the subject to this.\n* Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease).\n* Known human immunodeficiency virus (HIV) infection.\n* Pregnancy or breast-feeding women.\n* Ingredients mixed with small cell lung cancer patients.\n* History of neurologic or psychiatric disorders.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"02264210001","EMAIL":[{"email":"wsysums@163.net"}],"GEO":[23.11667,113.25]},{"TITLE":"A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Diagnosis of stage IV Non-Small Cell Lung Cancer (NSCLC) (histologically or cytologically confirmed stage), without known Epidermal Growth Factor Receptor (EGFR)- or Anaplastic Lymphoma Kinase (ALK)-alterations (according to label approved by EU)\n* Decision to initiate a first-line treatment with nivolumab plus ipilimumab combined with two cycles of chemotherapy for the treatment of NSCLC according to the German label has been made independently of the study\n\nExclusion Criteria:\n\n* Current primary diagnosis of a cancer other than NSCLC that requires systemic or other treatment\n* Participants with known EGFR- or ALK-alterations\n\nOther protocol-defined inclusion\/exclusion criteria apply","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04794010001","EMAIL":[{}],"GEO":[51.33962,12.37129]},{"TITLE":"Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)","CRITERIA":"Inclusion Criteria:\n\n* Participants capable of giving signed informed consent\/assent.\n* Male or female, aged 18 years or older at the time consent is obtained. Participants in Korea must be age 19 years or older at the time consent is obtained.\n* Participants with histologically or cytologically confirmed diagnosis of NSCLC (squamous or non-squamous) and\n\n  a) Documented disease progression based on radiographic imaging, during or after a maximum of 2 lines of systemic treatment for locally\/regionally advanced recurrent, Stage IIIb\/Stage IIIc\/Stage IV or metastatic disease. Two components of treatment must have been received in the same line or as separate lines of therapy: i) No more than or less than 1 line of platinum-containing chemotherapy regimen, and ii) No more than or less than 1 line of Programmed cell death ligand 1 (PD\\[L\\]1) monoclonal antibody (mAb) containing regimen.\n\n  b) Participants with known BRAF molecular alterations must have had disease progression after receiving the locally available SoC treatment for the molecular alteration.\n\n  c) Participants who received prior anti-PD(L)1 therapy must fulfill the following requirements: i) Have achieved a CR, PR or SD and subsequently had disease progression (per RECIST 1.1 criteria) either on or after completing PD(L)1 therapy ii) Have not progressed or recurred within the first 12 weeks of PD(L)1 therapy, either clinically or per RECIST 1.1 criteria\n* Measurable disease, presenting with at least 1 measurable lesion per RECIST 1.1.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1.\n* A tumor tissue sample obtained at any time from the initial diagnosis of NSCLC to time of study entry is mandatory. Although a fresh tumor tissue sample obtained during screening is preferred, archival tumor specimen is acceptable.\n* Adequate organ function as defined in the protocol.\n* A male participant must agree to use a highly effective contraception during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period.\n* A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions apply:\n\n  i) Not a woman of childbearing potential (WOCBP) or ii) A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment.\n* Life expectancy of at least 12 weeks.\n\nExclusion Criteria:\n\n* Participants who received prior treatment with the following therapies (calculation is based on date of last therapy to date of first dose of study treatment):\n\n  1. Docetaxel at any time.\n  2. Any of the investigational agents being tested in the current study.\n  3. Systemic approved or investigational anticancer therapy within 30 days or 5 half-lives of the drug, whichever is shorter. At least 14 days must have elapsed between the last dose of prior anticancer agent and the first dose of study drug is administered.\n  4. Prior radiation therapy: permissible if at least one non-irradiated measurable lesion is available for assessment per RECIST version 1.1 or if a solitary measurable lesion was irradiated, objective progression is documented. A wash out of at least 2 weeks before start of study drug for radiation of any intended use is required.\n* Received greater than (\\>)2 prior lines of therapy for NSCLC, including participants with BRAF molecular alternations.\n* Invasive malignancy or history of invasive malignancy other than disease under study within the last 2 years, except\n\n  * Any other invasive malignancy for which the participant was definitively treated, has been disease-free for at least 2 years and in the opinion of the principal investigator and GlaxoSmithKline Medical Monitor will not affect the evaluation of the effects of the study treatment on the currently targeted malignancy, may be included in this clinical trial.\n  * Curatively treated non-melanoma skin cancer or successfully treated in situ carcinoma.\n* Carcinomatous meningitis (regardless of clinical status) and uncontrolled or symptomatic Central nervous system (CNS) metastases.\n* Major surgery less than or equal to (\\<=) 28 days of first dose of study treatment.\n* Autoimmune disease (current or history) or syndrome that required systemic treatment within the past 2 years. Replacement therapies which include physiological doses of corticosteroids for treatment of endocrinopathies (for example, adrenal insufficiency) are not considered systemic treatments.\n* Receiving systemic steroids (\\>10 milligrams \\[mg\\]) oral prednisone or equivalent) or other immunosuppressive agents within 7 days prior to first dose of study treatment.\n* Prior allogeneic\/autologous bone marrow or solid organ transplantation.\n* Receipt of any live vaccine within 30 days prior to first dose of study treatment.\n* Toxicity from previous anticancer treatment that includes:\n\n  1. Greater than or equal to (\\>=) Grade 3 toxicity considered related to prior immunotherapy and that led to treatment discontinuation.\n  2. History of myocarditis of any grade during a previous treatment with immunotherapy\n  3. Toxicity related to prior treatment that has not resolved to \\<= Grade 1 (except alopecia, hearing loss, endocrinopathy managed with replacement therapy, and peripheral neuropathy which must be \\<= Grade 2).\n* History (current and past) of idiopathic pulmonary fibrosis, pneumonitis (for past- pneumonitis exclusion only if steroids were required for treatment), interstitial lung disease, or organizing pneumonia.\n* Recent history (within the past 6 months) of uncontrolled symptomatic ascites, pleural or pericardial effusions.\n* Recent history (within the past 6 months) of gastrointestinal obstruction that required surgery, acute diverticulitis, inflammatory bowel disease, or intra-abdominal abscess.\n* History or evidence of cardiac abnormalities within the 6 months prior to enrollment which include\n\n  1. Serious, uncontrolled cardiac arrhythmia or clinically significant electrocardiogram abnormalities including second degree (Type II) or third degree atrioventricular block.\n  2. Cardiomyopathy, myocardial infarction, acute coronary syndromes (including unstable angina pectoris), coronary angioplasty, stenting or bypass grafting.\n  3. Symptomatic pericarditis.\n* Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypo-albuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.\n* Active infection requiring systemic therapy \\<=7 days prior to first dose of study treatment.\n* Participants with known human immunodeficiency virus infection.\n* Participants with history of severe hypersensitivity to mAb or hypersensitivity to any of the study treatment(s) or their excipients.\n* Participants requiring ongoing therapy with a medication that is a strong inhibitor or inducer of the cytochrome P 3A4 (CYP3A4) enzymes.\n* Any serious and\/or unstable pre-existing medical (aside from malignancy), psychiatric disorder, or other condition that could interfere with participant's safety, obtaining informed consent, or compliance to the study procedures in the opinion of the investigator.\n* Pregnant or lactating female participants.\n* Participant who is currently participating in or has participated in a study of an investigational device within 4 weeks prior to the first dose of study treatment.\n* Participants with presence of hepatitis B surface antigen (HBsAg) at screening or within 3 months prior to first dose of study intervention.\n* Participants with positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention.\n* Participants with positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study treatment.\n* Receipt of transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including granulocyte colony stimulating factor \\[G-CSF\\], granulocyte-macrophage colony-stimulating factor, and recombinant erythropoietin) within 14 days before the first dose of study intervention.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03739710054","EMAIL":[{"email":"GSKClinicalSupportHD@gsk.com"},{"email":"GSKClinicalSupportHD@gsk.com"},{}],"GEO":[36.72016,-4.42034]},{"TITLE":"KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* At least 18 years of age.\n* Histologically or cytologically confirmed advanced solid tumors\n\n  * Arm #1 (Monotherapy): HRAS-mutant and\/or amplified tumors (any solid tumor type); HRAS overexpression (only for HNSCC tumors); KRAS and\/or NRAS, and\/or HRAS-mutant and\/or amplified NSCLC or CRC; KRAS-mutant and\/or amplified PDAC\n  * Arm #2 (Combination): Must have received at least 1 prior systemic therapy with IO-based treatment for locally advanced or metastatic RCC with predominantly clear cell subtype\n  * Arm #3 (Combination): Must have KRAS G12C-mutant locally advanced or metastatic NSCLC and have received at least 1 prior systemic therapy for advanced or metastatic NSCLC\n* Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n* Karnofsky Performance Status of 70 or higher with no clinically significant deterioration over the previous 2 weeks.\n* Acceptable liver, renal, endocrine, and hematologic function.\n* Other protocol-defined inclusion criteria may apply.\n\nExclusion Criteria:\n\n* Ongoing treatment with certain anticancer agents.\n* Prior treatment with an FTI or HRAS inhibitor.\n* Major surgery, other than local procedures, within 28 days prior to Cycle 1 Day 1, without complete recovery.\n* Spinal cord compression, leptomeningeal disease, or clinically active CNS metastases.\n* Toxicity (excluding alopecia) from prior therapy that has not been completely resolved to baseline at the time of consent.\n* Active or prior documented autoimmune or inflammatory disorders within the past 5 years prior to Cycle 1 Day 1 (with exceptions).\n* Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy.\n* Inability to swallow, impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the trial drugs.\n* Inadequate cardiac and\/or vascular function, including receipt of treatment for unstable angina, myocardial infarction, and\/or cerebro-vascular attack within the prior 6 months, mean QTcF \u2265470 ms, or Class II or greater congestive heart failure.\n* Other invasive malignancy within 2 years.\n* Other protocol-defined exclusion criteria may apply.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06026410010","EMAIL":[{"email":"cancerconnect@uwcarbone.wisc.edu"}],"GEO":[43.07305,-89.40123]},{"TITLE":"Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Fully informed about the study and voluntarily signed an informed consent form (ICF); \u226518 years and \u226475 years;\n2. ECOG score 0-1;\n3. non-small cell lung cancer (NSCLC) confirmed by histology or pathology;\n4. stage IV on imaging assessment;\n5. no EGFR or ALK gene mutations (genetic testing may not be performed in patients with squamous lung cancer);\n6. no previous antitumour treatment for NSCLC No prior antitumour therapy for NSCLC;\n7. lesions suitable for intratumour injection of drugs;\n8. measurable or assessable lesions according to RECIST 1.1 criteria.\n\nExclusion Criteria:\n\n1. histological or cytological pathology of the tumour confirms a combined small cell lung cancer component;\n2. those with tests suggesting severe organ dysfunction;\n3. subjects with any active, known or suspected autoimmune disease are excluded;\n4. expected survival is less than 3 months.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06136910001","EMAIL":[{"email":"liyunmiao462@163.com"},{"email":"2690213099@qq.com"}],"GEO":[26.06139,119.30611]},{"TITLE":"A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. be \u2265 18 years of age on the day of signing of informed consent.\n2. confirmed Stage 4 NSCLC (squamous or non-squamous) and be considered for standard of care.\n3. have confirmation that mutation-directed therapy is not indicated (documentation of absence of tumor activating mutations\/fusions that are approved for first line therapy).\n4. have at least 1 lesion with measurable disease at Baseline according to RECIST 1.1 as determined by the local site Investigator\/radiology assessment.\n5. have not received prior systemic treatment for advanced\/metastatic NSCLC.\n6. have an ECOG Performance Status of 0 to 1.\n7. have adequate organ function.\n\nExclusion Criteria:\n\n1. does not have predominantly squamous cell or non-squamous cell histology NSCLC. Mixed tumors will be categorized by the predominant cell type; if small cell elements are present, the participant is ineligible.\n2. is currently participating in or has participated in a study of an investigational agent and received investigational therapy within 4 weeks or 5 half-lives (whichever is shorter) of administration of EIK1001.\n3. prior to the first dose of EIK1001, has received prior systemic therapy for metastatic disease, or had major surgery (\\< 3 weeks prior to the first dose).\n4. has completed palliative radiotherapy within 7 days of the first dose of study drug administration.\n5. has a known history of prior malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years.\n6. has an active infection requiring therapy.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06246110033","EMAIL":[{"email":"amanda.thompson@usoncology.com"}],"GEO":[39.18566,-78.16333]},{"TITLE":"A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab","CRITERIA":"Inclusion Criteria (Phase 1 and 2 Stages)\n\n1. Histologic or cytologic evidence of a malignant solid cancer (any histology) with advanced or metastatic disease and no available therapies known to confer clinical benefit.\n2. Tumor tissue, or paraffin block, ideally from the patient's most recent biopsy. A fresh tumor biopsy will be obtained if archival samples are not available.\n3. Measurable by Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.\n4. At least 18 years old.\n5. An Eastern Cooperative Oncology Group (ECOG) performance status of \u2264 1.\n6. Adequate hematopoietic, kidney, and liver functions.\n7. A left ventricular ejection fraction (LVEF) \u2265 45%.\n8. Women of childbearing potential (WOCBP) must not be pregnant or breastfeeding. A WOCBP must agree to follow contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment.\n9. Male subjects must agree to follow contraceptive guidance during the study period and for at least 120 days after the last dose of study treatment.\n10. Patient must give informed written consent for the study.\n\nInclusion Criteria for HMBD-002 Phase 2 Stage\n\nTriple Negative Breast Cancer (TNBC)\n\n1. Histologic or cytologic evidence of TNBC that is advanced or metastatic.\n2. Will be requested to undergo a tumor biopsy before treatment and after 6 weeks of treatment.\n3. Must have received appropriate treatment with at least one prior regimen for TNBC and there are no available therapies known to confer clinical benefit.\n\nNon-Small Cell Lung Cancer (Monotherapy and Combination)\n\n1. Histologic or cytologic evidence of NSCLC that is advanced or metastatic.\n2. Will be requested to undergo a tumor biopsy before treatment and after 6 weeks of treatment.\n3. Absence of an activating mutation of the EGFR or ALK.\n4. Must have received treatment with an approved therapy if there are other genomic aberrations for which targeted therapies are approved and available.\n5. Must have had disease progression on at least one approved or comparable standard therapy for NSCLC.\n6. Must have received appropriate prior treatment with a mAb to PD-1 or PD-L1.\n\nMultiple Other Cancers (Combination Therapy Baskets)\n\n1. Histologic or cytologic evidence of an advanced or metastatic cancer aside from TNBC and NSCLC with no available therapies known to confer clinical benefit.\n2. Will be requested to undergo a tumor biopsy before treatment and after 6 weeks of treatment.\n3. Must have had appropriate treatment for their specific cancer and there is an absence of available therapy with a reasonable likelihood of conferring clinical benefit.\n\nExclusion Criteria\n\n1. If the patient received prior therapy with an anti-PD-1 or anti-PD-L1 mAb or with an agent targeting stimulatory or co-inhibitory T-cell receptor and was discontinued from that treatment due to a Grade 3 or higher immune related adverse event.\n2. Received radiotherapy within 2 weeks of treatment.\n3. Received radiotherapy exceeding 30 Gray (Gy) to the lung within 6 months of the first dose of study medication.\n4. Received an allogeneic tissue\/solid organ transplant.\n5. Received a live or live-attenuated vaccine within 30 days prior to the first dose of study medication.\n6. Received a VISTA targeting agent.\n7. The patient must have recovered from all AEs due to previous therapies to \u2264Grade 1 or baseline.\n8. The patient has an active autoimmune disease that required systemic treatment in the past.\n9. Presence of an uncontrolled endocrine disorder.\n10. Presence of clinically significant cardiovascular disease.\n11. History of (non-infectious) pneumonitis or interstitial pulmonary disease that required steroids or has current pneumonitis or interstitial pulmonary disease.\n12. Presence of uncontrolled, clinically significant pulmonary disease.\n13. A previous a severe hypersensitivity reaction (\u2265 Grade 3) to pembrolizumab and\/or any of its excipients.\n14. A diagnosis of immunodeficiency or is receiving chronic systemic corticosteroids at a dose that exceeds 10 mg daily of prednisone equivalent or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug. Inhaled or topical steroids are permitted in the absence of active autoimmune disease.\n15. An uncontrolled intercurrent illness that would limit compliance with the study.\n16. A positive status for human immunodeficiency virus (HIV).\n17. A known history of Hepatitis B (defined as HBsAg reactive) or known active Hepatitis C viral (defined as HCV RNA detected) infection.\n18. Oxygen-dependence.\n19. A medical condition which, in the opinion of the Investigator, places the patient at an unacceptably high risk for toxicity.\n20. A positive COVID test within one week of study treatment if not fully vaccinated.\n21. Another active malignancy that is progressing or has required active treatment within the past 3 years.\n22. Known active central nervous system metastases and\/or carcinomatous meningitis.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05082610006","EMAIL":[{"email":"jrodon@mdanderson.org"},{"email":"umvu@mdanderson.org"}],"GEO":[29.76328,-95.36327]},{"TITLE":"A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Histologically confirmed advanced NSCLC\n2. Positive testing result from any locally approved test (including but not limited to RT-PCR, Cobas and NGS) for EGFR exon 20 insertion mutation\n3. Diagnosis date from 1 Jan 2013 to 31 Dec 2022 (to allow for minimum 12 months of follow-up clinical and treatment outcome data)\n4. Male or female adults, age as defined by local regulations\n\nExclusion Criteria:\n\n1. Patients without an EGFR exon 20 insertion mutation","SEX":"ALL","AGE_MIN":21,"AGE_MAX":99,"SS_ID":"06418412003","EMAIL":[{}],"GEO":[25.04776,121.53185]},{"TITLE":"JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation","CRITERIA":"Inclusion Criteria:\n\n* A signed written informed consent is required before performing any study-related operations\n* Age greater than or equal to 18 years old\n* Histologically or cytologically confirmed locally advanced\/metastatic, unresectable non-squamous NSCLC with KRAS p. G12C mutation confirmed by the central lab\n* No history of systemic anticancer therapy to the local advanced\/metastatic disease\n* Expected survival period greater than or equal to 3 months\n* Having at least one target lesion according to RECIST 1.1\n* Eastern Cooperative Oncology Group (ECOG) \u2264 1\n\nExclusion Criteria:\n\n* Previous (\u22642 years) or current solid tumors or hematologic tumors of other pathological types\n* Carry other driver gene mutations with available target therapy, or carry other KRAS mutations\n* Subjects with untreated central nervous system (CNS) metastases were excluded;\n* Uncontrolled pleural effusion, pericardial effusion, and ascites\n* Subjects with impaired heart function or clinically significant heart disease","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06416410025","EMAIL":"clinicaltrials@jacobiopharma.com","GEO":[36.66833,116.99722]},{"TITLE":"Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy","CRITERIA":"Inclusion Criteria:\n\n* Advanced or metastatic (stage 3 or stage 4) histologically proven NSCLC patients not candidate for curative - intent treatment.\n* Have been previously treated with one prior immunotherapy (i.e. anti-PD1 or anti-PD-L1 antibodies, with or without chemotherapy) for advanced or metastatic NSCLC. Additional systemic treatment lines for metastatic disease are not allowed.\n\n  1. Previous chemotherapy treatment lines administered earlier for non-metastatic disease (adjuvant, neo-adjuvant) are allowed if completed more than six months prior to diagnosis of advanced disease.\n  2. Patients recurring within six months of end of adjuvant\/maintenance immunotherapy (e.g. durvalumab post-chemorads) are eligible for the study if no additional systemic treatment was administered prior to enrollment on the study (this situation is considered equivalent to progression on first-line immunotherapy).\n* Documented radiologic progression on immunotherapy. Minimal treatment time on first-line immunotherapy is 12 weeks. Progressive disease needs to be confirmed by a repeat scan performed at least 4 weeks after the first objective progression.\n* Availability of at least 1 disease site not previously irradiated to serve as a target for radiotherapy. However, a disease site that progressed after having received previously radiotherapy can serve as a radiotherapy target on this trial.\n* Availability of at least 1 measurable lesion not previously irradiated that is not planned to be irradiated during the study and measurable as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.\n* Availability of at least 1 disease site suitable for biopsy procedure (unless the patient has had a biopsy postprogression on immunotherapy), preferably, at site of disease progression on immunotherapy. Fine needle aspirate , ascites or effusion specimens are not acceptable . Selected sites for biopsy can serve afterwards as radiotherapy targets.\n* Patient must have had a treatment free interval of at least 4 weeks from any prior therapy (includes major surgery) before starting of study drugs.\n\nMinor surgical procedures (as defined by the investigator): 7 post-operative days.\n\nPatients who receive palliative radiation for nontarget tumour lesions need a washout period of 7 days.\n\n* Have an ECOG performance status of 0 or 1 and a minimum life expectancy of 12 weeks.\n* Have adequate normal organ and marrow function, including the following:\n\n  1. Absolute neutrophil count \u22651.0 \u00d7 109\/L.\n  2. Platelet count \u2265 75\u00d7 109\/L.\n  3. Haemoglobin \u2265 9.0 g\/dL.\n  4. Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) \u2264 2.5 \u00d7 the upper limit of normal (ULN) if no demonstrable liver metastases or \u2264 5 \u00d7 ULN in the presence of liver metastases.\n  5. Total bilirubin (TBL) \u2264 1.5 \u00d7 ULN or for patients with documented\/suspected Gilbert's disease, bilirubin \u2264 2 \u00d7 ULN.\n  6. Creatinine \u2264 1.5 \u00d7 ULN or creatinine clearance \u2265 40 mL\/min (creatinine clearance can be measured or calculated by Cockcroft and Gault equation; measurement\/calculation is only required when creatinine is \\>1.5 \u00d7 ULN).\n* Body weight \\>30kg\n* Be willing and able to provide written informed consent for the trial prior to any study specific procedures.The subject must also provide consent for correlative translational study.\n* Male or female subjects who are \u2265 18 years of age on the day of signing the informed consent.\n* Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Female subjects of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n  * Women \\<50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n  * Women \u226550 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \\>1 year ago, had chemotherapy-induced menopause with last menses \\>1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).\n* Female subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 180 days after the last dose of study medication.\n* Male subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 180 days after the last dose of study therapy.\n\nExclusion Criteria:\n\n* Progression (as defined by RECIST 1.1) within 12 weeks from initiation of immunotherapy (this criteria aims at exclusion of patients with primary resistance; this study focuses on acquired resistance).\n* Prior exposure to anti CTLA-4, including tremelimumab\n* All potential radiotherapy targets involve high risk of significant toxicity.\n* Mixed response to immunotherapy, where growth occurred only in a single lesion that is amendable to curative-intent radiotherapy (this criteria aims to exclude patients more likely to benefit from targeted radiotherapy to the growing mass and continuation of immunotherapy).\n* Any unresolved toxicity NCI CTCAE Grade \u22652 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria Patients with Grade \u22652 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab or tremelimumab may be included only after consultation with the Study Physician.\n* Any prior immune-related adverse events grade 3 or higher (as per CTCAE version 5.0).\n* Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients\n* Progressing brain metastasis. Stable brain metastasis (based on at least two brain imaging tests with a 4 week interval or more) are allowed (including non-treated lesions) as long as there no requirement for steroids due to the brain spread for \u22654 weeks prior to start of study treatment.\n* History of leptomeningeal carcinomatosis\n* Patients whose tumour samples are known to have activating mutations in the EGFR gene, translocations of the ALK gene, or rearrangement of the ROS1 gene that are indicated for treatment by approved TKI therapy are excluded.\n* Autoimmune or inflammatory disorders requiring systemic treatment during the year prior to study treatment including inflammatory bowel disease \\[eg, colitis or Crohn's disease\\], diverticulitis with the exception of diverticulosis, celiac disease (or other serious gastrointestinal chronic conditions associated with diarrhea), systemic lupus erythematosus, Sarcoidosis syndrome, Wegener syndrome (granulomatosis with polyangiitis), Graves' disease, rheumatoid arthritis, hypophysitis, uveitis. The following are exceptions to this criterion: Patients with vitiglio or alopecia, Patients with hypothyroidism (eg, following Hashimoto syndrome) and stable on hormone replacement not requiring systemic treatment, Psoriasis not requiring treatment. Additional exceptions are any chronic skin condition that does not require systemic therapy and patients with celiac disease controlled by diet alone. Patients without active disease in the last 5 years may be included but only after consultation with the study physician.\n* Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab. The following are exceptions to this criterion: Intranasal, inhaled, or topical steroids, or local steroid injections (e.g., intraarticular injection). Systemic corticosteroids at physiologic doses are allowed up to 10 mg\/day of prednisone or its equivalent. Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication) are allowed.\n* Active infection with hepatitis B (known positive HBV surface antigen\\[HBsAg\\] result), hepatitis C or tuberculosis. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg are eligible.Patients positive for hepatitis C (HCV) antibody are eligible only if the polymerase chain reaction is negative for HCV RNA. Tuberculosis clinical evaluation includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice.\n* Known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)-related illness.\n* Organ transplanted patients.\n* Any condition that, in the opinion of the Investigator, would interfere with the evaluation of IP or interpretation of patient safety or study results, including, but not limited to, uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness\/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.\n* History of another primary malignancy except for: Malignancy treated with curative intent and with no known active disease \u22653 years before the first dose of IP and of low potential risk for recurrence, Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease, adequately treated carcinoma in situ (breast DCIS, non-invasive cervical cancer, etc.) without evidence of disease. Patients with tumors with a very low risk of metastatic spread and recurrence that were treated successfully with a curative intent (e.g. resected local carcinoid tumor, recected low grade, non-muscle invasive bladder cancer) can be considered for inclusion based on decision of the study physician.\n* Receipt of live attenuated vaccine within 30 days prior to the first dose of study drugs.\n* Have received treatment with an investigational product or nonapproved use of a drug or device within 28 days prior to the initial dose of study drugs, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.\n* Female patients who are pregnant or breastfeeding.","SEX":"ALL","AGE_MIN":0,"AGE_MAX":200,"SS_ID":"05000710001","EMAIL":[{"email":"bar.jair@gmail.com"}],"GEO":[32.08227,34.81065]},{"TITLE":"Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Stage IV or recurrent\/metastatic non-squamous NSCLC that harbors an EGFR activating mutation (Exon 21 L858R, Exon 19 deletion, Exon 18 G719X, Exon 21 L861Q, etc). Local testing for EGFR mutations is acceptable provided it was performed in a CLIA certified lab.\n* Part I: Progressive disease on at least one prior EGFR TKI\n* Part II, Cohort 1: Progressive disease on osimertinib or other prior EGFR TKIs\n* Part II, Cohort 2: Receiving osimertinib as front line treatment for less than 12 weeks. Persistent ctDNA with EGFR mutation between weeks 6-12 from the start of osimertinib treatment.\n* Age at least 18\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2\n* Archival tissue from a biopsy performed after progression of disease on previous EGFR TKI or willing to consent for a fresh tumor biopsy.\n* Measurable disease by RECIST 1.1.\n* Patients with untreated brain metastases are allowed provided that the patient is clinically asymptomatic and stable.\n* Patients must have completed prior chemotherapy \u2265 3 weeks or radiotherapy \u2265 2 weeks prior to receiving study drugs.\n* If the subject's most recent line of therapy is treatment with osimertinib, then all adverse events must be resolved to Grade 2 or better\n* If the subject's most recent line of therapy is any other treatment than osimertinib, then all Adverse Events must be resolved to grade 1 or better, with the exception of fatigue, alopecia and neuropathy (which must resolve to CTCAE grade 2).\n* Adequate organ function\n* Women of childbearing potential and men must agree to use adequate contraception while on study.\n* Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.\n\nExclusion Criteria:\n\n* Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active interstitial lung disease.\n* Small cell lung cancer histology.\n* Other prior malignancy that might interfere with study endpoints per opinion of the investigator.\n* Prior exposure to carotuximab or any CD105 targeted antibody.\n* Any major surgical procedure within 2 weeks of starting therapy.\n* Patients must not have a history of uncontrolled or poorly-controlled hypertension defined as SBP \\> 150 mmHg or DBP \\> 90 mmHg within 28 days prior to enrollment.\n* Active bleeding or pathologic conditions that carries a high bleeding risk (e.g. gastric ulcers).\n* Use of thrombolytics within 10 days prior to the first day of carotuximab.\n* Known hypersensitivity to Chinese hamster ovary products or other recombinant human, chimeric, or humanized antibodies.\n* A known diagnosis of Osler-Weber-Rendu syndrome.\n* Ascites or pericardial or pleural effusion requiring external drainage procedures.\n* New evidence of leptomeningeal disease.\n* Acute cardiovascular event within the past 6 months.\n* Pregnancy or breastfeeding.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05401110005","EMAIL":[{}],"GEO":[33.83585,-118.34063]},{"TITLE":"Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Age \\>= 18 years. Children are excluded from this study because neither dosing nor safety data are currently available for AZD9291 or BC2059 in patients \\< 18 years of age\n* Pathology-confirmed metastatic NSCLC\n* A common activating mutation must be present in the EGFR gene, i.e., exon 19 deletion or L858R. The presence of uncommon EGFR mutations, e.g., G719X, S768I, or L861Q are also permitted if they co-occur with a common activating mutation. Mutation status must be determined using a tumor biopsy by local Clinical Laboratory Improvement Act (CLIA)-certified assessment. Mutations identified by blood-based testing can be provided, but must be verified by tumor biopsy\n* The presence of a concurrent T790M mutation, while uncommon in patients who are na\u00efve to treatment with EGFR TKIs, is also permitted\n* Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\< 2 (Karnofsky \\>= 60%)\n* The patient must be able to swallow pills\n* Life expectancy \\> 3 months\n* Leukocytes \\>= 3,000\/mcL\n* Absolute neutrophil count \\>= 1,500\/mcL\n* Platelets \\>= 100,000\/mcL\n* Hemoglobin \\>= 90 g\/L\n* Total bilirubin =\\< 1.5 x institutional upper limit normal (ULN) and up to 3 mg\/dL for patients with Gilbert's\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\])\/alanine aminotransferase ALT (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\< 2.5 x institutional ULN and =\\< 5 x institutional ULN for patients with liver metastases\n* Creatinine within 1.5 x ULN OR glomerular filtration rate (GFR) \\>= 50 mL\/min\/1.73 m\\^2 (measured or calculated by Cockcroft and Gault equation) -confirmation of creatinine clearance is only required for patients with creatinine levels above institutional upper limit of normal\n* If evidence of chronic hepatitis B virus (HBV) infection, HBV viral load must be undetectable on suppressive therapy if indicated\n* If history of hepatitis C virus (HCV) infection, it must be treated and have an undetectable viral load\n* Patients with treated brain metastases are asymptomatic and not requiring ongoing treatment\n* Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate central nervous system (CNS)-specific treatment is not required and is unlikely to be required during the first cycle of therapy. Clinical stability on a stable dose of decadron is permitted\n* Patients with a prior or concurrent malignancy whose natural history or treatment will not interfere with the safety or efficacy assessment of the investigational drugs are eligible for this trial\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients must be class 2B or better\n* Ability to understand and sign a written informed consent document\n\nExclusion Criteria:\n\n* Prior treatment with an EGFR TKI in any setting\n* Patients who have not recovered from adverse events (AEs) due to prior anti-cancer therapy (i.e., have residual toxicities \\> grade 1), with the exception of alopecia\n* Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active interstitial lung disease\n* Patients who are receiving any other investigational agent or immunotherapy within five half-lives of the compound or 3 months, whichever is greater\n* Patients with an uncontrolled intercurrent illness\n* Patients with psychiatric illness\/social situations that would limit compliance with study requirements\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition as BC2059 or AZD9291. Patients with hypersensitivity to any of the inactive excipients should also be excluded\n* Currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inducers of CYP3A4 (wash-out periods vary. All patients must try to avoid concomitant use of any medications, herbal supplements and\/or ingestion of foods with known inducer effects on CYP3A4\n* Pregnant women are excluded from this study because BC2059 has the potential for teratogenic or abortifacient effects. There is also an unknown but potential risk for AEs in nursing infants secondary to treatment of the mother with AZD9291 or BC2059. Breastfeeding patients will be excluded\n* Patients with a significant history of cardiovascular disease (e.g., myocardial infarction \\[MI\\], thrombotic or thromboembolic event in the last 6 months)\n* Any of the following cardiac criteria:\n\n  * Mean resting corrected QT interval (corrected QT \\[QTc\\] using Fredericia's formula \\[QTcF\\]) \\> 470 msec. RR is the time from the interval of 1 QRS complex to the next measured in seconds and is commonly calculated as (60\/HR)\n  * Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block)\n  * Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as decompensated heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives, or any concomitant medication known to prolong the QT interval\n  * Left ventricular ejection fraction (LVEF) \\< lower limit of normal (LLN) as assessed by either multigated acquisition (MUGA) scan or echocardiogram (ECHO)\n* Patients with active malignancies other than NSCLC or patients with prior curatively treated malignancy at high risk of relapse during the study period with the exception of localized squamous or basal cell skin cancers, ductal carcinoma in-situ (DCIS), or indolent cancer currently on observation (i.e. chronic lymphocytic leukemia \\[CLL\\] or low-risk prostate cancer)\n* Any evidence of severe or uncontrolled systemic disease, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol, or active infection with human immunodeficiency virus (HIV). Screening for chronic conditions is not required\n* Patients who are at risk for impaired absorption of oral medication including, but not limited to, refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD9291\n* Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, or requirements\n* Involvement in the planning and\/or conduct of the study (applies to both investigator staff and\/or staff at the study site)","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04780568001","EMAIL":[{"email":"regan.memmott@osumc.edu"},{}],"GEO":[39.96118,-82.99879]},{"TITLE":"A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Ability to give informed consent, signed and dated IRB\/EC approved informed consent, willing and able to comply with treatment planning visits, tests and other procedural requirements\n2. When signing the informed consent, the age is 18-75 years old (including both ends), and there is no gender limitation\n3. The ECOG score is 0 or 1\n4. The expected survival is \u226512 weeks\n5. Subjects with advanced or metastatic non-small cell lung cancer\n6. Formalin fixed, paraffin-embedded tumor tissue blocks or sections of unstained tumor specimens are provided\n7. Subjects who have failed prior standard care or are intolerant to standard care\n8. There is at least one measurable lesion\n9. Vital organs are functioning well\n10. Heart function is good\n11. Agree to birth control\n\nExclusion Criteria:\n\n1. There are untreated or active central nervous system (CNS) tumor metastases\n2. Pleural, ascites, or pericardial effusion requiring intervention occurred within 7 days prior to initial administration\n3. Systemic antitumor therapy was performed 4 weeks prior to study initiation\n4. Prior treatment with antibody-conjugated drugs\n5. Received \\>30 Gy chest radiation within 6 months prior to initial administration\n6. Palliative radiotherapy was completed within 7 days prior to initial administration\n7. Failure to recover from toxicity and\/or complications of previous interventions to nCI-CTCAE \u22641\n8. The half-life of CYP3A4 suppressor, moderate inhibitor or strong inducer or moderate inducer is less than 3 or less than 14 days from the date of first drug use, and the shorter is selected\n9. Received systemic immunosuppressant therapy within 14 days prior to the first study\n10. Subjects with known or suspected interstitial pneumonia\n11. In the first study, failure to swallow, chronic diarrhea, gastroenteritis, intestinal obstruction, gastrointestinal perforation, postgastrectomy, or colitis, or other medical conditions or special conditions affecting drug administration and absorption occurred within 28 days prior to administration\n12. Presence of any active, known or suspected autoimmune disease\n13. Have poorly controlled or severe cardiovascular disease\n14. Previous or concurrent malignancy\n15. Subjects who developed a severe infection within 28 days prior to the first dose\n16. Active hepatitis B\n17. There were active tuberculosis patients within 1 year before enrollment\n18. There is a history of immunodeficiency\n19. Live attenuated vaccine was administered within 28 days prior to initial study administration or is expected to be administered during study treatment\n20. Subjects who are participating in another clinical study or who have had their first dose less than 4 weeks since the end of the previous clinical study (last dose) or 5 half-lives of the study drug, whichever is shorter\n21. Major surgery other than diagnosis or biopsy was performed within 28 days prior to initial administration\n22. People who are known to be allergic to sir-A1811, pyrrolitinib, or any of the components of SIR-1316\n23. History of severe allergic reactions to other monoclonal antibody\/fusion protein drugs\n24. Female subjects who are pregnant, breast-feeding, or planning to become pregnant during the study\n25. Uncontrolled mental illness and other conditions known to affect the completion of the study process, such as alcohol, drug or substance abuse and detention\n26. Any other conditions that, in the investigator's judgment, may increase the risk of study participation, interfere with study results, or make study participation unsuitable","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05482568002","EMAIL":[{}],"GEO":[30.29365,120.16142]},{"TITLE":"Assessment of Cardiorespiratory Fitness and Lung Function in Lung Cancer Patients Undergoing NAT","CRITERIA":"Inclusion Criteria:\n\n* Adult patients with diagnosed non-small celll lung cancer (NSCLC) undergoing neoadjuvant therapy before lung resection surgery\n\nExclusion Criteria:\n\n* Physical impairments that prevent patients to perform a CardioPulmonary Exercise Test\n* Non-resectable tumours\n* Patients who refuse either surgical resection or neoadjuvant therapy","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05636969001","EMAIL":[{}],"GEO":[41.38879,2.15899]},{"TITLE":"Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Signed informed consent must be obtained prior to participation in the study.\n* Dose escalation and dose expansion group 1:\n\nPatients with histologically or cytologically confirmed diagnosis of advanced (metastatic or unresectable) NFE2L2\/KEAP1\/CUL3 mutant NSCLC. Local data confirming the NFE2L2\/KEAP1\/CUL3 mutation status in tissue must be available for enrollment.\n\n* Dose expansion group 2:\n\nPatients with histologically or cytologically confirmed diagnosis of advanced (metastatic or unresectable) NSCLC irrespective of NFE2L2\/KEAP1\/CUL3 mutation status.\n\n* All patients:\n\nPatients must have progressed after 1 platinum-based chemotherapy regimen and PD-(L)1 antibody therapy either sequentially or concurrent with chemotherapy, where indicated, for Stage IV NSCLC.\n\nPatients treated with neo-adjuvant \/ adjuvant platinum-based therapy that progressed within 6 months of treatment are permitted to participate.\n\nPrior therapy with VEGF\/VEGFR targeting agents is permitted. Prior treatment with approved targeted drugs (e.g., EGFRi, ALKi, METi) is mandatory in patients with NSCLC whose tumor bears actionable mutations.\n\n* Presence of at least one measurable lesion according to RECIST v1.1.\n* Patient must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines. Patient must be willing to undergo a new tumor biopsy at screening and during study treatment. A recent biopsy collected after the last systemic treatment and within 3 months before study entry may be submitted at screening.\n\nExclusion Criteria:\n\n* Having out of range laboratory values defined as:\n\nCreatinine clearance (calculated using Cockcroft-Gault formula, or measured) \\< 60 mL\/min Total bilirubin \\> 1.5 x ULN, except for patients with Gilbert's syndrome who are excluded if total bilirubin \\> 3.0 x ULN or direct bilirubin \\> 1.5 x ULN ALT \\> 3 x ULN AST \\> 3 x ULN ANC \\< 1.0 x 109\/L Platelet count \\< 75 x 109\/L Hemoglobin \\< 9 g\/dL\n\n* Impaired cardiac function or clinically significant cardiac disease, including any of the following:\n\nClinically significant and\/or uncontrolled heart disease such as congestive heart failure requiring treatment (NYHA Grade \u22652), uncontrolled hypertension or clinically significant arrhythmia.\n\nQTcF \\> 470 msec on screening ECG or congenital long QT syndrome. Acute myocardial infarction or unstable angina pectoris \\< 3 months prior to study entry.\n\n* Presence of symptomatic CNS metastases, or CNS metastases that require local CNS-directed therapy (such as radiotherapy or surgery) or increasing doses of corticosteroids within 2 weeks prior to study entry. Patients with treated symptomatic brain metastases should be neurologically stable (for 4 weeks post-treatment and prior to study entry) and at a dose of \u2264 10 mg per day prednisone or equivalent for at least 2 weeks before administration of any study treatment.\n* Known active COVID-19 infection.\n* Unable or unwilling to swallow capsules as per dosing schedule. Other protocol-defined inclusion\/exclusion criteria may apply.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05275868012","EMAIL":"novartis.email@novartis.com","GEO":[46.20222,6.14569]},{"TITLE":"Study of Oral MRT-2359 in Selected Cancer Patients","CRITERIA":"Phase 1 enrollment population:\n\n* NSCLC\n* SCLC\n* High-grade neuroendocrine cancer of any primary site\n* Any solid tumors with L-MYC or N-MYC amplification\n* DLBCL\n\nPhase 2 enrollment population:\n\n* Any solid tumors with L-MYC or N-MYC amplification\n* NSCLC with high or low L-MYC or N-MYC expression status (testing will be provided) or SCLC\n* HR-positive, HER2-negative breast cancer - MRT-2359 in combination with fulvestrant\n* Non-neuroendocrine prostate cancer - MRT-2359 in combination with enzalutamide\n\nPhase 1 and Phase 2 Inclusion Criteria:\n\n* Have a selected advanced solid tumor or DLBCL (listed above) for which there are no further standard therapeutic options available\n* Be age \u2265 18 years and willing to voluntarily complete the informed consent process\n* A predicted life expectancy of \u2265 3 months and an ECOG performance status \u2264 2\n* Have measurable disease by RECIST 1.1 (Eisenhauer et al., 2009) in case of solid tumors or Revised Response Criteria for Malignant Lymphoma (Phase 1 only) (Cheson et al., 2014) in case of DLBCL\n* Have adequate organ function defined by the selected laboratory parameters\n* If female of childbearing potential, avoid becoming pregnant and agree to use acceptable methods of contraception after informed consent, throughout the study, and for 90 days after the last dose of MRT-2359\n* Male of reproductive potential must use an approved methods of contraception from informed consent until 90 days after study discharge\n\nExclusion Criteria:\n\n* Have received prior chemotherapy, definitive radiation, biological cancer therapy or any investigational agent within 21 days before the first dose of study treatment, or have any AEs that have failed to recover to baseline. In patients with prostate cancer, continuance of systemic therapies to maintain castration levels of testosterone is allowed. Pre-menopausal patients with hormone-dependent breast cancer can continue on therapies used for suppression of ovarian function.\n* Have received bisphosphonates or denosumab within 14 days before the first administration of the study drug unless they were given for acute hypercalcemia\n* Inability to swallow oral medication\n* Have received prior therapy with a GSPT1 degrader that was discontinued due to an AE\n* Have received prior auto-HCT and not fully recovered from effects of the last transplant\n* Have received prior allogeneic hematopoietic stem cell transplantation within past 6 months and\/or have symptoms of graft-versus-host disease. Patients requiring minimal intervention such as topical steroids are eligible\n* Have received a live vaccine within 90 days before the first dose of study treatment\n* COVID-19 immunization within 14 days of receiving the first dose of MRT-2359\n* Current use of chronic systemic steroid therapy in excess of replacement doses (prednisone \u2264 10 mg\/day is acceptable)\n* Have clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of the study drug\n* Have a history of a second malignancy, unless controlled not requiring therapy\n* Have clinically active central nervous system involvement and\/or carcinomatous meningitis. Patients with treated and stable brain metastases (not progressing for at least 4 weeks prior to enrollment) not requiring steroids are eligible\n* Have a confirmed history of (non-infectious) pneumonitis that required steroids\n* Have known human immunodeficiency virus (HIV) unless the patient is on antiviral therapy with undetectable HIV RNA levels\n* Have known hepatitis B or C infection(s) unless treated with undetectable hepatitis B DNA or hepatitis C RNA levels\n* Clinically significant cardiac disease\n* Be pregnant or breastfeeding","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05546268021","EMAIL":"Clinicaltrials@monterosatx.com","GEO":[43.70011,-79.4163]},{"TITLE":"RCT of Uniport VATS for Lung Cancer","CRITERIA":"Inclusion Criteria:\n\npatients with cT1-3N0-1M0 NSCLC; good cardiopulmonary function; prepared to undergo radical resection;\n\nExclusion Criteria:\n\npatients with N3 or M1 NSCLC; poor cardiopulmonary function; not be prepared to undergo radical resection;","SEX":"ALL","AGE_MIN":25,"AGE_MAX":80,"SS_ID":"04212481001","EMAIL":[{}],"GEO":[36.66833,116.99722]},{"TITLE":"DS8201a and Pembrolizumab in Participants With Locally Advanced\/Metastatic Breast or Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Written informed consent\n* Adults \u226518 years\n* Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 1\n* Pathologically documented HER2-expressing locally advanced\/metastatic breast cancer, and HER2-expressing or HER2-mutant locally advanced\/metastatic NSCLC\n* Willing to provide a tumor biopsy during screening and during treatment\n* Have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as assessed by the Investigator\n* Adequate cardiac function, as defined by left ventricular ejection fraction (LVEF) \u226550% within 28 days before enrollment.\n* Adequate organ function\n* Adequate treatment washout period before enrollment\n\nInclusion Criteria Specific to Part 1\n\n* Participants in Part 1 should meet the additional inclusion criteria listed for 1 of the 4 cohorts in Part 2.\n\nInclusion Criteria Specific to Part 2\n\nInclusion Criteria for Cohort 1\n\n* Pathologically documented, locally advanced\/metastatic breast cancer that has centrally determined HER2-positive expression as per American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) Guidelines\n* Received prior trastuzumab emtansine (T-DM1) therapy with documented progression\n\nInclusion Criteria for Cohort 2\n\n* Pathologically documented, locally advanced\/metastatic breast cancer that has centrally determined HER2-low expression (immunohistochemistry \\[IHC\\] 1+ or IHC 2+\/in situ hybridization \\[ISH-\\])\n* Participants must have exhausted treatments that can confer any clinically meaningful benefit (eg, other therapies such as hormonal therapy for participants who are hormone receptor positive)\n\nInclusion Criteria for Cohort 3\n\n* Pathologically documented, locally advanced\/metastatic NSCLC that has centrally or locally determined HER2-expression (IHC 1+, 2+, or 3+)\n* Participants who have known epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK), BRAF V600E mutation, or ROS1 fusion should have disease progression after treatment with at least one genomically-targeted therapy for metastatic disease that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment\n\nInclusion Criteria for Cohort 4\n\n* Pathologically documented, locally advanced\/metastatic HER2-mutant NSCLC\n* Participants who have known EGFR mutation, ALK, BRAF V600E mutation, or ROS1 fusion should have disease progression after treatment with at least one genomically-targeted therapy for metastatic disease that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment\n\nExclusion Criteria:\n\n* Prior treatment with pembrolizumab or DS-8201a\n* Medical history of myocardial infarction (MI) within 6 months before enrollment, symptomatic congestive heart failure (New York Heart Association Class II to IV). Participants with troponin levels above the upper limit of normal at Screening (as defined by the manufacturer), and without any MI-related symptoms, should have a cardiologic consultation before enrollment to rule out MI\n* Corrected QT interval (QTc) prolongation to \\>470 ms (females) or \\>450 ms (males)\n* History of (non-infectious) interstitial lung disease (ILD)\/pneumonitis that required steroids, has current ILD\/pneumonitis, or where suspected ILD\/pneumonitis cannot be ruled out by imaging at screening\n* Spinal cord compression or clinically active central nervous system metastases\n* Active, known or suspected autoimmune disease\n* Condition requiring systemic treatment with either corticosteroids (\\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of start of study treatment\n* Prior therapy with an anti-PD-1 or anti-PD-L1 agent\n* Prior therapy with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137) and was discontinued from that treatment due to a Grade 3 or higher immune-related adverse event (irAE)\n* Prior anti-HER2 therapy is not allowed for participants with HER2 low-expressing breast cancer or participants with NSCLC (Cohorts 2, 3, or 4). Prior treatment with pan-HER tyrosine kinase inhibitor is allowed.\n* Prior systemic anticancer therapy, including investigational agents within 2 to 6 weeks prior to treatment\n* Unresolved toxicities from previous anticancer therapy\n* Live vaccine within 30 days prior to the first dose of study drug\n* Currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment\n* Multiple primary malignancies within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, other solid tumors curatively treated, or contralateral breast cancer\n* History of severe hypersensitivity reactions to other monoclonal antibodies and\/or any of the study drug components\n* Active infection requiring systemic therapy\n* Known history of human immunodeficiency virus (HIV) infection\n* Active hepatitis B or C virus infection\n* History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, or any other reason the participant is found not appropriate to participate in the opinion of the treating Investigator\n* Known psychiatric or substance abuse disorders\n* Prior organ transplantation, including allogeneic stem cell transplantation\n* Pregnant, breastfeeding, or planning to become pregnant\n* Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses\n* Uncontrolled infection requiring IV antibiotics, anti-virals, or anti-fungals","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04042701029","EMAIL":[{}],"GEO":[51.35,-0.2]},{"TITLE":"Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Age \u226518 years\n* Metastatic NSCLC enrolled in our CRCHUM Lung Cancer Registry and co-enrolled to the PERa registry\n* Ability to provide written informed consent\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-3\n* Oligoprogression to 1-5 extracranial lesions \u2264 5cm and involving \u2264 3 organs. Progression at the primary tumor site should be counted within the total of 5 lesions. For patients with lymph node metastases, each node is counted as one site of metastasis.\n* Oligoprogression while on ICI or TKI (any line)\n* Patients with brain metastasis are allowed; brain metastasis are not counted in the maximum number of lesions and should be treated as per standard of care\n* All sites of disease can, in the opinion of the investigator, be safely treated and targetable with SABR (taking into account prior local therapy, organ function and underlying medical condition such as inflammatory bowel disease, pulmonary fibrosis, etc.)\n* Patients with prior metastases that have been treated with ablative therapies (e.g. radiotherapy, surgery or radiofrequency ablation) before their current line of systemic therapy, are eligible.\n\nExclusion Criteria:\n\n* Any lesion beyond 5 cm\n* Pregnancy or breastfeeding\n* Any medical condition that could, in the opinion of the investigator, preclude radiotherapy or prevent follow-up after radiotherapy.\n* Presence of spinal cord compression Metastatic disease that invades the GI tract (including esophagus, stomach, small or large bowel)","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04405401001","EMAIL":[{"email":"diane.dt.trudel.chum@ssss.gouv.qc.ca"}],"GEO":[45.50884,-73.58781]},{"TITLE":"A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations","CRITERIA":"Key Inclusion Criteria:\n\n1. Willing and able to provide written informed consent\n2. Age \u2265 12 years\n3. A locally advanced or metastatic tumor who has progressed on or for which no standard therapy exists. Patients who are intolerant to standard therapy or who are not a candidate for standard therapy (in the opinion of the Investigator) or who decline standard therapy are also eligible.\n4. Documentation of a RAS Q61X mutation (tumor tissue or blood) prior to first dose of study treatment as determined locally with an analytically validated assay in a certified testing laboratory.\n5. Archival tumor tissue collected within 5 years prior to enrollment must be confirmed to be available at the time of Screening, which may be submitted before or after enrollment for exploratory biomarker analysis.\n6. ECOG performance status 0, 1 or 2\n7. Presence of at least 1 measurable lesion according to RECIST v1.1\n8. Able to swallow oral medication.\n\nExclusion Criteria:\n\n1. Prior therapy with an ERK-, MEK-, RAF-, or RAS-inhibitor\n2. Impairment of GI function or gastrointestinal (GI) disease that may significantly alter the absorption of study treatment (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection)\n3. History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndrome)\n4. Corrected QT interval using Fridericia's formula (QTcF) at Screening \\>450 ms based on triplicate average NOTE: criterion does not apply to patients with a right or left bundle branch block\n5. LVEF \\<50%\n6. All primary CNS tumors\n7. Symptomatic CNS metastases that are neurologically unstable. Patients with controlled CNS metastases are eligible.\n8. Patients receiving treatment with medications that are known to be strong inhibitors and\/or inducers of cytochrome P450 (CYP)3A; substrates of CYP2C8, CYP2C9, and CYP3A with a narrow therapeutic index and sensitive substrates of CYP3A;\n9. Are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial","SEX":"ALL","AGE_MIN":12,"AGE_MAX":99,"SS_ID":"05907304031","EMAIL":"clinicaltrials@erasca.com","GEO":[55.86515,-4.25763]},{"TITLE":"BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n1. Is willing and able to provide signed informed consent for the trial.\n2. Is \u226518 years of age on the day of signing the informed consent form.\n3. Has a histologically-confirmed advanced\/metastatic solid tumor.\n4. Has received standard of care and progressed or is intolerant of, or is not eligible to receive standard of care antineoplastic therapy.\n5. Has at least 1 measurable disease lesion as defined by RECIST v1.1.\n6. Must be willing to provide tumor biopsies as specified in the schedule of assessments\n7. Has a life expectancy of \u226512 weeks.\n8. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n9. Has adequate organ function as confirmed by laboratory values.\n\nExclusion Criteria:\n\n1. Needs doses of prednisolone \\>10 mg daily (or equipotent doses of other corticosteroids) while on the trial other than as premedication.\n2. Has known active central nervous system (CNS) metastases and\/or carcinomatous meningitis.\n3. Has known or suspected hypersensitivity to BI-1910 or pembrolizumab.\n4. Has cardiac or renal amyloid light-chain amyloidosis.\n5. Has received the following:\n\n   1. Chemotherapy or small molecule anti-cancer therapy products within 4 weeks, or 5 half-lives of the respective drug whichever is longer, of first dose of BI-1910.\n   2. Radiotherapy within 2 weeks of first dose of BI-1910. A 1-week washout is permitted for palliative radiation (\u22642 weeks of radiotherapy) for non-CNS disease.\n\n      Subjects who have previously had radiation pneumonitis are not allowed.\n   3. Immunotherapy within 4 weeks prior to the first dose of BI-1910.\n6. Has not recovered from AEs to at least Grade 1 by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) (v5.0 or higher).\n7. Has had Grade \u22653 autoimmune manifestations of previous immune checkpoint inhibitor treatments (e.g., anti-PD-1, anti-PD-L1, or anti-CTLA-4).\n8. Has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis.\n9. Has an active, known, or suspected autoimmune disease.\n10. Is a female subject and has the ability to become pregnant (or already pregnant or lactating\/breastfeeding). However, those female subjects who have a negative serum or urine pregnancy test up to 72 hours prior to their first dose of study treatment and agree to use a highly effective method of birth control for 4 weeks before entering the trial, during the trial, and for 12 months after their last dose of study treatment are considered eligible.\n11. Is a male subject with partner(s) of childbearing potential (unless he agrees to use a barrier method of contraception \\[condom plus spermicidal gel\\] with the female partner(s) who are using one highly effective method of contraception during the trial and for 12 months after completing treatment).\n12. Has had major surgery from which the subject has not yet recovered.\n13. Is at high medical risk because of nonmalignant systemic disease including severe active infections on treatment with antibiotics, antifungals, or antivirals other than the ones considered adequate for treatment of HBV.\n14. Has presence of chronic graft versus host disease.\n15. Has had an allogenic tissue\/solid organ transplant.\n16. Is positive for Human Immunodeficiency Virus (HIV).\n17. Has history of chronic HBV or HCV infections.\n18. Has a history of active tuberculosis (Bacillus tuberculosis).\n19. Has received a live vaccine within 30 days before the first dose of study treatment.\n20. Has uncontrolled or significant cardiovascular disease.\n21. Has a known psychiatric or substance abuse disorder that would interfere with the subject's ability to cooperate with the requirements of the trial.\n22. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator.\n23. Is participating or planning to participate in another interventional clinical trial or has participated in a trial of an investigational agent or has used an investigational device within 4 weeks prior to first dose of study treatment.\n24. Has a known additional malignancy of another type, with the exception of adequately treated cone-biopsied carcinoma in situ and basal or squamous cell carcinoma of the skin. Male subjects with asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for \\>1 year prior to start of study treatment are eligible.\n25. Has a confirmed diagnosis of primary immunodeficiency or an acquired condition that leads to an immunodeficiency disorder or taking any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06205706012","EMAIL":[{}],"GEO":[59.33258,18.0649]},{"TITLE":"A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Sign the informed consent form voluntarily and follow the protocol requirements;\n2. Gender is not limited;\n3. Age \u226518 years old;\n4. Expected survival time \u22653 months;\n5. Patients with locally advanced or metastatic non-small cell lung cancer confirmed by histopathology and\/or cytology;\n6. Consent to provide an archived tumor tissue sample or fresh tissue sample from the primary or metastatic site within 6 months for biomarker testing;\n7. At least one measurable lesion meeting the RECIST v1.1 definition was required;\n8. ECOG \u22641;\n9. The toxicity of previous antineoplastic therapy has returned to \u2264 grade 1 as defined by NCI-CTCAE v5.0;\n10. No severe cardiac dysfunction, left ventricular ejection fraction \u226550%;\n11. The level of organ function must meet the requirements on the premise that no blood transfusion and no use of any cell growth factor drugs are allowed within 14 days before the screening period;\n12. Coagulation function: international normalized ratio (INR) \u22641.5, and activated partial thromboplastin time (APTT) \u22641.5\u00d7ULN;\n13. Urinary protein \u22642+ or \u22641000mg\/24h;\n14. Fertile female subjects, or male subjects with fertile partners, must use highly effective contraception from 7 days before the first dose until 6 months after the first dose. Female subjects of childbearing potential had to have a negative serum pregnancy test within 7 days before the first dose.\n\nExclusion Criteria:\n\n1. Patients with previous systemic therapy;\n2. Cohort_B and Cohort_C were previously treated with EGFR-TKI;\n3. Who had participated in any other clinical trial within 4 weeks before the study dose;\n4. Received chemotherapy, radiotherapy, biological therapy, immunotherapy and other anti-tumor treatments within 4 weeks before the first use of study drugs;\n5. Had undergone major surgery within 4 weeks before the first dose;\n6. History of severe heart disease and cerebrovascular disease;\n7. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening;\n8. QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;\n9. Current interstitial lung disease, drug-induced interstitial pneumonia, radiation pneumonitis requiring steroid therapy, or a history of these diseases;\n10. Complicated with pulmonary diseases leading to clinically severe respiratory function impairment;\n11. Severe systemic infection within 4 weeks before screening;\n12. Patients at risk for active autoimmune disease or with a history of autoimmune disease;\n13. Complicated with other malignant tumors within 5 years before the first dose of medication;\n14. Human immunodeficiency virus antibody positive, active tuberculosis, active hepatitis B virus infection or hepatitis C virus infection;\n15. Hypertension poorly controlled by two antihypertensive drugs;\n16. Patients with poor glycemic control;\n17. Patients with massive effusions, or effusions with obvious symptoms, or poorly controlled effusions;\n18. Patients with active central nervous system metastases;\n19. Imaging examination showed that the tumor had invaded or enveloped the large blood vessels in the abdomen, chest, neck, and pharynx;\n20. Serious unhealed wound, ulcer or fracture within 4 weeks before signing the informed consent;\n21. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;\n22. Previous history of allogeneic stem cell, bone marrow or organ transplantation;\n23. Patients with a history of allergy to recombinant humanized antibody or to any of the excipients of BL-B01D1;\n24. Had a history of severe neurological or psychiatric disorders;\n25. Had a history of autologous or allogeneic stem cell transplantation;\n26. Pregnant or lactating women;\n27. Subjects scheduled for vaccination or who received live vaccine within 28 days before study randomization;\n28. Other conditions for participation in the trial were not considered appropriate by the investigator.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05880706001","EMAIL":[{"email":"fkyygcp@163.com"},{}],"GEO":[31.22222,121.45806]},{"TITLE":"Additional Chemotherapy for EGFRm Patients With the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)","CRITERIA":"Inclusion Criteria:\n\nPre-Screening Phase\n\n1. Provision of written informed consent for the pre-screening phase.\n2. Age \u2265 18 years\n3. Histologically confirmed stage IIIB or IV NSCLC\n4. Tumor positive for Ex19del or L858R EGFR mutation assessed according to local standard.\n5. Planned treatment with osimertinib 80mg\/d 1st-line as SoC or ongoing treatment for a maximum of 28 days\n6. Available radiographic chest and abdominal CT or MRI scans performed up to 42 days before initial osimertinib treatment\n7. Previously untreated with systemic treatment given as primary therapy for advanced or metastatic disease, except for osimertinib for a maximum of 28 days (see above)\n8. At least one measurable site of disease as defined by RECISTv1.1 criteria\n9. Female subjects of childbearing potential (WOCBP) should be using highly effective contraceptive measures and must have a negative urine or serum pregnancy test within 7 days prior to start of study treatment and must not be breast-feeding prior to start of trial. Further information in Appendix 20.7 (Definition of Women of Childbearing Potential and Acceptable Contraceptive Methods)\n10. Non-child-bearing potential must be evidenced by fulfilling one of the following criteria at screening:\n\n    * Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments\n    * Women under 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range for the institution.\n    * Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation\n\nTreatment Phase\n\n1. Provision of informed consent for the screening and treatment phase prior to any study specific procedures, including screening evaluations that are not SoC.\n2. Persistent mEGFR ctDNA signal 21 to 28 days after osimertinib initiation for advanced of metastatic ex19del or L858R EGFR mutation positive NSCLC as assessed by a liquid biopsy during the pre-screening phase of the trial in the central laboratory.\n3. ECOG performance status 0-2.\n4. The patient is willing and able to comply with the protocol for the duration of the study, including hospital visits for treatment and scheduled follow-up visits and examinations.\n5. Osimertinib no longer than 10 weeks before start of chemotherapy in the treatment phase\n\nExclusion Criteria:\n\nPre-Screening Phase\n\n1. History of another primary malignancy. Exceptions are:\n\n   * Malignancy treated with curative intent and with no known active disease \u22656 months before the first dose of IMP, and of low potential risk for recurrence\n   * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\n   * Adequately treated carcinoma in situ without evidence of disease\n2. History of leptomeningeal carcinomatosis\n3. Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study, or during the follow-up period of an interventional study\n4. Previous enrolment in the present study.\n\nTreatment Phase\n\n1. Symptomatic CNS metastases. \\[Patients with asymptomatic brain metastases may be included.\\]\n2. History of leptomeningeal carcinomatosis\n3. Currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of CYP3A4 (at least 3 weeks prior) (Appendix 20.5). All patients must try to avoid concomitant use of any medications, herbal supplements and\/or ingestion of foods with known inducer effects on CYP3A4.\n4. Osimertinib had to be withheld or administered at reduced dosage for toxicity management for more than 7 days or persistent unresolved toxicities which preclude study treatment.\n5. Any unresolved toxicities other than osimertinib from prior therapy greater than CTCAE grade 1 at the time of starting study treatment, with the exception of alopecia and grade 2 prior platinum-therapy-related neuropathy.\n6. History of hypersensitivity to active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib. History of hypersensitivity to any of the chemotherapy drugs used.\n7. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.\n8. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib.\n9. Any of the following cardiac criteria:\n\n   1. Mean resting corrected QT interval (QTc) \\> 470 msec obtained from 3 electrocardiograms (ECGs), using the screening clinic ECG machine derived QTc value\n   2. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block and second degree heart block.\n   3. Patient with any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, electrolyte abnormalities (including: Serum\/plasma potassium \\< LLN; Serum\/plasma magnesium \\< LLN; Serum\/plasma calcium \\< LLN), congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes. \\[Note: Electrolyte abnormalities (hypokalaemia, hypomagnesaemia, hypocalcaemia) can be corrected to be within normal ranges prior to first dose. No more than two re-tests may be performed in order to meet this criterion.\\]\n10. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.\n11. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:\n\n    1. Absolute neutrophil count below lower limit of normal (\\<LLN) \\*\n    2. Platelet count below lower limit of normal (\\<LLN) \\*\n    3. Hemoglobin \\<90 g\/L \\*\n\n       \\* The use of granulocyte colony stimulating factor support, platelet transfusion and blood transfusions to meet these criteria is not permitted.\n    4. Alanine aminotransferase \\>2.5 times ULN if no demonstrable liver metastases or \\>5 times ULN in the presence of liver metastases;\n    5. Aspartate aminotransferase \\>2.5 times ULN if no demonstrable liver metastases or \\>5 times ULN in the presence of liver metastases;\n    6. Total bilirubin \\>1.5 times ULN if no liver metastases or \\>3 times ULN in the presence of documented Gilbert's Syndrome \\[unconjugated hyperbilirubinaemia\\] or liver metastases;\n    7. Serum creatinine \\>1.5 times ULN concurrent with creatinine clearance \\<60 mL\/min \\[calculated by Cockcroft and Gault equation\\]-confirmation of creatinine clearance is only required when creatinine is \\>1.5 times ULN.\n    8. INR \u2264 1.4 or aPTT \u2264 40 sec during the last 7 days before chemotherapy \\[Subjects under therapeutic anticoagulation are permitted.\\]\n12. Judgement by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.\n13. Women who are pregnant or breast-feeding\n14. Male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 4 months (male patients) or 6 weeks (female patients) after the last dose of osimertinib and 6 months after the last dose of chemotherapy.\n15. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts \\[\u00a7 40 Abs. 1 S. 3 Nr. 3a AMG\\].\n16. Treatment with an investigational drug within five half-lives of the compound or 3 months, whichever is greater.\n17. Any chemotherapy, biologic, or hormonal therapy for cancer treatment used concurrently or within 6 months prior to first dose of study treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.\n18. Major surgery (as defined by the Investigator) within 4 weeks prior to starting the study; patients must have recovered from effects of preceding major surgery. Note: Local non-major surgery for palliative intent (e.g., surgery of isolated lesions) is acceptable","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05281406014","EMAIL":[{}],"GEO":[53.14118,8.21467]},{"TITLE":"Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD","CRITERIA":"Inclusion Criteria:\n\n* Stage IB-IIIA non-small cell cancer patients who after complete resection.\n* \u226518 years.\n* Two-round MRD tests confirm landmark undetectable MRD.\n* Expected survival \u226512 weeks.\n* Expected survival \u226512 weeks.\n* ECOG PS 1-2.\n* Willing to accept MRD monitoring every 3 months for a total of 2 years after operation.\n\nExclusion Criteria:\n\n* Patients who had previously undergone radiotherapy or chemotherapy or any other anti-tumor therapy.\n* Patients with a history of other malignancies in the past 5 years.\n* Any unstable systemic disease (eg, active infection, high-risk hypertension, unstable angina, congestive heart failure, etc.).","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05457049001","EMAIL":[{},{"email":"syylwu@live.cn"},{},{}],"GEO":[23.11667,113.25]},{"TITLE":"A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection","CRITERIA":"Inclusion Criteria\n\n1. Male or female, at least \u2265 18 years.\n2. NSCLC, of non-squamous histology.\n3. Stage IA2 or IA3 disease, based on TNM8 classification.\n4. Complete surgical resection (R0) of the primary NSCLC by lobectomy, bilobectomy, segmentectomy or sleeve resection.\n5. Complete recovery from surgery at the time of randomisation. Study intervention cannot commence within 4 weeks following surgery. No more than 12 weeks may have elapsed between surgery and randomisation for participants.\n6. World Health Organization performance status of 0 or 1.\n7. Provision of tumour sample for central pathology assessment of pathologic risk factors and to assess EGFR mutation status prior to randomisation.\n8. A tumour which harbours one of the 2 EGFR mutations (Ex19del, L858R) by cobas\u00ae EGFR Mutation Test v2 (Roche Diagnostics) or FoundationOne\u00ae test.\n9. Minimum life expectancy of \\> 6 months.\n10. Females must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of child-bearing potential, or must have evidence of non-child-bearing potential. Male subjects must be willing to use barrier contraception.\n\nExclusion Criteria\n\n1. Mixed small cell and non-small cell cancer history.\n2. Participants with incomplete (R1\/R2) resection, or who have undergone pneumonectomy or only wedge resection.\n3. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including HCV and HIV or active uncontrolled HBV infection.\n4. History of another primary malignancy, including any known or suspected synchronous primary lung cancer except for malignancy treated with curative intent with no known active disease \u2265 5 years before the first dose of study intervention and of low potential risk for recurrence.\n5. Any of the following cardiac criteria:\n\n   * Mean resting QTcF interval \\> 470 ms, obtained from triplicate ECGs performed at screening.\n   * Any abnormalities in rhythm, conduction, or morphology of resting ECG,\n   * Any factors that increase the risk of QTcF prolongation or risk of arrhythmic events.\n6. History of interstitial lung disease.\n7. Inadequate bone marrow reserve or organ function.\n8. Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study intervention.\n9. Prior treatment with any anticancer therapy for NSCLC (including chemotherapy, radiotherapy, immunotherapy, and EGFR-TKIs).\n10. Major surgery or significant traumatic injury within 4 weeks of the first dose of study intervention.\n11. Participants currently receiving medications or herbal supplements known to be strong inducers of CYP3A4.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05120349177","EMAIL":"information.center@astrazeneca.com","GEO":[53.38027,-2.2654]},{"TITLE":"Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation","CRITERIA":"Inclusion Criteria:\n\n* Histologically confirmed diagnosis of a solid tumor malignancy harboring KRAS G12D mutation in tumor tissue or ctDNA.\n* Unresectable or metastatic disease.\n* Patients must have received standard therapies appropriate for their tumor type and stage; first-line treatment for PDAC for certain cohorts.\n* Presence of tumor lesions to be evaluated per RECIST v1.1:\n\n  1. in the Phase 1 dose escalation cohorts, patients must have measurable or evaluable disease.\n  2. in the Phase 1b and Phase 2 cohorts, patients must have measurable disease.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate organ function.\n* Age \u2265 18 years\n\nExclusion Criteria:\n\n* Active brain metastases or carcinomatous meningitis.\n* Prior treatment with a KRAS G12D inhibitor (Phase 1b \\& Phase 2 only).\n* History of significant hemoptysis or hemorrhage within 4 weeks of the first dose of study treatment.\n* History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow oral medications.\n* History of malignant small bowel obstruction.\n* Cardiac abnormalities.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05737706014","EMAIL":[{}],"GEO":[47.60621,-122.33207]},{"TITLE":"PD-L1 Expression in Cancer (PECan Study).","CRITERIA":"Inclusion Criteria:\n\n* Aged 18 or above\n* Patients with histologically confirmed NSCLC or melanoma scheduled for PD1\/PDL1 immunotherapy alone or in combination with other systemic anti-cancer therapy.\n* Willingness and ability to comply with scheduled study visits and tests.\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Concomitant uncontrolled medical conditions\n* Patients likely to require palliative radiotherapy within the first 12 weeks of treatment or radiotherapy to target lesion(s) received within preceding 42 days\n* More than 3 months between IHC PDL1 and study recruitment\n* Patients who have received other systemic anti-cancer therapy within preceding 14 days\n* Prognosis less than 3 months\n* Previous anticancer treatment with any checkpoint inhibitor or other immunotherapy, i.e. only immunotherapy na\u00efve patients","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04436406001","EMAIL":[{"email":"daniel.hughes@kcl.ac.uk"},{"email":"gary.cook@kcl.ac.uk"},{},{}],"GEO":[51.50853,-0.12574]},{"TITLE":"Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.","CRITERIA":"Inclusion Criteria:\n\n* Male or female, \u226518 years old and \u226475years old;\n\n  * Non-squamous non-small cell lung cancer (NSCLC) confirmed by pathology (including histology or cytology); \u2462 EGFR mutation positive (exon 19 deletion or exon 21 L858R mutation); (4) \u22653 intracranial metastases, asymptomatic brain metastases; (5) Never received antitumor therapy before;\n\n    * There was at least 1 measurable intracranial and extracranial lesion in CT\/MRI according to RECIST1.1 criteria.\n\n      \u2466 Predicted survival \u22653 months;\n\n      \u2467 ECOG score 0-1;\n\n      \u2468 The main organs (liver, kidney, heart) function normally.\n\n      \u2469 Sign informed consent forms.\n\nExclusion Criteria:\n\n* The intracranial metastases were oligometastases;\n\n  * There are symptoms of increased intracranial pressure; (3) Previous or co-existing malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix); (4) Patients with hypertension and can not be reduced to the normal range after antihypertensive drug treatment, have grade I coronary heart disease, grade I arrhythmia and grade I cardiac insufficiency;\n\n    * Patients with definite tendency to gastrointestinal bleeding; \u2465 with hemoptysis symptoms; \u2466 Abnormal coagulation function (INR\\>1.5, APTT\\>1.5 ULN), with bleeding tendency; \u2467 Have a history of psychotropic drug abuse and can not abstain or have mental disorders; \u2468According to the investigator's judgment, Patients who have a serious concomitant disease that endangers the patient's safety or affects the patient's completion of the study, and who have previous or current objective evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, or severe impairment of lung function.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05754736001","EMAIL":[{"email":"sdtatszhenhua@126.com"},{}],"GEO":[36.18528,117.12]},{"TITLE":"A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Age above 18 years old (including 18 years old)\uff0cregardless of gender\uff1b\n* ECOG-PS score of 0-1,\uff1b\n* expected survival\u226512 weeks\uff1b\n* There was no tumor deterioration in the 2 weeks prior to study drug treatment.\n* Advanced non-small cell lung cancer without systemic chemotherapy.\n* At least one tumor lesion with a maximum diameter \u226510 mm (short diameter \u226515 mm if it is a lymph node) that could be measured accurately at baseline according to RECIST1.1 criteria. Baseline tumor imaging was performed within 28 days before the first dose.\n* Women of childbearing age should use appropriate contraception and should not breastfeed from screening until 3 months after discontinuation of study treatment.\n* Male subjects should use barrier contraception (i.e., condoms) for 3 months from screening until discontinuation of study treatment.\n* All subjects voluntarily participated and signed the informed consent form in person.\n\nExclusion Criteria:\n\n* Uncontrolled ischemic heart disease or clinically significant congestive heart failure (NYHA class III or IV);\n* stroke or cardio-cerebrovascular event within 6 months before enrollment;\n* QTcF interval \\> 480msec at screening or \\> 500msec for patients with implanted ventricular pacemakers;\n* Previous hematopoietic stem cell or bone marrow transplantation;\n* Allergy to the study drug or its components;\n* Others considered by the investigator to be unsuitable for this study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06328049001","EMAIL":[{"email":"liuyctx@163.com"}],"GEO":[32.16667,120.01361]},{"TITLE":"Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)","CRITERIA":"Inclusion Criteria:\n\n1. Male or female subjects aged \u226518 years old;\n2. Locally advanced or metastatic non-squamous non-small cell lung cancer confirmed by histology or cytology (stage \u2162B-\u2163, according to the 8th Edition of the AJCC Staging system);\n3. The tumour harbours one of the most common EGFR mutations (19del or L858R);\n4. The programmed death-ligand 1 (PD-L1) tumoral expression is positive;\n5. No previous systemic anti-tumor therapy for locally advanced or metastatic NSCLC;\n6. According to RECIST 1.1, subjects have at least one measurable tumor lesion at baseline;\n7. ECOG performance status score 0-2\uff1b\n8. Subjects have voluntarily participated, signed and dated informed consent.\n\nExclusion Criteria:\n\n1. Lung squamous carcinoma (including adenosquamous carcinoma and undifferentiated carcinoma) and small cell lung cancer;\n2. Subjects have no measurable tumor lesion at baseline;\n3. Subjects with spinal cord compression or symptomatic brain metastases;\n4. Subjects are suitable for surgery;\n5. Previous therapy with platinum-based chemotherapy, EGFR-TKIs, or anti-PD1\/PD-L1 agents;\n6. Aspartate aminotransferase (AST) and\/or alanine aminotransferase (ALT)\\>2.5 \u00d7 ULN, or serum total bilirubin (TBIL)\\>1.5 \u00d7 ULN, or Cr\\>1.0\u00d7ULN;\n7. Absolute value of neutrophil (ANC)\\<1.5 \u00d7 109\/L, or platelet (PLT) count\\<75 \u00d7 109\/L, or hemoglobin (HGB)\\<90 g\/L;\n8. Any of the following disease within 12 months: myocardial infarction, severe\/unstable stenocardia, coronary\/peripheral artery bypass grafting, symptomatic congestive heart failure, or cerebrovascular accident;\n9. Women who are pregnancy or lactation, or fertile but not using contraception;\n10. Suffering from other serious acute or chronic physical or mental problems;\n11. Subjects who are considered ineligible for the study for other reasons according to the investigator's assessment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05255406001","EMAIL":[{"email":"yhui30@hotmail.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C","CRITERIA":"Inclusion Criteria:\n\n* Age higher than 18 years;\n* ECOG less or equal to 1 at the time of screening;\n* Pathologically documented, previously treated, locally-advanced and unresectable or metastatic NSCLC with KRAS p.G12C mutation confirmed through molecular testing (results of both tissue and liquid biopsy are accepted);\n* Subjects will have progressed or experienced disease recurrence on or after receiving at least 1 prior systemic therapy for locally advanced and unresectable or metastatic disease.\n* Life expectancy of longer than 3 months from the time of screening, in the opinion of the investigator;\n* Patients must have lesions easily accessible to biopsy and must have accepted to perform pre-treatment, on-treatment and end-of-treatment biopsies;\n* Have adequate bone marrow reserve and organ function, based on local laboratory data within 14 days prior to registration\n* Patients must understand, sign and date the written informed consent from prior to any protocol-specific procedures performed.\n* Patients should be able and willing to comply with study visits and procedures as per protocol.\n* Patients must be affiliated to a Social Security System or beneficiary of the same.\n\nExclusion Criteria:\n\n* Patient unwilling to participate to the biological investigations and to perform biopsies and blood sample collection as required in the protocol;\n* Use of known cytochrome P450 (CYP) 3A4 or P-gp sensitive substrates (with a narrow therapeutic window), within 14 days or 5 half-lives of the drug or its major active metabolite, whichever is longer, prior to registration, that was not reviewed and approved by the principal investigator.\n* Use of strong inducers of CYP3A4 (including herbal supplements such as St. John's wort) within 14 days or 5 half-lives (whichever is longer) prior to registration, that was not reviewed and approved by the principal investigator.\n* Inadequate washout period prior to registration, defined as: Any cytotoxic chemotherapy, investigational agents or other anticancer drug(s) from a previous cancer treatment regimen or clinical study shorter than 14 days or 5 half-lives;\n* Prior treatment with a KRAS inhibitor.\n* Major surgery within 28 days of registration.\n* Significant gastrointestinal disorder that results in significant malabsorption, requirement for intravenous alimentation, or inability to take oral medication.\n* Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within 6 months prior to registration, unstable arrhythmias or unstable angina.\n* Severe infections within 2 weeks prior to registration, but not limited to hospitalization for complications of infection, bacteremia or severe pneumonia. Prophylactic antibiotics are allowed.\n* Baseline or unresolved pneumonitis from prior treatment;\n* Current CTCAE version 5.0 grade higher or equal to 2 peripheral neuropathy.\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures at a frequency greater than monthly. Subjects with PleurX catheters in place may be considered for the study with Principal Investigator approval.\n* Known history of Human Immunodeficiency Virus (HIV) infection\n* Exclusion of hepatitis infection based on the following results and\/or criteria:\n\n  1. Positive hepatitis B surface antigen (HepBsAg) (indicative of chronic Hepatitis B or recent acute hepatitis B)\n  2. Negative HepBsAg with a positive for hepatitis B core antibody (Hepatitis B core antibody testing is not required for screening, however if this is done and is positive, then hepatitis B surface antibody \\[Anti-HBs\\] testing is necessary.\n\n     Undetectable anti-HBs in this setting would suggest unclear and possible infection, and needs exclusion).\n  3. Positive Hepatitis C virus antibody: Hepatitis C virus RNA by polymerase chain reaction is necessary. Detectable Hepatitis C virus RNA renders the subject ineligible.\n* Leptomeningeal disease and active brain metastases. Subjects who have had brain metastases resected or have received whole brain radiation therapy or stereotactic radiosurgery ending at least 2 weeks prior to registration are eligible if they meet all of the following criteria:\n\n  1. residual neurological symptoms grade less or equal to 2;\n  2. on stable doses of dexamethasone or equivalent for at least 2 weeks, if applicable; and\n  3. follow-up brain imaging performed within 30 days of enrollment shows no progression or new lesions appearing.\n* Female subject is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 7 days after the last dose of sotorasib or during treatment if planning to become pregnant.\n* Female subjects of childbearing potential unwilling to use 1 highly effective method of contraception during treatment and for an additional 7 days after the last dose of sotorasib\n* Female subjects of childbearing potential with a positive pregnancy test assessed at Screening or day 1 by a serum pregnancy test and\/or urine pregnancy test.\n* Male subjects with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment and for an additional 7 days after the last dose of sotorasib\n* Male subjects with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment and for an additional 7 days after the last dose of sotorasib\n* Male subjects unwilling to abstain from donating sperm during treatment and for an additional 7 days after the last dose of investigational product.\n* Any evidence of primary malignancy other than locally advanced or metastatic lung cancer at within 3 years of registration, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated;\n* Participation in another clinical trial evaluating an experimental drug (except non-interventional research).\n* Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent.\n* Hypersensitivity to the active substance or to any excipient\n* Patients with hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05631249004","EMAIL":[{"email":"mihaela.aldea@gustaveroussy.fr"}],"GEO":[48.7939,2.35992]},{"TITLE":"A Study of SI-B001+SI-B003\u00b1 Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Voluntarily sign the informed consent and follow the requirements of the protocol;\n2. No gender limit;\n3. Age \u226518 years old and \u226475 years old;\n4. expected survival time \u22653 months;\n5. Participants must consent to complete ctDNA testing during the screening period, including: EGFR, ALK, MET, ROS1, BRAF, NTRK, RET, HER2, KRAS and other genes detection and complete data;\n6. Histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer; Stage Ib: locally advanced or metastatic non-small-cell lung cancer with negative driver genes (AGA-negative, including ALK fusion, MET exon 14 skipping mutation, ROS1 rearrangement, BRAF V600 mutation, NTRK fusion, and RET rearrangement) after failure of standard therapy;\n\n   Phase II:\n\n   Cohort_A: Previously untreated, locally advanced or metastatic non-small cell lung cancer patients with wild-type EGFR, wild-type ALK, and other driver genes negative (AGA negative, including MET exon 14 skipping mutation, ROS1 rearrangement, BRAF V600 mutation, NTRK fusion, and RET rearrangement negative); Cohort_B: Previously untreated patients with locally advanced or metastatic EGFRmut non-small cell lung cancer who had failed EGFR TKI therapy and had not received systemic chemotherapy.\n\n   Note: a. Patients were eligible if they were treated directly with third-generation EGFR TKI, or if they were treated with first-generation or second-generation EGFR TKI before progression to third-generation TKI; b. If the patient has progressed after the first and second generation EGFR TKI treatment, but there is no indication for the third generation EGFR TKI treatment (no EGFR T790M mutation), the third generation EGFR TKI treatment is not required;\n7. Consent to provide archived tumor tissue samples or fresh tissue samples of primary or metastatic lesions; Phase Ib: participants could be enrolled if they could not provide tumor tissue samples if they met other inclusion and exclusion criteria.\n\n   Stage II: PD-L1TPS test report (DAKO 22C3 antibody) of tumor tissue samples is required; If no relevant examination report is available, patients must provide a tumor tissue sample or fresh tissue sample (FFPE block or approximately 10-12 white slides with a size of 5\u03bcm) from the primary or metastatic tumor within 2 years for PD-L1 TPS, EGFR, or HER3 protein expression level detection.\n8. At least one measurable lesion meeting the RECIST v1.1 definition was required.\n9. Performance status score: ECOG \u22641;\n10. Toxicity from previous antineochemical therapy has returned to grade 1 or less as defined by NCI-CTCAE v5.0 (asymptomatic laboratory abnormalities such as elevated ALP, hyperuricemia, elevated serum amylase\/lipase, and elevated blood glucose were considered by the investigator, and toxicity with no safety risk was judged by the investigator; Except for alopecia, grade 2 peripheral neurotoxicity, and hypothyroidism stable with hormone replacement therapy).\n11. No severe cardiac dysfunction, left ventricular ejection fraction \u226550%;\n12. The level of organ function must meet the following requirements and meet the following standards:\n\n    1. Bone marrow function: absolute neutrophil count (ANC) \u22651.5\u00d7109\/L, platelet count \u2265100\u00d7109\/L, hemoglobin \u226590 g\/L;\n    2. Liver function: total bilirubin \u22641.5\u00d7ULN (total bilirubin \u22643\u00d7ULN in subjects with Gilbert's syndrome and liver metastasis), AST and ALT \u22643\u00d7ULN in subjects without liver metastasis, AST and ALT \u22645.0\u00d7ULN in subjects with liver metastasis;\n    3. Renal function: creatinine (Cr) \u22641.5\u00d7ULN, or creatinine clearance (Ccr) \u226550 mL\/min (according to Cockcroft and Gault formula).\n13. Coagulation function: international normalized ratio (INR) \u22641.5 and activated partial thromboplastin time (APTT) \u22641.5\u00d7ULN;\n14. Urine protein \u22641+ or \u22641000mg\/24h;\n15. Female subjects of childbearing potential or male subjects with a fertile partner must use highly effective contraception from 7 days before the first dose until 24 weeks after the dose. Female subjects of childbearing potential had to have a negative serum pregnancy test within 7 days before the first dose.\n\nExclusion Criteria:\n\n1. For stage Ib patients, patients with non-small-cell lung cancer with ALK fusion, MET exon 14 skipping mutation, ROS1 rearrangement, BRAF V600 mutation, NTRK fusion, or RET rearrangement on previous sequencing reports of tissue samples or ctDNA before informed consent were excluded; For phase II Cohort_A: Genetic sequencing reports from prior tissue samples or ctDNA before signing informed consent, or screening ctDNA suggesting the following genetic alterations: Patients with ALK fusion, MET exon 14 skipping mutation, ROS1 rearrangement, BRAF V600 mutation, NTRK fusion, or RET rearrangement were excluded.\n2. Phase II patients were excluded from the study if any of the following conditions occurred:\n\n   1. patients suitable for local treatment and willing to receive local treatment;\n   2. received systemic chemotherapy, but not chemotherapy for locally advanced disease as part of multimodal therapy (this treatment must have been completed more than 6 months after the first dose of trial medication; The above chemotherapy includes induction chemotherapy, concurrent chemoradiotherapy and adjuvant chemotherapy).\n3. Clinically symptomatic parenchymal or leptomeningeal metastases that were judged by the investigator to be ineligible for enrollment. Patients with central nervous system (CNS) metastases and\/or carcinomatous meningitis (meningeal metastases) and\/or spinal cord compression. Patients who had received treatment for brain metastases (radiotherapy or surgery; Patients who had stopped radiotherapy and surgery 28 days before the first dose) and stable brain metastases were eligible. Patients with cancerous meningitis (meningeal metastasis) were excluded even if they were treated and judged to be stable, and patients with brain edema and treated with mannitol were excluded even if they were judged to be asymptomatic. Stability is defined as meeting the following four criteria:\n\n   1. seizure-free status for \\> 12 weeks with or without antiepileptic medication;\n   2. no need for corticosteroids;\n   3. screening MRI results, which showed a stable imaging state compared to the subjects' previous MRI results;\n   4. stable and asymptomatic for more than one month after treatment;\n4. Participants who participated in any other clinical trial within 4 weeks before the study dose (whichever was the last dose);\n5. Chemotherapy, biotherapy, immunotherapy, definitive radiotherapy, major surgery, or large area radiotherapy (more than 30% bone marrow area or too large area irradiation) administered within 4 weeks or 5 half-lives prior to the first dose, whichever is shorter; Anti-tumor therapy such as palliative radiotherapy within 2 weeks (but palliative radiotherapy for bone lesions is allowed), small molecule targeted therapy (including small molecule tyrosine kinase inhibitors), and modern traditional Chinese medicine preparations approved by NMPA for anti-tumor therapy;\n6. Major surgery (investigator-defined) within 4 weeks before the first dose;\n7. Systemic corticosteroids (\\> 10mg\/ day of prednisone, or other corticosteroids equivalent) or immunosuppressive agents are required within 2 weeks before the study administration; Exceptions include inhaled or topical administration of steroids or physiological replacement doses of steroids for adrenal insufficiency;\n8. Pulmonary disease grade \u22653 according to NCI-CTCAE v5.0; Patients with existing or a history of interstitial lung disease (ILD);\n9. Have active infection requiring intravenous anti-infective therapy;\n10. Prior immunotherapy with grade \u22653 irAE or grade \u22652 immune-related myocarditis;\n11. Administration of live attenuated vaccine within 4 weeks before the first dose of study drug;\n12. Use of immunomodulatory drugs, including but not limited to thymosin, interleukin-2, interferon, etc., within 14 days before the first use of the study drug;\n13. Patients at risk for active autoimmune disease, or with a history of autoimmune disease, Including but not limited to Crohn's disease, ulcerative colitis, systemic lupus erythematosus, sarcoidosis, Wegener syndrome, autoimmune hepatitis, systemic sclerosis, Hashimoto's thyroiditis, autoimmune vasculitis, autoimmune neuropathy (Guillain-Barre syndrome), etc. Exceptions were type I diabetes, hypothyroidism that was stable with hormone-replacement therapy (including that due to autoimmune thyroid disease), psoriasis or vitiligo that did not require systemic therapy, and hypothyroidism that was stable with hormone-replacement therapy.\n14. Patients with other malignant tumors within 5 years before the first drug administration, except those who have been cured skin squamous cell carcinoma, basal cell carcinoma, superficial bladder cancer, prostate\/cervix\/breast cancer in situ and other researchers think can be enrolled;\n15. Human immunodeficiency virus antibody (HIV Ab) positive, active tuberculosis, active hepatitis B virus infection (HBsAg positive or HBcAb positive and HBV-DNA copy number \\> 500IU\/ml) or hepatitis C virus infection (HCV antibody positive and HCV-RNA \\> central detection limit);\n16. Hypertension poorly controlled by medication (systolic blood pressure \\&gt; 150 mmHg or diastolic blood pressure \\&gt; 100 mmHg);\n17. Has a history of severe cardiovascular and cerebrovascular diseases, including but not limited to:\n\n    1. severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias or \u2162 degree atrioventricular block requiring clinical intervention;\n    2. prolonged QT interval at rest (QTc \\> 450 msec in men or QTc \\> 470 msec in women); Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other grade 3 or higher cardiovascular and cerebrovascular events occurred within 6 months before the first dose;\n    3. patients with New York Heart Association (NYHA) functional class \u2265II heart failure;\n18. Previous history of allogeneic stem cell, bone marrow or organ transplantation;\n19. Patients with a history of allergy to recombinant humanized antibodies or to any of the excipients of SI-B001 or SI-B003;\n20. A history of autologous or allogeneic stem cell transplantation;\n21. Pregnant or lactating women;\n22. Other conditions for participation in the trial were not considered appropriate by the investigator.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05949606001","EMAIL":[{},{}],"GEO":[31.22222,121.45806]},{"TITLE":"Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET\/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions and Differentiating Multiple Primary Lung Cancer From Intrapulmonary Metastases of Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Accurately diagnosing primary liver cancer according to pathological diagnostic criteria or clinical diagnostic criteria.\n* Tumor volume (\\> 1 cm) displayed by enhanced CT or MRI or liver mass confirmed by arteriography .\n* For patients considering distant metastases, trunk metastases need to be confirmed by CT examination. Bone metastases need to be confirmed by whole-body bone scan. Brain metastases need to be confirmed with characteristic metastatic tumors by MRI.\n* The age is more than 18 years old and less than 65 years old. There is no gender restriction.\n* Untreated patients who have not received surgery, interventional therapy, chemotherapy, biotherapy, and radiation therapy.\n* Physical condition score ECOG: 0-2; no major organ dysfunction; oxygen partial pressure \u2265 10.64kPa; white blood cell count\u2265 4 \u00d7 109\/L; hemoglobin \u2265 9.5g\/dL; neutrophil absolute count \u2265 1.5 \u00d7 109 \/ L; platelet count \u2265 100 \u00d7 109 \/ L; total bilirubin \u2264 1.5 times of the upper limit of normal value; creatinine \u2264 1.25 times of the upper limit of normal value; and creatinine clearance \u2265 60ml \/ min.\n* Be able to obtain complete follow-up information, understand the situation of this study and sign informed consent.\n\nExclusion Criteria:\n\n* Poorly controlled diabetics (fasting blood glucose levels \\> 200 mg\/dL).\n* In addition to four types of malignant tumors that can be treated with radical resection, such as cervical cancer in situ, basal or squamous cell skin cancer, (breast) ductal carcinoma in situ, and organ localized prostate cancer, suffering from any other malignant tumors within 5 years.\n* Breastfeeding and\/or pregnant women.\n* Patients with severe bleeding tendencies (prothrombin time less than 50%, cannot be corrected by treatment with vitamin K, etc.).\n* Recent severe hemoptysis, severe cough, dyspnea or patients are not able to cooperate.\n* People with severe emphysema, pulmonary congestion, and pulmonary heart disease.\n* Researchers believe that the subject may not be able to complete this study or may not be able to comply with the requirements of this study (for management reasons or other reasons).","SEX":"ALL","AGE_MIN":18,"AGE_MAX":65,"SS_ID":"03679936001","EMAIL":[{"email":"jinhj3@mail.sysu.edu.cn"},{}],"GEO":[22.27694,113.56778]},{"TITLE":"A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-na\u00efve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)","CRITERIA":"Inclusion Criteria:\n\n* Participant has histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC\n* Participant has a ROS1 gene rearrangement\/fusion as detected by a local test.\n* At least 1 measurable lesion according to RECIST v1.1, as assessed by the investigator.\n* Participants must not be exposed previously with TKIs that demonstrated activities in ROS1-positive NSCLC\n* Up to 1 prior line of systemic treatment for NSCLC is permitted\n* ECOG Performance Status \u2264 2\n\nExclusion Criteria:\n\n* Symptomatic brain metastases or symptomatic leptomeningeal involvement.\n* History of previous cancer requiring therapy within the previous 2 years, except for NSCLC under study, squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma that has been completely resected.\n* Known tumor targetable co-mutations or rearrangements\n* Clinically significant cardiovascular disease (either active or within 6 months prior to enrollment)\n\nNote: Other protocol-defined inclusion\/exclusion criteria apply","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06140836135","EMAIL":[{}],"GEO":[47.47333,8.30592]},{"TITLE":"Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC","CRITERIA":"Inclusion Criteria:\n\nFor inclusion in the study subjects must fulfill all of the following criteria:\n\n1. Histologically confirmed NSCLC\n2. Clinical stage III (including N2 stage and potential candidate for resection)\n3. Written informed consent and any locally-required authorization (IRB) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations\n4. Age \\> 20 years at time of study entry\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n6. Adequate normal organ and marrow function as defined below:\n\n   * Haemoglobin \u2265 9.0 g\/dL\n   * Absolute neutrophil count (ANC) \u2265 1,500\u03bcL\n   * Platelet count \u2265 100,000\u03bcL\n   * Serum bilirubin \u2264 1.5 x institutional upper limit of normal (ULN). \\<This will not apply to subjects with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician.\\>\\>\n   * AST (SGOT)\/ALT (SGPT) \u2264 2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be \u2264 5x ULN\n   * Serum creatinine CL\\>40 mL\/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance:\n\n     * Males:\n\nCreatinine CL (mL\/min) = Weight (kg) x (140 - Age) 72 x serum creatinine (mg\/dL)\n\n--Females: Creatinine CL (mL\/min) = Weight (kg) x (140 - Age) x 0.85 72 x serum creatinine (mg\/dL) 6. Life expectancy of 6 months 8. Female subjects must either be of non-reproductive potential (ie, post-menopausal by history: \u226550 years old and no menses for 1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry.\n\n9. Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.\n\nExclusion Criteria:\n\nSubjects should not enter the study if any of the following exclusion criteria are fulfilled:\n\n1. Patients with metastatic lesions or clinical N3 lymph nodes\n2. Participation in another clinical study with an investigational product during the last 60 months\n3. Involvement in the planning and\/or conduct of the study (applies to both AstraZeneca staff and\/or staff at the study site) Previous enrollment in the present study\n4. Any previous treatment (chemotherapy, radiotherapy or surgery) to current disease - NSCLC\n5. Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab\n6. History of leptomeningeal carcinomatosis\n7. Brain metastases or spinal cord compression. Subjects with suspected brain metastases at screening should have an MRI (preferred) or CT each preferably with IV contrast of the brain prior to study entry\n8. Receipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) \u2264 36months prior to the first dose of study drug\n9. Mean QT interval corrected for heart rate (QTc) \u2265470 ms calculated from 3 electrocardiograms (ECGs) using Frediricia's Correction\n10. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg\/day of prednisone, or an equivalent corticosteroid\n11. Current or prior use of immunosuppressive medication within 14days (use 28 days if combining durvalumab with a novel agent) before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg\/day of prednisone, or an equivalent corticosteroid. The following are exceptions to this criterion:\n\n    * Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection)\n    * Systemic corticosteroids at physiologic doses not to exceed 10 mg\/day of prednisone or its equivalent\n    * Steroids as premedication for hypersensitivity reactions (eg, chemotherapy, CT scan premedication)\n12. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (eg, hormone replacement therapy) is acceptable.\n13. History of allogeneic organ transplant\n14. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \\[eg, colitis or Crohn's disease\\], diverticulitis \\[with the exception of diverticulosis\\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \\[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc\\]). The following are exceptions to this criterion:\n\n    * Subjects with vitiligo or alopecia\n    * Subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement\n    * Any chronic skin condition that does not require systemic therapy\n    * Subjects without active disease in the last 5 years may be included but only after consultation with the study physician\n    * Subjects with celiac disease controlled by diet alone\n15. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness\/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent\n16. History of another primary malignancy except for Malignancy treated with curative intent and with no known active disease \u22655 years before the first dose of IP and of low potential risk for recurrence\n\n    * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\n    * Adequately treated carcinoma in situ without evidence of disease\n    * Adequately treated thyroid cancer (except. Anaplastic thyroid cancer)\n17. History of primary immunodeficiency\n18. Active pulmonary tuberculosis (Patients with old tuberculosis can be enrolled) Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness\/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent\n19. Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab\n20. 21. Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control\n21. History of hypersensitivity to the combination or comparator agent\n22. Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.\n23. Inability to comply with protocol or study procedures.","SEX":"ALL","AGE_MIN":20,"AGE_MAX":200,"SS_ID":"03694236001","EMAIL":[{"email":"cbc1971@yuhs.ac"}],"GEO":[37.566,126.9784]},{"TITLE":"OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain","CRITERIA":"Inclusion Criteria:\n\n* Female or male patients, treated with osimertinib\n* Age \u2265 18 years at starts of osimertinib treatment (i.e., index date).\n* Patients histologically diagnosed with EGFRm NSCLC (before index date):\n\n  * Patients with first-line treatment with EGFRm locally advanced or metastatic NSCLC, not amenable to curative surgery or radiotherapy (Cohort 1).\n  * Patients with stage IB-IIIA after complete tumor resection (Cohort 2).\n* Provision of informed consent (for alive patients). Deceased patients who met the selection criteria when they started treatment with osimertinib could also be included in the study.\n\nExclusion Criteria:\n\n* Osimertinib treatment administration in a clinical trial setting.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06068049022","EMAIL":"information.center@astrazeneca.com","GEO":[41.65606,-0.87734]},{"TITLE":"Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+\/MET+ Locally Advanced or Metastatic NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Fully aware of this study and voluntary to sign the informed consent form, and being willing and able to comply with the study procedure;\n2. Age \u2265 18\n3. In accordance with the Eighth Edition of TNM Staging of Lung Cancer by the International Association for the Study of Lung Cancer and American Joint Committee on Cancer, and patients with histologically or cytologically confirmed unresectable locally advanced (stage \u2162B\/\u2162C), metastatic or recurrent (stage IV) NSCLC who are not suitable for radical concurrent chemoradiotherapy;\n4. Carrying two common EGFR mutations clearly related with the sensitivity to EGFR-TKI (i.e., exon 19 deletion, and L858R) and c-MET overexpression\n5. Having measurable lesions (in accordance with RECIST 1.1 criteria);\n6. ECOG Performance Status score 0 or 1, or Karnofsky score \u226580;\n7. Survival is expected to exceed 12 weeks;\n8. No any previous systematic antitumor therapy for advanced\/metastatic disease;\n9. adequate bone marrow reserve or organ function\n10. Female patients of childbearing potential must agree to use effective contraceptive methods from screening period to 4 weeks after discontinuation of the study drug 11. Male patients whose sexual partners are women of childbearing potential must use condoms during sexual intercourse during the study and within 6 months after discontinuation of study drug\n\n12. Being able to take or swallow the drug orally.\n\nExclusion Criteria:\n\n1. Previous treatment with EGFR inhibitors or MET inhibitors;\n2. Currently having other malignant tumors, or having other infiltrating malignant tumors in the past 5 years\n3. Antitumor therapy within 2 weeks prior to the start of study treatment, including hormone therapy, biotherapy, immunotherapy or the traditional Chinese medicine for antitumor indication;\n4. Having received extensive radiotherapy (including radionuclide therapy, e.g., Sr-89) within 4 weeks prior to the start of study treatment or palliative local radiotherapy within one week prior to the start of study treatment, or the above adverse reactions of radiotherapy did not recover;\n5. Having received a major surgery within 4 weeks prior to the start of study treatment or a minor surgery (except biopsy, and venous catheterization) within one week prior to the start of study treatment;\n6. Currently receiving the potent CYP3A4 inducers or potent CYP1A2 inhibitors within two weeks prior to the start of study treatment;\n7. Having not been sufficiently recovered from the toxicity and\/or complication resulting from any interventional measure prior to the start of treatment;\n8. Clinically significant active infection, including but not limited to tuberculosis, human immunodeficiency virus (HIV) infection (positive HIV1\/2 antibody);\n9. Active hepatitis B, or active hepatitis C;\n10. Acute myocardial infarction, unstable angina pectoris, stroke or transient ischemic attack;\n11. Uncontrollable hypertension despite the use of drugs,\n12. Mean resting corrected QT interval (QTcF) or Any important abnormality in rhythm;\n13. Patients whose known cancerous thrombus or deep vein thrombosis are stable for \u22652 weeks after receiving treatment with low molecular weight heparin (LMWH) or analogues with similar efficacy can be enrolled;\n14. Any important abnormality in rhythm\n15. Presence of meningeal metastasis, spinal cord compression or active brain metastasis prior to the start of study treatment.\n16. Known allergy to the active or inactive ingredient of Savolitinib or Osimertinib;\n17. Lack of compliance with participation in this clinical study or inability to comply with the limitations and requirements of the study, as judged by investigators;\n18. Having participated in other drug clinical trials and received the study drug within 3 weeks prior to the start of study treatment; 19. Known allergy to the active or inactive ingredient of Savolitinib or Osimertinib; 20. Previous history of interstitial lung diseases, drug-induced interstitial lung diseases, radiation pneumonitis requiring glucocorticoid therapy and any active interstitial lung diseases; 21. Pregnant and lactating women; 22. Any other disease, metabolic abnormality, physical examination abnormality or laboratory examination abnormality, certain disease or state, based on which there is a reason to suspect that the subject is not suitable for the study drug, or one condition that will affect intepretaton of the study results or put the subject at high risk.","SEX":"ALL","AGE_MIN":28,"AGE_MAX":200,"SS_ID":"05009836001","EMAIL":[{}],"GEO":[23.11667,113.25]},{"TITLE":"C-TIL051 in Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Able to understand and give written informed consent\n* Histologically and cytologically confirmed diagnosis of stage IV or recurrent non-small cell lung cancer (NSCLC) with adenocarcinoma or squamous histology\n* Planned for treatment with an anti-PD1 agent\n* Tumor accessible by surgery, previously not irradiated and \u2265 1.5 cm in diameter\n* Measurable disease after resection of tumor by RECIST 1.1\n* ECOG \u2264 1\n* Expected survival \\> 6 months\n* Adequate organ and marrow function\n* ECHO, MUGA or cardiac stress test within past 6 months showing LVEF \\>50% and without evidence of reversible ischemia\n* Pulmonary function tests within past 6 months showing DLCO \\>50% of predicted\n\nExclusion Criteria:\n\n* Previous treatment with PD1\/PDL1 inhibitor for metastatic disease, Immune checkpoint blockade (ICB) given as part of definitive therapy for stage Ib-III disease with surgery or after chemo\/radiation is acceptable if last dose of ICB is at least 6 months prior to enrollment in this study.\n* Known driver mutations such as EGFR, ALK, ROS1, RET, METex14, and NTRK alterations.\n* Current or prior use of any immunosuppressive medications within 14 days before tumor harvest\n* Known active CNS metastases which are symptomatic\n* History of leptomeningeal metastases\n* Uncontrolled intercurrent illness\n* Known history of HIV+ or AIDS, hepatitis C, acute or chronic active hepatitis B or other serious chronic infection\n* Live vaccine within 30 days of tumor harvest\n* History of allogeneic organ transplant\n* History of primary immunodeficiency\n* Hypersensitivity to anti-PD1 agent, cyclophosphamide, fludarabine, interleukin-2, gentamicin, or any excipient\n* Any condition that may interfere with evaluation of study treatment, safety or study results\n* Active infection that requires IV antibiotics within 7 days of tumor harvest\n* Unresolved greater than grade 1 toxicity (CTCAE v5.0) from previous therapy\n* History of interstitial pneumonitis of autoimmune etiology that is symptomatic or requires treatment\n* Pulmonary disease history requiring escalating amounts of oxygen \\> 2L\n* Known autoimmune conditions requiring systemic immune suppression therapy other than low dose prednisone or equivalent.\n* Other malignancy, other than cutaneous localized) that required active treatment in the last 2 years.\n* Women who are pregnant or lactating\n* Women of childbearing potential or fertile men who are unwilling to use effective contraception during study and 6 months after treatment","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05676749001","EMAIL":[{"email":"cci-trialreferrals@duke.edu"},{}],"GEO":[35.7721,-78.63861]},{"TITLE":"Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers","CRITERIA":"Inclusion Criteria:\n\n* Subjects older than 18 years.\n* Subjects of all genders and ethnicities.\n* Subjects with the diagnosis of a solid cancer (n=100) of all stages will be included (lung, esophageal, stomach, bile duct\/pancreas, colorectal, melanoma, sarcoma).\n* Ten patients with no present suspicion and no previous history of any cancer (except basal cell cancer of the skin) that undergo surgeries for other benign indications will serve as controls (n=20).\n* In patients undergoing surgery for cancer the histopathology should preferably be pathologically proven by a previous or novel biopsy. Yet, patients with a high cancer suspicion by radiology and clinical picture that undergo cancer surgery will not be excluded. No additional biopsies, testing or interventions will be performed for the purpose of this study if the medical treatment will not require it.\n* Subjects must be capable of giving informed consent.\n\nExclusion Criteria:\n\n* Pregnant women.\n* Subjects with the concurrent diagnosis of an active secondary (synchronous) malignancy besides basal cell carcinoma of the skin will be excluded, if there is evidence of disease burden or if the patient is currently being treated with chemotherapy.\n* Subjects with a hemoglobin of \\<8g\/dl in the morning of the procedure will be excluded.\n* In subjects who require intraoperative transfusions of \\>4 units of red packed blood cells (RPBCs), no further blood will be drawn for CTC\/DTC\/cfDNA analysis during surgery or on postoperative day 1.\n* In patients with coagulation disorders that could lead to significant bleeding (such as hemophilia, significant thrombocytopenia) requiring prophylactic administration of coagulative products, no bone marrow aspiration will be performed.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"02838836001","EMAIL":[{"email":"kaifij@health.missouri.edu"}],"GEO":[38.95171,-92.33407]},{"TITLE":"Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Subjects must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC) or neuroendocrine carcinoid tumor\n* All subjects must have one of the following stages: Stage IA(T1NO); IB (T2NO), II \\& IIIA (N2 negative); IIIA (N2+), IIIB (N3+)\n* Patients must have stable disease at the time of enrollment\n* Women and men at least 18 years of age\n* ECOG performance status 0-1(Appendix A)\n* Subjects must be within 4 to 24 weeks of standard of care treatment for their particular stage of disease\n* Subjects must have acceptable organ and marrow function as defined below:\n\n  * Leukocytes \\> 3,000\/\u00b5L\n  * Absolute Neutrophils \\> 1,500\/\u00b5L\n  * Hemoglobin \\> 10 g\/dL\n  * Platelets \\> 100,000\/\u00b5L\n  * Total Bilirubin within normal institutional limits\n  * Creatinine within normal institutional limits OR\n  * Creatinine clearance \\> 60 mL\/min\/1.73 m2 for subjects with above normal AST and ALT with alkaline phosphatase within \\< 1.5 times upper limit of normal\n* The effects of a MUC1vaccine on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, men and women of childbearing potential must be willing to use effective contraception (hormonal barrier method of birth control; abstinence) while on study treatment and for at least 3 months thereafter. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately\n\nExclusion Criteria:\n\n* Subjects may not be receiving any other investigational agents\n\n  - No history of prior malignancy, except for non-melanoma skin cancer\n* Any positive ANA titer above 1:160, even in an asymptomatic individual. Note:\n\nWeakly positive ANA defined as ANA titers up to 1:160 maximum (\u2264 1:160) will be acceptable in an asymptomatic individual who is otherwise eligible for the study.\n\n* Known Hepatitis B on immunomodulators (i.e. interferon)\n* Known Hepatitis C on immunomodulators (i.e. interferon)\n* No prior vaccine therapy\n* Patients may not be receiving any steroids or other anti-immune therapy at the time of registration.\n* Subjects must not be more than 24 weeks from standard of care treatment for their particular stage of disease\n* Subjects must not have post-obstructive pneumonia or other serious infection at the time of registration or other serious underlying medical condition that would impair the ability of the subjects to receive protocol treatment\n* Prior resection of lung cancer is allowed, if at least five years have elapsed between previous resection and registration\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\/social situations that would limit compliance with study requirements\n* Pregnant women are excluded from this study. Women of childbearing potential must have a negative pregnancy test\n* Subjects with immune deficiency are not expected to respond to the vaccine. Therefore, known HIV-positive patients are excluded from the study\n* Subjects with a history of known autoimmune disease are excluded from this study","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"01720836001","EMAIL":"wardj@upmc.edu","GEO":[40.44062,-79.99589]},{"TITLE":"Onco-primary Care Networking to Support TEAM-based Care","CRITERIA":"Inclusion Criteria:\n\nA total of 800 individuals who fall under the following criteria will be enrolled:\n\n* Diagnosed with -\n\n  * Stage I-III breast \\[female\\], colorectal, endometrial (carcinomas), head\/neck \\[H\/N\\] and non-small cell lung cancer \\[NSCLC\\]\n  * Stage I-IV prostate cancer\n  * Organ transplant recipients are not excluded as long as kidney function is within eligible range\n  * Chronic Lymphocytic Leukemia or small lymphocytic lymphoma on first or second line treatment\n* Treated with curative intent (not applicable for patients diagnosed with CLL\/SLL)\n* 18-79 years old\n* Has at least one of three CVD comorbidities (hypertension, diabetes, or hypercholesterolemia) - based upon whether the patient is currently on a medication for the comorbidity at time of recruitment\n* Had a visit with their PCP in the previous 12 months\n\nPatients will be approached for study participation within 120 days of starting their cancer treatment at Duke (except for men with prostate cancer on androgen deprivation therapy \\[ADT\\] and those previously on active surveillance). Those coming off active surveillance to receive treatment will be approached within the next 120 days. Men with prostate cancer that are on ADT can be approached for consent at any time while on treatment.\n\nSupplement:\n\nA sample size of 2800-3000 patients will be pulled from the Duke Cancer Registry. The retrospective cohort will consist of older adults \u226565 years who have \u22651 CVD comorbidity (hypertension, type 2 diabetes, dyslipidemia) and underwent cancer surgery for solid tumors (breast, prostate, colorectal, endometrial, gastric, esophageal, liver, pancreatic, renal cell, bladder, ovarian, head\/neck, and non-small cell lung cancer) at DUHS from January 1st, 2017 to December 31st 2019.\n\nThe qualitative component of the supplement (Appendix IV: Aim 3) will involve 12-20 PCPs who arepart of the Duke Primary Care Research Consortium. Eligible PCP participants will be English-speaking providers who have provided care to \u22651 older adult patient who has undergone cancer surgery within a 12-month period at DUHS.\n\nExclusion Criteria:\n\nIndividuals with a history of the following conditions will be ineligible:\n\n* Myocardial infarction in the previous 24 months\n* Stage III-IV heart failure (EF \\<30%)\n* Stage IV-V chronic kidney disease (eGFR \\<30)\n* Neuroendocrine tumors\n* Uterine sarcomas\n* Bilateral axillary dissections - due to the inability to collect an upper extremity BP\n\nPatients who are coming to Duke for surgery only and not planning to return are ineligible. Patients who cannot read, are blind or do not understand\/speak English will not be enrolled.\n\nParticipants who progress to metastatic disease during the course of the 18-month study period will be allowed to continue to participate unless they voluntarily withdraw from the study.\n\nAdditional health information may be assessed on a case by case basis by the PI to determine if the individual is an appropriate candidate for the intervention.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":79,"SS_ID":"04258813001","EMAIL":[{"email":"kevin.oeffinger@duke.edu"},{"email":"leah.zullig@duke.edu"}],"GEO":[35.99403,-78.89862]},{"TITLE":"TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases","CRITERIA":"Inclusion Criteria:\n\n1. Male or female aged \u226518 years and \\<80 years.\n2. Patients diagnosed with NSCLC by histology or cytology, with brain metastases.\n3. Presence of an activating EGFR-sensitive mutations (including exon 19 deletions, L858R, the above mentioned mutations alone or co-existed with other EGFR-mutated sites).\n4. No prior systemic antitumor therapy for locally advanced or metastatic NSCLC.\n5. Stable brain metastases that do not require immediate or planned local treatment for it during the study period.\n6. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1.\n7. The ECOG score is 0-1, and there is no deterioration 2 weeks before the study, and the expected survival is not less than 3 months.\n8. Adequate bone marrow reserve function, and no liver, kidney and coagulation dysfunction.\n9. Male patients and female patients of reproductive age should take adequate contraceptive measures from signing informed consent to 3 months after the last study drug treatment; Women of childbearing age have negative pregnancy test results within 7 days of the first dose.\n10. Patients having recovered from all grade \u2264 1 toxicities related to previous anticancer therapies (CTCAE v 5.0) except for alopecia, platinum-therapy-related neuropathy (where \u22642 is allowed) before first dose of study treatment.\n11. Patients can understand and voluntarily sign the informed consent form.\n12. Patient able to comply with study requirements.\n\nExclusion Criteria:\n\n1. Any of the following treatment:\n\n   1. Previous treatment with EGFR inhibitor;\n   2. Previous treatment with Systematic antitumor therapy (including targeted therapy, biotherapy and immunodrug therapy, etc.)\uff1b\n   3. Previous treatment with standard chemotherapy with 28 days before the first dose of the study drug, and traditional Chinese medicine antitumor therapy within 7 days before the first dose of the study drug;\n   4. Previous whole brain radiation therapy (WBRT); Receiving radiation to more than 30% of the bone marrow or with a wide field of radiation that had to be completed within 28 days of the first dose of study treatment; Radiotherapy with a limited field of radiation within 7 days of the first dose of study treatment or palliative radiation therapy for bone metastasis;\n   5. Uncontrollable or poorly controlled pleural, abdominal and pericardial effusion;\n   6. Uncontrollable cancerous pain; Anesthetic painkillers did not reach a stable dose at the time of enrollment;\n   7. Major surgery within 28 days of the first dose of study treatment;\n   8. Patients currently receiving (or at least within 14 days prior to receiving the first dose )medications or herbal supplements known to be potent inhibitors or inducers of cytochrome P450 isoenzyme (CYP)3A4;\n   9. Patients who are receiving and need to continue receiving medications during the study that are known to prolong the QTc interval or may cause tachycardia;\n   10. Participants in other clinical trials (other than non-interventional clinical trials) within 28 days prior to the first administration of the investigational drug.\n2. Patients with primary malignant brain tumors and unstable brain metastases.\n3. Patients who have had or have a history of other malignancies within the past 5 years (except cured basal cell or squamous cell carcinoma of the skin, papillary carcinoma of the thyroid gland, carcinoma in situ of the cervix, and ductal carcinoma in situ of the breast).\n4. The patient had symptoms of spinal cord compression caused by the tumor.\n5. Clinically severe gastrointestinal dysfunction may affect the ingestion, transport or absorption of the study drugs.\n6. Cardiac function and disease are consistent with the following:\n\n   1. Corrected QT interval(QTc)\\> 470 milliseconds from 3 electrocardiograms (ECGs);\n   2. Any clinically important abnormalities in rhythm;\n   3. Any factors that increase the risk of QTc prolongation;\n   4. Left ventricular ejection fraction (LVEF) \\<50%.\n7. Active human immunodeficiency virus (HIV), syphilis, hepatitis c virus (HCV) or hepatitis b virus (HBV) infection, with the exception of asymptomatic chronic hepatitis b or hepatitis c carriers.\n8. Previous history of interstitial lung disease(ILD) or drug-induced ILD or radiation pneumonitis require steroid treatment, or any evidence of clinically active ILD diseases.\n9. Previous allogeneic bone marrow transplant.\n10. Pregnant or lactating women.\n11. Any other disease or medical condition that is unstable or may affect the safety or study compliance.\n12. Hypersensitivity to TY-9591 or similar compounds or excipients.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"05948813001","EMAIL":[{"email":"syuankaipum@126.com"}],"GEO":[39.9075,116.39723]},{"TITLE":"Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: The VAPOR-C Trial","CRITERIA":"Inclusion Criteria:\n\n1. Male or female patients aged 18 years or older at screening\n2. Has provided written informed consent for the trial\n3. Patient with American Joint committee on Cancer (AJCC) 8th edition Stage I-III colorectal cancer or Stage I-IIIa NSCLC, as confirmed by histological or cytological diagnosis. In cases where a histological diagnosis is not possible, suspected diagnosis through imaging techniques is acceptable.\n4. Patient has an American Society of Anaesthesiologists (ASA) score of 1 to 3\n5. Scheduled to receive elective, surgical resection with curative intent\n6. Surgery expected to last \u22652 hours and expected to require \u22652 nights hospital stay\n7. Able to comply with protocol requirements and follow-up procedures\n\nExclusion Criteria:\n\n1. Confirmed or suspected allergy to propofol, sevoflurane or intravenous lidocaine\n2. Patient with significant liver disease (with elevated International Normalised Ratio (INR) or bilirubin and\/or low albumin; i.e. Childs-Pugh Score \\>Class A;\n3. Patient at personal or familial risk of malignant hyperthermia or porphyria\n4. Patient with a history of other malignancies within the past 5 years. However, patients with malignancies managed with curative therapy and considered to be at low risk of recurrence such as treated skin basal cell carcinoma, squamous cell carcinoma, malignant melanoma \u22641.0mm without ulceration, localised thyroid cancer, cervical carcinoma in situ or prior malignancies with high likelihood of cure (e.g. low grade prostate and breast cancer) may be included in the study\n5. Patient has distant metastases\n6. Patient with an actual body weight less than 45kg\n7. Patients taking the following drugs that are moderate-strong inhibitors of the CYP1A2 and CYP3A4 metabolic pathways within 72 hours prior to surgery: Antibiotics - 'mycin' class: Clarithromycin, Telithromycin, Azithromycin, Erythromycin Antibiotics - 'floxacin' class Ciprofloxacin (exception: can be used preoperatively within a bowel prep regime), Norfloxacin, Levofloxacin, Sparfloxacin Antibiotics - other: Chloramphenicol, Isoniazid Antifungals: Fluconazole, Itraconazole, Ketoconazole, Posaconazole, Voriconazole Antiretrovirals: Atazanavir; Darunavir; Indinavir; Lopinavir; Nelfinavir; Ombitasvir, Paritaprevir, Ritonavir and Saquinavir. Antidepressants\/ADHD: Fluvoxamine, Enoxacine. Calcium-channel blockers: Diltiazem, Verapamil Monoclonal Antibodies: Ceritinib, Idelalisib, Lonafarnib, Tucatinib. Other strong cytochrome P450 3A4 inhibitors: Cimetidine, Cobicistat; grapefruit juice, Mifepristone, Nefazodone.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04316013027","EMAIL":[{}],"GEO":[-36.84853,174.76349]},{"TITLE":"Prediction of Response to Treatment With Immunotherapy + Chemotherapy in Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* 18 years at time of diagnosis\n* Affiliation to a social insurance\n* Obtaining the patient's non opposition\n* Patients with non-small cell lung carcinoma, confirmed by anatomopathological, metastatic or locally advanced unresectable, not eligible for local curative treatment\n* Cellular or tissue FFPE available\n* Indication of treatment with pembrolizumab + first line chemotherapy in multidisciplinary consultation meeting\n* No mutation of the EGFR gene, no rearrangement of ALK and ROS,\n* At least one measurable tumor according to RECIST criteria\n\nExclusion Criteria:\n\n* Tissue or cellular FFPE not available\n* Systemic anti-neoplastic or immunotherapy previously received except neoadjuvant or adjuvant treatment completed 6 months or more","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04589013002","EMAIL":[{}],"GEO":[50.63297,3.05858]},{"TITLE":"Shared Decision Making on Radiation Dose for Lung Malignancies","CRITERIA":"Inclusion Criteria:\n\n* Age \u2265 18 years\n* Histologically confirmed or high probability of non-small cell lung cancer, or metastasis from other cancer, located \u2264 1 cm from the thoracic wall. High probability refers to consensus on the diagnosis at the local multi-disciplinary lung tumor conference.\n* Eligible for stereotactic body radiation therapy in ablative doses (i.e. 66\/45 Gy in 3 fractions) following national guidelines (2).\n* Can read and understand Danish.\n* Written and orally informed consent.\n* Performance status 0-2\n* Life expectancy \\> 6 months assessed by the physician during the consultation.\n\nExclusion Criteria:\n\n* Previous radiation therapy in the thoracic region (lung, breast or mediastinum), if it is not possible to produce a new radiation plan of 66 or 45 Gy in 3 fractions that considers previous radiation therapy and still complies with all constraints, including dose to the thoracic wall. Previous surgery in the thorax is allowed.\n* Mental or social conditions preventing full understanding of the information or the planned treatment and follow-up.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04940936001","EMAIL":[{"email":"thomas.leth.fink@rsyd.dk"}],"GEO":[55.70927,9.5357]},{"TITLE":"A Study of AMG 193 in Subjects With Advanced MTAP-null Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Participant has provided informed consent\/assent before initiation of any study specific activities\/procedures.\n* Age \u2265 18 years.\n* Evidence of homozygous loss of cyclin dependent kinase inhibitor 2A (CDKN2A) (null) (Parts 1a, 1j, 1k, and 2a only) and\/or methylthioadenosine phosphorylase (MTAP) (null) in the tumor tissue or blood (Parts 1a to 1k, Parts 2a and 2b) or lost MTAP expression in the tumor tissue (Parts 1a to 1k, Parts 2a and 2b).\n* Histologically confirmed metastatic or locally advanced solid tumor not amenable to curative treatment with surgery and\/or radiation.\n* Able to swallow and retain orally (PO) administered study treatment and willing to record daily adherence to investigational product.\n* Disease measurable as defined by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Note: except participants enrolling to Part 1m.\n\nEastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n\n* Adequate hematopoietic function per local laboratory\n* Adequate renal function per local laboratory\n* Adequate glucose control per local laboratory (Part 1 only)\n* Adequate liver function per local laboratory\n* Adequate coagulation parameters\n* Adequate pulmonary function\n* Adequate cardiac function\n* Minimum life expectancy of 12 weeks as per investigator judgement.\n* A total of 25 slides of archived tumor tissue (formalin-fixed, paraffin-embedded \\[FFPE\\] sample collected within 5 years) or an archival block must be available.\n* For Part 1f (MTAP-null or lost MTAP expression HNSCC): Must be willing to undergo tumor biopsy.\n* For Part 1a: Must be willing to undergo tumor biopsy, before start of treatment (archival sample acceptable if obtained with 6 months of enrollment and subject has not received any other treatment since sample was obtained) and while on treatment.\n* For DSPS study (Part 1j): Must be willing to participate in DSPS substudy (US sites only).\n\nFood Effect Substudy (Part 1k): Specific Inclusion Criteria\n\n* Subject able and willing to eat a standardized high-fat, high-caloric meal\n* Subject able and willing to fast for \u2265 6 hours\n\nSpecific Inclusion Criteria for subjects with glioma (Part 1m only)\n\n-Disease measurable as defined per Modified Response Assessment in Neuro-Oncology Criteria 2.0 (mRANO 2.0)\n\nExclusion Criteria:\n\n* Spinal cord compression or untreated brain metastases or leptomeningeal disease.\n* History of other malignancy within the past 2 years\n* Any evidence of current interstitial lung disease\n* Active infection\n* Evidence of active severe acute respiratory syndrome coronavirus 2 (SARS-COV2) infection.\n* History of arterial thrombosis\n* Myocardial infarction and\/or symptomatic congestive heart failure.\n* Gastrointestinal tract disease\n* History of bowel obstruction, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess\n* History of solid organ transplant.\n* Diagnosis of Congenital Short QT Syndrome.\n* Major surgery\n* Anti-tumor therapy within 28 days of study day 1.\n* Prior treatment with an methionine adenosyltransferase 2\u03b1 (MAT2A) inhibitor or a protein arginine methyltransferase 5 (PRMT5) inhibitor.\n* Prior treatment with docetaxel (Part 2 only)\n* Prior irradiation to 25% of the bone marrow.\n* Therapeutic or palliative radiation therapy within 2 weeks of study day 1.\n* Live vaccine therapy within 4 weeks before study drug administration.\n* Use of therapeutic anti-coagulation for treatment of active thromboembolic events.\n* Use of prescription medications that are known strong inducers of cytochrome P450 3A4 (CYP3A4) within 14 days or 5 half-lives (whichever is longer) before study day 1\n* Unresolved toxicity from prior anti-cancer therapy\n* Currently receiving treatment in another investigational device or drug study.\n* Known positive test for Human Immunodeficiency Virus (HIV).\n* Positive hepatitis B surface antigen\n* positive hepatitis C virus ribonucleic acid (RNA) by polymerase chain reaction (PCR)\n* Female participants of childbearing potential unwilling to use protocol specified method of contraception","SEX":"ALL","AGE_MIN":18,"AGE_MAX":100,"SS_ID":"05094336062","EMAIL":"medinfo@amgen.com","GEO":[51.50853,-0.12574]},{"TITLE":"A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy","CRITERIA":"Inclusion Criteria:\n\n* Male or female aged 18 years or older\n* Diagnosed as NSCLC stage II-IIIA (staging should be confirmed after surgery)\n* Have completely removed all of the cancer from the body surgically\n* Have been received 3 or 4 cycles of platinum-based chemotherapy after surgery\n\nExclusion Criteria:\n\n* Have received anti-cancer therapy before surgery\n* Have or had autoimmune disease in past 5 years","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06268613020","EMAIL":"sbregistry@samsung.com","GEO":[41.01384,28.94966]},{"TITLE":"Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1","CRITERIA":"Inclusion Criteria:\n\nPart A\n\n1. Subject must be at least 18 years old and must have histologically confirmed, unresectable, locally advanced, or metastatic PD-L1-expressing solid cancer not amenable to standard treatment, or for whom standard treatment is not available, or in the Investigator's opinion the standard treatment would not be in the subject's best interest. Any level of PD-L1 expression assessed by using any Food and Drug Administration (FDA) approved PD-L1 immunohistochemistry (IHC) assay is accepted. In addition, another PD-L1 assay may be considered acceptable if approved by the Medical Monitor. The assessment should have been performed on the most recent available tissue from a site of metastatic disease (if possible).\n2. Subject must have evaluable or measurable disease.\n\n   Part B\n3. Requirements for separate cohorts enrolled in Part B are as follows:\n\n   * Cohort 1: Histologically confirmed recurrent or metastatic NSCLC not amenable to standard treatment, or standard treatment is not available, or in the Investigator's opinion the standard treatment would not be in the subject's best interest. NOTE: subjects with driver mutations are only eligible if they have received all appropriate targeted therapies.\n   * Cohort 2: Histologically confirmed recurrent, resistant, or metastatic SCCHN (oral cavity, oropharynx, hypopharynx, or larynx) not amenable to standard treatment, or standard treatment is not available, or in the Investigator's opinion the standard treatment would not be in the subject's best interest. Subjects who refuse radical resection are eligible. NOTE: nasopharyngeal cancer, squamous cell carcinoma of any other primary anatomic location in the head and neck, subjects with SCCHN of unknown primary, and subjects with skin squamous cell carcinoma (SCC) of the head and neck are not eligible for this arm. The tumor must be platinum resistant or the subject ineligible for platinum therapy due to hypersensitivity or concerns with ototoxicity.\n   * Cohort 3: Subjects with any other relapsed or refractory PD-L1 positive solid tumor not amenable to standard treatment, or standard treatment is not available, or in the Investigator's opinion the standard treatment would not be in the subject's best interest, who received PD-1\/PD-L1 treatment. Subjects with PD-L1 positive solid tumor types, for which PD-1\/PD-L1 treatment is not approved, could be enrolled at the Investigator's discretion and after discussion with the Medical Monitor.\n4. Positive PD-L1 expression as assessed by an FDA approved PD-L1 IHC assay is required. The assessment should have been performed on the most recently available tissue and form a site of metastatic disease (if possible). Subjects without PD-L1 measured by an FDA-approved diagnostic must have PD-L1 expression confirmed by an FDA-approved diagnostic on either archived tissue or a fresh biopsy. Subjects for whom PD-L1 expression has not been determined and do not have archived tissue will require a fresh biopsy for PD-L1 determination by an FDA-approved diagnostic.\n5. Subjects must be willing to have a total of 2 on trial biopsies: one at baseline and the other within the last 2 weeks of Cycle 2. Subjects who required a fresh biopsy at screening may utilize the screening biopsy tissue in lieu of the baseline biopsy.\n6. Subject must have at least 1 measurable tumor lesion according to RECIST 1.1.\n\n   Parts A and B\n7. Subject must have Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1.\n8. Prior treatment must include a CPI (i.e., PD-1 inhibitors, PD-L1 inhibitors with or without CTLA-4 inhibitors) if there is an approved CPI for the specific cancer type. Subjects may also have received CPIs in an investigational setting. Subjects who have not received a CPI and where there is no approved CPI for the specific cancer type could be enrolled at the Investigator's discretion and after discussion with the Medical Monitor.\n9. Subject must have adequate bone marrow function (NOTE: administration of blood products and growth factors is not allowed within 2 weeks prior to screening laboratory tests):\n\n   * absolute neutrophil count (ANC) \u2265 1,500\/\u03bcL\n   * platelet count \u2265 100,000\/\u03bcL\n   * hemoglobin \u2265 8.0 g\/dL\n10. Subject must have adequate renal function, based on estimated creatinine clearance (eCrCl) \u2265 50 mL\/min, calculated by the Cockcroft-Gault equation.\n\n    NOTE: At the Investigator's discretion, the eCrCl result \\< 50 mL\/min may be verified by measured creatinine clearance (mCrCl) based on the 24-hour urine collection. Subjects with mCrCl \u2265 50 mL\/min will be eligible irrespective of the eCrCl result calculated by the Cockcroft-Gault equation.\n11. Subject must have adequate hepatic function, as determined by:\n\n    * total bilirubin (or direct bilirubin for subjects with Gilbert's disease) \\< 1.5 \u00d7 upper limit of normal (ULN)\n    * aspartate aminotransferase (AST) \u2264 3 \u00d7 ULN (or \u2264 5 \u00d7 ULN if liver metastasis)\n    * alanine aminotransferase (ALT) \u2264 3 \u00d7 ULN (or \u2264 5 \u00d7 ULN if liver metastasis)\n12. Subject must have adequate serum albumin (albumin \u2265 2.5 g\/dL)\n13. Subjects capable of having children must have a negative highly sensitive pregnancy test within 72 hours before the start of treatment. Subjects who are postmenopausal (\\> 1 year since last menstrual cycle) or permanently sterilized (e.g., bilateral tubal occlusion, hysterectomy, bilateral salpingectomy) may be considered as not of reproductive potential.\n14. Subjects of reproductive potential must agree either to abstain continuously from heterosexual intercourse or to use a highly effective birth control method from signing the informed consent until 30 days after the last dose of MT-6402 for subjects capable of bearing children and until 90 days after the last dose of MT-6402 for subjects capable of fathering children.\n\nExclusion Criteria:\n\nPart A\n\n1. Subjects without available tissue from a site of metastatic disease or easily biopsied lesion (biopsy sites of non significant risk, in the opinion of the Investigator) or unwilling to consent to biopsy.\n\n   Part B\n2. Subjects without easily biopsied lesions (biopsy sites of non significant risk, in the opinion of the Investigator) or unwilling to consent to baseline and end of Cycle 2 biopsy. Patients for whom a biopsy is not feasible must be discussed with the Medical Monitor.\n3. Subjects unwilling to have baseline and on-study core biopsy (last 2 weeks of Cycle 2) performed.\n\n   Parts A and B\n4. History or current evidence of another neoplastic disease, except cervical carcinoma in situ, superficial noninvasive bladder tumors, curatively treated Stage I to II non melanoma skin cancer or any previous cancer curatively treated \\> 2 years before the start of treatment.\n5. Active autoimmune disease currently under treatment or required systemic treatment within 2 years (replacement therapy, e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency is allowed). Subjects who have not required systemic treatment of an auto-immune disease for at least 2 years may be enrolled if permission is provided after discussion with the Medical Monitor.\n6. Ongoing \\> Grade 1 immune related toxicity caused by prior CPI therapy (i.e., PD-1 inhibitors, PD-L1 inhibitors, or CTLA-4 inhibitors). Subjects with stable endocrinological AEs, e.g., hypothyroidism, adrenal insufficiency, hypopituitarism, or diabetes mellitus, must have been on a stable dose of supplemental therapy for at least 2 weeks before screening to be eligible for this study. History of repeat Grade 2 pneumonitis or carditis on previous CPI and\/or Grade 3 immune related adverse event on previous CPI treatment.\n7. Evidence of active noninfectious \u2265 Grade 2 pneumonitis or current evidence of \u2265 Grade 3 other underlying pulmonary disease.\n8. Received any of the following PD-L1 inhibitors within the following time periods prior to the first dose of MT-6402: atezolizumab - 12 months; durvalumab - 7 months; avelumab - 2 months.\n9. Any concurrent cancer treatment, apart from local treatment of non-target lesions for palliative intent (e.g., local surgery or radiotherapy).\n10. Prior radiation therapy within 4 weeks before the start of study treatment. NOTE: A lesion in a previously irradiated area can only be considered target lesion if there has been radiographical disease progression since the end of radiation therapy.\n11. Received approved or investigational treatment for the disease under study (except PD L1 inhibitors where exclusion criterion 6 applies) within 4 weeks before the start of treatment. For small molecules (MW \\< 0.9 kDa), the washout is 5 half-lives, but at least 2 weeks.\n12. Subjects who have had allogeneic tissue or solid organ transplantation.\n13. Current evidence of new or growing central nervous system (CNS) metastases during screening. Subjects with known asymptomatic CNS metastases will be eligible if they meet all the following criteria:\n\n    1. Evidence of leptomeningeal metastasis.\n    2. Have stable CNS disease on the computed tomography (CT) or magnetic resonance imaging (MRI) scan within 4 weeks before screening compared with prior neuro imaging.\n14. Major surgical procedure (as defined by the Investigator) within 28 days prior to the start of study treatment.\n15. History or current evidence of significant cardiovascular disease before the start of treatment, including but not limited to the following conditions:\n\n    1. Angina pectoris requiring anti-anginal medication, (chest pain: Common Terminology Criteria for Adverse Events \\[CTCAE\\] Grade \u2265 2)\n    2. Clinically significant valvular disease.\n    3. Myocardial infarction within 12 months prior to the start of treatment.\n    4. Arterial thrombosis or pulmonary embolism within 3 months before the start of treatment.\n    5. History of Grade \u2265 2 symptomatic congestive heart failure (CHF) or New York Heart Association (NYHA) criteria Class \u2265 II.\n    6. Left ventricular ejection fraction (LVEF) \\< 55%, assessed preferably by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan if ECHO is not available, within 28 days before starting study treatment.\n    7. High-risk uncontrolled arrhythmias (i.e., atrial tachycardia with a heart rate \\> 100\/min at rest and upon repeated testing, significant ventricular arrhythmia (CTCAE Grade \u2265 2 \\[ventricular tachycardia\\], or higher-grade atrioventricular \\[AV\\]-block \\[second degree AV-block Type 2 \\[Mobitz 2\\] or third-degree AV-block\\]) or left ventricular bundle branch block. Subjects receiving digoxin, calcium channel blockers, or beta adrenergic blockers are eligible at the Investigator's discretion after consultation with the Medical Monitor if the dose has been stable for \u2265 2 weeks before the start of treatment with MT-6402.\n    8. Any of the following within 3 months before the start of treatment: pericarditis (any CTCAE Grade), pericardial effusion (CTCAE Grade \u2265 2), non-malignant pleural effusion (CTCAE Grade \u2265 2) or malignant pleural effusion (CTCAE Grade \u2265 3) (subjects with pleural effusion that is manageable and stable \\> 3 months prior to study are eligible).\n    9. QT interval correction for heart rate using Fridericia's formula (QTcF) \u2265 470 ms (average from 3 QTcF values on the triplicate 12-lead electrocardiogram \\[ECG\\]) at screening. In subjects with right bundle branch blocks, additional corrections will be performed to calculate the QT equivalent JT, and depending on the result the subject may be eligible with the agreement of the Medical Monitor.\n16. Current evidence of uncontrolled human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) at screening. Serology testing is not required if seronegativity is documented in the medical history, and if there are no clinical signs suggestive of HIV or hepatitis infections, or suspected exposure. The following exceptions apply for subjects with positive viral serology:\n\n    1. Subjects with HIV and an undetectable viral load and CD4 + T-cell (CD4+) counts \u2265 350 cells\/mL may be enrolled, but must be taking appropriate opportunistic infection prophylaxis, if clinically relevant.\n    2. Subjects with positive HBV serology are eligible if they have an undetectable viral load and the subject will receive antiviral prophylaxis for potential HBV reactivation per institutional guidelines.\n    3. Subjects with positive HCV serology are eligible if quantitative polymerase chain reaction (PCR) for plasma HCV RNA is below the lower limit of detection. Concurrent antiviral HCV treatment per institutional guidelines is allowed.\n17. Current treatment requiring systemic steroids at doses \\> 10 mg\/day prednisone equivalent.\n18. Subjects with a history of hypersensitivity or serious toxic reactions to kanamycin or other aminoglycosides.\n19. Subjects with unintentional weight loss \\> 10% of their body weight over the preceding 2 months or less before screening.\n20. Subjects who are pregnant or breastfeeding.\n21. History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the Investigator or Medical Monitor, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04795713016","EMAIL":[{"email":"isabel.jimenez@startsa.com"},{}],"GEO":[29.42412,-98.49363]},{"TITLE":"PET-CT Predicting Segement Specific Lymph Nodes Metastasis","CRITERIA":"Inclusion Criteria:\n\n* Solitary tumor, or multiple tumors with only ground-glass nodules (GGNs) apart from the primary lesion.\n* Diameter of the primary lesion \u22645cm, with a CTR between 0.5 and 1.\n* No enlarged mediastinal lymph nodes observed on preoperative contrast-enhanced CT.\n* Pathological confirmation of non-small cell lung cancer (NSCLC) either before or during surgery.\n* Systematic lymph node dissection performed during surgery.\n* No prior radiotherapy or chemotherapy for initial treatment.\n* No history of malignant tumors.\n\nExclusion Criteria:\n\n* Locally advanced or distant metastasis.\n* Pleural dissemination observed during surgery.\n* History of malignant tumors.\n* Received neoadjuvant therapy.\n* Systematic lymph node dissection not performed during surgery.\n* Histopathological examination reveals lung malignancies other than non-small cell lung cancer (NSCLC).","SEX":"ALL","AGE_MIN":20,"AGE_MAX":80,"SS_ID":"05970913001","EMAIL":[{"email":"drlihang@163.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial","CRITERIA":"Inclusion Criteria:\n\n1. Patient age between 18 and 75\n2. Signed Informed Consent Form.\n3. Confirmed TNM stage is III-\u2163 of NSCLC \uff0cand failed, refused or assessed ineligible to receive conventional treatments (surgery, chemoradiotherapy, chemotherapy )\uff1b Eastern Cooperative Oncology Group (ECOG) performance status \u2264 1\n4. Adequate hematologic and end-organ function.\n5. Expected life span \\> 3 months.\n6. Be able to provide fresh or archival tumor tissues for PD-L1 expression in tumor cells\n\nExclusion Criteria:\n\n1. Prior treatment targeting PD-1, PD-L1 or CTLA-4.\n2. Prior therapies of interventional therapy (I seed implantation, Ablation, BACE).\n3. Harboring EGFR sensitizing mutation or ALK gene translocation\n4. History of interstitial lung disease, non-infectious pneumonitis or participants with significantly impaired pulmonary function, or who require supplemental oxygen at baseline.\n5. With uncontrollable pleural effusion, pericardial effusion, or clinically significant ascites requiring interventional treatment.\n6. Symptomatic central nervous system metastasis\n7. Known HIV infection, participants with untreated chronic hepatitis B, active vaccination treatment.\n8. Prior allogeneic stem cell transplantation or organ transplantation\n9. Active autoimmune diseases or history of autoimmune diseases that may relapse.\n10. With conditions requiring systemic treatment with either corticosteroids (\\>10 mg daily prednisone or equivalent) or other immunosuppressive medications\n11. Known to be hypersensitive to contrast agent;\n12. Pregnant or breastfeeding women;\n13. Other protocol defined Inclusion\/Exclusion criteria may apply","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05605613008","EMAIL":[{"email":"xuhuaduan@163.com"}],"GEO":[34.75778,113.64861]},{"TITLE":"Pembrolizumab for Advanced NSCLC and PS 2-3","CRITERIA":"Inclusion Criteria:\n\n* Men and women, aged 18 years and older, with locally advanced NSCLC who are ineligible for definitive surgical resection or concurrent chemoradiation, or metastatic NSCLC\n* Patients must not have received any systemic therapy for metastatic cancer\n* Patients must not have received any PD-1 or PD-L1 inhibitor\n* ECOG performance status of 2 or 3 at the time of consent and on the first day of therapy\n* Patients may not have a molecular alteration in ALK, ROS1, EGFR, BRAF, NTRK, RET, MET, or any other gene for which first-line FDA approved targeted therapy exists.\n* Patients with treated brain metastases are eligible if there is no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period.\n* Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS directed therapy is not required and is unlikely to be required during the first cycle of therapy.\n* Patients with HIV on effective anti-retroviral therapy with an undetectable viral load within 6 months are eligible for this trial.\n* Adequate organ and marrow function as defined below:\n\n  * Leukocytes \u2265 3,000\/mcL\n  * Absolute neutrophil count \u2265 1,000\/mcL\n  * Platelets \u2265 100,000\/mcl\n  * Total bilirubin \u2264 1.5 x ULN\n  * AST (SGOT)\/ALT (SPGT) \u2264 3 x ULN or \u22645 x ULN if liver metastases present\n  * GFR (Cockroft-Gault) \u2265 30 mL\/min\n* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 3 days prior to C1D1 of pembrolizumab therapy. For the purposes of this trial, WOCBP are defined as women who have had a menstrual period within the last 48 months.\n* Provision of signed and dated informed consent form\n* Ability to take the study medication, and complete the study questionnaires\n* Stated willingness to comply with all study procedures for the duration of the study\n* For women of reproductive potential, agreement to use highly effective contraception during study treatment and for at least 4 months after the final dose\n* For men of reproductive potential, agreement to use condoms or other methods to ensure effective contraception with female partners of reproductive potential\n\nExclusion Criteria:\n\n* Autoimmune conditions requiring \\>10mg prednisone (or its equivalent) of daily therapy or other systemic immunosuppressive therapy.\n* Patients who are receiving other investigational agents\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\/social situations that would limit compliance with study requirements\n* Patients with known leptomeningeal disease for which CNS therapy is required\n* Pregnant or lactating patients","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05589818001","EMAIL":[{"email":"Katherine.Vandris@mssm.edu"},{"email":"Bailey.Fitzgerald@mountsinai.org"},{}],"GEO":[40.71427,-74.00597]},{"TITLE":"Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. stage IIIB or stage IV NSCLC by histology or cytology;\n2. All centers confirmed ALK positive by tissue samples (Abbott FISH, VENTANA ALK D5F3, NGS method confirmation);\n3. Without any ALK-TKI treatment;\n4. Voluntarily and capable of following the trial and follow-up procedures;\n5. Able to understand the nature of the trial, and be able to complete the signing of a written informed consent form.\n\nExclusion Criteria:\n\n* 1. Pereceived any ALK-TKI treatment ; 2. Received any chemotherapy within 4 weeks, or underwent major surgery or radiotherapy within the last 14 days; 3. The investigator believes that the patient is not suitable for Ensatinib treatment.\n\nHad a stem cell or organ transplant. 4. Having serious cardiovascular disease, including but not limited to: 5.Sino - QTcF interval \u2265450 ms or other significant ECG abnormalities. According to the study, researchers either ruled that hypertension was poorly controlled (systolic blood pressure \\>160 mmHg or diastolic blood pressure \\>100mmHg).\n\n6. Dysphagia, active gastrointestinal disease, or other disease that significantly affects drug absorption, distribution, metabolism, and excretion.\n\n7. Previous history of interstitial lung disease, drug-induced interstitial lung disease, radioactive pneumonia requiring steroid treatment, or any indication of clinically active interstitial lung disease.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05132218001","EMAIL":[{"email":"xiaotong10241@sina.com"}],"GEO":[39.9075,116.39723]},{"TITLE":"Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy","CRITERIA":"Inclusion Criteria:\n\n* Age at least 18 years.\n* Locally advanced (IIIB and IIIC) or metastatic (IV) NSCLC.\n* Tumor tissue samples or blood samples are confirmed to be EGFR sensitive mutations (including exon 19 deletion or L858R, both alone or coexist with other EGFR mutations).\n* Patients have been treated with one kind of EGFR-TKIs and suffered from drug-induced liver injury, and have stopped EGFR-TKIs treatment before enrollment; or patients with basic hepatopathy (alcoholic liver disease, viral liver disease, metabolism related fatty liver disease, autoimmune liver disease, genetic metabolic liver disease), and patients can be treated with EGFR-TKIs after medical specialist evaluation, and no longger treated with hepatoprotective drugs (anti-inflammatory drugs, liver cell membrane repair protective agents, detoxification drugs, antioxidant drugs, cholagogic drugs) for 4 weeks before enrollment.\n* ALT and AST \u2264 3 ULN, Child-Pugh grade A or B (\u2264 9 points), and maintained for 4 weeks before enrollment (liver function evaluation criteria according to CTCAE 5.0) .\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3, and has not deteriorated at least 2 weeks, and the expected survival period is not less than 12 weeks.\n* According to RECIST1.1, the patient has at least one intracranial target lesion and one extracranial target lesion. The requirements for target lesions are: measurable lesions that have not undergone local treatment such as irradiation or have clearly progressed after local treatment, with the longest diameter at baseline \u226510 mm (if it is a lymph node, the maximum short diameter is required to be \u226515 mm).\n\nExclusion Criteria:\n\n* As judged by the investigator, patients with any serious or poorly controlled systemic diseases, such as poorly controlled hypertension, active bleeding-prone constitution, or active infection.\n* Patients with any other malignant tumor in the past 5 years.\n* Patients with prior drug-induced liver injury other than EGFR-TKIs.\n* Patients with refractory nausea, vomiting or chronic gastrointestinal diseases, cannot swallow the study drug or who have received extensive intestinal resection, may affect the full absorption of Almonertinib.\n* A history of interstitial lung disease, a history of drug-induced interstitial lung disease, a history of radiation pneumonitis requiring steroid therapy, or any evidence of clinically active interstitial lung disease.\n* Before Almonertinib treatment, patients with unresolved residual toxicity from previous anti-tumor therapy greater than CTCAE level 3, except for hair loss.\n* Meet any of the following cardiac examination results:\n\n  1. The average value of QT interval (QTcF) corrected by Fridericia's formula obtained from 3 ECG examinations at rest\\> 470 msec;\n  2. Resting ECG suggests that there are various clinically significant rhythms, conduction or ECG morphological abnormalities that are judged by the investigator (such as complete left bundle branch block, 3 degree atrioventricular block, 2 degree atrium Ventricular block and PR interval\\> 250 msec, etc.);\n  3. There are any factors that increase the risk of QTc prolongation or arrhythmia events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death or prolonged QT of immediate family members under 40 Any concomitant drugs in the interval;\n  4. Left ventricular ejection fraction (LVEF) \\<50%.\n* Insufficient bone marrow reserve or organ function, reaching any one of the following laboratory limits (no corrective treatment within 1 week before laboratory examination of blood draw):\n\n  1. Absolute neutrophil count \\<1.5\u00d7109 \/ L;\n  2. Platelet count \\<100\u00d7109 \/ L;\n  3. Hemoglobin \\<90 g\/L (\\<9 g\/dL);\n  4. Creatinine\\>1.5\u00d7ULN and creatinine clearance rate\\<50 mL\/min (calculated by Cockcroft-Gault formula); Only when creatinine\\>1.5\u00d7ULN, creatinine clearance rate needs to be confirmed;\n  5. Serum albumin (ALB) \\<28 g\/L.\n* Female with positive blood or urine pregnancy test results during lactation or within 3 days before the first administration of the study treatment.\n* Active fungal, bacterial and\/or viral infections requiring systemic treatment.\n* Have a history of hypersensitivity to any active or inactive ingredients of Almonertinib or to drugs with similar chemical structure to Almonertinib or the same class of Almonertinib.\n* Patients with decompensated cirrhosis, hepatic encephalopathy, hepatorenal syndrome, esophageal and gastric varices bleeding, and intractable ascites.\n* Patients have treated with other three generations of EGFR-TKIs.\n* Patients with any serious or uncontrolled disease, investigator judged that there are any patients with conditions that endanger the safety of the patient or interfere with the evaluation of the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05662813001","EMAIL":[{}],"GEO":[39.9075,116.39723]},{"TITLE":"Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. signed informed consent;\n2. patients age 18 to 75 years old\n3. primary resectable, histologically confirmed non small cell lung cancer;\n4. non small cell lung cancer the clinical stage was IIA-IIIB (no N3 patient) (according to AJCC TNM stage, 8th edition).\n5. ECOG PS 0-1.\n6. the diseases could be resectable assessed by thoracic oncologist\n\nExclusion Criteria:\n\n1. with significant cardiovascular disease;\n2. current treatment with anti-viral therapy or HBV;\n3. Female patients who are pregnant or lactating;\n4. history of malignancy within 5 years prior to screening;\n5. active or history of autoimmune disease or immune deficiency;\n6. signs of distant metastases.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05882513001","EMAIL":[{"email":"iwuming22@zju.edu.cn"}],"GEO":[30.29365,120.16142]},{"TITLE":"Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage \u2162A-N2 Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Histology or cytology confirmed Non-small Cell Lung Cancer; EGFR mutation (EGFR 19del and\/or 21L858R) detected by tumor tissue biopsy of primary lesion or metastatic lesion or plasma ctDNA\n* No previous anti-tumor treatment such as surgery, chemotherapy, radiotherapy or biological therapy\n* Stage IIIA N2 NSCLC according to the pathological evidence of endobronchial ultrasound(EBUS) or PET-CT, the short-axis diameter of lymph node 1-2cm, and considered surgically resectable at baseline by the surgical oncologist\n* Sufficient tumor histological specimens (non-cytology) for molecular marker analysis\n* At least one lesion with measurable diameter and its longest diameter is large than 10 mm by CT measurement\n\nExclusion Criteria:\n\n* Previous systemic anti-tumor treatment of Non-small Cell Lung Cancer, including cytotoxic drug therapy, targeted drug therapy (tyrosine kinase inhibitors or monoclonal antibodies) and experimental treatment, etc\n* Previous local radiotherapy of Non-small Cell Lung Cancer\n* Be allergic to any component of Icotinib tablet (Conmana)\n* Other cancers within five years prior to the treatment of this study. Except for cervical carcinoma, basal cell carcinoma and bladder epithelial neoplasm (including Ta and Tis)\n* Any instable systemic disease, including: active infection, high blood pressure out of control, unstable angina, onset of angina pectoris within the past 3 months, congestive heart failure, myocardial infarction, severe arrhythmia, liver, kidney or metabolic disease\n* Previous interstitial lung disease, drug-induced interstitial disease, radiation pneumonia requiring hormone therapy or any active intersexual lung disease with clinical evidence\n* Idiopathic pulmonary fibrosis detected by CT scan at baseline;\n* Not fully controlled eye inflammation or infections, or any condition that may lead to the above eye diseases\n* Human immunodeficiency virus infection\n* Patients undergoing major surgery or severe trauma within 2 months prior to the first use of the experimental drug\n* Patients with Small Cell Lung Cancer\n* Pregnant or lactating women\n* Neurological or psychiatric disorders history, including epilepsy or dementia\n* Other situations not appropriate to enter the group considering by the investigators","SEX":"ALL","AGE_MIN":18,"AGE_MAX":70,"SS_ID":"03749213001","EMAIL":[{},{}],"GEO":[39.9075,116.39723]},{"TITLE":"Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Patients must volunteer participating in clinical trial; patients fully understand and sign the Informed Consent Form (ICF)\n* 18 \\~ 70 years old, gender not limited\n* Histologically confirmed resectable stage IIA-IIIA NSCLC without prior treatment\n* Patients must have at least one \"target\" lesion\" to be used to assess response on this protocol as defined by RECIST 1.1\n* Agree to provide PD-L1 immune tissue sections and corresponding pathology reports for biomarker evaluation (Tumor tissue samples must be fresh or archived samples obtained within 3 months before enrollment\n* Have a performance status of 0 or 1 on the ECOG Performance Scale\n* Good organ function: ANC \u2265 1500\/\u03bcL; PLT \u2265 100000\/\u03bcL; HB \u2265 10.0g\/dL; CR \u2264 1.5 \u00d7 ULN or CrCl \u2265 60 mL\/min (Use Cock-Gault formula); TB \u2264 1.5 \u00d7 ULN (For patients with total bilirubin levels \\> 1.5 \u00d7 ULN, direct bilirubin is within normal limits); AST and ALT \u2264 2.5 \u00d7 ULN; TSH is within normal limits. Note: If TSH is not within the normal range at baseline, if T3 and free T4 are within the normal range, then the patient can still meet the inclusion criteria. IN\u3001RPT\u3001APTT\u22641.5\u00d7ULN\n* Patients must volunteer and be able to follow research plan visits, treatment plans, laboratory tests, and other research procedures\n* According to the surgeon's assessment, the total lung function can withstand the proposed lung resection\n* Within 3 days before medication\uff0cthe serum of fertile woman must be tested by hcg\uff0cand the result is negative. Fertile women can use high effective method for contraception in the duration of clinical trail and 180 days after last Administration\n\nExclusion Criteria:\n\n* Locally advanced unresectable or metastatic disease\n* Non-small small lung cancer (NSCLC) involving the upper sulcus\uff0clarge cell neuroendocrine cancer (LCNEC), sarcomatoid tumor\n* Patients with known EGFR mutations or ALK translocations, non-squamous carcinoma patients need to know the status of EGFR and ALK mutations\n* Early NSCLC with prior systemic anticancer therapy, including experimental drug therapy\n* Have a history of (non-infectious) pneumonia \/ interstitial lung disease requiring steroid therapy, or currently have pneumonia \/ interstitial lung disease requiring steroid therapy\n* Known history of active tuberculosis\n* Known to have active infection requiring systemic treatment\n* known or suspected autoimmune diseases or immunodeficiency, except: patients with a history of hypothyroidism who do not require hormone therapy or are receiving physiological dose hormone replacement therapy; patients with stable type 1 diabetes whose blood glucose is controlled\n* Active hepatitis B or C\n* Has a known history of Human Immunodeficiency Virus (HIV) .\n* Received live vaccine treatment within 30 days before drug administration; but inactivated viral vaccine for seasonal influenza is allowed\n* Peripheral neuropathy \u2265 grade 2\n* Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).\n* Overly sensitive reaction to other monoclonal antibodies\n* Have a history of severe allergies to pemetrexed, paclitaxel or docetaxel, cisplatin, carboplatin or their preventive medicine\n* Known to have serious or uncontrolled underlying disease\n* According to the investigator's judgment, the patient has a history or current evidence of any disease, treatment or laboratory abnormality that may confuse the test results, interfere with the participant's participation in the full trial, or not in the best interest of the participant to participate in the trial","SEX":"ALL","AGE_MIN":18,"AGE_MAX":70,"SS_ID":"06065813001","EMAIL":[{"email":"wbhself@sina.com"},{},{},{},{},{}],"GEO":[32.39722,119.43583]},{"TITLE":"Safety and Efficacy of OBX-115 in Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n1. Participant must be 18 years of age or older at the time of signing the informed consent.\n2. Participant has a histologically confirmed diagnosis of advanced\/metastatic melanoma ore relapsed refractory metastatic non-small cell lung cancer (NSCLC).\n3. Melanoma participant experienced documented radiographic disease progression after systemic therapy containing a programmed cell death protein 1 (PD-1)\/programmed death ligand 1 (PD-L1) blocking antibody. If the tumor is BRAF V600 mutation-positive, the participant should also have received a BRAF inhibitor with or without a MEK inhibitor. Participants with non-small cell lung cancer should have relapsed or are refractory to approved systemic therapies (approved ICI-based regimen for all appropriate participants and\/or an approved targeted therapy for known molecular abnormalities if applicable to their disease).\n4. Participant is assessed as having at least one lesion (or aggregate lesions) suitable for OBX-115 generation.\n5. After tumor tissue procurement, the participant will have at least one remaining measurable lesion, as defined by RECIST v1.1.\n6. Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and an estimated life expectancy of \\>6 months.\n7. Participant has recovered from all prior anticancer treatment-related AEs to at least Grade 1 (per Common Terminology Criteria for Adverse Events \\[CTCAE\\]).\n8. Participants must have completed post-operative recovery from any prior surgical procedures with wound healing and resolution of all surgical complications prior to planned tumor procurement surgery.\n9. Both male and female (women of childbearing potential) participants agree to the follow protocol specified contraceptive and\/or abstinence requirements.\n10. Participant has protocol specified hematologic parameters for absolute neutrophil count (ANC) and platelet count.\n11. Participant has adequate cardiac, liver, lung, and kidney organ function as specified in the protocol.\n\nExclusion Criteria:\n\n1. Participant has melanoma of uveal origin.\n2. Participant has a history of brain metastases or leptomeningeal disease, except patients with brain metastases that are up to 1.5cm in diameter that have been treated and are stable.\n3. Participant has an active medical illness(es) that, in the opinion of the Investigator, would pose increased risks for study participation.\n4. Participants with non-small cell lung cancer with refractory and clinically significant pleural effusions.\n5. Participant has any form of primary or acquired immunodeficiency.\n6. Participant has a history of hypersensitivity to any component of the study intervention.\n7. Participant had another primary malignancy within the previous 3 years (with protocol specified exceptions).\n8. Participant has a history of allogeneic organ transplant, allogeneic cell therapy, or genetically engineered cell therapy. Prior unegineered TIL cell therapy is allowed.\n9. Participant requires systemic steroid therapy \\>10 mg\/day of prednisone or equivalent.\n10. Participant received a live or attenuated vaccination within 28 days prior to the start of lymphodepletion (LD).\n11. Participant has evidence of positive infectious disease screening and\/or any active uncontrolled viral, bacterial, or fungal disease requiring ongoing systemic treatment or identified during screening.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06060613006","EMAIL":[{"email":"lindsey.brown@ahn.org"},{}],"GEO":[40.44062,-79.99589]},{"TITLE":"A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)","CRITERIA":"Inclusion Criteria:\n\n1. Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.\n2. Age \u2265 18 years at the time of consent.\n3. ECOG Performance Status of 0, 1, or 2 within 28 days prior to registration\n4. Life expectancy of 6 months or greater as determined by the site investigator.\n5. Subjects with histologically or cytologically confirmed squamous non-small cell lung cancer (sqNSCLC).\n6. Subjects with stage IV NSCLC as defined by American Joint Committee on Cancer (AJCC) 8th Edition who have not received prior therapy for stage IV NSCLC. Patients with locally advanced or recurrent disease who are candidates for first-line induction systemic therapies for stage IV NSCLC are also allowed.\n\n   \u2022 Only patients with disease control, defined as complete response (CR), partial response (PR), or stable disease (SD) to induction therapy will be allowed to receive maintenance cabozantinib plus pembrolizumab arm of trial. Patients who have progression of disease (POD) following induction therapy will proceed to second-line therapy of local clinician's choice. Only those patients who proceed to maintenance cabozantinib and pembrolizumab therapy will be evaluable for primary and secondary objectives.\n7. Subjects whose tumors have been tested for PD-L1 expression.\n8. Demonstrate adequate organ function as defined below. All screening labs to be obtained within 14 days prior to registration.\n\n   System Laboratory Value Hematological. White blood cell (WBC) \u2265 2.5K\/uL Absolute Neutrophil Count (ANC) \u2265 1,500\/uL without the support of Filgrastim or \u2265 1,000\/L in subjects with constitutional neutropenia Hemoglobin (Hgb) \u2265 9 g\/dL Platelets (Plt) \u2265 100,000\/\u00b5L without transfusion. Renal Serum creatinine Calculated creatinine clearance1 \u2264 1.5 mg\/dL\n\n   \u2265 40 mL\/min; for subjects with serum creatinine \\> 1.5 mg\/dL Urine protein\/creatinine ratio (UPCR) \u2264 1 mg\/mg (\u2264 113.2 mg\/mmol), or 24-h urine protein \u2264 1 g Hepatic Total Bilirubin2 OR Direct Bilirubin \u2264 1.5 \u00d7 upper limit of normal (ULN) or \u2264 3 \u00d7 ULN for subjects with Gilbert's disease\n\n   \u2264 ULN for subjects with total bilirubin levels \\> 1.5 x ULN Aspartate aminotransferase (AST) \u2264 3 \u00d7 ULN or \u2264 5 x ULN for subjects with known hepatic metastasis Alanine aminotransferase (ALT) \u2264 3 \u00d7 ULN or \u2264 5 x ULN for subjects with known hepatic metastasis Alkaline phosphatase (ALP) \u2264 3 \u00d7 ULN or \u2264 5 x ULN with documented bone metastases.\n\n   Serum albumin \u2265 2.8 g\/dl Coagulation International Normalized Ratio (INR)\n   * 1.3 \u00d7 ULN; For subjects receiving warfarin or LMWH, the subjects must, in the site investigator's opinion, be clinically stable with no evidence of active bleeding while receiving anticoagulant therapy. The INR for these subjects may exceed 1.3 \u00d7 ULN if that is the goal of anticoagulant therapy.\n\n     1 Cockcroft-Gault formula will be used to calculate creatinine clearance (See SPM) 2 Except in patients with Gilbert's syndrome who must have a total bilirubin less than 3.0 mg\/dl.\n9. Recovery to baseline or \u2264 Grade 1 CTCAE v5.0 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and\/or stable on supportive therapy.\n10. Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 4 months after the last dose of cabozantinib and 4 months after the last dose of pembrolizumab.\n11. Females of childbearing potential must have a negative serum pregnancy test within 3 days prior to registration. Female subjects of childbearing potential must not be pregnant at screening. Female subjects are considered to be of childbearing potential unless one of the following criteria is met: documented permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal status (defined as 12 months of amenorrhea in a woman \\> 45 years-of-age in the absence of other biological or physiological causes. In addition, females \\< 55 years-of-age must have a serum follicle stimulating (FSH) level \\> 40 mIU\/mL to confirm menopause). Note: Documentation may include review of medical records, medical examinations, or medical history interview by study site.\n12. As determined by the enrolling physician or protocol designee, subjects should be capable of understanding and complying with the protocol requirements and must have signed the informed consent document.\n13. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n1. Active infection requiring systemic therapy.\n2. Pregnant or breastfeeding. NOTE: breast milk cannot be stored for future use while the mother is being treated on study.\n3. Prior treatment with cabozantinib.\n4. Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.\n5. Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment.\n6. Radiation therapy for bone metastasis within 2 weeks or any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.\n7. Radiologically documented evidence of major blood vessel invasion or encasement by cancer.\n8. Radiographic evidence of central cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation. Patients with peripheral cavitary lesions prior to induction therapy may be enrolled but will only be allowed to continue maintenance therapy on trial if they have disease control and resolution of cavitation after induction therapy. The development of cavitation recurrence or new intra-thoracic cavitations during maintenance therapy will require Cabozantinib to be stopped during maintenance therapy.\n9. Patients with targetable genomic aberrations for which FDA-approved targeted therapy is available (e.g. ROS1, MET exon 14 skipping mutations, BRAFV600E, ALK, EGFR, ALK, RET, and NTRK fusions).\n10. The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\n\n    1. Cardiovascular disorders:\n\n    i. Congestive heart failure New York Heart Association Class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias.\n\nii. Uncontrolled hypertension defined as sustained blood pressure (BP) \\> 140 mm Hg systolic or \\> 90 mm Hg diastolic despite optimal antihypertensive treatment.\n\niii. Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction (MI), or other ischemic event, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 6 months before first dose of study treatment.\n\niv. Subjects with a diagnosis of incidental, subsegmental PE or DVT within 6 months are allowed if stable, asymptomatic, and treated with a stable dose of permitted anticoagulation for at least 1 week before first dose of study treatment.\n\nb. Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation: i. The subject has evidence of tumor invading the GI tract, active peptic ulcer disease, inflammatory bowel disease (e.g., Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction.\n\nii. Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose of study treatment. Note: Complete healing of an intra-abdominal abscess must be confirmed before first dose of study treatment.\n\nc. Other clinically significant disorders that would preclude safe study participation.\n\ni. Serious non-healing wound\/ulcer\/bone fracture. ii. Malabsorption syndrome. iii. Uncompensated\/symptomatic hypothyroidism. iv. Moderate to severe hepatic impairment (Child-Pugh B or C). v. Requirement for hemodialysis or peritoneal dialysis. vi. Any condition requiring systemic treatment with either steroid therapy (\\>10 mg daily prednisone equivalent) or any other form of immunosuppressive therapy within 2 weeks prior to first dose of study treatment.\n\n1. Note: Inhaled, intranasal, intra-articular, or topical steroids are permitted. Adrenal replacement steroid doses \\> 10 mg daily prednisone equivalent are permitted. Transient short-term use of systemic corticosteroids for allergic conditions (e.g., contrast allergy) is also allowed.\n\n10. Clinically significant hematuria, hematemesis, or hemoptysis of \\> 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 12 weeks before first dose of study treatment.\n\n11. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and\/or surgery (including radiosurgery) and stable for at least 4 weeks prior to first dose of study treatment after radiotherapy or at least 4 weeks prior to first dose of study treatment after major surgery (e.g., removal or biopsy of brain metastasis). Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of first dose of study treatment.\n\n12. Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixaban, or platelet inhibitors (e.g., clopidogrel). Allowed anticoagulants are the following:\n\n1. Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).\n2. Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor.\n\n   13. Administration of a live, attenuated vaccine within 30 days before first dose of study treatment.\n\n   14. The subject has uncontrolled, significant intercurrent or recent illness, including, but not limited to, an active or history of autoimmune disease or immune deficiency; idiopathic pulmonary fibrosis, organizing pneumonia, pneumonitis; active infection requiring systemic treatment, infection with human immunodeficiency virus (HIV), AIDS-related illness, acute or chronic hepatitis B or C infection, positive test for tuberculosis, moderate to severe hepatic impairment (Child-Pugh B or C).\n\n   15. Previously identified allergy or hypersensitivity to components of the study treatment formulations or history of severe infusion-related reactions to monoclonal antibodies. Subjects with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption are also excluded.\n\n   16. Any other active malignancy at time of first dose of study treatment or diagnosis of another malignancy within 3 years prior to first dose of study treatment that requires active treatment, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.\n\n   17. Major surgery (e.g., laparoscopic nephrectomy, GI surgery, removal or biopsy of brain metastasis) within 2 weeks before first dose of study treatment. Minor surgeries within 10 days before first dose of study treatment. Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.\n\na. NOTE: Hepatic biliary stent placement, PleurX catheter, port placement, ureteral stent or other minor surgeries are allowed. NOTE: Subject must have adequately recovered from the toxicity and\/or complications of major surgery prior to study registration, as determined by the treating physician.\n\n18. Previously received a solid organ transplant or allogeneic progenitor\/stem cell transplant.\n\n19. Previous exposure or known allergy to cabozantinib or any of its excipients.\n\n20. Inability to swallow tablets or unwillingness or inability to receive IV administration.\n\n21. Corrected QT interval calculated by the Fridericia formula (QTcF) \\> 500 ms per electrocardiogram (ECG) within 14 days before first dose of study treatment. Furthermore, subjects with a history of additional risk factors for torsades de pointes (e.g., long QT syndrome) are also excluded \\[add reference for Fridericia formula\\].\n\na. Note: If a single ECG shows a QTcF with an absolute value \\> 500 ms, two additional ECGs at intervals of approximately 3 min must be performed within 30 min after the initial ECG, and the average of these three consecutive results for QTcF will be used to determine eligibility.\n\n22. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, interfere with protocol compliance, or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for enrollment in this study.\n\n23. Any mental or medical condition that prevents the subject from giving informed consent or participating in the trial.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05613413001","EMAIL":[{"email":"rnguye8@uic.edu"},{"email":"abguzma2@uic.edu"}],"GEO":[41.85003,-87.65005]},{"TITLE":"Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n1. Patient is greater or 18 years of age on the day of signing the informed consent.\n2. All genders. Female subject with pregnancy potential must have a negative pregnancy test.\n3. Patient must have a performance status of less than or equal to 1 on the ECOG Performance Scale.\n4. Patients must have a histological or cytological diagnosis of solid tumors and have progressive locally advanced or metastatic disease.\n5. Measurable disease as determined by RECIST v1.1 (either tumor lesion or lymph node lesion or both): Tumor mass: Must be accurately measurable in at least 1 dimension (longest diameter to be recorded) with a minimum size of: 10 mm by computed tomography (CT) scan (CT scan slide thickness must be less than 5 mm). Or: 20 mm by chest X-ray (if clearly defined and surrounded by aerated lung).\n\n   Malignant lymph nodes: greater than or equal to 15 mm in short axis when assessed by CT scan (CT scan slice thickness must be \\<5 mm). The measurement should be two dimensions at axial plane. The short axis should be in perpendicular to long diameter.\n6. Patient must have adequate organ function as indicated by the laboratory values. LDH less than or equal to ULN.\n7. Voluntary agreement to participate as evidenced by written informed consent.\n8. Female patient: agreement on contraceptive methods.\n9. Male patient: agreement on contraceptive methods.\n10. Life expectancy greater than or equal to 12 weeks.\n\nExclusion Criteria:\n\nPatients who have not recovered to NCI CTCAE v5.0 less than or equal toGrade 1 from an adverse event (AE) due to cancer therapeutics except endocrinopathy or the chemotherapy-associated peripheral neuropathy (motor or sensory) that has recovered to CTCAE v5.0 less than or equal to Grade 2 will be allowed. The washout period for cancer therapeutic drugs should be 21 days prior to the first AI-061 dose for chemotherapy, radiation, or targeted therapy or 28 days prior to the first AI-061 administration for monoclonal antibody therapy. Best supportive care, such as thyroxine, insulin, steroid replacement treatment, blood transfusion, and therapy for non-cancer conditions are allowed.\n\n2. Patients who are currently enrolled in any other clinical trial testing an investigational agent or device, or with concurrent other systemic cancer therapeutics.\n\n3. Patients who are on chronic systemic steroid therapy at doses higher than 10 mg\/day prednisone or equivalent within 7 days before the first treatment.\n\n4. Patients who have active brain metastases or leptomeningeal metastases. 5. Patients who have an active infection requiring systemic IV antibiotics within 14 days prior to administration of AI-061. Regular treatment of urinary tract infection (UTI) and\/or topical treatment are allowed.\n\n6. Patients who, in the opinion of the treating Investigator, have a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study or make study participation not in the best interest of the patient. The investigator should discuss this with the Sponsor.\n\n7. Patients with known psychiatric or substance abuse disorders that in the opinion of the investigator, would interfere with cooperation with the requirements of the trial.\n\n8. Patients who are pregnant or breastfeeding.\n\n9. Patients with active autoimmune diseases that require immunosuppressant treatment other than 10 mg per day or lower prednisone. Patients with inflammatory bowel disease or myasthenia gravis will be excluded.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05858736004","EMAIL":[{}],"GEO":[-34.92866,138.59863]},{"TITLE":"Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases","CRITERIA":"Inclusion Criteria:\n\n1. Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.\n2. Age \u2265 18 years at the time of consent.\n3. ECOG Performance Status of 0-1 within 28 days prior to registration.\n4. Confirmation of stage IV non-small cell lung cancer (NSCLC) per AJCC, 8th edition, or metastatic recurrence after treatment for earlier stage disease.\n5. Known to have a KRAS G12C mutation. KRAS G12C mutation can be determined based on local tissue and\/or ctDNA testing.\n6. Presence of brain metastases that meet the following criteria:\n\n   * Patients must have at least 1 untreated enhancing intracranial lesion, per local radiology interpretation, measuring at least 2mm. NOTE: intracranial lesions do not need to be measurable by RECIST 1.1 criteria to be eligible.\n   * Must have no more than 10 brain metastases and no single metastasis measuring larger than 3 cm.\n   * Patients with surgically resected brain metastases are eligible provided there are additional brain metastases amenable to SRS\n   * Patients with progression of previously radiated or surgically resected CNS metastases are eligible if solid component of lesion has enlarged and there is no concern for radionecrosis based on investigator discretion.\n   * Patients who received SRS within 3 weeks prior to registration are eligible provided baseline brain MRI prior to SRS treatment is within 4 weeks of study registration and SRS treatment meets requirements in #7 below.\n   * Symptomatic brain metastases are permitted if the following criteria are met:\n\n     * No evidence of cerebral herniation or symptomatic leptomeningeal disease\n     * No seizures within past 14 days; antiepileptic medications are permitted\n     * Patients on steroids must have stable or improving neurologic symptoms that have not worsened during a steroid taper. Must be receiving the equivalent of dexamethasone 8 mg total daily dose or less at the time of registration.\n7. CNS lesions have already been treated with SRS (within 3 weeks prior to Cycle 1 Day 1) or are amenable to SRS as determined by radiation oncologist and\/or neurosurgeon. SRS treatment must use GammaKnife or linear accelerator-based treatments with nominal x-ray energy of 6MV or greater.\n8. No contraindications to SRS. Patients on anticoagulation must be able to hold anticoagulation for SRS treatment based on investigator discretion.\n9. Patients may be treatment-na\u00efve OR have received up to 2 prior lines of systemic therapy. Treatment with systemic therapy for Stage I-III disease \\> 12 months prior to development of metastases do not count as a line of therapy. Treatment with platinum-doublet chemotherapy and checkpoint inhibitor immunotherapy (PD-1, PD-L1, CTLA-4, etc.) either in combination or sequentially counts as one line of therapy.\n10. Demonstrate adequate organ function as defined below. All screening labs to be obtained within 28 days prior to registration.\n\n    * Hemoglobin (Hgb): \u2265 8.0 g\/dL in the absence of transfusions within 7 days prior to testing.\n    * Calculated creatinine clearance: \u2265 60 mL\/min\n    * Bilirubin: \u2264 1.5 mg\/dL\n    * Aspartate aminotransferase (AST): \u2264 3.0 \u00d7 ULN\n    * Alanine aminotransferase (ALT): \u2264 3.0 \u00d7 ULN\n11. Females of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to treatment initiation.\n12. Females of childbearing potential who are sexually active with a male able to father a child must be willing to abstain from heterosexual activity or to use an effective method(s) of contraception. Males able to father a child who are sexually active with female of childbearing potential must be willing to abstain from heterosexual activity or to use an effective method(s) of contraception.\n13. HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial. Testing is not required at screening unless mandated by local policy.\n14. Patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, the HCV viral load must be undetectable to be eligible for this trial. Testing is not required at screening unless mandated by local policy.\n15. As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study.\n\nExclusion Criteria:\n\n1. Prior treatment with KRAS G12C tyrosine kinase inhibitor.\n2. Active infection requiring systemic therapy with the exception of #13 and #14 above.\n3. Uncontrolled, significant intercurrent or recent illness.\n4. Prolonged QTc interval \\> 480 milliseconds or history of congenital Long QT Syndrome\n5. Currently receiving radiation treatment at the time of enrollment to any extra-cranial lesion for prophylaxis or pain control. Patients may enroll after completion of palliative RT.\n6. Ongoing need for treatment with concomitant medication known as a strong inhibitor or inducer of CYP3A enzyme and that cannot be switched to an alternative treatment prior to study enrollment. NOTE: Discontinuation of CYP3A4 inducers should occur a minimum of 7 days or 5 times their half-life, whichever is longer, prior to C1D1 study treatment.\n7. Treatment with any investigational drug within 28 days prior to registration.\n8. Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).\n9. Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen, per treating physician discretion, are not eligible for this trial.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06248606001","EMAIL":[{"email":"mgt4n@virginia.edu"},{}],"GEO":[38.02931,-78.47668]},{"TITLE":"Dose-escalation by Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Non Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Histology confirmed that it was non-small cell lung cancer\n* 1 to 10 brain metastases detected by magnetic resonance imaging (MRI)\n* A life expectancy of \\>3 months according to the DS GPA.\n* KPS \u226570\n* Control of the primary lesions (thorax) at the time of SBRT\n* 2cm\\<Tumor size \u2264 4 cm\n* Age of 18-75 years old\n* Patients must be able to undergo contrast enhanced MRI for planning\n* Adequate bone marrow and organ function\n\nExclusion Criteria:\n\n* other malignant tumors\n* Prior surgery to brain metastasis\n* Prior brain radiotherapy\n* Non-small cell lung cancer with more than 10 brain metastases detected by MRI\n* Contraindication to receiving radiotherapy.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05588206001","EMAIL":[{"email":"15732192994@163.com"}],"GEO":[30.29365,120.16142]},{"TITLE":"CANPOS: Predictive Biomarkers of Tumor Progression in Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* patients with a diagnosis or suspected for a diagnosis of lung cancer, non-small cell lung cancer\n* age over 18 years\n* patient na\u00efve of any oncology treatment (excluding surgery alone) within the past 5 years\n* patient who signed the informed consent by the study protocol\n\nExclusion criteria were:\n\n* any ongoing treatment for cancer\n* any history of cancer within 5 years before the diagnosis of lung cancer\n* any psychological, sociological or geographical conditions that would not allow the study follow-up","SEX":"ALL","AGE_MIN":18,"AGE_MAX":70,"SS_ID":"02764606001","EMAIL":[{"email":"nicolas.girard@chu-lyon.fr"}],"GEO":[45.73333,4.91667]},{"TITLE":"Dabrafenib and\/or Trametinib Rollover Study","CRITERIA":"Inclusion Criteria:\n\n* Patient is currently receiving treatment with dabrafenib\/trametinib monotherapy or combination within a Novartis or former GSK sponsored study which has fulfilled the requirements for the primary objective.\n* In the opinion of the Investigator would benefit from continued treatment.\n\nExclusion Criteria:\n\n* Patient has been previously permanently discontinued from study treatment in the parent protocol.\n* Patient's indication is commercially available and reimbursed in the local country.\n* Patient currently has unresolved toxicities for which dabrafenib and\/or trametinib dosing has been interrupted in the parent study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":100,"SS_ID":"03340506026","EMAIL":"Novartis.email@novartis.com","GEO":[40.4165,-3.70256]},{"TITLE":"A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)","CRITERIA":"Inclusion Criteria:\n\n* Subject is considered an adult according to local regulation at the time of signing the informed consent form (ICF).\n* Subject has measurable disease by RECIST Version 1.1.\n* Subject has accessible archival tumor tissue from either the primary tumor or a metastatic site, for which source and availability have been confirmed prior to study treatment. If no archival tumor tissue is available, the subject will have a biopsy to obtain tumor tissue prior to study treatment. If the subject is unable to undergo a biopsy due to safety concerns, enrollment into the study must be discussed with the medical monitor.\n* For cohort 9 only: Subject should submit archival or fresh tumor tissue sample for programmed cell death-ligand 1 (PD-L1) central testing during screening if no local PD-L1 test result is available. Central test result for PD-L1 will be required prior to subject enrollment. For cohort 9 subjects with local PD-L1 test result confirming CPS \u2265 1, archival or fresh tissue sample for exploratory analysis should be submitted within 5 days of enrollment.\n* Subject has ECOG performance status of 0 or 1.\n* Subject has the following baseline laboratory data. If a subject has received a recent blood transfusion, the hematology tests must be obtained \u2265 28 days after any blood transfusion.\n\n  * absolute neutrophil count (ANC) \u2265 1.0 \u00d7 10\\^9\/L\n  * platelet count \u2265 100 \u00d7 10\\^9\/L\n  * hemoglobin \u2265 9 g\/dL\n  * serum total bilirubin \u2264 1.5 \u00d7 upper limit of normal (ULN) or \u2264 3 \u00d7 ULN for subjects with Gilbert's disease\n  * creatinine clearance (CrCl) \u2265 30 mL\/min as estimated per institutional standards or as measured by 24-hour urine collection (glomerular filtration rate \\[GFR\\] can also be used instead of CrCl).\n  * alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u2264 3 \u00d7 ULN\n* Subject agrees not to participate in another interventional study while receiving study treatment in the present study.\n* Additional contraceptive requirements exist for male and female subjects.\n\nDisease Specific Inclusion Criteria:\n\n* Evidence of progression on or after the last regimen received.\n* Locally advanced or metastatic disease that is not amenable to curative intent treatment.\n\nCohort 1: HR+\/HER2- breast cancer\n\n* Subject has evidence of radiographic progression on or after the last regimen received.\n* Subject has histologically- or cytologically-confirmed HR+\/HER2- (estrogen receptor \\[ER\\] positive and\/or progesterone receptor \\[PR\\] positive, and HER2 negative) breast cancers and are not considered a candidate for further hormonal therapy. Subject will be considered HR+ if biopsies show \u2265 1% expression of ER or PR as per current American Society of Clinical Oncology\/College of American Pathologists (ASCO\/CAP) guidelines.\n* Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.\n* Subject must have received a taxane or anthracycline in the neoadjuvant, adjuvant or incurable, locally advanced or metastatic setting.\n\n  * Prior cytotoxic regimen received in the neoadjuvant or adjuvant setting will count as a prior cytotoxic regimen if disease recurrence occurred during or within 6 months of completing the regimen.\n* Subject has progressed, relapsed, or discontinued for toxicity during or after at least 1 prior standard of care cytotoxic regimen in the incurable, unresectable locally advanced or metastatic setting, and has not received \\> 2 prior lines of cytotoxic therapy in the locally advanced or metastatic setting. No limit applies to endocrine therapies. Poly(ADP-ribose) polymerases (PARP) inhibitors do not count as a line of cytotoxic therapy.\n* Subject has progressed, relapsed, or discontinued for toxicity during or after receiving endocrine therapy or with hormonally-directed therapy with cyclin-dependent kinase (CDK) inhibitors. Prior therapy with CDK inhibitors is not required.\n\nCohort 2: triple negative breast cancer (TNBC)\n\n* Subject has evidence of radiographic progression on or after the last regimen received.\n* Subject has histologically- or cytologically-confirmed TNBC; defined as unequivocal TNBC histology (ER-negative\/PR-negative\/HER2-negative). This is defined by \\< 1% expression of ER and PR by immunohistochemistry (IHC), and that are, for HER2, either 0 to 1+ by IHC, or IHC 2+ and fluorescence in situ hybridization (FISH) negative (not amplified) as per current ASCO\/CAP guidelines.\n* Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.\n* Subject must have received a taxane or anthracycline in the neoadjuvant, adjuvant or incurable, locally advanced or metastatic setting.\n\n  * Prior cytotoxic regimen received in the neoadjuvant or adjuvant setting will count as a prior cytotoxic regimen if disease recurrence occurred during or within 6 months of completing the regimen.\n* Subject has progressed, relapsed, or discontinued for toxicity during or after at least 1 prior standard of care cytotoxic regimen in the incurable, unresectable locally advanced or metastatic setting, and has not received \\> 2 prior lines of cytotoxic therapy in the locally advanced or metastatic setting. Poly(ADP-ribose) polymerases (PARP) inhibitors do not count as a line of cytotoxic therapy.\n* Subject has received prior therapy with an anti-programmed cell death protein-1 (PD-1) or an anti-programmed cell death-ligand 1 (PD-L1) based on subject's tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed or discontinued treatment due to toxicity, or therapy is contraindicated for subject.\n\nCohort 3: squamous non-small cell lung cancer (NSCLC)\n\n* Subject has evidence of radiographic progression on or after the last regimen received.\n* Subject has histologically or cytologically-confirmed squamous NSCLC.\n\n  * Subjects with mixed histology NSCLC are eligible provided there is not any component of neuroendocrine histology.\n  * Subjects with known epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), reactive oxygen species (ROS), BRAF, or other actionable mutations are eligible if treated with mutation targeted therapy and have progressed, relapsed, or discontinued treatment due to toxicity.\n* Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.\n* Subject has progressed, relapsed, or discontinued treatment due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received \\> 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting.\n\n  1. Subjects with locally advanced disease who previously received curative intent treatment with platinum-based standard of care regimen in the adjuvant or neoadjuvant setting or as part of concomitant chemoradiation therapy are eligible if they have progressed or relapsed within 6 months of completion.\n  2. Maintenance therapy does not constitute a new chemotherapy regimen provided there was no progression after the initial platinum-based regimen.\n  3. Changing chemotherapy agents during platinum-based treatment for the management of toxicities does not constitute a new chemotherapy regimen provided no progression had occurred while on the initial therapy.\n* Subject has received prior therapy with an anti-PD-1 or anti-PD-L1 based on subject's tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed, relapsed, or discontinued treatment due to toxicity, or therapy is contraindicated for subject.\n\nCohort 4: non-squamous non-small cell lung cancer\n\n* Subject has evidence of radiographic progression on or after the last regimen received.\n* Subject has histologically- or cytologically-confirmed non-squamous NSCLC.\n\n  * Subjects with mixed histology NSCLC are eligible provided there is not any component of neuroendocrine histology.\n  * Subjects with known EGFR, ALK, ROS, BRAF, or other actionable mutations are eligible if treated with mutation targeted therapy and have progressed, relapsed, or discontinued treatment due to toxicity.\n* Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.\n* Subject has progressed, relapsed, or discontinued treatment due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received \\> 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting.\n\n  1. Subjects with locally advanced disease who previously received curative intent treatment with platinum-based standard of care regimen in the adjuvant or neoadjuvant setting or as part of concomitant chemoradiation therapy are eligible if they have progressed or relapsed within 6 months of completion.\n  2. Maintenance therapy does not constitute a new chemotherapy regimen provided there was no progression after the initial platinum-based regimen.\n  3. Changing chemotherapy agents during platinum-based treatment for the management of toxicities does not constitute a new chemotherapy regimen provided no progression has occurred while on the initial therapy.\n* Subject has received prior therapy with an anti-PD-1 or anti-PD-L1 based on subject's tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed, relapsed, or discontinued treatment due to toxicity, or therapy is contraindicated for subject.\n\nCohort 5: second-line or later head and neck cancer\n\n* Subject has evidence of radiographic progression on or after the last regimen received.\n* Subject has histologically- or cytologically-confirmed head and neck cancer.\n\n  * Primary tumor site must arise from the oral cavity, oropharynx, hypopharynx, and larynx; tumors arising from the nasopharynx are excluded. Salivary gland tumors and\/or parotid gland tumors are not eligible for Cohort 5.\n* Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.\n* Subject has progressed, relapsed, or discontinued treatment due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received \\> 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting.\n\n  * Subjects with locally advanced disease who previously received curative intent treatment with platinum-based standard of care regimen in the adjuvant or neoadjuvant setting or as part of concomitant chemoradiation therapy are eligible if they have progressed or relapsed within 6 months after completion.\n* Subject has received prior therapy with an anti-PD-1 or anti-PD-L1 based on subject's tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed, relapsed, or discontinued treatment due to toxicity, or therapy is contraindicated for subject.\n\nCohorts 6, 7 and 8: gastric or gastroesophageal junction (GEJ) or esophageal adenocarcinoma\n\n* Subject has evidence of radiographic progression on or after the last regimen received.\n* Subject has histologically- or cytologically-confirmed gastric, GEJ, or esophageal cancer.\n* Subject has locally advanced or metastatic disease that is not amenable to curative intent treatment.\n* Subject has progressed, relapsed, or discontinued due to toxicity after 1 platinum-based standard of care regimen for locally advanced or metastatic disease, and has not received \\> 2 prior lines of cytotoxic anticancer therapy in the locally advanced or metastatic setting.\n\n  * Neoadjuvant or adjuvant cytotoxic regimens will count as a prior regimen if relapsed or progressed \u2264 6 months after completion.\n* Subject must have received a HER2 directed therapy if known to have HER2 positive cancer.\n* Subject has received prior therapy with an anti-PD-1 or anti-PD-L1 based on subject's tumor PD-1 or PD-L1 expression and local treatment guidelines and has progressed, relapsed, or discontinued treatment due to toxicity, or therapy is contraindicated for subject.\n\nCohort 9: 1L HNSCC\n\n* Subject has histologically- or cytologically-confirmed head and neck squamous cell carcinoma.\n\n  a. Primary tumor site must arise from the oral cavity, oropharynx, hypopharynx, and larynx; tumors arising from the nasopharynx are excluded. Salivary gland tumors and\/or parotid gland tumors are not eligible for Cohort 9.\n* Subject has recurrent or metastatic disease that is incurable by local therapies.\n* Subject's tumor sample has PD-L1 combined positive score (CPS) of \u2265 1 as determined by local or central IHC testing.\n* Subject has had no prior systemic therapy administered with the exception of systemic therapy completed \\> 6 months prior if given as part of multimodal treatment for locally advanced disease. Subjects who have received a PD-1 or PD-L1 inhibitor in the curative setting are eligible if it has been at least 12 months since last dose of the anti PD-L1 agent.\n* Subject has ANC \u2265 1.5 \u00d7 10\\^9\/L.\n* International normalized ratio (INR) OR prothrombin time (PT) and activated partial thromboplastin (aPTT) both \u2264 1.5 \u00d7 ULN unless subject is receiving anticoagulant therapy as long as PT or aPTT is within the therapeutic range of intended use of anticoagulants. PTT may be used if local lab is unable to perform aPTT.\n* For subjects with oropharynx tumors, subject has results from testing of HPV status by p16 testing.\n\nExclusion Criteria:\n\nFor All Cohorts:\n\n* Subject has preexisting sensory or motor neuropathy Grade \u2265 2.\n* Subject has active central nervous system (CNS) metastases. Subjects with treated CNS metastases are permitted on study if all the following are true:\n\n  * CNS metastases have been clinically stable for \u2265 6 weeks prior to screening\n  * If requiring steroid treatment for CNS metastases, the subject is on a stable dose \u2264 20 mg\/day of prednisone or equivalent for \u2265 2 weeks\n  * Baseline imaging scans show no evidence of new or enlarged brain metastasis\n  * Subject does not have leptomeningeal disease\n* Subject has ongoing clinically significant toxicity (Grade 2 or higher with the exception of alopecia) associated with prior treatment (including systemic therapy, radiotherapy or surgery).\n* Subjects with ongoing \u2265 Grade 3 immunotherapy-related hypothyroidism or panhypopituitarism are excluded. Subjects with ongoing immunotherapy-related colitis, uveitis, myocarditis or pneumonitis, or subjects with other immunotherapy-related AEs requiring high doses of steroids (\\> 20 mg\/day of prednisone or equivalent), are excluded. Subject with \u2264 Grade 2 immunotherapy-related hypothyroidism or panhypopituitarism may be enrolled when well maintained\/controlled on a stable dose of hormone replacement therapy (if indicated).\n* Subject has a history of uncontrolled diabetes mellitus within 3 months before the first dose of study treatment. Uncontrolled diabetes (within 3 months before first dose) is defined as hemoglobin A1c (HbA1c) \u2265 8% or HbA1c between 7 and \\< 8% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained. The lowest HbA1c during the screening period will be used to determine eligibility.\n* Subject has prior treatment with enfortumab vedotin or other monomethyl auristatin E (MMAE) based antibody-drug conjugates (ADCs).\n* Subject has a second malignancy diagnosed within 3 years before first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Subjects with non-melanoma skin cancer, localized prostate cancer treated with curative intent with no evidence of progression, low-risk or very low-risk (per standard guidelines) localized prostate cancer under active surveillance\/watchful waiting without intent to treat, or carcinoma in situ of any type (if complete resection was performed) are allowed.\n* Subject is currently receiving systemic antimicrobial treatment for viral, bacterial, or fungal infection at the time of first dose of study treatment. Routine antimicrobial prophylaxis is permitted.\n* Subject has known active hepatitis B (e.g., hepatitis B surface antigen \\[HBsAg\\] reactive) or active hepatitis C (e.g., hepatitis C virus \\[HCV\\] RNA \\[qualitative\\] is detected).\n* Subject has known history of human immunodeficiency virus (HIV) infection (HIV 1 or 2).\n* Subject has documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction or cardiac symptoms (including congestive heart failure) consistent with New York Heart Association Class III-IV within 6 months prior to the first dose of study drug.\n* Subject has major surgery within 4 weeks prior to first dose of study drug.\n* Subject had radiotherapy, chemotherapy, biologics, investigational agents, and\/or antitumor treatment with immunotherapy that is not completed 2 weeks prior to first dose of study drug.\n* Subject has known hypersensitivity to enfortumab vedotin or to any excipient contained in the drug formulation of enfortumab vedotin (including histidine, trehalose dihydrate and polysorbate 20) OR subject has known hypersensitivity to biopharmaceutical produced in Chinese hamster ovary cells.\n* Subject has known active keratitis or corneal ulcerations. Subject with superficial punctate keratitis is allowed if the disorder is being adequately treated.\n* Subject has any condition which makes the subject unsuitable for study participation.\n\nCohort 9: 1L HNSCC\n\n* Had PD within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC.\n* Has had an allogeneic tissue\/solid organ transplant. Has severe hypersensitivity (\u2265grade 3) to pembrolizumab and\/or any of its excipients.\n* Has a history of (non-infectious) pneumonitis \/ interstitial lung disease that required steroids or has current pneumonitis \/ interstitial lung disease.\n* Has a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.\n* Has a life expectancy of less than 3 months and\/or has rapidly progressing disease (e.g. tumor bleeding, uncontrolled tumor pain) in the opinion of the treating investigator.\n* Active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).\n\n  1. Replacement therapy (e.g., thyroxine, insulin, physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.\n  2. Brief (\\<7 days) use of systemic corticosteroids is allowed when use is considered standard of care.\n  3. Subjects with vitiligo, psoriasis, type 1 diabetes mellitus, hypothyroidism, or resolved childhood asthma\/atopy will not be excluded.\n  4. Subjects requiring intermittent use of bronchodilators, inhaled steroids, or local steroid injections will not be excluded.\n  5. Subjects with hypothyroidism that is stable with hormone replacement or Sj\u00f6gren's syndrome will not be excluded.\n* Has an active infection requiring systemic therapy.\n* Has received prior therapy with an anti-PD-1 or anti-PD-L1 agent in the recurrent\/metastatic setting. If anti-PD-1 or anti-PD-L1 agent was given as part of curative intent therapy, it must be at least 1 year since last dose.\n* Has received a live vaccine within 30 days of planned start of study therapy. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette Gu\u00e9rin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist\u00ae) are live attenuated vaccines and are not allowed.\n* Subject has active tuberculosis","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04225117050","EMAIL":"astellas.registration@astellas.com","GEO":[35.2946,139.57059]},{"TITLE":"A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery","CRITERIA":"Key Inclusion Criteria:\n\n1. Patients with newly diagnosed, histologically confirmed, fully resectable stage II to IIIB (N2) NSCLC as per American Joint Committee on Cancer (AJCC) version 8\n2. For patients with evidence of mediastinal adenopathy on imaging, mediastinal lymph node sampling is required as defined in the protocol\n3. All patients must have disease status showing no evidence of distant metastases documented by a complete physical examination and imaging studies performed within 4 weeks prior to randomization as defined in the protocol\n4. A patient must have an evaluable Programmed cell death ligand-1 (PD-L1) immunohistochemistry (IHC) result as defined in the protocol\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n6. Adequate bone marrow, hepatic and kidney function as defined in the protocol\n\nKey Exclusion Criteria:\n\n1. Any evidence of locally advanced unresectable or metastatic disease as defined in the protocol\n2. Patients with tumors with known Epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations as defined in the protocol\n3. Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B (HBV) or hepatitis C virus (HCV) infection as defined in the protocol\n4. Treatment with anti-cancer therapy including immunotherapy, chemotherapy, radiotherapy, or biological therapy in the 3 years prior to randomization. Adjuvant hormonotherapy used for breast cancer or other hormone-sensitive cancers in long term remission is allowed.\n5. Patients with a history of myocarditis\n\nNote: Other protocol-defined Inclusion\/ Exclusion Criteria apply","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06161441012","EMAIL":"clinicaltrials@regeneron.com","GEO":[41.69411,44.83368]},{"TITLE":"Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Aged 18 years or older\n2. Histologically or cytologically confirmed non-small-cell lung cancer\n3. ECOG PS=0-2\n4. EGFR mutations confirmed by tissue or peripheral blood\n5. Can provide tumor tissue samples (fresh or archived)\n6. The subject should have good compliance, who would participate in the research voluntarily, and sign the informed consent\n\nExclusion Criteria:\n\n1. History of other malignancies within 5 years (excluding basal cell carcinoma of the skin or other carcinoma in situ that has been resected).\n2. Unable to provide sufficient tumor tissue for analysis.\n3. Subjects with active, unstable systemic diseases, such as active infection, uncontrolled hypertension, heart failure (NYHA class \\>= II), unstable angina pectoris, acute coronary syndrome, severe arrythmia, severe liver, kidney or metabolic diseases, HIV infection.\n4. Subjects who are deemed unable to comply with the study requirements or complete the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05997719001","EMAIL":[{"email":"zhangli@sysucc.org.cn"}],"GEO":[41.69411,44.83368]},{"TITLE":"The Impact of Thymosin \u03b1-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC","CRITERIA":"Inclusion Criteria:\n\n* aged \u226518 years old\n* histologically confirmed locally advanced and unresectable NSCLC;\n* no prior radiotherapy or surgery;\n* with the life expectancy over 12 weeks;\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;\n* adequate bone marrow and hepatic and renal functions;\n* informed consent\n\nExclusion Criteria:\n\n* Concurrent enrollment in another clinical trial, unless it is an observational (non-interventional) clinical study;\n* With histologically documented combined small-cell lung carcinoma;\n* Major surgery (excluding vascular access placement) within 4 weeks prior to enrollment in the study;\n* Active or prior documented autoimmune disease within the past 2 years;\n* Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis);\n* History of innate immunodeficiency;\n* History of organ transplant that requires the use of immunosuppressives;\n* A mean heart rate-corrected QT interval (QTc) \u2265 470 ms, calculated using Bazett correction from 3 ECG calculation cycles;\n* Poorly managed health conditions that include but are not limited to persistent or active infections, symptomatic congestive heart failure, poorly controlled hypertension, unstable angina, arrhythmia, active peptic ulcer disease or gastritis, active hemorrhagic diseases, hepatitis C or human immunodeficiency virus (HIV) infection, hepatitis B (positive HBsAg and HBV DNA \\> 500 IU\/ml), and mental disorders\/social conditions that may hinder the compliance with the study requirements or the ability to give written informed consent willingly;\n* Active tuberculosis;\n* Receipt of live or attenuated vaccination within 30 days prior to the first dose of the investigational agents;\n* History of another primary malignancy within the past 5 years, excluding adequately treated basal or squamous cell skin cancers or cervical carcinoma in situ;\n* Pregnant\/breastfeeding women or males\/females of reproductive potential who do not use contraception.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06139419001","EMAIL":[{"email":"liuhui@sysucc.org.cn"}],"GEO":[23.11667,113.25]},{"TITLE":"Tumor Treating Fields for Locally Advanced NSCLC","CRITERIA":"Inclusion Criteria:\n\nStep 1: Pre-Chemoradiation Inclusion Criteria\n\n* Histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC).\n* Clinical AJCC (AJCC, 8th ed.) stage IIIA or IIIB NSCLC with unresectable disease. Staging FDG-PET\/CT and MRI brain (preferred) or CT head with contrast scan must have been completed within 60 days prior to initiation of concurrent CRT. Unresectable disease must be determined by a multi-disciplinary team unless, in the opinion of the the treating investigator, the subject's disease is clearly unresectable. Subjects who refuse surgery will be considered to have unresectable disease.\n* Able to operate the NovoTTF-200T System independently or with the help of a caregiver.\n* Eligible to receive standard of care chemoradiation per institutional standards.\n* Subject must have measurable disease by RECIST 1.1 criteria by CT.\n* ECOG Performance Status \u2264 1.\n* Adequate organ function as defined as:\n* Hematologic:\n\n  * Absolute neutrophil count (ANC) \u2265 1500\/mm3\n  * Platelet count \u2265 100,000\/mm3\n  * Hemoglobin \u2265 10 g\/dL (transfusions are allowed for Device Duration Level 2 only if anemia is due to prior therapy.)\n* Hepatic:\n\n  * Total Bilirubin \u2264 1.5x institutional upper limit of normal (ULN) or direct bilirubin \u2264ULN for participants with total bilirubin levels \\>1.5 \u00d7 ULN.\n  * AST(SGOT)\/ALT(SGPT) \u2264 3 \u00d7 institutional ULN\n  * Subjects with liver metastases will be allowed to enroll with AST and ALT levels \u2264 5 x ULN.\n* Renal:\n\n  * Estimated creatinine clearance \u2265 50 mL\/min by Cockcroft-Gault formula:\n* Males:\n\n  * ((140-age)\u00d7weight\\[kg\\])\/(serum creatinine \\[mg\/dL\\]\u00d772)\n* Females:\n\n  * (((140-age)\u00d7weight\\[kg\\])\/(serum creatinine \\[mg\/dL\\]\u00d772))\u00d70.85\n* For subjects of childbearing potential:\n\n  * Negative pregnancy test or evidence of post-menopausal status. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n* Subjects \\< 50 years of age:\n\n  * Amenorrheic for \u2265 12 months following cessation of exogenous hormonal treatments; and\n  * Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or\n  * Underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n* Subjects \u2265 50 years of age:\n\n  * Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or\n  * Had radiation-induced menopause with last menses \\>1 year ago; or\n  * Had chemotherapy-induced menopause with last menses \\>1 year ago; or\n  * Underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).\n* Subjects of childbearing potential and subjects with a sexual partner of childbearing potential must agree to use a highly effective method of contraception as described in Section 4.6.\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n\nStep 2: Pre-Consolidative Immunotherapy Phase Inclusion Criteria\n\n* The subject must have previously completed and been eligible for Step 1 registration.\n* Completion of post-chemoradiation CT scan and RECIST 1.1 assessment.\n* Eligible to receive consolidation immunotherapy per institutional standards and Investigator judgement.\n* Able to operate the NovoTTF-200T System independently or with the help of a caregiver.\n* ECOG Performance Status \u2264 1.\n* Adequate organ function as defined as:\n* Hematologic:\n\n  * Absolute neutrophil count (ANC) \u2265 1500\/mm3\n  * Platelet count \u2265 100,000\/mm3\n  * Hemoglobin \u2265 10 g\/dL (transfusions are allowed for Device Duration Level 2 only if anemia is due to prior therapy with concurrent chemoradiation.)\n* Hepatic:\n\n  * Total Bilirubin \u2264 1.5x institutional upper limit of normal (ULN) or direct bilirubin \u2264ULN for participants with total bilirubin levels \\>1.5 \u00d7 ULN.\n  * AST(SGOT)\/ALT(SGPT) \u2264 3 \u00d7 institutional ULN\n  * Subjects with liver metastases will be allowed to enroll with AST and ALT levels \u2264 5 x ULN.\n* Renal:\n\n  * Estimated creatinine clearance \u2265 50 mL\/min by Cockcroft-Gault formula:\n* Males:\n\n  * ((140-age)\u00d7weight\\[kg\\])\/(serum creatinine \\[mg\/dL\\]\u00d772)\n* Females:\n\n  * (((140-age)\u00d7weight\\[kg\\])\/(serum creatinine \\[mg\/dL\\]\u00d772))\u00d70.85\n* Recovery to baseline or \u2264 Grade 1 CTCAE v5.0 from toxicities related to any prior cancer therapy (except for alopecia or fatigue) unless considered clinically not significant and\/or stable by the treating investigator.\n* Resolution of any pneumonitis from prior radiation therapy to \\< grade 1 per the treating investigator.\n\nExclusion Criteria:\n\nStep 1: Pre-Chemoradiation Phase Exclusion Criteria\n\n* Prior thoracic radiation, including breatbreast radiation.\n* Prior exposure to TTFields.\n* Prior systemic immunotherapy or radiotherapy for NSCLC.\n* nown underlying skin hypersensitivity or known allergy to skin adhesives or hydrogel.\n* Known hypersensitivity to radiation due to genetic susceptibility, connective tissue disease, or any other cause.\n* Receiving other investigational agents.\n* Major surgery (per treating investigator) within 4 weeks prior to starting study drug or who have not fully recovered from major surgery. Note: Biopsies without significant complications will not be considered major surgery.\n* The diagnosis of another malignancy within \u2264 2 years before study enrollment, except for those considered to be adequately treated with no evidence of disease or symptoms and\/or will not require therapy during the study duration (i.e., basal cell or squamous cell skin cancer, carcinoma in situ of the breast, bladder or of the cervix, or low-grade prostate cancer with Gleason Score \u2264 6).\n* Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions:\n* Cardiovascular disorders:\n\n  * Congestive heart failure New York Heart Association Class III or IV, unstable angina pectoris, serious or clinically significant cardiac arrhythmias.\n  * Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction (MI), or other ischemic events, or thromboembolic event (eg, deep venous thrombosis, pulmonary embolism) within 3 months before the first dose.\n  * QTc prolongation defined as a QTcF \\> 500 ms.\n  * Known congenital long QT.\n  * Left ventricular ejection fraction \\< 50%.\n  * Uncontrolled hypertension defined as persistent blood pressure of \u2265 160\/90 as assessed from the mean of three consecutive blood pressure measurements taken over 10 minutes.\n  * Implanted pacemaker, defibrillator or other electrical medical devices;\n  * Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection\/inflammation, intestinal obstruction, unable to swallow medication, \\[subjects may not receive the drug through a feeding tube\\], social\/ psychological issues, etc.)\n* Known HIV infection with a detectable viral load within 6 months of the anticipated start of treatment. Note: Subjects on effective antiretroviral therapy with an undetectable viral load within 6 months of the anticipated start of treatment are eligible for this trial.\n* Active known infection including tuberculosis (clinical evaluation that includes clinical history, physical examination, radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), or hepatitis C. Note: Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible. Subjects positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n* Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.\n* History of allogenic stem cell or solid organ transplantation\n* Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \\[e.g., colitis or Crohn's disease\\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \\[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, uveitis, etc.\\]). The following are exceptions to this criterion:\n\n  * Patients with vitiligo or alopecia\n  * Patients with endocrine disorders with controlled disease on hormone replacement therapy (e.g. adrenal, thyroid, or pituitary replacement therapy)\n  * Any chronic skin condition that does not require systemic therapy\n  * Patients without active disease in the last 5 years may be included but only after consultation with the principal investigator.\n  * Patients with celiac disease controlled by diet alone\n* Current or prior use of immunosuppressive medication within 14 days of cycle one day one, EXCEPT for the following permitted steroids:\n\n  * Intranasal, inhaled, topical steroids, eye drops, or local steroid injection (e.g., intra-articular injection);\n  * Systemic corticosteroids at physiologic doses \u2264 10mg\/day of prednisone or equivalent;\n  * Steroids as premedication for hypersensitivity reactions (e.g., computed tomography (CT) scan premedication).\n* Subjects taking prohibited medications as described in Section 5.11. A washout period of prohibited medications for a period of at least five half-lives or as clinically indicated should occur before the start of treatment.\n* History of exudative pleural effusions, regardless of cytology.\n* Peripheral neuropathy \\> grade 1 for patients receiving concurrent carboplatin and paclitaxel with radiation.\n\nStep 2 Pre-Consolidative Immunotherapy Phase Exclusion Criteria\n\n* Subjects who in the investigators opinion had disease progression following concurrent chemoradiation.\n* Known underlying skin hypersensitivity or known allergy to skin adhesives or hydrogel.\n* Major surgery (per treating investigator) 4 weeks prior to starting study drug or who have not fully recovered from major surgery.\n* Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions:\n* Cardiovascular disorders:\n\n  * Congestive heart failure New York Heart Association Class III or IV, unstable angina pectoris, serious or clinically significant cardiac arrhythmias.\n  * Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction (MI), or other ischemic events, or thromboembolic event (eg, deep venous thrombosis, pulmonary embolism) within 3 months before the first dose.\n  * QTc prolongation defined as a QTcF \\> 500 ms.\n  * Known congenital long QT.\n  * Left ventricular ejection fraction \\< 50%.\n  * Uncontrolled hypertension defined as persistent blood pressure of \u2265 160\/90 as assessed from the mean of three consecutive blood pressure measurements taken over 10 minutes.\n  * Implanted pacemaker, defibrillator or other electrical medical devices;\n  * Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection\/inflammation, intestinal obstruction, unable to swallow medication, \\[subjects may not receive the drug through a feeding tube\\], social\/ psychological issues, etc.)\n* Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.\n* History of allogenic stem cell or solid organ transplantation\n* Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \\[e.g., colitis or Crohn's disease\\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \\[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, uveitis, etc.\\]).\n* The following are exceptions to this criterion:\n\n  * Patients with vitiligo or alopecia\n  * Patients with endocrine disorders with controlled disease on hormone replacement therapy (e.g. adrenal, thyroid, or pituitary replacement therapy)\n  * Any chronic skin condition that does not require systemic therapy\n  * Patients without active disease in the last 5 years may be included but only after consultation with the principal investigator\n  * Patients with celiac disease controlled by diet alone.\n* Current or prior use of immunosuppressive medication within 14 days of cycle one day one, EXCEPT for the following permitted steroids:\n\n  * Intranasal, inhaled, topical steroids, eye drops, or local steroid injection (e.g., intra-articular injection)\n  * Systemic corticosteroids at physiologic doses \u2264 10mg\/day of prednisone or equivalent\n* History of exudative pleural effusions, regardless of cytology.","SEX":"ALL","AGE_MIN":22,"AGE_MAX":200,"SS_ID":"06124118001","EMAIL":[{"email":"Kaitlin.Stephens@hci.utah.edu"}],"GEO":[40.76078,-111.89105]},{"TITLE":"Safety and Efficacy of Xalkori ROS1","CRITERIA":"Inclusion Criteria:\n\n* patients with unresectable progressive\/recurrent NSCLC who are naive to XALKORI and whose tumor is ROS1 gene positive\n\nExclusion Criteria:\n\n* Patients with past history of hypersensitivity to any of the ingredients of XALKORI","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03375242001","EMAIL":"ClinicalTrials.gov_Inquiries@pfizer.com","GEO":[35.6895,139.69171]},{"TITLE":"Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment","CRITERIA":"Inclusion Criteria:\n\n* Provision of signed and dated written ICF prior to any mandatory and non-mandatory study-specific procedures, sampling and analyses.\n* Participant must be \u226518 years (\u2265 19 years of age in South Korea) at the time of signing the informed consent. All genders are permitted.\n* Histologically or cytologically confirmed locally advanced or metastatic NSCLC which is not amenable to curative therapy.\n* Must have at least one documented sensitising EGFR mutation: exon19 deletion, L858R mutation, and\/or T790M.\n* Documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy.\n* Mandatory provision of FFPE tumour tissue.\n* MET overexpression and\/or amplification in tumour specimen collected following progression on prior osimertinib treatment.\n* Measurable disease as defined by RECIST 1.1.\n* Adequate haematological, liver, renal and cardiac functions, and coagulation parameters.\n* ECOG performance status of 0 or 1.\n\nExclusion Criteria:\n\n* Predominant squamous NSCLC, and small cell lung cancer.\n* Prior or current treatment with a third-generation EGFR-TKI other than Osimertinib.\n* Prior or current treatment with savolitinib or another MET inhibitors.\n* Spinal cord compression or brain metastases, unless asymptomatic and are stable.\n* History or active leptomeningeal carcinomatosis.\n* Unresolved toxicities from any prior therapy greater than CTCAE Grade 1 and prior platinum-therapy related Grade 2 neuropathies with the exception of alopecia and haemoglobin \u2265 9.0 g\/dL.\n* Active\/unstable cardiac diseases currently or within the last 6 months, clinically significant ECG abnormalities, and\/or factors\/medications that may affect QTc intervals.\n* History of liver cirrhosis of any origin and clinical stage; or history of other serious liver disease or chronic disease with relevant liver involvement.\n* Known serious active infection including, but not limited to, tuberculosis, or HIV, HBV or HCV or gastrointestinal disease.\n* Receipt of live attenuated vaccine (including against COVID-19) within 30 days prior to the first dose of study intervention.\n* Past medical history of ILD, drug-induced ILD, radiation pneumonitis, which required steroid treatment, or any evidence of clinically active ILD.\n* Participants currently receiving medications or herbal supplements known to be strong inducers of cytochrome P450 (CYP)3A4 or strong inhibitors of CYP1A2.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":130,"SS_ID":"05261399273","EMAIL":"information.center@astrazeneca.com","GEO":[10.82302,106.62965]},{"TITLE":"Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion","CRITERIA":"Inclusion Criteria:\n\n* Participant must be at least 18 years of age\n* Advanced or metastatic solid tumor that has progressed on at least one prior line of treatment or is intolerant to additional effective standard therapy\n* Have evidence of homozygous loss of MTAP or MTAP deletion\n* Willing to undergo paired fresh biopsy (pre- and post-treatment) procedure. Exceptions may be made for feasibility and safety concerns\n* Measurable disease\n* ECOG performance status \\<= 1\n* Adequate organ function\n* Able to swallow and retain orally administered study treatment\n* Recovery from acute effects of prior therapy\n* Able to comply with contraceptive\/barrier requirements\n\nExclusion Criteria:\n\n* Known symptomatic brain metastases\n* Known primary CNS malignancy\n* Current active liver or biliary disease\n* Impairment of gastrointestinal (GI) function\n* Active uncontrolled infection\n* Clinically significant cardiac abnormalities\n* Previous treatment with a MAT2A inhibitor and \/ or PRMT inhibitor or sacituzumab govitecan\n* Systemic anti-cancer therapy or major surgery within 4 weeks prior to study entry\n* Radiation therapy within 2 weeks prior to study entry\n* Prior irradiation to \\>25% of the bone marrow\n* Current use or anticipated need for food or drugs that are known strong CYP3A4\/5 inhibitors or inducers\n* Currently receiving another investigational study drug.\n* Known or suspected hypersensitivity to IDE397\/excipients or components","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04794699038","EMAIL":[{"email":"cclin1@ntu.edu.tw"}],"GEO":[25.04776,121.53185]},{"TITLE":"A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Male or female \u2265 18 years of age\n* Have been diagnosed with stage IV non-squamous NSCLC\n* Have not received any prior systemic anti-cancer therapy for metastatic NSCLC\n* Agree to use adequate methods of contraception\n\nExclusion Criteria:\n\n* Unable or unwilling to take folic acid and vitamin B12 supplementation\n* Severe hypersensitivity to treatment with another monoclonal antibody, any ingredient contained in SB27 or Keytruda, or any component of platinum-containing compounds or pemetrexed.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06348199052","EMAIL":"sbregistry@samsung.com","GEO":[16.44671,102.833]},{"TITLE":"EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study","CRITERIA":"Inclusion Criteria:\n\n* The subject has given written consent to participate in the study.\n* Histological or cytological diagnosis of NSCLC.\n* Clinical stage III\/IV disease (with or without CNS metastasis) or a recurrence not amenable for curative treatment intention.\n* Measurable disease according to RECIST 1.1 criteria or equivalent\/modified criteria.\n* Any WHO PS.\n* Age \u2265 18 years, no upper age limit.\n* EGFR-mutation in tumor (in cases where tumor tissue is not available for mutation analysis, circulating tumor-DNA (ctDNA) in plasma may serve as inclusion criteria), which is presumably predictive of sensitivity to EGFR TKI.\n* Treatment-naive with regard to TKI's\n* Negative pregnancy test (blood or urine test)\n* For fertile participants, adequate contraception should be used; intrauterine device, bilateral tubal occlusion, vasectomy or abstinence (a reduced effect of hormonal contraception methods due to the drugs cannot be excluded). Pregnancy should be avoided during treatment and the first 4 months following treatment discontinuation.\n\nExclusion Criteria:\n\n* Condition incompatible with the study or with the planned treatment.\n* Present (not radically treated\/no planned radical treatment of) other primary malignancy with metastatic potential.\n* Co-enrolment in other interventional trial if incompatible with ERIS according to investigator (e.g. due to potential drug interactions).\n* Intake of hypericum perforatum (intake must be interrupted before start of study treatment).\n* All subjects should avoid concomitant use of medications with known interaction with planned treatment, whenever feasible. If the administration of a medication interacts with any of the three investigational treatments and cannot be exchanged or managed in order to avoid interactions the patient is excluded from the trial.\n\n  * Drugs that can either increase or decrease the concentration of osimertinib in plasma:\n\n    * Strong activators of CYP3A. Simultaneous administration should be avoided.\n    * Regular CYP3A4-inhibitors should be used with caution or be avoided.\n  * Drugs that can either increase or decrease the concentration of afatinib in plasma:\n\n    * Strong inhibitors of P-glycoprotein should not be administered simultaneously with afatinib, instead it should preferably be 6-12 hours between.\n    * Strong activators of P-glycoprotein may reduce exposure of afatinib\n  * Drugs that can either increase or decrease the concentration of dacomitinib in plasma:\n\n    * Proton pump inhibitors should be avoided.\n    * Simultaneous administration of drugs that are metabolized by CYP2D6 should be avoided. If simultaneous use of that kind of medications are considered necessary, dose recommendations for simultaneous use of respective drug should be followed.\n* Any evidence of severe or uncontrolled systemic diseases which in the investigator's opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol. Screening for chronic conditions is not required.\n* Gastrointestinal conditions incompatible with swallowing or precluding absorption of the study drug.\n* Pregnancy or refusal to use contraceptives.\n* Abnormal findings of blood chemistry not compatible with the study drug according to investigator.\n* History of hypersensitivity to the study drug (or drugs with a similar chemical structure or class) or any excipients.\n* Severe hepatic impairment\/renal function incompatible with study drug according to investigator.\n* Hereditary conditions with galactose intolerance, total lactase deficiency or glucose -galactose malabsorption.\n* Congenital long QT syndrome.\n* Judgment by the investigator that the subject should not participate in the study, e.g., if the subject is unlikely to comply with study procedures, restrictions and requirements.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06486142001","EMAIL":[{"email":"maria.planck@skane.se"}],"GEO":[55.70584,13.19321]},{"TITLE":"MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Patients must have histologically confirmed metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation including typical and atypical mutations in egfr exons 19 and 21\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Patients in the expansion cohort must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as \\>= 20 mm (\\>= 2 cm) by chest x-ray or as \\>= 10 mm (\\>= 1 cm) with computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam\n* Ability to safely swallow oral medication\n* Absolute neutrophil count \\>= 1500\/mm\\^3\n* Platelet count \\>= 100,000\/mm\\^3\n* Hemoglobin \\>= 8.5 g\/dL (must be \\> 2 weeks post-red blood cell transfusion)\n* Bilirubin =\\< 1.5 x the upper limit of normal (ULN). For subjects with documented Gilbert's disease, bilirubin =\\< 3.0 mg\/dL. For subjects with documented liver metastases, bilirubin =\\< 2.5 x ULN\n* Serum creatinine =\\< 1.5 x the ULN or creatinine clearance (CrCl) \\>= 50 mL\/min. For creatinine clearance estimation, the Cockcroft and Gault equation should be used\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\\< 3 x the ULN (=\\< 5 x the ULN for subjects with liver metastases)\n* The effects of MRX-2843 and osimertinib on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of study drug administration\n* Females of childbearing potential who are sexually active with a non-sterilized male partner agree to use 2 methods of effective contraception from screening, and agree to continue using such precautions for 90 days after the final dose of study drug; cessation of birth control after this point should be discussed with a responsible physician. Females of childbearing potential are defined as those who are not surgically sterile (i.e., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as 12 months with no menses without an alternative medical cause)\n* Non-sterilized males who are sexually active with a female of childbearing potential must agree to use an acceptable method of effective contraception from Day 1 and for 90 days after the final dose of study drug\n* Female subjects of childbearing potential must be nonpregnant, and have a negative pregnancy test result at screening and day 1 of cycles 1-6\n* Ability to understand and the willingness to sign a written informed consent document\n* COHORT SPECIFIC ELIGIBILITY REQUIREMENTS\n* Dose Escalation Cohort: Patients with progressive EGFR (+) NSCLC disease; previously treated or naive to EGFR-tyrosine kinase inhibitor (TKI) (previous treatment with 3rd generation EGFR-TKI including osimertinib allowed\n* Dose Expansion Cohort A (Treatment naive):\n\n  * Be treatment naive to osimertinib or any other EGFR TKI,\n  * If treated with an EGFR TKI in the adjuvant, must have discontinued treatment prior to disease recurrence and be free of recurrence for at least 12 months (+1 day) while off treatment\n* Dose Expansion Cohort B (EGFR TKI resistant):\n\n  * Have progression of disease on osimertinib, erlotinib, gefitinib or afatinib as last previous systemic treatment,\n  * If not previously treated with osimertinib, must be EGFR-T790M negative as confirmed using a standard testing platform (circulating tumor deoxyribonucleic acid \\[ctDNA\\] or tissue based testing) prior to study treatment\n* Backfill Cohort C: This cohort will be open to candidates who are not able to get into any of the dose escalation or expansion cohorts. Examples will be a patient already on osimertinib but without disease progression or an otherwise eligible patient who is unable to wait for new cohorts to open due to disease burden and symptoms.\n\nSuch patients may be enrolled into the backfill cohort if they meet the following criteria:\n\n* Patients must meet the general eligibility requirements but do not meet cohort specific requirements,\n* If currently on osimertinib, must have tolerated the standard dose of 80 mg for at least 2 cycles without any grade \\> 2 adverse events,\n* Will be treated at a dose previously established to be safe from the dose escalation cohort,\n* Will not be included in the dose limiting toxicity (DLT) or maximum tolerated dose (MTD) determination,\n* Approval by the study sponsor\n\nExclusion Criteria:\n\n* Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study\n* Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> grade 1)\n* Patients who are receiving any other investigational agents\n* Patients with symptomatic untreated brain metastases would be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Patient with treated or asymptomatic untreated brain metastasis is allowed on study\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to MRX-2843 or osimertinib\n* Patients with known diagnosis of interstitial lung disease\/pneumonitis\n* Patients with corrected QT (QTc) interval prolongation \\> 500 msec (average of 3 readings), family history of congenital long QTc syndrome or torsades\n* Patients with known cardiomyopathy or decreased left ventricular ejection fraction (LVEF) \\< 50%\n* Patient with known history of keratitis or symptoms suggestive of keratitis (such as eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain and\/or red eye)\n* Patients receiving any medications or substances that are inhibitors or inducers of CYP450 enzyme(s) are ineligible. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment\/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\/social situations that would limit compliance with study requirements\n* Pregnant women are excluded from this study because osimertinib is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with osimertinib and MRX-2843, breastfeeding should be discontinued if the mother is treated with the study agents\n* Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with osimertinib and MRX-2843. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated\n* Subject has known or suspected history of retinitis pigmentosa or known or suspected familial history of retinitis pigmentosa\n* Subject has a history of type 1 diabetes (T1D) or is considered at high risk for T1D, where high risk is defined as\n\n  * Subject has one first-degree relative (defined as parents, offspring or siblings) with T1D and A1C value \\> 6.5% or subject with two or more first-degree relatives with T1D","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04762199001","EMAIL":[{"email":"roy.daneker@emory.edu"},{}],"GEO":[33.749,-84.38798]},{"TITLE":"Alectinib Pharmacokinetic in Patients With NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Both sexes\n* \u2265 18 years old\n* Pathologically confirmed diagnosis of NSCLC\n* Stage IIIB - IV by the American Joint Committee of Cancer Version 8.\n* Recurrent disease (at least 180 days from curative intent treatment)\n* ALK rearrangements tested by FDA-approved tests (IHQ or FISH)\n* Karnofsky PS scale \u2265 70%\n* Having received first-line treatment with anti-ALK inhibitors and one previous line of platinum-based chemotherapy.\n* Measurable disease as referred by RECIST version 1.1\n* Symptomatic brain metastases could receive prior treatment with radiotherapy or surgery for at least two weeks before treatment initiation.\n* Asymptomatic brain metastases could not receive local therapy before study inclusion.\n* Negative highly sensitive pregnancy test (serum or urine) within 72 days before first dose intervention.\n* Sexually active patients should use a contraceptive method with a failure rate of less than 1% per year.\n* Signed written informed consent\n* Adequate organ function (hematological, liver, and renal function)\n* Life expectancy of at least 12 weeks\n\nExclusion Criteria:\n\n* Carcinomatous meningitis confirmed by a positive CRL cytology or highly suspicious brain MRI.\n* Previous malignancies except for any carcinoma in-situ\n* Treatment with other anti-cancer therapy\n* Participating in other clinical trials in the former four weeks\n* Any other serious condition or uncontrolled active infection, altered mental status, or psychiatric condition that, in the investigator\u00b4s opinion, would limit the ability of an individual to meet the requirements of the study or which affects the interpretability of the results.\n* Active hepatitis virus infection (any serotype) or chronic infection with a potential risk of reactivation evaluated through a serological panel.\n* Active HIV infection.\n* Breastfeeding.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05713006001","EMAIL":[{"email":"ogar@unam.mx"}],"GEO":[19.42847,-99.12766]},{"TITLE":"A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors","CRITERIA":"Key Inclusion Criteria\n\n* Locally advanced, recurrent, or metastatic, incurable (any number of previous lines of therapy is allowed), histologically or cytologically confirmed: colorectal cancer; gastric cancer; non-small cell lung cancer; HER2- breast cancer; squamous cell carcinoma of the head and neck; urothelial cancer; or select gynecologic cancer (ovarian cancer, cervical cancer, or endometrial cancer)\n* Willing and able to provide written informed consent for this study\n* Adults \u2265 18 years old at time of consent\n* Known PIK3CA mutations or amplifications as determined at a CAP\/CLIA-certified or equivalently accredited diagnostic laboratory using a validated test\n* Measurable disease by RECIST 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Life expectancy \u2265 3 months, as determined by the investigator\n* Adequate bone marrow, liver, and kidney function within 14 days prior to first dose of investigational product\n* Fasting plasma glucose \\< 126 mg\/dL AND hemoglobin A1c (HbA1c) \\< 5.7%\n* Available archived or fresh tumor tissue sample for detection of PIK3CA mutation by central laboratory test\n\nKey Exclusion Criteria\n\n* Recent systemic anticancer treatment prior to start of treatment\n* Prior treatment with any PI3K, AKT, or mTOR inhibitor, or any agent whose mechanism of action is to inhibit the PI3K-AKT-mTOR pathway, except for patients with breast cancer\n* Second malignancy (solid or hematologic) within the past 3 years except: Adequately treated basal cell or squamous cell skin cancer; carcinoma in situ of the cervix, or prostate cancer with Gleason score \\< 6 and undetectable prostate specific antigen over 12 months ;ductal breast carcinoma in situ with full surgical resection (ie, negative margins); treated medullary or papillary thyroid cancer; metaplastic breast cancer\n* History of diabetes of any type\n* Body mass index (BMI) \u2265 30\n* Cushing syndrome\n* Congestive heart failure (New York Heart Association Class III to IV), symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, or myocardial infarction within 6 months prior to the first dose of investigational product\n* Known active central nervous system (CNS) metastases.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05683418016","EMAIL":[{"email":"carrie.friedman@usoncology.com"},{}],"GEO":[38.84622,-77.30637]},{"TITLE":"Phase Ia\/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Patients who have consented for the participation to the trial.\n* Patients of both sexes aged between 18-75 years.\n* Patients who have biopsy material prior to the participation in order to confirm the expression of integrin \u03b1v\u03b26 (for Phase Ib only).\n* Patients with stage IIIB or IV NSCLC and measurable disease by Response Evaluation Criteria in Solid Tumors and availability of at least one measurable tumor focus under RECIST v.1.1 criteria.\n* Patients with NSCLC who progressed after standard therapy options consisting of chemotherapy and\/or immunotherapy.\n* Patients who completed the previous treatments 21 days before the first dose of the study drug.\n* Patients who have at least three months of life expectancy.\n* Patients with ECOG performance score 0-1\n* Patients with the following laboratory results:\n\n  * Hemoglobin \u226510 mg\/dl\n  * Neutrophil \u22651,500\/\u00b5L\n  * Platelet \u2265100,000\/\u00b5L\n  * Creatinine \u22641.5xULN or creatinine clearance \u226560mL\/sec\/1.73m2\n  * Total bilirubin \u2264 1.5xULN\n  * AST\/ALT \u22642.5xULN; for patients who have confirmed liver metastasis: AST\/ALT \u22645xULN.\n  * Prothrombin time \u22641.5xULN (in case of no anticoagulant treatment).\n  * Normal levels of serum magnesium and potassium concentrations\n\nExclusion Criteria:\n\n* Patients who have active and\/or uncontrolled central nervous system (CNS) metastasis.\n* Patients who have pulmonary carcinosarcoma.\n* Patients who have presence of small cell lung cancer components.\n* Patients who have interstitial lung disease or interstitial pneumonia.\n* Patients who have cavitary lung lesions.\n* Patients who have serious cardiac dysfunction.\n* Patients who have insufficient target organ function.\n* Patients who experienced Grade 3 or higher toxicity related to the previous docetaxel treatment.\n* Patients who are pregnant or breastfeeding.\n* Patients who are enrolled in a clinical trial.\n* Patients who have serious medical conditions such as uncontrolled infection or untreated wound.\n* Patients who have bone marrow transplantation history.\n* Patients who have hypersensitivity to docetaxel and\/or similar medicines.\n* Patients who, in the judgment of the Investigator, are likely to be non-compliant or unable to cooperate.\n* Patients who cannot be contacted in case of emergency.\n* Patients who are the investigator or sub-investigator, research assistant, pharmacist, study coordinator or other staff directly involved in conducting the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04261413002","EMAIL":[{"email":"horer@ku.edu.tr"}],"GEO":[41.01384,28.94966]},{"TITLE":"Multicenter Observational Study of Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Rare Driver Gene Mutation","CRITERIA":"Inclusion Criteria:\n\n1. Female or male, 18 years of age or older\uff1b\n2. Histologically or cytologically proven diagnosis of NSCLC\uff1b\n3. Able to get tumor tissue gene testing results by lung cancer PCR panel kit carried out in hospital\uff1b\n4. Signed and dated informed consent\u3002\n\nExclusion Criteria:\n\n1. Combine with other tumor type\n2. The investigator judges the situation that may affect the clinical search process and results","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04137718001","EMAIL":[{}],"GEO":[31.22222,121.45806]},{"TITLE":"HMBD-001 in Advanced HER3 Positive Solid Tumours","CRITERIA":"Inclusion Criteria:\n\n1. Written (signed and dated) informed consent and be capable of co-operating with HMBD-001 administration and follow-up.\n2. Histologically confirmed advanced or metastatic solid tumours resistant or refractory to conventional treatment, or for which no conventional therapy exists or is not considered appropriate by the Investigator or is declined by the patient.\n\n   Part A Arm 1 Monotherapy Dose Escalation:\n\n   Patients with tumour types known to overexpress HER3 including:\n   * Bladder cancer\n   * Triple negative breast cancer\n   * Castration resistant prostate cancer\n   * Cervical cancer\n   * RAS wild type colorectal cancer\n   * Endometrial cancer\n   * Gastric cancer\n   * Hepatocellular carcinoma (HCC)\n   * Melanoma\n   * Non-small cell lung cancer (NSCLC)\n   * Oesophageal cancer\n   * Ovarian Cancer\n   * Pancreatic cancer\n   * Squamous cell cancers of the head and neck\n\n   Part B Arm 1 Monotherapy Dose Expansion:\n\n   Patients with castration resistant prostate cancer, RAS wild type colorectal cancer, triple negative breast cancer or squamous cell cancers of the head and neck with confirmed high HER3 expression by Immunohistochemistry (IHC) on pre screening biopsy prior to study enrolment or confirmed existing NRG1 gene fusion.\n3. Life expectancy of at least 12 weeks.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n5. Haematological and biochemical indices within the protocol specified ranges.\n6. Patients with advanced prostate cancer must have castrate levels of testosterone and have received a next generation hormonal agent (at least one of abiraterone, enzalutamide, apalutamide or darolutamide).\n7. Aged 16 years or over at the time consent is given.\n\nExclusion Criteria:\n\n1. Radiotherapy (except for palliative reasons), chemotherapy, endocrine therapy (with the exception of life-long hormone suppression such as luteinising hormone-releasing hormone (LHRH) agents in prostate cancer), immunotherapy or investigational medicinal products during the previous 4 weeks before trial Cycle 1 Day 1.\n2. Patients with ongoing toxic manifestations of previous treatments greater than NCI CTCAE Grade 1. Exceptions apply.\n3. Patients with symptomatic brain or leptomeningeal metastases should be excluded. Exceptions apply.\n4. Women of child-bearing potential (or are already pregnant or lactating). Exceptions apply.\n5. Male patients with partners of child-bearing potential. Exceptions apply.\n6. Major surgery from which the patient has not yet recovered.\n7. At high medical risk because of non-malignant systemic disease including active uncontrolled infection.\n8. Known to be serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection.\n9. Known or suspected hypersensitivity reaction to previous biological therapy that in the opinion of the Investigator is a contraindication for their participation in this study.\n10. Concurrent congestive heart failure, prior history of \\> class II cardiac disease (New York Heart Association \\[NYHA\\]), history of clinically significant cardiac ischaemia or prior history of clinically significant cardiac arrhythmia. Patients with significant cardiovascular disease as defined in the protocol are excluded.\n11. Patients with an active autoimmune disease including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sj\u00f6gren's syndrome, Guillain-Barr\u00e9 syndrome, multiple sclerosis, vasculitis or glomerulonephritis. Exceptions apply.\n12. Patients receiving doses of prednisolone \\>10mg daily (or equipotent doses of other corticosteroids) within 7 days prior to the first dose of study drug are not eligible unless administered as pre-medication.\n13. Patients having received a live vaccination within 4 weeks prior to first dose of HMBD 001.\n14. Is a participant or plans to participate in another interventional clinical trial, whilst taking part in this Phase I\/IIa trial of HMBD-001. Participation in an observational trial or interventional clinical trial which does not involve administration of an IMP and which would not place an unacceptable burden on the patient in the opinion of the Investigator and Medical Advisor would be acceptable.\n15. Any other condition which in the Investigator's opinion would not make the patient a good candidate for the clinical trial.\n16. Current or prior malignancy which could affect safety or efficacy assessment of the IMP or compliance with the protocol or interpretation of results. Patients with curatively-treated non-melanoma skin cancer, non-muscle-invasive bladder cancer, or carcinomas-in-situ are generally eligible.","SEX":"ALL","AGE_MIN":16,"AGE_MAX":200,"SS_ID":"05057013002","EMAIL":[{"email":"simon.lord@oncology.ox.ac.uk"}],"GEO":[51.75222,-1.25596]},{"TITLE":"Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Pathologically documented, locally advanced or metastatic solid tumor with a KRAS G12D-mutation\n* Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage\n* ECOG performance status 0 or 1\n* Adequate organ function\n\nExclusion Criteria:\n\n* Primary central nervous system (CNS) tumors\n* Known or suspected leptomeningeal or active brain metastases or spinal cord compression\n* Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication\n* Participant was previously treated with an investigational KRAS G12D inhibitor, pan- or multi-RAS inhibitor, or had prior therapy with any direct RAS-targeted therapy (eg, degraders and inhibitors)\n\nOther inclusion\/exclusion criteria may apply.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06040541017","EMAIL":"CT-inquiries@RevMed.com","GEO":[38.84622,-77.30637]},{"TITLE":"Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI","CRITERIA":"Inclusion Criteria:\n\n* Patients over 18 years with a diagnosis of non-small lung cancer and planned for a definitive course of radiation therapy.\n* Preferred patients will have had successful radiation therapy for a prior lung cancer and developed a secondary lung cancer for which are to be treated.\n* Other de-nuovo lung cancer patients planned for radiation therapy with lung heterogeneity from natural co-morbidities (e.g., COPD stage 3+).\n\nExclusion Criteria:\n\n* Patients less than 18 years old\n* Patients known to be pregnant - a positive pregnancy test will be used to respectively exclude pregnant patients,\n* Any known contraindication to MRI examination\n* Anyone with an implanted metal device\n* Inability to provide informed consent\n* A language, communication, cognitive or behavioral impairment that might interfere with fully informed participation in the study.\n* History of uncompensated organ failure (i.e. organ failure that is not stabilized through medical intervention), which will be assessed by the PI.\n* Homelessness or other unstable living situation\n* Active drug or alcohol dependence\n* Claustrophobia\n* Subjects weighting more than 300 pounds.\n* Subjects with chest size larger than the bore of MRI machine can accommodate","SEX":"ALL","AGE_MIN":18,"AGE_MAX":85,"SS_ID":"05302817001","EMAIL":[{"email":"steven.feigenberg@pennmedicine.upenn.edu"},{"email":"stephen.kadlecek@pennmedicine.upenn.edu"}],"GEO":[39.95233,-75.16379]},{"TITLE":"Routine Electronic Monitoring Of Quality Of Life -Poumon (REMOQOL-Poumon)","CRITERIA":"Inclusion Criteria for patients:\n\n* Any patient diagnosed with locally advanced or metastatic non-small cell lung cancer\n* Patients treated at University Hospital of Besan\u00e7on\n* No prior systemic therapy for cancer\n* Males and Females, age \u226518 years old\n* Patient able to complete the HRQoL questionnaires\n* Patients who gave their informed consent to participate.\n\nInclusion Criteria for the sub cohort of patients undergoing the semi-structured interview with the researcher in psychology:\n\n* Patients who realized 4 clinical encounters with collection of HRQoL\n* For patients from experimental arm, the physician must have checked HRQoL results\n\nInclusion Criteria for physicians:\n\n\u2022 Any physician treating patients included in the study REMOQOL-Poumon\n\nExclusion Criteria:\n\n* Patients with tumor recurrence\n* Patients receiving oral antineoplastic therapy for whom at least monthly follow-up is not feasible\n* Patients with psychopathology or serious cognitive problems","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04857970001","EMAIL":[{},{}],"GEO":[47.24878,6.01815]},{"TITLE":"Molecular Profiling and Dynamic Changes of ctDNA in Unresectable Locally Advanced NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Patients with newly diagnosed, histologically confirmed, unresectable locally advanced NSCLC.\n* \u226518 years of age.\n* Ability to understand the written informed consent and willingness to sign it.\n\nExclusion Criteria:\n\n* Patients who are unwilling to follow-up evaluation of response to therapy.\n* Any condition that, in the opinion of the investigator, would interfere with study results.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05641870001","EMAIL":[{"email":"earriola@psmar.cat"},{"email":"psimoes@psmar.cat"}],"GEO":[41.38879,2.15899]},{"TITLE":"Dose Escalation\/Expansion Study of PT199 (an Anti-CD73 mAb) Administered Alone and in Combination With a PD-1 Inhibitor (the MORNINGSTAR Study)","CRITERIA":"Inclusion Criteria:\n\n1. 18 years or older and able to sign informed consent and comply with the protocol.\n2. At least one measurable lesion as defined by RECIST V1.1 criteria for solid tumors.\n3. For Part A, a histologically or cytologically confirmed unresectable advanced or metastatic solid tumors previously treated with all available systemic standard therapy or for which treatment is not available or not tolerated.\n4. For Part B and C either:\n\n   (i) A histologically or cytologically confirmed diagnosis of NSCLC and radiological documentation of disease progression on standard of care, treatment may include a checkpoint inhibitor. (ii) NSCLC patients with confirmation that the tumor harbors an EGFR mutation known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q) are eligible providing they have documented radiological progression after standard of care, including tyrosine kinase inhibitor (TKI) therapy, and are immune-checkpoint inhibitor (ICI) naive. (iii) A histologically or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma (PDAC) and documented radiological progression on standard of care treatment, with no more than 2 lines of treatment for metastatic disease.\n5. In Part A, able to provide a formalin fixed, paraffin embedded (FFPE) tumor tissue sample (archival tissue or fresh biopsy), to be assessed for CD73 and other biomarkers (PD-L1) expression. In Parts B and C, fresh tumor biopsies are required if patients are clinically doing well, unless deemed by the Investigator to cause risk to the patient. If a fresh biopsy is not possible at baseline during Part B and C, archival tissue will be acceptable if the biopsy was collected within 6 months of screening.\n\n   * Biopsy must be excisional, incisional, or core. Needle aspiration is insufficient.\n   * Archival tissue is acceptable if biopsy was completed within 6 months. (Part A, and applicable to Part B and C if a fresh biopsy is not possible).\n   * Biopsies are optional for patients enrolled in the monotherapy dose escalation Part A of the study. Fresh, pretreatment and on-treatment biopsies are required for the Q3W dosing schedules in Part B and C of the study. The on-treatment biopsy is only required if that patient provided a fresh biopsy at baseline, and is showing signs of radiological response following their first scheduled scan. If the biopsy poses a safety risk to the patient, it should be discussed with the Sponsor Medical Monitor.\n6. ECOG performance status of 0 or 1.\n7. Adequate organ function confirmed at screening and within 72 hours of initiating treatment, as evidenced by:\n\n   * Absolute neutrophil count (ANC) \u2265 1.5 \u00d7 109\/L\n   * Hemoglobin (Hgb) \u2265 9.0 g\/dl\n   * Platelets (plt) \u2265 75 \u00d7 109\/L\n   * Use of transfusions are permitted but must be \\> 2 weeks prior to Cycle 1 Day1.\n   * AST\/SGOT and ALT\/SGPT \u2264 2.5 \u00d7 Upper Limit of Normal (ULN) or \u2264 5.0 \u00d7 ULN if liver metastases are present\n   * Total bilirubin \u2264 1.5 \u00d7 ULN\n   * Calculated creatinine clearance \u2265 50 mL\/min (Cockcroft Gault formula)\n8. Resolution of all acute adverse events resulting from prior cancer therapies to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE V5.0) Grade \u2264 1 or baseline (except alopecia or neuropathy).\n9. Negative serum pregnancy test within 72 hours before starting study treatment in all pre-menopausal women and women \\< 24 months after the onset of menopause (had a menstrual period in past 24 months) and are of childbearing potential (women who underwent hysterectomy or bilateral oophorectomy do not need a pregnancy test).\n10. Must agree to use effective contraceptive methods to avoid pregnancy (including male and female participants and partners of study patients) during the study and until at least 6 months after ceasing study treatment. Examples of contraceptive methods with a failure rate of \\< 1% per year include bilateral tubal ligation, male sterilization, established, proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception.\n11. Life expectancy \\> 3 months.\n\nExclusion Criteria:\n\n1. Women who are pregnant or lactating.\n2. Women of child-bearing potential (WOCBP) who do not use adequate birth control.\n3. Autoimmune disease requiring systemic treatment within the past twelve months. Active autoimmune disease or a history of autoimmune diseases that may relapse. Note: Patients with the following diseases are not excluded and may proceed to further screening:\n\n   * Controlled Type I diabetes\n   * Hypothyroidism (provided it is managed with hormone replacement therapy only)\n   * Controlled celiac disease\n   * Skin diseases not requiring systemic treatment (eg, vitiligo, psoriasis, alopecia)\n   * Any other disease that is not expected to recur in the absence of external triggering factors\n4. Condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days prior to study treatment. Corticosteroids doses equivalent to Prednisone 10mg per day or less are allowed. Note: Patients who are currently or have previously been on any of the following steroid regimens are not excluded:\n\n   * Adrenal replacement steroid (dose \u2264 10 mg daily of prednisone or equivalent).\n   * Topical, ocular, intra-articular, intranasal, or inhalational corticosteroid with minimal systemic absorption\n   * Short course (\u2264 7 days) of corticosteroid prescribed prophylactically (eg, for contrast dye allergy) or for the treatment of a non-autoimmune condition (eg, delayed-type hypersensitivity reaction caused by contact allergen)\n5. Patients with a history of (non-infectious) pneumonitis that required steroids, current pneumonitis, or has a history of interstitial lung disease.\n6. Patients with untreated brain or central nervous system (CNS) metastases or brain\/CNS metastases that have progressed (e.g., evidence of new or enlarging brain metastasis or new neurological symptoms attributable to brain\/CNS metastases). Note: Patients with treated brain metastases that are off corticosteroids and have been clinically stable for 28 days are eligible for enrollment.\n7. Patients with a known concurrent malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, carcinoma in situ of the cervix or other noninvasive or indolent malignancy that has previously undergone potentially curative therapy.\n8. Patients who have received an investigational product, \\< 5 half-lives duration in part A (monotherapy arm). Patients who have received an investigational product at any time in parts B and C (combination therapy arms).\n9. Patients who have previously received immune checkpoint inhibitor therapy and discontinued treatment because of immune-related adverse events.\n10. Patients who have allergies or hypersensitivity reactions to immune checkpoint inhibitor therapy or any of the inactive ingredients.\n11. Prior T-cell, NK cell, or CD73 inhibitor therapy (Prior Checkpoint inhibitor anti PD-1 and anti PD-L1 therapies are allowed).\n12. Patients that have received a live-virus vaccination within 30 days of planned treatment start.\n13. Impaired cardiac function or significant diseases, including but not limited to any of the following:\n\n    * LVEF \\< 45% as determined by MUGA scan or ECHO\n    * Congenital long QT syndrome\n    * QTcF \u2265 480 msec on screening ECG\n    * Unstable angina pectoris\n    * Acute myocardial infarction \u2264 3 months prior to starting study drug\n14. Patients with uncontrolled hypertension, or with blood pressure of \u2265 150 mmHg systolic and\/or \u2265 90 mmHg diastolic after triplicate measurements, each collection at least 10 minutes apart, at screening. The average from the triplicate measurements will be used for eligibility criteria. Patient must be in a stable condition with blood pressures controlled at \\< 150 systolic and \\< 90 diastolic, at least for the past 28 days, as evidence by records from the charts.\n\n    Patient must also be on a stable dose of antihypertensives.\n15. Other concurrent severe and\/or uncontrolled concomitant medical conditions (e.g., uncontrolled hypertriglyceridemia \\[triglycerides \\> 500 mg\/dL\\], or active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol.\n16. Patients who have received chemotherapy, \u2264 5 half-lives or 3 weeks, whichever is shorter (6 weeks for nitrosourea or mitomycin-C), targeted therapy, or immunotherapy within 4 weeks prior to starting study drug.\n17. Patients who have \u2265 Grade 3 neuropathy.\n18. Patients who have received wide field radiotherapy \u2264 4 weeks or limited field radiation for palliation \u2264 2 weeks prior to starting study drug or who have not recovered from adverse events of prior therapy.\n19. Patients who have undergone major surgery \u2264 4 weeks prior to starting study drug or who have not recovered from adverse events of prior therapy.\n20. Patients who are currently receiving treatment with therapeutic doses of warfarin sodium (Coumadin\u00ae) or any other coumarin-derivative anticoagulants (Other anticoagulants such as anti-thrombin or factor X are allowed).\n21. Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory; patients with well controlled HIV might be enrolled per investigator's discretion and Sponsor approval.\n22. Evidence of active infection with Hepatitis B or Hepatitis C that is not adequately controlled. For patients with known prior history of Hepatitis B or Hepatitis C, enrollment may be allowed per investigator's discretion and Sponsor approval.\n23. Has a history or current evidence of any medical or psychiatric condition, therapy, or laboratory abnormality that, in the opinion of the investigator, might confound the results of the trial, interfere with the patient's safe participation and compliance in the trial. For example, conditions that depend on the establishment of collateral circulation, such as peripheral arterial vascular disease, myocardial infraction recovery period, etc.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05431270006","EMAIL":[{"email":"bpatterson@nextoncology.com"},{}],"GEO":[38.84622,-77.30637]},{"TITLE":"Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Thin-slice HRCT shows single GGN with C\/T \u2264 0.5 and no lymph node metastasis;\n* Clinical stage IA NSCLC (TNM 8th classification) diagnosed prior or in surgery;\n* No history of malignancies within past 5 years or lung surgery;\n* No anti-cancer treatment prior to surgery.\n\nExclusion Criteria:\n\n* Simultaneous or metachronous (within the past 5 years) double cancers;\n* Active bacterial or fungous infection;\n* Interstitial pneumonitis, pulmonary fibrosis, or severe pulmonary emphysema;\n* Systemic steroidal medication;\n* Uncontrollable diabetes mellitus; (vi) Uncontrollable hypertension or history of severe heart disease, heart failure.","SEX":"ALL","AGE_MIN":0,"AGE_MAX":200,"SS_ID":"04631770001","EMAIL":[{"email":"chengdongyan916@163.com"},{},{}],"GEO":[39.14222,117.17667]},{"TITLE":"An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA\/mNSCLC","CRITERIA":"Inclusion Criteria:\n\n* Voluntary agreement to provide written informed consent.\n* Man or woman \u2265 18 years and \u226475 years of age at the time of enrollment.\n* Histologically and\/or cytologically-confirmed locally advanced or metastatic NSCLC.\n* Measurable lesion according to RECIST 1.1.\n* Progression after systemic treatment for advanced NSCLC.\n* Available archived paraffin-embedded or fresh tumor tissue from the primary tumor or metastasis for submission to the central laboratory.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Measurable and\/or non-measurable disease as per RECIST 1.1 criteria.\n* Adequate organ function as assessed by laboratory tests.\n* Male or female subjects of child-producing potential must agree to use avoidance of pregnancy measures during the study and for 6 months after the last day of treatment.\n\nExclusion Criteria:\n\n* Patient has received previous treatment with DR5 targeted regimen or antibody-MMAE conjugate.\n* Brain metastases unless asymptomatic, stable and not requiring steroids for at least 7 days prior to start of study treatment.\n* Subject with positive HCV-Ab, Anti-HIV or positive HBS-Ag with copies of HBV DNA \\> ULN.\n* Pregnancy, lactation, or breastfeeding.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06083870001","EMAIL":[{"email":"shunlu@sjtu.edu.cn"}],"GEO":[31.22222,121.45806]},{"TITLE":"A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Voluntarily sign the informed consent and follow the requirements of the protocol;\n2. Age \u226518 years old;\n3. Expected survival time \u22653 months;\n4. Histologically or cytologically confirmed locally advanced or metastatic non-squamous non-small cell lung cancer;\n5. Documented classical EGFR mutations detected from tumor tissue or blood samples;\n6. Had not received any systemic therapy other than EGFR-TKIs;\n7. Radiographic disease progression documented during or after third-generation EGFR-TKI therapy for metastatic or locally advanced disease;\n8. Consent to provide archival tumor tissue samples or fresh tissue samples of primary or metastatic lesions within 3 years;\n9. Must have at least one measurable lesion according to RECIST v1.1 definition;\n10. ECOG score 0 or 1;\n11. Toxicity of previous antineoplastic therapy has returned to \u2264 grade 1 defined by NCI-CTCAE v5.0;\n12. No severe cardiac dysfunction, left ventricular ejection fraction \u226550%;\n13. The level of organ function must meet the requirements on the premise that blood transfusion is not allowed within 14 days before the screening period and no cell growth factor drugs are allowed;\n14. Coagulation function: international normalized ratio (INR) \u22641.5 and activated partial thromboplastin time (APTT) \u22641.5\u00d7ULN;\n15. Urine protein \u22642+ or \\< 1000mg\/24h;\n16. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the start of treatment, serum or urine must be negative for pregnancy, and must be non-lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.\n\nExclusion Criteria:\n\n1. The patient has histologic or cytologic evidence of small cell or mixed small\/non-small cell component or squamous non-small cell lung cancer;\n2. Chemotherapy, biological therapy, immunotherapy, etc., have been used within 4 weeks or 5 half-lives before the first dose, small molecule targeted therapy has been used within 5 days, palliative radiotherapy or anti-tumor therapy has been used within 2 weeks;\n3. Previous treatment with: a. an ADC with TOPI inhibitor as toxin; b. any systemic therapy in the context of metastatic\/locally advanced disease;\n4. The history of severe cardiovascular and cerebrovascular diseases in the past six months prior screening;\n5. Thrombotic events requiring therapeutic intervention within 6 months before screening; Infusion-related thrombosis more than 4 weeks later was excluded;\n6. Complete left bundle branch block, III degree atrioventricular block, frequent and uncontrolled severe arrhythmia;\n7. Other malignancies diagnosed within 3 years before randomization;\n8. Hypertension poorly controlled by two antihypertensive drugs;\n9. History of interstitial lung disease (ILD) requiring steroid therapy, or current ILD or grade \u22652 radiation pneumonitis;\n10. Patients with poor glycemic control;\n11. Complicated pulmonary diseases leading to clinically severe respiratory function impairment;\n12. Patients with active central nervous system (CNS) metastases;\n13. Severe infection within 4 weeks before randomization; Evidence of pulmonary infection or active pulmonary inflammation within 2 weeks before randomization;\n14. Patients with massive or symptomatic effusions or poorly controlled effusions;\n15. Imaging examination showed that the tumor had invaded or wrapped the abdomen, chest, neck, and large blood vessels;\n16. Severe unhealed wound, ulcer, or fracture within 4 weeks before signing the informed consent;\n17. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;\n18. Patients with inflammatory bowel disease, extensive bowel resection history, immune enteritis history, intestinal obstruction or chronic diarrhea;\n19. Have a history of allergy to recombinant humanized antibodies or any of the ingredients of BL-B01D1;\n20. Human immunodeficiency virus antibody positive, active hepatitis B virus infection, or hepatitis C virus infection;\n21. A history of severe neurological or psychiatric illness;\n22. Received other unmarketed investigational drug or treatment within 4 weeks before randomization;\n23. Subjects who were scheduled to receive live vaccine or received live vaccine within 28 days before study randomization;\n24. Other circumstances that were assessed by the investigator as inappropriate for participation in the trial.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06382116001","EMAIL":[{}],"GEO":[23.11667,113.25]},{"TITLE":"Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy","CRITERIA":"Inclusion Criteria:\n\n1. Histological diagnosis of non-small cell lung cancer (Stage I-IV, International Association for the Study of Lung Cancer staging eighth edition)\n2. Patients who have previously undergone immune checkpoint inhibitors as the neoadjuvant treatment;\n3. No previous history of malignant tumors and other malignant tumors at the same time, without any anti-tumor treatment;\n4. Eastern Cooperative Oncology Group (ECOG) score 0-1, heart, lung, liver, brain and kidney function can tolerate surgery;\n5. At least one measurable lesion (RECIST v1.1).\n\nExclusion Criteria:\n\n1. Patients included in unblinded clinical trials or anti-tumor drug intervention.\n2. Radiotherapy or systemic therapy were used for NSCLC patients before the surgery.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":85,"SS_ID":"06317558001","EMAIL":[{"email":"gaoshugeng@cicams.ac.cn"}],"GEO":[39.9075,116.39723]},{"TITLE":"A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements","CRITERIA":"PHASE 1\n\nKey Inclusion Criteria:\n\n1. Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor (including primary CNS tumors) (Stage IV, American Joint Committee on Cancer v.7) that harbors an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement by protocol specified tests.\n2. ECOG PS 0-1.\n3. Age \u226518 (or age \u2265 20 of age as required by local regulation).\n4. Capability to swallow capsules intact (without chewing, crushing, or opening).\n5. At least 1 measurable target lesion according to RECIST version 1.1. CNS-only measurable disease as defined by RECIST version 1.1 is allowed.\n6. Prior cytotoxic chemotherapy is allowed.\n7. Prior immunotherapy is allowed.\n8. Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Grade less than or equal to 1.\n9. Patients with asymptomatic CNS metastases (treated or untreated) and\/or asymptomatic leptomeningeal carcinomatosis are eligible to enroll if they satisfy the protocol specified criteria.\n10. Baseline laboratory values fulfilling the following requirements:Absolute neutrophils count (ANC) \u22651500\/mm3 (1.5 \u00d7 109\/L); Platelets (PLTs) \u2265100,000\/mm3 (100 \u00d7 109\/L); Hemoglobin \u2265 9.0 g\/dL transfusions are allowed; Serum creatinine or creatinine clearance Within normal limits or \\> 40 mL\/min; Total serum bilirubin \\< 1.5 \u00d7 ULN; Liver transaminases (ASTs\/ALTs) \\< 2.5 \u00d7 ULN; \\< 5 \u00d7 ULN if liver metastases are present Alkaline phosphatase (ALP); \\< 2.5 \u00d7 ULN; \\< 5 \u00d7 ULN if liver and\/or bone metastasis are present; Serum calcium, magnesium, and potassium Normal or CTCAE grade \u2264 1 with or without supplementation\n11. Life expectancy \u2265 3 months.\n\nPHASE 2 Key Inclusion Criteria\n\n1. Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor (including primary CNS tumors) that harbors a ROS1, or NTRK1-3 gene fusion.\n2. Subject must have a documented ROS1 or NTRK1-3 gene fusion determined by tissue-based local testing using either:\n\n   1. a next-generation sequencing (NGS) or quantitative polymerase chain reaction (qPCR) test will be accepted to determine molecular eligibility.\n\n      \u2022 Adequate tumor tissue needs to be sent to the Sponsor designated central diagnostic laboratory for retrospective confirmation by a central diagnostic laboratory test selected by the Sponsor.\n\n      OR\n   2. a fluorescence in situ hybridization (FISH) test AND prospective confirmation of fusion status by a central diagnostic laboratory test selected by the Sponsor PRIOR to enrollment will be accepted to determine molecular eligibility.\n\n      * Adequate tumor tissue must be sent to the Sponsor designated central diagnostic laboratory for prospective confirmation by a central diagnostic laboratory test selected by the Sponsor PRIOR to enrollment.\n3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.\n4. Age \u226512 (or age \u2265 20 as required by local regulation).\n5. Willing and able to provide written institutional review board (IRB)\/institutional ethics committee-approved Informed Consent or an Assent signed by a parent or legal guardian for subjects age 12 to 17.\n6. At least 1 measurable target lesion according to RECIST (v1.1) prospectively confirmed by Blinded Independent Central Radiology Review (BICR), selected by Sponsor, PRIOR to enrollment. Subjects with CNS-only measurable disease \u226510 mm as defined by RECIST (v1.1) are eligible.\n7. Subjects with advanced solid tumors harboring ROS1, NTRK1, NTRK2, or NTRK3 rearrangement will be assigned into 6 distinct expansion (EXP) cohorts provided all inclusion and exclusion criteria are met.\n\n   i. EXP-1: ROS1 TKI-na\u00efve ROS1+ NSCLC ii. EXP-2: 1 Prior ROS1 TKI and 1 Platinum based chemo ROS1+ NSCLC iii. EXP-3: 2 Prior ROS1 TKIs ROS1+ NSCLC (No Chemo or IO) iv. EXP-4: 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or IO) v. EXP-5: TRK TKI-na\u00efve NTRK+ solid tumors vi. EXP-6: TRK TKI-pretreated NTRK+ solid tumors\n8. Subjects with asymptomatic CNS metastases (treated or untreated) and\/or asymptomatic leptomeningeal carcinomatosis are eligible to enroll if they satisfy the protocol specified criteria.\n9. Baseline laboratory values fulfilling the following requirements:Absolute neutrophils count (ANC) \u22651500\/mm3 (1.5 \u00d7 109\/L); Platelets (PLTs) \u2265100,000\/mm3 (100 \u00d7 109\/L); Hemoglobin \u2265 9.0 g\/dL transfusions are allowed; Serum creatinine or creatinine clearance \\> 40 mL\/min; Total serum bilirubin \\< 1.5 \u00d7 ULN; Liver transaminases (ASTs\/ALTs) \\< 2.5 \u00d7 ULN; \\< 5 \u00d7 ULN if liver metastases are present Alkaline phosphatase (ALP); \\< 2.5 \u00d7 ULN; \\< 5 \u00d7 ULN if liver and\/or bone metastasis are present; Serum calcium, magnesium, and potassium Normal or CTCAE grade \u2264 1 with or without supplementation\n10. Life expectancy \u2265 3 months.\n\nKey Exclusion Criteria PHASE 1 and PHASE 2\n\n1. Concurrent participation in another therapeutic clinical trial.\n2. Symptomatic brain metastases or leptomeningeal involvement.\n3. History of previous cancer, except for squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma that has been completely resected, requiring therapy within the previous 2 years.\n4. Major surgery within 4 weeks of start of repotrectinib treatment. Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study entry. Palliative radiation (\u226410 fractions) must have been completed at least 48 hours prior to study entry\n5. Clinically significant cardiovascular disease (either active or within 6 months prior to enrollment): myocardial infarction, unstable angina, coronary\/peripheral artery bypass graft, symptomatic congestive heart failure (New York Heart Association Classification Class \u2265 II), cerebrovascular accident or transient ischemic attack, symptomatic bradycardia, requirement for anti-arrhythmic medication. Ongoing cardiac dysrhythmias of NCI CTCAE grade \u22652\n6. Any of the following cardiac criteria:\n\n   Mean resting corrected QT interval (ECG interval measured from the onset of the QRS complex to the end of the T wave) for heart rate (QTcF) \\> 470 msec obtained from 3 ECGs, using the screening clinic ECG machine-derived QTc value Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval \\> 250 msec) Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or any concomitant medication known to prolong the QT interval.\n7. Known active infections (bacterial, fungal, viral including HIV positivity).\n8. Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact drug absorption.\n9. Peripheral neuropathy of CTCAE \u2265grade 2.\n10. History of extensive, disseminated, bilateral, or presence of CTCAE grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis. Subjects with history of prior radiation pneumonitis are not excluded.","SEX":"ALL","AGE_MIN":12,"AGE_MAX":200,"SS_ID":"03093116141","EMAIL":[{}],"GEO":[51.35,-0.2]},{"TITLE":"Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy","CRITERIA":"Inclusion Criteria:\n\n* ECOG functional status score was 0-1.\n* Histologically confirmed stage IV primary NSCLC;\n* Genetic testing showed that the common driver genes including EGFR, ALK and ROS-1 were negative;\n* Patients with brain metastases were eligible if they were neurologically asymptomatic and had stable disease without receiving systemic glucocorticoids;\n* According to the investigator's judgment, the patient does not need to receive palliative radiotherapy for any site at present;\n* Male\/female of childbearing age agreed to use contraception (surgical ligation or oral contraceptive\/intrauterine device plus condom) during the trial;\n* Life expectancy \u22653 months;\n* One week before enrollment, the organ function level met the following criteria:\n\n  \u2460 Bone marrow function: hemoglobin \u226580g\/L, white blood cell count \u22654.0\\*10\\^9\/L or neutrophil count \u22651.5\\*10\\^9\/L, platelet count \u2265100\\*10\\^9\/L;\n\n  \u2461 Liver: serum total bilirubin level \u22641.5 times upper limit of normal, direct bilirubin level must be \u22641.5 times upper limit of normal, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u22642.5 times upper limit of normal;\n\n  \u2462 Kidney: serum creatinine \\< 1.5 times upper limit of normal or creatinine clearance \u226550ml\/min, urea nitrogen \u2264200mg\/L; Serum albumin \u226530g\/L;\n* Patients must be able to understand and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* The patient had severe autoimmune diseases: active inflammatory bowel disease (including Crohn's disease, ulcerative colitis), rheumatoid arthritis, scleroderma, systemic lupus erythematosus, autoimmune vasculitis (such as Wegener's granulomatosis), etc.\n* Symptomatic interstitial lung disease or active infectious\/non-infectious pneumonia;\n* Patients with risk factors for intestinal perforation: active diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction, abdominal cancer, or other known risk factors for intestinal perforation;\n* History of other malignant tumors;\n* Patients with active infection, heart failure, myocardial infarction, unstable angina or unstable arrhythmia within the past 6 months;\n* Medical examination or clinical findings, or other uncontrollable conditions that the investigator considers may interfere with the results or increase the patient's risk of treatment complications;\n* Patients who were considered by the investigator to have lesions requiring palliative and subtractive radiotherapy;\n* Mixed with small cell lung cancer components;\n* Lactating or pregnant women;\n* Congenital or acquired immunodeficiency diseases including human immunodeficiency virus (HIV), organ transplantation or allogeneic stem cell transplantation;\n* Known HBV, HCV, active pulmonary tuberculosis infection;\n* Patients had received a cancer vaccine or received another vaccine within 4 weeks before starting treatment (note: injectable seasonal influenza vaccine is usually inactivated, so vaccination is allowed, while intranasal vaccine is usually live attenuated, so it is not allowed);\n* Patients with concurrent use of other immune agents, chemotherapy drugs, drugs in other clinical studies, and long-term use of cortisol were excluded.\n* Patients with mental disorders, substance abuse, or social problems that affect adherence were excluded from the study after physician review;\n* Patients who are allergic to or contraindicated to PD-1 monoclonal antibody or chemotherapy drugs.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06313541001","EMAIL":[{"email":"fuscczzf@163.com"},{"email":"nijianjiao8@sina.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT","CRITERIA":"Inclusion Criteria:\n\n* Patients with cytologically or histologically proven non-small cell lung cancer\n* Stage T1-3N0M0\n* \u2265 70 years old\n* In a multidisciplinary setting the patient is considered medically inoperable, too frail for operation due to age and\/or comorbidity or that the patient refuse surgery and therefore candidate for SBRT.\n\nExclusion Criteria:\n\n* Missing histology\/cytology\n* Another current malignancy\n* Higher staging at treatment planning\n* Not able to provide informed consent\n* Do not speak or understand Danish","SEX":"ALL","AGE_MIN":70,"AGE_MAX":200,"SS_ID":"05919641004","EMAIL":[{"email":"Charlotte.Kristiansen@rsyd.dk"}],"GEO":[55.70927,9.5357]},{"TITLE":"Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)","CRITERIA":"Inclusion Criteria:\n\n* patient with EGFR mutation-positive inoprable or recurrent NSCLC who have not received VIZIMPRO(dacomitinib hydrate)\n\nExclusion Criteria:\n\n* Exclusion criteria is not provided in this study","SEX":"ALL","AGE_MIN":0,"AGE_MAX":200,"SS_ID":"04155541001","EMAIL":"ClinicalTrials.gov_Inquiries@pfizer.com","GEO":[35.6895,139.69171]},{"TITLE":"Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors","CRITERIA":"Inclusion Criteria:\n\n1. Adults age \u2265 18 inclusive at the time the Informed Consent Form (ICF) is signed.\n2. Histologically proven, metastatic or advanced epithelial cancer including the following cancer types:\n\n   1. Urothelial\n   2. Cervical\n   3. Ovarian epithelial\n   4. Triple-negative breast\n   5. HR+\/HER2- breast\n   6. Pancreatic ductal adenocarcinoma\n   7. Gastric adenocarcinoma\n   8. Esophageal carcinoma\n   9. Non-small cell lung\n   10. Colorectal\n3. Progressive disease at baseline, refractory or relapsed to standard of care or who have declined standard therapy.\n4. Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria v 1.1.\n5. Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1.\n6. Life expectancy of \\> 12 weeks.\n7. Echocardiogram (ECHO) or multiple gated acquisition scan showing an ejection fraction greater than or equal to 50%.\n8. Electrocardiogram (ECG) showing no clinically significant abnormality at Screening or showing an average QTc interval \\< 450 msec in males and \\< 470 msec in females (\\< 480 msec for participants with bundle branch block). Either Fridericia's or Bazett's formula may be used to correct the QT interval.\n9. Oxygen saturation of greater than or equal to 90% on room air measured by pulse oximetry.\n10. Adequate organ function as defined by laboratory values at Screening.\n11. Willing and able to provide written informed consent.\n12. Willing to perform and comply with all study procedures including undergoing study-related biopsies and attending clinic visits as scheduled.\n13. Men must abstain from sperm donation during study treatment or for 4 months following last dose of study treatment.\n14. Men and WOCBP must be willing to practice a highly effective method of contraception.\n\nExclusion Criteria:\n\n1. Known active CNS metastasis and\/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, (ie, without evidence of progression for at least 4 weeks by repeat imaging), clinically stable, and without requirement of steroid treatment for at least 14 days prior to the first dose of study intervention.\n2. Pregnant or nursing women.\n3. Must be \\> 28 days beyond major surgery, including hepatectomy or joint replacement.\n4. Prior allogeneic bone marrow transplantation or solid organ transplant.\n5. Spinal cord compression not definitively treated with surgery and\/or radiation.\n6. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.\n7. Any acute illness including fever (\\> 100.4\u00b0 F or \\> 38\u00b0 C) within 7 days prior to Day 1\n8. Active systemic bacterial, fungal, or viral infection within 7 days prior to Day 1. Participant cannot have tested positive for COVID-19 within 7 days prior to Day 1.\n9. Active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV).\n10. Other primary malignancies, except:\n\n    1. Adequately treated basal cell or squamous cell carcinoma\n    2. In situ carcinoma of the cervix or bladder, treated curatively and without evidence of recurrence for at least 2 years prior to the study, or\n    3. A primary malignancy which has been completely resected and in complete remission for at least 2 years\n11. History of (noninfectious) pneumonitis\/interstitial lung disease that required steroids or has current pneumonitis\/interstitial lung disease.\n12. Prior grade \\> 3 immune-related AEs such as pneumonitis, colitis, hepatitis, nephritis; prior dermatitis and endocrinopathies are allowed provided corticosteroids are no longer required and endocrine-replacement therapy is stable and discontinued from prior therapy.\n13. Active autoimmune disease not related to prior therapy for primary malignancy that has required systemic therapy in the last 1 year.\n14. History of symptomatic congestive heart failure (New York Heart Association classes II-IV) or serious active arrhythmias or other clinically significant cardiac disease within 12 months of enrollment.\n15. Toxicity from previous anti-cancer therapy defined as toxicities (other than alopecia, or laboratory values listed above) not yet resolved to NCI CTCAE v5.0 Grade \u2264 1 or baseline. Participants with chronic Grade 2 toxicities (eg, peripheral neuropathy, laboratory values) may be eligible per the discretion of the Investigator and Medical Monitor.\n16. Has received:\n\n    1. Radiotherapy within 2 weeks of first administration of MT-302\n    2. Cytotoxic chemotherapy for treatment of the primary malignancy within 28 days or 5 half-lives, whichever is shorter, of administration of MT-302\n    3. Immune therapy for primary malignancy (eg, monoclonal antibody therapy, checkpoint inhibitors) within 28 days or 5 half-lives, whichever is shorter of first administration of MT-302\n    4. Targeted therapies for primary malignancy within 28 days or 5 half-lives, whichever is shorter, of first administration of MT-302\n    5. Anti-cancer vaccine within 12 weeks of first administration of MT-302\n    6. COVID-19 mRNA vaccine within 6 weeks of first administration of MT-302\n17. Has received a live vaccine \u2264 6 weeks prior to first administration of MT-302\n18. Has received packed red blood cells or platelet transfusion within 2 weeks prior to first administration of MT-302\n19. History of an allergic reaction to any of the excipients\n20. Enrollment in another interventional clinical trial within 28 days or 5 half-lives of the drug, whichever is shorter, of first administration of MT-302\n21. Any other condition that, in the opinion of the Investigator, would make the participant unsuitable for the study or unable to comply with the study requirements.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05969041006","EMAIL":[{}],"GEO":[-31.98184,115.8073]},{"TITLE":"A Study of DB-1310 in Advanced\/Metastatic Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n1. Male or female adults (defined as \u2265 18 years of age or acceptable age according to local regulations at the time of voluntarily signing of informed consent).\n2. Have relapsed or progressed on or after standard systemic treatments, or intolerable with standard treatment, or for which no standard treatment is available. Documented radiological disease progression during\/after most recent treatment regimen for advanced\/unresectable, or metastatic disease.\n3. At least one measurable lesion as assessed by the investigator according to response evaluation criteria in solid tumors (RECIST) version 1.1 criteria. Subjects with nonmeasurable disease only are allowed in Cohort 2c of Phase 2a.\n4. Has a life expectancy of \u2265 3 months.\n5. Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1.\n6. Has LVEF \u2265 50% by either echocardiography (ECHO) or multiple-gated acquisition (MUGA) within 28 days before enrollment.\n7. Has adequate organ functions within 7 days prior to Day 1 of Cycle 1.\n8. Has adequate treatment washout period prior to Day 1 of Cycle 1.\n9. Is willing to provide pre-existing resected tumor samples or undergo fresh tumor biopsy for the measurement of HER3 level and other biomarkers if no contraindication.\n10. Is capable of comprehending study procedures and risks outlined in the informed consent and able to provide written consent and agree to comply with the requirements of the study and the schedule of assessments.\n11. Male and female subjects of reproductive\/childbearing potential must agree to use adequate contraceptive methods (e.g., double barrier or intrauterine contraceptive) during the study and for at least 4 months and 7 months after the last dose of study drug, respectively.\n12. Male subjects must not freeze or donate sperm starting at screening and throughout the study period, and at least 4 months after the final study drug administration.\n13. Female subjects must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and for at least 7 months after the final study drug administration.\n\nExclusion Criteria:\n\n1. Prior treatment with HER3 targeted therapy.\n2. Prior treatment with antibody drug conjugate with topoisomerase I inhibitor (exclusive of trastuzumab deruxtecan for Cohort 2e of Phase 2a).\n3. Has a medical history of symptomatic congestive heart failure (CHF) (New York Heart Association \\[NYHA\\] classes II-IV) or serious cardiac arrhythmia requiring treatment.\n4. Has a medical history of myocardial infarction or unstable angina within 6 months before enrollment.\n5. Has any clinically important abnormalities in rhythm, conduction or morphology of resting electrocardiogram (ECG), e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, or PR interval \\> 250 milliseconds (ms).\n6. Has an average of Fredericia's formula-QT corrected interval (QTcF) prolongation to \\> 470 millisecond (ms) in males and females based on a 12-lead electrocardiogram (ECG) in triplicate.\n7. Unable or unwilling to discontinue concomitant drugs that are known to prolong the QT interval.\n8. Has a medical history of interstitial lung diseases (e.g., non-infectious interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or current interstitial lung diseases or who are suspected to have these diseases by imaging at screening.\n9. Has an uncontrolled infection requiring intravenous injection of antibiotics, antivirals, or antifungals.\n10. Has clinically significant corneal disease.\n11. Know human immunodeficiency virus (HIV) infection.\n12. Subjects have active viral (any etiology) hepatitis are excluded. However, subjects with positive hepatitis B surface antigen (HBsAg) who have the HBV DNA (viral load) below the lower limit quantification or HBV DNA titer \\< 1000 cps\/mL or 200 IU\/mL per local testing and are not currently on viral suppressive therapy may be eligible and should be discussed with the Sponsor's Medical Monitor. However, subjects with a history of hepatitis C virus (HCV) infection who have completed curative antiviral treatment and have the HCV RNA below the lower limit of quantification per local testing are eligible for study entry.\n13. Is a lactating mother (women who are willing to temporarily interrupt breastfeeding will also be excluded), or pregnant as confirmed by serum pregnancy tests performed within 7 days prior to Cycle 1 Day 1.\n14. Has clinically active brain metastases, defined as untreated and symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. However, subjects with asymptomatic central nervous system (CNS) metastases who are radiologically and neurologically stable for at least 4 weeks following CNS-directed therapy, and who are on stable or decreasing doses of corticosteroids equivalent to \u226410 mg\/day prednisone are eligible for study entry.\n\nNOTE: Other protocol defined Inclusion\/Exclusion criteria may apply.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05785741020","EMAIL":[{}],"GEO":[41.79222,123.43278]},{"TITLE":"Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas","CRITERIA":"Inclusion:\n\n1. Metastatic or advanced stage, histologically or cytologically confirmed NSCLC and molecular identification of oncogenic KRAS mutation.\n\n   * KRAS mutant NSCLC must be refractory, relapsed, and previously treated with doublet chemotherapy and immune checkpoint inhibitor (unless there is a specific contraindication to checkpoint inhibitor).\n   * Molecular characterization (tissue- or blood-based \\[ie, cell-free\/circulating tumor DNA\\]) must have been performed and must have demonstrated an oncogenic KRAS mutation (e.g., exon 12, 13, 61, or 117 mutation detected by sequencing) by a CLIA-certified assay (source documentation required). KRAS mutations at other codons require review and approval by Study Chair.\n2. Subjects' EGFR mutation and ALK gene rearrangement status must be known prior to study entry. Subjects with EGFR mutation or ALK gene rearrangement must have progressed after appropriate FDA-approved targeted therapy options prior to eligibility.\n3. Patient has evidence of disease progression on most recent line of therapy.\n4. Patient has measurable disease by RECIST v1.1 (Eisenhauer, 2009).\n5. Age \u2265 18 years.\n6. ECOG performance status of 0 or 1.\n7. Predicted life expectancy of \\>3 months.\n8. Adequate organ and marrow function as defined below:\n\n   * absolute neutrophil count \u2265 1,500\/mcL\n   * platelets \u2265 75,000\/mcL\n   * total bilirubin \\<2X institutional upper limit of normal\n   * AST and ALT \u22645X institutional upper limit of normal\n   * serum creatinine \\<1.5X institutional upper limit of normal\n   * LVEF \\>50%\n   * QTcF \\<470msec\n9. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n\n   * A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n\n     * Has not undergone a hysterectomy or bilateral oophorectomy; or\n     * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).\n10. No significant ischemic heart disease or myocardial infarction within 6 months of first dose of TVB-2640 and with current adequate cardiac function as in 3.1.8.\n11. Ability to understand and the willingness to sign a written informed consent.\n\nExclusion:\n\n1. Patient is unable to swallow oral medications or has impairment of GI function or GI disease that may significantly alter drug absorption such as active inflammatory bowel disease, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome.\n2. Patient has a history of risk factors for torsade de pointes such as uncontrolled heart failure, severe hypokalemia with potassium less than 3mM\/L, history of long QT syndrome or require use during study participation of concomitant medications known to prolong QT\/QTc interval.\n3. Patients who require use of strong CYP3A4\/5 agonists or inhibitors during study participation.\n4. Patient has uncontrolled or severe intercurrent medical condition including uncontrolled brain metastases. Patients with stable brain metastases either treated or untreated, on a stable dose of steroids\/anticonvulsants, with no dose increase within 4 weeks before the first dose of TVB-2640, and no anticipated dose change, are allowed.\n5. Patient underwent major surgery within 4 weeks before the first dose of TVB-2640 or received cancer-directed therapy either chemotherapy, radiotherapy, hormonal therapy, biologic or immunotherapy, etc. or an investigational drug or device within 2 weeks (6 weeks for mitomycin C and nitrosoureas) or 5 half-lives of that agent, whichever is shorter before the first dose of TVB-2640. In addition, any drug- related toxicity, with the exception of alopecia, an endocrinopathy controlled with replacement therapy, or a clinically stable toxicity not expected to increase from study therapy (eg, cisplatin-associated ototoxicity) should have recovered to \\<Grade 1.\n6. If female, patient is pregnant or breast-feeding.\n7. Patient has evidence of a serious active infection-infection requiring treatment with intravenous antibiotics.\n8. Patient has known immunodeficiency virus-HIV or hepatitis B or C infection, as such patients may be at increased risk for toxicity due to concomitant treatment and disease-related symptoms may preclude accurate assessment of the safety of TVB-2640.\n9. Patient has an important medical illness or abnormal laboratory finding that, in the Investigator's opinion, would increase the risk of participating in this study.\n10. Patients with prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational agent.\n11. History of clinically significant dry eye (xerophthalmia) or other corneal abnormality or, if a contact lens wearer, does not agree to abstain from contact lens use from baseline through the last study drug dose.\n12. Patient has a known allergy or hypersensitivity to components of TVB-2640.\n13. Patient has a prior history of hypersensitivity, drug\/radiation-induced, or other immune-mediated pneumonitis.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03808558002","EMAIL":[{"email":"David.Gerber@utsouthwestern.edu"},{}],"GEO":[32.78306,-96.80667]},{"TITLE":"A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Participants with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Laboratory values meeting the protocol's criteria within the screening period (-28 days) prior to the first dose of study drug.\n* Participants with a diagnosis of a malignant solid tumor by histology (World Health Organization \\[WHO\\] criteria).\n* Participants with measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).\n\nExclusion Criteria:\n\n* Unresolved Grade \\> 1 adverse events (AEs) from prior anti-cancer therapy except for alopecia.\n* Active systemic or uncontrolled local bacterial, fungal, or viral infection requiring antimicrobial therapy.\n* History of hypersensitivity to the active ingredients or any excipients of ABBV-303 and budigalimab (ABBV-181).\n* Body weight \\< 35 kg.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06158958016","EMAIL":"abbvieclinicaltrials@abbvie.com","GEO":[34.23333,135.16667]},{"TITLE":"A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Individuals with histologically or cytologically confirmed stage IIIB-IV non-small cell lung cancer (NSCLC)\n* Must have been treated with (a) anti-programmed death protein 1 (anti-PD-1) or programmed cell death ligand 1 (PD-L1) therapy and (b) platinum-based chemotherapy and have progressed. Individuals who cannot tolerate or have previously refused platinum-based chemotherapy are eligible to enroll based on progression after anti-PD-1\/PD-L1 therapy alone\n* Can have a prior or concurrent second malignancy (other than the disease under study), which due to natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment(s)\n* Have an eastern cooperative oncology group (ECOG) performance status of 0 or 1\n* Adequate liver function:\n\n  1. Participants with no underlying hepatic metastases are eligible if they have: i) aspartate aminotransferase (AST) less than (\\<)3 x upper limit of normal (ULN), ii) alanine aminotransferase (ALT) \\<3 x ULN, and iii) Total bilirubin \\<1.5 x ULN\n  2. Participants with known hepatic metastases are eligible if they have: i) AST \\<5 x ULN, ii) ALT \\<5 x ULN, and iii) Total bilirubin \\<3 x ULN\n* Part 1: NSCLC with a known actionable genetic mutation (for example, epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 \\[ROS1\\], v-raf murine sarcoma viral oncogene homolog B1 \\[BRAF\\]) must have received all approved targeted therapies and have progressed. Participants with unknown mutation status due to a failed testing status or lack of access to testing are allowed in the study\n* Part 2: Participants must have at least 3 lesions on baseline scan, one of which is evaluable as a target lesion for response assessment per RECIST Version 1.1\n* Part 2: Agree to submit tumor samples prior to study treatment which can be an archival tumor tissue sample obtained within 3 months prior to start of treatment and without any therapy for NSCLC being administered within these 3 months, or newly obtained core or incisional biopsy of a tumor lesion during screening\n\nExclusion Criteria:\n\n* Active disease involvement of the central nervous system with the exception of definitively locally treated brain metastases that are clinically stable\n* Active autoimmune disease that requires systemic immunosuppressive medications (for example, chronic corticosteroid, methotrexate, or tacrolimus) within the 12 months prior to signing consent\n* Active infection or condition that requires treatment with systemic anti-infective agents (for example, antibiotics, antifungal or antivirals) within 7 days prior to the first dose of study treatment or chronic use of anti-infective agents\n* History of solid organ or hematologic stem cell transplantation\n* Part 2: NSCLC with an actionable genetic mutation for which an approved therapy is available: EGFR, ALK, ROS1, or BRAF. Confirmation of the absence of actionable mutations is required","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06116786010","EMAIL":"Participate-In-This-Study@its.jnj.com","GEO":[41.38879,2.15899]},{"TITLE":"A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China","CRITERIA":"Inclusion Criteria:\n\n1. Subject must be \u226518 years-of-age at the time of signature of the informed consent form (ICF).\n2. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.\n3. Subjects with histologically or cytologically confirmed advanced solid tumors which have progressed despite standard therapy or for which no standard therapy exists.\n4. Subjects with life expectancy \u22653 months.\n5. Patients must have at least one measurable lesion as defined by RECIST v1.1.\n6. Patients who have sufficient baseline organ function\n\nExclusion Criteria:\n\n1. Severe autoimmune disease (including immune-related adverse events of prior immune-oncology therapy) or autoimmune disorder that requires chronic systemic corticosteroid treatment at immunosuppressive doses (prednisone \\>10 mg\/day or equivalent).\n2. Known malignant central nervous system disease other than neurologically stable, treated brain metastases.\n3. History or evidence of interstitial lung disease, radiation pneumonitis which required steroid treatment, or idiopathic pulmonary fibrosis, pleural or pericardial effusion that required intervention such as a drain.\n4. History of seropositive status for hepatitis B, hepatitis C and human immunodeficiency virus (HIV).\n5. History or evidence of active infections (Grade \u22652).\n6. History or evidence of significant inflammatory or vascular eye disorder.\n7. History of an allogeneic bone marrow or solid organ transplant.\n8. Use of systemic anti-cancer agent (except for anti-androgen therapy for prostate cancer) or investigational drug \u226428 days prior to the first dose of JAB-3312.\n9. History of radiation therapy \u226428 days prior to the first dose of JAB-3312, or likely to require radiation therapy at any time until the 30 days after the last dose of JAB-3312.\n10. History of transfusion of whole blood, red blood cell or platelet packets \u22642 weeks before the start of treatment.\n11. Subjects experiencing unresolved Grade \\>1 toxicity before the start of treatment","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04121286005","EMAIL":[{}],"GEO":[41.38879,2.15899]},{"TITLE":"Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations","CRITERIA":"Inclusion Criteria:\n\n* LEUKAPHERESIS: Diagnosis of metastatic pancreatic adenocarcinoma (PDAC), colorectal adenocarcinoma (CRC), or non-small cell lung cancer (NSCLC)\n* LEUKAPHERESIS: Tissue confirmation of pancreatic adenocarcinoma (PDAC), colorectal adenocarcinoma (CRC), or non-small cell lung cancer (NSCLC): Confirmation of diagnosis must be or have been performed by internal pathology review of archival biopsy material or other pathologic material at Fred Hutch\/University of Washington Cancer Consortium (UWMC)\n* LEUKAPHERESIS: HLA-A\\*11:01 confirmed through HLA typing\n* LEUKAPHERESIS: Previously documented KRASG12V mutation in tumor or plasma cell-free deoxyribonucleic acid (cfDNA) specimens by polymerase chain reaction (PCR) or next-generation sequencing (NGS) test\n* LEUKAPHERESIS: Measurable disease by RECIST 1.1 criteria: Participants must have measurable disease, defined as at least one target lesion that can be measured in at least one dimension (longest diameter to be recorded) as \u2265 10 mm, unless lymph node in which case short axis must be \u2265 15 mm. Baseline imaging (for example, diagnostic CT chest\/abdomen\/pelvis and imaging of the affected extremity as appropriate), brain imaging (MRI or CT scan) must be obtained within 8 weeks of the first planned T cell infusion. MRI can be substituted for CT in participants unable to have CT contrast\n* LEUKAPHERESIS: Participants must be willing to undergo tumor biopsy for research purposes if safe and feasible at baseline (prior to first T cell infusion), 2-3 weeks after the first T cell infusion, and approximately 2 weeks +\/- 1 week after the 2nd infusion (if applicable), if safe and feasible (these windows may vary due to manufacturing or clinical reasons). Should there be no tumor tissue that is accessible for biopsy, subjects will still be considered for participation, at the discretion of the investigator. Similarly, should an investigator determine that a biopsy cannot be performed safely for clinical reasons, biopsies may be cancelled or rescheduled. Patients can also refuse biopsies at any time after enrollment\n* LEUKAPHERESIS: Participants must be at least two weeks or five half-lives (for small molecules) from last systemic treatment: At least 2 weeks must have passed since any: immunotherapy (for example, T-cell infusions, immunomodulatory agents, interleukins, vaccines), or chemotherapy cancer treatment. At least five half-lives must have passed from treatment with small molecules or other investigational agents. There is no washout period for radiation, so long as radiated lesion is not the lesion being evaluated for RECIST measurements on the protocol. Bisphosphonates and denosumab are permitted\n* LEUKAPHERESIS: Participants must have progressed on, be intolerant of, or refused at least one line of standard systemic therapy for their current metastatic malignancy\n* LEUKAPHERESIS: Patients with NSCLC, CRC, and PDA harboring targetable molecular alterations including but not limited to EGFR mutations, ALK, ROS, NTRK fusions, microsatellite instability (MSI)-high, tumor mutational burden (TMB) high, BRAF v600 mutations, HER2 amplifications, must have been treated or refused treatment with applicable targeted therapies, as applicable\n* LEUKAPHERESIS: Fertile male and female participants must be willing to use an effective contraceptive method before, during, and for at least 4 months after the last A11KRASG12V-TCR infusion\n* LEUKAPHERESIS: 18 years or older at the time of enrollment\n* LEUKAPHERESIS: Capable of understanding and providing a written informed consent\n* LEUKAPHERESIS: Eastern Cooperative Oncology Group (ECOG) performance status of =\\< 1\n\n  * No uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage more than once every 28 days\n* LEUKAPHERESIS: No uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage more than once every 28 days\n* LEUKAPHERESIS: Renal: Creatinine clearance \\>= 50 ml\/min by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) or 24-hour urine clearance\n* LEUKAPHERESIS: Hepatic: Total bilirubin \\< 2.0 mg\/dL\n* LEUKAPHERESIS: Hepatic: Aspartate transferase (AST) and alanine transaminase (ALT) \\< 5x upper limit of normal (ULN)\n* LEUKAPHERESIS: Hepatic: Participants with suspected Gilbert syndrome may be included if total bilirubin (Bili) \\> 3 mg\/dL but no other evidence of hepatic dysfunction\n* LEUKAPHERESIS: Cardiac: Participants 60 years of age or older are required to have left ventricular ejection fraction (LVEF) evaluation performed within 60 days prior to enrollment. LVEF may be established with echocardiogram or MUGA scan, and LVEF must be \\>= 35%. Cardiac evaluation for other participants is at the discretion of the treating physician\n* LEUKAPHERESIS: Hematologic: Absolute neutrophil count (ANC) \\>= 1000 cells\/ mm\\^3\n* LEUKAPHERESIS: Nutrition: Albumin \\>= 3 g\/dL\n* START OF TREATMENT: Measurable disease by RECIST 1.1 criteria: Participants must have measurable disease, defined as at least one target lesion that can be measured in at least one dimension (longest diameter to be recorded) as \\>= 10 mm, unless lymph node in which case short axis must be \\>= 15 mm. Baseline imaging (for example, diagnostic CT chest\/abdomen\/pelvis and imaging of the affected extremity as appropriate), brain imaging (MRI or CT scan) must be obtained within 8 weeks of the first planned T cell infusion. MRI can be substituted for CT in participants unable to have CT contrast\n* START OF TREATMENT: Participants must be willing to undergo tumor biopsy for research purposes if safe and feasible at baseline (prior to first T cell infusion), 2-3 weeks after the first T cell infusion, and approximately 2 weeks +\/- 1 week after the 2nd infusion (if applicable), if safe and feasible (these windows may vary due to manufacturing or clinical reasons). Should there be no tumor tissue that is accessible for biopsy, subjects will still be considered for participation, at discretion of the investigator. Similarly, should an investigator determine that a biopsy cannot be performed safely for clinical reasons, biopsies may be cancelled or rescheduled\n* START OF TREATMENT: Participants must be at least two weeks from last systemic treatment: At least 2 weeks must have passed since any: immunotherapy (for example, T-cell infusions, immunomodulatory agents, interleukins, vaccines), or chemotherapy cancer treatment. At least five half-lives must have passed from treatment with small molecules or other investigational agents. There is no washout period for radiation, so long as radiated lesion is not the lesion being evaluated for RECIST measurements on the protocol. Bisphosphonates and denosumab are permitted\n* START OF TREATMENT: ECOG performance status of =\\< 1\n* START OF TREATMENT: Renal: Creatinine clearance \\>= 50 ml\/min by CKD-EPI or 24-hour urine clearance\n\n  * Exceptions may be at the discretion of the PI to allow participants with organ function affected by their organ-specific tumor involvement\n* START OF TREATMENT: Hepatic: Total bilirubin \\< 2.0 mg\/dL\n\n  * Exceptions may be at the discretion of the PI to allow participants with organ function affected by their organ-specific tumor involvement\n* START OF TREATMENT: AST and ALT \\< 5x upper limit of normal (ULN)\n* START OF TREATMENT: Participants with suspected Gilbert syndrome may be included if total Bili \\> 3 mg\/dl but no other evidence of hepatic dysfunction\n* START OF TREATMENT: Pulmonary: =\\< grade 1 dyspnea and oxygen saturation of arterial blood (SaO2) \\>= 92% on ambient air. If pulmonary function tests (PFTs) are performed based on the clinical judgement of the treating physician, participants with forced expiratory volume in the first second (FEVI) \\>= 50% of predicted and diffusing capacity of the lungs for carbon monoxide (DLCO) (corrected) \\>= 40% of predicted will be eligible\n\n  * Exceptions may be at the discretion of the PI to allow participants with organ function affected by their organ-specific tumor involvement\n* START OF TREATMENT: Hematologic: ANC \\>= 1000 cells\/ mm\\^3\n\n  * Exceptions may be at the discretion of the PI to allow participants with organ function affected by their organ-specific tumor involvement\n* START OF TREATMENT: Nutrition: Albumin \\>= 3 g\/dL\n\n  * Exceptions may be at the discretion of the PI to allow participants with organ function affected by their organ-specific tumor involvement\n* START OF TREATMENT: Participants with a history of chronic obstructive pulmonary disease (COPD), emphysema, or greater than 30 pack year smoking history should undergo PFTs and meet the following criteria:\n\n  * FEVI \\>= 50% of predicted and DLCO (corrected) \\>= 40% of predicted will be eligible\n\nExclusion Criteria:\n\n* LEUKAPHERESIS: Prior solid organ transplant or allogeneic hematopoietic stem cell transplant: Kidney transplant participants will be considered on a case-by-case basis requiring discussion with PI. If the participant has had a kidney transplant, participant must have dialysis access, dialysis plan, supportive nephrologist, willingness to stop transplant immunosuppression, and express understanding that rejection is possible outcome. Dialysis or costs related to transplant kidney will not be supported by the study. Participants having had any other solid organ transplants will be excluded, as will those with any history of allogeneic hematopoietic stem cell transplant\n* START OF TREATMENT: Pregnancy, breastfeeding, or expecting to conceive or father children for the duration of the trial through 4 months after last T-cell infusion. Participants of childbearing potential must have a negative serum pregnancy test within the 2 weeks (14 days) preceding T cell infusion. Childbearing potential is defined as women who have not been surgically sterilized and who are not post-menopausal (free of menses for at least 1 year)\n* START OF TREATMENT: Active autoimmune disease: Participants with active autoimmune disease requiring immunosuppressive therapy are excluded. Case by case exemptions are possible with approval by PI\n* START OF TREATMENT: Corticosteroid therapy at a dose equivalent of \\> 0.5 mg\/kg of prednisone per day. The following treatments are permitted: intranasal, inhaled, topical, or local steroid applications; systemic corticosteroids at physiologic doses equivalent to no more than \\> 0.5 mg\/kg\/day prednisone; steroids as premedication for contrast dye allergy\n* START OF TREATMENT: Concurrent use of other investigational anti-cancer agents\n* START OF TREATMENT: Active uncontrolled infection: Human immunodeficiency virus (HIV) positive participants on highly active antiretroviral therapy (HAART) with a CD4 count \\> 500 cells\/mm\\^3 are considered controlled, as are individuals with a history of hepatitis C who have successfully completed antiviral therapy with an undetectable viral load, and those with hepatitis B who have hepatitis well controlled on medication\n* START OF TREATMENT: Uncontrolled concurrent illness: Participants may not have uncontrolled or concurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\/social situations that would limit compliance with study requirements\n* START OF TREATMENT: Untreated brain metastases: Participants with small asymptomatic brain metastases (\\< 1 cm) or those with brain metastases previously treated and controlled with surgery or radiotherapy will be considered for inclusion at discretion of PI, so long as all other eligibility criteria are met\n* START OF TREATMENT: Active treatment for prior immune related adverse event to any immunotherapy: Participants receiving ongoing treatment for prior serious immune-related adverse events are excluded, with exception of hormone supplementation or corticosteroid therapy at equivalent of up to 0.5mg\/kg\/day prednisone per day, unless otherwise approved by PI\n* START OF TREATMENT: Other medical, social, or psychiatric factor that interferes with medical appropriateness and\/or ability to comply with study, as determined by the PI\n* START OF TREATMENT: Known allergic reactions to any of the components of study treatments\n* START OF TREATMENT: Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage more than once every 28 days","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06043713001","EMAIL":[{"email":"hutchdoc@fredhutch.org"},{}],"GEO":[47.60621,-122.33207]},{"TITLE":"Imaging Biomarkers for Immune Checkpoint Inhibitor Treatment in Patients With Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. 18 years old or over\n2. pathologically proven non-small cell lung cancer: adenocarcinoma or squamous cell carcinoma\n3. patients to be treated with immune checkpoint inhibitors (nivolumab or pembrolizumab or atezolizumab)\n4. ECOG performance status \u2264 2\n5. A person who have heard the detailed explanation of this clinical trial and are willing to voluntarily decide to participate and sign the informed consent form\n\nExclusion Criteria:\n\n1. subjects without measurable lesion: They must have at least one measurable lesion with a diameter of 10 mm by spiral CT or multi-detector CT (MD CT) or 20 mm or larger by conventional CT.\n2. subjects with a history of other malignant diseases within the past 5 years, except for treated basal cell carcinoma of the skin, carcinoma in situ of the cervix, cured thyroid cancer, and early gastric cancer\n3. subjects with clinically significant uncontrolled seizures, central nervous system disease, or psychiatric disorders that, in the investigator's judgment, interferes with or is likely to interfere with the understanding of informed consent\n4. subjects with uncontrolled diabetes\n5. subjects with severe uncontrolled infection\n6. subjects who underwent major surgery within 4 weeks prior to the start of the clinical trial or who have not fully recovered from the effects of major surgery\n7. pregnant or lactating patients\n8. subjects who have not received a pregnancy test or have a positive result during the basic test (menopause women with amenorrhea period of at least 12 months or longer are considered infertile subjects)\n9. women or men of childbearing potential who are unwilling to use contraception during the clinical trial period","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05260606001","EMAIL":[{"email":"seunghwan.moons.moon@samsung.com"}],"GEO":[37.566,126.9784]},{"TITLE":"A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and\/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation","CRITERIA":"Key Inclusion Criteria\n\n* Subjects must be at least 18 years of age, at the time of signing the informed consent.\n* Subjects must be capable of giving signed informed consent.\n* Subject must be diagnosed with one of the histologies below:\n\n  * NSCLC\n  * Colorectal adenocarcinoma\n  * HNSCC\n  * Pancreatic adenocarcinoma\n  * Breast cancer\n  * Ovarian cancer\n  * Any other solid tumor\n* Tumors must harbor a TP53 R175H variant mutation and subject must be HLA-A\\*02:01 positive (at least 1 allele) as confirmed by an CLIA-accredited laboratory-based test.\n* Subject has advanced solid cancer, defined as unresectable, advanced, and\/or metastatic disease (Stage III or IV) after at least 1 line of approved systemic standard of care (SOC) treatment regimen and for which there are no available curative treatment options.\n* Subject has at least 1 measurable lesion per computed tomography (CT) scan or magnetic resonance imaging (MRI) per RECIST version 1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at the time of enrollment\n* Adequate hematological, renal, hepatic, pulmonary, and cardiac function\n* Per Investigator judgement, subject is likely to complete study visits and\/or procedures per the protocol and comply with study requirements for study participation\n\nKey Exclusion Criteria\n\n* Any another primary malignancy within the 3 years prior to enrollment (except for non-melanoma skin cancer, carcinoma in situ (eg, cervix, bladder, breast) or low-grade prostate cancer\n* Known, active primary central nervous system (CNS) malignancy\n* History of prior adoptive cell and gene therapy, allogeneic stem cell transplant or solid organ transplantation.\n* History of stroke or transient ischemic attack within the 12 months prior to enrollment.\n* History of clinically significant cardiac disease within the 6 months prior to enrollment or heart failure at any time prior to enrollment.\n* Systemic therapy within at least 2 weeks or 3 half-lives, whichever is shorter, prior to enrollment.\n* History of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, or rIL-2; or known sensitivity or allergy to methotrexate, gentamicin, or other aminoglycosides.\n* Any form of primary immunodeficiency.\n* Live vaccine \u2264 4 weeks prior to enrollment or plans to have a live vaccine prior to planned lymphodepleting chemotherapy and\/or NT-175 treatment.\n* Active immune-mediated disease requiring systemic steroids or other immunosuppressive treatment (except if related to prior checkpoint inhibitor therapy)\n* Female of childbearing potential who is lactating or breast feeding at the time of enrollment.\n* Known to have Li-Fraumeni syndrome or is known to have relatives who are diagnosed with Li-Fraumeni syndrome.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05877599008","EMAIL":[{"email":"EEIleana@mdanderson.org"},{"email":"mailto:MNGavriliuc@mdanderson.org"}],"GEO":[29.76328,-95.36327]},{"TITLE":"GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors","CRITERIA":"Key Inclusion Criteria:\n\nMonotherapy - Dose Escalation and Dose Expansion Parts\n\n* Subjects with non-CNS solid tumors that is metastatic or unresectable and for whom there is no available standard therapy.\n* Subjects with a confirmed diagnosis of relapsed or refractory, advanced and\/or metastatic melanoma, NSCLC, or CRC and for whom there is no available standard therapy\n\nCombination Therapy - Dose Expansion Part\n\n* Subjects with unresectable Stage III or Stage IV melanoma with no prior systemic anticancer therapy for unresectable or metastatic disease. Primary ocular or mucosal melanoma is excluded.\n* Subjects with Stage IV metastatic or recurrent NSCLC with no prior systemic anticancer therapy, no actionable mutation.\n* Subjects with recurrent or metastatic HNSCC with no prior systemic therapy administered in the recurrent or metastatic setting.\n* Subjects with confirmed metastatic PDAC with no previous radiotherapy, surgery, chemotherapy, or investigational therapy for the treatment of metastatic disease.\n\nGeneral (all phases):\n\n* Must be age \u2265 18 years of age on the day of signing informed consent, or the legal age of consent in the jurisdiction in which the trial is taking place.\n* Measurable disease according to RECIST 1.1\n* Eastern Cooperative Oncology Group (ECOG) 0-1\n* Normal or adequate liver, renal, cardiac and bone marrow function\n\nKey Exclusion Criteria:\n\nMonotherapy - Dose Escalation and Dose Expansion Parts\n\n* Treatment with an anti-cancer agent (within 21 days or after at least 5 half-lives of the drug, whichever is shorter), prior to GEN1042 administration\n* Radiotherapy within 14 days prior to first GEN1042 administration\n* Toxicities from previous anti-cancer therapies that have not resolved\n\nCombination Therapy - Dose Expansion Part\n\n* Has received prior systemic cytotoxic chemotherapy, biological therapy, OR major surgery within 3 weeks or at least 5 half-lives of the drug (whichever is shorter) of the first dose of trial treatment.\n* Radiotherapy within 14 days of start of trial treatment or received lung radiation therapy of \\> 30 Gy within 6 months of the first dose of trial treatment.\n\nGeneral (all phases)\n\n* Subject has an active, known, or suspected autoimmune disease.\n* History of non-infectious pneumonitis that required steroids or currently has pneumonitis.\n* History of \u2265 grade 3 allergic reactions to monoclonal antibody (mAb) therapy\n* Subject with a condition requiring systemic treatment with either corticosteroids (\\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first treatment.\n\nNOTE: Other protocol defined Inclusion\/Exclusion criteria may apply.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04083599074","EMAIL":"clinicaltrials@genmab.com","GEO":[24.95233,121.20193]},{"TITLE":"A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC","CRITERIA":"Inclusion Criteria:\n\n* 1. Age 18-75 years old;\n* 2. Histologically or cytologically confirmed non-small cell lung cancer. If the pathological type of the patient is adenocarcinoma, genetic testing should be performed to exclude EGFR\/ALK mutations. Tumor tissue should be the first choice for genetic testing. If sufficient tumor tissue is not available, genetic testing using serum can be performed.\n* 3. According to AJCC 8th Edition, the patient had stage IIIA-IIIB (T1-4N2M0). N2 was a non-giant type with lymph node diameter \u22643cm and no invasion or exocapsular invasion. Pathological biopsy of mediastinal lymph nodes is recommended to be clear, and patients without pathology should at least meet the short diameter of enhanced chest CT \u22651cm and high metabolism of PET-CT.\n* 4. All lesions (including primary lesions and lymph nodes\/metastases evaluated as metastases) of the patient should be evaluated jointly by surgeons, radiologists, and radiologists to be potentially resectable.\n* 5. Subjects must have measurable target lesions (according to RECIST 1.1 criteria);\n* 6. ECOG behavior status score 0-1;\n* 7. No previous history of other malignant tumors;\n* 8. Never received anti-tumor therapy such as surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy related to non-small cell lung cancer;\n* 9. The patient should have adequate cardiopulmonary function: FEV1 and DLCO of the patient were \u226550% of the predicted value, and the ultrasonography suggested LVEF\u226555%, and no clear signs of heart failure and severe coronary artery stenosis were found in various tests. The cardiopulmonary function was assessed by the surgeon as being able to tolerate surgical treatment.\n* 10.The functional level of all vital organs must meet the following requirements:\n\n  1. Bone marrow: absolute neutrophil count (ANC) \u22651.5\u00d7 109\/L, platelet \u2265100 \u00d7 109\/L, hemoglobin \u22659 g \/dl;\n  2. Good coagulation function: defined as International standardized ratio (INR) or prothrombin time (PT) \u22641.5 times ULN;\n  3. Liver: total bilirubin \u22641.5 times the upper limit of normal, aspartate aminotransferase (AST) and alanine aminotransferase (ALT)\u22642.5 times the upper limit of normal;\n  4. Kidney: serum creatinine \u22641.25 times the upper limit of normal or creatinine clearance (calculated by Cockcroft-Gault formula) \u226560 ml\/min;\n* 11. Fertile men and women of childbearing age must consent to effective contraceptive use from the time they sign the master informed consent until 180 days after the final administration of the study drug. Women of reproductive age include premenopausal women and women within 2 years after menopause. Pregnancy test results of women of reproductive age must be negative within \u2264 7 days before the first study drug administration;\n* 12. Voluntary participation in clinical research; Fully understand and know this study and sign ICF (Informed Consent).\n\nExclusion Criteria:\n\n* 1. All lesions could not be completely resected by surgery;\n* 2. Have any active autoimmune disease or history of autoimmune disease (such as uveitis, enteritis, hepatitis, pituitaritis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (may be included after hormone replacement therapy), tuberculosis); Patients with complete remission of childhood asthma without any intervention or vitiligo in adulthood could be included, but patients requiring medical intervention with bronchodilators could not be included;\n* 3. Have a congenital or acquired immune deficiency, such as human immunodeficiency virus (HIV) infection, active hepatitis B (HBV DNA \u2265 500 IU\/ml), hepatitis C (HCV antibody positive and HCV-RNA above the lower detection limit of analytical methods), or co-infection with hepatitis B and hepatitis C;\n* 4. There is a third lacunar effusion that is difficult to control, such as a large amount of pleural effusion or ascites or pericardial effusion;\n* 5. Subjects requiring systemic therapy with corticosteroids (\\>10 mg\/ day of prednisone or equivalent) or other immunosuppressants within 14 days prior to initial medication. In the absence of active autoimmune disease, inhaled or topical corticosteroids are permitted, as well as adrenal hormone replacement therapy at doses \\> 10 mg\/ day of prednisone efficacy;\n* 6. Subjects who have been treated with anti-tumor vaccine or other immunostimulating anti-tumor drugs (interferon, interleukin, thymosin, immunocell therapy, etc.) within 1 month before the first administration;\n* 7. Participants who are participating in another clinical study or whose first dose is less than 4 weeks (or 5 half-lives of the investigational drug) since the end (last dose) of the previous clinical study;\n* 8. Evidence of past or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiological pneumonia, drug-induced pneumonia, and severe impairment of lung function;\n* 9. Major surgery, open biopsy, or significant trauma were performed within 28 days prior to enrollment;\n* 10. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;\n* 11. Pregnant or lactating women; A fertile patient who is unwilling or unable to take effective contraceptive measures;\n* 12. Known allergic reactions, hypersensitivities, or intolerances to study drugs;\n* 13. There are other circumstances in which the investigator considers it inappropriate to participate in the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06424899001","EMAIL":[{"email":"luotaobo@163.com"}],"GEO":[30.29365,120.16142]},{"TITLE":"RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial","CRITERIA":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed adenocarcinoma of the lung that is unresectable stage IIIB\/C or stage IV, does not have an EGFR sensitizing (activating) mutation or ALK or ROS1 translocation. BRAF, RET, NTRK, MET ex 14 splice site mutation\n* Measurable disease based on RECIST 1.1\n* Tumor sample requirements\n\n  * Mandatory provision of an unstained, archived tumor tissue sample in a quantity sufficient to allow for biomarker and genomic analysis. A minimum of 10 unstained slides should be available for evaluation.\n  * Known PD-L1 TC expression status assayed by Ventana SP263. Patients who have known PDL-1 as assayed by PharmDx 22C3 assay may be eligible; however, available archival tissue will be used to assay with Ventana SP263 test.\n* Prior chemotherapy or immunotherapy as adjuvant therapy for lung cancer is permitted as long as it has been \\>6 months from last dose at the time of enrollment. Local treatment of isolated lesions, excluding target lesions, for palliative intent is acceptable (e.g. by local surgery or radiotherapy). Prior systemic therapy for advanced\/metastatic NSCLC makes the patient ineligible for this study.\n* Patients with treated brain metastasis are eligible as long as they have stable symptoms, are more than 2 weeks from completion of therapy, and do not require more than 10mg of daily prednisone or equivalent.\n* ECOG Performance status of 0 or 1\n* Body weight of \\>30 kg\n* Adequate organ function within 14 days of study enrollment defined as:\n\n  * Hemoglobin \u2265 9.0 g\/dL\n  * Absolute neutrophil count \u22651,500\/mcL\n  * Platelets \u2265 100,000\/mcL\n  * Total bilirubin \u22641.5x upper limit of normal (ULN) - this will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician.\n  * AST (SGOT) and ALT (SGPT) \u22642.5 x institutional ULN unless liver metastases are present, in which case it must be \u22645x ULN\n  * Measured creatinine clearance (CL) \\>40 mL\/min or calculated creatinine CL\\>40 mL\/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance:\n* Expected life expectancy of at least 12 weeks in the opinion of the enrolling investigator as documented in the medical record\n* Women of childbearing potential and men with partners of child-bearing potential must agree to use effective contraception for the time of screening to the duration of treatment and 3 months after the last dose of study drug\n* Provide voluntary written consent prior to the performance of any research related tests or procedures.\n\nExclusion Criteria:\n\n* Not pregnant or breast feeding. Evidence of post-menopausal status, or negative urine or serum pregnancy test for female pre-menopausal patients. Women will be considered postmenopausal if they have amenorrhea for 12 months without an alternative medical explanation\n* Dysphagia or inability to swallow medications\n* Squamous cell, large cell, or NSCLC NOS (not otherwise specified) histology or mixed tumors\n* Has untreated brain metastasis or active leptomeningeal carcinomatosis\n* Has a known sensitivity to any component of therapeutic agents used in this study\n* Receipt of any immunotherapy or investigational drug within 4 weeks prior to the first dose of study drug; and in the case of monoclonal antibodies 6 weeks prior to the first dose of study drug\n* Prior treatment with any other anti-PD-1, or PD-L1, including durvalumab or an anti-PD-L2 agent or an antibody or a small molecule targeting other immuno-regulatory receptors except as adjuvant therapy for NSCLC so long as it has been greater than six months since the last treatment\n* Current or prior use of immunosuppressive medication within 28 days before the first dose of study drug, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg\/day of prednisone, or an equivalent corticosteroid\n* Recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access) that would prevent administration of study drug\n* Active or prior documented autoimmune disease within the past 2 years requiring systemic treatment (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Patients with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n* Active documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis) who require immunosuppression or patients who exceed 10 mg\/day of prednisone, or an equivalent corticosteroid are excluded\n* History of primary immunodeficiency\n* History of organ transplant that requires therapeutic immunosuppression\n* Taking daily probiotics (patients with last probiotic \\> 4weeks prior to first dose of RMT are eligible)\n* History of Human Immunodeficiency Virus (HIV) (known HIV 1\/2 antibodies positive) who are on anti-retroviral treatment for \\< 6 months and absolute CD4 count\\<500 (patients with HIV not meeting these criteria are eligible)\n* Has known active Hepatitis B or C. Active Hepatitis B is defined as a known positive HBsAg, and positive hepatitis B virus quantification assay (patients with history of Hepatitis B who have seroconversion i.e. Hepatitis B core antibody positive and Hepatitis B surface antibody positive are eligible). Active Hepatitis C is defined by a known positive Hep C Ab result and positive quantitative HCV RNA results (Patients with Hepatitis C who are on anti-viral suppressive therapy and negative quantitative HCV RNA results are eligible)\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses\n* Myocardial infarction or stroke within 3 months prior to enrollment\n* History of systolic or diastolic heart failure with New York Heart Association (NYHA) class III or IV symptoms (refer to Appendix II)\n* Has active or prior history of (non-infectious) pneumonitis that required steroids or patients with interstitial lung disease\n* Psychiatric illness\/social situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent\n* Known history of active tuberculosis. Patients with prior history of latent TB could be included if they have been treated previously with isoniazid.\n* Patients who are on chronic systemic antibiotic therapy (antibiotics for \u226560 consecutive days within 12 weeks of enrollment). Patients who receive systemic antibiotics between enrollment and start of RMT are eligible\n* Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving RMT\n* History of another primary malignancy (excluding non-melanoma skin cancer) within 5 years prior to starting RMT, except if the patient has undergone potentially curative therapy with no evidence of disease recurrence for 5 years since initiation of that therapy\n* Any condition that, in the opinion of the investigator, would interfere with evaluation of the study drug or interpretation of patient safety or study results","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04105270001","EMAIL":"ccinfo@umn.edu","GEO":[44.97997,-93.26384]},{"TITLE":"Confocal Laser Endomicroscopy VERification","CRITERIA":"Inclusion Criteria:\n\n1. \u226518 years of age\n2. Suspected malignant peripheral lung lesion with an indication for a bronchoscopic diagnostic work-up as determined by the attending physician or tumor board. Peripheral pulmonary lesions are defined as lesions located beyond the visible segmental bronchi, not detectable by regular flexible bronchoscopy\n3. Bronchus sign on pre-procedural CT or estimated confidence for successful navigation to the nodule resulting in a r-EBUS signal\n4. Solid part of the lesion must be \u226710 mm\n5. Largest dimension of lesion size on CT \u226630 mm (long-axis)\n6. Ability to understand and willingness to sign a written informed consent\n\nExclusion Criteria:\n\n1. Inability or non-willingness to provide informed consent\n2. Endobronchial visible malignancy on bronchoscopic inspection\n3. Target lesion within reach of the linear EBUS scope\n4. Failure to comply with the study protocol\n5. Known allergy or risk factors for an allergic reaction to fluorescein\n6. Pregnancy or breastfeeding\n7. Hemodynamic instability\n8. Refractory hypoxemia\n9. Therapeutic anticoagulant use that cannot be withheld for an appropriate interval before the procedure\n10. Unable to tolerate general anesthesia according to the anesthesiologist\n11. Undergoing chemotherapy as several chemotherapies have fluorescent properties at the same wavelength (e.g., doxorubicin)","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06079970006","EMAIL":[{},{},{},{},{},{},{}],"GEO":[52.37403,4.88969]},{"TITLE":"Neoadjuvant Furmonertinib and Cisplatin\/Pemetrexed as in EGFR Mutated Stage IIIA-IIIB Resectable NSCLC (FORESEE)","CRITERIA":"Inclusion Criteria:\n\n* With written informed consent before any study procedure\n* Histology or cytology diagnose of non-small cell lung cancer within 60 days\n* Stage IIIA\/IIIB, with resectable lesion(s) by radiology\n* EGFR mutation positive (exon 19 deletions or exon 21 L858R, with or without other EGFR mutations)\n* Without prior anti-tumor treatment\n* With at least one measurable lesions (The longest axis \u226510mm)\n* ECOG performance status 0-1\n* Using adequate and effective contraception, women should refrain from breastfeeding and have a negative pregnancy test prior to the first administration of the study drug if within during child-bearing age\n\nExclusion Criteria:\n\n* EGFR Exon 20 insertions positive\n* Mixed with small cell cancer, or other mixed types of lung cancer\n* Any prior anti-tumor treatment\n* Major surgery within 4 weeks before enrolment\n* Women with pregnancy or breastfeeding\n* Use of strong CYP3A4 inhibitors within 7 days or strong CYP3A4 inducers within 21 days before enrolment; use of traditional Chinese medicine with anti-tumor effect within 21 days before enrolment\n* With history of other malignancy except for radical resected tumors without recurrence for 5 years or more\n* With severe or uncontrolled systemic disease such as uncontrolled hypertention, diabetes mellitus, chronic heart failure, unstable angina, myocardial infarction within 1 year, active hemorrhage, active HBV\/HCV\/HIV or other infections requiring infusion treatment\n* Severe gastrointestinal diseases which may affect the intake and absorption of study drug\n* Prolongation of ECG QTc or with relative risk factors\n* History of interstitial lung disease or with relative risk factors\n* Inadequate organ function of hematology, liver and kidney\n* Allergic to study drugs or any component\n* Poor adherence or other situation judged by investigator\n* Patients who had participated other clinical studies of tumors","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05430802001","EMAIL":[{"email":"leijiemd@163.com"}],"GEO":[34.25833,108.92861]},{"TITLE":"Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Participants must have signed and dated an IRB\/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal participant care.\n* Participants must be willing and able to comply with scheduled visits, treatment schedule, and laboratory testing.\n* Subjects with cytologically or histologically confirmed advanced stage or recurrent NSCLC (per the 8th International Association for the Study of Lung Cancer classification, eligible for treatment of NSCLC with pembrolizumab in line with ESMO guidelines.\n* Prior adjuvant or neoadjuvant chemotherapy is permitted as long as the last administration of the prior regimen occurred at least 3 months prior to enrolment.\n* Prior chemoradiation for locally advanced disease is also permitted as long as the last administration of chemotherapy or radiotherapy (which ever was given last) occurred at least 3 months prior to enrolment.\n* Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status.\n* Males and Females, ages 18 years (or age of majority) and older.\n* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU\/L or equivalent units of HCG) within 24 hours prior to the start of study treatment.\n* Women must not be breastfeeding.\n* Women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of contraception for the duration of 5 months (30 days of ovulatory cycle plus the time required for the investigational drug to undergo five half-lives).\n* Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of 7 months (90 days plus the time required for pembrolizumab to undergo five half-lives) after the last dose of investigational drug. In addition, male participants must be willing to refrain from sperm donation during this time.\n\nExclusion Criteria:\n\n* Subjects with symptomatic untreated CNS metastases are excluded. Subjects are eligible if CNS metastases are asymptomatic and \/ or adequately treated and subjects are neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to enrolment.In addition, participants must be either off corticosteroids, or on a stable or decreasing dose of \u2264 10 mg daily prednisone (or equivalent) for at least 2 weeks prior to treatment assignment.\n* Subjects with a condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive medications (see list below) within 14 days of enrolment. Inhaled or topical steroids, and adrenal replacement steroid doses \u2264 10 mg daily prednisone equivalent, are permitted.\n* a CD4+ T-cell count of less than 100 cells\/\u03bcL\n* Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.\n* History of allergy or hypersensitivity to study drug components.\n* Subjects may not have previously received a solid organ transplantation.\n* Total body weight \\<40 or \\>140 kg\n* Absence of or unknown PD-L1 status","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04909684001","EMAIL":[{"email":"Michel.vandenHeuvel@radboudumc.nl"},{"email":"Berber.Piet@radboudumc.nl"},{},{},{}],"GEO":[51.8425,5.85278]},{"TITLE":"A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Patients with stage III non-small cell lung cancer were confirmed by imaging and histological biopsy\n2. Age\u2265 18\n3. ECOG PS:0-1\n4. Tumor molecular testing by EBUS or biopsy confirmed positive for one or more of the following driver genes:EGFR\\\\ALK\\\\ROS1\\\\RET\\\\KRAS\\\\PIK3CA\\\\BRAF\\\\HER2\\\\MET\n5. Patients who met and agreed to surgery or radical chemoradiotherapy, and the remaining samples after cutting tissue sections did not affect the possible further clinical treatment of the subject\n6. Provide 20 mL peripheral blood samples periodically\n7. The subjects volunteered to join the study, and signed the informed consent form, with good compliance, and actively cooperated with the hospital for routine clinical diagnosis and treatment follow-up\n\nExclusion Criteria:\n\n1. Patients with other malignancies within 5 years\n2. According to the investigator, the patient also had other diseases that may affect the follow-up and short-term survival\n3. The subject had other factors that may lead to the termination of the study, such as other serious diseases (including mental illness), serious laboratory abnormalities, and family or social factors that affected the safety of the subject, or the collection of data and samples","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06443684011","EMAIL":[{},{}],"GEO":[30.29365,120.16142]},{"TITLE":"An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis","CRITERIA":"Inclusion Criteria:\n\n1. at least 18 years of age;\n2. Histologically or cytologically confirmed metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC);\n3. Patient with EGFR 19Del or L858R mutation diagnosed histologically or cytologically.( EGFR L858R or Del 19 with\/without T790M )\n4. Imaging (MR\/CT) confirmed untreated brain metastases before Furmonertinib initiation;\n5. Organ function is compatible with oral Furmonertinib therapy (investigator determination based on real-world practice);\n6. Life expectancy \u226512 weeks before Fumonertinib initiation;\n7. ECOG PS of 0 to 2;\n8. Sign the informed consent form.\n\nExclusion Criteria:\n\n1. Any Third-Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) before Furmonertinib initiation;\n2. Known hypersensitivity to Furmonertinib or its excipient components;\n3. Simultaneous systemic chemotherapy or WBI;\n4. The time from the treatment with any other investigational product or its analogue before Furmonertinib initiation does not exceed 5 half-lives of the drug or 14 days, whichever is longer;\n5. Any evidence of severe or uncontrolled systemic diseases;\n6. Presence of any disease that may strongly interfere with oral drug absorption; presence of any factor that contributes to QTc prolongation or increased risk of arrhythmia; presence of interstitial pneumonitis.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06352502001","EMAIL":[{"email":"such@fmmu.edu.cn"},{"email":"minjie1504@163.com"},{},{}],"GEO":[34.25833,108.92861]},{"TITLE":"Induction Lorlatinib in Stage III Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Age :18 Years to 75 Years;\n* ECOG physical score 0-2 points; expected survival time \u2265 1 year;\n* Pathologically confirmed diagnosis with Stage III NSCLC which harbored ALK fusion detected by next generation sequencing (NGS) or immunohistochemistry (IHC) with or without FISH. Suspected N2 (station 2\/4\/7) for stage III disease should be confirmed by either mediastinoscopy or EBUS.\n* At least one measurable target lesion according to the RECIST 1.1 standard;\n* The main organ function meets the following criteria: 1) blood routine: absolute value of neutrophils \u2265 1.5 \u00d7 109 \/ L, platelets \u2265 75 \u00d7 109 \/ L, hemoglobin \u2265 80 g \/ L; 2) blood biochemistry: total bilirubin \u2264 1.5 times the upper limit of normal value, aspartate aminotransferase and alanine aminotransferase \u2264 2.5 times the upper limit of normal value (if liver metastasis, \u2264 upper limit of normal value 5 times), serum creatinine \u2264 1.5 times the upper limit of normal;\n* Subjects voluntarily joined the study and signed informed consent, with good compliance to follow-up.\n\nExclusion Criteria:\n\n* Stage I, stage II and metastatic stage IV NSCLC;\n* Histologically confirmed small cell lung cancer (including lung cancer mixed with small cell lung cancer and non-small cell lung cancer);\n* Patients who have previously used any other anti-tumor drugs or received surgery\/radiotherapy;\n* Patients with any underlying disease that investigators consider it may affect patient's prognosis including sever cardiovascular, pulmonary disease or serious infections.\n* Clinically obvious gastrointestinal abnormalities, which may affect the intake, transport or absorption of drugs (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.), or patients with total gastrectomy;\n* Pregnant or lactating women; those who have fertility are unwilling or unable to take effective contraceptive measures;\n* Patients with low compliance or willingness to take the drugs and surveillance.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05740943001","EMAIL":[{},{},{},{},{}],"GEO":[23.11667,113.25]},{"TITLE":"Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab","CRITERIA":"Inclusion Criteria:\n\nAge \u2265 18 years\n\nAbility to provide written informed consent and HIPAA authorization\n\nPatients with inoperable or unresectable stage III NSCLC who are planning to receive concurrent CRT followed by consolidation Durvalumab OR Patients with inoperable or unresectable stage III NSCLC who have previously received concurrent CRT and are planning or currently receiving C1-4 consolidation durvalumab\n\nMust have viable tissue for ctDNA profiling, (fresh or archived tissue)\n\nExclusion Criteria:\n\nPatient unwilling to provide tissue and blood samples for ctDNA testing.\n\nPatient has contraindications to treatment with concurrent CRT and\/or consolidation Durvalumab.\n\nPatients with any other active cancer; excluding squamous cell or basal cell cancer.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05757843001","EMAIL":[{}],"GEO":[39.76838,-86.15804]},{"TITLE":"Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Able to sign a written consent form, understand, and agree to comply with requirements of the study.\n* Documented locally advanced or recurrent NSCLC that is not eligible for curative surgery and\/or definitive radiotherapy, with or without chemotherapy, or metastatic non-squamous or squamous NSCLC.\n* No prior systemic treatment for advanced or metastatic NSCLC, including but not limited to chemotherapy or targeted therapy.\n* At least one measurable lesion as assessed by RECIST v1.1.\n* Eastern Cooperative Oncology Group (ECOG) PS \u2264 1.\n* Adequate organ function as indicated by laboratory tests.\n\nExclusion Criteria:\n\n* Participants diagnosed with NSCLC that harbor a driver mutation (eg, EGFR-sensitizing mutation, ALK fusion oncogene, and BRAF V600E mutation or ROS1 mutation).\n* Participant has received any Chinese herbal medicine or Chinese patent medicines used to control cancer within 14 days before first dose of study drug.\n* Active leptomeningeal disease or uncontrolled, untreated brain metastasis.\n* Active autoimmune diseases or history of autoimmune diseases that may relapse.\n* Any cancer \u2264 5 years before first dose of study drug except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, localized prostate cancer, carcinoma in situ of the cervix or breast).\n* Any condition that required systemic treatment with either corticosteroids (\\> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication \u2264 14 days before first dose of study drug.\n\nNote: Other protocol defined Inclusion\/Exclusion criteria may apply.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06091943015","EMAIL":"clinicaltrials@beigene.com","GEO":[47.00556,28.8575]},{"TITLE":"Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","CRITERIA":"Inclusion Criteria:\n\n* Diagnosis of histologically or cytologically confirmed metastatic nonsquamous non-small cell lung cancer (NSCLC) with no known epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) mutation, or other genomic aberration for which a locally approved targeted therapy is available.\n* Must have at least 1 measurable lesion per response evaluation criteria in solid tumors (RECIST) v1.1 as determined by the local site Investigator\/radiology assessment.\n* Life expectancy of at least 3 months and adequate organ function.\n\nExclusion Criteria:\n\n- Received prior systemic therapy for the treatment of metastatic NSCLC.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06236438014","EMAIL":"abbvieclinicaltrials@abbvie.com","GEO":[24.95233,121.20193]},{"TITLE":"Adjuvant Chemotherapy Combined With Camrelizumab for \u2161A -\u2162A NSCLC Patients","CRITERIA":"Inclusion Criteria:\n\n1. Sign the informed consent form before starting the study;\n2. For patients with non-small cell lung cancer who have undergone surgical resection, the TNM stage after surgery is IIA-IIIA;\n3. Patients cannot receive targeted adjuvant therapy;\n4. 18-80 years old;\n5. The patient can recover within 3-8 weeks after the operation, and receive postoperative adjuvant treatment;\n6. The ECOG PS score is 0 or 1;\n7. Have not received any chemotherapy for non-small cell lung cancer before enrollment;\n8. Within 7 days before enrollment, the laboratory inspection must meet all the following requirements:\n\n   * Absolute neutrophil count \u2265 1.5 \u00d7 109\/L, platelet count \u2265 100 \u00d7 109\/L, hemoglobin \u2265 9g\/dL;\n   * Total bilirubin \u2264 1.5 ULN; AST and ALT \u2264 2.5 ULN;\n   * Serum creatinine \u2264 1.25 ULN, or serum creatinine clearance \u2265 60ml\/min;\n9. Female patients must meet: menopause or have undergone surgical sterilization. Women with fertility must take effective contraceptive measures. Do not breastfeed.\n10. Male patients must agree to use appropriate contraceptive measures.\n\nExclusion Criteria:\n\n1. Known or suspected to be allergic to the drug or any component of the drug related to the test;\n2. Patients who can receive targeted treatment;\n3. Other malignant tumors in five years before enrollment, excluding the cured cervical carcinoma in situ, the cured skin basal cell carcinoma, and other types of tumors that were cured only after surgical treatment;\n4. Myocardial infarction, unstable angina pectoris and grade II congestive heart failure in six months before enrollment; New angina pectoris occurred within 3 months; Ventricular arrhythmia requiring medication;\n5. Uncontrolled hypertension after treatment with antihypertensive drugs, i.e. systolic blood pressure \u2265 140mmHg or diastolic blood pressure \u2265 90mmHg;\n6. History of HIV infection, active period of HCV infection, active period of HBV infection (HBV-DNA\\>1000 copies\/ml);\n7. The researcher judged that there was a risk of bleeding;\n8. Active severe clinical infection (\u2265 grade 3 CTCAE V5.0);\n9. Epilepsy patients who need medication;\n10. Allogeneic organ transplantation;\n11. Patients who need kidney dialysis;\n12. Thrombotic or embolic venous or arterial events occurred within six months before enrollment;\n13. Serious uncured wounds, ulcers or fractures;\n14. Interstitial pneumonia;\n15. Any malabsorption disease;\n16. Any disease that is unstable or may endanger the patient's safety;\n17. Drug abuse, medical, psychological or social diseases;\n18. Participate in other clinical studies within 3 months before enrollment;\n19. During pregnancy or lactation;","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"05825443001","EMAIL":[{"email":"david_lu189@163.com"}],"GEO":[24.95233,121.20193]},{"TITLE":"Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]","CRITERIA":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of squamous squamous non-small cell lung cancer (NSCLC) \\[Stage IV: M1a, M1b, M1c, American Joint Committee on Cancer Staging Manual, version 8\\]\n* Measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 as assessed by the local site investigator\/radiology\n* Has life expectancy \u22653 months\n* Has Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1 assessed within 7 days prior to allocation\n* Archival tumor tissue sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated has been provided\n* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)\n* Participants who are hepatitis B surface antigen (HBsAg)-positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before allocation\n* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening\n* Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to \u2264 Grade 1 or baseline (participants with endocrine-related AEs who are adequately treated with hormone replacement are eligible)\n* Has adequate organ function\n* For Maintenance only (prior to randomization): is without disease progression of their NSCLC, as determined by BICR using RECIST 1.1 after completion of study-specified Induction with an evaluable scan at Week 12\n* For Maintenance only (prior to randomization): has ECOG PS of 0 or 1 as assessed at the Prerandomization Visit\n* For Maintenance only (prior to randomization): all AEs (with the exception of alopecia, Grade 2 fatigue, and Grade \u22642 endocrine-related AEs requiring treatment or hormone replacement) have recovered\n* For Maintenance only (prior to randomization): has adequate organ function\n\nExclusion Criteria:\n\n* Diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements\n* Grade \u22652 peripheral neuropathy\n* History of documented severe dry eye syndrome, severe Meibomian gland disease and\/or blepharitis, or corneal disease that prevents\/delays corneal healing\n* Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease\n* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QTcF interval to \\>480 ms, and other serious cardiovascular and cerebrovascular diseases within 6 months before study intervention\n* HIV-infected participants who have been newly diagnosed or with a history of Kaposi's sarcoma and\/or Multicentric Castleman's Disease\n* Received prior systemic anticancer therapy for their metastatic NSCLC\n* Received prior therapy with an anti-programmed cell death-1 (PD-1), anti-PD-Ligand 1 (PD-L1), or anti-PD-Lignad 2 (PD-L2) agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, cytotoxic Tlymphocyte-associated protein 4, OX-40, CD137) \\[Note: Prior treatment with chemotherapy and\/or radiation as a part of neoadjuvant or adjuvant therapy or chemoradiation therapy for nonmetastatic NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC.\\]\n* Received prior treatment with a tumor-associated calcium signal transducer 2 (TROP2)-targeted antidrug conjugate (ADC)\n* Received prior systemic anticancer therapy including investigational agents within 4 weeks before allocation\n* Received radiation therapy to the lung that is \\>30 Gray within 6 months of start of study intervention\n* Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids\n* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention\n* Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease\n* Participants who have not adequately recovered from major surgery or have ongoing surgical complications\n* Received prior treatment with a topoisomerase I inhibitor-containing ADC\n* Is currently receiving a strong inducer\/inhibitor of CYP3A4 that cannot be discontinued for the duration of the study (the required washout period before starting sac-TMT is 2 weeks)\n* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.\n* Has known central nervous system (CNS) metastases\/carcinomatous meningitis (participants with previously treated brain metastases may participate provided they are clinically stable for t least 2 weeks and, have no evidence of new or enlarging brain metastases and also are off steroids 3 days prior to dosing with study medication. Subjects with known untreated, asymptomatic brain metastases \\[ie, no neurological symptoms, no requirements for corticosteroids, no or minimal surrounding edema, and no lesion \\>1.5 cm\\] may participate but will require regular imaging of the brain as a site of disease)\n* Severe hypersensitivity (\u2265Grade 3) to study intervention and\/or any of its excipients or to another biologic therapy\n* Active autoimmune disease that has required systemic treatment in the past 2 years (replacement therapy \\[eg, thyroxine, insulin, or physiologic corticosteroid\\] is allowed)\n* History of (noninfectious)pneumonitis\/interstitial lung disease that required steroids or has current pneumonitis\/interstitial lung disease\n* Active infection requiring systemic therapy\n* History of allogeneic tissue\/solid organ transplant","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06422143012","EMAIL":[{}],"GEO":[37.566,126.9784]},{"TITLE":"A Phase \u2161 Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)","CRITERIA":"Inclusion Criteria:\n\n1. Ability to understand and willingness to sign a written informed consent document.\n2. Aged at least 18 years old.\n3. Histologically or cytologically confirmed locally advanced or metastatic NSCLC (stage IIIB\\~IV).\n4. According to the prior treatments having received for advanced disease (platinum containing or\/and immunotherapy containing systemic therapy, not more than three lines), participants were randomized to two cohorts.\n5. Participants with EGFR ex20ins mutation.\n6. ECOG performance status 0 to 1.\n7. Life expectancy is not less than 12 weeks.\n8. At least one measurable lesion as defined by RECISTV1.1.\n9. Participants must have specific organ and bone marrow function.\n\nExclusion Criteria:\n\n* Exclusion\n\n  1. Having the anticancer therapy prior to the first dose of PLB1004 as follows:\n\n     1. Any monoclonal antibodies targeting EGFR\/HER2\/VEGFR within 4 weeks.\n     2. Any cytotoxic drugs or other anticancer drugs from a previous treatment regimen within 14 days.\n     3. Any anticancer herbal medicine within 7 days\n     4. Major surgery within 4 weeks prior to starting PLB1004 or who have not recovered from side effects of such procedure except for the biopsy of Thoracoscopy and the clinical test of Mediastinoscopy could \u2264 7 days prior to starting PLB1004..\n     5. Radiotherapy to lung fields and whole-brain fields \u22644 weeks prior to starting PLB1004. For all other anatomic sites, radiotherapy \u22642 weeks prior to starting PLB1004 or patients who have not recovered from radiotherapy-related toxicities. Palliative radiotherapy for bone lesions is not included.\n     6. Any anti-EGFR TKI for the EGFR ex20ins mutation.\n     7. Any third-generation anti-EGFR TKI during the treatment having achieved a best overall response of the partial response or complete response.\n  2. Had not recovered from the adverse events and comorbidities caused by prior Systemic chemotherapy ,surgery ,radiotherapy to \u2264 Grade 1\uff08except for hair loss and permanent radiotherapy damage \uff09,the neurological toxicity caused by platinum could \u2264 Grade 2.\n  3. Patients receiving treatment with medications that meet one of the following criteria and that cannot be discontinued at least 1 week prior to the start of treatment with PLB1004 and for the duration of the study:\n\n     * Strong inhibitors of CYP3A4\n     * Strong inducers of CYP3A4\n     * metformin a MATE transporter substrate\n  4. Patients with spinal cord compression ,brain membrane metastasis and symptomatic central nervous system (CNS), who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study manage CNS symptoms.\n  5. Patients with uncontrolled and symptomatic pleural effusions, peritoneal effusions and pericardial effusions within 4 weeks prior to the start of treatment with PLB1004.\n  6. Presence or history of a malignant disease other than NSCLC that has been diagnosed and\/or required therapy within the past 3 years. Exceptions to this exclusion include the following: completely resected basal cell and squamous cell skin cancers, indolent malignancies that currently do not require treatment, and completely resected carcinoma in situ of any type.\n  7. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.\n  8. Konwn positive hepatitis B (hepatitis B virus , HBV) surface antigen(HBsAg) and HBV-DNA test value\u2265ULN.\n  9. known positive hepatitis C antibody(anti-HCV) and Anti-HIV(+).Note: Subjects with a prior history of HCV, who have completed antiviral treatment and have subsequently documented HCV RNA below the lower limit of quantification per local testing are eligible.\n  10. Having significant or uncontrolled systemic disease, including but not limited to:\n\n      1. Poorly controlled hypertension (referring to systolic blood pressure\\>100 mmHg after treatment) .\n      2. Ongoing or active infection.\n      3. Keratitis or onset of ulcerative keratitis.\n      4. Other significant disease, mental illness or laboratory abnormalities that could affect the compliance of the patient on the protocol or investigator's judgement.\n  11. Clinically significant, uncontrolled heart disease, including but not limited to:\n\n      1. Abnormal QT interval on screening electrocardiogram (ECG), defined as the average value of triplicate QTcF\\>470ms.\n      2. Have significant arrhythmias such as ventricular arrhythmia, supraventricular arrhythmia which could not be controlled by drugs, nodal arrhythmia and other cardiac arrhythmias which could not be controlled by drugs, Grade\u22653 of Congestive heart failure by the New York Heart Association (NYHA).\n      3. Any factors that increase the risk of QTc interval prolongation, such as hypokalemia, genetic long QT syndrome, taking drugs that causing the QT interval prolongation.\n  12. Medical history of deep vein thrombosis or pulmonary embolism within 6 months prior to enrolment or any of the following: Myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary\/peripheral artery bypass graft, or any acute coronary syndrome. Or bleeding tendencies or hypercoagulable coagulopathy within 6 months prior to first dose.\n  13. Have active digestive system disease, or major gastrointestinal surgery which may significantly affect the taking or absorption of PLB1004(such as ulcerative lesions, uncontrollable nausea, vomiting, diarrhea, and malabsorption syndrome).\n  14. History of hypersensitivity to active or inactive excipients of PLB1004 or drugs with a similar chemical structure of class to PLB1004.\n  15. pregnant or nursing women.\n  16. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06015503001","EMAIL":[{"email":"yangjinji@gdph.org.cn"}],"GEO":[23.11667,113.25]},{"TITLE":"A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab","CRITERIA":"Inclusion criteria:\n\n* Signed and dated, written informed consent form (ICF) prior to any trial-specific procedures\n* Male or female aged \u2265 18 years (no upper limit of age) at the time of ICF signature\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Life expectancy of at least 3 months\n* For Arm A, only patients with a Signal Regulatory Protein-alpha (SIRP\u03b1) polymorphism V1\/V1 will be eligible; SIRP\u03b1 polymorphism will be assessed in blood sampling (patient deoxyribonucleic acid (DNA)) in a central laboratory; V1 allele is understood to include V1 and potential V1-like alleles. If, at a later time, V1\/V2 heterozygous patients are considered for inclusion in this Arm of the trial, these patients will require to be centrally confirmed with at least one V1 allele.\n* Patients with histologically or cytologically documented advanced\/metastatic primary or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC), melanoma, Non-Small Cell Lung Cancer (NSCLC) who failed or are not eligible to standard therapy\n* Patients with at least one measurable lesion are allowed as per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1\n* Patient must have at least one Positron Emission Tomography (PET) imageable and evaluable tumor lesion with a diameter of at least 20 millimeter Further inclusion criteria apply.\n\nExclusion criteria:\n\n* Patients with symptomatic\/active central nervous system (CNS) metastases; patients with previously treated brain metastases are eligible if there is no evidence of progression for at least 28 days before the first study treatment administration, as ascertained by clinical examination and brain imaging (Magnetic Resonance Imaging (MRI) or Computed Tomography (CT)) during the screening period\n* Other tumor location necessitating an urgent therapeutic intervention (e.g., palliative care, surgery or radiation therapy, such as spinal cord compression, other compressive mass, uncontrolled painful lesion, bone fracture)\n* Presence of other active invasive cancers other than the one treated in this trial within 5 years prior to screening (or less, pending discussion with sponsor), except appropriately treated basal cell carcinoma of the skin, or in situ carcinoma of uterine cervix, or other local tumors considered cured by local treatment\n* Patients with active autoimmune disease or a documented history of autoimmune disease, that requires systemic treatment (i.e. corticosteroids or immunosuppressive drugs); except patients with vitiligo, resolved childhood asthma\/atopy, alopecia, or any chronic skin condition that does not require systemic therapy, patients with autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone and\/or controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible\n* Known severe infusion related reactions to monoclonal antibodies (Grade \u2265 3 National Cancer Institute (NCI)- Common Terminology Criteria for Adverse Events (CTCAE) v5.0) and patients removed from previous anti-Programmed-cell-death-protein-1 (PD-1) or anti-Programmed-cell-death ligand-1 (PD-L1) therapy because of a severe or life-threatening immune-related adverse event (irAE) (Grade \u2265 3 NCI-CTCAE v5.0)\n* Patients receiving systemic treatment with any immunosuppressive medication within one-week prior to treatment start with SIRP\u03b1 antibody (BI 765063 or BI 770371) and ezabenlimab; steroids of max. 10 mg prednisolone equivalent per day are allowed, topical and inhaled steroids are not considered as immunosuppressive\n* Patients who have interstitial lung disease or active, non-infectious pneumonitis.\n* Patients with uncontrolled disease-related metabolic disorders (e.g., hypercalcemia, Syndrome of Inappropriate of AntiDiuretic Hormone Secretion (SIADH)) or uncontrolled diabetes Further exclusion criteria apply.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05068102001","EMAIL":[{"email":"nederland@bitrialsupport.com"}],"GEO":[52.37403,4.88969]},{"TITLE":"GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results","CRITERIA":"Inclusion Criteria:\n\n1. Male or female subjects greater than or equal to 18 years old\uff1b\n2. Written informed consent obtained prior to any study-related procedure being performed;\n3. Subjects with life expectancy \u22653 months;\n4. Eastern Cooperative Oncology Group performance score 0 - 2;\n5. Subjects must have histologically or cytologically confirmed advanced or metastatic solid tumor;\n6. At least one measurable lesion based on RECIST version 1.1 .\n\nExclusion Criteria:\n\n1. History of other malignancies within 3 years before screening,unless radical non-melanoma skin cancer or basal cell carcinoma of the skin or carcinoma in the situ of the cervix;\n2. Have central nervous system metastases;\n3. Prior treatment with SHP2 inhibitor;\n4. Have major surgery within 28 days prior to the first dose of GH21;\n5. Left ventricular ejection fraction (LVEF) \\<50 %;\n6. Females who are pregnant or breastfeeding ;\n7. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection;\n8. Conditions that the investigator considers inappropriate for participation in this clinical trial.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05183243009","EMAIL":[{"email":"302861459@qq.com"}],"GEO":[28.85535,121.14469]},{"TITLE":"ELobectomy for NSCLC by VATS Versus Thoracotomy (ECTOP-1007)","CRITERIA":"Inclusion Criteria:\n\n* Clinical stage T1N0M0 and surgical resectable.\n* Solid appearance on computed tomography scan.\n* Age 18 to 75 year.\n* Signed the informed consent form.\n\nExclusion Criteria:\n\n* Not NSCLC in pathological analysis.\n* Not lobectomy or sublobar resection.\n* History of other malignant tumors within 5 years.\n* History of thoracic surgery or unsuitable for VATS.\n* Previous radiation or chemotherapy.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"03786003001","EMAIL":[{"email":"haoxuanwu@hotmail.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"Esomeprazole and Radiation Induced Esophagitis","CRITERIA":"Inclusion Criteria:\n\n* Patient is \u2265 18 years of age.\n* Patient or patient's legal representative is willing and able to provide written informed consent and HIPAA authorization prior to performance of any study related activity.\n* Patient is willing and able to comply with scheduled visits and treatment schedules.\n* Patient has histopathologically confirmed diagnosis of NSCLC clinical stage III (as per the 8th edition of American Joint Committee on Cancer Staging).\n* Patients will receive thoracic radiation with estimated maximum dose to esophagus of at least 30 Gy (EQD2) in combination with concomitant chemotherapy.\n* Patient has Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2.\n* Women of childbearing potential (WOCBP) must have a negative pregnancy test (serum or urine HCG) within 2 weeks of enrollment).\n* Double inclusion in any ongoing trial (if the other trial permits) will be allowed.\n\nExclusion Criteria:\n\n* Patient has history of gastroesophageal junction or stomach cancer.\n* Patient has history of pre-existing severe or very severe dysphagia.\n* Patient has history of severe liver disease, acute or subacute systemic lupus erythematosus.\n* Patient has interstitial nephritis.\n* Patient has history of peptic ulcer disease.\n* Patient has prior history of upper gastrointestinal bleeding.\n* Patient has a history of thoracic radiotherapy within 2 years of enrollment.\n* Patient has known or suspected allergic response and prior adverse drug reaction with proton pump inhibitors.\n* Patient is currently on clopidogrel, nelfinavir, rilpivirine, methotrexate, rifampin, digoxin, tacrolimus, or phenytoin as these may have major drug interaction with esomeprazole.\n* Patients without concomitant chemoradiotherapy and with estimated maximum dose to esophagus of less than 30 Gy (EQD2).","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06120803001","EMAIL":[{"email":"soumyajit_roy@rush.edu"}],"GEO":[41.85003,-87.65005]},{"TITLE":"Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Able to provide written informed consent by patient or legally acceptable representative\n* Meets the criteria in the approved regulatory indication for first line treatment with osimertinib and agree to the restrictions, monitoring, and dose-adjustment criteria stipulated in the associated product label\n* Epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations)\n* No prior systemic therapy except neoadjuvant, adjuvant or concurrent chemotherapy given greater than 3 months prior to enrollment on study\n* Asymptomatic or minimally symptomatic brain metastases (ie. Headache, nausea, or seizure responsive to dexamethasone\/analgesic\/antiepileptic on stable doses of medications for a minimum of 3 days)\n* Brain metastases must meet the following criteria on a diagnostic MRI: at least one lesion can be classified as measurable disease per RANO-BM, \u2264 10 brain or brainstem metastases, \u2264 30 mm and brainstem metastases must be \u2264 5 mm, metastases \\> 5 mm from the optic nerve or chiasm\n* ECOG performance status 0-2\n* Life expectancy \\> 6 months\n* Willing to abstain from sexual activity or willing to use double-barrier method during sexual intercourse\n\nExclusion Criteria:\n\n* Previous treatment with osimertinib, or any other EGFR TKI\n* Patient with symptomatic brain metastases causing any neurologic deficit (not including headache, nausea, or medically controlled seizure)\n* Multiple sclerosis\n* Pacemaker or MRI-incompatible metal in the body\n* Allergy to gadolinium MRI contrast\n* Brain metastasis requiring surgery for decompression\n* Leptomeningeal disease\n* Previous cranial RT, or surgery for brain metastases\n* Uncontrolled systemic lupus erythematosis, scleroderma or other connective tissue disorders considered a contraindication for radiotherapy\n* Active cancer from another anatomical site within 5 years (non-melanomatous skin and cervical cancers permitted)\n* Any medical or non-medical issue that would render patient unable to reliably complete regular QOL and neurocognitive assessments\n* Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements\n* Treatment with an investigational drug within five half-lives of the compound or 3 months, whichever is greater\n* Patients with symptomatic CNS metastases who are neurologically unstable\n* Patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inducers of cytochrome P450 (CYP) 3A4\n* Patients taking any drugs that are known to prolong QT interval that can't be withdrawn prior to Osimertinib\n* Pregnant or breastfeeding","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03769103003","EMAIL":[{},{}],"GEO":[43.70011,-79.4163]},{"TITLE":"HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease","CRITERIA":"* GENERAL INCLUSION CRITERIA (Patients will be included in the study only if they meet all the following inclusion criteria):\n\n  1. Patient must be capable to understand the purpose of the study and have signed written informed consent form (ICF) prior to beginning specific protocol procedures.\n  2. Age \u2265 18 years at the time of signing ICF.\n  3. Life expectancy \u2265 6 weeks.\n  4. Karnofsky Performance Status (KPS) \u226570%, Eastern Cooperative Oncology Group (ECOG) performance status (PS) \u2264 2.\n  5. Patient must be able to tolerate therapy.\n  6. Availability and willingness to provide the most recently available tumor tissue sample (formalin-fixed paraffin-embedded \\[FFPE\\], no cytology\/cell block, no bone\/decalcified bone sample) of primary tumor or any metastatic site from biopsy collected after last round of prior treatment and \u2264 6 months prior to HER3-DXd, if possible, for retrospective exploratory biomarker testing. If archival tissue is not available, a newly obtained baseline biopsy of an accessible tumor lesion is required prior to start of study treatment (unless not possible because of inaccessible tumor location or safety concerns). Collection and\/or shipment of pre-treatment tumor tissue biopsy for retrospective biomarker testing should be at least initiated treatment at the time of inclusion.\n  7. No indication for immediate local therapy.\n  8. Patient has adequate bone marrow, liver, and renal function:\n\n     1. Hematological (without platelet, red blood cell transfusion, and\/or granulocyte colony-stimulating factor support within 7 days before first study treatment dose): White blood cell (WBC) count \\> 3.0 x 109\/L, absolute neutrophil count (ANC) \u2265 1.5 x 109\/L, platelet count \u2265 100.0 x109\/L, and hemoglobin \u2265 10.0 g\/dL (\u2265 6.2 mmol\/L).\n     2. Hepatic: Serum albumin \u2265 2.5 g\/dL; total bilirubin \u2264 1.5 times upper limit of normal (ULN) (\u2264 3 in patients with liver metastases or know history of Gilbert's disease); alkaline phosphatase (ALP) \u2264 2.5 times ULN; aspartate transaminase (AST); alanine transaminase (ALT) \u2264 3 times ULN (\u2264 5 in patients with liver metastases); international normalized ratio (INR) \\< 1.5.\n     3. Renal: serum creatinine \u2264 1.5 x ULN or creatinine clearance \u2265 50 mL\/min\/1.73 m2 based on Cockcroft-Gault glomerular filtration rate estimation for patients with creatinine levels above institutional normal.\n  9. Patients must have received at least 1 prior line of systemic treatment\\* in the advanced setting.\n\n     * Prior systemic treatments for eligible patients with BC are defined as follows:\n\n       * Patients with triple-negative breast cancer (TNBC) must have received at least one line of prior systemic therapy for advanced disease.\n       * Patients with luminal BC must have received at least one line of ET and one line of CT in the advanced setting.\n       * Patients with HER2-positive BC must have progressed to at least two previous treatments with HER2-targeted therapies in the advanced setting.\n     * Prior systemic treatments for eligible patients with aNSCLC are defined as follows:\n\n       * Patients without activating driver alterations must have received at least one prior line of standard of care systemic therapy for locally advanced or metastatic disease.\n       * Patients with activating driver alterations must have received at least one prior line of an approved genotype-directed therapy.\n       * Patients with EGFR T790M mutation who received first-line treatment with erlotinib, gefitinib, afatinib, or dacomitinib must have received second-line treatment with osimertinib and have documentation of radiological disease progression.\n  10. Resolution of all acute toxic effects of prior anti-cancer therapy to grade \u2264 1 as determined by the US National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (v.5.0).\n\n      Note: Except for alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion.\n  11. For women of childbearing potential: agreement to remain abstinent (must refrain from heterosexual intercourse) or use highly effective contraceptive methods, or two effective contraceptive methods, as defined in the protocol, during the treatment period and for at least 7 months after the last dose of study treatment, whichever is longer. Women of childbearing potential must have a negative serum pregnancy test within 14 days before study treatment initiation and must agree to refrain from donating eggs during the entire study treatment period and for 7 months after the last administration of the study drug.\n  12. For male subjects: being surgically sterile or having agreed to true abstinence (must refrain from heterosexual intercourse) or having female partners willing to agree with true abstinence or use barrier contraceptive measures mentioned above during the entire study treatment period and for 4 months after the last administration of the study drug. Male patients must agree to refrain from donating sperm during the entire study treatment period and for 4 months after the last administration of the study drug.\n  13. Patient must be accessible for treatment and follow-up.\n* SPECIFIC INCLUSION CRITERION FOR COHORT 1 AND COHORT 2 (Cohort 1 and cohort 2 patients will be included in the study only if they meet all the following inclusion criteria):\n\n  1. Histologically documented BC (cohort 1) or NSCLC of squamous or non-squamous histologic types (cohort 2).\n  2. Radiologically documented metastatic disease.\n  3. Newly diagnosed BM or BM progressing after local treatment.\n  4. Measurable disease according to Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria, with at least one measurable brain lesion of \u226510 mm on T1-weighted, gadolinium-enhanced MRI.\n* SPECIFIC INCLUSION CRITERION FOR COHORT 1 AND COHORT 2 (Cohort 1 and cohort 2 patients will be included in the study only if they meet all the following inclusion criteria):\n\n  1. Histologically documented BC (cohort 1) or NSCLC of squamous or non-squamous histologic types (cohort 2).\n  2. Radiologically documented metastatic disease. 3. Newly diagnosed BM or BM progressing after local treatment. 4. Measurable disease according to Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria, with at least one measurable brain lesion of \u226510 mm on T1-weighted, gadolinium-enhanced MRI.\n* SPECIFIC INCLUSION CRITERION FOR COHORT 1 (Cohort 1 patients will be included in the study only if they meet the following inclusion criterion):\n\n  1. Locally determined HER2 status.\n* SPECIFIC INCLUSION CRITERIA FOR COHORT 3 (Cohort 3 patients will be included in the study only if they meet all the following inclusion criteria):\n\n  1. Histologically documented solid tumor of any type.\n  2. Type I LMD, defined by positive CSF cytology or leptomeningeal biopsy, or type II LMD, defined by clinical findings and neuroimaging only, according to European Society for Molecular Oncology (ESMO) Standard Operating Procedures (SOPs) for Clinical Practice Guideline (CPG) 2017.\n  3. Newly diagnosed LMD or LMD progressing after radiotherapy.\n* EXCLUSION CRITERIA (Patients will be excluded from the study if they meet any of the following criteria):\n\n  1. Current participation in another therapeutic clinical trial.\n  2. Treatment with approved or investigational cancer therapy within 14 days prior to initiation of study drug.\n  3. Patients have a concurrent malignancy or malignancy within five years of study enrollment with the exception of carcinoma in situ of the cervix, non-melanoma skin carcinoma, or stage I uterine cancer. For other cancers considered to have a low risk of recurrence, discussion with the Medical Monitor is required.\n  4. Previous systemic therapy with any anti-HER3 directed drug.\n  5. Known allergy or hypersensitivity to HER3-DXd or any of the drug components.\n  6. Radiotherapy or limited-field palliative radiotherapy within seven days prior to study enrolment, or patients who have not recovered from radiotherapy-related toxicities to baseline or grade \u2264 1 and\/or from whom \u2265 25% of the bone marrow has been previously irradiated.\n  7. Patients with an active cardiac disease or a history of cardiac dysfunction or conduction abnormalities including any of the following:\n\n     1. Unstable angina pectoris or documented myocardial infarction within 6 months prior to study entry.\n     2. Symptomatic pericarditis.\n     3. Documented congestive heart failure (CHF) (New York Heart Association \\[NYHA\\] Class III-IV).\n     4. Left ventricular ejection fraction (LVEF) \\< 50% as determined by multigated acquisition (MUGA) scan or echocardiogram (ECHO).\n     5. Ventricular arrhythmias except for benign premature ventricular contractions.\n     6. Other cardiac arrhythmias requiring a pacemaker or not controlled with medication.\n     7. Long QT syndrome (QTcF interval \\> 450 ms).\n  8. Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (i.e., pulmonary emboli within three months of the study enrolment, severe asthma, severe chronic obstructive pulmonary disease \\[COPD\\], restrictive lung disease, pleural effusion etc.), and any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement (i.e., rheumatoid arthritis, Sjogren's syndrome, sarcoidosis etc.), or prior pneumonectomy.\n  9. History of non-infectious interstitial lung disease (ILD)\/pneumonitis that required steroids, has current ILD\/pneumonitis, or has suspected ILD\/pneumonitis that cannot be ruled out by imaging at screening.\n  10. Pregnant or lactating women.\n  11. Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study.\n  12. Current known infection with hepatitis B virus (HBV), or hepatitis C virus (HCV). Patients with past HBV infection or resolved HBV infection (defined as having a negative hepatitis B surface antibody \\[HBsAg\\] test and a positive hepatitis B core antibody \\[HBcAb\\] test, accompanied by a negative HBV DNA test) are eligible. Patients positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.\n  13. Known human immunodeficiency virus (HIV) infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA, CD4-positive cells' count \u2265 350, no history of AIDS-defining opportunistic infection within the past 12 months, and stable for at least 4 weeks on the same anti-HIV medications (meaning there are no expected further changes in that time to the number or type of antiretroviral drugs in the regimen). If an HIV infection meets the above criteria, monitoring of viral RNA load and CD4-positive cells' count is recommended.\n  14. History of a major surgical procedure (defined as requiring general anesthesia) or significant traumatic injury within 21 days prior to randomization, or patients who have not recovered from the side effects of any major surgery.\n  15. History of uncontrolled seizures, CNS disorders or serious and\/or unstable pre-existing psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drugs or interfering with subject safety.\n  16. Patients requiring concomitant use of chronic systemic (intravenously \\[IV\\] or oral) corticosteroids at doses higher than 8 mg dexamethasone per day or other immunosuppressive medications except for managing adverse events (AEs), including immune-related adverse events (irAEs) for patients that received immunotherapy in a previous line; (inhaled steroids or intra articular steroid injections are permitted in this study).\n\n      Note: The use of stable corticosteroid therapy in patients with brain metastases can be discussed with the Medical Monitor.\n  17. Patients with known substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions, that may, in the opinion of the investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results.\n  18. Participants who are unable or unwilling to comply with the requirements of the protocol in the opinion of the investigator.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05865990009","EMAIL":[{}],"GEO":[39.46975,-0.37739]},{"TITLE":"A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)","CRITERIA":"Inclusion Criteria\n\n1. Age \u2265 18 years.\n2. Participant with histologically\/cytologically confirmed locally advanced or metastatic NSCLC.\n3. Participants with ALK gene rearrangement confirmed by local hospital medical records.\n4. During the period from September 1, 2022 to December 31, 2023, participants who received brigatinib as first line treatment confirmed by medical records.\n5. Participants who have at least one medical record after the start of brigatinib treatment.\n\nExclusion Criteria\n\n1. Participants participated in NSCLC-related interventional clinical trials after locally advanced or metastatic NSCLC diagnosis and during brigatinib treatment.\n2. Previously received any other TKIs, including ALK-targeted TKIs.\n3. Previously received more than 1 regimen of systemic anticancer therapy for locally advanced or metastatic disease.\n4. Participants have been diagnosed as malignancies (excluding completely resected basal cell carcinoma, bladder carcinoma in situ, cervical carcinoma in situ) in addition to NSCLC within the past 5 years.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05721950001","EMAIL":[{"email":"caicunzhoudr@163.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)","CRITERIA":"Key Inclusion Criteria:\n\n* Histologically or cytologically documented, locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) not amenable to curative surgery or radiotherapy.\n* Documented results of the presence of an Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutation in tumor tissue or blood from local or central testing.\n* No prior systemic anticancer therapy regimens received for locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) including prior treatment with any Epidermal Growth Factor Receptor (EGFR)-targeting agents (e.g., previous (EGFR) TKIs, monoclonal antibodies, or bispecific antibodies).\n* Patients who have received prior neo-adjuvant and\/or adjuvant chemotherapy, immunotherapy, or chemo radiotherapy for non-metastatic disease (excluding EGFR-TKIs) must have experienced a treatment free interval of at least 12 months.\n* Patients with a history of treated CNS metastases or new asymptomatic CNS metastases are eligible.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05607550200","EMAIL":[{"email":"FURMO004CT@arrivent.com"}],"GEO":[51.35,-0.2]},{"TITLE":"Addition of Radiotherapy to Standard Medical Treatment for Stage IV NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Histological or cytological confirmed non-small cell lung cancer (NSCLC)\n* Stage IV disease\n* Previously untreated disease (before first line treatment)\n* No symptomatic brain metastases\n* Performance status (WHO) 0-2\n* FEV1 (forced expiratory volume one second) \u2265 1 L or \\>40% of predicted\n* Written informed consent\n* Life expectancy \u2265 12 weeks\n* Platelet count \u2265 100,00\/mm3\n* Hemoglobin \u2265 10 g\/dl\n* WBC (White blod cells) \u2265 3,000\/mm3\n* Kidney function allowing chemotherapy\n* Patients scheduled for standard platinum based chemotherapy, chemo-immunotherapy or immunotherapy\n* Willing and able to comply with study treatment\n\nExclusion Criteria:\n\n* Requirement for daily supplemental oxygen\n* Second primary malignancy within 3 years, except for any of the following which can be included even if diagnosed within the past 3 years: Carcinoma in situ of the cervix, nonmelanoma skin cancer, history of low-grade (Gleason score \u2264 6) localized prostate cancer, definitely treated stage I breast cancer, other malignancy that was diagnosed and definitely treated \u2265 3 years ago with no subsequent evidence of recurrence\n* Concurrent severe and\/or uncontrolled medical condition, including any of the following:\n* Angina pectoris\n* Congestive heart failure within the past 3 months, unless LVEF (left ventricular ejection fraction) \\> 40%\n* Myocardial infarction within the past 6 months\n* Clinically significant infection\n* Psychiatric illness or social situation that would limit compliance with study requirements\n* EGFR (epidermal growth factor receptor) mutation or ALK (anaplastic lymphoma kinas) - rearrangement detected","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04530708003","EMAIL":[{"email":"jan.nyman@oncology.gu.se"},{"email":"bengt.bergman@vgregion.se"},{},{},{},{},{},{},{},{},{}],"GEO":[57.70716,11.96679]},{"TITLE":"Taste and Smell Dysfunction in Patients More Than Two Years After Start of Immune Checkpoint Inhibitor Therapy","CRITERIA":"Inclusion Criteria:\n\n* 1. Patients with melanoma, NSCLC or urogenital cancers \\> 2 years since treatment with at least one cycle of immune checkpoint inhibitor (CTLA-4 inhibitor, PD-(L)1 inhibitor, or both) within the Department of Medical Oncology or Pulmonary Oncology of the UMCG.\n* 2. Age \\>18 years at time of immune checkpoint inhibitor treatment\n* 3. Understand or abide to the study procedures\n* 4. Have given informed consent\n\nA caregiver must meet all of the following criteria:\n\n* 1. Age \\>18 years\n* 2. Understand or abide to the study\n\nExclusion Criteria:\n\n* 1. As previous or subsequent therapies, only surgery and palliative radiotherapy is allowed (excluding radiotherapy in the head-neck and brain region)\n* 2. Previous treatment in the past ten years for malignancy other than melanoma (excluding non-melanoma skin cancer, cervical intra-epithelial neoplasia (CIN) or carcinoma in situ of breast) (for patients: other than current malignancy)\n* 3. History of ear-nose-throat disease or auto-immune disorder affecting taste, smell, mouth mucosa, or saliva production (for patients: before start ICI)","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06495008001","EMAIL":[{"email":"j.j.de.haan@umcg.nl"}],"GEO":[53.21917,6.56667]},{"TITLE":"Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)","CRITERIA":"Inclusion Criteria:\n\n1. Histologically and IHC confirmed diagnosis of metastatic NSCLC which has not received any prior anticancer medicinal therapy for metastatic disease.\n2. Negative for actionable EGFR mutations and ALK rearrangements.\n3. Patients with recurrence after prior neoadjuvant or adjuvant chemotherapy or radiation therapy or immune checkpoint inhibitors for non-metastatic disease are eligible if recurrence occurred \\>6 months after the end of neoadjuvant or adjuvant treatment.\n4. Documented informed consent of the participant and\/or legally authorized representative\n5. \u2265 18 years of age.\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n7. Life expectancy \u2265 3 months.\n8. Patients should have measurable metastatic disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and iRECIST guidelines.\n9. Total bilirubin \u2264 1.5 x upper limit of normal (ULN) (within 7 days prior to day 1 of protocol therapy) (except subjects with Gilbert syndrome who must have a total bilirubin level of \u22643.0 \u00d7 ULN).\n10. Aspartate aminotransferase (AST) \u2264 2.5 x ULN, unless presence of liver metastases for which \u2264 5 x ULN is allowed (within 7 days prior to day 1 of protocol therapy).\n11. Alanine aminotransferase (ALT) \u2264 2.5 x ULN, unless presence of liver metastases for which \u2264 5 x ULN is allowed (within 7 days prior to day 1 of protocol therapy).\n12. Creatinine clearance \u2265 45 ml\/min (within 7 days prior to day 1 of protocol therapy).\n13. Alkaline phosphatase \u2264 3 x ULN (within 7 days prior to day 1 of protocol therapy).\n14. Hemoglobin \u2265 9 g\/dl (within 7 days prior to day 1 of protocol therapy).\n15. Absolute neutrophil count (ANC) \u2265 1500\/ul (within 7 days prior to day 1 of protocol therapy).\n16. Platelets \u2265 100,000\/mm\\^3 (within 7 days prior to day 1 of protocol therapy).\n17. Albumin \u2265 3.0 g\/dl (within 7 days prior to day 1 of protocol therapy).\n18. Women of childbearing potential (WOCBP): negative serum pregnancy test (within 7 days prior to day 1 of protocol therapy)\n\n    a) Females of non-childbearing potential are defined as: i. \u2265 50 years of age and has not had menses for greater than 1 year ii. Amenorrheic for \u2265 2 years without a hysterectomy and bilateral oophorectomy and a follicle-stimulating hormone value in the postmenopausal range upon pre-study (screening) evaluation iii. Status is post-hysterectomy, bilateral oophorectomy, or tubal ligation.\n19. Male and female patients of reproductive potential must use effective methods of contraception (defined in Appendix A) or abstain from sexual activity for the course of the study through at least 90 days after the last dose of balstilimab and\/or botensilimab\n20. Is willing and able to comply with the requirements of the protocol.\n\nExclusion Criteria:\n\n1. Prior treatment with anti-CTLA-4 and anti-PD-(L)1 therapy. Note: Prior treatment with anti-PD-(L)1 therapy in the adjuvant setting is permitted if recurrence occurred \\>6 months after the end of adjuvant treatment.\n2. Patients with a condition requiring systemic treatment with either corticosteroids (\\>10 mg daily prednisone equivalent) within 14 days or another immunosuppressive medication within 30 days of the first dose of study treatment. Inhaled or topical steroids, and adrenal replacement steroid dose \u2264 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.\n3. Prior allogeneic organ transplantation.\n4. Surgical intervention within 4 weeks prior to study treatment, except for minor procedures such as port placement.\n5. Prior allergic reaction or hypersensitivity to any of the study drug components.\n6. Active autoimmune disease or history of autoimmune disease that required systemic treatment within 2 years before starting treatment, i.e., with use of disease-modifying agents or immunosuppressive drugs.\n7. Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident\/stroke or myocardial infarction within 6 months of enrollment, unstable angina, congestive heart failure (New York Heart Association class \u2265 III), serious uncontrolled cardiac arrhythmia requiring medication.\n\n   a. QTcF (QTc interval corrected using Fridericia's formula) of \\> 480 ms.\n8. Any persistent toxicities (Common Terminology Criteria for Adverse Events \\[CTCAE\\] grade \u2265 2) from prior cancer therapy, excluding endocrinopathies stable on medication, stable neuropathy that is grade 2 or less, and alopecia.\n9. Active brain metastases or leptomeningeal metastases with the following exceptions:\n\n   a. Treated brain metastases require a) surgical resection, or b) stereotactic radiosurgery. Whole-brain radiation is not allowed. Subjects must have also discontinued steroid treatment 28 days prior to enrollment for the purpose of managing their brain metastases and they must be asymptomatic and radiologically stable \u226528 days before enrollment.\n10. Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 730 days (or 2 years) prior to enrollment, i.e., subjects with a history of prior malignancy are eligible if treatment was completed at least 730 days (or 2 years) before enrollment and the subject has no evidence of disease. Subjects with history of prior early-stage basal\/squamous cell skin cancer, low-risk prostate cancer eligible for active surveillance or noninvasive or in situ cancers who have undergone definitive treatment at any time are also eligible.\n11. Any evidence of current interstitial lung disease (ILD) or pneumonitis, or prior history of ILD or non-infectious pneumonitis requiring glucocorticoids.\n12. Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.\n13. History or current evidence of any condition, co-morbidity, therapy, any active infections, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating investigator.\n14. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine or booster \\< 7 days before C1D1. For vaccines requiring more than 1 dose, the full series should be completed prior to C1D1, when feasible. Booster shot not required but also must be administered \\> 7 days from C1D1 or \\> 7 days from future cycle on study.\n15. Uncontrolled infection with human Immunodeficiency virus (HIV). Patients on stable highly active antiretroviral therapy (HAART) with undetectable viral load and normal CD4 counts for at least 6 months prior to study entry are eligible. Serological testing for HIV at screening is not required.\n16. Known to be positive for hepatitis B virus (HBV) surface antigen, or any other positive test for HBV indicating acute or chronic infection. Subjects who are receiving or who have received anti-HBV therapy and have undetectable HBV DNA for at least 180 days prior to enrollment are eligible. Serological testing for HBV at screening is not required.\n17. Known active hepatitis C virus (HCV) as determined by positive serology and confirmed by polymerase chain reaction (PCR). Subjects on or who have received antiretroviral therapy are eligible provided they are virus-free by PCR for at least 180 days prior to enrollment. Serological testing for HCV at screening is not required.\n18. Known active tuberculosis. Tuberculosis testing at screening is required.\n19. Grade 3 or above neuropathy at the time of enrollment.\n20. Dependence on total parenteral nutrition or intravenous hydration.\n21. Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.\n22. Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\/logistics).","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06322108001","EMAIL":[{"email":"samvelbardakhchyan@gmail.com"},{"email":"amalyasargsyan@gmail.com"}],"GEO":[40.18111,44.51361]},{"TITLE":"The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Histologically or cytologically documented, locally advanced or metastatic (i.e., Stage IIIB not eligible for definitive chemoradiotherapy, Stage IV, or recurrent) NSCLC (per the American Joint Committee \/AJCC staging system)\n* ECOG performance status of 0 to 1\n* Measurable disease per RECIST v1.1 criteria\n* Arm 1a, and 1b and 1c: Prior PD-1 axis inhibitor therapy (anti-PD-1 or anti-PD-L1, e.g. nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab) either alone or in combination with other systemic agents, with documented progressive disease.\n* Arm 2a: PD-L1 expression of less than 50 percent (PD-1 axis inhibitor therapy na\u00efve)\n* Patients with NSCLC known to harbor an ALK rearrangement, ROS1 rearrangement, EGFR mutation or BRAF mutation known to be sensitive to FDA approved tyrosine kinase inhibitors (TKI), are only eligible after experiencing disease progression (during or after treatment) or intolerance to respective TKI:\n\n  1. Patients with TKI treated EGFR mutant NSCLC harboring the secondary EGFR T790M tumor must have received prior osimertinib.\n  2. Patients with crizotinib treated ALK rearranged NSCLC must have received a next generation ALK inhibitor (e.g. ceritinib, alectinib, brigatinib or lorlatinib).\n* At least one tumor amenable to incisional, excisional, core or forceps (transbronchial) biopsy. Patients must be willing to undergo a tumor biopsy before starting trial therapy and at the time of disease progression.\n* Adequate hematologic and end-organ function\n\nExclusion Criteria:\n\n* Subjects must not have a history of life-threatening toxicity related to prior anti-PD-1 axis therapy:\n\n  a. Subjects with history of anti-PD-1 axis therapy toxicities that are unlikely to recur with standard countermeasures (e.g., hormone replacement after adrenal crisis) are eligible.\n* Symptomatic or untreated CNS metastases. Patients with a history of treated asymptomatic CNS metastases are eligible, provided they meet all of the following criteria:\n\n  1. No evidence of interim progression between the completion of CNS-directed therapy and the start of trial therapy\n  2. No ongoing requirement for dexamethasone as therapy for CNS disease; anticonvulsants at a stable dose are allowed.\n  3. Completed stereotactic radiosurgery at least 1 week prior to initiation of trial therapyCycle 1, Day 1 or whole-brain radiation at least 2 weeks prior to initiation of trial therapyCycle 1, Day 1.\n* History of leptomeningeal carcinomatosis\n* Prior palliative radiotherapy outside the CNS within 2 weeks of the first dose of study drug\n* Treatment with systemic immunosuppressive medications (including but not limited to, dexamethasone at doses \\> 2 mg daily (or equivalent dose of other corticosteroids), cyclophosphamide, tacrolimus, sirolimus, azathioprine, methotrexate, thalidomide, and antitumor necrosis factor \\[anti-TNF\\] agents) within 2 weeks prior to initiating trial therapy. (Inhaled or topically applied steroids, and acute and chronic standard-dose NSAIDs are permitted. Replacement steroids are also permitted). Prophylactic corticosteroids prior to imaging with intravenous contrast are allowed per institutional guidelines, without need for delay of 2 weeks. Arm 2a: No prior PD-1 axis inhibitor therapy","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04699123001","EMAIL":[{"email":"scott.gettinger@yale.edu"}],"GEO":[41.30815,-72.92816]},{"TITLE":"A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea","CRITERIA":"Inclusion Criteria:\n\n1. With ALK-positive advanced or metastatic NSCLC.\n2. Who initiate brigatinib for the first time.\n\nExclusion Criteria:\n\n1. Treated with brigatinib outside of the locally approved label in Korea.\n2. Whom brigatinib is contraindicated as per product label.\n3. Participating in other clinical trials of NSCLC treatment.","SEX":"ALL","AGE_MIN":19,"AGE_MAX":200,"SS_ID":"04592523001","EMAIL":"medinfoUS@takeda.com","GEO":[35.10278,129.04028]},{"TITLE":"Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin\/Nab Paclitaxel in Resectable Non-squamous NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Informed consent, patients age \u2265 18-year-old including, signed and dated\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Histologically confirmed NSCLC of non-squamous histology, cStage II, IIIA or select IIIB (T3N2 only); for T-status \u2264 T3 allowed; for N2 patients only IIIa1-3 Robinson classification allowed\n* Deemed surgically resectable with curative intent by an attending thoracic surgeon after adequate staging including PET-CT (positron emission tomography)\n* Adequate lung and cardiac function for intended lung resection according to German S3 regulation\n* Radiologically measurable disease as defined by response evaluation criteria in solid tumors RECIST v1.1\n* Sufficient availability of the tissue sample from primary tumor before start of neoadjuvant treatment\n* Females of child-bearing potential must agree to use, and be able to comply with, effective contraception (\\<\/=1% failure rate annually) without interruption, 28 days prior to starting therapy (including dose interruptions), and while on study medication or for a period of 120 days after the last dose of study medication\n* Females must have a negative serum pregnancy test (\u03b2 -hCG) result at screening and agree to ongoing pregnancy testing during the course of the study, and after the end of study therapy.\n* Male subjects must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 6 months following treatment discontinuation, even if he has undergone a successful vasectomy.\n* adequate renal, hepatic, and bone marrow function as defined below\n\n  * Absolute neutrophil count (ANC) \\> 1500\/\u03bcl\n  * Platelet count \u2265 100000\/\u03bcl\n  * Hemoglobin \u2265 9 g\/dl (can be post-transfusion)\n  * International normalized ratio (INR) \u2264 1.4 in patients not receiving anticoagulation; for patients receiving respective anticoagulation an INR \u22643.0 allowed\n  * Activated partial thromboplastin time (aPTT) \u2264 1.5 times upper limit of normal (ULN) in patients not receiving anticoagulation; for patients receiving respective anticoagulation a PTT \u22642.5 ULN allowed\n  * Bilirubin \\< 1.5 times ULN (for patients with known Gilbert disease Bilirubin \u2264 3 times ULN allowed)\n  * ALT and AST \\< 2.5 times ULN\n  * Creatinine \u2264 1.5 ULN or calculated creatinine clearance \\> 60 ml\/min for subjects with creatinine levels \\> 1.5 ULN; for patients meeting the criterion of creatinine \u2264 1.5 ULN also a calculated creatinine clearance of \\> 30 ml\/min is mandatory\n\nExclusion Criteria:\n\n* Illness or condition that may interfere with a patient's capacity to understand, follow, and\/or comply with study procedures\n* Treatment in any other clinical trial within 30 days before screening.\n* NSCLC Stage cT4\n* NSCLC stage cN3 or cN2 IIIA4 (bulky or fixed multi-station N2 disease) according to Robinson classification\n* NSCLC of squamous cell histology\n* Any prior therapy for lung cancer (including systemic therapy, radiotherapy or major surgery)\n* Malignancies other than NSCLC within 5 years prior to study inclusion with the exception of malignancies with a negligible risk of metastasis or death (5-year OS \\> 90%) like localized prostate cancer, ductal carcinoma in situ, adequately treated carcinoma in situ of the cervix, Stage I uterine cancer or non-melanoma skin carcinoma\n* History of allogeneic tissue \/ solid organ transplant or allogeneic stem cell transplantation\n* Patients with active hepatitis B or C infections or a history of HIV infection\n* Pregnant or lactating women\n* Active autoimmune disease or history of severe autoimmune disease or immunodeficiency or a syndrome that requires systemic steroids or immunosuppressive agents\n* The following exceptions are granted:\n\n  * patients with vitiligo, eczema, lichen simplex or resolved childhood asthma\/atopy\n  * subjects requiring intermittent use of bronchodilatators or local steroid injections\n  * patients with hypothyroidism stable on hormone replacement\n* Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, and anti-tumor necrosis factor (anti-TNF) agents) within 2 weeks prior to Cycle 1, Day 1 (except low-dose steroids for adrenal failure or emesis prophylaxis)\n* History of idiopathic pulmonary fibrosis, interstitial lung disease, organizing pneumonia, drug-induced pneumonitis, or evidence of active pneumonitis on screening chest Computed Tomography (CT) scan\n* Prior treatment with cluster of differentiation 137 (CD137) agonist or immune checkpoint blockade therapies, anti-programmed-death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibody\n* Live vaccine within 30 days prior to first dose of trial treatment\n* Cerebrovascular accident within the past 6 months\n* Severe infection or significant traumatic injury within the past 4 weeks\n* Clinically significant history of cardiovascular disease, including any of the following:\n\n  * Myocardial infarction or unstable angina within the past 6 months\n  * New York Heart Association class II, III-IV congestive heart failure\n  * Poorly controlled cardiac arrhythmia despite medication, except rate-controlled atrial fibrillation\n* Known allergy or hypersensitivity to any component of the chemotherapy regimen Patients who have been incarcerated or involuntarily institutionalized by court order or by the authorities, as well as patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04865250001","EMAIL":[{}],"GEO":[49.40768,8.69079]},{"TITLE":"A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. voluntary participation in clinical research; Fully understand and Informed the study and sign the Informed Consent Form (ICF); Be willing to follow and be able to complete all trial procedures.\n2. Age \u226518 years old and \u226475 years old when signing ICF.\n3. histologically or cytologically confirmed advanced or postoperative recurrent non-small cell lung cancer (AJCC 8th edition).\n4. STK11 mutations were detected by NGS, and no other sensitive mutations could be targeted therapy (including EGFR, ALK, ROS1, RET, c-Met, HER2, BRAF gene rearrangement, fusion, amplification, and skipping).\n5. The patient had not received systemic antitumor therapy.\n6. Patients who had received one prior chemotherapy regimen were allowed, regardless of whether chemotherapy was administered before, after, or concurrently with targeted therapy.\n7. Patients receiving adjuvant or neoadjuvant therapy were allowed if adjuvant\/neoadjuvant therapy had been completed at least 12 months before diagnosis of advanced or postoperative recurrent NSCLC.\n8. The interval between the end of previous nonsystemic antitumor therapy and the start of study medication had to be 4 weeks or more. Treatment-related AE recovered to CTCAE 4.03\u2264 grade 1 (except grade 2 alopecia).\n9. have at least one measurable target lesion as assessed by the investigator according to iRECIST requirements within 4 weeks before enrollment.\n10. If available, patients can provide eligible tumor tissue for PD-L1 expression level measurement.\n11. an ECOG PS score of 0 or 1 within 7 days before the first dose of study medication.\n12. predicted survival time \u226512 weeks (3 months).\n13. had good major organ function, defined as meeting the following criteria, and had not received blood transfusions, albumin, recombinant human thrombopoietin, or colony-stimulating factor (CSF) within 14 days before the first dose of study medication.\n14. Female patients must meet one of the following conditions:\n\n1) menopause, defined as absence of menses for at least 1 year and no confirmed cause other than menopause, or (2) having undergone sterilization (removal of ovaries and\/or uterus) 3) be fertile, provided that: Patients had to have a negative serum pregnancy test within 7 days before randomization and agree to use contraception with an annual failure rate of \\<1% or to abstain from heterosexual intercourse for at least 120 days from the date of written informed consent until the last dose of trial drug was administered. At least 150 days after the last dose of chemotherapy) (contraceptive methods with an annual failure rate of \\<1% include bilateral tubal ligation, male sterilization, proper use of ovulation-suppressing hormonal contraceptives, hormone-releasing intrauterine devices, and copper intrauterine devices or condoms), and Do not breastfeed.\n\n15.Male patients had to agree to either abstain from sex (avoid heterosexual intercourse) or to use contraception, as specified by either abstinence or use of condoms to prevent exposure of the drug to the embryo during chemotherapy (paclitaxel\/pemetrexed\/carboplatin) for the duration of treatment with a woman of reproductive age or a pregnant partner and for at least 150 days after the last dose of chemotherapy. Regular abstinence (e.g., calendar day, ovulation, basal body temperature, or postovulatory methods of contraception) and in vitro ejaculation are ineligible methods of contraception.\n\nExclusion Criteria:\n\n1. received systemic therapy for advanced NSCLC within 4 weeks after enrollment;\n2. the subjects had a history or concurrent history of other malignant tumors (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix).\n3. candidates for or prior recipients of organ or bone marrow transplantation.\n4. uncontrollable pleural, pericardial, or ascites with appropriate interventions.\n5. subjects with clinically symptomatic CNS metastases (e.g., brain edema, need for hormonal intervention, or progression of brain metastases). Patients who had received previous treatment for brain or meningeal metastases were eligible if they had been clinically stable (on MRI) for at least 2 months and had stopped systemic hormone therapy (at a dose of \\>10mg per day of prednisone or other iso-efficacy hormones) for more than 2 weeks.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06331650001","EMAIL":[{"email":"doctorzcz@163.com"}],"GEO":[49.40768,8.69079]},{"TITLE":"Phase I Study of ANK-101 in Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* \u2265 18 years of age on day of signing informed consent\n* histologically or cytologically confirmed diagnosis of cutaneous, subcutaneous, soft tissue, or nodal advanced solid tumor malignancy; metastatic disease eligible\n* measurable disease per RECIST v1.1 - Note: Must have at least 1 tumor lesion with longest dimension of \u2265 10 mm (\u2265 15 mm for the short axis for malignant lymph node lesions) that - For Part 1 only: can be easily palpated or detected by ultrasound to facilitate IT injection of ANK-101 (i.e., tumor in skin, muscle, subcutaneous tissue, or accessible lymph node) or; - For Part 2 only: can be accessed by interventional radiologic or endoscopic procedures for injection (e.g., ultrasound or computed tomography \\[CT\\] guided). - For Part 2 Dose Expansion Cohort only: Histologically confirmed Stage III or Stage IV NSCLC\n* documented disease progression, be refractory to, or intolerant of existing SOC therapy(ies) known to provide clinical benefit (including surgical cure) or not be eligible for SOC therapy(ies)\n* ECOG performance status 0-1\n* life expectancy \\> 12 weeks\n* adequate bone marrow, hepatic and renal function\n* baseline electrocardiogram (EKG) without evidence of acute ischemia or prolonged QTc interval \\> 460 msec\n* Human immunodeficiency virus (HIV) infected participants must be on anti-retroviral therapy (ART) and have well-controlled HIV infection\/disease\n* last dose of previous anticancer therapy (including investigational agents) \u2265 28 days, radiotherapy \u2265 14 days (targeted palliative radiotherapy is allowed for lesions not planned for injections), or surgical intervention \u2265 21 days prior to the start of treatment\n* resolution of all prior anticancer therapy toxicities (except for alopecia or vitiligo) to \u2264 Grade 1 (as per NCI CTCAE Version 5.0)\n* willing to provide pre- and post-treatment tumor biopsy samples if medically feasible\n* participant is capable of understanding and complying with protocol requirements\n\nExclusion Criteria:\n\n* injectable tumors impinging upon major airways or blood vessels\n* prior treatment with recombinant interleukin-12 (IL-12)\n* have received systemic therapy with immunosuppressive agents \u2264 28 days before the start of treatment\n* have received live vaccines within 28 days prior to the start of ANK-101 treatment\n* have primary or acquired immunodeficient states (e.g., leukemia, lymphoma)\n* a woman of childbearing potential (WOCBP) who has a positive serum pregnancy test (within 72 hours) prior to the start of treatment or female participant who is breastfeeding\n* prior organ transplantation\n* known history of hepatitis B virus, known active hepatitis C virus, or a positive serological test at screening within 28 days prior to the start of treatment\n* HIV-infected participants with a history of Kaposi sarcoma and\/or Multicentric Castleman Disease\n* active autoimmune disease or medical conditions requiring chronic steroid (i.e., \u2265 20 mg\/day prednisone or equivalent) or other immunosuppressive therapy within 28 days prior to the start of treatment\n* known active central nervous system (CNS) metastases\n* congestive heart failure (\\> New York Heart Association Class II), active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest), or clinically significant cardiac arrhythmias\n* uncontrolled bleeding disorders within 4 weeks prior to the start of treatment or known bleeding diathesis - Note: Part 2 only: Participants with active bleeding diathesis or requirement for therapeutic anticoagulation that cannot be interrupted or altered for procedures\n* history of hypersensitivity to compounds of similar biological composition to IL-12, aluminum hydroxide, or drugs formulated with polysorbate-20\n* other systemic conditions or organ abnormalities that, in the opinion of the Investigator, may interfere with the conduct and\/or interpretation of the current study\n* any acute or chronic psychiatric problems or substance abuse disorder that, in the opinion of the Investigator, make the participant unsuitable for participation","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06171750004","EMAIL":[{"email":"Marcus.Butler@uhn.ca"}],"GEO":[43.70011,-79.4163]},{"TITLE":"Determination of Peripheral Immune Cell Activity During Treatment With Either Surgery or Radiotherapy in Patients With Early Stage NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Cytologically or histologically proven cT1-2aN0M0 NSCLC\n* Patients \u2265 18 years old\n* Patients should be fit to undergo both treatments in accordance with institutional protocols\n\nExclusion Criteria:\n\n* Patients with any signs of any co-existing infectious disease or immunosuppressive treatment (inhalation steroids are permitted)\n* Mentally incapacitated subjects","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"02488850003","EMAIL":[{}],"GEO":[52.37403,4.88969]},{"TITLE":"Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles","CRITERIA":"Inclusion Criteria:\n\n* Age at least 18 years old.\n* The Eastern Cancer Organization Collaboration Group (ECOG) had a physical fitness score of 0 to 3, and had not worsened in the previous 2 weeks, with a minimum expected survival of 12 weeks.\n* NSCLC confirmed by histology or cytology, positive cerebrospinal fluid cytology, and combined with central nervous system function and brain imaging findings, diagnosed as NSCLC with meningeal metastasis (including advanced patients who had relapsed or were initially diagnosed after previous surgical treatment; GPA is recommended for grading and typing in the diagnosis of meningeal metastasis from lung cancer).\n* Tumor tissue samples or blood samples were tested and confirmed as EGFR sensitive mutations (including exon 19 deletion or L858R, both alone or coexisting with other EGFR site mutations). The first choice is to submit tumor tissue for examination; If the tumor tissue is inaccessible or the subject is not eligible for tissue biopsy, a blood sample may be sent for examination.\n* The patient has implanted an Ommaya capsule;\n* CT examination of clinical symptom areas (spine and\/or brain) and\/or head within the past 3 months to rule out contraindications to cerebrospinal fluid examination;\n* The subjects agreed to provide two cerebrospinal fluid samples (before treatment and within one week after disease progression) for genetic testing;\n* Women of childbearing age need to take appropriate contraceptive measures and should not breastfeed three months after screening and discontinuing study treatment. \"Before starting administration, the pregnancy test was negative, or one of the following criteria was met to demonstrate that there was no risk of pregnancy:\n\n  1. Postmenopause is defined as amenorrhea at least 12 months after age greater than 50 years and cessation of all exogenous hormone replacement therapy.\n  2. Women younger than 50 years of age may also be considered postmenopausal if they have amenorrhea for 12 months or more after stopping all exogenous hormone therapy, and their luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels are within the laboratory postmenopausal reference values.\n  3. Have undergone irreversible sterilization surgery, including hysterectomy, bilateral ovariectomy, or bilateral salpingectomy, except for bilateral tubal ligation.\n* Male subjects should use barrier contraception (i.e., condoms) three months after screening and discontinuation of study treatment.\n* The subject voluntarily participated and signed an informed consent form in writing.\n\nExclusion Criteria:\n\n* Have received any of the following treatments:\n\n  1. Within 4 weeks before the first administration of the investigational drug, the subject had undergone major surgery (such as craniotomy, thoracotomy, or laparotomy). The definition of major surgical surgery refers to Level 3 and Level 4 surgery specified in the \"Management Measures for Clinical Application of Medical Technology\" implemented on November 1, 2018;\n  2. Within 7 days before the first administration of the study drug, a strong CYP3A4 inhibitor, inducer, or CYP substrate (CYP2C8, CYP2D6, etc.) was used.\n  3. Subjects with other malignant tumors, excluding basal cell carcinoma of the skin and carcinoma in situ.\n* At the beginning of the study treatment, there was a residual toxicity greater than CTCAE level 3 that could not be alleviated from previous treatment.\n* There are pleural effusion\/peritoneal effusion requiring clinical intervention (patients who do not require drainage of the effusion or who have been stable for 2 weeks or more after drainage can be enrolled); Presence of pericardial effusion (small amounts of pericardial effusion that are stable for 2 weeks or more are allowed to be included in the group). If local use (such as thoracic perfusion) of anti-tumor drugs is used during drainage, and at least 5 drug half-lives or 21 days (whichever is shorter) must be eluted before the first administration of the study treatment before enrollment;\n* Subjects are unwilling to provide cerebrospinal fluid samples or clinical information;\n* Subjects have contraindications for cerebrospinal fluid examination;\n* Previously or currently suffering from primary malignant tumors of the central nervous system;\n* Suffering from autoimmune or inflammatory diseases of the central nervous system (not limited to multiple sclerosis, neurosarcoidosis, chronic fungal, rickettsial, or bacterial meningitis);\n* Subjects who are allergic to the MRI contrast agent gadolinium or who cannot tolerate MRI examination (such as having a cardiac pacemaker, having metal in their body, etc.).\n* According to the judgment of the researcher, there are any serious or poorly controlled systemic diseases, such as poorly controlled hypertension, active hemorrhagic constitution, or active infection. There is no need to screen for chronic diseases.\n* Clinically severe gastrointestinal dysfunction may affect the intake, transportation, or absorption of drugs, such as inability to take orally, uncontrollable nausea or vomiting, a history of extensive gastrointestinal resection, untreated recurrent diarrhea, atrophic gastritis, untreated stomach diseases requiring long-term administration of mass pump inhibitors, Crohn's disease, ulcerative colitis, and so on.\n* Hepatic encephalopathy, hepatorenal syndrome, or cirrhosis.\n* Meet any of the following cardiac examination results:\n\n  1. The mean value of the QT interval (QTcF) corrected by Fridericia's formula from three electrocardiogram (ECG) examinations at rest is\\>470 msec;\n  2. resting ECG indicates conduction or ECG morphological abnormalities (such as complete left bundle branch block, 3rd degree atrioventricular block, 2nd degree atrioventricular block, and PR interval\\>250 msec);\n  3. The presence of any factors that increase the risk of QTc prolongation or arrhythmia events, such as heart failure, hypokalemia, congenital long QT syndrome, a family history of long QT syndrome, or any concomitant medication that causes unexplained sudden death or prolongs the QT interval in immediate family members under the age of 40;\n  4. Left ventricular ejection fraction (LVEF)\\<50%.\n* Insufficient bone marrow reserve or organ function, reaching any of the following laboratory limits (no corrective treatment within 1 week before laboratory examination and blood sampling):\n\n  1. Absolute neutrophil count\\<1.5 \u00d7 109 \/ L\uff1b\n  2. Platelet count\\<100 \u00d7 109 \/ L\uff1b\n  3. Hemoglobin\\<90 g\/L (\\<9 g\/dL);\n  4. If there is no clear liver metastasis, alanine aminotransferase is\\>3 times the upper normal limit (ULN); If there is liver metastasis, alanine aminotransferase\\>5 \u00d7 ULN\uff1b\n  5. If there is no clear liver metastasis, aspartate aminotransferase\\>3 \u00d7 ULN\uff1b If there is liver metastasis, aspartate aminotransferase\\>5 \u00d7 ULN\uff1b\n  6. If there is no clear liver metastasis, total bilirubin\\>1.5 \u00d7 ULN\uff1b Or presence of Gilbert syndrome (unconjugated hyperbilirubinemia) or liver metastasis with total bilirubin\\>3 \u00d7 ULN\uff1b\n  7. Creatinine\\>1.5 \u00d7 ULN and creatinine clearance\\<50 mL\/min (calculated using the Cockcroft Gault formula); Only when creatinine\\>1.5 \u00d7 It is only necessary to confirm the creatinine clearance rate at ULN;\n  8. Serum albumin (ALB)\\<28 g\/L.\n* Active fungal, bacterial, and\/or viral infections that require systemic treatment.\n* Female subjects who are pregnant, nursing, or planning to become pregnant during the study period.\n* Have a history of interstitial lung disease, a history of drug-induced interstitial lung disease, a history of radiation pneumonia requiring steroid treatment, or any evidence of clinically active interstitial lung disease.\n* A history of hypersensitivity to any active or inactive component of aumolertinib, or to drugs with a chemical structure similar to or in the same category as aumolertinib.\n* Patients who are allergic to or contraindicated to pemetrexed.\n* Any serious or uncontrolled ocular lesions (especially severe dry eye syndrome, dry corneal conjunctivitis, severe exposure keratitis, or other diseases that may increase epithelial damage) that, in the judgment of a doctor, may increase the safety risk of the subject; Or eye abnormalities that require surgery or are expected to require surgical treatment during the study period.\n* Subjects who, according to the judgment of the investigator, may have poor compliance with the research procedures and requirements, such as having a clear history of neurological or mental disorders (including epilepsy or dementia), or currently suffering from mental disorders.\n* The investigator determines that there are any conditions that endanger the safety of the subject or interfere with the evaluation of the study, or other conditions that the researcher believes are not suitable for enrollment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05810350001","EMAIL":[{}],"GEO":[29.56278,106.55278]},{"TITLE":"Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Signed written informed consent\uff1b\n* Aged 18-75 years old\uff1b\n* Histologically or cytologically confirmed, locally advanced (Stage IIIB\/C) not amenable to curative surgery or radiotherapy, or metastatic\/recurrent (Stage IV) squamous NSCLC according to American Joint Committee on Cancer, 8th Edition\uff1b\n* At least 1 measurable lesion as defined by RECIST v1.1\uff1b\n* ECOG performance status 0-1\uff1b\n* No systematic antitumor treatment for advanced \/ metastatic diseases has been received in the past\uff1b\n* Life expectancy sup 3 months\uff1b\n* Adequate organ function\uff1b\n* For female subjects of childbearing age, urine or serum pregnancy test shall be conducted 3 days before receiving the first study drug administration, and the result is negative\uff1b\n* The subject and the subject's sexual partner need to use a medically approved contraceptive measure during the study treatment period and within 6 months after the end of the study treatment period.\n\nExclusion Criteria:\n\n* Histology was non squamous cell NSCLC. Mixed cell types must distinguish the dominant cell morphology (squamous cell carcinoma components \\> 50% can be included in the group); If there are small cell carcinoma, neuroendocrine carcinoma and sarcoma, they can not be included in the group;\n* EGFR sensitive mutations or ALK rearrangements;\n* Imaging (CT or MRI) showed that the tumor invaded large blood vessels or it was judged that the tumor was very likely to invade important blood vessels and cause fatal bleeding during the follow-up study;\n* Concurrent participation in another clinical trial;\n* Have previously received the following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or drugs that stimulate or co inhibit T cell receptors (e.g., CTLA-4, OX-40, CD137);\n* Received Chinese patent medicine with anti-tumor indications or drugs with immunomodulatory effect (thymosin, interferon, interleukin, etc.) within 2 weeks, or major surgical treatment within 3 weeks before the first administration;\n* There are active hemoptysis, active diverticulitis, abdominal abscess, gastrointestinal obstruction and peritoneal metastasis that need clinical intervention;\n* Grade III-IV congestive heart failure (New York Heart Association classification), poorly controlled and clinically significant arrhythmia;\n* Any arterial thrombosis, embolism or ischemia, such as myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack, occurred within 6 months before enrollment;\n* Known allergic reactions to PD-1\/L1 monoclonal antibodies, taxanes, cisplatin or carboplatin, recombinant human endostatin active ingredients and or any excipients;\n* Patients requiring long-term systemic use of corticosteroids;\n* Symptomatic central nervous metastasis;\n* Active infection requiring treatment or systemic anti infective drugs used within one week before the first administration;\n* Not fully recovered from toxicity and\/or complications caused by any intervention before starting treatment (i.e. \u2264 grade 1 or reaching baseline, excluding fatigue or hair loss);\n* Known HIV infection;\n* Untreated active hepatitis B (defined as HBsAg positive and HBV-DNA copy number detected greaterthan the upper limit of normal value in the laboratory of the research center);\n* Active HCV infected;\n* Live vaccine was administered within 30 days before the first administration;\n* Pregnant or lactating women;\n* Medical history or disease evidence, abnormal treatment or laboratory test values that may interfere with the test results, prevent the subjects from participating in the whole study, or other situations that the researchers believe are not suitable for inclusion.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05243355001","EMAIL":[{},{},{}],"GEO":[36.66833,116.99722]},{"TITLE":"The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study","CRITERIA":"Inclusion Criteria:\n\n1. Age\\>18 years old, gender unlimited;\n2. According to the Diagnosis and Treatment Guidelines for Primary Lung Cancer (2018 Edition), NSCLC was diagnosed by pathological histology;\n3. TNM staging is III - IV;\n4. Failure of second-line treatment according to the CSCO guidelines;\n5. ECOG PS score \u2264 2 points;\n6. Estimated survival time\\>3 months;\n7. Sign informed consent form\n\nExclusion Criteria:\n\n1. Individuals who have previously received interventional therapy (iodine particle implantation, ablation, BACE treatment), or have received PD-L1 inhibitor immunotherapy during the first or second line standard treatment period of the patient;\n2. Patients with other malignant tumors that have not been cured;\n3. White blood cells\\<3 \u00d7 109\/L, absolute value of neutrophils\\<1.5 \u00d7 109\/L, neutrophil\/lymphocyte ratio \u2265 3, platelet count\\<50 \u00d7 109\/L, hemoglobin concentration\\<90 g\/L;\n4. Liver and kidney dysfunction (creatinine\\>176.8) \u03bc Mol\/L; Aspartate aminotransferase (AST) and\/or alanine aminotransferase (ALT)\\>twice the normal upper limit;\n5. Central squamous cell carcinoma with cavity features;\n6. Incorrectable coagulation dysfunction or concomitant active massive hemoptysis;\n7. Patients with concurrent active infections who require antibiotic treatment;\n8. Uncontrollable hypertension, diabetes, and cardiovascular diseases with obvious symptoms;\n9. Contrast agent allergy;\n10. Women with concurrent pregnancy or lactation","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06188650001","EMAIL":[{"email":"vanssi@163.com"}],"GEO":[29.87819,121.54945]},{"TITLE":"Development and Analysis of a Stool Bank for Cancer Patients","CRITERIA":"Inclusion Criteria:\n\n* Men or women who are \u2265 18 years old who are undergoing any type of cancer immunotherapy\n* Subjects who are able to provide written informed consent\n\nExclusion Criteria:\n\n* Subjects with HIV, Hepatitis B, or Hepatitis C\n* Subjects without the mental capacity to complete either a written or online questionnaire, alone or with assistance, or make sound decisions\n* Women who are pregnant or who plan on becoming pregnant\n* Women who are nursing","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04291755002","EMAIL":[{"email":"ndenmark@bondclinic.com"},{}],"GEO":[28.02224,-81.73286]},{"TITLE":"Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma","CRITERIA":"Inclusion Criteria:\n\n1. Subjects aged \u226518 and \u226475 years old\uff1b\n2. ECOG performance status score 0-1\uff1b\n3. Stage \u2160B-\u2161A\uff08according to the 8th Edition of the AJCC Staging system\uff09\uff1b\n4. Complete surgical resection of the primary NSCLC is mandatory\uff1b\n5. Histologically confirmed diagnosis of high-risk pathological subtype (micropapillary, solid pattern or spread through air spaces \\[STAS\\], etc.);\n6. The tumour harbours one of the most common EGFR mutations (19del or L858R) ;\n7. Normal organ and bone marrow function measured before the study as defined below:\n\n1) Hemoglobin (HGB)\u226590g\/L 2) White blood cell count (WBC) is 4.0\\~10\u00d710\\^9\/L 3) Absolute value of neutrophil (ANC)\u22651.5\u00d710\\^9\/L 4) Platelet (PLT) count\u2265100\u00d7109\/L 5) Serum total bilirubin (TBIL)\u22641.5\u00d7ULN 6) AST and\/or ALT\u22642.5\u00d7ULN 7) International normalized ratio\uff08INR\uff09\u22641.5 and activated partial thromboplastin time (APTT) is normal 8) Serum creatinine (SCr)\u22641.5 \u00d7 ULN 8. No previous systemic anti-tumor therapy for malignant tumor, such as chemotherapy, radiotherapy or hormonotherapy. No history of other malignancies, subjects with prostate cancer who received hormone therapy and had more than 5 years of DFS were excluded; 9. Subjects have voluntarily participated, signed and dated informed consent.\n\nExclusion Criteria:\n\n1. Double primary lung cancer or multiple primary lung cancer;\n2. Subjects with mental illness;\n3. Presence or concomitant hemorrhagic diseases;\n4. Pregnancy or lactation;\n5. Known or suspected to be allergic to Furmonertinib and \/ or other components of their preparations.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05165355001","EMAIL":[{"email":"fan_jiang@tongji.edu.cn"},{}],"GEO":[31.22222,121.45806]},{"TITLE":"Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Newly diagnosed NSCLC patients with resectable disease (Stage IIA to Stage IIIB).\n* WHO or Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate organ and bone marrow function.\n* Provision of tumour samples (newly acquired or archival tumour tissue \\[\u2264 6 months old\\]) to confirm Programmed death-ligand 1 (PD-L1) status, epidermal growth factor receptor (EGFR), or anaplastic lymphoma kinase (ALK) status.\n* Adequate pulmonary function.\n\nExclusion Criteria:\n\n* Participants with sensitising EGFR mutations or ALK translocations.\n* Active or prior documented autoimmune or inflammatory disorders.\n* Uncontrolled intercurrent illness, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active bleeding diseases, serious chronic gastrointestinal conditions associated with diarrhoea, or psychiatric illness\/social situations that would limit compliance with study requirement.\n* History of another primary malignancy.\n* Participants with small-cell lung cancer or mixed small-cell lung cancer.\n* History of active primary immunodeficiency.\n* History of non-infectious ILD\/pneumonitis that required steroids, has current ILD\/pneumonitis, or has suspected ILD\/pneumonitis that cannot be ruled out by imaging at screening.\n* Participants who have preoperative radiotherapy treatment as part of their care plan.\n* Participants who require or may require pneumonectomy, segmentectomies, or wedge resections, as assessed by their surgeon at baseline, to obtain potentially curative resection of primary tumour.\n* QTcF (QT interval corrected by Fridericia's formula) interval \u2265 470 ms.\n* Any medical contraindication to treatment with chemotherapy as listed in the local labelling.\n* Participants with moderate or severe cardiovascular disease.\n* Any concurrent chemotherapy, investigational product, biologic, or hormonal therapy for cancer treatment.\n* Receipt of live attenuated vaccine within 30 days prior to the first dose of study interventions.\n* Prior exposure to approved or investigational immune-mediated therapy including, but not limited to, other anti-CTLA-4, anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies. Participants who received agents targeting the adenosine pathway, anti-NKG2A, anti-HLA-E agents, and anti-LIF agents are also excluded. Participants who have received previous treatment with a TROP2 targeting ADC or with another ADC containing a chemotherapy agent that inhibits TOP1 activity are also excluded.\n* Current or prior use of immunosuppressive medication within 14 days before the first dose of study interventions.\n* Active or uncontrolled infections including HBA, HBV, HCV, and HIV.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":95,"SS_ID":"05061550094","EMAIL":"information.center@astrazeneca.com","GEO":[38.41273,27.13838]},{"TITLE":"Study of RET Inhibitor TAS0953\/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities","CRITERIA":"Inclusion Criteria:\n\nPhase I - Common inclusion criteria for Dose-Escalation \/ Dose-Expansion:\n\n* Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1\n* Available RET-gene abnormalities determined on tissue or liquid biopsy\n* Documented progression of disease following existing therapies deemed by the Investigator to have demonstrated clinical benefit or unable to receive such therapies.\n* Adequate hematopoietic, hepatic and renal function\n\nPhase I Dose-Escalation - Specific inclusion criteria:\n\n* Advanced solid tumors\n* Measurable and\/or non-measurable disease as determined by RECIST 1.1\n* If patient has brain and\/or leptomeningeal metastases, (s)he should be asymptomatic.\n\nPhase I Dose-Expansion - Specific inclusion criteria:\n\n* Locally advanced or metastatic non small cell lung cancer (NSCLC) patients with primary RET gene fusion and prior exposure to RET selective inhibitors\n* Measurable disease as determined by RECIST 1.1\n* If patient has brain and\/or leptomeningeal metastases,(s)he should have:\n\n  * asymptomatic untreated brain\/leptomeningeal metastases off steroids and anticonvulsant for at least 7 days or\n  * asymptomatic brain metastases already treated with local therapy and be clinically stable on steroids and anticonvulsant for at least 7 days before study drug administration.\n\nPhase II :\n\n* Available RET-gene abnormalities determined on tissue or liquid biopsy\n* Locally advanced or metastatic:\n\n  * NSCLC patients with primary RET gene fusion and prior exposure to RET selective inhibitors;\n  * NSCLC patients with RET gene fusion and without prior exposure to RET selective inhibitors\n  * patients with advanced solid tumors that harbour RET gene abnormalities (other than NSCLC patients with primary RET gene fusions) and has failed all the available therapeutic options\n* Eastern Cooperative Oncology Group (ECOG) performance score of 0-2\n* Measurable disease as determined by RECIST 1.1\n* If patient has brain and\/or leptomeningeal metastases,(s)he should have:\n\n  * asymptomatic untreated brain\/leptomeningeal metastases off steroids and anticonvulsant for at least 7 days or\n  * asymptomatic brain metastases already treated with local therapy and be clinically stable on steroids and anticonvulsant for at least 7 days before study drug administration.\n* Adequate hematopoietic, hepatic and renal function\n\nExclusion Criteria:\n\nCommon exclusion criteria for Phase 1 and Phase 2\n\n* Investigational agents or anticancer therapy within 5 half-lives prior to the first dose of study drug\n* Major surgery (excluding placement of vascular access) within 4 weeks prior to the first dose of study drug or planned major surgery during the course of study treatment.\n* Whole Brain Radiotherapy within 14 days or other palliative radiotherapy within 7 days prior to the first dose of study drug, or persisting side effects of such therapy, in the opinion of the Investigator.\n* Clinically significant, uncontrolled, cardiovascular disease including myocardial infarction within 3 months prior to Day 1 of Cycle 1, unstable angina pectoris, significant valvular or pericardial disease, history of ventricular tachycardia, symptomatic Congestive Heart Failure (CHF) New York Heart Association (NYHA) class III-IV, and severe uncontrolled arterial hypertension, according to the Investigator's opinion.\n* QT interval corrected using Fridericia's formula (QTcF) \\>470 msec; personal or family history of prolonged QT syndrome or history of Torsades de pointes (TdP). History of risk factors for TdP\n* Treatment with strong CYP3A4 inhibitors within 1 week prior to the first dose of study drug or strong CYP3A4 inducers within 3 weeks prior to the first dose of study drug.\n\nPhase I Dose-Expansion - and Phase II specific exclusion criteria:\n\n* Presence of known EGFR, KRAS, ALK, HER2, ROS1, BRAF and METex14 activating mutations.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04683250012","EMAIL":[{}],"GEO":[35.66667,139.81718]},{"TITLE":"Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI","CRITERIA":"Inclusion Criteria:\n\nOnly the patients meeting all the following criteria can be eligible to participate in the trial:\n\n* Fully informed consent and signed ICF;\n* Age of 18-75 years;\n* Histologically and\/or cytologically confirmed advanced or recurrent stage III B-C or IV (AJCC Version 8) NSCLC with TKI-resistant EGFR-mutated tumors, which also satisfy following conditions: Without T790M mutation in exon 20 after 1st or 2nd generation EGFR-TKI (eg, gefitinib, erlotinib, icotinib, afatinib,etc.) treatment failure;If with T790M mutation in exon 20 after 1st or 2nd generation EGFR-TKI (eg, gefitinib, erlotinib, icotinib, afatinib,etc.),participants are required to have osimertinib or other 3rd generation EGFR-TKI treatment failure prior to enrollment.Participants with osimertinib treatment failure as 1st line therapy (regardless of their EGFR T790M mutation status);Previous neoadjuvant\/adjuvant chemotherapy is allowed, but the time interval between the last dose of chemotherapy and recurrence\/metastasis must be at least 6 months.\n* With at least one measurable disease per RECIST 1.1;\n* Agree to provide formalin fixed tumor specimen after EGFR-TKI treatment failure or provide fresh biopsy tissue;\n* ECOG performance status of 0-1;\n* Life expectancy \u2265 3 months;\n* Good organ function;\n* Any adverse event resulting from prior treatment, surgery, or radiotherapy must return to grade 0 or 1 according to NCI-CTCAE v5.0, except for alopecia of any grade;\n* Willing and able to follow protocol visits, treatment plans, laboratory tests and other study procedures;\n* Women of childbearing potential must have negative serum pregnancy test within 3 days prior to the first dose of investigational product:\n\nExclusion Criteria:\n\n* Exclusion of tumor histology or cytology confirmed the presence of small cell lung cancer components, or squamous cell carcinoma components of more than 10%;\n* Combined with other driver mutations with known therapeutic drug, including but not limited to: ALK rearrangement, ROS1 mutation, BRAF600E mutation;\n* Previous systematic chemotherapy for advanced NSCLC;\n* Subjects with no measurable lesions;\n* Subjects with cancer meningitis and spinal cord compression;\n* Subjects with untreated central nervous system (CNS) tumor metastasis;\n* Subjects were previously treated with an anti-PD-1, anti-PD-L1 or anti-CTLA-4 agent;\n* Subjects with any active, known or suspected autoimmune disease;\n* Subjects who are now participating in other clinical studies or the last dose of prior investigational drug was given in \\< 4 weeks (or 5 half-lives) from the first investigational product administration of this study;\n* Subjects who were expected to receive any other antitumor therapy (eg, other maintenance therapy for NSCLC, radiotherapy, and\/or surgical excision);\n* Subjects who received major surgery within 4 weeks prior to enrollment or were not fully recovered from prior surgery;\n* Subjects with other malignancies requiring concurrent treatment;\n* Subjects with grade II or above myocardial ischemia or myocardial infarction, or subjects with arrhythmia with poor control;\n* Subjects with uncontrolled pleural\/pericardial effusion, or with ascites requiring repeated drainage;\n* Subjects with uncontrolled tumor-related pain;\n* Subjects with severe allergic reactions to other monoclonal antibodies and subjects with severe allergic reactions to pemetrexed, platinum or its prophylaxis;\n* Subjects with psychological disorder, alcohol alcoholism, drug abuse or drug dependency","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"03924050002","EMAIL":[{"email":"563904040@qq.com"}],"GEO":[22.54554,114.0683]},{"TITLE":"Efficacy and Safety of Modified Si Jun Zi Tang in Perioperative NSCLC Treatment","CRITERIA":"Inclusion Criteria:\n\n1. Age \u2265 18 and \u2264 75 years.\n2. Pathologically confirmed non-small cell lung cancer (NSCLC) with no prior treatment for this tumor.\n3. Clinical stage II-IIIB (N2) tumors assessed as resectable or potentially resectable by a multidisciplinary team (MDT).\n4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 - 1.\n5. Adequate organ function, including:\n\n   Bone marrow: Absolute neutrophil count (ANC) \u2265 1.5 x 10\\^9\/L, platelets \u2265 80 x 10\\^9\/L, hemoglobin \u2265 90 g\/L.\n\n   Liver: Total bilirubin \u2264 1.5 times the upper limit of normal (ULN), aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \u2264 3 times ULN.\n\n   Kidneys: Creatinine clearance rate \u2265 45 mL\/min (using the standard Cockcroft-Gault formula) or \u2264 1.5 times ULN.\n6. At least one measurable lesion according to RECIST v1.1 criteria.\n7. For women: Must be surgically sterilized, postmenopausal, or use highly effective contraception during and for 3 months after treatment; must not be pregnant or breastfeeding during the treatment period.\n8. Patients must have compliance and geographic proximity to ensure adequate follow-up.\n\nExclusion Criteria:\n\n1. Patients with a history of autoimmune diseases, active tuberculosis, active hepatitis (HBV DNA \\<2000 IU), or HIV infection.\n2. Patients expected to be unable to tolerate surgery, such as those with severe cardiopulmonary insufficiency or coagulation disorders (APTT \\<1.5 times ULN, INR \\>2.0, PT \\>16 seconds).\n3. History of other malignancies within the past 2 years, except for cured cervical carcinoma in situ, basal cell carcinoma of the skin, superficial bladder cancer \\[Ta, Tis \\& T1\\], or papillary thyroid carcinoma.\n4. Any unstable systemic disease (including active systemic infections requiring systemic treatment, liver disease, kidney disease, or metabolic disorders, acute cerebral infarction or cerebral hemorrhage, etc.).\n5. Significant cardiovascular events: congestive heart failure \\> NYHA Class 2; unstable angina, active coronary artery disease (CAD) (myocardial infarction over 1 year before study entry is allowed); severe arrhythmias requiring treatment (use of beta-blockers or digoxin is allowed) or uncontrolled hypertension.\n6. Significant neurological or psychiatric disorders, including epilepsy, dementia, etc.\n7. Patients with interstitial lung disease or a history of interstitial pneumonia.\n8. Participation in other anti-tumor drug clinical trials within 4 weeks prior to enrollment.\n9. Previous use of PD-1\/PD-L1 inhibitors or other anti-tumor immunotherapy drugs.\n10. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation or planned transplantation.\n11. Known allergy to the drugs or drug excipients used in the study or severe allergic reactions to other monoclonal antibodies.\n12. Presence of other severe physical or laboratory abnormalities that may increase the risk of participating in the study, interfere with study results, or any other condition that, in the investigator's judgment, may affect the conduct or results of the clinical study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06445881001","EMAIL":[{"email":"jianzhenshan@163.com"},{"email":"liuzhen@cancer.ac.cn"}],"GEO":[30.29365,120.16142]},{"TITLE":"Study of NEO-201 in Solid Tumors Expansion Cohorts","CRITERIA":"Inclusion Criteria:\n\n* Age: \\>\/=18 years\n* Diagnosis:\n\n  * Subjects must have histologically or cytologically confirmed recurrent, locally advanced unresectable or metastatic cancer confirmed by the Laboratory of Pathology, NCI\n  * Subjects enrolled in the expansion cohorts must have advanced non-small cell lung cancer, HNSCC, uterine cancer, or cervical cancer that has progressed during or after at least one front-line standard of care treatment, including chemotherapy and\/or targeted therapy\n  * Tumor is positive for NEO-201 antigen expression (defined as at least 10% of tumor cells expressing NEO-201 target antigen).\n  * Patient is not a candidate for potentially curative surgery or radiation.\n\nTumor has the additional characteristics described below for the disease specific expansion cohorts:\n\nNSCLC:\n\n* Tumor(s) must express PD-L1 (TSP \\> 1%) as determined by an FDA-approved test and\/or is microsatellite instability-high (MSI-H) or mismatch repair deficient, and\/or is tumor mutational burden-high (TMB-H) \\[\u226510 mutations\/megabase (mut\/Mb)\\], as determined by an FDA-approved test.\n* Patients with EGFR, ALK1, ROS1 or BRAF V600E genomic tumor aberrations must have had disease progression on FDA-approved agents for these aberrations.\n* Patients without these genomic tumor aberrations must have received immune-checkpoint inhibitor previously, either as a single agent or in combination with chemotherapy.\n\nCervical Cancer:\n\n\u2022 Tumor(s) express a combined positive score (CPS) \\> 1, as determined by an FDA approved test and\/or is microsatellite instability-high (MSI-H) or mismatch repair deficient, and\/or is tumor mutational burden-high (TMB-H) \\[\u226510 mutations\/megabase (mut\/Mb)\\], as determined by an FDA-approved test\n\nHNSCC \u2022 Patients are allowed to have received pembrolizumab previously, either alone or as part of a multiagent regimen.\n\nUterine carcinoma\n\n\u2022 Patients who are eligible to have received the combination of pembrolizumab plus lenvatinib (i.e. patients with tumors that are not MSI or dMMR) must have received this regimen, unless considered unsafe due to comorbid conditions (e.g. hypertension, proteinuria).\n\n* Must have archived tissue (10 unstained slides or tissue block), or must have tumor which can be safely biopsied percutaneously and be willing to undergo a tumor biopsy\n* MEASURABLE\/EVALUABLE DISEASE: Measurable disease (by RECISTv1.1)\n* INFORMED CONSENT: Voluntary written informed consent before performance of any study-related procedure that is not part of normal medical care\n* PERFORMANCE STATUS: ECOG \u2264 2; or Karnofsky performance status of \u2265 50%\n* LABORATORY FUNCTION:\n\n  * Screening laboratory data within 21 days of the first dose of study drug. Subject must have adequate organ function:\n  * Hemoglobin \\> 9 g\/dL, or on stable doses (hematocrit stable within 1 gram and dose stable for one month) of erythropoietin or similar medication\n  * Absolute neutrophil count (ANC) \u22651,500\/mm3\n  * Platelets \u2265 100,000\/mm3\n  * Total bilirubin \u2264 2.0 mg\/dL\n  * ALT and AST \u2264 3 times the ULN, or, if the subject has liver metastases, \u2264 5 times the ULN\n  * Creatinine \u2264 1.5 mg\/dL or creatinine clearance \\> 40 mL\/min\/1.73 m2 for subjects with creatinine levels above institutional normal, as calculated by the Cockcroft Gault formula\n* PRIOR THERAPY:\n\n  * At least 14 days must have elapsed since treatment with oral tyrosine kinase inhibitors, or until toxicities associated with TKI therapy have resolved\n  * At least 21 days must have elapsed since treatment with previous monoclonal antibodies, or until toxicities associated with mAb therapy have resolved\n  * At least 4 weeks must have elapsed since any chemotherapeutic agents at the time of enrollment (or 6 weeks for regimens containing BCNU or mitomycin C)\n  * At least 2 weeks must have elapsed since any systemic corticosteroids at the time of enrollment\n  * Immunotherapy: At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines.\n  * XRT: At least 7 days after local palliative XRT (small port)\n* Subjects must have recovered from any acute toxicity related to prior therapy, except for alopecia. Toxicity should be \u2264 grade 1, or \u2264 grade 2 for peripheral neuropathy, or hypothyroidism\n* Subject is expected to be able to remain on a study protocol for at least 8 weeks\n* BIRTH CONTROL: Female subject is post-menopausal, surgically sterilized, or willing to use acceptable methods of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, or condom with spermicide, or abstinence) for the duration of the study, and 2 weeks after completion of NEO-201 administration or 4 months after the last dose of pembrolizumab (according to package labeling), whichever is later.\n\nShould a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n\nMen treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 2 weeks after completion of NEO-201 administration or 4 months after the last dose of pembrolizumab (according to package labeling), whichever is later.\n\nExclusion Criteria:\n\n* History of disseminated or uncontrolled brain metastases or central nervous system disease. Brain metastases will be considered controlled if SD on two consecutive brain MRIs, performed at least 2 months apart, and subject is without seizures.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to NEO-201 or other agents used in this study.\n* Any major surgery within 14 days of enrollment.\n* Receiving any other investigational agents.\n* No archival tissue available and a lesion(s) that cannot be safely biopsied via percutaneous route, or is unwilling to undergo biopsy.\n* Has an uncontrolled concomitant illness including, but not limited to, ongoing or active infection, uncontrolled diabetes mellitus, symptomatic congestive heart failure, unstable angina pectoris, hypokalemia, family history of Long QT Syndrome or presence of cardiac arrhythmia.\n* Subjects who are assessed to have unacceptable risk of developing infection from neutropenia will be excluded at the Investigator's discretion.\n* HIV-positive subjects on combination antiretroviral therapy are ineligible because of the unknown potential for pharmacokinetic interactions with NEO-201. In addition, these subjects are at increased risk of lethal infections which could complicate the toxicity assessment of this study. Appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated.\n* Subject has other serious medical illness, including a second malignancy, or psychiatric illness that could, in the Investigator's opinion, potentially interfere with the completion of treatment according to this protocol.\n* Pregnant women are excluded from this study because the potential for teratogenic or abortifacient effects due to NEO-201 is unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with NEO-201, breastfeeding should be discontinued if the mother is treated with NEO-201.\n\nAdditional Exclusion Criteria for Expansion Cohorts\n\nBecause patients in the expansion cohort will be receiving pembrolizumab, the following additional exclusion criteria apply:\n\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to start of study therapy.\n* Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g.., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment\n* Subjects who experienced severe or life-threatening immune-related AEs with prior immune checkpoint therapy requiring medical intervention (steroid or immunosuppressant drugs) and permanent discontinuation of therapy, will be excluded. These include, but not limited to colitis, autoimmune hepatitis, hypophysitis, hyperthyroidism, nephritis, myocarditis, GBS, encephalitis.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03476681002","EMAIL":[{"email":"Mahwish.Bari@inova.org"},{}],"GEO":[38.84622,-77.30637]},{"TITLE":"A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma","CRITERIA":"Inclusion Criteria:\n\n1. Sign the informed consent voluntarily and follow the program requirements;\n2. No gender limitation;\n3. Age \u226518 years and \u226480 years;\n4. Expected survival time \u22653 months;\n5. Histologically or cytologically confirmed, locally advanced or metastatic EGFR wild-type, ALK wild-type, and other driver negative (AGA negative, including MET 14 exon jump mutation, ROS1 rearrangement, BRAF V600 mutation, NTRK fusion, RET rearrangement, HER2 mutation, Patients with HER2 amplification (\\> 3.2 copies), KRAS G12 mutation (e.g., G12C, G12D, G12V, etc.) negative), non-small cell lung cancer (squamous cell carcinoma, adenocarcinoma), who only received anti-PD-1 \/PD-L1 monoclonal antibody + platino-containing dimorphization and disease progression or intolerance at the first line; Note: a. Platinum-containing chemotherapy (induction chemotherapy, chemoradiotherapy and adjuvant chemotherapy) in multi-mode therapy for locally advanced patients with disease progression during treatment or within 6 months after the last administration can be counted as first-line therapy. If no treatment with anti-PD-1 \/PD-L1 monoclonal antibody is received, the inclusion criteria cannot be met. Inclusion criteria were met if maintenance therapy with anti-PD-1 \/PD-L1 monoclonal antibody and disease recurrence\/progression occurred within 6 months after the last administration of platinum-containing chemotherapy drugs; b. For patients who need genetic testing or IHC testing and receive platinum-containing diplination first, they should only receive platinum-containing diplination at most in the first 2 cycles, and then add anti-PD-1 \/PD-L1 monoclonal antibody for combination therapy, which meets the inclusion criteria; Patients receiving anti-PD-1 \/PD-L1 monoclonal antibody and then sequential chemotherapy drugs did not meet the inclusion criteria; c. Any change of medication during front-line treatment shall be counted as an increase in the number of treatment lines;\n6. Subject shall agree to complete ctDNA test during the screening period, including: EGFR, ALK, MET, ROS1, BRAF, NTRK, RET, HER2, KRAS and other genes detection and complete data;\n7. There must be at least one measurable lesion consistent with the RECIST v1.1 definition;\n\n   1. If there is only one measurable lesion, baseline imaging of the lesion should not be performed until at least 14 days after biopsy if biopsy has been performed;\n   2. If the target lesion at the site of previous radiotherapy is the only measurable lesion, the investigator must provide imaging data before and after showing significant progression of the lesion to confirm clear progression of the lesion and at least 3 months after the end of radiotherapy;\n8. Physical status score ECOG 0 or 1;\n9. The toxicity of previous antitumor therapy has returned to class 1 as defined by NCI-CTCAE v5.0 (alopecia, fatigue, hyperpigmentation, hypothyroidism stabilized by hormone replacement therapy, grade 2 peripheral neurotoxicity after chemotherapy, and other inclusion criteria excluded);\n10. No serious cardiac dysfunction, left ventricular ejection fraction \u226550%;\n11. If blood transfusion, albumin, colony-stimulating factors, any cell growth factors, and\/or thrombocytophors are not permitted within 14 days prior to the initial use of the study drug, organ function levels must meet the following requirements and meet the following criteria:\n\n    1. Bone marrow function: absolute neutrophil count (ANC) \u22651.5\u00d7109\/L, platelet count \u2265100\u00d7109\/L, hemoglobin \u226590 g\/L;\n    2. Liver function: total bilirubin TBIL\u22641.5\u00d7ULN (total bilirubin \u22643\u00d7ULN in subjects with Gilbert's syndrome or liver metastasis), AST and ALT \u22642.5\u00d7ULN in subjects without liver metastasis, AST and ALT \u22645.0\u00d7ULN in patients with liver metastasis, albumin \u226530 g\/L;\n    3. Renal function: creatinine (Cr) \u22641.5\u00d7ULN, or creatinine clearance (Ccr) \u226550 mL\/min (according to Cockcroft and Gault formula);\n12. Coagulation function: International standardized ratio (INR) \u22641.5, and activated partial thromboplastin time (APTT) \u22641.5\u00d7ULN;\n13. Urinary protein \u22642+ or \\< 1000mg\/24h;\n14. A pregnancy test must be performed within 7 days before the start of treatment for premenopausal women who are likely to have children, and the serum-pregnancy must be negative and must be non-lactation; All enrolled patients (male or female) should take adequate barrier contraception throughout the treatment cycle and for 6 months after completion of treatment.\n\nExclusion Criteria:\n\n1. Patients with previous use of docetaxel;\n2. Patients with non-small cell lung cancer except lung squamous cell carcinoma and lung adenocarcinoma confirmed by histological or cytological examination (excluding patients with squamous cell carcinoma or adenocarcinoma combined with other types of non-small cell lung cancer);\n3. The gene sequencing report of previous tissue samples or ctDNA before signing the informed consent, or the gene sequencing report of ctDNA during the screening period indicated that there were positive MET 14 exon jump, positive ROS1 rearrangement, positive BRAF V600 mutation, positive NTRK fusion, positive RET rearrangement, and positive HER2 mutation. Patients with HER2 amplification (\\> 3.2 copies) and KRAS G12 mutation positive (e.g., G12C, G12D, G12V, etc.) should be excluded.\n4. Used chemotherapy, biotherapy, immunotherapy, radical radiotherapy, major surgery, extensive radiotherapy (more than 30% bone marrow radiotherapy or extensive radiotherapy) within 4 weeks before the first dose or within 5 half-lives (whichever is shorter), Anti-tumor therapy has been used within 2 weeks, such as palliative radiotherapy (but it is allowed for bone lesions), small-molecule targeted therapy (including small-molecule tyrosine kinase inhibitors), and modern Chinese medicine preparations approved and marketed for anti-tumor therapy with NMPA;\n5. The medical history of severe cardiac and cerebrovascular diseases in the previous six months was screened, such as: symptomatic congestive heart failure (CHF) \u22652 (CTCAE v5.0) medical history, New York Heart Society (NYHA) \u22653 heart failure, unstable angina pectoris, acute coronary syndrome, myocardial infarction, cerebrovascular accident, transient ischemic attack, cerebral infarction, etc.;\n6. Prolonged QT interval (male QTc \\> 450 msec or female QTc \\> 470 msec, QTc interval calculated by Fridericia formula), complete left bundle branch block, degree III atrioventricular block, frequent and uncontrolled arrhythmias: Such as atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter (transient atrial fibrillation, except for atrial flutter);\n7. Active autoimmune diseases and inflammatory diseases, such as systemic lupus erythematosus, psoriasis requiring systemic treatment, rheumatoid arthritis, inflammatory bowel diseases, Hashimoto's thyroiditis, etc., except type I diabetes mellitus, hypothyroidism that can be controlled by alternative therapy alone, and skin diseases that do not require systemic treatment (e.g. Vitiligo, psoriasis);\n8. Diagnosis of other malignancies within 5 years prior to initial administration, with the exception of radically treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and\/or radically resected carcinoma in situ, which the investigators considered acceptable for inclusion;\n9. Hypertension poorly controlled by two antihypertensive drugs (systolic blood pressure \\&gt; 150 mmHg or diastolic blood pressure \\&gt; 100 mmHg);\n10. Patients with past and present clinical manifestations or high risk factors of interstitial lung disease (ILD), drug-related pneumonia, radiation pneumonia, severe impairment of lung function or suspected interstitial lung disease;\n11. Patients with central nervous system (CNS) metastasis and\/or cancerous meningitis (meningeal metastasis) and\/or spinal cord compression. But have received brain metastases (radiation or surgery; Patients with stable BMS who had stopped radiotherapy or surgery 28 days before the first dose were enrolled. Patients with cancerous meningitis (meningeal metastasis) were excluded even after treatment and judged to be stable, and patients with cerebral edema and mannitol prophylaxis\/treatment were excluded even if asymptomatic. The definition of stability should meet the following four requirements:\n\n    1. The seizure-free state persists for \\> 12 weeks with or without the use of antiepileptic drugs;\n    2. glucocorticoids are not required;\n    3. MRI results during the screening period showed stable imaging status compared with previous MRI results of the subjects;\n    4. asymptomatic and stable for more than 1 month after treatment;\n12. Patients who have a history of allergy to recombinant humanized antibody or human and mouse chimeric antibody or to SI-B001 and any excipient components of the chemotherapy drugs used in this study;\n13. History of autologous or allogeneic stem cell transplantation or organ transplantation;\n14. Positive human immunodeficiency virus antibodies (HIVAb), active hepatitis B virus infection (HBV-DNA \\> 103 copies\/ml) or hepatitis C virus infection (HCV-RNA \\> lower limit of centre detection);\n15. Severe infections (CTCAE \\> Grade 2), such as severe pneumonia, bacteremia, sepsis, tuberculosis, etc., occurred within 4 weeks prior to the first use of the study drug; There was active pulmonary inflammation during screening;\n16. Patients with a large amount of serous effusion, or with symptoms of serous effusion, or poorly controlled serous effusion (poorly controlled is defined as two or more times of puncture and drainage in a month);\n17. Contraindicated fluid replenishment with superior vena cava syndrome;\n18. Received other investigational drugs or treatments within 4 weeks prior to initial dosing;\n19. A history of severe neurological or mental illness, including but not limited to: dementia, depression, seizures, bipolar disorder, etc.;\n20. Imaging examination indicated that the tumor had invaded or wrapped the great vessels of the chest (such as the pulmonary trunk, aorta trunk, pulmonary veins, etc.);\n21. Severe and unhealed wounds, sores or fractures within 4 weeks prior to signing the notice;\n22. Coughed up or coughed up (defined as coughing up or coughed up \u22651 teaspoon of blood or small blood clots or coughed up blood without sputum) within 4 weeks before signing the notification, but did not exclude blood in the sputum;\n23. Severe infusion reaction to antibody therapy in the past (CTCAE grade \u22653);\n24. Subjects with clinically significant bleeding or significant bleeding tendency within 4 weeks prior to signing the information, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, vasculitis, etc.;\n25. History of intestinal obstruction, inflammatory bowel disease or extensive bowel resection, or presence of Crohn's disease, ulcerative colitis, or chronic diarrhea;\n26. Subjects who plan to receive live vaccine or receive live vaccine within 30 days prior to initial administration;\n27. Other conditions associated with participation in this clinical trial were not considered appropriate by the investigators.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"05943795001","EMAIL":[{"email":"llwyh@sysucc.org.cn"},{}],"GEO":[23.11667,113.25]},{"TITLE":"A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Ability to understand and willingness to sign a written informed consent document;\n2. Male or female adult patients 18 years of age or older;\n3. Patients should have recovered from toxicities related to prior anti-tumor therapy;\n4. Patients should have recovered from the effects of major surgery;\n5. Have a documented EGFR mutation by a local test in tissue or plasma;\n6. At least 12 weeks life expectancy;\n7. Must have at least one measurable lesion per RECIST v 1.1;\n8. Sexually active males and females of childbearing potential must agree to take effective contraceptive measures.\n\nExclusion Criteria:\n\n1. Received radiotherapy within 14 days before enrollment;\n2. Have significant or uncontrolled systemic disease;\n3. Have significant or uncontrolled cardiovascular disease;\n4. Have had other diagnosed malignant diseases that required treatment within the past 3 years besides NSCLC;\n5. Currently have or had a history of interstitial lung disease, drug-induced interstitial lung disease, or radiation pneumonia that requires steroid therapy;\n6. Have known hypersensitivity to the similar drugs and excipients of PLB1004;\n7. Pregnant or lactating women;\n8. Have used other experimental drugs within 2 weeks prior to the first dose of PLB1004;\n9. Have any condition or illness that could affect the compliance with the protocol.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06046495004","EMAIL":[{}],"GEO":[47.60621,-122.33207]},{"TITLE":"Clinical Study of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Sign written informed consent prior to implementing any trial-related procedures; 2. Male or female \u226518 years old and \u226475 years old; 3. Cytological or histological diagnosis of non-small cell lung cancer; 4. According to the efficacy evaluation criteria for solid tumors (RECIST version 1.1), at least one lesion can be measured on imaging; 5. Untreated stage \u2170 B - \u2172 A non-small cell lung cancer (TNM staging according to UICC\/AJCC Edition 8); 6. Primary tumor can be biopsied; 7. Patients who agree to receive radical surgical treatment; 8. Patients who can be resected by surgeons and have no contraindications; 9. ECOG score 0-1; 10. Expected survival time \\> 6 months; 11. Adequate organ function, subject will meet the following laboratory criteria: 1) Absolute value of neutrophils (ANC) \u22651.5x10\\^9\/L without the use of granulocyte colony-stimulating factor in the last 14 days. 2) Platelets \u2265100\u00d710\\^9\/L in the last 14 days without blood transfusion. 3) In the absence of blood transfusion or erythropoietin in the last 14 days, hemoglobin\\>9 g\/dL. 4) Total bilirubin \u22641.5\u00d7 upper normal value (ULN); 5) Aspartate aminotransferase (AST), alanine aminotransferase (ALT) \u22642.5\u00d7ULN 6) Serum creatinine \u22641.5\u00d7ULN and creatinine clearance rate (calculated by Cockcroft-Gault formula) \u226560 mL \/min; 7) Good coagulation function, defined as international standardized ratio (INR) or prothrombin time (PT) \u22641.5 ULN; 8) Normal thyroid function, defined as thyroid stimulating hormone (TSH) within the normal range. If the baseline TSH is outside the normal range, subjects with total T3 (or FT3) and FT4 within the normal range may be enrolled; 9) The myocardial enzyme profile is within the normal range (if the investigator comprehensively determines that the simple laboratory abnormality is not clinically significant, it is allowed to be included in the group); 12. For female subjects of reproductive age, a negative urine or serum pregnancy test should be performed within 3 days prior to receiving the first study drug administration (day 1 of cycle 1). If a urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is requested. Women of childbearing age were defined as at least 1 year after menopause or having undergone surgical sterilization or hysterectomy; If there is a risk of pregnancy, all subjects (both men and women) are required to use a contraceptive with an annual failure rate of less than 1% for the entire treatment period up to 120 days after the last study drug (or 180 days after the last chemotherapeutic drug).\n\nExclusion Criteria:\n\n1. Malignant diseases other than NSCLC were diagnosed within 5 years prior to first administration (excluding radical basal cell carcinoma of the skin, squamous carcinoma of the skin, and\/or radical resected carcinoma in situ); 2. Are currently participating in an interventional clinical study or have been treated with another study drug or study device within 4 weeks prior to initial administration; 3. Prior treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs or drugs that target another stimulating or co-inhibiting T-cell receptor (e.g., CTLA-4, OX-40, CD137); 4. Received systemic systemic therapy with anti-tumor indications of Proprietary Chinese medicines or immunomodulatory drugs (including thymosin, interferon and interleukin, except for local use to control pleural effusion) within 2 weeks before the first administration; 5. An active autoimmune disease requiring systemic therapy (e.g., palliative drugs, glucocorticoids, or immunosuppressants) has occurred within 2 years prior to first dosing. Alternative therapies (e.g. thyroxine, insulin, or physiologic glucocorticoids for adrenal or pituitary dysfunction) are not considered systemic; 6. Were receiving systemic glucocorticoid therapy (excluding nasal spray, inhalation, or other topical glucocorticoid) or any other form of immunosuppressive therapy within 7 days prior to initial dosing; Note: Physiological doses of glucocorticoids (\u226410 mg\/ day of prednisone or equivalent) are permitted; 7. Allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation is known; 8. Those who are known to be allergic to the active ingredient or excipient of sindilizumab; 9. Has not fully recovered from toxicity and\/or complications associated with any intervention prior to initiation of treatment (i.e., \u2264 grade 1 or baseline, excluding fatigue or hair loss); 10. Known history of human immunodeficiency virus (HIV) infection (i.e. HIV 1\/2 antibody positive); 11. Untreated active hepatitis B (defined as HBsAg positive with hbV-DNA copy number greater than the upper limit of the normal value in the laboratory department of the research center); Note: Hepatitis B subjects who meet the following criteria can also be enrolled: 1) HBV viral load before initial administration \\< 1000 copies\/mL (200 IU\/ml). Subjects should receive anti-HBV therapy throughout study chemotherapy to avoid virus reactivation 2) For subjects resistant to HBc (+), HBsAg (-), anti-HBS (-), and HBV viral load (-), prophylactic anti-HBV therapy is not required, but close monitoring of virus reactivation is required 12. Active HCV-infected subjects (HCV antibody positive and HCV-RNA level above the detection limit); 13. Received live vaccine within 30 days prior to initial administration (cycle 1, day 1); Note: Acceptance of injectable inactivated virus vaccine against seasonal influenza is permitted within 30 days prior to first administration; Intranasally administered live attenuated flu vaccines are not allowed. 14. Pregnant or lactating women; 15. Presence of any serious or uncontrollable systemic illness, such as: 1) Serious and uncontrollable abnormalities in the rhythm, conduction or morphology of resting electrocardiogram, such as complete left bundle branch block, heart block above degree \u2171, ventricular arrhythmia or atrial fibrillation; 2) Unstable angina pectoris, congestive heart failure, NYHA grade \u2265 2 chronic heart failure; 3) Any arterial thrombosis, embolism or ischemia, such as myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack, occurred within 6 months prior to treatment inclusion; 4) Poor blood pressure control (systolic \\> 140 mmHg, diastolic \\> 90 mmHg); 5) A history of non-infectious pneumonia requiring glucocorticoid treatment within 1 year prior to initial administration, or the current presence of clinically active interstitial lung disease; 6) Active tuberculosis; 7) The presence of active or uncontrolled infections requiring systemic treatment; 8) Clinical active diverticulitis, abdominal abscess and gastrointestinal obstruction; 9) Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis; 10) Poor control of diabetes (FBG \\> 10mmol\/L); 11) Urine routine showed urine protein \u2265++, and confirmed 24-hour urine protein quantity \\> 1.0g; 12) Patients with mental disorders and unable to cooperate with treatment; Any medical history or disease evidence that may interfere with the study results, prevent the subjects from participating fully in the study, abnormal values of treatment or laboratory tests, or other conditions that the investigator considers inappropriate for the study because of other potential risks that the investigator considers inappropriate for the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05170581001","EMAIL":[{"email":"sdtatszhenhua@126.com"},{}],"GEO":[36.18528,117.12]},{"TITLE":"Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)","CRITERIA":"Inclusion Criteria:\n\n1. Subjects must have signed and dated an IRB\/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care. Subjects must be willing and able to comply with scheduled visits, treatment schedule, and laboratory testing.\n2. Patients diagnosed with histologically or cytologically confirmed locally advanced not eligible to a local treatment or metastatic NSCLC (Stage IIIB, IIIC or IV accordingly to 8th classification TNM, UICC 2015).\n3. Patients are eligible for trial entry on the basis of locally determined ALK testing. ALK Immunohistochemistry (IHC) assay (3+ only), DNA-based or RNA-based next generation sequencing (NGS) assay or nCounter Nanostring assay performed locally are accepted ALK testing assays after review by the promotor. If ALK rearrangement diagnostic is performed using IHC and the result is + or 2+, a confirmation with a second method performed locally (DNA-based or RNA-based next generation sequencing (NGS) assay, nCounter Nanostring assay or ALK FISH performed) is required.\n4. All Patients must have at least one measurable target lesion according to RECIST v1.1 per investigator assessment. The radiological assessment has to be done within the timelines indicated.\n5. Patients with asymptomatic and neurologically stable CNS metastases (including patients controlled with less than 10mg\/day of methylprednisolone within the last week prior to study entry) will be eligible.\n6. Tumor Sample Requirement: sufficient tumor tissue for central analysis should be available (tumor block or a minimum of 10 unstained slides of 4 \u00b5m of analyzable tissue).\n7. Age \u226518 years.\n8. Life expectancy of at least 12 weeks, in the opinion of the Investigator.\n9. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.\n10. Adequate Bone Marrow Function, including: Absolute Neutrophil Count (ANC) \u22651.5 x 109\/L; Platelets \u2265100 x 109\/L; Hemoglobin \u22659 g\/dL.\n11. Adequate Pancreatic Function, including: Serum lipase \u22641.5 ULN.\n12. Adequate Renal Function, including: Estimated creatinine clearance \u226545 mL\/min as calculated using the standard method of the institution.\n13. Adequate Liver Function, including: Total serum bilirubin \u22641.5 x ULN (\\<3.0 \u00d7 ULN for patients with Gilbert syndrome); Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) \u22642.5 x ULN; \u22645.0 x ULN if there is liver metastases involvement.\n14. Participants must have recovered from toxicities related to prior anticancer therapy to CTCAE Grade \u2264 1.\n15. Participants must have recovered from effects of any major surgery, or significant traumatic injury, at least 35 days before the first dose of treatment.\n16. Have normal QT interval on screening ECG evaluation, defined as QT interval corrected (Fridericia) (QTcF) of \u2264450 milliseconds (msec) in males or \u2264470 msec in females.\n17. Female patients who: are postmenopausal for at least 1 year before the screening visit, OR are surgically sterile, OR if they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, one of them being nonhormonal, from the time of signing the informed consent through 6 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse.\n18. Male patients, even if surgically sterilized (i.e., status post-vasectomy), who: agree to practice effective barrier contraception during the entire study treatment period and through 6 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse.\n19. Willingness and ability to comply with the study scheduled visits, treatment plans, laboratory tests and other procedure.\n20. Participant has national health insurance coverage.\n\nExclusion Criteria:\n\n1. Previously received an investigational antineoplastic agent for NSCLC.\n2. Previously received any prior TKI, including ALK-targeted TKIs.\n3. Known molecular co-alteration i.e. activating EGFR\/BRAF\/KRAS\/MET mutation and ROS1\/RET\/NTRK fusion.\n4. Previously received neo-adjuvant or adjuvant systemic chemotherapy or consolidation immunotherapy if completion of (neo) adjuvant\/consolidation therapy occurred \\<12 months prior to randomization.\n5. Patients who have leptomeningeal disease (LM) or carcinomatous meningitis (CM) according to MRI data and\/or in case of documented cerebral spinal fluid (CSF) positive cytology.\n6. Spinal cord compression.\n7. Patients with symptomatic or neurologically instable CNS metastases.\n8. Major surgery within 30 days of study entry. Minor surgical procedures (e.g., port insertion, mediastinoscopy, surgical procedure for re-sampling) are not excluded, but sufficient time at investigator discretion should have passed for wound healing.\n9. Radiation therapy within 2 weeks of study entry. Stereotactic or small field brain irradiation must have completed at least 2 weeks prior to study entry. Whole brain radiation must have completed at least 4 weeks prior to study entry.\n10. Active and clinically significant bacterial, fungal, or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS)-related illness.\n11. Have significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to: a) myocardial infarction within 6 months prior to the first dose of study drug; b) unstable angina within 6 months prior to the first dose of study drug; c) congestive heart failure within 6 months prior to the first dose of study drug; d) any history of ventricular arrhythmia; e) history of clinically significant atrial arrhythmia or clinically significant bradyarrhythmia as determined by the treating physician; f) cerebrovascular accident or transient ischemic attack within 6 months prior to the first dose of study drug.\n12. Have uncontrolled hypertension. Patients with hypertension should be under treatment on study entry to control blood pressure.\n13. History of grade 3 or 4 of interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, pulmonary fibrosis and radiation pneumonitis.\n14. Presence of interstitial fibrosis of any grade at baseline.\n15. Other severe acute or chronic medical or psychiatric condition, including recent (within the past year) or active suicidal ideation or behavior, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.\n16. Evidence of active malignancy (other than current NSCLC, non-melanoma skin cancer, in situ cervical cancer, papillary thyroid cancer, DCIS of the breast or localized and presumed cured prostate cancer) within the last 3 years.\n17. Active inflammatory gastrointestinal disease, malabsorption syndrome, chronic diarrhea, symptomatic diverticular disease or previous gastric resection or lap band.\n18. Current use or anticipated need for food or drugs prohibited.\n19. Patients presenting with abnormal Left Ventricular Ejection Fraction (LVEF) by echocardiogram or Multi-Gated Acquisition Scan (MUGA) according to institutional lower limits.\n20. Have a known or suspected hypersensitivity to brigatinib, carboplatin or pemetrexed or their excipients.\n21. Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before first dose of study drug.\n22. Received systemic treatment with strong cytochrome p-450 (cyp)3a inhibitors, strong cyp3a inducers, or moderate cyp3a inducers within 14 days before enrolment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05200481032","EMAIL":[{}],"GEO":[45.98333,4.71667]},{"TITLE":"Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Patients willingly contribute their clinical data for this study\n* Patients with ALK-positive non-small cell lung cancer\n* Age \u2265 18 years\n* Patients who have undergone treatment with Iruplinalkib.\n\nExclusion Criteria:\n\n* Known pregnant or lactating females\n* Patients with interstitial lung diseases, drug-related pneumonitis, or radiation pneumonitis require ongoing medical intervention.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05991895001","EMAIL":[{"email":"wanglinlinatjn@163.com"}],"GEO":[36.66833,116.99722]},{"TITLE":"Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients","CRITERIA":"Inclusion Criteria:\n\nPatients who meet all of the following criteria are eligible for the project:\n\n* Age \u2265 18 years\n* Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments\n\nMain project (Metatstatic NSCLC):\n\n* Confirmed non-small cell lung cancer (NSCLC)\n* Informed consent no later than four weeks after start of first-line systemic treatment or no later than four weeks after diagnosis for patients receiving \"best supportive care only\"\n* Stage IV, or stage IIIB\/C (UICC8) if patient is ineligible for curative surgery and\/or radiochemotherapy\n* Systemic therapy or best supportive care\n\nSatellite Stage I\/II\/III (NSCLC):\n\n* Confirmed non-small cell lung cancer (NSCLC)\n* Informed consent no later than four weeks after start of first anti-tumor treatment (including surgery and radiotherapy) or no later than four weeks after diagnosis for patients receiving \"best supportive care only\" (i.e. no anti-tumor treatment = no surgery, radiotherapy or systemic therapy)\n* Stage I, Stage II, stage IIIA, or stage IIIB\/C (UICC8)\n* Systemic (chemo)therapy and\/or radiation therapy and\/or surgery or best supportive care\n\nSatellite SCLC\n\n* Confirmed Small cell lung cancer (SCLC)\n* Informed consent no later than four weeks after start of first anti-tumor treatment or no later than four weeks after diagnosis for patients receiving \"best supportive care only\" (i.e. no anti-tumor treatment = no surgery, radiotherapy or systemic therapy)\n* Systemic (chemo)therapy and\/or radiation therapy and\/or surgery or best supportive care\n\nExclusion Criteria:\n\nnone","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"02622581001","EMAIL":[{"email":"Frank.griesinger@pius-hospital.de"}],"GEO":[53.14118,8.21467]},{"TITLE":"The Research Plan of Taiwan Precision Medicine","CRITERIA":"Inclusion Criteria\n\n1. Ages 20 and above.\n2. Pathological reports showed adenocarcinoma, squamous cell carcinoma, large cell carcinoma, adenosquamous carcinoma, and sacromatoid carcinoma.\n3. For patients with squamous cell carcinoma, only never smokers and light smokers (less than 10 cigarettes per day) are indicated.\n4. For patients with advanced EGFR (-) and ALK (-) adenocarcinoma or other histological types regardless of EGFR\/ALK status, treatment-na\u00efve or failure to \u2264 two lines of systemic treatment is allowed.\n5. For patients with advanced EGFR (+) or ALK (+) adenocarcinoma, failure to \u2264 two lines of systemic treatment, including tyrosine kinase inhibitor is allowed.\n6. For patients with advanced EGFR exon 20 insertion\/mutation (excluding T790M mutation) adenocarcinoma, failure to \u2264 four lines of systemic treatment, including tyrosine kinase inhibitor is allowed.\n7. Reacquisition of tumor tissue after the failure of previous systemic treatment\n8. Willingness to provide the residual biopsy\/operative slides.\n9. Life expectancy more than 3 months.\n10. Patients fully understand the protocol with the willingness to have regular follow-up.\n11. For patients with advanced EGFR exon 20 insertion\/mutation (excluding T790M mutation) adenocarcinoma: if the patient had died before 2022\/07\/31, the waiver of Informed Consent Form(s) is allowed under the permission of Independent Ethics Committee\/Institutional Review Board (IEC\/IRB). Exclusion Criteria\n\n1.Inability to cooperate by providing a complete medical history. 2.No available tumor tissues for genetic testing. 3.Undesirable compliance.","SEX":"ALL","AGE_MIN":20,"AGE_MAX":200,"SS_ID":"04849481013","EMAIL":[{}],"GEO":[24.95233,121.20193]},{"TITLE":"Paclitaxel Therapeutic Drug Monitoring in Cancer Patients","CRITERIA":"Inclusion Criteria:\n\n* Male or female sex\n* Age \u2265 18 years\n* Individuals receiving treatment at the Wake Forest Comprehensive Cancer Center who are anticipated to receive paclitaxel for curative or palliative intent, with or without surgery and\/or radiation (i.e. neoadjuvant, adjuvant, or in the setting of recurrent or metastatic disease) as per decision with their medical oncologist for the following malignancies and dosing regimens:\n* Invasive breast cancer (any HER2 and ER\/PR status)\n* Patients considered for curative or palliative chemotherapy with paclitaxel 80-175 mg\/m2 with or without doxorubicin, cyclophosphamide, carboplatin, trastuzumab, bevacizumab, or pertuzumab\n\nCervical cancer \u2022 Patients considered for curative or palliative chemotherapy with paclitaxel 135-175 mg\/m2 with or without cisplatin, carboplatin, topotecan, or bevacizumab\n\nNon-small cell lung cancer\n\n\u2022 Patients considered for curative or palliative chemotherapy with paclitaxel 45-200 mg\/m2 with or without carboplatin, cisplatin, bevacizumab, atezolizumab, or pembrolizumab\n\nOvarian cancer \u2022 Patients considered for curative or palliative chemotherapy with paclitaxel 60-175 mg\/m2 with or without carboplatin, cisplatin, ifosfamide, gemcitabine, pazopanib, or bevacizumab\n\nUterine neoplasms\n\n\u2022 Patients considered for curative or palliative chemotherapy with paclitaxel 135-175 mg\/m2 with or without carboplatin, cisplatin, doxorubicin, ifosfamide, bevacizumab, or trastuzumab\n\nVulvar cancer (squamous cell carcinoma)\n\n* Patients considered for curative or palliative chemotherapy with paclitaxel 60-175 mg\/m2 with or without cisplatin, carboplatin, or bevacizumab\n* Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative)\n* Patients with prior radiation treatment or surgery will not be disqualified from enrollment into the study, unless the aforementioned interventions resulted in peripheral neuropathy as a complication\n\nExclusion Criteria:\n\n* Prior treatment with PTX, for any duration or indication\n* Prior treatment with neurotoxic chemotherapy including any taxane, vinca alkaloid, platinum-containing agent, bortezomib, or thalidomide that has resulted in clinical symptoms of persistent, CTCAE grade II or higher peripheral neuropathy\n* Concurrent enrollment in a clinical study of a neuroprotective intervention at the time of study initiation\n* Any contraindication to Paclitaxel (e.g. history of allergic reaction to paclitaxel or Kolliphor EL)\n* Current signs or symptoms of peripheral neuropathy at the time of enrollment, e.g. due to diabetes, HIV, or other conditions\n* Known personal or family history of hereditary peripheral neuropathy (e.g. Charcot-Marie-Tooth disease)","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03987555001","EMAIL":[{}],"GEO":[36.09986,-80.24422]},{"TITLE":"TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Age: 16 years to 90 years\n* Histologically diagnosed as primary\/relapsed\/metastasized brain glioma\n* Expected life span more than 3 months\n* Karnofsky\u226560% or ECOG score 0-2\n* Test subjects have failed standard treatment regimens, or there are no standard treatment regimens available.\n* Test subjects must have tumor regions eligible for biopsy or resection, or malignant body fluid where TILs can be isolated\n* At least 1 evaluable tumor lesion\n* Hematology and Chemistry\uff08within 7 days prior to enrollment\uff09:\n* Absolute count of white blood cells\u22652.5\u00d710\\^9\/L\n* Absolute count of neutropils\u22651.5\u00d710\\^9\/L\n* Absolute count of lymphocytes \u22650.7\u00d7109\/L\n* Platelet count\u2265100\u00d710\\^9\n* hemoglobin\u226590 g\/L\n* Activated partial thromboplastin time (APTT) \u22641.5xULN (Unless received anticoagulant therapy within the previous 3 days)\n* International normalized ratio (INR) \u22641.5xULN (Unless received anticoagulant therapy within the previous 3 days)\n* Serum creatinine \u22641.5mg\/dL(or \u2264132.6\u03bcmol\/L), or clearance rate\u226550mL\/min\n* Serum ALT\/AST \u22643\u00d7ULN(subjects with liver metastasis \u22643\u00d7ULN)\n* Totol bilirubin\u22641.5\u00d7ULN\n* No absolute or relative contraindications to operation or biopsy\n* Test subjects with child-bearing potential must be willing to practice approved highly effective methods of contraception at the time of informed consent and continue within 1 year after the completion of lymphodepletion\n* Any malignant tumor-targeting therapies, including radiotherapy, chemotherapy, and biologics must cease 28 days before obtaining TILs\n* Be able to understand and sign the informed consent document;\n* Be able to stick to follow-up visit plan and other requirements in the agreement.\n\nExclusion Criteria:\n\n* Need glucocorticoid treatment, and daily dose of Prednisone greater than 15mg (or equivalent doses of hormones) or outoimmune diseases requiring immunomodulatory treatment\n* Forced expiratory volume in one second (FEV1) less than 2L, diffusing capacity of the lung for carbon monoxide (DLCO) (calibrated) less than 40%\n* Significant cardiovascular anomalies according to any of the following definitions:\n* New York Heart Association (NYHA) Grade III or IV congestive heart failure, clinically significant\n* Low blood pressure, uncontrollable symptomatic coronary artery diseases, or ejection fraction less than 35%; Severe cardiac rhythm and conduction anomaly, such as ventricular arrhythmia requiring clinical intervention, second-third degree atrioventricular conductive block, etc.\n* Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive, active HBV or HCV infection (HBsAg positive and\/or anti-HCV positive), syphilis infection or Treponema pallidum antibody positive.\n* Severe physical or mental diseases;\n* Have a systemic active infection requiring treatment, or have positive blood cultures(or imaging evidence of infection).\n* Having been treated within a month or being treated now with other medicines, or other biologic therapy, chemo-or radiotherapy.\n* History of allergy to chemical compounds consisting of chemical and biological substances resembling cell therapy.\n* Having received immunotherapy and developed an irAE level greater than Level 3.\n* Previous anti-tumor treatment AE did not return to CTCAE5.0 version grade 1 or below (toxicity considered by the investigator as non-safety concerns like alopecia excluded).\n* Females in pregnancy or lactation. History of organ transplantation, allogeneic stem cell transplantation, and renal replacement therapy.\n* Researchers consider the test subject as having a history of other severe systemic diseases, or other reasons inappropriate for the clinical study.","SEX":"ALL","AGE_MIN":16,"AGE_MAX":90,"SS_ID":"06538012001","EMAIL":[{"email":"SFM@districtonehospital.com"}],"GEO":[39.9075,116.39723]},{"TITLE":"Image Mining and ctDNA to Improve Risk Stratification and Outcome Prediction in NSCLC Applying Artificial Intelligence.","CRITERIA":"Inclusion Criteria:\n\n* Patients with new pathological diagnosis of lung cancer, available baseline imaging (CT and FDG-PET\/CT), age \\> 18 years, and eligibility for surgery will be considered for inclusion.\n\nExclusion Criteria:\n\n* pregnant or breast- feeding women.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":70,"SS_ID":"06163846001","EMAIL":[{}],"GEO":[45.46427,9.18951]},{"TITLE":"Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)","CRITERIA":"Inclusion Criteria:\n\n1. Patients who sign the informed consent form and are willing to complete the study according to the plan;\n2. Aged from 18 to 80 years old;\n3. ECOG equals 0 or 1;\n4. Not receiving lung cancer surgery before;\n5. Resectable peripheral cT1N0M0 tumors with CTR\\>0.5 located in the apical segment;\n6. Non-lepidic predominant invasive NSCLC dignosed by frozen section;\n7. Not receiving chemotherapy or radiotherapy before.\n\nExclusion Criteria:\n\n1. Not cT1N0M0;\n2. Nodules not located in the apical segment or CTR\u22640.5;\n3. Pre-invasive lung adenocarcinoma, lepidic predominant adenocarcinoma, or not lung adenocarcinoma diagnosed cytologically or pathologically;\n4. Receiving lung cancer surgery before;\n5. Receiving radiotherapy or chemotherapy.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"06031246001","EMAIL":[{"email":"fdudengcq@163.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy","CRITERIA":"Inclusion Criteria:\n\n* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization obtained from the patient\/legal representative prior to performing any protocol- related procedures.\n* Patient age \u2265 18 at time of consent\n* Early stage NSCLC (Stage I to IIIA; T1-4 excluding patients with satellite nodules in the same or ipsilateral lobes, N0; AJCC 8th edition)\n* Ineligible for or unwilling to undergo surgical resection. Reasons for surgical ineligibility include: medically inoperable or surgically unresectable (due to tumor size, location etc.), as assessed by MSKCC thoracic surgeon or multi-disciplinary tumor board consensus. Reasons for ineligibility or patient's unwillingness to undergo surgical resection must be clearly documented.\n* Histological and\/or cytological confirmation of NSCLC as per standard of care biopsy; no additional research protocol-specific biopsy is needed.\n* ECOG\/WHO PS 0-1 (KPS 70-100)\n* Candidates for definitive SBRT\n\n  \u00b0 If, after candidates have been planned for RT, they are unable to be treated with the institutional dose constraints as listed in the appendix, they will be labeled ineligible and removed from the study. Ineligible patients will be replaced.\n* A predicted 2-year PFS of \\<80% (\u226520% risk for disease progression) based on an MSKCC-developed radiomics risk prediction model (see section 9.0).\n* Body weight \\> 30kg\n* Adequate normal organ and marrow function as defined below:\n\n  * Hemoglobin \u22659.0 g\/dL\n  * Absolute neutrophil count (ANC) 1.5 x (\\> 1500 per mm\\^3)\n  * Platelet count \u226575 x 10\\^9\/L (\\>75,000 per mm\\^3)\n  * Serum bilirubin \u22641.5 x institutional upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician.\n  * AST (SGOT)\/ALT (SGPT) \u22642.5 x institutional upper limit of normal\n* Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered postmenopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age- specific requirements apply:\n\n  * Women \\<50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the postmenopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n  * Women \u226550 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \\>1 year ago, had chemotherapy-induced menopause with last menses \\>1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).\n* Must have a life expectancy of at least 12 weeks\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational product during the last 4 weeks.\n* Previous thoracic radiation precluding definitive SBRT to the current tumor.\n* Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \\[e.g., colitis or Crohn's disease\\], diverticulitis \\[with the exception of diverticulosis\\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \\[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc\\]). The following are exceptions to this criterion:\n\n  1. Patients with vitiligo or alopecia\n  2. Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement\n  3. Any chronic skin condition that does not require systemic therapy\n  4. Patients without active disease in the last 5 years may be included but only after consultation with the PI\n  5. Patients with celiac disease controlled by diet alone\n* Any unresolved toxicity NCI CTCAE Grade \u22652 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria\n\n  1. Patients with Grade \u22652 neuropathy will be evaluated on a case-by-case basis after consultation with the PI.\n  2. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the PI.\n* Prior\/Current Therapies:\n\n  1. Treatment with a monoclonal antibody within 4 weeks prior to study Day 1 or has not recovered (i.e., \u2265 Grade 1 at baseline) from adverse events due to agents administered \\> 4 weeks earlier (intraocular bevacizumab is acceptable).\n  2. Prior chemotherapy or targeted small molecule therapy, within 3 weeks prior to study Day 1 or has not recovered (i.e., \u2265 Grade 1 at baseline) from adverse events due to a previously administered agent).\n  3. Prior therapy with an anti-PD-1, anti-PD-L1, including durvalumab, anti-PDL2, anti-CD137, anti-Cytotoxic T- lymphocyte-associated antigen-4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.\n  4. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:\n\n  i. Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection) ii. Systemic corticosteroids at physiologic doses not to exceed \\<\\<10 mg\/day\\>\\> of prednisone or its equivalent iii. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication) e. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable. f. Prior chemotherapy for this diagnosis of lung cancer\n* Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable.\n* History of allogenic organ transplantation.\n* Severe concurrent illness:\n\n  1. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n  2. Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.\n  3. Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1\/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n  4. Active infection requiring systemic therapy.\n  5. Evidence of interstitial lung disease or active, non-infectious pneumonitis.\n  6. Clinically significant (i.e., active) cardiovascular disease: symptomatic cerebral vascular accident\/stroke (\\< 6 months prior to enrollment), myocardial infarction (\\< 6 months prior to enrollment), unstable angina, congestive heart failure (\u2265 New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.\n* Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ a highly effective birth control from screening to 90 days after the last dose of durvalumab monotherapy.\n\n  a. Highly effective methods of contraception, defined as one that results in a low failure rate (ie, less than 1% per year) when used consistently and correctly are described in Appendix B. Note that some contraception methods are not considered highly effective (e.g. male or female condom with or without spermicide; female cap, diaphragm, or sponge with or without spermicide; non-copper containing intrauterine device; progestogen-only oral hormonal contraceptive pills where inhibition of ovulation is not the primary mode of action \\[excluding Cerazette\/desogestrel which is considered highly effective\\]; and triphasic combined oral contraceptive pills).\n* Live vaccination within 4 weeks prior to the first dose of durvalumab and while on trial is prohibited except for administration of inactivated vaccines.\n* Connective tissue disorders or idiopathic pulmonary fibrosis involving the lungs and\/or esophagus\n* Known actionable EGFR or ALK mutation\n* Known contraindications to radiotherapy\n* History of leptomeningeal carcinomatosis\n* History of active primary immunodeficiency\n* Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.\n* Prior randomization or treatment in a previous durvalumab clinical study regardless of treatment arm assignment.\n* Participants must not donate blood while on durvalumab therapy.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04716946009","EMAIL":[{}],"GEO":[40.65871,-73.64124]},{"TITLE":"Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)","CRITERIA":"Inclusion Criteria:\n\n* Arm 1: Histologically or cytologically confirmed advanced\/metastatic solid tumor by pathology report and have received, or been intolerant to, all treatment known to confer clinical benefit.\n* Arms 2 and 3: Have a histologically or cytologically confirmed diagnosis of advanced or metastatic NSCLC (Stage IIIB or IIIC disease and not candidates for surgical resection or definitive chemoradiation, or Stage IV NSCLC, AJCC Staging Manual, version 8).\n* Arms 2 and 3: Confirmation that EGFR-, ALK-, or ROS1-directed therapy is not indicated as primary therapy\n* Arm 2: Has tumor tissue that demonstrates PD-L1 TPS \u2265 50% as determined by PD-L1 IHC 22C3 pharmDx assay by local laboratory\n* If capable of producing sperm, the participant agrees to the following during the intervention period and for at least the time needed to eliminate each study intervention after the last dose of study intervention (100 days for sacituzumab tirumotecan and 90 days for carboplatin \\[no restriction for pembrolizumab\\]) AND agrees to refrain from donating sperm AND is either abstinent and agrees to remain abstinent or uses highly effective contraception\n* For females (assigned at birth), is not pregnant or breastfeeding and \u22651 of the following applies: is not a participant of childbearing potential (POCBP) OR is a POCBP and uses highly effective contraception\n* Arm 1: Participants who have AEs due to previous anticancer therapies must have recovered to \u2264Grade 1 or baseline\n* Measurable disease by RECIST 1.1 as assessed by the local site investigator\/radiology\n* Archival tumor tissue sample or newly obtained core or incisional biopsy of a tumor lesion not previously irradiated has been provided\n* Have a life expectancy of at least 3 months\n* Have an ECOG performance status of 0 or 1 within 3 days before the start of study intervention\n\nExclusion Criteria:\n\n* Has symptomatic ascites or pleural effusion. A participant who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible\n* Has Grade \u22652 peripheral neuropathy\n* Has history of documented severe dry eye syndrome, severe Meibomian gland disease and\/or blepharitis, or corneal disease that prevents\/delays corneal healing\n* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease\n* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QTcF interval to \\>480 ms, and\/or other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention\n* Received prior treatment with a TROP2-targeted ADC\n* Received prior treatment with a topoisomerase I-containing ADC\n* Arm 1: Has received any prior immunotherapy and was discontinued from that treatment due to a Grade 3 or higher irAE (except endocrine disorders that can be treated with replacement therapy) or was discontinued from that treatment due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis\n* Arms 2 and 3: Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137)\n* Arms 2 and 3: Has received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their advanced or metastatic NSCLC\n* Arms 2 and 3: Has received radiation therapy to the lung that is \\>30 Gy within 6 months of the first dose of study intervention\n* Received prior systemic anticancer therapy including investigational agents within 4 weeks before allocation\n* Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids\n* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention\n* Requires treatment with a strong inhibitor or inducer of CYP3A4 at least 14 days before the first dose of study intervention and throughout the study\n* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration\n* Arms 2 and 3: Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication\n* Arms 2 and 3: Active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid)\n* Known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Known active CNS metastases and\/or carcinomatous meningitis\n* History of (noninfectious) pneumonitis\/interstitial lung disease that required steroids or has current pneumonitis\/interstitial lung disease\n* Active infection requiring systemic therapy\n* History of HIV infection\n* Concurrent active Hepatitis B (defined as HBsAg positive and\/or detectable HBV DNA) and Hepatitis C virus (defined as anti-HCV Ab positive and detectable HCV RNA) infection\n* History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator\n* Known psychiatric or substance abuse disorder\n* A severe hypersensitivity reaction to treatment a monoclonal antibody\/component of the study intervention","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06049212004","EMAIL":[{}],"GEO":[35.43333,139.65]},{"TITLE":"Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab","CRITERIA":"Inclusion Criteria:\n\n1. Body weight \\>30kg\n2. Recurrent or metastatic NSCLC relapsed during or after completion of chemoradiotherapy with curative intent and maintenance durvalumab for stage III disease. Patients are eligible if they receive at least two cycles of platinum based chemotherapy or radical radiotherapy\n3. Tumor tissue available for biomarker testing.\n4. Evidence of disease progression during durvalumab maintenance or at the end of planned treatment. Patients who have interrupted planned durvalumab treatment after at least 6 months for reasons other than toxicity or progression (e.g. patient's choice, logistic reasons, intercurrent acute illnesses) are eligible. Patients progressing during the first three months of Durvalumab are not eligible\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n6. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up\n7. Age \\>18 years at time of study entry\n8. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization obtained from the patient\/legal representative prior to performing any protocol-related procedures, including screening evaluations.\n9. Life expectancy of at least 16 weeks\n10. Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below::\n\n    * Haemoglobin \u226510.0 g\/dL with no blood transfusion in the past 28 days\n    * Absolute neutrophil count (ANC) \u22651.5 \u00d7 109 \/L\n    * Platelet count \u2265100 \u00d7 109\/L\n    * Serum bilirubin \u22641.5 x institutional upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician.\n    * AST (SGOT)\/ALT (SGPT) \u22642.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be \u22645x ULN\n    * creatinine clearance estimated of \u226551 mL\/min using the Cockcroft-Gault equation or based on a 24 hour urine test:\n\n    Males:\n\n    Creatinine CL = Weight (kg) x (140 - Age) (mL\/min) ---------------------------------------- 72 x serum creatinine (mg\/dL)\n\n    Females:\n\n    Creatinine CL = Weight (kg) x (140 - Age) (mL\/min) ----------------------------------------- x 0.85 72 x serum creatinine (mg\/dL)\n11. Female patients should be using adequate contraceptive measures (highly effective method of contraception are present in table 3 of protocol \"Highly Effective Methods of Contraception (\\<1% Failure Rate)\"), should not be breastfeeding, from the time of screening throughout the total duration of the drug treatment and the drug washout period (90 days after the last dose of durvalumab monotherapy) or for at least 1 month after last dose of olaparib, or they must totally\/truly abstain from any form of sexual intercourse. Females of childbearing potential are defined as those who are not surgically sterile (ie, bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy) or post-menopausal.\n12. Postmenopausal or evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on day 1.\n\n    Postmenopausal is defined as:\n    * Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments\n    * Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) levels in the post menopausal range for women under 50\n    * radiation-induced oophorectomy with last menses \\>1 year ago\n    * chemotherapy-induced menopause with \\>1 year interval since last menses\n    * surgical sterilisation (bilateral oophorectomy or hysterectomy)\n\n    The following age-specific requirements apply:\n    * Women \\<50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution.\n    * Women \u226550 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \\>1 year ago, had chemotherapy-induced menopause with last menses \\>1 year ago.\n13. Male patients must use a condom during treatment and for 3 months after the last dose of olaparib when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of contraception if they are of childbearing potential. Male patients should not donate sperm throughout the period of taking olaparib and for 3 months following the last dose of Olaparib.\n\nExclusion Criteria:\n\n1. No evidence of disease progression\n2. Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment\n3. Patients not pretreated with durvalumab with curative intent\n4. Patients treated with non-radical radiotherapy or with non conventional radiotherapy\n5. More than 4 cycles of platinum-based chemotherapy\n6. Rapid progressors. Progressors within first 3 month of treatment will be excluded from this trial\n7. Any clinical reason that makes the patient ineligible to receive any investigator's choice single-agent chemotherapy regimen (for patients enrolled in cohorts A and B)\n8. Any clinical reason that makes the patient ineligible to receive any investigator's choice platinum-based doublet chemotherapy regimen (for patients enrolled in cohorts C and D)\n9. Persistent toxicities (\\>Common Terminology Criteria for Adverse Event (CTCAE) grade 2) caused by previous cancer therapy, excluding alopecia.\n10. Patients with myelodysplastic syndrome\/acute myeloid leukaemia or with features suggestive of MDS\/AML.\n11. Disease progression within the first three months of Durvalumab therapy\n12. Tumor tissue not available\n13. Evidence of EGFR mutations or ALK or ROS1 rearrangements\n14. Performance status \\>1 (ECOG)\n15. Brain metastases are allowed if asymptomatic and pretreated. A scan to confirm the absence of brain metastases is not required. The patient can receive a stable dose of corticosteroids before and during the study as long as these were started at least 4 weeks prior to treatment.\n16. Diagnosis of another cancer in the last 3 years, except for in situ carcinoma of cervix, breast and bladder or skin carcinoma (squamous or basaloid)\n17. Patient with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days prior to enrolment..\n18. Leptomeningeal disease.\n19. Resting ECG indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (eg., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, QTcF prolongation \\>500 ms, electrolyte disturbances, etc.), or patients with congenital long QT syndrome.\n20. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Patients with indwelling catheters (e.g., PleurX) are allowed.\n21. Malignancies other than NSCLC within 5 years prior to enrollment, with the exception of those with a negligible risk of metastasis or death (e.g., expected 5-year OS\\> 90%) treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent, grade 1 endometrial carcinoma)\n22. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins and patient with a known hypersensitivity to olaparib or any of the excipient of the product.\n23. Known hypersensitivity or allergy to any component of the Durvalumab formulation\n24. History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, p psoriatic arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener granulomatosis, Sj\u00f6gren's syndrome, Guillain- Barr\u00e9 syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. Patients with: 1) history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone, 2) controlled Type I diabetes mellitus who are receiving a stable dose of insulin regimen and 3) eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only in less than 10% of body surface area, well controlled at baseline and only requiring low potency topical steroids are eligible for this study.\n25. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent.\n26. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.\n27. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.\n28. Positive test for HIV\n29. Patients with active hepatitis B (chronic or acute; defined as having a positive hepatitis B surface antigen \\[HBsAg\\] test at screening) or hepatitis C. Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[HBc Ab\\] and absence of HBsAg) are eligible. HBV DNA must be obtained in these patients prior to randomization. Patients positive for hepatitis C virus (HCV) antibody are eligible only if PCR is negative for HCV RNA.\n30. Active tuberculosis\n31. Concomitant use of known strong CYP3A inhibitors (eg. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg.\n\n    ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting study treatment is 2 weeks.\n32. Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort ) or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting study treatment is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.\n33. Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.\n34. Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT).\n35. Pregnancy or breast feeding women","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05568212001","EMAIL":[{"email":"federico.cappuzzo@ifo.it"},{"email":"lorenza.landi@ifo.it"}],"GEO":[41.89193,12.51133]},{"TITLE":"A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","CRITERIA":"Inclusion Criteria:\n\nKey Inclusion Criteria:\n\n1. Appropriately enrolled in the BASECAMP-1 A2 Biotherapeutics, Inc. study, with tissue demonstrating LOH of HLA-A\\*02 by NGS (whenever possible from the primary site), successful apheresis and PBMC processing, and with sufficient stored cells available for Tmod CAR T-cell therapy\n2. Histologically confirmed recurrent unresectable, locally advanced, or metastatic CRC, NSCLC, PANC, OVCA, MESO, or other solid tumors with MSLN expression. Measurable disease is required with lesions of \\>1.0 cm by CT.\n3. Received previous required therapy for the appropriate solid tumor disease as described in the protocol\n4. Has adequate organ function as described in the protocol\n5. ECOG performance status of 0 to 1\n6. Life expectancy of \u22653 months\n7. Willing to comply with study schedule of assessments including long term safety follow up\n\nKey Exclusion Criteria:\n\n1. Has disease that is suitable for local therapy or able to receive standard of care therapy that is therapeutic and not palliative\n2. Prior allogeneic stem cell transplant\n3. Prior solid organ transplant\n4. MESO with pleural involvement extending into the peritoneum\n5. Cancer therapy within 3 weeks or 3 half lives of A2B694 infusion\n6. Radiotherapy within 28 days of A2B694 infusion\n7. Unstable angina, arrhythmia, myocardial infarction, or any other significant cardiac disease within the last 6 months\n8. Any new symptomatic pulmonary embolism (PE) or a deep vein thrombosis (DVT) within 3 months of enrollment. Therapeutic dosing of anticoagulants is allowed for history of PE or DVT if greater than 3 months from time of enrollment, and adequately treated\n9. History of interstitial lung disease including drug-induced interstitial lung disease and radiation pneumonitis that requires treatment with prolonged steroids or other immune suppressive agents within 1 year\n10. Requires supplemental home oxygen\n11. Females of childbearing potential who are pregnant or breastfeeding\n12. Subjects, both male and female, of childbearing potential who are not willing to practice birth control from the time of consent through 6 months post infusion of A2B694","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06051695009","EMAIL":[{"email":"salman.punekar@nyulangone.org"},{"email":"Peter.Warren@nyulangone.org"}],"GEO":[40.71427,-74.00597]},{"TITLE":"Feasibility of Targeted Bronchial Washing for Molecular Testing by Next Generation Sequencing in Early-stage Lung Cancer","CRITERIA":"1. Inclusion Criteria:\n\n   * Age \u2265 20 years\n   * Obtained written informed consent\n   * Subjects suspected of having resectable lung cancer on computed tomography\n   * Subjects without contraindication to brochoscopy\n   * Subjects planning to undergo surgery for suspected lung cancer and opting for tissue or liquid biopsy for genetic alteration using Next Generation Sequencing\n2. Exclusion Criteria:\n\n   * Subjects who withdraw informed consent\n   * Subjects who are unable to undergo liquid biopsy (plasma) and tissue biopsy - for genetic alteration with Next Generation Sequencing based on the investigator's judgement\n   * Subjects diagnosed with a cancer other than non-small cell lung cancer from the lung tissue lesion\n   * Subjects diagnosed with a benign lesion from the lung tissue lesion","SEX":"ALL","AGE_MIN":20,"AGE_MAX":200,"SS_ID":"06301295001","EMAIL":[{"email":"ejspulm@gmail.com"},{"email":"kshyjt1004@gmail.com"}],"GEO":[35.10278,129.04028]},{"TITLE":"Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation","CRITERIA":"Inclusion Criteria:\n\n* Histologically or cyologically confirmed stage II-IIIa NSCLC patients;\n* NSCLC patients with negative driver gene: EGFR wild-type, no ALK fusion mutation, no ROS1 fusion mutation;\n* ECOG PS: 0\\~1;\n* Pulmonary function index meets the surgical criteria;\n* No previous systemic anti-tumor treatment.\n\nExclusion Criteria:\n\n* Patients with central cavitary squamous cell carcinoma or investigator-assessed bleeding symptoms or bleeding tendency were excluded.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05460195001","EMAIL":[{}],"GEO":[31.22222,121.45806]},{"TITLE":"Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), in Subjects With Tumors With Oncogene Amplifications","CRITERIA":"Key Inclusion Criteria:\n\n* Locally advanced or metastatic non-resectable solid tumors, whose disease has progressed despite all standard therapies or for whom no further standard or clinically acceptable therapy exists,\n* Single agent arm: Evidence of oncogene amplification,\n* BBI-355 combination with erlotinib arm: Evidence of amplification of wildtype EGFR,\n* BBI-355 combination with futibatinib arm: Evidence of amplification of wildtype FGFR1, FGFR2, FGFR3, or FGFR4,\n* Availability of FFPE tumor tissue, archival or newly obtained,\n* Measurable disease as defined by RECIST Version 1.1,\n* Adequate hematologic function,\n* Adequate hepatic and renal function,\n* Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1,\n* Other inclusion criteria per study protocol.\n\nKey Exclusion Criteria:\n\n* Well-known tumor activating oncogene mutations or fusions,\n* Prior exposure to CHK1 inhibitors,\n* BBI-355 combination with erlotinib arm: Prior exposure to EGFR inhibitors,\n* BBI-355 combination with futibatinib arm: Prior exposure to FGFR inhibitors,\n* Hematologic malignancies,\n* Primary CNS malignancy, leptomeningeal disease, or symptomatic active CNS metastases, with exceptions per study protocol,\n* Prior or concurrent malignancies, with exceptions per study protocol,\n* History of HBV, HCV, or HIV infection,\n* Clinically significant cardiac condition,\n* Active or history of interstitial lung disease (ILD) or pneumonitis, or history of ILD or pneumonitis requiring steroids or other immunosuppressive medications,\n* QTcF \\> 470 msec,\n* Prior organ allograft transplantations or allogeneic peripheral blood stem cell\/bone marrow transplantation,\n* Other exclusion criteria per study protocol.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05827614012","EMAIL":"ClinicalDevelopment@boundlessbio.com","GEO":[38.84622,-77.30637]},{"TITLE":"Phase Ib\/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n1. Eighteen years and older;\n2. phase Ib:Histological or cytological diagnosis of Locally advanced or metastatic solid tumors (excluding hepatocellular carcinoma and thyroid carcinoma) that have progressed after standard treatment or are intolerant or have no effective treatment;\n3. phase II cohort 1:Histological or cytological diagnosis of NSCLC\uff0cRCC, HCC, resistance to previous treatment with PD-(L)1 inhibitor; previous system treatment lines\u22642;\n4. phase II cohort 2\uff1aUnresectable locally advanced or metastatic or recurrent RCC;\n5. Tumor tissue samples or biopsies from FFPE archived or fresh biopsies with locally advanced\/metastatic disease must be provided, and if biopsies are not available, samples obtained prior to receiving adjuvant\/neoadjuvant chemotherapy are allowed;\n6. phase Ib and phase II cohort 1: Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1; Phase II cohort 2: Karnofsky physical status (KPS) assessment \u226570\uff1b\n7. Life expectancy of at least 12 weeks;\n8. At least one measurable lesion per RECIST 1.1;\n9. Adequate organ function;\n10. Signed informed consent.\n\nExclusion Criteria:\n\n1. Prior anticancer treatment within 4 weeks prior to the first dose of study drugs;\n2. Toxicity from prior anticancer therapy prior to the first dose of study drugs not recovered to \u2264 grade1;\n3. Hypertension did not satisfactory controlled after antihypertensive medication\n4. Phase Ib\/II: Subjects who were previously treated with Lenvatinib or who participated in a clinical trial of a generic version of Lenvatinib\n5. Phase II cohort 1, intolerance to treatment with A PD-(L)1 inhibitor; History of severe digestive disease that can affect the oral absorption of Lenvatinib\/Sunitinib;\n6. Uncontrollable or significant cardiovascular or cerebrovascular disease;\n7. Active, known history or suspected autoimmune disease;\n8. Have used or require treatment with \\>10 mg\/day of prednisone or an equivalent dose of systemic corticosteroids within 14 days prior to the first dose of study drugs;\n9. have received live attenuated vaccine within 28 days prior to the first study drug treatment or are scheduled to receive it during the study period;\n10. Subjects with known or suspected interstitial pneumonia;\n11. Any serious active infection requiring systemic antibacterial, antifungal or antiviral therapy at screening, including active tuberculosis; Known history of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)\n12. Active hepatitis B or hepatitis C;\n13. Known history of severe gastrointestinal bleeding or active hemoptysis or other severe bleeding within 6 months prior to first study drug therapy;\n14. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage ;\n15. Known active or symptomatic central nervous system (CNS) metastases and\/or carcinomatous meningitis;\n16. Have other primary malignancies within 5 years;\n17. Known history of contraindications or hypersensitivity reactions to any investigational drug component or any known excipients\n18. Women who are pregnant or breastfeeding.\n19. Radiographic evidence of major blood vessel invasion\/infiltration may be considered for enrollment if the investigator assesses that the risk is manageable.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05024214023","EMAIL":[{}],"GEO":[31.22222,121.45806]},{"TITLE":"H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Males or females aged \u2265 18 years at time of signing informed consent form (ICF).\n2. Histological or cytological confirmed diagnosis of unresectable locally advanced or metastatic NSCLC.\n3. Subjects must have NSCLC harboring one or more active EGFR mutations known to be associated with EGFR-TKI sensitivity (including, but not limited to Del19 and L858R).\n\n   * Part A: All subjects may provide tumor sample to central laboratory to analyze the EGFR mutation status according to their own willingness;\n   * Part B: All subjects must provide tumor sample to central laboratory to analyze the EGFR mutation status. And subjects must have NSCLC harboring EGFR C797S mutation.\n\n   Note: Tumor sample can be either an archival sample or a sample obtained by pretreatment biopsy prior to H002 treatment.\n4. \u2022 Part A: Subjects have received the best treatment available as determined by the physician and must have radiological documented disease progression on the last treatment administered prior to enrolling in the study.\n\n   \u2022 Part B: Subjects have received at least one previous EGFR-TKI treatment and have radiological documented disease progression on the previous continuous EGFR-TKI treatment. In addition, subjects may have received other antitumor treatments and must have radiological documented disease progression on the last treatment administered prior to enrolling in the study.\n5. Presence of at least one measurable lesion according to RECIST v1.1 per investigator assessment.\n6. ECOG performance status of 0-1.\n7. Life expectancy \u2265 12 weeks.\n8. Adequate hematologic and organ function per protocol.\n9. Women of childbearing potential (WOCBP) and fertile males with WOCBP partners must use highly effective contraception per protocol throughout the study. WOCBP must have a negative serum and\/or urine pregnancy test result within 7 days prior to the first dose of H002.\n10. Signed ICF, and this must be obtained before the performance of any protocol-specific procedures.\n\nExclusion Criteria:\n\n1. Treatment with any of the following:\n\n   Prior treatment with an EGFR-TKI within 8 days or approximately 5 \u00d7 t1\/2 prior to the first dose of H002, whichever is longer; Prior treatment with immunotherapy or biotherapy within 4 weeks prior to the first dose of H002; Radiotherapy (palliative radiotherapy is completed at least 2 weeks prior to the first dose of H002 can be enrolled) within 4 weeks prior to the first dose of H002; Herbal therapy that has anti-tumor effects within 2 weeks prior to the first dose of H002; Mitomycin and nitrosourea within 6 weeks prior to the first dose of H002; Oral fluorouracil such as tegafur and capecitabine within 2 weeks prior to the first dose of H002; Chemotherapy (except for mitomycin, nitrosourea, and fluorouracil oral drugs), or other anti-tumor drugs for the treatment of NSCLC within 4 weeks or approximately 5 \u00d7 t1\/2 prior to the first dose of H002, whichever is longer.\n2. Subjects with EGFR exon 20 insertion mutations only.\n3. Prior marketed and\/or investigational treatment for EGFR C797S mutation (including, but not limited to BTP-661411, TQB3804 and BLU-945).\n4. Is currently participating and receiving investigational therapy or using an investigational device, or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks or 5 \u00d7 t1\/2 of the investigational product, whichever is longer, prior to the first dose of H002.\n5. Is expected to require any other form of anti-tumor therapy while on study.\n6. Unresolved toxicity greater than CTCAE v5.0 Grade 1 from prior anti-tumor therapy.\n7. \u2265 CTCAE v5.0 Grade 2 skin toxicity at screening.\n8. Treatment with strong inhibitors and strong inducers of CYP3A4 within 2 weeks prior to the first dose of H002, or anticipation of need for such drugs during study treatment.\n9. Uncontrollable pleural effusion, ascites, or pericardial effusion.\n10. Subjects who have symptomatic brain metastases, meningeal metastasis or spinal cord compression.\n11. Subjects who have a chronic or active infection that required systemic treatment within 2 weeks prior to the first dose of H002.\n12. Subjects who have gastrointestinal disorders that will affect oral administration or the investigator judges that the absorption of H002 will be interfered.\n13. History of hypersensitivity to active or inactive excipients of H002 or drugs with a similar chemical structure or class to H002.\n14. Subjects who received a diagnosis of, and\/or tested positive at screening for human immunodeficiency virus (HIV).\n15. Subjects with active hepatitis B.\n16. Presence or history of malignancy other than NSCLC with the exception of some certain early-stage cancers.\n17. Subjects who have clinically significant cardiovascular diseases that occurred within 6 months prior to the first dose of H002, include but not limited to QTc interval \u2265 450 msec (male) or \u2265 470 msec (female).\n18. Major surgery or significant traumatic injury occurring within 4 weeks prior to the first dose of H002 or anticipation of need for a major surgery during the study.\n19. Medical history of ILD.\n20. Medical history of severe eye disease without recovery to CTCAE v5.0 Grade 0 or 1.\n21. Severe gastrointestinal disease within 4 weeks prior to the first dose of H002 and did not recover to \u2264 CTCAE v5.0 Grade 2.\n22. Has any bleeding tendency or coagulopathy within 6 months prior to the first dose of H002.\n23. Administration of a live, attenuated vaccine within 4 weeks prior to the first dose of H002 or anticipation of need for such a vaccine during the study.\n24. Female subjects in pregnancy or lactation.\n25. Any other circumstances that would, in the investigator's judgment, prevent the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05552781008","EMAIL":[{"email":"drzjy@163.com"},{"email":"chenjunjun1985@126.com"}],"GEO":[30.29365,120.16142]},{"TITLE":"Precision Medicine Randomized Clinical Trial Comparing Molecular Tumor Board Assisted Care to Usual Care","CRITERIA":"Inclusion Criteria:\n\n* Clinically suspected or histologically confirmed stage IIb-IV NSCLC who are planning to undergo treatment\n* No prior systemic therapies for NSCLC, with the exception of adjuvant therapy for early stage NSCLC. Prior surgery and\/or radiation is allowed.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\/social situations that would limit compliance with targeted therapy, in the opinion of the treating physician.\n* Pregnancy","SEX":"ALL","AGE_MIN":18,"AGE_MAX":120,"SS_ID":"05254795001","EMAIL":[{}],"GEO":[37.98869,-84.47772]},{"TITLE":"Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Adult \u226518 years old\n* Patient diagnosed with Stage IV NSCLC (de novo or earlier stage progression to stage IV)\n* Absence of oncogene activating mutations eligible patients to targeted therapy (EGFR, ALK)\n* Cohort A: Received first line treatment with pembrolizumab monotherapy\n* Cohort B: Received first line treatment with chemotherapy and pembrolizumab combination therapy\n* Cohort C: Received first line treatment with chemotherapy doublet\n\nExclusion Criteria:\n\n* Prior anti-cancer therapy for actual stage IV NSCLC\n* Critical data missing (e.g., PD-L1 status, baseline millimetric imaging, first evaluation millimetric imaging)\n* Patients participating in other clinical trials that modify the standard of care","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04994795030","EMAIL":[{},{}],"GEO":[39.46975,-0.37739]},{"TITLE":"Consolidation Conventional Radiotherapy + Stereotactic Body Radiotherapy at 3 Months After First-line Chemotherapy in Stage IV Oligometastatic Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Patients with previously untreated, non-resectable, stage IV NSCLC verified with histology or cytology (according to American Joint Committee on Cancer Version 8).\n* Patients must undergo 2-4 cycles of first-line chemotherapy, with the effect of disease stabilization or partial response.\n* Patients over 18 years of age.\n* Patients with measureable disease (on CT, PET\/CT, MRI).\n* Patients with 3-10 extracranial\/intracranial lesions confirmed on CT, PET\/CT, MRI, max. 4 weeks prior to start of SBRT.\n* Max. 10 irradiated volumes (primary tumour + lymphadenopathy in one volume, if technically feasible).\n* Performance status (PS) 0-2 according to ECOG. Assessment of PS max. 7 days prior to start of treatment.\n* AST, ALT \\& ALP \u2264 2.5x norm. Total bilirubin must be within the normal range. 9. Normal function of bone marrow - Adiponectin \u2265 1.5, Haemoglobin \u2265 100, thrombo \u2265 100.\n* Serum creatinine \u22641.5x norm.\n* The entry laboratory tests must not be older than 14 days prior to start of treatment.\n* Negative pregnancy test and use of contraception in women of childbearing age.\n* Patients undergoing SBRT for pulmonary nidi must undergo entry spirometry with the value FEV1 (forced expiratory volume in 1 second) \u2265 1L.\n* Patients must sign informed consent.\n\nExclusion Criteria:\n\n* Patients with small-cell lung cancer or with mixed aetiology with SCLC.\n* Serious ongoing infections.\n* Patients with a history of haematopoiesis disorders.\n* Weight loss exceeding 10% within the last 3 months.\n* Patients with skin metastases of NSCLC.\n* Patients treated for other malignity within the last 5 years\n* Patients with more than 10 extracranial\/intracranial metastases.\n* Malignant fluidothorax \\> 1 cm prior to start of treatment.\n* Patients treated with targeted treatment for EGFR mutation or EML-4-ALK translocation in the 1st-line (Erlotinib, Gefitinib, Afatinib, Crizotinib, ...).\n* Patients treated with immunotherapy (anti-PD-1, anti-PD-L1 or anti-PD-L2, anti CTLA-4, ...).\n* Participation in another clinical trial within the last month before the start of NSCLC treatment.\n* Inability to cooperate or comply with the study protocol.\n* Decision of the patient to discontinue participation in the study.\n* Pregnant women.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04758481001","EMAIL":[{"email":"jiri.hyncica@fno.cz"},{},{},{},{}],"GEO":[49.83465,18.28204]},{"TITLE":"Effect of an Oral Nutritional Supplement on Muscle Mass During Anticancer Treatment","CRITERIA":"Inclusion Criteria:\n\n* Diagnosis of stage III or IV colorectal or non-small cell lung cancer\n* Scheduled for the first cycle of any line of a systemic treatment: chemotherapy, concurrent chemoradiotherapy, immunotherapy or targeted treatment with a planned duration of at least 9 weeks\n* Performance status Eastern Cooperative Oncology Group (ECOG) score 0 or 1\n* Age \u2265 18 years\n\nExclusion Criteria:\n\n* Weight loss \\>10% in the last 6 months\n* Body Mass Index \\> 30.0 kg\/m2\n* Life expectancy \\< 3 months\n* Receiving enteral (tube) or parenteral nutrition\n* Presence of ileostoma or ileal pouch (except for an ileostomy at or near the terminal ileum which does not affect absorption of nutrients other than sodium, potassium, and water, in the opinion of the investigator)\n* Allergy to cow's milk protein, soy or fish, requiring a fibre-free diet or suffering galactosemia or lactose intolerance\n* Known pregnancy or lactation\n* Current alcohol or drug abuse in the opinion of the investigator\n* Wearing an electronic implant and\/or pacemaker\n* Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements\n* Participation in any other studies involving investigational or marketed products concomitantly or within 14 days prior to entry into the study","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05648955001","EMAIL":[{}],"GEO":[51.89797,-8.47061]},{"TITLE":"Dupilumab_Metastatic NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Patients must have a pathologically confirmed diagnosis of NSCLC\n* Patients must have progressed (clinically or radiographically) on or following prior therapy with a PD-1 or PD-L1 targeted antibody\n* Patients may have only 0 or 1 intervening lines of therapy from the prior PD-(L)1 blocking therapy\n* Patient must be willing and able to provide blood samples (12 green-top tubes, roughly 100mL) at the time points indicated in the Study Calendar.\n* Patient must be willing and able to have core needle biopsies, or forceps biopsies if clinically feasible by (Goal 3-6 biopsies, final number to be determined by the interventionalist performing the procedure as safe) of tumor prior to initiation of dupilumab and at the on-treatment time point. Should patients undergo pre-treatment or on-treatment biopsy procedure, and inadequate number of biopsies are obtained, they may proceed with initiation\/continuation of treatment at the discretion of the investigator and treating physician\n* Age \u2265 18 years.\n* ECOG 0-2. The exception will be patients carrying long term disability (such as cerebral palsy) where the disability is not acute nor progressive, and unlikely to significantly affect their response to therapy.\n* Women of child-bearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 3 months following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n* Has not undergone a hysterectomy or bilateral oophorectomy; or\n* Has not been naturally postmenopausal for at least 12 consecutive months\n* Ability to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n* Patients who have had chemotherapy within 14 days from start of therapy.\n* Palliative radiotherapy is permitted at any time, if deemed in the best interest of the patient.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring antibiotics (exception is a brief (\u226410days) course of antibiotics to be completed before initiation of treatment), symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness\/social situations that would limit compliance with study requirements.\n* Patients must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.\n* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. Patients on chronic steroids (more than 4 weeks at stable dose) equivalent to \u2264 10mg prednisone will not be excluded.\n* Has active autoimmune disease that has required systemic treatment in the past 1 year (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is acceptable.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator.\n* HIV positive with detectable viral load, or anyone not on stable anti-viral (HAART) regimen, or with \\<350 CD4+ T cells\/microliter in the peripheral blood.\n* Has known active Hepatitis B (e.g., HBV detected by PCR or active Hepatitis C (e.g., HCV RNA \\[qualitative\\] is detected). Patients with hepatitis B (HepBsAg+) who have controlled infection (serum hepatitis B virus DNA PCR that is below the limit of detection AND receiving anti-viral therapy for hepatitis B) are permitted. Patients with controlled infections must undergo periodic monitoring of HBV DNA. Patients must remain on anti-viral therapy for at least 6 months beyond the last dose of investigational study drug.\n* History of allogeneic hematopoietic cell transplantation or solid organ transplantation.\n* Receipt of a live vaccine within 30 days of planned start of study medication\n* Documented allergic or hypersensitivity response to any protein therapeutics (e.g., recombinant proteins, vaccines, intravenous immune globulins, monoclonal antibodies, receptor traps)Principle investigator believes that for one or multiple reasons the patient will be unable to comply with all study visits, or if they believe the trial is not clinically in the best interest of the patient.\n* History of irAE in response to prior immunotherapy that has not improved to a Grade 0 or 1; this does not include chronic conditions such as endocrinopathies which can be treated with hormone replacement therapy\n* History of interstitial lung disease (e.g., idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis attributed to prior use of cancer immunotherapy that required immune-suppressive doses of glucocorticoids to assist with management. A history of radiation pneumonitis in the radiation field is permitted.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05013450002","EMAIL":[{"email":"Nicholas.Rohs2@mountsinai.org"}],"GEO":[40.71427,-74.00597]},{"TITLE":"Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Age \u226518 and \u226475 years old (calculated based on the date of signing informed consent);\n2. Diagnosed as drug-resistant\/relapsed non-small cell lung cancer;\n3. After at least two systemic treatments and the disease progresses;\n4. According to the efficacy evaluation criteria of solid tumors (RECIST 1.1), at least one lesion that has not received radiation therapy, has not received other local therapies, and can obtain tumor tissue (can be from a single lesion source or multiple lesions combined) is used for organoid establishment;\n5. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-1;\n6. Expected survival time\\>3 months;\n7. Before a tumor sample can be taken, there must be a record of disease progression on imaging after the previous treatment.;\n8. The patient has informed consent and signed a written consent form;\n9. The patients had good compliance and willingly followed the study plan, including scheduled visits, treatments, laboratory tests, and other research steps.\n\nExclusion Criteria:\n\n1. Extremely weakened overall condition, unable to tolerate bronchoscopy examination;\n2. Patients with acute suppurative inflammation of the respiratory tract accompanied by high fever, acute asthma attacks, and ongoing hemoptysis;\n3. Have a history of interstitial lung disease, non infectious pneumonia or uncontrolled systemic diseases, including diabetes, hypertension, pulmonary fibrosis, acute lung disease, etc\n4. Patients with active leptomeningeal disease or brain metastasis;\n5. Diagnosed with other malignant diseases other than NSCLC within 5 years prior to initial administration (excluding curative basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and\/or curative resection of carcinoma in situ);\n6. Have a history of immunodeficiency, including positive HIV serum tests;\n7. Active hepatitis B without treatment (defined as HBsAg positive and HBV-DNA copy number detected is greater than the upper limit of normal value in the laboratory of the research center);\n8. The presence of any serious or uncontrollable systemic diseases;\n9. Pregnant or lactating female patients;\n10. The researchers believe that patients who are not suitable to participate in this study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06406608001","EMAIL":[{"email":"qimingwang1006@126.com"}],"GEO":[34.75778,113.64861]},{"TITLE":"A Trial of AK112 (PD1\/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC","CRITERIA":"Inclusion Criteria:\n\n* 18 to 75 years old (at the time of inform consent obtained).\n* Be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures).\n* Have histologically- or cytologically-confirmed diagnosis of Stage IIIB\/C or IV NSCLC.\n* Be able to provide formalin fixed, paraffin-embedded (FFPE) tumor tissue obtained from either a core or excisional tumor biopsy.\n* Have a life expectancy of at least 3 months.\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by investigator\n* Has adequate organ function\n* All female and male subjects of reproductive potential must agree to use an effective method of contraception, as determined by the Investigator, during and for 120 days after the last dose of study treatment.\n\nExclusion Criteria:\n\n* Is currently participating in a study of an investigational agent or using an investigational device;\n* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy within 2 years prior to the first dose of study treatment;\n* Has undergone major surgery within 30 days prior to the first dose of study treatment;\n* Has a known history of prior malignancy except that basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer\n* Has known active central nervous system (CNS) metastases;\n* Has carcinomatous meningitis\n* Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment NOTE: Subjects with vitiligo or resolved childhood asthma\/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study;\n* Has an active infection requiring systemic therapy;\n* Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \\[qualitative\\] is detected);\n* History of myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or surgery within 12 months prior to day 1 of study treatment;\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of this subject to participate, in the opinion of the treating investigator;\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study\n* Has received a live virus vaccine within 30 days prior to first dose of study treatment\n* Is pregnant, breastfeeding, or expecting to conceive or father a child within the projected duration of the study including 120 days following the last dose of study treatment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"04736823001","EMAIL":[{"email":"zhangli@sysucc.org.cn"},{}],"GEO":[34.75778,113.64861]},{"TITLE":"Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda\u00ae in Stage IV NSCLC","CRITERIA":"Inclusion Criteria:\n\nIndividuals must meet all of the following criteria to be included in the study:\n\n1. Willing and able to provide written informed consent for the study before the initiation of any study-specific procedures.\n2. Greater than or equal to 18 years of age at the time of signing the ICF.\n3. Body weight \u226550 kg at Screening.\n4. Having newly diagnosed stage IV (defined by the eighth edition of the TNM classification) non-squamous NSCLC, without prior systemic treatment for the disease. For those subjects in whom the pleural or pericardial effusion is the only location of metastatic disease, confirmation of its malignant etiology is required.\n5. At least 1 radiographically measurable lesion per RECIST version 1.1, locally assessed.\n6. Programmed death-ligand 1 (PD-L1) expression \u226550%, locally determined by immunohistochemistry, as determined by a Food and Drug Administration (FDA) validated method.\n7. Life expectancy of at least 3 months.\n8. ECOG performance status of 0 to 1.\n9. Adequate hepatic, renal, hematologic, endocrine, and coagulation function, defined as:\n\n   1. Liver function: bilirubin level \u22641.5 \u00d7 the upper limit of normal (ULN) (\u22643 \u00d7 ULN for subjects with Gilbert's syndrome), albumin level \u2265 lower limit of normal (LLN), aspartate aminotransferase (AST)\/alanine aminotransferase (ALT) \u22642.5 \u00d7 ULN in subjects without liver metastases or \u22645 \u00d7 ULN in subjects with liver metastases.\n   2. Renal function: serum creatinine level \u22641.5 \u00d7 ULN, calculated creatinine clearance \u226550 mL\/min (Cockcroft-Gault formula).\n   3. Hematologic function: absolute neutrophil count \u22651.5 \u00d7 109\/L; platelet count \u2265100 \u00d7 109\/L, hemoglobin \u22659 g\/dL.\n   4. Endocrine function: thyroid stimulating hormone (TSH) within normal limits. If TSH is not within normal limits, the subject may still be eligible if T3 and free T4 are within normal limits.\n   5. Coagulation: international normalized ratio (INR) and activated partial thromboplastin time (aPTT) \u2264 1.5 \u00d7 ULN unless subject is receiving anticoagulant therapy. Subjects on anticoagulant therapy must be on a stable anticoagulation regimen and have an INR not above the target therapeutic range for the 14 days before the first dose of the study drug.\n10. Subjects with a negative COVID-19 test (done at the discretion of investigator or per local regulation) within previous 24 hours before randomization. In case of confirmed COVID-19 infection before Screening, documentation of resolution of infection by appropriate laboratory test is required.\n11. No history of prior malignancy, except for basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, or cervical cancer in situ, or has undergone potentially curative therapy without evidence of disease recurrence for 3 years from the start of that therapy.\n12. Women of childbearing potential (WOCBP) must either abstain from sexual intercourse or employ highly effective contraception measures during the study and for at least 6 months after the last dose of the study drug. Highly effective measures include 2 forms of contraception. Postmenopausal or surgically sterile women (ie, hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) are eligible. Postmenopausal status is defined as either: amenorrheic for \u226512 months following cessation of exogenous hormonal treatments and without an alternative medical cause; luteinizing hormone and follicle stimulating hormone levels in the postmenopausal range for women under 50 years of age; radiation-induced ovarian ablation with last menses \u22651 year ago; or chemotherapy-induced menopause with a \u22651-year interval since last menses. Female subjects must refrain from donating or banking eggs (ova, oocytes) and retrieving eggs for use during study treatment and for 6 months after the last dose of the study drug.\n13. Male subjects, if not surgically sterile, must either abstain from sexual intercourse or employ highly effective contraception (condoms or other barrier forms of contraception) during the study and for at least 6 months after the last dose of the study drug. Male subjects should also avoid semen donation or providing semen for in-vitro fertilization during the above mentioned duration.\n\nExclusion Criteria:\n\n1. Unwilling or unable to comply with scheduled visits, drug administration plan, laboratory tests, or other study procedures and study restrictions.\n2. Predominantly squamous cell histology NSCLC. Mixed tumors will be categorized by the predominant cell type; if small cell elements are present, the subject is ineligible.\n3. Participation in another clinical trial or treatment with another investigational agent within 4 weeks or 5 half-lives before randomization, whichever is longer.\n4. Known actionable mutations for which there is an approved and available therapy.\n5. Known central nervous system metastases and\/or carcinomatous meningitis.\n6. Previous systemic steroid therapy (prednisone at a dose of 10 mg or equivalent) within 3 days before the first dose of the study drug or receiving any other form of immunosuppressive medication. Subjects receiving daily steroid replacement therapy (daily prednisone at a dose of 5 to 7.5 mg or equivalent) could be included in the study.\n7. Subject who requires any other form of localized or systemic antineoplastic therapy during the study.\n8. Prior anti-programmed cell death-1 (anti-PD-1), anti-PD-L1, anti programmed death-ligand 2 (anti-PD-L2), anti-CD137, or anti cytotoxic T lymphocyte antigen (CTLA)-4 therapy (including ipilimumab or any other antibody or drug that specifically targets co stimulation of T cells or immune checkpoints).\n9. Prior systemic cytotoxic chemotherapy, biological therapy, or major surgery within 3 weeks before the first dose of the study drug; have received thoracic radiation therapy of \\>30 gray (Gy) within 6 months before the first dose of the study drug. Palliative radiotherapy is allowed if completed \\>14 days before the first dose of the study drug.\n10. Known history of severe hypersensitivity to another monoclonal antibody.\n11. Active autoimmune disease which has required systemic treatment in the last 2 years before the first dose of the study drug (eg, disease modifying agents, corticosteroids, or immunosuppressive treatment). Replacement therapy (eg, thyroxine, insulin, or physiological corticosteroid replacement therapy for pituitary or adrenal insufficiency) is not considered a form of systemic treatment.\n12. Interstitial lung disease or pneumonitis requiring oral or intravenous steroids.\n13. Active infection or a previous infection requiring intravenous systemic treatment within 30 days before the first dose of the study drug.\n14. Subject who has received or is about to receive a live virus vaccination within 30 days before the first dose of the study drug. Seasonal flu and COVID-19 vaccines that do not contain live virus are permitted.\n15. Known history of human immunodeficiency virus (HIV)-1 or HIV-2.\n16. Known active tuberculosis or hepatitis B (hepatitis B surface antigen \\[HBsAg\\] positive) or hepatitis C (hepatitis C antibody positive and hepatitis C virus \\[HCV\\] RNA positive).\n17. Subject who has received a solid organ\/tissue allogeneic transplant.\n18. Known psychiatric disorders that could interfere with cooperation with study requirements.\n19. At the time of signing the ICF, the subject is a regular user (including \"recreational use\") of any illicit drug or has a recent history (within the past year) of substance abuse (including alcohol).\n20. Subject is pregnant or lactating or expecting to conceive during the study or up to 120 days after the last dose of the study drug.\n21. Immediate family member who is at the research site or sponsoring staff who is directly involved in this study","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05668650001","EMAIL":[{"email":"marcelo.guthmann@elea.com"}],"GEO":[-40.81345,-62.99668]},{"TITLE":"Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab","CRITERIA":"Inclusion Criteria:\n\n* Age \u226518 years\n* Histologically confirmed diagnosis of NSCLC (squamous or nonsquamous) with KRAS G12C mutation.\n\n  * Diagnostic core biopsy specimens must be reviewed by a faculty pathologist at the enrolling\/treating institution, and biopsy tissue must be available for further biomarker evaluation. If no archived tissue is available, patients will require a repeat biopsy prior to initiation of study treatment. See section 6.5.1 and lab manual for details of pretreatment biopsy tissue required.\n  * KRAS G12C mutation determined by any CLIA-certified testing platform on patient tumor tissue or plasma sample.\n* Stage IB-IIIA NSCLC\n\n  * T2aN0, T3N0, T1-2N1, T3-4N1, T1-2N2. This includes T2aN0 tumors \u22653 cm. Subjects with N3 nodal involvement are not included.\n* Primary resection option for potential cure as assessed by a faculty surgeon at treating institution.\n* ECOG performance status 0-1 (See Appendix B)\n* Adequate organ function within the screening period as follows:\n\n  * Leukocytes \u2265 2,000\/mm3\n  * Absolute neutrophil count (ANC) \u2265 1000\/mm3\n  * Platelet count \u2265 100,000\/mm3\n  * Hemoglobin \u2265 9 g\/dL\n  * Creatinine \u2264 1.5 x institutional upper limit of normal (ULN) or creatinine clearance (CrCl) \u226560 mL\/min\n  * Total Bilirubin \u2264 1.5 x institutional ULN (except subjects with Gilbert Syndrome, who can have total bilirubin \\< 3.0 mg\/dL)\n  * AST(SGOT), ALT(SGPT), and alkaline phosphatase \u2264 3 x institutional ULN\n* Pulmonary Function Testing to include DLCO must be performed to determine feasibility of surgical resection.\n* Women of child-bearing potential (WOCBP):\n\n  * Agree to use contraception while participating in this study, and for a period of 6 months following last dose of Adagrasib or nivolumab, as effects of these agents on the developing human fetus are unknown. Men whose partner is a WOCBP must also agree to use contraception during this period.\n  * Negative pregnancy test (minimum sensitivity 25 IU\/L or equivalent units of HCG) within two weeks of registration.\n  * Women must not be breastfeeding or plan to breastfeed for the duration of therapy or 6 months after.\n* Completed informed consent process, including signing IRB\/EC-approved informed consent form.\n* Willing and able to comply with clinical trial instructions and requirements. Subjects must be competent to report AEs, understand the drug dosing schedule, and use of medications to control AEs.\n\nExclusion Criteria:\n\n* Patients presenting with any of the following will not be included in the study:\n\n  * NSCLC not amenable to curative intent resection based on evaluation by faculty surgeon at treating institution.\n\n    * This includes any patient with pathologically confirmed N3 disease.\n  * Prior systemic treatment for lung cancer including chemotherapy, immune checkpoint inhibitor therapy, or a therapy targeting KRAS G12C mutation.\n  * Prior thoracic radiation.\n  * Any concurrent malignancies for which active therapy is being received.\n\n    * Exceptions: non-melanoma skin cancers; in situ dysplasia of the bladder, gastric, breast, colon, or cervix\n  * Brain metastases at time of screening.\n\n    * All patients must have brain imaging prior to enrollment (MRI brain or CT brain with contrast preferred).\n  * Active or prior documented autoimmune or inflammatory disease as follows (Arm B only):\n\n    * Medically relevant autoimmune disease requiring systemic treatment within 2 years prior to the first dose of study treatment.\n  * Systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration (Arm B only). Inhaled or topical steroids are permitted.\n\n    * Adrenal replacement doses \\> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.\n  * Major surgery within 4 weeks prior to first dose of study treatment.\n  * History of allogeneic transplant or primary immunodeficiency.\n  * Uncontrolled human immunodeficiency virus (HIV) infection or acute or chronic hepatitis B or C infection.\n\n    * Patients treated for hepatitis C with no detectable viral load and patients treated for HIV with no detectable viral load for at least 1 month while on a stable regimen of agents that are not strong inhibitors of CYP3A4 are permitted.\n    * HIV testing is not required in absence of clinical suspicion of HIV.\n  * Any of the following cardiac abnormalities:\n\n    * Unstable angina pectoris or myocardial infarction within the past 6 months.\n    * Symptomatic or uncontrolled atrial fibrillation within the past 6 months.\n    * Congestive heart failure \u2265NYHA Class 3 within the past 6 months.\n    * QTc \u2265 480 msec in screening ECG measured using standard institutional method or history of familial long QT syndrome.\n  * Ongoing need for a medication with any of the following characteristics that cannot be switched to alternative treatment prior to study entry (see Appendix D): known risk of Torsades de Pointes; substrate of CYP3A with narrow therapeutic index; strong inducer or inhibitor of CYP3A and\/or P-gp; strong inhibitor of BCRP; and proton pump inhibitors.\n  * History of stroke or transient ischemic attack within 6 months prior to first dose of study treatment.\n  * History of intestinal disease or major gastric surgery likely to alter absorption of study treatment or inability to swallow oral medications.\n  * Underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity or adverse events.\n  * Women who are pregnant or nursing.\n  * Prisoners or subjects who are involuntarily incarcerated or compulsorily detained for treatment of either a psychiatric or physical (e.g. infectious disease) illness.\n  * Receipt of a live vaccine within 30 days prior to first dose of study treatment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05472623001","EMAIL":[{"email":"ifaldu1@jh.edu"},{"email":"amichal2@jh.edu"},{}],"GEO":[39.29038,-76.61219]},{"TITLE":"Study of Pembrolizumab\/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab\/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006\/KEYVIBE-006)","CRITERIA":"The main inclusion and exclusion criteria include but are not limited to the following:\n\nInclusion Criteria\n\n* Has pathologically (histologically or cytologically) confirmed diagnosis of NSCLC.\n* Has Stage IIIA, IIIB, or IIIC NSCLC by American Joint Committee on Cancer Version 8\n* Is determined to have unresectable, Stage III NSCLC as documented by a multidisciplinary tumor board or by the treating physician in consultation with a thoracic surgeon\n* Has no evidence of metastatic disease, indicating Stage IV NSCLC, in whole-body fluorodeoxyglucose (FDG)-positron emission tomography (PET) or FDG-PET\/ computed tomography (CT) and CT or magnetic resonance imaging (MRI) scans of diagnostic quality of chest, abdomen, pelvis and brain\n* Has measurable disease as defined by RECIST 1.1, with at least 1 lesion being appropriate for selection as a target lesion, as determined by local site investigator\/radiology review\n* Has not received prior treatment (chemotherapy, targeted therapy, or radiotherapy) for their Stage III NSCLC\n* Has provided tumor tissue sample (tissue biopsy \\[core, incisional, or excisional\\])\n* Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 assessed within 7 days prior to the first administration of study intervention\n* Has a life expectancy of at least 6 months\n\nExclusion Criteria\n\n* Has small cell lung cancer (SCLC) or tumors with the presence of small cell elements. Mixed squamous\/nonsquamous tumors are eligible\n* Has received prior radiotherapy to the thorax, including radiotherapy to the esophagus, mediastinum, or for breast cancer\n* Has received major surgery (with the exception of replacement of vascular access) within 4 weeks before randomization. If the participant had a major operation, the participant must have recovered adequately from the procedure and\/or any complications from the operation before starting study intervention\n* Is expected to require any other form of antineoplastic therapy, while on study\n* Has received colony-stimulating factors (e.g., Granulocyte Colony-Stimulating Factor \\[G-CSF\\], Granulocyte Macrophage Colony-Stimulating Factor \\[GM-CSF\\], or recombinant erythropoietin) within 28 days prior to the first dose of study intervention\n* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication\n* Has a known additional malignancy that is progressing or has required active treatment within the past 5 years\n* Has an active autoimmune disease that has required systemic treatment in past 2 years\n* Has a history of (noninfectious) pneumonitis\/interstitial lung disease that required steroids or has current pneumonitis\/interstitial lung disease\n* Has an active infection requiring systemic therapy\n* Has a known history of human immunodeficiency virus (HIV) infection\n* Has a known history of Hepatitis B (defined as hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV ribonucleic acid \\[RNA\\] qualitative is detected) infection\n* Has had an allogenic tissue\/solid organ transplant\n\nPemetrexed-specific Criteria:\n\n* Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose \u22641.3 grams per day, for at least 2 days (5 days for long-acting agents \\[for example, piroxicam\\]) before, during, and for at least 2 days after administration of pemetrexed\n* Is unable\/unwilling to take folic acid, vitamin B12, and dexamethasone","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05298423143","EMAIL":[{}],"GEO":[50.45466,30.5238]},{"TITLE":"Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Participant or legal representative is able to provide written informed prior to performing any protocol-related procedures\n* Is willing and able to comply with scheduled visits, treatment schedule, laboratory testing and other requirements of the study\n* Men or women at least 18 years of age with histologically or cytologically confirmed non-small cell lung cancer\n* Previous history of other than lung cancer is allowed if no active treatment for that cancer within 1 year\n* Life expectancy of at least 6 months\n* De novo stage IV or recurrent NSCLC without actionable mutation (e.g. EGFR\/ ALK\/ ROS-1) that was previously treated with either PD-1 \/ PD-L1 or the combination of PD1\/PDL1 and cytotoxic chemotherapy, no more than 2 systemic regimens for metastatic disease with measurable disease \\*. Maintenance therapy will be considered part of the 1 regimen\n* At least 1 measurable lesion\n* PDL1 TPS score less than 1% or unknown: first-line must be PD1\/PDL1 inhibitor in combination with chemotherapy\n* Early stage (I-III) NSCLC treated with adjuvant or neoadjuvant chemotherapy then PD1\/PDL1 inhibitor treatment for recurrent disease\n* Recurrent Unresectable stage III NSCLC treated with prior chemoradiation followed by maintenance PD1\/PDL1 inhibitor with measurable disease\n* Eastern Cooperative Group (ECOG) Performance Status 0 - 2\n* Is able to swallow oral medications\n* Adequate hematologic function\n* Adequate organ function\n\nExclusion Criteria:\n\n* The presence of any other concurrent severe and\/or uncontrolled medical condition that would, in the investigator or treating physician's judgement, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol\n* Has received investigational agents within 14 days or 5 half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment\n* Has a known hypersensitivity to atezolizumab or pirfenidone\n* Has active medical or psychiatric illness that would interfere with the study treatment\n* Has uncontrolled diabetes\n* Has any of the following cardiac diagnoses:\n\nUnstable angina Myocardial infarction within 6 months Uncontrolled congestive heart failure Left ventricular ejection fraction \\< 35%\n\n* Has a history of any Grade 3 or 4 toxicities to a prior checkpoint inhibitor treatment\n* Is pregnant or breast feeding\n* Uncontrolled HIV\n* Clinically diagnosed with grade 2 or 3 radiation-induced lung injury within the last 3 months prior to registering for the study\n* Has a history of idiopathic pneumonitis that required systemic agent including steroid\n* Has drug-induced pneumonitis\n* Has evidence of active pneumonitis on screening chest computed tomography (CT) scan\n* Smoker of more than 1 pack \/ day\n* Has active peptic ulcer diagnosed within 4 weeks of enrollment\n* Active infection requiring systemic treatment\n* Current use of systemic antibacterial or antifungal agent\n* Prior monoclonal antibody within 4 weeks before study Day 1 Exception: The use of denosumab\n* Patient not recovered to \u2264 Grade 1 from AEs due to agents administered more than 4 weeks earlier\n* Concurrent use of other investigational agents\n* Uncontrolled or symptomatic brain metastasis or leptomeningeal disease that requires use of steroids\n* Use of strong CYP1A2 inhibitors\n* Previous history of cancer with active treatment within less than 1 year of enrollment\n* Active auto-immune diseases","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04467723002","EMAIL":[{"email":"kucc_navigation@kumc.edu"}],"GEO":[39.11417,-94.62746]},{"TITLE":"99mTc-H7ND SPECT\/CT Imaging in NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Patients aged from 18 to 80 years old;\n2. patients with NSCLC confirmed by needle aspiration cytology or surgical pathology, who cannot undergo radical surgery due to recurrence, metastasis or patient's own conditions;\n3. Has completed 2-4 cycles of first-line therapy (including chemotherapy, immunotherapy, chemotherapy combined with immunotherapy, chemotherapy combined with targeted therapy, etc.), and has SD assessed by RECIST 1.1 during the same period;\n4. Patients had at least one measurable lesion;\n5. No local radiotherapy for primary or metastatic lesions within 28 days;\n6. ECOG score 0-2;\n7. Expected survival time \u22653 months;\n8. Voluntarily participate and sign informed consent.\n\nExclusion Criteria:\n\n1. Women who plan to become pregnant within 6 months, or are pregnant or lactating.\n2. Patients with severe brain or bone metastases;\n3. Severe anemia and severe liver and kidney damage;\n4. Pathological or long-term follow-up results may not be available;\n5. The relevant control imaging data and clinical data were not available;\n6. Severe illness is difficult to cooperate (such as acute cardiovascular and cerebrovascular events or serious cardiovascular diseases);\n7. Received any surgery or invasive treatment or procedure within 4 weeks before enrollment;\n8. Cannot tolerate standard second-line therapy or other first-line therapies.\n9. Known allergy to 99mTc-H7ND or any of its components; He had a history of severe allergies;\n10. Protocol imaging contraindications were present;\n11. The investigator considered it inappropriate to participate in the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"05999214001","EMAIL":[{"email":"jacky_mg@xjtufh.edu.cn"},{"email":"lixinru@xjtu.edu.cn"}],"GEO":[34.25833,108.92861]},{"TITLE":"Prophylactic Cranial Irradiation Versus Observation in Stage IV NSCLC Randomized Controlled Clinical Study","CRITERIA":"Inclusion Criteria:\n\n* Patients with pathologically or cytologically confirmed NSCLC; patients with clinical stage IV and no brain metastases \\[AJCC 8th edition\\]; no previous treatment\n* Age 18 \\~ 80 years old, body condition score ECOG 0 \\~ 2 or KPS\u226570;\n* No contraindications such as radiotherapy, EGFR-TKI, chemotherapy, or immunotherapy;\n* IMRT is required for primary tumor radiotherapy. DT: 60-70Gy\n* Metastases are treated with three-dimensional radiotherapy (IMRT\/SRT\/SBRT\/VMAT, etc.) and large segmentation radiotherapy.\n* The subject must have no major organ dysfunction or laboratory tests that meet the following requirements:\n* Hematological tests such as liver and kidney function were in the normal range of laboratory standards;\n* Cardiac function: electrocardiogram excluded organic arrhythmia;\n* Pulmonary function test: FEV1\\>50%, mild-moderate lung function limited.\n* Signed informed consent before treatment (radiotherapy, chemotherapy, immunization, targeted drug therapy); The patient had good compliance with the treatment and follow-up received.\n\nExclusion Criteria:\n\n* Patients with brain metastasis;\n* Stage IV NSCLC patients with malignant pleural effusion, pericardial effusion and other serous effusion;\n* Patients with extensive liver metastasis and intrapulmonary metastasis that have seriously affected liver and lung function;\n* Patients with uncontrolled hypertension, diabetes, unstable angina, history of myocardial infarction, or symptomatic congestive heart failure or uncontrolled arrhythmia within the past 12 months; Have a clinically clear diagnosis of heart valve disease; The disease active phase of bacterial, fungal, or viral infection; Mental disorders; Severe impaired lung function;\n* Pregnant or lactating patients;\n* Patients with a history of active malignancy other than small cell lung cancer prior to enrollment; Non-melanoma skin basal cell carcinoma, in situ cervical cancer, cured early prostate cancer excepted;\n* Patients with an allergy and known or suspected allergy to any investigational drug for which no alternative medicine is available;\n* Patients with poor compliance;\n* Researchers consider it inappropriate to participate in this experiment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"06014450001","EMAIL":[{"email":"574679514@qq.com"}],"GEO":[26.58333,106.71667]},{"TITLE":"A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)","CRITERIA":"Inclusion Criteria:\n\n1. Male or female \\>= 70 years of age.\n2. Histological documentation of primary squamous or non squamous non-small cell lung carcinoma.\n3. Availability of archived tumor tissue block or newly cut unstained slides for PD-L1 determination.\n4. Stage IV or IIIB disease with supraclavear metastatic nodes (according to TNM 7th edition).\n5. Clinical or radiologic evidence of disease (at least one measurable or non measurable lesion).\n6. ECOG performance status 0 to 1.\n7. Life expectancy \\> 3 months.\n8. Adequate renal and hepatic function, defined as:\n\n   1. Total serum bilirubin \u2264 1.5 institutional ULN.\n   2. AST and\/or ALT \u2264 2.5 x ULN for the institution (or \u2264 5 x ULN if liver metastases are present)\n   3. Serum creatinine \u2264 1.5 x ULN for the institution (or calculated creatinine clearance \u2265 40 mL\/min\/1.73 m2).\n9. Adequate bone marrow function, defined as:\n\n   1. Haemoglobin \\<= 9.0 g\/dL\n   2. Absolute neutrophils count (ANC) \\>= 1.5 x 109\/L (\\> 1500 per mm3)\n   3. Platelet count \\<= 100 x 109\/L(\\>100,000 per mm3).\n10. Written informed consent obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.\n\nExclusion Criteria:\n\nCancer related\n\n1. Activating epidermal growth factor receptor mutation (exon19 deletion or exon 21 L858R mutation or other activating\/sensitizing mutations).\n2. ALK or ROS1 positive (immunohistochemistry or FISH)\n3. Mixed small-cell lung cancer and NSCLC histology.\n\n   Prior, current or planned treatment related\n4. Prior chemotherapy or any other medical treatment for advanced NSCLC (previous neoadjuvant or adjuvant chemotherapy is allowed if \\> 6 months previously).\n5. Prior exposure to immunomodulatory therapy, including, but not limited to, other anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), anti-programmed cell death1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti PD-L2 antibodies.\n6. Current or prior use of immunosuppressive medication within 14 days before the first dose of study treatment (intranasal and inhaled corticosteroids at physiological doses not exceeding 10 mg\/day of prednisone or an equivalent corticosteroid are allowed).\n7. Any concurrent investigational product or other anticancer treatment.\n\n   Prior or concomitant conditions or procedures related\n8. Active or prior documented autoimmune disease within the past 2 years (subjects with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment within the past 2 years, are not excluded).\n9. Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)\n10. History of allogeneic organ transplant\n11. History of active primary immunodeficiency.\n12. Active infection, including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1\/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n13. Receipt of live attenuated vaccine within 30 days prior to the first dose of study drugs.\n14. Patients with previous malignancies (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer or surgically resected prostate cancer with normal PSA) are excluded only if the histological diagnosis of the current disease does not definitely support the pulmonary origin.\n15. Brain metastases or spinal cord compression, unless asymptomatic, previously treated, and stable off steroids and anti-convulsants for at least one month prior to study entry.\n16. Leptomeningeal carcinomatosis\n17. Clinically significant cardiovascular disease, including:\n\n    1. Myocardial infarction or unstable angina pectoris within \\< 6 months prior to the first study treatment\n    2. New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF)\n    3. Uncontrolled hypertension\n    4. Serious cardiac arrhythmia requiring medication (with the exception of atrial fibrillation or paroxysmal supraventricular tachycardia)\n    5. Peripheral vascular disease \\> grade 3 (i.e. symptomatic and interfering with activities of daily living requiring repair or revision)\n    6. Mean QT interval corrected for heart rate (QTc) \u2265470 ms calculated from 3 electrocardiograms (ECGs) using Fredericia's Correction.\n18. Serious active infection requiring i.v. antibiotics at enrollment.\n19. Known hypersensitivity to any of the study drugs or excipients.\n20. Evidence of any other concomitant pathologies, physical examination or laboratory findings (including but not limited to active peptic ulcer disease or gastritis, active bleeding diatheses or psychiatric illness) or social situation that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment related complications.\n21. Radiotherapy treatment to the chest or to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study treatment (patients who have had radiotherapy \u2265 4 weeks prior to the first dose of study treatment, but who are still experiencing acute toxic effects of radiotherapy are also excluded).\n22. Major surgical procedure within 28 days prior to the first dose of study drugs.\n23. Male patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of study treatment.","SEX":"ALL","AGE_MIN":70,"AGE_MAX":200,"SS_ID":"03975114001","EMAIL":[{"email":"a.morabito@istitutotumori.na.it"}],"GEO":[40.85216,14.26811]},{"TITLE":"Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)","CRITERIA":"Inclusion Criteria:\n\n* Written informed consent according to ICH-GCP regulations before registration and prior to any trial specific procedures.\n* Histologically (cytology is accepted if histology is not possible) confirmed NSCLC (adeno-, squamous-, large cell carcinoma, or NSCLC not otherwise specified (NOS)) irrespective of genomic aberrations or PD-L1 expression status.\n* Tumor stage T1-4\\>7 N2 M0 (i.e. T1-3 N2 or T4 N2 but T4 only allowed if due to size \\> 7cm, not allowed if due to invasion or nodule in different ipsilateral lobe), according to the TNM classification, 8th edition, December 2016 (see Appendix 2). Mediastinal lymph node staging has to follow the process chart.\n* Tumor is considered resectable based on a multidisciplinary tumor board decision made before neoadjuvant treatment. Resectable is when a complete resection can be achieved according to Rami-Porta\n* Patients with a prior malignancy (except NSCLC) and treated with curative intention are eligible if all treatment of that malignancy was completed at least 2 years before registration and the patient has no evidence of disease at registration. Less than 2 years is acceptable for malignancies with low risk of recurrence and\/or no late recurrence, after consultation with CI.\n* Measurable disease per RECIST v1.1 criteria by PET\/CT with contrast enhanced CT-scan.\n* Tumor tissue is available for the mandatory translational research (formalin-fixed; preferably histology, cytology allowed if histology is not possible)\n* Age 18-75 years at time of registration\n* WHO performance status 0-1\n* Adequate bone marrow function: absolute neutrophil count \u2265 1.5 x 109\/L, platelet count \u2265 100 x 109\/L, hemoglobin \u2265 90 g\/L (transfusion allowed)\n* Adequate hepatic function: total bilirubin \u2264 1.5 x ULN (except for patients with Gilbert's disease \u2264 3.0 x ULN), AST and ALT \u2264 1.5 x ULN, AP \u2264 2.5 x ULN.\n* Adequate renal function: calculated creatinine clearance \u2265 60 mL\/min, according to the formula of Cockcroft-Gault\n* Appropriate lung function based on the ESTS guidelines:\n\n  * For pneumonectomy: FEV1 and DLCO \u226580%. If one of both \\<80%, an exercise test peak VO2 \\>75% or 20ml\/kg\/min is needed\n  * For resection less than pneumonectomy (resection up to the calculated extent): exercise test peak VO2 \u226535% or \u226510ml\/kg\/min, with predicted postoperative FEV1 and DLCO \u2265 30%.\n  * NB: if Spiroergometry would be needed according to ESTS guidelines but is not possible in due time due to patient factors or the center's resources alternative assessment methods of fitness for resection can be used (e.g. Stair climbing test, V\/P scan)\n* Adequate cardiac function according to investigator's decision based on evaluation of risk according to NYHA classification\n* Women of childbearing potential must use highly effective contraception, are not pregnant or lactating and agree not to become pregnant during trial treatment and until 90 days after the last dose of investigational drug. A negative pregnancy test performed within 7 days before registration is required for all women of childbearing potential.\n* Men agree not to donate sperm or to father a child during trial treatment and until 90 days after the last dose of investigational drug.\n\nExclusion criteria:\n\n* Presence of any distant metastasis or N3 disease. Brain metastases have to be excluded by CT or MRI.\n* Sulcus superior tumors (Pancoast tumors) or T4 for any other reason than size \\>7cm.\n* Any previous treatment for NSCLC\n* Any previous treatment with immune checkpoint inhibitors, including durvalumab\n* Previous radiotherapy to the chest (with the exception of tangential breast irradiation with minimal dose to lung and mediastinum, and superficial orthovoltage or electron irradiation of localized skin lesions)\n* Concomitant or recent (within 30 days of registration) treatment with any other experimental drug and\/or enrollment in another clinical trial.\n* Concomitant use of other anti-cancer drugs or radiotherapy.\n* Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or IV) unstable angina pectoris, history of myocardial infarction within the last three months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia), uncontrolled hypertension.\n* Preexisting peripheral neuropathy (\\> Grade 1)\n* Body weight less than 30 kg\n* Known history of human immunodeficiency virus (HIV) or active chronic Hepatitis C or Hepatitis B virus infection or any uncontrolled active systemic infection requiring intravenous (iv) antimicrobial treatment.\n* Known history of allogeneic organ transplant\n* Active autoimmune disease or a syndrome requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease. Exceptions: vitiligo, resolved childhood asthma\/atopy, hypothyroidism stable on hormone replacement, Sj\u00f6gren's syndrome\n* Active or prior documented inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis)\n* Concomitant or prior use of immunosuppressive medication within 28 days before registration, with the exceptions of intranasal and inhaled corticosteroids, or systemic corticosteroids which must not exceed 10 mg\/day of prednisone or a dose equivalent corticosteroid, and the premedication for chemotherapy\n* Any concomitant drugs contraindicated for use with the trial drugs according to the approved product information.\n* Known hypersensitivity to trial drugs (cisplatin and docetaxel, durvalumab) or to any excipient\n* Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"04245514013","EMAIL":[{"email":"mathias.schmid@triemli.zuerich.ch"},{}],"GEO":[47.36667,8.54999]},{"TITLE":"A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and\/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation","CRITERIA":"Key Inclusion Criteria:\n\n* Age \u226518 years\n* Diagnosed with NSCLC, Colorectal adenocarcinoma, Pancreatic adenocarcinoma, Endometrial Cancer or any other solid tumor\n* Tumors must harbor a KRAS G12D variant mutation and subject must be HLA-C\\*08:02 positive\n* Subject has advanced solid cancer, defined as unresectable, advanced, and\/or metastatic disease (Stage III or IV) after at least 1 line of approved systemic standard of care (SOC) treatment regimen and for which there are no available curative treatment options.\n* Presence of at least 1 measurable lesion per RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at the time of enrollment\n\nKey Exclusion Criteria:\n\n* Any other primary malignancy within the 3 years prior to enrollment (except for non-melanoma skin cancer, carcinoma in situ (eg, cervix, bladder, breast) or low-grade prostate cancer\n* Known, active primary central nervous system (CNS) malignancy\n* History of prior adoptive cell and gene therapy, allogeneic stem cell transplant or solid organ transplantation.\n* History of stroke or transient ischemic attack within the 12 months prior to enrollment.\n* History of clinically significant cardiac disease within the 6 months prior to enrollment or heart failure at any time prior to enrollment.\n* Systemic therapy within at least 2 weeks or 3 half-lives, whichever is shorter, prior to enrollment.\n* Any form of primary immunodeficiency.\n* Active immune-mediated disease requiring systemic steroids or other immunosuppressive treatment (except if related to prior checkpoint inhibitor therapy)\n* Female of childbearing potential who is lactating or breast feeding at the time of enrollment","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06218914007","EMAIL":[{"email":"lwinkowski@mcw.edu"},{"email":"kwendorf@mcw.edu"},{}],"GEO":[43.0389,-87.90647]},{"TITLE":"Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Subject type and disease characteristics\n\n  1. Suffer from NSCLC diagnosed by pathology (histology or cytology).\n  2. Have stage IIIA, IIIB, or IIIC NSCLC diagnosed according to the 8th edition of the American Joint Committee on Cancer.\n  3. It is confirmed and recorded by the multidisciplinary oncology committee or the treating physician and the thoracic surgeon to have stage III NSCLC that cannot accept radical surgery.\n  4. In whole-body fluorodeoxyglucose (FDG)-PET or FDG-PET\/CT and diagnostic-quality CT or MRI scans of the chest, abdomen, pelvis, and brain, there is no evidence of metastatic disease as stage IV NSCLC.\n\n     Note: Unless otherwise proven, the presence of pleural\/pericardial effusion is considered to indicate metastatic disease. For the presence of pleural effusion in both the CT chest scan and the chest X-ray in the front view, thoracentesis is required to confirm that the pleural effusion is cytologically negative. Exclude participants whose effusion is exudate, even if the effusion is cytologically negative. Subjects who have met the remaining inclusion\/exclusion criteria and whose pleural effusion is not visible on chest X-rays in the front and side views, or who have too little effusion to be safely extracted can enter the study.\n  5. Suffer from a measurable disease defined by RECIST 1.1, and at least one lesion is suitable as a target lesion (determined by the investigator\/imaging review of the local research center).\n  6. No previous treatment (chemotherapy, targeted therapy or radiotherapy) for stage III NSCLC.\n  7. A tumor tissue sample (tissue biopsy \\[thick needle biopsy, excision biopsy, or excision biopsy\\]) is provided. The tissue block of FFPE is better than the slice. The newly obtained tumor sample is better than archived tissue and should be obtained before chest imaging at screening.\n\n     Note: If an unstained section is submitted, the new section must be submitted to the testing laboratory within 14 days of preparation.\n  8. The ECOG performance status assessed within 7 days before the first dose of the study intervention is 0 or 1 point.\n  9. The life expectancy is at least 6 months.\n  10. Sufficient PFT is defined as FEV1\\> 50% of predicted normal expiratory volume and lung carbon monoxide diffusion volume (DLCO)\\> 40% of predicted normal value. For subjects without DLCO measurement values, if the measured pulse oximetry (O2 saturation) in indoor air is \u226590%, it will be deemed to have sufficient oxygen transmission.\n  11. Have adequate organ functions, as defined in Table 1; all laboratory tests during the screening period should be completed 10 days before the start of the research intervention.\n\n      1. ANC \u2265 1.5\u00d7109\/L;\n      2. HB \u2265 90 g\/L;\n      3. PLT \u2265 100\u00d7109\/L;\n\n      The biochemical inspection must meet the following standards:\n      1. TBIL \u2264 1.5ULN;\n      2. ALT, AST\u2264 2.5 ULN;\n      3. Serum creatinine sCr\u22641.5ULN, endogenous creatinine clearance \u226550ml\/min (Cockcroft-Gault formula);\n      4. Coagulation function must meet: INR\u22641.5 and APTT\u22641.5ULN;\n      5. Heart color Doppler ultrasound LVEF\u226550% Demographics\n  12. Men or women who are at least 18 years old and up to 120 years old (including 18 and 120 years old) when signing the informed consent form.\n\n      Male subjects The contraceptive measures used by men should comply with the local regulations regarding contraceptive measures participating in clinical research.\n  13. Male subjects must agree to take contraceptive measures during treatment and at least 180 days after the last dose of the study intervention.\n\n      Note: Male subjects must avoid donating sperm during treatment and for at least 180 days after the last dose of the study intervention.\n\n      Female subjects The contraceptive measures used by women should comply with local regulations regarding contraceptive measures participating in clinical research.\n  14. Female subjects who are not pregnant, are not breastfeeding, and meet at least one of the following conditions, can participate in the study:\n\n      1. Women of non-bearing age. or\n      2. Agree to take contraceptive measures during treatment and at least 180 days after the administration of the last study intervention Informed consent\n  15. Subjects (or their legal representatives, if applicable) provide written informed consent to participate in the study. Subjects may also need to provide informed consent for future biomedical research. However, subjects can only participate in the main experiment and not participate in future biomedical research.\n\nExclusion Criteria:\n\n* Patients with any of the following cannot be included in this study:\n\nMedical condition\n\n1. People with small cell lung cancer or mixed tumors with small cell components and positive for EGFR, ALK and other driver genes. Note: Subjects with squamous NSCLC are not eligible for chemotherapy with pemetrexed.\n2. Have a medical history of MDS\/AML, current diagnosis or features suggestive of these diseases.\n3. There is a record of weight loss\\> 10% (from baseline) in the past 3 months. Previous\/combined treatment\n4. There is a radiotherapy plan in which the whole lung (whole lung V20-GTV) receiving a total dose of \\>20 Gy (V20) may exceed 34% of the lung volume.\n\n   Note: Subjects must be evaluated by a radiation oncologist during screening.\n5. Received previous chest radiotherapy, including radiotherapy for esophagus, mediastinum or breast cancer.\n6. Have previously received anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or drugs that target another stimulating or co-inhibitory T cell receptor (such as CTLA-4, OX-40, CD137) treatment.\n7. Have previously received fluzoparib or any other PARP inhibitor treatment.\n8. Underwent major surgery (other than vascular access) within 4 weeks before the first administration of the study drug.\n\n   Note: If the subject has undergone major surgery or vascular access, it must have fully recovered from treatment toxicity and\/or complications before starting the research intervention.\n9. It is expected that any other form of anti-tumor therapy will be required during the study period.\n10. Live vaccines have been vaccinated within 30 days before the first administration of the test drug. Examples of live vaccines include, but are not limited to, the following vaccines: measles, mumps, rubella, varicella\/shingles (chickenpox), yellow fever, BCG, and typhoid vaccine. Since seasonal influenza vaccines for injection are usually inactivated virus vaccines, their use is permitted; however, intranasal influenza vaccines (for example, FluMist\u00ae) are live attenuated vaccines, so their use is not allowed.\n11. Received colony stimulating factor (such as granulocyte colony stimulating factor \\[GCSF\\], granulocyte-macrophage colony stimulating factor \\[GM-CSF\\] or recombinant erythropoietin) within 28 days before the first administration of the research intervention.\n12. Currently receiving strong inducers of CYP3A4 (phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine) that cannot be discontinued during the study period And St. John's Wort) or intermediate inducers (such as bosentan, efavirenz, modafinil). Before starting fluzoparib treatment, pentobarbital needs a washout period of 5 weeks, and other drugs need a washout period of 3 weeks.\n13. Currently receiving strong inhibitors of cytochrome P450 (CYP) 3A4 that cannot be discontinued during the study period (such as itraconazole, telithromycin, clarithromycin, boosted with ritonavir or cobiastat) Protease inhibitors, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate inhibitors (such as ciprofloxacin, erythromycin, diltiazem, fluconazole) , Verapamil). The washout period required before initiating fluzoparib is 2 weeks.\n\n    Pemetrexed specific\n14. At least 2 days before pemetrexed administration (5 days for long-acting drugs (such as piroxicam)), during administration, and at least 2 days after administration, aspirin or other NSAIDs cannot be suspended, except for the daily dose of aspirin \u22641.3 grams outside.\n15. Unable\/unwilling to take folic acid, vitamin B12 and dexamethasone. Past\/concurrent clinical research experience\n16. Are currently participating in or have previously participated in research drug research, or have used research devices within 4 weeks before the first administration of the research intervention.\n\n    Note: Subjects who have entered the follow-up period of the experimental study can participate in this study as long as it is more than 4 weeks after the last administration of the previous investigational drug.\n\n    Diagnostic evaluation\n17. According to the investigator's judgment, resting electrocardiogram (ECG) indicates uncontrolled and potentially reversible heart disease (for example, unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, electrolyte imbalance, etc.) , Or the subject has congenital long QT syndrome.\n18. Have a diagnosis of immunodeficiency or are receiving chronic systemic steroid therapy (taking more than 10 mg prednisone or equivalent daily) or any form of immunosuppressive therapy within 7 days before the first administration of the study drug.\n\n    Note: The following indications allow the use of glucocorticoids:\n    * For eye, intranasal or topical use.\n    * Inhalers for the management of asthma or chronic obstructive pulmonary disease.\n    * Systemic physiological corticosteroid replacement therapy for hormone replacement therapy, prevention of vomiting, regulation of symptoms suspected of immunological etiology, or as a pretreatment for IV contrast agent allergy or chemotherapeutics.\n19. In the past 5 years, there are other malignant tumors that are progressing or require active treatment.\n\n    Note: Patients with skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder that have received potential radical treatment Subjects with cystic carcinoma or carcinoma in situ (eg, breast cancer, cervical cancer in situ) may not be excluded.\n20. Severely allergic to research intervention and\/or any of its excipients (\u2265Grade 3).\n21. Suffered from an active autoimmune disease that requires systemic treatment in the past 2 years (ie use of disease modifiers, corticosteroids, or immunosuppressive agents). Replacement therapies (for example, thyroxine, insulin, or physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency) are not considered systemic treatments and are allowed.\n22. A history of (non-infectious) pneumonia\/interstitial lung disease that requires steroid treatment, or current non-infectious pneumonia\/interstitial lung disease. Lymphatic spread of NSCLC is not an exclusion criterion.\n23. Have an active infection that requires systemic treatment.\n24. Known history of human immunodeficiency virus (HIV) infection. Unless mandatory by local health authorities, HIV testing is not required.\n25. A known history of hepatitis B (defined as HBsAg responsiveness) or active hepatitis C virus (defined as detection of HCV RNA \\[qualitative\\]) infection.\n\n    Note: Hepatitis B and C tests are not required unless required by local health authorities\n26. Patients with active tuberculosis (TB; Mycobacterium tuberculosis) and are being treated (unless mandatory by the local health authority, TB testing is not required; subjects who have received previous treatment are allowed to enter the group).\n27. There is historical or current evidence of any disease, treatment, or abnormal laboratory value that may interfere with the results of the research, prevent the subject from participating in the research throughout, or cause the researcher to believe that participating in the research is not in the subject's best interests.\n28. According to the opinions of treatment investigators, serious, uncontrolled medical diseases or non-malignant systemic diseases are regarded as adverse medical risks. Examples include, but are not limited to: uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled grand mal seizures, unstable spinal cord compression, or superior vena cava syndrome.\n29. Suffer from known mental illness or substance abuse disease, and these diseases will interfere with the subject's ability to cooperate with the research requirements.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04828395001","EMAIL":[{"email":"liuningbo@tjmuch.com"}],"GEO":[39.14222,117.17667]},{"TITLE":"Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB","CRITERIA":"Inclusion Criteria:\n\n* Eligible subjects selected for this study must meet all of the following criteria:\n\n  1. Sign written informed consent before implementing any trial-related procedures;\n  2. Age \u226518 years old and \u226475 years old; No limit on the gender;\n  3. Previously untreated, histologically confirmed resectable stage II, IIIA, IIIB (N2) (AJCC stage VIII) NSCLC; cTNM stage can be confirmed by PET-CT or pathological biopsy; resectable stage II non-small cell lung cancer is defined as radical resection as assessed by a qualified thoracic surgeon; resectable is resectable and potentially resectable as defined by the Expert Consensus on Multidisciplinary Diagnosis and Treatment of Stage III Non-small Cell Lung Cancer (2019 version); resectable includes IIIA (N0-1), some single-station mediastinal lymph node metastases with N2 and some T4 (satellite nodules present in adjacent lobes) N1; potentially resectable includes some stage IIIA and IIIB, including single-station N2 mediastinal lymph node short diameter \\< 3 cm stage IIIA NSCLC, potentially resectable T3 or T4 central tumors; Solid\/solid pulmonary nodules, not pure ground-glass opacity (GGO), are strongly recommended for pathological puncture verification;\n  4. Patients diagnosed with squamous cell carcinoma do not require genetic testing, and if they test positive for EGFR, ALK or ROS1, they are considered as exclusion criteria; if they are adenocarcinoma, they must undergo genetic testing containing at least EGFR, ALK and ROS1, and the acceptable detection method is ARMS or NGS, of which NGS is a cFDA-approved kit;\n  5. Measurable disease by Response Evaluation Criteria in Solid Tumors version 1.1;\n  6. Twenty tissue sections (4-6 microns in thickness) should be submitted before enrollment for biomarker evaluation (tumor tissue samples must be fresh or archival samples obtained within 3 months before enrollment; fresh tissues must be biopsy specimens by hollow needle aspiration, resection or incision);\n  7. ECOG score 0-1;\n  8. Good organ function: (1) hematology: absolute neutrophil count (ANC) \u2265 1500\/\u03bcL; platelets \u2265 100,000\/\u03bcL; hemoglobin \u2265 9.0 g\/dL or \u2265 5.6 mmol\/L; (2) kidney: serum creatinine \u2264 1.5 times ULN or calculated creatinine clearance (CrCl) \u2265 60 mL\/min (using the Cock-Gault formula); (3) liver: total bilirubin \u2264 1.5 \u00d7 ULN or for subjects with total bilirubin levels \\> 1.5 \u00d7 ULN, direct bilirubin is within normal limits; AST (SGOT) and ALT (SGPT) \u2264 2.5 \u00d7 ULN; (4) endocrine system: thyroid stimulating hormone (TSH) is within normal limits. Note: If TSH is not within normal range at baseline, if T3 and free T4 are within normal range, then the subject can still meet the inclusion criteria; (5) Coagulation function: international normalized ratio (INR) or prothrombin time (PT), activated partial thromboplastin time (aPTT) \u2264 1.5 \u00d7 ULN, except: subjects receiving anticoagulant therapy, as long as PT or aPTT is within the proposed use range of anticoagulant drugs; (6) Cardiac function tests: baseline ECG showed no PR interval prolongation or atrioventricular block;\n  9. The total lung function can withstand the proposed pneumonectomy surgery according to the surgeon's assessment;\n  10. Women should agree to use contraceptive measures (such as intrauterine device (IUD), contraceptives or condoms) during the study and within 6 months after the end of the study; serum or urine pregnancy test is negative within 7 days before study entry, and must be non-lactating patients; men should agree to use contraceptive measures during the study and within 6 months after the end of the study period.\n\nExclusion Criteria:\n\n* Subjects who meet the following criteria cannot be selected for this study:\n\n  1. Histopathology is neuroendocrine carcinoma and sarcomatoid tumor\uff1b\n  2. The presence of locally advanced unresectable or metastatic disease; unresectable including stage III non-small cell lung cancer multidisciplinary diagnosis and treatment expert consensus (2019 version) defined unresectable, including partial IIIA, IIIB and all IIIC, usually including single-station N2 mediastinal lymph nodes short diameter \u2265 3 cm or multi-station lymph nodes fused into a mass (CT lymph nodes short diameter \u2265 2 cm) N2, invading the esophagus, heart, aorta, pulmonary veins T4 and all N3;\n  3. Subjects with known EGFR mutations or ALK, ROS1 translocations, non-squamous cell carcinoma subjects need to clarify the EGFR, ALK and ROS1 mutation status\uff1b\n  4. Early stage NSCLC previously treated with systemic anticancer therapy, including treatment with investigational agents\uff1b\n  5. History of (non-infectious) pneumonia\/interstitial lung disease requiring steroid therapy, or current pneumonia\/interstitial lung disease requiring steroid therapy\uff1b\n  6. Known history of active tuberculosis;\n  7. Known active infection requiring systemic treatment;\n  8. Any known or suspected autoimmune disease or immunodeficiency subjects, except: patients with a history of hypothyroidism, if hormone therapy is not required, or are receiving physiological doses of hormone replacement therapy; subjects with stable type I diabetes whose blood glucose is controlled;\n  9. Subjects with active hepatitis B (defined as positive hepatitis B virus surface antigen \\[HBsAg\\] test results and HBV-DNA test values higher than the upper limit of normal of the laboratory of the study site) or hepatitis C (defined as positive hepatitis C virus surface antibody \\[HCsAb\\] test results and positive HCV-RNA test results during the screening period);\n  10. Known human immunodeficiency virus (HIV) infection (known HIV antibody positive);\n  11. Live vaccines within 30 days prior to the first dose. Including but not limited to the following: mumps, rubella, measles, varicella\/herpes zoster (chickenpox), yellow fever, rabies, bacillus Calmette-Guerin (BCG) and typhoid vaccines (inactivated viral vaccines are allowed);\n  12. Have \u2265 grade 2 peripheral neuropathy;\n  13. Previous treatment with PD-1\/PD-L1 drugs or treatment with another drug targeting T cell receptor (such as CTLA-4, OX-40, etc.);\n  14. Patients with any severe and\/or uncontrolled diseases, such as: (1) unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6 months before randomization, severe uncontrolled arrhythmia; patients with unsatisfactory blood pressure control (systolic blood pressure \\> 140 mmHg, diastolic blood pressure \\> 90 mmHg); (2) active or uncontrolled severe infection; (3) liver diseases such as cirrhosis, decompensated liver disease, chronic active hepatitis; (4) poor control of diabetes (fasting blood glucose (FBG) \\> 10 mmol\/L); (5) urine routine showed urine protein \u2265 + +, and confirmed 24-hour urine protein \\> 1.0g; (6) a history of psychiatric drug abuse and can not quit or mental disorders;\n  15. Use of immunosuppressive drugs 2 times before the first study drug treatment, excluding topical glucocorticoids or systemic glucocorticoids no more than 10 mg\/day prednisone or equivalent doses of other glucocorticoids;\n  16. Pregnant or lactating women;\n  17. Prisoners who are unlawfully incarcerated or compulsorily detained for non-mental illness or physical (such as infectious diseases) diseases;\n  18. Patients with bleeding tendency (such as active gastrointestinal ulcers) or treatment with anticoagulants or vitamin K antagonists such as warfarin, heparin or its analogues;\n  19. History of allergy to study drug ingredients;\n  20. According to the investigator's judgment, there are concomitant diseases that seriously endanger the patient's safety or affect the patient's completion of the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05295212001","EMAIL":[{"email":"zhangyongchang@csu.edu.cn"}],"GEO":[28.19874,112.97087]},{"TITLE":"A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n1. Subjects who are able to understand and voluntarily sign informed consent forms (ICFs).\n2. Male and female subjects at the age of \u226518 and \u226480 at the time of screening.\n3. Patients with histologically or cytologically-confirmed, locally advanced, or metastatic solid tumors with (a) failure of prior standard therapy, (b) no standard therapy available, or (c) for whom standard therapy is not applicable considered by the patient or treating physician. There is no limit to the number of prior treatment lines. Subjects who were previously treated with BRAF and\/or MEK inhibitors are allowed to be enrolled in this study.\n4. Documentation of positive BRAF V600 mutation is required for enrollment (the blood BRAF V600 test report is received at the dose-escalation stage). Representative tumor specimens suitable for confirmation of BRAF V600 mutations by retrospective analysis are required (for dose-expansion stage only). It is recommended to provide sufficient fresh\/archived tumor tissue samples (formalin-fixed paraffin-embedded tumor specimens \\[preferred\\]) or 5-10 available unstained sections of good quality for verification of BRAF V600 mutation status at the central laboratory. For any subject who is unable to provide suitable and adequate tumor specimens, re-biopsy (with controllable safety) can be performed in a non-mandatory manner if it is feasible as assessed by the investigator and the subject gives informed consent; if re-biopsy is impossible or refused by the subject, his\/her eligibility for enrollment shall be confirmed by both the investigator and the sponsor.\n5. Patients with BMs\/primary intracranial solid tumors that are asymptomatic, or that are symptomatic but on a stable or decreasing dose of steroids for at least 2 weeks are eligible for enrollment. The specific criteria are as follows:\n\n   * Subjects with inactive and asymptomatic BMs\/primary intracranial solid tumors;\n   * Subjects who have active, mild neurological signs and symptoms currently requiring no therapy with steroids, and have no history of epileptic seizure within 2 weeks prior to initiation of treatment;\n   * Subjects who have active, neurological signs and symptoms and were on a stable or gradually reducing dose up to 4 mg of dexamethasone (or equivalent) per day within 2 weeks prior to initiation of treatment;\n6. Subjects who only have evaluable lesions are allowed to be included for the dose escalation stage. They must have at least one measurable lesion (intracranial or extracranial) as defined by RECIST V1.1 criteria or modified RECIST v1.1 for subjects with BMs or the RANO criteria for subjects with primary intracranial solid tumors during screening at the dose expansion stage. Lesions previously treated with radiotherapy shall not be deemed as target lesions unless significant progression as shown on imaging.\n\n   o For BMs from solid tumors;At least one measurable extracranial lesion is required if the longest diameter of the intracranial lesion is less than 0.5 cm (for dose expansion stage only).Subjects with measurable intracranial lesions of 0.5-3 cm in longest diameter (the lower limit of the longest diameter is defined according to the modified RECIST V1.1 criteria are allowed for the study, and measurable extracranial lesions are not required.Subjects with intracranial lesions \\> 3 cm in longest diameter are not eligible for the study.\n7. ECOG score of 0 or 1 or Karnofsky PS score of \u2265 70.\n8. Life expectancy \\> 3 months.\n9. Adequate organ function (no blood transfusion and no use of granulocyte colony-stimulating factor, or other hematopoietic stimulator support within 2 weeks before the first administration of the study drug) confirmed as evidenced by:\n\n   * Absolute Neutrophil Count (ANC) \u2265 1.5\u00d710\\^9\/L;\n   * Hemoglobin (Hgb) \u2265 90 g\/dl;\n   * Platelets (Plt) \u2265 75\u00d710\\^9\/L;\n   * AST\/ALT \u2264 2.5 x ULN or \u2264 5.0 x ULN if liver metastases are present;\n   * Bilirubin total \u2264 1.5 x ULN, or bilirubin direct \\< ULN for patients with bilirubin total levels \\>1.5 ULN;\n   * Serum creatinine \\< 1.5 x ULN or creatinine clearance \\> 50 mL\/min (as calculated via Cockcroft-Gault formula based on the actual body weight of the subject ;\n   * International normalized ratio (INR) and activated partial thromboplastin time (APTT) \u2264 1.5 x ULN for subjects not receiving anticoagulant therapy, and INR is maintained within the standard range of treatment prior to starting study drug for subjects receiving anticoagulant therapy.\n10. Hepatitis B virus surface antigen (HBsAg) is negative, or HBsAg is positive but HBV DNA titer is below the lower limit of positive detection of the participating site at screening.\n\n    o HBsAg-positive or HBV-DNA positive subjects shall be managed according to institutional guidelines (anti-HBV therapy, where appropriate, and close monitoring of liver function and HBV-DNA replication shall be performed).\n11. Negative hepatitis C virus (HCV) antibody test or positive HCV antibody test at the time of screening followed by a negative HCV-RNA test result.\n\n    o HCV-RNA testing is performed only for subjects with a positive HCV antibody test result.\n12. Negative HIV test result at the time of screening.\n13. All pre-menopausal women and women with menolipsis \\< 12 months should have a negative pregnancy test result within 7 days before starting study treatment.\n14. Must agree to take sufficient contraceptive methods before initiation of study treatment, during the study, and for at least 3 months after the last dose of the study drug.\n15. Subjects who are able to swallow a capsule in whole (without chewing, crushing, or opening).\n\nExclusion Criteria:\n\n1. Women who are pregnant or breast-feeding.\n2. Subjects with history of neoplasm malignant within 5 years prior to screening, excluding cured carcinoma in situ of cervix, non-melanoma skin cancer, localized prostate cancer and other tumors\/cancers that have undergone radical treatment and shown no signs of disease for at least 3 years (This exclusion criterion is only applicable for dose expansion stage. For the dose escalation stage, any patient with double primary malignant solid tumors who can indeed benefit from this study as confirmed by the investigator is eligible for the screening; however, those with any combined primary hematological malignant tumor shall be excluded).\n3. Subjects with intracranial hypertension or associated risks (e.g., intracranial infection, intracranial hemorrhage).\n4. Subjects with clinically uncontrolled pleural effusion, pericardial effusion, or ascites who, in the judgement of the investigator, are not eligible for enrollment.\n5. Subjects with cancerous meningitis (leptomeningeal disease \\[LMD\\]).\n6. Subjects with history of symptomatic stroke within 6 months prior to initiation of study treatment.\n7. Subjects with epileptic seizure within 14 days prior to initiation of study treatment.\n8. Impaired cardiac function or clinically significant cardiovascular disorder, including but not limited to any of the following:\n\n   * Left Ventricular Ejection Fraction (LVEF) \\< 50% as determined via cardiac ultrasound.\n   * Long QT syndrome congenital.\n   * QTcF (as corrected via Fridericia formula) \u2265 450 ms (males) or 470 ms (females) at screening.\n   * Second-degree type II AV block or third-degree AV block.\n   * Unstable angina pectoris within 6 months prior to starting study drug.\n   * Acute myocardial infarction within 6 months prior to starting study drug.\n   * New York Heart Association (NYHA) Class II or higher heart failure within 6 months prior to study treatment.\n   * Ventricular arrhythmias \\> Grade 2 within 6 months prior to study treatment.\n   * Poorly controlled hypertension as defined as systolic blood pressure of \\>160 mmHg or diastolic blood pressure of \\> 100 mmHg despite use of antihypertensive medications.\n   * Combined with any pulmonary embolism, or presence of any serious deep vein thrombosis on lower extremities that require medical interventions such as vena cava filter insertion at the screening .\n9. Poorly controlled diabetes (fasting glucose \\> 10 mmol\/L or Glycosylated Haemoglobin (HbA1c) \\> 8%) despite standard drug therapy.\n10. Subjects with:\n\n    * CTCAE grade 2 or higher unresolved diarrhea, or\n    * Impaired gastrointestinal (GI) function or GI diseases that may significantly alter the absorption of ABM-1310 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)\n11. Previous or current, Grade 2 or higher eye disorder, such as retinal vein occlusion (RVO).\n12. Severe chronic or active infections requiring intravenous anti-infective therapy within 2 weeks prior to study treatment, including but not limited infectious complications leading to hospitalization, bacteremia, severe pneumonia, or active tuberculosis.\n\n    o Subjects with local fungal infections of skin or nails are allowed for enrollment. Subjects receiving prophylactic antibiotics (e.g., to prevent urinary tract infections or exacerbations of chronic obstructive pulmonary disease) are eligible for study (except for antibiotics prohibited by the protocol).\n13. Subjects with solid organ or hematopoietic stem cell transplant within the past 5 years.\n14. Patients receiving chemotherapy, targeted therapy, or immunotherapy within 4 weeks prior to study treatment, including the followings:\n\n    * Receiving nitrosourea or mitomycin-C within 6 weeks prior to study treatment.\n    * Receiving fluorouracil or small molecule targeted drug therapy within 5 half-lives or 2 weeks (whichever is longer) prior to study treatment.\n    * Receiving Chinese herbal or patent medicine within 2 weeks prior to study treatment for anti-tumor indications.\n15. Subjects receiving radical radiotherapy or radiotherapy to more than 30% of bone marrow or whole-brain radiotherapy (WBRT) within 4 weeks or palliative radiotherapy for non-target lesions with the aim of relieving symptoms (e.g., bone radiotherapy for pain relief) or stereotactic radiosurgery (including SRS) within 2 weeks prior to starting study drug.\n16. Adverse reactions resulted from prior antitumor therapy that have not resolved to baseline or \u2264 grade 1 (CTCAE 5.0), except alopecia or \u2264 grade 2 peripheral neuropathy, hypothyroidism stabilized by hormone replacement therapy, etc.\n17. Subjects who have undergone major surgery within 4 weeks prior to study treatment or who have not recovered from side effects of such therapy or who are expected to undergo major surgery during study treatment. However, a minimum of 2 weeks recovery time from major surgery to starting study drug is required if in investigator's opinion the patient has recovered from such major surgery.\n18. Subjects currently receiving therapeutic doses of warfarin sodium or any other coumarin-derivative anticoagulants.\n19. Subjects who have received systemic corticosteroids within 2 weeks prior to starting study drug or who have not recovered from side effects of such treatment, excluding conditions described in inclusion criteria for subjects with BMs.\n\n    Note: subjects with topical, intranasal, or inhaled corticosteroids administered; adrenal replacement steroid doses of \u2264 10 mg\/day prednisone or the equivalent given; single-use glucocorticoids administered for prophylaxis of contrast media allergy prior to contrast-enhanced imaging are eligible for the study.\n20. Subjects who are currently receiving treatment with medication that has a known risk to prolong the QT interval and cannot either be discontinued or switched to a different medication prior to starting study drug.\n21. History of alcohol abuse or addiction within 3 months prior to the first dose.\n22. Known, documented or suspected history of drug abuse, expect opioids prescribed for pain relief, etc.\n23. Past or current evidence of any condition, therapy, or laboratory abnormality that, in the opinion of the investigator, might affect the results of the study, and interfere with the subject's participation and study compliance.\n24. Other severe and\/or uncontrolled concomitant diseases that could cause unacceptable safety risks or compromise compliance with the study protocol.\n25. Other conditions that, in the judgement of the investigator, are inappropriate for enrollment in the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"05501912013","EMAIL":[{"email":"lijin@csco.org.cn"},{}],"GEO":[31.22222,121.45806]},{"TITLE":"Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Received radical resection of non-small cell lung cancer without prior anti-tumor therapies including radiotherapy, chemotherapy, target therapy and immunotherapy.\n* Histologically diagnosed Non-small cell lung cancer based on the judgement of at least 2 pathologists.\n* Stage IA with high risk factors including micropapillae or solid components, vascular invasion, spread through air spaces, low differentiation, tumor budding and insufficient lymph node dissection; Stage IB with or without high-risk factors. The pathological stage is based on the 8th edition of AJCC lung cancer staging.\n* EGFR mutation positive according to NGS testing by tissue, including deletions in exon 19, L858R, S768I, G719X, L861Q, T790M mutations et al.\n* ECOG performance status 0-1.\n* Sufficient organ function in liver, renal, kidney and hematology.\n* With written signed informed consent form, ability to report adverse events, and good adherence to clinical study.\n\nExclusion Criteria:\n\n* Lung cancer with small cell or neuroendocrine cancer cell.\n* EGFR exon 20 insertion positive.\n* Concurrent with other diver mutations including alterations in ALK, ROS1, MET et al.\n* Women who are pregnant or breastfeeding.\n* Use of CYP3A4 strong depressant within 7 days or CYP3A4 strong inducer within 21 days prior to initial administration, use of other anti-tumor treatment including traditional Chinese medicine within 14 days before enrollment.\n* Concurrent with other malignancies excluding carcinoma in situ.\n* With uncontrolled systematic diseases such as active bleeding, unstable angina, heart infarction within 1 year, chronic heart failure and uncontrolled hypertension and diabetes mellitus; with active infection of HBV, HCV or HIV, or other infections requiring injection of antibiotics.\n* Gastrointestinal disorders which may affect drug taking or absorption.\n* With history of QT prolongation or relative risk factors including heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome et al.\n* With history of interstitial lung disease or relative risk.\n* Allergic to any component of furmonertinib tablet.\n* Mental illness or drug abuse.\n* Live vaccination within 30 days before enrollment.\n* Other situation judged by investigator such as failure to follow the rules of study.\n* Attending another study of investigational drug, or received other study drugs or medical devices with 4 weeks before enrollment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05445310001","EMAIL":[{"email":"ginkrice@sina.com"}],"GEO":[39.9075,116.39723]},{"TITLE":"ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1\/PD-L1 Inhibitors","CRITERIA":"Inclusion Criteria (Major criteria):\n\n1. Adult (\u2265 18 years), all genders, capable of signing informed consent.\n2. Histologically- or cytologically- confirmed diagnosis of metastatic NSCLC, metastasis can be regional lymph nodes or distant organs.\n3. Radiographic progression after treatment with the most recent line of treatment being either 3a or 3b:\n\n   1. At least 12 weeks of PD-1\/PD-L1 inhibitor in combination with platinum-based chemotherapy;\n   2. Prior treatment with at least 2 cycles of a platinum-based chemotherapy, followed by at least 12 weeks of standard doses of PD-1 or PD-L1 inhibitor-based immunotherapy.\n\n   Antibodies against CTLA-4, LAG-3, TIGIT, VEGF or VEGFR in combination with PD-1\/PD-L1 inhibitor are allowed.\n4. At least one measurable tumor lesion according to RECIST 1.1.\n5. ECOG score of 0 or 1.\n6. Adequate organ functions. Serum LDH level \u2264 2xULN.\n7. Life expectancy \u2265 3 months.\n\nExclusion Criteria (Major criteria):\n\n1. Cancer treatment related AEs have not recovered to NCI CTCAE grade\u2264 1 except endocrinopathy.\n2. Last anti-PD-1\/PD-L1 dosing within 28 days prior to first dose of study treatment.\n3. Receiving systemic steroid therapy with \\>10 mg\/day prednisone or equivalent within 7 days prior to the first dose of study treatment.\n4. Having documented actionable mutations or genomic alterations in any of the following genes: EGFR, ALK, ROS1, HER2, MET, BRAF, RET or NTRK;. Exception: KRAS mutations are not excluded.\n5. Patients who have symptomatic brain metastasis. Palliative radiotherapy or radiosurgery to brain metastasis within 14 days of the first dose of study drug.\n6. Active GI disease, including peptic ulcer disease, pancreatitis, diverticulitis, or inflammatory bowel disease.\n7. Active interstitial lung disease (ILD) or non-infectious pneumonitis.\n8. Active infections with IV antibiotics within 14 days prior to first dose of study treatment.\n9. Impaired heart function.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05671510157","EMAIL":[{}],"GEO":[51.50853,-0.12574]},{"TITLE":"Smartphone-based Remote Symptom Monitoring to Improve Postoperative Rehabilitation Exercise Adherence After Video-assisted Thoracic Surgery (VATS) for Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Age 18-75 years old\n* Undergoing minimally invasive lung cancer resection\n* Able to use smartphones and complete electronic questionnaires\n* Signed informed consent\n\nExclusion Criteria:\n\n* conversions to open thoracotomy during surgery\n* ECOG score \\> 1\n* Received neoadjuvant therapy\n* Previous lung resection surgery\n* Unable to exercise due to physical limitations\n* Continuous systemic corticosteroid use within 1 month before enrollment\n* Unresolved toxicity above Grade 1 from previous treatments\n* Significant comorbidities or medical history","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05990946001","EMAIL":[{"email":"1002381745@qq.com"}],"GEO":[21.31992,110.5723]},{"TITLE":"NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts","CRITERIA":"Inclusion Criteria:\n\n* Voluntary informed consent.\n* Aged at least 18 years.\n* Diagnosis of locally advanced or metastatic RCC, Melanoma or NSCLC\n* In the opinion of the investigator deemed suitable to receive first-line combination immunotherapy (RCC and MM) or combination immunotherapy and chemotherapy (NSCLC).\n* Willingness to comply with scheduled trial procedures.\n* Capable of performing own dry blood sampling procedure, or a carer who is willing and able to perform them.\n\nExclusion Criteria:\n\n* Previous immunotherapy (including any CPI either as single agent on in combination, or high dose interleukin-2).\n* Judgement by the investigator that the individual should not participate if they are unlikely to comply with study procedures and requirements.\n* Patients receiving long term oral anticoagulation deemed by the clinician to be at risk from daily finger pricking.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04960059001","EMAIL":[{"email":"the-christie.notion@nhs.net"},{"email":"donna.graham8@nhs.net"}],"GEO":[53.48095,-2.23743]},{"TITLE":"Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC\uff1aProspective Study","CRITERIA":"Inclusion Criteria:\n\n1. Age \u2265 18.\n2. Histologically or cytologically confirmed advanced non-small cell lung adenocarcinoma(stage IIIB\\~IV).\n3. Patients with EGFR mutations (deletions in exon 19 and L858R in exon 21 of the EGFR gene), plan to receive First-generation EGFR-TKIs (Gefitinib, Erlotinib, Icotinib) or third generation EGFR-TKIs (including but not limited to Osimertinib, Almonertinib, Furmonertinib) monotherapy for the first time (patients who have been using first- or third-generation EGFR-TKIs for less than 28 days can be enrolled).\n4. Patients positive for EGFR gene mutation (deletions in exon 19 and L858R in exon 21 of the EGFR gene), with disease progression after receiving chemotherapy can be enrolled.\n5. Confirmed by investigators, tumor tissue can't be surgically excised.\n6. No prior exposure to elemene injectable and\/or oral emulsion within one month.\n7. Prior exposure to other Chinese patent medicine with similar efficacy within one month. If more than one month, patients can be enrolled after a 30-day washout period (without continuing to use the above medications).\n8. The participant must be capable of understanding and complying with the protocol and willing to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Patients with any EGFR mutations other than 19DEL or 21L858R.\n2. Accompanied by other active tumors. (Except for stable basal cell carcinoma after treatment\uff0c If metachronous tumors have been controlled, participating was allowed )\n3. Exposure to First- or third-generation EGFR-TKIs combined treatment, for example, chemotherapy, anti-angiogenesis therapy.\n4. Receiving radiotherapy or chemotherapy.\n5. Pregnant or lactating women.\n6. Allergic to Elemene.\n7. Participating in other drug clinical trials.\n8. Refuse to comply with the follow-up.\n9. The researchers did not consider it appropriate to participate in this study for other reasons.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04401059007","EMAIL":[{},{}],"GEO":[39.9075,116.39723]},{"TITLE":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n1. Sign the informed consent form voluntarily and follow the protocol requirements;\n2. Any gender;\n3. Age: \u226518 years old and \u226475 years old;\n4. Expected survival time for 3 months or more;\n5. Patients with locally advanced or metastatic non-small cell lung cancer or nasopharyngeal carcinoma confirmed by histopathology and\/or cytology;\n6. Subjects were able to provide 6-10 slides of archived tumor tissue samples or fresh tissue samples of primary or metastatic lesions within 2 years;\n7. At least one measurable lesion meeting the RECIST v1.1 definition was required;\n8. ECOG 0 or 1;\n9. The toxicity of previous antineoplastic therapy has returned to \u2264 grade 1 as defined by NCI-CTCAE v5.0;\n10. No serious cardiac dysfunction, left ventricular ejection fraction 50% or higher;\n11. screening period not allowed within 14 days before a blood transfusion, are not allowed to use any cell growth factor, and\/or liters of platelet medicine, organ function level must conform to the requirements;\n12. Coagulation function: international normalized ratio (INR) \u22641.5, and activated partial thromboplastin time (APTT) \u22641.5ULN;\n13. The urine protein + 2 or 1000 mg \/ 24 h or less or less;\n14. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, serum or urine must be negative for pregnancy, and must be non-lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.\n\nExclusion Criteria:\n\n1. Stage 1 EGFR-sensitive mutant non-small cell lung cancer patients with systemic chemotherapy; Stage 2 patients who had received previous systemic therapy;\n2. In the second stage queue one signed informed consent before gene sequencing report suggests patients such as mutation of ALK fusion;\n3. Anti-tumor therapy such as chemotherapy or biological therapy has been used within 4 weeks or 5 half-lives before the first dose; Mitomycin and nitrosoureas were administered within 6 weeks before the first dose; Fluorouracil class oral drugs, etc.;\n4. Serious heart disease;\n5. Long QT, complete left bundle branch block, III degree atrioventricular block; Serious arrhythmia;\n6. Active autoimmune and inflammatory diseases;\n7. Before the first delivery within 5 years diagnosed as other malignant tumor;\n8. Two antihypertensive drugs poorly controlled hypertension;\n9. Patients with poor glycemic control;\n10. With a history of ILD, current ILD or suspected suffering from such diseases during screening;\n11. Complicated with pulmonary diseases leading to severe respiratory function impairment;\n12. There is a lot of serous cavity effusion, or have a serous cavity effusion and has symptoms, or poorly controlled serous cavity effusion patients;\n13. Imaging studies suggest tumor has violated or package around the chest, neck, pharyngeal large blood vessels;\n14. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening; Infusion-related thrombosis was excluded;\n15. Active central nervous system of patients;\n16. For restructuring or human mouse chimeric antibody on study of humanized anti-platelet antibody has a history of allergies or allergic to BL - B01D1 any supplementary material composition of patients;\n17. Before transplant or allogeneic hematopoietic stem cell transplantation (Allo - HSCT);\n18. Human immunodeficiency virus antibody positive, active tuberculosis, active hepatitis B virus infection or active hepatitis C virus infection;\n19. Active infection requiring systemic therapy;\n20. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;\n21. Had participated in another clinical trial within 4 weeks before the first dose;\n22. Other conditions for trial participation were not considered appropriate by the investigator.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06475300001","EMAIL":[{}],"GEO":[23.11667,113.25]},{"TITLE":"A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy","CRITERIA":"Inclusion Criteria:\n\nVoluntarily participate in clinical research; Fully understand and be informed of this study and sign the informed consent form;\n\n1. Age \u2265 18 and \u2264 75, male or female;\n2. ECOG physical performance score of 0-2;\n3. Patients with histologically confirmed squamous or non-squamous advanced non- small cell lung cancer (according to AJCC, 8th edition);\n4. Patients who tested negative for driver genes after genetic testing;\n5. Patients who have undergone previous systemic therapy and failed anti-PD-1\/PD- L1 immunotherapy;\n6. Presence of at least one measurable lesion as defined by Recist criteria 1.1;\n7. Liver function: Total serum bilirubin \u2264 1.5 \u00d7 ULN; For subjects without liver metastasis, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u2264 2.5 \u00d7 ULN, and for those with liver metastasis, ALT and AST \u2264 5 \u00d7 ULN;\n8. Renal function: Serum creatinine \u2264 1.5 \u00d7 ULN or creatinine clearance rate \u2265 45 mL\/min (using the Cockcroft\/Gault formula); Blood routine: Absolute neutrophil count \u2265 1.5 \u00d7 109\/L, platelet count \u2265 70 \u00d7 109\/L; Hemoglobin \u2265 80g\/L (no blood transfusion or use of hematopoietic stimulating drugs for correction within 7 days before screening) with an expected lifespan of more than 3 months.\n\nExclusion Criteria:\n\n1. ECOG physical performance score \\> 2;\n2. Previous treatment with bispecific antibodies;\n3. Participation in other clinical trials within 30 days prior to screening;\n4. Tumor metastasis to the brain and\/or leptomeninges;\n5. History of other malignancies (excluding cervical carcinoma in situ or skin basal cell carcinoma that has been cured, and other malignancies that have been cured for more than 5 years);\n6. Accompanied by other serious diseases, including but not limited to:\n\n   1. Difficult-to-control congestive heart failure (NYHA class III or IV), unstable angina, poorly controlled arrhythmia, uncontrolled moderate to severe hypertension (SBP \\> 160mmHg or DBP \\> 100mmHg);\n   2. Severe active infection;\n   3. Difficult-to-control diabetes (referring to large fluctuations in blood sugar despite standard insulin therapy and frequent blood glucose monitoring, affecting the patient's life and frequently causing hypotension);\n   4. Mental illness affecting informed consent and\/or protocol compliance.\n7. Allergy to the drugs used in this protocol or their ingredients;\n8. Pregnant (confirmed by blood or urine HCG testing) or breastfeeding women, or subjects of reproductive age who are unwilling or unable to take effective contraceptive measures (applicable to both male and female subjects) until at least 6 months after the last experimental treatment;\n9. Investigators consider it inappropriate to participate in this study;\n10. Unwilling to participate in this study or unable to sign the informed consent form.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06467500001","EMAIL":[{"email":"2732774352@qq.com"}],"GEO":[30.71444,111.28472]},{"TITLE":"A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)","CRITERIA":"Inclusion Criteria:\n\n* Must have histologically confirmed Stage IB, II, or IIIA NSCLC.\n* Must have an activating RET gene fusion in tumor based on polymerase chain reaction (PCR), next generation sequencing (NGS), or another molecular test per sponsor's approval.\n* Must have received definitive locoregional therapy with curative intent (surgery or radiotherapy) for Stage IB, II, or IIIA NSCLC.\n\n  -- Must have undergone the available anti-cancer therapy (including chemotherapy or durvalumab) or not be suitable for it, based on the investigator's discretion.\n* Maximum time allowed between definitive therapy completion and randomization must be:\n\n  * 10 weeks if no chemotherapy was administered\n  * 26 weeks if adjuvant chemotherapy was administered\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Adequate hematologic, hepatic, and renal function.\n* Willingness of men and women of reproductive potential to observe conventional and highly effective birth control for the duration of the study and for at least 2 weeks after last dose of study drug.\n\nExclusion Criteria:\n\n* Additional oncogenic drivers in NSCLC, if known.\n* Evidence of small cell lung cancer.\n* Clinical or radiologic evidence of disease recurrence or progression following definitive therapy.\n* Known or suspected interstitial fibrosis or interstitial lung disease or history of (noninfectious) pneumonitis that required steroids.\n* Clinically significant active cardiovascular disease or history of myocardial infarction within six months prior to planned start of selpercatinib or prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF) greater than 470 milliseconds.\n* Have known uncontrolled human immunodeficiency virus (HIV)-1\/2 infection.\n* Have known active hepatitis B or C.\n* Active uncontrolled systemic bacterial, viral, or fungal infection or serious ongoing intercurrent illness, such as hypertension or diabetes, despite optimal treatment.\n* Major surgery within 4 weeks prior to planned start of selpercatinib.\n* Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of the study drug.\n* Other malignancy unless nonmelanoma skin cancer, carcinoma in situ of the cervix or other in situ cancers or a malignancy diagnosed greater than or equal to two years previously and not currently active.\n* Pregnancy or lactation.\n* Prior treatment with a selective RET inhibitor (e.g. selpercatinib or pralsetinib).","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04819100198","EMAIL":[{}],"GEO":[52.58547,-2.12296]},{"TITLE":"Obstructive Sleep Apnea Influences Efficacy of PD-1-Based Immunotherapy Against Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Histologically or cytologically confirmed, advanced NSCLC\n2. Participants with no prior treatment for advanced NSCLC\n3. Measurable disease as defined by RECIST v1.1\n4. Eligible to receive first-line treatment including PD-1 antibody\n5. Adequate hematologic and end organ function\n\nExclusion Criteria:\n\n1. Severe infection within 4 weeks prior to recruitment.\n2. Significant organ dysfunction or other serious diseases.\n3. Previous or current OSA related treatment, including oral appliance, surgery, mechanical ventilation therapy.\n4. Illness or condition that interferes with the participant's capacity to understand, follow and\/or comply with study procedures.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04743752001","EMAIL":[{"email":"majjmail@163.com"}],"GEO":[39.9075,116.39723]},{"TITLE":"A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies","CRITERIA":"Key Inclusion Criteria:\n\n* Monotherapy-specific criteria for dose escalation cohorts:\n\n  * Participants may have cytologically or pathologically confirmed non-small cell lung carcinoma (NSCLC), colorectal carcinoma (CRC), breast, ovarian, renal cell carcinoma (RCC), head and neck squamous cell carcinoma (HNSCC), or bladder carcinoma that has progressed or was non-responsive to available therapies with no standard of care (SOC) options, or for whom standard therapy has proven ineffective, intolerable, or considered inappropriate; or for whom a clinical study of an investigational agent is a recognized SOC.\n* Disease-specific criteria for dose-expansion Cohort 1 (STK11m \\[mutated or deleted\\] NSCLC):\n\n  * Cytologically or pathologically confirmed locally advanced unresectable or metastatic (Stage IIIB-IV per American Joint Committee on Cancer \\[AJCC\\] version 8) non-squamous NSCLC with documented mutation or deletion in the STK11 gene.\n  * Negative for actionable mutations including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK), mesenchymal-epithelial transition factor (C-MET) or ret proto-oncogene (RET). Mixed small-cell lung carcinoma (SCLC) and squamous NSCLC histology is not permitted.\n  * Previously treated in the unresectable locally advanced or metastatic setting with a platinum-containing chemotherapy and programmed cell death ligand-1 (PD-L1) inhibitor.\n* Disease-specific criteria for dose-expansion Cohort 2 (NSCLC):\n\n  * Cytologically or pathologically confirmed locally advanced unresectable or metastatic (Stage IIIB-IV per American Joint Committee on Cancer version 8) non-squamous NSCLC negative for actionable mutations in EGFR, ALK, ROS1, NTRK, C-MET, or RET. Mixed SCLC and squamous NSCLC histology is not permitted.\n  * Previously treated in the unresectable locally advanced or metastatic setting with a platinum-containing chemotherapy and PD-(L)-1inhibitor.\n* Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) guidance (Version 1.1) (Section 1.1). The measurable lesion must be outside of a radiation field if the participant received prior radiation unless discussed and approved by the study physician.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n\nKey Exclusion Criteria:\n\n* Use of any live vaccines against infectious diseases (eg, influenza, varicella) within 4 weeks (28 days) of initiation of investigational product.\n* Underlying medical conditions or adverse events that, in the physician or sponsor's opinion, will make the administration of investigational products hazardous.\n* Prolonged QT interval defined as mean corrected QT interval (QTc) \u2265 450 milliseconds (ms).\n* Any active or documented history of autoimmune disease, including but not limited to inflammatory bowel disease, celiac disease, Wegner syndrome, Hashimoto syndrome, systemic lupus erythematosus, scleroderma, sarcoidosis, or autoimmune hepatitis, within 3 years of the first dose of study treatment.\n* Treatment with systemic immunosuppressive medication (including but not limited to corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and antitumor necrosis factor-\u03b1 agents) administered within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressant medication during study treatment.\n\nNote: Other protocol defined Inclusion\/Exclusion criteria may apply.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06120075007","EMAIL":"ClinicalTrials@arcusbio.com","GEO":[38.84622,-77.30637]},{"TITLE":"A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Na\u00efve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Have a histologically or cytologically confirmed diagnosis of metastatic NSCLC (stage IV according to the TNM staging criteria \\[8th edition\\] published by the International Association for the Study of Lung Cancer \\[IASLC\\]), or NSCLC that recurs after curable surgery, radiotherapy, or radiochemotherapy.\n2. Have measurable disease based on RECIST v1.1.\n3. ECOG PS score: 0-1.\n4. Have a life expectancy of at least 3 months.\n5. Non-surgically sterilized female subjects or women of childbearing potential must be negative for a serum pregnancy test within 3 days prior to the first dose and must be non-lactating. Female subjects of childbearing potential and male subjects with partners of childbearing potential must agree to take highly effective contraceptive measures during the study period and within 6 months after the last dose of study drugs.\n6. Have voluntarily agreed to participate by giving written informed consent for the study, have good compliance, and cooperate with follow-up visits.\n\nExclusion Criteria:\n\n1. Accompanied with EGFR activating mutation, ALK fusion gene positive or ROS1 mutation.\n2. Have uncontrolled clinically symptomatic pleural effusion, pericardial effusion, or ascites.\n3. Have known history of prior malignancy in the past 3 years.\n4. Have had an allogeneic tissue\/solid organ transplant.\n5. Have active pulmonary tuberculosis.\n6. Have clinical symptoms of the heart or heart diseases that are not well controlled.\n7. Have hypertension which cannot be well controlled by antihypertensives\n8. Urinalysis has indicated that the urine protein is \u2265 ++ and quantitative test of urine protein has confirmed that the 24-h urine protein is \\> 1.0 g.\n9. Have a thrombosis tendency or are currently receiving thrombolysis\/anticoagulation therapy.\n10. Have received major surgery within 4 weeks prior to randomization; or palliative radiotherapy within 2 weeks prior to randomization; or have not recovered from the toxicities and\/or complications of previous interventions to NCI-CTCAE Grade \u2264 1.\n11. Have known history of arterial\/venous thrombosis within 6 months prior to randomization, such as cerebrovascular accidents, deep vein thrombosis and pulmonary embolism.\n12. Have received prior therapy with anti-PD-1\/PD-L1 monoclonal antibodies, anti-CTLA-4 monoclonal antibodies, or small molecule VEGFR inhibitors.\n13. Have known allergies to other monoclonal antibodies or any component of famitinib.\n14. Are currently participating and receiving study therapy or have participated in a study and received the last dose of study drug within 4 weeks (or 5 half-lives of the study drug) prior to randomization.\n15. Have other potential factors that may affect the study results or result in the premature discontinuation as determined by the investigator, such as alcoholism, drug abuse, substance abuse, other serious diseases (including mental illness) requiring concomitant treatment, serious laboratory abnormalities, or family or social factors that could affect the safety of medication.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05042375074","EMAIL":[{}],"GEO":[39.14222,117.17667]},{"TITLE":"Induction Chemo-Nivo in Unresectable Stage III NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Squamous and non-squamous non-small cell lung cancer that is at baseline, unresectable stage IIIA-IIIC (8th edition AJCC) and not previously treated\n* PD-L1 level needs to be measured with values 0-100% eligible\n* EGFR\/ALK\/ROS1 Wild Type or unknown genetic alterations in these genes\n* ECOG Performance Status \u2264 1\n* Adequate organ and marrow function\n* Adequate pulmonary reserve (e.g., FVC, FEV1, TLC, FRC, and DLCO) capable of tolerating the proposed lung resection\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen\n* Clinical risk assessment of cardiac function using the New York Heart Association Functional Classification class 2B or better\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Patients who have participated in a study with an investigational agent or device within 2 weeks of enrollment\n* Any prior radiotherapy to the lung\n* Any prior treatment for NSCLC\n* Any prior therapy with anti-PD-1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways\n* Any history of a severe hypersensitivity reaction to any monoclonal antibody\n* Any history of allergy to the study drug components\n* primary tumors involving the esophagus\n* pancoast tumors\n* Patients cannot have primary tumors which would remain unresectable\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to Nivolumab or other agents used in study\n* Any active or history of autoimmune disease (including any history of inflammatory bowel disease), or history of syndrome that required systemic steroids or immunosuppressive medications\n* Ongoing requirement for systemic corticosteroids greater than the equivalent of prednisone 10mg\n* previous malignancies\n* history of interstitial lung disease\n* Patients requiring continuous supplemental oxygen\n* Use of any live vaccines against infectious diseases (e.g., influenza, varicella. etc.) within 4 weeks (28 days) of initiation of study therapy\n* Active systemic infection requiring therapy\n* Patients with uncontrolled intercurrent illness\n* Patients with psychiatric illness\/social situations that would limit compliance with study requirements\n* Pregnant or lactating women","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06003075001","EMAIL":[{}],"GEO":[37.98869,-84.47772]},{"TITLE":"Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)","CRITERIA":"Inclusion Criteria:\n\n* Sign and date the Main Informed Consent Form (ICF), prior to the start of any study- specific qualification procedures.\n* Adults \u226518 at the time the Main ICF is signed.\n* Has tumor with PD-L1 TPS \\<50% as determined by PD-L1 IHC 22C3 pharmDx assay by central testing.\n* Has provided a formalin-fixed tumor tissue sample for the measurement of TROP2 protein expression and for the assessment of other exploratory biomarkers.\n* Has not been treated with systemic anticancer therapy for advanced or metastatic non-squamous NSCLC.\n* Has measurable disease based on local imaging assessment using RECIST v1.1.\n* Histologically documented NSCLC that meets all of the following criteria:\n\n  * Stage IIIB or IIIC disease and not candidates for surgical resection or definitive chemoradiation, or Stage IV NSCLC disease at the time of randomization (based on the American Joint Committee on Cancer, Eighth Edition).\n  * Documented negative test results for epidermal growth factor receptor (EGFR), lymphoma kinase (ALK), and proto-oncogene1 (ROS1) actionable genomic alterations based on analysis of tumor tissue.\n  * No known actionable genomic alterations in neurotrophic tyrosine receptor kinase (NTRK), proto-oncogene B-raf (BRAF), rearranged during transfection (RET), mesenchymal-epithelial transition factor (MET), or other actionable driver kinases with locally approved therapies.\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at screening.\n* Has an adequate treatment washout period before Cycle 1 Day 1.\n* Is willing and able to participate in the collection of patient-reported outcomes (PRO) data.\n\nExclusion Criteria:\n\n* Has received prior systemic treatment for advanced\/metastatic NSCLC.\n* Has received prior treatment with any of the following, including in the adjuvant\/neoadjuvant (for NSCLC) setting:\n\n  * Any agent, including an antibody-drug conjugate, containing a chemotherapeutic agent targeting topoisomerase I.\n  * TROP2-targeted therapy.\n  * Any anti-programmed death receptor-1 (PD-1), anti-PD-L1, or anti-PD-ligand 2 (L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX40, CD137).\n  * Any other immune checkpoint inhibitors.\n* Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of study drug. For any participant receiving an approved severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine, please follow the vaccine label and\/or local guidance.\n* Has spinal cord compression or clinically active untreated central nervous system (CNS) metastases and\/or carcinomatous meningitis.\n* Uncontrolled or significant cardiovascular disease, including:\n\n  * Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) interval \\>470 msec regardless of sex.\n  * Myocardial infarction within 6 months prior to randomization.\n  * Uncontrolled angina pectoris within 6 months prior to randomization.\n  * LVEF \\<50% by ECHO or MUGA scan within 28 days before randomization.\n  * New York Heart Association Class 2 to 4 congestive heart failure (CHF) at screening.\n  * Uncontrolled hypertension within 28 days before randomization.\n* Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses.\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy.\n* History of another primary malignancy (beyond NSCLC) except for:\n\n  * Malignancy treated with curative intent and with no known active disease \u22653 years before the first dose of study treatment and of low potential risk for recurrence.\n  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n  * Adequately treated carcinoma in situ without evidence of disease.\n  * Participants with a history of prostate cancer (tumor\/node\/metastasis stage) of Stage \u2264T2cN0M0 without biochemical recurrence or progression.\n* Has a history of severe hypersensitivity reactions to either the drugs or inactive ingredients of Dato-DXd, pembrolizumab, carboplatin, cisplatin or pemetrexed.\n* Has a history of severe hypersensitivity reactions to other monoclonal antibodies.\n* Has known human immunodeficiency virus (HIV) infection that is not well controlled.\n* Has active or uncontrolled hepatitis B or C infection.\n* Female who is pregnant or breastfeeding or intends to become pregnant.\n* Any other medical conditions, including cardiac disease or psychological disorders, and\/or substance abuse.\n* Has a history of (non-infectious) interstitial lung disease (ILD)\/pneumonitis that required steroids, has current ILD\/pneumonitis, or where suspected ILD\/pneumonitis cannot be ruled out by imaging at screening.\n* Has active, known, or suspected autoimmune disease.\n* Has clinically significant corneal disease.\n* Has had an allogeneic tissue\/solid organ transplantation.\n* Has received prior radiotherapy \u22644 weeks of start of study intervention or more than 30 Gy to the lung within 6 months of Cycle 1 Day 1.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05555732187","EMAIL":"CTRinfo@dsi.com","GEO":[37.00167,35.32889]},{"TITLE":"Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Between the ages of 18 and 80.\n2. ECOG general status score of 0-2 .\n3. Primary non-small cell lung cancer (NSCLC) confirmed by histology or cytological pathology, T1-2N0M0, stage Ia-IIa (AJCC\/UICC 8th edition).\n4. The location of the tumor belongs to the peripheral type defined in this study (2cm and beyond (\u22652cm) from the esophagus, main bronchial tree, spinal cord, heart, great blood vessels, brachial plexus and stomach, and 1cm and beyond (\u22651cm) from the chest wall).\n5. Medically inoperable, or patient refuses surgery.\n6. Adequate organ function: 1). Blood function: absolute neutrophil count (ANC) \u22651.5 x 109\/L, platelet count \u226580 x 109\/L, hemoglobin \u22659 g\/dL 2). Lung function: FEV1\\>25%, DLCO\\>25% 3). Cardiac function: no serious pulmonary hypertension, cardiovascular and cerebrovascular diseases, peripheral vascular diseases, serious chronic heart disease and other complications that may affect radiotherapy.4). Adequate liver function: total bilirubin \\<1.5 times the upper limit of normal value, and AST, ALT\\<2 times the upper limit of normal value. 5). Adequate renal function: serum creatinine \u22641.5 times the upper limit of normal or calculated creatinine clearance \u226550 ml \/min, and urinary protein \\<2+. Patients with a baseline urinary protein level of 2+ or more should have a 24-hour urine collection and evidence of a 24-hour urinary protein level of 1g or less.\n7. Sign the informed consent.\n\nExclusion Criteria:\n\n1. Multiple primary tumors.\n2. Patient fails to comply with the treatment protocol.\n3. Complicated with other malignant tumors that have not been controlled.\n4. Patient whose particle radiotherapy plan cannot meet the minimum target dose coverage and dose volume limitation requirements, or cannot meet the dose constrains of normal tissue or organs.\n5. Chest radiation therapy or radioactive particle implantation history.\n6. Cardiac pacemakers or other internal metal prosthesis implants that may be affected by high-energy radiation or may affect the dose distribution to the radiation target area.\n7. Pregnancy (confirmed by serum or urine \u03b2-HCG test) or lactation period.\n8. HIV positive. Hepatitis virus replication phase, need to receive antiviral therapy, but because of concomitant disease cannot receive antiviral therapy. Active stage of syphilis.\n9. A history of mental illness may hinder the completion of treatment.\n10. With serious comorbidity that may interfere with radiotherapy, including: (a) Acute infectious diseases or acute active phase of chronic infection. b) Unstable angina pectoris, congestive heart failure, myocardial infarction that has been hospitalized in the past 6 months. c) Exacerbations of chronic obstructive pulmonary disease or other respiratory conditions requiring hospitalization. d) Severely impaired immune function. e) Diseases with excessive sensitivity to radiation such as ataxia telangiectasia. f) Other diseases that may affect particle radiotherapy.\n11. Other circumstances that the physician considers inappropriate to participate in clinical study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"05613452001","EMAIL":[{"email":"jing.li@sphic.org.cn"},{"email":"kun.liu@sphic.org.cn"},{},{},{}],"GEO":[31.22222,121.45806]},{"TITLE":"Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients","CRITERIA":"Inclusion Criteria:\n\n1. Regardless of sex, age \u2265 65, PS 0-2.\n2. metastatic NSCLC of American Joint Committee on Cancer (AJCC) 8th edition confirmed by histology or cytology.\n3. No mutation or fusion of common driving genes, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS-1).\n\n   (adenocarcinoma requires genetic testing).\n4. Positive expression of Programmed cell death 1 ligand 1\uff08PD-L1\uff09 (TPS \u2265 1%).\n5. First-line treatment (stable brain or bone metastasis, or stable symptoms after local treatment).\n6. Before treatment, there were perfect enhanced CT images of chest and supraclavicular area, and measurable tumor lesions.\n7. The estimated survival time is not less than 6 months.\n8. The clinical laboratory criteria within 2 weeks before treatment are as follows: hemoglobin \u2265 110g \/ L, leukocytes \u2265 4x109 \/ L, platelet \u2265 100x109 \/ L, liver and kidney function indexes (such as glutamic pyruvic transaminase, glutamic oxaloacetic transaminase, urea nitrogen, creatinine) were all within 1.25 times of the upper limit of the normal value.\n9. Informed understanding and voluntary participation in this study, and informed consent has been signed.\n\nExclusion Criteria:\n\n1. Mutation or fusion of common driving genes (EGFR,ALK or ROS1).\n2. Have received systemic treatment before.\n3. Previous suffering from other malignant tumors (except stage I non-melanotic skin cancer or cervical carcinoma in situ) or other malignant tumors at the same time.\n4. Other drugs are being tested.\n5. Patients with positive HIV and are receiving antiviral therapy .\n6. Active pulmonary tuberculosis.","SEX":"ALL","AGE_MIN":65,"AGE_MAX":200,"SS_ID":"06032052001","EMAIL":[{},{}],"GEO":[30.58333,114.26667]},{"TITLE":"Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Aged \u2265 18, regardless of gender.\n* Subjects with histologically or cytologically confirmed diagnosis of metastatic or unresectable advanced NSCLC or other solid tumors (including but not limited to head and neck cancer, colorectal, etc.) who have disease progression on, or were not resistant to, or reject the standard treatment.\n* For Part 1, subjects must be diagnosed with EGFR positive and\/or MET positive after testing.\n* For Part 2, patients need to undergo the centralized biomarker testing.\n* Subjects of the dose escalation phase in Part 1 must have evaluable diseases, and others must have measurable diseases as defined in RECIST v1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status scores are 0-1.\n* Expected survival is \u22653 months.\n* With certain organ system functions (without transfusion, use of blood components, or G-CSF support within 14 days before testing), as defined below:\n\n  * Absolute Neutrophil Count (ANC) \u22651.5\u00d710\\^9 \/L\n  * Platelet count (PLT\uff09\u226575\u00d710\\^9 \/L\n  * Hemoglobin (HB) \u226510 g\/dL\n  * Total bilirubin \u22641.5 times the upper limit of normal (ULN)\n  * Alanine amino transferase (ALT) and aspartate amino transferase (AST) \u22643\u00d7ULN\n  * Creatinine \u22641.5\u00d7ULN. If creatinine is \\>1.5\u00d7ULN, creatinine clearance is \u226550 mL\/min as calculated by Cockcroft-Gault formula, or \u226550 mL\/min within 24 h as measured, the patients can still be included.\n* Willing to and capable of following the trial and follow-up schedule.\n* Capable of understanding the trial nature and voluntarily signing the written informed consent form.\n* The subjects of Part 2 must agree that the tumor tissue samples before treatment of the investigational drug can be collected or provided.\n\nExclusion Criteria:\n\n* Use of certain investigational drug or antineoplastic agent within 14 days before first administration of MCLA-129 or within 5 half lives (whichever is longer).\n* Execution of large surgery and radiotherapy (except focal palliative radiotherapy at least 2 weeks before first administration), immunotherapy, chemotherapy (for Nitrosoureas or Mitomycin C and other chemotherapeutics with delayed toxicity, it shall be 6 weeks before first administration) within 4 weeks before first administration of MCLA-129.\n* Patients with colorectal who are diagnosed with AS or BRAF gene mutation through testing.\n* Subjects with NSCLC who previously received more than 2 lines of cytotoxicity chemotherapy for treatment of focal advanced or metastatic disease (excluding maintenance therapy).\n* Subjects who previously received EGFR-TKI (e.g. Poziotinib or TAK-788) that is known to be effective to exon 20 insertion mutation\n* Prior use of EGFR\/c-Met bispecific antibody drugs.\n* Response of toxic reactions related to prior therapy (except alopecia) not up to Grade 1 or below (CTCAE 5.0 criteria) before first administration of MCLA-129.\n* With other malignant tumors in the past 3 years, except cancers that have been cured significantly or can be focally cured, e.g. basosquamous carcinoma of skin, carcinoma cervix in situ, or in situ breast carcinoma.\n* Patients with primary malignant tumor of central nervous system, or metastases to meninges, or concomitantly with symptomatic brain metastases, or new therapy naive brain metastases.\n* With clinically significant cardiovascular disorder, including but not limited to:\n\n  * Deep vein thrombosis or lung embolism diagnosed within 1 month before first administration of the investigational drug. Non-obstructive catheter related clot and other clinically irrelevant thrombosis are not included in the exclusion criteria.\n  * With any of the following medical history within 6 months before first administration of the investigational drug: myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary or peripheral artery bypass, or any acute coronary syndrome.\n  * With abnormal ECG corrected QT interval (QTcF) at rest in the screening period. Re-measurement is made twice at an interval of 4 h above. For average QTcF of 3 ECG inspections: male: \u2265 450 msec, and female: \u2265 470 msec. With clinically significant abnormal heart rate, conduction, and ECG form at rest, e.g. complete left bundle branch block, third-degree conduction block, second-degree conduction block, and PR interval \\> 250 msec.\n  * Poorly controlled hypertension in the investigator's opinion (systolic blood pressure \\> 180 mmHg, or diastolic blood pressure \\> 100 mmHg).\n  * New York Heart Association Grade III-IV congestive heart failure, or hospitalization due to congestive heart failure within 6 months before first administration of the investigational drug.\n  * Pericarditis\/clinically significant pericardial effusion.\n  * Cardiomyopathy.\n  * With clinically significant cardiovascular disorder as believed by other investigators.\n* Active hepatitis B (hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive, and serum HBV DNA \u2265 2000 IU\/mL (equal to 104 copies\/mL)), hepatitis C virus antibody, HIV antibody and treponema pallidum antibody positive.\n* Patients with Interstitial lung disease, including drug-induced Interstitial lung disease or radiation pneumonitis.\n* Current severe disease or medical condition, including but not limited to uncontrolled active infection, and clinically significant lung, metabolic or psychiatric disorders.\n* Women with child bearing potential, pregnant women or lactating women with pregnancy test positive 7 days before treatment, and male and female unwilling to take effective contraception measures or having a birth plan during the treatment and within 3 months after end of treatment.\n* Patients who are known to have allergic reactions and hypersensitivity reactions, or be allergic to MCLA-129 or any other excipients.\n* Patients poorly compliant, unable or unwilling to follow the study and\/or follow-up procedure listed in the protocol, or patients unsuitable to participate in this trial in the investigator's opinion.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04930432053","EMAIL":"wanlin.chen@bettapharma.com","GEO":[30.58333,114.26667]},{"TITLE":"PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer","CRITERIA":"INCLUSION CRITERIA:\n\n1. Patient must have signed a written informed consent form prior to any study specific procedures\n2. Histologically or cytologically confirmed advanced (stage IIIB\/IIIC\/IV), squamous or non-squamous NSCLC\n3. NSCLC patients eligible for treatment with pembrolizumab and chemotherapy according to the European Marketing Authorization:\n\n   1. squamous: in combination with carboplatin and either paclitaxel or nab-paclitaxel\n   2. non squamous with no EGFR or ALK positive mutations: in combination with pemetrexed and a platinum based chemotherapy\n4. Patient \u226518 of age\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1\n6. Life expectancy \\>3 months\n7. Measurable lesion as assessed by RECIST version 1.1\n8. Metastases and\/or primary tumour eligible for 3 dimensional conventional radiotherapy (3D-CRT) or stereotactic ablative radiotherapy (SABR) in terms of dose constraints at organ at risk (according to QUANTEC review)\n9. Patients must have adequate organ function defined by the following laboratory results obtained within 14 days prior to the first study treatment:\n\n   1. absolute neutrophil count of \u22651 500 \/mm\u00b3\n   2. platelets \u2265 100 000\/mm\u00b3\n   3. haemoglobin \\>9 g\/dL (transfusions allowed)\n   4. creatinine clearance \\>60 mL\/min\n   5. bilirubin \u22641.5 X upper limit of normal (ULN) (unless Gilbert's syndrome where 3 X ULN is permitted)\n   6. serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u22642.5 X ULN (unless documented liver metastasis where \u22645 X ULN is permitted)\n   7. Alkaline phosphatase (ALP) \u22642.5 X ULN (unless documented bone or liver metastasis where \u22645 X ULN is permitted)\n   8. International normalized ratio (INR), prothrombin (PT), and prothrombin time (PTT) \u22641.5 X ULN (unless the subject is receiving anticoagulant therapy)\n10. Woman of childbearing potential and male patients must agree to use adequate contraception for the duration of study participation and up to 6 months after completing treatment\/therapy\n11. Patients affiliated to the social security system (or equivalent)\n12. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits, and examinations including follow-up\n\nNON-INCLUSION CRITERIA:\n\n1. Non-squamous NSCLC with targetable tumor mutations, activating EGFR mutations or ALK translocation Note: documentation of these mutation for non-squamous histology is mandatory as standard of care\n2. Stage IIIB\/IIIC NSCLC patient eligible to curative (thoracic radiotherapy or surgery) treatments in first line treatment\n3. Prior therapy with T-cell costimulation or checkpoint-targeted agents Note: Stage I-III NSCLC who previously received single-agent anti-PD(L)1 immunotherapy and ultimately develop metastases remain eligible (minimal immunotherapy washout period of 3 months)\n4. Clinical need of radiotherapy (e.g.: whole brain irradiation, painful metastasis, bleeding, compressive metastases)\n5. Irradiation within 2 months before inclusion\n6. Leptomeningeal carcinomatosis, or metastases with indistinct borders making targeting not feasible\n7. Patient with evidence of active (presence of symptoms or requiring steroid treatment) central nervous system (CNS) metastases and\/or carcinomatous meningitis. Patient with brain metastasis can be included if asymptomatic and not requiring steroids\n8. Metastases located within 3 cm of the previously irradiated structures (EQD2doses):\n\n   1. Spinal cord previously irradiated to \\>40 Gy;\n   2. Brachial plexus previously irradiated to \\>50 Gy;\n   3. Small intestine, large intestine, or stomach previously irradiated to \\>45 Gy;\n   4. Brainstem previously irradiated to \\>50 Gy;\n   5. Lung previously irradiated with prior V20Gy \\>30%\n9. Active autoimmune disease except vitiligo, type-1 diabetes, hypothyroid stabilized with hormonal substitution, psoriasis\n10. Symptomatic interstitial lung disease\n11. Systemic immunosuppression or systemic immunosuppressive medicinal products within 2 weeks prior to study entry\n12. Concomitant treatment with steroids \\> 10 mg Note1: higher dose of steroids can be prescribed in case of occurrence of toxicities during radiotherapy; prophylactic dose of maximum 1 mg per kg during 2 weeks are authorized during the delivery of more than 6 Gy per fraction Note2: temporary use of steroid (less than 4 weeks) at a dose of 1 mg\/kg is accepted\n13. Prior invasive malignancy within the past 2 years (except non-melanomatous skin cancer non-invasive carcinoma in-situ of the breast, oral cavity, bladder or cervix)\n14. Known Acquired Immune Deficiency Syndrome (AIDS) or severe uncontrolled co-morbidity\n15. Known currently active infection including hepatitis B and hepatitis C\n16. Patient who was administered a live, attenuated vaccine within 28 days prior to enrolment\n17. Patient with any other disease or illness that requires hospitalisation or is incompatible with the study treatment are not eligible. Patient unable to comply with study obligations for geographic, social, or physical reasons, or who is unable to understand the purpose and procedures of the study\n18. Patient who have taken any investigational medicinal product or have used an investigational device within 30 days of inclusion\n19. Pregnant or breast feeding woman\n20. Person deprived of their liberty or under protective custody or guardianship\n21. If pemetrexed: patient is unable or unwilling to take folic acid or vitamin B12 supplementation\n22. Pre-existing peripheral neuropathy of a severity of grade \u2265 2 by NCI CTCAE v5.0\n23. Known hypersensitivity to one of the compounds or substances used in this protocol\n24. Major surgery within the 28 days before initiating study treatment","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03774732058","EMAIL":[{}],"GEO":[43.73333,7.41667]},{"TITLE":"Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment","CRITERIA":"Inclusion Criteria:\n\n* 1. Previously untreated patients with histologically- or cytologically- documented NSCLC who present stage IIIA disease (according to 8th version of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology) and also, potentially resectable locally advanced NSCLC patients' stage IIIB with T3N2 disease according to 8th edition can be included.\n* 2. Tumor should be considered resectable before study entry by a multidisciplinary team\n* 3. ECOG 0-1\n* 4. Age \u2265 18 years at time of study entry\n* 5. Patients that are going to be treated with neoadjuvant treatment before surgery\n* 6. Patient capable of proper therapeutic compliance and accessible for correct follow-up\n* 7. Patients must have signed, dated and IRB\/EC-approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol-related procedures that are not part of normal subject care.\n\nExclusion Criteria:\n\n* 1. Patients who refuse to sign and date an IRB\/IEC-approved written informed consent form.\n* 2. No possibility of venipuncture\n* 3. Any medical, mental, or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05382052020","EMAIL":[{},{}],"GEO":[41.65518,-4.72372]},{"TITLE":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","CRITERIA":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of unresectable Stage IIIb not amenable to treatment with combined modality chemoradiation (advanced) or Stage IV (metastatic) NSCLC\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2\n* Measurable disease\n* Adequate recovery from most recent systemic or local treatment for cancer\n* Adequate organ function\n* Life expectancy greater than or equal to (\\>\/=) 12 weeks\n* For female participants of childbearing potential and male participants, willingness to use acceptable methods of contraception\n\nExclusion Criteria:\n\n* Inability to swallow oral medication\n* Women who are pregnant or lactating\n* Symptomatic, untreated CNS metastases\n* History of malignancy other than NSCLC within 5 years prior to screening with the exception of malignancies with negligible risk of metastasis or death\n* Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within 3 months prior to randomization, unstable arrhythmias, or unstable angina\n* Known active or uncontrolled human immunodeficiency virus (HIV) infection\n* Either a concurrent condition or history of a prior condition that places the patient at unacceptable risk if he\/she were treated with the study drug or confounds the ability to interpret data from the study\n* Inability to comply with other requirements of the protocol","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03178552204","EMAIL":"global-roche-genentech-trials@gene.com","GEO":[41.01384,28.94966]},{"TITLE":"A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Patients should voluntarily join this study and sign the informed consent form\n2. NSCLC patients diagnosed by cytology or histology and not previously receiving anti-tumor treatments (including systemic treatments, local treatments .etc)\n3. Patients with IIIB - IVA oligometastatic NSCLC : (a) IIIB - IIIC stage (T1-4N2-3): patients are not suitable or refuse to receive upfront surgical resection or radiotherapy; (b) oligometastatic stage IV (T1-3N0-2): radical resection\/radiotherapy is feasible for metastatic lesions (the number of metastases being up to 3, and the maximum diameter of metastases being up to 2cm)\n4. After evaluation by MDT, upfront surgical resection is not the preferred treatment, but after induction systemic treatments, radical resection of the primary tumor is feasible, and radical resection\/radiotherapy is feasible for extrathoracic metastases (if any)\n5. Age from 18 to 75 years old, both male and female\n6. ECOG score 0-1\n7. According to the RECIST v1.1 , patients should have at least one measurable lesion\n8. For suspicious mediastinal lymph nodes (including pathological enlargement or PET-CT indicating malignancy, etc.), further sampling is required for pathological diagnosis by EUBS, thoracoscopy, or mediastinoscopy\n9. According clinical evaluation, the lung function of patients (such as FVC, FEV1, TLC, FRC, DLco, etc.) should be sufficient for pneumonectomy\n10. The function of important organs should meet the following requirements: absolute count of neutrophils \u2265 1.5 \u00d7 109\/L\uff1b Platelets \u2265 100 \u00d7 109\/L\uff1b Hemoglobin \u2265 90g\/L; Serum albumin \u2265 35g\/L; Thyroid hormone (TSH) \u2264 1 \u00d7 ULN\uff1b Serum bilirubin \u2264 1.5 \u00d7 ULN\uff1b ALT and AST \u2264 3 \u00d7 ULN\uff1b International standardized ratio (INR) \u2264 1.5 or prothrombin time (PT) \u2264 1.5 \u00d7 ULN\uff1b Serum creatinine \u2264 1.5 \u00d7 ULN\n11. Female patients at childbearing age are required to use contraceptive measures; for male patients whose partners are women at childbearing age, effective methods of contraception should be used during the trial period\n\nExclusion Criteria:\n\nPatients who meet any of the following conditions will not be enrolled in this study:\n\n1. NSCLC patients have sensitive EGFR mutation, EML4-ALK fusion or other forms of ALK gene changes\n2. Patients have previously received immune checkpoint inhibitors such as PD-1\/ PD-L1\/CTLA4 antibody\n3. Patients with other primary malignancies within the past 3 years (excluding cured skin basal cell carcinoma and cervical carcinoma in situ)\n4. Patients with active hepatitis B\/C\n5. Patients with any active autoimmune diseases or a history of autoimmune diseases\n6. Patients who are using immunosuppressive agents or require systemic hormone therapy\n7. Patients with hypertension but without good control even through antihypertensive medication treatment ; patients with clinical symptoms or diseases related to unsatisfying cardiac function\n8. Patients with abnormal coagulation function (INR\\>2.0, PT\\>16s)\n9. Arterial\/venous thrombotic events occurred before screening within 6 months\n10. Patients with active infection\n11. Patients with congenital or acquired immune dysfunction (such as HIV infection)\n12. According to the judgment of the researchers, patients have other factors that may affect the results of the research or cause the research to be terminated","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05837052001","EMAIL":[{"email":"weijiafang@zju.edu.cn"}],"GEO":[30.29365,120.16142]},{"TITLE":"The Effect of Beta-glucan in Non-Small Cell Lung Cancer","CRITERIA":"AIM 2:\n\nInclusion Criteria:\n\n* suspected or definitive diagnosis of non-small cell lung cancer (NSCLC)\n* treatment naive or no treatment within 6 months prior to enrollment\n* able to swallow pills\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3\n* absolute neutrophil count (ANC) at least 1500\/microl\n* able to understand and willing to sign a written informed consent document\n\nExclusion Criteria:\n\n* history of hypersensitivity reactions attributed to beta-glucan\n* currently receiving continuous corticosteroids or other ongoing immunosuppressive therapy\n* presence of an uncontrolled intercurrent illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\/social situations that would limit compliance with study requirements\n\nAIM 3:\n\nInclusion Criteria:\n\n* resectable non-small cell lung cancer (NSCLC), as determined by a thoracic surgeon\n* treatment naive\n* able to swallow pills\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n* must be an operative candidate\n* absolute neutrophil count (ANC) at least 1500\/microl\n* able to understand and willing to sign a written informed consent document\n\nExclusion Criteria:\n\n* history of hypersensitivity reactions attributed to beta-glucan\n* currently receiving continuous corticosteroids or other ongoing immunosuppressive therapy\n* presence of an uncontrolled intercurrent illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\/social situations that would limit compliance with study requirements","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"00682032001","EMAIL":[{}],"GEO":[38.25424,-85.75941]},{"TITLE":"A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC","CRITERIA":"Inclusion Criteria:\n\n1.18 to 75 years old, both male and female;\n\n2.ECOG score: 0-1;\n\n3.Histopathologically or cytologically confirmed, stage III (AJCC 8th) non-small cell lung cancer;\n\n4.Multidisciplinary team (MDT) discussion confirmed unresectable disease but can be treated by curative radiotherapy;\n\n5.Measurable lesions available;\n\n6.Major organ function is basically normal;\n\n7.Estimated survival time is at least 6 months;\n\n8.Non-surgically sterile female subjects of childbearing age must have a negative serum HCG test before inclusion.\n\nExclusion Criteria:\n\n1. Histologically or cytologically confirmed mixed SCLC and NSCLC;\n2. Subjects with driver gene mutations(EGFR mutation, ALK fusion, etc.);\n3. Previous systemic anti-tumor therapy including immune checkpoint inhibitors for NSCLC;\n4. Previous thoracic radiotherapy;\n5. Subjects who participated in other clinical trials within 4 weeks or 5 drug half-lives(whichever is shorter) before the first dose;\n6. Systemic immunostimulant therapy before the first dose;\n7. Systemic immunosuppressive therapy before the first dose or were expected to require systemic immunosuppressive drugs during the study treatment;\n8. Subjects with autoimmune diseases;\n9. Other malignant tumors other than non-small cell lung cancer within 5 years before screening;\n10. Known or suspected interstitial pneumonia;\n11. Other moderate to severe lung diseases that may interfere with the detection or treatment of drug-related pulmonary toxicity and seriously affect respiratory function;\n12. Severe cardiovascular and cerebrovascular diseases;\n13. Clinically significant bleeding symptoms or significant bleeding tendency within 1 month before the first dose;\n14. Arteriovenous thrombotic events within 3 months before the first dose;\n15. Positive HIV test;\n16. Active hepatitis B or C;\n17. Evidence of active tuberculosis infection within 1 year before the first dose;\n18. Serious infection within 4 weeks before the first dose;\n19. History of attenuated live vaccination 28 days before the first dose or expected to receive attenuated live vaccination during the study;\n20. Major surgeries other than diagnosis or biopsy within 28 days prior to the first dose;\n21. Previous or planned allogeneic bone marrow transplantation or solid organ transplantation;\n22. History of severe allergic reactions to other monoclonal antibodies\/fusion proteins;\n23. Allergic to any component of the randomized treatment regimen;\n24. Female subjects who are pregnant, lactating, or planning to get pregnant during the study period;\n25. Subjects who have a known history of psychotropic drug abuse, alcoholism, or drug abuse;\n26. Presence of other conditions that, in the opinion of the investigator, would make participation in this clinical trial inappropriate.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05940532001","EMAIL":[{"email":"liuhuai@hnca.org.cn"}],"GEO":[28.19874,112.97087]},{"TITLE":"Immunotherapy in Lung Cancer: Treatment After IO Cessation.","CRITERIA":"Inclusion Criteria:\n\n* Histological diagnosis of non-small cell lung cancer (NSCLC)\n* Stage IVA\/IVB and unresectable and non irradiable stage III NSCLC na\u00efve of immunotherapy.\n* Patients who receive immunotherapy (any type) monotherapy, combined immunotherapy or in combination with chemotherapy for first or second-line treatment.\n* Availability for participating in the detailed follow-up of the protocol.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients receiving adjuvant immunotherapy for stage I-III NSCLC are not eligible\n* Tumours for which TNM stage at time of study inclusion cannot be assessed.\n* History of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or of the bladder or cured malignant tumor (more than 5-year disease free interval).\n* Any type of immunotherapy for previous cancer","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04465942001","EMAIL":[{},{}],"GEO":[50.85045,4.34878]},{"TITLE":"A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Men or women aged more than or equal to (\u2265) 18 years.\n2. Histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC with RET fusion-positive, including recurrent or initial diagnosed Stage IIIB-IIIC\/IV NSCLC that is not suitable for radical surgery.\n3. A RET gene fusion is required by using tumor tissue for central testing.\n4. At least one measurable lesion in accordance with RECIST 1.1\n5. Eastern Cooperative Oncology Group (ECOG) performance status: 0\\~1.\n6. Estimated life expectancy \\>12 weeks.\n7. Reproductive-age women agree to use adequate contraception and cannot breastfeed while participating in this study and for a period of 6 months after the last dose. Likewise, men also consent to use adequate contraceptive method within the same time limit.\n8. Females must have evidence of non-childbearing potential.\n9. Signed and dated Informed Consent Form.\n\nExclusion Criteria:\n\n1. Treatment with any of the following:\n\n   Additional validated oncogenic drivers in NSCLC if known. Previous or current treatment with selective RET inhibitors or multi-kinase Inhibitor of RET.\n\n   Prior systemic therapy for metastatic disease. Treatment (including chemotherapy or immunotherapy) in the adjuvant\/neoadjuvant setting is permitted if it was completed at least 6 months prior to relapse.\n\n   Local radiotherapy for palliation within 2 weeks of the first dose of study drug, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks of the first dose.\n\n   Major surgery (including craniotomy, thoracotomy, or laparotomy, etc.) within 4 weeks of the first dose of study drug.\n2. Inadequate bone marrow reserve or serious organ dysfunction.\n3. Uncontrolled pleural effusion or ascites or pericardial effusion.\n4. Known and untreated, or active central nervous system metastases.\n5. Active autoimmune diseases or active infectious disease\n6. Refractory nausea, vomiting, or chronic gastrointestinal diseases, or inability to swallow oral medications.\n7. History of severe allergic reaction, hypersensitivity to any active or inactive ingredient of HS-10365 or to drugs with a similar chemical structure or class to HS-10365.\n8. The subject who is unlikely to comply with study procedures, restrictions, or requirements judged by the investigator.\n9. The subject whose safety cannot be ensured or study assessments would be interfered judged by the investigator.\n10. Pregnant women, breastfeeding women or woman who has a child-bearing plan during the study.\n11. History of neuropathy or mental disorders, including epilepsy and dementia","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06147570001","EMAIL":[{"email":"shun_lu@hotmail.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors","CRITERIA":"* INCLUSION CRITERIA:\n* Patients with histologically or cytologically confirmed NSCLC, SCLC, ESCC, PNET, and TET.\n* Patients consulted in the Clinical Center without a definitive diagnosis, but clinically considered likely to have a thoracic malignancy of the above histologies, pending further tissue acquisition and\/or pathology review.\n* Age greater than or equal to18 years. Children are excluded from the study, as the above thoracic malignancies are rare in this population.\n* Ability of subject to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* Active symptomatic major organ disorder that would increase the risk of biopsy, including but not limited to ischemic heart disease, recent myocardial infarction, active congestive heart failure, pulmonary dysfunction.\n* Active concomitant medical or psychological illnesses that may increase the risk to the subject, at the discretion of the principal investigator.\n* Known HIV-positive patients on combination antiretroviral therapy are ineligible.\n* Pregnant women are ineligible.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"02146170001","EMAIL":[{"email":"ccopr@nih.gov"}],"GEO":[38.98067,-77.10026]},{"TITLE":"Liquid Biopsy in Advanced Oligometastatic NSCLC Receiving Surgery","CRITERIA":"Inclusion Criteria:\n\n* Written informed consent must be obtained from patients and ability for patients to comply with the requirements of the study\uff1b\n* Patients must be a man or woman of more than 18 years;\n* ECOG PS \u22661\uff1b\n* The function of the organs was evaluated by the surgeon to tolerate local surgical treatment\uff1b\n* The classification was evaluated as simultaneous oligometastases at initial treatment or oligoresidual\/oligoprogression\/oligorecurrence after induction therapy; \\[Define: Initial treatment of simultaneous oligometastases: without systemic treatment, at the time of diagnosis, up to 5 metastases and up to 3 organs were involved, excluding pleural metastases or myeloid metastases.\n\nOligoresidual after induction therapy: after systemic therapy, distant metastases were stable or reduced, primary lesions were stable or reduced, PET\/CT metabolism was reduced, and no more than 5 residual lesions and no more than 3 organs were involved.\n\nOligoprogression after induction therapy: After systemic therapy, some lesions were stable or reduced, while some original lesions were larger than before.\n\nOligorelapses after induction therapy: after systemic therapy, systemic lesions were stable or reduced, and new local lesions appeared.\\]\n\n* Lesion evaluation can be surgically removed. \\[Definition of operable resection: the lesion is limited and can be completely removed through surgery as assessed by the surgeon, with no significant impact on postoperative quality of life. Pulmonary surgical procedures include lobectomy, segmental resection and wedge resection. Pneumonectomy is not included.\\]\n\nExclusion Criteria:\n\n* Patients with a confirmed or suspected autoimmune disease;\n* Patients with a history of human immunodeficiency virus (HIV) positive or acquired immunodeficiency syndrome (AIDS);\n* Patients with a history of any arterial thrombosis within 6 months and history of deep vein thrombosis, pulmonary embolism, or any other severe thromboembolism within 3 months;\n* Patients with any unstable systemic disease (eg, active infection, high-risk hypertension, unstable angina, congestive heart failure, etc.);\n* Patients with a history of other malignancies in the past 5 years;\n* Patients identified by the investigators patients with contraindications to local treatment;\n* Patients with serious mental illness;\n* Patients who cannot sign informed consent;\n* Patients who cannot be followed up as scheduled;","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05648370001","EMAIL":[{"email":"syzhongwenzhao@scut.edu.cn"},{"email":"ruifu66@foxmail.com"}],"GEO":[23.11667,113.25]},{"TITLE":"A Study of IMM-6-415 in RAS\/RAF Mutant Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Age \u226518 years\n* Life expectancy \\>16 weeks\n* Part 1: Histologically or cytologically confirmed diagnosis of a locally advanced unresectable or metastatic solid tumor malignancy harboring RAS (NRAS, KRAS, or HRAS)- or RAF- (ARAF, BRAF, RAF1) activating mutations, as documented by genomic analysis. Results of mutation analysis must be available prior to participant enrollment. A prior genomics report from archival tissues or liquid biopsy demonstrating mutation is acceptable\n* Part 2: Histologically or cytologically confirmed diagnosis of one of the following locally advanced unresectable or metastatic solid tumor malignancies: pancreatic adenocarcinoma, RASmut melanoma, Class I BRAFmut melanoma, RASmut NSCLC, other RASmut GI cancers (aside from CRC) or any other RAFmut solid tumor as documented by genomic analysis. Results of mutation analysis must be available prior to participant enrollment. A prior genomics report from archival tissues or liquid biopsy demonstrating mutation is acceptable\n* Participants must have received at least 1 line of systemic standard-of-care treatment for their advanced or metastatic disease and in the assessment of the Investigator, would be unlikely to tolerate or derive clinically meaningful benefit from other treatment options\n* Participants previously treated with codon-specific inhibitors of KRAS (including investigational agents) are eligible\n* KRASG12C mutant participants must have received prior treatment with a KRASG12C inhibitor for any approved indication\n* Radiologic evidence of measurable disease (i.e., at least 1 target lesion) according to RECIST 1.1 criteria\n* ECOG performance status 0 or 1.\n* Participant has adequate organ function\n\nExclusion Criteria:\n\n* Inability to swallow oral medications.\n* Symptomatic, untreated, or actively progressing known central nervous system metastases.\n* Uncontrolled pleural or pericardial effusion or ascites requiring repeated drainage more than once every 28 days. In dwelling catheters are allowed.\n* History of severe COVID-19 infection resulting in current need of supplemental O2 therapy to maintain resting oxygen saturations \u226590%.\n* Presence of ongoing toxicities related to prior anticancer therapy that have not resolved to Grade \u22641 and are not otherwise allowed\n* Impaired cardiac function or clinically significant cardiac disease\n* Uncontrolled intercurrent illness including but not limited to poorly controlled diabetes or any medical condition determined by the Investigator to be a risk\n* History or concurrent evidence of retinal vein occlusion (RVO) or current risk factors for RVO. History of clinically significant serous retinopathy, central serous chorioretinopathy or retinal edema.\n* History of rhabdomyolysis within 3 months prior to Study Day 1\n* HIV-infected participant must be on anti-retroviral therapy and have a well-controlled HIV infection\/disease\n* Participants with a history of HBV infection no longer requiring treatment are eligible; participants with a history of HCV infection are eligible if HCV viral load is undetectable at screening.\n* Females who are pregnant, breastfeeding, or planning to become pregnant and males who plan to father a child while enrolled in this study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06208124005","EMAIL":[{}],"GEO":[29.76328,-95.36327]},{"TITLE":"Local Therapy in Advanced NSCLC With Non-progressive Disease (PD) After First Line Therapy","CRITERIA":"Inclusion Criteria:\n\n* Male or female, age \\>= 18 years, with life expectancy of at least 12 weeks.\n* Patients with histologically documented metastatic (stage IV) non-small cell lung cancer.\n* Subjected to driving genes examination including EGFR, ALK and ROS1.\n* Achieve complete response (CR)\/partial response (PR)\/stable disease (SD) after front line systemic treatment (chemotherapy, targeted therapy or immunological checkpoint inhibitors).\n* Total metastatic lesions is limited to five.\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of \\<= 2.\n* Patients must have measurable disease according to the RECIST (version 1.1) criteria.\n* Adequate organ function as defined by the following criteria:\n\n  * Liver function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\<= 2.5 upper limit of normal (ULN) in the absence of liver metastases or up to 5 ULN in case of liver metastases. Total bilirubin \\<= 1.5 ULN.\n  * Bone marrow function: Granulocyte count \\>= 1,500\/mm3 and platelet count \u2265100,000\/mm3 and hemoglobin \\>= 80g\/dl.\n  * Renal function: serum creatinine \\<= 1.5 ULN or creatinine clearance \\>= 60 ml\/min. (based on modified Cockcroft-Gault formula).\n  * Adequate coagulating function.\n* For all females of childbearing potential a negative serum\/urine pregnancy test must be obtained within 48 hours before enrollment. Postmenopausal women must have been amenorrhoeic for at least 12 months to be considered of non-childbearing potential. Males must agree to use effective contraception during the study period and for at least 12 weeks after completion of the study treatment.\n* Written (signed) informed Consent to participate in the study.\n* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n* Stage I-III a NSCLC completing radical treatment , then undergoing systemic anti-cancer treatment after recurrence.\n* Patients with PFS no more than 3 months. to first line theray.\n* Patients with history of any other malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer).\n* Prior palliative surgery or other local therapy specifically directed against advanced lung cancer.\n* Contraindication for localized treatment including surgery, radiotherapy or interventional therapy judged by physicians.\n* Patients with any unstable systemic disease (including active infections, significant cardiovascular disease, any significant hepatic, renal or metabolic disease).\n* Patients who are at risk (in the investigator's opinion) of transmitting human immunodeficiency virus (HIV) through blood or other body fluids.\n* Nursing or lactating women.\n* Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study.\n* Patients who has mental disorder or other disease that contribute to no compliance.\n* Unwilling to write informed consent to participate in the study.\n* Patients who is unwilling to accept the follow-up.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03046316001","EMAIL":[{"email":"hunterol@163.com"},{"email":"huifen8839@163.com"}],"GEO":[23.11667,113.25]},{"TITLE":"Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer","CRITERIA":"Key Inclusion Criteria:\n\n1. Histologically confirmed NSCLC that is at advanced stage for which there are no approved therapies available expected to confer clinical benefit as defined in the protocol\n2. Willing to provide tumor tissue from newly obtained biopsy from tumor site. Newly obtained biopsies at tissue screening are required. An archival sample can be accepted only after discussion with the medical monitor and if the sample is not more than 6 months old and was obtained on the treatment regimen prior to study screening or after completion of the last therapy. The enrollment of patients will be based on an immunohistochemistry (IHC)-based assay using freshly obtained tumor biopsies or an archival biopsy as described above. Only patients with MET overexpressing tumors by central IHC analysis will be enrolled. For expansion cohorts only: tumor site for biopsy must not have been irradiated previously and must not be the only measurable lesion.\n3. Tumor must overexpress MET protein as defined in the protocol\n4. For expansion only: At least one lesion that is measurable by RECIST 1.1. Tumor lesions in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions after radiation.\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n6. Adequate organ and bone marrow function as defined in the protocol\n\nKey Exclusion Criteria:\n\n1. Has received treatment with an approved systemic therapy or has participated in any study of an investigational agent or investigational device within 2 weeks or 5 half-lives of the prior treatment, whichever is shorter with a minimum of 7 days from the first dose of study therapy\n2. Has not yet recovered (ie, grade \u22641 or baseline) from any acute toxicities resulting from prior therapy except as described in the protocol\n3. Has received radiation therapy or major surgery within 14 days of first administration of study drug or has not recovered from adverse events as defined in the protocol\n4. Another malignancy that is progressing or requires active treatment except as noted in the protocol\n5. Untreated or active primary brain tumor, central nervous system (CNS) metastases, leptomeningeal disease, or spinal cord compression as defined in the protocol\n6. Encephalitis, meningitis, organic brain disease (eg Parkinson's disease) or uncontrolled seizures in the year prior to first dose of study therapy\n7. Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection; or diagnosis of immunodeficiency as defined in the protocol\n\nNOTE: Other protocol-defined Inclusion\/ Exclusion criteria apply","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04982224012","EMAIL":[{"email":"Carrie.Friedman@usoncology.com"},{}],"GEO":[38.84622,-77.30637]},{"TITLE":"Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI na\u00efve Patients","CRITERIA":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer which is not amenable to treatment with a curative aim (e.g. surgery or radiation). Patients who underwent curative intent surgery or definitive CRT and experience recurrence after 6 months are eligible.\n* Stage IIIC or IV by AJCC 8th edition\n* Confirmed EGFR mutations (exon 19 deletion, L858R)(The result from both cell-free DNA or tissue-based DNA from the local test is allowed.)\n* Age of 19 or more.\n* Performance status of Eastern Cooperative Oncology Group 0 to 2.\n* Expected minimum life expectancy of 12 weeks\n* Adequate organ function.\n\n  * Available to provide the adequate tissue and blood for the genomic tests- At least 15 unstained slide and 20 cc of blood at baseline (mandatory) and disease progression.\n* Agreed to perform re-biopsy at the timepoint of disease progression.\n* At least two weeks after the chemotherapy\n* Female subjects must either be of non-reproductive potential\n* Subject willing and able to comply with the protocol\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Previously treatment with any kind of EGFR TKI (Previously chemotherapy treated patients is allowed)\n* Any concurrent and\/or other active malignancy that has required systemic treatment within 2 years of first dose of study drug. (allowed for participation if investigator decided that previous malignancy is cured and not need for any additional treatment)\n* Uncontrolled central nervous system metastases- patient with asymptomatic brain metastases or CNS symptom manageable with TKI and evaluated by investigator can be enrolled.\n* Spinal cord compression, leptomeningeal carcinomatosis\n* Uncontrolled systemic illness, including uncontrolled hypertension, active bleeding, or active infection\n* Radiotherapy with a wide field of radiation within 2 weeks or radiotherapy with a limited field of radiation (localized radiotherapy or gamma knife surgery) for palliation within 1 week\n* Any unresolved toxicities from prior therapy, greater than CTCAE grade 1\n* Mean QT interval corrected for heart rate (QTc) \u2265 470 ms\n* No measurable lesion\n* Unable to swallow the product due to refractory nausea, vomiting or chornic gastrointestinal disease.","SEX":"ALL","AGE_MIN":19,"AGE_MAX":200,"SS_ID":"05463224001","EMAIL":[{}],"GEO":[37.566,126.9784]},{"TITLE":"A Study of YL-17231 in Patients With Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\nThe patients must meet all the following inclusion criteria to be eligible for enrollment in this trial:\n\n1. Age between 18 and 75 years (inclusive), with no gender restriction.\n2. Locally advanced or metastatic solid tumors diagnosed histologically and genomically confirmed with KRAS mutation, excluding patients with a clear KRAS wild-type test report in the case of pancreatic cancer.\n\n   A. For patients with NSCLC, previous treatment failure based on platinum-based first-line therapy; B. For patients with colorectal cancer, previous experience with at least two lines of systemic therapy (patients with colorectal cancer and high microsatellite instability should have received PD-1 or PD-L1 therapy if clinically applicable); C. For patients with solid tumors other than NSCLC or colorectal cancer, at least one prior systemic treatment is required.\n3. In the dose escalation phase, measurable or non-measurable tumor lesions are acceptable based on RECIST1.1 criteria; in the dose expansion phase, at least one measurable tumor lesion is required.\n4. ECOG performance status (PS) of 0-1.\n5. Estimated life expectancy of \u22653 months.\n6. Good organ function levels:\n\n   * Absolute neutrophil count (ANC) \u22651.5\u00d7109\/L;\n   * Platelet count (PLT) \u2265100\u00d7109\/L;\n   * Hemoglobin (Hb) \u226590g\/L (no blood transfusion within 14 days before screening);\n   * Total bilirubin (TBIL) \u22641.5 times the upper limit of normal;\n   * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u22642.5 times the upper limit of normal (\u22645.0 times the upper limit of normal for patients with liver metastasis);\n   * Serum creatinine (Cr) \u22641.5 times the upper limit of normal or creatinine clearance \u226550ml\/min;\n   * Left ventricular ejection fraction (LVEF) \u226550%;\n   * Fridericia-corrected QT interval (QTcF) \\<450ms.\n7. Washout period of \u22654 weeks for macromolecular agents and intravenous chemotherapy drugs, and \u22652 weeks for oral fluoropyrimidine and small molecule targeted drugs.\n8. Fertile males and females must agree to use medically approved contraceptive measures during the study period and for 6 months following the last administration of the study drug.\n9. Women of childbearing potential must have a negative pregnancy test within 7 days prior to the first administration of the study drug; patients must not be breastfeeding, and if the subject has already ceased breastfeeding at the time of study entry, breastfeeding must have been discontinued from the day of the first administration of the study drug till at least 30 days after last administration of the study drug .\n10. No previous treatment with investigational drugs within 1 month prior to participation in this trial.\n11. High compliance and willingness to complete the trial as assessed by the investigator, and ability to adhere to the study protocol.\n12. Voluntary participation in this clinical trial, understanding of the study procedures, and ability to provide written informed consent.\n\nExclusion Criteria:\n\nPatients with any of the following conditions are not eligible for enrollment in this study:\n\n1. Uncontrollable third-space effusion (such as large amounts of pleural or ascitic fluid).\n2. Grade 3 or 4 gastrointestinal bleeding or variceal bleeding requiring transfusion, endoscopy, or surgical intervention within the past 3 months.\n3. Previous diagnosis of other malignancies within the past five years, except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or cured in situ cervical cancer.\n4. Inability to swallow, chronic diarrhea, or intestinal obstruction that could affect medication intake and absorption.\n5. History of significant neurological or psychiatric disorders.\n6. Active hepatitis B (positive for hepatitis B surface antigen and\/or hepatitis B core antibody with HBV-DNA \u2265103 copies\/mL or \u2265200 IU\/mL) or hepatitis C (positive for hepatitis C virus antibody and\/or HCV-RNA).\n7. History of immunodeficiency, including positive HIV test, acquired or congenital immunodeficiency disorders, organ transplantation, or allogeneic bone marrow transplantation.\n8. Major surgical procedures (excluding biopsy) within the past 4 weeks prior to the first administration of the study drug, significant trauma, or the need for elective surgery during the study period, or radical radiotherapy within the past 4 weeks prior to the first administration of the study drug.\n9. Moderate or severe cardiac diseases:\n\n   * Myocardial infarction, angina, III\/IV congestive heart failure, pericardial effusion, or uncontrolled severe hypertension (up to 150\/90 mmHg or below) within the past 6 months prior to the first administration of the study drug;\n   * Clinically significant electrocardiogram abnormalities, such as symptomatic or persistent atrial or ventricular arrhythmias, second or third-degree atrioventricular block, bundle branch block, or ventricular hypertrophy;\n   * Significant abnormalities on echocardiography, such as moderate or severe valvular dysfunction, assessed based on institutional lower limits; patients with minimal or mild valve regurgitation (tricuspid, pulmonary, mitral, or aortic) can be included in this study;\n   * Various factors that may increase the risk of QTcF prolongation or cardiac arrhythmia events, such as hypokalemia, congenital long QT syndrome, or concomitant use of drugs that may prolong the QT interval.\n10. Untreated brain metastases that meet one or more of the following criteria:\n\n    * Requiring corticosteroids or dehydration treatment (excluding the use of antiepileptic drugs after surgery or radiotherapy);\n    * Presence of clinically significant symptoms;\n    * Tumor stability after radiotherapy or surgery lasting no longer than 4 weeks. Asymptomatic or controlled stable patients with treated brain metastases are eligible for enrollment.\n11. Unresolved treatment-related toxicity greater than Grade 1 according to CTCAE 5.0 at the start of study treatment (alopecia excluded).\n12. Medical conditions that, in the opinion of the investigator, pose a serious risk to patient safety or could interfere with the patient's ability to complete the study, such as uncontrolled diabetes, thyroid disease, interstitial lung disease, severe active infections, or uncontrolled chronic infections, Child-Pugh Class B or C liver cirrhosis.\n13. Other reasons deemed unsuitable for participation in this study by the investigator.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06078800001","EMAIL":[{"email":"xurh@sysucc.org.cn"}],"GEO":[23.11667,113.25]},{"TITLE":"Heterogeneity of Dendritic Cells in Colon and Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* men and women aged \u226518 years;\n* clinical diagnosis confirmed by common investigations to establish the presence of colon or lung cancer;\n* lesions\\> 1 cm;\n* legal capacity to give informed consent in accordance with ICH \/ EU GCP and national \/ local regulations.\n\nExclusion Criteria:\n\n* pregnancy;\n* presumed pregnancy;\n* known coagulation defects;\n* alcohol or drug abuse","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04789252002","EMAIL":[{},{}],"GEO":[45.58005,9.27246]},{"TITLE":"Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study","CRITERIA":"Inclusion Criteria:\n\n1. Provision of written informed consent prior to any study specific procedures, including screening evaluations that are not SOC.\n2. Age \u2265 18 years at time of study entry.\n3. Histologically confirmed NSCLC\n4. Ongoing or planned osimertinib treatment according to marketing authorization (first line treatment of tumor positive for a common or uncommon EGFR mutation, or later line treatment of tumor positive for EGFR T790M mutation, assessed according to local standard. First line therapy is defined as therapy used to treat advanced disease. Each subsequent line of therapy is preceded by disease progression. A switch of an agent within a regimen in order to manage toxicity does not define the start of a new line of therapy. Experimental therapies when given as separate regimen are considered as separate line of therapy. Maintenance therapy following platinum doublet-based chemotherapy is not considered as a separate regimen of therapy.)\n5. Clinical indication for radiotherapy of one or more lesions, for instance for local symptom control of primary tumor or metastasis, for oligoprogressive metastasis, or for disease control with conventional or stereotactic strategy. Radiotherapy of metastatic sites can be for bone, solid organ or soft-tissue lesions; initial size of brain metastases should be \\< 3 cm. Lung lesions should be no more than 5 cm.\n6. ECOG performance status 0-2.\n7. Life expectancy \u226512 weeks\n8. Female subjects should be using highly effective contraceptive measures, and must have a negative pregnancy test and not be breast-feeding prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:\n\n   * Post-menopausal defined as aged 50 years or more and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments\n   * Women under 50 years would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range for the institution.\n   * Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation\n9. Male subjects who are sexually active with WOCBP should be willing to use highly effective contraception. Men who are azoospermic do not require contraception.\n10. The patient is willing and able to comply with the protocol for the duration of the study, including hospital visits for treatment and scheduled follow-up visits and examinations.\n11. Negative COVID-19 test within 1 week prior to starting irradiation if clinically required by current regional COVID-19 outbreak situation.\n\nExclusion Criteria:\n\n1. Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study, or during the follow-up period of an interventional study.\n2. Treatment with an investigational drug within five half-lives of the compound or 3 months, whichever is greater\n3. Previous enrolment in the present study.\n4. Any chemotherapy, biologic or hormonal cancer therapy other than EGFR-TKIs used concurrently or within 4 weeks prior to study enrolment, or checkpoint inhibitors within 130 days prior to study enrolment. Hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.\n5. Any unresolved toxicities from prior therapy greater than grade I (exception: alopecia, grade 2 neuropathy) which in the investigator's opinion would jeopardise compliance with the protocol or worsen during irradiation\n6. Cardiac side-effects of osimertinib not sufficiently improved by dose reduction as suggested by the label\/ German \"Fachinformation\".\n7. In patients with indication for radiotherapy of lung lesions: past medical history of ILD\/pneumonitis, radiation pneumonitis grade 2 or higher (CTCAE V5.0) or requiring steroid treatment, or any evidence of clinically active ILD, in particular interstitial pulmonary fibrosis (IPF).\n8. Major surgery (as defined by the Investigator) within 4 weeks prior to starting the study; patients must have recovered from effects of preceding major surgery. Note: Local non-major surgery for palliative intent (e.g., surgery of isolated lesions) is acceptable.\n9. Congenital long QT syndrome\n10. Any of the following cardiac criteria:\n\n    * Mean resting corrected QT interval (QTc) \\> 470 msec obtained from 3 electrocardiograms (ECGs), using the screening clinic ECG machine derived QTc value\n    * Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block and second degree heart block.\n    * Patient with any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, electrolyte abnormalities (including: Serum\/plasma potassium \\< LLN; Serum\/plasma magnesium \\< LLN; Serum\/plasma calcium \\< LLN) , congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes\n11. Inadequate bone marrow reserve or organ function (as demonstrated by any of the following laboratory values:\n\n    * Absolute neutrophil count \\<1.5 x 109\/L;\n    * Platelet count \\<100 x 109\/L;\n    * Hemoglobin \\<90 g\/L (9 g\/dL);\n    * Alanine aminotransferase \\>2.5 times ULN if no demonstrable liver metastases or \\>5 times ULN in the presence of liver metastases;\n    * Aspartate aminotransferase \\>2.5 times ULN if no demonstrable liver metastases or \\>5 times ULN in the presence of liver metastases;\n    * Total bilirubin \\>1.5 times ULN if no liver metastases or \\>3 times ULN in the presence of documented Gilbert's Syndrome \\[unconjugated hyperbilirubinemia\\] or liver metastases;\n    * Serum creatinine \\>1.5 times ULN concurrent with creatinine clearance \\<50 mL\/min \\[measured or calculated by Cockcroft and Gault equation\\]-confirmation of creatinine clearance is only required when creatinine is \\>1.5 times ULN.\n12. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol, or active infection.\n13. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.\n14. History of hypersensitivity to active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib.\n15. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.\n16. Active infection will include any patients receiving treatment for infection.\n17. Clinical suspicion of COVID-19 with or without negative COVID-19 test\n18. Participants with HBV infection are eligible only if they meet the following criteria:\n\n    * Demonstrated absence of HCV co-infection or history of HCV co-infection\n    * Demonstrated absence of HIV infection\n    * Participants with active HBV infection are eligible if:\n    * they are receiving anti-viral treatment for at least 6 weeks prior to study treatment,\n    * HBV DNA is suppressed to \\<100 IU\/mL,\n    * transaminase levels are below ULN.\n\n    Participants with a resolved or chronic HBV infection are eligible if they are:\n\n    \u2022 Negative for HBsAg and positive for hepatitis B core antibody \\[anti-HBc IgG\\] In addition, patients must be receiving anti-viral prophylaxis for 2-4 weeks prior to study treatment.\n\n    or\n\n    \u2022 Positive for HBsAg, but for \\> 6 months have had transaminases levels below ULN and HBV DNA levels \\<100 IU\/mL (i.e., are in an inactive carrier state). In addition, patients must be receiving anti-viral prophylaxis for 2-4 weeks prior to study treatment. Refer to section \"5.5.2. Special warnings and precautions\"\n\n    Participants with HIV infection are only eligible if they meet all the following criteria:\n    * Undetectable viral RNA load for 6 months\n    * CD4+ count of \\>350 cells\/\u03bcL\n    * No history of AIDS-defining opportunistic infection within the past 12 months\n    * Stable for at least 4 weeks on the same anti-HIV medications\n19. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib.\n20. Currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of CYP3A4 (at least 3 week prior). All patients must try to avoid concomitant use of any medications, herbal supplements and\/or ingestion of foods with known inducer effects on CYP3A4.\n21. Women who are pregnant or breast-feeding\n22. Male or female patients of reproductive potential who are not willing to employ highly effective birth control from screening to 4 months after the last dose of osimertinib\n23. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts \\[\u00a7 40 Abs. 1 S. 3 Nr. 3a AMG\\]","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05089916001","EMAIL":[{"email":"Amanda.Tufman@med.uni-muenchen.de"}],"GEO":[48.13743,11.57549]},{"TITLE":"Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Stage IIIB\/IV NSCLC non eligible to locoregional treatment with curative intent\n* ALK rearrangement confirmed by IHC and\/or FISH or NGS according to local methods\n* Patient included in the EXPLORE ALK study\n* Age \\> or = 18 years\n* Patient treated with first-line new generation ALKi\n* Patient agrees to sign an informed consent form and to collect blood samples at inclusion, first tumor evaluation and progression and for whom tumor biopsy at diagnosis is available\n* Patient enrolled in the french National Health Insurance program or with a third- party payer\n\nExclusion Criteria:\n\n* Patients who do not wish to participate in Bioexalk\n* Patients under guardianship","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05122806039","EMAIL":[{"email":"bylicki.olivier@yahoo.fr"},{}],"GEO":[43.12442,5.92836]},{"TITLE":"Palliative Thoracic ImmunoRT","CRITERIA":"Inclusion Criteria:\n\n1. Pathologically confirmed AJCC 7th\/8th edition Stage IV adenocarcinoma or squamous cell carcinoma not eligible for curative treatment.\n2. Indication and suitability to receive palliative radiotherapy to the thorax (30Gy\/10).\n3. Receiving or planned to receive nivolumab or pembrolizumab\n4. Prior history of systemic chemotherapy is permitted given a washout period of 4 weeks\n5. Age 18 or older\n6. ECOG Performance Status 0-2\n7. Life expectancy greater than 3 months\n8. Able and willing to provide informed consent\n9. Able to complete patient reported outcome questionnaires\n\nExclusion Criteria:\n\n1. Contraindications to radiotherapy, including a history of SLE, systemic scleroderma, IPF, ataxia telangiectasia\n2. Previous history of thoracic radiotherapy with an overlapping field\n3. Previous history of checkpoint inhibitor related pneumonitis or esophagitis\n4. Pregnancy","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03705806001","EMAIL":[{"email":"Alex.Sun@rmp.uhn.on.ca"},{}],"GEO":[43.70011,-79.4163]},{"TITLE":"A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Patients must be \u226518 years.\n* Provision of fully informed consent prior to any study specific procedures.\n* Previously untreated, histologically confirmed resectable stage II, IIIA, IIIB (N2) (AJCC stage VIII) NSCLC; cTNM stage can be confirmed by PET-CT or pathological biopsy; resectable stage II non-small cell lung cancer is defined as radical resection as assessed by a qualified thoracic surgeon; resectable is resectable and potentially resectable as defined by the Expert Consensus on Multidisciplinary Diagnosis and Treatment of Stage III Non-small Cell Lung Cancer (2019 version); resectable includes IIIA (N0-1), some single-station mediastinal lymph node metastases with N2 and some T4 (satellite nodules present in adjacent lobes) N1; potentially resectable includes some stage IIIA and IIIB, including single-station N2 mediastinal lymph node short diameter \\< 3 cm stage IIIA NSCLC, potentially resectable T3 or T4 central tumors; Solid\/solid pulmonary nodules, not pure ground-glass opacity (GGO), are strongly recommended for pathological puncture verification.\n* According to the RECIST 1.1 standard, the patient must have at least one measurable lesion.\n\nExclusion Criteria:\n\n* None\n\nExclusion Criteria:\n\n-","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05991206001","EMAIL":[{"email":"yangnong0217@163.com"},{"email":"zhangyongchang@csu.edu.cn"}],"GEO":[28.19874,112.97087]},{"TITLE":"Aumolertinib With or Without Chemotherapy as 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Sensitizing EGFR Mutations","CRITERIA":"Inclusion Criteria:\n\n* 1. Provision of informed consent before any study-specific procedures, sampling and analyses.\n\n  2. Male or female, age at least 18 years. 3. Histologically confirmed locally advanced or metastatic NSCLC (included patients with stage IIIB, IIIC or IV disease who had relapsed after prior surgery or were newly diagnosed). Patients must be treatment-na\u00efve for locally advanced or metastatic NSCLC. Prior adjuvant and neo-adjuvant therapies are permitted as long as treatment was completed at least 12 months prior to the development of recurrent disease.\n\n  4. The tumor harbors 1 of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations assessed by central testing using tumor tissue sample or blood sample.\n\n  5. At least 1 lesion that has not previously been irradiated, and that can be accurately measured at Baseline as \u2265 10 mm in the longest diameter (except lymph nodes, which must have short axis \u2265 15mm).\n\n  6. An Eastern Cooperative Oncology Group (ECOG) performance status equal to 0-1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks.\n\n  7. Female patients should be using adequate contraceptive measures and should not be breastfeeding at the screening period, during the study, and six months after the last dosing of study. Patient must have a negative pregnancy test prior to start of dosing if of childbearing potential or must have evidence of non-childbearing potential by fulfilling 1 of the following criteria at screening:\n  1. Postmenopausal defined as age more than 50 years and amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments.\n  2. Women under 50 years old would be considered postmenopausal if they have been amenorrhea for 12 months or more, following cessation of exogenous hormonal treatments, and with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the postmenopausal range for the laboratory.\n  3. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, but not by tubal ligation.\n\n     8. Male patients should be willing to use barrier contraception (i.e., condoms).\n\n     Exclusion Criteria:\n* 1. Treatment with any of the following:\n\n  1. Prior treatment with an EGFR TKI.\n  2. Major surgery (excluding placement of vascular access) within 4 weeks of randomization.\n  3. Radiotherapy to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of randomization.\n  4. Spinal cord compression or brain metastases unless asymptomatic, stable for at least 4 weeks, and not requiring steroids for at least 2 weeks prior to start of study treatment.\n  5. Medications that are predominantly CYP3A4 strong inhibitors or inducers or sensitive substrates of CYP3A4 with a narrow therapeutic range within 7 days of the first dose of study drug.\n\n     2. Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 at the time of starting study treatment.\n\n     3. History of other malignancies, excluding full treated non-melanoma skin cancer, in-situ cancer, or other solid tumors that hadn't recurrent for \\> 5 years following the end of treatment.\n\n     4. Inadequate bone marrow reserve or organ function. 5. Any of the following cardiac criteria:\n\n  <!-- -->\n\n  1. Mean resting corrected QT interval (QTc) \\> 470 ms obtained from 3 electrocardiograms (ECGs), using the screening clinic's ECG machine and Fridericia's formula for QT interval correction (QTcF).\n  2. Any clinically important abnormalities in rhythm, conduction, or morphology of the resting ECG (e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, PR interval \\> 250 ms).\n  3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval.\n  4. Left ventricular ejection fraction (LVEF) \\< 50%. 6. Any evidence of severe or uncontrolled systemic diseases (including uncontrolled hypertension and active bleeding diatheses) or active infection. Screening for chronic conditions is not required.\n\n     7. Refractory nausea, vomiting, or chronic gastrointestinal diseases, inability to swallow the study drug, or previous significant bowel resection that would preclude adequate absorption of Aumolertinib.\n\n     8. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis that required steroid treatment, or any evidence of clinically active interstitial lung disease.\n\n     9. Women who are breastfeeding or have a positive urine or serum pregnancy test at the Screening Visit.\n\n     10. History of hypersensitivity to any active or inactive ingredient of study drugs (pemetrexed, cisplatin, carboplatin, Aumolertinib) or to drugs with a similar chemical structure or class to Aumolertinib.\n\n     11. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.\n\n     12. Any severe and uncontrolled ocular disease that may, in the ophthalmologist's opinion, present a specific risk to the patient's safety.\n\n     13. Any disease or condition that, in the opinion of the investigator, would compromise the safety of the patient or interfere with study assessments.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04923906001","EMAIL":[{"email":"shun_lu@hotmail.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC","CRITERIA":"INCLUSION CRITERIA:\n\n1. Participant must be \u2265 18 years at the time of screening.\n2. Histologically- or cytologically-documented NSCLC and have been treated with concurrent CRT for locally advanced, unresectable (Stage III) disease\n3. Provision of a tumour tissue sample obtained prior to CRT\n4. Documented tumour PD-L1 status \u2265 1% by central lab\n5. Documented EGFR and ALK wild-type status (local or central).\n6. Patients must not have progressed following definitive, platinum-based, concurrent chemoradiotherapy\n7. Participants must have received at least 2 cycles of platinum-based chemotherapy concurrent with radiation therapy\n8. Participants must have received a total dose of radiation of 60 Gy \u00b110% (54 Gy to 66 Gy) as part of the chemoradiation therapy, to be randomised. Radiation therapy should be administered by intensity modulated RT (preferred) or 3D-conforming technique.\n9. WHO performance status of 0 or 1 at randomization\n10. Adequate organ and marrow function\n\nEXCLUSION CRITERIA:\n\n1. History of another primary malignancy, except for:\n\n   * Malignancies treated with curative intent and adequate follow-up with no known active disease and have not required active treatment within the past 3 years before the first dose of study intervention and of low potential risk of recurrence.\n   * Adequately resected non melanoma skin cancer or lentigo maligna without evidence of disease .\n   * Adequately treated carcinoma in situ, including Ta tumors without evidence of disease.\n2. Mixed small cell and non-small cell lung cancer histology.\n3. Participants who receive sequential (not inclusive of induction) chemoradiation therapy for locally advanced (Stage III) unresectable NSCLC.\n4. Participants with locally advanced (Stage III) unresectable NSCLC who have progressed during platinum-based cCRT.\n5. Any unresolved toxicity CTCAE \\>Grade 2 from the prior chemoradiation therapy (excluding alopecia).\n6. Participants with \u2265 grade 2 pneumonitis from prior chemoradiation therapy.\n7. History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, or idiopathic pneumonitis - regardless of time of onset prior to randomisation. Evidence of active non-CRT induced pneumonitis (\u2265 Grade 2), active pneumonia, active ILD, active or recently treated pleural effusion, or current pulmonary fibrosis\n8. Active or prior documented autoimmune or inflammatory disorders (with exceptions)\n9. Active EBV infection, or known or suspected chronic active EBV infection at screening\n10. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05211895226","EMAIL":"information.center@astrazeneca.com","GEO":[52.9536,-1.15047]},{"TITLE":"A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)","CRITERIA":"Inclusion Criteria:\n\n1. Male or female aged at least 18 years.\n2. Histologically confirmed diagnosis of primary NSCLC on predominantly non-squamous histology.\n3. Magnetic Resonance Imaging (MRI) or contrast computed tomography (CT) scan of the brain.\n4. Participants must be classified post-operatively as Stage II, IIIA, or IIIB on the basis of surgical pathologic criteria.\n5. Confirmation by the local laboratory that the tumour harbours one of the two common EGFR mutations (Ex19del, L858R), either alone or in combination with other EGFR mutations including de novo EGFR mutation resulting in substitution of threonine with methionine at amino acid position 790 in exon 20 of EGFR (T790M) or uncommon EGFR mutations G719X, S768I, and L861Q, either alone, in combination with each other, or in combination with other uncommon EGFR mutations (excluding all exon 20 insertions) (Uncommon EGFRm Cohort).\n6. Complete surgical resection of the primary NSCLC is mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumour.\n7. Complete recovery from surgery and standard post-operative therapy (if applicable) at start of study intervention.\n8. World Health Organisation Performance Status of 0 to 1.\n9. Female participants must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of childbearing potential.\n10. Male participants must use effective barrier contraception.\n\nExclusion Criteria:\n\n1. Major surgery (including primary tumour surgery, excluding placement of vascular access) within 4 weeks prior to the first dose of study drug.\n2. Participants currently receiving medications or herbal supplements known to be strong inducers of CYP3A4 (at least 3 weeks prior to first dose).\n3. Participants who have had only segmentectomies or wedge resections.\n4. History of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer, or other solid tumours curatively treated with no evidence of disease for \\> 5 years before the start of study intervention.\n5. Treatment with any of the following:\n\n   * Pre-operative or post-operative or planned radiation therapy for the current lung cancer.\n   * Pre-operative (neo-adjuvant) platinum-based or other chemotherapy.\n   * Any prior anti-cancer or immunological therapy, including investigational therapy, for treatment of NSCLC other than standard platinum-based doublet post-operative adjuvant chemotherapy.\n   * Prior treatment with neoadjuvant or adjuvant EGFR tyrosine kinase inhibitor (TKI).\n6. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib.\n7. Any of the following cardiac criteria:\n\n   * Mean resting corrected QT (QTc) interval \\> 470 msec, obtained from 3 electrocardiograms (ECGs).\n   * Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG.\n   * Any factors that increase the risk of QTc prolongation or risk of arrhythmic events.\n   * Heart failure, congenital long QT interval (QT) syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes (TdP).\n8. Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD.\n9. Inadequate bone marrow reserve or organ function.\n10. Women who are breastfeeding.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":130,"SS_ID":"05526755068","EMAIL":"information.center@astrazeneca.com","GEO":[52.9536,-1.15047]},{"TITLE":"A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC","CRITERIA":"Inclusion criteria:\n\n* Adult M\/F\/X (\\>= 18 years)\n* Histologically and clinically confirmed diagnosis of non-small cell lung cancer (according to IASLC Staging Handbook in Thoracic Oncology v7)\n* Patients receiving first-line treatment per guidelines\n* Not included in other clinical trials\n* Signed informed consent form\n\nExclusion criteria:\n\n\u2022 Collected material not suitable for further processing in this study (e.g. bad quality). This decision will be made in consultation with a lab technician and\/or bio-informatician, specialized in single-cell analysis.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":120,"SS_ID":"04807114001","EMAIL":[{"email":"els.wauters@uzleuven.be"}],"GEO":[50.87959,4.70093]},{"TITLE":"Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease","CRITERIA":"Inclusion Criteria:\n\n1. Signed written informed consent\n2. Histologic confirmation of malignancies under treatment with single agent anti-PD1\/PDL1 immunotherapy per clinical practice (see cohort specific inclusion criteria) with immune checkpoint inhibitors approved by Italian national drug regulatory agencies (Agenzia Italiana del Farmaco, AIFA)\n3. Having a disease stability as assessed by AIFA monitoring sheet\n4. Presence of at least 2 measurable target lesions, of which at least one to be followed up as per RECIST and one suitable for CIRT\n5. Willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study\n6. Females and males, 18 years of age or older (no upper limit for age)\n7. Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2\n8. Subjects must have measurable disease by CT or MRI per RECIST 1.1\n\nExclusion Criteria:\n\n1. Patients treated with chemo-immunotherapy associations\n2. Patients treated with immunotherapy combinations (e.g. subjects treated with anti-CTLA4 + anti-PD1\/PDL1 are excluded)\n3. Patients receiving immunotherapy within clinical trials\n4. Patients receiving off-label immunotherapy or within expanded access programs or as compassionate use\n5. Patients with high tumor burden defined as \\> 10 lesions and\/or sum of diameters \\> 19 cm\n6. Patients with distant metastases only located in the CNS are excluded\n7. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results\n8. Patients with autoimmune diseases (ADs), including local and systemic collagen-vascular (CVD) and inflammatory bowel diseases (IBD)\n9. Previous RT, regardless of energy, on the metastatic site selected to be irradiated.\n10. Any immune-related CTCAE grade 4 adverse event, before study entry\n11. Any CTCAE grade \u22653 immune-related adverse event observed within 3 weeks prior to CIRT start\n12. Presence of metal prostheses or any other condition to prevent adequate imaging for identification of the target volume and calculation of the dose\n13. Loco-regional conditions not allowing hadron therapy (e.g. active infections in RT target region)\n14. Prisoners or subjects who are involuntarily incarcerated\n15. Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness (e.g. infectious disease)","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05229614004","EMAIL":[{},{}],"GEO":[45.19205,9.15917]},{"TITLE":"A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Have one of the following solid tumor cancers:\n\n  * Cohort A1: urothelial carcinoma, triple negative breast cancer, non-small cell lung cancer, esophageal cancer, pancreatic cancer, ovarian cancer, cervical cancer (squamous cell carcinoma), head and neck squamous cell carcinoma or prostate cancer\n  * Cohort A2\/B1\/B2: urothelial carcinoma\n  * Cohort C1: triple negative breast cancer\n  * Cohort C2: non-small cell lung cancer\n  * Cohort C3: ovarian or fallopian tube cancer\n  * Cohort C4: cervical cancer\n  * Cohort C5: head and neck squamous cell carcinoma\n* Prior Systemic Therapy Criteria:\n\n  * Cohort A1\/C1-5: Individual has received all standard therapies for which the participant was deemed to be an appropriate candidate by the treating investigator; OR there is no standard therapy available for the disease. There is no restriction on number of prior therapies\n  * Cohort A2\/B1\/B2: Individual must have received at least one prior regimen in the advanced or metastatic setting. There is no restriction on number of prior therapies.\n* Prior enfortumab vedotin specific requirements:\n\n  * Cohorts A1\/A2\/C1-5: prior treatment with enfortumab vedotin is allowed, but not required\n  * Cohort B1: individual must be enfortumab vedotin naive in the advanced\/metastatic setting\n  * Cohort B2: individual must have received enfortumab vedotin in the metastatic\/advanced setting.\n* Measurability of disease\n\n  * Cohort A1: measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST 1.1)\n  * Cohorts A2, B1, B2, C1-5: measurable disease required as defined by RECIST v1.1\n\n    * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n    * Have adequate archival tumor tissue sample available or undergo a screening biopsy if allowed per country specific regulations\n\nExclusion Criteria:\n\n* Individual with known or suspected uncontrolled CNS metastases\n* Individual with uncontrolled hypercalcemia\n* Individual with uncontrolled diabetes\n* Individual with evidence of corneal keratopathy or history of corneal transplant\n* Any serious unresolved toxicities from prior therapy\n* Significant cardiovascular disease\n* Current of history of intestinal obstruction in the previous 3 months\n* Recent thromboembolic event or bleeding disorder\n* Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) \u2265 470 ms\n* History of pneumonitis\/interstitial lung disease\n* History of Grade \u22653 skin toxicity when receiving enfortumab vedotin\n* Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06238479008","EMAIL":[{}],"GEO":[35.66667,139.81718]},{"TITLE":"Efficacy and Safety of NSCLC Patients With\/Without Adjuvant Immunotherapy Who Have Achieved pCR After Neoadjuvant Immunotherapy","CRITERIA":"Inclusion Criteria:\n\n1. Histologically or cytologically confirmed resectable\/potentially resectable NSCLC of stage IB-IIIB (AJCC 8th edition).\n2. Completed neoadjuvant immunotherapy (3 cycles) and achieved pathological complete response (pCR) postoperatively.\n3. With or without adjuvant immunotherapy postoperatively.\n4. Underwent at least one effective imaging evaluation during the adjuvant treatment period.\n\nExclusion Criteria:\n\n1. Incomplete clinical data for patients, such as missing treatment history, surgical specimen pathology results, etc.\n2. Follow-up data less than 36 months.\n3. Patients with multiple primary tumors.\n4. History of malignancy other than NSCLC within the past 5 years.\n5. Previous treatment with PD-1\/PD-L1 inhibitors.\n6. Excluded patients with positive EGFR\/ALK driver gene mutations\n7. Receipt of other investigational drugs during the observation period.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06243679001","EMAIL":[{}],"GEO":[28.19874,112.97087]},{"TITLE":"An Observational Study to Evaluate the Clinical Utility of the Oncomine Precision Assay Within the Exactis Network","CRITERIA":"Inclusion Criteria:\n\n* Patients with NSCLC, which is (i) advanced or metastatic (stage IIIb\/IV), (ii) non- squamous histology NSCLC as confirmed by local histopathology (mixed squamous and adenocarcinoma is allowed), and has (iii) radiographically measurable disease with at least one bidimensionally measurable lesion of \\> 1 cm by CT scan\n* No prior treatment for advanced or metastatic NSCLC, except for palliative radiation therapy to non-lung or non-thorax metastases. Patients who received palliative radiation therapy to metastases located within or approximately to the lung or thorax must be evaluated for eligibility.\n* Willing and able to provide adequate blood sample prior to starting treatment.\n* Willing to provide primary or metastatic tissue, if available.\n* Signed and dated Research Ethics Board (REB)-approved informed consent form for Exactis-01 or PMT.\n* Not pregnant or breastfeeding\n\nExclusion Criteria:\n\n\u2022 Patients who have a history of another active cancer within the past 2 years from date of consent except cervical cancer in situ, basal cell carcinoma of the skin or another in situ carcinoma that is considered cured by the investigator.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04564079006","EMAIL":[{"email":"noemie.poirier.ciussse-chus@ssss.gouv.qc.ca"},{"email":"suzanne.maltais.ciussse-chus@ssss.gouv.qc.ca"},{}],"GEO":[45.40008,-71.89908]},{"TITLE":"SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation","CRITERIA":"Key Inclusion Criteria:\n\n* Patients must have histologically documented, locally advanced and unresectable, or metastatic NSCLC with documentation of a KRAS mutation within the 1 year prior to screening.\n* Patients must have measurable disease by RECIST v1.1.\n* Patients must have a minimum life expectancy of \\>12 weeks after start of study treatment.\n* Patients must have progression or disease recurrence on or after at least one prior line of systemic therapy, which must include platinum-based doublet chemotherapy and anti-PD-(L)1 therapy.\n* Patients must have experienced progressive or recurrent disease occurring either during treatment or within 90 days after discontinuing anti-PD-(L)1 therapy.\n* Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.\n* Patients must have adequate organ function.\n\nKey Exclusion Criteria:\n\n* Patients that have participated in an interventional clinical study within the last 4 weeks.\n* Patients that have received radiotherapy or proton therapy with a limited field of radiation for palliation within 1 week of the start of study treatment, OR radiation to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the start of study treatment.\n* Patients with known central nervous system (CNS) tumors or active CNS metastases.\n* Patients that have experienced progressive disease (PD) within the first 120 days of initiating treatment with an anti- PD-(L)1 agent (e.g., primary refractory).\n* Patients that have a history of allogenic bone marrow transplant.\n* Patients that have select known or suspected autoimmune disease.\n* Patients that have a condition requiring systemic treatment with either corticosteroids (\\>10 mg prednisone equivalent) or other immunosuppressive medication within 14 days of study start.\n* Patients that have received any live\/attenuated vaccine within 30 days of first study treatment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05375084015","EMAIL":[{"email":"bpatterson@nextoncology.com"},{}],"GEO":[38.84622,-77.30637]},{"TITLE":"AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Has a histologically or cytologically confirmed diagnosis of NSCLC.\n* Has Stage IIIB\/C or IV NSCLC (American Joint Committee on Cancer \\[AJCC 8th\\]).\n* 18-75 years old (at the time consent is obtained).\n* Be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures).\n* Be able to provide formalin fixed, paraffin-embedded (FFPE) tumor tissue.\n* Has a life expectancy of at least 3 months.\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the site study team.\n* Has no EGFR-sensitive mutations or ALK gene translocations.\n* Has adequate organ function.\n* Has recovered from the effects of any prior radiotherapy or surgery.\n* All female and male subjects of reproductive potential must agree to use an effective method of contraception, during and for 120 days after the last dose of study treatment.\n\nExclusion Criteria:\n\n* Has any histologically small cell carcinoma component.\n* Is currently participating in a study of an investigational agent or using an investigational device.\n* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy within 2 years prior to the first dose of study treatment.\n* Has undergone major surgery within 30 days of Study Day 1.\n* Has a known additional malignancy that is progressing or requires systemic treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.\n* Has known active central nervous system (CNS) metastases.\n* Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).\n* Has an active infection requiring systemic therapy.\n* Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \\[qualitative\\] is detected).\n* Has a history of myocardial infarction, unstable angina, congestive heart failure within 12 months prior to day 1 of study treatment.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of this subject to participate, in the opinion of the treating investigator.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.\n* Has received a live virus vaccine within 30 days of the planned first dose of study therapy.\n* Has any concurrent medical condition that, in the opinion of the Investigator, would complicate or compromise compliance with the study or the well-being of the subject.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05904379002","EMAIL":[{"email":"caicunzhoudr@163.com"},{}],"GEO":[31.22222,121.45806]},{"TITLE":"Vactosertib in Combination With Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects","CRITERIA":"Inclusion Criteria:\n\n* Have a histologically- or cytologically-documented NSCLC advanced or stage IV lung cancer\n* Have confirmation that EGFR, ALK, BRAF, ROS1-directed therapy is not indicated\n* Have measurable disease based on RECIST 1.1\n* PD-L1 expression is \u22651% as determined by the PD-L1 IHC 22C3 pharmDx assay\n* Have a life expectancy of at least 3 months.\n* ECOG 0 or 1\n* Subjects must be able to swallow tablets and absorb vactosertib.\n* Have adequate organ function as indicated by the following laboratory values in\n\nExclusion Criteria:\n\n* Is currently participating in a study of an investigational agent\n* Has received prior systemic cytotoxic chemotherapy for metastatic disease\/ antineoplastic biological therapy \/Had major surgery \/ radiation therapy to the lung\n* Has received a live vaccine within 30 days prior to the first dose of study drug.\n* Is taking prohibited medications\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy\n* Has known active central nervous system (CNS) metastases and\/or carcinomatous meningitis.\n* Had a severe hypersensitivity reaction to treatment with another mAb previously.\n* Has severe hypersensitivity to vactosertib and\/or any of its excipients","SEX":"ALL","AGE_MIN":19,"AGE_MAX":200,"SS_ID":"04515979001","EMAIL":[{}],"GEO":[37.566,126.9784]},{"TITLE":"Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection","CRITERIA":"Inclusion Criteria:\n\n1. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n2. Age \\> 18 years at time of study entry.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n4. Body weight \\>30 kg\n5. Adequate normal organ and marrow function as defined below Hemoglobin \u22659.0 g\/dL Absolute neutrophil count (ANC) \u22651.0 \u00d7 10\\^9\/L Platelet count \u226575 \u00d7 10\\^9\/L Serum bilirubin in normal range with the exception of Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician AST (SGOT)\/ALT (SGPT) \u22642.5 x institutional upper limit of normal\n\n   Measured creatinine clearance (CL) \\>40 mL\/min or Calculated creatinine CL\\>40 mL\/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance:\n\n   Males:\n\n   Creatinine CL (mL\/min)=Weight (kg) x (140 - Age) \/ 72 x serum creatinine (mg\/dL)\n\n   Females:\n\n   Creatinine CL (mL\/min)=Weight (kg) x (140 - Age) x 0.85 \/ 72 x serum creatinine (mg\/dL)\n6. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.\n7. Must have a life expectancy of at least 12 weeks\n8. Tumor amenable to biopsy\n9. Patients with NSCLC stage IIB to IIIB.\n10. PD-L1 positive tumors defined by tumor proportion score (TPS) \\>1%\n11. Patient suitable for surgery and combined modality therapy in the opinion of the investigator.\n12. Complete R0 resection of the primary tumor and involved lymph nodes is anticipated based on the clinical staging and radiological evaluation according to the baseline pre-treatment imaging.\n\nExclusion Criteria:\n\n1. Participation in another clinical study with an investigational product during the last 8 weeks before enrollment\n2. Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study\n3. Known oncogenic driver mutations such as EGFR mutant or ALK mutant\n4. The presence of N3 disease in the contralateral mediastinum, contralateral hilum, or contralateral supraclavicular lymph node confirmed histologically.\n5. Any unresolved toxicity NCI CTCAE Grade \u22652 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria Patients with Grade \u22652 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Sponsor.\n\n   Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the StudySponsor.\n6. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.\n7. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP.\n8. History of allogenic organ transplantation.\n9. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \\[e.g., colitis or Crohn's disease\\], diverticulitis \\[with the exception of diverticulosis\\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \\[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc\\]). The following are exceptions to this criterion:\n\n   Patients with vitiligo or alopecia Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement Any chronic skin condition that does not require systemic therapy Patients without active disease in the last 5 years may be included but only after consultation with the Study Sponsor Patients with celiac disease controlled by diet alone\n10. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness\/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent\n11. History of another primary malignancy except for:\n\n    Malignancy treated with curative intent that does not require treatment, nor anticipated to require treatment for the duration of the study, and in the opinion of the investigator would not pose a risk of increased toxicity, or difficulty to follow the protocol and assess study endpoints Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease Adequately treated carcinoma in situ without evidence of disease\n12. History of leptomeningeal carcinomatosis, malignant pleural effusion or distant metastasis (M1)\n13. Patients with suspected brain metastases at screening should have an MRI (preferred) or CT each preferably with IV contrast of the brain prior to study entry\n14. History of active primary immunodeficiency\n15. Known active hepatitis infection, positive hepatitis C virus (HCV) antibody, hepatitis B virus (HBV) surface antigen (HBsAg) or HBV core antibody (anti-HBc), at screening. Participants with a past or resolved HBV infection (defined as the presence of anti HBc and absence of HBsAg) are eligible. Participants positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n16. Known to have tested positive for human immunodeficiency virus (HIV) (positive HIV 1\/2 antibodies) or active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).\n17. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:\n\n    Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection) Systemic corticosteroids at physiologic doses not to exceed 10 mg\/day of prednisone or its equivalent Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)\n18. Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP.\n19. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy.\n20. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.\n21. Prior randomization or treatment in a previous durvalumab clinical study regardless of treatment arm assignment.\n22. Patients who have received prior anti-PD-1, anti PD-L1 or anti CTLA-4:\n\n    Must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy.\n\n    All AEs while receiving prior immunotherapy must have completely resolved or resolved to baseline prior to screening for this study.\n\n    Must not have experienced a \u2265Grade 3 immune related AE or an immune related neurologic or ocular AE of any grade while receiving prior immunotherapy. NOTE:\n\n    Patients with endocrine AE of \u2264Grade 2 are permitted to enroll if they are stably maintained on appropriate replacement therapy and are asymptomatic.\n\n    Must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged, and not currently require maintenance doses of \\> 10 mg prednisone or equivalent per day.\n23. Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":99,"SS_ID":"06331455001","EMAIL":[{},{}],"GEO":[43.70011,-79.4163]},{"TITLE":"A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Na\u00efve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* ECOG performance status of 0 or 1.\n* Histologically or cytologically confirmed, Stage IV non-squamous or squamous NSCLC.\n* No prior treatment for Stage IV non-squamous or squamous NSCLC.\n* Patients who have received prior neo-adjuvant, adjuvant chemotherapy, radiotherapy, or chemo-radiotherapy with curative intent for non-metastatic disease must have experienced a treatment free interval of at least 6 months from enrollment since the last chemotherapy, radiotherapy, or chemo-radiotherapy cycle.\n* Tumor TC3 or IC3, as determined by SP142 performed by a central laboratory on previously obtained archival tumor tissue or tissue obtained from a biopsy at screening.\n* Measurable disease, as defined by RECIST v1.1.\n* Adequate hematologic and end-organ function.\n* Life expectancy \u22653 months.\n* For women of childbearing potential: agreement to remain abstinent or use contraception, and agreement to refrain from donating.\n\nExclusion Criteria:\n\n* Known sensitizing mutation in the EGFR gene or ALK fusion oncogene.\n* Symptomatic, untreated, or actively progressing CNS metastases.\n* Spinal cord compression not definitively treated with surgery and\/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for \u22652 weeks prior to enrollment.\n* Current leptomeningeal disease.\n* Uncontrolled tumor-related pain.\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.\n* Uncontrolled or symptomatic hypercalcemia.\n* Malignancies other than NSCLC within 5 years prior to enrollment, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome.\n* Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within at least 5 months after the last dose of atezolizumab.\n* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.\n* Known allergy or hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation.\n* Active or history of autoimmune disease or immune deficiency.\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.\n* Positive human immunodeficiency virus (HIV) test result at screening.\n* Patients with active hepatitis B or active hepatitis C at screening.\n* Active tuberculosis.\n* Severe infections within 4 weeks prior to randomization, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia.\n* Significant cardiovascular disease.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05047250020","EMAIL":"global.rochegenentechtrials@roche.com","GEO":[24.47979,118.08187]},{"TITLE":"Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab","CRITERIA":"Inclusion Criteria:\n\n* Dose-escalation cohorts only:\n\n  -- Must have an advanced solid tumor who are considered refractory to or intolerant of all existing therapies known to provide a clinical benefit for their condition.\n* Relapsed Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) dose-expansion cohorts only:\n\n  * Must have histologically or cytologically confirmed advanced or metastatic NSCLC or HNSCC that is not suitable for surgical resection and \/ or radiation therapy and has been treated with platinum-based chemotherapy and a programmed cell death (PD)-1 or PD ligand 1 (PD-L1) targeting agent (separately or in combination therapy).\n  * Must have failed (or refused) treatment with available therapies known to be active for treatment of their disease.\n* Participants enrolled in dose escalation must have disease that is evaluable or measurable per Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1).\n* Participants enrolled in dose expansion must have measurable disease per RECIST, version 1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status of \\<= 1.\n* Laboratory values meeting the criteria outlined in the protocol.\n\nExclusion Criteria:\n\n- Relapsed Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) dose-expansion cohorts only:\n\n-- Non-Small Cell Lung Cancer (NSCLC) participants with known EGFR mutations or ALK gene rearrangements are ineligible.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05005403027","EMAIL":"abbvieclinicaltrials@abbvie.com","GEO":[25.04776,121.53185]},{"TITLE":"A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers","CRITERIA":"Inclusion Criteria:\n\n* Pathologically confirmed diagnosis of cancers with evidence of locally advanced (unresectable) and\/or metastatic disease. Cancers that are refractory to all available standard of care (SOC) treatment, cancers for which no SOC treatment is available, or the participant cannot tolerate or refuses SOC therapy.\n* An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.\n* Adequate cardiac left ventricular function, as defined by left ventricular ejection fraction \u2265 50% as determined by either echocardiogram or multigated acquisition scan.\n* Adequate organ function.\n\nExclusion Criteria:\n\n* Known additional malignancy that is progressing or that has required active treatment.\n* Undergone prior allogenic tissue (e.g., hematopoietic stem cell) or solid organ transplantation within the last 5 years.\n* Ongoing, clinically significant toxicity (Grade \u2265 2) associated with prior cancer therapies, with the exception of alopecia.\n* Advanced\/metastatic, symptomatic, visceral spread, at risk of life-threatening complications in the short-term (including participants with massive uncontrolled effusion \\[pleural, pericardial\\], pulmonary lymphangitis, active unresolved bowel obstruction, massive ascites \\[requiring paracentesis \\>2 times within 2 weeks prior to the first dose\\], and over 50% liver involvement).\n* Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease (with exception of participants with Gilbert's Syndrome, asymptomatic gall stones, liver metastases, or stable chronic liver disease per investigator assessment).\n* Active or recurrent clinically significant autoimmune disease requiring systemic high-dose corticosteroids or immunosuppressive drugs.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06523803001","EMAIL":[{}],"GEO":[38.25424,-85.75941]},{"TITLE":"High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases","CRITERIA":"Inclusion Criteria:\n\n* Signed written informed consent before any study-related procedure.\n* Age \u2265 18 years.\n* ECOG PS of 0 to 1 at screening,and with no clinically significant deterioration in the previous 2 weeks.\n* Expected survival \u226512 weeks.\n* Histologically or cytologically confirmed metastatic Non-Small Cell Lung Cancer (International Association for the Study of Lung Cancer and Joint Committee on the American Classification of Cancer, TNM Lung cancer stage 8). Documented validated results from local testing of either tumor tissue or blood confirming the presence of EGFR 19del or exon 21del L858R mutation. These mutations above may exist alone or together.\n* According to RECIST 1.1, patients must have at least one central nervous system (CNS) metastatic tumor lesion at baseline that meets the following requirements: accurately and repeatably measurable at baseline, have no radiotherapy or biopsy.\n* Patients who have untreated for advanced\/metastatic non-small cell lung cancer, including chemotherapy, biological therapy, targeted therapy, immunotherapy, or experimental therapy, prior to initiation of study drug therapy. Patients who have received adjuvant therapy or neoadjuvant therapy (chemotherapy and\/or radiotherapy) are allowed to enroll if there is no progression within 6 months of treatment. Patients who have received topical therapy (radiotherapy or perfusion therapy) are allowed to enroll if the lesion within the local therapeutic area is non-targeted.\n* For premenopausal women with childbearing potential, a pregnancy test must be performed within 14 days before the first dose, and the pregnancy test (blood or urine test) must be negative; female subjects must not be lactating;\n* Willing to use contraception.\n* Voluntary and agree to follow the study treatment protocol as well as follow-up plan, and can accept the oral medicine treatment.\n\nExclusion Criteria:\n\n* Small cell lung carcinoma;\n* History of hypersensitivity to active or inactive excipients of investigational agent with a similar chemical structure.\n* Confirmed EGFR 20 exon insertion mutations at any time after the initial diagnosis.\n* Patient who receive prior treatment including any of the following:\n* Any Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI).\n* The patients who have received intrapleural perfusion therapy can only be enrolled 28 days or more after the pleural effusion is stable;\n* Major surgery within 4 weeks of the first dose of investigational agent.\n* Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of investigational agent;\n* CYP3A4 strong inhibitor or strong inducer is used within 7 days prior to the first dose, or need to receive these drugs during the study period.\n* Traditional Chinese medicine and traditional Chinese medicine preparations with anti-tumor as indications and with adjuvant treatment of tumor is used within 7 days prior to the first dose, or need to receive these drugs during the study period.\n* Patients who are receiving drugs known to prolong QTc interval or may cause torsade de pointe and need to continue to receive these drugs during the study period.\n* The time from the treatment with any other investigational product or its analogue to the first dose does not exceed 5 half-lives of the drug or 14 days, whichever is longer.\n* Prior treatment with any systemic anti-cancer therapy for advanced Non-Small Cell Lung Cancer (NSCLC) including chemotherapy, biologic therapy, target therapy, immunotherapy, or any investigational drug, except neoadjuvant or adjuvant therapy before 6 months prior to the first dose investigational treatment.\n* At the beginning of study treatment, any unresolved toxic reaction to prior treatment is present, which exceeds Grade 1 in accordance with Common Terminology Criteria for Adverse Events (CTCAE) (except for alopecia), and exceeds Grade 2 for prior platinum treatment-related neuropathy.\n* Spinal cord compression; symptomatic and unstable brain metastases, except for those patients who have completed definitive therapy, are not on steroids, and have a stable neurological status for at least 2 weeks after completion of the definitive therapy and steroids.\n* Diagnosed other malignant tumors or had a history of other malignant tumors in last 5 years, except for skin basal cell carcinoma, cervical carcinoma in situ and breast ductal carcinoma in situ which have been effectively controlled;\n* Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of investigational agent.\n* Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, and active infection, which in the Investigator's opinion makes it undesirable for the patient to participate in the trial.\n* Past medical history of Interstitial Lung Disease (ILD), drug-induced Interstitial Lung Disease, radiation pneumonitis that required steroid treatment, or any evidence of clinically active Interstitial Lung Disease.\n* Any evidence of corneal injury:\n* Inadequate bone marrow reserve or organ function.\n* QT prolongation or any clinically important abnormalities in rhythm and heart function.\n* Patients who may have poor compliance with the research procedures and requirements, etc., as judged by investigators.\n* Pregnancy or lactation.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05379803001","EMAIL":[{"email":"zhangyongchang@csu.edu.cn"}],"GEO":[28.19874,112.97087]},{"TITLE":"Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Histologically- or cytologically-documented NSCLC presenting with locally-advanced, unresectable stage III disease (Version 8 of AJCC Staging Manual) or NSCLC with locoregional recurrence after previous definitive treatment.\n2. For stage III or recurrent disease, must have completed platinum-based chemotherapy and radiation therapy to all known tumor sites (60 Gy +\/- 10%). Must not have known progression of disease.\n3. Must be receiving consolidation durvalumab following completion of radiation and chemotherapy, and less than 32 weeks has elapsed from their first dose of durvalumab. (Patients may sign consent for study before start of durvalumab, but confirm eligibility and enroll only after first dose of durvalumab is received).\n4. Able to potentially receive further consolidation chemotherapy plus durvalumab and tremelimumab, but not be currently intended to receive additional systemic consolidation chemotherapy apart from this durvalumab.\n5. Pre-treatment tumor tissue or tumor DNA sample is believed to be available for analysis\n6. Aged 18 years or older\n7. Weight \\> 30kg\n8. Life expectancy \u2265 12 weeks\n9. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n10. Absolute neutrophil count \\> 1.0 x 109\/L (1000\/mm3)\n11. Platelets \\> 75 x 109\/L (100,000\/mm3)\n12. Hemoglobin \u2265 9.0 g\/dL (5.59 mmol\/L)\n13. Measured creatinine clearance \\> 40 mL\/min, by either 24 hour urine collection or the Cockcroft Gault formula\n\n    Males:\n\n    Mass(kg) x (140-Age) \/ 72 x serum creatinine (mg\/dL)\n\n    Females:\n\n    Mass(kg) x (140-Age) x 0.85 \/ 72 x serum creatinine (mg\/dL)\n14. Serum bilirubin \u2264 1.5 x upper limit of normal (ULN). This will not apply to subjects with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of evidence of hemolysis or hepatic pathology) who will be allowed in consultation with their physician.\n15. aspartate aminotransferase (AST) (SGOT)\/Alanine Aminotransferase (ALT) (SGPT) \u2264 2.5 x institutional upper limit of normal (ULN) unless liver metastases are present, in which case it must be \u2264 5 x ULN\n16. Ability to understand and the willingness to sign the written IRB approved informed consent document.\n\nExclusion Criteria:\n\nInvolvement in the planning and\/or conduct of the study\n\n2. Previous enrollment or randomization in the present study\n\n3. Received Investigational product as part of another clinical study\n\n4. Mixed small cell and non small cell lung cancer histology\n\n5. History of another primary malignancy and currently undergoing active treatment.\n\nException: May participate if receiving adjuvant endocrine therapy for breast or prostate cancer.\n\n6. Current or prior use of immunosuppressive medication within 14 days before enrollment, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg\/day of prednisone, or an equivalent corticosteroid. Systemic steroid administration required to manage toxicities arising from radiation therapy delivered as part of the chemoradiation therapy for locally advanced NSCLC is allowed.\n\n7. Any unresolved toxicity CTCAE \\> Grade 2 from the prior chemoradiation therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria.\n\n* Subjects with Grade \u2265 2 neuropathy will be evaluated on a case by case basis after consultation with the Protocol Director \/ Principal Investigator\n* Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by treatment with durvalumab may be included (ie, hearing loss) only after consultation with the Protocol Director \/ Principal Investigator.\n\n  8. Any prior Grade \u2265 3 immune related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE \\> Grade 1) that may limit subject from continuing durvalumab during the study\n\n  9. Recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access) that would prevent administration of study drug.\n\n  10. Active or prior documented autoimmune or inflammatory disorders which is likely to limit the subjects ability to continue durvalumab on the study (including inflammatory bowel disease \\[eg, colitis or Crohn's disease\\], diverticulitis \\[with the exception of diverticulosis\\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \\[granulomatosis with polyangiitis; Graves' disease; rheumatoid arthritis; hypophysitis; uveitis; etc\\]). Those with history of autoimmune or inflammatory disorders who are currently tolerating durvalumab may be eligible to participate with approval from the PI. The following are also exceptions to this criterion:\n  1. Vitiligo or alopecia\n  2. Hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement\n  3. Chronic skin condition not requiring systemic therapy\n  4. Celiac disease controlled by diet alone\n\n     11. History of primary immunodeficiency\n\n     12. History of organ transplant requiring therapeutic immunosuppression\n\n     13. History of hypersensitivity to carboplatin, pemetrexed, paclitaxel, or nab-paclitaxel that is likely to prevent re-administration of these agents\n\n     14. Active infection including but not limited to:\n* Grade 3 or higher clinically significant infection\n* Active known Hepatitis B \\[known positive results for HBV surface antigen (HBsAg) within 2 months prior to enrollment\\]. EXCEPTION: Subjects with a past or resolved HBV infection, defined as the presence of hepatitis B core antibody (anti-HBc) and absence of HBsAg are eligible\n* Active known Hepatitis C (HCV). EXCEPTION: Subjects positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA\n* Active known tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).\n* Active known HIV infection\n\n  15. Receipt of live attenuated vaccine within 30 days prior to the first dose of concurrent chemotherapy and durvalumab. Note: Subjects, if enrolled, should not receive live vaccine through 30 days after the last dose of chemotherapy concurrent with durvalumab.\n\n  16. Uncontrolled intercurrent illness, including but not limited to:\n  * Ongoing or active infection\n  * Symptomatic congestive heart failure\n  * Uncontrolled hypertension\n  * Unstable angina pectoris\n  * Cardiac arrhythmia\n  * Interstitial lung disease\n  * Serious chronic gastrointestinal conditions associated with diarrhea\n  * Psychiatric illness\/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the subject to give written informed consent.\n\n    17. Female subjects who are pregnant or breast feeding; or subjects of reproductive potential of any gender who are not employing or who do not agree to employ an effective method of birth control prior to trial enrollment.ollment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04585490001","EMAIL":[{"email":"rbonilla@stanford.edu"},{}],"GEO":[37.42411,-122.16608]},{"TITLE":"Efficacy Study of Osimertinib in Treatment-na\u00efve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.","CRITERIA":"Inclusion Criteria:\n\n* Provision of informed consent prior to any study specific procedures.\n* Patients (male\/female) must be \\> 18 years of age.\n* Locally advanced or metastatic EGFR mutant NSCLC, not amenable to curative surgery or radiotherapy with confirmation of the presence of EGFR exon 19 deletion or exon 21 p.L858R.\n* Mandatory provision of an unstained, archived tumour tissue sample in a quantity sufficient to allow central analysis.\n* Patients must be treatment-na\u00efve for locally advanced or metastatic NSCLC and eligible to receive first-line treatment with osimertinib. Prior adjuvant and neo-adjuvant therapy is permitted (chemotherapy, radiotherapy) if at least 6 months has elapsed between the end of chemotherapy and enrolment.\n* World Health Organization (WHO) performance status 0-2.\n* Patients must have a life expectancy \u2265 12 weeks.\n* Females should be using adequate contraceptive measures, should not be breastfeeding and must have a negative pregnancy test prior to start of dosing if of child- bearing potential or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:\n\n  1. Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments.\n  2. Women under 50 years old would be consider postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range for the institution.\n  3. Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.\n* Male patients should be willing to use barrier contraception.\n* Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.\n* At least one lesion, not previously irradiated, that can be accurately measured at baseline as \u2265 10 mm in the longest diameter (except lymph nodes which must have short axis \u2265 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) and which is suitable for accurate repeated measurements.\n\nExclusion Criteria:\n\n* Involvement in the planning and\/or conduct of the study (applies to both sponsor staff and\/or staff at the study site).\n* Previous treatment with osimertinib or other drugs targeting EGFR.\n* Treatment with an investigational drug within five half-lives of the compound or 3 months, whichever is greater.\n* Patients currently receiving (or unable to adequately stop use prior to receiving the first dose of study treatment) medications or herbal supplements included in Annex 6 (Guidance Regarding Potential Interactions with Concomitant Medications).\n* Any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting study treatment with the exception of alopecia and grade 2, prior platinum-therapy related neuropathy.\n* Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.\n* Patients with spinal cord compression, symptomatic and unstable brain metastases except for those patients who have completed definitive therapy, and have had a stable neurological status for at least 2 weeks after completion of definitive therapy. Patients may be on corticosteroids to control brain metastases if they have been on a stable dose for 2 weeks (14 days) prior to the start of study treatment and are clinically asymptomatic.\n* Past medical history of ILD, drug-induced ILD, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active ILD.\n* Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:\n\n  1. Absolute neutrophil count \\<1.5 x 109\/L.\n  2. Platelet count \\<100 x 109\/L.\n  3. Haemoglobin \\<90 g\/L.\n  4. Alanine aminotransferase \\>2.5 times the upper limit of normal (ULN) if no demonstrable liver metastases or \\>5 times ULN in the presence of liver metastases.\n  5. Aspartate aminotransferase \\>2.5 times ULN if no demonstrable liver metastases or \\>5 times ULN in the presence of liver metastases.\n  6. Total bilirubin \\>1.5 times ULN if no liver metastases or \\>3 times ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases.\n  7. Creatinine \\>1.5 times ULN concurrent with creatinine clearance \\<50 ml\/min (measured or calculated by Cockcroft and Gault equation); confirmation of creatinine clearance is only required when creatinine is \\>1.5 times ULN.\n* Any of the following cardiac criteria:\n\n  1. Mean resting corrected QT interval (QTc using Fredericia's formula) \\> 470 msec.\n  2. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, and second degree heart block).\n  3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, electrolyte abnormalities (including serum\/plasma potassium \\< LLN, serum\/plasma magnesium \\< LLN, and serum\/plasma calcium \\<LLN), congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any\n* Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib.\n* Active second malignancy; i.e., patient known to have potentially fatal cancer present for which he\/she may be (but not necessarily) currently receiving treatment. Patients with a history of malignancy that has been completely treated, with no evidence of that cancer currently, are permitted to enrol in the trial provided all chemotherapy was completed \\> 6 months prior and\/or bone marrow transplant \\> 2 years prior to first day of study treatment.\n* Patients with other serious diseases or clinical conditions, including but not limited to uncontrolled active infection and any other serious underlying medical processes that could affect the patient's capacity to participate in the study.\n* History of hypersensitivity to osimertinib (or drugs with a similar chemical structure or class to osimertinib) or any excipients of these agents.\n* Males and females of reproductive potential who are not using an effective method of birth control and females who are pregnant or breastfeeding or have a positive (urine or serum) pregnancy test prior to study entry.\n* Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05785208008","EMAIL":[{"email":"emilio.bria@policlinicogemelli.it"}],"GEO":[41.89193,12.51133]},{"TITLE":"Chemoradiation Followed by Durvalumab in Poor Risk and\/or Elderly Patients With Stage III NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Participants must have histologically or cytologically confirmed stage IIIA-C (AJCC 8th edition) non-small cell lung cancer, that will be treated with curative intent.\n2. Participants must have been deemed medically inoperable by multidisciplinary team\/tumor board\n3. Participants must have been staged with a PET\/CT within 30 days of enrollment\n4. Patients must have undergone an MRI Brain w\/IV contrast, or CT brain if MRI not feasible, confirming no evidence of brain metastases, within 30 days of enrollment.\n5. Participants must be elderly (age 70 years or older and PS 0-1) or \\>18 years old AND poor risk (ECOG 2)\n6. Participants ideally have endobronchial ultrasound biopsy (EBUS) or mediastinoscopy to confirm nodal status, but can be deferred if PET\/CT imaging characteristics are highly suggestive of nodal metastases\n7. Participants should have a life expectancy of \\>6 months\n8. Participants must have normal organ and marrow function: Leukocytes \\>3000\/mcL; ANC \\>1500\/mcL; PLT\\>100000\/mcL; Hemoglobin \u22659.0 g\/dL\n9. Serum bilirubin \u22641.5 x institutional upper limit of normal (ULN)\n10. AST\/ALT \\<2.5 x institutional upper limit of normal\n11. Measured creatinine clearance (CL) \\>40 mL\/min or Calculated creatinine CL\\>40 mL\/min by the Cockcroft-Gault formula\n\n    Males:\n\n    Creatinine CL (mL\/min) = Weight (kg) x (140 - Age) 72 x serum creatinine (mg\/dL)\n\n    Females:\n\n    Creatinine CL (mL\/min) = Weight (kg) x (140 - Age) x 0.85 72 x serum creatinine (mg\/dL)\n12. Patients must be capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization (eg, Health Insurance Portability and Accountability Act in the US, European Union \\[EU\\] Data Privacy Directive in the EU) obtained from the patient\/legal representative prior to performing any protocol-related procedures, including screening evaluations. If study includes Japan add (For patients aged \\<20 years and enrolling in Japan, a written informed consent should be obtained from the patient and his or her legally acceptable representative.)\n13. Body weight \\>30kg\n14. Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n    Women \\<50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n\n    Women \u226550 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \\>1 year ago, had chemotherapy-induced menopause with last menses \\>1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).\n15. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.\n\nExclusion Criteria:\n\n1. History of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin, pemetrexed (for patients with adenocarcinoma), etoposide (for patients with squamous cell carcinoma), or immunotherapy\n2. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic CHF, unstable angina pectoris, cardiac arrhythmia, or psychiatric\/social situations that would limit compliance with study requirements.\n3. Pregnant women\n4. HIV positive patients\n5. Participation in another clinical study with an investigational product during the last 6 months\n6. Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study\n7. Receipt of the last dose of anticancer therapy (CRT) \u22647 days prior to the first dose of study drug. If sufficient wash-out time has not occurred due to the schedule or PK properties of an agent, a longer wash-out period will be required, as agreed by AstraZeneca\/MedImmune and the investigator\n8. Any unresolved toxicity NCI CTCAE Grade \u22652 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria\n\n   1. Patients with Grade \u22652 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician.\n   2. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the Study Physician.\n9. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.\n10. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable.\n11. History of allogenic organ transplantation.\n12. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \\[e.g., colitis or Crohn's disease\\], diverticulitis \\[with the exception of diverticulosis\\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \\[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc\\]). The following are exceptions to this criterion:\n\n    1. Patients with vitiligo or alopecia\n    2. Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement\n    3. Any chronic skin condition that does not require systemic therapy\n    4. Patients without active disease in the last 5 years may be included but only after consultation with the study physician\n    5. Patients with celiac disease controlled by diet alone\n13. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness\/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent\n14. History of another primary malignancy except for\n\n    1. Malignancy treated with curative intent and with no known active disease \u22655 years before the first dose of IP and of low potential risk for recurrence\n    2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\n    3. Adequately treated carcinoma in situ without evidence of disease\n15. History of leptomeningeal carcinomatosis\n16. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) \u2265470 ms calculated from 3 ECGs (within 15 minutes at 5 minutes apart) \\<\\<for durvalumab monotherapy.\n17. History of active primary immunodeficiency\n18. Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1\/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n19. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:\n\n    1. Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)\n    2. Systemic corticosteroids at physiologic doses not to exceed \\<\\<10 mg\/day\\>\\> of prednisone or its equivalent\n    3. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)\n20. Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP.\n21. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy.\n22. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.\n23. Prior randomisation or treatment in a previous durvalumab clinical study regardless of treatment arm assignment.\n24. Patients who have received prior anti-PD-1, anti PD-L1, including durvalumab or anti CTLA-4:\n\n    1. Must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy.\n    2. All AEs while receiving prior immunotherapy must have completely resolved or resolved to baseline prior to screening for this study.\n    3. Must not have experienced a \u2265Grade 3 immune related AE or an immune related neurologic or ocular AE of any grade while receiving prior immunotherapy. NOTE: Patients with endocrine AE of \u2264Grade 2 are permitted to enroll if they are stably maintained on appropriate replacement therapy and are asymptomatic.\n    4. Must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged, and not currently require maintenance doses of \\> 10 mg prednisone or equivalent per day.\n25. Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.\n\nProcedures for withdrawal of incorrectly enrolled patients are presented in Section 4.3 Withdrawal of patients from study treatment and\/or study","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04441138001","EMAIL":[{"email":"Gaurav_Marwaha@rush.edu"},{},{},{},{},{}],"GEO":[41.85003,-87.65005]},{"TITLE":"A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.","CRITERIA":"Inclusion Criteria\n\n* Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.\n* Participants must have at least 1 lesion accessible for biopsy in addition to the target lesion, from which a fresh pre treatment biopsy must be obtained.\n* Participants must have an unresectable\/metastatic carcinoma.\n\nExclusion Criteria\n\n* Participants must not have Leptomeningeal metastases.\n* Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment.\n* Participants must not have had any prior radiation therapy within 2 weeks prior to start of study treatment.\n* Other protocol-defined Inclusion\/Exclusion criteria apply.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06476808003","EMAIL":[{}],"GEO":[40.88593,-74.04347]},{"TITLE":"A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR Mutations","CRITERIA":"Inclusion Criteria:\n\n1. 18 years and older\n2. Provision of informed consent prior to any study specific procedures\n3. Histologically or cytologically confirmed NSCLC(non small cell lung cancer) , performed on a biopsy\n4. Documented activating EGFR mutation (Exon 19 deletion or L858R)\n5. Positron emission tomography (PET)-computed tomography (CT) within the last 60 days showing radiographic stage I to IIIa lung cancer (mediastinal staging biopsy is allowed but not required)\n6. Brain magnetic resonance imaging (MRI) (or CT if contraindication to MRI) within the last 60 days showing no evidence of metastatic disease\n7. Documentation that the patient is a candidate for surgical resection of their lung cancer by certified surgeon\n8. Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria\n9. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-1\n10. All toxicity from previous chemotherapy, radiation therapy, or surgical procedures according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 recovered to Grade 1 .\n11. Patients may receive supplements to meet this requirement this requirement\n\n    * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\\< 2.5 x upper limit of normal (ULN)\n    * Bilirubin =\\< 1.5 x ULN (Patients with documented Gilbert's syndrome and conjugated bilirubin within the normal range may be allowed into the study; in this event, it will be documented that the patient was eligible based on conjugated bilirubin levels)\n    * Leukocytes \\> 3,000\/mcL\n    * Hemoglobin \\>= 9 g\/dL, with no blood transfusions in the 28 days prior to study entry\n    * Absolute neutrophil count \\> 1,500\/mcL\n    * Platelets \\> 100,000\/mcL\n    * Creatinine =\\< 1.5 x upper limit of normal (ULN) OR creatinine clearance \\> 50 mL\/min\/1.73 m2 for patients with creatinine levels =\\< 1.5 x upper limit above institutional normal\n12. Ability to swallow oral medications\n13. Women of childbearing potential (WoCBP) must have a negative serum pregnancy test and agree to use highly effective contraception, during the study and for 2 months following the last dose of osimertinib\n14. Women NOT of childbearing potential: women who are permanently or surgically sterilized or postmenopausal\n\n    * Permanent sterilization includes hysterectomy and\/or bilateral oophorectomy and\/or bilateral salpingectomy but excludes bilateral tubal occlusion; tubal occlusion is considered a highly effective method of birth control but does not absolutely exclude possibility of pregnancy; (the term occlusion refers to both occluding and ligating techniques that do not physically remove the oviducts)\n    * Women who have undergone tubal occlusion should be managed on trials as if they are of WoCBP (e.g. undergo pregnancy testing etc., as required by the study protocol)\n15. Women will be considered postmenopausal if they are amenorrhoeic for 12 months without an alternative medical cause; the following age-specific requirements apply:\n\n    * Women under 50 years old will be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and with luteinizing hormone and follicle-stimulating hormone levels in the postmenopausal range\n    * Women over 50 years of age will be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatments\n16. Acceptable contraception methods are:\n\n    * Total sexual abstinence (abstinence must be for the total duration of the trial and the follow-up period)\n    * Vasectomized sexual partner plus male condom (with participant assurance that partner received post-vasectomy confirmation of azoospermia)\n    * Tubal occlusion plus male condom\n    * Intra-uterine device - provided coils are copper-banded, plus male condom\n    * Intra-uterine system (IUS) levonorgestrel IUS (e.g., Mirena), plus male condom\n    * Medroxyprogesterone injections (Depo-Provera) plus male condom\n    * Etonogestrel implants (e.g., Implanon, Norplant) plus male condom\n    * Normal and low dose combined oral contraceptive pills, plus male condom\n    * Norelgestromin \/ ethinylestradiol transdermal system plus male condom\n    * Intravaginal device (e.g., ethinylestradiol and etonogestrel) plus male condom\n    * Cerazette (desogestrel) plus male condom (Cerazette is currently the only highly efficacious progesterone based pill) For more information, see Appendix E (Definitions of Women of Fertility and Acceptable Contraception Methods).\n17. The following methods are considered not to be highly effective and are therefore not acceptable contraceptive methods: - Triphasic combined oral contraceptives; All progesterone only pills except, Cerazette; All barrier methods, if intended to be used alone; Non-copper containing intra-uterine devices; Fertility awareness methods; Coitus interruptus\n18. Men must agree to the use of high-efficiency contraception.\n\nExclusion Criteria:\n\n1. Leptomeningeal carcinomatosis or other central nervous system (CNS) metastases\n2. Stage IIIB, or distant metastases (including malignant pleural effusion) identified on PET-CT scan or biopsy\n3. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease\n4. History of confirmed, corneal ulceration\n5. Patients who are known to be serologically positive for human immunodeficiency virus (HIV)\n6. Active second malignancy, i.e. patient known to have potentially fatal cancer present for which he\/she may be (but not necessarily) currently receiving treatment; patients with a history of malignancy that has been completely treated, with no evidence of that cancer currently, are permitted to enroll in the trial provided all chemotherapy for prior malignancy was completed \\> 12 months prior and\/or bone marrow transplant \\> 2 years prior\n7. Patients who are currently receiving treatment with contraindicated corrected QT interval (QTc) prolonging medications or potent CYP3A4 inducers, if that treatment cannot be either discontinued or switched to a different medication prior to first day of study treatment\n8. Any of the following cardiac criteria:\n\n   * Mean resting corrected QT interval (QTc) \\> 470 msec obtained from 3 electrocardiograms (ECGs), using the screening clinic ECG machine derived QTc value\n   * Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block and second degree heart block.\n   * Patient with any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, electrolyte abnormalities (including: Serum\/plasma potassium \\< LLN; Serum\/plasma magnesium \\< LLN; Serum\/plasma calcium \\< LLN) congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes\n9. Inadequate bone marrow reserve or organ function (as demonstrated by any of the following laboratory values:\n\n   * Absolute neutrophil count \\<1.5 x 109\/L;\n   * Platelet count \\<100 x 109\/L;\n   * Haemoglobin \\<90 g\/L;\n   * Alanine aminotransferase \\>2.5 times ULN if no demonstrable liver metastases or \\>5 times ULN in the presence of liver metastases;\n   * Aspartate aminotransferase \\>2.5 times ULN if no demonstrable liver metastases or \\>5 times ULN in the presence of liver metastases;\n   * Total bilirubin \\>1.5 times ULN if no liver metastases or \\>3 times ULN in the presence of documented Gilbert's Syndrome \\[unconjugated hyperbilirubinaemia\\] or liver metastases;\n   * Serum creatinine \\>1.5 times ULN concurrent with creatinine clearance \\<50 mL\/min \\[measured or calculated by Cockcroft and Gault equation\\]-confirmation of creatinine clearance is only required when creatinine is \\>1.5 times ULN.\n10. Treatment with prohibited medications (concurrent anticancer therapy including chemotherapy, radiation, hormonal treatment \\[except corticosteroids and megesterolacetate\\], or immunotherapy) =\\< 14 days prior to treatment with osimertinib\n11. Prior treatment with osimertinib or other drugs that target EGFR mutant non-small cell lung cancer (including erlotinib, afatinib, gefitinib, rocelitinib)\n12. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, or known active infection including chronic active hepatitis B, hepatitis C and human immunodeficiency virus (HIV); screening for chronic conditions is not required; patients with chronic hepatitis B virus (HBV) with negative HBV viral load on appropriate antiviral therapy will be permitted, if able to continue appropriate antiviral therapy throughout treatment period\n13. Treatment with an investigational drug within five half-lives of the compound or 3 months, whichever is greater.\n14. Currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of CYP3A4 (at least 3 week prior) (Appendix DE). All patients must try to avoid concomitant use of any medications, herbal supplements and\/or ingestion of foods with known inducer effects on CYP3A4.\n15. Any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting study treatment, with the exception of alopecia and grade 2 prior platinum-therapy-related neuropathy.\n16. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib.\n17. Active tuberculosis\n18. Signs or symptoms of infection within 2 weeks prior to first day of study drug treatment\n19. Females who are pregnant or breastfeeding\n20. Presence of active gastrointestinal (GI) disease (including GI bleeding or ulceration) or other condition that could affect GI absorption (e.g. malabsorption syndrome, history of biliary tract disease), including refractory nausea or vomiting, or chronic GI disease which may affect absorption or tolerance to oral medications\n21. History of hypersensitivity to active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib\n22. Involvement in the planning and\/or conduct of the study (applies to both investigator staff and\/or staff at the study site)\n23. Uncontrolled medical, psychological, familial, sociological, or geographical conditions that interfere with the patient's safety, ability to provide informed consent, or ability to comply with the protocol.\n24. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.","SEX":"ALL","AGE_MIN":20,"AGE_MAX":200,"SS_ID":"04816838001","EMAIL":[{"email":"limlove2008@yuhs.ac"}],"GEO":[37.566,126.9784]},{"TITLE":"An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)","CRITERIA":"Inclusion Criteria:\n\n* Be willing and able to provide written informed consent.\n* Be \u2265 18 years of age on day of signing informed consent.\n* Have histologically or cytologically confirmed diagnosis of inoperable hepatocellular carcinoma (HCC) or non-squamous non-small cell lung cancer (NSCLC) with liver metastases with at least one measurable lesion.\n* NSCLC patients who were previously treated with chemotherapy or treatment na\u00efve patients with a programmed death ligand-1 (PD-L1) tumor proportion score \u226550% or tumor cell score 3\/immune cell score 3 are included.\n* NSCLC patients must be epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild type.\n* HCC patients may be treatment na\u00efve or treated with prior tyrosine kinase inhibitor(s).\n* Have a current liver function meeting Child Pugh Class A (5-6 points) in patients with HCC, with no encephalopathy or ascites.\n* Be willing to provide tumor tissue from a core biopsy of a tumor lesion (archival not acceptable). The subject must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy. In addition, the subject must be willing to give blood for correlative studies, and have no contraindications to this.\n* Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.\n* Have recovered (to \u2264 grade 1) from prior toxicities related to previous treatments at the time of study enrollment, with the exception of alopecia or skin depigmentation.\n* Be tested for Hepatitis B-virus surface antigen (HBsAg) status. Patients may be included in the study if they have adequately controlled hepatitis B\n* Patients must be tested for hepatitis C virus (HCV) status. Subjects with chronic infection by HCV who are untreated are allowed on study. In addition, subjects with successful HCV treatment are allowed as long as 4 weeks have passed between completion of HCV therapy and start of study treatment.\n* Demonstrate adequate organ function.\n* Agrees to use use highly effective contraceptive methods, not donate egg or sperm, during study participation, and for at least 6 months after the last dose of study medications.\n* Life expectancy expected to be 3 months or greater.\n\nExclusion Criteria:\n\n* Has received stereotactic radiotherapy within 4 weeks of trial commencement. For chemotherapy, tyrosine kinase inhibitors and palliative-dose radiotherapy, a 2 week washout is required.\n* Is currently participating and receiving experimental treatment as part of a clinical trial, or has participated in a study of an immune checkpoint inhibitor and received study therapy, or used an investigational device within 4 weeks of the first dose of treatment.\n* Inadequately controlled hypertension (defined as systolic blood pressure \\[BP\\] \\> 150 mmHg and\/or diastolic blood pressure \\> 100 mmHg), based on an average of \u2265 3 BP readings on \u2265 2 sessions. Anti-hypertensive therapy to achieve these parameters is allowed.\n* History of hypertensive crises or hypertensive encephalopathy\n* Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident within 3 months prior to initiation of study treatment), unstable arrhythmia, or unstable angina\n* Significant vascular disease (eg. aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to randomization\n* History of Grade \u2265 4 venous thromboembolism.\n* History of Grade \u2265 2 hemoptysis (defined as \u2265 2.5 mL of bright red blood per episode) within 1 month prior to screening for HCC and within 3 months for NSCLC.\n* History or evidence of bleeding diathesis or significant coagulopathy at risk of bleeding (ie. In the absence of therapeutic anticoagulation)\n* Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to initiation of study treatment and wounds are fully healed, or anticipation of need for major surgical procedure during the course of the study.\n* Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture.\n* Evidence of tumor invading or abutting major blood vessels.\n* History of abdominal fistula, gastrointestinal (GI) perforation, intra-abdominal abscess, or active GI bleeding within 6 months prior to randomization.\n* Serious, non-healing wound, active ulcer, or untreated bone fracture\n* Current or recent (\\< 10 days prior to initiation of study treatment) use of aspirin (\\> 325 mg\/day) or treatment with dipyramidole, ticlopidine, clopidogrel (\\> 75 mg\/day) and cilostazol.\n* Current or recent (\\< 10 days prior to initiation of study treatment) use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purpose\n* Has symptomatic, untreated or actively progressing central nervous system (CNS) metastases. Asymptomatic patients treated for CNS metastases may be eligible if they meet required criteria.\n* Uncontrolled tumor-related pain\n* Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 \\[IL-2\\]) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment.\n* Has had a previous allogeneic stem cell or solid organ transplant, a diagnosis of immunodeficiency, or is receiving systemic corticosteroid therapy or any other form of immunosuppressive therapy (eg. cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \\[TNF\\]-\u03b1 agents) within 7 days prior to the first dose of trial treatment, or anticipation of need for systemic immunosuppressive medication during study treatment.\n* Has histological or cytological diagnosis of fibrolamellar HCC, mixed cholangiocarcinoma or sarcomatoid HCC.\n* Untreated or incompletely treated esophageal and\/or gastric varices with bleeding or high risk for bleeding\n* Has had a prior bleeding event due to esophageal and\/or gastric varices within 6 months prior to initiation of study treatment.\n* History of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to either Atezolizumab or Bevacizumab.\n* Has had hepatic encephalopathy in the past 6 months, or has clinically apparent ascites at the time of study enrollment\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (eg. bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan.\n* Has active Bacillus Tuberculosis (TB)\n* Has had prior treatment-related toxicity and not recovered (i.e. \u2264 Grade 1 or at baseline)\n* Chronic daily treatment with a non-steroidal anti-inflammatory drug (NSAID)\n* Has a known history of prior clinically relevant invasive malignancy except if the subject has undergone curative-intent therapy with no evidence of disease recurrence for 2 years prior to study entry. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, low-risk prostate cancer or in-situ cervical cancer.\n* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy at a dose of \u2264 10 mg\/day of prednisolone or equivalent) is not considered a form of systemic therapy.\n* Has a known history of, or any evidence of active, non-infectious pneumonitis.\n* Has an active infection requiring systemic oral or intravenous (IV) antibiotic therapy within 2 weeks prior to initiation of treatment.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subjects participation for the full duration of the trial, or is not in the best interest of the subject to participate in the opinion of the treating investigator.\n* Has known psychiatric, substance abuse disorder, or any other condition that, in the opinion of the investigator, would interfere with cooperation with the requirements of the trial\n* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through at least 6 months after the last dose of study drugs\n* Has received prior therapy with CD137 agonists or immune checkpoint blockade therapies including anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4), anti-programmed death-1 (PD-1), anti-PD-L1, anti-programmed death ligand-2 (PD-L2) agent, or bevacizumab.\n* Has a known history of Human Immunodeficiency Virus (HIV)\n* Has received a live vaccine within 30 days of planned start of study therapy or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the last dose of atezolizumab.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04563338001","EMAIL":[{},{}],"GEO":[43.70011,-79.4163]},{"TITLE":"Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform","CRITERIA":"Subject Inclusion Criteria\n\n1. Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.\n2. Age \u2265 18 years at the time of consent.\n3. Subjects suspected of or diagnosed with Stage IV\/metastatic NSCLC and meet one of the following criteria:\n\n   1. Subjects who are undiagnosed, have undergone imaging and are suspected to have Stage IV lung cancer.\n   2. Subjects with a previous Stage I, II, or III diagnosis of NSCLC, who are being re-biopsied due to suspected progression to metastatic disease.\n   3. Subjects who have a newly confirmed diagnosis of Stage IV NSCLC, have undergone a SOC biopsy procedure and will undergo a separate procedure for the purposes of this study prior to starting first line treatment.\n   4. Subjects who have a previous Stage IV\/metastatic NSCLC diagnosis and have already received first line treatment.\n4. Subjects must be clinically able, at investigator discretion, to undergo additional CNB or forceps biopsy passes during their biopsy. These additional biopsies may either be collected from the primary tumor or a metastatic site amenable to additional passes (e.g., liver or lymph nodes) per the clinician.\n5. Subjects who are newly diagnosed or have suspected cancer must be treatment-na\u00efve at the time of biopsy. All other subjects should have the biopsy performed before starting their next line of treatment.\n\nSubject Exclusion Criteria\n\n1. Any patient for whom an extra biopsy might pose a clinical risk based on the discretion of the clinician.\n2. Any mental impairment that would render the patient unable to understand his\/her participation in the study would disqualify the patient from consenting and participating.\n3. Subjects with an auto-immune disease that would render them ineligible for immune- oncology treatment.\n4. Immunocompromised subjects, and subjects known to be HIV positive and currently receiving antiretroviral therapy. NOTE: Patients known to be HIV positive, but without clinician evidence of an immunocompromised state, are eligible for this trial.\n5. Subjects who are enrolled or plan to be enrolled in a blinded oncology treatment trial are not eligible.\n6. Subjects who are pregnant are not eligible.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05478538007","EMAIL":[{"email":"Lorie.Fares@BSWHealth.org"},{}],"GEO":[31.09823,-97.34278]},{"TITLE":"Combination of Paclitaxel-bevacizumab \u00b1 Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy","CRITERIA":"Inclusion Criteria:\n\n1. Patients must have signed and dated an IRB\/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal patient care.\n\n   Patients must be willing and able to comply with scheduled visits, treatment schedule, and laboratory testing.\n2. Male or female aged at least 18 years old.\n3. ECOG Performance Status of 0 or 1.\n4. Histologically or cytologically documented locally advanced unresectable NSCLC (i.e. stage IIIB\/IIIC not eligible for definitive chemo-radiotherapy) or metastatic NSCLC (i.e. Stage IV) (per the 8th edition of Union Internationale Contre le Cancer\/American Joint Committee on Cancer \\[UICC\/AJCC\\] staging system) of non-squamous histology.\n\n   Note: patients with tumours of mixed histology must be classified as non-squamous or squamous based on the major histological component.\n5. Patients progressing after treatment with immunotherapy (anti-PD-1 or anti-PD-L1 Ab) and a doublet of platinum-based chemotherapy, given concomitantly or sequentially\n6. Patients without contraindications to bevacizumab.\n7. The investigator must confirm prior to enrolment that the patient has adequate tumour tissue available. Tumour biopsy should be exploitable for molecular analysis.\n\n   Note: Tumour tissue collected after the patient was diagnosed with metastatic disease is preferred.\n\n   Tumour tissue sample must not be from previously radiated locations. Tumour sample must be one block or at least 10 unstained slides of analysable tissue.\n\n   If archival tissue is either insufficient or unavailable, the patient may still be eligible upon discussion with IFCT.\n8. All patients must have at least one measurable target lesion according to RECIST v1.1. Previously irradiated lesions can only be considered measurable disease if disease progression has been unequivocally documented at that site since radiation and the previously irradiated lesion is not the only site of measurable disease.\n9. Life expectancy \u2265 12 weeks\n10. Adequate hematologic and end-organ function, defined by the following laboratory test results:\n\n    * ANC \u2265 1500 cells\/\u00b5L (without granulocyte colony-stimulating factor support within 14 days prior to C1D1).\n    * WBC count \u2265 2500\/\u00b5L.\n    * Lymphocyte count \u2265 500\/\u00b5L.\n    * Platelet count \u2265 100 000\/\u00b5L (without transfusion within 14 days prior to C1D1).\n    * Haemoglobin \u2265 9.0 g\/dL (patients may be transfused or receive erythropoietic treatment as per local standard of care).\n    * Total bilirubin \u2264 1.5 x upper limit of normal (ULN).\n    * Patients with known Gilbert's disease or hepatic metastasis who have serum bilirubin level \u2264 3 x ULN may be enrolled.\n    * AST and ALT \u2264 3 x ULN, with the following exception: patients with documented liver metastases: AST and ALT \u2264 5 x ULN; ALP \u2264 2.5 x ULN; or patients with documented bone metastases: ALP \u2264 5 x ULN.\n    * Serum albumin \u2265 2.5 g\/dL.\n    * LDH \u2264 3 x ULN.\n    * aPTT or PTT and PT or INR \u2264 1.5 x ULN. This applies only to patients who are not receiving therapeutic anticoagulation. Patients receiving therapeutic anticoagulation should be on a stable dose for at least 1 week prior to C1D1.\n11. Measured or calculated creatinine clearance \u2265 50 mL\/min calculated using the local standard method.\n12. Recovered from all toxicities associated with prior treatment, to acceptable baseline status, or NCI CTCAE v5.0 Grade 0 or 1, except for toxicities not considered a safety risk, such as alopecia or vitiligo.\n13. For women of childbearing potential (including women who have had a tubal ligation), serum pregnancy test must be performed and documented as negative within 14 days prior to C1D1.\n14. Women of childbearing potential must remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of \\< 1% per year during the treatment period and for at least 6 months after the last dose of study drugs. Women must refrain from donating eggs during this same period. A woman is considered to be of childbearing potential if she is post-menarcheal, has not reached a postmenopausal state (\u2265 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries or uterus). Examples of contraceptive methods with a failure rate of \\<1% per year include bilateral tubal ligation, male sterilization, established proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. Hormonal contraceptive methods must be supplemented by a barrier method plus spermicide. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g. calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.\n15. Men with female partners of childbearing potential or pregnant female partners, must remain abstinent or use a condom during the treatment period and for at least 6 months after the last dose of study treatment to avoid exposing the embryo. Men must refrain from donating sperm during this same period. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g. calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.\n16. Participant has national health insurance coverage.\n\nExclusion Criteria:\n\n1. Patients with non-squamous carcinoma who have documentation of any of the following: EGFR mutation, ALK fusion oncogene, ROS1 rearrangement, RET\/NTRK fusions.\n2. Patients previously treated by bevacizumab combined with first-line chemotherapy for NSCLC.\n3. Patients with a previous treatment by taxane (docetaxel, paclitaxel). A patient with a previous treatment by peri-operative taxane or in association with radiotherapy is eligible if the treatment has been stopped for more than 6 months.\n4. Patients with symptomatic brain metastasis, leptomeningeal disease or other active CNS metastases are not eligible. Note: patients with previously treated or untreated brain metastases may participate, provided they are stable (e.g. without evidence of progression by radiographic imaging for at least 28 days before the first dose of study treatment and neurologic symptoms have returned to baseline). Patients must have no evidence of new or enlarging brain metastases or CNS oedema. Patients must have discontinued use of steroids (with a dose \\> 10 mg prednisone equivalent daily) at least 7 days before the first dose of study treatment.\n5. Spinal cord compression not definitively treated with surgery or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for \u2265 2 weeks prior to screening.\n6. Malignancies other than NSCLC within 3 years prior to randomization, with the exception of those with a negligible risk of metastasis or death, or treated with expected curative outcome (such as adequately treated in situ cervical cancer, basal or squamous cell skin cancer, localized prostate cancer, ductal carcinoma in situ, or stage I uterine cancer).\n7. Inability to comply with study or follow-up procedures.\n8. Pregnant, lactating, or breastfeeding women.\n9. Severe infections (including active tuberculosis) within 4 weeks prior to initiation of study treatment, including but not limited to hospitalization for complications of infection, bacteraemia, or severe pneumonia.\n10. Received oral or IV antibiotics (including antifungals) within 2 weeks prior to randomization. Patients receiving prophylactic antibiotics (e.g. for prevention of a urinary tract infection or chronic obstructive pulmonary disease exacerbations) are eligible.\n11. Major surgical procedure within 4 weeks prior to randomization, or anticipation of need for a major surgical procedure during the course of the study.\n12. Inability to understand the local language (French).\n13. Any disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, that may affect the interpretation of the results, or that may render the patient at high risk from treatment complications.\n14. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.\n15. Known hypersensitivity or allergy to Chinese hamster ovary cell products or any component of the atezolizumab formulation.\n16. Active or history of autoimmune disease with the following exceptions:\n\n    * Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study following discussion with IFCT.\n    * Patients with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible for this study following discussion with IFCT.\n    * Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g. patients with psoriatic arthritis would be excluded) are permitted provided they meet the following conditions:\n\n      * Rash must cover less than 10% of body surface area (BSA).\n      * Disease is well controlled at baseline and only requires low potency topical steroids.\n      * No acute exacerbations of the underlying condition within the last 12 months requiring treatment with either PUVA (psoralen plus ultraviolet A radiation), methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral steroids.\n17. Prior allogeneic bone marrow transplantation or prior solid organ transplantation.\n18. History of idiopathic pulmonary fibrosis (including pneumonitis), organizing pneumonia (i.e. bronchiolitis obliterans, cryptogenic organizing pneumonia), drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on chest computed tomography (CT) scan at screening. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.\n19. Patients with a known history of a positive test for HIV or known AIDS who have not received effective antiretroviral therapy (ART) for the last 4 weeks and who have an HIV viral load \\>200 copies\/mL, regardless of CD4+ T-cell count.\n20. Patients with known acute viral hepatitis B or C (HBV, HBC) according to serological tests. Patients with serological sequelae of cured viral hepatitis are eligible.\n21. Administration of live, attenuated vaccine within 4 weeks prior to initiation of study treatment or anticipation that such a live attenuated vaccine will be required during the study. Influenza vaccination should be given during influenza season only. Patients must not receive live, attenuated influenza vaccine within 4 weeks prior to enrolment or at any time during the study, and for 5 months following the last study treatment.\n22. Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone \\> 10 mg\/day, cyclophosphamide, azathioprine, methotrexate, thalidomide, and tumour necrosis factor \\[TNF-\u03b1\\] antagonists) within 2 weeks prior to randomization. Patients who have received acute, low dose, systemic immunosuppressant medications (e.g. a one-time dose of dexamethasone for nausea) may be eligible for this study following discussion with IFCT. The use of inhaled corticosteroids is allowed. The use of mineralocorticoids (e.g. fludrocortisone) for patients with orthostatic hypotension is allowed. Physiologic doses of corticosteroids for adrenal insufficiency may be allowed after discussion with IFCT.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05781308025","EMAIL":[{}],"GEO":[47.75,7.33333]},{"TITLE":"Tai-Chi and Aerobic Exercise to Improve Emotional Symptom Cluster in Late-stage Lung Cancer Patients","CRITERIA":"Inclusion Criteria:\n\n* diagnosed with stage IIIB or IV non-small cell lung cancer confirmed by pathology, with no other cancer diagnosis within the previous year;\n* a current Eastern Cooperative Oncology Group Performance Status of 0-2;\n* experience of sleep disturbance, anxiety, depression, and fatigue in the past week (rating of 1 or more on a 0-10 numeric rating scale \\[NRS\\] for each symptom);\n* able to communicate in Cantonese, Mandarin, or English;\n* conscious and alert\n\nExclusion Criteria:\n\n* suffering from a condition that hinders exercise performance (e.g., active neurological disorder, recent heart attack);\n* currently participating in any other exercise or mind-body classes; or 3) performing regular exercises, defined as at least 150 minutes of moderate-intensity exercise weekly","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05778708001","EMAIL":"cclin@hku.hk","GEO":[22.27832,114.17469]},{"TITLE":"Neuroendocrine Transformation in RB1\/TP53 Inactivated NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Age \u2265 18 years old;\n2. ECOG function status score 0-2 points;\n3. Pathological diagnosis of stage III-IV non neuroendocrine non-small cell lung cancer;\n4. RB1\/TP53 gene\/protein testing (IHC, NGS, or other techniques are acceptable) has been completed and confirmed to be dual inactivation of RB1\/TP53;\n5. For patients with baseline pathology of adenocarcinoma, complete driver gene testing (including at least EGFR and ALK);\n6. The patient undergoes at least one systemic treatment (chemotherapy, targeted drug therapy, immunotherapy, etc.) and receives regular follow-up;\n7. After discovering disease progression during the follow-up process, the patient will undergo further pathological biopsy of the progressing lesion after evaluation by the sub center PI;\n8. According to the researcher's assessment, the patient currently does not require palliative radiation therapy in any area;\n9. If the subject undergoes surgery, they must fully recover from the toxicity and complications of the surgical intervention before starting treatment;\n10. The subjects need to agree to provide corresponding peripheral blood and biopsy tissue samples before and during the follow-up treatment in accordance with the clinical trial protocol requirements;\n11. Men\/women of childbearing age agree to use contraception during the trial period (surgical ligation or oral contraception\/intrauterine device+condom contraception);\n12. Life expectancy \u2265 3 months;\n13. Patients must have the ability to understand and voluntarily sign informed consent forms.\n\nExclusion Criteria:\n\n1. Baseline pathological examination reveals neuroendocrine components (including any percentage of small cell carcinoma, large cell carcinoma, differentiated neuroendocrine carcinoma, etc);\n2. Unable to perform RB1\/TP53 testing ;\n3. Patients with baseline pathology of adenocarcinoma and inability to perform driver gene testing (including at least EGFR, ALK);\n4. Symptomatic interstitial lung disease or active infection\/non infectious pneumonia;\n5. History of other malignant tumors;\n6. Physical examination or clinical trial findings that researchers believe may interfere with the results or increase the risk of treatment complications for patients, or other uncontrollable diseases\n7. Breastfeeding or pregnant women;\n8. Congenital or acquired immunodeficiency diseases, including human immunodeficiency virus (HIV), or a history of organ transplantation or allogeneic stem cell transplantation;\n9. Patients who require long-term treatment with cortisol or immunosuppressants;\n10. Patients with mental illnesses, substance abuse, or social issues that affect compliance will not be included in the group after being reviewed by a doctor\n11. Individuals who receive other long-term medication treatments and have been assessed by a doctor as potentially affecting disease progression.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06369181001","EMAIL":[{"email":"fuscczzf@163.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients","CRITERIA":"Inclusion Criteria:\n\n* Older than 75 years old.\n* ECOG general status score of 0-2.\n* Primary non-small cell lung cancer (NSCLC) confirmed by histology or cytological pathology, T1-4N1-3M0, stage IIb-IIIc (AJCC\/UICC 8th edition).\n* Medically inoperable, or patient refuses surgery.\n* Adequate organ function: 1). Blood function: absolute neutrophil count (ANC) \u22651.5 x 109\/L, platelet count \u226580 x 109\/L, hemoglobin \u22659 g\/dL 2). Lung function: FEV1\\>25%, DLCO\\>25% 3). Cardiac function: no serious pulmonary hypertension, cardiovascular and cerebrovascular diseases, peripheral vascular diseases, serious chronic heart disease and other complications that may affect radiotherapy.4). Adequate liver function: total bilirubin \\<1.5 times the upper limit of normal value, and AST, ALT\\<2 times the upper limit of normal value. 5). Adequate renal function: serum creatinine \u22641.5 times the upper limit of normal or calculated creatinine clearance \u226550 ml \/min, and urinary protein \\<2+. Patients with a baseline urinary protein level of 2+ or more should have a 24-hour urine collection and evidence of a 24-hour urinary protein level of 1g or less.\n* Sign informed consent.\n\nExclusion Criteria:\n\n* Patient with squamous cell carcinoma was treated with bevacizumab before carbon ion radiotherapy.\n* Complicated with other malignant tumors that have not been controlled.\n* Patient whose particle radiotherapy plan cannot meet the minimum target dose coverage and dose volume limitation requirements, or cannot meet the dose constrains of normal tissue or organs.\n* Chest radiation therapy or radioactive particle implantation history.\n* Cardiac pacemakers or other internal metal prosthesis implants that may be affected by high-energy radiation or may affect the dose distribution to the radiation target area.\n* HIV positive. Hepatitis virus replication phase, need to receive antiviral therapy, but because of concomitant disease cannot receive antiviral therapy. Active stage of syphilis.\n* A history of mental illness may hinder the completion of treatment.\n* With serious comorbidity that may interfere with radiotherapy, including: (a) Acute infectious diseases or acute active phase of chronic infection. b) Unstable angina pectoris, congestive heart failure, myocardial infarction that has been hospitalized in the past 6 months. c) Exacerbations of chronic obstructive pulmonary disease or other respiratory conditions requiring hospitalization. d) Severely impaired immune function. e) Diseases with excessive sensitivity to radiation such as ataxia telangiectasia. f) Other diseases that may affect particle radiotherapy.\n* Other circumstances that the physician considers inappropriate to participate in clinical study.","SEX":"ALL","AGE_MIN":75,"AGE_MAX":200,"SS_ID":"06311981001","EMAIL":[{"email":"jing.li@sphic.org.cn"},{"email":"kun.liu@sphic.org.cn"},{},{},{}],"GEO":[31.22222,121.45806]},{"TITLE":"A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C","CRITERIA":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed NSCLC with Stage IIIB-IIIC or Stage IV disease, not suitable for curative intent radical surgery or radiation therapy.\n* Part B and Safety Lead-In Part B: the histology of the tumor must be predominantly non-squamous (in line with pemetrexed label).\n* Must have disease with evidence of KRAS G12C mutation.\n* Must have known programmed death-ligand 1 (PD-L1) expression\n\n  * Part A: Greater than or equal to (\u2265)50 percent (%).\n  * Part B: 0% to 100%.\n* Must have measurable disease per RECIST v1.1.\n* Must have an ECOG performance status of 0 or 1.\n* Estimated life expectancy \u226512 weeks.\n* Ability to swallow capsules.\n* Must have adequate laboratory parameters.\n* Contraceptive use should be consistent with local regulations for those participating in clinical studies.\n* Women of childbearing potential must\n\n  * Have a negative pregnancy test.\n  * Not be breastfeeding during treatment and after study intervention for at least 180 days.\n\nExclusion Criteria:\n\n* Have a documented additional validated targetable oncogenic driver mutation or alteration in genes such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF (V600E), human epidermal growth factor receptor 2 (HER2), MET (exon 14), ROS1, rearranged during transfection (RET), or neurotrophic tyrosine receptor kinase (NTRK)1\/2\/3.\n* Have had any of the following prior to randomization:\n\n  -- Prior systemic therapy (chemotherapy, immunotherapy, targeted therapy, or biological therapy) for advanced or metastatic NSCLC.\n\n  --- 1 cycle of standard-of-care treatment prior to study enrollment will be allowed for cases where immediate treatment is clinically indicated:\n* Have known active central nervous system metastases and\/or carcinomatous meningitis.\n\nExclusion Criteria for Participants receiving Pemetrexed and Platinum (Part B and Safety Lead-In Part B)\n\n* Squamous cell and\/or mixed small cell\/nonsmall cell histology is not permitted.\n* Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs)\n* Is unable or unwilling to take folic acid or vitamin B12 supplementation.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06119581338","EMAIL":[{},{}],"GEO":[41.27976,36.3361]},{"TITLE":"Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases","CRITERIA":"Inclusion Criteria:\n\n* Patients must have histologically or cytologically confirmed non-squamous NSCLC.\n* Patients must have asymptomatic brain metastases with at least one untreated evaluable (per RANO-BM) brain metastasis of 5 mm or more. A growing lesion previously treated with whole brain radiotherapy is acceptable given the lower incidence of radiation necrosis. Lesions previously treated with SRS may not be used as target lesions.\n\n  o Patients are not required to have measurable disease outside the CNS per RECIST 1.1.\n* Prior chemotherapy, immunotherapy or radiation given with curative intent in early stage or locoregionally advanced NSCLC is permitted, if completed more than 12 months prior to initiation of study treatment.\n* Prior radiation with palliative intent in the metastatic setting to non-CNS lesions is permitted (no wash-out period).\n* Age \u226518 years.\n* ECOG performance status \u2264 1.\n* Life expectancy \u226512 weeks.\n* Patients must have normal organ and marrow function as defined below:\n\n  * Absolute neutrophil count \u22651,500\/mcL\n  * Platelets \u2265100,000\/mcL\n  * Total bilirubin \u2264 institutional upper limit of normal (ULN)\n  * AST(SGOT)\/ALT(SGPT) \u22642.5 \u00d7 institutional ULN\n  * Creatinine Clearance (CrCl) \u226545 mL\/min\/1.73 m2\n* No known history of HIV, with the following exception: patients who are HIV positive are eligible provided they are stable on anti-retroviral therapy, have a CD4 count \u2265 200\/\u00b5L, and have an undetectable viral load.\n* Negative hepatitis B surface antigen (HBsAg) test at screening. If positive, an HBV DNA test must also be performed to determine if the patient has an HBV infection, which would render the patient ineligible. Patients receiving treatment with anti-viral therapy for HBV are excluded.\n* Negative hepatitis C antibody. If positive, an HCV RNA test must also be performed to determine if the patient has an HCV infection, which would render the patient ineligible.\n* Availability of a representative tumor specimen for exploratory biomarker research.\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception:\n* Women must remain abstinent or use contraceptive methods with a failure rate of \\< 1% per year during the treatment period and for 90 days after the final dose of tiragolumab, 5 months after the final dose of atezolizumab, and 6 months after the final dose of paclitaxel, pemetrexed, gemcitabine, carboplatin, or cisplatin.\n\n  * A woman is considered to be of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (\u2265 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (i.e., removal of ovaries, fallopian tubes, and\/or uterus) or another cause as determined by the investigator (e.g., M\u00fcllerian agenesis). Per this definition, a woman with a tubal ligation is considered to be of childbearing potential. The definition of childbearing potential may be adapted for alignment with local guidelines or regulations.\n  * Examples of contraceptive methods with a failure rate of \\< 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.\n  * The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception. If required per local guidelines or regulations, locally recognized adequate methods of contraception and information about the reliability of abstinence will be described in the local Informed Consent Form.\n* Women who would like to become pregnant after study treatment discontinuation should seek advice on oocyte cryopreservation prior to initiation of study treatment because of the possibility of irreversible infertility due to treatment with cisplatin and carboplatin.\n* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below:\n\n  * With a female partner of childbearing potential, men who are not surgically sterile must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \\< 1% per year during the treatment period, for 90 days after the final dose of tiragolumab, and for 6 months after the final dose of paclitaxel, pemetrexed, gemcitabine, carboplatin or cisplatin. Men must refrain from donating sperm during this same period.\n  * With a pregnant female partner, men must remain abstinent or use a condom during the treatment period for 90 days after the final dose of tiragolumab, and for 6 months after the final dose of paclitaxel, pemetrexed, gemcitabine, carboplatin, or cisplatin to avoid exposing the embryo.\n  * The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception. If required per local guidelines or regulations, locally recognized adequate methods of contraception and information about the reliability of abstinence will be described in the local Informed Consent Form.\n* Men who would like to father a child after study treatment initiation should be advised regarding the conservation of sperm prior to treatment because of the possibility of irreversible infertility resulting from chemotherapies used in this study.\n* Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Symptoms related to brain metastases requiring CNS radiation \u2264 2 weeks of treatment initiation are exclusionary. Steroids greater than prednisone 10 mg\/d or equivalent, or anti-epileptic therapy \u2264 2 weeks of treatment initiation are exclusionary.\n* Prior systemic therapy for metastatic disease is not allowed.\n* Patients whose tumors harbor oncogenic drivers with an approved 1st line therapy (e.g. EGFR, ALK, and ROS1 alterations) are excluded.\n* Patients who are receiving any other investigational agents.\n* Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sj\u00f6gren syndrome, Guillain-Barr\u00e9 syndrome, or multiple sclerosis, with the following exceptions:\n\n  * Patients with a history of autoimmune-related hypothyroidism who are on thyroid replacement hormone are eligible for the study.\n  * Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.\n  * Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:\n\n    * Rash must cover \\< 10% of body surface area\n    * Disease is well controlled at baseline and requires only topical corticosteroids\n  * No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral corticosteroids within the previous 12 months.\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis or fibrosis in a radiation field is permitted.\n* History of leptomeningeal disease.\n* Active tuberculosis.\n* Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina.\n* Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study.\n* History of malignancy other than NSCLC within 2 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate \u2265 90%).\n* Severe infection within 2 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia.\n* Prior allogeneic stem cell or solid organ transplantation.\n* Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications.\n* Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab.\n* Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids in excess of prednisone 10 mg\/d or equivalent, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-\u03b1 agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions:\n\n  * Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study.\n  * Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to atezolizumab or other agents used in study.\n* History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins.\n* Known hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab or tiragolumab formulation.\n* Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment, within 90 days after the final dose of tiragolumab, 5 months after the final dose of atezolizumab, or 6 months after the final dose of pemetrexed, gemcitabine, paclitaxel, carboplatin, or cisplatin o Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05746481001","EMAIL":[{"email":"ruthj2@upmc.edu"},{}],"GEO":[40.44062,-79.99589]},{"TITLE":"Clinical and Molecular Study With Digital Support of Patients With Inoperable Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Patients with non-small cell lung cancer stage IV\n* No younger than 18 years old patients\n* Performance status: 0-2\n* Existence of biological material for the molecular analysis\n* Patients who have not been treated with any other treatment than adjuvant\n* Ability to use a mobile device or computer for digital communication\n\nExclusion Criteria:\n\n* Childbearing women\n* Patients with PS \\> 3\n* Limited ability to use a mobile device for basic digital communication","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05372081015","EMAIL":[{"email":"sofialampaki@yahoo.gr"},{}],"GEO":[40.64361,22.93086]},{"TITLE":"Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels","CRITERIA":"Inclusion Criteria:\n\n* Patients with locally advanced or metastatic NSCLC (stage IIIB to stage IV by AJCC 8th)\n* ECOG performance status 0-4\n* Histologically or cytology confirmed NSCLC\n* Documented ALK rearrangement based on an EMA approved test\n* Patients can either be chemotherapy-na\u00efve or have received one line of platinum-based chemotherapy\n* Patients with brain or leptomeningeal metastases are allowed on the study if the lesions are asymptomatic without neurological signs and clinically stable for at least 2 weeks without steroid treatment. Patients who do not meet these criteria are not eligible for the study\n* Measurable disease (by RECIST criteria version 1.1) prior to the first dose of study treatment\n* Signed writte Institutional Review Board (IRB)\/Ethical Committee (EC) approved informed consent form, prior to performing any study-related procedures\n* Observational other studies are allwoed for patients included in this study\n* Local radiotherapy is allowed for pain\n\nExclusion Criteria:\n\n* Any significant concomitant disease determined by the investigator to be potentially aggravated by the investigational drug\n* Consumption of agents which modulate CYP3A4 or agents with potential QT prolonging effects within 14 days prior to admission and during the study (see concomitant medication restrictions)\n* Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study, or absorption of oral medications, or that would, in the opinion of the Principal Investigator, pose an unacceptable risk to the subject in this study.\n* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol requirements and\/or follow-up procedures; those conditions should be discussed with the patient before trial entry.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05525338008","EMAIL":[{}],"GEO":[53.21917,6.56667]},{"TITLE":"Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification","CRITERIA":"Inclusion Criteria:\n\n1. Fully aware this study and voluntary to sign the informed consent form, and willing and able to comply with the study procedure;\n2. Age \u2265 18 and \u226475 years;\n3. In accordance with the 8th Edition of TNM staging for lung cancers by International Association for the Study of Lung Cancer and American Joint Committee on Cancer, patients with histologically or cytologically confirmed unresectable and non-suitable for radical concurrent chemoradiotherapy, locally advanced or metastatic (stage IIIB, IIIC or IV) NSCLC;\n4. EGFR sensitive mutations prior to the first-line EGFR-TKI therapy;\n5. Radiologically documented disease progression after the first-line EGFR-TKI;\n6. MET amplification after disease progression following the first-line therapy;\n7. Having measurable lesions (in accordance with RECIST 1. 1 criteria);\n8. United States Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1;\n9. Expected survival \\>12 weeks;\n10. Adequate bone marrow reserve or organ function\n11. Female patients of childbearing potential must agree to use effective contraceptive methods from screening period to 4 weeks after discontinuation of the study drug;\n12. Male subjects should be willing to agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm. ;\n13. Being able to take or swallow the drug orally.\n\nExclusion Criteria:\n\n1. Patients with positive T790M mutations;\n2. Previous treatment for c-MET;\n3. Currently having other malignant tumors, or having other infiltrating malignant tumors in the past 5 years.;\n4. Previous use of systematic antitumor therapy other than EGFR-TKI for advanced NSCLC;\n5. Currently having received antiangiogenic therapy or traditional Chinese medicine with antitumor indication\u3001extensive radiotherapy \u3001palliative local radiotherapy, a major surgery,or participated in other drug clinical trials and received corresponding tudy drug etc;\n6. Currently receiving the potent CYP3A4 inducers or potent CYP1A2 inhibitors within two weeks prior to the start of study treatment;\n7. Having not been sufficiently recovered from the toxicity and\/or complication resulting from any interventional measure prior to the start of treatment;\n8. Clinically significant active infection, including but not limited to tuberculosis, human immunodeficiency virus (HIV) infection (positive HIV1\/2 antibody);\n9. Active hepatitis B, or active hepatitis C;\n10. Acute myocardial infarction, unstable angina pectoris, stroke or transient ischemic attack;\n11. Known cancerous thrombus or deep vein thrombosis or uncontrollable hypertension despite the use of drugs;\n12. Mean resting corrected QT interval (QTcF) or Any important abnormality in rhythm;\n13. Presence of meningeal metastases, spinal cord compression or active brain metastases prior to the start of study treatment;\n14. Active gastrointestinal disease or other conditions significantly affecting the absorption, distribution, metabolism or excretion of oral study drug;\n15. Lack of compliance with participation in this clinical study or inability to comply with the limitations and requirements of the study, as judged by investigators;\n16. Known allergy to the active or inactive ingredient of Savolitinib or Osimertinib;\n17. Previous history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis and any active interstitial lung disease;\n18. Pregnant or breastfeeding women;","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05015608001","EMAIL":[{}],"GEO":[31.22222,121.45806]},{"TITLE":"SBRT Dose Escalation for Reirradiation of Inoperable Lung Lesions","CRITERIA":"Inclusion Criteria:\n\n* Inoperable primary non-small cell lung cancer or other metastatic primaries with lung metastases, already treated with radical dose RT;\n* Peripheral lesion (\\> 2 cm from trachea-bronchial tree);\n* Inoperable local recurrence (defined as a tumor recurrence overlapping the 50% isodose field) confirmed by documented radiographic findings and\/or pathological biopsies within the thoracic area;\n* Patients had previously received curative intent RT of more than 50 Gy for conventionally fractionated RT or a biologically equivalent dose of more than 75 Gy for SBRT;\n* No active distant metastasis or controlled distant metastasis at the time of re-irradiation\n\nExclusion Criteria:\n\n* Central or ultra-central lesion(s);\n* Incapability of understanding and signing informed consent.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04455438001","EMAIL":[{"email":"davide.franceschini@humanitas.it"},{"email":"mauro.loi@humanitas.it"}],"GEO":[45.38193,9.1559]},{"TITLE":"A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy","CRITERIA":"Inclusion Criteria:\n\n* The subject voluntarily joins the study, signs the informed consent form, and has good compliance;\n* Age: 18\\~75 years old (when signing the informed consent form); ECOG PS score: 0-1 points; Expected survival beyond 6 months; body weight\\> 40 kg;\n* Patients with pathologically confirmed limited-stage small cell lung cancer (according to the Veterans Administration Lung Study Group (VALG stage);\n* Through the neck, chest, abdomen, pelvic enhanced CT and brain plain scan + enhanced MRI examination with diagnostic quality, there is no evidence of metastatic disease (PET-CT examination is recommended before starting radiotherapy and chemotherapy, if not performed before radiotherapy and chemotherapy PET-CT examination, bone scan examination should be performed; PET-CT examination must be performed during the screening period after chemoradiotherapy to exclude metastasis);\n* It is expected that no tumor resection will be required during the study (patients who are not suitable for surgery or those who are unwilling to undergo surgery are acceptable);\n* Radiotherapy technology adopts three-dimensional conformal radiotherapy, conformal intensity-modulated radiotherapy, tomographic radiation therapy and other precision radiotherapy technologies;\n* Patients must achieve CR, PR or SD after receiving radical platinum-based CRT and cannot develop disease progression;\n* Patients with at least one measurable lesion confirmed according to RECIST 1.1 criteria prior to chemoradiotherapy;\n\nExclusion Criteria:\n\n* Complex small cell lung cancer confirmed by histopathology or cytopathology;\n* Subjects with known central nervous system metastasis and\/or cancerous meningitis;\n* Malignant pleural effusion and pericardial effusion;\n* Imaging shows that the tumor has invaded important blood vessels, or the researcher has determined that the tumor is highly likely to invade important blood vessels and cause fatal massive bleeding during subsequent studies;\n* Within 2 weeks before the start of the study treatment, he has received the treatment of traditional Chinese patent medicines and simple preparations with anti-tumor indications specified in the NMPA approved drug manual;\n* Patients who have received immunomodulatory drugs within 30 days before starting treatment;\n* Previously received anti PD-1, anti PD-L1, or anti PD-L2 drugs or medication targeting another stimulating or co inhibitory T cell receptor;\n* Previous use of antivascular survival drugs\uff08 bevacizumab, arotinib, apatinib ,ect);","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05942508001","EMAIL":[{"email":"mengxiangjiao@sina.com"}],"GEO":[36.66833,116.99722]},{"TITLE":"TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n1. patients with advanced lung tumor or other solid tumor where biopsy is obtainable\n2. Life expectancy \\>12 weeks\n3. Child-Pugh-Turcotte score \\<7\n4. Adequate heart,lung,liver,kidney function\n5. Available autologous transduced T cells with greater than or equal to 20% expression of targeted TCR sequences determined by flow-cytometry and killing of tumor cells greater than or equal to 20% in cytotoxicity assay\n6. Informed consent explained to, understood by and signed by patient\/ guardian. Patient\/guardian given copy of informed consent. -\n\nExclusion Criteria:\n\n1. Had accepted gene therapy before;\n2. Tumor size more than 25cm;\n3. Severe virus infection such as HBV, HCV, HIV, et al\n4. Known HIV positivity\n5. History of lung transplantation\n6. Active infectious disease related to bacteria, virus,fungi,et al\n7. Other severe diseases that the investigators consider not appropriate;\n8. Pregnant or lactating women\n9. Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent\/kg\/day)\n10. Other conditions that the investigators consider not appropriate.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"03778814001","EMAIL":[{"email":"zhangzhf@gzhmu.edu.cn"}],"GEO":[36.66833,116.99722]},{"TITLE":"Endobronchial Ultrasound-guided Transbronchial Needle Aspiration for Lymph Node Staging in Patients With Non-small Cell Lung Cancer Pursuing Stereotactic Body Radiotherapy (SBRT)","CRITERIA":"Inclusion Criteria:\n\n1. Age 18 years or older\n2. Patients with confirmed lung cancer who require EBUS-TBNA as part of their staging investigations of the mediastinum and hilum prior to SBRT\n3. Performance status score (WHO\/ECOG) of 0-2.\n4. Cytological or histological proof of non-small cell cancer\n5. Stage T1-2 disease, with no evidence of distant metastasis\n6. Patients are screened by both computed tomography (CT) and positron emission tomography (PET)\n7. Medically inoperable for surgical resection\n8. Patients who refused surgery\n\nExclusion Criteria:\n\n1. Patients who are deemed on clinical grounds not to be medically fit for a bronchoscopy\n2. Active systemic, pulmonary, or pericardial infection\n3. Patients who are pregnant or lactating\n4. Patients with plans to receive conventional radiotherapy, chemotherapy, biological therapy, vaccine therapy, or surgery as treatment (except at disease progression).\n5. Inability to give informed consent","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"01786590001","EMAIL":[{"email":"judy.mcconnell@uhn.ca"},{"email":"alexandria.grindlay@uhn.ca"}],"GEO":[43.70011,-79.4163]},{"TITLE":"The Registry of Oncology Outcomes Associated With Testing and Treatment","CRITERIA":"Inclusion Criteria:\n\n* Patient or representative provides written informed consent\n* Patient is diagnosed with advanced malignancy\n* Patient is willing to be treated for this malignancy according to a plan determine by them and their physician\n* patient will be willing to have regular follow up visits as part of their standard of care\n\nExclusion Criteria:\n\n* patient is not a candidate or does not desire any treatment for their disease","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04028479002","EMAIL":[{"email":"cesar.flores@prismsgrp.com"},{}],"GEO":[27.50641,-99.50754]},{"TITLE":"Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Participant is at least 18 years of age.\n* Participant has proven recurrent or advanced solid tumor and has disease progression after treatment with available anti cancer therapies, or is intolerant to treatment that meets the following requirements for the part of the study they will participate in:\n* a. Part 1: Any histologically or cytologically proven recurrent advanced solid tumor\n* b. Part 2A: : Any histologically or cytologically proven recurrent advanced solid tumor\n* c. Part 2B: Histologically of cytologically proven recurrent or advanced solid tumor with measurable lesion(s) per RECIST version 1.1 and meets one of the following disease types:\n* The criteria below should be met for participant participating in: Cohort A1 (dMMR\/MSI-H endometrial cancer) and Cohort A2 (MMR-proficient\/MSS endometrial cancer)\n* Participants who have progressed on or after platinum doublet therapy\n* Participants have received no more than 2 lines of anti-cancer therapy for recurrent or advanced (\\>=Stage IIIB) disease. Prior treatment with hormone therapies is acceptable and does not count towards the number of anti-cancer therapies noted in the criterion above for this cohort.\n* All endometrial cancer histologies are allowed except endometrial sarcoma (including carcinosarcoma).\n* Participants must submit 2 scans demonstrating increase in tumor measurement that meet criteria for PD on or after the latest systemic anti-cancer therapy based on RECIST Version 1.1 to Central Radiology prior to the first dose of dostarlimab.\n* Presence of at least 1 measurable lesion on Baseline scan will be confirmed by central radiology review.\n* Status of tumor MMR\/MSI: Participants can be screened based on local MMR\/MSI testing results using immunohistochemistry (IHC), polymerase chain reaction (PCR), or next generation sequencing (NGS) performed in a certified local laboratory, but participant eligibility needs to be determined by MMR IHC results. For participant with available local MMR IHC results for the respective cohort(s), tumor samples have to be submitted to a central IHC laboratory and its quality has to be checked and cleared prior to Cycle 1 Day 1 (C1D1). For participants without available local MMR IHC test results (participants with local PCR or NGS test results), central IHC results have to confirm eligibility prior to proceeding with other screening procedures. After the central IHC test is completed, remaining tumor tissue may be tested for further exploratory biomarkers or may be sent to a central NGS laboratory for further testing.\n* Cohort E - Participants with NSCLC who progressed after at least 1 prior platinum-based systemic chemotherapy regimen for recurrent or advanced disease. Chemotherapy regimen in the adjuvant or neoadjuvant setting following surgery and\/or radiation is acceptable if recurrent or advanced disease develops within 6 months from completion of therapy.\n* Participants with a known epidermal growth factor receptor (EGFR) mutation must have received a chemotherapy regimen and an EGFR tyrosine-kinase inhibitor (TKI) (e.g., erlotinib, gefitinib, afatinib, or experimental)\n* Participants with a known anaplastic lymphoma kinase (ALK) translocation must have received a chemotherapy regimen and an ALK inhibitor (e.g., crizotinib, ceritinib or experimental)\n* Cohort F - Participants with recurrent or advanced dMMR\/MSI-H solid tumors except endometrial cancers and gastrointestinal cancers, who have received prior systemic therapy and who have no alternative treatment options. Prior treatment with hormone therapies alone given for recurrent or advanced disease is acceptable and does not count towards the number of anti-cancer therapies.\n* Measurable lesion by RECIST 1.1 Radiology on baseline scan will be confirmed by central radiology review prior to first dose of dostarlimab. Patients with primary CNS tumor should provide brain MRI at baseline.\n* a. Presence of deficient mismatch repair (dMMR) and\/or microsatellite instability (MSI-H) in the tumor defined by either:\n* b. deficient DNA mismatch repair (dMMR); MMR status must be assessed by immunohistochemistry (IHC) for MMR protein expression (MLH1, MSH2, MSH6, PMS2) where loss of one or more proteins indicates dMMR; dMMR may be determined either locally or by the central reference lab; OR\n* c. Microsatelillite instability (MSI-H); MSI-H as determined by polymerase chain reaction (PCR) or by tissue Next generation sequencing (NGS); MSI-H may be determined locally\n* Cohort G: Participants must have recurrent high-grade serous, endometrioid, or clear cell ovarian, fallopian tube, or primary peritoneal cancer. Participants must have presence of at least 1 measurable lesion on Baseline scan that will be confirmed by central radiology review.\n* Participants must be considered resistant to the last administered platinum therapy, that is, the time from the last administered platinum dose until the initial documented progression (as evidenced by radiographic progression per RECIST version 1.1) must be less than 6 months.\n* Participants must have completed at least 1 but no more than 3 prior lines of therapy for advanced or metastatic ovarian cancer. Neoadjuvant, adjuvant, and the combination of both will be considered as 1 line of therapy. Treatment with single-agent bevacizumab given as maintenance is not counted as a separate line of therapy. If a therapeutic regimen is modified or changed for a reason other than lack of response or PD (such as allergic reaction, toxicity, or drug availability), this is not counted as a separate line of therapy. The use of single-agent hormonal therapy given for reasons other than PD per RECIST version v1.1 (i.e., hormonal therapy given for increasing Cancer antigen \\[CA\\]-125 levels) is not counted as a separate line of therapy.\n* Participants must have been previously treated with platinum-based regimen, taxane agent(s), and bevacizumab (bevacizumab could be used as a single agent or in combination with another agent, in frontline therapy, as maintenance, or for treatment of recurrent disease).\n* Part 2B: Participants must have archival tumor tissue available that is formalin-fixed and paraffin-embedded (FFPE).\n* For participants who do not have archival tissue, a new biopsy must be performed to obtain a tissue sample prior to study treatment initiation. For participants without available archival tissue, the biopsy should be taken from the tumor lesions (either primary or metastatic) that have easy accessibility and low biopsy-associated risks and will exclude biopsies of the liver, brain, lung\/mediastinum, pancreas, or endoscopic procedures extending beyond the esophagus, stomach or bowel.\n* For Cohort F an FFPE tissue sample must be submitted to the central laboratory for testing. For patients with available local MMR\/MSI-H results, tumor samples have to be submitted to a central laboratory and its quality has to be checked and cleared prior to C1D1\n* For Cohort G, participant must provide formalin fixed paraffin embedded (FFPE) tumor tissue block(s) with sufficient tumor content (as confirmed by the Sponsor's designated central laboratory) during screening to enable, for example, measures of homologous recombination pathway defects and PD-L1 status. The use of slides created from paraffin-embedded tissue as opposed to FFPE blocks must be approved by the Sponsor.\n* Female participants must have a negative serum pregnancy test within 72 hours prior to the date of the first dose of study medication: unless they are of non-child bearing potential.\n* Non child bearing potential is defined as: \\>= 45 years of age and has not had menses for \\> 1 year; Amenorrheic for \\< 2 years without a hysterectomy and oophorectomy and have a follicle- stimulating hormone (FSH) value in the postmenopausal range upon pre-study (screening) evaluation. Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound, magnetic resonance imaging (MRI) or computed tomography (CT) scan. Tubal ligation must be confirmed with medical records of the actual procedure.\n* Female participants of childbearing potential must agree to use 1 highly effective form of contraception with their partner starting with the screening visit through 150 days after the last dose of study therapy.\n* Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of \\<= 2 for Part 1 and \\<= 1 for Part 2.\n* Participant has an adequate organ function.\n\nExclusion Criteria\n\n* Participant has received prior therapy with an anti- programmed death receptor 1 (anti-PD-1), anti-PD-1- ligand-1 (anti-PD-L1), or anti-PD-1 ligand-2 (anti-PD- L2) agent.\n* Participant has a known uncontrolled central nervous system (CNS) metastases and\/or carcinomatous meningitis.\n* Participant has a known additional malignancy that progressed or required active treatment within the last 2 years. Exceptions include basal cell carcinoma of the skin, squamous cell cancer (SqCC) of the skin that has undergone potentially curative therapy, or in situ cervical cancer, or other neoplastic condition which has undergone curative therapy and is considered cured by the investigator.\n* Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active infection requiring systemic therapy. Specific examples include, but are not limited to, active, non-infectious pneumonitis; uncontrolled ventricular arrhythmia; recent (within 90 days) myocardial infarction; uncontrolled major seizure disorder; unstable spinal cord compression; superior vena cava syndrome; or any psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study (including obtaining informed consent).\n* Participant is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study, starting with the Screening Visit through 150 days after the last dose of study treatment.\n* Participant has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.\n* Participant has a known history of human immunodeficiency virus (HIV) (HIV 1\/2 antibodies).\n* Participant has a known active hepatitis B (eg, hepatitis B surface antigen \\[HBsAg\\] reactive) or hepatitis C (eg, hepatitis C virus ribonucleic acid (HCV RNA) (qualitative) is detected).\n* Participant has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease- modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Use of inhaled steroids, local injection of steroids, and steroid eye drops are allowed.\n* Participant has as history of interstitial lung disease.\n* Participant has not recovered (i.e., to \\<= Grade 1 or to Baseline) from radiation- and chemotherapy-induced AEs or received transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including granulocyte-colony stimulating factor \\[G-CSF\\], granulocyte macrophage colony-stimulating factor \\[GM-CSF\\] or recombinant erythropoietin) within 3 weeks prior to the first dose of study drug.\n* Participant has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of study drug.\n* Participant has received prior anti-cancer therapy (chemotherapy, targeted therapies, radiotherapy, or immunotherapy) within 21 days, or less than 5 times the half-life of the most recent therapy prior to study Day 1, whichever is shorter.\n* Participant has not recovered adequately (\\<= Grade 1) from AEs and\/or complications from any major surgery prior to starting therapy.\n* Participant has received a live vaccine within 14 days of planned start of study therapy.\n* Participant has a known hypersensitivity to dostarlimab components or excipients.\n* For Cohort G, participants will not be eligible if they meet the following criteria: Participants who experienced disease progression within 3 months (as evidenced by radiographic progression per RECIST) of first-line platinum therapy.\n* Participants with known deleterious or suspicious deleterious mutation in BRCA1 or BRCA2 genes (local testing permitted).\n* Participants has received prior therapy with a poly(adenosine diphosphate-ribose) polymerase (PARP)-1\/PARP-2 inhibitor.\n* Participant has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, might interfere with the participant's participation for the full duration of the study treatment, or is not in the best interest of the participant to participate.\n* Participant is immunocompromised. Participants with splenectomy are allowed.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"02715284151","EMAIL":[{"email":"GSKClinicalSupportHD@gsk.com"},{"email":"GSKClinicalSupportHD@gsk.com"},{}],"GEO":[54.97328,-1.61396]},{"TITLE":"A Study of CDX-585 in Patients With Advanced Malignancies","CRITERIA":"Key Inclusion Criteria:\n\n1. Recurrent, locally advanced, or metastatic solid tumor cancer excluding primary central nervous system tumors (e.g., glioblastoma).\n2. Receipt of standard therapy for the tumor type in the recurrent, locally advanced, or metastatic setting.\n3. Measurable (target) disease by iRECIST.\n4. If of childbearing potential (male or female), agrees to practice an effective form of contraception during study treatment and for at least 3 months following last treatment.\n5. Willingness to undergo a pre-treatment and on-treatment biopsy, if required.\n\nKey Exclusion Criteria:\n\n1. History of severe hypersensitivity reactions to other monoclonal antibodies.\n2. Previous treatment with any anti-ILT4 antibody.\n3. Patients who have received more than 1 anti-PD-1 or anti-PD-L1 targeted therapy, including in the adjuvant setting.\n4. Prior anti-PD-L1 based therapy within 12 weeks and prior anti-PD-1 based therapy within four weeks to the planned start of study treatment.\n5. Other prior malignancy, except for adequately treated basal or squamous cell skin cancer or in situ cancers. For all other cancers, the patient must be disease-free for at least one year to be allowed to enroll.\n6. Thrombotic events within the last six months prior to study treatment\n7. Active, untreated central nervous system metastases.\n8. Active autoimmune disease or documented history of autoimmune disease.\n9. History of (non-infectious) pneumonitis or has current pneumonitis.\n\nThere are additional criteria your study doctor will review with you to confirm eligibility.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05788484004","EMAIL":[{"email":"canrsrchstudies@providence.org"}],"GEO":[45.52345,-122.67621]},{"TITLE":"A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Have measurable disease per Response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) as assessed by the local site investigator.\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n* Participants with histologically confirmed diagnosis of a solid tumor (specifications for the different parts of the study below) will be enrolled onto this study:\n\n  \u2022 Dose escalation: All solid cancers, except primary central nervous system cancers\n* The following tumor types will be recruited to the monotherapy expansion cohorts:\n\n  * Non-small cell lung cancer (NSCLC)\n  * Gastric\/Gastroesophageal Junction (GEJ) adenocarcinoma\n* The following tumor types will be recruited to the BAY 2965501 and pembrolizumab combination expansion cohorts:\n\n  * NSCLC: participants with tumors that are TPS score \u226550% PDL-1 high (based on local historical testing) and are eligible for standard of care anti-PD(L)-1 monotherapy in the first line incurable treatment setting.\n  * NSCLC\n  * Gastric\/GEJ adenocarcinoma\n\nExclusion Criteria:\n\n* Previous therapy with a DGK inhibitor is prohibited for monotherapy cohorts (participants previously treated with BAY 2965501 or BAY 2862789 must have progressed on that DGK inhibitor (and not discontinued for toxicity) to be eligible for combination).\n* Has received a prior therapeutic regimen containing an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or an agent directed to another co-stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137) and was discontinued from that treatment due to a Grade 3 or higher infusion-related adverse event (irAE).\n* Participants with new brain metastases on screening brain MRI\/CT. Previously treated brain metastases that are progressive at screening compared to a brain MRI\/CT at least 6 weeks earlier are also excluded. Participants with known previously treated brain metastases, which are radiologically stable compared to a CT\/MRI scan at least 6 weeks earlier, clinically stable and without the requirement of steroid treatment for at least 14 days prior to the first dose of study treatment may be eligible.\n* Primary central nervous system malignancy or presence of leptomeningeal disease (i.e., positive cerebrospinal fluid cytology or unequivocal radiological or clinical evidence of leptomeningeal involvement).\n* Participants with gastrointestinal conditions that may compromise oral absorption such as short bowel syndrome or active tumor-related bowel obstruction with ongoing symptoms compromising absorption over last 6 months.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05614102023","EMAIL":"clinical-trials-contact@bayer.com","GEO":[54.97328,-1.61396]},{"TITLE":"Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1\n* Histologically confirmed Stage II-IIIA NSCLC (per the Eighth American Joint Committee on Cancer\/Union Internationale Contre le Cancer \\[NSCLC\\] staging system)\n* Evaluation by an attending thoracic surgeon to confirm eligibility for an R0 resection with curative intent\n* Adequate hematologic and organ function, defined by protocol-specified laboratory test results, obtained \u2264 7 days before randomization\n* Provide formalin-fixed paraffin-embedded block (preferred) or at least 15 freshly cut unstained FFPE slides of the primary tumor for biomarker evaluation during screening\n\nExclusion Criteria:\n\n* Any prior antineoplastic therapy(ies) for current lung cancer (eg, radiotherapy, targeted therapies, ablation, or other systemic or local antineoplastic treatment)\n* Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, anti-cell immunoglobulin and ITIM domain (TIGIT), anti-lymphocyte activation gene-3 (LAG-3), or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways\n* Has mixed small cell lung cancer\n* Participants with large cell neuroendocrine carcinoma (LCNEC)\n* The presence of locally advanced unresectable NSCLC regardless of stage or metastatic disease\n* Known EGFR sensitizing mutations and\/or ALK rearrangement\n\nNOTE: Other protocol defined Inclusion\/Exclusion criteria may apply.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05577702013","EMAIL":"clinicaltrials@beigene.com","GEO":[31.22222,121.45806]},{"TITLE":"SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation","CRITERIA":"* Will be treated with a first- or second-line systemic and\/or oral standard of care regimen at the enrolling site\n* Patient is either treatment naive and has not yet commenced first line SOC therapy OR patient has completed a prior line of SOC therapy and will commence subsequent line of SOC therapy\n* Provide written informed consent to participate in the study\n* Diagnosed with an unresectable advanced solid malignancy and have a histologically confirmed cancer that qualifies for inclusion, defined as:\n\n  * Non-small cell lung cancer (stage III-IV)\n  * Colorectal adenocarcinoma (stage III-IV)\n  * Breast Cancer (stage III-IV)\n\nExclusion Criteria:\n\n* History of a prior solid or hematological malignancy within 5 years of enrollment\n* Life expectancy \\< 12 weeks\n* Unable to collect baseline blood sample prior to starting SOC regimen\n* Is participating in an interventional clinical trial or another observational study that is evaluating the performance of another genomic test for detecting\/predicting clinical response\/progression","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05935384001","EMAIL":[{}],"GEO":[42.03336,-87.73339]},{"TITLE":"Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Age \u226518 years\n* Histologically or cytologically documented nonsquamous NSCLC. NSCLC of mixed histology is allowed.\n* Stage IIIB or IIIC or Stage IV metastatic NSCLC or recurrent NSCLC (based on the American Joint Committee on Cancer Edition 8) not amenable to curative surgery or definitive chemoradiation.\n* EGFR sensitive mutation-positive (Ex19del and\/or 21 L858R)\n* WHO performance status of 0 to 2 at screening with no clinically significant deterioration in the previous 2 weeks.\n* Patients who receive Osimertinib plus chemotherapy as first-line treatment based on physician's medical assessment are eligible (For patients who received prior chemotherapy alone\/Osimertinib monotherapy\/Osimertinib plus chemotherapy as first-line therapy ahead of enrolment, they are diseases progression-free at the time of enrolment and the duration of prior therapy \u22643 months).\n* Patients with asymptomatic CNS metastases or patients who have completed definitive therapy, are not on steroids and have a stable neurological status for at least 2 weeks after completion of the definitive therapy and steroids are allowed.\n* Prior adjuvant and neo-adjuvant therapies (chemotherapy, radiotherapy, immunotherapy, biologic therapy, investigational agents), or definitive radiation\/chemoradiation with or without regimens including immunotherapy, biologic therapies, investigational agents are permitted as long as treatment was completed at least 12 months prior to the development of recurrent disease.\n\nExclusion Criteria:\n\n* Spinal cord compression and symptomatic brain metastases\n* Past medical history of ILD, drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD\n* Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, etc\n* Any banned substance in label","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06376084001","EMAIL":"information.center@astrazeneca.com","GEO":[31.22222,121.45806]},{"TITLE":"A Real World Study Based on NGS (TRUMPRWS)","CRITERIA":"Inclusion Criteria:\n\n1. Patients must be \u226520 years of age.\n2. Provision of fully informed consent prior to any study specific procedures.\n3. Histologically or cytologically confirmed, unresectable stage IIIB or stage IV NSCLC.\n4. Genetic variants of tumor tissue detected by NGS.\n\nExclusion Criteria:\n\nNone.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03605602001","EMAIL":[{"email":"syylwu@live.cn"},{"email":"799836599@qq.com"}],"GEO":[23.11667,113.25]},{"TITLE":"A Phase 1 of CTX-8371 in Patients With Advanced Malignancies","CRITERIA":"Inclusion Criteria:\n\n1. Age 18 years or older\n2. Patients must have a histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic disease that is relapsed\/refractory to standard therapy or for which no effective standard therapy is available, including\n\n   1. Malignant Melanoma (MM)\n\n      * Patients who have progressed after a minimum of 2 doses of a PD-1\/PD-L1 treatment. Study enrollment (C1D1) must be within 12 weeks of the last dose of the anti-PD-1\/PD-L1 blocking antibody.\n      * Patients must have had prior testing for BRAF V600 mutations.- Patients with BRAF V600 activating mutation must have received prior therapy with a BRAF\/MEK inhibitor.\n      * Uveal and mucosal melanoma are excluded.\n   2. Head and Neck squamous cell carcinoma (HNSCC)\n\n      * HNSCC of oral cavity, oropharynx, hypopharynx, or larynx\n      * Patients who have progressed after a minimum of 2 doses of a PD-1\/PD-L1 treatment. Study enrollment (C1D1) must be within 12 weeks of the last dose of the anti-PD-1\/PD-L1 blocking antibody.\n      * Patients must have received prior treatment with platinum-based chemotherapy.\n   3. Non-Small Cell Lung Cancer (NSCLC)\n\n      * Patients who have progressed after a minimum of 2 doses of a PD-1\/PD-L1 treatment. Study enrollment (C1D1) must be within 12 weeks of the last dose of the anti-PD-1\/PD-L1 blocking antibody.\n      * Patients must have received prior treatment with platinum-based chemotherapy.\n   4. Triple Negative Breast Cancer (TNBC)\n\n      * ER\/PR and HER2 status should be defined by ASCO\/CAP guidelines (JCO Allison et al 2020).\n      * Patients with HER2-low cancers (IHC 1+ or FISH-negative) are excluded.\n      * Patients must have received prior sacituzumab govitecan and if PD-L1 \u226510% by CPS pembrolizumab with chemotherapy.\n   5. Classical Hodgkin Lymphoma (HL)\n\n      * Patients must have received at least two prior systemic therapies including brentuximab vedotin (if eligible) and a prior PD-1 inhibitor\n      * Patients must have experienced less than a CR (according to Lugano criteria to anti- PD-1 treatment\n3. Patients with NSCLC, MM, TNBC, and HNSCC must have measurable disease per RECIST 1.1. Patients with HL must have at least one measurable lesion \\> 1.5 cm for nodal, \\> 1.0 cm for extranodal FDG-avid disease by the Lugano (2014) response criteria. Tumor sites that are considered measurable must not have received prior radiation\n4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n5. Adequate bone marrow function defined by absolute neutrophil (ANC) of \u2265 1.5\u00d7109\/L, platelet count of \u2265 100.0\u00d7109\/L, and hemoglobin of \u2265 9.0 g\/dL (with or without transfusion)\n6. Adequate hepatic function defined as serum total bilirubin \u2264 1.5 \u00d7 ULN, AST\/ALT \u2264 2.5 \u00d7 ULN (or \u2264 5 \u00d7 ULN in patients with liver metastases)\n7. Adequate renal function defined as creatinine clearance \u2265 30mL\/min by Cockcroft-Gault equation\n8. Female patients must be surgically sterile (or have a monogamous partner who is surgically sterile) or be at least 2 years postmenopausal or commits to use 2 acceptable forms of birth control (defined as the use of an intrauterine device (IUD), a barrier method with spermicide, condoms, any form of hormonal contraceptives) or abstinence for the duration of the study and for 4 months following the last dose of study treatment. Male patients must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study and for 4 months following the last dose of study treatment.\n9. Female patients who are women of childbearing potential (WOCBP) must have a negative serum pregnancy test at Screening within 7 days of dosing with CTX-8371\n10. Last dose of previous PD-1 or PD-L1 therapy \u2265 28 days, other anticancer therapy \\> 21 days (or 2 half-lives for proteins, whichever is longer), radiotherapy \\>21 days (concurrent localized palliative radiotherapy is allowed during CTX-8371 treatment), or surgical intervention \\>21 days prior to the first dose of CTX-8371\n11. Resolution of all prior anti-cancer therapy toxicities \u2264 Grade 2\n12. Capable of understanding and complying with protocol requirements\n13. Signed and dated institutional review board (IRB)\/independent ethics committee (IEC)-approved informed consent form (ICF) before any protocol-directed screening procedures are performed\n\nExclusion Criteria:\n\n1. Developed clinically significant adverse reaction to PD-1 or PD-L1 therapy, including immune related adverse reactions, which led to discontinuation of treatment\n2. Systemic therapy with immunosuppressive agents within 7 days before the start of CTX-8371 treatment. Topical, intranasal, intraocular, or inhaled corticosteroids and physiologic replacement for patients with adrenal insufficiency are allowed\n3. Patient is a pregnant or lactating WOCBP\n4. Prior organ transplantation\n5. Patients with evidence of active hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection. Patients with positive HBsAg and\/or detectable HBV DNA are eligible only if adequately controlled on antiviral therapy according to institutional standards and liver function eligibility criteria are also met. HCV patients showing sustained viral response or patients with immunity to HBV infection may enroll.\n6. Active autoimmune disease or medical conditions requiring chronic steroid (i.e., \\> 10 mg\/day prednisone or equivalent) or immunosuppressive therapy. Patients with a prior history of autoimmune disease may be eligible following discussion with the Medical Monitor\n7. Other medical condition that in the opinion of the Investigator and\/or Sponsor Medical Monitor may interfere with the conduct and\/or interpretation of the current study, including:\n\n   1. Congestive heart failure (\\> New York Heart Association Class II), active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or clinically significant cardiac arrhythmias\n   2. QTc interval (using Fridericia correction calculation) \\> 480 msec","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06150664005","EMAIL":[{"email":"Kimberly.Benczkowski@RoswellPark.org"},{}],"GEO":[42.88645,-78.87837]},{"TITLE":"Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC","CRITERIA":"Inclusion criteria:\n\nAll Patients (unless otherwise noted):\n\n* \u2265 18 years of age\n* ECOG PS is 0 to 1\n* Adequate organ function as outlined by the study\n* Received prior standard therapy appropriate for tumor type and stage\n* Must have pathologically documented, locally advanced or metastatic KRAS G12C-mutated solid tumor malignancy (not amenable to curative surgery) (Subprotocol A)\n* Must have pathologically documented, locally advanced or metastatic RAS-mutated NSCLC (Subprotocol B)\n\nExclusion criteria:\n\nAll Patients:\n\n* Primary central nervous system (CNS) tumors\n* Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs\n* Major surgery \\< 28 days of first dose\n* Active or history of interstitial lung disease (ILD) or pneumonitis requiring steroids\n\nOther inclusion\/exclusion criteria may apply.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06162221024","EMAIL":"CT-inquiries@RevMed.com","GEO":[39.46975,-0.37739]},{"TITLE":"A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)","CRITERIA":"Inclusion Criteria:\n\n1. Males and females \u2265 18 years of age.\n2. Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1.\n3. Acceptable bone marrow and organ function at screening as described below:\n\n   1. ANC \u2265 1500\/\u03bcL (without WBC growth factor support)\n   2. Platelet count \u2265 100,000\/\u03bcL without transfusion support\n   3. Hemoglobin \u2265 9 g\/dL (Transfusion is allowed to achieve this Hb)\n   4. Total Bilirubin \u2264 1.5 x ULN; (Patients with known Gilbert's syndrome are allowed with a Total Bilirubin \u2264 2.5 x ULN)\n   5. AST (SGOT) \u2264 3 x ULN (\u2264 5 \u00d7 ULN if known liver metastases)\n   6. ALT (SGPT) \u2264 3 x ULN (\u2264 5 \u00d7 ULN if known liver metastases)\n   7. Creatinine clearance (CrCl) \u2265 60 mL\/min (either measured or estimated by the Cockcroft-Gault formula).\n4. Ability to swallow and retain oral medications.\n5. Histopathological diagnosis of a solid tumor. Note: The solid tumors must be in Stage IV at screening.\n6. Evidence of measurable disease per RECIST, v1.1 for solid tumors.\n7. Standard curative measures do not exist, and the patient must have exhausted all effective therapies available locally.\n\nNotes:\n\n7a. At a minimum, solid tumor patients must have received at least two lines of systemic therapies in the metastatic incurable settings (these two lines must be in the metastatic setting and not in the earlier stage of cancer).\n\n7b. Any cancer patient with access to any effective therapy must not be enrolled\n\nExclusion Criteria:\n\n1. Systemic anti-cancer therapy, such as chemotherapy, biological therapy, or immunomodulatory drug therapy, received within the past 28 days or 5 half-lives, whichever is longer, from Cycle 1 Day 1 of the study.\n\n   Note: Concomitant use of low-dose prednisone (up to 10 mg\/day) or medroxyprogesterone is allowed.\n\n   Note: Patients with CRPC (castrate-resistant prostate cancer) should continue to receive ongoing medical castration with LHRH analogs, and such patients are allowed.\n2. Presence of acute or chronic toxicity resulting from prior anticancer treatment, with the exception of alopecia or nail changes, that has not resolved to Grade \u2264 1, as determined by NCI CTCAE v 5.0.\n3. Definitive Radiotherapy within the last 21 days of Cycle 1 Day 1 (limited field palliative radiation is allowed and no restrictions during the screening period or during the trial)\n\n   \u2022 Use of any investigational agent within 28 days or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1.\n4. Use of drugs which are moderate \/ strong CYP3A4 inducers and\/or drugs which are predominantly metabolized by CYP3A4 within 1week or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1.\n\n   \u2022 Note: This class of drugs are also prohibited during DLT evaluation period and must be either avoided or used with caution beyond DLT evaluation period.\n5. Known symptomatic or untreated or recently treated (\u2264 6 months of screening) central nervous system (CNS) metastases. Patients with previously treated (\\> 6 months of screening) CNS metastases and are now stable and asymptomatic, from CNS perspective, are allowed.\n6. Major surgery \u2264 28 days from Cycle 1 Day 1 (major surgery is defined as a procedure requiring general anesthesia).\n7. Patients with leukemia, myelodysplastic syndrome, multiple myeloma, or lymphoma.\n8. Active infection requiring systemic therapy. Note: Prophylactic use of antibiotics is allowed. Any infection detected during the screening period which is resolved adequately according to investigator before the Cycle 1 Day 1, is allowed.\n9. Known to be human immunodeficiency virus (HIV) positive or have an acquired immunodeficiency syndrome-related illness.\n10. Known active or chronic hepatitis B (HBsAg +ve) or hepatitis C infection (HCV antibody +ve).\n11. The patient who is expected to require any other form of antineoplastic therapy or targeted therapy while on study.\n12. Uncontrolled congestive heart failure (New York Heart Association \\[NYHA\\] Class 2-4), angina, myocardial infarction, cerebrovascular accident, coronary\/peripheral artery bypass graft surgery, or transient ischemic attack, or pulmonary embolism within 3 months prior to Cycle 1 Day 1.\n13. Ongoing cardiac dysrhythmias requiring treatment of any grade or treatment of cardiac dysrhythmias in the past 3 months, before Cycle 1 Day 1.\n14. QTc (Bazzett) interval \\>460 ms on ECG at screening and\/or at Cycle 1 Day 1 pre-dose.\n15. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or significant gastritis, active bleeding diatheses, presence of any major medical illness (e.g., renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, or psychiatric illness\/social situations or clinically significant laboratory \/ ECG abnormalities at screening, any or a combination of illnesses, which, in the opinion of the PI, may either put the patient at risk because of participation in the study or influence the results or the patient's ability to participate in the study.\n16. Current swab-positive or suspected (under investigation) Covid-19 infection or fever and other signs or symptoms suggestive of Covid-19 infection with recent contact of the person(s) with confirmed Covid-19 infection, at screening or Day 1 of Cycle 1.\n17. Positive pregnancy test for women of childbearing potential (WOCBP) at the screening or enrolment visit.\n18. Lactating women or WOCBP who are neither surgically sterilized nor willing to use reliable contraceptive methods. (hormonal contraceptive, IUD, or any double combination of the male or female condom, spermicidal gel, diaphragm, sponge, cervical cap).","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05865002008","EMAIL":[{"email":"deepampushpam@gmail.com"}],"GEO":[28.63576,77.22445]},{"TITLE":"Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax","CRITERIA":"Inclusion Criteria:\n\n* Pathologic diagnosis of Non-Small Cell Lung Cancer (NSCLC) without targetable\/oncogene driven mutations (i.e., EGFR mutations, ALK-rearrangement, ROS1 rearrangement).\n* T1-4(or Tx)N0-3M1a-c, Stage IV disease (using the 8th edition of the AJCC staging manual) or metastatic recurrence of primary Stage I-III NSCLC that had been treated with curative intent therapy, without prior thoracic radiotherapy.\n* Thoracic lung and\/or nodal lesion(s) amenable to palliative chest radiotherapy.\n* All subjects are required to have one or more of the following high-risk features: a) a non-central primary lung lesion \u22655 cm in size (at least T3 by criteria); b) bulky (\u22652 cm) parenchymal lung lesions and\/or nodal lesions abutting (within 1 cm) any of the following: Proximal bronchial tree, Esophagus, Vertebra, Heart, brachial plexus or subclavian vessels (if brachial plexus not well visualized), Superior vena cava\n* Prior systemic therapy is allowed. Subjects must be enrolled within 6 months of first cycle of systemic therapy for Stage IV disease.\n* Systemic therapy following the thoracic radiotherapy (on protocol) is allowed.\n* Prior palliative surgical treatment (including airway debridement) is allowed.\n* Concurrent chemotherapy (chemotherapy delivered from \u22642 days of before through \u22642 days after radiotherapy) is NOT allowed.\n* Concurrent immunotherapy therapy is allowed.\n* Subjects may undergo (or may have undergone) standard extrathoracic radiotherapy off protocol, including (but not limited to): Palliation of symptomatic bone metastases, prophylactic palliation of high-risk bone metastases, cranial radiosurgery (with controlled intracranial metastases if performed prior to enrollment), Ablative or non-ablative definitive radiotherapy for oligometastases.\n* Subjects may undergo concurrent palliative thoracic radiotherapy (per study) and palliative radiotherapy for thoracic bone metastases (i.e., painful spine or rib metastases). It is anticipated that the study will be open at multiple sites within the Wilmot Cancer Institute network. Among these sites, subjects may be consulted and consented at any site, simulated and planned at any site, and treated at any site (even if different from the site(s) at which the subject was consulted and simulated).\n\nExclusion Criteria:\n\n* Prior radiation therapy to the thoracic region.\n* Active systemic lupus or Sjogren's disease.\n* NSCLC (primary, nodal sites or metastases) causing severe symptoms requiring thoracic palliative radiotherapy for indications other than bone pain. These symptoms include superior vena cava syndrome, active and large volume (\\>100 ml per day) hemoptysis, airway obstruction (stridor, post-obstructive pneumonia, progressive dyspnea not attributed to other causes), compression of the spinal cord or spinal nerve roots, vertebral compression fracture, brachial plexopathy (from compression).\n* Baseline ECOG performance status of 3-4. For the purposes of eligibility, Karnofsky Performance Score (KPS) will be converted to ECOG\/Zubrod performance score, per ECOG guidelines.\n* Brain metastases not amenable to immunotherapy alone, resection or stereotactic radiosurgery (i.e., brain metastases requiring whole brain radiotherapy).\n* Malignant pleural effusion attributable to grossly apparent pleural disease. Subjects with malignant pleural effusion amenable to therapeutic thoracenteses and without radiographic evidence of pleural disease (i.e., studding or masses) are potentially eligible.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06262321001","EMAIL":[{}],"GEO":[43.15478,-77.61556]},{"TITLE":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Life expectancy at least 3 months\n* Adequate hematologic and end organ function\n* Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy\n* Measurable disease according to RECIST v1.1 on computed tomography (CT) or magnetic resonance imaging (MRI) images within 28 days prior to enrollment\n* Availability of representative tumor specimens in formalin-fixed, paraffin-embedded (FFPE) blocks or at least 15 unstained slides\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding, or intending to become pregnant during the study or within 9 months after the final dose of oxaliplatin and within 6 months after the final dose of all other study treatment\n* Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, and\/or radiotherapy, within 3 weeks prior to initiation of study treatment\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina\n* History of leptomeningeal disease\n* Uncontrolled tumor-related pain\n* Positive test for human immunodeficiency virus (HIV) infection\n* Positive hepatitis B surface antigen (HbsAg) test, and\/or positive total hepatitis B core antibody (HbcAb) test at screening\n* Positive hepatitis C virus (HCV) antibody test at screening\n* Known allergy or hypersensitivity to any component of the RO7496353 formulation or any of the study drugs or their excipients\n\nOther protocol-defined inclusion\/exclusion criteria may apply.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05867121022","EMAIL":"global-roche-genentech-trials@gene.com","GEO":[39.46975,-0.37739]},{"TITLE":"Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Written informed consent must be obtained before implementing any trial-related procedures;\n* Aged 18-80 years;\n* Expected survival of more than 3 months;\n* The investigator confirms the presence of at least one measurable lesion according to RECIST 1.1 criteria;\n* Wild-type EGFR\/ALK;\n* Patients with locally advanced (stage IIIb\/IIIc), metastatic, or recurrent (stage IV) NSCLC confirmed by histology or cytology, who are not eligible for curative surgery and cannot undergo definitive radiotherapy\/chemotherapy, according to the 8th edition of the TNM staging classification by the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer;\n* PD-L1 expression in tumor tissue with Tumor Proportion Score (TPS) \\< 1%;\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;\n* No prior systemic anti-tumor treatment for advanced\/metastatic disease; patients who have previously received platinum-based adjuvant chemotherapy\/radiotherapy, neoadjuvant chemotherapy\/radiotherapy, or curative radiotherapy for advanced disease and experienced disease progression more than 6 months after the last treatment can participate in this study;\n* Adequate hematologic function, defined as absolute neutrophil count (ANC) \\>= 1.5 x 10\\^9\/L, platelet count \\>= 100 x 10\\^9\/L, hemoglobin \\>= 90 g\/L (without transfusion history within 7 days);\n* Adequate liver function, defined as total bilirubin level \\<= 1.5 times the upper limit of normal (ULN) and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels \\<= 2.5 times ULN in all patients, or \\<= 5 times ULN in patients with liver metastases;\n* Adequate renal function, defined as serum creatinine \\<= 1.5 times ULN;\n* Adequate coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT) \\<= 1.5 times ULN; for subjects receiving anticoagulant therapy, INR\/PT should be within the range planned by the anticoagulant;\n* Women of childbearing potential must have a negative pregnancy test within 7 days before starting treatment, and must use reliable contraceptive measures (such as intrauterine device, contraceptive pills, and condoms) during the trial and for 30 days after the end of the trial; male subjects of reproductive potential must use condoms for contraception during the trial and for 30 days after the end of the trial;\n* Willingness to comply with regular follow-up visits and trial requirements.\n\nExclusion Criteria:\n\n* Currently participating in interventional clinical research treatment;\n* Previously received the following therapies: anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs, or drugs targeting another stimulatory or co-inhibitory T-cell receptor (such as CTLA-4, OX-40, CD137);\n* Received traditional Chinese medicine or immunomodulatory drugs (such as thymopeptide, interferon, interleukin, etc.) with anti-tumor indications within 2 weeks prior to the first dose;\n* Known allergy to the active ingredient or any excipients of Cadonilimab;\n* Active hemoptysis, active diverticulitis, intra-abdominal abscess, gastrointestinal obstruction, or peritoneal metastasis requiring clinical intervention;\n* Uncontrolled pleural effusion\/ascites clinically (patients who do not require drainage of effusion or whose effusion does not increase significantly for 3 days can be included);\n* Tumor compression of important organs (such as the esophagus) with accompanying symptoms, compression of the superior vena cava, or invasion of mediastinal large blood vessels, heart, etc.;\n* History of severe complications such as severe pulmonary or cardiac disease, with any arterial thrombosis, embolism, or ischemia occurring within 6 months prior to enrollment, such as myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack. History of deep vein thrombosis, pulmonary embolism, or any other serious thrombotic events within 3 months prior to enrollment (thrombotic events related to implanted venous infusion ports or catheters, or superficial vein thrombosis are not considered \"serious\" thrombotic events);\n* History of autoimmune diseases, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vasculitis, or glomerulonephritis related to antiphospholipid syndrome; Patients with stable hypothyroidism on replacement therapy with thyroid hormones are eligible to participate in this study; Patients with controlled type 1 diabetes after receiving a stable insulin treatment regimen are eligible to participate in this study;\n* Received systemic corticosteroids (\\> 10 mg\/day of prednisone or equivalent) or other systemic immunosuppressive agents (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \\[anti-TNF\\] drugs) within 2 weeks prior to randomization; Use of topical, ocular, intra-articular, intranasal, and inhaled corticosteroids is allowed;\n* Active systemic infections, including tuberculosis (TB) (clinical diagnosis based on clinical history, physical examination, radiographic findings, and TB testing according to local medical practices), hepatitis B (known positive for hepatitis B surface antigen (HBsAg) with HBV DNA \\>= 1,000 cps\/mL or its lower limit of reference range), hepatitis C, or human immunodeficiency virus (HIV) (positive for HIV antibody);\n* Known presence of mental illness or substance abuse that may affect compliance with trial requirements;\n* History of conditions, diseases, treatments, or laboratory abnormalities that may interfere with trial results or hinder the subject's full participation in the study, or as determined by the investigator that participation in the study is not in the best interest of the subject.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"06424821002","EMAIL":[{}],"GEO":[29.87819,121.54945]},{"TITLE":"Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Histologically documented locally advanced or metastatic non-small cell lung cancer with a KRAS G12C mutation\n* Measurable disease by RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1\n\nExclusion Criteria:\n\n* Patients with malignancy within the last 2 years as specified in the protocol\n* Patients with untreated brain metastases\n* Patients with known hypersensitivity to BBO-8520 or its excipients\n* For Cohorts 2a and 2b:\n* Patients with a known hypersensitivity to pembrolizumab or its excipients\n* Patients with active autoimmune disease of history of autoimmune disease that might recur\n* Patients with a history of interstitial lung disease\/pneumonitis that required steroids, or current interstitial lung disease\/pneumonitis\n\nOther inclusion\/exclusion criteria may apply","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06343402011","EMAIL":"onkoras-101ct.gov@bridgebiooncology.com","GEO":[-37.814,144.96332]},{"TITLE":"Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor","CRITERIA":"Key Inclusion Criteria:\n\n1. Confirmed KRAS G12V mutational status and HLA-A\\*11:01 allele\n2. Histologically confirmed advanced or metastatic, unresectable solid tumor\n3. Progressed on or intolerant of at least one prior line of standard systemic therapy for the current malignancy.\n4. Measurable disease per RECIST v1.1.\n5. ECOG performance status 0-1\n6. Adequate organ and bone marrow function\n\nKey Exclusion Criteria:\n\n1. Any systemic cytotoxic chemotherapy, investigational agents, or any anti-tumor drug from a previous treatment regimen or clinical study (including small molecules and I\/O compounds) within 5 half-lives or 14 days of Screening, whichever is shorter.\n2. Any prior gene therapy utilizing an integrating vector\n3. Previous allogeneic stem cell transplantation or prior organ transplantation\n4. History of treated primary immunodeficiency, autoimmune, or inflammatory disease including inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, myasthenia gravis, or Grave's disease\n5. Primary brain tumor\n6. Untreated central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression.\n7. Uncontrolled active bacterial, viral, fungal, or mycobacterial infection\n8. Pregnant or lactating subjects\n9. Surgery or catheter-based interventions\n10. Previously identified allergy, hypersensitivity, or known contraindication to cyclophosphamide, fludarabine, or any other agent associated with lymphodepleting chemotherapy (LDC) or AFNT-211 product\n11. Uncontrolled significant intercurrent or recent illness\n12. Diagnosis of another malignancy within 2 years prior to screening.\n13. Seropositive for hepatitis B surface antigen (HBsAg) and\/or hepatitis B core antibody (HBcAb)\n14. Seropositive for hepatitis C antibody.\n15. Known human immunodeficiency virus (HIV) infection","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06105021007","EMAIL":[{"email":"GIClinicalTrials@mdanderson.org"},{}],"GEO":[29.76328,-95.36327]},{"TITLE":"Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy","CRITERIA":"Inclusion Criteria:\n\nTargetable Oncogene - Biopsy Cohort (includes blood draw)\n\n1. Carry a diagnosis of locally advanced or stage IV NSCLC responsive to targeted therapies (per current NCCN guidelines)\n2. Aged 18 years or older\n3. ECOG 0-2\n4. Have a histologically confirmed diagnosis of NSCLC harboring an activating mutation responsive to targeted therapy (per NCCN guidelines)\n5. No prior systemic therapy for locally advanced or metastatic disease.\n6. Planned treatment with targeted therapy specific to the oncogene driver mutation.\n7. Patients must have at least one site of measurable disease \u2265 2cm.\n8. Primary disease site or site of metastatic disease must be amenable to biopsy.\n9. Patients must have the ability to understand and willingness to sign an informed consent document.\n\nTargetable Oncogene - Blood Draw Only Cohort\n\n1. Carry a diagnosis of locally advanced or stage IV NSCLC responsive to targeted therapy (per NCCN guidelines)\n2. Aged 18 years or older\n3. ECOG 0-2\n4. Have a histologically confirmed diagnosis of NSCLC harboring an activating mutation responsive to targeted therapy (per NCCN guidelines)\n5. No prior systemic therapy or radiotherapy for metastatic lung cancer (surgery alone permitted)\n6. Planned treatment with targeted therapy specific to the oncogene driver mutation.\n7. Declines repeat biopsy option or does not have tumor site amenable to biopsy.\n8. Patients must have the ability to understand and willingness to sign an informed consent document.\n\nImmunotherapy Cohort - Blood Draw Only\n\n1. Have a histologically confirmed diagnosis of locally advanced or stage IV NSCLC without a treatable activating mutation that would be amenable to targeted therapy AND planned first line treatment with immunotherapy or chemotherapy plus immunotherapy.\n2. Aged 18 years or older\n3. ECOG 0-2\n4. No prior systemic therapy or radiation therapy for lung cancer (surgery alone permitted)\n5. Patients must have the ability to understand and willingness to sign an informed consent document.\n\nExclusion Criteria:\n\nTargetable Oncogene - Biopsy Cohort (includes blood draw)\n\n1. Concurrent health problem which would preclude tissue biopsy (e.g. hemophilia or other bleeding predisposition).\n2. Patients whose only biopsy source would involve sampling an anatomic area that carries an unacceptably high procedural risk (e.g. pericardium or kidney) as deemed by the treating physician or by a proceduralist performing the biopsy.\n3. Patients whose only biopsy source involves a sample that may not be evaluable due to insufficient genomic material (such as cerebrospinal or ascitic fluid) as deemed by the treating physician. .\n\nTargetable Oncogene Cohort and Immunotherapy Cohort - Blood Draw Only\n\n1. Planned follow up on therapy outside of the University of Colorado Health System\n2. Unwillingness to allow for residual clinical biopsy specimens to be utilized in this study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":85,"SS_ID":"03042221001","EMAIL":[{"email":"brandi.kubala@cuanschutz.edu"},{"email":"erin.schenk@cuanschutz.edu"},{}],"GEO":[39.72943,-104.83192]},{"TITLE":"De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction","CRITERIA":"Inclusion Criteria:\n\n1. Signed Written Informed Consent:\n\n   * Subjects must have signed and dated an IRB\/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care.\n   * Subjects must be willing and able to comply with scheduled visits, treatment schedule, and laboratory testing.\n2. Patients with histologically confirmed metastatic NSCLC (Stage IV accordingly to 8th classification TNM, UICC 2015). A cytologically-proven NSCLC is allowed if a cytoblock has been prepared.\n3. PD-L1 tumor content as assessed locally by the investigator center.\n4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.\n5. Weight loss\\< 10% within 3 months of study entry.\n6. No prior systemic anticancer therapy (including EGFR or ALK inhibitors) given as primary therapy for advanced or metastatic disease.\n7. Age\u2265 18 years, \\<75 years\n8. Life expectancy \\> 3 months\n9. Measurable tumor disease by CT or MRI per RECIST 1.1 criteria\n10. The Investigator must confirm prior to enrolment that the patient has adequate tumor tissue available. Tumor biopsy should be exploitable for molecular analysis. If archival tissue is either insufficient or unavailable, the patient may still be eligible upon discussion with IFCT.\n\n    Note: Tumor tissue collected after the patient was diagnosed with metastatic disease is preferred.\n\n    Tumor tissue sample must not be from locations previously radiated. Tumor sample must be 1 block or at least 7 unstained slides of analyzable tissue.\n11. Adequate biological functions:\n\n    Creatinine Clearance \u2265 45 mL\/min (Cockcroft or MDRD or CKD-epi); neutrophils\u2265 1500\/mm3 ; platelets \u2265100 000\/mm3 ; Hemoglobin\u2265 9g\/dL ; AST and ALT\\< 3x ULN, total bilirubin \\< 2xULN (patients with hepatic metastases or Gilbert's syndrome must have AST and ALT \u2264 5 x ULN and a baseline total bilirubin \u2264 2xULN).\n12. Women of childbearing potential (WOCBP) and sexually active should use an efficacious contraception method within the 28 days preceding the first dose and during the 6 months following the last dose of treatment. Women must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU\/L or equivalent units of HCG) prior to the start of study drug.\n13. For Male subjects who are sexually active with WOCBP, an efficacious contraception method should be used during the treatment and during the 6 months following the last dose.\n14. Patient has national health insurance coverage.\n\nExclusion Criteria:\n\n1. Small cell lung cancer or tumors with mixed histology including a SCLC component.\n\n   Note : Sarcomatoid histology is allowed. Neuro-endocrine large cell lung cancer with molecular features of small-cell lung cancer (i.e; Rb loss associated with TP53 mutation) will not be eligible. Other neuro-endocrine large cell subtypes, i.e. with adenocarcinoma features (STK11 or K-Ras mutations) will be eligible. In case of doubt, please contact the sponsor.\n2. Known EGFR activating tumor mutation (deletion LREA in exon 19, L858R ou L861X mutations in exon 21, G719A\/S mutation in exon 18, exon 20 insertion) or HER2 exon 20 insertion (either tissue or plasma cfDNA mutation).\n3. Known ALK, ROS1, Ret, NTRK, NRG1 gene rearrangement as assessed by immunohistochemistry, FISH or NGS (ADN or ARN) sequencing by local genetics and\/or pathology laboratory.\n4. Previous or active cancer within the previous 3 years (except for treated carcinoma in situ of the cervix, or basal cell skin cancer treated or not). Patients with a prostate adenocarcinoma history within the previous 3 years could be included in case of localized prostate cancer, with good prognostic factors according to d'Amico classification (\u2264T2a, score de Gleason \u2264 6 and PSA \u2264 10 (ng\/ml)) provided they were treated in a curative way (surgery or radiotherapy, without any chemotherapy).\n5. Superior vena cava syndrome persisting despite VCS stenting.\n6. Radiotherapy needed at initiation of tumour treatment, except bone palliative radiotherapy on a painful or compressive metastasis, respecting 1 week delay between the end of radiotherapy and the beginning of treatment\n7. Symptomatic untreated brain metastasis (without previous whole brain radiotherapy or stereotactic ablative brain radiotherapy or without surgical resection). At least 2 weeks delay between the end of radiotherapy and the beginning of induction immunotherapy treatment should be respected. Asymptomatic brain metastasis, not needing corticosteroids greater than 10 mg prednisone equivalent daily or mannitol infusions, are allowed.\n8. History of previous primary immunodeficiency, organ transplantation needing an immunosuppressive treatment, any immunosuppressive drug within 28 days before randomization date, or history of severe toxicity (grade 3\/4) by immune mechanism linked to another immunotherapy treatment.\n9. Systemic treatment with corticosteroids with greater dose than 10 mg prednisone equivalent daily, within 14 days before initiation of the immunotherapy induction. Inhaled, nasal or topic corticosteroids are allowed.\n10. History of active autoimmune disease including but not limited to rheumatoid polyarthritis, myasthenia, autoimmune hepatitis, systemic Lupus, Wegener's granulomatosis, vascular thrombosis associated with antiphospholipid syndrome, Sjogren's syndrome with interstitial pulmonary disease, recent Guillain-Barr\u00e9 syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.\n\n    Patients with type I diabetes, or hypothyroidism, or immune cutaneous disease (vitiligo, psoriasis, alopecia) or benign rheumatoid polyarthritis not needing any immunosuppressive systemic treatment, or benign sicca syndrome (Sjogren) without interstitial pulmonary disease, or history of past Guillain-Barre syndrome, totally reversible with no sequelae, no systemic immunosuppressive treatment during the last 20 years, are allowed to be included.\n11. Active inflammatory intestinal disease (Crohn disease, Hemorrhagic recto-colitis, coeliac disease) or any serious chronic intestinal disease with uncontrolled diarrhea.\n12. Active uncontrolled infection including tuberculosis, known acute viral hepatitis B and C according to serological tests. Patients with serological sequelae of cured viral hepatitis are allowed to be included. Past primary pulmonary tuberculosis in youth does not consist of a contra-indication. Past tuberculosis disease history does not consist of a contra-indication provided the patient was treated during at least 6 months by anti-tuberculosis antibiotic treatment.\n13. Known HIV infection\n14. Living attenuated vaccine received within the 30 previous days\n15. Previous treatment with anti-PD-1, anti-PD-L1, Anti-CTLA4 or any ICI antibody\n16. Previous treatment with chemotherapy for lung cancer. However, if a patient has a lung adenocarcinoma, previous cisplatin treatment for another cancer type with squamous histology (Head and Neck, bladder) may be allowed provided the sponsor accepts, and provided blood tests are normal (see above).\n17. General serious condition such as congestive uncontrolled cardiac failure, uncontrolled cardiac arrythmia, uncontrolled ischemic cardiac disease (unstable angina or history of myocardial infarction within the previous 6 months), history or stroke within the 6 previous months. Patients with a significant cardiac history, even if controlled, should have a LVEF \\> 50%.\n18. Pre-existing moderate or severe lung interstitial disease as assessed by the diagnosis CT-scan.\n19. Inability to comply with study and\/or follow-up procedures for family, social, geographic or psychological reasons.\n20. Pregnant, lactating, or breastfeeding women.\n21. Patients deprived of liberty by judicial or administrative decision\n22. Patient who is subject to legal protection or who is unable to express his will","SEX":"ALL","AGE_MIN":18,"AGE_MAX":74,"SS_ID":"05255302030","EMAIL":[{"email":"contact@ifct.fr"}],"GEO":[48.85341,2.3488]},{"TITLE":"Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Written informed consent in accordance with federal, local, and institutional guidelines. The patient must provide informed consent prior to the first screening procedure.\n* Previously treated (up to three prior lines of therapy), histologically proven advanced squamous NSCLC.\n* No prior treatment with EGFR inhibitors, IMIDs (eg, thalidomide, lenalidomide), or anti-TNF antibodies.\n* No treatment with systemic glucocorticoids within 3 weeks of initiation of study therapy (topical and inhaled glucocorticoids are permitted).\n* Age \u2265 18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate organ and marrow function as defined below:\n* absolute neutrophil count \u2265 1,000\/\u03bcL\n* platelets \u2265 50,000\/\u03bcl\n* total bilirubin within normal institutional limits\n* AST(SGOT)\/ALT(SPGT) \u2264 2.5 X institutional upper limit of normal\n* CrCl \u2265 45 ml\/min\n* For both male and female patients, effective methods of contraception must be used throughout the study and for 3 months following the last dose of study treatment.\n* Adequate archival tissue (5-10 slides) for correlative studies.\n* Subject must have measurable disease per RECIST 1.1\n\nExclusion Criteria:\n\n* Chemotherapy, radiotherapy, or other cancer therapy within two weeks prior to starting study treatment. Subjects must have recovered from prior treatment-related to toxicities to grade 1 or baseline (excluding alopecia and clinically stable toxicities requiring ongoing medical management, such as hypothyroidism from prior immune checkpoint inhibitor treatment).\n* Subjects may not be receiving any other investigational agents for the treatment of the cancer under study.\n* Symptomatic brain metastases or brain metastases requiring escalating doses of corticosteroids\n* History of hypersensitivity or allergic reactions attributed to afatinib or prednisone.\n* Uncontrolled intercurrent illness including but not limited to poorly controlled diabetes (which may worsen in setting of chronic prednisone therapy), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\/social situations that, in the opinion of the investigator, would limit compliance with study requirements.\n* Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04497584001","EMAIL":[{"email":"ebele.mbanugo@utsouthwestern.edu"}],"GEO":[32.78306,-96.80667]},{"TITLE":"A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers","CRITERIA":"Criteria: Inclusion Criteria:\n\n1. Have histological or cytological evidence of a diagnosis of selected cancer types that is locally advanced and\/or metastatic\n\n1. Have the presence of evaluable disease for the Phase 1b Monotherapy\n2. Have the presence of evaluable and measurable disease for the Phase 1b combination part and the Phase 2a part of the study.\n3. The patient must be, in the judgment of the investigator, an appropriate candidate for experimental therapy after available standard therapies have failed to provide clinical benefit for their disease or patients who have refused standard treatments.\n\n   2. Cancer treatment and type criteria:\n   * Have received at least 1 but no more than 4 prior systemic therapies for locally advanced or metastatic disease (e.g., hormonal, cytotoxic, etc.) for the following cancer types, for Phase 1b:\n   * Triple Negative Breast Cancer (TNBC): Must have recurrent\/refractory TNBC, defined as any breast cancer that expresses less than (\u02c2)1% estrogen receptor (ER), \u02c2 1% progesterone receptor (PR), and is Human Epidermal Growth Factor Receptor 2 (Her2) negative. Must have failed at least one chemotherapy regimen.\n   * Gastric Cancer: Must have failed a platinum-containing chemotherapy regime.\n   * Cervical Cancer: Must have failed at least one chemotherapy regimen.\n   * Ovarian Cancer: Must have failed a platinum-containing chemotherapy regimen but not be platinum refractory.\n   * Hepatocellular Cell Carcinoma (HCC): May have failed unlimited liver local therapies.\n   * Sarcoma: Must have failed at least one prior chemotherapy regimen.\n   * Squamous Cell Carcinoma of Head and Neck (SCCHN): Must have failed a platinum-containing chemotherapy regiment. Must have failed a previous immune checkpoint inhibitor.\n   * Bladder Cancer: Must have failed a platinum-containing chemotherapy regiment. Must have failed a previous immune checkpoint inhibitor.\n   * Non Small Cell Lung Cancer (NSCLC): Must have failed a platinum-containing chemotherapy regimen or Immuno Oncology (IO) agent in the first line. Must have failed a previous immune checkpoint inhibitor. Must not have any history of tumors that test positive for epidermal growth factor receptor (EGFR), Receptor Tyrosine Kinase (ROS1), Anaplastic Lymphoma Kinase (ALK) mutations or ALK fusions or any other mutations for which tyrosine kinase inhibitors are available.\n   * Renal Cell Carcinoma (RCC): Must have failed at least one prior systemic therapy. Must have failed a previous IO agent.\n   * Urothelial Cancer: Must have failed at least one prior systemic therapy. Must have failed a previous IO agent.\n   * Merkel Cell: Must have failed at least 1 prior systemic therapy for advanced disease and may have failed a previous IO agent.\n   * Squamous Cell Carcinoma of the Skin: Must have failed at least 1 prior systemic therapy for advanced disease and may have failed a previous IO agent.\n\n     3. Phase 1b - combination dose escalation:\n   * Cervical Cancer Must have failed at least 1 chemotherapy regimen.\n   * Bladder Cancer Must have failed a platinum-containing chemotherapy regimen. Must have failed a previous immune checkpoint inhibitor.\n   * RCC Must have failed at least 1 prior systemic therapy. Must have failed a previous IO agent.\n   * Urothelial cancer Must have failed at least 1 prior systemic therapy. Must have failed a previous IO agent.\n   * Diffuse large B cell lymphoma Must have failed prior rituximab therapy. May have failed prior chemotherapy or other IO agents.\n   * NSCLC Must have failed a single agent PD-1 or PD-L1 inhibitor as the last regimen and must have responded to the agent.\n   * Must not have any history of tumors that test positive for EGFR, ROS1, ALK mutations or ALK fusions, or any other mutations for which tyrosine kinase inhibitors are available or are under development.\n\n     4. For Phase 2a: Must have histological or cytological confirmation of a solid tumor that is locally advanced or metastatic. At least two cancer type will be selected amongst the ones evaluated in the Phase 1b combination dose escalation part of the study.\n\n     5. Have adequate organ function 6 Have a performance status (PS) of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale 7 Have discontinued cytotoxic therapy, biologic therapy, immunotherapy, radiotherapy, and cancer-related hormonal therapy at least 21 days prior to study enrollment 8. Are recovered or recovering from the acute adverse effects of any chemotherapy, biologic, therapy, immunotherapy, cancer-related hormonal therapy, or radiotherapy 9. Patients who have had major surgery must be fully recovered and greater than (\u2265)4 weeks post-operative 10. Men with partners of child-bearing potential or women with child-bearing potential must agree to use a medically approved contraceptive method during and for at least 12 weeks following the last dose of study drug (e.g., intrauterine device (IUD), birth control pills, or barrier method) 11. Women of child-bearing potential must have a negative serum pregnancy test documented 12. Have an estimated life expectancy of at least 3 months\n\n   Exclusion Criteria:\n   1. Have symptomatic central nervous system (CNS) metastasis. Patients with treated CNS metastases are eligible for this study if they are asymptomatic and off of corticosteroids for a minimum of 7 days. Patients with primary brain tumors are not eligible\n   2. Have a history of major organ transplant (e.g., heart, lungs, liver, and kidney) or an autologous or allogeneic hematopoietic stem cell transplant\n   3. Females who are pregnant or nursing\n   4. Have known, symptomatic acquired immuno deficiency syndrome (AIDS) or active hepatitis A, B or C\n   5. Previous treatment-related, severe (\u2265Grade 3) Adverse Event (AE) or any neurologic or ocular AE while receiving an IO agent\n   6. Active or prior documented autoimmune disease within the past 2 years Patients with vitiligo, Grave's disease or psoriasis not requiring systemic treatment within the past 2 years are eligible\n   7. Active or prior documented inflammatory bowel disease\n   8. History of tuberculosis, interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required corticosteroid therapy\n   9. Receipt of live attenuated vaccination within 28 days prior\n   10. Current or prior use of immunosuppressive medication within 28 days prior\n   11. Are currently enrolled in another clinical study of an investigational medicinal product\n   12. Have a second primary malignancy that may affect the interpretation of results\n   13. Are unwilling or unable to participate in, or do not have tissue adequate for a tumor biopsy","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04260802005","EMAIL":[{"email":"marie-eve.rego.chum@ssss.gouv.qc.ca"},{}],"GEO":[45.50884,-73.58781]},{"TITLE":"Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Age 18-70 years; ECOG score 0-2.\n2. Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).\n3. Unresectable Stage II-III NSCLC (according to AJCC 8th edition) with maximum tumor diameter T \u2265 5 cm in the primary tumor or minimum diameter N \u2265 2 cm in mediastinal metastatic lymph nodes.\n4. No other previous anti-tumor history, at least 3 months of expected survival.\n5. No serious medical diseases and dysfunction of major organs, such as blood routine, liver, kidney, heart and lung function.\n\nExclusion Criteria:\n\n1. Pathologic type was adenocarcinoma with EGFR gene mutation or ALK gene rearrangement.\n2. Patients with other active malignancies within 5 years or at the same time.\n3. Active or previously documented autoimmune or inflammatory diseases (including inflammatory bowel disease, diverticulitis \\[except diverticular disease\\], systemic lupus erythematosus, Sarcoidosis syndrome, Wegener' s syndrome).\n4. History of allogeneic organ transplantation.\n5. History of active primary immunodeficiency.\n6. Patients with uncontrolled concurrent diseases, including but not limited to persistent or active infection (including tuberculosis, hepatitis B, hepatitis C, human immunodeficiency virus, etc.), symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled arrhythmia, active interstitial lung disease, severe chronic gastrointestinal disease with diarrhea or mental illness.\n7. Women of child-bearing potential who are pregnant or breastfeeding.\n8. Allergic to research drug ingredients.\n9. Ongoing or prior use of immunosuppressive agents within 14 days prior to first dose\n10. The investigator judged other situations not suitable for inclusion in this study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":70,"SS_ID":"05888402001","EMAIL":[{"email":"binan_email@163.com"}],"GEO":[39.9075,116.39723]},{"TITLE":"A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n1. Male or female subjects aged \u226518 years old;\n2. Phase I dose escalation period: Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor, assessed by investigator that no standard therapy exists, or the tumor has relapsed, progressed or was nonresponsive to available therapies, or intolerance, or not suitable to standard therapy at current stage. Priority will be given to patients who have previously documented NTRK or ROS1 gene fusion confirmed by the central laboratory; Phase I dose expansion and Phase II: Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor, patients can provide a written report of pathological diagnosis of NTRK or ROS1 positive tested by qualified laboratory;\n3. Phase I dose expansion cohort 1 and Phase II cohort 1: locally advanced, or metastatic solid tumor with NTRK gene fusion Phase I dose expansion cohort 2 and Phase II cohort 2\uff1a locally advanced, or metastatic NSCLC with ROS1 gene fusion that has progressed to crizotinib and other therapies or was intolerance to crizotinib Phase I dose expansion cohort 3: locally advanced, or metastatic NSCLC with ROS1 gene fusion who have not previously received crizotinib or other therapy.\n4. phase I dose escalation: at least 1 measurable target lesion according to RECIST version 1.1 Phase I dose expansion and Phase II: at least 1 measurable target lesion according to RECIST version 1.1 (Tumor lesions treated with prior radiation or other local treatment are considered measurable if they show definite progression)\n5. ECOG PS 0-1\n6. Life expectancy \u2265 3 months.\n7. Adequate organ function:\n\n   Baseline laboratory values fulfilling the following requirements: Absolute neutrophils count (ANC) \u22651.5 \u00d7 109\/L; Platelets (PLTs) \u226575 \u00d7 109\/L; Hemoglobin \u2265 85g\/L; Serum creatinine\u2264 1.5 \u00d7 ULN\uff0c or creatinine clearance \u226550 mL\/min\/1.73m2(only when serum creatinine\\>1.5 \u00d7 ULN); Total serum bilirubin \u22641.5 \u00d7 ULN; Liver transaminases (AST\/ALT) \u2264 2.5 \u00d7 ULN\uff0c\u22643\u00d7 ULN if liver metastases are present or liver cancer patients; Activated Partial Thromboplastin Time\u22641.5\u00d7 ULN\uff1bInternational Normalized Ratio (INR)\u22641.5\u00d7 ULN\uff1b\n8. Eligible patients (male and female) who are fertile must agree to at least use a reliable contraceptive method with partner during the trial and within 90 days from the last dose; Women of childbearing age must have a negative serum pregnancy test within 7 days before the first dose of the trial.\n\nExclusion Criteria:\n\n1. Received anti-tumor therapy such as chemotherapy, radiotherapy, biotherapy, endocrine therapy, immunotherapy or other therapy within 4 weeks prior to the first dose of the investigational drug except the following:\n\n   Nitroso ureas or mitomycin C within 6 weeks before the first dose of the drug; Oral fluorouracil and small molecule targeted drugs within 2 weeks prior to the first dose of drug or within 5 half life (whichever is longer);\n2. Received other unmarketed investigational drugs or treatments within 4 weeks prior to the first dose of the investigational drug;\n3. Major organ surgery (except biopsy) or significant trauma within 4 weeks prior to first dose of the investigational drug or required elective surgery during the trial;\n4. Adverse reactions to previous antitumor therapy have not recovered to NCI CTCAE 5.0 \u2264 grade 1 (except for alopecia, grade 2 peripheral neurotoxicity, stable hypothyroidism after hormone replacement therapy, etc.);\n5. Inability to swallow drug, or a condition that the investigator judged to severely affect gastrointestinal absorption (eg:Chronic Diarrhea, intestinal obstruction, etc.);\n6. Cerebral or meningeal metastases with clinical symptoms. The below patients were allowed to be included: those who were asymptomatic, stable, and did not require steroid treatment for more than 4 weeks prior to the start of study treatment (if the cerebral metastases had undergone radiotherapy or\/and surgery, radiotherapy and surgery should be at least 1 month prior to the first dose) ;\n7. Known active infections and currently need intravenous anti-infective therapy;\n8. History of immune deficiencies, including positive HIV antibody tests;\n9. Active Hepatitis B (HBsAg and\/or HBcAb positive with HBV-DNA \\> 500IU\/ml) or hepatitis c virus infection (positive test results of anti-HCV with positive HCV-RNA );\n10. Known interstitial lung disease (except for radioactive pulmonary fibrosis that does not require steroid therapy);\n11. History of serious cardiovascular disease;\n12. Pregnant or lactating women.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04996121001","EMAIL":[{"email":"syuankaipumc@126.com"},{}],"GEO":[39.9075,116.39723]},{"TITLE":"The Efficacy and Safety of the Bispecific Anti-PD-1\/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC.","CRITERIA":"Inclusion Criteria:\n\n* Eligible subjects selected for this study must meet all of the following criteria:\n\n  1. Sign written informed consent before implementing any trial-related procedures;\n  2. Age \u226518 years old and \u226475 years old;\n  3. No limit on the gender;\n  4. Cohort A: histological or cytological confirmed locally advanced (IIIB-IIIC) or metastatic (stage IV) NSCLC (International Association for the Study of Lung Cancer and Joint Committee on the American Classification of Cancer, TNM Lung cancer stage 8) without EGFR gene sensitive mutations, ALK gene fusion or ROS1 gene fusion confirmed by histological specimens, Relapse after failure of first-line anti-PD-1 \/PD-L1 antibody therapy, as follows:\n\n  <!-- -->\n\n  1. Only one anti-PD-1\/PD-L1 antibody monotherapy or combination therapy is accepted in the advanced stage of the disease, and other immunotherapy is not allowed;\n  2. Previous anti-PD-1\/L1 antibody monotherapy or combination therapy has the best curative effect (according to RECIST 1.1 criteria) as partial remission, complete remission, or stable disease for \u22656 months (defined as within 6 months from the first medication) No disease progression has occurred);\n  3. Disease progression confirmed by imaging studies occurred during or after the most recent treatment.\n\nCohort B: histological or cytological confirmed locally advanced (IIIB-IIIC) or metastatic (stage IV) NSCLC (International Association for the Study of Lung Cancer and Joint Committee on the American Classification of Cancer, TNM Lung cancer stage 8) with histologically confirmed EGFR-sensitive mutations or ALK fusion, Relapse after failure of anti-EGFR-TKI or ALK-TKI therapy, as follows:\n\nIn patients with EGFR-tKI sensitive mutations, the specific history of previous EGFR-TKI treatment can be one of the following:\n\n1. There is no T790M mutation in 20 exon after the failure of previous one or two generations of EGFR-TKI (including gefitinib, erlotinib, icotinib and afatinib);\n2. The 20 exon T790M mutation occurred after the treatment failure of the first or second generation EGFR-TKI monotherapy (including gefitinib, erlotinib, icotinib, and afatinib, etc.), and disease progression recurred after treatment with osimertinib or other third generation EGFR-TKI;\n3. Failure of prior osimertinib or other third-generation EGFR-TKI therapy as first-line therapy (regardless of EGFR T790M mutation status);\n4. Those who are allowed to receive neoadjuvant\/adjuvant targeted therapy in the early stage and develop drug resistance after subsequent adjuvant targeted therapy, and their drug resistance status meets one of the three requirements of appeal.\n\n   For patients with ALK fusion NSCLC, disease progression should occur after adequate ALK-TKI treatment, and there is no opportunity for subsequent targeted therapy.\n\n   Cohort C: Locally advanced NSCLC that is not suitable for radical surgery or radiotherapy, or that has relapsed without systematic treatment, or that has metastasized without systematic treatment and is negative for PD-L1 expression. Patients who have previously received neoadjuvant or adjuvant therapy can also receive neoadjuvant or adjuvant therapy (but neoadjuvant or adjuvant therapy is chemotherapy\/radiotherapy, not immunotherapy), and the end of neoadjuvant\/adjuvant therapy should be \u22656 months after tumor progression; If the pathological type is adenocarcinoma, the absence of EGFR-sensitive mutations or ALK fusion or ROS1 fusion should be confirmed. Negative expression of PD-L1 was defined as TPS \\<1% using 22C3 test.\n\n5. According to the evaluation criteria for the efficacy of solid tumors (RECIST v1.1 version), there is at least one imaging measurable lesion. The lesions located in the radiation field of the previous radiotherapy can be regarded as measurable lesions if the progress is confirmed; 6. Subjects with brain metastases asymptomatic or with stable symptoms after local treatment are allowed to be included in the group, as long as the subjects meet the following conditions:\n\n1. There are measurable lesions outside the central nervous system;\n2. no symptoms of the central nervous system or no worsening of symptoms within at least 2 weeks;\n3. No need for glucocorticoid therapy, or stop glucocorticoid therapy within 7 days before the first administration, or the dosage of glucocorticoid is stable and reduced to less than 10mg\/day prednisone (or equivalent dose) within 7 days before the first administration ; 7. Subjects are allowed to receive palliative radiotherapy (including craniocerebral radiotherapy for symptomatic brain metastases), but the radiotherapy must be completed at least 1 week before enrollment, and the radiotherapy-related toxicity should be restored to less than or equal to 1 degree (CTCAE 5.0, except for hair loss).\n\n8. ECOG score 0-1 points; 9. Expected survival time\\> 3 months; 10. Sufficient organ function, subjects need to meet the following laboratory indicators:\n\n1. The absolute value of neutrophils (ANC) \u22651.5x109\/L when no granulocyte colony-stimulating factor is used in the past 14 days;\n2. In the case of no blood transfusion in the past 14 days, platelets \u2265100\u00d7109\/L;\n3. In the past 14 days without blood transfusion or erythropoietin, hemoglobin\\>9g\/dL;\n4. Total bilirubin\u22641.5\u00d7upper limit of normal (ULN);\n5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) within \u22642.5\u00d7ULN (subjects with liver metastases are allowed to have ALT or AST \u22645\u00d7ULN);\n6. Serum creatinine \u22641.5\u00d7ULN and creatinine clearance rate (calculated by Cockcroft-Gault formula) \u226550ml\/min;\n7. Good coagulation function, defined as International Normalized Ratio (INR) or Prothrombin Time (PT) \u2264 1.5 times ULN;\n8. Normal thyroid function is defined as thyroid-stimulating hormone (TSH) within the normal range. If the baseline TSH is out of the normal range, subjects whose total T3 (or FT3) and FT4 are within the normal range can also be included in the group;\n9. Myocardial enzyme spectrum is within the normal range (for example, simple laboratory abnormalities that are judged by the investigator to be of no clinical significance are also allowed to be included in the group); 11. For female subjects of childbearing age, a urine or serum pregnancy test and the result should be negative within 3 days before receiving the first study drug administration (day 1 of cycle 1). If the urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is required. Women of non-bearing age are defined as at least 1 year after menopause, or have undergone surgical sterilization or hysterectomy; 12. If there is a risk of conception, all subjects (whether male or female) need to adopt a low annual failure rate during the entire treatment period until 120 days after the last study drug administration (or 180 days after the last study drug administration) Less than 1% of contraceptive measures; 13. Blood pressure can be adequately controlled with or without anti hypertensive medication, defined as blood pressure\u2264150\/ 90 mm Hg, and blood pressure was under stable control within 1 week before randomization.\n\n14. Patients must have recovered from toxicity or complications if they have previously received surgery or radiation \\> 30Gy.\n\nExclusion Criteria:\n\n* Subjects who meet the following criteria cannot be selected for this study:\n\n  1. The pathology is small cell lung cancer (SCLC), including lung cancer mixed with SCLC and NSCLC;\n  2. There is imaging evidence of tumor voids, tumor inclusion or invasion of large vessels. In addition, the proximity of the tumor to the large blood duct should be considered and the risk of severe bleeding associated with tumor shrinkage\/necrosis after lenvatinib treatment should be excluded. (The large vessels in the chest include the main pulmonary artery, left pulmonary artery, right pulmonary artery, 4 pulmonary veins, superior vena cava, inferior vena cava and aorta);\n  3. To cohort A: subjects who have previously used anti-PD-1, PD-L1 or other immunotherapy and meet the following conditions:\n\n  <!-- -->\n\n  1. The toxicity that caused permanent discontinuation occurred before the termination of immunotherapy;\n  2. Prior to the administration of the study drug, the toxicity of the previous immunotherapy has not recovered or has not recovered to level 0-1. Asymptomatic and stable control of endocrine toxicity level 2 with appropriate replacement therapy is allowed to enter the group;\n  3. Adverse events that require additional immunosuppressive agents in addition to corticosteroids, or adverse events that still recur in the use of corticosteroids during previous immunotherapy.\n\nTo cohort B and C: Prior treatment: anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs or drugs that target another stimulating or co-inhibiting T-cell receptor (including but not limited to CTLA-4, OX-40, CD137, etc.); Anti-pd-1, anti-PD-L1, or anti-PD-L2 drugs or drugs that target another stimulating or co-inhibiting T cell receptor (including but not limited to CTLA-4, OX-40, CD137, etc.); 4. Have received the following treatments:\n\n1. Received systemic anti-tumor therapy within 2 weeks before treatment, such as chemotherapy, targeted therapy, immunotherapy (including Chinese herbal medicine with anti-tumor indications), etc.;\n2. Previously received lenvatinib, bevacizumab, anlotinib monotherapy, or in combination with anti-PD-1 \/ PD-L1 drugs\n3. Have received any investigational drug treatment within 4 weeks before treatment;\n4. Received large doses of immunosuppressive drugs within 4 weeks before treatment (systemic glucocorticoid exceeding 10mg\/day prednisone or its equivalent dose);\n5. Received live attenuated vaccine within 4 weeks before treatment (or plan to receive live attenuated vaccine during the study period);\n6. Have received major surgery (such as open cavity, thoracotomy, or Kaifu surgery), or unhealed surgical wounds, ulcers or fractures within 4 weeks before treatment.\n\n5. Clinically significant cardiovascular damage occurred within 12 months of the first dose of study treatment.\n\n6. Gastrointestinal diseases that may affect oral absorption of study drugs. 7. Prior gastrointestinal or grade \u22653 non-gastrointestinal fistula. 8. A history of other malignancies is known, and unless the participant has undergone potentially curative treatment, there is no evidence of disease recurrence in the 3 years since the start of that treatment.\n\n9. Severe allergy to IBI318 and lenvatinib. 10. There is clinically uncontrollable pleural effusion\/abdominal effusion (subjects who do not need to drain the effusion or stop drainage for 3 days without a significant increase in effusion can be included in the group); 11. Subjects who have received thoracic radiotherapy of greater than 30 Gy within 6 months before treatment or palliative radiotherapy of 30 Gy or less within 7 days before treatment (allowing palliative treatment of bone lesions or intracranial lesions) Radiation Therapy); 12. An active autoimmune disease that requires systemic treatment (such as the use of disease-relieving drugs, glucocorticoids, or immunosuppressive agents) occurred within 2 years before the first administration. Alternative therapies (such as thyroxine, insulin, or physiological glucocorticoids for adrenal or pituitary insufficiency, etc.) are not considered systemic treatments; 13. Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation; 14. Before starting treatment, have not fully recovered from toxicity and\/or complications caused by any intervention (ie, \u2264 Grade 1 or reached baseline, excluding fatigue or hair loss); 15. Known history of human immunodeficiency virus (HIV) infection (ie HIV 1\/2 antibody positive); 16. Untreated active hepatitis B (defined as HBsAg positive and the number of HBV-DNA copies detected at the same time is greater than the upper limit of the normal value of the laboratory department of the research center);\n\nNote: Hepatitis B subjects who meet the following criteria can also be included in the group:\n\n1. Before the first administration, the HBV viral load is less than 1000 copies\/ml (200 IU\/ml), and the subject should receive anti-HBV treatment during the entire study chemotherapy drug treatment to avoid viral reactivation\n2. For subjects with anti-HBc (+), HBsAg (-), anti-HBs (-) and HBV viral load (-), there is no need to receive preventive anti-HBV treatment, but close monitoring of virus reactivation is required 17. Active HCV infected subjects (HCV antibody-positive and HCV-RNA level is higher than the lower limit of detection); 18. Live vaccines have been vaccinated within 30 days before the first administration (cycle 1, day 1); Note: It is allowed to receive inactivated virus vaccine for seasonal influenza injection within 30 days before the first administration; however, it is not allowed to receive live attenuated influenza vaccine for intranasal administration.\n\n19. Pregnant or lactating women; 20. There are any serious or uncontrollable systemic diseases, such as:\n\n1. The resting electrocardiogram has major abnormalities in rhythm, conduction or morphology that are severe and difficult to control, such as complete left bundle branch block, heart block above degree II, ventricular arrhythmia or atrial fibrillation;\n2. Left ventricular ejection fraction (LVEF) was lower than normal; 3\uff09QTc interval is extended to more than 480 ms\uff1b\n\n4) Unstable angina pectoris, congestive heart failure, chronic heart failure of New York Heart Association (NYHA) grade \u2265 2; 5) Myocardial infarction occurred within 6 months before enrollment; 6) A history of non-infectious pneumonia requiring glucocorticoid treatment within 1 year before the first administration, or current clinically active interstitial lung disease; 7) Active tuberculosis; 8) There is an active or uncontrolled infection that requires systemic treatment; 9) There is clinically active diverticulitis, abdominal abscess, gastrointestinal obstruction; 10) Liver diseases such as liver cirrhosis, decompensated liver disease, acute or chronic active hepatitis; 11) Poor control of diabetes (fasting blood glucose (FBG)\\> 10mmol\/L); 12) Urine routines suggest that urine protein is \u2265++, and the 24-hour urine protein quantification is confirmed to be greater than 1.0 g; 13) Subjects who have mental disorders and cannot cooperate with treatment; 21. The medical history or disease evidence, abnormal treatment or laboratory test values that may interfere with the test results, prevent the subject from participating in the study, or the investigator believes that it is not suitable for inclusion this research.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"04777084001","EMAIL":[{"email":"zhangyongchang@csu.edu.cn"}],"GEO":[28.19874,112.97087]},{"TITLE":"Prospective Trial of Induction Immunotherapy in Locally Advanced or Oligometastatic NSCLC Without a Primary Curative Option","CRITERIA":"Inclusion Criteria:\n\n* newly diagnosed NSCLC\n* histologically or cytologically proven\n* stage III - IVA (oligometastatic) by complete staging\n* ECOG 0-2\n* life expectancy 3 months\n* ability to provide written informed consent\n\nExclusion Criteria:\n\n* primary resectability\n* primary definitive chemoradiotherapy feasible","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04926584001","EMAIL":[{"email":"studienbuero@klinikum-esslingen.de"}],"GEO":[48.73961,9.30473]},{"TITLE":"ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\nPhase 1a Monotherapy Dose Escalation and Exploration:\n\n* Pathologically documented advanced stage solid tumor\n* Progressed following all standard treatment or not appropriate for standard treatment\n* HER2 mutation, HER2 amplification or HER2 positive based on local testing\n\nPhase 1b Monotherapy\n\n* Pathologically documented unresectable and\/or metastatic non-squamous NSCLC\n* HER2 mutation identified by tissue (fresh or archival) or ctDNA. Local testing for up to 20 patients the remainder centrally confirmed.\n* Measurable disease\n* No known epidermal growth factor receptor (EGFR), ROS1, anaplastic lymphoma kinase (ALK), or BRAF V600E mutation\n* Progressed after receiving at least 1 prior systemic therapy including a platinum-based chemotherapy with or without immunotherapy, or not appropriate for standard treatment.\n* No prior HER2 tyrosine kinase inhibitor. Prior HER2 directed antibodies or anti-body drug conjugates are allowed\n* No limit on prior number of therapies\n\nPhase 1a Combination with T-DXd\n\n* Pathologically documented advanced stage NSCLC\n* Progressed after receiving at least 1 prior systemic therapy.\n* HER2 mutation based on local\/historical testing of tissue or circulating tumor DNA\n* No known EGFR, ROS1, ALK, or BRAF V600E mutation\n* No prior T-DXd\n* No clinically severe pulmonary compromise\n* No limit on prior number of therapies\n\nPhase 1a Combination Breast Cancer\n\n* Documented HER2 positive (Immunohistochemical \\[IHC\\] 3+ or IHC2+\/in situ hybridization (ISH+) breast cancer\n* Must have previously received trastuzumab, a taxane, and T-DXd (if available and appropriate) in the metastatic setting.\n* No limit on prior number of therapies\n* No prior T-DM1\n\nAll Phases\n\n* Eastern Cooperative Oncology Group performance status of 0-1\n* Left ventricular ejection fraction \u2265 50%\n* Platelet count \u2265 100 x 109\/L\n* Hemoglobin \u2265 8.5 g\/dL\n* Absolute neutrophil count \u22651.0 x 109\/L\n* Total bilirubin \\< 1.5 times upper limit of normal range (ULN), except for patients with Gilbert's syndrome\n* Aspartate aminotransferase (AST), alanine aminotransferase (ALT) \\< 3 times ULN. In the setting of liver metastases \\< 5 times ULN.\n* Creatinine clearance \u2265 60 mL\/minute\n\nExclusion Criteria All Phases:\n\n* Severe cardiac arrhythmias, requiring treatment, symptomatic congestive heart failure, myocardial infarction within 28 days prior to first dose, or unstable angina.\n* Another active malignancy within 2 years except basal cell skin cancer and carcinoma in situ treated curatively\n* Active or chronic liver disease\n* Active infection requiring systemic therapy within 14 days before the first dose\n* Brain lesion requiring immediate local therapy\n* Leptomeningeal disease\n* Uncontrolled seizures\n* Corrected QT interval (QTc) of \\>470 milliseconds (ms) females or \\>450 ms for males by Fridericia (QTcF)","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05650879039","EMAIL":[{}],"GEO":[25.04776,121.53185]},{"TITLE":"Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Patient must have pathologically-confirmed and previously untreated:\n\n   * Non-small cell lung cancer, Stage IIIA (T1-3 N2 M0); OR\n   * Localized esophageal cancer, \u2265T2, or N+, and M0 according to the American Joint Committee on Cancer (AJCC) 7th edition staging.\n2. The planned treatment regimen must be concurrent chemoradiation with Carboplatin-Paclitaxel followed by surgery.\n3. Age \\> 18 years.\n4. Eastern Cooperative Oncology Group (ECOG) performance status is 0-1.\n5. Laboratory studies must meet each of the following criteria (with labs drawn within 4 weeks prior to the registration):\n\n   * Absolute neutrophil count (ANC) \u2265 1,500 cells\/mm3\n   * Platelets \u2265100,000 cells\/mm3\n   * Hemoglobin \u2265 8.0 g\/dl (Note: The use of transfusion or other intervention to achieve Hgb \u2265 8.0 g\/dl is acceptable)\n   * Creatinine \u22642 X the upper limit of normal\n   * Bilirubin \u2264 1.5 X upper limit of normal\n   * Aspartate transaminase (AST) \u2264 3 X upper limit of normal\n6. Men and women of childbearing potential must be willing to exercise an effective form of birth control (abstinence\/contraception) while on study and for 3 months after therapy completed.\n7. Patients must be able to read and write English to comply with the questionnaire portions of the protocol.\n8. Subjects must sign a written informed study consent and HIPAA consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment and follow up.\n\nExclusion Criteria:\n\n1. Patients who have had previous radiotherapy in the thorax.\n2. Patients who have a history of ataxia telangiectasia or other documented history of radiation hypersensitivity.\n3. Patients who have a history scleroderma or other active connective tissue disease.\n4. Women of childbearing potential must not be pregnant with a negative urine pregnancy test within 72 hours prior to registration and non-lactating; postmenopausal woman must have been amenorrheic for at least 12 months to be considered of non-childbearing potential; woman status post oophorectomy or hysterectomy are considered non-childbearing potential\n5. Patients who have uncontrolled inter-current illness including, but not limited to, psychiatric illness\/social situations that would limit compliance with study requirements.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03094884001","EMAIL":[{"email":"joshua.meyer@fccc.edu"}],"GEO":[39.95233,-75.16379]},{"TITLE":"Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)","CRITERIA":"Inclusion Criteria:\n\n* a) histologically confirmed diagnosis of advanced NSCLC with ALK rearrangement detection by NGS (ALK+ NSCLCs patients detected at diagnosis by in hybridization (FISH), immunohistochememistry (IHC), or reverse transcriptase-PCR (RT-PCR) can be included if adequate tissue for NGS is available)\n\n  b) to have received upfront treatment with alectinib, brigatinib or lorlatinib for at least 28 days\n\n  c) ECOG PS 0-2\n\n  d) adult patients (aged \u2265 18 years) at the moment of diagnosis\n\n  e) signing of informed consent approved by the local Ethic Committee\n\nExclusion Criteria:\n\na) Diagnosis of lung cancer without ALK rearrangement\n\na) early withdrawn of treatment due to toxicity without evidence of radiological disease progression cannot be eligible for the study","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06234579001","EMAIL":[{"email":"emilio.bria@policlinicogemelli.it"}],"GEO":[41.89193,12.51133]},{"TITLE":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","CRITERIA":"Inclusion Criteria\n\n* Patient must be \u2265 18yrs of age.\n* Patient must have the ability to understand, and the willingness to sign, a written informed consent form.\n* Patient has been on a stable or decreasing dose of steroids for at least five days prior to the date of informed consent.\n* Any toxicity from prior therapy must be resolved or at maximum Grade 1 prior to initiation of NEO212.\n* If progression of disease occurs within 90 days or conformal radiation, the progression\/recurrence must be outside of the radiation field or proven by biopsy\/resection.\n* Patient with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype must have a Karnofsky Performance Status (KPS) of \u2265 60.\n* Patient with select solid tumors must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Patient must have an expected survival or at least three months.\n* Patient must have a baseline MRI of the brain with gadolinium within 14 days of administration of NEO212.\n* Patient must have a baseline CT scan with IV contrast and oral contrast of neck, chest, abdomen and pelvis within 14 days of administration of NEO212.\n* Patients must be able to comply with all study assessments.\n* If patient suffers from seizures (s)he must be controlled on a stable dose of anti-epileptics for 14-days prior to the date of informed consent.\n* Patient must have adequate organ and marrow function as follows:\n* Absolute neutrophil count \u2265 1,500\/microliter\n* Platelets \u2265 100,000\/microliter\n* Total bilirubin within normal institutional limits\n* AST (SGOT) \/ ALT (SPGT) \u2264 2.5 x institutional upper limit of normal\n* Creatinine clearance (CrCl) of \\>60 mL\/min (using the Cockcroft-Gault formula or 24-hour urine collection).\n* Female patients of child-bearing potential and male patients must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for 30 days prior to the first dose of NEO212, for the duration of study participation, and for 90 days following completion of therapy.\n\n  * 1. A female of child-bearing potential is any women (regardless of sexual orientation, not having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n\n    * Has not undergone a hysterectomy or bilateral oophorectomy; or\n    * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has not had menses at any time in the preceding 12 consecutive months).\n    * A negative serum pregnancy test will be required of all female patients of child-bearing potential within seven days prior to the receipt of NEO212.\n    * A serum pregnancy test will be repeated immediately if pregnancy is suspected.\n\nPhase 1: (dose escalation)\n\n1. Patient must:\n\n   * have radiographically confirmed Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype following previous radiation therapy or treatment with temozolomide and radiation, or\n   * have select solid tumors with uncontrolled metastases to the brain (confirmed by cranial CT or MRI) that is not controlled by surgery or radiation therapy and receiving one of the protocol approved SOC regimens.\n2. Patients receiving prior systemic therapy must have a minimum wash-out period (defined as the period prior to receipt of the first dose of NEO212) of:\n\n   * 28 days or 5 half-lives (whichever is shorter) elapsed from the administration from any experimental agent;\n   * 2 weeks from administration of immunotherapies;\n   * 28 days from administration of cytotoxic agents; and\n   * 7 days from administration of non-cytotoxic agents (interferon, tamoxifen, thalidomide, cis-retinoic acid, and herbal medicine).\n\nNOTE: No washout is necessary for alternating electrical fields.\n\nPhase 2a: (safety run-in)\n\n1. Patient must have select solid tumors with uncontrolled metastases to the brain (confirmed by cranial CT or MRI) that is not controlled by surgery or radiation therapy and receiving one of the protocol approved SOC regimens.\n2. Patients receiving prior systemic therapy must be receiving one of the protocol approved Standard of Care (SOC) regimens.\n3. Patient must have measurable\/evaluable CNS disease per RANO or RANO-BM criteria.\n4. Patient must have measurable\/evaluable systemic disease per RECIST v1.1 criteria.\n\nPhase 2b: (efficacy)\n\n1. Patient must:\n\n   * have radiographically confirmed Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype following previous radiation therapy or treatment with temozolomide and radiation, or\n   * have select solid tumors with uncontrolled metastases to the brain (confirmed by cranial CT or MRI) that is not controlled by surgery or radiation therapy and receiving one of the protocol approved SOC regimens.\n2. Patients receiving prior systemic therapy must be receiving one of the protocol approved Standard of Care (SOC) regimens.\n3. Patient must have measurable\/evaluable CNS disease per RANO or RANO-BM criteria.\n4. Patient must have measurable\/evaluable systemic disease per RECIST v1.1 criteria.\n5. Creatinine clearance (CrCl) of \\>60 mL\/min (using the Cockcroft-Gault formula or 24-hour urine collection).Female patients of child-bearing potential and male patients must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for 30 days prior to the first dose of NEO212, for the duration of study participation, and for 90 days following completion of therapy\n\nExclusion Criteria: (all Phases)\n\n1. Patient in Phase 1 concurrently receiving any other antitumor therapy.\n2. Patient in Phase 2a or 2b who is concurrently receiving any SOC therapy not listed in Appendix 1.\n3. Patients with metastases to the spinal cord parenchyma.\n4. Patients with metastases to the meninges.\n5. Patient has had more than one recurrence or progression of his\/her CNS tumor(s).\n6. Patient has received stereotactic or highly conformal radiotherapy to CNS lesions within 2 weeks before receipt of NEO212.\n7. Patient with history of known leptomeningeal involvement.\n8. Patient has prior history or new diagnosis of secondary cancer within five years prior to the date of informed consent, except for basal cell carcinoma or squamous cell carcinoma of the skin.\n9. Patient has a corrected QT interval (using Fridericia's correction formula) (QTcF) of \\> 470 msec, , a history of additional risk factors for TdP (e.g. heart failure, hypokalemia), and\/or the use of concomitant medications that prolong QT\/QTc interval.\n10. Patient had surgery within 7 days prior to the date of informed consent.\n11. Patient has not recovered to Grade 1 from treatment related adverse events due to chemotherapy, immunotherapy, or radiation therapy.\n12. Patient had prior treatment with perillyl alcohol.\n13. Patient has a history of allergic reactions attributed to perillyl alcohol.\n14. Patients with an autoimmune disease that required systemic therapy or a medical condition that requires immunosuppression.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06047379002","EMAIL":[{},{}],"GEO":[47.25288,-122.44429]},{"TITLE":"The Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer (STRESS-LUNG)","CRITERIA":"Cohort 1 (STRESS-LUNG-1):\n\nInclusion Criteria:\n\n1. Age \u2265 18 years;\n2. Histologically confirmed diagnosis of NSCLC;\n3. Unresectable locally advanced, metastatic, or recurrent stage \u2162B-\u2163 based on AJCC TNM staging 8th edition;\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;\n5. Systematic treatments naive ( e. g., chemotherapy, anti-angiogenic drugs, targeted drugs, and immunotherapy );\n6. Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1) ;\n7. Receiving PD-1\/PD-L1 inhibitors monotherapy or combination with chemotherapy;\n8. Informed and agreed to participate in the study;\n\nExclusion Criteria:\n\n1. Epidermal growth factor receptor (EGFR)-sensitizing mutation and\/or anaplastic lymphoma kinase (ALK) gene and\/or ROS proto-oncogene 1 (ROS1) fusion-positive;\n2. Combined with other malignant tumors in the past 3 years;\n3. Concurrent acute or chronic psychiatric disorders;\n4. Current receiving anti-depressive or anti-anxiety therapy;\n5. Previous treatment with other clinical drug trials;\n6. Patients with symptomatic brain metastasis;\n7. Can't cooperate with psychological scale assessment;\n\nCohort 2 (STRESS-LUNG-2):\n\n1. Age \u2265 18 years\uff1b\n2. Pathologically diagnosed as small cell lung cancer\uff1b\n3. Unresectable locally advanced, metastatic, or recurrent stage \u2162-\u2163 based on AJCC TNM staging 8th edition;\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;\n5. Systematic treatments naive ( e. g., chemotherapy, anti-angiogenic drugs, targeted drugs, and immunotherapy );\n6. Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1) ;\n7. Receiving PD-1\/PD-L1 inhibitors monotherapy or combination with chemotherapy;\n8. Informed and agreed to participate in the study;\n\nExclusion Criteria:\n\n1. Combined with other malignant tumors in the past 3 years;\n2. Concurrent acute or chronic psychiatric disorders;\n3. Current receiving anti-depressive or anti-anxiety therapy;\n4. Previous treatment with other clinical drug trials;\n5. Patients with symptomatic brain metastasis;\n6. Can't cooperate with psychological scale assessment;\n\nCohort 3 (STRESS-LUNG-3):\n\n1. Age \u226518 years \uff1b\n2. Pathologically diagnosed as non-small cell lung cancer;\n3. Resectable clinical stage IB-IIIB based on AJCC TNM staging 8th edition;\n4. At least one measurable lesion can be evaluated according to the RECIST 1.1 standard\uff1b\n5. Systematic treatments naive ( e. g., chemotherapy, anti-angiogenic drugs, targeted drugs, and immunotherapy );\n6. Receiving PD-1\/PD-L1 inhibitors combined with chemotherapy as neoadjuvant therapy.\n\n6. Cardiopulmonary function can withstand surgery; 7. Informed and agreed to participate in the study;\n\nExclusion Criteria:\n\n1. Epidermal growth factor receptor (EGFR)-sensitizing mutation and\/or anaplastic lymphoma kinase (ALK) gene and\/or ROS proto-oncogene 1 (ROS1) fusion-positive;\n2. Combined with other malignant tumors in the past 3 years;\n3. Concurrent acute or chronic psychiatric disorders;\n4. Current receiving anti-depressive or anti-anxiety therapy;\n5. Previous treatment with other clinical drug trials;\n6. Can't cooperate with psychological scale assessment;\n\nCohort 4 (STRESS-LUNG-4):\n\n1. Age \u226518 years;\n2. Pathologically diagnosed as non-small-cell lung cancer\uff1b\n3. Pathologically stage conformed as early stage of IA-IIIA\n4. Available for tumor tissue samples\uff1b\n5. Systematic treatments naive ( e. g., chemotherapy, anti-angiogenic drugs, targeted drugs, and immunotherapy );\n6. Receiving radical surgery;\n7. Informed and agreed to participate in the study;\n\nExclusion Criteria:\n\n1. Combined with other malignant tumors in the past 3 years;\n2. Concurrent acute or chronic psychiatric disorders;\n3. Current receiving anti-depressive or anti-anxiety therapy;\n4. Previous treatment with other clinical drug trials;\n5. Can't cooperate with psychological scale assessment;","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05477979001","EMAIL":[{"email":"wufang4461@csu.edu.cn"}],"GEO":[28.19874,112.97087]},{"TITLE":"Phase II Umbrella Study Directed by Next Generation Sequencing","CRITERIA":"Inclusion Criteria:\n\n1. Histologically or cytologically confirmed, unresectable stage IIIB or stage IV NSCLC\n2. Patients who have never received any anticancer treatment regimen Note: Patients that have received adjuvant or neoadjuvant chemotherapy and developed metastatic disease after 12 months from the end of that therapy would be eligible for enrollment.\n3. Measurable disease according to RECIST v.1.1 (Irradiated lesions are not considered measurable unless they have clearly progressed since radiotherapy)\n4. With or without brain or leptomeningeal metastasis (BM\/LM). For patients with symptoms of BM\/LM, no need for local therapy should be confirmed by investigator and no dramatic decline of performance status in 2 weeks.\n5. ECOG performance status \u2264 2\n6. Expected survival \\> 12 weeks\n7. Patients must be suitable and willing to undergo mandatory tumor biopsy according to treating institution's guidelines and requirements for such procedure if there is no archival biopsy available.\n8. Provision of signed and dated written informed consent by the patient or legally acceptable representative prior to any study-specific procedures.\n9. Palliative radiotherapy was allowed before enrollment, and radiotherapy-related toxicity grade should no more than 1 (ctcae4.03).\n10. No anti-tumor Chinese medicine has been used in the past, or has been used for no more than 3 doses, and stopped for more than 2 weeks before enrollment.\n11. Absolute neutrophil count (ANC) \u2265 1.5x10\\^9\/L without the use of growth factor in the past 14 days. Platelets \u2265 90 \u00d7 10\\^9\/L without blood transfusion in the past 14 days. Hemoglobin \\> 9g\/dL.\n12. Negative pregnancy test (only for women with pregnancy possibility). No possibility of pregnancy defined as at least one year after menopause, or having undergone surgical sterilization or hysterectomy. All patients (male or female) agreed to take contraceptive measures during the treatment and within 8 weeks after the treatment.\n\nExclusion Criteria:\n\n1. Active hepatitis (HBsAg positive and HBV copy number in upper limit of normal)\n2. Previous or current active interstitial lung disease (ILD)\n3. Patients known to be HIV positive or with other acquired, congenital immunodeficiency diseases, or with a medical history of organ transplantation.\n4. Major surgery \u2264 2 weeks prior to study entry.\n5. Any other malignancies within the last 5 years before study enrollment, except for un completely resected basal cell carcinoma, in situ bladder cancer, cervical carcinoma in situ.\n6. Patients previously treated with the investigational drugs or known to be allergic to ingredients or excipients of the investigational drugs.\n7. Pregnant or lactating women.\n8. Patients with swallowing dysfunction, active gastrointestinal disease or other diseases that significantly affect the absorption, distribution, metabolism and excretion of oral drugs. The patients who have had subtotal gastrectomy before. (this standard is applicable to the arms with oral drugs only)\n9. Body temperature above 38 \u2103 in the past week, or there was active infection with clinical significance. Active tuberculosis;\n10. Evidence of serious or uncontrollable systemic diseases (such as severe mental, neurological, epilepsy or dementia, unstable or uncompensated respiratory, cardiovascular, liver or kidney diseases, uncontrolled hypertension \\[higher than CTCAE Level 3 hypertension after drug treatment\\]);\n11. Patients with bleeding tendency or taking anticoagulants ;\n12. There are significant clinical abnormalities in rhythm, conduction or morphology of resting ECG, such as complete left bundle branch block, heart block above degree II, clinically significant ventricular arrhythmia or atrial fibrillation, unstable angina, congestive heart failure, chronic heart failure with NYHA grade \u2265 2.\n13. Myocardial infarction, coronary \/ peripheral artery bypass or cerebrovascular accident occurred within 3 months.\n14. QTc of 12 lead ECG was \u2265 450 ms in male and \u2265 470 ms in female;\n15. Diagnosed with another malignant disease in the past five years besides NSCLC.\n16. More than 30% of the bone marrow had received radiotherapy within 4 weeks before treatment.\n17. Any drugs known to extend QT interval were being used within 2 weeks prior to first administration.\n18. Strong CYP3A4 inhibitor\/inductionor or CYP3A4 substrate were used within 2 weeks, including but not limited to azanavir, clarithromycin, inddenavir, itraconazole, ketoconazole, nefazodone, nefinavir, ritonavir, xaquinavir, talicamycin, acesodamycin, voriconazole, carbamazepine, phenobarbital, phenytoin, rifampin, rifampin, Hypericum perforatum, dihydroergotamine, ergotamine, pimozite, astemizole, cisapride and terfenadine.\n19. Strong P-gp inhibitor was used within 2 weeks (including but not limited to verapamil, cyclosporine A and right verapamil).\n20. Other potential risks that are not suitable for the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03574402001","EMAIL":[{"email":"syylwu@live.cn"},{"email":"gzzhouqing@126.com"}],"GEO":[23.11667,113.25]},{"TITLE":"Effect and Long-Term Outcomes of Indocyanine Green Fluorescence Imaging Method Versus Modified Inflation-Deflation Method in Identification of Intersegmental Plane\uff08IMPLANE-0529\uff09","CRITERIA":"Inclusion Criteria:\n\n1. Aged 18 to 80 years old;\n2. According to the surgical standards of the Eighth edition of People's Medical Publishing House, patients whose blood pressure was under 160\/100mmHg and blood glucose was under 5.6-11.2mmol \/L with normal functions of major organs such as heart, lung, liver and kidney before surgery are included. The main criteria are as follows:\n\n   i. Cardiac function examination indicated Goldman index grade 1-2; ii. Pulmonary function examination suggested postoperative predicted FEV1\u226540% and DLCO\u226540%; iii. Total bilirubin \u22641.5 times the upper limit of normal; iv. Alanine aminotransferase and aspartate aminotransferase \u22642.5 times the upper limit of normal value; v. Creatinine \u22641.25 times the upper limit of normal value and creatinine clearance \u226560ml\/min;\n3. The center of the lesion is located in the other lobes except the middle lobe, and in the middle and outer third of the lung;\n4. The maximum diameter of the tumor was not more than 2cm on TLC(Thin layer CT) scan and the clinical stage was cT1a-1bN0M0(according to AJCC staging criteria, eighth edition);\n5. Consolidation tumor rate \\<1\uff1b\n6. ECOG PSscore 0-1;\n7. All relevant examinations should be completed within 28 days before surgery;\n8. Patients who understand the study and have signed informed consent.\n\nExclusion Criteria:\n\n1. Patient with a history of iodine or indocyanine green allergy;\n2. Patient who had received antitumor therapy (radiotherapy, chemotherapy, targeted therapy, immunotherapy) prior to surgery;\n3. Patient with a history of other malignancies;\n4. Patient with secondary primary cancer at enrollment;\n5. Small cell lung cancer;\n6. Prior history of unilateral thoracotomy;\n7. Woman in pregnant or breastfeeding period;\n8. Patient with interstitial pneumonia, pulmonary fibrosis or severe emphysema;\n9. An active bacterial or fungal infection that is difficult to control;\n10. Severe mental illness;\n11. History of severe heart disease , heart failure , myocardial infarction or angina pectoris within the last 6 months;\n12. patient that researcher considers inappropriate to participate in this study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"05453721001","EMAIL":[{"email":"tangjianku@yeah.net"},{"email":"ciccy516615@163.com"}],"GEO":[28.68396,115.85306]},{"TITLE":"LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib","CRITERIA":"Inclusion Criteria:\n\n1. Male or female, \u2265 18 years of age\n2. Established histological diagnosis of advanced NSCLC, not suitable for radical treatment, with an EGFR actionable mutation receiving first-line targeted TKI therapy with osimertinib\n3. Initial radiologically confirmed response (at least stable disease) to osimertinib assessed 3 months post commencing osimertinib according to RECIST criteria v1.1.\n4. Confirmed OPD defined as \u2264 3 intra- and extracranial sites of progressive disease. OP may be defined as progression of an individual metastasis according to RECIST or on 2 consecutive imaging studies at least 2 months apart with a minimum of 5mm increase in size from baseline or an unambiguous development of a new metastatic lesion with a grand total of 3 lesions. All sites must be visible, imaging defined targets, not previously treated with radiation or radiofrequency and suitable for treatment with LAT as determined by the local multi-disciplinary team (MDT).\n5. Adequate baseline organ function to allow LAT to all the OP targets.\n6. Predicted life expectancy \u2265 6 months\n7. Karnofsky Index \u2265 60% and ECOG 0-2\n8. Provision of written informed consent\n9. Female participants must be surgically sterile or postmenopausal if SBRT is planned to the abdominal area or must agree to use effective contraception during the period of therapy.\n\nExclusion Criteria:\n\n1. \\> 3 sites of progressive disease\n2. Oligoprogressive metastases not amenable to LAT\n3. Radiotherapy or radiofrequency ablation near the OP lesion prior to the inclusion in the LAT-FLOSI study\n4. Co-morbidities considered clinically precluding the safe use of LAT\n5. Any psychological, sociological or geographical issue potentially hampering compliance with the study\n6. Pregnancy","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04216121001","EMAIL":[{},{},{},{},{}],"GEO":[50.87959,4.70093]},{"TITLE":"Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.","CRITERIA":"Inclusion Criteria:\n\n1. Histologically or cytologically confirmed previously untreated non-small cell lung cancer. If a diagnostic biopsy is available, a pre-treatment biopsy is not required. Patients with a suspected lung cancer are eligible, but pathology must be confirmed prior to initiating treatment on study.\n2. Patients with stage IIIA must not have more than one mediastinal lymph node station involved by tumor.\n3. All patients must have lymph node evaluation of contralateral stations 2 and\/or 4 to exclude N3 disease.\n4. The patient must be a suitable candidate for surgery, in the opinion of the treating physician.\n5. Signed and dated written informed consent must be provided by the patient prior to admission to the study in accordance with International Conference on Harmonization-Good Clinical Practice (ICH-GCP) guidelines and to the local legislation.\n6. Eastern Cooperative Oncology Group (ECOG) performance status score 0-1.\n7. Absolute neutrophil count (ANC) \\>= 1.5 x 10\\^9\/L; Hemoglobin \\>= 8.0 g\/dL; Platelets \\>= 100 x 10\\^9\/L; Total bilirubin =\\< 1.5 x upper limit of normal (ULN) (except subjects with Gilbert syndrome who can have total bilirubin \\< 3.0 mg\/dL); Creatinine =\\< 1.5 x ULN or calculated creatinine clearance \\>= 50 mL\/min using Cockcroft-Gault formula for creatinine clearance calculation OR 24-hour urine creatinine clearance \\>= 50 mL\/min.\n\nExclusion Criteria:\n\n1. Prior systemic therapy or radiation therapy for treatment of the current lung cancer.\n2. Currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy) or investigational anti-cancer drug.\n3. Pregnant or lactating female.\n4. Unwillingness or inability to follow the procedures required in the protocol.\n5. Patients with pre-existing sensorineural hearing impairment\/loss or newly diagnosed as documented by an audiology assessment performed prior to study enrollment may not be eligible for cisplatin and may be dispositioned to carboplatin, as determined by the treating physician.\n6. Patients with a history of severe hypersensitivity reaction to taxotere and or polysorbate 80 must be excluded.\n7. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results.\n8. Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.\n9. Subjects with a condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses \\> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted, even if \\> 10 mg\/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permitted.\n10. Prior treatment with an anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibody.\n11. Known positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid indicating acute or chronic infection.\n12. Known history of testing positive for human immunodeficiency virus or known acquired immunodeficiency syndrome.\n13. History of severe hypersensitivity reaction to any monoclonal antibody and\/or to study drug components.\n14. Serious illness or concomitant non-oncological disease such as neurologic, psychiatric, infectious disease or laboratory abnormality that may increase the risk associated with study participation or study drug administration and in the judgment of the investigator would make the patient inappropriate for entry into the study.\n15. Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule.\n16. Allergic to contrast agent.\n17. Any agents which could affect the absorption or pharmacokinetics of the study drugs.\n18. Other conditions that investigator decides not suitable for the trial.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06492421001","EMAIL":[{"email":"zhangzhf@gzhmu.edu.cn"}],"GEO":[50.87959,4.70093]},{"TITLE":"Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo\/Immunotherapy","CRITERIA":"Inclusion Criteria:\n\n* Patients must have a cytological or histological diagnosis of non-small cell lung cancer that is metastatic or unresectable for which standard curative measures do not exist.\n* No prior systemic treatment with either chemotherapy or immunotherapy for non-curative intent. Patients may have previously received cancer treatment with curative intent for prior early stage disease.\n* At least 18 years old.\n* ECOG performance status of 0-2, as determined by the treating physician in the consult note.\n* Life expectancy of greater than 3 months.\n* Patients must have radiographically measurable metastatic disease by RECIST criteria.\n* Patients must have normal organ and marrow function as defined below:\n* absolute neutrophil count \u22651,000\/mcL\n* platelets \u2265100,000\/mcL\n* Chemotherapy agents are known to be teratogenic, therefore women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n* Ability to understand and the willingness to sign an IRB-approved informed consent document.\n\nExclusion Criteria:\n\n* Nonsmall cell lung cancer that is known at registration to be positive for a tumor activating alteration for which first line targeted therapy is indicated; specifically, a targetable mutation in epidermal growth factor receptor (EGFR), gene rearrangement of anaplastic lymphoma kinase (ALK), gene rearrangement of c-ros oncogene 1 (ROS1), or mutation in B isoform of rapidly accelerated fibrosarcoma (B-Raf).\n* Known to have an active autoimmune disease that required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, systemic corticosteroids, or immunosuppressive drugs).\n* History of (non-infectious) pneumonitis that required systemic corticosteroids.\n* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\/social situations that would limit compliance with study requirements.\n* Pregnant women are excluded from this study because of the potential for teratogenic or abortifacient effects with chemotherapy. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with chemotherapy, breastfeeding should be discontinued.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04253964001","EMAIL":[{"email":"saverill@wakehealth.edu"},{}],"GEO":[36.09986,-80.24422]},{"TITLE":"Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers","CRITERIA":"Inclusion Criteria:\n\n1. Have histologically or cytologically confirmed diagnosis of neoplasia\n2. Measurable (per RECIST v1.1 criteria) metastatic cancer or locally advanced refractory\/recurrent malignancy not amenable to curative treatment. Lesions previously irradiated may be considered measurable only if growth has been documented since local treatment completion.\n3. The tumor expresses ESO as assessed immunohistochemistry of resected tissue. To this end, archived tumor tissue suitable for analysis must be available or re-biopsy performed on study. Tissue staining must encompass more than 10% of tumor section.\n4. Patients must have previously either (1) received at least first-line or second-line standard therapy for metastatic disease, if known to be effective for that disease, and have been either non-responders (progressive disease), intolerable or have recurred or (2) Recurred within 6 months of adjuvant systemic therapy known to be active also in the metastatic setting.\n5. Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and asymptomatic are eligible. Lesions that have been treated with stereotactic radiosurgery must be clinically stable for 1 month after treatment for the patient to be eligible. Patients with surgically resected brain metastases are eligible.\n6. More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients' toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo).\n7. Age \u2265 18 years and \u2264 70 years.\n8. Patient is able to understand and willing to sign a written informed consent.\n9. Clinical performance status of ECOG 0, 1 or 2.\n10. HLA-A\\*0201or A\\*0206 positive.\n11. Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after treatment.\n12. Women of child-bearing potential must have a negative pregnancy test.\n13. Serology: Seronegative for HIV antibody, hepatitis B antigen, and hepatitis C antibody. If hepatitis C antibody test is positive, then patient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative.\n14. Hematology\n\n    * ANC \\> 1500\/mm3 without the support of filgrastim\n    * WBC \u2265 3000\/mm3\n    * Platelet count \u2265 100,000\/mm3\n    * Hemoglobin \\> 8.0 g\/dL. Subjects may be transfused to reach this cut-off.\n15. Chemistry\n\n    * Serum ALT\/AST \u2264 2.5 x ULN\n    * Creatinine clearance \u226540ml\/min\n    * Total bilirubin \u2264 1.5 mg\/dL, except in patients with Gilbert's Syndrome, who must have a total bilirubin \\< 3.0 mg\/dL.\n    * INR \\< 1.5\n\nExclusion Criteria:\n\n1. Women of child-bearing potential who are pregnant or breastfeeding.\n2. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease).\n3. Active systemic infections requiring anti-infective treatment, coagulation disorders, or any other active or uncompensated major medical illnesses\n4. Concurrent systemic steroid therapy, not including replacement therapy or treatment with prednisone up to 10mg daily or its equivalent. Or any other form of immunosuppressive therapy within 7 days before the first dose of study intervention.\n5. History of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, or aldesleukin.\n6. Subjects with a history of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within 3 months.\n7. Subjects unable to maintain normal oxygen saturation level in room air.\n8. Subjects who have had a venous thromboembolic event requiring anticoagulation and who meet any of the following criteria:\n\n   * Have been on a stable dose of anticoagulation for \\< 1 month (except for acute line insertion induced thrombosis).\n   * Have had a Grade 2, 3, or 4 hemorrhage in the last 30 days or are experiencing continued symptoms from their venous thromboembolic event (e.g. continued dyspnea or oxygen requirement).\n9. Has a known additional malignancy within the last 3 years. Exceptions include early stage cancers (carcinoma in situ, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer, or in situ breast cancer that has undergone potentially curative therapy).\n10. LVEF \u2264 40%\n11. Documented FEV1 \u2264 60% predicted tested in patients with:\n\n    * A prolonged history of cigarette smoking (\u2265 20 pack-year smoking history, with cessation within the past two years).\n    * Symptoms of respiratory dysfunction.\n12. Patients who are at the time of study initiation receiving any other investigational agents.\n13. Carcinomatosis meningitis or other brain involvement exceeding that allowed above.\n14. Has received live vaccine within 30 days before the first dose of study intervention. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacillus Calmette-Gu\u00e9rin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist\u00ae) are live attenuated vaccines and are not allowed.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":70,"SS_ID":"05296564001","EMAIL":[{"email":"mlotem@hadassah.org.il"}],"GEO":[31.76904,35.21633]},{"TITLE":"BostonGene and Exigent Genomic INsight Study","CRITERIA":"Inclusion Criteria:\n\n* Patients must have a confirmed malignancy of:\n\nLocally recurrent, unresectable, or metastatic breast cancer or; Unresectable stage III or metastatic non-small cell lung cancer or; Unresectable or metastatic melanoma or; Locally advanced or metastatic l sarcoma.\n\n* Life expectancy \\> 3 months as per the treating physician\n* Willingness to provide informed consent\n* Living in the United States at time of enrollment\n* Agree to participate in genomic and molecular profiling\n\nExclusion Criteria:\n\n* not meeting the inclusion criteria","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06272864001","EMAIL":[{}],"GEO":[47.18538,-122.2929]},{"TITLE":"Phase I\/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor","CRITERIA":"Inclusion Criteria:\n\n-\n\nFor Phase I:\n\n1. Male or female, at least 18 years of age.\n2. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.\n3. Estimated life expectancy \\>12 weeks.\n4. Patients must have at least one assessable lesion in dose-escalation part and one measurable lesion in dose-expansion part per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n5. Dose-escalation Part: patients must have histological or cytological confirmed advanced solid tumours with RET alteration (fusion or mutation) and have progressed after standard therapy, or no standard or available curative therapy exists.\n\n   Dose-expansion Part: Patients with advanced tumor must have histological or cytological confirmed RET alteration, including NSCLC patients with RET-fusion or MTC patients with RET-mutation or other patients with RET alteration, and either have progressed after standard therapy or no standard\/ available curative therapy exists.\n6. Patients must have adequate organ function as defined in the below:\n\n   Hepatic function:\n\n   Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \u2264 3 times the upper limit of normal (ULN) if no hepatic metastases are present, or otherwise \u2264 5 times ULN, Total serum bilirubin (TBIL) \u2264 1.5 times ULN.\n\n   Bone marrow function (No blood transfusion or haematopoietic stimulating factor treatment within 10 days prior to testing):\n\n   Absolute neutrophil count (ANC) \u2265 1.5 x 10\u2079\/L; Platelets (PLT) count \u2265 75 x 10\u2079\/L; Hemoglobin (Hb) \u2265 85 g\/L.\n\n   Renal function:\n\n   Creatinine clearance \u2265 50 mL\/min.\n\n   Coagulation function:\n\n   Prothrombin time (PT) or International Normalized Ratio (INR) \u2264 1.5 times ULN.\n\n   Serum lipid:\n\n   Cholesterol \u2264 500mg\/dL\uff0812.92mmol\/L\uff09.\n7. Female patients with reproductive potential must have a negative serum pregnancy test within 7 days prior to the first dose, male and female patients of childbearing potential must be willing to completely abstain or agree to use an appropriate method of contraception during the entire study duration and for at least 3 months after the last dose of study medication.\n8. Willingness and ability to give informed consent and follow protocol procedures, and comply with follow-up visit requirements.\n\n   For Phase II: As for phase I with the following modifications:\n9. Participants must have histological or cytological confirmed locally advanced or metastatic RET Fusion-Positive NSCLC, have progressed following platinum-based chemotherapy and\/or PD-1\/PD-L1 immunotherapy, or have not received prior systemic therapy, or in the opinion of the Investigator, they would be unlikely to tolerate or derive significant clinical benefit from appropriate standard of care therapy, or they declined standard therapy.\n10. The participants' tumor tissue or blood sample test results meet 1 of the following 2 criteria:\n\n    1. Previous tumor tissue or blood sample confirmed positive for RET fusion by local laboratory.\n    2. If no previous positive RET fusion test report is available, a compliant tumor tissue or blood sample must be tested at a central laboratory designated by the sponsor, using a second-generation sequencing (NGS)-based assay, and confirmed as positive for RET fusion.\n\nExclusion Criteria:\n\n1. Dose-expansion Part: Patient's cancer has a known primary driver alteration other than RET. e.g. EGFR, ALK, ROS1, KRAS, etc.\n2. Dose-expansion Part: Patients previously treated with a selective RET inhibitor.\n3. Patients received systemic antitumor therapy, including chemotherapy, radiotherapy, biologic therapy, endocrine therapy, or immunotherapy within 3 weeks prior to the first dose, except for the following:\n\n   Nitrosoureas or mitomycin C within 6 weeks; Oral fluorouracils and small molecule drugs within 2 weeks or within 5 half-life periods of the drug (whichever is longer); Antitumour traditional Chinese medicine within 2 weeks.\n4. Patients received other unlisted clinical trial drugs or treatments within 4 weeks prior to the first dose.\n5. Patients underwent major organ surgery (excluding puncture biopsy) or had significant trauma within 4 weeks prior to the first dose.\n6. Adverse effects of previous anti-tumor therapy have not recovered to CTCAE 5.0 grade rating of \u2264 grade 1 (except for toxicity judged by the investigator be of no safety risk, such as alopecia, grade 2 peripheral neurotoxicity, etc.)\n7. Patients have symptomatic central nervous system (CNS) metastases, meningeal metastases, or a primary CNS tumor that is associated with progressive neurological symptoms.\n8. Patients with active uncontrolled systemic bacterial, viral, or fungal infection despite optimal treatment (chronic disease screening not required).\n9. Active hepatitis (Hepatitis B: HBsAg-positive and HBV-DNA \u2265 2000 IU\/ mL; Hepatitis B: HCV antibody-positive and HCV-RNA \u2265 1000 IU\/ml), HIV antibody-positive; Active syphilis.\n10. Patients have a history of severe cardiovascular disease, including but not limited to:\n\n    Severe cardiac rhythm or conduction abnormalities, e.g. ventricular arrhythmia requiring clinical intervention, II-III degree atrioventricular block, etc.\n\n    Mean QT interval corrected using Fridericia's formula (QTcF)\\> 480ms at rest. Acute coronary syndrome, congestive heart failure, aortic coarctation, stroke or other grade 3 or higher cardiovascular or cerebrovascular events within 6 months prior to the first dose.\n\n    New York Heart Association (NYHA) \u2265 class II heart failure or left ventricular ejection fraction (LVEF) \\< 50%.\n\n    Hypertension remains uncontrolled after aggressive antihypertensive therapy.\n11. Patients have been treated with any CYP3A inhibitors or inducers within 14 days prior to the first dose.\n12. Patients with malignancies other than tumors treated in this study (except: malignancies that are cured and have not recurred within 3 years prior to study entry; completely resected basal cell and squamous cell skin cancer; completely resected carcinoma in situ of any type).\n13. Patients are unable to swallow the drug orally, or has a condition that seriously affects gastrointestinal absorption in the judgment of the investigator.\n\n    For Phase II: As for phase I with the following modifications:\n14. Patients received any selective RET inhibitor (including marketed drugs such as selpercatinib, pralsetinib, and unmarketed experimental drugs).\n15. Patients have a history of hypersensitivity to any component or excipient of SY-5007 capsule.\n16. Patients participated in another clinical study within 4 weeks prior to the first dose or is scheduled to participate in another clinical study during the study period.\n17. Pregnant or breastfeeding female patients.\n18. Other conditions deemed by the investigator to be inappropriate for participation in this clinical trial.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05278364002","EMAIL":[{"email":"Headandneck2008@126.com"}],"GEO":[39.14222,117.17667]},{"TITLE":"A Trial of SHR-1316\/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Have previously untreated, pathologically confirmed resectable Stage II, IIIA, or Selected IIIB NSCLC. Staging should be based on the 8th edition of the AJCC\/UICC staging system\n* Evaluation by an attending thoracic surgeon to confirm eligibility for an R0 resection with curative intent\n* Adequate tumor tissue sample blocks for central programmed death-ligand 1 (PD-L1) testing\n* Measurable disease as defined by RECIST v1.1\n* Adequate organ function\n* Women of childbearing age without sterilizing or male, must agree to use contraception or practice abstinence at least 180 days after the last dose of study treatment\n\nExclusion Criteria:\n\n* Any previous systematic anti-cancer therapy for lung cancer\n* With active, known or suspected autoimmune disease of autoimmune disease\n* Malignancies other than NSCLC within 5 years prior to randomization\n* Has or suspected has a history of pneumonitis \/interstitial lung disease or any serve lung diseases which will influence the examination of lung function\n* Significant history of cardiovascular and cerebrovascular disease\n* Significant haemorrhagic disease\n* Has an arteriovenous thrombotic events\n* Has a known history of human immunodeficiency virus (HIV) infection\n* Has a known active Hepatitis B or Hepatitis C\n* Allergic to monoclonal antibodies or other protein drugs\n* Allergic to the intervention regimens\n* Pregnant or lactating women\n* Has known psychiatric or substance abuse disorders\n* Confirmed COVID-19 infection or suspected COVID-19 infection or close contact with a person with known or suspected COVID-19 infection.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":70,"SS_ID":"04316364007","EMAIL":[{}],"GEO":[30.29365,120.16142]},{"TITLE":"A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality","CRITERIA":"Inclusion Criteria:\n\n* Subjects voluntarily participate in this study and sign informed consent;\n* Between the ages of 18-75 years (subject to the date of signing the informed consent); Eastern cooperative oncology group (ECOG) score 0-1; estimated survival time \u22653 months;\n* Patients with locally advanced, metastatic, or recurrent non-small cell lung cancer that is cytologically or histologically proven to be inoperable and cannot be treated with radical concurrent chemoradiotherapy;\n* Previous standard treatments failed\uff1b\n* At least one measurable lesion (based on Response Evaluation Criteria In Solid Tumors 1.1);\n* Female participants of childbearing age should agree to use contraception during the study period and for 6 months after the end of the study; Have a negative serum pregnancy test within 7 days prior to study enrollment and must be a non-lactating subject; Male participants should agree that contraception must be used during the study period and for 6 months after the end of the study period.\n\nExclusion Criteria:\n\n* Has diagnosed and\/or treated additional malignancy within 3 years prior to take medication;\n* Adverse effects due to any prior treatment have not been restored to CommonTerminology Criteria for Adverse Events (CTCAE) 5.0 \u2264 level 1 (Excluding hair loss);\n* Major surgical treatment, incision biopsy, or significant traumatic injury were received within 28 days prior to study treatment,and minor traumatic surgery (biopsy, bronchoscopy, and chest drainage) within 7 days;\n* Long-term unhealed wounds or fractures;\n* History of interstitial lung disease, radiation pneumonia, and immune-related pneumonia treated with steroids in the past, or active non-infectious pneumonia with interstitial changes such as interstitial lung disease, radiation pneumonia, and immune-related pneumonia in the screening period, active pulmonary tuberculosis, pneumoconiosis, or other types of pneumonia \u2265 grade 2, or severe impairment of lung function confirmed by pulmonary function examination;\n* Arterial\/deep vein thrombosis events occurred within 6 months prior to treatment, such as cerebrovascular accident, deep vein thrombosis and pulmonary embolism;\n* Patients who have a history of psychotropic substance abuse and are unable to abstain or have mental disorders;\n* Patients with any severe and\/or uncontrolled disease;\n* Any anticancer therapy or any other investigational drug treatment within 28 days or 5 half-lives prior to the first dosing of this study;\n* Within 1 week prior to the first administration of this study, the Chinese patent drugs with anti-tumor indications clearly stated in the National MedicalProducts Administration approved drug instructions were treated;\n* Local focal palliative radiotherapy was received within 2 weeks before the first dose;\n* Patients with serous effusion requiring repeated drainage to relieve clinical symptoms or who have received serous effusion drainage for therapeutic purposes within 2 weeks prior to treatment;\n* There is symptomatic or progressive exacerbation of central nervous system metastatic or cancerous meningitis with diffuse spread. Subjects with a history of brain metastases may be considered for inclusion if they are clinically stable;\n* Severe bone injury caused by tumor bone metastasis, including pathological fractures and spinal cord compression that occurred within 6 months or are likely to occur in the near future;\n* Pain associated with uncontrolled bone metastases;\n* Allergic to humanized monoclonal antibody products;\n* Allergic to any investigational drug or to any ingredient or excipient in the drug;\n* Persons who have received live attenuated vaccine within 4 weeks prior to treatment;\n* Subjects who, in the investigator's judgment, have concomitant diseases that seriously endanger the safety of subjects or interfere with the completion of the study, or who are deemed unsuitable for enrollment for other reasons.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06496490001","EMAIL":[{"email":"penghaixu@163.com"}],"GEO":[26.06139,119.30611]},{"TITLE":"Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed, locally advanced or metastatic NSCLC patients, who is not suitable for surgery or radiotherapy\n* Evaluable or measurable disease per Response Evaluation Criteria in Solid Tumors(RECIST1.1)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Life expectancy \u226512 weeks\n* Must have evidence of positive c-Met protein expression by IHC from either local data or the results of molecular pre-screening evaluations\uff1bMust haved evidence of MET exon 14 skipping alterations in blood and\/or tissue samples.\n* Adequate bone marrow, hepatic, and renal function\n* Patients of child bearing potential must agree to take contraception during the study and for 3 months after the last day of treatment\n* Signed Informed Consent Form\n\nExclusion Criteria:\n\n* Prior or current treatment with the type II of c-MET inhibitor or HGF\/c-Met antibody therapy\n* Confirmed ALK or ROS1 rearrangement\n* Prior treatment with targeting agents (Including EGFR tyrosine kinase inhibitors,VEGFR TKIs,the tpye I of MET TKIs, etc.) within 14 days or 5 half-life\n* Prior treatment with anticancer agents (Including cytotoxic chemotherapy,radiotherapy, immunotherapy etc.) within 4 weeks\n* Brain\/meninges metastases unless asymptomatic, stable and not requiring steroids for maintenance\n* History of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease, radiological documentation of idiopathic pulmonary fibrosis at baseline; uncontrolled pleural effusion\/pericardial effusion\n* Any evidence of severe or uncontrolled systemic diseases, including CTCAE 2 or higher active infection, unstable angina pectoris, congestive cardiac failure and severe liver\/renal or metabolic disease\n* Active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV)\n* History of organ transplant; had surgery or severe injury within 4 weeks\n* Uncontrolled hypertension\uff08Systolic blood pressure\u2265160mmHg and\/or diastolic blood pressure\u2265100mmHg \uff09\n* Patients unable to swallow orally administered medication, prior surgical procedures affecting absorption.\n* Pregnant (positive pregnancy test) or lactating women","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"02929290007","EMAIL":[{}],"GEO":[41.79222,123.43278]},{"TITLE":"Efficacy and Safety Study of Medical Thoracoscope Cryotherapy Combined Standard First-line Treatment of Advanced Non-small Cell Lung Cancer and Malignant Pleural Effusion","CRITERIA":"Inclusion Criteria:\n\n1. 18-75 years old;\n2. Non-small cell lung cancer with pleural metastasis confirmed by histopathology or cytology;\n3. ECOG score 0-1;\n4. Cardiopulmonary function can tolerate painless thoracoscopic examination;\n5. Patients who underwent medical thoracoscopy for pleural effusion at first diagnosis and underwent medical thoracoscopy cryotherapy at the same time of biopsy were also included in the study. Non-small cell lung cancer was confirmed by pathological results;\n6. All subjects or their guardians must sign the informed consent before entering the study.\n\nExclusion Criteria:\n\n1. Expected survival \\<2 months;\n2. Hemoglobin \\<110g\/L, white blood cell count \\<3\u00d7109\/L, neutrophil \\<2.0\u00d7109\/L, platelet \\<100\u00d7109\/L;\n3. severe cardiac insufficiency, abnormal liver and kidney function (blood test results of transaminase and creatinine \\> 1.5 times the normal upper limit);\n4. have received chemotherapy or anti-angiogenic drugs (such as bevacizumab, endu, anlotinib, etc.);\n5. History of radiotherapy;\n6. history of intrathoracic local treatment;\n7. multiple serous cavity effusion, or bilateral pleural effusion;\n8. patients allergic to erythromycin;\n9. the lung cannot be reopened.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05291403001","EMAIL":[{"email":"qiqianqlh@163.com"}],"GEO":[36.66833,116.99722]},{"TITLE":"Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC","CRITERIA":"Inclusion Criteria\n\n1. Informed consent has been signed and, in the judgment of the investigator, the patient is able to comply with the study protocol and sign a written informed consent.\n2. Participants diagnosed with stage IIIB or above non-small cell lung cancer confirmed by histopathology (whether newly diagnosed or not) meet the requirements of SBRT radiotherapy (mass limited, less than 5 cm) and immune checkpoint inhibitor therapy (according to CSCO guidelines).\n3. Age \u2265 18 and less than 75.\n4. Eastern Cooperative Oncology Group Performance Status Score (ECOG PS) 0-3.\n\nExclusion Criteria\n\n1. The participant's compliance is poor and the test regulations are violated.\n2. Dysfunction of important organs of liver and kidney, such as myocardial infarction, angina pectoris, and significant increase of liver transaminase.\n3. Any disease requiring systemic treatment with corticosteroids or other immunosuppressive drugs within 14 days prior to enrollment.\n4. Serious infection within 4 weeks before enrollment, including but not limited to hospitalization due to infection complications, bacteremia or severe pneumonia.\n5. Severe chronic or active infections (including tuberculosis infection) requiring systemic (oral or intravenous) antibiotic therapy within 14 days before enrollment.\n6. Participants with untreated chronic hepatitis B or HBV carriers with hepatitis B virus (HBV) DNA \u2265 500 IU\/mL, or patients with active hepatitis C virus (HCV) should be excluded. Note: Inactive hepatitis B, HBsAg carriers, treated and stable hepatitis B carriers (HBV DNA \\< 500 IU\/mL), and cured hepatitis C patients can be included in the group.\n7. Known history of HIV infection.\n8. Receive any other investigational drug treatment or participate in other clinical trials within 28 days.\n9. There are no contraindications to stereotactic radiotherapy and immune checkpoint inhibitors.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05754203001","EMAIL":[{"email":"sunjg09@aliyun.com"}],"GEO":[29.56278,106.55278]},{"TITLE":"P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Males or females, Subjects \u226518 years with life expectancy \\>3 months\n* Must have a confirmed diagnosis of unresectable, locally advanced or metastatic epithelial-derived cancer, refractory to standard of care therapy or ineligible or refused other existing treatment options\n* Must have progressed during or after last therapy and have measurable disease\n* Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 or Karnofsky performance status \u226570%\n* Must have adequate vital organ function within pre-determined parameters\n* Must have archived tumor tissue available or consent to a biopsy collection\n* Must be willing to practice birth control\n* Must have a negative pregnancy test at screening and prior to initiating lymphodepletion chemotherapy or study drug administration\n* Must have recovered from toxicities due to prior therapies\n\nExclusion Criteria:\n\n* Has inadequate venous access\n* Has an active second malignancy in addition to the studied malignancy, excluding low-risk neoplasms such as non-metastatic basal cell or squamous cell skin carcinoma\n* Is pregnant or lactating\n* Has a history of or active autoimmune disease\n* Has a history of significant central nervous system (CNS) disease, such as stroke, epilepsy\n* Has an active systemic (viral, bacterial, or fungal) infection\n* Has New York Heart Association (NYHA) Class III or IV heart failure, unstable angina, or a history of myocardial infarction or significant arrhythmia\n* Has any psychiatric or medical disorder that would preclude safe participation in and\/or adherence to the protocol\n* Has received anticancer medications within 2 weeks of the time of initiating conditioning chemotherapy\n* Has received immunosuppressive medications within 2 weeks of administration of P-MUC1C-ALLO1, and\/or expected to require them while enrolled in the study\n* Has received systemic corticosteroid therapy within 1 week of the administration of P-MUC1C-ALLO1 or is expected to require it during the course of the study\n* Has known CNS metastases or symptomatic CNS involvement\n* Has a history of significant liver disease or active liver disease\n* Has a history of known genetic predisposition to HLH\/MAS","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05239143013","EMAIL":"clinicaltrials@poseida.com","GEO":[43.0389,-87.90647]},{"TITLE":"Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy","CRITERIA":"Inclusion Criteria:\n\n* The patient or a legally authorized representative must provide study-specific informed consent prior to study entry, had good compliance and cooperated with the follow-up.\n* Age at least 18 years\n* Pathologically (histologically or cytologically) proven diagnosis of limited stage small cell lung cancer (Stage Tx, T1-T4, N0-3, M0, American Joint Committee on Cancer \\[AJCC\\] staging, 8th edition \\[Ed.\\]), within 60 days prior to registration\n* Patients must have had measurable disease (per Response Evaluation Criteria in Solid Tumors \\[RECIST\\], version 1.1) prior to the required cycle of cCRT\n* Patients must be free of disease progression and not be able to receive other antitumor therapy within 6 weeks of completion of cCRT\n* Patients must submit archived or freshly biopsied tumor tissue (formalin-fixed, paraffin-embedded tissue block or approximately 15 unstained sections \\[must have \\>8 sections\\]) along with the relevant pathology report.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 30 days prior to registration\n* Patient life expectancy must be \\>12 weeks\n\nExclusion Criteria:\n\n* Mixed SCLC or NSCLC confirmed by histology\n* Previous tumor resection for LS-SCLC\n* Any patient treatable by surgery or stereotactic body radiation therapy\/stereotactic ablative radiation therapy should be excluded\n* Expected to receive any other form of anti-tumor therapy during the study period\n* Previous treatment with PARP inhibitor drugs\n* Any active malignancy within 2 years prior to enrollment, excluding the specific cancers being studied in this study and locally recurrent cancers that have been cured (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, cervical cancer carcinoma in situ or carcinoma in situ of the breast)\n* Women who are pregnant, breastfeeding, or planning to become pregnant during the study\n* Concurrent participation in another therapeutic clinical trial","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05483543002","EMAIL":[{"email":"fuscczzf@163.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"APG-2449 in Patients With Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n1. Dose exploration stage: non-small cell lung cancer diagnosed by histology and\/or cytology and positive for ALK\/ROS1 gene fusion (molecular diagnosis confirmed by the investigator) and malignant pleural mesothelioma, esophageal cancer and ovarian cancer. Kind of patients with advanced tumors.\n\n   Expansion stage: cohort one, Patients with non-small cell lung cancer who have progressed or are not tolerated on second-generation ALK TKI therapy or any ROS1 TKI therapy treatment ; cohort two, ALK\/ROS1 fusion gene positive without TKI treatment Patients with non-small cell lung cancer. The molecular diagnosis results of the above patients can be confirmed by the investigator.\n2. ECOG Performance Status \u2264 1.\n3. Expectation of life \u2265 3 months.\n4. According to RECIST version 1.1, there is at least 1 measurable lesion.\n5. Adequate hematologic and bone marrow functions.\n6. Adequate renal and liver function.\n7. Normal cardiac function.\n8. Brain metastases with clinically controlled neurologic symptoms.\n9. Serum pregnancy test results of women of childbearing age were negative within 7 days before taking the first dose of study drug.\n10. Men, women of childbearing age (postmenopausal women must have been menopausal for at least 12 months before they can be considered infertile) and their partners voluntarily take the study drug for at least 30 days after signing the informed consent form and taking the study drug as deemed effective by the investigator Contraceptive measures\n11. Ability to understand and willingness to sign a written informed consent form\n12. Subjects must be willing and able to complete the research procedures and follow-up inspections.\n13. Subjects are required to provide fresh (for recurrent subjects only) or archived tumor tissue samples from within 28 days prior to treatment. If none of these specimens are available, they may be included after consultation with the sponsor.\n\nExclusion Criteria:\n\n1. Receiving concurrent anti-cancer therapy (chemotherapy, radiotherapy, immunotherapy, biologic therapy); or any investigational therapy within 28 days prior to the first dose of study drug.\n2. Receiving TKI therapy within 8 days prior to the first dose of study drug.\n3. Continuance of toxicities due to prior therapy that do not recover (CTCAE V5.0 Grade\\> 1).\n4. Has difficulty in swallowing, absorbing barrier, or other diseases blocking APG-2449' taken.\n5. Obvious cardiovascular disease history.\n6. Failure to recover adequately, as judged by the investigator, from prior surgical procedures. Patients who have had major surgery within 28 days from study entry, and patients who have had minor surgery within 14 days of study entry.\n7. Active symptomatic fungal, bacterial and\/or viral infection including, but not limited to, active human immunodeficiency virus (HIV) or viral hepatitis (B or C).\n8. Known allergies to study drug ingredients or their analogs.\n9. Female subjects who are pregnant or breastfeeding, or expecting to become pregnant during the study period.\n10. According to the judgment of the investigator or sponsor, any symptoms or disease of the subject may endanger its safety or interfere with the safety assessment of the study drug.\n11. Subjects who have used CYP3A4, CYP2C9, or CYP2C19 moderately potent inhibitors or moderately potent inducers 1 week before receiving the study drug for the first time.\n12. Subjects who used CYP3A4 substrates and narrow treatment window 1 week before the first study drug.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03917043010","EMAIL":[{}],"GEO":[30.29365,120.16142]},{"TITLE":"Genomic Investigation of Unusual Responders","CRITERIA":"Inclusion Criteria:\n\n1. The patient must have either an exceptionally good or poor response to treatment, as indicated by their treating physician.\n\n   1. The exact definition of this is adaptable to the disease but a suggested guideline is a Complete Response, Partial Response or progression free interval of at least 6 months\n   2. Exceptionally poor response includes patients who were expected to respond favourably to a treatment but instead responded poorly (e.g dramatic tumor growth or death)\n2. The patient must have sufficient archival tumor available for sequencing.\n3. Deceased patients will also be considered for analysis (up to 30 patients per year) if they meet at least one of the following requirements:\n\n   a)) Patients who have archival tissue stored within the UHN Laboratory Medicine Program who have had a consent waiver granted by the REB to access the tissue.\n\n   b) Patients who have archival tissue banked for further research within the UHN Biospecimen Sciences Program\n\n   Exclusion Criteria:\n   * None","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03740503001","EMAIL":[{"email":"celeste.yu@uhn.ca"},{"email":"elizabeth.shah@uhn.ca"}],"GEO":[43.70011,-79.4163]},{"TITLE":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","CRITERIA":"Inclusion Criteria:\n\n1. Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form.\n2. Age \u2265 18 years.\n3. Histologically or cytologically confirmed, Stage IV NSCLC.\n4. Oncogenic mutations confirmed by an accredited local laboratory, including EGFR, ALK, ROS1 etc.\n5. ECOG 0-1.\n6. Predicted survival \u2265 12 weeks.\n7. Adequate bone marrow hematopoiesis and organ function\n8. Presence of measurable lesions according to RECIST 1.1.\n\nExclusion Criteria:\n\nThe patient did not match from the Inclusion Criteria.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04322890001","EMAIL":[{"email":"zhangyongchang@csu.edu.cn"}],"GEO":[28.19874,112.97087]},{"TITLE":"BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab","CRITERIA":"Inclusion Criteria:\n\n1. Pathologically confirmed NSCLC\n2. Age \\> 18\n3. ECOG Performance Status 0-1.\n4. Pulmonary function capacity capable of tolerating the proposed lung resection. FEV1 at least 2 L. If less than 2 L, the predicted postoperative forced expiratory volume in 1 second (FEV1) must be \\> 0.8 L or be \\> 35% of the predicted value. Postoperative predicted DLCO \u2265 35% is required.\n5. Resectable stage IB-IIIB (T2-3N0, T1-T3N1-2) NSCLC (per the 8th Edition American Joint Committee on Cancer (AJCC) classification) who are candidates for surgery with intent of R0 resection. Invasive T3 disease (eg, phrenic nerve, pericardium, chest wall other than Pancoast superior sulcus) may be included if the surgeon and study team deem it to be resectable.\n6. N2 nodes must be discrete (ie, not invading surrounding structures). If patients have N2 disease, as suspected by CT or PET, histologic proof of N2 status is recommended.\n7. Patients must be evaluated by a Thoracic Surgeon prior to registration. Operability is defined as having adequate pulmonary, cardiac, renal, nutritional, musculoskeletal, neurologic, and cognitive capacity to undergo major pulmonary resection with acceptable morbidity and mortality. Absence of major associated comorbidities that increase the surgery risk to an unacceptable level.\n8. No prior history of thoracic radiation.\n9. Adequate Organ and marrow function as defined below\n\n   * leukocytes \u22652,000\/mcL,\n   * absolute neutrophil count \u22651,000\/mcL,\n   * platelets \u2265100,000\/mcL,\n   * Hemoglobin \\>8.0 g\/dL\n   * Total bilirubin within normal institutional limits\n   * AST(SGOT)\/ALT(SGPT) \u22642.5 \u00d7 institutional upper limit of normal\n   * creatinine within normal institutional limits OR creatinine clearance \u226550 mL\/min\/1.73 m2 for participants with creatinine levels above institutional normal.\n10. Patients are capable of giving informed consent and\/or have an acceptable surrogate capable of giving consent on the subject's behalf.\n11. Nonpregnant and non-nursing. The effect of ipilimumab and nivolumab on the fetus is unknown.\n12. Women of childbearing potential (WOCBP) must be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 5 months after the last dose of study medication. Patients of childbearing potential are those who have not been surgically sterilized or have not been free of menses \\>1 year.\n13. Evidence of postmenopausal status or negative urinary or serum pregnancy test for female premenopausal patients. Women will be considered postmenopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n14. Women \\<50 years of age would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the postmenopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n15. Women \u226550 years of age would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \\>1 year ago, had chemotherapy-induced menopause with last menses \\>1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).\n16. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.\n17. Male patients must agree to use an adequate method of contraception starting with the first dose of study therapy through 7 months after the last dose of study therapy.\n\nExclusion Criteria:\n\n1. Pathologically confirmed NSCLC \\*\n2. Age \\> 18 \\*\n3. ECOG Performance Status 0-1.\n4. Pulmonary function capacity capable of tolerating the proposed lung resection. FEV1 at least 2 L. If less than 2 L, the predicted postoperative forced expiratory volume in 1 second (FEV1) must be \\> 0.8 L or be \\> 35% of the predicted value. Postoperative predicted DLCO \u2265 35% is required.\n5. Resectable stage IB-IIIB (T2-3N0, T1-T3N1-2) NSCLC (per the 8th Edition American Joint Committee on Cancer (AJCC) classification) who are candidates for surgery with intent of R0 resection. Invasive T3 disease (eg, phrenic nerve, pericardium, chest wall other than Pancoast superior sulcus) may be included if the surgeon and study team deem it to be resectable.\n6. N2 nodes must be discrete (ie, not invading surrounding structures). If patients have N2 disease, as suspected by CT or PET, histologic proof of N2 status is recommended.\n7. Patients must be evaluated by a Thoracic Surgeon prior to registration. Operability is defined as having adequate pulmonary, cardiac, renal, nutritional, musculoskeletal, neurologic, and cognitive capacity to undergo major pulmonary resection with acceptable morbidity and mortality. Absence of major associated comorbidities that increase the surgery risk to an unacceptable level. \\*\n8. No prior history of thoracic radiation.\n9. Adequate Organ and marrow function as defined below\n\n   * leukocytes \u22652,000\/mcL,\n   * absolute neutrophil count \u22651,000\/mcL,\n   * platelets \u2265100,000\/mcL,\n   * Hemoglobin \\>8.0 g\/dL\n   * Total bilirubin within normal institutional limits\n   * AST(SGOT)\/ALT(SGPT) \u22642.5 \u00d7 institutional upper limit of normal\n   * creatinine within normal institutional limits OR creatinine clearance \u226550 mL\/min\/1.73 m2 for participants with creatinine levels above institutional normal.\n10. Patients are capable of giving informed consent and\/or have an acceptable surrogate capable of giving consent on the subject's behalf.\n11. Nonpregnant and non-nursing. The effect of ipilimumab and nivolumab on the fetus is unknown.\n12. Women of childbearing potential (WOCBP) must be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 5 months after the last dose of study medication. Patients of childbearing potential are those who have not been surgically sterilized or have not been free of menses \\>1 year.\n13. Evidence of postmenopausal status or negative urinary or serum pregnancy test for female premenopausal patients. Women will be considered postmenopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n14. Women \\<50 years of age would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the postmenopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n15. Women \u226550 years of age would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \\>1 year ago, had chemotherapy-induced menopause with last menses \\>1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).\n16. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.\n17. Male patients must agree to use an adequate method of contraception starting with the first dose of study therapy through 7 months after the last dose of study therapy.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04933903001","EMAIL":[{"email":"BrUOG@Brown.edu"},{},{}],"GEO":[41.82399,-71.41283]},{"TITLE":"Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Patients who are over 70 years of age may be allowed to enroll after discussion with the Medical Monitor.\n* Have historically or pathologically confirmed diagnosis of metastatic Stage IV NSCLC without EGFR, ALK, or ROS1 genomic alterations.\n* For patients who have actionable mutations (other than EGFR, ALK, or ROS1 genomic alterations), 1 additional line of therapy with the appropriate health authority approved targeted therapy is required.\n* Patients must have documented radiographic disease progression on or after the first-line therapy, including concurrent or sequential ICI and platinum-based chemotherapy \u00b1 bevacizumab. No more than 1 prior line is allowed if ICI and platinum-based chemotherapy were administered concurrently and no more than 2 prior lines are allowed for sequential administration of platinum-based chemotherapy and ICI as 2 separate lines.\n* LN-145 manufacture is allowed for patients who have residual resectable disease after completion of the platinum-based chemotherapy component of the front-line ICI and platinum-based chemotherapy combination and meet all eligibility criteria except documented disease progression. These patients must intend to receive TIL therapy after disease progression\n* Prior systemic therapy in the adjuvant or neoadjuvant setting, or as part of definitive chemoradiotherapy, will count as a line of therapy if the patient had disease progression during or within 12 months after the completion of such therapy.\n* At least 1 resectable lesion for TIL production and at least one remaining measurable lesion, as defined by RECIST v1.1\n* Have adequate organ function\n* LVEF \\> 45%, NYHA Class 1\n* Have adequate pulmonary function\n* ECOG performance status of 0 or 1\n* Patients of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control during treatment and up to 12 months after all protocol-related therapy\n\nExclusion Criteria:\n\n* Patients who have EGFR, ALK or ROS1 driver mutations\n* Patients who have symptomatic, untreated brain metastases.\n* Patients who have had allogeneic organ transplant or prior cell therapy within the past 20 years\n* Patients who have any form of primary immunodeficiency\n* Patients who are on systemic steroid therapy \u2265 10 mg\/day of prednisone or equivalent.\n* Patients who have received a live or attenuated vaccination within 28 days prior to the start of treatment\n* Patients who have had another primary malignancy within the previous 3 years\n* Participation in another interventional clinical study within 21 days","SEX":"ALL","AGE_MIN":18,"AGE_MAX":70,"SS_ID":"04614103043","EMAIL":"Clinical.Inquiries@iovance.com","GEO":[52.37403,4.88969]},{"TITLE":"Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer","CRITERIA":"* INCLUSION CRITERIA:\n\n  1. Histologically or cytologically non-small cell lung cancer confirmed by outside pathology report or via the Laboratory of Pathology, NCI.\n  2. Have measurable disease, per RECIST 1.1, that is not amenable to surgery.\n  3. PD-L1 Tumor Proportion Score (TPS) \\>=1% detected at any time since diagnosis, based on a pathology report from an outside hospital or Laboratory of Pathology, NCI. PD- L1 expression testing must be conducted using one of the FDA approved diagnostic devices listed here: https:\/\/www.fda.gov\/medical-devices\/in-vitro-diagnostics\/list- cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools.\n  4. Received at least one previous line of standard frontline therapy that must include a PD-1\/PD-L1-targeting ICI.\n  5. Age \\>=18 years.\n  6. ECOG performance status \\<=2.\n\n     Must have adequate organ and marrow function as defined below:\n\n     Leukocytes \\>=3,000\/mcL\n\n     absolute neutrophil count \\>=1,500\/mcL\n\n     platelets \\>=100,000\/mcL\n\n     total bilirubin\\<TAB\\>within normal institutional limits\n\n     AST\/ALT \\<=2.5 X institutional upper limit of normal\n\n     creatinine clearance\\<TAB\\>\\>=60 mL\/min\/1.73 m\\^2 (calculated based on CKD-EPI formula or directly measured) for participants with creatinine levels above institutional normal.\n  7. Participants with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.\n  8. Participants with new or progressive brain metastases (active brain metastases) are eligible if immediate CNS specifictreatment is not required per standard of care and is unlikely to be required during the first cycle of therapy.\n  9. Human immunodeficiency virus (HIV)-infected participants on effective anti-retroviral therapy with undetectable viral load within the 6 months before study treatment initiation are eligible for this trial.\n  10. For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n  11. Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n  12. Women of child-bearing potential (WOCBP) must agree to use effective contraception (e.g., hormonal intrauterine device \\[IUD\\], tubal ligation, partner has had prior vasectomy) beginning at study entry until 4 months after the completion of therapy. Note: abstinence, defined as no heterosexual sexual intercourse when this is in line with the preferred and usual lifestyle of the participant is also acceptable.\n  13. Breastfeeding participants must be willing to discontinue breastfeeding for the duration of study treatment.\n  14. Ability of participant to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n1. Participants who are receiving any other investigational agents.\n2. Participants with ongoing Epstein-Barr virus or cytomegalovirus infection\n3. History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab, aztreonam, vancomycin and albuterol.\n4. Pregnancy (confirmed with beta-HCG serum or urine pregnancy test performed in females of childbearing potential at screening).\n5. Pulmonary function FEV1 (Forced Expiratory Volume in the first second) \\<25% will be excluded based on the requirement of receiving aerosolized aztreonam.\n6. Participants with targetable EGFR, ALK, ROS1, BRAF V600E, NTRK1\/2\/3, METex14 skipping, RET, and HER2 genomic tumor aberrations. Genomic testing must be based on a pathology report from an outside hospital or Laboratory of Pathology, NCI and must be conducted using TSO500 or one of the FDA approved diagnostic devices listed here: https:\/\/www.fda.gov\/medical-devices\/in-vitro-diagnostics\/list-cleared-or- approved-companion-diagnostic-devices-in-vitro-and-imaging-tools.\n7. Participants with KrasG12C mutation not previously treated with sotorasib or other approved KrasG12C small molecule inhibitor.\n8. History of severe immune-related adverse events (irAEs), defined as any grade neurological or cardiac irAEs, any grade 3 or 4 irAE (except fully controlled endocrine irAEs with appropriate hormone supplementation), and any grade pneumonitis.\n9. Uncontrolled intercurrent illness that would limit compliance with study requirements.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":120,"SS_ID":"05777603001","EMAIL":[{}],"GEO":[38.98067,-77.10026]},{"TITLE":"FOG-001 in Locally Advanced or Metastatic Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate organ and marrow function.\n\nAdditional Inclusion Criteria for Dose Escalation Cohorts (Part 1a):\n\n* Diagnosis of treatment-refractory advanced\/metastatic solid tumor that is non-MSI-H or non-dMMR colorectal cancer (CRC) or any other solid tumor with documented WNT- pathway activating mutations (WPAMs).\n\nAdditional Inclusion Criteria for Dose Escalation Cohorts (Part 1b):\n\n* Diagnosis of treatment-refractory advanced\/metastatic non-MSI-H or non-dMMR CRC.\n* At least one lesion that is suitable for a core needle biopsy.\n\nAdditional Inclusion Criteria for Dose Expansion Cohort (Cohort 2a): Colorectal Cancer (CRC) Cohort\n\n* Diagnosis of treatment-refractory advanced\/metastatic non-MSI-H or non-dMMR CRC.\n\nAdditional Inclusion Criteria for Dose Expansion Cohort (Cohort 2b): Non-small Cell Lung Cancer (NSCLC) Cohort\n\n* Diagnosis of treatment-refractory advanced\/metastatic NSCLC with documented WPAMs in adenomatous polyposis coli (APC) or Beta-catenin.\n\nAdditional Inclusion Criteria for Dose Expansion Cohort (Cohort 2c): Gastric\/Gastroesophageal junction (GEJ) Cohort\n\n* Diagnosis of treatment-refractory advanced\/metastatic gastric\/GEJ cancer with documented WPAMs in APC or Beta-catenin.\n\nAdditional Inclusion Criteria for Dose Expansion Cohort (Cohort 2d): Tumor Agnostic Cohort\n\n* Diagnosis of treatment-refractory advanced\/metastatic solid tumor with documented WPAMs.\n\nExclusion Criteria:\n\n* Known history of bone metastasis.\n* Evidence of vertebral compression fracture or non-traumatic bone fracture within the past 12 months and who are not receiving antiresorptive therapy.\n* Osteoporosis, which is defined as a T-score of \\<-2.5 at the lumbar spine (L1 - L4), left (or right) femoral neck or left (or right) total hip as determined by DXA scan, or a FRAX 10-year probability of hip fracture \u22653% or a 10-year probability of major osteoporosis-related fracture \u226520%, based on the US-adapted WHO algorithm for postmenopausal women and men \u226550 years of age.\n* Inflammatory bowel disease (i.e., ulcerative colitis or Crohn's disease) that is recently active or requires therapy currently.\n* Unstable\/inadequate cardiac function.\n* Has known meningeal carcinomatosis, leptomeningeal carcinomatosis, spinal cord compression, or symptomatic or unstable brain metastases.\n* Pregnant, lactating, or planning to become pregnant.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05919264009","EMAIL":[{}],"GEO":[29.42412,-98.49363]},{"TITLE":"Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Patients must sign the informed consent form and commit to complying with the requirements of this study.\n2. Male or female, \u2265 18 years of age, \u2264 70 years of age.\n3. Histologically or cytologically confirmed NSCLC, diagnosed as stage IV or stage IIIB-IIIC not amenable to radical surgery according to the IASLC (International Association for the Study of Lung Cancer) 8th edition staging system.\n4. The subject has at least one evaluable lesion (measurable or non-measurable) by the RECIST 1.1.\n5. The subject must have received a prior systemic chemotherapy (including neoadjuvant\/adjuvant therapy) with a platinum-containing regimen, and are allowed to have \u2264 2 prior lines of chemotherapy for advanced cancer (excluding neoadjuvant\/adjuvant chemotherapy).\n6. Patients without driver genes can be treated with\/ not be treated with PD-1\/PD-L1 inhibitors previously.\n7. EGFR-positive patients are required to have received at least one or more EGFR-TKI (including Erlotinib, Gefitinib, Icotinib, Afatinib, Osimertinib, or other TKI for EGFR mutations, etc.), with disease progression or intolerance during or after treatment.\n\n   * Patients having had disease progression or intolerance to Osimertinib or other third-generation EGFR-TKI are eligible for enrollment (regardless of prior treatment with first\/second-generation EGFR-TKI)\n   * Patients having had disease progression or intolerance to first- or second-generation EGFR-TKI (e.g., Erlotinib, Gefitinib, Icotinib, Afatinib, etc.) without evidence of EGFR T790M mutation after this treatment are eligible for enrollment.\n8. ALK fusion-positive patients who have received at least one or more ALK-TKI therapies and experienced disease progression or intolerance during or after treatment.\n\n   -Patients having had disease progression or intolerance to the third-generation ALK-TKI Lorlatinib are eligible for enrollment (regardless of prior treatment with first- or second-generation ALK-TKI).\n9. Baseline routine blood tests within 1 week prior to enrollment is normal, with CTCAE grade \u22641 (based on normal values at each site's laboratory). No rhG-CSF use and no blood transfusion\/EPO etc. within 14 days prior to enrollment.\n\n   * White blood cell count (WBC) \u22654.0 \u00d7 109\/L.\n   * Neutrophil count (ANC) \u2265 1.5 \u00d7 109\/L.\n   * platelet count (PLT) \u2265 100 \u00d7 109\/L\n   * Hemoglobin \u22659.0 g\/dL.\n10. Blood biochemistry test result is normal within 1 week prior to enrollment, with CTCAE grade \u22641 (based on normal values at each site's laboratory).\n\n    * Total bilirubin (TBIL) \u2264 1.5\u00d7 the upper limit of normal value (ULN)\n    * Serum Glutamic Pyruvic Transaminase\/Alanine Amino transferease (SGPT \/ALT) \u2264 3\u00d7 ULN (in the case of liver metastases \u2264 5 \u00d7 ULN)\n    * Serum Glutamic-oxaloacetic Transaminase\/Aspartate Aminotransferase (SGOT \/AST) \u2264 3\u00d7 ULN (in the case of liver metastases \u2264 5 \u00d7 ULN)\n    * Creatinine clearance (Ccr) \u226560 ml\/min.\n11. ECOG performance status 0-1.\n12. Fertile males and females of childbearing potential must agree to use effective contraception during the study and within 90 days after the last dose. The blood or urine pregnancy test for female patients of childbearing age prior to enrollment must be negative.\n13. Patients with a life expectancy of more than 3 months.\n\nExclusion Criteria:\n\n1. Patients who had other malignancies within the past 5 years, excluding cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and papillary thyroid cancer.\n2. Patients who have received antitumor therapy, including chemotherapy, radiotherapy, biologic therapy, targeted therapy, immunotherapy, or antitumor herbal therapy, within 4 weeks or 5 half-lives (\u2265 2 weeks), whichever is shorter, prior to the first dose of the study drug.\n3. Patients who have had surgery of their major organs (excluding puncture biopsy) or had major injuries within 4 weeks prior to the first dose of study drug, or require elective surgery during the study.\n4. Patients with symptomatic peripheral neuropathy with CTCAE 5.0 grade \u22652\n5. Patients with known allergic reactions to any ingredient of the study drug.\n6. Patients who have previously been treated with docetaxel.\n7. Patients who are pregnant (positive result from the pregnancy test) or lactating.\n8. Patients whose prior adverse reactions to anti-tumor therapy have not recovered to CTCAE 5.0 grade \u22641 (except for toxicity such as alopecia which poses no safety risk in the judgment of the investigator).\n9. Patients with symptomatic CNS metastases or meningeal metastases, or uncontrollable metastases, i.e., metastatic lesion progression confirmed by examination within 2 months after radiotherapy or other localized treatment, or those who are unsuitable for enrollment in the judgment of the investigator.\n10. Patients with uncontrollable bone metastases, i.e., patients who have had fracture or have the risk of fracture in recent days, patients who need surgery or localized radiotherapy in recent days, and patients under critical conditions in the judgment of the investigator.\n11. Patients with uncontrollable pleural effusion, pericardial effusion, or ascites requiring repeated drainage (once a month or more frequently)\n12. Patients with an active infection that currently requires systemic anti-infective therapy\n13. Patients having a history of immunodeficiency, including a positive HIV antibody test.\n14. Patients with active hepatitis B\/C infection; patients with known active infection of syphilis.\n15. Patients with history of severe cardiovascular disease, including but not limited to:\n\n    * Serious cardiac rhythm or conduction abnormalities such as ventricular arrhythmias requiring clinical intervention, second- to third- degree atrioventricular block; mean QTcF \\>470ms from 3 12-lead ECGs at rest.\n    * Patients who had acute coronary syndrome, congestive heart failure, aortic dissection, stroke or other cardiovascular events at Class 3 or higher within 6 months prior to the first dose.\n    * Patients with clinically uncontrollable hypertension.\n    * Patients with other high-risk cardiac conditions in the judgment of the investigator.\n16. Patients with uncontrolled diabetes mellitus.\n17. Patients with mental disorders or poor compliance.\n18. Patients who concurrently participate in another clinical trial or use another investigational treatment.\n19. Subjects who, in the opinion of the investigator, have a history of other serious systemic diseases, or other reasons that make participation in this trial inadvisable.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":70,"SS_ID":"05673590001","EMAIL":[{}],"GEO":[31.22222,121.45806]},{"TITLE":"Safety and Efficacy of Lorbrena","CRITERIA":"Inclusion Criteria:\n\n* All administered patients\n\nExclusion Criteria:\n\n* Nothing","SEX":"ALL","AGE_MIN":0,"AGE_MAX":200,"SS_ID":"03844464001","EMAIL":"ClinicalTrials.gov_Inquiries@pfizer.com","GEO":[35.6895,139.69171]},{"TITLE":"A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)","CRITERIA":"Inclusion Criteria:\n\n* At least 18 years of age\n* Untreated metastatic NSCLC\n* Absence of tumor activating EGFR mutations and absence of ALK gene rearrangements\n* Measurable disease according to RECIST 1.1\n* Adequate organ function\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n\nExclusion Criteria:\n\n* Squamous cell or mixed histology in NSCLC\n* Known history of hypersensitivity (grade \u22653) to pembrolizumab, chemotherapy or their excipients\n* Active autoimmune disease that has required chronic systemic treatment in the past 2 years.\n* Received live vaccine \u226430 days before the first study treatment\n* Prior treatment with pembrolizumab or any other anti-PD-1, or anti-PD-L1 or anti-PD-L2, or anti-CTLA-4 agent or any antibody targeting other immune-regulatory receptors or mechanisms for lung cancer.\n\nOther protocol-defined inclusion\/exclusion criteria apply.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06159790001","EMAIL":"sandoz.disclosure@sandoz.com","GEO":[41.69411,44.83368]},{"TITLE":"A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Capable of giving signed informed consent\n* Be \u226518 years of age on day of signing informed consent.\n* Have measurable disease per Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) as assessed by the local site investigator.\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n* Participants with a histologically confirmed diagnosis of a solid tumor that have exhausted available treatments known to be beneficial for this tumor type or for whom these treatments are not acceptable and for whom this trial is a reasonable option for them, will be enrolled onto this study. Appropriate molecular profiling of tumors should have been performed according to local national guidelines prior to trial entry. Specifications for the different parts of the study are below:\n\n  -- Dose escalation: All solid cancers, except primary central nervous system cancers.\n* Non-small cell lung cancer (NSCLC): Participants with NSCLC must have received an approved PD1\/L-1 containing regimen and platinum chemotherapy, as applicable. Participants with known targetable genomic aberrations should have received available targeted drugs deemed appropriate by the investigator. (apart from NSCLC participants with endothelial growth factor receptor \\[EGFR\\] or alkaline phosphatase \\[ALK\\] mutations who will not be eligible).\n* Provision of archival tumor sample at baseline is mandatory for all participants in escalation, and expansion cohorts.\n* Participants recruited to expansion cohorts must be willing to undergo mandatory paired biopsies of tumor (re and on treatment).\n* Have adequate organ function.\n* Agree to use contraception during the treatment period and for at least 6 months after the last dose of study treatment.\n\nExclusion Criteria:\n\n* Had an allogeneic tissue\/solid organ transplant.\n* Previous therapy with a diacylglycerol kinase (DGK) inhibitor\n* Has received a prior therapeutic regimen containing an anti-programmed cell death protein 1 (anti-PD-1), anti-programmed death-ligand 1 (anti-PD-L1), or anti-programmed cell death 1 ligand 2 (anti PD-L2) agent or an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX 40, CD137) and was discontinued from that treatment regimen due to a Grade 3 or higher immune related adverse event (irAE) or any toxicity that was life-threatening.\n* Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks or 5 half-lives, whatever is shorter, prior to treatment. Growth factor treatments such as granulocyte colony-stimulating factor (G-CSF) must have been discontinued 4 weeks prior to entering the study.\n* Participants must have recovered from previous radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis.\n* Participants cannot have had a blood transfusion within 2 weeks of starting therapy.\n* Has received a live vaccine within 30 days prior to the first dose of study drug.\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.\n* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.\n* Participants with new brain metastases on screening brain magnetic resonance imaging\/computed tomography (MRI\/CT).\n* Primary central nervous system malignancy or presence of leptomeningeal disease.\n* Participants with gastrointestinal conditions that may compromise oral absorption such as short bowel syndrome or active tumor-related bowel obstruction with ongoing symptoms compromising absorption over last 6 months.\n* Has an active autoimmune disease including inflammatory bowel disease that has required systemic treatment in past 2 years.\n* Current pneumonitis \/ interstitial lung disease.\n* Has an active infection requiring systemic therapy.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05858164019","EMAIL":"clinical-trials-contact@bayer.com","GEO":[37.566,126.9784]},{"TITLE":"Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC","CRITERIA":"Inclusion Criteria:\n\n* 18\uff0cAdvanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology\n\n  * Uncommon EGFR Mutant Advanced NSCLC\n\nExclusion Criteria:\n\n* Patients with contraindication of chemotherapy\n* Pregnant or breast feeding women","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04324164001","EMAIL":[{"email":"zhangyongchang@csu.edu.cn"}],"GEO":[28.19874,112.97087]},{"TITLE":"Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI","CRITERIA":"Inclusion Criteria:\n\n1. Ability to understand and willingness to sign a written informed consent document.\n2. Aged at least 18 years old.\n3. Histologically or cytologically confirmed locally advanced or metastatic NSCLC (stage IIIB\\~IV).\n4. EGFR mutations, including exon 19 deletion and exon 21 L858R.\n5. C-Met overexpression and\/or c-Met amplification confirmed after treatment with EGFR-TKI.\n6. At least one measurable lesion as defined by RECIST V1.1.\n7. ECOG performance status 0 to 1.\n\nExclusion Criteria:\n\n1. Previous treatment with MET inhibitors or HGF-targeted therapy.\n2. There are mutations of ALK or ROS1.\n3. Have symptomatic and neurologically unstable central nervous system (CNS) metastases or CNS disease that requires increased steroid doses for control.\n4. Pregnant or nursing women.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06343064001","EMAIL":[{"email":"caicunzhoudr@163.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG)","CRITERIA":"Inclusion Criteria:\n\n* Cohort I: diagnosis of advanced non-small cell lung cancer from 2012-2016;\n* Cohort II: documented positive driver gene mutations; and diagnosis of advanced non-small cell lung cancer;\n* Cohort III: diagnosis of advanced non-small cell lung cancer and in immune-therapy;\n* Cohort IV: diagnosis of advanced non-small cell lung cancer, and with wild-type driver gene or unknown driver gene status;\n* Cohort V: treated with anti-VEGF drug in first line, diagnosis of advanced non-squamous and non-small cell lung cancer in 6 months before recruit;\n* Age\\>18 years;\n* Provision of written informed consent.\n\nExclusion Criteria:\n\n* not applicable","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03334864001","EMAIL":[{}],"GEO":[39.9075,116.39723]},{"TITLE":"SBRT\/RT in Oligometastatic Stage IV NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Patients must have biopsy-proven metastatic NSCLC (Stage IV).\n* Patients must have received three months of first-line chemotherapy and achieved stable disease or partial response.\n* Age \u2265 18 years\n* Patients must have measurable disease at baseline.\n* Patients can have up to 10 discrete active extracranial\/intracranial lesions identified by PET\/CT or MRI scan within 8 weeks prior to the initiation of SBRT.\n* Patients must have a Karnofsky Performance Scale (KPS) \\>60\n* AST, ALT \\& Alkaline phosphates must be \u2264 2.5x the upper limit of normal. Total bilirubin must be within the limit of normal.\n* Patients should have adequate bone marrow function as defined by peripheral granulocyte count of \u22651500\/mm\u00b3.\n* Patients should have adequate renal function (serum creatinine \u22641.5 times the upper limit of normal (ULN).\n* Females of childbearing potential should have a negative pregnancy test.\n* Patients who would be receiving SBRT for lung tumors must have a documented forced expiratory volume in 1 second (FEV1) \u2265 1L.\n* Patients must provide verbal and written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Patients receiving first-line erlotinib, gefitinib, or crizotinib for EGFR mutant-positive or EML4-ALK-positive NSCLC will be excluded.\n* Patients who previously received radiotherapy at the primary site with CT evidence of disease progression at the primary site within 3 months following the initial radiotherapy\n* Patients with serious, uncontrolled, concurrent infection(s)\n* Significant weight loss (\\>10%) in the prior 3 months\n* Patients with cutaneous metastasis of NSCLC\n* Treatment for other carcinomas within the last five years, except cured non-melanoma skin and treated in-situ cancers\n* Patients with more than 10 discrete extra\/intracranial lesions\n* Participation in any investigational drug study within 4 weeks preceding the start of study treatment\n* Unwillingness to participate or inability to comply with the protocol for the duration of the study\n* Patients who are pregnant; patients with reproductive capability will need to use adequate contraception during the time of participation in the study","SEX":"ALL","AGE_MIN":18,"AGE_MAX":85,"SS_ID":"05647590001","EMAIL":[{"email":"jiri.hyncica@fno.cz"},{},{}],"GEO":[49.83465,18.28204]},{"TITLE":"Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Patients must have histologically or cytologically confirmed, refractory or recurrent, advanced non-small cell lung carcinoma regardless of histology.\n2. Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria v. 1.1 as described in detail in section 11.0\n3. Patients must have completed one line of prior therapy in both cohorts. For participation in the Cohort A, they must have completed at least 4 cycles of platinum doublet therapy. For participation in Cohort B, they must have received PD-1, PD-L1 and\/or CTLA-4 immunotherapy, alone or in combination with chemotherapy or in combination with other IO agents. Treatment on this protocol may begin as long as the patient has recovered from toxicities of prior therapy at the discretion of the treating physician. A washout period of at least 2 weeks is required prior to starting on this trial.\n4. Patients with recurrent disease who had received adjuvant or neoadjuvant therapy or chemoradiotherapy for locally advanced disease if their disease has progressed up to 6 months after completion of adjuvant or neoadjuvant platinum-based therapy, or if their disease has progressed more than 6 months after therapy and during or after a subsequent platinum-based chemotherapy regimen\n5. Patients with molecular targets (EGFR, ALK, ROS1) who have progressed on targeted agents and are not eligible for other treatments or trials specific for this population are allowed.\n6. Age \\> 18 years.\n7. ECOG performance status 0 or 1\n8. Patients must have normal organ and marrow function as defined below. Patients should be able to maintain ANC levels without the need for G-CSF transfusion. If blood transfusion is performed for achieving hemoglobin levels, the levels should stay at \u2265 9.0 mg\/ml for at least a week after transfusion.\n\n   Absolute neutrophil count \\> 1,500\/mcL Hemoglobin \u2265 9.0 mg\/ml Platelets \\> 100,000\/mcL Total bilirubin \u22641.5 X institutional upper limit of normal (ULN) AST\/ALT (SGOT\/SGPT) \\< 3 times institutional normal limits, or up to 5 times institutional normal limits if the patient has liver metastases Creatinine OR Creatinine clearance \u22641.5 X ULN, OR \\> 40 Ml\/min\/1.73 m2 for patients with creatinine levels above institutional normal as per Cockcroft-Gault formula International Normalized Ratio (INR) or Prothrombin Time (PT) \u22641.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants Activated Partial Thromboplastin Time (aPTT) \\<1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants\n9. Patients on full-dose anticoagulation must be on a stable dose (minimum duration 14 days) of oral anticoagulant or low molecular weight heparin (LMWH). If receiving warfarin, the patient must have an INR \u22643.0. For heparin and LMWH there should be no active bleeding (that is, no bleeding within 14 days prior to first dose of protocol therapy) or pathological condition present that carries a high risk of bleeding (for example, tumor involving major vessels or known varices).\n10. Ability to understand and willingness to sign a written informed consent and HIPAA consent document\n11. A core tumor biopsy obtained after progression on the last treatment must be available at study entry for the study. The biopsy sample must not be more than 90 days old at the time of registration and the sample must be adequate for analyses. If the sample is not adequate patient must agree to provide a fresh biopsy specimen before the start of treatment. Any available archival tissue will also be collected.\n12. The patient's urinary protein must be \u22641+ on dipstick or routine urinalysis (UA; if urine dipstick or routine analysis is \u22652+, a 24-hour urine collection for protein must demonstrate \\<1000 mg of protein in 24 hours to allow participation in this protocol).\n13. Female subject of childbearing potential should have a negative serum pregnancy within 72 hours prior to receiving the first dose of study medication.\n14. Female subjects of childbearing potential and male subjects must be willing to use an effective method of contraception - Contraception, for the course of the study through 150 days after the last dose of study medication.\n15. Male patients who have women of child bearing potential (WOCBP) partners must agree to use effective method of contraception - Contraception, for the course of the study through 210 days after the last dose of study medication.\n16. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n\nExclusion Criteria:\n\n1. Patients who have not recovered from their most recent chemotherapy or radiotherapy prior to entering the study at the discretion of investigators. Patients may not be currently receiving any other investigational agents or immunomodulatory agents (e.g. ipilimumab). Patients treated with prior PD-1 or PD-L1 directed therapies are ineligible Cohort A.\n2. Prior ramucirumab treatment\n3. The patient has experienced any Grade 3-4 GI bleeding within 3 months prior to first dose of protocol therapy.\n4. The patient has a history of deep vein thrombosis (DVT), pulmonary embolism (PE), or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered \"significant\") during the 3 months prior to first dose of protocol therapy.\n5. Cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis.\n6. The patient has experienced any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, within 6 months prior to first dose of protocol therapy.\n7. The patient has uncontrolled or poorly-controlled hypertension (\\>160 mmHg systolic or \\> 100 mmHg diastolic for \\>4 weeks) despite standard medical management.\n8. The patient with history of hemoptysis (defined as bright red blood or \u2265 1\/2 teaspoon) within 2 months prior to first dose of protocol therapy or with radiographic evidence of intra-tumor cavitation or has radiologically documented evidence of major blood vessel invasion or encasement by cancer.\n9. The patient has a serious or non-healing wound, ulcer, or bone fracture (as per physician's discretion) within 28 days prior to first dose of protocol therapy.\n10. The patient has a prior history of GI perforation\/fistula (within 6 months of first dose of protocol therapy) or risk factors for perforation.\n11. The patient has undergone major surgery within 28 days prior to first dose of protocol therapy, or minor surgery\/subcutaneous venous access device placement within 7 days prior to first dose of protocol therapy. The patient has elective or planned major surgery to be performed during the course of the clinical trial.\n12. The patient is receiving chronic antiplatelet therapy other than aspirin, including nonsteroidal anti-inflammatory drugs (NSAIDs, including ibuprofen, naproxen, and others), dipyridamole or clopidogrel, or similar agents. Once-daily aspirin use (maximum dose 325 mg\/day) is permitted. Occasional use of NSAIDS is allowed (occasional use would constitute daily use for less than a week; treating physician discretion is permitted to differentiate between occasional Vs chronic use).\n13. Patients who have not recovered from adverse events due to agents administered earlier except neuropathy and alopecia. Physician's discretion is allowed to decide which unresolved adverse events from previous therapy (for NSCLC) prohibit patient participation in this study.\n14. Patients with active autoimmune disease that has required systemic treatment in the past 1 year (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Hormone replacement therapy (eg. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n15. Patients requiring more than 10mg prednisolone (or its equivalent) per day are excluded.\n16. Patients with untreated symptomatic brain metastases are excluded. Patients with treated brain metastases will be allowed if brain imaging obtained within 28 days of trial enrollment reveals stable disease. Patients with small (\\<5mm) asymptomatic brain metastasis are allowed to enroll.\n17. Patients with interstitial lung disease or active, noninfectious pneumonitis. Patients with active tuberculosis infection are excluded.\n18. Patient who have received a live vaccine within 30 days prior to Cycle1 Day 1.\n19. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (significant), cirrhosis, or psychiatric illness\/social situations that would limit compliance with study requirements.\n20. Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)\n21. Known history of chronic hepatitis B virus infection or chronic hepatitis C virus indicating chronic infection that is not cured.\n22. Subjects with previous malignancies (except non-melanoma skin cancers, and in situ cancers such as the following: bladder, gastric, colon, cervical\/dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry and no additional therapy is required or anticipated to be required during the study period.\n23. Pregnant or breast-feeding.\n24. Patients with prior grades 3 and 4 immune related adverse effects as a result of prior therapy with a checkpoint inhibitor are excluded\n\n    -","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03527108002","EMAIL":[{"email":"Hossein.Borghaei@fccc.edu"}],"GEO":[39.95233,-75.16379]},{"TITLE":"Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations","CRITERIA":"Inclusion Criteria:\n\n1. Histological or cytologically confirmed NSCLC.\n2. No prior systemic therapy for advanced stage disease.\n3. Presence of a PACC mutation (detected either in blood or tumour) as defined by Robichaux et al (24). Compound mutations classified as PACC mutations are permitted (24).\n4. The presence of measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (28).\n5. Estimated life expectancy of at least 3 months.\n6. ECOG performance status 0-1.\n7. Age \u226521 years old.\n8. Have adequate organ and hematologic function, as defined by:\n\n   * Alanine aminotransferase (ALT)\/aspartate aminotransferase (AST) \u22643.0 x upper limit of normal (ULN) or \u22645 times ULN if related to liver metastases.\n   * Total serum bilirubin \u22641.5 \u00d7 ULN (\\<3.0 \u00d7 ULN for patients with Gilbert syndrome)\n   * Creatinine clearance \\>=45mL\/min (Cockcroft Gault)\n   * Absolute neutrophil count \u22651.5 \u00d7 10\\^9\/L\n   * Platelet count \u2265100 \u00d7 10\\^9\/L\n   * Hemoglobin \u2265 9.0 g\/dL\n9. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n10. For female patients of childbearing potential, have a negative pregnancy test documented \u2264 14 days prior to start of study medication.\n11. Female patients of childbearing potential and male patients with partners of childbearing potential must agree to use a highly effective form of contraception with their sexual partners during the dosing period and for a period of at least 4 months after the end of treatment. Evidence of non-child-bearing potential is fulfilled by one of the following criteria at screening:\n\n    * The post-menopausal period defined as age \u226550 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments\n    * Women \\<50 years old they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range.\n    * Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not a tubal ligation\n12. Signed written informed consent.\n\nExclusion Criteria:\n\n1. Prior EGFR TKI therapy.\n2. Prior chemotherapy for Stage IIIB\/IV adenocarcinoma of the lung. Neo-\/adjuvant chemotherapy, CT-RT or RT is permitted if it has been elapsed for \u226512 months prior to disease progression.\n3. Have been diagnosed with another primary malignancy other than NSCLC, except for adequately treated non melanoma skin cancer or cervical cancer in situ; definitively treated non metastatic prostate cancer; or patients with another primary malignancy who are definitively relapse-free with at least 3 years elapsed since the diagnosis of the other primary malignancy.\n4. Known leptomeningeal carcinomatosis.\n5. Unstable spinal cord compression\/brain metastases unless asymptomatic and not requiring steroids for at least 2 weeks prior to the start of study treatment. For patients with brain metastases, gamma knife or stereotactic brain surgery is allowed prior to study treatment.\n6. Symptomatic and untreated spinal cord compression.\n7. Have significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to: myocardial infarction within 6 months prior to study enrolment; unstable angina within 6 months prior to study enrolment; congestive heart failure within 6 months prior to study enrolment; history of clinically significant atrial arrhythmia (including clinically significant bradyarrhythmia), as determined by the treating physician; any history of clinically significant ventricular arrhythmia; prolonged QTc.\n8. Had a cerebrovascular accident or transient ischemic attack within 6 months prior to enrolment.\n9. Major surgery within 4 weeks of starting study treatment and patients must have recovered from any effects of any major surgery. Minor surgery is allowed.\n10. Radiotherapy to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks before the study entry.\n11. Inability to swallow oral medication.\n12. Refractory nausea and vomiting, chronic gastrointestinal diseases or previous significant bowel resection that would preclude adequate absorption of afatinib.\n13. Have a history or the presence at baseline of pulmonary interstitial disease, drug-related pneumonitis, or radiation pneumonitis.\n14. Have an ongoing or active infection, including, but not limited to, the requirement for intravenous antibiotics.\n15. Have a known history of human immunodeficiency virus infection or active hepatitis B or C infection, active tuberculosis.\n16. Have a known or suspected hypersensitivity to afatinib or its excipients.\n17. Are pregnant, planning a pregnancy, or breastfeeding.\n18. Males and females of reproductive potential who are not using an effective method of contraception and females who are pregnant or breastfeeding or have a positive serum pregnancy test prior to study entry.\n19. Previous allogeneic bone marrow transplant.\n20. Have any condition or illness that, in the opinion of the investigator, would compromise patient safety or interfere with the study treatment.","SEX":"ALL","AGE_MIN":21,"AGE_MAX":99,"SS_ID":"06062823001","EMAIL":[{"email":"ross_soo@nuhs.edu.sg"},{}],"GEO":[1.28967,103.85007]},{"TITLE":"A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Histologically or cytologically confirmed NSCLC (nonsquamous or squamous) that is locally advanced or recurrent and not eligible for curative surgery and\/or definitive chemoradiotherapy, or metastatic NSCLC.\n2. No prior systemic treatment given as primary therapy for metastatic NSCLC. Prior adjuvant\/neoadjuvant chemotherapy or definitive chemoradiation\/adjuvant radiotherapy for locally advanced disease is allowed provided the last dose of chemotherapy and\/or radiotherapy occurred at least 6 months before randomization\/enrollment.\n3. Evaluable tumor PD-L1 expression as determined by a local laboratory or by central laboratory on archival tumor tissue or fresh biopsy. Patients with unknown PD-L1 expression will not be eligible for this study.\n4. At least 1 measurable lesion as defined per RECIST v1.1.\n5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n\nExclusion Criteria:\n\n1. Has mixed small cell lung cancer.\n2. Participants with known actionable mutations (including but not limited to EGFR, ALK, BRAF, RET, and ROSI mutations) for which a targeted therapy is available per local standard of care.\n3. Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-TIGIT, anti-LAG-3 or any other antibody or drug targeting T-cell costimulation or immune checkpoint pathways. Note: Patients who received prior neoadjuvant, adjuvant or immuno-oncology therapies targeting PD-1 or PD-L1 in consolidation are eligible, if there has been a treatment-free interval of \u2265 6 months from last dose of immuno-oncology therapy prior to radiologic recurrence of disease.\n4. Has received any Chinese herbal medicine or Chinese patent medicines used to control cancer \u2264 14 days before randomization\/enrollment.\n5. Active leptomeningeal disease or uncontrolled, untreated brain metastasis, or active autoimmune diseases.\n\nNOTE: Other protocol and sub-study protocol defined criteria may apply","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05635708056","EMAIL":"clinicaltrials@beigene.com","GEO":[14.12117,101.00364]},{"TITLE":"Clinical Study of Ivonescimab for First-line Treatment of Metastatic Squamous NSCLC Patients","CRITERIA":"Inclusion Criteria:\n\n* Age \u2265 18 years old at the time of enrollment\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n* Expected life expectancy \u2265 3 months\n* Metastatic (Stage IV) NSCLC\n* Histologically or cytologically confirmed squamous NSCLC\n* Tumor Proportion Score (TPS) with PD-L1 expression percent\n* At least one measurable noncerebral lesion according to RECIST 1.1\n* No prior systemic treatment for metastatic NSCLC\n\nExclusion Criteria:\n\n* Histologic or cytopathologic evidence of the presence of small cell lung carcinoma, or non-squamous NSCLC histology.\n* Known actionable genomic alterations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS1 or genes for which first-line approved therapies are available\n* Has received any prior therapy for NSCLC in the metastatic setting\n* Tumor invasion, encasement of organs (e.g. heart, trachea, esophagus), or major blood vessels (e.g aorta, central veins), if poses a significant increased risk of bleeding.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05899608037","EMAIL":"medicalinformation@smmttx.com","GEO":[50.45008,-104.6178]},{"TITLE":"Study of DF6215 in Patients With Advanced Solid Tumors","CRITERIA":"Key Inclusion Criteria - General (applies to all cohorts)\n\n* Signed written informed consent\n* Male or female patients aged \u2265 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at study entry and an estimated life expectancy of at least 3 months\n* Adequate hematological function\n* Adequate cardiac function\n* Effective contraception\n\nInclusion Criteria - 3+3 Dose Escalation\n\n* Histologically or cytologically proven locally advanced or metastatic solid tumor, for which no standard therapy exists, or standard therapy has failed\n* Evidence of objective disease (but participation does not require a measurable lesion)\n* Archived tumor biopsy. If archival tissue is unavailable, a fresh tumor biopsy is required, obtained within the screening window.\n\nInclusion Criteria - Safety\/PK\/PD\n\n* Histologically or cytologically proven locally advanced or metastatic solid tumor from the following list, where standard therapy does not exist or has failed:\n\n  * Melanoma\n  * HPV-positive advanced malignancies\n  * Ovarian cancer\n  * Head and neck cancer\n  * Lung cancer (non-small-cell lung cancer \\[NSCLC\\])\n  * Renal cell carcinoma (RCC)\n  * Other tumor types may be eligible after discussion with the Sponsor medical monitor\n* Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST 1.1\n* A fresh tumor biopsy must be obtained during the screening window and on-treatment\n\nInclusion Criteria - Efficacy Expansion\n\n* Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST 1.1\n* A fresh tumor biopsy must be obtained during the screening window and on-treatment\n\nKey Exclusion Criteria - General (applies to all cohorts)\n\n* Patients receiving chemotherapy, radiotherapy (other than palliative bone-directed radiotherapy), major surgery, or receiving another therapeutic agent within 28 days before the start of study drug or within 5 half-lives of the previous therapeutic agent (if known), whichever is shorter\n* Concurrent anticancer treatment (eg, cytoreductive therapy, radiotherapy \\[except for palliative bone-directed radiotherapy\\], immune therapy, or cytokine therapy \\[except for erythropoietin\\]), major surgery (excluding prior diagnostic biopsy), concurrent systemic therapy with steroids or other immunosuppressive agents, or use of any investigational drug within 28 days before the start of treatment or within 5 half-lives of the previous therapeutic agent (if known), whichever is shorter. Short-term administration of systemic steroids (eg, for allergic reactions or the management of immune-related adverse events \\[irAEs\\]) is allowed.\n\n  * Note: Patients receiving bisphosphonate or denosumab are eligible, provided treatment was initiated at least 14 days before the first dose of DF6215\n* Previous malignant disease (other than the target malignancy to be investigated in this study) within the last 3 years, with the exception of basal or squamous cell carcinoma of the skin, low-grade prostate cancer (Gleason score \u2264 6 and must be Stage I or II), or cervical carcinoma in situ\n* Life expectancy of less than 3 months\n* Patients with brain metastases are excluded, unless all of the following criteria are met:\n\n  * Central nervous system (CNS) lesions are asymptomatic and previously treated\n  * Patient does not require ongoing daily steroid treatment for replacement for adrenal insufficiency (except \u2264 10 mg prednisone \\[or equivalent\\])\n  * Imaging demonstrates stable disease 28 days after last treatment\n* Receipt of any organ transplant, including autologous or allogeneic stem-cell transplantation\n* Pregnancy or lactation during the study","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06108479006","EMAIL":[{}],"GEO":[43.29551,5.38958]},{"TITLE":"KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Histologically- or cytologically-proven adenocarcinoma of the lung deemed to be locally advanced\/unresectable or metastatic as per American Joint Committee on Cancer (AJCC) version 8, who has not received prior therapy for this stage of disease.\n\n  \u2022 Prior therapy for early stage NSCLC allowed. Progressive disease after at least 6 months of anti-programmed death (PD) ligand therapy (anti-PD-L1 therapy) (i.e. Durvalumab) for Stage III disease is allowed.\n* Must have tumor lesions amenable to repeated biopsy, and patient's acceptance to have a tumor biopsy of an accessible lesion at baseline and on treatment if the lesion can be biopsied with acceptable clinical risk (as judged by the Principal Investigator).\n* Measurable disease as defined by RECIST v1.1.\n* Have one of the six KRAS mutations (KRAS G12C, KRAS G12V, KRAS G12D, KRAS G12A, KRAS G13D or KRAS G12R) in vaccine expressed in tumor as defined by a Clinical Laboratory Improvement Amendments (CLIA) certified tumor or plasma based genomic testing platform performed either through a local laboratory or through the investigators' central laboratory.\n* Age \u226518 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Appendix A).\n* Patients must have adequate organ and marrow function as defined below:\n\nMicroliters (mcL) Microliter (uL)\n\n* Leukocytes \u2265 3,000\/mcL\n* Lymphocytes \\> 500\/mm3\n* Absolute neutrophil count \u2265 1,000\/mcL\n* Platelets \u2265 75 \u00d7 103\/uL\n* Hemoglobin \u2265 8.0 g\/dL\n* Total bilirubin \u2264 1.5 x ULN (\\< 2.0 x ULN for subjects with documented Gilbert's syndrome)\n* aspartate aminotransferase (AST) (SGOT) and alanine aminotransferase (ALT)(SGPT)\u2264 2.5 \u00d7 ULN (if liver metastases are present, \u2264 5 x ULN)\n* Alkaline phosphatase \u22645.0 \u00d7 ULN\n* Creatinine \u22641.5 \u00d7 ULN or creatinine clearance (CrCl) \u2265 40 mL\/min (if using the Cockcroft-Gault formula below):\n\nFemale CrCl = (140 - age in years) x weight in kg x 0.85 \/ 72 x serum creatinine in mg\/dL\n\nMale CrCl = (140 - age in years) x weight in kg x 1.00 \/ 72 x serum creatinine in mg\/dL\n\n* Women of childbearing potential (WOCBP) must have a negative serum pregnancy test (minimum sensitivity 25 IU\/L or equivalent units of human chorionic gonadotropin (HCG). WOCBP is defined in Section 4.6. Note: If a patient has a positive or indeterminate serum or urine pregnancy test, then an ultrasound must be done to rule out pregnancy to enroll on trial.\n* WOCBP must agree to follow instructions for method(s) of contraception from the time of enrollment for the duration of treatment with study drug(s) plus 5 half-lives of study drug(s) plus 4 weeks (duration of ovulatory cycle) for a total of 5 months post treatment completion.\n* Men who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) plus 5 half-lives of study drug(s) plus 90 days (duration of sperm turnover) for a total of 7 months post-treatment completion.\n* At least one barrier method of contraception must be employed by all sexually active patients (male and female), regardless of other methods, to prevent the transfer of body fluids.\n* Ability to understand and willingness to sign a written informed consent document.\n* Last dose of adjuvant chemotherapy or radiation therapy administered within 6 months of screening date\n\nExclusion Criteria:\n\n* Patient is expected to require any other form of systemic or localized antineoplastic therapy while on study.\n* Any of the following procedures or medications:\n* Within 2 weeks prior to initiation of study treatment:\n\n  * Systemic or topical corticosteroids at immunosuppressive doses (\\> 10 mg\/day of prednisone or equivalent). Inhaled or topical steroids, and adrenal replacement steroid doses \u2264 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.\n  * Palliative or adjuvant radiation or gamma knife radiosurgery.\n  * Chemotherapy\n* Within 4 weeks prior to initiation of study treatment:\n\n  * Any investigational cytotoxic drug. Exposure to any cytotoxic drug within 4 weeks or 5 half-lives (whichever is shorter) is prohibited. If 5 half-lives are shorter than 4 weeks, agreement with Investigational New Drug (IND) Sponsor is mandatory.\n  * Any investigational device\n  * Non-oncology vaccines containing live virus. Examples include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacillus Calmette-Gu\u00e9rin (BCG), and typhoid vaccine. Influenza, pneumonia vaccines (polysaccharide and conjugated forms) and Corona Virus Disease 2019 (COVID-19) vaccines will be allowed, however the investigators recommend that subjects not receive any dose of vaccine within 7 days before or after the subjects' scheduled KRAS peptide vaccination.\n  * Allergen hyposensitization therapy.\n  * Growth factors, e.g. granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), erythropoietin\n  * Major surgery (excludes celiac plexus block, biliary stent placement, and other minor procedures such as dental work, skin biopsy, etc.).\n* Patients with a history of prior treatment with immunotherapy agents (including, but not limited to: Interleukin 2 (IL-2), interferon, anti-PD-L2, anti-cluster of differentiation 137 (anti-CD137), anti-oxidation (OX) 40 (anti-OX-40), anti-cluster of differentiation 40 (anti-CD40), anti-cytotoxic T-lymphocyte-associated (CTLA) antigen 4 (anti-CTLA-4), or anti-lymphocyte activating gene (LAG) 3 (anti-LAG-3) antibodies).\n\n  * Prior anti-PD-(L)1 therapy for non-metastatic NSCLC (ie\/Durvalumab) is allowed if patient had received at least 6 months of therapy prior to having disease progression.\n* History of severe hypersensitivity reaction to any monoclonal antibodies or related compounds or to any of these agents' components (e.g., history of severe hypersensitivity reactions to drugs formulated with polysorbate 80).\n\n  * This includes any prior immunotherapy agents; patients having toxicity with prior anti-PD-L1 therapy requiring cessation of treatment must be excluded.\n* Untreated or symptomatic brain metastases.\n\n  * Treated brain metastases allowed on study if asymptomatic and therapy was completed at least 2 weeks prior to treatment start, and steroid dosing is as 3.2.2\n* Has an active known or suspected autoimmune disease or which has required systemic therapy in the last 2 years. Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.\n* Known history of interstitial lung disease or of (non-infectious) pneumonitis that required steroids or current pneumonitis.\n* Has a pulse oximetry \\< 90% on room air.\n* Requires the use of home oxygen.\n* Has a known history of Human Immunodeficiency Virus (HIV) (HIV1\/2 antibodies), hepatitis B, or hepatitis C infection.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness that would limit compliance with study requirements.\n* Patients who have been diagnosed with another cancer or myeloproliferative disorder in the past 5 years except for superficial bladder cancer, non-melanoma skin cancers, or a low grade prostate cancer not requiring therapy.\n* Has a diagnosis of immunodeficiency.\n* Presence of any tissue or organ allograft, regardless of need for immunosuppression, including corneal allograft. Patients with a history of allogeneic hematopoietic stem cell transplant will be excluded.\n* Any other sound medical or psychiatric reason as determined by the Investigator.\n* Patient is, at the time of signing informed consent, a regular user (including \"recreational use\") of any illicit drugs or other substance abuse (including alcohol) that could potentially interfere with adherence to study procedures or requirements.\n* Patient is unwilling or unable to follow the study schedule for any reason.\n* Patient is pregnant or breastfeeding.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":100,"SS_ID":"05254184001","EMAIL":[{"email":"kmarron1@jhmi.edu"},{"email":"mfitzpa7@jhmi.edu"}],"GEO":[39.29038,-76.61219]},{"TITLE":"Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Both sexes\n* \u2265 18 years old\n* Pathologically confirmed diagnosis of NSCLC\n* Stage IIIB - IV by the American Joint Committee of Cancer Version 8.\n* Candidates to receive EGFR-TKI treatment (1st \\& 2nd generation TKI)\n* ECOG score \u2264 2\n* Life expectancy \\> eight weeks\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Patients who cannot attend the first protocol appointment.\n* Treatment with other anti-cancer therapy\n* Participating in other clinical trials in the former four weeks\n* Any other serious condition or uncontrolled active infection, altered mental status or psychiatric disorder that, in the investigator\u00b4s opinion, would limit the ability of an individual to meet the requirements of the study or which affects the interpretability of the results.\n* Active hepatitis virus infection (any serotype) or chronic infection with a potential risk of reactivation evaluated through a serological panel.\n* Active HIV infection.\n* Breastfeeding.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"05852990001","EMAIL":[{}],"GEO":[19.42847,-99.12766]},{"TITLE":"ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma","CRITERIA":"Inclusion Criteria:\n\n1. Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form.\n2. Age \u2265 18 years.\n3. Histopathology or cytology confirmed and recorded local progression or metastatic Advanced Squamous Cell Carcinoma without systemic treatment.\n4. ALK fusion positive evaluated by IHC (ventana), NGS or FISH.\n5. ECOG 0 - 1.\n6. Predicted survival \u2265 12 weeks.\n7. Adequate bone marrow hematopoiesis and organ function\n8. Presence of measurable lesions according to RECIST 1.1.\n9. Subjects with stable brain metastases may be included in the study.\n\nExclusion Criteria:\n\n1. Prior systemic therapy for locally advanced or metastatic disease.\n2. Subjects who have received any of the following treatments must be excluded:\n\n   * Treatment with molecules such as EGFR, VEGFR antibodies within 4 weeks prior to the first dose of study drug.\n   * Have received radiation within 14 days prior to the first dose or have not recovered from radiation-related toxicity. Chest and extra-brain palliative radiotherapy, stereotactic radiosurgery, and stereotactic body radiotherapy may be performed 7 days prior to the first dose.\n   * Ongoing (or inability to discontinue) possibly potent CYP1A2, CYP3A inhibitor (1 week), or inducer (2 weeks) drug therapy or herbal supplements within 1-2 weeks prior to the first dose.\n3. Presence of spinal cord compression or meningeal metastasis.\n4. History of other malignant tumors within 2 years.\n5. Adverse events (except alopecia of any degree) of CTCAE \\> grade 1 due to prior treatment (e.g., adjuvant chemotherapy, radiotherapy, etc.) prior to the first dose.\n6. History of stroke or intracranial hemorrhage within 6 months prior to the first dose.\n7. The presence of any severe or poorly controlled systemic disease, including poorly controlled hypertension and active bleeding in the judgment of the investigator.\n8. Subjects with persistent or active infection, including but not limited to hepatitis B (HBV), hepatitis C (HCV), human immunodeficiency virus (HIV) and COVID-19 infection.\n9. Heart-related diseases or abnormalities\n10. Past history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy or interstitial lung disease with active clinical symptoms, immune pneumonia caused by immunotherapy.\n11. Refractory nausea and vomiting, chronic gastrointestinal disease, difficulty swallowing drugs, or inability to adequately absorb sunvozertinib or anlotinib due to previous bowel resection.\n12. Live vaccine was given 2 weeks before the first medication.\n13. Women who are breastfeeding or pregnant.\n14. Hypersensitivity to the test drug and the ingredients.\n15. Other conditions assessed by the investigator to be unsuitable for participation in the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05014464001","EMAIL":[{"email":"zhangyongchang@csu.edu.cn"},{"email":"yangnong0217@163.com"}],"GEO":[28.19874,112.97087]},{"TITLE":"Phase 1\/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations","CRITERIA":"Phase 2 Eligibility:\n\nKey Inclusion Criteria Required for locally advanced or metastatic NSCLC:\n\n* Measurable disease by RECIST 1.1 criteria.\n* Adequate bone marrow or organ function.\n* Life expectancy of \u2265 3 months.\n* Sufficient performance status.\n* Confirmed NSCLC, without small cell lung cancer transformation with or without brain metastases.\n* Disease progression following or intolerance of standard of care (excluding patients in the treatment-na\u00efve non-classical driver cohort):\n\n  * Cohort 1 (Non-Classical driver cohort): Advanced\/metastatic NSCLC with a non-classical driver EGFR mutation (eg, G719X) following up to 2 lines of therapy with only 1 prior EGFR TKI regimen (third-generation preferred; other approved EGFR TKI acceptable).\n  * Cohort 2 (Acquired resistance C797S cohort): Advanced\/metastatic NSCLC with the acquired resistance C797S EGFR mutation following up to 2 lines of therapy, including only one EGFR TKI, which must be a third generation EGFR TKI (eg, osimertinib).\n  * Cohort 3 (First-line non-classical driver cohort): Treatment-na\u00efve advanced\/metastatic NSCLC with a non-classical driver EGFR mutation (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion.\n* Identification of one (or more) of the following EGFR mutations by Next Generation Sequencing (NGS) as determined by a local assay performed in a validated laboratory in the absence of other known resistance mutations (eg, T790M, MET):\n\n  * Non-classical driver EGFR mutations (eg, L861R, S768I, G719X).\n  * EGFR acquired resistance mutation (eg, C797S) to a 3rd generation EGFR TKI.\n  * For Phase 2, dose expansion, patients in Cohort 1 who received 3rd generation EGFR TKI (eg, osimertinib), the NGS report within 6 months prior to the start of Screening is acceptable. For patients in Cohort 2, the NGS report must be from the last disease progression on the immediate prior therapy. For patients in Cohort 3, the NGS report must be at the time of diagnosis.\n\nKey Exclusion Criteria:\n\n* Known resistant mutations in tumor tissue or by liquid biopsy (eg, T790M, MET).\n* Received more than 1 EGFR TKI therapy (ie, erlotinib or gefitinib) for the treatment of metastatic or recurrent EGFR NSCLC.\n* Any history of interstitial lung disease related to EGFR TKI use.\n* Symptomatic or radiographic leptomeningeal disease.\n* Symptomatic brain metastases or spinal cord compression requiring urgent clinical intervention.\n* Unresolved toxicity from prior therapy.\n* Significant cardiovascular disease.\n* Major surgery within 4 weeks of study entry or planned during study.\n* Ongoing or recent anticancer therapy or radiation therapy.\n* Evidence of malignancy (other than study-specific malignancies) requiring active therapy within the next 2 years.\n* Active hepatitis B or C infection and\/or known human immunodeficiency virus (HIV) carrier.\n* Poorly controlled gastrointestinal disorders.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05256290024","EMAIL":[{"email":"swoodman@fredhutch.org"}],"GEO":[47.60621,-122.33207]},{"TITLE":"Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage \u2162 NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Written informed consent provided.\n* Unresectable stage III non-small cell lung cancer confirmed by histopathology or cytology.\n* ECOG score is 0 or 1.\n* Adequate hematological function, liver function and renal function.\n\nExclusion Criteria:\n\n* Previously received systemic anti-tumor therapy for non-small cell lung cancer.\n* history or current (non-infectious) pneumonia\/interstitial pneumonia requiring steroid treatment.\n* History or active pulmonary tuberculosis.\n* Active infections that require systemic treatment.\n* History or suspected autoimmune disease or immune deficiency who, in the judgment of the investigator, cannot tolerate immunotherapy.\n* Untreated active Hepatitis B.\n* Has a known history of human immunodeficiency virus (HIV) infection (HIV 1\/2 antibody positive).\n* Grade 3 or above peripheral neuropathy.\n* Severe allergic history to pemetrexed, paclitaxel, albumin-bound paclitaxel, carboplatin or other preventive drugs.\n* Underlying severe or uncontrolled disease.\n* Malignant tumors other than NSCLC within 5 years.\n* Any medical condition requiring systemic treatment with corticosteroids (prednisone or equivalent at a dose of \\>10mg\/ day) or other immunosuppressive agents within 14 days prior to treatment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":70,"SS_ID":"05611879001","EMAIL":[{"email":"Yfa01087@btch.edu.cn"}],"GEO":[39.9075,116.39723]},{"TITLE":"Abequolixron (RGX-104) and Durvalumab in Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Willing and able to provide written informed consent obtained to participate in the study and\n\n   HIPAA authorization for the release of personal health information.\n2. Age \u2265 18 years at the time of consent.\n3. Histologically or cytologically confirmed non-small cell lung cancer for which surgical resection\n\n   would be standard of care.\n4. ECOG Performance Status of 0-1\n5. Body weight of \\> 40 kg\n6. Is able to swallow and retain oral medication.\n\nExclusion Criteria:\n\n1. Participation in another clinical study with an investigational product during the last 3 weeks\n2. Concurrent enrollment in another clinical study unless it is an observational (non-interventional)\n\n   clinical study or during the follow-up period of an interventional study.\n3. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment with the\n\n   exception of those mentioned in this protocol. Concurrent use of hormonal therapy for noncancer-\n\n   related conditions (e.g., hormone replacement therapy) is acceptable.\n4. Lack of full recovery from a major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP.\n5. History of allogenic organ transplantation.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05911308002","EMAIL":[{"email":"lqhiggin@ad.unc.edu"},{}],"GEO":[35.9132,-79.05584]},{"TITLE":"Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients","CRITERIA":"Inclusion Criteria:\n\nPatients fulfilling all of the following inclusion criteria at screening may be enrolled in the trial.\n\n* The inclusion criteria are irrespective from the tumor burden at the time of primary diagnosis before initiation of first line systemic therapy. Neurosurgical diagnostic resection of one single CNS metastasis or laparoscopic resection of one adrenal metastasis before trial inclusion is allowed.\n* Adults (18 years or older)\n* Tissue confirmed, pre-treatment clinical stage IV NSCLC\n* ECOG performance status \u2264 1\n* Patients responding after 3 cycles (4th bridging cycle up until randomization is allowed) or 3 months of first line SoC systemic therapy with PR or SD in restaging imaging, and presenting with (induced) oligometastatic or oligopersistent NSCLC defined as a maximum of 5 residual extracranial, distant metastases\n* Patients may have up to 5 cranial metastases in addition to the oligoresidual extracranial metastases as long as they are amenable for radiotherapy or surgery.\n* The primary tumor and all oligopersistent metastases must be amenable for radical LAT (surgery or radiotherapy)\n* Patients of reproductive age agree to use double contraception during the study\n* Patient is able to understand trial procedures and is able\/willing to adhere to trial procedures as confirmed by signature\n\nExclusion Criteria:\n\nThe presence of any one of the following exclusion criteria at screening will lead to exclusion of the participant:\n\n* Serious concomitant disorder that would compromise patient safety during LAT\n* Unresolved complications from initial systemic anticancer treatment, higher than CTCAE grade 2\n* Metastatic locations such as malignant ascites, malignant pleural or malignant pericardial effusion, diffuse lymphangiosis of skin or lung, diffuse bone marrow metastasis, abdominal masses\/abdominal organomegaly, identified by physical exam that is not measurable by reproducible imaging techniques, leptomeningeal carcinomatosis\n* Women who are pregnant or breast feeding\n* Patient is currently involved in another trial if either: interventional trial that aims to improve survival, not permitted by other trial, would result in too much patient burden","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06114108008","EMAIL":[{"email":"isabelle.schmitt-opitz@usz.ch"},{}],"GEO":[47.36667,8.54999]},{"TITLE":"Evaluation of Clinical Performance and IVD Test of LifeOS Digital PCR Liquid Biopsy Kits for EGFR T790M Mutation","CRITERIA":"Inclusion Criteria:\n\n1. aged \u226518 years old.\n2. Patients with Stage IIIB or IV non-small cell lung cancer (NSCLC) with EGFR mutations.\n\nExclusion Criteria:\n\n1. Pregnant women.\n2. Any condition that, in the opinion of the doctors, may pose a severe risk to the patient or interfere with trial results or participation.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06573073001","EMAIL":[{"email":"slyu@ntu.edu.tw"}],"GEO":[25.04776,121.53185]},{"TITLE":"Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Signed informed consent by patients \u2265 18 years of age and, assent for patients \u2265 12 up to \\< 18 years of age\n* Patients must have radiographically-recurrent or radiographically-progressive disease that is measurable using the appropriate tumor response criteria (e.g. RECIST version 1.1)\n* Archival tumor tissue (preferably less than 3 years old) or fresh tumor tissue for correlative studies is required\n* If brain metastases are present, they must have been previously treated and be stable as assessed by radiographic imaging\n\n(Closed to Enrollment) Substudy A-specific inclusion criterion:\n\n* Patients must have a report of histologically confirmed diagnosis of melanoma or other solid tumor and a concurrent BRAF fusion, CRAF\/RAF1 fusion, or CRAF\/RAF1 amplification through a tumor or liquid biopsy as assessed by genomic sequencing, polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), or another clinically accepted molecular diagnostic method recognized by local laboratory or agency.\n\nSubstudy B-specific inclusion criterion:\n\n* Patients must have a report of histologically confirmed diagnosis of melanoma or other solid tumor and a concurrent MAPK pathway alteration (genomic alterations in RAS, RAF, MEK, or NF1) through a tumor or liquid biopsy as assessed by genomic sequencing, PCR, FISH, or another clinically accepted molecular diagnostic method recognized by local laboratory or agency.\n\nExclusion Criteria:\n\n* Known presence of concurrent activating mutation\n* Patients with current evidence or a history of central serous retinopathy (CSR), retinal vein occlusion (RVO)\n\n(Closed to Enrollment) Substudy A-specific exclusion criterion:\n\n* Prior therapy of any RAS- RAF-, MEK-, or ERK-directed inhibitor therapy","SEX":"ALL","AGE_MIN":12,"AGE_MAX":200,"SS_ID":"04985604013","EMAIL":"clinicaltrials@dayonebio.com","GEO":[43.70011,-79.4163]},{"TITLE":"Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Male or female patients: \u226518 years old\n2. Histologically or cytologically confirmed non-small cell lung cancer, and the disease has progressed after first-generation and\/or second-generation TKIs treatment with first-line therapy and no T790 mutation, or after third-generation EGFR-TKI treatment After the disease progresses, the guidelines do not recommend a standard protocol.\n3. No other concurrent cancer.\n4. At least one previously unirradiated lesion that can be accurately measured at baseline with longest diameter \u2265 10 mm (must have a short lymph node excluding axis \u2265 15 mm) according to RECIST criteria with computed tomography (CT), magnetic resonance imaging (MRI) or clinical examination for accurate repeated measures. Or an unevaluable lesion, including but not limited to pleural and ascites, bone metastasis, etc.\n5. ECOG physical condition score: 0-3 points.\n6. Expected survival period \u2265 3 months.\n7. The function of major organs is good, that is, the relevant inspection indicators within 14 days before randomization meet the following requirements: a) Routine blood test:i. Hemoglobin \u2265 90 g\/L (no blood transfusion within 14 days); ii. Neutrophil count \\> 1.5\u00d7109\/L; iii. Platelet count \u2265 90\u00d7109\/L; b) Biochemical examination: i. Total bilirubin \u2264 1.5\u00d7ULN (upper limit of normal); ii. Blood alanine aminotransferase (ALT) or blood aspartate aminotransferase (AST) \u2264 2.5\u00d7ULN; if liver metastasis, ALT or AST \u2264 5\u00d7ULN; iii. Endogenous creatinine clearance \u2265 60 ml\/min (Cockcroft-Gault formula); c) Cardiac Doppler ultrasound assessment: Left ventricular ejection fraction (LVEF) \u2265 50%.\n8. Sign the informed consent.\n9. The patient is willing and able to comply with the protocol during the study, including receiving treatment and scheduled visits and examinations, including follow-up.\n\nExclusion Criteria:\n\n1. Participated in clinical trials of other drugs within four weeks.\n2. Histologically or cytologically confirmed small cell, large cell neuroendocrine or carcinoid.\n3. There are clinical symptoms or diseases of the heart that cannot be well controlled, such as: NYHA class 2 or higher heart failure, unstable angina pectoris, myocardial infarction within 1 year, clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention of patients.\n4. For female subjects: should be surgically sterilized, postmenopausal patients, or agree to use a medically approved contraceptive during the study treatment period and within 6 months after the end of the study treatment period; Serum or urine pregnancy test must be negative within 7 days and must be non-nursing. Male subjects: Patients who should be surgically sterilized, or who agree to use a medically-approved contraceptive method during the study treatment period and within 6 months after the end of the study treatment period.\n5. The patient has active pulmonary tuberculosis, bacterial or fungal infection (\u2265 grade 2 of NCI-CTC, 3rd edition); HIV infection, HBV infection, HCV infection.\n6. Those who have a history of psychotropic substance abuse and cannot quit or have mental disorders.\n7. The subject has any active autoimmune disease or has a history of autoimmune disease (such as the following, but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, nephritis, hyperthyroidism, thyroid Reduced function; subjects with vitiligo or complete remission of asthma in childhood without any intervention in adulthood can be included; subjects with asthma requiring bronchodilator medical intervention are not included).\n8. According to the judgment of the investigator, there are concomitant diseases that seriously endanger the patient's safety or affect the patient's completion of the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05573373001","EMAIL":[{"email":"quanliu@jiangnan.edu.cn; quanliu.lq@outlook.com"},{}],"GEO":[31.56887,120.28857]},{"TITLE":"Couple-Based Meditation for Metastatic Lung Cancer Patients and Their Partners","CRITERIA":"Inclusion Criteria:\n\n1. ALL PHASES, PATIENTS ONLY: Diagnosed with stage IV Non-Small Cell Lung Cancer (NSCLC)\n2. ALL PHASES, PATIENTS ONLY: Currently receiving treatment (e.g. radiotherapy, chemotherapy) at MD Anderson Cancer Center\n3. ALL PHASES, PATIENTS ONLY: Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2\n4. ALL PHASES, PATIENTS ONLY: Have a romantic partner with whom they have resided for a minimum of 6 months\n5. ALL PHASES, PATIENTS AND PARTNERS: Must be at least 18 years old\n6. ALL PHASES, PATIENTS AND PARTNERS: Able to read and speak English\n7. ALL PHASES, PATIENTS AND PARTNERS: Able to provide consent.\n\nExclusion Criteria:\n\n1. ALL PHASES, PATIENTS AND PARTNERS: Not oriented to time, place, or person as deemed by the clinical team\n2. ALL PHASES, PATIENTS AND PARTNERS: Regular (self-defined) participation in psychotherapy or a formal cancer support group\n3. ALL PHASES, PATIENTS AND PARTNERS: Prior enrollment in a couple-based mind-body intervention research study (protocols 2011-1179, 2013-0496, 2014-0036) conducted by the principal investigator including phase 1 or phase 2 of the current study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"02596490002","EMAIL":"KMilbury@mdanderson.org","GEO":[29.76328,-95.36327]},{"TITLE":"TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)","CRITERIA":"Inclusion Criteria:\n\n1. Willing to follow the treatment protocol and visit schedule, and participate in the study with the ICF signed;\n2. \u2265 18 years of age on the day of ICF signing, regardless of gender.\n3. With ALK-positive advanced inoperable NSCLC and having disease progression or intolerance after continuous treatment with second-generation ALK inhibitors;\n4. Providing prior ALK positive test results at screening;\n5. Patients could have metastases to central nervous system at screening if the condition is asymptomatic, stable or completely recovered;\n6. Drug discontinuation for \u2265 5 half-lives prior to the first dose for subjects previously treated with ALK inhibitors;\n7. At least one measurable lesion;\n8. An ECOG PS score within 0-2;\n9. Adequate bone marrow, liver, kidney, coagulation and pancreatic functions;\n10. Expected survival \u2265 3 months;\n11. Willing to take effective contraceptive measures (for men of reproductive potential and women of reproductive age only) from ICF signing to 6 months after administration of the investigational drug. Women of reproductive age include women before menopause and within 2 years after menopause. Those women must have a negative pregnancy test \u2264 7 days prior to the first dose of the investigational drug.\n\nExclusion Criteria:\n\n1. Previous use of any third-generation ALK inhibitors other than TGRX-326;\n2. Known hypersensitivity to any of the active ingredients or excipients of TGRX-326 or a history of severe allergic reactions that makes himself\/herself unsuitable for TGRX-326 treatment in the judgment of the investigator;\n3. Having another type of cancer except for lung cancer;\n4. Major surgery within 4 weeks prior to the first dose;\n5. Spinal cord compression caused by tumor, unless the subject achieves significant pain control and full recovery of neurological function within 4 weeks prior to the first dose.\n6. Abnormal gastrointestinal function that affect absorption within the past 6 months;\n7. History of active pneumonia or clinically significant interstitial pneumonia, or radiation or drug-induced lung disorder with treatment needs;\n8. Cardiac insufficiency;\n9. Abnormal and clinically significant QTc on ECG or need of concomitant use of any drug known to prolong QT interval and cause torsades de pointes;\n10. Uncontrolled hypertension after drug treatment;\n11. Uncontrolled hyperglycaemia, acute attack of cholelithiasis, and susceptibility to acute pancreatitis;\n12. Severe or uncontrolled systemic diseases causing expected intolerance to the investigational drug as judged by the investigator;\n13. Use within 14 days before the first dose or expected concomitant use during the treatment period of drugs that pose risk of QTC interval prolongation and\/or ventricular tachycardia;\n14. Previous antineoplastic treatments within 28 days prior to the first dose of the investigational drug;\n15. Toxic reactions associated with prior surgery and prior antineoplastic therapies that have not recovered and may affect the subject safety as assessed by the investigator.\n16. Clinically significant active bacterial, fungal or viral infections, including a positive result for hepatitis B surface antigen and HBV DNA \u2265 ULN, one or more positive results for hepatitis C antibody or HIV antibody, or the presence of any uncontrolled infection.\n17. Use of strong CYP3A4 inducers or inhibitors or CYP3A4 substrates with a narrow therapeutic window within two weeks prior to the first dose of the investigational drug;\n18. Pregnant and breastfeeding female;\n19. Women of childbearing age who are unwilling or unable to use acceptable methods for contraception during the entire treatment period in the trial and within 6 months after the last dose of the investigational drug (women of childbearing age include: any one with menarche, and those who have not received successful artificial sterilization \\[hysterectomy, bilateral fallopian tube ligation, or bilateral oophorectomy\\] or premenopausal women); a fertile male patient who is unwilling or unable to take effective contraceptive measures, and whose partner is a woman of childbearing age;\n20. Being involved in other clinical studies (except for the non-interventional phase of interventional clinical study, such as survival follow-up period); less than 4 weeks from the end of the dose of other investigational drug to the first dose of the investigational drug or 5 half-lives of the previous drug, whichever is shorter;\n21. Any mental or cognitive disorders which may limit subjects' understanding and implementation of the informed consent form;\n22. Other situations, such as poor compliance, which are considered by the investigator to be not suitable for participation in the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05955391001","EMAIL":[{"email":"zhangli6@mail.sysu.edu.cn"}],"GEO":[23.11667,113.25]},{"TITLE":"A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) \u226550% (MK-1084-004)","CRITERIA":"The main inclusion and exclusion criteria include but are not limited to the following:\n\nInclusion Criteria:\n\n* Has a histologically or cytologically confirmed diagnosis of NSCLC\n* Has newly diagnosed Stage IV NSCLC by American Joint Committee on Cancer (AJCC) Staging Manual, Version 8\n* Has measurable disease based on RECIST 1.1\n* Has provided tumor tissue that demonstrates PD-L1 expression in \u226550% of tumor cells\n* Has provided tumor tissue that demonstrates presence of KRAS G12C mutation\n* Has life expectancy of at least 3 months\n* Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days before randomization\n* For participant assigned male sex at birth: If capable of producing sperm, participant must agree to the following during the study treatment period and for at least 10 days after the last dose of oral intervention: Either be abstinent or must agree to use male condom plus additional contraceptive method.\n* For participant assigned female sex at birth: Either be a person of nonchildbearing potential (PONCBP) or must agree to follow contraceptive guidance during the study treatment period and for at least 10 days after the last dose of oral intervention and 120 days after the last dose of pembrolizumab. Must abstain from breastfeeding during the study intervention period and for at least 120 days after study intervention.\n* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART).\n* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before randomization\n\nExclusion Criteria:\n\n* Diagnosis of small cell lung cancer\n* Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease\n* Has a known history of, or active, neurologic paraneoplastic syndrome\n* Has an active infection requiring systemic therapy\n* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QT interval corrected for heart rate by Fridericia's formula (QTcF) interval to \\>470 ms, and\/or other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention\n* Is considered a poor medical risk due to a serious, uncontrolled medical disorder or nonmalignant systemic disease. Examples include, but are not limited to, uncontrolled major seizure disorder, unstable spinal cord compression, or superior vena cava syndrome.\n* Has one or more of the following ophthalmological findings\/conditions: intraocular diagnosis of central serous retinopathy, retinal vein occlusion, or retinal artery occlusion, diagnosis of retinal degenerative disease pressure \\>21 mm Hg and\/or any diagnosis of glaucoma\n* Is unable to swallow orally administered medication, or has a gastrointestinal disorder affecting absorption (eg, gastrectomy, partial bowel obstruction, or malabsorption)\n* Received prior systemic anticancer therapy for their metastatic NSCLC\n* Received prior therapy with an anti-programmed cell death-1 (anti-PD-1), anti-programmed cell death-ligand 1 (anti-PD-L1), or anti PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor within 12 months before diagnosis of metastatic NSCLC\n* Has received radiotherapy within 2 weeks of start of study intervention\n* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.\n* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration\n* Has known active central nervous system (CNS) metastases and\/or carcinomatous meningitis.\n* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention\n* Active autoimmune disease that has required systemic treatment in the past 2 years\n* History of (noninfectious) pneumonitis\/interstitial lung disease that required steroids or has current pneumonitis\/interstitial lung disease\n* HIV-infected participants with a history of Kaposi's sarcoma and\/or Multicentric Castleman's Disease\n* History of allogeneic tissue\/solid organ transplant\n* Has not fully recovered from any effects of major surgical procedure. Surgical procedures that required general anesthesia must be completed at least 2 weeks before first study intervention administration.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06345729019","EMAIL":[{}],"GEO":[49.23278,28.48097]},{"TITLE":"Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab","CRITERIA":"Inclusion Criteria:\n\n* Diagnosis of malignant solid tumor (World Health Organization \\[WHO\\] criteria).\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n* For Part 1 only - advanced solid tumors including (but not limited to) non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), gastroesophagel junction adenocarcinoma (GEA), colorectal cancer (CRC), and renal cell carcinoma (RCC), who have progressed on all standard of care therapy and are not amenable to surgical resection or other approved therapeutic options that have demonstrated clinical benefit.\n* For Part 2 only - advanced non-squamous squamous Non-Small Cell Lung Cancer (NSCLC) that have progressed after treatment with at least:\n\n  * Platinum-based chemotherapy and an immune checkpoint inhibitor and\/or appropriate targeted therapy for an actionable gene alteration, if applicable, for non-squamous wtEGFR NSCLC (Part 2i) and squamous NSCLC (Part 2iii).\n  * Platinum-based chemotherapy doublet and tyrosine kinase inhibitor(s) (TKI\\[s\\]) for non- squamous mutEGFR NSCLC (Part 2ii).\n  * Must have no more than 2 lines of prior cytotoxic chemotherapy excluding adjuvant therapy and must have advanced NSCLC that is not amenable to surgical resection or other approved therapeutic options that have demonstrated clinical benefit.\n* For Part 3 only - Participants with advanced GEA that has progressed after treatment with at least 1 prior cytotoxic chemotherapeutic regimen for locally advanced or metastatic disease and have not received more than 2 prior lines of cytotoxic chemotherapy regimens. Participants must have progressed on\n\n  * If applicable, an immune checkpoint inhibitor.\n  * If applicable, appropriate available therapies, including HER2-directed therapies.\n\nParticipants who are considered ineligible for or are intolerant of standard therapy per investigator are eligible.\n\n* For Part 4 only - Participants with history of advanced histopathologically or cytologically confirmed colorectal cancer (CRC) that does not harbor the BRAF V600E mutation and are not dMMR+\/MSI-Hi with progression on:\n\n  * A fluoropyrimidine (e.g., 5-fluorouracil or capecitabine).\n  * Oxaliplatin.\n  * Irinotecan.\n  * If applicable, anti-EGFR (including, but not limited to cetuximab or panitumumab).\n  * If applicable, anti-vascular endothelial growth factor (VEGF) monoclonal antibody (including but not limited to bevacizumab, ramucirumab, or aflibercept).\n  * If applicable, targeted therapy\n  * Participants who are considered ineligible for or are intolerant of standard therapy per investigator are eligible. Prior trifluridine\/tipiracil (TAS-102) or Regorafenib treated participants are eligible.\n* For Part 5 only - participants with advanced histologically or cytologically confirmed solid tumors characterized by MET amplification who are not amenable to surgical resection and who have disease progression after at least one prior systemic therapy and\/or who have no satisfactory alternative treatment options. Participants who are intolerant to standard treatment are eligible.\n\nFor Part 6 only - Participants with advanced histologically or cytologically confirmed solid tumors harboring MET mutations including: mutations in the tyrosine kinase domain, the juxtamembrane region and the extracellular domain (as locally determined by next-generation sequencing (NGS) or a validated qPCR on tissue), who are not amenable to surgical resection and who have disease progression after at least one prior systemic therapy and\/or who have no satisfactory alternative treatment options.\n\n* Intolerant to the standard treatment are eligible\n* For Part 7 (CRC combination) only: Participants with history of advanced histopathologically or cytologically confirmed CRC that does not harbor the mutation and are not dMMR+\/MSI-H with progression on:\n\n  * A fluoropyrimidine (e.g., 5-fluorouracil or capecitabine)\n  * Oxaliplatin\n  * Irinotecan\n  * If applicable, anti-EGFR (including, but not limited to cetuximab or panitumumab)\n  * If applicable, anti-vascular endothelial growth factor (VEGF) monoclonal antibody (including but not limited to bevacizumab, ramucirumab, or aflibercept)\n  * If applicable, targeted therapy Participants who are considered ineligible for or are intolerant of standard therapy per investigator are eligible. Participants treated previously with TAS-102 or regorafenib are not eligible.\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.\n* Laboratory values meeting the criteria outlined in the protocol.\n\nExclusion Criteria:\n\n* History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, nor any evidence of active ILD or on screening chest CT scan..\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis.\n* History of clinically significant, intercurrent lung-specific illnesses, as noted in the protocol.\n* For Part 7 only: Prior TAS-102 or regorafenib treated participants are not eligible.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05029882079","EMAIL":"abbvieclinicaltrials@abbvie.com","GEO":[24.95233,121.20193]},{"TITLE":"Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6","CRITERIA":"Inclusion Criteria:\n\n\\[68Ga\\]Ga DOTA-5G PET\/CT Inclusion Criteria:\n\n1. Ability to understand and willingness to sign a written informed consent document.\n2. Age 18 or more years\n3. Pathologically confirmed NSCLC with metastatic disease and measurable disease per RECIST (version 1.1) (i.e. at least 1 lesion \\> 1 cm or lymph node \\> 1.5 cm in short axis)\n4. Participant must have documented tumor progression for metastatic disease during or following at least one prior FDA approved systemic regimen as established by diagnostic imaging.\n5. Available archival tumor tissue (excisional, core, or FNA is acceptable). Tissue from a metastatic site is preferred when available.\n6. Eastern Cooperative Oncology Group Performance Status \u2264 2\n7. Participant must have completed prior systemic therapy at least 2 weeks (washout period) prior to \\[68Ga\\]Ga DOTA-5G PET scan. Any clinically significant toxicity (with the exceptions of hair loss and sensory neuropathy) related to prior therapy resolved to Grade 1 or baseline.\n8. Hematologic parameters defined as:\n\n   Absolute neutrophil count (ANC) \u2265 1000 cells\/mm3 Platelet count \u2265 100,000\/mm3 Hemoglobin \u2265 8 g\/dL\n9. Blood chemistry levels defined as:\n\n   AST, ALT, alkaline phosphatase \u2264 5 times upper limit of normal (ULN) Total bilirubin \u2264 2 times ULN Creatinine \u2264 2 times ULN\n10. Anticipated life expectancy \u2265 3 months\n11. Able to remain motionless for up to 30-60 minutes per scan\n\n\\[177Lu\\]Lu DOTA-ABM-5G therapy Inclusion Criteria:\n\n1. Completion of entry into \\[68Ga\\]Ga DOTA-5G PET study and completion of scan\n2. The presence of at least one measurable disease by \\[68Ga\\]Ga DOTA-5G PET\/CT (SUVmax\\>2-fold above normal bone, brain, lung or liver and identified on standard of care diagnostic imaging) Patients with a history of brain metastases and or any clinical concern for brain metastases will be evaluated with brain MRI as per standard of care for patients with metastatic NSCLC.\n\nExclusion Criteria:\n\n\\[68Ga\\]Ga DOTA-5G and \\[177Lu\\]Lu DOTA-ABM-5G therapy Exclusion Criteria:\n\n1. Participants with Class 3 or 4 NYHA Congestive Heart Failure\n2. Clinically significant bleeding within two weeks prior to trial. entry (e.g. gastrointestinal bleeding, intracranial bleeding)\n3. Pregnant or lactating women\n4. Major surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (i.e., larger than what is required for placement of a central venous access, percutaneous feeding tube, or biopsy) within 28 days prior to study day 1 or anticipated surgery within the subsequent 6 weeks\n5. Has an additional active malignancy requiring therapy within the past 2 years (other than early stage, surgically managed basal and squamous skin cancer and in situ malignancies of the breast and cervix)\n6. Active, uncontrolled bacterial, viral, or fungal infection(s) despite systemic therapy\n7. Psychiatric illness\/social situations that would interfere with compliance with study requirements\n8. Cannot undergo PET\/CT or SPECT\/CT scanning because of weight limits (350 lbs.)\n9. Known interstitial lung disease or pre-existing pulmonary fibrosis\n10. INR \\>2.0: PTT\\>15 seconds above ULN","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06228482001","EMAIL":[{"email":"jlsutcliffe@ucdavis.edu"},{}],"GEO":[38.58157,-121.4944]},{"TITLE":"A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation","CRITERIA":"Inclusion Criteria:\n\nKey Inclusion Criteria:\n\nMale or female at least 18 years of age at the time of signing the ICF prior to initiation of any study specific activities\/procedures\n\nAdvanced malignant solid tumors with KRAS G12C mutation- as determined by genetic testing\n\nMust have failed or refused standard of care therapy, are not eligible for standard of care therapy, or cannot benefit from standard of care therapy, in the opinion of the Investigator\n\nAt least 1 measurable target lesion that meets the definition of RECIST v1.1\n\nECOG Performance Status of 0 or 1\n\nDemonstrate adequate organ function\n\nExpected survival time \\> 3 months in the opinion of the investigator\n\nMust be able to swallow oral medications and must not have gastrointestinal abnormalities that significantly affect drug absorption\n\nExclusion Criteria:\n\nKey Exclusion Criteria:\n\nHistory of another concurrent malignancy within 3 years prior to study entry, unless the malignancy was treated with curative intent and the likelihood of relapse is \\<5% in 2 years Note: Subjects with a history of squamous or basal cell carcinoma of the skin or carcinoma in the situ of the cervix may be enrolled\n\nUntreated or symptomatic central nervous system (CNS) metastases Note: Subjects with asymptomatic treated CNS metastases are eligible provided they have been clinically stable and not requiring steroids for at least 4 weeks\n\nClinically significant cardiovascular disease, including stroke or myocardial infarction within 6 months prior to first dose of HBI-2438; or the presence of unstable angina or congestive heart failure of New York Heart Association Grade 2 or higher\n\nAny unresolved Grade 2 or greater toxicity from previous anti-cancer therapy, except alopecia, within 4 weeks of first study treatment administration\n\nActive autoimmune diseases or history of autoimmune diseases that may relapse\n\nPregnant or nursing\n\nPrior treatment with any KRAS G12C inhibitors\n\nAny condition that required systemic treatment with either corticosteroids (\\>10 mg daily of prednisone or equivalent) or other immunosuppressive medication \u226414 days before the first study treatment administration\n\nTreatment with other investigational drugs\/devices within 4 weeks prior to first study treatment administration","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05485974014","EMAIL":[{"email":"marcia.cruzcorrea@panoncologytrials.com"},{}],"GEO":[18.39745,-66.04989]},{"TITLE":"Phase Ib\/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Age 18\\~75 years old, both male and female\n2. Stage 1: pathologically diagnosed, incurable NSCLC subjects who have failed standard treatment\n3. Stage 2: have a histologically or cytologically confirmed diagnosis of relapsed or metastatic NSCLC; have not received prior systemic treatment for their recurrent or metastatic NSCLC; PD-L1 TPS \\<50% as confirmed by central laboratory\n4. At least one measurable lesion based on RECIST v1.1 criteria\n5. ECOG PS score: 0-1 points\n6. Expected survival period \u2265 3 months\n7. Good levels of organ function\n8. Patients voluntarily joined the study and signed informed consent\n\nExclusion Criteria:\n\n1. Patients with EGFR activating mutation, positive ALK fusion gene or known ROS1 fusion gene\n2. Untreated brain metastases; or associated with meningeal metastases, spinal cord compression, etc.\n3. Uncontrolled pleural, pericardial, or ascites with clinical symptoms\n4. Severe bone damage caused by tumor bone metastasis\n5. Suffering from other malignant tumors in the past 3 years or at the same time\n6. Presence of any active or known autoimmune disease\n7. Systemic treatment with corticosteroids or other immunosuppressants within 2 weeks before the first dose\n8. Have clinical symptoms or diseases of the heart that are not well controlled\n9. Serious infection occurred within 1 month before the first dose\n10. Past or current active interstitial lung disease requiring treatment, non-infectious pneumonia requiring glucocorticoid system treatment; current active pneumonia or pulmonary function test confirmed severe impairment of pulmonary function\n11. With active pulmonary tuberculosis\n12. Known positive history of human immunodeficiency virus test or acquired immunodeficiency syndrome, known active viral hepatitis\n13. Known history of inflammatory bowel disease\n14. Inoculated with live attenuated vaccine within 28 days before the first dose\n15. Known allergic reaction to other monoclonal antibodies\n16. Received \\>30 Gy of pulmonary radiotherapy within 6 months before the first dose; received major surgical treatment, systemic chemotherapy, immunotherapy or other clinical trial drugs within 4 weeks before the first dose; within 2 weeks before the first dose Received palliative radiotherapy; oral molecularly targeted drugs, discontinued to less than 5 half-lives before first dose; failure to recover from toxicity and\/or complications of previous interventions to NCI-CTC AE \u22641 degree\n17. According to the judgment of the researcher, there are other factors that may affect the results of the study or cause the study to be terminated halfway.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05416775013","EMAIL":[{}],"GEO":[32.06167,118.77778]},{"TITLE":"[18F]F-AraG PET Imaging to Visualize Tumor Infiltrating T-cell Activation in Non-small Cell Lung Cancer.","CRITERIA":"Inclusion Criteria:\n\n1. Histologically confirmed NSCLC, a histological biopsy is mandatory.\n2. Patients that are resectable upfront as per multidisciplinary tumor board evaluation.\n3. Be willing and able to provide written informed consent for the trial.\n4. Be above 18 years of age on day of signing informed consent.\n5. Have a performance status of 0-1 on the ECOG Performance Scale at screening.\n\nExclusion Criteria:\n\n1. Subjects with a condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of screening. Inhaled or topical steroids, and adrenal replacement steroid \\>10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.\n2. Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n3. Patient is pregnant or breastfeeding or expecting to conceive within the projected duration of the trial, starting with the screening visit through 12 weeks after the last \\[18F\\]F-AraG PET scan.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05157659001","EMAIL":[{"email":"i.bahce@amsterdamumc.nl"},{"email":"long@vumc.nl"}],"GEO":[52.37403,4.88969]},{"TITLE":"a Single-arm, Single-center, Open Clinical Study","CRITERIA":"Inclusion Criteria:\n\n* Participants who meet all of the following criteria are eligible for admission to the study:\n\n  1. 18\u2264 age \u226475 years old, male or female;\n  2. Patients with incurable advanced gastric cancer, esophageal cancer, cervical cancer, triple-negative breast cancer, non-small cell lung cancer, and other malignancies who have failed standard treatment (standard treatment failure is defined as those treated according to the 2022 CSCO Guidelines and whose tumor efficacy is assessed as disease progression (PD) or tumor recurrence or inability to tolerate existing treatment options);\n  3. There are tumor tissues or cancerous exudative thoracoabdominal fluid that can be used to isolate TRTs: the total volume of the solid tissue taken must be \\&amp;amp;gt; 0.5cm3 or the weight must be \\&amp;amp;gt;0.5g, the cancerous exudative thoracoabdominal fluid taken should contain at least 5\u00d710\\^8 total cells, and the lesions taken have not been treated with oncolytic virus.\n  4. There is at least one measurable lesion (according to RECIST1.1 criteria) even after TRTs sampling\/puncture biopsy;\n  5. ECOG score 0-1;\n  6. The expected survival period is greater than 3 months;\n  7. Sufficient hematology and end-organ function, as defined by the following laboratory test results, should be completed within 14 days prior to TRTs tumor tissue collection:\n\n     1. Blood routine: white blood cell count \u22652.5\u00d710\\^9\/L; Absolute neutrophil count (ANC) \u22651.5\u00d710\\^9\/L; Absolute lymphocyte count (ALC) \u22651.0\u00d710\\^9\/L; Platelet (PLT) \u226580\u00d710\\^9\/L; Hemoglobin (HGB) \u226590g\/L;\n     2. Coagulation function: International standardized ratio of prothrombin time (INR) \u22641.5\u00d7ULN; Partial prothrombin time (APTT) \u22641.5\u00d7ULN, unless anticoagulant therapy has been received within the previous 7 days;\n     3. Renal function: serum creatinine \u22641.5mg\/dL (or 132.6\u03bcmol\/L) or creatinine clearance \u226560mL\/ min;\n     4. Liver function: aspartate aminotransferase (AST\/SGOT) \u22643\u00d7ULN; Alanine transaminase (ALT\/SGPT) \u22643\u00d7ULN; Total bilirubin (TBIL) \u22641.5\u00d7ULN; Note: In patients with liver metastasis or primary liver tumor, aspartate and alanine aminotransferase should be \u22645\u00d7ULN; For patients with a history of Gilbert syndrome or suspected Gilbert syndrome, total bilirubin (TBIL) should be \u22643\u00d7ULN;\n     5. Urine routine: urinary protein \\&amp;amp;lt;2+, or 24-hour urinary protein quantity \\&amp;amp;lt;1g;\n     6. Left ventricular ejection fraction (LVEF) \u226550% by echocardiography;\n     7. Pulmonary function tests with FEV1\\&amp;amp;gt;60% or FEV1\/FVC\\&amp;amp;gt;0.7;\n     8. Blood oxygen saturation \u2265 93%.\n  8. Women of childbearing age who have a negative urine pregnancy test during screening and baseline and agree to use highly effective contraception for at least 1 year after the infusion; Male subjects whose partners are fertile must agree to use effective contraceptive methods and refrain from sperm donation for at least 1 year after the infusion;\n  9. No absolute or relative contraindications to surgery or puncture;\n  10. Any treatment for malignant tumors, including radiotherapy, chemotherapy, endocrine therapy, targeted therapy, tumor embolization, or Chinese medicine\/herbal therapy with anti-tumor indications, must be discontinued 7 days before TRT sampling;\n  11. Sign a written informed consent (ICF) voluntarily, and have good compliance with the protocol requirements for visits or planned visits and other relevant research procedures.\n\nExclusion Criteria:\n\n* Subjects who meet any of the following criteria will not be eligible to participate in this clinical trial:\n\n  1. Prior allergy to cyclophosphamide, fludarabine and interleukin-2 contraindications or to any component of the infusion product formulation or to other drugs to be used during the study (antibiotics, human serum albumin, dextran 40, etc.);\n  2. Any NCI CTCAE5.0 immune-related adverse reaction (irAE) grade \\&amp;amp;gt;3 that has been permanently discontinued during any previous immunotherapy;\n  3. Patients with prior primary immunodeficiency and active autoimmune disease;\n  4. Previous history of organ allotransplantation, allogeneic stem cell transplantation and kidney replacement therapy;\n  5. Patients with current or past irreversible interstitial lung disease (except those caused by radiotherapy);\n  6. Combined with 2 or more malignant tumors; (Except for the following cases: malignant tumors that have been cured, such as non-melanoma skin cancer and in situ cervical cancer, bladder cancer, breast cancer, thyroid cancer, etc. that have survived more than 5 years without disease.)\n  7. Uncontrolled co-morbidity includes, but is not limited to, uncontrolled hypertension (systolic blood pressure \u2265160mmHg and\/or diastolic blood pressure \u2265100mmHg) even after standard treatment, or any unstable cardiovascular and cerebrovascular disease, including transient ischemic attack, cerebrovascular accident, myocardial infarction, and unstable angina pectoral, that has occurred in the 6 months prior to treatment induction; Congestive heart failure rated III or IV by the New York Heart Association (NYHA); Ejection fraction \\&amp;amp;lt; 50%; Severe heart rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, degree II-III atrioventricular block, etc. Electrocardiogram results show clinically significant abnormalities, or QTcF\u2265450ms (if the first examination is abnormal, the interval of at least 5 minutes, retest twice, using the comprehensive result\/average value to judge eligibility);\n  8. Patients with esophageal or gastric varices that require immediate intervention (such as ligation or sclerotherapy) or are considered by the investigator or gastroenterologist or hepatologist to be at high risk of bleeding, have evidence of portal hypertension (including splenomegalysis on imaging), or have a history of varicose bleeding must undergo endoscopic evaluation within 3 months prior to enrollment;\n  9. Uncontrolled metabolic disorders, such as in patients with diabetes, or other non-malignant organ or systemic disease or cancer secondary reactions that can lead to higher medical risk and\/or uncertainty in the evaluation of survival;\n  10. Hepatic encephalopathy, hepatorenal syndrome or Child-Pugh grade C or more severe cirrhosis, liver failure;\n  11. Clinically uncontrollable third space effusion, such as pleural fluid and ascites that could not be controlled by drainage or other methods before enrollment;\n  12. Combined with other serious organic disease or mental illness;\n  13. Patients with central nervous system metastasis;\n  14. Uncontrolled systemic active infection;\n  15. Receive vaccination within 2 months before signing the informed consent, or plan to receive vaccination during the study;\n  16. Currently or within 30 days before signing the informed consent to participate in clinical trials of other drugs or biotherapeutics, except cell therapy that has been fully metabolized;\n  17. have used within 4 weeks prior to the treatment, or have concomitant disease or active autoimmune disease that the investigator determined required the use of glucocorticoids or other immunosuppressive drugs during the trial period, excluding local percutaneous absorption of glucocorticoids (i.e., no more than 5 mg\/ day of prednisone or equivalent doses of other glucocorticoids);\n  18. Surgical treatment, interventional therapy, radiotherapy, chemotherapy and immunotherapy for the studied disease were performed within 2 weeks before the treatment;\n  19. HIV positive, serological test positive for syphilis, or clinically active hepatitis B or C, including carriers of the virus (for hepatitis B, HBsAg positive persons should be excluded; For hepatitis C, HCVAB-positive patients need to be excluded);\n  20. Women who are breastfeeding during pregnancy or lactation;\n  21. Poor compliance due to physiological, family, social, geographical and other factors, unable to cooperate with the study protocol and follow-up plan;\n  22. Other conditions deemed unsuitable for participation in this experiment by the researcher.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06431100001","EMAIL":[{"email":"yizhang@zzu.edu.cn"}],"GEO":[34.75778,113.64861]},{"TITLE":"Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and\/or Metastatic Solid Tumors","CRITERIA":"Inclusion criteria\n\n* Patient must have histologically or cytologically confirmed advanced and\/or metastatic solid tumor malignancies for which standard curative or palliative measures do not exist, are no longer effective, or are not acceptable to the patient\n* Eastern Cooperative Oncology Group Performance Status 0-1\n* Fresh biopsies may be required\n* Women of childbearing potential and male participants must agree to remain abstinent or use contraceptive methods as defined by the protocol\n\nAdditional Specific Inclusion Criteria for Participants with Melanoma\n\n* Histologically confirmed, unresectable stage III or stage IV melanoma\n* Not more than 2 prior lines of treatment for metastatic disease are allowed prior to enrolling in the study\n* Prior treatment with an approved anti-PD-1 or anti-PD-L1 agent\n\nAdditional Specific Inclusion Criteria for Participants with Non-Small Cell Lung Cancer who Previously Received Treatment for Metastatic Disease\n\n* Participants with histologically confirmed advanced non-small cell lung cancer\n* Not more than 2 prior lines of treatment for metastatic disease are allowed prior to enrolling in the study\n* Previously treated with approved PD-L1\/PD-1 inhibitors\n* Tumor PD-L1 expression as determined by immunohistochemistry assay of archival tumor tissue or tissue obtained at screening\n\nAdditional Specific Inclusion Criteria for Participants with Esophageal Squamous Cell Carcinoma\n\n* Participants whose major lesion was histologically confirmed as squamous cell carcinoma or adenosquamous cell carcinoma of the esophagus\n* Participants who have previously received not more than 1 prior line of treatment for metastatic disease prior to enrolling in the study\n\nAdditional Specific Inclusion Criteria for Participants with Non-Small Cell Lung Cancer who Previously did not Receive Treatment for Metastatic Disease\n\n* Participants with histologically confirmed advanced non-small cell lung cancer\n* Tumor PD-L1 expression as determined by immunohistochemistry assay of archival tumor tissue or tissue obtained at screening\n\nExclusion criteria\n\n* Pregnancy, lactation, or breastfeeding\n* Known hypersensitivity to any of the components of RO7247669\n* Active or untreated central nervous system (CNS) metastases\n* An active second malignancy\n* Evidence of concomitant diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk from treatment complications\n* Positive HIV, hepatitis B, or hepatitis C test result\n* Known active or uncontrolled bacterial, viral, fungal, mycobacterial, parasitic, or other infection\n* Vaccination with live vaccines within 28 days prior to Cycle 1 Day 1\n* Treatment with oral or IV antibiotics within 2 weeks prior to Cycle 1 Day 1\n* Active or history of autoimmune disease or immune deficiency\n* Prior treatment with adoptive cell therapies, such as CAR-T therapies\n* Concurrent therapy with any other investigational drug \\< 28 days or 5 half-lives of the drug, whichever is shorter, prior to the first RO7247669 administration\n* Regular immunosuppressive therapy\n* Radiotherapy within the last 4 weeks before start of study drug treatment, with the exception of limited palliative radiotherapy\n* Prior treatment with a lymphocyte activation gene-3 (LAG-3) inhibitor\n\nAdditional Specific Exclusion Criteria for Participants with Non-Small Cell Lung Cancer who Previously Received Treatment for Metastatic Disease\n\n* Participants with the following muations, rearrangements, translocations are not eligible: EGFR, ALK, ROS1, BRAFV600E, and NTRK\n\nAdditional Specific Exclusion Criteria for Participants with Esophageal Squamous Cell Carcinoma\n\n* Prior therapy with any immunomodulatory agents\n\nAdditional Specific Exclusion Criteria for Participants with Non-Small Cell Lung Cancer who Previously did not Receive Treatment for Metastatic Disease\n\n* Prior therapy for metastatic disease is not permitted\n* Neo-adjuvant anti-PD-1 or anti-PD-L1 therapy is not allowed","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04140500033","EMAIL":"global-roche-genentech-trials@gene.com","GEO":[52.48142,-1.89983]},{"TITLE":"A Real-world Study of Durvalumab for Lung Cancer in China","CRITERIA":"Inclusion Criteria:\n\n1. Patient capable of proper therapeutic compliance, and accessible to correct follow-up.\n2. Written Informed Consent (IC) for trial treatment must be signed and dated by the patient and the investigator prior to any trial-related evaluation and\/or intervention.\n3. Age \u2265 18 years at time of study entry or adult according to each country regulations for age of majority.\n4. Patients must have histologically or cytologically documented diagnosis of NSCLC with a locally advanced, or locally recurrent, unresectable (stage III) disease (according to American Joint Committee on Cancer \\[AJCC\\] lung cancer edition 8). Histologically or cytologically documented extensive disease (American Joint Committee on Cancer Stage (8th edition) IV SCLC. Brain MRI or high-quality brain CT with intravenous contrast at the time of staging mandatory is strongly recommended.\n5. Patients who received definitive concurrent chemoradiation therapy and have not progressed were enrolled in the Cohort 1. Patients who received chemotherapy, radiotherapy or sequential chemotherapy were enrolled in the Cohort 2.\n6. Tumour sample requirements: Provision of an unstained tumor samples in a quantity sufficient to allow for analysis (\u22643 months newly collected sample is preferred, \u22646 months archival sample is also accepted.)\n7. No prior exposure to immune-mediated therapy including, but not limited to, other.\n8. anti-CTLA-4, anti-PD-1, anti-PD-L1, and anti-programmed cell death ligand 2.\n9. (anti-PD-L2) antibodies, excluding therapeutic anticancer vaccines.\n\nExclusion Criteria:\n\n1. Patients should not enter the study if any of the following exclusion criteria are fulfilled:\n2. History of allogenic organ transplantation.\n3. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \\[eg, colitis or Crohn's disease\\], diverticulitis with the exception of diverticulosis, systemic lupus erythematosus, sarcoidosis syndrome, or Wegener syndrome \\[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, and uveitis, etc\\]). The following are exceptions to this criterion:\n\n   * Patients with vitiligo or alopecia\n   * Patients with hypothyroidism (eg, following Hashimoto syndrome) and stable\n   * on hormone replacement\n   * Any chronic skin condition that does not require systemic therapy\n   * Patients without active disease in the last 5 years may be included but only after\n   * consultation with the Study Physician\n   * Patients with celiac disease controlled by diet alone\n4. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, interstitial lung disease, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness\/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.\n5. History of another primary malignancy except for\n\n   * Malignancy treated with curative intent and with no known active disease \u22655 years before the first dose of IP and of low potential risk for recurrence\n   * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\n   * Adequately treated carcinoma in situ without evidence of disease\n6. History of active primary immunodeficiency.\n7. Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen \\[HbsAg\\] result), hepatitis C, or human immunodeficiency virus (positive HIV 1\/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HbsAg) are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n8. Mixed small cell and non-small cell lung cancer histology\n9. Any unresolved toxicity CTCAE \u2265Grade 2 from the prior chemoradiation therapy. Patients with irreversible toxicity that is not reasonably expected to be exacerbated by study drug may be included (eg, hearing loss) after consultation with the AstraZeneca\/MedImmune medical monitor.\n10. Patients with \u2265Grade 2 pneumonitis from prior chemoradiation therapy\n11. Known allergy or hypersensitivity to durvalumab or any of their excipients\n12. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment\n13. Receipt of live, attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP.\n14. Recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access) that would prevent administration of study drug\n15. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab. The following are exceptions to this criterion:\n\n    * Intranasal, inhaled, topical steroids or local steroid injections (eg, intra articular injection).\n    * Systemic corticosteroids at physiologic doses not to exceed 10 mg\/day of prednisone or its equivalent.\n    * Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication). Premedication with steroids for chemotherapy is acceptable. Systemic steroid administration required to manage toxicities arising from radiation therapy delivered as part of the chemoradiation therapy for locally advanced NSCLC is allowed\n16. Participation in another clinical study with an IP during the last 4 weeks\n17. Previous enrolment or randomisation in the present study\n18. Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study\n19. Prior randomization or treatment in a previous durvalumab and\/or tremelimumab clinical study regardless of treatment arm assignment.\n20. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from Screening to 90 days after the last dose of durvalumab monotherapy\n21. According to the investigator, if the subject is unable to comply with procedures required by the clinical investigation, the subject is not allowed to participate in this study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04672759001","EMAIL":"zhanglipumch@aliyun.com","GEO":[39.9075,116.39723]},{"TITLE":"Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases","CRITERIA":"Inclusion Criteria:\n\n* Histologically or PET-CT confirmed untreated early-stage non-small cell lung cancer (T1-2N0M0) that is inoperable or where the patient is unwilling to undergo surgery, or PET-CT\/chest CT confirmed lung oligometastases (number of metastases \u22643, single lesion diameter \u22645cm).\n* Age 18 years or older, regardless of gender.\n* ECOG performance status score of 0-2.\n* Serum hemoglobin \u2265 80 g\/L, platelets \u2265 100,000\/\u03bcL, absolute neutrophil count \u2265 1,500\/\u03bcL.\n* Serum creatinine \u2264 1.25 times the upper normal limit (UNL) or creatinine clearance \u2265 60 ml\/min.\n* Serum bilirubin \u2264 1.5 times UNL, AST (SGOT) and ALT (SGPT) \u2264 2.5 times UNL, alkaline phosphatase \u2264 5 times UNL.\n* FEV1 \u2265 0.5 L.\n* Normal CB6 range.\n* The patient and their family agree and sign the informed consent form.\n\nExclusion Criteria:\n\n* Tumors with bronchial invasion are excluded.\n* Any other disease or condition that contraindicates radiotherapy (e.g., active infections, within 6 months post-myocardial infarction, symptomatic heart disease including unstable angina, congestive heart failure, or uncontrolled arrhythmias).\n* Pregnant or breastfeeding women, women who have not undergone pregnancy testing, and pregnant individuals.\n* Individuals with substance abuse issues, chronic alcoholism, or AIDS.\n* Individuals with uncontrollable seizures or loss of self-control due to psychiatric disorders.\n* Individuals with a history of severe allergies or specific sensitivities.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06542159001","EMAIL":[{"email":"liuhuisysucc@126.com"}],"GEO":[23.11667,113.25]},{"TITLE":"Phase 1\/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion","CRITERIA":"Inclusion Criteria\n\n* Histologically confirmed diagnosis of a solid tumor malignancy with homozygous deletion of the MTAP gene detected in tumor tissue or ctDNA.\n* Unresectable or metastatic disease.\n* Presence of a tumor lesion amenable to mandatory biopsy for pharmacodynamic evaluation at baseline and on-study unless Sponsor-confirmed as medically unsafe or infeasible.\n* Age \u2265 18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate organ function.\n\nExclusion Criteria\n\n* Prior treatment with a PRMT5 or MAT2A inhibitor therapy.\n* Active brain metastases or carcinomatous meningitis.\n* History of significant hemoptysis or hemorrhage within 4 weeks of the first dose of study treatment.\n* Major surgery within 4 weeks of first dose of study treatment.\n* History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications.\n* Cardiac abnormalities.\n* Other protocol-defined Inclusion\/Exclusion criteria apply.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05245500021","EMAIL":[{}],"GEO":[43.0389,-87.90647]},{"TITLE":"Microbiome in Immunotherapy na\u00efve NSCLC Patients Receiving PD-1\/L1 Blockade (MIP_NSCLC)","CRITERIA":"Inclusion Criteria:\n\n* Must have tumor tissue biopsy-proven to be NSCLC\n* Must have a target lesion to evaluate treatment response\n* Immunotherapy na\u00efve metastatic\/advanced\/recurrent NSCLC patients\n* Will receive single agent anti-PD-1\/PD-L1 therapy (e.g. pembrolizumab, nivolumab, atezolizumab, avelumab or durvalumab, etc.). Patients can be on other interventional trial if they will be receiving single agent anti-PD-1\/PD-L1\n\nExclusion Criteria:\n\n* Prior treatment with any forms of cancer immunotherapy\n* Not competent to make medical decision, noncommunicative or noncompliant per treating physician's judgement\n* Not English-speaking\n* Patients that are pregnant\n* Prisoners\n* Students and employees\n* Psychiatric illness\/social situations that would limit compliance with study requirements","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04636775003","EMAIL":[{"email":"kucc_navigation@kumc.edu"}],"GEO":[39.11417,-94.62746]},{"TITLE":"A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed\/Refractory Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n1. Patients with advanced solid tumors clearly diagnosed by histology and\/or cytology.\n2. Failure of standard treatment or patient unwillingness to receive other antitumor therapy.\n3. Age 18 to 75 years.\n4. Subjects with ECOG score of 0-2.\n5. Expected survival of 3 months or more.\n6. Have at least one measurable lesion (according to RECIST 1.1 criteria) that is amenable to intratumoral or intraperitoneal drug delivery.\n7. Subjects must have appropriate organ function, and laboratory tests during the screening period must meet the following requirements: a) absolute neutrophil count (ANC) \u2265 1.5 \u00d7 109\/L, platelets (PLT) \u2265 80 \u00d7 109\/L, and hemoglobin (Hb) \u2265 85 g\/L; b) serum creatinine (Cr) and blood urea nitrogen (BUN) within 1.5 times the upper limit of normal values; c) serum c) serum total bilirubin (TBIL) \u2264 2 times the upper limit of normal values; d) glutamic aminotransferase (ALT) and glutamic oxalacetic aminotransferase (AST) \u2264 2.5 times the upper limit of normal values; subjects with liver metastases do not exceed 5 times the upper limit of normal values; e) activated partial thromboplastin time (APTT), prothrombin time (PT) within 1.5 times the upper limit of normal values.\n8. Any treatment for malignancy, including radiotherapy, chemotherapy and biological agents, must be discontinued 28 days prior to R130 treatment.\n9. Eligible patients of childbearing potential must agree to use a reliable method of contraception (hormonal or barrier method or abstinence) with their partner for the duration of the trial and for at least 180 days after the last dose; female patients of childbearing potential must have a negative urine pregnancy test within 7 days prior to enrollment.\n10. Subjects voluntarily sign an informed consent form and are in good compliance.\n\nExclusion Criteria:\n\n1. Have had any serious adverse reactions associated with immunotherapy.\n2. Subjects with any severe and\/or uncontrolled disease, including: a) poorly controlled hypertension (systolic blood pressure \u2265 150 mmHg or diastolic blood pressure \u2265 100 mmHg); b) suffering from class I or higher myocardial ischemia or myocardial infarction, arrhythmia (QTc \u2265 470 ms and \u2265 grade 2 congestive heart failure (New York Heart Association (NYHA) classification); c) active or uncontrolled severe infection (\u2265 CTCAE grade 2 infection); d) Patients with previous organ transplantation, bone marrow transplantation (hematopoietic stem cell transplantation) and severe immune deficiency; e) Urine routine suggesting urine protein \u2265++ and confirmed 24-hour urine protein quantification \\> 1.0 g.\n3. Patients with past history of type I diabetes mellitus or HIV.\n4. Severe abnormalities in thyroid and cortisol testing; active, known or suspected autoimmune disease requiring systemic therapy.\n5. Patients with severe prior interstitial lung changes (as determined by the investigator).\n6. Patients with active tuberculosis and a strong positive OT test.\n7. Patients with active bleeding or severe coagulation dysfunction.\n8. Have had antitumor therapy, including endocrine, chemotherapy, radiotherapy, targeted therapy, immunotherapy and antitumor herbal therapy, 4 weeks prior to the first dose.\n9. Have not recovered to CTCAE 4.0 grade rating 0 or 1 level of toxicity after previous antineoplastic therapy.\n10. Current active hepatitis B, active hepatitis C, immunodeficiency virus or other active infection of clinical significance.\n11. Patients who have undergone surgery of grade 3 or higher or whose surgical wounds have not healed within 4 weeks prior to enrollment.\n12. Pregnant, lactating and planning to have children within six months.\n13. Subjects who, in the judgment of the investigator, are unsuitable for participation in this trial for any reason.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05886075001","EMAIL":[{"email":"chenh5751@yeah.net"}],"GEO":[30.51365,117.04723]},{"TITLE":"Segmentectomy After Induction Therapy (SAINT)","CRITERIA":"Inclusion Criteria:\n\n* Patients must have histologically confirmed non-small-cell lung cancer that is clinically staged as \u2264ycT1cN0M0 (tumor size 3cm or less on greatest dimension measured by cross-sectional imaging) after receiving induction therapy.\n* Patients may have received any regimen of neoadjuvant chemotherapy, neoadjuvant immunotherapy, or neoadjuvant chemoimmunotherapy.\n* Patients must have the ability to understand and the willingness to sign a written informed consent document.\n* Patients must be age \u2265 18 years.\n* Patients must exhibit a\/an ECOG (Eastern Cooperative Oncology Group) performance status of \\<3.\n* Patients must have adequate organ function as defined below: These are guidelines that may or should be modified based on protocol-specific or drug development-specific needs.\n\nTable 1: Measures of Adequate Organ Function. FEV1 or DLCO \u226540% (DLCO: diffusing capacity of lung for carbon monoxide)\n\n* For patients with a known history of Human immunodeficiency virus (HIV), infected patients on effective anti-retroviral therapy must have a viral load undetectable for 6 months prior to registration.\n* For patients with a known history of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n* Patients with a known history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be considered a candidate for surgical resection under general anesthesia.\n* Females of child-bearing potential (FOCBP) must have a negative pregnancy test prior to registration on study.\n\nNOTE: A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n\n* Has not undergone a hysterectomy or bilateral oophorectomy\n* Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for \\> 12 months)\n\nExclusion Criteria:\n\n* Patients who have had prior lung resection or thoracic surgery.\n* Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> Grade 1) with the exception of alopecia.\n* Patients who are receiving any other investigational agents.\n* Patients with evidence of distant metastases including brain metastases will be excluded from this study because they will not benefit from surgical resection.\n* Patients that do not have documented consensus agreement on the feasibility of anatomic sublobar resection (segmentectomy) from at least 2 study surgeons will not be enrolled.\n* Patients with pre-induction therapy tumor involving greater than 1 lobe.\n* Patients who have an uncontrolled intercurrent illness including, but not limited to any of the following, are not eligible:\n\n  * Hypertension that is not controlled on medication\n  * Ongoing or active infection requiring systemic treatment\n  * Symptomatic congestive heart failure\n  * Unstable angina pectoris\n  * Cardiac arrhythmia\n  * Psychiatric illness\/social situations that would limit compliance with study requirements\n  * Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety or study endpoints\n* Female patients who are pregnant. Pregnant patients are excluded from this study because the study protocol requires frequent cross-sectional imaging with potential for teratogenic effects.\n* Patients with another malignancy within 3 years (except for non-melanoma skin cancer, CIS of cervix (a preinvasive carcinomatous change of the cervix), superficial bladder cancer). Patients with prior malignancies are excluded to isolate overall survival outcomes.\n* Patients with active smoking status or cessation \\<4 weeks prior to surgical resection.\n* Patients with biopsy positive hilar or mediastinal lymph nodes following induction therapy detected by EBUS (endobronchial ultrasound), mediastinoscopy, or intraoperative sampling.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":89,"SS_ID":"06496659001","EMAIL":[{"email":"Ankit.Bharat@northwestern.edu"},{"email":"nisha.palanisamy@nm.org"}],"GEO":[41.85003,-87.65005]},{"TITLE":"Resistance to the Tyrosine Kinase Inhibitor Osimertinib and Pharmacokinetics in Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Age\\> 18 years old\n* Man or woman\n* Diagnosis of locally advanced non-small cell bronchial adenocarcinoma (not eligible for locoregional treatment) or metastatic\n* Tumor with an activating mutation of EGF-R (deletion of exon 19 or L858R, L861x, or G719x mutation)\n* No one opposed to his participation in the research\n* Dated and signed consent form\n* Patient in good general condition according to WHO (PS: 0 or 1)\n\nExclusion Criteria:\n\n* Previous treatment of NSCLC with an EGF-R tyrosine kinase inhibitor\n* Adult persons subject to legal protection (safeguard of justice, curatorship, guardianship), persons deprived of their liberty.\n* Treatment with Osimertinib on going\n* Co-treatments with a potent enzyme inducing or inhibitor compound within 2 weeks before starting treatment with Osimertinib\n* Participation in intervention research on a drug","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05020275004","EMAIL":[{"email":"gonzague.dechabot@ch-bretagne-atlantique.fr"}],"GEO":[47.66667,-2.75]},{"TITLE":"LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Obtain written informed consent before implementing any trial-related procedures;\n* Aged \\>= 18 years old;\n* Patients with locally advanced (stage IIIB\/IIIC), metastatic, or recurrent (stage IV) NSCLC confirmed by histology or cytology, who are not candidates for surgical treatment and cannot undergo curative radiotherapy or chemotherapy according to the 8th edition of the TNM staging classification by the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer;\n* Absence of the following gene mutations: EGFR gene, ALK fusion oncogene, ROS1, etc. For other types of gene mutations, patients without approved targeted therapies are allowed to be included;\n* Cohort 1: Patients with non-small cell lung cancer who have developed acquired resistance to PD-1 inhibitors (alone or in combination with another systemic therapy) after being responsive to treatment (for 6 months or more) can participate in this study. Cohort 2: Patients who have not received any systemic anti-tumor treatment for advanced\/metastatic disease before; for patients who have previously received platinum-based adjuvant chemo\/radiotherapy, neoadjuvant chemo\/radiotherapy, or curative radiotherapy for advanced disease, disease progression occurred more than 6 months after the last treatment, they can participate in this study;\n* The investigator confirms at least one measurable lesion according to RECIST 1.1 criteria;\n* Estimated life expectancy \\>= 3 months;\n* ECOG PS: 0-1 score;\n* Provide archived tumor tissue (including formalin-fixed paraffin-embedded tissue blocks containing tumor \\[preferred\\] or approximately 15 freshly cut unstained tissue sections) for confirmation of immunohistochemistry for PD-L1, CCR8, CCL1, FOXP3, etc. If archived tissue cannot be obtained, subjects must agree to undergo a tumor biopsy during the screening period;\n* Hematological function is sufficient, defined as absolute neutrophil count \\>= 1.5\u00d710\\^9 \/L, platelet count \\>= 100\u00d710\\^9 \/L, hemoglobin \\>= 90g\/L (no history of transfusion within 7 days);\n* Liver function is sufficient, defined as total bilirubin level \\<= 1.5 times the upper limit of normal (ULN) and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels \\<= 2.5 times ULN for all patients, or for patients with liver metastases, AST and ALT levels \\<= 5 times ULN;\n* Renal function is sufficient, defined as serum creatinine \\<= 1.5 times ULN;\n* Coagulation function is sufficient, defined as international normalized ratio (INR) or prothrombin time (PT) \\<= 1.5 times ULN; if the subject is receiving anticoagulant therapy, INR\/PT within the range specified by the anticoagulant drug is acceptable;\n* Childbearing-age women must have a negative pregnancy test within 7 days before starting treatment; and reliable contraception measures (such as intrauterine devices, contraceptive pills, and condoms) should be used within 30 days of the start and end of the trial. Childbearing-age male subjects should use condoms for contraception during the trial and for 30 days after the end of the trial;\n* Cooperate with regular follow-up visits and comply with the requirements of the trial.\n\nExclusion Criteria:\n\n* Prior use of CCR8 drugs or other unapproved investigational drugs or treatments;\n* Known history of intolerance to PD-1 inhibitor therapy;\n* Receipt of any approved systemic anti-cancer therapy or systemic immunostimulant treatment within 28 days prior to the start of the study treatment;\n* Use of traditional Chinese medicine or immunomodulatory drugs with anti-tumor indications within the first 2 weeks prior to first dosing;\n* History of allergic reactions to any components of the investigational drug;\n* Known presence of brain metastases. Patients judged by the investigator to have stable brain metastases may be enrolled;\n* Active hemoptysis, active diverticulitis, intra-abdominal abscess, gastrointestinal obstruction, or peritoneal metastasis requiring clinical intervention;\n* Clinically uncontrollable pleural effusion\/ascites (patients who do not require fluid drainage or have no significant increase in fluid for 3 days may be enrolled);\n* Tumor compression of vital organs (such as esophagus) with associated symptoms, compression of superior vena cava, or invasion of major mediastinal vessels, heart, etc.;\n* Severe comorbidities such as a history of severe pulmonary or cardiac disease, any arterial thrombosis, embolism, or ischemia occurring within 6 months prior to enrollment, such as myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack. History of deep vein thrombosis, pulmonary embolism, or any other severe thromboembolic event within 3 months prior to enrollment;\n* Receipt of systemic corticosteroids (\\> 10 mg\/day prednisone or equivalent) or other systemic immunosuppressive agents (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \\[anti-TNF\\] drugs) within 2 weeks prior to enrollment. The use of topical, ocular, intra-articular, intranasal, and inhaled corticosteroids is allowed;\n* History of autoimmune diseases, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vasculitis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sj\u00f6gren's syndrome, Guillain-Barr\u00e9 syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. Patients with autoimmune-related hypothyroidism receiving stable doses of thyroid hormone replacement therapy are eligible to participate in this study. Patients with type 1 diabetes controlled with a stable insulin regimen are eligible to participate in this study;\n* Active systemic infections, including tuberculosis (clinically diagnosed based on clinical history, physical examination, and radiological findings, as well as TB tests performed according to local medical practice), hepatitis B (known positive for HBV surface antigen \\[HBsAg\\], and HBV DNA \\>= 1000 cps\/ml or its lower limit of reference), hepatitis C, or human immunodeficiency virus (HIV antibody positive);\n* Known presence of psychiatric disorders or substance abuse that may affect compliance with trial requirements;\n* Recent use of a full therapeutic dose of oral or non-oral anticoagulants or thrombolytic agents. Prophylactic use of anticoagulants is allowed;\n* History, disease, treatment, or laboratory abnormalities that may interfere with trial results, hinder the subject's full participation in the study, or are deemed by the investigator to be not in the subject's best interest to participate in the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06479759001","EMAIL":[{"email":"leewang8023@126.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"PROspective Trial on EOsinophilia in Non-Small Cell Lung Cancer (NSCLC).","CRITERIA":"Inclusion Criteria:\n\n* o All stages of NSCLC\n\n  * Stage III-IV NSCLC eligible for ICI treatment\n  * 18 years or older; non pregnant women\n  * in stage III-IV: no previous ICI and before ICI (mono- or combination therapy) initiation\n  * Signed informed consent\n  * Clinical, biological and radiological evaluation at the CHU de Li\u00e8ge for at least 6 months following treatment initiation\n\nExclusion Criteria:\n\n* Probable noncompliance with the follow-up requirements of the study (psychiatric condition, socio-economic factors)\n* Inclusion in a clinical study contraindicating the enrolment in the PROTEON study","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05602259001","EMAIL":[{"email":"anne.sibille@chuliege.be"},{"email":"aurore.cuealvarez@chuliege.be"}],"GEO":[50.63373,5.56749]},{"TITLE":"MONDRIAN: Multi-omics Integrative Modelling for Stereotactic Body Radiotherapy in Early-stage Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Histologically proven NSCLC; all histologies will be considered eligible (e.g. squamous, adenocarcinoma, large cell carcinoma);\n* American Joint Committee on Cancer Tumor Node Metastasis (AJCC TNM) classification (8th Edition) clinical stage I-II;\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1;\n* No absolute contraindications to either surgery (e.g. severe comorbidities) or SBRT (e.g. active connective diseases, severe pulmonary fibrosis);\n* Ability and willingness to sign a written informed consent for treatment and study participation.\n\nExclusion Criteria:\n\n* Prior diagnosis of invasive cancer (within 3 years before the diagnosis of ES-NSCLC);\n* Mental diseases or psychiatric disorders preventing the acquisition of a valid informed consent.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05974475002","EMAIL":[{"email":"stefania.volpe@ieo.it"}],"GEO":[45.46427,9.18951]},{"TITLE":"Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)","CRITERIA":"Key Inclusion Criteria:\n\n* Are at least 18 years old (or old enough to legally make their own treatment decisions, according to local laws).\n* Have advanced NSCLC or metastatic NSCLC (NSCLC that started in the lungs and then spread to other parts of the body) with the KRAS G12C mutation.\n* Have had previous treatment with 1) chemotherapy that included a drug called cisplatin or a drug called carboplatin and 2) a type of drug called an immune checkpoint inhibitor.\n* Have recovered from their prior treatment and blood tests are within a safe range.\n\nKey Exclusion Criteria:\n\n* Have had previous treatment with a drug that targets KRAS G12C.\n* Have cancer that can potentially be removed with surgery.\n* Patients with brain lesions are not eligible if 1) any untreated brain lesions are \\> 2.0 cm in size 2) any brainstem lesions are present 3) ongoing steroid dosing \\>10 mg daily prednisone (or equivalent) and 4) poorly controlled (\\> 1\/week) generalized or complex partial seizures or neurologic progression\/instability due to brain lesions.\n* Have certain medical conditions or need to take certain medications that, in the opinion of a trial doctor, could make it unsafe for them to participate or difficult to complete the trial assessments, or are pregnant.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05853575094","EMAIL":[{}],"GEO":[41.01384,28.94966]},{"TITLE":"Exercise Prehabilitation for Patients With NSCLC Before Surgery","CRITERIA":"Inclusion Criteria:\n\n1. Capacity to give informed consent.\n2. Are able to tolerate surgery (i.e., segmentectomy, lobectomy) as indicated by standard clinical pre-op evaluation, including pulmonary function tests and cardiopulmonary exercise testing.\n3. Patients who can use a smartphone application.\n4. Patients who are diagnosed of stage I or II Non-small-cell lung carcinoma (NSCLC) diagnosis, with or without pre-operative histologic confirmation.\n5. Patients who can perform an exercise program for at least 4 weeks from the first visit to the preoperative clinic to elective surgery.\n\nExclusion Criteria:\n\n1. Known contraindication for cardiopulmonary exercise testing.\n2. Patients who have a major medical or psychiatric disorder that is expected to affect exercise.\n3. Pregnancy or lactating women.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05608759001","EMAIL":[{"email":"247046170@qq.com"}],"GEO":[30.58333,114.26667]},{"TITLE":"Immune Profiling of Stage III Non-small Cell Lung Cancer Patients Treated With Concurrent Chemoradiation and Adjuvant Durvalumab: A Prospective Observational Phase II Trial","CRITERIA":"Inclusion Criteria:\n\n* Pathological diagnosis of adequately staged (according to standard practice using chest-CT, FDG-PET, brain imaging MRI\/CT) NSCLC\n* Participant is willing and able to give informed consent for participation in the trial\n* Male or female, aged 18 years or above\n* Scheduled to receive one of the following two therapeutic strategies:\n\n  * Concurrent chemotherapy and radiotherapy with photons (60 Gy in 30 fractions of 2 Gy) in patients with stage III NSCLC\n  * Concurrent chemotherapy and radiotherapy with protons (60 Gy in 30 fractions of 2 Gy) in patients with stage III NSCLC\n* Is able and willing to comply with all trial requirement\n\nExclusion Criteria:\n\n* Mixed non-small cell lung cancer with other histologies such as small cell lung cancer\n* Not able to comply with the study protocol\n* Less than 18 years' old\n* Pregnancy or not able to comply with adequate contraception in women with child baring potential\n* Previous radiotherapy to the chest for benign or malignant conditions, including radiation for breast cancer\n* Previous malignancy treated with chemotherapy, immune therapy or radiotherapy (irrespective of when this happened)\n* Previous malignancies treated with surgery only are allowed if 2 years or more before inclusion in the present study","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04432142001","EMAIL":[{"email":"dirk.deruysscher@maastro.nl"},{}],"GEO":[50.84833,5.68889]},{"TITLE":"ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)","CRITERIA":"* Key Inclusion criteria\n* Age \u226518 and \u2264 75 years\n* Subject is positive for at least 1 HLA-A\\*02 inclusion allele\n* Histologically or cytogenetically confirmed diagnosis of urothelial cancer, esophageal, esophagogastric junction (EGJ) cancer, gastric cancer, non-small cell lung carcinoma (NSCLC), head and neck or ovarian cancer, endometrial cancer, melanoma\n* Measurable disease according to RECIST v1.1 prior to leukapheresis and lymphodepletion.\n* Tumor shows MAGE-A4 expression as confirmed by central laboratory\n* ECOG Performance Status of 0 or 1.\n* Left ventricular ejection fraction (LVEF) \u226550% or the institutional lower limit of normal range, whichever is lower Note: other protocol defined Inclusion\/Exclusion criteria may apply\n* Subjects must have \u2265 90% room air oxygen saturation at rest at Screening (within 7 days of leukapheresis) and at Baseline.\n\nKey exclusion criteria\n\n* Positive for any HLA-A\\*02 allele other than: one of the inclusion alleles\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide or other agents used in the study\n* Active autoimmune or immune mediated disease\n* Leptomeningeal disease, carcinomatous meningitis or symptomatic CNS metastases\n* Other prior malignancy that is not considered by the Investigator to be in complete remission. Clinically significant cardiovascular disease\n* Uncontrolled intercurrent illness\n* Active infection with human immunodeficiency virus, hepatitis B virus, hepatitis C virus, or human T cell leukemia virus\n* Pregnant or breastfeeding\n\nNote: other protocol defined Inclusion\/Exclusion criteria may apply.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"04044859022","EMAIL":[{"email":"espe.m.garcia@gmail.com"},{}],"GEO":[37.38283,-5.97317]},{"TITLE":"Differences in Rate of Decline in CT-defined Skeletal Muscle Mass and Physical Performance in Patients With Advanced Non-small Cell Lung Cancer Receiving Chemotherapy and Targeted Therapy\/Immunotherapy, Before and After Treatment.","CRITERIA":"Inclusion Criteria:\n\n1. Age \\>18years old,\n2. Stage IIIB and IIIC (if patients are treated with TKI\/IO), and Stage IV non-small cell lung cancer patients confirmed by histopathology.\n3. Patients should be either on chemotherapy, molecular targeted therapy or immunotherapy.\n\nExclusion Criteria:\n\n1. Unable to perform CT scan due to various reasons.\n2. Patients with metastatic disease at L3 vertebral level.\n3. If unable to perform SPPB test due to physical disability or patient's refusal.\n4. Patients with known other primary malignancies. 5 . Patients who have underwent definitive surgery.\n\n6. Pregnant patients. 7. Patients with physical deformities\/neurological deficits which restricts their physical movements.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06326086001","EMAIL":"timsinasraj@gmail.com","GEO":[7.00836,100.47668]},{"TITLE":"Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy.","CRITERIA":"Inclusion Criteria:\n\n* age over 18\n* informed of the objectives of the project and signed consent\n* non small cell lung cancer, stage IIIA, IIIB or IV\n* PS (WHO performance status) \\< or =2\n* treatment based on immunotherapy (monotherapy or combination)\n* at least one measurable target\n* available results of PD-L1 expression\n\nExclusion Criteria:\n\n* concomitant other type of cancer\n* another cancer in the last 5 years","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04720339008","EMAIL":[{"email":"c.clementduchene@nancy.unicancer.fr"},{},{}],"GEO":[48.65,6.18333]},{"TITLE":"NSCLC Isotoxic Hypofractionated Chemoradiotherapy","CRITERIA":"Inclusion Criteria:\n\n1. Pathological or cytological diagnosis of non-small cell lung cancer patients, the clinical stage using the eighth edition of American Joint Committee on Cancer\uff08AJCC\uff09, including stage III without resectable or who when SBRT\/SABR are not suitable;\n2. Age \u2265 18 years\uff0c\u2264 75 years;\n3. The expected survival period is \u2265 3 months;\n4. Karnofsky performance status \uff08KPS\uff09 score \u2265 60;\n5. Normal blood account , liver and kidney function;\n6. Forced expiratory volume in 1 second of 0.75 L or greater.\n\nExclusion Criteria:\n\n1. Serious medical problems require hospitalization, include (but not limited to ): history of pulmonary fibrosis, previous myocardial infarction within 6 months, heart failure grade II and above, uncontrolled heart failure, uncontrolled chronic obstructive pulmonary disease \uff08COPD\uff09, uncontrolled diabetes .et al;\n2. Esophageal invasion (cT4);\n3. Others are not suitable for receiving radiotherapy and chemotherapy.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"03606239001","EMAIL":[{"email":"xxy0636@163.com"},{}],"GEO":[38.04139,114.47861]},{"TITLE":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","CRITERIA":"Major Inclusion Criteria:\n\n1. Men and women 18 years of age or older.\n2. 9 cohorts will be enrolled:\n\n   * Cohort A1 \/ Exon 14 NSCLC MET inhibitor naive in first line: Histologically or cytologically confirmed NSCLC with Exon 14 skipping mutations; all histologies; unresectable or metastatic disease (Stage 3b\/4); treatment-naive subjects in first line; not received any MET inhibitor and no known MET kinase inhibitor resistance mutations\n   * Cohort A2 \/ Exon 14 NSCLC - MET inhibitor na\u00efve: Histologically or cytologically confirmed NSCLC with Exon 14 skipping mutations; all histologies; unresectable or metastatic disease (Stage 3b\/4); pretreated subjects refractory to or intolerant of standard therapies with no more than three lines of prior therapy in the unresectable or metastatic setting; not received any MET inhibitor and no known MET kinase inhibitor resistance mutations\n   * Cohort B \/ Exon 14 NSCLC MET inhibitor experienced: ENROLLMENT COMPLETED\n   * Cohort C \/ MET amplification basket tumor types excluding primary CNS tumors: Any solid tumor type regardless of histology excluding primary CNS tumors, with MET amplification; unresectable or metastatic disease, refractory to or intolerant of standard therapies, or refused standard therapies, or if therapy was unavailable or unfeasible, with no more than 3 prior lines of therapy in the unresectable or metastatic setting; not received any MET inhibitor and no known MET kinase inhibitor resistance mutations\n   * Cohort C1 \/ MET amplification and wild-type EGFR NSCLC: NSCLC regardless of histology, harboring MET amplification and wild-type EGFR; unresectable or metastatic disease, previously untreated or treated with no more than 3 prior lines of therapy in the unresectable or metastatic setting; not received any MET inhibitor and no known MET kinase inhibitor resistance mutations\n   * Cohort C2 \/ EGFR positive NSCLC with acquired MET amplification (APL-101 Add-on Therapy): Unresectable or metastatic NSCLC regardless of histology, harboring EGFR activating mutations with acquired MET-Amplification as resistance mechanism to the EGFR-I; developed resistance to first-line EGFR-inhibitor therapy after an initial response (documented PR for at least 12 weeks); radiological documentation of disease progression per RECIST on first-line EGFR inhibitor therapy; currently on an EGFR-inhibitor therapy and agrees to receive APL-101 as an add-on therapy during the study; no history of interstitial lung disease (ILD)\/pneumonitis, Grade \u22653 liver toxicity or QT prolongation with EGFR-I therapy; not received any MET inhibitor and no known MET kinase inhibitor resistance mutations\n   * Cohort D \/ MET fusion basket tumor types excluding primary CNS tumors: any solid tumor type regardless of histology excluding primary CNS tumors; unresectable or metastatic disease, refractory to or intolerant of standard therapies, or refused standard therapies, or if therapy was unavailable or unfeasible, with no more than 3 prior lines of therapy in the unresectable or metastatic setting; not received any MET inhibitor and no known MET kinase inhibitor resistance mutations\n   * Cohort E \/ Primary CNS tumors with MET alterations: subjects with primary CNS tumors who meet inclusion criteria of MET dysregulations defined as single or co-occurred MET fusion including PTPRZ1-MET (ZM) fusion, MET Exon 14 skipping mutations, or MET amplification; refractory to or intolerant of standard therapies, or refused standard therapies, or if therapy was unavailable or unfeasible, with no more than 3 prior lines of therapy in the unresectable or metastatic setting; not received any MET inhibitor and no known MET kinase inhibitor resistance mutations; neurological symptoms controlled on a stable\/decreasing dose of steroids for at least 2 weeks before C1D1\n   * Cohort F \/ Basket tumor types harboring wild-type MET with over-expression of HGF and MET: any solid tumor type regardless of histology harboring wild-type MET with overexpression of HGF and MET; Unresectable or metastatic disease, refractory to or intolerant of standard therapies, or refused standard therapies, or if therapy was unavailable or unfeasible, with no more than 3 prior lines of therapy in the unresectable or metastatic setting; not received any MET inhibitor and no known MET kinase inhibitor resistance mutations\n3. Treated or untreated asymptomatic parenchymal CNS disease or leptomeningeal disease is allowed.\n4. Presence of \u22651 measurable lesion (scan done \u226428 days of C1D1) to serve as target lesion according to relevant criteria\n5. ECOG performance status of 0-1. For subjects with primary CNS tumors, KPS score \u226570.\n6. Acceptable organ function\n7. For all prior anticancer treatment, a duration of 30 days or 5 half-lives of the agents used, whichever is shorter, must have elapsed, and any encountered toxicity must have resolved to levels meeting all the other eligibility criteria prior to the first dose of study treatment. Palliative radiotherapy to non-target lesions should be completed within 2 weeks prior to APL-101 administration.\n8. Adequate cardiac function\n9. Women of child-bearing potential must have a negative serum or Beta-hCG at screening or evidence of surgical sterility or evidence of post-menopausal status\n10. No planned major surgery within 4 weeks of first dose of APL-101\n11. Expected survival (life expectancy) \u2265 3 months from C1D1\n12. Provision of sample; e.g. archival or a fresh tumor biopsy sample (if safe and feasible) either from the primary or a metastatic site) or liquid biopsy sample (if tumor tissue is insufficient or lacking, and approved by the sponsor) is required for prospective central lab confirmation for study entry (subjects with previously confirmed molecular status by the Sponsor designated central lab or FDA approved NGS based MET testing may be exempted, subjected to Sponsor approval.\n\nMajor Exclusion Criteria:\n\n1. Hypersensitivity to APL-101, excipients of the drug product, or other components of the study treatment regimen.\n2. Known actionable mutation\/gene rearrangement of EGFR (except for NSCLC subjects in Cohort C and C-2), ALK, ROS1, RET, NTRK, KRAS, and BRAF.\n3. Use or intended use of any other investigational product, including herbal medications, through Study Treatment Termination.\n4. Active uncontrolled systemic bacterial, viral, or fungal infection or clinically significant, active disease process, which in the opinion of the investigator makes the risk: benefit unfavorable for the participation of the trial.\n5. Life-threatening illness, significant organ system dysfunction or comorbid conditions, or other reasons that, in the investigator's opinion, could compromise the subject's safety or the integrity of the study outcomes, or interfere with the absorption or metabolism of APL-101.\n6. Unstable angina or myocardial infarction within 1 year prior to first dose of APL-101, symptomatic or unstable arrhythmia requiring medical therapy, history of congenital prolonged QT syndrome, prolonged QT interval corrected by Fridericia formula (QTcF) at screening, or concurrent treatment with a medication that is a known risk for prolonging the QT interval. Chronic controlled atrial fibrillation is not excluded.\n7. Historical seropositive results consistent with active infection for hepatitis C virus (HCV) or hepatitis B virus (HBV) with high viral loads not actively managed with antiviral therapy and human immunodeficiency virus (HIV) positive subjects who are not clinically stable or controlled on their medication (asymptomatic subjects with CD4+ T-cell (CD4+) counts \u2265 350 cells\/\u03bcL and have not had an opportunistic infection within the past 12 months prior to first dose of APL-101 would be eligible for study entry. If history is unclear, relevant test(s) at Screening will be required to confirm eligibility.\n8. Known significant mental illness or other conditions such as active alcohol or other substance abuse that, in the opinion of the investigator, predisposes the subject to high risk of noncompliance with the protocol treatment or assessments.\n9. Unable to swallow orally administered medication whole.\n10. Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter drug absorption\n11. Women who are breastfeeding\n12. History of another malignancy within 3 years prior to C1D1. A subject with the following malignancies is allowed if considered cured or unlikely to recur within 3 years:\n\n    1. Carcinoma of the skin without melanomatous features.\n    2. Curatively treated cervical carcinoma in situ.\n    3. Bladder tumors considered superficial such as noninvasive (T1a) and carcinoma in situ (T1s), thyroid papillary cancer with prior treatment, prostate cancer which has been surgically or medically treated and not likely to recur within 3 years.\n13. Subjects who are unable or unwilling to discontinue excluded medications (drugs with known QTc risk and known strong cytochrome P450 \\[CYP\\]3A4 inducer and\/or strong inhibitors) for at least 5 half-lives prior to first dose of study drug. Subjects may qualify if such medication(s) can be safely replaced with alternate medications with less risk of drug-drug interaction.\n14. Subjects with active COVID-19 infection.\n15. Symptomatic and\/or neurologically unstable CNS metastases, or who require an increase in steroid dose to control CNS disease. Subjects who have been receiving a stable steroid dose for at least 2 weeks prior to C1D1 may be allowed.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03175224091","EMAIL":"clinops@apollomicsinc.com","GEO":[51.49353,-0.04802]},{"TITLE":"Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form.\n2. Age \u2265 18 years.\n3. Histopathology or cytology confirmed lung cancer\n4. Failed from first line Chemo-immunotherapy.\n5. ECOG 0-1.\n6. Predicted survival \u2265 12 weeks.\n7. Adequate bone marrow hematopoiesis and organ function\n8. Presence of measurable lesions according to RECIST 1.1.\n9. Subjects with stable brain metastases may be included in the study.\n\nExclusion Criteria:\n\n1. Subjects who have received any of the following treatments must be excluded:\n\n   * Treatment with molecules such as EGFR, VEGFR antibodies within 4 weeks prior to the first dose of study drug.\n   * Have received radiation within 14 days prior to the first dose or have not recovered from radiation-related toxicity. Chest and extra-brain palliative radiotherapy, stereotactic radiosurgery, and stereotactic body radiotherapy may be performed 7 days prior to the first dose.\n   * Ongoing (or inability to discontinue) possibly potent CYP1A2, CYP3A inhibitor (1 week), or inducer (2 weeks) drug therapy or herbal supplements within 1-2 weeks prior to the first dose.\n2. Presence of spinal cord compression or meningeal metastasis.\n3. History of other malignant tumors within 2 years.\n4. Adverse events (except alopecia of any degree) of CTCAE \\> grade 1 due to prior treatment (e.g., adjuvant chemotherapy, radiotherapy, etc.) prior to the first dose.\n5. History of stroke or intracranial hemorrhage within 6 months prior to the first dose.\n6. The presence of any severe or poorly controlled systemic disease, including poorly controlled hypertension and active bleeding in the judgment of the investigator.\n7. Subjects with persistent or active infection, including but not limited to hepatitis B (HBV), hepatitis C (HCV), human immunodeficiency virus (HIV) and COVID-19 infection.\n8. Heart-related diseases or abnormalities\n9. Past history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy or interstitial lung disease with active clinical symptoms, immune pneumonia caused by immunotherapy.\n10. Refractory nausea and vomiting, chronic gastrointestinal disease, difficulty swallowing drugs, or inability to adequately absorb sunvozertinib or anlotinib due to previous bowel resection.\n11. Live vaccine was given 2 weeks before the first medication.\n12. Women who are breastfeeding or pregnant.\n13. Hypersensitivity to the test drug and the ingredients.\n14. Other conditions assessed by the investigator to be unsuitable for participation in the study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04322617001","EMAIL":[{"email":"zhangyongchang@csu.edu.cn"}],"GEO":[28.19874,112.97087]},{"TITLE":"Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy","CRITERIA":"Inclusion Criteria:\n\n* Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older\n* Prior exposure to at least 1 line of therapy\n* Exposure to a including checkpoint inhibitor in line of therapy immediately prior to enrollment on trial\n* ECOG PS 0-2\n\nExclusion Criteria:\n\n* Presence of a driver mutation that is susceptible to targeted therapy\n* No greater than CTCAE v5 grade 3 toxicity attributed to prior immunotherapy\n* Other active invasive malignancy requiring ongoing therapy\n* Evidence of progressing or untreated brain metastases\n* Evidence or history of leptomeningeal disease\n* Uncontrolled tumor related pain\n* History of an autoimmune disease or IPF","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04691817001","EMAIL":[{"email":"Melissa.volpe@pennmedicine.upenn.edu"},{}],"GEO":[39.95233,-75.16379]},{"TITLE":"Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Men or women aged more than or equal to (\u2265) 18 years.\n2. Patients histologically or cytologically confirmed with locally advanced or metastatic NSCLC.\n3. According to Recist1.1, at least 1 target lesion that should be measurable lesions without local treatment like irradiation or with definite progression after local treatment and can be accurately measured at baseline as \u2265 10 mm in the longest diameter (except lymph nodes, which must have short axis \u2265 15mm)\n4. ECOG performance status of 0-1with no deterioration within 2 weeks before enrollment.\n5. Estimated life expectancy \u2265three months.\n6. Females of child bearing age should adapt adequate contraceptive measures and should not be breastfeeding from the signing of informed consent to 6 months after the last treatment of the study. Male patients should be willing to use barrier contraception (i.e., condoms) from the signing of informed consent to 6 months after the last treatment of the study.\n7. Females must have a negative pregnancy test in 7 days prior to start of first dose if of childbearing potential or must have evidence of non-childbearing potential by fulfilling any one of the following criteria:\n\n   1. Postmenopausal defined as age more than 60 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments.\n   2. Women under 60 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more, following cessation of exogenous hormonal treatments, and with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the postmenopausal range for the laboratory.\n   3. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, but not by tubal ligation.\n8. Signed and dated Informed Consent Form. Specific inclusion criteria Part 1 Patients have previously received any EGFR TKI continuous treatment (such as Gefitinib, Erlotinib, Osimertinib or Almonertinib) and had disease progression by imaging recorded. Before the first dose, all patients must provide imaging evidence of disease progression during or after the last treatment period. Before the start of study treatment, patients need to provide all the following test results detected by tumor biopsy tissue or blood samples with disease progression during or after the last treatment: EGFR sensitive mutation (either exon 19 deletion or L858R mutation); T790M status (negative or positive). The above test results of local laboratories can be accepted without confirmation of the central laboratory. If there are no local laboratory test results, then tumor tissue or blood samples meeting the protocol requirements should be sent to the central laboratory for testing and the results should be obtained before the first dose of study drug.\n\nPart2 Cohort 1 -Patients have previously received the 1st\/2nd\/3rd-generation EGFR TKI (only one kind of them) and had disease progression by imaging recorded with centrally confirmed EGFR mutation, T790M negative and MET-positive.\n\nCohort2- Patients have not received any systemic treatment of advanced NSCLC with centrally confirmed EGFR mutation and MET-positive.\n\nCohort3- Patients have previously received both 1st\/2nd and 3rd-generation EGFR-TKI and had disease progression by imaging recorded with centrally confirmed EGFR mutation and MET-positive.\n\nCohort4-Patients have previously received the 1st\/2nd-generation EGFR TKI continuous treatment (not received the 3rd-generation EGFR TKI treatment) and had disease progression by imaging recorded with centrally confirmed EGFR mutation, T790M positive and MET-positive.\n\n\\*Definition of MET-positive (any one of the following): \u2460 Fluorescence in situ hybridization (FISH): MET gene copy number \u2265 5 or MET\/CEP7 ratio \u2265 2; \u2461 Immunohistochemistry (IHC): \u2265 50% tumor cells MET 3+.\n\nExclusion Criteria:\n\n1. Treatment with any of the following:\n\n   1. Previous or current treatment with drugs targeting the c-MET\/HGF pathway.\n   2. Any cytotoxic chemotherapy, investigational agents, antitumor traditional Chinese Medicine and any other anticancer drugs for the treatment of advanced NSCLC within 14 days before the first dose of study drug; or requiring treatment with these drugs during the study.\n   3. Any antitumor monoclonal antibody therapy within 28 days before the first dose of study drug.\n   4. Local radiotherapy within 2 weeks of the first dose of study drug; receiving radiation to \\> 30% of the bone marrow or with a wide field of radiation within 4 weeks before the first dose of study drug.\n   5. Pleural or peritoneal effusion requiring clinical intervention (except for effusion not requiring drainage or being stable after drainage for at least 14 days before the first dose of study drug). Pericardial effusion (except for effusion being stable after drainage for at least 14 days before the first dose of study drug).\n   6. Major surgery within 4 weeks of the first dose of study drug.\n   7. Spinal cord compression or brain metastases (except for that being asymptomatic and stable for at least 4 weeks, not requiring steroids for at least 2 weeks prior to start of study treatment and with no obvious edema around the tumor focus by imaging examination).\n   8. Treatment with drugs that are predominantly CYP3A4 strong inhibitors or inducers or sensitive substrates of CYP3A4 with a narrow therapeutic range within 7 days of the first dose of study drug; or requiring treatment with these drugs during the study.\n   9. Currently receiving drugs known to prolong QT interval or may cause torsade de pointe; or requiring treatment with these drugs during the study.\n   10. Currently receiving or requiring long-term treatment with warfarin (LMWH is allowed).\n2. Any unresolved toxicities from prior therapy greater than Grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE) 5.0 with the exception of alopecia or neurotoxicity.\n3. History of other primary malignancies, excluding:\n\n   1. Malignancies that have been recovered and inactive for \u22655 years prior to inclusion with a very low risk of recurrence.\n   2. Non-melanoma skin cancer or malignant freckle mole with adequate treatment and no evidence of disease recurrence.\n   3. Carcinoma in situ with adequate treatment and no evidence of disease recurrence.\n   4. Non metastatic prostate cancer with definite treatment.\n4. Inadequate bone marrow reserve or organ function, as demonstrated by any of the following laboratory values:\n\n   1. Absolute neutrophil count (ANC) \\<1.5\u00d7109 \/ L\n   2. Platelet count \\<90\u00d7109 \/ L\n   3. Hemoglobin \\<90 g\/L\n   4. Total bilirubin (TBL) \\> 1.5 \u00d7 ULN or \\> 3 \u00d7 ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases.\n   5. One or both of Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) \\> 2.5 \u00d7 upper limit of normal (ULN) or \\> 5 \u00d7 ULN in the presence of liver metastases.\n   6. Creatinine \\> 1.5 \u00d7 ULN concurrent with creatinine clearance \\< 50 mL\/min; confirmation of creatinine clearance is only required when creatinine is \\> 1.5 \u00d7 ULN.\n   7. International normalized ratio (INR) \\> 1.5, and partially activated prothrombin time (APTT) \\> 1.5 \u00d7 ULN.\n   8. Serum albumin (ALB) \\< 28 g\/L\n   9. Serum lipase or serum amylase \\> 1.5 \u00d7 ULN.\n5. Any of the following cardiac criteria:\n\n   1. Resting corrected QT interval (QTc) \\> 470 ms obtained from electrocardiogram (ECG), using the screening clinic's ECG machine and Fridericia's formula for QT interval correction (QTcF). See Appendix G for fridericia formula.\n   2. Any clinically important abnormalities in rhythm, conduction, or morphology of the resting ECG (e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, PR interval \\> 250 ms).\n   3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, such as heart failure, intractable hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval.\n   4. Left ventricular ejection fraction (LVEF) \u2264 50%.\n6. Severe, uncontrolled or active cardiovascular diseases.\n7. Diabetes ketoacidosis or hyperglycemia hypertonic occurring within 6 months before the first dose of the study drug, or the glycosylated hemoglobin value \u2265 7.5% in the screening period.\n8. Severe or poorly controlled hypertension.\n9. Bleeding symptoms with apparent clinical significance or obvious bleeding tendency within 1 months prior to the first dose of study drug.\n10. Serious arteriovenous thrombosis events occurred within 3 months before the first dose.\n11. Severe infections occurred within 4 weeks before the first dose.\n12. Patients who have received continuous steroid treatment for more than 30 days within 30 days before the first dose, or need long-term (\u2265 30 days) steroid treatment (except for asthma patients who need long-term inhaled glucocorticoids and patients with topical corticosteroids), or who have other acquired and congenital immunodeficiency diseases, or have a history of organ transplantation\n13. Clinically severe gastrointestinal dysfunction that may affect drug intake, transport or absorption.\n14. The presence of active infectious diseases has been known before the first dose such as hepatitis B (the test result of virus surface antigen \\[HBsAg\\] in the screening stage is positive, and the test value of HBV-DNA is \u2265 2 \u00d7 103iu \/ ml; if the retested result after regular antiviral treatment has been reduced to 2 \u00d7 103 IU \/ ml or less, patients can be enrolled), hepatitis C, tuberculosis, syphilis, or human immunodeficiency virus HIV infection, etc.\n15. Hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh Grade B or more severe cirrhosis.\n16. Other moderate or severe lung diseases that may interfere with the detection or treatment of drug-related pulmonary toxicity or may seriously affect respiratory function.\n17. Previous history of serious neurological or mental disorders, including epilepsy, dementia or severe depression and any other status that may interfere in assessment.\n18. Women who are breastfeeding or pregnant or planned to be pregnant during the study period.\n19. History of hypersensitivity to any active or inactive ingredient of HS-10241\/Almonertinib or to drugs with a similar chemical structure or class to HS-10241\/Almonertinib.\n20. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.\n21. Any disease or condition that, in the opinion of the investigator, would compromise the safety of the patient or interfere with study assessments.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05430386001","EMAIL":[{"email":"chestgcp@126.com"},{}],"GEO":[31.22222,121.45806]},{"TITLE":"Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Provision of written Informed Consent Form (ICF) prior to any study specific procedures\n2. Age \u2265 18 years, \u226480 years\n3. Histologically or cytologically confirmed advanced NSCLC\n4. At least two or more systemic therapies prior treatment of cytotoxic chemotherapy, treatment failure or intolerable toxicities\n5. ECOG 0-2\n6. Patients must have measurable lesions\n7. Expected overall survival \u22656 months\n8. AST, ALT and alkaline phosphatase \u2264 2.5 times the upper limit of normal (ULN)\uff0cSerum bilirubin \u2264 1.5 x ULN\uff0ccreatinine\\<ULN\n9. Prothrombin time (PT), international standard ratio (INR) \u22641.5 \u00d7 ULN\n10. Women of childbearing age must be willing to use adequate contraceptives during the study period of drug treatment\n\nExclusion Criteria:\n\n1. Patients have received Surufatinib treatment\n2. Patients with small cell lung cancer (including mixed small cell lung cancer and non-small cell lung cancer)\n3. EGFR mutation \/ALK rearrangement positive but not using relevant targeted drugs\n4. Central squamous cell carcinoma with cavity or non-small cell lung cancer with hemoptysis (\\> 50 ml \/ D)\n5. Have received other systemic anti-tumor therapies within 2 weeks before recruited(eg.chemotherapy or radiotherapy, immunotherapy, biological or hormonal therapy, or any VEGFR inhibitor treatment)\n6. Participated in the clinical trials of other drugs that have not been approved or marketed in China and received the corresponding experimental drug treatment within 2 weeks before enrollment\n7. systolic blood pressure \\> 140mmHg or diastolic blood pressure \\> 90mmHg regardless of any antihypertensive drugs; Or patients need more than two antihypertensive drugs\n8. Clinically significant electrolyte abnormality\n9. Proteinuria \u2265 2+ (1.0g\/24hr)\n10. Patients have untreated central nervous system metastasis\n11. Received any operation or invasive treatment or operation (except venous catheterization, puncture and drainage, etc.) within 4 weeks before enrollment\n12. Patients have not recovered from all toxicities associated with prior anti-tumor therapy ,to acceptable baseline status, or a National Cancer Institute Common Terminology Criteria for Adverse Events(NCI CTCAE v5.0) Grade of 0 or 1, except for alopecia and oxaliplatin induced neurotoxicity \u2264 2 , and the previous surgery did not recover completely\n13. Dysphagia or known malabsorption of drugs\n14. Active gastric and duodenal ulcer, ulcerative colitis or uncontrolled hemorrhage in GI\n15. Have evidence or history of bleeding tendency within 2 months after enrollment, the researcher assessed that moderate or severe bleeding tendency was not suitable for enrollment\n16. Patients had other malignant tumors in the past 5 years or at the same time (except for the cured skin basal cell carcinoma and cervical carcinoma in situ);\n17. Pregnant or lactating women\n18. Allergic to Surufatinib\/Vinorelbine\n19. History of immunodeficiency, including HIV positive, other acquired or congenital immunodeficiency diseases, or organ transplantation\n20. Patients with acute myocardial infarction, severe \/ unstable angina pectoris or coronary artery bypass grafting within 6 months before admission; Or a history of arterial thrombosis or deep venous thrombosis\n21. There are concomitant diseases (such as severe hypertension, diabetes, thyroid disease, active infection, etc.) that seriously endanger the safety of patients or affect the completion of the study, or any laboratory abnormalities that are not suitable for participating in the clinical trial according to the judgment of the researcher\n22. Serious psychological or mental disorders that may affect the compliance study","SEX":"ALL","AGE_MIN":18,"AGE_MAX":80,"SS_ID":"04922658001","EMAIL":"18665000236@163.com","GEO":[23.11667,113.25]},{"TITLE":"A Study to Investigate the Family History of Cancer in Patients With Non-small Cell Lung Cancer (FAHIC - Lung).","CRITERIA":"Inclusion Criteria:\n\n* Histopathological diagnosis of Non-Small Cell Lung Cancer (all stages)\n* Age \u2265 18 years old\n* Signed informed consent\n* Availability of familiar and\/or personal anamnestic data of cancer\n\nExclusion Criteria:\n\n* Unavailability of familiar and\/or personal anamnestic data of cancer\n* Patient's refusal","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06196424002","EMAIL":[{"email":"a.cortellini@policlinicocampus.it"},{"email":"f.citarella@policlinicocampus.it"}],"GEO":[41.89193,12.51133]},{"TITLE":"Traditional Chinese Medicine Combined With Thermal and Cold Ablation for Early-stage Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* The patient can understand and voluntarily join the study, sign the informed consent form, and the compliance is good.\n* Patients with lung nodule.\n* Maximum diameter of lung nodule \u22658mm.\n* The pathology of lung nodules biopsy was non-small cell lung cancer.\n* I period according to the eighth edition of the TNM staging period.\n* No mediastinal lymph node metastasis.\n* Eastern Cooperative Oncology Group performance status of 0 to 1.\n* No prior anticancer treatments including surgery, radiation,chemotherapy or local treatments.\n* Sufficient organ functions.\n\nExclusion Criteria:\n\n* Patients with previous use of various hormones, immunosuppression or autoimmune diseases.\n* Women during pregnancy or breast-feeding.\n* Patients with severe heart, lung, kidney disease or other systemic diseases\n* Patients with severe hemorrhagic diseases.\n* Patients with a history of drug abuse or mental illness.\n* Other conditions that the investigator has determined are not suitable for participation in this study","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05097417001","EMAIL":[{}],"GEO":[31.22222,121.45806]},{"TITLE":"Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation","CRITERIA":"Inclusion Criteria:\n\n* Adult patients age \\> 18) with unresectable, metastatic melanoma (cutaneous, acral, mucosal) or NSCLC who have evidence of disease control after at least 12 months of ICI based therapy (pembrolizumab, nivolumab, nivolumab-relatimab, ipilimumab\/nivolumab, atezolizumab, ipilimumab, durvalumab, cemiplimab) with or without chemotherapy in the case of NSCLC. Any line of therapy is permitted with the exception of adjuvant therapy\n* Participants must be actively receiving standard of care ICI-based therapy (ICI monotherapy or in combination)\n* At time of enrollment patients must have received at least 12months (+\/- 4 weeks) from the start of anti-PD-1 therapy and have not experienced a toxicity that prevented them from continuing therapy.\n* Participants must have evidence of disease control (stable disease, partial response, or complete response) that is maintained on restaging CT scans or PET CT scans obtained at 12 months (+\/- 4 weeks) from the start of initial ICI therapy\n* Prior radiation to any site is allowed\n* Available tumor tissue (archival) for baseline tissue testing with FoundationOne CDx or previous FoundationOne CDx testing results (within 2 years and prior test results must be after June 30, 2021)\n* Life expectancy of greater than 3 months\n* Participants with a prior malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment are eligible for this trial.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Participants with clinical or radiographic evidence of progressive disease in the 3 months prior to consideration of screening and enrollment\n* Participants who are receiving an investigational agent (s)\n* Participants who have had ICI discontinued due an immune-related adverse event.\n* Patients with a history of an irAE but resumed ICI therapy and are receiving ICI at the time of screening are eligible to enroll.\n* Participants on \\> 10mg of oral prednisone or its equivalent for treatment of ongoing immune-related toxicity.\n* Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> Grade 1) with the exception of alopecia, endocrine toxicity requiring chronic supplementation\n* Participants with a concurrent, active malignancy\n* Participants in whom F1CDx generation fails\n* Participants without available tumor tissue for F1CDx test result or prior F1CDx","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06146920001","EMAIL":[{"email":"alawless@mgh.harvard.edu"},{"email":"jczapla@mgh.harvard.edu"}],"GEO":[42.35843,-71.05977]},{"TITLE":"A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor","CRITERIA":"Inclusion Criteria:\n\n1. Participants must sign the informed consent form voluntarily and follow the plan requirements.\n2. No gender limit.\n3. Age: \u226518 years old and \u226475 years old (stage Ia); \u226518 years old (stage Ib).\n4. Expected survival time \u2265 3 months.\n5. Locally advanced or metastatic solid tumor confirmed by histopathology and\/or cytology, which are incurable or currently without standard treatment.\n6. Agrees to provide archived tumor tissue specimens or fresh tissue samples from the primary lesion or metastasis within 2 years; If a subject is unable to provide a tumor tissue sample, he\/she may be enrolled after being evaluated by the investigator if other inclusion criteria are met.\n7. Participants must have at least one measurable lesion that meets the definition of RECIST v1.1.\n8. Physical fitness score ECOG 0 or 1 point\n9. Toxicity of previous antitumor therapy has returned to \u2264 level 1 as defined by NCI-CTCAE v5.0 (except for asymptomatic laboratory abnormalities considered by the investigators, such as elevated ALP, hyperuricemia, and elevated blood glucose; Toxicities with no safety risk, such as hair loss and grade 2 peripheral neurotoxicity, were excluded. Or decreased hemoglobin except \u226590 g\/L).\n10. No serious cardiac dysfunction, left ventricular ejection fraction (LVEF) \u226550%\n11. The organ function level must meet the following requirements: a) bone marrow function: absolute neutrophilic granulocyte count (ANC) \u22651.5\u00d7109\/L, platelet count \u226590\u00d7109\/L, hemoglobin \u226590 g\/L; b) Liver function: total bilirubin (TBIL\u22641.5 ULN), AST and ALT \u22642.5 ULN in patients without liver metastasis, AST and ALT \u22645.0 ULN in patients with liver metastasis; c) Kidney function: creatinine (Cr) \u22641.5 ULN, or creatinine clearance (Ccr) \u226550 mL\/min (according to Cockcroft and Gault formula).\n12. Coagulation function: International normalized ratio (INR)\u22641.5\u00d7ULN, and activated partial thromboplastin time (APTT)\u22641.5ULN.\n13. Urinary protein \u22642+ or \u22641000mg\/24h.\n14. For premenopausal women with childbearing potential, a pregnancy test must be taken within 7 days prior to the start of treatment. Serum or urine pregnancy must be negative and must be non-lactating; all participants (regardless of male or female) in the group should be treated throughout the treatment. Adequate barrier contraceptive measures should be taken during the treatment and 6 months after the treatment.\n\nExclusion Criteria:\n\n1. Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, major surgery, targeted therapy (including small molecule inhibitor of tyrosine kinase), and other anti-tumor therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to the first administration; mitomycin and nitrosoureas treatment within 6 weeks prior to the first administration; oral fluorouracil-like drugs such as S-1, capecitabine, or palliative radiotherapy within 2weeks prior to the first administration.\n2. Participants with history of severe heart disease, such as: symptomatic congestive heart failure (CHF) \u2265 grade 2 (CTCAE 5.0), New York Heart Association (NYHA) \u2265 grade 2 heart failure, history of transmural myocardial infarction, unstable angina pectoris etc.\n3. Participants with prolonged QT interval (male QTc\\> 450 msec or female QTc\\> 470 msec), complete left bundle branch block, III grade atrioventricular block.\n4. Active autoimmune diseases and inflammatory diseases, such as: systemic lupus erythematosus, psoriasis requiring systemic treatment, rheumatoid arthritis, inflammatory bowel disease and Hashimoto's thyroiditis, etc., except for type I diabetes, hypothyroidism that can be controlled only by alternative treatment, and skin diseases that do not require systemic treatment (such as vitiligo, psoriasis).\n5. Other malignant tumors were diagnosed within 5 years prior to the first administration with the following exceptions: basal cell carcinoma of the skin, squamous cell carcinoma of the skin and\/or carcinoma in situ after radical resection.\n6. Participants with poorly controlled hypertension by two kinds of antihypertensive drugs (systolic blood pressure\\>150 mmHg or diastolic blood pressure\\>100 mmHg).\n7. Participants have grade 3 lung disease defined according to NCI-CTCAE v5.0, or a history of interstitial lung disease (ILD).\n8. Unstable thrombotic events such as deep vein thrombosis, arterial thrombosis and pulmonary embolism requiring therapeutic intervention within 6 months prior to screening; Thrombus formation associated with infusion set is excluded.\n9. Symptoms of active central nervous system metastasis. However, patients with stable brain parenchymal metastases can be enrolled. Stable was defined as: a. The seizure-free state lasted for \\> 12 weeks with or without the use of antiepileptic drugs; b. Glucocorticoid use is not required; c. Consecutive MRI scans (at least 8 weeks between scans) showed stable imaging status.\n10. Patients with a history of allergy to recombinant humanized antibody or mouse chimeric antibody or to any excipients of BL-B01D1.\n11. Previous recipients of organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT).\n12. In previous adjuvant therapy with anthracyclines, the cumulative dose of anthracyclines was \\> 360 mg\/m2.\n13. Positive human immunodeficiency virus antibody (HIVAb), active tuberculosis, active hepatitis B virus infection (HBV-DNA copy number \\> 103 IU\/ml) or active hepatitis C virus infection (HCV antibody positive and HCV-RNA \\> lower limit of detection).\n14. Active infections requiring systemic treatment, such as severe pneumonia, bacteremia, septicemia, etc.\n15. Participated in another clinical trial (calculated from the time of the last dose) within 4 weeks prior to the first dose.\n16. The other conditions of participation in this clinical trial were not considered appropriate by the investigators.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05194982008","EMAIL":[{}],"GEO":[37.86944,112.56028]},{"TITLE":"A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Have at least 1 injectable measurable cutaneous, subcutaneous or nodal lesion (direct injection or through the use of ultrasound guidance) not exceeding 50mm in longest diameter and whenever possible 1 distant non-injected measurable lesion.\n* Provision of a fresh tumor sample of the lesion that will be injected first and, whenever possible, from another lesion that is planned to be injected, at baseline and be willing to supply new tumor samples from a biopsy during treatment.\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.\n* Have adequate hematological, hepatic and renal functions.\n* Have histologically confirmed, advanced\/metastatic sarcoma (soft tissue and bone), Merkel cell carcinoma, melanoma, triple negative breast cancer or non-small cell lung cancer, with cutaneous or, palpable subcutaneous lesions or easily injectable lymph nodes.\n* Have failed and\/or are intolerant to standard therapeutic options.\n\nExclusion Criteria:\n\n* Have had major surgery within 4 weeks of first study drug administration.\n* Have received prior treatment with a vaccinia oncolytic virus.\n* Have received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to the start of treatment.\n* Have received prior radiotherapy within 2 weeks of start of study treatment or have had a history of radiation pneumonitis\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 28 days prior the first dose of study drugs\n* Have a known additional malignancy that is progressing or has required active treatment within the past 3 years.\n* Have an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs).\n* Have a history of (non-infectious) pneumonitis \/ interstitial lung disease that required steroids or has current pneumonitis \/ interstitial lung disease\n* Have an active infection requiring systemic therapy\n* Have a known history of HIV infection\n* Is taking an anticoagulant medication that cannot be interrupted prior to IT injections\n* Have had an allogenic tissue\/solid organ transplant or allogenic stem cell or bone marrow transplantation\n* History of severe exfoliative skin conditions (e.g., eczema or atopic dermatitis) requiring systemic therapy for more than 4 weeks within 2 years prior to BT-001 initiation.\n* Have received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137), and was discontinued from that treatment due to a Grade 3 or higher immune-related Adverse Event (irAE).\n* Have known active CNS metastases and\/or carcinomatous meningitis.\n* Have a known history of Hepatitis B (defined as HBsAg reactive) or known active Hepatitis C virus (defined as HCV RNA \\[qualitative\\] is detected) infection.n.\n* Woman of childbearing potential who has a positive serum pregnancy test (within 72 hours) prior to the start of treatment.\n* Have received or receiving any live or live-attenuated vaccine within 30 days prior to the first dose of study intervention..\n* History of myocarditis or congestive heart failure, unstable angina, uncontrolled infection, or myocardial infarction 6 months prior to clinical trial entry.\n* Interstitial lung disease that is symptomatic and may interfere with the detection or management of suspected drug-related pulmonary toxicity\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment\n* Have severe hypersensitivity to the active substance or, to any of the excipients of (\u2265Grade 3) to pembrolizumab. and\/or any of its excipients","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04725331005","EMAIL":[{}],"GEO":[48.7939,2.35992]},{"TITLE":"A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)","CRITERIA":"Inclusion Criteria:\n\n* Has a histologically- or cytologically-confirmed early stage or advanced\/ metastatic solid tumor by pathology report and meet the following conditions based on tumor type:\n\n  * Surgically resected Stage IIB and IIC (pathological or clinical), or III cutaneous melanoma per American Joint Committee on Cancer (AJCC) eighth edition.\n  * Surgically resected renal cell carcinoma (RCC) with intermediate-high or high risk of recurrence as defined by the Fuhrman grading status.\n  * Stage IV non-small cell lung cancer (NSCLC) per AJCC eight edition, with an anti-programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) \u226550% determined using the Dako PD-L1 immunohistochemistry (IHC) 22C3 pharmDx diagnostic kit, and confirmation that epidermal growth factor receptor (EGFR-), anaplastic lymphoma kinase (ALK-), or c-ros oncogene 1 (ROS1)- directed therapy is not indicated as primary therapy.\n* Has a life expectancy of at least 3 months.\n* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART).\n* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load before randomization.\n* Participants with history of hepatitis C virus (HCV) infection are eligible if have completed curative antiviral therapy at least 4 weeks before randomization and HCV viral load is undetectable at screening.\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 3 days before the start of study intervention.\n\nExclusion Criteria:\n\n* Non-small cell lung cancer (NSCLC) participants with a diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements.\n* Melanoma participants with ocular, mucosal, or conjunctival melanoma.\n* Renal Cell Carcinoma (RCC) participants who have had major surgery, other than nephrectomy, within 12 weeks before randomization.\n* Has received prior radiotherapy for RCC.\n* RCC participants who have residual thrombus post nephrectomy in the vena renalis or vena cava.\n* Has received prior therapy with an anti-programmed cell death 1 protein (PD-1), PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137).\n* Has received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization.\n* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.\n* Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids.\n* Received prior systemic anticancer therapy for their metastatic NSCLC. Note: Prior treatment with neoadjuvant or adjuvant therapy for nonmetastatic NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC.\n* Received radiation therapy to the lung that is \\>30 Gray within 6 months of start of study intervention.\n* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration.\n* Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication.\n* Has known additional malignancy that is progressing or has required active treatment within the past 3 years.\n* Has known active central nervous system (CNS) metastases and\/or carcinomatous meningitis.\n* Has active autoimmune disease that has required systemic treatment in the past 2 years.\n* Has history of (noninfectious) pneumonitis\/interstitial lung disease that required steroids or has current pneumonitis\/interstitial lung disease.\n* Has active infection requiring systemic therapy.\n* HIV-infected participants with a history of Kaposi's sarcoma and\/or Multicentric Castleman's Disease.\n* Has history of allogeneic tissue\/solid organ transplant corticosteroids.\n* Has severe hypersensitivity (\u2265Grade 3) to pembrolizumab and\/or any of its excipients.\n* Has not adequately recovered from major surgery or have ongoing surgical complications.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06099782043","EMAIL":[{}],"GEO":[38.41273,27.13838]},{"TITLE":"Study With Immunotherapy Combinations in Participants With Metastatic Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Histologically confirmed, documented diagnosis of Stage IV metastatic, NSCLC\n* Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1\n* At least one measurable target lesion per RECIST v1.1.\n* Adequate organ and marrow function\n* Participants must be willing to provide adequate tumor tissue\n\nExclusion Criteria:\n\n* Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will make the administration of Investigational Product(s) (IPs) hazardous\n* Use of any live vaccines against infectious diseases within 28 days of first dose of IP(s).\n* Concurrent chronic medical condition requiring the use of supra-physiologic doses of corticosteroids (\\> 10 mg\/day of oral prednisone or equivalent) or immunosuppressive medications (absorbable topical corticosteroids are not excluded).\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma\/atopy\n\nNOTE: Other protocol defined Inclusion\/Exclusion criteria may apply.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05676931030","EMAIL":"GileadClinicalTrials@gilead.com","GEO":[51.50853,-0.12574]},{"TITLE":"A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2","CRITERIA":"Inclusion Criteria:\n\n* Cohort 1: Head and neck squamous cell carcinoma (HNSCC)\n\n  * Pathologically-documented squamous cell carcinoma of the head and neck with primary tumor site arising from the oral cavity, oropharynx, hypopharynx, and larynx\n  * Unresectable locally recurrent or metastatic stage disease\n  * Prior therapies:\n\n    * Participants must have disease progression after treatment with a platinum-based therapy\n    * No more than 1 line of cytotoxic chemotherapy for advanced disease\n* Cohort 2: Non-small cell lung cancer (NSCLC)\n\n  * Pathologically documented NSCLC\n  * Unresectable locally-advanced or metastatic stage disease\n  * Prior therapies\n\n    * Must have progressed during or after a platinum-based therapy or, within 6 months of platinum-based adjuvant, neoadjuvant, or concomitant chemoradiotherapy for early or locally-advanced stage disease\n    * Must have received prior anti-PD(L)1 therapy, unless contraindicated\n    * No more than 2 prior lines of cytotoxic chemotherapy for advanced disease\n* Cohort 3: Ovarian Cancer\n\n  * Pathologically documented epithelial cancers of ovarian, fallopian tube, or peritoneal origin\n  * Unresectable locally-advanced or metastatic stage disease\n  * Prior therapies\n\n    * Must have platinum resistant disease (6 months or less between the completion of platinum-based treatment and identification of recurrence)\n    * Must not have received more than 4 lines of prior cytotoxic chemotherapies for advanced disease\n    * May have received prior anti-PD(L)1 therapy\n* Cohort 4: Endometrial Cancer\n\n  * Must have pathologically documented adenocarcinoma of the endometrium\n  * Must have unresectable locally-advanced or metastatic stage disease.\n  * Prior therapies\n\n    * Must have relapsed\/progressed after at least one prior platinum-based chemotherapy for recurrent, metastatic or primary unresectable disease\n    * Must not have received more than 3 lines of prior cytotoxic chemotherapies for advanced disease\n    * May have received prior anti-PD(L)1 therapy\n* HER2 expression of 1+, 2+, or 3+, as determined by local IHC testing on a fresh or archival tumor tissue. Note: Participants with HER2 mutations are eligible.\n* Measurable disease per RECIST v1.1 criteria as assessed by the investigator\n* Able to provide formalin-fixed, paraffin-embedded (FFPE) tumor tissue blocks (or freshly sectioned slides)\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n\nExclusion Criteria:\n\n* Prior treatment with an MMAE-containing agent.\n* Known hypersensitivity to any excipient contained in the drug formulation of disitamab vedotin.\n* History of another invasive malignancy within 2 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy.\n* Active untreated CNS or leptomeningeal metastasis","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06003231032","EMAIL":[{}],"GEO":[46.81228,-71.21454]},{"TITLE":"Osimertinib for Advanced EGFR-positive NSCLC Patients","CRITERIA":"Inclusion Criteria:\n\n* For inclusion in the study subjects should fulfil the following criteria:\n\n  1. Provision of informed consent prior to any study-specific procedure\n  2. Patients must be \u2265 18 years old\n  3. Locally advanced \/metastatic NSCLC not responsive to surgery or radiotherapy\n  4. Validated activating EGFR sensitising mutations with or without T790M resistance mutation at the time of recruitment for patients who have no prior EGFR TKI treatment.\n  5. Patients must be EGFR treatment na\u00efve.\n  6. ECOG Performance status is 0-1 with no deterioration over the last 2 weeks prior to study recruitment.\n  7. Normal organ and bone marrow function measured within 28 days before the study as defined below:\n\n     * Haemoglobin \u2265 9.0 g\/dL and no blood transfusions in the 28 days prior to entry\n     * Absolute neutrophil count (ANC) \u2265 1.5 x 109\/L\n     * No features suggestive of MDS\/AML on peripheral blood smear\n     * White blood cells (WBC) \\> 3x109\/L\n     * Platelet count \u2265 100 x 109\/L\n     * Total bilirubin \u2264 1.5 x institutional upper limit of normal (ULN)\n     * AST (SGOT)\/ALT (SGPT) \u2264 2.5 x institutional upper limit of normal unless liver metastases are present in which case it must be \u2264 5x ULN\n     * Serum creatinine \u2264 1.5 x institutional upper limit of normal (ULN)\n     * ECOG performance status 0-2\n  8. A life expectancy \u2265 12 weeks in all patients.\n  9. Females in childbearing age should be using adequate contraceptive measures, should not be breastfeeding and their pregnancy test prior to the start of treatment must be negative. Evidence of non-child-bearing potential is fulfilled by one of the following criteria at screening:\n\n     * The post-menopausal period defined as age \u226550 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments\n     * Women \\<50 years old they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range.\n     * Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not a tubal ligation\n  10. Male patients should be willing to use barrier contraception\n  11. The patient is willing to comply with the protocol during the study including undergoing treatment and scheduled visits and examinations including follow up.\n  12. At least one lesion, not previously irradiated, that can be accurately measured at baseline as \u2265 10 mm in the longest diameter (except lymph nodes which must have short axis \u2265 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) and is considered suitable for accurate repeated measurements.\n\nExclusion Criteria:\n\n* Patients should not enter the study if any of the following exclusion criteria are fulfilled:\n\n  1. Treatment with other EGFR-TKI within 8 days or within five half-lives of the compound before study entry whichever is the longer; any cytotoxic chemotherapy, or other anticancer drugs against NSCLC within 14 days of study entry\n  2. Previously treated with an immune checkpoint inhibitor\n  3. Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for \u2265 5 years\n  4. Radiotherapy to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks before the study entry\n  5. Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of study treatment with the exception of alopecia grade 2 and platinum-related neuropathy.\n  6. Unstable spinal cord compression\/brain metastases unless asymptomatic and not requiring steroids for at least 2 weeks prior to the start of study treatment. For patients with brain metastases, gamma knife or stereotactic brain surgery is allowed prior to study treatment.\n  7. Major surgery within 4 weeks of starting study treatment and patients must have recovered from any effects of any major surgery. Minor surgery is allowed.\n  8. Patients currently receiving or unable to stop use medications or herbal supplements that are potent inhibitors of CYP3A4 (at least 1 week prior) and potent inducers of CYP3A4 (at least 3 weeks prior). All patients must avoid concomitant use of any medications, herbal supplements and\/or foods with known inducer\/inhibitory effects on CYP3A4 unless part of protocol treatment.\n  9. Severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which based on investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol, or having active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.\n  10. Past medical history of ILD, drug-induced ILD, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active ILD\n  11. Any of the following cardiac criteria:\n\n      1. Mean resting corrected QT interval (QTc using Fredericia's formula) \\> 470 msec\n      2. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third-degree heart block, second-degree heart block)\n      3. Any factors increasing the risk of QTc prolongation or arrhythmias such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval\n  12. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the drug or previous significant bowel resection that would preclude adequate absorption of Osimertinib\n  13. History of hypersensitivity to Osimertinib (or drugs with a similar chemical structure or class to Osimertinib) or any excipients of these agents\n  14. Males and females of reproductive potential who are not using an effective method of contraception and females who are pregnant or breastfeeding or have a positive serum pregnancy test prior to study entry\n  15. Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements\n  16. Previous allogeneic bone marrow transplant.","SEX":"ALL","AGE_MIN":21,"AGE_MAX":99,"SS_ID":"05037331001","EMAIL":[{},{}],"GEO":[1.28967,103.85007]},{"TITLE":"LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)","CRITERIA":"Inclusion Criteria:\n\n1. Must have one of the following histologically and\/or biochemically confirmed genitourinary malignancies:\n\n   1. Cohort A: Non-small cell cancer\n   2. Cohort B: Small cell cancer\n2. Provision of signed and dated informed consent form.\n3. Stated willingness to comply with all study procedures and availability for the duration of the study.\n4. Age \u226518 years at time of consent.\n5. Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy.\n6. \u2265 1 line of systemic therapy for metastatic disease with \u2265 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. \\[Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment and not requiring an immediate change in systemic treatment\\]\n7. \u2264 5 progressing or new metastatic lesions.\n8. All progressing or new metastatic lesions can be safely treated with locally ablative therapies at discretion of treating radiation oncologist and\/ interventional radiologist.\n\nExclusion Criteria:\n\n1. Medical comorbidities precluding locally ablative therapies.\n2. History of treatment related toxicities that limit or prohibit application of locally ablative therapies.\n3. Progressing intracranial lesions.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06103682001","EMAIL":[{"email":"sblaqui@ucdavis.edu"},{}],"GEO":[38.58157,-121.4944]},{"TITLE":"The Efficacy of Babaodan Capsules in Preventing Radiation Pneumonia","CRITERIA":"Inclusion Criteria:\n\n* \uff081\uff0918 to 70 years\uff1b\uff082\uff09Histologically\/cytologically confirmed NSCLC\uff1b\uff083\uff09ECOG \u22642\uff1b\uff084\uff09Weight loss \u226410%\uff1b\uff085\uff09 Inoperable AJCC stage IIIA, or IIIB disease\uff1b\uff086\uff09Neutrophils \u22651.5\u00d710\\^9\/L and platelets \u2265100\u00d710\\^9\/L\uff1b\uff087\uff09Adequate liver and renal function.\n\nExclusion Criteria:\n\n* \uff081\uff09Malignant pleural effusion\uff1b\uff082\uff09Active uncontrolled infection\uff1b\uff083\uff09Significant cardiovascular disease\uff1b\uff084\uff09History of other malignancies\uff1b\uff085\uff09Forced expiratory volume in 1 second \\<40% of normal\uff1b\uff086\uff09Previous history of cervical and chest radiation therapy.","SEX":"ALL","AGE_MIN":17,"AGE_MAX":70,"SS_ID":"06079931001","EMAIL":[{"email":"zengqi37@mail.sysu.edu.cn"}],"GEO":[22.27694,113.56778]},{"TITLE":"START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Written informed consent.\n2. Male or female, \u226518 years of age.\n3. Patients with any 1 of the following histologically confirmed tumors and who qualifies for new or continued CPI therapy and relapsing to\/after standard therapy or the patient has refused or does not tolerate standard therapy:\n\n   * Inoperable\/metastatic cutaneous malignant melanoma\n   * Relapsed or newly diagnosed locally advanced inoperable\/metastatic TNBC\n   * Inoperable advanced\/metastatic non-squamous NSCLC\n   * Inoperable and\/or advanced Synovial or myxoid round cell sarcoma\n   * Inoperable and\/or advanced colorectal cancer, patients assessed as positive for NY-ESO-1 or MAGE-A3 expression at baseline\n4. Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.\n5. Tumor lesion which is deemed feasible for biopsy and injection\n6. ECOG\/WHO performance status 0 to 1.\n7. Acceptable liver and renal function, defined as:\n\n   * Total bilirubin \u22641.5 x upper limit of normal (ULN; does not include patients with Gilbert's Disease), and\n   * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u22643.0 x ULN, and\n   * Serum creatinine \u22641.5 x ULN\n8. Acceptable hematological function, defined as:\n\n   * Hemoglobin \u226510 g\/dL, and\n   * Neutrophils \u22651.5 x 109\/L, and\n   * Platelet count \u2265100 x 109\/L Patients may be transfused to meet the hemoglobin entry criteria.\n9. Acceptable coagulation status defined by international normalized ratio (INR) of blood clotting, prothrombin time and activated partial thromboplastin time within \u22641.5 x upper limit of normal.\n10. Negative pregnancy test at screening in all women of childbearing potential (WOCBP). Such patients must agree to use a highly effective method of contraception (Appendix 1) during study intervention and for 3 months after the last virus treatment, 4 months after the last dose of pembrolizumab, and 12 months after CPO dosing. Male patients and male partners of female patients must also use barrier contraception, i.e., condom, for the time periods specified for WOCBP, plus a further 3 month period.\n\n    Urine pregnancy tests should have a sensitivity of at least 25 mIU\/mL for human chorionic gonadotropin (hCG). If the urine test is positive, it must be followed by a quantitative analysis of hCG concentration in blood.\n11. Prior therapy with an immune CPI is allowed provided a 6-week washout period is observed for patients with prior programmed cell death (PD)1 or PDL1 treatment\n\nExclusion Criteria:\n\n1. Receipt of any oncolytic virus treatment, or administration of a vaccine containing live virus within 4 weeks before Day 1.\n2. Use of significant immunosuppressive medication, including high dose corticosteroid (defined as the equivalent of \\>10 mg\/day prednisone) within 4 weeks before Day 1. Inhaled or topical corticosteroid use is allowed.\n3. Prior or concomitant radiotherapy within 4 weeks before Day 1.\n4. Participation in a study with an investigational drug or device within 4 weeks prior to Day 1.\n5. Active bacterial, viral, or fungal infection that requires systemic therapy.\n6. Active autoimmune disease that has required systemic treatment in the past two years.\n7. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the patient, if included in this study.\n8. Any concomitant medical condition requiring receipt of a therapeutic anticoagulant that, in the opinion of the treating physician, cannot safely be withheld to allow for repeated injection of PeptiCRAd 1 and tumor biopsies.\n9. Known infection with human immunodeficiency virus, hepatitis B, or hepatitis C or active tuberculosis.\n10. Known active central nervous system metastases. Patients with leptomeningeal disease, carcinomatous meningitis, symptomatic brain metastases, or radiographic signs of CNS hemorrhage are excluded.\n\n    Note: Participants with asymptomatic brain metastases (i.e. off corticosteroids and anticonvulsants for at least 7 days) are permitted.\n11. Any prior severe AE according to Common Terminology Criteria for Adverse Events (CTCAE), severe hypersensitivity reaction attributed to prior anti-PD1 or PDL1 therapy or components of the study intervention or has a history of any contraindication that, in the investigator's opinion, would contraindicate pembrolizumab administration such as:\n\n    * Resolution of side effect of prior anti-PD1 or PDL1 therapy to Grade 1\n    * Grade 2 or higher pneumonitis\n    * Grade 4 AST or ALT elevation\n    * Grade 3 or higher colitis attributable to immunotherapy Note: in the absence of clinical symptoms of pancreatitis, elevations of amylase or lipase are not contraindications to therapy on this trial.\n12. History of or planned tissue \/ organ transplant.\n13. Females who are pregnant or breast feeding or expecting to conceive within the projected duration of the study starting with the screening visit or males expecting to father children within the projected duration of the study starting with the screening visit.\n14. Unwillingness or inability to comply with the study protocol for any reason.\n15. Admission to an institution by virtue of an order issued by the judicial or administrative authorities.\n16. Sponsor or Contract Research Organization employees, or employees under the direct supervision of the investigator or the investigational sites and\/or involved directly in the study.\n17. Prior or concurrent malignancy, unless the natural history or treatment of the disease does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05492682003","EMAIL":"info@valotx.com","GEO":[48.52266,9.05222]},{"TITLE":"Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)","CRITERIA":"Inclusion Criteria:\n\n* Previously untreated, histologically confirmed (by core biopsy) NSCLC and histologically confirmed stages IA3, IB and IIA NSCLC (AJCC 8th edition).\n* Able to undergo protocol therapy, including necessary surgery.\n* If female: may participate if no active pregnancy, not breastfeeding, and at least one of the following: is not a woman of childbearing potential (WOCBP), or is a WOCBP using contraceptive methods.\n* If male: must agree to refrain from donating sperm, and must either be abstinent or agree to use contraception.\n* ECOG 0-1\n* Available formalin-fixed paraffin embedded (FFPE) tumor tissue samples\n\nExclusion Criteria:\n\n* Has one of the following tumor locations\/types: NSCLC involving the superior sulcus, large cell neuroendocrine cancer (LCNEC) or sarcomatoid tumor.\n* History of immunodeficiency, HBV, HCV, HIV. No HBV, HCV or HIV testing is required unless mandated by local health authority.\n* Has a history of (non-infectious) pneumonitis\/interstitial lung disease.\n* Has an active infection requiring systemic therapy.\n* Has had an allogenic tissue\/solid organ transplant.\n* Has a known severe hypersensitivity (\u2265 Grade 3) to pembrolizumab, its active substance and\/or any of its excipients. (Refer to the respective Investigator's Brochure for a list of excipients.)\n* Has a known severe hypersensitivity (\u2265 Grade 3) to any of the study chemotherapy agents and\/or to any of their excipients.\n* Has an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the participant's participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperating with the requirements of the trial.\n* Has received colony-stimulating factors (eg, G-CSF, GM-CSF or recombinant erythropoietin) within 2 weeks before randomization\n* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).\n* Has received prior systemic anticancer therapy including investigational agents for the current malignancy prior to randomization\/allocation.\n* Has received prior radiotherapy within 2 weeks of start of trial treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis.\n* Has received a live or live attenuated vaccine within 30 days prior to the first dose of trial drug. Note: killed vaccines are allowed.\n* Is currently participating in or has participated in a trial of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of trial treatment.\n* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (dose exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of trial drug.\n* Has a known additional malignancy that is progressing or requires active treatment within the past (5 years).","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04638582001","EMAIL":[{},{}],"GEO":[45.50884,-73.58781]},{"TITLE":"Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study","CRITERIA":"Inclusion Criteria:\n\nA) To be checked before the induction phase (only for patient included before induction phase) :\n\n1. Histologically or cytologically confirmed diagnosis of non-squamous non-small cell lung cancer (NSCLC).\n2. Non-operable \/ non-irradiable stage III or stage IV.\n3. Patient must be eligible to receive 3 or 4 cycles of induction treatment combination with pembrolizumab plus platinum (cisplatin or carboplatin) and pemetrexed.\n4. In the presence of an EGFR mutation, an ALK or ROS1 rearrangement the patient must have received at least one specific targeted therapy line.\n5. Age \u2265 18 years old.\n6. Performance status 0 or 1.\n7. Signed informed consent.\n8. Patient affiliated to a social security system or beneficiary of the same.\n\nB) To be checked before the maintenance phase (for all patient) :\n\n1. Histologically or cytologically confirmed diagnosis of non-squamous non-small cell lung cancer (NSCLC).\n2. Non-operable \/ non-irradiable stage III or stage IV.\n3. Received 3 or 4 cycles of induction treatment combination with pembrolizumab plus platinum (cisplatin or carboplatin) and pemetrexed.\n4. Patient must be eligible to receive maintenance pembrolizumab with or without pemetrexed, last induction chemotherapy cycle within 42 days before randomization.\n5. Stable disease, partial or complete response according to RECIST 1.1 criteria after induction chemotherapy and pembrolizumab. Targets lesions are not required before randomization.\n6. In the presence of an EGFR mutation, an ALK or ROS1 rearrangement the patient must have received at least one specific targeted therapy line (not needed a second time if already checked before induction phase).\n7. Patients with baseline brain metastases will be eligible in case of stability or no evidence of progression and if they remain clinically stable.\n8. Age \u2265 18 years old.\n9. Performance status 0 or 1.\n10. Signed informed consent (only for patient included after induction phase).\n11. Patient affiliated to a social security system or beneficiary of the same.\n12. Creatinine clearance \\> 30 ml\/min by Cockcroft-Gault\\* or MDRD in case that patient will start maintenance just with pembrolizumab but \u2265 45 ml\/min if the patient will receive pemetrexed plus pembrolizumab.\n\n    \\*Cockcroft- Gault Formula:\n    * Female CrCl = \\[(140 - age in years) x weight in kg x 0.85\\] \/ 72 x serum creatinine in mg\/dL;\n    * Male CrCl = \\[(140 - age in years) x weight in kg x 1.00\\] \/72 x serum creatinine in mg\/dL.\n13. Neutrophils \u2265 1500\/\u03bcL and platelets \u2265 100 000\/\u03bcL.\n14. Bilirubin \u2264 1.5 upper limit normal (ULN).\n15. Transaminases, Alkaline phosphatase \u2264 2.5 x the ULN except in case of liver metastases (5 x ULN).\n16. Patients might have received platinum-based chemotherapy as an adjuvant or neoadjuvant treatment, or with radiotherapy for a localized lung cancer, provided that the chemotherapy was ended more than 6 months before the first cycle of induction chemotherapy.\n17. Patients might have received previous immune checkpoint inhibitors as an adjuvant or neoadjuvant treatment, or as a consolidation treatment after radiotherapy for a localized lung cancer, but the immune checkpoint inhibitors must be finished at least than 12 months before the first cycle of induction chemotherapy for advanced stage.\n18. A woman is eligible for the study if she is no longer likely to procreate (physiologically unfit to carry out a pregnancy), which includes women who have had: a hysterectomy, an oophorectomy, a bilateral tubal ligation.\n\n    Post-menopausal women:\n    * Patients not using hormone replacement therapy should have had a complete cessation of menstruation for at least one year and be over 40 years of age, or, if in doubt, have an FSH (Follicle Stimulating Hormone) level \\> 40 mIU\/mL and an estradiol level \\< 40 pg\/mL (\\< 150 pmol\/L).\n    * Patients using hormone replacement therapy must have had a complete cessation of menstruation for at least one year and be over 45 years of age or have evidence of menopause (FSH and estradiol levels) before starting hormone replacement therapy.\n19. Women who are likely to procreate are eligible if they have a negative serum pregnancy test in the week before the first dose of treatment and preferably as close as possible to the first dose and if they agree to use an effective contraceptive method during the course of the study through 4 months after the last dose of study medication.\n\nSexually active males patients must agree to use condom during the study and for at least 4 months after the last study treatment administration. Also, it is recommended their women of childbearing potential partner use a highly effective method of contraception.\n\nExclusion Criteria:\n\nA) To be checked before the induction phase (only for patient included before induction phase) :\n\n1. Mixed small-cell, squamous-cell carcinoma.\n2. Mental or psychological illness that does not allow the patient to give informed consent.\n3. Pregnant or breastfeeding women.\n4. History of HIV or chronic hepatitis B or C.\n5. Active or uncontrolled infection.\n6. History of one or more of the following cardiovascular disorders in the previous 6 months:\n\n   * Coronary artery bypass or peripheral arterial bypass, cardiac angioplasty or stent.\n   * Myocardial infarction\n   * Severe or unstable angina pectoris\n   * Peripheral vascular disease, pulmonary embolism or untreated thromboembolic events, stroke or transient ischemic attack. Note: Patients with recent deep vein thrombosis (including pulmonary embolism) treated with anticoagulant for at least 4 weeks and clinically stable are eligible.\n   * Congestive heart failure class III or IV as defined by the NYHA\n7. Concomitant treatment with another experimental treatment or participation in another clinical trial.\n\nB) To be checked before the maintenance phase (for all patient) :\n\n1. Presence of grade 3 or 4 toxicity related to pembrolizumab limiting maintenance treatment continuation.\n2. Mixed small-cell, squamous-cell carcinoma.\n3. Corticosteroids at a dose greater than 20 mg per day of prednisone or equivalent.\n4. Patient unable to follow the therapeutic program.\n5. Mental or psychological illness that does not allow the patient to give informed consent.\n6. Pregnant or breastfeeding women.\n7. Ongoing immunosuppressive systemic therapy (cyclophosphamide, aziatropin, methotrexate, thalidomide and anti-TNF).\n8. Active autoimmune diseases. History of autoimmune diseases including myasthenia gravis, lupus erythematosus, rheumatoid arthritis, irritable bowel syndrome, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sj\u00f6gren's syndrome, Guillain-Barr\u00e9 syndrome, multiple sclerosis, vasculitis or glomerulonephritis. Patients with a history of autoimmune hypothyroidism treated with a stable dose of hormone replacement therapy are eligible. Patients with diabetes treated with insulin are eligible.\n9. History of idiopathic pulmonary fibrosis, organized pneumonia (i.e., obliterating bronchiolitis), drug-induced lung disease or active signs of pneumonia, pulmonary infiltration (regardless of cause) detected on the baseline chest CT-scan.\n10. History of any other hematologic or primary solid tumor malignancy unless in remission for at least 2 years and without specific treatment (as example, not allowed hormonal therapy to replace for breast cancer or hormonal therapy substitution in prostate cancer). pT1-2 prostatic cancer Gleason score \\< 6, superficial bladder cancer, non-melanoma skin cancer or carcinoma in situ of the cervix are allowed.\n11. Presence of a condition or condition that makes patient participation in the study inappropriate, including serious unresolved or unstable toxicities from previous administration of another experimental treatment or any medical condition that could interfere with patient safety, obtaining consent or compliance with study procedures.\n12. Administration of a live attenuated vaccine within the 4 weeks before day 1 of Cycle 1 or administration of a live attenuated vaccine planned for the duration of the study. The flu vaccine can be given during the flu season (approximately from October to May). Patients should not receive a live attenuated influenza vaccine during the 4 weeks preceding day 1 of Cycle 1 and should not receive this type of vaccine during the study.\n13. History of HIV or chronic hepatitis B or C (not needed a second time if already checked before induction phase).\n14. Active or uncontrolled infection.\n15. History of one or more of the following cardiovascular disorders in the previous 6 months:\n\n    * Coronary artery bypass or peripheral arterial bypass, cardiac angioplasty or stent.\n    * Myocardial infarction\n    * Severe or unstable angina pectoris\n    * Peripheral vascular disease, pulmonary embolism or untreated thromboembolic events, stroke or transient ischemic attack. Note: Patients with recent deep vein thrombosis (including pulmonary embolism) treated with anticoagulant for at least 4 weeks and clinically stable are eligible.\n    * Congestive heart failure class III or IV as defined by the NYHA\n16. Concomitant treatment with another experimental treatment or participation in another clinical trial.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05692999001","EMAIL":[{"email":"Benjamin.BESSE@gustaveroussy.fr"}],"GEO":[48.7939,2.35992]},{"TITLE":"Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.","CRITERIA":"Inclusion Criteria:\n\n1. Be willing and able to provide written informed consent\/assent for the trial.\n2. Be \u226518 years of age on day of signing informed consent.\n3. Patients with histologically or cytologically confirmed stage IV NSCLC.\n4. Be willing to undergo repeat biopsy of tumor lesions according to the study protocol.\n5. Patients who have failed the standard therapy, or who are unsuitable for standard treatment, or refuse chemotherapy.\n6. At least one measurable lesion according to RECIST 1.1. A lesion that has previously received radiotherapy can be considered a target lesion only if this lesion is clearly progressed after radiotherapy.\n7. The target lesions (irradiated lesions) are \\> 5cm in in diameter\n8. ECOG 0-2.\n9. Life expectancy of \\> 3 months.\n10. Patients must have normal organ and bone marrow function as defined below: Total bilirubin \\<\/= 1.5 x upper limit of normal (ULN). Aminotransferase (AST) Serum Glutamic Oxaloacetic Transaminase (SGOT)\/ Alanine Aminotransferase (ALT) Serum Glutamic-Pyruvic Transaminase (SGPT) \\<2.5 X institutional upper limit of normal (\\<\/= 5 X institutional ULN for subjects with liver metastases) \\*WBC \\>\/= 3500\/uL, ANC \\>\/= 1500\/uL \\*Platelets \\>\/= 90K\/ul \\*Hemoglobin \\>\/= 9g\/dL \\*Creatinine \\<\/= 1.5 x ULN, or creatinine clearance \u2265 50 ml\/min\uff08Cockcroft-Gault equation\uff09. Coagulation: International Normalized Ratio (INR)\u2264 1.5 \u00d7 ULN, Partial thromboplastin time (PTT) \u22641.5 \u00d7 ULN; left ventricular ejection fraction (LVEF) \\>\/= 50% and QTcF (Fridericia's formula) \u2264 450ms\n11. Patients has recovered (i.e., \u2264 Grade 1 or at baseline) from adverse events due to a previously administered agent.\n12. Wash out period for chemotherapy is more than \u2265 4 weeks, for targeted small molecule therapy \u2265 5 half-lives; palliative radiotherapy must have been completed for at least \u2265 2 weeks, chest radiotherapy must have been completed for at least \u2265 4 weeks, and major surgery must have been completed for \u2265 4 weeks.\n13. Subjects with no severe pulmonary ventilation dysfunction, no acute heart failure, and no contraindication to radiotherapy as judged by the radiotherapist. Subjects who agree to receive immunotherapy and radiotherapy treatment.\n14. Subjects should agree to use an adequate method of contraception.\n\nExclusion Criteria:\n\n1. Has known active central nervous system (CNS) metastases and\/or carcinomatous meningitis and\/or spinal cord compression, etc.\n2. With oncologic emergencies that require immediate treatment\n3. EGFR\/ALK\/ROS-1 mutation or mutation status unknown.\n4. Has evidence of interstitial lung disease or active and\/or non-infectious pneumonitis (drug-induced pneumonia, radiation-induced pneumonia, etc.) requiring steroid therapy.\n5. History of pulmonary fibrosis, pulmonary hypertension, severe irreversible airway obstruction disease\n6. Patients with peripheral neuropathy.\n7. Significant heart disease or impairment of cardiac function\n8. Fluid accumulating in the third space, such as pericardial effusion, pleural effusion and peritoneal effusion that remains uncontrolled by aspiration or other treatment\n9. Known allergy to drugs or excipients, known severe allergic reaction to any of the PD-1 monoclonal antibodies\n10. Severe infection within 4 weeks prior to the start of study treatment, including but not limited to hospitalization for infection, bacteremia, or severe pneumonia; treatment with oral or intravenous antibiotics within 2 weeks prior to the start of study treatment; patients receiving prophylactic antibiotic therapy (e.g., to prevent urinary tract infection or exacerbation of COPD) are eligible for this study.\n11. Known or suspected active autoimmune disease (congenital or acquired) such as uveitis, enterocolitis, hepatitis, pituitary inflammation, vasculitis, nephritis, thyroiditis, etc. (patients with vitiligo, or resolved childhood asthma may be enrolled; patients with type I diabetes with good insulin control may also be enrolled)\n12. Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05615142001","EMAIL":[{"email":"luorenbu@gmail.com"}],"GEO":[30.66667,104.06667]},{"TITLE":"GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* 1. Voluntarily join the study, signed informed consent form,, willing and able to comply with the study protocol;\n* 2. Age 18 to 70 years old;\n* 3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;\n* 4. Expected survival time of \u2265 12 weeks;\n* 5. Good function of vital organs;\n* 6. Subjects entering this study due to disease progression must have an imaging record of disease progression before tumor sampling;\n* 7. At least one measurable target lesion that meets the definition of RECIST v1.1 after tumor sampling.\n\nExclusion Criteria:\n\n* 1.Patients with uncontrollable tumor-related pain as judged by the investigator; participants requiring analgesic medication must already have a stable analgesic regimen at the time of study entry; symptomatic lesions suitable for palliative radiotherapy should be completed prior to study entry;\n* 2.Known mental illness, alcoholism, drug use or substance abuse;\n* 3.Pregnant or lactating women; or women who are pregnant, breastfeeding, or planning to become pregnant within 1 year after cell infusion;\n* 4.Those who have received other clinical trial drug treatment within 4 weeks before preconditioning by lymphodepletion,plan to participate in other clinical trial drug treatment during the study;\n* 5.The investigators determine that other conditions that make the patient not suitable for enrollment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":70,"SS_ID":"06235242002","EMAIL":[{"email":"doctorjael@qq.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Previously consented and\/or prospective collection of consent for research use of banked biological materials and clinical data.\n* Confirmed advanced and\/or metastatic non-squamous (NSQ) non-small cell lung cancer (NSCLC).\n* Has formalin-fixed paraffin-embedded (FFPE) tissue collected since 2019.\n\nExclusion Criteria:\n\n* Specimens collected before 2019.\n* Insufficient specimen tissue for testing.\n* Insufficient specimen quality (e.g., not 4-5 \u00b5m in thickness) which precludes testing.\n* Adenosquamous and sarcomatous histologies of NSCLC.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06068842012","EMAIL":"carlos.hader@abbvie.com","GEO":[52.48142,-1.89983]},{"TITLE":"A Study of KK2269 in Adult Participants With Solid Tumors","CRITERIA":"* Key Common Inclusion Criteria for Parts 1 and 2:\n\n  * Patients who are \u2265 18 years old at the time of informed consent\n  * Patients who have disease measurable by RECIST v1.1\n  * Patients with an ECOG PS of 0 or 1\n  * Patients with a life expectancy of at least 3 months in the judgement of the investigator or subinvestigator\n  * The specified periods have passed respectively after the completion of previous cancer treatments as of the date of enrollment\n  * Patients who agree to use a medically effective method of contraception\n* Key Additional Inclusion Criterion for Part 1:\n\n  \u2022Patients with histological or cytological evidence of at least one locally advanced or metastatic non-CNS solid tumor\n* Key Additional Inclusion Criteria for Part 2:\n\n  * Patients with histological or cytological evidence of any of the following disease:\n  * Gastric adenocarcinoma, GEJ adenocarcinoma, or esophageal adenocarcinoma\n  * NSCLC\n  * Patients who are suitable for docetaxel treatment\n* Key Common Exclusion Criteria for Parts 1 and 2:\n\n  * Patients with an uncontrolled or serious intercurrent illness\n  * Patients with known active central nervous system metastasis\n  * Patients with a history of \u2265 Grade 3 allergic reaction to any antibody drug\n  * Patients with a history of autoimmune disease\n  * Patients with a history of HIV, HBV, or HCV at screening\n  * Patients who have a history of primary immunodeficiency\n* Key Additional Exclusion Criterion For Part 2:\n\n  * Patients with a history of treatment with docetaxel","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06266299002","EMAIL":"clinical.info.jp@kyowakirin.com","GEO":[35.57779,139.71685]},{"TITLE":"Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform","CRITERIA":"Inclusion Criteria:\n\n* Subjects suspected of or diagnosed with Stage IV\/metastatic or patients receiving neoadjuvant CPI for resectable early stage of solid malignancies:\n\n  * Lung: Non-small cell lung cancer (NSCLC)\n  * Kidney: Clear Cell Renal Cell Carcinoma (ccRCC)\n  * Bladder: Urothelial Carcinoma (UC)\n  * Skin: Cutaneous Malignancy, excluding Uveal Melanoma\n  * Breast Cancer: Triple negative breast cancer (TNBC)\n  * Liver and Esophageal cancers\n  * Colon cancer: Mismatch repair deficient (dMMR) colorectal cancer (CRC) only\n  * All tumor types with high tumor mutational burden (TMB_ or are microsatellite instability high (MSI-H)Mismatch repair deficient (dMMR) tumors\n  * Cervical and endometrial cancer\n* LOCALLY ADVANCED\/METASTATIC PATIENTS: measurable disease as defined per protocol\n\n  * NOTE: Tumor lesions in a previously irradiated area are not considered measurable disease; Disease that is measurable by physical examination only is not eligible.\n* Eligible based on investigator discretion to receive CPI monotherapy or combination therapy (e.g. combining two CPIs such as anti-PD-1 plus anti-CTLA-4) or CPI therapy in combination with chemotherapy or genome-targeted therapy.\n\n  * Subjects must be treatment-na\u00efve at the time of biopsy if they are newly diagnosed\n  * Subjects who are Stage I, II, or III and have progressed to metastatic cannot have received any anti-cancer treatment for at least 2-4 weeks (depending upon the washout period of prior anti-cancer treatment) prior to biopsy as per the agents used.\n  * Subjects with a confirmed diagnosis who have previously undergone a standard of care (SOC) biopsy must be willing to undergo a separate biopsy procedure solely for the purposes of this study.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0, 1 or 2\n* Negative pregnancy test done \u22647 days prior to enrollment, for persons of childbearing potential only\n* Female subjects must not be pregnant or breastfeeding\n* Female subjects must use appropriate methods of contraception when applicable\n* Clinically able, at investigator discretion, to undergo extra core needle biopsy passes during their biopsy from a tumor site that yields a biopsy of at least 10 mm in length\n* Subjects with a known secondary cancer diagnosis are eligible to participate if participation does not interfere with systemic anti-cancer standard of care treatment for primary diagnosis\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Pregnant women because this study involves a greater than minimal risk procedure (study biopsy)\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety for the biopsy\n* Immunocompromised patients and patients known to be HIV positive and currently receiving antiretroviral therapy\n\n  * NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial\n* Uncontrolled intercurrent illness including, but not limited to:\n\n  * ongoing or active infection\n  * psychiatric illness\/social situations that would limit compliance with study requirements\n* Receiving any investigational agent which would be considered as a treatment for the primary neoplasm","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06349642001","EMAIL":[{"email":"mayocliniccancerstudies@mayo.edu"},{}],"GEO":[30.33218,-81.65565]},{"TITLE":"Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Stage 4 Metastatic NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Signed and dated informed consent form.\n* Male or female, \\> 18 years old.\n* Minimum body weight of 50 kilograms (kg).\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Histologically or cytologically confirmed stage 4 metastatic NSCLC\n* Progressed on at least 2 lines of SOC therapy including platinum-based chemotherapy and immune checkpoint inhibitors.\n* Genomic screening, with tumors with known actionable molecular alterations, such as EGFR, ALK, ROS-1, BRAF, RET, MET, and KRAS etc., must have progressed on appropriate target-directed molecular therapy.\n* At least one measurable target lesion based on RECIST v1.1\n* All toxicity associated with previous treatments are recovered to CTCAE grade of \u22641, except for continuing alopecia.\n* Life expectancy of at least 6 months.\n* Adequate hematopoietic, hepatic and renal function\n* Agree to adequate contraception for up to 120 days after the last dose of study drug.\n* Negative serum pregnancy test for women of childbearing potential\n\nExclusion Criteria:\n\n* Chemotherapy, investigational, and\/or check-point inhibitor therapy within the 30 days prior to study Day 1.\n* Major surgery, except for vascular access placement, within the 30 days prior to study Day 1.\n* Active autoimmune disease requiring immunosuppressive therapy.\n* Infection requiring systemic treatment within 30 days prior to study Day 1.\n* History of peritoneal effusion (ascites), pericardial, or pleural effusions\/nodules.\n* Uncontrolled hypertension, history of arrhythmia including atrial fibrillation, unstable angina, decompensated congestive heart failure, cardiac ejection fraction \u2264 50%, myocardial infarction, or marked baseline prolonged QT\/QTc intervals.\n* Human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C detection.\n* Participation in the treatment portion of a clinical trial or completed a clinical trial within the 30 days prior to the first dose of KB-GDT-01.\n* Presence of any condition that may, in the opinion of the Investigator, render the patient inappropriate from participating in the study.\n* Breastfeeding or pregnant female, or patient is expecting to conceive or father children during the study.\n* Allergy or intolerance to any of the study product ingredients or excipients.\n* Live vaccines administered within 30 days prior to study Day 1.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06069570005","EMAIL":[{"email":"Karen.mcclain@usoncology.com"},{}],"GEO":[36.84681,-76.28522]},{"TITLE":"Stereotactic Radiotherapy (SBRT) of Lung Metastasis","CRITERIA":"Inclusion Criteria:\n\n* Histological confirmation of malignancy, unless the risks of biopsy are unacceptable and the lesion has grown on serial CT scan and\/or is PET positive.\n* Eligible patients must have staging studies (e.g. chest radiograph, CT scan, MRI\/CT Brain\/Bone Scan) identifying them as:\n* patients with stage I or II, non-metastatic NSCLC (T1, N0, M0; T2, N0, M0; or T3, N0, M0 chest wall primary tumors only)\n* patients with a non-lung primary that is controlled and which has metastasized to the lungs alone, in whom potentially curative surgery would otherwise be an option (e.g. colorectal, breast, sarcoma...etc)\n* the subset of patients with limited (low) volume metastatic NSCLC or other primary site tumors whom it is felt may derive benefit from highdose SBRT treatment to the primary or metastatic lung tumor. And in whom other sites of metastatic disease are being treated with the desire to achieve long term control. Lesions must meet size criteria in 4.1.2.1\n* Patients who have potentially resectable disease should be considered medically inoperable, or else in the judgement of the thoracic surgeon and lung team, surgery is not considered the preferred management option\n* Early stage lung cancer: \u22643 parenchymal lung lesions, Metastatic disease to lungs: \u22645 parenchymal lung lesions\n* Patients with early stage primary NSCLC should have hilar or mediastinal lymph nodes that are considered N0 on clinico-radiological grounds (i.e. no clinico-radiological evidence of lymph node spread)\n* In patients with early stage primary NSCLC and a co-existing malignancy, the co-existing malignancy must have an expected prognosis better than primary lung lesion\n* Adequate lung function to tolerate the planned stereotactic radiation\n* Previous conventional RT to mediastinum\/lung allowed as long as SBRT is not expected to have a high probability of impairing lung function\n* Must be \u2265 18 years of age\n* Zubrod performance status must be between 0 and 3\n* Women of child bearing potential and male participants must use an effective contraceptive method\n* Willing and able to give informed consent\n\nExclusion Criteria:\n\n* Patients with active systemic, pulmonary or pericardial infection\n* No concurrent systemic therapy (chemotherapy, immunotherapy or biological therapy), apart from hormone therapy, is allowed\n* History of active auto-immune diseases, including systemic lupus erythematous, rheumatoid arthritis, C.R.E.S.T., systemic sclerosis,scleroderma\n* Potential candidate for concurrent chemo-radiation therapy\n* Patient enrollment on other studies may be permissible. This will depend on patient and study characteristics.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"01803542001","EMAIL":[{"email":"John.Cho@rmp.uhn.on.ca"},{}],"GEO":[43.70011,-79.4163]},{"TITLE":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable\/Metastatic Solid Tumors, Refractory to Standard Therapies","CRITERIA":"Diagnosis and Main Criteria for Inclusion:\n\nInclusion Criteria:\n\nPatients must meet the following criteria for inclusion into the study:\n\nPhase I:\n\n1. Patients must be able to provide documented voluntary informed consent.\n2. Male or female patient aged 18-75 years.\n3. Histologically documented, incurable, locally advanced or metastatic epithelial origin malignant cancer, priority to include but not limited to the following tumor types:\n\n   Breast cancer Ovarian epithelial cancer Non-small cell lung cancer Gastric adenocarcinoma Small cell lung cancer Urothelial carcinoma Note: Confirmation of TROP2 expression by immunohistology or other means is not required, but the Sponsor will request tissue specimens from fresh or archived materials for determination of TROP2 expression.\n4. Measurable disease by CT\/MRI during dose escalation.\n5. Patients should have an unresectable locally advanced or metastatic solid tumor that is refractory to standard therapies, or have no standard therapies, or standard treatment is not applicable at this stage.\n6. Granulocyte count \u2265 1.5\u00d7109\/L, platelet count \u2265 100\u00d7109\/L, and hemoglobin \u2265 9 g\/dL.\n7. International normalized ratio (INR) and activated partial thromboplastin time (aPTT) \u2264 1.5\u00d7ULN.\n8. Serum bilirubin \u2264 1.5 mg\/dL (Patients with known Gilbert disease who have serum bilirubin level \u2264 3 \u00d7ULN may be enrolled)., aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase \u2264 2.5 \u00d7 upper limit of normal (ULN), with the exception of patients with hepatic metastases (ALT and AST \u2264 5 \u00d7 ULN) and patients with hepatic and\/or bone metastases (alkaline phosphatase \u2264 5 \u00d7 ULN).\n9. Creatinine clearance \u2265 50 mL\/min calculated by Cockcroft-Gault, Chronic Kidney Disease Epidemiology Collaboration, or Modification of Diet in Renal Disease formulas. Note that 24 hour urine collection is not required but is allowed.\n10. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.\n11. For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and\/or partner) to use a highly effective form(s) of contraception during study treatment. Female and male patient treated with SKB264 should continue contraception use for 7 months after the last dose. Such methods include combined (estrogen and progestogen containing) hormonal contraception, progestogen-only hormonal contraception associated with inhibition of ovulation together with another additional barrier method always containing a spermicide, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion or vasectomized partner (on the understanding that this is the only one partner during the whole study duration), and sexual abstinence.\n\n    * Oral contraception should always be combined with an additional contraceptive method because of a potential interaction with the study drug. The same rules are valid for male patients involved in this clinical trial if they have a partner of childbirth potential. Male patients must always use a condom.\n    * Women are excluded from birth control if they had had tubal ligation or a hysterectomy.\n12. Patients must have recovered (i.e., improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo.\n13. Expected survival \u2265 3 months.\n\nPhase II:\n\n1. Patients must be able to provide documented voluntary informed consent.\n2. Male or female patient aged \u2265 18 years.\n3. Histologically or cytologically documented, incurable, locally advanced, recurrent or metastatic cancer, including the following tumor types:\n\n   * Cohort 1: triple negative breast cancer (\\< 1% expression for estrogen receptor \\[ER\\] and progesterone receptor \\[PR\\] and HER2 negative)\n   * Cohort 2: ovarian cancer, fallopian tube cancer, or primary peritoneal cancer\n   * Cohort 3: non-small cell lung cancer\n   * Cohort 4: gastric adenocarcinoma or gastroesophageal junction adenocarcinoma (HER2 negative)\n   * Cohort 6: HR+\/ HER2- breast cancer (\u22651% expression for ER and\/or PR and HER2 negative)\n   * Cohort 7: Head and neck squamous cell carcinoma (including primary tumor location of oropharynx, oral cavity, hypopharynx, or larynx. Other primary tumor sites of HNSCC are not eligible)\n   * Cohort 8: Endometrial carcinoma (including carcinosarcoma, but excluding sarcoma and neuroendocrine endometrial carcinoma)\n   * Cohort 9: Urothelial carcinoma (including urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra, patients with mixed histology are eligible provided urothelial component \\> 50% and plasmacytoid component\\<10%, patients whose tumors contain any neuroendocrine component are not eligible)\n   * Cohort 10: Cervical cancer (including squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix) Note: Evaluation of TROP-2 expression is required.\n4. Measurable disease by CT\/MRI.\n5. Patients should have an unresectable locally advanced or metastatic solid tumor that is refractory to standard therapies.\n6. Neutrophil count \u2265 1.5\u00d7109\/L, platelet count \u2265 100\u00d7109\/L, and hemoglobin \u2265 9 g\/dL.\n7. International normalized ratio (INR) and activated partial thromboplastin time (aPTT) \u2264 1.5\u00d7ULN.\n8. Serum bilirubin \u2264 1.5 \u00d7ULN (Patients with known Gilbert disease who have serum bilirubin level \u2264 3 \u00d7ULN may be enrolled), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase \u2264 2.5 \u00d7 upper limit of normal (ULN), with the exception of patients with hepatic metastases (ALT and AST \u2264 5 \u00d7 ULN) and patients with hepatic and\/or bone metastases (alkaline phosphatase \u2264 5 \u00d7 ULN).\n9. Creatinine clearance \u2265 30 mL\/min calculated by Cockcroft-Gault, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), or Modification of Diet in Renal Disease (MDRD) formulas. Note that 24 hour urine collection is not required but is allowed.\n10. ECOG Performance Status 0 or 1.\n11. For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and\/or partner) to use a highly effective form(s) of contraception during study treatment. Female and male patient treated with SKB264 should continue contraception use for 6 months after the last dose. Such methods include combined (estrogen and progestogen containing) hormonal contraception, progestogen-only hormonal contraception associated with inhibition of ovulation together with another additional barrier method always containing a spermicide, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion or vasectomized partner (on the understanding that this is the only one partner during the whole study duration), and sexual abstinence.\n\n    * Oral contraception should always be combined with an additional contraceptive method because of a potential interaction with the study drug. The same rules are valid for male patients involved in this clinical trial if they have a partner of childbirth potential. Male patients must always use a condom.\n    * Women are excluded from birth control if they had had tubal ligation or a hysterectomy.\n12. Patients must have recovered (i.e., improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo. Note: Subjects with endocrine AE of any grade are permitted to enroll if they are stably maintained on appropriate replacement therapy and are asymptomatic.\n13. Expected survival \u2265 3 months.\n\nExclusion Criteria:\n\nPatients that meet the following criteria will be excluded from entry into the study:\n\nPhase I:\n\n1. Severe or uncontrolled cardiac disease requiring treatment, congestive heart failure (New York Heart Association) III or IV, unstable angina pectoris even if medically controlled, history of myocardial infarction during the last 6 months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia).\n2. Symptomatic brain metastases or any radiation or surgery for brain metastases within 1 months of first infusion of study drug.\n3. Subjects with second primary cancers (except for cured in situ non-melanoma skin cancer and in situ cervical cancer with no relapse in the last 3 years).\n4. Require supplemental oxygen for daily activities.\n5. Documented Grade \u2265 2 peripheral neuropathy.\n6. History of documented severe dry eye syndrome, severe Meibomian gland disease and\/or blepharitis, corneal disease that prevents\/delays corneal healing, macular degeneration.\n7. Subjects previously treated with TROP 2 targeted therapies.\n8. Any standard cancer therapy (e.g. chemotherapy, hormonal therapy, radiotherapy, immunotherapy, biologic therapy treatment, or therapy with traditional Chinese medicines approved for anti-tumor treatment, etc.) within 4 weeks or five half-lives, whichever is shorter, of first infusion of study drug.\n9. Any experimental therapy within 4 weeks or five half-lives, whichever is shorter, of first infusion of study drug.\n10. Any major surgical procedure within 4 weeks of first infusion of study drug.\n11. Diagnosed active liver disease, including viral or other hepatitis, current or history of alcoholism, or cirrhosis.\n12. Have known prior positive test results or medical history for human immunodeficiency virus.\n13. Uncontrolled hypertension (systolic blood pressure \u2265 160 mmHg and\/or diastolic blood pressure \u2265 100 mmHg) or diabetes (HbA1c \u2265 9.0%).\n14. Subjects who require use of strong inhibitors or inducers of CYP3A4 at least 14 days prior to and throughout Study. Use of strong inhibitors or inducers of CYP3A4 is not allowed in this study. List of representative examples of strong inhibitors or inducers of CYP3A4 is provided in Appendix III.\n15. Pregnancy or lactation.\n16. Left ventricular ejection fraction \\< 45% determined by echocardiogram or multiple gated acquisition scan.\n17. Resting QTc \\> 480 msec at baseline.\n18. Ascites requiring paracentesis \u22651 per week.\n19. Symptomatic pleural effusion (\\< 90% oxygen saturation).\n20. Subjects with non-infectious interstitial lung diseases (ILD) or medical history of pneumonia requiring steroid treatments; severe pulmonary dysfunction caused by lung diseases.\n21. New diagnosed thromboembolic events that requires therapeutic intervention over the last 6 months (patients with stable control of lower limb deep venous thrombosis are allowed).\n22. The investigator considers other situations that patients are not appropriate to participate in this trial.\n\nPhase II:\n\n1. Any patient who was treated in the Phase I part of this study.\n2. Severe or uncontrolled cardiac disease requiring treatment, congestive heart failure (New York Heart Association) III or IV, unstable angina pectoris even if medically controlled, history of myocardial infarction during the last 6 months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia).\n3. Subjects with known meningeal metastases, brainstem metastases, spinal cord metastases and\/or compression, or other active CNS metastases.\n4. Patients with active second primary cancers (except for cured in situ non-melanoma skin cancer and in situ cervical cancer with no relapse in the last 3 years, or other malignant cancers that have been cured and no evidence of recurrence).\n5. Require supplemental oxygen for daily activities.\n6. Documented Grade \u2265 2 peripheral neuropathy.\n7. History of documented severe dry eye syndrome, severe Meibomian gland disease and\/or blepharitis, corneal disease that prevents\/delays corneal healing, macular degeneration.\n8. Patients previously treated with TROP 2 targeted therapies at any time for early stage or metastatic disease.\n9. Any standard cancer therapy (e.g. chemotherapy, hormonal therapy, radiotherapy, immunotherapy, biologic therapy treatment, or therapy with traditional Chinese medicines approved for anti-tumor treatment, etc.) within 4 weeks or 5 half-lives, whichever is shorter, of first infusion of study drug.\n10. Any experimental therapy within 4 weeks or 5 half-lives, whichever is shorter, of first infusion of study drug.\n11. Any major surgical procedure within 4 weeks of first infusion of study drug.\n12. Diagnosed active liver disease, including viral or other hepatitis, current or history of alcoholism, or cirrhosis.\n13. Have known prior positive test results or medical history for human immunodeficiency virus.\n14. Uncontrolled hypertension (systolic blood pressure \u2265 160 mmHg and\/or diastolic blood pressure \u2265 100 mmHg) or diabetes (HbA1c \u2265 9.0%).\n15. Subjects who require use of strong inhibitors or inducers of CYP3A4 at least 14 days prior to and throughout Study. Use of strong inhibitors or inducers of CYP3A4 is not allowed in this Study. List of representative examples of strong inhibitors or inducers of CYP3A4 is provided in Appendix III.\n16. Pregnancy or lactation.\n17. Left ventricular ejection fraction \\< 45% determined by echocardiogram or multiple gated acquisition scan.\n18. Resting QTcF \\> 480 msec at baseline.\n19. Ascites requiring paracentesis \\>1 per week.\n20. Symptomatic pleural effusion (\\< 90% oxygen saturation).\n21. History of interstitial lung diseases (ILD) or non-infectious pneumonitis requiring steroid treatments; severe pulmonary dysfunction caused by lung diseases.\n22. New diagnosed thromboembolic events that requires therapeutic intervention over the last 6 months (patients with stable control of lower limb deep venous thrombosis are allowed).\n23. Known allergic to any components of SKB264, including excipients (including polysorbate-20); or history of severe hypersensitivity to another biologic therapy.\n24. The investigator considers other situations that patients are not appropriate to participate in this trial.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04152499143","EMAIL":[{}],"GEO":[37.566,126.9784]},{"TITLE":"Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform","CRITERIA":"1. Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.\n2. Age \u2265 18 years at the time of consent.\n3. Subjects must meet one of the following criteria:\n\n   * Subjects suspected or diagnosed with Stage III or IV:\n\n     * Bladder: Urothelial Carcinoma (UC)\n     * Kidney: Clear Cell Renal Cell Carcinoma (ccRCC)\n   * Subjects suspected or diagnosed with Stage IV\/metastatic:\n\n     * Colon and Rectum: Microsatellite instability-high (MSI-H)\/deficient mismatch repair (dMMR) Colorectal Cancer (CRC)\n     * Head and Neck: Squamous Cell Carcinoma (HNSCC), excluding nasopharyngeal and salivary gland cancers\n     * Lung: Non-small cell lung cancer (NSCLC)\n     * Skin: Cutaneous Melanoma, excluding Uveal Melanoma\n     * Uterus: endometrial cancer\n   * Subjects suspected or diagnosed with:\n\n     * Any metastatic solid tumor with high TMB, MSI-High or dMMR and are being considered for treatment with ICI therapy.\n     * Any metastatic solid tumor that the clinician plans to treat with ICI therapy. NOTE: This can be either in the setting of a trial, compassionate use, or the use of appropriate LDT tests that per clinician, render the patient eligible for ICI therapy, either frontline or a later line.\n4. Subjects must be clinically able, at investigator discretion, to undergo additional core needle or forceps biopsy passes during their biopsy.\n5. Subjects who are newly diagnosed or have suspected cancer must be treatment-na\u00efve at the time of biopsy. All other subjects should have the biopsy performed before starting their next line of treatment.\n6. Subjects with a newly confirmed diagnosis who have previously undergone a standard of care biopsy must be willing to undergo a separate biopsy procedure solely for the purposes of this study.\n7. Female subjects must not be pregnant.\n8. Subjects with a known auto-immune disease that would render them ineligible for immune-oncology treatment are not eligible.\n9. Immunocompromised subjects, and subjects known to be HIV positive and currently receiving antiretroviral therapy are not eligible. NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial.\n10. Subjects who are enrolled or plan to be enrolled in a blinded oncology treatment trial are not eligible.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05520099010","EMAIL":[{"email":"sjohn2@uwhealth.org"},{}],"GEO":[43.07305,-89.40123]},{"TITLE":"Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Written informed consent to undergo cell procurement explained to, understood by, and signed by the subject.\n2. Subject has a life expectancy of \u2265 12 weeks.\n3. Subject must be platinum-refractory and either currently receiving or has previously received a PD1\/PDL1 inhibitor\n4. Use of systemic corticosteroids at doses \u226510 mg prednisone daily or it's equivalent; those receiving \\<10 mg daily may be enrolled at the discretion of the investigator.\n5. Female subjects of childbearing potential must have a negative serum pregnancy test within 72 hours prior to cell procurement.\n6. Subject has demonstrated adequate organ function.\n\nExclusion Criteria:\n\n1 . Subject has less than 12 weeks of life expectancy.\n\n2. Subject did not receive platinum-based chemotherapy\n\n3. Subject does not have adequate organ function.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05620342001","EMAIL":[{"email":"catherine_cheng@med.unc.edu"},{"email":"caroline_babinec@med.unc.edu"},{}],"GEO":[35.9132,-79.05584]},{"TITLE":"Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab \u00b1 Bevacizumab and Definitive Concurrent Chemoradiation Therapy","CRITERIA":"Inclusion Criteria:\n\n* For inclusion in neoadjuvant therapy, patients should fulfil the following criteria:\n\n  * Provision of signed, written and dated informed consent prior to any study specific procedures;\n  * Male or female aged 18\\~75 years old;\n  * Patients must have histologically- or cytologically-documented NSCLC who present with locally advanced (Stage III) disease;\n  * Without prior chemotherapy, radiotherapy, surgery, targeted therapy or immunotherapy;\n  * A recent tumour biopsy (taken following completion of the most recent therapy) is an optional requirement, provided that a biopsy procedure is technically feasible and the procedure is not associated with unacceptable clinical risk;\n  * Life expectancy \u226512 weeks;\n  * World Health Organization (WHO) Performance Status of 0 or 1;\n  * Evidence of post-menopausal status, or negative urinary or serum pregnancy test for female pre-menopausal patients within 14 days before the use of study drug (HCG has a minimum sensitivity of 25 IU\/L or equivalent);\n  * Women must be non-breastfeeding\n  * Forced expiratory volume in 1 second (FEV1) \u2265800ml\n  * Absolute neutrophil count \\>1.5 x 109\/L (1500 per mm3)\n  * Platelets \\>100 x 109\/L (100,000 per mm3)\n  * Haemoglobin\u22659.0 g\/dL (5.59 mmol\/L)\n  * Serum creatinine clearance(CL) \\>50 mL\/min by the Cockcroft-Gault formula (Cockcroft and -Gault 1976)\n  * Serum bilirubin \u22641.5 x upper limit of normal (ULN). Aspartate Transaminase(AST) and Alanine Transaminase(ALT) \u22642.5 x ULN\n\nExclusion Criteria:\n\n* Exclusion criteria for enrolment for neoadjuvant therapy Patients should not enter the study if any of the following exclusion criteria are fulfilled:\n\n  * Concurrent enrolment in another clinical study, unless it is an observational(non-interventional) clinical study;\n  * Mixed small cell and non-small cell lung cancer histology;\n  * Current or prior use of immunosuppressive medication within 28 days before the first dose of Tislelizumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg\/day of prednisone, or an equivalent corticosteroid. Systemic steroid administration required to manage toxicities arising from radiation therapy delivered as part of the chemoradiation therapy for NSCLC is allowed.\n  * Prior exposure to any anti-programmed cell death protein(PD)-1 or anti-PD-L1 antibody;\n  * Recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access) that would prevent administration of Tislelizumab;\n  * Active or prior documented autoimmune disease within the past 2 years;\n  * Active or prior documented inflammatory bowel disease (eg. Crohn's disease, ulcerative colitis);\n  * History of primary immunodeficiency;\n  * History of organ transplant that requires therapeutic immunosuppression;\n  * The tumor has completely approached, encircled, or invaded the intravascular space of the great vessels (e.g., the pulmonary artery or the superior vena cava)\n  * Bleeding tendency or coagulation disorder\n  * Hypertensive crisis, hypertensive encephalopathy, symptomatic heart failure (New York class II or above), active cerebrovascular disease or cardiovascular disease occurred within 6 months\n  * Uncontrolled hypertension (systolic \\> 150mmHg and\/or diastolic \\> 100mmHg)\n  * Major surgery within 28 days or minor surgery or needle biopsy within 48 hours\n  * Urine protein 3-4+, or 24h urine protein quantitative \\>1g\n  * Mean QT interval corrected for heart rate (QTc) \u2265470 ms calculated from 3 electrocardiograms (ECGs) using Bazett's Correction;\n  * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness\/social situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent;\n  * Known history of tuberculosis;\n  * Receipt of live attenuated vaccination within 30 days prior to study entry or within30 days of receiving Tislelizumab;\n  * History of another primary malignancy within 5 years prior to starting Tislelizumab, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ and the disease under study;\n  * Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control;\n  * Any condition that, in the opinion of the investigator, would interfere with evaluation of the Tislelizumab or interpretation of patient safety or study results.\n* Exclusion criteria for concurrent chemoradiation following neoadjuvant therapy\n\nPatients should not enter the concurrent chemoradiation phase if any of the following exclusion criteria are fulfilled:\n\n* Patients who develop disease progression and the irradiation dose of normal tissue will exceed the limit as defined in Section 7.\n* World Health Organization (WHO) Performance Status of 2-4;\n* Inadequate organ and marrow function as defined below:\n* Forced expiratory volume in 1 second (FEV1) \\<800ml\n* Absolute neutrophil count \\<1.5 x 109\/L (1500 per mm3)\n* Platelets \\<100 x 109\/L (100,000 per mm3)\n* Haemoglobin\\<9.0 g\/dL (5.59 mmol\/L)\n* Serum creatinine CL \\<50 mL\/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976)\n* Serum bilirubin \\>1.5 x upper limit of normal (ULN).\n* Aspartate Transaminase(AST) and Alanine Transaminase(ALT) \\>2.5 x ULN\n\n  * Further exclusion criteria for Tislelizumab consolidation:\n\nPatients should not enter the Tislelizumab consolidation if any of the following exclusion criteria are fulfilled:\n\n* Patients who have progressed whilst definitive platinum based, concurrent chemoradiation therapy;\n* Current or prior use of immunosuppressive medication within 28 days before the first dose of Tislelizumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg\/day of prednisone, or an equivalent corticosteroid. Systemic steroid administration required to manage toxicities arising from radiation therapy delivered as part of the chemoradiation therapy for locally advanced NSCLC is allowed.\n* Any unresolved toxicity CTCAE \\>Grade 2 from the prior chemoradiation therapy will be excluded from randomization;\n* Patients with Grade \u22652 pneumonitis from prior chemoradiation therapy will be excluded from randomization; Any prior Grade \u22653 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE\\>Grade 1.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05468242001","EMAIL":[{"email":"liuhui@sysucc.org.cn"}],"GEO":[23.11667,113.25]},{"TITLE":"A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer","CRITERIA":"Inclusion Criteria:\n\n1. \u226518 years old\n2. Male or female patients with pancreatic ductal adenocarcinoma, colorectal carcinoma or adenocarcinoma of the lung as specified above leading to new treatment line.\n3. Signed and dated written informed consent in accordance with International Council on Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the study.\n4. Willingness to undergo pre- and on-treatment liquid biopsies for biomarker assessment. Patients can be enrolled without tissue tumour biopsy upon agreement between the Investigator and the Sponsor.\n\nExclusion Criteria:\n\n1. Patients not expected to comply with the protocol requirements or not expected to complete the study as scheduled (e.g. chronic alcohol or drug abuse or any other condition that, in the investigator's opinion, makes the patient an unreliable study participant).\n2. Women who are pregnant or who plan to become pregnant during the study.\n3. Participation at a clinical trial involving an investigational medicine where the treatment details cannot be disclosed.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05708599001","EMAIL":[{"email":"deutschland@bitrialsupport.com"}],"GEO":[54.32133,10.13489]},{"TITLE":"A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2\/B7-H7","CRITERIA":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed recurrent, metastatic solid tumor refractory to standard of care therapy in one of the following indications: Part 1a: non-small cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), colorectal carcinoma (CRC), cholangiocarcinoma (CCA), pancreatic cancer (PDAC), urothelial carcinoma (UCC), gastric\/gastroesophageal carcinoma, triple negative breast carcinoma, endometrial carcinoma, cervical cancer, osteosarcoma, and prostate cancer\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Normal bone marrow, kidney and liver function\n* Willing to use highly effective contraceptive measures throughout the trial\n\nExclusion Criteria:\n\n* Have any unresolved toxicity of Grade \u2265 2 from previous anti-cancer treatment, except for alopecia, chronic neuropathy \\> 6 months, or changes in skin pigmentation\n* Have known or suspected brain metastases, unless they are clinically stable\n* Known autoimmune disease requiring immunosuppressive treatment requiring the equivalent of more than 10 mg prednisone daily\n* History of grade 3 immune-related pneumonitis or colitis","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05958199007","EMAIL":[{"email":"bpatterson@nextoncology.com"},{}],"GEO":[38.84622,-77.30637]},{"TITLE":"Integrative Multi-Omics Testing for Immunotherapy Response in Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Patients who are 18 years or older at the time of signing the informed consent form;\n2. Patients with histologically or cytologically confirmed non-small cell lung cancer that is metastatic or locally advanced unresectable, not eligible for local curative treatment (Stage IIIB or IV according to AJCC);\n3. Patients without contraindications for immunotherapy according to CSCO guidelines for Non-Small Cell Lung Cancer (NSCLC) version 2022\uff08No EGFR mutations, ALK or ROS1 rearrangement);\n4. Patients with at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors \\[RECIST\\], version 1.1;\n5. Patients who have not received systemic treatment in the past, or who have previously received (neo) adjuvant treatment\/radical treatment programs and have relapsed for more than 6 months;\n6. Patients who signed the informed consent and are willing to participate in the study.\n\nExclusion Criteria:\n\n1. Patients with the history of autoimmune disease or immunodeficiency disease;\n2. Any severe, uncontrolled diseases, including: (1) Active or uncontrolled heart diseases, (2) Renal failure requires hemodialysis or peritoneal dialysis; (3) Liver diseases such as liver cirrhosis, decompensated liver disease, chronic active hepatitis;\n3. Any severe, uncontrolled urological diseases, or urine total protein \\>1.0g\/day.\n4. Any severe, uncontrolled metabolic diseases, including uncontrolled diabetes mellitus (fasting blood glucose (FBG)\\>10mmol\/L);","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05928299001","EMAIL":"liulaiyu@sina.com","GEO":[23.11667,113.25]},{"TITLE":"A Phase I\/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Aged \u2265 18 years old, male or female;\n2. Histologically or cytologically confirmed locally advanced or recurrent\/metastatic advanced NSCLC that is inoperable, is subject to progression or intolerability after the standard of care, or is unable to be treated or has not been treated by the standard of care;\n3. Dose escalation: patients with EGFR sensitive mutation who have experienced disease progression after third-generation EGFR-TKI therapy;\n4. Dose expansion and efficacy expansion: patients with proven EGFR C797X mutation;\n5. Patients who agree to provide tumor tissues and blood samples for EGFR mutation analysis (certain patients who are unable to provide qualified tumor tissues may be enrolled once approved by investigators and the Sponsor);\n6. At least one measurable lesion as per RECIST v1.1;\n7. ECOG PS score of 0-1;\n8. Expected survival of more than 12 weeks;\n9. Sufficient vital organ functions at screening (requiring no blood transfusion, use of hematopoietic stimulating factor, or use of human albumin preparation within 14 days before screening):\n\n   1. ANC \u2265 1.5 \u00d7 109\/L;\n   2. Platelet \u2265 100 \u00d7 109\/L;\n   3. Hemoglobin \\> 90 g\/L;\n   4. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) \u2264 2.0 \u00d7 upper limit of normal (ULN) (in the presence of liver metastasis, \u2264 5 \u00d7 ULN);\n   5. Total bilirubin (TBIL) \u2264 1.5 \u00d7 ULN;\n   6. Coagulation function (INR) \u2264 1.5 \u00d7 ULN;\n   7. Blood creatinine \u2264 1.5 \u00d7 ULN or creatinine clearance (Ccr, calculated by the Cockcroft-Gault formula) \u2265 45 mL\/min;\n   8. Serum lipase and amylase \u2264 1.5 \u00d7 ULN;\n10. Females with childbearing potential and a negative serum pregnancy test within 7 days before enrollment who agree to use effective contraception during the IMP treatment and 6 months after the last dose. This protocol defines \"females with childbearing potential\" as sexually mature women who: 1) have not undergone a hysterectomy or bilateral ovariectomy; 2) have not had spontaneous menopause for 24 consecutive months (i.e., no menstrual bleeding at any time within the last 24 consecutive months; amenorrhea after cancer treatment does not indicate infertility). Male patients whose sexual partners are females with childbearing potential must agree to use effective contraception during the study treatment and 6 months after the last dose;\n11. Patients who voluntarily participate in this study and have signed the informed consent form after an all-inclusive informed consent process.\n\nExclusion Criteria:\n\n1. Patients who have received systemic anti-tumor therapy within 4 weeks before the first dose, including chemotherapy, targeted therapy, anti-vascular drug therapy, biologic therapy, immunotherapy, radiotherapy, or other IMP therapy; moreover, patients who have received EGFR-TKI targeted therapy may be enrolled if 5 half-lives have passed after discontinuation;\n2. Patients who are receiving strong CYP3A inhibitors or inducers; or those who have yet to reach 5 half-lives after discontinuation of a strong inhibitor, or 5 half-lives or 14 days (whichever is longer) after discontinuation of a strong inducer at the time of the first WJ13404 dosing;\n3. Patients who have experienced adverse events caused by previous anti-tumor therapy that have yet to improve to CTCAE v5.0 grade \u2264 1 at screening (except for neurotoxicity and alopecia, which cannot be recovered as assessed by investigators);\n4. Patients who are plagued by other malignancies (except for non-melanoma basal or squamous cell carcinoma of the skin, carcinoma in situ of the breast\/cervix, superficial bladder cancer, thyroid cancer, and other carcinomas in situ, treated with curative intent and without evidence of recurrent disease) concurrently or within 5 years before treatment initiation;\n5. History of diseases causing chronic diarrhea, including but not limited to Crohn's disease and irritable bowel syndrome;\n6. Active gastrointestinal disease or other conditions that may significantly compromise drug absorption, metabolism, or excretion;\n7. Patients known to have undergone organ transplantation or stem cell transplantation; patients who have undergone major surgery or serious trauma within 4 weeks before the first dose (excluding needle biopsy for sample collection);\n8. Patients who are suffering from carcinomatous meningitis and spinal cord compression;\n9. Patients who meet one of the following cardiac criteria: Unexplained or cardiovascular-caused presyncope or syncope, ventricular tachycardia, ventricular fibrillation, or cardiac arrest, with average corrected QT interval (based on 3 ECGs taken at rest, QTc, using the Fridericia's correction formula) \\> 450 ms in males or \\> 470 ms in females. Various clinically significant cardiac rhythm, conduction, or resting ECG morphological abnormalities, such as complete left bundle branch block, third-degree conduction block, second-degree conduction block, PR interval \\> 250 ms, and echocardiography-suggested left ventricular ejection fraction (LVEF) \\< 50%. Various factors that may increase the risks of QTc prolongation or arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, history of immediate family members with long QT syndrome or sudden death of unknown cause before age 40, and current receipt of any drug known to prolong the QT interval;\n10. Unstable systemic diseases, such as active infection requiring systemic drug therapy, poorly controlled hypertension, unstable angina, congestive heart failure, serious hepatic, renal, or metabolic conditions including cirrhosis, renal failure, and uremia;\n11. Patients who experience dyspnea or require continuous oxygen therapy, or who are suffering from CTCAE v5.0 grade \u2265 2 active pneumonitis or interstitial lung disease (except mild radiation pneumonitis);\n12. Central nervous system metastasis with symptoms. Patients who have received treatment for brain metastases may be considered for enrollment, provided that no disease progression confirmed by radiologic imaging evaluation occurs within 4 weeks before the first dose of the IMP, no evidence shows new or enlarging brain metastases, and radiation, surgery, or steroid therapy has been discontinued for at least 4 weeks before the first dose of the IMP;\n13. HBV-RNA \\> upper limit of the reference value when positive for hepatitis B surface antigen or hepatitis B core antibody;\n14. HCV-RNA \\> upper limit of the reference value when positive for hepatitis C antibody;\n15. Positive for human immunodeficiency virus (HIV);\n16. Patients with a confirmed history of mental disorders who are receiving drugs for treatment;\n17. History of substance or drug abuse;\n18. Patients who have received traditional Chinese medicine for anti-tumor therapy within 1 week before the first dose of the study treatment;\n19. Previous serious eye disorders that have not recovered to grade \u2264 1;\n20. Skin toxicity at \\> grade 2 within 4 weeks before the first dose;\n21. Pregnancy and lactation;\n22. Other factors, as evaluated by investigators, that have potential effects on study results and may interfere with the patient's participation, including previous or existing physical conditions (such as eye disorders, including corneal ulcers and conjunctivitis), treatment or laboratory test abnormalities, patient unwillingness to abide by the study procedures, restrictions, and requirements, and the presence of psychological or social conditions that may interfere with their participation or affect the study result evaluation.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05662670001","EMAIL":[{"email":"Shfkgcp@163.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"A Study of MGC026 in Participants With Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n* Adults \u2265 18 years old, able to provide informed consent\n* Adequate performance and laboratory parameters\n* Unresectable, locally advanced or metastatic solid tumors including: squamous cell cancer (SCC) of the head and neck, esophageal SCC, squamous and non-squamous non-small cell lung cancer, small cell lung cancer, bladder cancer, sarcoma, endometrial cancer, melanoma, castration resistant prostate cancer, breast cancer, ovarian cancer, cervical cancer, colorectal cancer gastric or gastroesophageal cancer, pancreatic carcinoma, clear cell renal cell cancer or hepatocellular cancer.\n* Measurable disease per RECIST v1.1. Participants with metastatic CRPC without measurable disease are eligible.\n* Must be willing to use highly effective methods of birth control from the time of consent through 7 months after discontinuation of MGC026.\n* Not pregnant or breastfeeding.\n\nExclusion Criteria:\n\n* Any underlying medical or psychiatric condition impairing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures.\n* Another cancer that required treatment within the past 2 years, with the exception of those with low risk of cancer spreading or death such as adequately treated non melanomatous skin cancer, localized prostate cancer (Gleason Score \\< 6), or carcinoma in situ.\n* Patients with history of prior central nervous system (CNS) metastasis must have been treated, be asymptomatic, and not have concurrent treatment for CNS disease, progression of CNS metastases on magnetic resonance imaging, computed tomography or positron emission tomography, or history of leptomeningeal disease or cord compression at the time of enrollment.\n* Treatment with surgery, systemic cancer therapy, immunotherapy, chimeric antigen receptor-T therapy, or anti-hormonal within protocol specified intervals.\n* Prior autologous or allogeneic stem cell or solid organ transplant.\n* Clinically significant cardiovascular, pulmonary, or gastrointestinal disorders.\n* Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 1 week of first study drug administration.\n* Known history of hepatitis B or C infection or known positive test for hepatitis B surface antigen or core antigen, or hepatitis C polymerase chain reaction.\n* Known positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome.\n* History of primary immunodeficiency.\n* Major trauma or major surgery within 4 weeks of first study drug administration.\n* Known hypersensitivity to recombinant proteins.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06242470007","EMAIL":"info@macrogenics.com","GEO":[-37.75,145.06667]},{"TITLE":"Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC","CRITERIA":"Inclusion Criteria:\n\n1. Age \\> 18 years\n2. Patients with ECOG performance status of 0-2\n3. Patients with pathologically proven diagnosis of NSCLC\n4. Patients with 1-5 sites of metastatic disease not including the primary tumor and regional nodes (less than or equal to 3 metastatic lesions in one organ will be eligible and 4 or more metastatic lesions in one organ will be ineligible)\n5. Patients who have received standard duration of systemic therapy (4 - 6 cycles) without progression of the disease\n6. Patients suitable for definitive therapy to the primary disease\n7. All the Oligometastases lesions should be radiologically visible and suitable for ablative doses of radiation in accordance with the dose fractionation regimens specified in the protocol.\n8. Patients who have received ablative radiation therapy or surgery or RFA for metastatic sites at presentation or during systemic therapy will be eligible provided the total number of oligometastatic sites at the time of study entry (treated site included) is less than or equal to five.\n9. Patients who have received palliative RT for symptomatic bony metastases or RFA will also be eligible provided the treated site is under control on imaging. If not controlled, could be eligible for study if further ablative doses of radiation can be delivered according to the treating physician.\n10. Patients who underwent surgical decompression, or stabilization followed by palliative radiation therapy for bony metastases will be eligible in the study provided the treated site is under control on imaging and patient has less than 5 sites of metastases at the time of study entry.\n11. Adequate end organ function CBC\/differential obtained within 15 days prior to registration on study, with adequate bone marrow function defined as follows:\n\n    * Absolute neutrophil count (ANC) \u2265 500 cells\/mm3;\n    * Platelets \u2265 50,000 cells\/mm3;\n    * Hemoglobin \u2265 8.0 g\/dl (Use of transfusion or other intervention to achieve Hgb \u2265 8.0 g\/dl is acceptable);\n12. For females of child-bearing potential, negative serum or urine pregnancy test within 14 days prior to study registration;\n13. Patients willing for written informed consent and must be willing to comply with the specified follow up schedule\n\nExclusion Criteria:\n\n1. Patients with progressive disease after initial standard systemic therapy\n2. Patients with oncogene driver mutations\n3. Patients with more than 5 sites of oligo metastases\n4. Patients with metastatic lesion size of more than 5 cm\n5. Patients with more than three metastatic lesion in one organ\n6. Patients not suitable for definitive radiation therapy to primary disease\n7. Patients not suitable for ablative radiation therapy to metastatic sites\n8. Patients with malignant peritoneal disease\n9. Patients with malignant pleural effusion\n10. Leptomeningeal disease\n11. Brain metastases in the brain stem\n12. Clinical or radiological evidence of spinal cord compression or metastases within 2 mm of spinal cord on MRI\n13. Severe, active co-morbidity defined as follows:\n\n    * Unstable angina and\/or congestive heart failure requiring hospitalization within the last 6 months;\n    * Transmural myocardial infarction within the last 6 months;\n    * Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration;\n14. Patients with prior history of radiation therapy to thorax\n15. Patients with previous history of malignancy within last 3 years from the date of diagnosis\n16. Pregnancy","SEX":"ALL","AGE_MIN":18,"AGE_MAX":99,"SS_ID":"05278052001","EMAIL":[{"email":"aniltibdewal@gmail.com"},{}],"GEO":[19.07283,72.88261]},{"TITLE":"Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies","CRITERIA":"Inclusion Criteria:\n\n1. Able to understand and sign the informed consent form\n2. Age 18 years or older at the time of informed consent\n3. Has disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n5. Subjects enrolled in Part 1 and Part 2 dose escalation cohorts must have:\n\n   a. Histologically\/cytologically confirmed melanoma, triple-negative breast cancer (TNBC), clear cell renal cell cancer (ccRCC), ovarian cancer, head and neck cancer, colorectal cancer, or non-small cell lung cancer (NSCLC) that is metastatic or unresectable with tumor progression after standard therapy who have no options for standard therapies which are known to confer clinical benefit. Subjects with ovarian cancer must have platinum resistant or platinum- refractory tumors.\n6. Subjects enrolled in Part 3 and Part 4 dose expansion cohorts must have histologically\/cytologically confirmed metastatic or unresectable disease with tumor progression after standard therapy.\n7. Adequate organ function defined as follows:\n\n   1. Hematology: i. Absolute neutrophil count \u2265 1500 cells\/mm3; ii. Platelet count \u2265 75,000 cells\/mm3 (without transfusion for 14 days); iii. Hemoglobin \u2265 9 g\/dL (and without transfusion within 14 days)\n   2. Renal: creatinine clearance \u2265 30 mL\/min by Cockcroft-Gault estimate\n   3. Coagulation: Prothrombin time or international normalized ratio and activated partial thromboplastin time \u2264 1.5 \u00d7 upper limit of normal (ULN) (unless receiving anticoagulation therapy)\n   4. Hepatic: i. Aspartate aminotransferase and alanine transaminase (ALT) \u2264 3 \u00d7 ULN (or \u2264 5 \u00d7 ULN in subjects with known hepatic metastases); ii. Total bilirubin \u2264 1.5 \u00d7 ULN (isolated value \\> 1.5 \u00d7 ULN is acceptable if direct bilirubin is \\< 35% of total)\n8. Expected life expectancy of \\> 12 weeks per the Investigator\n9. Women of childbearing potential (WOCBP) must use a highly effective contraceptive measure (a method that can achieve a failure rate of less than 1% per year) during treatment and until 4 months after the end treatment, such as:\n\n   1. Estrogen and progestin containing hormonal contraception that inhibits ovulation\n   2. Progestin-only hormonal contraception that inhibits ovulation\n   3. Intrauterine device\n   4. Vasectomized partner\n   5. Sexual abstinence\n   6. Intrauterine hormone-releasing system\n   7. Bilateral tubal occlusion Note: For WOCBP with breast cancer, alternative non-hormonal contraceptive measures are recommended (c, d, e, g).\n10. Potent men that are partners of WOCBP must be willing to use condoms in combination with a second highly effective method of female contraception and agree not to donate sperm from screen through at least 4 months after last dose of study treatment. A male partner will be considered as potent unless surgically sterilized (with appropriate documentation of sterility).\n\nExclusion Criteria:\n\n1. Active systemic yeast infection within 4 weeks before study treatment\n2. Prior hospitalization for asthma during past year\n3. Central nervous system metastases except for disease that is asymptomatic, clinically stable, and has not required steroids for at least 28 days before starting study treatment\n4. Cardiac disease including:\n\n   1. Congestive heart failure New York Heart Association classes II-IV\n   2. QTcF prolongation \\> 480 milliseconds (ms) based on a 12-lead electrocardiogram (ECG)\n   3. Serious or uncontrolled cardiac arrhythmia within 6 months before starting study treatment\n   4. Myocardial infarction, unstable angina pectoris, or coronary angioplasty, stenting, or surgery within 6 months before starting study treatment\n   5. Uncontrolled hypertension (\u2265 180 mmHg systolic or \u2265 120 mmHg diastolic)\n   6. Pericarditis or pericardial effusion that is symptomatic within 6 months before starting study treatment\n5. Pulmonary disease including idiopathic pulmonary fibrosis, noninfectious interstitial lung disease, pneumonitis, chronic obstructive pulmonary disease (requiring daily treatment for dyspnea, oxygen therapy on an ongoing basis, or hospitalization within the past 6 months)\n6. Hepatic disease resulting in symptomatic ascites, encephalopathy, coagulopathy, esophageal\/gastric varices, or persistent jaundice\n7. Arterial thrombotic event, stroke, or transient ischemia attack within 6 months before starting study treatment\n8. Clinically significant bleeding diathesis or uncontrolled bleeding within 7 days before starting study treatment\n9. Bone marrow transplant or solid organ transplant\n10. Infection including:\n\n    1. Disease requiring systemic therapy within 7 days before starting study treatment\n    2. Ongoing COVID-19 as determined by viral testing\n    3. Active human immunodeficiency virus (HIV) infection as determined at screening\n    4. Active hepatitis B infection as determined at screening\n    5. Active hepatitis C infection as determined at screening\n11. Autoimmune disease requiring systemic disease-modifying or immunosuppressive therapy within 2 years before starting study treatment. Exceptions include disease managed with only replacement therapies (eg, thyroxine, etc.)\n12. History of hemophagocytic lymphohistiocytosis\/macrophage activation syndrome\n13. Malignancy within 2 years before starting study treatment other than the disease under study. Exceptions include indolent or definitively treated disease not expected to require treatment during the study, affect the safety of subjects, or affect the endpoints of the trial\n14. Any medical condition requiring corticosteroids (\\> 10 mg daily oral prednisone or equivalent) or other systemic immunosuppressive therapy within 28 days before starting study treatment. Exception: Intermittent or sporadic use of inhaled or topical steroids is allowed\n15. Residual toxicity from previous treatment including:\n\n    1. Toxicity related to prior treatment not resolved to Grade 1, except for alopecia or dysgeusia\n    2. Neuropathy Grade \\> 2 Note: Exceptions to the above criteria include toxicities that do not pose a risk to vital organ systems (eg, alopecia) or toxicities that are stable as managed by replacement therapies (eg, hypothyroidism)\n16. Subjects receiving cemiplimab: those that have permanently discontinued immuno- modulating therapies due to drug-related toxicity.\n17. Subjects receiving cemiplimab: hypersensitivity to cemiplimab or any of its excipients or contraindicated to cemiplimab per approved local labeling\n18. Any investigational agent within 28 days before starting study treatment or within 5 estimated elimination half-lives, whichever is shorter\n19. Radiation therapy within 14 days before starting study treatment\n20. History of severe hypersensitivity to any ingredient of BDC-3042 or study treatment (as applicable for combination study treatment)\n21. Received live\/attenuated virus vaccine within 28 days before starting study treatment\n22. Major surgery within 28 days of starting study treatment (consult with Medical Monitor)\n23. Actively enrolled in another clinical study, unless it is an observational (noninterventional) clinical study or the follow-up component of an interventional study\n24. Patient is a lactating mother or pregnant as confirmed by pregnancy tests within 7 days prior to start of study treatment\n25. Patient is unwilling or unable to follow protocol requirements\n26. Ongoing bowel perforation or presence of bowel fistula or intra-abdominal abscess\n27. Any condition that, in the opinion of the Investigator, would interfere with evaluation of BDC-3042 or interpretation of the patient's safety or study results","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06052852005","EMAIL":[{"email":"bpatterson@nextoncology.com"},{}],"GEO":[38.84622,-77.30637]},{"TITLE":"Survival Validation and Gene Mutations of N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer","CRITERIA":"Inclusion Criteria:\n\nPathological N2.\n\nExclusion Criteria:\n\nPatients undergoing neoadjuvant chemotherapy","SEX":"ALL","AGE_MIN":0,"AGE_MAX":200,"SS_ID":"06349252001","EMAIL":[{"email":"hqchen1@yahoo.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers","CRITERIA":"Inclusion Criteria:\n\n* PATIENT ONLY: Diagnosed with stage I-IV non-small cell lung cancer (NSCLC) or esophageal cancer and going to receive at least 3 weeks of thoracic radiotherapy (RT)\n* PATIENT ONLY: Eastern Cooperative Oncology Group (ECOG) performance status of \u2264 2\n* PATIENT ONLY: Able to read, write and speak English\n* PATIENT ONLY: Able to provide informed consent\n* PATIENT ONLY: Having a family caregiver (e.g., spouse, sibling, adult child) who assists the patient during the cancer treatment (e.g., emotional support, transportation, meal preparation, care coordination, etc) per patient self-report. Note, patients must identify a family caregiver; however, the participation of the family caregiver is optional. For caregivers to be eligible, they must be at least 18 years old; able to read, write and speak English; and able to provide informed consent. Family caregivers may consent to participate in the intervention and caregiver assessments or only the assessments based on their preference.\n\nExclusion Criteria:\n\n* PATIENT ONLY: Who have regularly (self-defined) participated in a mind-body practice in the year prior to diagnosis\n* PATIENT ONLY: Patients who metastatic disease involving the central nervous system","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03948100001","EMAIL":[{"email":"kmilbury@mdanderson.org"},{}],"GEO":[29.76328,-95.36327]},{"TITLE":"Exercise in Extended Oncogene Addicted Lung Cancer in Active Treatment","CRITERIA":"Inclusion Criteria:\n\n1. Age 18 years or older\n2. Willingness to provide written informed consent.\n3. Life expectancy \\>12 weeks.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n5. Body massa index \\> 18.\n6. Oncogene-addicted (EGFR, ALK, ROS1, RET, BRAF) stage IV or III b not suitable for local treatment receiving first- or second-line systemic treatment (palliative radiotherapy and prior chemotherapy allowed). Patients undergoing treatment in clinical trials are excluded.\n\nExclusion Criteria:\n\n1. Inability to walk.\n2. Immobility for more than 3 days before study enrollment.\n3. Previously untreated (non-irradiated or non-resected) symptomatic brain metastases.\n4. Severe cardiac impairment (e.g. cardiac insufficiency New York Heart Association (NYHA) \\> III, myocardial infarction within the last three months, severe cardiac arrhythmias, high grade aortic stenosis).\n5. Severe respiratory failure.\n6. Uncontrolled pain.\n7. Bone metastasis inducing increased risk of pathological fractures.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05306652001","EMAIL":[{"email":"chiara.bennati@auslromagna.it"}],"GEO":[44.41344,12.20121]},{"TITLE":"Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects","CRITERIA":"Inclusion Criteria:\n\n* 1. Advanced\/Metastatic non-small cell lung cancer NSCLC patients.\n* 2. The patient himself\/herself must be 18 years of age on day of signing informed consent.\n* 3. The subject has signed the informed consent form.\n* 4. The patient must be eligible to receive FDA approved and non-approved PD1 inhibitors (i.e. pembrolizumab, nivolumab) or PDL1 inhibitor (i.e. atezolizumab, durvalumab) either single agent or as combination therapy with chemotherapy, or be eligible to receive FDA approved and non-approved tyrosine kinase inhibitors.\n* 5. The subject will be registered upon submission of the samples. When submitted on separate dates, the submission occurring later will be considered the date of registration\n\nExclusion Criteria:\n\n* 1. Those subjects who are determined clinically unstable of the participation of this study as determined by the PI or treating physician will be excluded and asked to focus on their treatment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06221800001","EMAIL":[{"email":"ucstudy@uci.edu"}],"GEO":[33.78779,-117.85311]},{"TITLE":"A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Participant must have histologically or cytologically confirmed NSCLC and must have metastatic NSCLC at the time of enrollment\n* Participant must have at least 1 measurable lesion, according to RECIST v1.1, that has not been previously irradiated\n* May have brain metastases only if previously definitively treated, and participant is clinically stable and asymptomatic for \\>2 weeks and is off or receiving low-dose corticosteroid treatment (\\<=10 mg prednisone or equivalent) for at least 2 weeks prior to start of study treatment\n* May have a prior malignancy (other than the disease under study) if the natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment(s)\n* Have an ECOG performance status of 0 or 1\n\nExclusion Criteria:\n\n* For Phase 2 only: Participant has known oncogenic driver mutations (EGFR, MET, HER2, ALK, ROS1, NTRK, BRAF, RET, or KRAS) as detected by local testing or by central ctDNA testing\n* Participant has received radiotherapy for palliative purposes less than 14 days prior to the first dose of study treatment\n* Participant has: a.(Or has a history of) leptomeningeal disease (carcinomatous meningitis); b. Spinal cord compression not definitively treated with surgery or radiation.\n* Medical history of (non-infectious) ILD\/pneumonitis, or has current ILD\/pneumonitis, or where suspected ILD\/pneumonitis cannot be ruled out by imaging at screening- Participant has history of any significant drug allergy (such as anaphylaxis, hepatotoxicity, or immune-mediated thrombocytopenia or anemia) or has known allergies, hypersensitivity, or intolerance to: a. amivantamab or amivantamab excipients (refer to the amivantamab IB); b.docetaxel, docetaxel excipients or to other drugs formulated with polysorbate and paclitaxel","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06532032002","EMAIL":"Participate-In-This-Study@its.jnj.com","GEO":[25.04776,121.53185]},{"TITLE":"A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)","CRITERIA":"Inclusion Criteria:\n\n1. Patients must be able to understand the nature of the trial and provide a signed and dated informed consent form prior to screening.\n2. Aged at least 18 years old when sign ICF.\n3. Histological or cytological confirmed locally advanced or metastatic NSCLC.\n4. Patients must exhibit Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1 at ICF signature with no deterioration over the previous 2 weeks.\n5. Predicted life expectancy \u2265 12 weeks.\n6. Patients with brain metastasis (BM) can only be enrolled under the condition that BM is previously treated and stable e.g. no evidence of progression for at least 2 weeks after CNS-directed treatment as ascertained by clinical examination and brain imaging (magnetic resonance image \\[MRI\\] or computed tomography \\[CT\\] scan) during the screening period), neurologically asymptomatic and not require corticosteroid treatment.\n7. Adequate organ system functions, as outlined below\n\n   * Absolute neutrophil count (ANC) \u2265 1.5 x 109\/L\n   * Absolute lymphocyte count \u2265 0.8 x 109\/L\n   * Platelets \u2265 100 x 109\/L\n   * Hemoglobin \u2265 9 g\/dL\n   * Total bilirubin \u2264 1.5 x ULN if no liver metastases or \u2264 3 x ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases\n   * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u2264 2.5 x ULN if no liver involvement or \u2264 5 x ULN with liver involvement\n   * Creatinine \u2264 1.5 x ULN, or measured creatinine clearance \u2265 50 mL\/min as calculated by the Cockcroft-Gault method\n   * International normalized ratio (INR) \u2264 1.5 x ULN and activated partial thromboplastin time (APTT) \u2264 1.5 x ULN;\n   * Serum amylase \u2264 1.5 x ULN and serum lipase \u2264 1.5 x ULN\n8. Male subjects with a female partner who intend to have children should use barrier contraception (e.g. condom) during their participation in the clinical study until 6 months after the last dose. Male subjects should not donate sperm during the clinical study until 6 months after the last dose. If the male subject has fertility requirements, it is recommended that sperm be frozen prior to the start of the clinical study.\n9. Female subjects should use contraception at screening until 6 weeks after the last dose of DZD9008 or 3 months after the last dose of AZD4205, whichever is later, should not be breastfeeding and should have a negative pregnancy test (blood or urine \u03b2-HCG) at the time of screening.\n\nPart A specific inclusion criteria:\n\n1. Subjects should harbour any type of EGFR mutation.\n2. Subjects should have progressed on, or be intolerant of prior standard systemic therapy for metastatic\/locally advanced disease.\n\nPart B specific inclusion criteria:\n\n1. Subjects must have documented EGFR sensitizing mutation from a local certified laboratory.\n2. Subjects should have progressed on, or be intolerant of prior standard systemic therapy for metastatic\/locally advanced disease.\n3. Patient must have measurable disease according to RECIST 1.1: At least one lesion, not previously irradiated, that can be accurately measured at baseline as \u2265 10 mm in the longest diameter (except lymph nodes which must have short axis \u226515 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) and which is suitable for repeated measurement.\n4. Agree and be willing to provide an adequate amount of the required tumor tissue for exploratory studies.\n\nExclusion Criteria:\n\n1. Treatment with any of the followings:\n\n   * Prior treatment with any onco-immunotherapy (e.g. PD-1) within 4 weeks before the first administration of IP.\n   * Any cytotoxic chemotherapy, or other anticancer drugs from a previous treatment regimen within 2 weeks before the first administration of IP.\n   * Radiotherapy within 2 weeks of the first dose or have not recovered from radiotherapy-related toxicity May receive palliative radiotherapy other than chest and brain, stereotactic radiosurgery and stereotactic body radiation therapy within 1 week prior to first dose a limited field of radiation for palliation within 1 week of the first administration of IP.\n   * Patients currently receiving (or unable to stop using) medications known to be potent inhibitors or inducers of CYP3A or herbal supplements within 2 weeks before the first administration of IP.\n   * Patients should avoid eating food known to be inhibitors of CYP3A such as grapefruit and Seville oranges (and other products containing these fruits, e.g., grapefruit juice or marmalade) within 2 weeks before the first administration of IP and 2 weeks after the therapy.\n   * Drugs that prolong the QT interval need to be discontinued before the start of IP\n   * Major surgery (excluding biopsy) within 4 weeks before the first administration of IP, or expect to have major surgery during study.\n   * Treatment with any investigational drug (or unable to stop using) within 4 weeks before the first administration of IP\n2. Spinal cord compression or leptomeningeal metastasis.\n3. Prior malignancy within 2 years requires active treatment, except for adequately treated basal cell skin carcinoma, in situ cervical carcinoma, or other cancer type which has been disease free for \\> 2 years with life expectancy \\>2 years\n4. Any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting IP with the exception of alopecia.\n5. History of stroke or intracranial haemorrhage within 6 months before the first administration of IP.\n6. As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses (e.g., hemophilia, Von Willebrand disease).\n7. Presence of persistent or active infection, including but not limited to:\n\n   * Active or latent tuberculosis\n   * Active herpes simplex, herpes zoster infection\n   * COVID-19\n   * active HBV, HCV, HIV infection\n8. Any of the following cardiac abnormal and disease:\n\n   * resting corrected QT interval (QTc) \\> 470 msec\n   * Any clinically significant abnormalities in rhythm, conduction or morphology of resting ECG, e.g., complete left bundle branch block, third degree heart block, and second-degree heart block, PR interval \\> 250 msec\n   * Any factors that increase the risk of QTc prolongation, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval\n   * Prior history of atrial fibrillation except prior drug treatment related and recovered\n   * Prior history of myocardial infarction, congestive heart failure, arrhythmias that are poorly controlled by medication\n   * LVEF \\< 55% accessed by ECHO\n9. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease, immunotherapy-induced immune pneumonitis.\n10. Significant pulmonary function impairment (i.e. pulmonary function test showing FEV1 and DLCO \\< 60% of expected values).\n11. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of IP.\n12. Receiving live vaccines within 2 weeks before the first administration of IP.\n13. Women who are pregnant or breast feeding.\n14. Involvement in the planning and conduct of the study (applies to Dizal staff or staff at the study site).\n15. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06295432001","EMAIL":[{"email":"wangzhen@gdph.org.cn"}],"GEO":[23.11667,113.25]},{"TITLE":"Phase 1a\/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors","CRITERIA":"Selected Inclusion Criteria\n\n1. Patients must have selected tumor types and must have progressed after standard of care treatment, or be intolerant to treatment, or refused standard treatment.\n2. Patients must be amenable to a fresh tissue biopsy, unless medically contraindicated.\n3. Patients with central nervous system (CNS) metastases must have been treated and be asymptomatic.\n\nSelected Exclusion Criteria:\n\n1. Received systemic anti-cancer therapy within 3 weeks of the first dose of study treatment or small molecule kinase inhibitors within 6 elimination half-lives of the first dose of study treatment.\n2. Received radiotherapy within 2 weeks of the first dose of study treatment.\n3. Received prior IL-2-based or IL-15-based cytokine therapy.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05098132013","EMAIL":[{"email":"fgatlin@nextoncology.com"}],"GEO":[38.84622,-77.30637]},{"TITLE":"Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n1. Sign informed consent\n2. Expected survival \\> or = 3months\n3. Has histologically documented, incurable, locally advanced or metastatic epithelial origin malignant cancer, priority to include the following tumor types: Non-Small Cell Lung Cancer, HER2- breast cancer, esophageal cancer, Small Cell Lung Cancer, and Nasopharyngeal Cancer\n4. Agree to provide a tumor sample\n5. Has at least one measurable lesion based on RECIST 1.1\n6. Has an Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 1\n7. Toxicity of previous antitumor therapy has returned to level \u22641 as defined by NCI-CTCAE V5.0 (except for asymptomatic laboratory abnormalities such as elevated ALP, hyperuricemia, elevated serum or plasma amylase\/lipase, and elevated blood glucose; except for toxicity that the investigator determined to have no safety risk, such as alopecia, grade 2 peripheral neurotoxicity, hypothyroidism stabilized by hormone replacement therapy, etc.)\n8. Has no serious cardiac dysfunction, left ventricular ejection fraction \u226550%.\n9. Has adequate organ function before registration\n10. Coagulation function: international normalized ratio (INR) \u22641.5\u00d7ULN, and activated partial thromboplastin time (APTT) \u22641.5 ULN\n11. Urinary protein \u22642+ or \u22641000mg\/24 hours\n12. For premenopausal women with childbearing potential, a pregnancy test must be taken within 7 days prior to the start of treatment. Serum or urine pregnancy must be negative and must be non-lactating\n13. Must agree to use adequate barrier contraceptive measures during the treatment and 6 months after the end of treatment for all subjects (regardless of gender)\n\nExclusion Criteria:\n\n1. Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, major surgery, targeted therapy and other anti-tumor therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to the first administration\n2. Subjects with history of severe heart disease\n3. Active autoimmune diseases and inflammatory diseases\n4. Other malignant tumors were diagnosed within 5 years\n5. Subjects with poorly controlled hypertension\n6. Subjects have Grade 3 lung disease or a history of interstitial lung disease\n7. Unstable thrombotic events such as deep vein thrombosis, arterial thrombosis, and pulmonary embolism requiring therapeutic intervention within the previous 6 months before screening\n8. Symptoms of active central nervous system metastasis\n9. Subjects who have a history of allergies to recombinant humanized antibodies or human mouse chimeric antibodies or any of the components of BL-B01D1\n10. Subjects have a history of autologous or allogeneic stem cell transplantation\n11. Known HIV, active tuberculosis, active Hepatitis B virus infection or active Hepatitis C virus infection\n12. Subjects with active infections requiring systemic treatment\n13. Participated in another clinical trial within 4 weeks prior to participating in the study\n14. Other conditions that the investigator believes that it is not suitable for participating in this clinical trial\n15. Subjects with prolonged QT interval (QTc \\>470 msec), complete left bundle branch block, Grade 3 atrioventricular block\n16. Has received treatment with anthracyclines with a cumulative dose exceeding 360 mg\/m2","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05983432016","EMAIL":"tara.barrineau@systimmune.com","GEO":[40.4165,-3.70256]},{"TITLE":"National Network Genomic Medicine Lung Cancer, Germany","CRITERIA":"Inclusion Criteria:\n\n* Age \u2265 18 years\n* Histologically confirmed, locally advanced or metastatic NSCLC (Union for International Cancer Control \\[UICC\\] stage IIIb\/IV; non-resectable NSCLC)\n* From 07\/2023: histologically confirmed NSCLC stage Ib, II, III (UICC)\n\nExclusion Criteria:\n\n* Missing written informed consent","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05934032001","EMAIL":[{"email":"anna.rasokat@uk-koeln.de"}],"GEO":[50.93333,6.95]},{"TITLE":"A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)","CRITERIA":"Inclusion Criteria\n\n1. Subjects must be at least 18 years of age on day of signing informed consent, regardless of gender;\n2. Subjects with histologically or cytologically confirmed locally advanced or metastatic NSCLC ;\n3. Subjects for NSCLC should be confirmed to be EGFR (Epidermal growth factor receptor) wild-type and ALK (Anaplastic lymphoma kinase) fusion gene negative; or confirmed to harbor EGFR mutation;\n4. Locally advanced or metastatic NSCLC subjects without actionable EGFR mutations and ALK fusion genes, no prior systemic treatment; subjects with EGFR mutation, no prior systemic treatment or failed prior EGFR-TKI (Tyrosine kinase inhibitor) treatment;\n5. Subjects are able to provide tumor blocks or slides before the first dose of study intervention;\n6. Subject must have at least one radiographically measurable lesion as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria;\n7. Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1;\n8. Life expectancy at least 3 months for the subject;\n9. Adequate organ function;\n10. Subjects must have recovered from all toxicities led by prior treatment;\n11. Contraceptive methods used by male and female subjects must comply with contraceptive methods of local regulations for clinical study subjects;\n12. Subjects should voluntarily participate in the study, sign the ICF, and will be able to comply with the protocol-specified visits and relevant procedures.\n\nExclusion Criteria\n\n1. Subjects with mixed SCLC histopathological features;\n2. Subjects with a known history of prior malignancy;\n3. Subjects with known meningeal metastases, brainstem metastases, spinal cord metastases and\/or compression, or active central nervous system (CNS) metastases;\n4. Subjects with \u2265 Grade 2 peripheral neuropathy;\n5. Subjects who had arteriovenous thromboembolic events;\n6. Subjects with active inflammatory bowel disease or previous clear history of inflammatory bowel disease;\n7. Subjects who suffer from cardiovascular diseases of clinical significance;\n8. Subjects with a history of interstitial lung disease (ILD)\/non-infectious pneumonitis that required steroids;\n9. Subjects with uncontrolled systemic disease as judged by the Investigator;\n10. Subjects with active autoimmune disease that required systemic treatment in the past 2 years;\n11. Subjects with active hepatitis B or hepatitis C;\n12. Subjects with known history of Human Immunodeficiency Virus (HIV)\n13. Subjects with known active tuberculosis;\n14. Subjects with known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation;\n15. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study;\n16. Subjects whose condition deteriorated rapidly, such as severe changes in performance status, during the screening process prior to the first dose of study intervention;\n17. Subjects with other circumstances that, in the opinion of the Investigator, are not appropriate for participation in this study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05816252034","EMAIL":[{}],"GEO":[30.29365,120.16142]},{"TITLE":"The Efficacy and Safety of KN046 Combined With Axitinib","CRITERIA":"Inclusion Criteria:\n\n1. The subject is at least 18 years old and\\<75 years old on the day of signing the informed consent form, regardless of gender, and is willing to follow the research procedure;\n2. Confirmed by histology or cytology as non-small cell lung cancer;\n3. NSCLC patients evaluated by researchers as resectable in stage IB-IIIB (stage IIIB only limited to T3N2M0) (AJCC 8th edition);\n4. Has not received any anti-tumor treatment in the past, including but not limited to systemic chemotherapy, immunotherapy, or radiotherapy;\n5. No allergenic EGFR mutation or ALK change;\n6. The ECOG score is 0-1 points.\n\nExclusion Criteria:\n\n1. The lesion of squamous non-small cell lung cancer presents as a central type of lung cancer accompanied by cavity formation or invasion of blood vessels, with a high risk of hemoptysis;\n2. Previously or currently suffering from interstitial pneumonia\/lung disease that requires systemic hormone therapy;\n3. Previous history of allogeneic bone marrow or organ transplantation;\n4. Subjects who have undergone major surgical treatment (such as abdominal or thoracic surgery; excluding diagnostic puncture or peripheral vascular pathway replacement surgery) or have not recovered from surgical treatment within 28 days before the administration of this trial;\n5. Prior to allocation, they have received systemic anti-cancer treatment, including research drugs targeting current malignant tumors;\n6. Other known malignant tumors are progressing or require active treatment within the past 5 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (excluding bladder carcinoma in situ) who have received possible radical treatment are not excluded;\n7. Pregnant and\/or lactating women.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"06020352002","EMAIL":[{"email":"chenthoracic@163.com"}],"GEO":[31.22222,121.45806]},{"TITLE":"Surgery Versus Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n* Clinical stage I NSCLC (T1 or T2a, N0, M0) by CT performed within 90 days of screening.\n\n  * PET\/CT is required within 90 days of screening except under circumstances where the clinical picture suggests, or biopsy confirms, a low-grade adenocarcinoma.\n  * Biopsy is strongly encouraged. In the event biopsy is not performed, rationale must be provided for performing empiric treatment.\n  * Patients with hilar or mediastinal lymph nodes \u2264 1 cm and no abnormal hilar or mediastinal uptake on PET will be considered N0. Pre-treatment mediastinal lymph node sampling by any technique is allowed but not required. Patients with \\> 1 cm hilar or mediastinal lymph nodes on CT or abnormal PET (including suspicious but nondiagnostic uptake) are be eligible only if directed tissue biopsies of all abnormally identified areas are negative for cancer.\n* First primary NSCLC on the ipsilateral side.\n* At least 18 years of age.\n* Clinically eligible for either treatment (surgical resection or SBRT). Because this is a pragmatic study and treatment decisions are at the discretion of the treating physicians and their patients, patients must be eligible for either treatment. To be considered eligible for either treatment, patients must have:\n\n  * ECOG performance status \u2264 2\n  * No home oxygen use\n  * FEV1 and DLCO \u2265 40% predicted\n  * No symptomatic congestive heart failure as documented by NYHA I-II functional classification\n  * Been deemed operable by a thoracic surgeon, per clinical visit or review of the medical record and as documented by e-mail, tumor board, study meetings, or other acceptable source documentation. In addition to operability, the surgeon must define what anticipated surgical approach and procedure would be undertaken.\n  * Been deemed treatable by a radiation oncologist with 10 or fewer fractions of SBRT, per clinical visit or review of the medical record and as documented by e-mail, tumor board, study meetings, or other acceptable source documentation. In addition to suitability for SBRT, the radiation oncologist must define which dose and fractionation would be undertaken.\n* Ability to understand and willingness to sign an IRB-approved written informed consent document.\n* Agrees to receive treatment for clinical stage I NSCLC (either surgical resection or SBRT).\n\nExclusion Criteria:\n\n* Prior or concurrent malignancies, unless the natural history of the prior or concurrent malignancy does not have the potential to interfere with the interpretation of the results of the study.\n* Clinically diagnosed or biopsy proven low-grade neuroendocrine carcinoma (carcinoid).\n* Prior thoracic radiation therapy that would overlap with the lung cancer being treated on study.\n* Previous chemotherapy, radiotherapy, or surgical resection specifically for the lung cancer being treated on study.\n* Prior lung resection on the ipsilateral side positive for malignancy.\n* Patients with central tumors requiring a sleeve lobectomy or pneumonectomy.\n* \"Ultra-central\" lesions (defined as a lesion that directly contacts or overlaps the trachea, main bronchus, esophagus, or pulmonary vessels).\n* Concurrent enrollment in a therapeutic trial for the index cancer.\n* Synchronous primary lung cancer.\n* Uncontrolled or symptomatic psychiatric condition.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05183932008","EMAIL":[{},{},{}],"GEO":[43.70011,-79.4163]},{"TITLE":"JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer\uff08NSCLC\uff09","CRITERIA":"Inclusion criteria\uff1a\n\n1. Age \u226518 years at the time of signing informed consent, both male and female.\n2. Histologically or cytologically confirmed relapsed or metastatic non-squamous NSCLC.\n3. Proof of no detection of EGFR-sensitive mutations and ALK fusions.\n4. No prior systemic anti-tumor therapy for advanced or metastatic non-squamous NSCLC. Subjects who have received adjuvant therapy or neoadjuvant therapy (chemotherapy, radiotherapy, or other treatments) for recurrent non-squamous NSCLC can be enrolled if the interval between the last treatment and recurrence is more than 6 months.\n5. Subject has at least 1 measurable lesion according to RECIST v1.1 criteria.\n6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.\n7. Expected survival \u2265 12 weeks.\n8. The function of vital organs meets the following requirements (Note: no blood components and hematopoietic growth factors are allowed to be used within 14 days before screening);\n\n   1. Absolute neutrophil count (ANC) \u22651.5\u00d7109\/L\n   2. Platelet \u2265 100\u00d7109\/L;\n   3. Hemoglobin \u22659 g\/dL;\n   4. Bilirubin \u22641.5\u00d7 upper limit of normal (ULN);\n   5. Alanine aminotransferase (ALT) \u2264 2.5\u00d7 ULN, aspartate aminotransferase (AST) \u2264 2.5\u00d7 ULN;\n   6. Creatinine clearance (CrCL) \u2265 60 mL\/min (cisplatin) or CrCL \u226550 mL\/min (carboplatin) (Cockcroft-Gault formula);\n   7. Activated partial thromboplastin time (APTT) \u2264 1.5 \u00d7 ULN, International normalized ratio (INR) \u2264 1.5 (for prophylactic anticoagulation at stable doses, drug-specific monitoring requirements are acceptable beyond this range).\n9. Female subjects of childbearing potential, as well as male subjects whose partner is a female of childbearing potential, are required to use a highly effective contraceptive method for the duration of study treatment and for at least 6 months after the last treatment.\n10. Voluntarily join this study, sign the informed consent form, have good compliance, and cooperate with follow-up plan.\n\nExclusion criteria\uff1a\n\n1. Concomitant study disease states of:\n\n   1. Histological or cytological pathology of the tumor confirmed with small cell lung cancer component or sarcomatoid lesion, or squamous cell carcinoma component \\>10%;\n   2. Patients with known meningeal metastases;\n   3. Patients with untreated brain metastases, who have received radiation therapy for brain metastases and are judged by the investigator to be stable brain metastases can be enrolled, and the criteria for stability need to meet all of the following conditions: no symptoms related to brain metastases, corticosteroid therapy needs to be discontinued at least 7 days before study drug administration, and no disease progression is found after the end of treatment for brain metastases and before randomization imaging compared with pre-treatment imaging (at least 4 weeks apart);\n   4. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage (once a month or more frequently);\n   5. Spinal cord compression that has not undergone radical treatment with surgery and\/or radiotherapy, or previously diagnosed spinal cord compression that has no clinical evidence of stable disease for \u2265 4 weeks prior to enrollment after treatment;\n2. Have received any of the following treatments:\n\n   1. Received local small-area radiotherapy (such as palliative radiotherapy for bone metastases) within 14 days prior to the first study drug administration;\n   2. Prior immune-mediated therapy, including but not limited to anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapy (or any other antibodies acting on T cell synergistic stimulation or checkpoint pathways such as IDO, IL-2R, GITR);\n   3. Receipt of any investigational drug within 4 weeks or 5 half-lives prior to the first dose of study drug, whichever is shorter;\n   4. Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study, or the subject is in the follow-up period of the interventional clinical study;\n   5. Systemic therapy with corticosteroids (\\> 10 mg prednisone equivalent dose per day) or other immunosuppressants within 2 weeks prior to the first dose of study drug. Inhaled or topical corticosteroids are permitted. Receipt of short-term corticosteroids (such as pre-intravenous contrast) within 2 weeks prior to the first dose of study drug is permitted;\n   6. Subjects who have received proprietary Chinese medicines or immunomodulatory drugs with anti-tumor indications (thymus peptide, interferon, interleukin, etc.) within 2 weeks before the first dose of study drug, or who need to continue to receive these drugs during the study;\n   7. Those who have been vaccinated with anti-tumor vaccines or have received live vaccines within 4 weeks before the first dose of study drug;\n   8. Major surgery or severe trauma within 4 weeks prior to the first use of study drug.\n3. Toxicity from previous anti-tumor therapy has not recovered to \u2264 CTCAE grade 1 (except for toxicity judged by the investigator to have no safety risk);\n4. Known hypersensitivity to any of the study treatments and their excipients;\n5. Unable or unwilling to use folic acid or vitamin B12 injection;\n6. Active autoimmune disease, history of autoimmune disease (including but not limited to interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism); except for:\n\n   1. Subjects with vitiligo or cured childhood asthma\/allergies that do not require any intervention after adulthood;\n   2. Subjects with autoimmune-mediated hypothyroidism treated with stable doses of thyroid replacement hormone;\n   3. Subjects on stable doses of insulin for the treatment of type I diabetes mellitus;\n7. Have a history of immunodeficiency, including a positive HIV test, or have other acquired or congenital immunodeficiency diseases, or have a history of organ transplantation and allogeneic bone marrow transplantation, or autologous hematopoietic stem cell transplantation;\n8. Severe infection (CTCAE\\> grade 2) within 4 weeks before the first use of the study drug, such as severe pneumonia requiring hospitalization, infection comorbidities, etc., active lung inflammation on baseline chest imaging, symptoms and signs of infection within 2 weeks prior to the first dose of the study drug requiring oral or intravenous antibiotic treatment (except for prophylactic antibiotic use);\n9. Confirmed or suspected history of interstitial lung disease or idiopathic pulmonary fibrosis, drug-induced pneumonitis, idiopathic pneumonitis, or other moderate to severe pulmonary diseases that seriously affect lung function (except for \u2264 grade 1 radiation pneumonitis);\n10. Subjects with active pulmonary tuberculosis infection found by medical history or CT examination, or with a history of active pulmonary tuberculosis infection within 1 year prior to enrollment, or subjects with a history of active pulmonary tuberculosis infection more than 1 year ago but without formal treatment;\n11. Presence of active hepatitis B (hepatitis B virus surface antigen (HBsAg) positive with HBV DNA \u2265500 IU\/mL), hepatitis C (hepatitis C antibody positive, and HCV-RNA above the lower limit of detection of the analytical method);\n12. Diagnosis of any other malignancy prior to the first dose of study drug, with the exception of malignancies with low risk of metastasis (5-year survival rate \\>90%), such as adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or breast, or adequately treated localized prostate cancer;\n13. Pregnant or lactating women;\n14. Uncontrolled intercurrent illness including, but not limited to: symptomatic congestive heart failure, left ventricular ejection fraction (LVEF) \\<50%, uncontrolled hypertension, unstable angina, uncontrolled arrhythmia, major seizures, superior vena cava syndrome, or psychiatric illness\/social situation that may affect study compliance, result in a significant increase in the risk of adverse events, or affect the subject's ability to provide written informed consent;\n15. As judged by the investigator, the subject has other factors that may lead to the forced termination of the study, such as other serious diseases (including mental illnesses) requiring concomitant treatment, serious abnormalities in laboratory test values, and\/or family or social factors that may affect the safety of the subject or the collection of experimental data.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06505837001","EMAIL":[{"email":"wulin-calf@vip.163.com"},{}],"GEO":[43.70011,-79.4163]},{"TITLE":"Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours","CRITERIA":"Inclusion Criteria:\n\n* 18 years or older\n* histologically or cytologically confirmed advanced or refractory solid tumour and no longer eligible for approved, available standard therapies. Tumour types must have:\n\n  1. proven MET activating mutations, determined by previous next generation sequencing (NGS), whole exome sequencing (WES), whole transcriptome sequencing (WTS) or other genomic analysis methods, or\n  2. proven amplification (\u2265 10 copies) on archived tumour tissue. or\n  3. Hereditary Renal Papillary Cancer\n* measurable disease in accordance with RECIST 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status \u2264 1\n* adequate bone marrow function, without the support of cytokines\n* adequate liver function\n* adequate renal function\n* agree to follow the contraception requirements of the trial\n* signed informed consent, indicating study patients understand the purpose of and procedures required for the study and are willing to participate in the study.\n\nExclusion Criteria:\n\n* major surgery within 3 weeks before enrollment\n* chemotherapy (in the case of nitrosoureas and mitomycin C within 6 weeks), radiotherapy, immunotherapy, or any other study drug within 3 weeks before study drug administration\n* antibody based cancer therapy within 4 weeks before administration of the first dose of DO-2\n* patients who became progressive on previous treatment with a MET-kinase inhibitor\n* patients with brain metastases are excluded unless all of the following criteria are met:\n\n  1. CNS lesions are asymptomatic and previously treated\n  2. No ongoing requirement for corticosteroids as therapy for CNS metastases\n  3. Imaging demonstrates stability of disease \\> 28 days from last treatment for CNS metastases\n* leptomeningeal involvement (leptomeningeal carcinomatosis)\n* history of uncontrolled heart disease including unstable angina, congestive heart failure, myocardial infarction within preceding 12 months, clinically significant rhythm or conduction abnormality, congenital long QT syndrome, obligate use of a cardiac pacemaker, QTc at screening greater than 450 milliseconds in males and greater than 470 milliseconds in females\n* uncontrolled arterial hypertension despite appropriate therapy\n* positive pregnancy test (urinary beta-hCG) at screening (applicable to women of child-bearing potential who are sexually active)\n* mental status alteration or history of major psychiatric illness, which may potentially impair patient's compliance with study procedures\n* signs and symptoms of active infection requiring systemic therapy\n* other medical condition (e.g. pre-existing kidney dysfunction) that in the opinion of the investigator makes it undesirable for a patient to participate","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"05752552008","EMAIL":[{"email":"d.robbrecht@erasmusmc.nl"},{}],"GEO":[51.9225,4.47917]},{"TITLE":"Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors","CRITERIA":"Inclusion Criteria:\n\n1. Signed informed consent form and able to comply with the protocol;\n2. Male and female subjects \u226518 years of age;\n3. ECOG PS of 0 or 1, the estimated life expectancy \u2265 3 months;\n4. LVEF \u2265 50% as determined by echocardiography (ECHO);\n5. Patients must have pathologically documented advanced\/unresectable or metastatic solid tumor with HER2-positive (as defined below) that is relapsed or refractory to standard therapy or for which there is no standard therapy and progressed. Patients must have a least one measurable disease lesion. Tumor specimens to identify HER2 status should be obtained within the past 6 months.\n\n   Definition of HER2-positive\n   * Advanced\/unresectable or metastatic breast cancer: immunohistochemistry (IHC) 3+, or IHC 2+ and in situ hybridization positive (ISH+)\\*;\n   * Advanced\/unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: IHC 3+, or IHC 2+ and ISH+\\*;\n   * Other HER2-positive advanced\/unresectable or metastatic solid malignant tumor: determined by IHC, ISH, Next Generation Sequencing, or other analysis techniques as appropriate;\n\n     * ISH: fluorescence in situ hybridization (FISH) or dual in situ hybridization (DISH); ISH positivity is defined as a ratio of \u2265 2.0 for the number of HER2 gene copies to the number of signals for CEP17. ISH assay is not required when IHC result is 3+. ISH assay should be performed to confirm HER2 positivity when IHC result is 2+.\n6. Adequate organ function confirmed at screening and within 7 days before the first treatment, as evidenced by:\n\n   Platelet count: \u2265 100,000\/mm3 ; Hemoglobin : \u2265 9 g\/dL; Absolute neutrophil count (ANC): \u2265 1500\/mm3 ; Serum creatinine: \u2264 1.5 \u00d7 ULN (upper limit of normal), or creatinine clearance \u2265 60 mL\/min (using Cockcroft Gault formula) ; Aspartate aminotransferase (AST)\/alanine aminotransferase (ALT) : \u2264 2.5 \u00d7 ULN (\u2264 5 \u00d7 ULN if liver metastases are present); Total bilirubin : \u2264 1.5 \u00d7 ULN (except for patients with Gilbert's Syndrome); Prothrombin time and activated partial thromboplastin time: \u2264 1.5 \u00d7 ULN.\n7. Adequate washout period before the first treatment as defined by:\n\n   Major surgery: \u2265 4 weeks. Radiation therapy: \u2265 4 weeks (\u2265 2 weeks for palliative stereotactic radiation therapy without abdominal). Autologous transplantation: \u2265 3 months.\n\n   Hormonal therapy: \u2265 2 weeks or per Investigator's discretion for breast cancer patients.\n\n   Chemotherapy or targeted therapy (including antibody drug therapy): \u2265 3 weeks (\u2265 2 weeks for 5 flourouracil-based agents, folinate agents, and\/or weekly paclitaxel; \u2265 2 weeks (or 5 half-lives, whichever is shorter) for tyrosine kinase inhibitors; \u2265 4 weeks for HER2-directed biologic therapies; \u2265 6 weeks for nitrosoureas or mitomycin C). Immunotherapy: \u2265 4 weeks. Strong cytochrome P450 enzyme 3A4 (CYP3A4) inhibitor: \u2265 3 elimination half-lives . Any investigational agents or treatments: \u2265 4 weeks.\n8. Patients without a history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections or with a history of AIDS-defining opportunistic infections and have not had an opportunistic infection within the past 12 months may be enrolled per the discretion of the Investigator.\n\nExclusion Criteria:\n\n1. Clinically active brain metastases, defined as untreated and symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. Subjects with treated brain metastases that are no longer symptomatic and who require no treatment with steroids may be included in the study if they have recovered from the acute toxic effect of chemotherapy or radiotherapy;\n2. Subjects with multiple primary malignancies within 2 years, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, other solid tumors curatively treated, or contralateral breast cancer);\n3. Cardiovascular dysfunction or clinically significant cardiac disease, including but not limited to:\n\n   * Medical history of symptomatic chronic heart failure (New York Heart Association (NYHA) classes II-IV) or serious cardiac arrhythmia requiring treatment;\n   * Medical history of myocardial infarction or unstable angina within 6 months of the first treatment;\n   * Corrected QT interval by Fridericia (QTcF) prolongation of \\> 450 milliseconds (ms) in males and \\> 470 ms in females;\n4. Medical history of clinically significant lung disease (e.g., interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis), or patients who are suspected to have these diseases by imaging at screening or requirement for supplemental oxygen;\n5. Known hypersensitivity to either the drug substances or inactive ingredients in the drug product;\n6. Existing Grade \u2265 2 peripheral neuropathy;\n7. Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI CTCAE version 5.0, Grade \u2264 1 or baseline. Subjects with chronic Grade 2 toxicities may be eligible per the discretion of the Investigator;\n8. Cumulative anthracycline dose \\> 360 mg\/m2 doxorubicin or equivalent;\n9. Uncontrolled infection requiring i.v. of antibiotics, antivirals or antifungals;\n10. Active infection with hepatitis C (e.g., detectable antibodies to hepatitis C virus \\[HCV\\]) or hepatitis B (e.g., hepatitis B surface antigen \\[HBsAg\\] positive) except subjects with occult or prior hepatitis B infection (defined as positive total hepatitis B core antibody and negative HBsAg) may be included if hepatitis B virus (HBV) deoxyribonucleic acid (DNA) is undetectable at the time of screening, and these subjects must be willing to undergo monthly DNA testing and appropriate antiviral therapy as indicated;\n11. Patients with a history or current evidence of any concomitant condition, therapy, or laboratory abnormality that, in the opinion of the Investigator, might confound the results of the trial, interfere with the patient's participation and compliance;\n12. Women who are lactating or pregnant, as confirmed by pregnancy test within 7 days before first treatment;\n13. Male and female subjects who are unwilling to use adequate contraceptive methods (e.g., concomitant use of a spermicidal agent, barrier contraceptive, or\/and intrauterine contraceptive) during the study and for at least 7 months after the last dose of GQ1001.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04450732024","EMAIL":[{}],"GEO":[30.29365,120.16142]},{"TITLE":"Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC","CRITERIA":"Inclusion Criteria:\n\n* Male or female subject aged \u2265 18 years.\n* Histologically or cytologically confirmed lung cancer.\n* Metastatic non-squamous non-small cell lung cancer.\n* Body weight \\>30kg\n* Patient has measurable disease as defined by RECIST 1.1 as assessed by either CT or MRI.\n* Chemoimmunotherapy na\u00efve (including durvalumab).\n* ECOG Performance Status \u2264 2.\n\n  --Note: If performance status = 2, ensure that there is a slot available prior to registration as only 20 PS = 2 patients will be enrolled on the protocol.\n* Must have a life expectancy of at least 12 weeks.\n* Adequate organ function as defined as:\n\n  * Hematologic:\n\n    * White blood cell count \\> 2.0 g\/dL\n    * Platelet count \u2265 100,000\/mm3\n    * Hemoglobin \u2265 9 g\/dL\n    * Absolute neutrophil count (ANC) \u2265 1,500\/mm3\n  * Hepatic:\n\n    * Total Bilirubin \u2264 1.5 x institutional upper limit of normal (ULN)\n    * Except for patients with Gilbert's syndrome.\n    * AST(SGOT)\/ALT(SGPT) \u2264 2.5 \u00d7 institutional ULN or \u2264 5 \u00d7 institutional ULN if liver metastases are present\n  * Renal:\n\n    * eGFR \u2265 30 mL\/min\/1.73m2 or creatinine clearance \u2265 30 mL\/min by Cockcroft-Gault:\n    * Males: ((140-age)\u00d7weight\\[kg\\])\/(serum creatinine \\[mg\/dL\\]\u00d772)\n    * Females: (((140-age)\u00d7weight\\[kg\\])\/(serum creatinine \\[mg\/dL\\]\u00d772))\u00d70.85\n* FOR PATIENTS ENROLLED PRIOR TO AMENDMENT V18MAR2024: Concurrent enrollment in the study, \"Rethinking Measurement of Performance Status in Cancer Patients,\" IRB 112529.\n* FOR PATIENTS ENROLLED PRIOR TO AMENDMENT V18MAR2024: Concurrent enrollment in the study, \"An Observational Study Assessing the Clinical Effectiveness of the VeriStrat\u00ae Test and Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer,\" IRB 100314.\n* Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n  * Women \\<50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n  * Women \u226550 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \\>1 year ago, had chemotherapy-induced menopause with last menses \\>1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).\n* Highly effective contraception for both male and female subjects throughout the study and for at least 3 months after the last dose of study therapy.\n* Recovery to baseline or \u2264 Grade 1 CTCAE v.5 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and\/or stable on supportive therapy.\n* Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.\n* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization (eg, Health Insurance Portability and Accountability Act in the US, European Union \\[EU\\] Data Privacy Directive in the EU) obtained from the patient\/legal representative prior to performing any protocol-related procedures, including screening evaluations.\n\nExclusion Criteria:\n\n* ALK or EGFR non-squamous non-small cell lung cancer.\n* Prior radiation therapy within 2 weeks prior to cycle one day one.\n\n  -Exception: Prior palliative radiotherapy is permitted, provided it has been completed at least 2 days prior to study enrollment and no clinically significant toxicities are expected.\n* Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP.\n\n  -Note: Local surgery of isolated lesions for palliative intent is acceptable.\n* History of allogenic organ transplantation.\n* Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \\[e.g., colitis or Crohn's disease\\], diverticulitis \\[with the exception of diverticulosis\\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \\[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc\\]). The following are exceptions to this criterion:\n\n  * Patients with vitiligo or alopecia\n  * Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement\n  * Any chronic skin condition that does not require systemic therapy\n  * Patients without active disease in the last 5 years may be included but only after consultation with the principal investigator\n  * Patients with celiac disease controlled by diet alone\n* Current or prior use of immunosuppressive medication within 14 days of cycle one day one, EXCEPT for the following permitted steroids:\n\n  * Intranasal, inhaled, topical steroids, eye drops or local steroid injection (eg,intra-articular injection);\n  * Systemic corticosteroids at physiologic doses \u2264 10mg\/day of prednisone or equivalent;\n  * Steroids as premedication for hypersensitivity reactions (eg, computed tomography (CT) scan premedication).\n  * Other immunosuppressive agents which, in the opinion of the investigator, are not expected to significantly impact study participation or the mechanism of action of the study therapy.\n* History of active primary immunodeficiency\n* Diagnosis of any other malignancy within 2 years prior to study enrollment, except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the breast, bladder or of the cervix, and low-grade (Gleason 6 or below) prostate cancer on surveillance with no plans for treatment intervention (eg, surgery, radiation, or castration) or prostate cancer that has been adequately treated with prostatectomy or radiotherapy and currently with no evidence of disease or symptoms is allowed.\n* Uncontrolled CNS metastases; subjects with previously treated brain metastases will be allowed if the brain metastases have been treated, toxicities have resolved to grade 1 or baseline and steroids are no longer required.\n\n  --Patients with asymptomatic brain metastasis are allowed if previous steroid treatment was discontinued \u2265 6 weeks.\n* History of leptomeningeal carcinomatosis\n* Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness\/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent\n* Known HIV infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA load 12 months, CD4+ count of \u2265 350 cells\/uL, no history of AIDS-defining opportunistic infection within the past 12 months, and stable for at least 1 month on the same anti HIV medications.\n* Active infection including: tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), or hepatitis C.\n\n  -Note: Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n* Vaccination with a live vaccine within 30 days of cycle one day one and while on trial is prohibited except for administration of inactivated vaccines.\n* Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy\n* Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies, cisplatin, other platinum-containing compounds, or mannitol. (NCI CTCAE v5.0 Grade \u2265 3).\n* Subjects taking prohibited medications as described in Section 6.5.2. A washout period of prohibited medications for a period of at least 5 half-lives or as clinically indicated should occur prior to the start of treatment.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04163432001","EMAIL":[{"email":"kaitlin.stephens@hci.utah.edu"}],"GEO":[40.76078,-111.89105]},{"TITLE":"A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours","CRITERIA":"Key Inclusion Criteria:\n\nHistologically and\/or cytologically confirmed solid tumor that is metastatic, locally advanced, recurrent or inoperable.\n\nDisease that has progressed despite prior treatment, and for which additional effective standard therapy is not available or is contraindicated, not tolerable, or the participant refuses standard therapy.\n\nMeasurable disease as defined by RECIST Version 1.1\n\nECOG Performance status of 0 or 1\n\nAdequate organ function\n\nKey Exclusion Criteria:\n\nPrevious treatment with any systemic radiopharmaceutical\n\nPrior anti-cancer therapy unless adequate washout and recovery from toxicities\n\nContraindications to or inability to perform the imaging procedures required in this study\n\nRadiation therapy (RT) within 28 days prior to the first dose of \\[111In\\]-FPI-2107\n\nUncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (\u2265 once per month)\n\nPatients with known CNS metastatic disease unless treated and stable","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06147037001","EMAIL":[{"email":"Gary.ulaner@hoag.org"},{"email":"Beth.thomsen@hoag.org"},{}],"GEO":[33.66946,-117.82311]},{"TITLE":"Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease","CRITERIA":"Inclusion Criteria:\n\n* Metastatic disease detected on imaging and histologically confirmed\n\n  * Metastatic breast cancer (all subtypes)\n  * Non-small cell lung cancer (NSCLC) without known targetable molecular alterations in EGFR, ALK, or ROS1\n  * NSCLC with EGFR, ALK, or ROS1 targetable molecular alterations who had a history of disease progression on first-line tyrosine kinase inhibitor\n* Patient can either have newly diagnosed metastatic disease, or have non-progressive disease on systemic therapy (for at least 3 months on systemic imaging)\n* Patients must have measurable disease at baseline (RECIST or PERCIST 2.0) and with 5 or fewer discrete disease sites that are technically amendable to SBRT (with the exception that if the primary disease is not amendable to SBRT it is allowed to be treated with conventionally fractionated or hypfractionated radiotherapy).\n\n  * Two lesions in such close proximity to one another that treatment with one isocenter is more accurate and safer in the liver, lungs, or other similar anatomic locations should be viewed as one site of metastatic disease treatment\n  * Disease in 2 contiguous vertebral bodies (with up to 6 cm of paraspinal extension) can represent one site of disease in the spine; non-contiguous lesions in vertebral bodies separated by one vertebral body free of disease should be viewed as 2 sites of treatment\n  * If the clinical scenario deem that other forms of local therapy may be more suitable for the metastatic disease, such as surgical resection and interventional radiology-guided ablation, patients would be able to undergo other forms of local therapy with discussion with the PI.\n* For de novo stage IV patients (patients with metastatic disease at first presentation), primary disease must be treatable with local therapy. If the primary tumor or other locoregional disease has not been definitively treated and is not amendable to SBRT, it must be treated with conventionally fractionated or hypofractionated radiotherapy using a regimen that delivers a minimum BED of 48 Gy10. If the clinical scenario deem that other forms of local therapy may be more suitable for the primary and locoregional disease, such as surgical resection and interventional radiology-guided ablation, patients would be able to undergo other forms of local therapy with discussion with the PI.\n* If primary disease was previously treated with local therapy in the form of surgery or radiation, any new local\/regional disease recurrence should be technically treatable with SBRT or hypofractionated radiation. If the clinical scenario deem that other forms of local therapy may be more suitable for the local\/regional recurrent disease, such as surgical resection and interventional radiology-guided ablation, patients would be able to undergo other forms of local therapy with discussion with the PI.\n* Patients may receive palliative radiotherapy for symptomatic metastases or primary disease prior to enrollment provided that there is at least one other non-irradiated lesion amenable to SBRT at the time of enrollment.\n* Patients with brain metastases are eligible if these lesions have been treated prior to enrollment.\n* ECOG Performance status 0 - 2.\n* Age \\>\/= 18 years.\n* Able to provide informed consent.\n* Female subjects must either be of non-reproductive potential (i.e. post-menopausal by history: \\>\/= 60 years old or no menses for 1\\> year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test within 2 weeks prior to starting treatment.\n* Adequate baseline organ function to allow SBRT to all relevant targets, as determined by the treating radiation oncologist based on lesion location, lesion size, and proximity to relevant organs at risk.\n\nExclusion Criteria:\n\n* Serious medical co-morbidities precluding radiotherapy, determined at the discretion of the treating investigator.\n* Pregnant or lactating women.\n* Other active malignancy within the last year, even if without evidence of disease.\n* Clinical or radiological evidence of spinal cord compression\n* Malignant pleural effusion or ascites.\n* Patients whose entry to the trial will cause unacceptable clinical delays in their planned management.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"03808337012","EMAIL":[{}],"GEO":[40.60843,-75.49018]},{"TITLE":"Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer","CRITERIA":"Inclusion Criteria:\n\n1. Voluntary provision of informed consent.\n2. Males or females aged 18-75.\n3. Histological or cytologically confirmed NSCLC, metastatic or non-resectable (stage IIIB-\u2163).\n4. At least one lesion can be measured by imaging.\n5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1.\n6. Life expectancy \u2265 12 weeks.\n7. None previous chemotherapy or targeted therapy(Arm:wild-type genotype).\n8. Patients should be confirmed acquired EGFR T790M mutation and received adequate EGFR-TKI treatment(Arm:EGFR mutation).\n9. Female of childbearing age must have a negative pregnancy test (serum or urine) within 7 days before enrolment.\n\nExclusion Criteria:\n\n1. Histological or cytologically confirmed small cell lung cancer (SCLC), including lung cancer mixed with SCLC and NSCLC.\n2. Diagnosed with other malignant diseases other than NSCLC within 5 years.\n3. Have participated in other interventional clinical research treatments now or within 4 weeks.\n4. Have previously received multi-targeted kinase inhibitors therapy.\n5. Have active autoimmune diseases requiring systemic treatment within 2 years.\n6. Received systemic glucocorticoid therapy or immunosuppressive therapy within 2 weeks.\n7. Clinically uncontrollable pleural effusion\/abdominal effusion.\n8. Vaccinated vaccines or attenuated vaccines within 4 weeks before the group;\n9. Pregnant or breastfeeding females.\n10. Other serious hazards to the safety of patients.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":75,"SS_ID":"05003037001","EMAIL":[{"email":"fangwf@sysucc.org.cn"}],"GEO":[23.11667,113.25]},{"TITLE":"A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface","CRITERIA":"Inclusion Criteria:\n\n* Signed and dated, written informed consent form (ICF) (ICF1 for B7-H6 testing for all patients except those with advanced or metastatic colorectal cancer (CRC); and ICF2 for all patients) describing the study in accordance with International Council on Harmonisation Good Clinical Practice (ICH-GCP) and local legislation prior to any trial-specific procedures, sampling, or analyses.\n* Patient must be \u226518 years of age at the time of signature on the ICFs (ICF1 and ICF2).\n* Patients with a histologically or cytologically confirmed diagnosis of an advanced, unresectable, and\/or metastatic colorectal carcinoma (CRC), non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), head and neck squamous cell carcinoma (HNSCC), gastric carcinoma, and pancreatic carcinoma. At least 1 patient in each back-fill slot must be a non-CRC patient (i.e., NSCLC, HCC, HNSCC, gastric carcinoma, or pancreatic carcinoma).\n* Patients with disease progression despite conventional treatment, intolerant to or not a candidate for conventional treatment, or with a tumor for which no conventional treatment exists.\n* All patients must agree to the collection of tumor samples (as slides from archival diagnostic samples or fresh tumor biopsies) for confirmation of B7-H6 expression either at Screening visit 02 (for CRC patients) or Screening visit 01 (for all other patients). To qualify for a back-fill slot or recommended dose expansion (RDE) cohort, the patient must agree to the collection of mandatory pre-treatment and on-treatment fresh tumor biopsies.\n* Patient diagnosed with advanced or metastatic CRC or patient with confirmed B7-H6 expression on tumor tissue sample (archived or fresh tumor biopsy) based on central pathology review.\n* Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Patient must have at least one evaluable target lesion outside of the central nervous system (CNS) as defined per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 separate from any lesion(s) identified for tumor biopsy. Tumor lesions that have been irradiated at least \u226528 days before the start of treatment, and have subsequently had documented progression, may be chosen as target lesions only in the absence of measurable lesions that have not been irradiated.\n* Further inclusion criteria apply\n\nExclusion Criteria:\n\n* Patient with a history of a major surgery within 28 days prior to first dose of BI 765049 (major according to the Investigator's and\/or Medical Monitor's assessment).\n* Patient with a history of a previous or concomitant malignancies. Patient with a malignancy considered effectively treated and cured by 'local treatment' within the last 2 years and that is distinct from the one treated in this trial will be allowed.\n* Patient with known leptomeningeal disease or spinal cord compression due to disease.\n* Patient requiring anticoagulant treatment which cannot be safely interrupted, if medically needed for a study procedure (e.g., biopsy) based on the opinion of the Investigator.\n* History of systemic antimicrobials required for an infection within 7 days of first dose BI 765049.\n* Patient with any of the following laboratory evidence of hepatitis virus infection. Test results obtained in routine diagnostics are acceptable for screening if done within 14 days before the ICF2 date:\n\n  * Positive results of hepatitis B surface (HBs) antigen\n  * Presence of hepatitis B core (HBc) antibody together with hepatitis B virus (HBV)-DNA\n  * Presence of hepatitis C-RNA\n* Patient with known human immunodeficiency virus (HIV) infection.\n* Patient previous treatment history:\n\n  * Treatment with a systemic anti-cancer therapy or investigational drug within 21 days or 5 half-lives (whichever is shorter) of the first administration of BI 765049.\n  * Treatment with extensive field radiotherapy including whole brain irradiation within 14 days prior to first administration of BI 765049.\n* Further exclusion criteria apply","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04752215014","EMAIL":[{"email":"canada@bitrialsupport.com"}],"GEO":[43.70011,-79.4163]},{"TITLE":"Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study","CRITERIA":"Inclusion Criteria:\n\n1. Age \u2265 18 years,\n2. Histology: colorectal cancer, non-small cell lung cancer,\n3. Locally advanced\/unresectable and\/or metastatic solid tumor,\n4. Eastern Cooperative Oncology Group (ECOG) performance status \\< 2 (Appendix 1),\n5. Measurable disease according to RECIST 1.1 (lesion in previously irradiated filed can be considered as measurable if progressive at inclusion according to RECIST v1.1). At least one site of disease must be uni-dimensionally \\> 10 mm,\n6. No previous systemic treatment for advanced disease,\n7. Availability of suitable paraffin embedded (FFPE) archive tumor material or at least one target lesion that can be biopsied for research purpose,\n8. Eligible to first-line systemic therapy,\n9. Patient with a social security in compliance with the French law,\n10. Voluntary signed and dated written informed consent prior to any study specific procedure.\n\nExclusion Criteria:\n\n1. Inability to swallow,\n2. Major problem with intestinal absorption,\n3. Previous allogeneic bone marrow transplant,\n4. Previous or current malignancies of other histologies within the last 2 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin and prostate cancer,\n5. Evidence of severe or uncontrolled systemic disease (uncontrolled hypertension, active bleeding diatheses, or active Hepatitis B, C and HIV),\n6. Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in a clinical trial or which would jeopardize compliance with the protocol,\n7. Individuals deprived of liberty or placed under guardianship,\n8. Pregnant or breast feeding women,\n9. Previous enrolment in the present study,\n10. Any contraindication to first-line systemic therapy.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04258137006","EMAIL":[{},{"email":"sylvestre.lemoulec@gmail.com"}],"GEO":[43.3,-0.36667]},{"TITLE":"A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metastasis","CRITERIA":"Inclusion Criteria:\n\n* must be at least 18 years when fisrt dose of Trilaciclib, regardless of gender\uff1b\n* ECOG-PS score of 0-1\uff0cand no worsening in the 2 weeks before the study drug\uff1b\n* expected survival\u226512 weeks\uff1b\n* Advanced non-small cell lung cancer with leptomeningeal metastasis\uff1b\n* with an Ommaya sac has been implanted\uff1b\n* At least one measurable lesion meeting RECIST1.1 criteria was present\uff1b\n* Laboratory tests met the following criteria: hemoglobin \u2265100 g\/L (female), 110g\/L (male) \uff1bneutrophil count \u2265 2\u00d7109\/L \uff1bplatelet count \u2265100\u00d7109\/L; Creatinine \u2264 15mg\/L or creatinine clearance (CrCl) \u2265 60 mL\/min (Cockcroft-Gault formula); Total bilirubin \u2264 1.5\u00d7 upper limit of normal value (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u2264 3 \u00d7 ULN or 5\u00d7 ULN (for patients with liver metastases); Albumin \u2265 30 g\/L;\n* Patients of reproductive age(including female and male patients'female companions)must use effective birth control measures;\n* Voluntarily participate and sign informed consent;\n\nExclusion Criteria:\n\n* Patients of reproductive age(including female and male patients'female companions)must use effective birth control measures;\n* Stroke or cardio-cerebrovascular event within 6 months before enrollment;\n* QTcF interval \\> 480msec at screening, QTcF \\> 500msec for patients with implanted ventricular pacemakers;\n* Previous hematopoietic stem cell or bone marrow transplantation;\n* Allergy to the study drug or its components;\n* If the investigator considers that it is not suitable to participate in this study.","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"06332287001","EMAIL":[{"email":"fang1984@aliyun.com"}],"GEO":[31.30408,120.59538]},{"TITLE":"Coformulation of Pembrolizumab\/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)","CRITERIA":"Inclusion Criteria:\n\n* Has a histologically or cytologically confirmed diagnosis of Stage IV: M1a, M1b, or M1c non-small cell lung cancer (NSCLC) per the American Joint Committee on Cancer (AJCC) Staging Manual, version 8\n* Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, as determined by the local site assessment\n* Has confirmation that epidermal growth factor receptor (EGFR)-, anaplastic lymphoma kinase (ALK)-, or reactive oxygen species proto-oncogene 1 (ROS1)-directed therapy is not indicated as primary therapy and absence of ALK and ROS1 gene rearrangements\n* Has provided tumor tissue that demonstrates Programmed Cell Death 1 Ligand 1 (PD-L1) expression in \u22651% of tumor cells as assessed by immunohistochemistry (IHC) at a central laboratory\n* Has an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1 assessed within 7 days prior to randomization\n* Has a life expectancy of at least 3 months\n* A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:\n\n  * Is not a woman of childbearing potential (WOCBP)\n  * Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \\<1% per year), with low user dependency or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis), during the intervention period and for at least 120 days after the last dose of study intervention\n* Has adequate organ function\n\nExclusion Criteria:\n\n* Has a known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for at least 3 years since initiation of that therapy\n* Has received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC.\n\n  * Prior treatment with chemotherapy and\/or radiation as part of neoadjuvant\/adjuvant or chemoradiation therapy for nonmetastatic NSCLC is allowed as long as therapy was completed at least 6 months before the diagnosis of metastatic NSCLC.\n  * Participants must have recovered from all AEs due to previous therapies to Grade \u22641 or baseline. Participants with Grade \u22642 neuropathy may be eligible. Participants with endocrine-related AEs Grade \u22642 requiring treatment or hormone replacement may be eligible.\n* Has received prior therapy with an anti-programmed cell death receptor 1 (PD-1), anti-programmed cell death receptor ligand 1 (PD-L1), or anti-programmed cell death receptor ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137)\n* Has received previous treatment with another agent targeting the T cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibition motif (ITIM) domains (TIGIT) receptor pathway\n* Has received radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (\u22642 weeks of radiotherapy) to non-central nervous system (CNS) disease\n* Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention. Administration of killed vaccines is allowed.\n\n  * Any licensed COVID-19 vaccine (including for Emergency Use) in a particular country is allowed in the study as long as they are mRNA vaccines, adenoviral vaccines, or inactivated vaccines. These vaccines will be treated just as any other concomitant therapy.\n  * Investigational vaccines (i.e., those not licensed or approved for Emergency Use) are not allowed.\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention\n* Has known active or untreated CNS metastases and\/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable for at least 4 weeks by repeat imaging, clinically stable, and without requirement of steroid treatment for at least 14 days prior to first dose of study intervention\n* Has severe hypersensitivity (\u2265Grade 3) to pembrolizumab\/vibostolimab or pembrolizumab and\/or any of its excipients\n* Has an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention\n* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis\n* Has a known history of interstitial lung disease. Lymphangitic spread of the NSCLC is not exclusionary.\n* Has an active infection requiring systemic therapy\n* Has a known history of human immunodeficiency virus (HIV) infection. No HIV testing is required unless mandated by local health authority\n* Has a known history of Hepatitis B or known active Hepatitis C virus infection\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that prevents the participant from receiving platinum-doublet chemotherapy for first line NSCLC, or that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n* Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study","SEX":"ALL","AGE_MIN":18,"AGE_MAX":200,"SS_ID":"04738487191","EMAIL":[{}],"GEO":[10.82302,106.62965]}]